PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Griffiths, F; Green, E; Tsouroufli, M				Griffiths, F; Green, E; Tsouroufli, M			The nature of medical evidence and its inherent uncertainty for the clinical consultation: qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To describe how clinicians deal with the uncertainty inherent in medical evidence in clinical consultations. Design Qualitative study. Setting Clinical consultations related to hormone replacement therapy, bone densitometry, and breast screening in seven general practices and three secondary care clinics in the UK NHS. Participants Women aged 45-64. Results 45 of the 109 relevant consultations included sufficient discussion for analysis. The consultations could be categorised into three groups: focus on certainty for now and this test, with slippage into general reassurance; a coherent account of the medical evidence for risks and benefits, but blurring of the uncertainty inherent in the evidence and giving an impression of certainty; and acknowledging the inherent uncertainty of the medical evidence and negotiating a provisional decision. Conclusion Strategies health professionals use to cope with the uncertainty inherent in medical evidence in clinical consultations include the use of provisional decisions that allow for changing priorities and circumstances over time, to avoid slippage into general reassurance from a particular test result, and to avoid the creation of a myth of certainty.	Univ Warwick, Ctr Primary Hlth Care Studies, Coventry CV4 7AL, W Midlands, England; Univ Teesside, Ctr Social & Policy Res, Middlesbrough TS1 3BA, Cleveland, England; Univ Cardiff, Inst Soc Hlth & Eth, Cardiff CF10 3AT, S Glam, Wales	University of Warwick; University of Teesside; Cardiff University	Griffiths, F (corresponding author), Univ Warwick, Ctr Primary Hlth Care Studies, Coventry CV4 7AL, W Midlands, England.	f.e.griffiths@warwick.ac.uk		Griffiths, Frances/0000-0002-4173-1438	National Institute for Health Research [CSA03/003] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		BERESFORD EB, 1991, HASTINGS CENT REP, V21, P6, DOI 10.2307/3562993; Bond M, 1998, WOMEN STUD INT FORUM, V21, P65, DOI 10.1016/S0277-5395(97)00082-4; Edwards A, 2002, BMJ-BRIT MED J, V324, P827, DOI 10.1136/bmj.324.7341.827; Fox RC, 2002, GENDER HLTH HEALING, P236; GOROVITZ S, 1976, J MED PHILOS, V1, P51, DOI 10.1093/jmp/1.1.51; Green EE, 2002, HEALTH RISK SOC, V4, P273, DOI 10.1080/1369857021000016632; GRIFFITHS F, 2003, DEBATING BIOL SOCIOL, P210; GRIFFITHS FE, 2003, INNOVATIVE HLTH TECH; Haynes RB, 2002, BMJ-BRIT MED J, V324, P1350, DOI 10.1136/bmj.324.7350.1350; Lewis DK, 2003, BMJ-BRIT MED J, V327, P841, DOI 10.1136/bmj.327.7419.841; Masse R, 2001, SOCIOL HEALTH ILL, V23, P44, DOI 10.1111/1467-9566.00240; McWhinney I R, 1989, Fam Med, V21, P296; MINELLI CAK, 2004, BRIT MED J, P328; ROSENBERGER NR, 1992, SOC SCI MED, V34, P237, DOI 10.1016/0277-9536(92)90266-S; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Summerskill WSM, 2002, FAM PRACT, V19, P605, DOI 10.1093/fampra/19.6.605; TANENBAUM SJ, 1993, NEW ENGL J MED, V329, P1268, DOI 10.1056/NEJM199310213291713; Tanenbaum SJ, 1999, ACAD MED, V74, P757, DOI 10.1097/00001888-199907000-00008; TANENBAUM SJ, 1994, J HEALTH POLIT POLIC, V19, P27, DOI 10.1215/03616878-19-1-27; Willis J, 1995, PARADOX PROGR; WONCA European, 2002, EUR DEF GEN PRACT FA	21	68	70	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 5	2005	330	7490					511	515		10.1136/bmj.38336.482720.8F	http://dx.doi.org/10.1136/bmj.38336.482720.8F			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	905PM	15684026	Green Published, Green Submitted			2022-12-28	WOS:000227581400017
J	He, X; He, X; Dave, VP; Zhang, Y; Hua, X; Nicolas, E; Xu, WH; Roe, BA; Kappes, DJ				He, X; He, X; Dave, VP; Zhang, Y; Hua, X; Nicolas, E; Xu, WH; Roe, BA; Kappes, DJ			The zinc finger transcription factor Th-POK regulates CD4 versus CD8 T-cell lineage commitment	NATURE			English	Article							GENE-EXPRESSION; FACTOR GATA-3; LYMPHOCYTE DEVELOPMENT; THYMOCYTE DEVELOPMENT; TRANSGENIC MICE; SELECTION; DIFFERENTIATION; DNA; PROTEINS; DURATION	Development of immature T-cell precursors (thymocytes) to either the CD4 helper or CD8 killer T-cell lineages correlates precisely with their T-cell receptor specificity for major histocompatibility complex class II or class I molecules, respectively, indicating that the process is carefully regulated. Although intensively studied owing to its importance in determining the composition of the mature T-cell compartment and as a general model of binary lineage decisions, the underlying molecular pathways remain obscure. We have previously reported a spontaneous mouse mutant (HD ( helper deficient) mice) in which lineage commitment is specifically perturbed without affecting positive selection. Here we show that a point mutation in the zinc finger transcription factor Th-POK (T-helper-inducing POZ/Kruppel-like factor) is responsible for redirection of class-II-restricted thymocytes to the CD8 lineage in HD mice. Furthermore, we demonstrate that constitutive expression of this factor during thymic development leads to redirection of class-I-restricted thymocytes to the CD4 lineage, indicating that Th-POK is a master regulator of lineage commitment.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA	Fox Chase Cancer Center; University of Oklahoma System; University of Oklahoma - Norman	Kappes, DJ (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	dj_kappes@fccc.edu	He, Xi/GXH-3286-2022	He, Xi/0000-0002-4383-0157; He, Xiao/0000-0002-9286-9859				Aliahmad P, 2004, J EXP MED, V199, P1089, DOI 10.1084/jem.20040051; BLOBEL GA, 1995, MOL CELL BIOL, V15, P626; Dave VP, 1998, P NATL ACAD SCI USA, V95, P8187, DOI 10.1073/pnas.95.14.8187; GALERA P, 1994, P NATL ACAD SCI USA, V91, P9372, DOI 10.1073/pnas.91.20.9372; Germain RN, 2002, NAT REV IMMUNOL, V2, P309, DOI 10.1038/nri798; Goldrath AW, 1997, IMMUNITY, V6, P633, DOI 10.1016/S1074-7613(00)80351-9; Hendriks RW, 1999, EUR J IMMUNOL, V29, P1912, DOI 10.1002/(SICI)1521-4141(199906)29:06<1912::AID-IMMU1912>3.3.CO;2-4; Hernandez-Hoyos G, 2000, IMMUNITY, V12, P313, DOI 10.1016/S1074-7613(00)80184-3; Hernandez-Hoyos G, 2003, IMMUNITY, V19, P83, DOI 10.1016/S1074-7613(03)00176-6; Itano A, 1996, J EXP MED, V183, P731, DOI 10.1084/jem.183.3.731; Keefe R, 1999, SCIENCE, V286, P1149, DOI 10.1126/science.286.5442.1149; KILLEEN N, 1993, NATURE, V364, P729, DOI 10.1038/364729a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KLEVIT RE, 1991, SCIENCE, V253, P1367, DOI 10.1126/science.1896847; Legname G, 2000, IMMUNITY, V12, P537, DOI 10.1016/S1074-7613(00)80205-8; Liu XL, 2004, NAT IMMUNOL, V5, P280, DOI 10.1038/ni1040; Matechak EO, 1996, IMMUNITY, V4, P337, DOI 10.1016/S1074-7613(00)80247-2; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; Pai SY, 2003, IMMUNITY, V19, P863, DOI 10.1016/S1074-7613(03)00328-5; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; Schmedt C, 1998, NATURE, V394, P901, DOI 10.1038/29802; Singer A, 2004, ADV IMMUNOL, V83, P91; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Tyznik AJ, 2004, J EXP MED, V199, P559, DOI 10.1084/jem.20031961; Widom RL, 2001, MATRIX BIOL, V20, P451, DOI 10.1016/S0945-053X(01)00167-6; Wilkinson B, 2002, NAT IMMUNOL, V3, P272, DOI 10.1038/ni767; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Yasutomo K, 2000, NATURE, V404, P506, DOI 10.1038/35006664; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S	32	303	312	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 24	2005	433	7028					826	833		10.1038/nature03338	http://dx.doi.org/10.1038/nature03338			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	899VT	15729333	Bronze			2022-12-28	WOS:000227174600033
J	Altshuter, D; Clark, AG				Altshuter, D; Clark, AG			Genetics - Harvesting medical information from the human family tree	SCIENCE			English	Editorial Material							POLYMORPHISM; RECOMBINATION; METABOLISM; GENES		Harvard Univ, Broad Inst, Boston, MA 02114 USA; MIT, Boston, MA 02114 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Cornell University	Altshuter, D (corresponding author), Harvard Univ, Broad Inst, Boston, MA 02114 USA.	altshuler@molbio.mgh.harvard.edu; ac347@cornell.edu	Altshuler, David M/A-4476-2009	Altshuler, David M/0000-0002-7250-4107; Clark, Andrew/0000-0001-7159-8511				Ahmadi KR, 2005, NAT GENET, V37, P84, DOI 10.1038/ng1488; Clark AG, 2003, AM J HUM GENET, V73, P285, DOI 10.1086/377138; Crawford DC, 2004, AM J HUM GENET, V74, P610, DOI 10.1086/382227; Evans DM, 2004, GENET EPIDEMIOL, V27, P375, DOI 10.1002/gepi.20045; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Hill WG, 2005, SCIENCE, V307, P683, DOI 10.1126/science.1105459; Hinds DA, 2005, SCIENCE, V307, P1072, DOI 10.1126/science.1105436; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Kim Y, 2003, GENETICS, V164, P389; Laurie CC, 2004, GENETICS, V168, P2141, DOI 10.1534/genetics.104.029686; McVean GAT, 2004, SCIENCE, V304, P581, DOI 10.1126/science.1092500; Pritchard JK, 2002, HUM MOL GENET, V11, P2417, DOI 10.1093/hmg/11.20.2417; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918	14	20	20	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2005	307	5712					1052	1053		10.1126/science.1109682	http://dx.doi.org/10.1126/science.1109682			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ED	15718454				2022-12-28	WOS:000227197300029
J	Crary, FJ; Clarke, JT; Dougherty, MK; Hanlon, PG; Hansen, KC; Steinberg, JT; Barraclough, BL; Coates, AJ; Gerard, JC; Grodent, D; Kurth, WS; Mitchell, DG; Rymer, AM; Young, DT				Crary, FJ; Clarke, JT; Dougherty, MK; Hanlon, PG; Hansen, KC; Steinberg, JT; Barraclough, BL; Coates, AJ; Gerard, JC; Grodent, D; Kurth, WS; Mitchell, DG; Rymer, AM; Young, DT			Solar wind dynamic pressure and electric field as the main factors controlling Saturn's aurorae	NATURE			English	Article							RADIO-EMISSION; MAGNETIC-FIELD; MAGNETOSPHERE; OVAL	The interaction of the solar wind with Earth's magnetosphere gives rise to the bright polar aurorae and to geomagnetic storms(1), but the relation between the solar wind and the dynamics of the outer planets' magnetospheres is poorly understood. Jupiter's magnetospheric dynamics and aurorae are dominated by processes internal to the jovian system(2), whereas Saturn's magnetosphere has generally been considered to have both internal and solar-wind-driven processes. This hypothesis, however, is tentative because of limited simultaneous solar wind and magnetospheric measurements. Here we report solar wind measurements, immediately upstream of Saturn, over a one-month period. When combined with simultaneous ultraviolet imaging(3) we find that, unlike Jupiter, Saturn's aurorae respond strongly to solar wind conditions. But in contrast to Earth, the main controlling factor appears to be solar wind dynamic pressure and electric field, with the orientation of the interplanetary magnetic field playing a much more limited role. Saturn's magnetosphere is, therefore, strongly driven by the solar wind, but the solar wind conditions that drive it differ from those that drive the Earth's magnetosphere.	SW Res Inst, San Antonio, TX 78228 USA; Boston Univ, Boston, MA 02215 USA; Univ London Imperial Coll Sci Technol & Med, Blackett Lab, London SW7 2BZ, England; Univ Michigan, Ann Arbor, MI 48109 USA; Los Alamos Natl Lab, Los Alamos, NM 87545 USA; UCL, Mullard Space Sci Lab, Dorking RH5 6NT, Surrey, England; Univ Liege, B-4000 Liege, Belgium; Univ Iowa, Dept Phys & Astron, Iowa City, IA 52242 USA; Johns Hopkins Univ, Appl Phys Lab, Laurel, MD 20723 USA	Southwest Research Institute; Boston University; Imperial College London; University of Michigan System; University of Michigan; United States Department of Energy (DOE); Los Alamos National Laboratory; University of London; University College London; University of Liege; University of Iowa; Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory	Crary, FJ (corresponding author), SW Res Inst, Culebra Rd, San Antonio, TX 78228 USA.	fcrary@swri.edu	Mitchell, Donald G/H-4601-2016; Coates, Andrew/C-2396-2008; Clarke, John/C-8644-2013; Kurth, William/AAA-7334-2019; Hansen, Kenneth C/F-3693-2011	Mitchell, Donald G/0000-0003-1960-2119; Coates, Andrew/0000-0002-6185-3125; Kurth, William/0000-0002-5471-6202; Hansen, Kenneth C/0000-0002-8502-1980; GERARD, Jean-Claude/0000-0002-8565-8746				AKASOFU SI, 1980, PLANET SPACE SCI, V28, P495, DOI 10.1016/0032-0633(80)90031-8; Cowley SWH, 2003, PLANET SPACE SCI, V51, P57, DOI 10.1016/S0032-0633(02)00118-6; Cowley SWH, 2001, PLANET SPACE SCI, V49, P1067, DOI 10.1016/S0032-0633(00)00167-7; DESCH MD, 1982, J GEOPHYS RES-SPACE, V87, P4549, DOI 10.1029/JA087iA06p04549; DESCH MD, 1984, J GEOPHYS RES-SPACE, V89, P6819, DOI 10.1029/JA089iA08p06819; DUNGEY JW, 1961, PHYS REV LETT, V6, P47, DOI 10.1103/PhysRevLett.6.47; Gurnett DA, 2002, NATURE, V415, P985, DOI 10.1038/415985a; Hanlon PG, 2004, J GEOPHYS RES-SPACE, V109, DOI 10.1029/2003JA010112; Hill T. W., 1983, PHYSICS JOVIAN MAGNE, P353, DOI DOI 10.1017/CBO9780511564574.012; Kivelson MG, 2003, PLANET SPACE SCI, V51, P891, DOI 10.1016/S0032-0633(03)00075-8; Meurant M, 2004, J GEOPHYS RES-SPACE, V109, DOI 10.1029/2004JA010453; RUSSELL CT, 1973, J GEOPHYS RES, V78, P92, DOI 10.1029/JA078i001p00092; Southwood DJ, 2001, J GEOPHYS RES-SPACE, V106, P6123, DOI 10.1029/2000JA000236; Toth G, 1996, ASTROPHYS LETT COMM, V34, P245; YOUNG DT, IN PRESS SPACE SCI R; ZARKA P, 1983, NATURE, V306, P767, DOI 10.1038/306767a0	16	118	119	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 17	2005	433	7027					720	722		10.1038/nature03333	http://dx.doi.org/10.1038/nature03333			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897XH	15716946	Green Published			2022-12-28	WOS:000227039200032
J	Bal, SK; Hollingworth, GR				Bal, SK; Hollingworth, GR			10-minute consulation - Headache	BRITISH MEDICAL JOURNAL			English	Article									Univ Ottawa, Fac Med, Dept Family Med, Ottawa, ON K1N 5C8, Canada	University of Ottawa	Bal, SK (corresponding author), Univ Ottawa, Fac Med, Dept Family Med, Ottawa, ON K1N 5C8, Canada.	sharon_k_bal@yahoo.ca							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 12	2005	330	7487					346	346		10.1136/bmj.330.7487.346	http://dx.doi.org/10.1136/bmj.330.7487.346			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897OZ	15705692	Green Published, Bronze			2022-12-28	WOS:000227015800026
J	Goossens, H; Ferech, M; Stichele, RV; Elseviers, M				Goossens, H; Ferech, M; Stichele, RV; Elseviers, M		ESAC Project Grp	Outpatient antibiotic use in Europe and association with resistance: a cross-national database study.	LANCET			English	Article							STREPTOCOCCUS-PNEUMONIAE; ANTIMICROBIAL CONSUMPTION; ESCHERICHIA-COLI; TRENDS	Background Resistance to antibiotics is a major public-health problem and antibiotic use is being increasingly recognised as the main selective pressure driving this resistance. Our aim was to assess outpatient use of antibiotics and the association with resistance. Methods We, investigated outpatient antibiotic use in 26 countries in Europe that provided. internationally M comparable distribution or reimbursement data, between Jan 1, 1997, and Dec 31, 2002; by calculating the number R of defined daily doses (DDD) per 1000 inhabitants per day, according to WHO anatomic therapeutic chemical M classification and DDD measurement methodology. We assessed the ecological association between antibiotic use and antibiotic resistance rates using Spearman's correlation coefficients. Findings Prescription of antibiotics in primary care in Europe varied greatly; the highest rate was in France (32.2 DDD per 1000 inhabitants daily) and the lowest was in the Netherlands (10.0 DDD per 1000 inhabitants daily). We noted a shift from the old narrow-spectrum antibiotics to the new broad-spectrum antibiotics. We also recorded striking seasonal fluctuations with heightened winter peaks in countries with high yearly use of antibiotics. We showed higher rates of antibiotic resistance in high consuming countries, probably related, to the higher consumption in southern and eastern Europe than in northern Europe. Interpretation These data might provide a useful method for assessing public-health strategies that aim to reduce antibiotic use and resistance levels.	Univ Antwerp, Dept Microbiol, ESAC Management Team, B-2610 Antwerp, Belgium; Leiden Univ, Med Ctr, Dept Med Microbiol, NL-2300 RA Leiden, Netherlands	University of Antwerp; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Goossens, H (corresponding author), Univ Antwerp, Dept Microbiol, ESAC Management Team, B-2610 Antwerp, Belgium.	Herman.Goossens@uza.be	Stichele, Robert Vander/K-7203-2015	Stichele, Robert Vander/0000-0001-9118-9651; Elseviers, Monique/0000-0001-9415-6900				Albrich WC, 2004, EMERG INFECT DIS, V10, P514, DOI 10.3201/eid1003.030252; Austin DJ, 1999, P NATL ACAD SCI USA, V96, P1152, DOI 10.1073/pnas.96.3.1152; Bergman M, 2004, CLIN INFECT DIS, V38, P1251, DOI 10.1086/383309; BRONZWAER S, 2003, THESIS RIJKSUNIVERSI; Bronzwaer SL, 2000, EMERG INFECT DIS, V3, P278; Cars O, 2001, LANCET, V357, P1851, DOI 10.1016/S0140-6736(00)04972-2; Chow KM, 2003, ARCH INTERN MED, V163, P1617, DOI 10.1001/archinte.163.13.1617-a; *DAN VET LAB, 2001, DANMAP 2000 CONS ANT; De Laat E., 2002, DOES PHARM MARKETING; DESCHEPPER R, 2002, PATIENT EDUC COUNS, V1590, P1; Enne VI, 2001, LANCET, V357, P1325, DOI 10.1016/S0140-6736(00)04519-0; Garcia-Rey C, 2004, J ANTIMICROB CHEMOTH, V54, P465, DOI 10.1093/jac/dkh375; GARCIAREY C, IMPORTANCE LOCAL VAR; Goossens H, 1998, BRIT MED J, V317, P654, DOI 10.1136/bmj.317.7159.654; GOOSSENS H, 2003, CORRELATION MACROLID, P111; Guillemot D, 1998, J INFECT DIS, V177, P492, DOI 10.1086/517384; Ho PL, 2001, J ANTIMICROB CHEMOTH, V48, P659, DOI 10.1093/jac/48.5.659; Hooper DC, 2002, LANCET INFECT DIS, V2, P530, DOI 10.1016/S1473-3099(02)00369-9; Hutchinson JM, 2001, CAN FAM PHYSICIAN, V47, P1217; Kahlmeter G, 2003, J ANTIMICROB CHEMOTH, V52, P1005, DOI 10.1093/jac/dkg488; Kahlmeter G, 2003, J ANTIMICROB CHEMOTH, V51, P69, DOI 10.1093/jac/dkg028; McCormick AW, 2003, NAT MED, V9, P424, DOI 10.1038/nm839; Monnet DL, 2004, J ANTIMICROB CHEMOTH, V53, P1109, DOI 10.1093/jac/dkh230; Nasrin D, 2002, BRIT MED J, V324, P28, DOI 10.1136/bmj.324.7328.28; Orero A, 1997, MED CLIN-BARCELONA, V109, P782; Price DB, 2004, RESP MED, V98, P17, DOI 10.1016/j.rmed.2003.08.011; Rovers MM, 2004, LANCET, V363, P465, DOI 10.1016/S0140-6736(04)15495-0; Van Zuijlen DA, 2001, PEDIATR INFECT DIS J, V20, P140, DOI 10.1097/00006454-200102000-00004; Vander Stichele RH, 2004, BRIT J CLIN PHARMACO, V58, P419, DOI 10.1111/j.1365-2125.2004.02164.x; World Health Organization (WHO), 2004, AN THER CHEM CLASS S; WORLD HEALTH ORGANIZATION (WHO) REGIONAL OFFICE FOR EUROPE, 2003, EUR HLTH ALL DAT	31	2089	2157	12	284	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	2005	365	9459					579	587		10.1016/S0140-6736(05)17907-0	http://dx.doi.org/10.1016/S0140-6736(05)17907-0			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DN	15708101				2022-12-28	WOS:000226984300030
J	Remuzzi, G; Weening, JJ				Remuzzi, G; Weening, JJ			Albuminuria as early test for vascular disease	LANCET			English	Editorial Material							STAGE RENAL-DISEASE		Mario Negri Inst Pharmacol Res, Lab Negri Bergamo, Bergamo, Italy; Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Weening, JJ (corresponding author), Mario Negri Inst Pharmacol Res, Lab Negri Bergamo, Bergamo, Italy.	j.j.weening@amc.uva.nl	Remuzzi, Giuseppe/V-9766-2017	Remuzzi, Giuseppe/0000-0002-6194-3446				Barsoum RS, 2002, ARTIF ORGANS, V26, P737, DOI 10.1046/j.1525-1594.2002.07061.x; Brenner Barry M, 2003, Kidney Int Suppl, pS77; Brenner BM, 2003, KIDNEY INT, V64, P370, DOI 10.1046/j.1523-1755.2003.t01-2-00052.x; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Hillege HL, 2002, CIRCULATION, V106, P1777, DOI 10.1161/01.CIR.0000031732.78052.81; Lysaght MJ, 2002, J AM SOC NEPHROL, V13, pS37; Moeller S, 2002, NEPHROL DIAL TRANSPL, V17, P2071, DOI 10.1093/ndt/17.12.2071; Ruggenenti P, 2004, NEW ENGL J MED, V351, P1941, DOI 10.1056/NEJMoa042167; Ruggenenti P, 1997, LANCET, V349, P1857; Verhave JC, 2004, KIDNEY INT, V66, pS18, DOI 10.1111/j.1523-1755.2004.09205.x; Wild SH, 2004, DIABETES CARE, V27, P2569, DOI 10.2337/diacare.27.10.2569-a; Xue JL, 2001, J AM SOC NEPHROL, V12, P2753, DOI 10.1681/ASN.V12122753	12	38	46	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	2005	365	9459					556	557						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DN	15708086				2022-12-28	WOS:000226984300009
J	Sustar, A; Schubiger, G				Sustar, A; Schubiger, G			A transient cell cycle shift in Drosophila imaginal disc cells precedes multipotency	CELL			English	Article							ADULT STEM-CELLS; ECTOPIC EXPRESSION; CLONAL ANALYSIS; WING FORMATION; LEG DISKS; MELANOGASTER; GENE; TRANSDETERMINATION; REGENERATION; GROWTH	When Drosophila imaginal discs regenerate, specific groups of cells can switch disc identity so that, for example, cells determined for leg identity switch to wing. Such switches in cell determination are known as transdetermination. We have developed a system by which individual cells are marked and monitored in vivo as they transdetermine so that their proliferation, cell sizes, and differentiation are accurately traced. Here, we document that when cells transdetermine, they do not convert to a younger cell cycle. Instead, cell cycle changes precede transdetermination and are different from those observed at any time in normal development. We propose that it is not a younger but a unique cell cycle progression and a big cell size that conditions the cells for developmental plasticity.	Univ Washington, Dept Biol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Schubiger, G (corresponding author), Univ Washington, Dept Biol, Seattle, WA 98195 USA.	gerold@u.washington.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058282] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58282] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashburner M., 1989, DROSOPHILA LAB HDB M; Avots A, 2002, IMMUNOL REV, V187, P9, DOI 10.1034/j.1600-065X.2002.18702.x; Britton JS, 1998, DEVELOPMENT, V125, P2149; Brumby AM, 2002, EMBO J, V21, P3377, DOI 10.1093/emboj/cdf334; BRYANT PJ, 1975, J EXP ZOOL, V193, P49, DOI 10.1002/jez.1401930106; del Alamo D, 2002, DEVELOPMENT, V129, P1975; EDGAR BA, 1986, CELL, V44, P365, DOI 10.1016/0092-8674(86)90771-3; Edgar Bruce A., 2004, VVolume 42, P23; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; GEHRING W, 1968, J EMBRYOL EXP MORPH, V20, P307; GEHRING W, 1967, DEV BIOL, V16, P438, DOI 10.1016/0012-1606(67)90058-9; GEHRING W, 1966, J EMBRYOL EXP MORPH, V15, P77; Gehring W., 1972, BIOL IMAGINAL DISKS, P35; GIRTON JR, 1980, DEV BIOL, V77, P1, DOI 10.1016/0012-1606(80)90453-4; GRAVES BJ, 1982, DEV BIOL, V93, P104, DOI 10.1016/0012-1606(82)90243-3; HADORN E, 1970, P NATL ACAD SCI USA, V65, P633, DOI 10.1073/pnas.65.3.633; HADORN E, 1978, GENET BIOL DROSOPHIL, P555; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; JAN YN, 1985, J NEUROSCI, V5, P2453; Johnston LA, 1996, DEVELOPMENT, V122, P3519; Johnston LA, 2003, NAT CELL BIOL, V5, P827, DOI 10.1038/ncb1041; KIEHLE CP, 1985, DEV BIOL, V109, P336, DOI 10.1016/0012-1606(85)90460-9; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; LOOSLI R, 1959, DEV BIOL, V1, P24, DOI 10.1016/0012-1606(59)90040-5; Maves L, 1998, DEVELOPMENT, V125, P115; Maves L, 2003, CURR OPIN GENET DEV, V13, P472, DOI 10.1016/j.gde.2003.08.006; MAVES L, 1995, DEVELOPMENT, V121, P1263; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; MINDEK G, 1968, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V161, P249, DOI 10.1007/BF00573805; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Okubo Tadashi, 2004, J Biol, V3, P11, DOI 10.1186/jbiol3; Oldham S, 2002, DEVELOPMENT, V129, P4103; Popperl H, 2000, MOL CELL, V6, P255, DOI 10.1016/S1097-2765(00)00027-7; Priller J, 2001, J CELL BIOL, V155, P733, DOI 10.1083/jcb.200105103; Quesenberry PJ, 2002, BLOOD, V100, P4266, DOI 10.1182/blood-2002-04-1246; Raff M, 2003, ANNU REV CELL DEV BI, V19, P1, DOI 10.1146/annurev.cellbio.19.111301.143037; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SCHUBIGE.G, 1973, EXPERIENTIA, V29, P631, DOI 10.1007/BF01926712; Schubiger G., 1968, Wilhelm Roux Archiv fur Entwicklungsmechanik der Organismen, V160, P9, DOI 10.1007/BF00573645; SCHUBIGER G, 1971, DEV BIOL, V26, P277, DOI 10.1016/0012-1606(71)90127-8; Serrano N, 1997, CURR BIOL, V7, pR186, DOI 10.1016/S0960-9822(97)70085-X; Spemann H., 1938, EMBRYONIC DEV INDUCT; Tanaka EM, 2003, CURR OPIN GENET DEV, V13, P497, DOI 10.1016/j.gde.2003.08.003; TOBLER H, 1966, J EMBRYOL EXP MORPH, V16, P609; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; Voncken JW, 1999, J CELL SCI, V112, P4627; Wagers AJ, 2004, CELL, V116, P639, DOI 10.1016/S0092-8674(04)00208-9; WILDERMU.H, 1968, DEV BIOL, V18, P1, DOI 10.1016/0012-1606(68)90019-5; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0	51	57	60	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 11	2005	120	3					383	393		10.1016/j.cell.2004.12.008	http://dx.doi.org/10.1016/j.cell.2004.12.008			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	897TS	15707896	Bronze			2022-12-28	WOS:000227028900013
J	Teuten, EL; Xu, L; Reddy, CM				Teuten, EL; Xu, L; Reddy, CM			Two abundant bioaccumulated halogenated compounds are natural products	SCIENCE			English	Article							POLYBROMINATED DIPHENYL ETHERS; SPONGE DYSIDEA-HERBACEA; MARINE SPONGE; RADIOCARBON; DERIVATIVES; CONGENERS	Methoxylated polybrominated diphenyl ethers (MeO-PBDEs) have been found bioaccumulated in the tissues of a variety of aquatic animals and at concentrations comparable to those of anthropogenic halogenated organic compounds, including polychlorinated biphenyls (PCBs). The origin of the MeO-PBDEs has been uncertain; circumstantial evidence supports a natural and/or an industrial source. By analyzing the natural abundance radiocarbon content of two MeO-PBDEs isolated from a True's beaked whale (Mesoplodon mirus), we show that these compounds were naturally produced.	Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA	Woods Hole Oceanographic Institution	Reddy, CM (corresponding author), Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA.	creddy@whoi.edu		Reddy, Christopher/0000-0002-7814-2071				Anjaneyulu V, 1996, INDIAN J CHEM B, V35, P89; CAPON R, 1981, J CHEM SOC PERK T 1, P2464, DOI 10.1039/p19810002464; CARTE B, 1981, TETRAHEDRON, V37, P2335, DOI 10.1016/S0040-4020(01)88886-4; Eriksson J, 2004, ENVIRON SCI TECHNOL, V38, P3119, DOI 10.1021/es049830t; FU XO, 1995, J NAT PROD, V58, P1384, DOI 10.1021/np50123a008; Haglund PS, 1997, ENVIRON SCI TECHNOL, V31, P3281, DOI 10.1021/es9702834; Hakk H, 2003, ENVIRON INT, V29, P801, DOI 10.1016/S0160-4120(03)00109-0; Handayani D, 1997, J NAT PROD, V60, P1313, DOI 10.1021/np970271w; HIGA T, 1977, MARINE NATURAL PRODU, P35; Hundt K, 2000, APPL ENVIRON MICROB, V66, P4157, DOI 10.1128/AEM.66.9.4157-4160.2000; Kierkegaard A, 1999, ENVIRON SCI TECHNOL, V33, P1612, DOI 10.1021/es9807082; Kierkegaard A, 2004, ENVIRON POLLUT, V130, P187, DOI 10.1016/j.envpol.2003.12.011; KUNIYOSHI M, 1985, EXPERIENTIA, V41, P523, DOI 10.1007/BF01966182; LETCHER RJ, 2003, ORGANOHALOGEN COMPD, V61, P29; Liu HW, 2004, J NAT PROD, V67, P472, DOI 10.1021/np0304621; Mead J.G., 1989, P349; MEIRONYTE D, 2003, J TOXICOL ENV HLTH, V58, P329; Nydal R, 2000, RADIOCARBON, V42, P81; PEARSON A, 2000, THESIS WOODS HOLE OC; Reddy CM, 2004, ENVIRON SCI TECHNOL, V38, P1992, DOI 10.1021/es030568i; Reddy CM, 2002, ENVIRON POLLUT, V120, P163, DOI 10.1016/S0269-7491(02)00162-8; SCHMIDT S, 1992, APPL ENVIRON MICROB, V58, P2744, DOI 10.1128/AEM.58.9.2744-2750.1992; Stapleton HM, 2004, ENVIRON SCI TECHNOL, V38, P1054, DOI 10.1021/es0348804; Stegeman JJ, 1993, AQUATIC TOXICOLOGY M, P87; Stringer R, 2001, CHLORINE ENV OVERVIE; UNSON MD, 1994, MAR BIOL, V119, P1, DOI 10.1007/BF00350100; Utkina NK, 2002, J NAT PROD, V65, P1213, DOI 10.1021/np0106438; Vetter W, 2002, ENVIRON TOXICOL CHEM, V21, P2014, DOI 10.1897/1551-5028(2002)021<2014:SHNPFA>2.0.CO;2; Vetter W, 2001, ARCH ENVIRON CON TOX, V41, P221; *VIRG MAR SCI MUS, 2003, NECR EX REP	30	278	293	3	116	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	2005	307	5711					917	920		10.1126/science.1106882	http://dx.doi.org/10.1126/science.1106882			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897DV	15705850				2022-12-28	WOS:000226985100051
J	Snyder, SH				Snyder, SH			Julius Axelrod (1912-2004) - Obituary	NATURE			English	Biographical-Item									Johns Hopkins Med Sch, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	Snyder, SH (corresponding author), Johns Hopkins Med Sch, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.	ssnyder@bs.jhmi.edu							0	3	3	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 10	2005	433	7026					593	593		10.1038/433593a	http://dx.doi.org/10.1038/433593a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	895KX	15703735				2022-12-28	WOS:000226862000030
J	Hayek, E; Gring, CN; Griffin, BP				Hayek, E; Gring, CN; Griffin, BP			Mitral valve prolapse	LANCET			English	Review							LEFT-VENTRICULAR FUNCTION; ATRIAL SEPTAL-DEFECT; CEREBRAL ISCHEMIC EVENTS; EHLERS-DANLOS-SYNDROME; MULTIPLANE TRANSESOPHAGEAL ECHOCARDIOGRAPHY; AMERICAN-HEART-ASSOCIATION; CORONARY-ARTERY-DISEASE; TERM FOLLOW-UP; SUDDEN-DEATH; INFECTIVE ENDOCARDITIS	Mitral valve prolapse is a common valvular abnormality that is the most common cause of severe non-ischaemic mitral regurgitation in the USA. The overall prognosis of patients with mitral valve prolapse is excellent, but a small subset will develop serious complications, including infective endocarditis, sudden cardiac death, and severe mitral regurgitation. We present a comprehensive review of mitral valve prolapse, examining normal mitral anatomy, the clinical and echocardiographic: features of mitral valve prolapse, and the pathophysiology and genetics of the disorder. We discuss the contemporary management of both asymptomatic and symptomatic prolapse, with particular attention to the timing and technique of surgical repair. We conclude that echocardiography is the method of choice for diagnosing mitral valve prolapse, that clinical and echocardiographic features can predict which patients with prolapse are at highest risk for complications, and that mitral valve repair is the treatment of choice for symptomatic prolapse.	Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Akron Gen Hosp, Akron, OH USA	Cleveland Clinic Foundation	Griffin, BP (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA.	griffib@ccf.org						AGOZZINO L, 1992, INT J CARDIOL, V37, P79, DOI 10.1016/0167-5273(92)90135-P; Agricola E, 2004, HEART, V90, P406, DOI 10.1136/hrt.2002.009621; Agricola E, 2003, J AM SOC ECHOCARDIOG, V16, P61, DOI 10.1067/mje.2003.23; Akhtar S, 1999, CARDIOVASC PATHOL, V8, P191, DOI 10.1016/S1054-8807(99)00004-6; AKINS CW, 1994, ANN THORAC SURG, V58, P668, DOI 10.1016/0003-4975(94)90725-0; ANWAR A, 1991, AM J MED SCI, V302, P89, DOI 10.1097/00000441-199108000-00004; AROCHA F, 1985, AM J HEMATOL, V19, P21, DOI 10.1002/ajh.2830190104; Avierinos JF, 2003, STROKE, V34, P1339, DOI 10.1161/01.STR.0000072274.12041.FF; Avierinos JF, 2002, CIRCULATION, V106, P1355, DOI 10.1161/01.CIR.0000028933.34260.09; BALLESTER M, 1983, EUR HEART J, V4, P472, DOI 10.1093/oxfordjournals.eurheartj.a061504; Barber JE, 2001, J THORAC CARDIOV SUR, V122, P955, DOI 10.1067/mtc.2001.117621; Barber JE, 2001, J HEART VALVE DIS, V10, P320; BARLOW JB, 1966, AM HEART J, V71, P166, DOI 10.1016/0002-8703(66)90179-7; BARNETT HJM, 1980, NEW ENGL J MED, V302, P139, DOI 10.1056/NEJM198001173020303; Bonow R O, 1998, J Heart Valve Dis, V7, P672; Bonow RO, 1998, J AM COLL CARDIOL, V32, P1486, DOI 10.1016/S0735-1097(98)00454-9; BRAUNBERGER E, 2001, CIRCULATION S1, V104, P8; CARPENTIER A, 1983, J THORAC CARDIOV SUR, V86, P323; Cheitlin MD, 2003, J AM COLL CARDIOL, V42, P954, DOI 10.1016/S0735-1097(03)01065-9; CHESLER E, 1983, CIRCULATION, V67, P632, DOI 10.1161/01.CIR.67.3.632; CHESLER E, 1985, AM J MED, V78, P754, DOI 10.1016/0002-9343(85)90279-7; Chou HT, 2004, INT J CARDIOL, V95, P299, DOI 10.1016/j.ijcard.2003.05.026; Ciancamerla F, 2003, J CARDIOVASC SURG, V44, P283; CLEMENS JD, 1982, NEW ENGL J MED, V307, P776, DOI 10.1056/NEJM198209233071302; COHN LH, 1994, J THORAC CARDIOV SUR, V107, P143; CRILEY JM, 1966, BRIT HEART J, V28, P488; Dajani AS, 1997, J AM DENT ASSOC, V128, P1142, DOI 10.14219/jada.archive.1997.0375; David TE, 1998, J THORAC CARDIOV SUR, V115, P1279, DOI 10.1016/S0022-5223(98)70210-7; David TE, 2003, J THORAC CARDIOV SUR, V125, P1143, DOI 10.1067/mtc.2003.406; DAVIDSEN B, 1989, J INTERN MED, V226, P433, DOI 10.1111/j.1365-2796.1989.tb01420.x; DAVIES MJ, 1978, BRIT HEART J, V40, P468; DEVEREUX R B, 1986, Journal of the American College of Cardiology, V8, P763; DEVEREUX RB, 1994, AM J CARDIOL, V74, P1024, DOI 10.1016/0002-9149(94)90853-2; DEVEREUX RB, 1986, AM J MED, V81, P751, DOI 10.1016/0002-9343(86)90339-6; DEVEREUX RB, 1982, ANN INTERN MED, V97, P826, DOI 10.7326/0003-4819-97-6-826; Devlin William H., 1994, Comprehensive Therapy, V20, P569; Disse S, 1999, AM J HUM GENET, V65, P1242, DOI 10.1086/302624; Dolan AL, 1997, BRIT J RHEUMATOL, V36, P459; ENRIQUEZSARANO M, 1995, CIRCULATION, V91, P1022, DOI 10.1161/01.CIR.91.4.1022; ENRIQUEZSARANO M, 1994, J AM COLL CARDIOL, V24, P1536, DOI 10.1016/0735-1097(94)90151-1; FISHER M, 1983, NEUROLOGY, V33, P384, DOI 10.1212/WNL.33.3.384; Flack JM, 1999, AM HEART J, V138, P486, DOI 10.1016/S0002-8703(99)70151-1; Flemming MA, 2000, AM HEART J, V140, P476, DOI 10.1067/mhj.2000.108242; Fornes P, 1999, CARDIOVASC PATHOL, V8, P81, DOI 10.1016/S1054-8807(98)00021-0; Foster GP, 1998, ANN THORAC SURG, V65, P1025, DOI 10.1016/S0003-4975(98)00084-8; FRARY CJ, 1994, AM J CARDIOL, V73, P263, DOI 10.1016/0002-9149(94)90231-3; Freed LA, 1999, NEW ENGL J MED, V341, P1, DOI 10.1056/NEJM199907013410101; Freed LA, 2003, AM J HUM GENET, V72, P1551, DOI 10.1086/375452; Freed LA, 2002, J AM COLL CARDIOL, V40, P1298, DOI 10.1016/S0735-1097(02)02161-7; FUKUDA N, 1995, AM J CARDIOL, V76, P503, DOI 10.1016/S0002-9149(99)80139-8; GAFFNEY FA, 1979, CIRCULATION, V59, P894, DOI 10.1161/01.CIR.59.5.894; GAFFNEY FA, 1983, AM J CARDIOL, V52, P316; Gillinov AM, 1998, J THORAC CARDIOV SUR, V116, P734, DOI 10.1016/S0022-5223(98)00450-4; Gillinov AM, 1999, ANN THORAC SURG, V68, P820, DOI 10.1016/S0003-4975(99)00805-X; Gillinov AM, 1999, ANN THORAC SURG, V68, P2356, DOI 10.1016/S0003-4975(99)01157-1; Gillinov AM, 2000, ANN THORAC SURG, V69, P717, DOI 10.1016/S0003-4975(99)01543-X; Gilon D, 1999, NEW ENGL J MED, V341, P8, DOI 10.1056/NEJM199907013410102; GLESBY MJ, 1989, JAMA-J AM MED ASSOC, V262, P523, DOI 10.1001/jama.262.4.523; Grande-Allen KJ, 2001, J HEART VALVE DIS, V10, P325; Grayburn PA, 2000, AM J MED SCI, V320, P202, DOI 10.1097/00000441-200009000-00012; GREENSPAN M, 1980, CHEST, V77, P47, DOI 10.1378/chest.77.1.47; Grigioni F, 1999, J AM COLL CARDIOL, V34, P2078, DOI 10.1016/S0735-1097(99)00474-X; GUTHRIE RB, 1976, MINN MED, V59, P637; HENNEY AM, 1989, BRIT HEART J, V61, P292; HIRATA K, 1992, AM HEART J, V123, P743, DOI 10.1016/0002-8703(92)90515-W; Host U, 1997, AM J CARDIOL, V80, P655, DOI 10.1016/S0002-9149(97)00445-1; JAFFE AS, 1981, CIRCULATION, V64, P121, DOI 10.1161/01.CIR.64.1.121; KAMBE T, 1981, JPN CIRC J, V45, P260, DOI 10.1253/jcj.45.260; KING BD, 1982, CIRCULATION, V66, P288, DOI 10.1161/01.CIR.66.2.288; Kizilbash AM, 1998, J AM COLL CARDIOL, V32, P427, DOI 10.1016/S0735-1097(98)00236-8; KLIGFIELD P, 1985, AM J CARDIOL, V55, P1545, DOI 10.1016/0002-9149(85)90970-1; KLIGFIELD P, 1987, AM HEART J, V113, P1298, DOI 10.1016/0002-8703(87)90958-6; KOLIBASH AJ, 1986, AM J CARDIOL, V58, P762, DOI 10.1016/0002-9149(86)90352-8; KOSTUK WJ, 1977, LANCET, V2, P313; KRAMER HM, 1984, ARCH INTERN MED, V144, P2360, DOI 10.1001/archinte.144.12.2360; Kulan K, 1996, INT J CARDIOL, V54, P251, DOI 10.1016/0167-5273(96)02609-5; LAX D, 1992, AM HEART J, V124, P1533, DOI 10.1016/0002-8703(92)90068-7; LEBWOHL MG, 1982, NEW ENGL J MED, V307, P228, DOI 10.1056/NEJM198207223070406; LEIER CV, 1980, ANN INTERN MED, V92, P171, DOI 10.7326/0003-4819-92-2-171; LENDERS JWM, 1986, CLIN CARDIOL, V9, P177, DOI 10.1002/clc.4960090502; Leung DY, 1996, J AM COLL CARDIOL, V28, P1198, DOI 10.1016/S0735-1097(96)00281-1; Leung DY, 1997, AM HEART J, V134, P1052, DOI 10.1016/S0002-8703(97)70025-5; LEVINE RA, 1989, CIRCULATION, V80, P589, DOI 10.1161/01.CIR.80.3.589; LEVINE RA, 1988, J AM COLL CARDIOL, V11, P1010, DOI 10.1016/S0735-1097(98)90059-6; LEVINE RA, 1987, CIRCULATION, V75, P756, DOI 10.1161/01.CIR.75.4.756; LEVY D, 1987, AM HEART J, V113, P1281, DOI 10.1016/0002-8703(87)90956-2; LIMA SD, 1985, AM J CARDIOL, V55, P739, DOI 10.1016/0002-9149(85)90148-1; LIN SL, 1989, CAN J CARDIOL, V5, P84; Ling LH, 1996, NEW ENGL J MED, V335, P1417, DOI 10.1056/NEJM199611073351902; Ling LH, 1997, CIRCULATION, V96, P1819, DOI 10.1161/01.CIR.96.6.1819; MACMAHON SW, 1987, AM HEART J, V113, P1291, DOI 10.1016/0002-8703(87)90957-4; MACMAHON SW, 1987, AM J CARDIOL, V59, P105, DOI 10.1016/S0002-9149(87)80080-2; MARKS AR, 1989, NEW ENGL J MED, V320, P1031, DOI 10.1056/NEJM198904203201602; MartinezRubio A, 1997, CIRCULATION, V96, P500; Martini F, 1996, THROMB RES, V83, P299, DOI 10.1016/0049-3848(96)00138-7; Matsumura T, 2003, J AM COLL CARDIOL, V42, P458, DOI 10.1016/S0735-1097(03)00649-1; MILLS P, 1977, NEW ENGL J MED, V297, P13, DOI 10.1056/NEJM197707072970103; Mills WR, 2002, AM J CARDIOL, V89, P1394, DOI 10.1016/S0002-9149(02)02352-4; MOHTY D, 2001, CIRCULATION S1, V104, P1, DOI 10.1161/hc37t1.094903; Nascimento R, 1997, AM J CARDIOL, V79, P226, DOI 10.1016/S0002-9149(96)00722-9; Nasuti JF, 2004, ANN THORAC SURG, V77, P532, DOI 10.1016/S0003-4975(03)01584-4; NISHIMURA RA, 1985, NEW ENGL J MED, V313, P1305, DOI 10.1056/NEJM198511213132101; OLSEN EGJ, 1980, BRIT HEART J, V44, P674; OLSON LJ, 1987, MAYO CLIN PROC, V62, P22, DOI 10.1016/S0025-6196(12)61522-5; Omran AS, 2002, J AM SOC ECHOCARDIOG, V15, P950, DOI 10.1067/mje.2002.121534; ORENCIA AJ, 1995, STROKE, V26, P7, DOI 10.1161/01.STR.26.1.7; Otto CM, 2003, HEART, V89, P100, DOI 10.1136/heart.89.1.100; Ozkan M, 2000, AM J CARDIOL, V85, P516, DOI 10.1016/S0002-9149(99)00786-9; PASTERNAC A, 1982, AM J MED, V73, P783, DOI 10.1016/0002-9343(82)90758-6; Pellerin D, 2003, HEART, V89, P9; Perry GJ, 2002, J AM COLL CARDIOL, V39, P1374, DOI 10.1016/S0735-1097(02)01763-1; PETTY GW, 1994, MAYO CLIN PROC, V69, P632, DOI 10.1016/S0025-6196(12)61338-X; Phillips MR, 2000, ANN THORAC SURG, V69, P25, DOI 10.1016/S0003-4975(99)01313-2; POCOCK WA, 1984, AM HEART J, V107, P378, DOI 10.1016/0002-8703(84)90389-2; PRATT CM, 1989, CHEST, V95, P139, DOI 10.1378/chest.95.1.139; PYERITZ RE, 1979, NEW ENGL J MED, V300, P772, DOI 10.1056/NEJM197904053001406; Rabkin E, 2001, CIRCULATION, V104, P2525, DOI 10.1161/hc4601.099489; SANDOK BA, 1982, STROKE, V13, P448, DOI 10.1161/01.STR.13.4.448; SAVAGE DD, 1983, AM HEART J, V106, P577, DOI 10.1016/0002-8703(83)90705-6; SAVAGE DD, 1983, AM HEART J, V106, P582, DOI 10.1016/0002-8703(83)90706-8; SCHARF RE, 1982, STROKE, V13, P454, DOI 10.1161/01.STR.13.4.454; SCHREIBER TL, 1980, CIRCULATION, V61, P888, DOI 10.1161/01.CIR.61.5.888; SHAPPELL SD, 1973, CIRCULATION, V48, P1128, DOI 10.1161/01.CIR.48.5.1128; Singh RG, 2000, AM J CARDIOL, V85, P193, DOI 10.1016/S0002-9149(99)00645-1; Smedira NG, 1996, J THORAC CARDIOV SUR, V112, P287, DOI 10.1016/S0022-5223(96)70251-9; STECKELBERG JM, 1993, INFECT DIS CLIN N AM, V7, P9; STEWART WJ, 1994, J AM COLL CARDIOL, V24, P1544, DOI 10.1016/0735-1097(94)90152-X; STEWART WJ, 1992, J AM COLL CARDIOL, V20, P1353, DOI 10.1016/0735-1097(92)90248-L; STODDARD MF, 1995, J AM COLL CARDIOL, V25, P693, DOI 10.1016/0735-1097(94)00408-I; STRAHAN NV, 1983, AM J MED, V74, P967, DOI 10.1016/0002-9343(83)90791-X; Suchon E, 2004, ACTA CARDIOL, V59, P237; Szombathy T, 2000, AM HEART J, V139, P101, DOI 10.1016/S0002-8703(00)90315-6; TAMURA K, 1995, AM HEART J, V129, P1149, DOI 10.1016/0002-8703(95)90397-6; Tentolouris C, 1995, EUR HEART J, V16, P1960, DOI 10.1093/oxfordjournals.eurheartj.a060854; TIELEMAN RG, 1995, BRIT HEART J, V73, P37; Tischler MD, 1998, AM J CARDIOL, V82, P242, DOI 10.1016/S0002-9149(98)00325-7; Totaro P, 1999, EUR J CARDIO-THORAC, V15, P119, DOI 10.1016/S1010-7940(98)00304-2; Tse HF, 1997, J AM COLL CARDIOL, V30, P1813, DOI 10.1016/S0735-1097(97)00380-X; Ulgen MS, 1999, JPN CIRC J, V63, P929, DOI 10.1253/jcj.63.929; WALLER BF, 1982, AM HEART J, V104, P276, DOI 10.1016/0002-8703(82)90204-6; WALSH PN, 1981, CIRCULATION, V63, P552, DOI 10.1161/01.CIR.63.3.552; WARTH DC, 1985, J AM COLL CARDIOL, V5, P1173, DOI 10.1016/S0735-1097(85)80021-8; WEIS AJ, 1995, AM HEART J, V129, P314, DOI 10.1016/0002-8703(95)90014-4; WEISS AN, 1975, CIRCULATION, V52, P1091, DOI 10.1161/01.CIR.52.6.1091; WILCKEN DEL, 1988, CIRCULATION, V78, P10, DOI 10.1161/01.CIR.78.1.10; Wisenbaugh T, 2003, J AM COLL CARDIOL, V42, P464, DOI 10.1016/S0735-1097(03)00651-X; WORDSWORTH P, 1989, BRIT HEART J, V61, P300; Wu TC, 1999, JPN HEART J, V40, P571, DOI 10.1536/jhj.40.571; Zuppiroli A, 1998, AM J CARDIOL, V82, P823, DOI 10.1016/S0002-9149(98)00454-8; ZUPPIROLI A, 1995, AM J CARDIOL, V75, P1028, DOI 10.1016/S0002-9149(99)80718-8	150	193	207	1	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 5	2005	365	9458					507	518						12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894SS	15705461				2022-12-28	WOS:000226812500029
J	Honkala, K; Hellman, A; Remediakis, IN; Logadottir, A; Carlsson, A; Dahl, S; Christensen, CH; Norskov, JK				Honkala, K; Hellman, A; Remediakis, IN; Logadottir, A; Carlsson, A; Dahl, S; Christensen, CH; Norskov, JK			Ammonia synthesis from first-principles calculations	SCIENCE			English	Article							RUTHENIUM CATALYSTS; IRON; ADSORPTION; POTASSIUM; NITROGEN; SURFACES; RU(0001); STEPS	The rate of ammonia synthesis over a nanoparticle ruthenium catalyst can be calculated directly on the basis of a quantum chemical treatment of the problem using density functional theory. We compared the results to measured rates over a ruthenium catalyst supported on magnesium aluminum spinet. When the size distribution of ruthenium particles measured by transmission electron microscopy was used as the [ink between the catalyst material and the theoretical treatment, the calculated rate was within a factor of 3 to 20 of the experimental rate. This offers hope for computer-based methods in the search for catalysts.	Tech Univ Denmark, Ctr Atom Scale Mat Phys, DK-2800 Lyngby, Denmark; Tech Univ Denmark, Dept Phys, DK-2800 Lyngby, Denmark; Tech Univ Denmark, Dept Chem, DK-2800 Lyngby, Denmark; Haldor Topsoe Res Labs, DK-2800 Lyngby, Denmark	Technical University of Denmark; Technical University of Denmark; Technical University of Denmark; Haldor Topsoe	Norskov, JK (corresponding author), Tech Univ Denmark, Ctr Atom Scale Mat Phys, DK-2800 Lyngby, Denmark.	norskov@fysik.dtu.dk	Dahl, Søren/A-4898-2011; Honkala, Karoliina/F-9305-2014; Carlsson, Anna/M-9708-2018; Norskov, Jens K/D-2539-2017; Hellman, Anders/A-4591-2016; Remediakis, Ioannis N/B-6423-2008	Carlsson, Anna/0000-0002-8554-0895; Norskov, Jens K/0000-0002-4427-7728; Hellman, Anders/0000-0002-1821-159X; Remediakis, Ioannis N/0000-0002-1049-4775; Honkala, Karoliina/0000-0002-3166-1077				Bligaard T, 2003, J PHYS CHEM B, V107, P9325, DOI 10.1021/jp034447g; Bosch C., 1966, NOBEL LECT CHEM 1922; BOSZO F, 1977, J CATAL, V49, P18; Boudart M, 1994, TOP CATAL, V1, P405, DOI 10.1007/BF01492292; BOWKER M, 1994, TOP CATAL, V1, P165; Dahl S, 2000, J CATAL, V192, P391, DOI 10.1006/jcat.2000.2857; Dahl S, 1999, PHYS REV LETT, V83, P1814, DOI 10.1103/PhysRevLett.83.1814; DUMESIC JA, 1989, J CATAL, V116, P119, DOI 10.1016/0021-9517(89)90080-8; Emmett PH, 1933, J AM CHEM SOC, V55, P1738, DOI 10.1021/ja01331a507; Emmett PH, 1934, J AM CHEM SOC, V56, P35, DOI 10.1021/ja01316a011; ERTL G, 1983, J VAC SCI TECHNOL A, V1, P1247, DOI 10.1116/1.572299; ERTL G, 1979, CHEM PHYS LETT, V60, P391, DOI 10.1016/0009-2614(79)80595-3; ERTL G, 1982, SURF SCI, V114, P527, DOI 10.1016/0039-6028(82)90702-6; Haber F., 1966, NOBEL LECT CHEM 1901; Hammer B, 1999, PHYS REV B, V59, P7413, DOI 10.1103/PhysRevB.59.7413; Jacobsen CJH, 2000, J MOL CATAL A-CHEM, V163, P19, DOI 10.1016/S1381-1169(00)00396-4; Linic S, 2003, J AM CHEM SOC, V125, P4034, DOI 10.1021/ja029076g; Logadottir A, 2003, J CATAL, V220, P273, DOI 10.1016/S0021-9517(03)00156-8; Logadottir A, 2001, J CATAL, V197, P229, DOI 10.1006/jcat.2000.3087; MITTASCH A, 1950, ADV CATAL, V2, P81, DOI 10.1016/S0360-0564(08)60375-2; PAAL Z, 1981, APPL SURF SCI, V8, P231, DOI 10.1016/0378-5963(81)90119-7; PERDEW JP, 1992, PHYS REV B, V46, P6671, DOI 10.1103/PhysRevB.46.6671; Reuter K, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.116105; SPENCER ND, 1982, J CATAL, V74, P129, DOI 10.1016/0021-9517(82)90016-1; STOLTZE P, 1985, PHYS REV LETT, V55, P2502, DOI 10.1103/PhysRevLett.55.2502; STRONGIN DR, 1987, J CATAL, V103, P213, DOI 10.1016/0021-9517(87)90109-6; STRONGIN DR, 1988, J CATAL, V109, P51, DOI 10.1016/0021-9517(88)90184-4	27	920	935	32	828	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2005	307	5709					555	558		10.1126/science.1106435	http://dx.doi.org/10.1126/science.1106435			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893BJ	15681379				2022-12-28	WOS:000226694000040
J	Sanchez, PA; Swaminathan, MS				Sanchez, PA; Swaminathan, MS			Hunger in Africa: the link between unhealthy people and unhealthy soils	LANCET			English	Article									Columbia Univ, Earth Inst, Palisades, NY 10964 USA; MS Swaminathan Res Fdn, Madras, Tamil Nadu, India	Columbia University	Sanchez, PA (corresponding author), Columbia Univ, Earth Inst, Lamont Doherty Campus,61 Route 9W,POB 1000,Lamont, Palisades, NY 10964 USA.	sanchez@iri.columbia.edu						[Anonymous], 2001, STAT FOOD INS WORLD; [Anonymous], 2003, CROP VARIETY IMPROVE; De Onis M., 2003, WHO GLOBAL DATABASE; KADIYALA S, 2003, 159 INT FOOD POL RES; PELLETIER DL, 1995, B WORLD HEALTH ORGAN, V73, P443; Sanchez PA, 2002, SCIENCE, V295, P2019, DOI 10.1126/science.1065256; SANCHEZ PA, IN PRESS SCIENCE; *UN, SECR GEN CALLS UN AF; *UN ACC SCN, 2000, 4 UN ACCSCN IFPRI; *UN MILL PROJ TASK, 2005, INV DEV PRACT GUID A; [No title captured]; [No title captured]	12	105	112	0	48	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN-FEB	2005	365	9457					442	444						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891WE	15680461				2022-12-28	WOS:000226610900033
J	Kump, L				Kump, L			Ocean science - Ironing out biosphere oxidation	SCIENCE			English	Editorial Material									Penn State Univ, Dept Geosci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Kump, L (corresponding author), Penn State Univ, Dept Geosci, University Pk, PA 16802 USA.	lkump@psu.edu	Kump, Lee/H-8287-2012					ARTHUR MA, 1994, ANNU REV EARTH PL SC, V22, P499, DOI 10.1146/annurev.ea.22.050194.002435; Beard BL, 1999, SCIENCE, V285, P1889, DOI 10.1126/science.285.5435.1889; BLUTH G, 1988, EOS, V69, P515; Canfield DE, 1998, NATURE, V396, P450, DOI 10.1038/24839; Dauphas N, 2004, SCIENCE, V306, P2077, DOI 10.1126/science.1104639; Holland HD., 1984, CHEM EVOLUTION ATMOS; Isley AE, 1999, J GEOPHYS RES-SOL EA, V104, P15461, DOI 10.1029/1999JB900066; Rankama K., 1954, ISOTOPE GEOLOGY; Rouxel OJ, 2005, SCIENCE, V307, P1088, DOI 10.1126/science.1105692; VALLEY GE, 1947, J AM CHEM SOC, V69, P1871, DOI 10.1021/ja01200a010	10	7	8	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	2005	307	5712					1058	1059		10.1126/science.1107482	http://dx.doi.org/10.1126/science.1107482			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ED	15718458				2022-12-28	WOS:000227197300033
J	Zhao, J; Goldman, AS; Hartwig, JF				Zhao, J; Goldman, AS; Hartwig, JF			Oxidative addition of ammonia to form a stable monomeric amido hydride complex	SCIENCE			English	Article							STRUCTURAL-CHARACTERIZATION; CARBENE COMPLEX; H ACTIVATION; REACTIVITY; CHEMISTRY; IRIDIUM; BONDS; THERMODYNAMICS; WATER; PCP	The insertion of an iridium complex into an N-H bond in ammonia leads to a stable monomeric amido hydride complex in solution at room temperature. This reaction advances the transition-metal. coordination chemistry of ammonia beyond its role for more than. a century as an ancillary ligand. The precursor for this insertion reaction is an iridium(I) olefin complex with an aliphatic ligand containing one carbon and two phosphorus donor atoms. Kinetic and isotopic labeling studies indicate that olefin dissociates to give a 14-electron iridium(I) fragment, which then reacts with ammonia. This cleavage of the N-H bond under neutral conditions provides a foundation on which to develop future mild catalytic transformations of ammonia, such as olefin hydroamination and arene oxidative amination.	Yale Univ, Dept Chem, New Haven, CT 06520 USA; Rutgers State Univ, Dept Chem, Piscataway, NJ 08854 USA	Yale University; Rutgers State University New Brunswick	Hartwig, JF (corresponding author), Yale Univ, Dept Chem, POB 208107, New Haven, CT 06520 USA.	John.Hartwig@yale.edu	Goldman, Alan/D-9521-2011	Goldman, Alan/0000-0002-2774-710X				ALSALEM NA, 1979, J CHEM SOC DALTON, P1972, DOI 10.1039/dt9790001972; BRYAN EG, 1977, J CHEM SOC DALTON, P1328, DOI 10.1039/dt9770001328; BRYNDZA HE, 1988, CHEM REV, V88, P1163, DOI 10.1021/cr00089a009; Campora J, 2004, ORGANOMETALLICS, V23, P5653, DOI 10.1021/om049312r; CASALNUOVO AL, 1987, INORG CHEM, V26, P971, DOI 10.1021/ic00254a001; Conner D, 2004, ORGANOMETALLICS, V23, P2724, DOI 10.1021/om049836r; CROCKER C, 1982, J CHEM SOC DALTON, P1217, DOI 10.1039/dt9820001217; EMPSALL HD, 1977, J CHEM SOC CHEM COMM, P589, DOI 10.1039/c39770000589; Fox DJ, 2004, ORGANOMETALLICS, V23, P1656, DOI 10.1021/om0499660; Fulton JR, 2002, J AM CHEM SOC, V124, P4722, DOI 10.1021/ja011876o; Fulton JR, 2002, ACCOUNTS CHEM RES, V35, P44, DOI 10.1021/ar000132x; HAGGIN J, 1993, CHEM ENG NEWS, V71, P23, DOI 10.1021/cen-v071n022.p023; HARTWIG JF, 1991, J AM CHEM SOC, V113, P3404, DOI 10.1021/ja00009a028; HILLHOUSE GL, 1984, J AM CHEM SOC, V106, P5472, DOI 10.1021/ja00331a015; Holland PL, 1997, J AM CHEM SOC, V119, P12800, DOI 10.1021/ja971829p; JOSLIN FL, 1991, ORGANOMETALLICS, V10, P2781, DOI 10.1021/om00054a048; Kanzelberger M, 2003, J AM CHEM SOC, V125, P13644, DOI 10.1021/ja037363u; Kanzelberger M, 2000, J AM CHEM SOC, V122, P11017, DOI 10.1021/ja001626s; Kaplan AW, 1998, J AM CHEM SOC, V120, P6828, DOI 10.1021/ja980632+; KAUFFMAN GB, 1994, ACS SYM SER, V565, P3; Krogh-Jespersen K, 2002, J AM CHEM SOC, V124, P10797, DOI 10.1021/ja010547t; MCLOUGHLIN MA, 1994, ORGANOMETALLICS, V13, P3816, DOI 10.1021/om00022a017; Mohammad HAY, 2002, ORGANOMETALLICS, V21, P5775, DOI 10.1021/om020621w; Morales-Morales D, 2001, ORGANOMETALLICS, V20, P1144, DOI 10.1021/om000940s; RIEHL JF, 1992, ORGANOMETALLICS, V11, P729, DOI 10.1021/om00038a035; Ruiz J, 1997, J CHEM SOC DALTON, P4271, DOI 10.1039/a704203e	26	329	330	2	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2005	307	5712					1080	1082		10.1126/science.1109389	http://dx.doi.org/10.1126/science.1109389			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ED	15718464				2022-12-28	WOS:000227197300039
J	Parmet, WE; Goodman, RA; Farber, A				Parmet, WE; Goodman, RA; Farber, A			Individual rights versus the public health - 100 years after Jacobson v. Massachusetts	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Northeastern Univ, Sch Law, Boston, MA 02115 USA; Ctr Dis Control & Prevent, Publ Hlth Law Program, Atlanta, GA USA; Harvard Univ, Sch Med, Dept Social Med, Boston, MA 02115 USA	Northeastern University; Centers for Disease Control & Prevention - USA; Harvard University; Harvard Medical School	Parmet, WE (corresponding author), Northeastern Univ, Sch Law, Boston, MA 02115 USA.							HAGGLUND SG, 1931, MY CHURCH ILLUSTRATE, V17, P160; 2002, BOSTON HERALD   0316, P10; 2002, BOSTON HERALD   0209, P1; 2002, CAMBRIDGE CHRON 0726, P4	4	29	29	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2005	352	7					652	654		10.1056/NEJMp048209	http://dx.doi.org/10.1056/NEJMp048209			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897UO	15716558				2022-12-28	WOS:000227031100003
J	Anthonisen, NR; Skeans, MA; Wise, RA; Manfreda, J; Kanner, RE; Connett, JE				Anthonisen, NR; Skeans, MA; Wise, RA; Manfreda, J; Kanner, RE; Connett, JE		Lung Hlth Study Research Grp	The effects of a smoking cessation intervention on 14.5-year mortality - A randomized clinical trial	ANNALS OF INTERNAL MEDICINE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; LUNG-CANCER INCIDENCE; HIGHER RISK; HEALTH; SMOKERS; PARTICIPANTS	Background: Randomized clinical trials have not yet demonstrated the mortality benefit of smoking cessation. Objective: To assess the long-term effect on mortality of a randomly applied smoking cessation program. Design: The Lung Health Study was a randomized clinical trial of smoking cessation. Special intervention participants received the smoking intervention program and were compared with usual care participants. Vital status was followed up to 14.5 years. Setting: 10 clinical centers in the United States and Canada. Patients: 5887 middle-aged volunteers with asymptomatic airway obstruction. Measurements: All-cause mortality and mortality due to cardiovascular disease, lung cancer, and other respiratory disease. Intervention: The intervention was a 10-week smoking cessation program that included a strong physician message and 12 group sessions using behavior modification and nicotine gum, plus either ipratropium or a placebo inhaler. Results: At 5 years, 21.7% of special intervention participants had stopped smoking since study entry compared with 5.4% of usual care participants. After up to 14.5 years of follow-up, 731 patients died: 33% of lung cancer, 22% of cardiovascular disease, 7.8% of respiratory disease other than cancer, and 2.3% of unknown causes. All-cause mortality was significantly lower in the special intervention group than in the usual care group (8.83 per 1000 person-years vs. 10.38 per 1000 person-years; P = 0.03). The hazard ratio for mortality in the usual care group compared with the special intervention group was 1.18 (95% CI, 1.02 to 1.37). Differences in death rates for both lung cancer and cardiovascular disease were greater when death rates were analyzed by smoking habit. Limitations: Results apply only to individuals with airway obstruction. Conclusion: Smoking cessation intervention programs can have a substantial effect on subsequent mortality, even when successful in a minority of participants.	Univ Minnesota, Minneapolis, MN USA; Johns Hopkins Univ, Baltimore, MD USA; Univ Utah, Salt Lake City, UT USA; Univ Manitoba, Winnipeg, MB, Canada	University of Minnesota System; University of Minnesota Twin Cities; Johns Hopkins University; Utah System of Higher Education; University of Utah; University of Manitoba	Connett, JE (corresponding author), Univ Minnesota, Coordinating Ctr Biometr Res, 2221 Univ Ave SE,Room 200, Minneapolis, MN 55414 USA.	john-c@ccbr.umn.edu		Wise, Robert/0000-0002-8353-2349	NHLBI NIH HHS [1U10-HL59275] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL059275] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anthonisen NR, 2002, AM J RESP CRIT CARE, V166, P333, DOI 10.1164/rccm.2110093; Anthonisen NR, 2002, AM J RESP CRIT CARE, V166, P675, DOI 10.1164/rccm.2112096; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; ASHLEY F, 1975, ANN INTERN MED, V82, P739, DOI 10.7326/0003-4819-82-6-739; CONNETT JE, 1993, CONTROL CLIN TRIALS, V14, pS3; CUTLER JA, 1991, PREV MED, V20, P183, DOI 10.1016/0091-7435(91)90019-Z; DEBACKER G, 1988, EUR HEART J, V9, P238, DOI 10.1093/oxfordjournals.eurheartj.a062491; DURKIN DA, 1993, CONTROL CLIN TRIALS, V14, pS20; HJERMANN I, 1986, AM J MED, V80, P7, DOI 10.1016/0002-9343(86)90154-3; Hole DJ, 1996, BRIT MED J, V313, P711; HULLEY SB, 1986, AM J CARDIOL, V58, P1; ISLAM SS, 1994, CANCER EPIDEM BIOMAR, V3, P289; KJELSBERG MO, 1990, JAMA-J AM MED ASSOC, V263, P1795; Kjelsberg MO, 1996, CIRCULATION, V94, P946; LANGE P, 1990, J CLIN EPIDEMIOL, V43, P867, DOI 10.1016/0895-4356(90)90070-6; Murray RP, 2002, PREV MED, V35, P314, DOI 10.1006/pmed.2002.1087; RISCH HA, 1993, AM J EPIDEMIOL, V138, P281, DOI 10.1093/oxfordjournals.aje.a116857; SAS I, 1991, SAS STAT US GUID VER; SKILLRUD DM, 1986, ANN INTERN MED, V105, P503, DOI 10.7326/0003-4819-105-4-503; TOCKMAN MS, 1987, ANN INTERN MED, V106, P512, DOI 10.7326/0003-4819-106-4-512; *US DHHS, 1990, DHHS PUBL; *US DHHS, 1990, DHHS PUBL CDC, P75; *US DHHS, 1990, DHHS PUBL, P200; VANDENEEDEN SK, 1992, EPIDEMIOLOGY, V3, P253, DOI 10.1097/00001648-199205000-00011	24	862	890	1	57	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	2005	142	4					233	239		10.7326/0003-4819-142-4-200502150-00005	http://dx.doi.org/10.7326/0003-4819-142-4-200502150-00005			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900UJ	15710956				2022-12-28	WOS:000227239500001
J	Larcher, V				Larcher, V			ABC of adolescence - Consent competence, and confidentiality	BMJ-BRITISH MEDICAL JOURNAL			English	Review									Barts & London NHS Trust, London, England	Barts Health NHS Trust	Larcher, V (corresponding author), Barts & London NHS Trust, London, England.	rviner@ich.ucl.ac.uk						Alderson P, 1996, HLTH CARE CHOICES MA; British Medical Association, 2001, CONS RIGHTS CHOIC HL; *DEP HLTH, 2004, 3382 DOH; *GEN MED COUNC, 2000, CONF PROT PROV INF; Royal College of Paediatrics and Child Health, 2004, RESP DOCT CHILD PROT	5	42	43	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 12	2005	330	7487					353	356		10.1136/bmj.330.7487.353	http://dx.doi.org/10.1136/bmj.330.7487.353			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897OZ	15705696	Green Published			2022-12-28	WOS:000227015800030
J	Cazzola, M; Malcovati, L				Cazzola, M; Malcovati, L			Myelodysplastic syndromes - Coping with ineffective hematopoiesis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Pavia, Sch Med, I-27100 Pavia, Italy; Policlin San Matteo, Ist Ric & Cura Carattere Sci, Div Hematol, I-27100 Pavia, Italy	University of Pavia; IRCCS Fondazione San Matteo	Cazzola, M (corresponding author), Univ Pavia, Sch Med, Via Palestro 3, I-27100 Pavia, Italy.		Cazzola, Mario/AAQ-8854-2021; Malcovati, Luca/CAJ-1695-2022	Cazzola, Mario/0000-0001-6984-8817; Malcovati, Luca/0000-0002-1460-1611				Alessandrino EP, 2002, HAEMATOLOGICA, V87, P1286; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Greenberg, 1998, BLOOD, V91, P1100; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Vardiman JW, 2002, BLOOD, V100, P2292, DOI 10.1182/blood-2002-04-1199	5	262	276	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2005	352	6					536	538		10.1056/NEJMp048266	http://dx.doi.org/10.1056/NEJMp048266			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895KY	15703418				2022-12-28	WOS:000226862100003
J	List, A; Kurtin, S; Roe, DJ; Buresh, A; Mahadevan, D; Fuchs, D; Rimsza, L; Heaton, R; Knight, R; Zeldis, JB				List, A; Kurtin, S; Roe, DJ; Buresh, A; Mahadevan, D; Fuchs, D; Rimsza, L; Heaton, R; Knight, R; Zeldis, JB			Efficacy of lenalidomide in myelodysplastic syndromes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; BONE-MARROW-CELLS; MULTIPLE-MYELOMA; FUSION PROTEIN; GROWTH-FACTOR; THALIDOMIDE; APOPTOSIS; LEUKEMIA; RECEPTOR; EXPRESSION	BACKGROUND: Ineffective erythropoiesis is the hallmark of myelodysplastic syndromes. Management of the anemia caused by ineffective erythropoiesis is difficult. In patients with myelodysplastic syndromes and symptomatic anemia, we evaluated the safety and hematologic activity of lenalidomide, a novel analogue of thalidomide. METHODS: Forty-three patients with transfusion-dependent or symptomatic anemia received lenalidomide at doses of 25 or 10 mg per day or of 10 mg per day for 21 days of every 28-day cycle. All patients either had had no response to recombinant erythropoietin or had a high endogenous erythropoietin level with a low probability of benefit from such therapy. The response to treatment was assessed after 16 weeks. RESULTS: Neutropenia and thrombocytopenia, the most common adverse events, with respective frequencies of 65 percent and 74 percent, necessitated the interruption of treatment or a dose reduction in 25 patients (58 percent). Other adverse events were mild and infrequent. Twenty-four patients had a response (56 percent): 20 had sustained independence from transfusion, 1 had an increase in the hemoglobin level of more than 2 g per deciliter, and 3 had more than a 50 percent reduction in the need for transfusions. The response rate was highest among patients with a clonal interstitial deletion involving chromosome 5q31.1 (83 percent, as compared with 57 percent among those with a normal karyotype and 12 percent among those with other karyotypic abnormalities; P=0.007) and patients with lower prognostic risk. Of 20 patients with karyotypic abnormalities, 11 had at least a 50 percent reduction in abnormal cells in metaphase, including 10 (50 percent) with a complete cytogenetic remission. After a median follow-up of 81 weeks, the median duration of transfusion independence had not been reached and the median hemoglobin level was 13.2 g per deciliter (range, 11.5 to 15.8). CONCLUSIONS: Lenalidomide has hematologic activity in patients with low-risk myelodysplastic syndromes who have no response to erythropoietin or who are unlikely to benefit from conventional therapy.	H Lee Moffit Canc Ctr & Res Inst, Hematolog Malignancies Program, Tampa, FL 33612 USA; Univ S Florida, Dept Interdisciplinary Oncol, Tampa, FL USA; Univ Arizona, Coll Med, Dept Med, Tucson, AZ USA; Univ Arizona, Coll Med, Dept Pathol, Tucson, AZ 85721 USA; Mel & Enid Zuckerman Arizona Coll Publ Hlth, Tucson, AZ USA; Celgene, Warren, NJ USA	State University System of Florida; University of South Florida; University of Arizona; University of Arizona; Bristol-Myers Squibb; Celgene Corporation	List, A (corresponding author), H Lee Moffit Canc Ctr & Res Inst, Hematolog Malignancies Program, SRB Rm 24038,12902 Magnolia Dr, Tampa, FL 33612 USA.	listaf@moffitt.usf.edu		LIST, ALAN/0000-0002-1647-2972	NCI NIH HHS [5 PO1 CA17094, 1U54CA90821-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA017094, U54CA090821] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bellamy WT, 2001, BLOOD, V97, P1427, DOI 10.1182/blood.V97.5.1427; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; Bumm T, 2003, BLOOD, V101, P1941, DOI 10.1182/blood-2002-07-2053; *CANC THER EV PROG, 1988, COMM TOX CRIT VERS 2; Cheson BD, 2000, BLOOD, V96, P3671; Claessens YE, 2002, BLOOD, V99, P1594, DOI 10.1182/blood.V99.5.1594; Corral LG, 1999, J IMMUNOL, V163, P380; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; Davies FE, 2001, BLOOD, V98, P210, DOI 10.1182/blood.V98.1.210; Deeg HJ, 2002, LEUKEMIA, V16, P162, DOI 10.1038/sj.leu.2402356; Gersuk GM, 1996, BLOOD, V88, P1122, DOI 10.1182/blood.V88.3.1122b.bloodjournal8831122b; Goldberg SL, 2003, BLOOD, V101, P781, DOI 10.1182/blood-2002-09-2769; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; HELLSTROMLINDBERG, 1997, BRIT J HAEMATOL, V99, P344; Jaffe ES, 2001, WHO CLASSIFICATION T; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kitagawa M, 1997, LEUKEMIA, V11, P2049, DOI 10.1038/sj.leu.2400844; List AF, 2004, EXP HEMATOL, V32, P526, DOI 10.1016/j.exphem.2004.03.005; List AF, 2004, WINTROBES CLIN HEMAT, P2207; Maciejewski JP, 2002, BRIT J HAEMATOL, V117, P119, DOI 10.1046/j.1365-2141.2002.03381.x; MOREIRA AL, 1993, J EXP MED, V177, P1675, DOI 10.1084/jem.177.6.1675; Peddie CM, 1997, BRIT J HAEMATOL, V99, P625, DOI 10.1046/j.1365-2141.1997.4373247.x; Rajapaksa R, 1996, BLOOD, V88, P4275; Raza A, 2001, BLOOD, V98, P958, DOI 10.1182/blood.V98.4.958; RAZA A, 1995, BLOOD, V86, P268, DOI 10.1182/blood.V86.1.268.bloodjournal861268; Richardson PG, 2002, BLOOD, V100, P3063, DOI 10.1182/blood-2002-03-0996; ROSE EH, 1995, BRIT J HAEMATOL, V89, P831; Tauro S, 2002, LEUKEMIA, V16, P785, DOI 10.1038/sj.leu.2402440; Turk BE, 1996, P NATL ACAD SCI USA, V93, P7552, DOI 10.1073/pnas.93.15.7552	29	651	712	2	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2005	352	6					549	557		10.1056/NEJMoa041668	http://dx.doi.org/10.1056/NEJMoa041668			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895KY	15703420	Bronze			2022-12-28	WOS:000226862100005
J	Seres, J; Seres, E; Verhoef, AJ; Tempea, G; Strelill, C; Wobrauschek, P; Yakovlev, V; Scrinzi, A; Spielmann, C; Krausz, F				Seres, J; Seres, E; Verhoef, AJ; Tempea, G; Strelill, C; Wobrauschek, P; Yakovlev, V; Scrinzi, A; Spielmann, C; Krausz, F			Source of coherent kiloelectronvolt X-rays	NATURE			English	Editorial Material							ORDER HARMONIC-GENERATION; LASER		Vienna Tech Univ, Inst Photon, A-1040 Vienna, Austria; Univ Wurzburg, Phys Inst EP1, D-97074 Wurzburg, Germany; Max Planck Inst Quantum Opt, D-85748 Garching, Germany; Femtolasers Prod GmbH, A-1100 Vienna, Austria; Tech Univ Vienna, Osterreich Univ, Atominst, A-1020 Vienna, Austria; Univ Munich, Dept Phys, D-85748 Garching, Germany	Technische Universitat Wien; University of Wurzburg; Max Planck Society; Technische Universitat Wien; University of Munich	Seres, J (corresponding author), Vienna Tech Univ, Inst Photon, A-1040 Vienna, Austria.	ferenc.krausz@mpq.mpg.de	Spielmann, Christian/G-9476-2013; Yakovlev, Vladislav S/C-4091-2015; Seres, Jozsef/A-9263-2013; Streli, Christina/K-6941-2015	Spielmann, Christian/0000-0002-5223-4170; Yakovlev, Vladislav S/0000-0002-0648-9375; Seres, Jozsef/0000-0002-8335-399X; Streli, Christina/0000-0002-5141-3177; Verhoef, Aart/0000-0003-2691-214X				Gibson EA, 2003, SCIENCE, V302, P95, DOI 10.1126/science.1088654; Kienberger R, 2004, NATURE, V427, P817, DOI 10.1038/nature02277; LEWENSTEIN M, 1994, PHYS REV A, V49, P2117, DOI 10.1103/PhysRevA.49.2117; LHUILLIER A, 1993, PHYS REV LETT, V70, P774, DOI 10.1103/PhysRevLett.70.774; MACKLIN JJ, 1993, PHYS REV LETT, V70, P766, DOI 10.1103/PhysRevLett.70.766; Rischel C, 1997, NATURE, V390, P490, DOI 10.1038/37317; Scrinzi A, 1999, PHYS REV LETT, V83, P706, DOI 10.1103/PhysRevLett.83.706; Seres E, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.163002; Seres J, 2003, OPT LETT, V28, P1832, DOI 10.1364/OL.28.001832	9	245	250	2	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 10	2005	433	7026					596	596		10.1038/433596a	http://dx.doi.org/10.1038/433596a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	895KX	15703738				2022-12-28	WOS:000226862000032
J	Poulsen, M; Boomsma, JJ				Poulsen, M; Boomsma, JJ			Mutualistic fungi control crop diversity in fungus-growing ants	SCIENCE			English	Article							LEAF-CUTTING ANTS; SYMBIOTIC FUNGI; SOMATIC INCOMPATIBILITY; EVOLUTION; SPECIALIZATION; AGRICULTURE; HYMENOPTERA; CONFLICT	Leaf-cutting ants rear clonal fungi for food and transmit the fungi from mother to daughter colonies so that symbiont mixing and conflict, which result from competition between genetically different clones, are avoided. Here we show that despite millions of years of predominantly vertical transmission, the domesticated fungi actively reject mycelial fragments from neighboring colonies, and that the strength of these reactions are in proportion to the overall genetic difference between these symbionts. Fungal incompatibility compounds remain intact during ant digestion, so that fecal droplets, which are used for manuring newly grown fungus, elicit similar hostile reactions when applied to symbionts from other colonies. Symbiont control over new mycelial growth by manurial imprinting prevents the rearing of multiple crops in fungus gardens belonging to the same colony.	Univ Copenhagen, Dept Populat Biol, Inst Biol, DK-2100 Copenhagen, Denmark	University of Copenhagen	Poulsen, M (corresponding author), Univ Copenhagen, Dept Populat Biol, Inst Biol, Univ Pk 15, DK-2100 Copenhagen, Denmark.	Mpoulsen@bi.ku.dk	Boomsma, Jacobus J/M-2785-2014; Poulsen, Michael/C-6276-2012	Boomsma, Jacobus J/0000-0002-3598-1609; Poulsen, Michael/0000-0002-2839-1715				Aanen DK, 2002, P NATL ACAD SCI USA, V99, P14887, DOI 10.1073/pnas.222313099; Adams RMM, 2000, NATURWISSENSCHAFTEN, V87, P491, DOI 10.1007/s001140050765; BASS M, 1994, ECOL ENTOMOL, V19, P215, DOI 10.1111/j.1365-2311.1994.tb00412.x; Bekkevold D, 1999, BEHAV ECOL SOCIOBIOL, V46, P103, DOI 10.1007/s002650050598; Bot ANM, 2001, EVOLUTION, V55, P1980, DOI 10.1111/j.0014-3820.2001.tb01315.x; CHAPELA IH, 1994, SCIENCE, V266, P1691, DOI 10.1126/science.266.5191.1691; CURRIE C, COMMUNICATION; Currie CR, 2001, P ROY SOC B-BIOL SCI, V268, P1033, DOI 10.1098/rspb.2001.1605; Diamond J, 1998, SCIENCE, V281, P1974, DOI 10.1126/science.281.5385.1974; Frank SA, 1996, P ROY SOC B-BIOL SCI, V263, P339, DOI 10.1098/rspb.1996.0052; Frank SA, 2003, EVOLUTION, V57, P693; Green AM, 2002, MOL ECOL, V11, P191, DOI 10.1046/j.1365-294X.2002.01433.x; HANSEN EM, 1993, MYCOL RES, V97, P1229, DOI 10.1016/S0953-7562(09)81290-2; Herre EA, 1999, TRENDS ECOL EVOL, V14, P49, DOI 10.1016/S0169-5347(98)01529-8; Holldobler B., 1990, pi; Katoh H, 2002, MOL ECOL, V11, P1565, DOI 10.1046/j.1365-294X.2002.01535.x; MARTIN MM, 1970, SCIENCE, V169, P16, DOI 10.1126/science.169.3940.16; Mueller UG, 1996, MOL ECOL, V5, P119, DOI 10.1111/j.1365-294X.1996.tb00297.x; Mueller UG, 1998, SCIENCE, V281, P2034, DOI 10.1126/science.281.5385.2034; Mueller UG, 2002, AM NAT, V160, pS67, DOI 10.1086/342084; Mueller UG, 2004, BEHAV ECOL, V15, P357, DOI 10.1093/beheco/arh020; Murata M., 1997, Recent Research Developments in Agricultural & Biological Chemistry, V1, P15; North RD, 1997, TRENDS ECOL EVOL, V12, P386, DOI 10.1016/S0169-5347(97)87381-8; Ridley P, 1996, EXPERIENTIA, V52, P631, DOI 10.1007/BF01969745; RISSING SW, 1989, NATURE, V338, P420, DOI 10.1038/338420a0; Ronhede S, 2004, MYCOL RES, V108, P101, DOI 10.1017/S0953756203008931; Schultz TR, 1998, INSECT SOC, V45, P457, DOI 10.1007/s000400050101; SCHULTZ TR, 2004, ECOLOGICAL EVOLUTION, P149; Viana AMM, 2001, CHEMOECOLOGY, V11, P29, DOI 10.1007/PL00001829; Villesen P, 2004, EVOLUTION, V58, P2252; Weber N. A., 1972, GARDENING ANTS ATTIN; Worrall JJ, 1997, MYCOLOGIA, V89, P24, DOI 10.2307/3761169; Zhu YY, 2000, NATURE, V406, P718, DOI 10.1038/35021046	33	127	130	1	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2005	307	5710					741	744		10.1126/science.1106688	http://dx.doi.org/10.1126/science.1106688			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	894TQ	15692054				2022-12-28	WOS:000226814900048
J	Kaminski, MS; Tuck, M; Estes, J; Kolstad, A; Ross, CW; Zasadny, K; Regan, D; Kison, P; Fisher, S; Kroll, S; Wahl, RL				Kaminski, MS; Tuck, M; Estes, J; Kolstad, A; Ross, CW; Zasadny, K; Regan, D; Kison, P; Fisher, S; Kroll, S; Wahl, RL			I-131-tositumomab therapy as initial treatment for follicular lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IODINE I-131 TOSITUMOMAB; NON-HODGKINS-LYMPHOMA; B-CELL LYMPHOMA; TERM-FOLLOW-UP; ANTI-CD20 MONOCLONAL-ANTIBODY; LOW-GRADE; STAGE-I; CHEMOTHERAPY; RITUXIMAB; RADIOIMMUNOTHERAPY	BACKGROUND: Advanced-stage follicular B-cell lymphoma is considered incurable. Anti-CD20 radioimmunotherapy is effective in patients who have had a relapse after chemotherapy or who have refractory follicular lymphoma, but it has not been tested in previously untreated patients. METHODS: Seventy-six patients with stage III or IV follicular lymphoma received as initial therapy a single course of treatment with I-131-tositumomab therapy (registered as Tositumomab and Iodine I 131 Tositumomab [the Bexxar therapeutic regimen]). This consisted of a dosimetric dose of tositumomab and I-131-labeled tositumomab followed one week later by a therapeutic dose, delivering 75 cGy of radiation to the total body. RESULTS: Ninety-five percent of the patients had any response, and 75 percent had a complete response. The use of polymerase chain reaction (PCR) to detect rearrangement of the BCL2 gene showed molecular responses in 80 percent of assessable patients who had a clinical complete response. After a median follow-up of 5.1 years, the actuarial 5-year progression-free survival for all patients was 59 percent, with a median progression-free survival of 6.1 years. The annualized rate of relapse progressively decreased over time: 25 percent, 13 percent, and 12 percent during the first, second, and third years, respectively, and 4.4 percent per year after three years. Of 57 patients who had a complete response, 40 remained in remission for 4.3 to 7.7 years. Hematologic toxicity was moderate, with no patient requiring transfusions or hematopoietic growth factors. No cases of myelodysplastic syndrome have been observed. CONCLUSIONS: A single one-week course of I-131-tositumomab therapy as initial treatment can induce prolonged clinical and molecular remissions in patients with advanced follicular lymphoma.	Univ Michigan, Med Ctr, Ctr Canc, Dept Internal Med,Div Hematol & Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Radiol, Div Nucl Med, Ann Arbor, MI 48109 USA; Norwegian Radium Hosp, Dept Oncol, Oslo, Norway; Corixa, Seattle, WA USA; Johns Hopkins Univ, Sch Med, Dept Radiol & Radiol Sci, Div Nucl Sci, Baltimore, MD USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Oslo; Corixa; Johns Hopkins University	Kaminski, MS (corresponding author), Univ Michigan, Med Ctr, Ctr Canc, Dept Internal Med,Div Hematol & Oncol, Rm 4316,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	mkaminsk@umich.edu		WAHL, RICHARD L./0000-0002-7306-2590	NATIONAL CANCER INSTITUTE [R01CA056794] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA56794] Funding Source: Medline; NCRR NIH HHS [M01 RR00042] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BUCHSBAUM DJ, 1992, CANCER RES, V52, P6476; Cardarelli PM, 2002, CANCER IMMUNOL IMMUN, V51, P15, DOI 10.1007/s00262-001-0247; Coleman M, 2003, BLOOD, V102, p29A; Colombat P, 2001, BLOOD, V97, P101, DOI 10.1182/blood.V97.1.101; COX DR, 1972, J R STAT SOC B, V34, P187; Czuczman M, 2003, BLOOD, V102, p411A; Czuczman MS, 1999, J CLIN ONCOL, V17, P268, DOI 10.1200/JCO.1999.17.1.268; DANA BW, 1993, J CLIN ONCOL, V11, P644, DOI 10.1200/JCO.1993.11.4.644; Fisher RI, 2000, J CLIN ONCOL, V18, P2010, DOI 10.1200/JCO.2000.18.10.2010; GOLDSMITH SJ, 2001, PROG P AM SOC CLIN S, V20, pA295; Hainsworth JD, 2002, J CLIN ONCOL, V20, P4261, DOI 10.1200/JCO.2002.08.674; Harris NL, 1999, J CLIN ONCOL, V17, P3835, DOI 10.1200/JCO.1999.17.12.3835; Horning SJ, 2002, BLOOD, V100, p357A; Johnson PWM, 1999, ANN ONCOL, V10, P1349, DOI 10.1023/A:1008385924543; Kaminski MS, 2000, BLOOD, V96, P1259, DOI 10.1182/blood.V96.4.1259.h8001259_1259_1266; Kaminski MS, 2001, J CLIN ONCOL, V19, P3918, DOI 10.1200/JCO.2001.19.19.3918; Kaminski MS, 1996, J CLIN ONCOL, V14, P1974, DOI 10.1200/JCO.1996.14.7.1974; KAMINSKI MS, 1993, NEW ENGL J MED, V329, P459, DOI 10.1056/NEJM199308123290703; KAMINSKI MS, 1998, P AN M AM SOC CLIN, V17, pA2; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lopez-Guillermo A, 1999, BLOOD, V93, P3081, DOI 10.1182/blood.V93.9.3081; MacManus MP, 1996, J CLIN ONCOL, V14, P1282, DOI 10.1200/JCO.1996.14.4.1282; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; REDDY S, 1989, INT J RADIAT ONCOL, V16, P687, DOI 10.1016/0360-3016(89)90486-0; Shan D, 1998, BLOOD, V91, P1644, DOI 10.1182/blood.V91.5.1644.1644_1644_1652; SOLALCELIGNY P, 1993, NEW ENGL J MED, V329, P1608, DOI 10.1056/NEJM199311253292203; TEDDER TF, 1986, EUR J IMMUNOL, V16, P881, DOI 10.1002/eji.1830160802; Tsimberidou AM, 2002, BLOOD, V100, P4351, DOI 10.1182/blood-2001-12-0269; Vose JM, 2000, J CLIN ONCOL, V18, P1316, DOI 10.1200/JCO.2000.18.6.1316; Wahl RL, 2003, SEMIN ONCOL, V30, P31, DOI 10.1053/sonc.2003.23799; ZELENETZ A, 2001, PROG P AM SOC CLIN S, V20, pA287	31	513	542	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 3	2005	352	5					441	449		10.1056/NEJMoa041511	http://dx.doi.org/10.1056/NEJMoa041511			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	893NE	15689582				2022-12-28	WOS:000226725400004
J	Winckler, W; Myers, SR; Richter, DJ; Onofrio, RC; McDonald, GJ; Bontrop, RE; McVean, GAT; Gabriel, SB; Reich, D; Donnelly, P; Altshuler, D				Winckler, W; Myers, SR; Richter, DJ; Onofrio, RC; McDonald, GJ; Bontrop, RE; McVean, GAT; Gabriel, SB; Reich, D; Donnelly, P; Altshuler, D			Comparison of fine-scale recombination rates in humans and chimpanzees	SCIENCE			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; GLOBIN GENE-CLUSTER; MEIOTIC RECOMBINATION; HUMAN GENOME; DNA-SEQUENCE; HOT-SPOT; HOTSPOT; CONVERSION; CROSSOVER	We compared fine-scale recombination rates at orthologous loci in humans and chimpanzees by analyzing polymorphism data in both species. Strong statistical evidence for hotspots of recombination was obtained in both species. Despite similar to 99% identity at the level of DNA sequence, however, recombination hotspots were found rarely (if at all) at the same positions in the two species, and no correlation was observed in estimates of fine-scale recombination rates. Thus, local patterns of recombination rate have evolved rapidly, in a manner disproportionate to the change in DNA sequence.	Univ Oxford, Dept Stat, Oxford OX1 3TG, England; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Med, Diabet Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Broad Inst, Program Med & Populat Genet, Cambridge, MA 02141 USA; MIT, Cambridge, MA 02141 USA; Biomed Primate Res Ctr, Dept Comparat Genet & Refinement, NL-2280 GH Rijswijk, Netherlands	University of Oxford; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT)	Donnelly, P (corresponding author), Univ Oxford, Dept Stat, Oxford OX1 3TG, England.	donnelly@stats.ox.ac.uk; attshuler@molbio.mgh.harvard.edu	Altshuler, David M/A-4476-2009; Bontrop, Ronald E/J-3628-2012; Bontrop, Ronald E./D-4844-2011; Myers, Simon R/A-6792-2015	Altshuler, David M/0000-0002-7250-4107; Bontrop, Ronald E/0000-0003-0874-6467; Myers, Simon R/0000-0002-2585-9626; Richter, Daniel/0000-0002-9238-5571; Donnelly, Peter/0000-0001-9495-3408				Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Boulton A, 1997, P NATL ACAD SCI USA, V94, P8058, DOI 10.1073/pnas.94.15.8058; CHAKRAVARTI A, 1984, AM J HUM GENET, V36, P1239; Crawford DC, 2004, NAT GENET, V36, P700, DOI 10.1038/ng1376; Ebersberger I, 2002, AM J HUM GENET, V70, P1490, DOI 10.1086/340787; Falush D, 2003, GENETICS, V164, P1567; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gerton JL, 2000, P NATL ACAD SCI USA, V97, P11383, DOI 10.1073/pnas.97.21.11383; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; Jeffreys AJ, 2000, HUM MOL GENET, V9, P725, DOI 10.1093/hmg/9.5.725; Jeffreys AJ, 2001, NAT GENET, V29, P217, DOI 10.1038/ng1001-217; Jeffreys AJ, 2002, NAT GENET, V31, P267, DOI 10.1038/ng910; McVean GAT, 2004, SCIENCE, V304, P581, DOI 10.1126/science.1092500; Myers SR, 2003, GENETICS, V163, P375; NICOLAS A, 1989, NATURE, V338, P35, DOI 10.1038/338035a0; Ptak SE, 2004, PLOS BIOL, V2, P849, DOI 10.1371/journal.pbio.0020155; Schneider JA, 2002, HUM MOL GENET, V11, P207, DOI 10.1093/hmg/11.3.207; SCHUCHERT P, 1991, EMBO J, V10, P2157, DOI 10.1002/j.1460-2075.1991.tb07750.x; Smith RA, 1998, BLOOD, V92, P4415, DOI 10.1182/blood.V92.11.4415.423a07_4415_4421; Wall JD, 2003, AM J HUM GENET, V73, P1330, DOI 10.1086/380311; Watanabe H, 2004, NATURE, V429, P382, DOI 10.1038/nature02564; WU TC, 1994, SCIENCE, V263, P515, DOI 10.1126/science.8290959; Yauk CL, 2003, EMBO J, V22, P1389, DOI 10.1093/emboj/cdg136	23	286	294	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 1	2005	308	5718					107	111		10.1126/science.1105322	http://dx.doi.org/10.1126/science.1105322			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	914IQ	15705809				2022-12-28	WOS:000228221500043
J	Lucas, MES; Deen, JL; von Seidlein, L; Wang, XY; Ampuero, J; Puri, M; Ali, M; Ansaruzzaman, M; Amos, J; Macuamule, A; Cavailler, P; Guerin, PJ; Mahoudeau, C; Kahozi-Sangwa, P; Chaignat, C; Barreto, A; Songane, FF; Clemens, JD				Lucas, MES; Deen, JL; von Seidlein, L; Wang, XY; Ampuero, J; Puri, M; Ali, M; Ansaruzzaman, M; Amos, J; Macuamule, A; Cavailler, P; Guerin, PJ; Mahoudeau, C; Kahozi-Sangwa, P; Chaignat, C; Barreto, A; Songane, FF; Clemens, JD			Effectiveness of mass oral cholera vaccination in Beira, Mozambique	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							B-SUBUNIT; FIELD TRIAL; VACCINES; EFFICACY; BANGLADESH; DIARRHEA	BACKGROUND: New-generation, orally administered cholera vaccines offer the promise of improved control of cholera in sub-Saharan Africa. However, the high prevalence of human immunodeficiency virus (HIV) infection in many cholera-affected African populations has raised doubts about the level of protection possible with vaccination. We evaluated a mass immunization program with recombinant cholera-toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in Beira, Mozambique, a city where the seroprevalence of HIV is 20 to 30 percent. METHODS: From December 2003 to January 2004, we undertook mass immunization of nonpregnant persons at least two years of age, using a two-dose regimen of rBS-WC vaccine in Esturro, Beira (population 21,818). We then assessed vaccine protection in a case-control study during an outbreak of El Tor Ogawa cholera in Beira between January and May 2004. To estimate the level of vaccine protection, antecedent rates of vaccination were compared between persons with culture-confirmed cholera severe enough to have prompted them to seek treatment and age- and sex-matched neighborhood controls without treated diarrhea. RESULTS: We assessed the effectiveness of the vaccine in 43 persons with cholera and 172 controls. Receipt of one or more doses of rBS-WC vaccine was associated with 78 percent protection (95 percent confidence interval, 39 to 92 percent; P=0.004). The vaccine was equally effective in children younger than five years of age and in older persons. A concurrently conducted case-control study designed to detect bias compared persons with treated, noncholeraic diarrhea and controls without diarrhea in the same population and found no protection associated with receipt of the rBS-WC vaccine. CONCLUSIONS: The rBS-WC vaccine was highly effective against clinically significant cholera in an urban sub-Saharan African population with a high prevalence of HIV infection.	Int Vaccine Inst, Seoul 151600, South Korea; Minist Hlth, Maputo, Mozambique; Ctr Hlth & Populat Res, Dhaka, Bangladesh; Epicentre, Paris, France; Med Sans Frontieres, Geneva, Switzerland; WHO, Maputo, Mozambique; NICHHD, Bethesda, MD 20892 USA	International Vaccine Institute; Doctors Without Borders; World Health Organization; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Deen, JL (corresponding author), Int Vaccine Inst, POB 14, Seoul 151600, South Korea.	jdeen@ivi.int	Ali, Mohammad/E-2365-2017; Cavailler, Philippe/G-4138-2017; Guerin, Philippe/AAH-8873-2021	Ali, Mohammad/0000-0003-1410-388X; Guerin, Philippe/0000-0002-6008-2963; Ampuero, Julia/0000-0001-5486-1656				Ansaruzzaman M, 2004, EMERG INFECT DIS, V10, P2057, DOI 10.3201/eid1011.040682; Clemens J, 1996, JAMA-J AM MED ASSOC, V275, P390, DOI 10.1001/jama.275.5.390; CLEMENS JD, 1986, LANCET, V2, P124; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; CLEMENS JD, 1990, AM J EPIDEMIOL, V131, P400, DOI 10.1093/oxfordjournals.aje.a115515; CLEMENS JD, 1988, J INFECT DIS, V158, P372, DOI 10.1093/infdis/158.2.372; Dorlencourt F, 1999, B WORLD HEALTH ORGAN, V77, P949; ERIKSSON K, 1993, AIDS, V7, P1087, DOI 10.1097/00002030-199308000-00010; HOLMGREN J, 2004, NEW GENERATION VACCI, P499; Legros D, 1999, B WORLD HEALTH ORGAN, V77, P837; LEWIS DJM, 1994, AIDS, V8, P779, DOI 10.1097/00002030-199406000-00009; MONSUR K. A., 1961, TRANS ROY SOC TROP MED AND HYG, V55, P440, DOI 10.1016/0035-9203(61)90090-6; ORENSTEIN WA, 1985, B WORLD HEALTH ORGAN, V63, P1055; Ortigao-deo-Sampaio MB, 1998, AIDS, V12, pF145, DOI 10.1097/00002030-199814000-00001; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; PELTOLA H, 1991, LANCET, V338, P1285, DOI 10.1016/0140-6736(91)92590-X; SANCHEZ JL, 1994, LANCET, V344, P1273, DOI 10.1016/S0140-6736(94)90755-2; Shapiro ED, 2004, PEDIATR INFECT DIS J, V23, P127, DOI 10.1097/01.inf.0000109248.32907.1d; Stolley PD, 1982, CASE CONTROL STUDIES, P69; *WHO, 1990, WHOCDDSER802; *WHO, MOZ SUMM COUNTR PROF; *WHO GLOB TASK FOR, 2003, REP CHOL CONTR PROGR; *WHO GLOB TASK FOR, 2004, WHOCDSCPEZFK20045 WH	23	186	199	1	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2005	352	8					757	767		10.1056/NEJMoa043323	http://dx.doi.org/10.1056/NEJMoa043323			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899MC	15728808	Green Accepted			2022-12-28	WOS:000227147500005
J	Pasupathy, A; Miller, EK				Pasupathy, A; Miller, EK			Different time courses of learning-related activity in the prefrontal cortex and striatum	NATURE			English	Article							BASAL-GANGLIA; NEURONAL-ACTIVITY	To navigate our complex world, our brains have evolved a sophisticated ability to quickly learn arbitrary rules such as 'stop at red'. Studies in monkeys using a laboratory test of this capacity-conditional association learning-have revealed that frontal lobe structures ( including the prefrontal cortex) as well as subcortical nuclei of the basal ganglia are involved in such learning(1-5). Neural correlates of associative learning have been observed in both brain regions(6-14), but whether or not these regions have unique functions is unclear, as they have typically been studied separately using different tasks. Here we show that during associative learning in monkeys, neural activity in these areas changes at different rates: the striatum ( an input structure of the basal ganglia) showed rapid, almost bistable, changes compared with a slower trend in the prefrontal cortex that was more in accordance with slow improvements in behavioural performance. Also, pre-saccadic activity began progressively earlier in the striatum but not in the prefrontal cortex as learning took place. These results support the hypothesis that rewarded associations are first identified by the basal ganglia, the output of which 'trains' slower learning mechanisms in the frontal cortex(15).	MIT, Picower Ctr Learning & Memory, RIKEN MIT Neurosci Res Ctr, Cambridge, MA 02139 USA; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); RIKEN; Massachusetts Institute of Technology (MIT)	Pasupathy, A (corresponding author), MIT, Picower Ctr Learning & Memory, RIKEN MIT Neurosci Res Ctr, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	anitha@mit.edu	Miller, Earl K./AAE-8187-2019	Miller, Earl K./0000-0002-0582-6958				Asaad WF, 1998, NEURON, V21, P1399, DOI 10.1016/S0896-6273(00)80658-3; Bar-Gad I, 2003, PROG NEUROBIOL, V71, P439, DOI 10.1016/j.pneurobio.2003.12.001; Brasted PJ, 2004, EUR J NEUROSCI, V19, P721, DOI 10.1111/j.0953-816X.2003.03181.x; DeLong M. R., 1981, HDB PHYSL NERVOUS SY, P1017; Fuster J., 2015, PREFRONTAL CORTEX, V5th; Graybiel AM, 1998, NEUROBIOL LEARN MEM, V70, P119, DOI 10.1006/nlme.1998.3843; GRAYBIEL AM, 1990, REV NEUROL, V146, P570; Hadj-Bouziane F, 2003, EXP BRAIN RES, V153, P190, DOI 10.1007/s00221-003-1592-4; Hanes DP, 1996, SCIENCE, V274, P427, DOI 10.1126/science.274.5286.427; Hikosaka O, 2000, PHYSIOL REV, V80, P953, DOI 10.1152/physrev.2000.80.3.953; Hoshi E, 2004, J NEUROPHYSIOL, V91, P2707, DOI 10.1152/jn.00904.2003; HOUK JC, 1995, CEREB CORTEX, V5, P95, DOI 10.1093/cercor/5.2.95; Lauwereyns J, 2002, NATURE, V418, P413, DOI 10.1038/nature00892; McClure SM, 2003, NEURON, V38, P339, DOI 10.1016/S0896-6273(03)00154-5; Middleton FA, 2002, CEREB CORTEX, V12, P926, DOI 10.1093/cercor/12.9.926; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Murray EA, 2000, EXP BRAIN RES, V133, P114, DOI 10.1007/s002210000406; Packard MG, 2002, ANNU REV NEUROSCI, V25, P563, DOI 10.1146/annurev.neuro.25.112701.142937; PASSINGHAM RE, 1995, FRONTAL LOEBS VOLUNT; PETRIDES M, 1994, HDB NEUROPSYCHOLOGY, P59; Reilly R. O., 2000, COMPUTATIONAL EXPLOR; Reynolds JNJ, 2001, NATURE, V413, P67, DOI 10.1038/35092560; Schultz W, 2000, ANNU REV NEUROSCI, V23, P473, DOI 10.1146/annurev.neuro.23.1.473; Schumacher EH, 2003, J COGNITIVE NEUROSCI, V15, P1111, DOI 10.1162/089892903322598085; Toni I, 1999, EXP BRAIN RES, V127, P19, DOI 10.1007/s002210050770; Tremblay L, 1998, J NEUROPHYSIOL, V80, P964, DOI 10.1152/jn.1998.80.2.964; White IM, 1999, EXP BRAIN RES, V126, P315, DOI 10.1007/s002210050740; Wilson CJ, 1996, J NEUROSCI, V16, P2397; Wirth S, 2003, SCIENCE, V300, P1578, DOI 10.1126/science.1084324; Wise SP, 1996, CRIT REV NEUROBIOL, V10, P317, DOI 10.1615/CritRevNeurobiol.v10.i3-4.30	30	528	536	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 24	2005	433	7028					873	876		10.1038/nature03287	http://dx.doi.org/10.1038/nature03287			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	899VT	15729344				2022-12-28	WOS:000227174600044
J	Wainberg, MA				Wainberg, MA			Generic HIV drugs - Enlightened policy for global health	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RESISTANCE		McGill Univ, Jewish Gen Hosp, AIDS Ctr, Montreal, PQ H3T 1E2, Canada	McGill University	Wainberg, MA (corresponding author), McGill Univ, Jewish Gen Hosp, AIDS Ctr, Montreal, PQ H3T 1E2, Canada.							*GLOB HIV AIDS PRO, 2004, AIDS S, V18, pS1; Kuritzkes DR, 1996, AIDS, V10, P975, DOI 10.1097/00002030-199610090-00007; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Weidle PJ, 2002, LANCET, V360, P34, DOI 10.1016/S0140-6736(02)09330-3; *WHO, 2004, 3 AIDS MED REM PREQ	5	17	18	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2005	352	8					747	750		10.1056/NEJMp048356	http://dx.doi.org/10.1056/NEJMp048356			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899MC	15728804				2022-12-28	WOS:000227147500001
J	Call, SA; Vollenweider, MA; Hornung, CA; Simel, DL; McKinney, WP				Call, SA; Vollenweider, MA; Hornung, CA; Simel, DL; McKinney, WP			Does this patient have influenza?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY SYNCYTIAL VIRUS; VIRAL-INFECTIONS; RAPID DETECTION; DIAGNOSING INFLUENZA; CLINICAL-DIAGNOSIS; COST-EFFECTIVENESS; B VIRUSES; COMMUNITY; SURVEILLANCE; VACCINATION	Context Influenza vaccination lowers, but does not eliminate, the risk of influenza. Making a reliable, rapid clinical diagnosis is essential to appropriate patient management that may be especially important during shortages of antiviral agents caused by high demand. Objectives To systematically review the precision and accuracy of symptoms and signs of influenza. A secondary objective was to review the operating characteristics of rapid diagnostic tests for influenza (results available in <30 min). Data Sources Structured search strategy using MEDLINE (January 1966-September 2004) and subsequent searches of bibliographies of retrieved articles to identify articles describing primary studies dealing with the diagnosis of influenza based on clinical signs and symptoms. The MEDLINE search used the Medical Subject Headings EXP influenza or EXP influenza A virus or EXP influenza A virus human or EXP influenza B virus and the Medical Subject Headings or terms EXP sensitivity and specificity or EXP medical history taking or EXP physical examination or EXP reproducibility of results or EXP observer variation or symptoms.mp or clinical signs.mp or sensitivity. mp or specificity.mp. Study Selection Of 915 identified articles on clinical assessment of influenza-related illness, 17 contained data on the operating characteristics of symptoms and signs using an independent criterion standard. of these, 11 were eliminated based on 4 inclusion criteria and availability of nonduplicative primary data. Data Extraction Two authors independently reviewed and abstracted data for estimating-the likelihood ratios (LRs) of clinical diagnostic findings. Differences were resolved by discussion and consensus. Data Synthesis No symptom or sign had a summary LR greater than 2 in studies that enrolled patients without regard to age. For decreasing the likelihood of influenza, the absence of fever (LR, 0.40; 95% confidence interval [CI], 0.25-0.66), cough (LR, 0.42; 95% Cl, 0.31-0.57), or nasal congestion (LR, 0.49; 95% Cl, 0.42-0.59) were the only findings that had summary LRs less than 0.5. In studies limited to patients aged 60 years or older, the combination of fever, cough, and acute onset (LR, 5.4; 95% Cl, 3.8-7.7), fever and cough (LR, 5.0; 95% Cl, 3.5-6.9), fever alone (LR, 3.8; 95% Cl, 2.8-5.0), malaise (LR, 2.6; 95% Cl, 2.2-3.1), and chills (LR, 2.6; 95% Cl, 2.0-3.2) increased the likelihood of influenza to the greatest degree. The presence of sneezing among older patients made influenza less likely (LR, 0.47; 95% Cl, 0.24-0.92). Conclusions Clinical findings identify patients with influenza-like illness but are not particularly useful for confirming or excluding the diagnosis of influenza. Clinicians should use timely epidemiologic data to ascertain if influenza is circulating in their communities, then either treat patients with influenza-like illness empirically or obtain a rapid influenza test to assist with management decisions.	Univ Louisville, Dept Med, Louisville, KY 40202 USA; Louisville VA Med Ctr, Louisville, KY USA; Univ Louisville, Sch Publ Hlth & Informat Sci, Louisville, KY 40292 USA; Durham Vet Affairs Med Ctr, Durham, NC USA; Duke Univ, Med Ctr, Durham, NC USA	University of Louisville; University of Louisville; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Duke University	McKinney, WP (corresponding author), Univ Louisville, Dept Med, Ambulatory Care Bldg,3rd Floor,530 S Jackson St, Louisville, KY 40202 USA.	mckinney@louisville.edu						Bellei N, 2003, J VIROL METHODS, V109, P85, DOI 10.1016/S0166-0934(03)00050-8; Boivin G, 2000, CLIN INFECT DIS, V31, P1166, DOI 10.1086/317425; Bonner AB, 2003, PEDIATRICS, V112, P363, DOI 10.1542/peds.112.2.363; Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885; Carman WF, 2000, BRIT MED J, V321, P736, DOI 10.1136/bmj.321.7263.736; Carrat F, 1999, CLIN INFECT DIS, V28, P283, DOI 10.1086/515117; Carrat F, 1997, BRIT J GEN PRACT, V47, P217; Cazacu AC, 2004, J CLIN MICROBIOL, V42, P3661, DOI [10.1128/JCM.42.8.3661-3664.2004, 10.1128/jcm.42.8.3661-3664.2004]; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P1197; *CDCP, 2004 05 FLU VACC SHO; Cox NJ, 1999, LANCET, V354, P1277, DOI 10.1016/S0140-6736(99)01241-6; DEARRUDA E, 1991, J INFECT DIS, V164, P252, DOI 10.1093/infdis/164.2.252; Demicheli V, 2001, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD001269.PUB2, 10.1002/14651858.CD001269]; DEVILLE WL, 2002, EVIDENCE BASE CLIN D, P156; Ebell MH, 2004, J AM BOARD FAM PRACT, V17, P1, DOI 10.3122/jabfm.17.1.1; FLEISS JL, 1991, J CLIN EPIDEMIOL, V44, P127, DOI 10.1016/0895-4356(91)90261-7; Glas AS, 2003, J CLIN EPIDEMIOL, V56, P1129, DOI 10.1016/S0895-4356(03)00177-X; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; Govaert TME, 1998, FAM PRACT, V15, P16, DOI 10.1093/fampra/15.1.16; Hak E, 2001, ARCH INTERN MED, V161, P1351, DOI 10.1001/archinte.161.10.1351; Hall CB, 2001, CLIN INFECT DIS, V33, P792, DOI 10.1086/322657; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P313, DOI 10.1001/jama.273.4.313; Hulson TD, 2001, J FAM PRACTICE, V50, P1051; Lee PY, 2002, ANN INTERN MED, V137, P225, DOI 10.7326/0003-4819-137-4-200208200-00005; Lina B, 1996, J CLIN MICROBIOL, V34, P3007, DOI 10.1128/JCM.34.12.3007-3011.1996; Long CE, 1997, ARCH FAM MED, V6, P459, DOI 10.1001/archfami.6.5.459; MANTEL N, 1977, AM J EPIDEMIOL, V106, P125, DOI 10.1093/oxfordjournals.aje.a112441; Marcante R, 1996, MICROBIOLOGICA, V19, P141; Monto AS, 2000, ARCH INTERN MED, V160, P3243, DOI 10.1001/archinte.160.21.3243; Nichol KL, 2001, ARCH INTERN MED, V161, P749, DOI 10.1001/archinte.161.5.749; Nicholson KG, 1997, BRIT MED J, V315, P1060, DOI 10.1136/bmj.315.7115.1060; Noyola DE, 2000, PEDIATR DEVEL PATHOL, V3, P162, DOI 10.1007/s100240050020; Poland GA, 1997, ARCH FAM MED, V6, P466, DOI 10.1001/archfami.6.5.466; Quach C, 2002, CLIN DIAGN LAB IMMUN, V9, P925, DOI 10.1128/CDLI.9.4.925-926.2002; Rodriguez WJ, 2002, PEDIATR INFECT DIS J, V21, P193, DOI 10.1097/00006454-200203000-00006; Rothberg MB, 2003, ANN INTERN MED, V139, P321, DOI 10.7326/0003-4819-139-5_Part_1-200309020-00007; Schmid ML, 1998, BRIT MED J, V316, P275, DOI 10.1136/bmj.316.7127.275; Smith KJ, 2002, AM J MED, V113, P300, DOI 10.1016/S0002-9343(02)01222-6; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; van Elden LJR, 2001, BRIT J GEN PRACT, V51, P630; Zambon M, 2001, ARCH INTERN MED, V161, P2116, DOI 10.1001/archinte.161.17.2116	42	259	268	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	2005	293	8					987	997		10.1001/jama.293.8.987	http://dx.doi.org/10.1001/jama.293.8.987			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899LR	15728170				2022-12-28	WOS:000227146400021
J	Hendrix, SL; Cochrane, BB; Nygaard, IE; Handa, VL; Barnabei, VM; Iglesia, C; Aragaki, A; Naughton, MJ; Wallace, RB; McNeeley, SG				Hendrix, SL; Cochrane, BB; Nygaard, IE; Handa, VL; Barnabei, VM; Iglesia, C; Aragaki, A; Naughton, MJ; Wallace, RB; McNeeley, SG			Effects of estrogen with and without progestin on urinary incontinence	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTMENOPAUSAL WOMEN; STRESS-INCONTINENCE; RISK-FACTORS; RECEPTORS; SYMPTOMS; PREVALENCE; MANAGEMENT; SUPPLEMENTATION; ESTRADIOL; HORMONES	Context Menopausal hormone therapy has long been credited with many benefits beyond the indications of relieving hot flashes, night sweats, and vaginal dryness, and it is often prescribed to treat urinary incontinence (UI). Objective To assess the effects of menopausal hormone therapy on the incidence and severity of symptoms of stress, urge, and mixed UI in healthy postmenopausal women. Design, Setting, and Participants Women's Health Initiative multicenter double-blind, placebo-controlled, randomized clinical trials of menopausal hormone therapy in 27347 postmenopausal women aged 50 to 79 years enrolled between 1993 and 1998, for whom UI symptoms were known in 23 296 participants at baseline and 1 year. Interventions Women were randomized based on hysterectomy status to active treatment or placebo in either the estrogen plus progestin (E + P) or estrogen alone trials. The E + P hormones were 0.625 mg/d of conjugated equine estrogen plus 2.5 mg/d of medroxyprogesterone acetate (CEE + MPA); estrogen alone consisted of 0.625 mg/d of conjugated equine estrogen (CEE). There were 8506 participants who received CEE + MPA (8102 who received placebo) and 5310 who received CEE alone (5429 who received placebo). Main Outcome Measures Incident UI at 1 year among women without UI at baseline and severity of UI at 1 year among women who had UI at baseline. Results Menopausal hormone therapy increased the incidence of all types of UI at 1 year among women who were continent at baseline. The risk was highest for stress UI (CEE + MPA: relative risk [RR], 1.87 [95% confidence interval {CI}, 1.61-2.18]; CEE alone: RR, 2.15 [95% CI, 1.77-2.62]), followed by mixed UI (CEE + MPA: RR, 1.49 [95% Cl, 1.10-2.01]; CEE alone: RR, 1.79 [95% Cl, 1.26-2.53]). The combination of CEE + MPA had no significant effect on developing urge UI (RR, 1.15; 95% Cl, 0.99-1.34), but CEE alone increased the risk (RR, 1.32; 95% Cl, 1.10-1.58). Among women experiencing UI at baseline, frequency worsened in both trials (CEE + MPA: RR, 1.38 [95% Cl, 1.28-1.49]; CEE alone: RR, 1.47 [95% Cl, 1.35-1.61]). Amount of UI worsened at 1 year in both trials (CEE + MPA: RR, 1.20 [95% Cl, 1.06-1.36]; CEE alone: RR, 1.59 [95% Cl, 1.39-1.82]). Women receiving menopausal hormone therapy were more likely to report that UI limited their daily activities (CEE + MPA: RR, 1.18 [95% Cl, 1.06-1.32]; CEE alone: RR, 1.29 [95% Cl, 1.15-1.45]) and bothered or disturbed them (CEE + MPA: RR, 1.22 [95% Cl, 1.13-1.32]; CEE alone: RR, 1.50 [95% Cl, 1.37-1.65]) at 1 year. Conclusions Conjugated equine estrogen alone and CEE + MPA increased the risk of UI among continent women and worsened the characteristics of UI among symptomatic women after 1 year. Conjugated equine estrogen with or without progestin should not be prescribed for the prevention or relief of UI.	Wayne State Univ, Sch Med, Hutzel Womens Hosp, Dept Obstet & Gynecol, Detroit, MI 48201 USA; Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA; Univ Iowa, Carver Coll Med, Dept Obstet & Gynecol, Iowa City, IA USA; Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA; Johns Hopkins Univ, Sch Med, Dept Obstet & Gynecol, Baltimore, MD 21205 USA; Med Coll Wisconsin, Dept Obstet & Gynecol, Milwaukee, WI 53226 USA; Washington Hosp Ctr, Dept Obstet & Gynecol, Washington, DC 20010 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27103 USA	Wayne State University; Fred Hutchinson Cancer Center; University of Iowa; University of Iowa; Johns Hopkins University; Medical College of Wisconsin; MedStar Washington Hospital Center; Wake Forest University; Wake Forest Baptist Medical Center	Hendrix, SL (corresponding author), Wayne State Univ, Sch Med, Hutzel Womens Hosp, Dept Obstet & Gynecol, Detroit, MI 48201 USA.	shendrix@med.wayne.edu						*1 DATABANK INC, 2000, MDDB PROD LIN DOC MA; AHLSTROM K, 1990, GYNECOL OBSTET INVES, V30, P37, DOI 10.1159/000293211; *AM COLL OBST GYN, 2003, RESP WOM HLTH IN RES; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Andersson KE, 1999, BJU INT, V84, P923; BATRA SC, 1987, J UROLOGY, V138, P1301, DOI 10.1016/S0022-5347(17)43588-9; Brown JS, 1996, OBSTET GYNECOL, V87, P715, DOI 10.1016/0029-7844(96)00013-0; Brown JS, 1999, OBSTET GYNECOL, V94, P66, DOI 10.1016/S0029-7844(99)00263-X; Butler RN, 1999, GERIATRICS, V54, P31; Fantl JA, 1996, OBSTET GYNECOL, V88, P745; FANTL JA, 1994, OBSTET GYNECOL, V83, P12; Fornell EU, 2004, ACTA OBSTET GYN SCAN, V83, P383, DOI 10.1111/j.0001-6349.2004.00367.x; Grady D, 2001, OBSTET GYNECOL, V97, P116, DOI 10.1016/S0029-7844(00)01115-7; Griebling TL, 1997, ENDOCRIN METAB CLIN, V26, P347, DOI 10.1016/S0889-8529(05)70251-6; Grodstein F, 2003, AM J OBSTET GYNECOL, V189, P428, DOI 10.1067/S0002-9378(03)00361-2; Hays J, 2003, ANN EPIDEMIOL, V13, pS18, DOI 10.1016/S1047-2797(03)00042-5; Hunskaar S, 2003, UROLOGY, V62, P16, DOI 10.1016/S0090-4295(03)00755-6; IOSIF CS, 1981, AM J OBSTET GYNECOL, V141, P817, DOI 10.1016/0002-9378(81)90710-9; IOSIF CS, 1984, ACTA OBSTET GYN SCAN, V63, P257, DOI 10.3109/00016348409155509; Jackson S, 2002, BJOG-INT J OBSTET GY, V109, P339; Jackson S, 1999, BRIT J OBSTET GYNAEC, V106, P711, DOI 10.1111/j.1471-0528.1999.tb08372.x; JUDGE TG, 1969, GERONTOL CLIN, V11, P159, DOI 10.1159/000245230; Moehrer B, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001405; Muscatello DJ, 2001, INTERN MED J, V31, P151, DOI 10.1046/j.1445-5994.2001.00035.x; Novielli Karen D., 2003, International Urology and Nephrology, V35, P423, DOI 10.1023/B:UROL.0000022868.73066.9a; Patterson RE, 1999, ANN EPIDEMIOL, V9, P178, DOI 10.1016/S1047-2797(98)00055-6; RESNICK NM, 1994, J AM GERIATR SOC, V42, P202, DOI 10.1111/j.1532-5415.1994.tb04953.x; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rufford J, 2003, INT UROGYNECOL J, V14, P78, DOI 10.1007/s00192-003-1054-3; SAEZ S, 1981, J STEROID BIOCHEM, V15, P317, DOI 10.1016/0022-4731(81)90291-0; Sampselle CM, 2002, OBSTET GYNECOL, V100, P1230, DOI 10.1016/S0029-7844(02)02241-X; Sarkar PK, 2000, J CLIN PHARM THER, V25, P251; SCHREITER F, 1976, UROL INT, V31, P13, DOI 10.1159/000280026; Swithinbank LV, 1999, BRIT J GEN PRACT, V49, P897; Thom DH, 1998, J AM GERIATR SOC, V46, P1411; WILSON PD, 1987, BRIT J OBSTET GYNAEC, V94, P568, DOI 10.1111/j.1471-0528.1987.tb03152.x	37	330	336	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	2005	293	8					935	948		10.1001/jama.293.8.935	http://dx.doi.org/10.1001/jama.293.8.935			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899LR	15728164	Bronze			2022-12-28	WOS:000227146400015
J	Melnick, DJ; Navarro, YK; McNeely, J; Schmidt-Traub, G; Sears, RR				Melnick, DJ; Navarro, YK; McNeely, J; Schmidt-Traub, G; Sears, RR			The Millennium Project: the positive health implications of improved environmental sustainability	LANCET			English	Article							INFECTIOUS-DISEASE; BIODIVERSITY; EMERGENCE; RISK		Columbia Univ, Ctr Environm Res & Conservat, New York, NY 10027 USA; Fdn Futuro Latinoamer, Quito, Ecuador; IUCN, CH-1196 Gland, Switzerland; UN, Millennium Project, New York, NY 10017 USA	Columbia University	Melnick, DJ (corresponding author), Columbia Univ, Ctr Environm Res & Conservat, 1200 Amsterdam Ave, New York, NY 10027 USA.	djm7@columbia.edu		Sears, Robin/0000-0002-8925-1441				Bruce N, 2000, B WORLD HEALTH ORGAN, V78, P1078; Burke LA, 2000, PILOT ANAL GLOBAL EC; DASZAK P, 2002, CONSERVATION MED ECO; Fedson DS, 2003, CLIN INFECT DIS, V36, P1562, DOI 10.1086/376761; Kojima M., 2001, 508 WORLD BANK; LoGiudice K, 2003, P NATL ACAD SCI USA, V100, P567, DOI 10.1073/pnas.0233733100; MANGA L, 1995, ANN SOC BELG MED TR, V75, P129; Molyneux DH, 1997, ANN TROP MED PARASIT, V91, P827, DOI 10.1080/00034989760581; Norris DE, 2004, ECOHEALTH, V1, P19, DOI DOI 10.1007/S10393-004-0008-7; Patz JA, 2004, ENVIRON HEALTH PERSP, V112, P1092, DOI 10.1289/ehp.6877; PATZ JA, 2002, CONSERVATION MED ECO; Pauly D, 1998, SCIENCE, V279, P860, DOI 10.1126/science.279.5352.860; PEARL M, 2004, HUMAN I CAPACITY BUI; Portner H.-O., 2022, CLIMATE CHANGE 2022, P3; Roberts CM, 2002, SCIENCE, V295, P1280, DOI 10.1126/science.1067728; Sodhi NS, 2004, TRENDS ECOL EVOL, V19, P654, DOI 10.1016/j.tree.2004.09.006; Taylor LH, 2001, PHILOS T R SOC B, V356, P983, DOI 10.1098/rstb.2001.0888; United Nations (UN) Millennium Project, 2005, ENV HUM WELL BEING P; Vasconcelos P F, 2001, Cad Saude Publica, V17 Suppl, P155, DOI 10.1590/S0102-311X2001000700025; Walsh JF, 1993, PARASITOLOGY, V106, P55	20	11	11	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 19	2005	365	9460					723	725						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	898SP	15721479				2022-12-28	WOS:000227096800031
J	Nojima, S; Schal, C; Webster, FX; Santangelo, RG; Roelofs, WL				Nojima, S; Schal, C; Webster, FX; Santangelo, RG; Roelofs, WL			Identification of the sex pheromone of the German cockroach, Blattella germanica	SCIENCE			English	Article							CALLING BEHAVIOR; LOW-INCOME; ALLERGEN; ABATEMENT; BLA-G-1	The sex pheromone of the German cockroach, Blattella germanica, has been characterized as gentisyl quinone isovalerate. This cockroach is a major cause of allergic disease and serves as a mechanical vector of pathogens, making it one of the most important residential and food-associated pests worldwide. The sex pheromone-producing gland in adult females was identified in 1993, but thermal instability of the pheromone made characterization difficult. Now, using a new preparative gas chromatography approach coupled with electro-, antennographic detection, we have isolated and characterized the pheromone, which we term btattellaquinone, and confirmed the identification by chemical synthesis. The synthetic pheromone was active in behavioral assays and highly effective in field trapping tests, which suggest that it may provide a new tool in cockroach population detection, monitoring, and control.	Cornell Univ, New York State Agr Expt Stn, Dept Entomol, Geneva, NY 14456 USA; N Carolina State Univ, Dept Entomol, Raleigh, NC 27695 USA; N Carolina State Univ, WM Keck Ctr Behav Biol, Raleigh, NC 27695 USA; SUNY Coll Environm Sci & Forestry, Dept Chem, Syracuse, NY 13210 USA	Cornell University; University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University; State University of New York (SUNY) System; State University of New York (SUNY) College of Environmental Science & Forestry	Roelofs, WL (corresponding author), Cornell Univ, New York State Agr Expt Stn, Dept Entomol, Geneva, NY 14456 USA.	wlr1@cornell.edu	Schal, Coby/A-8717-2010	Schal, Coby/0000-0001-7195-6358				Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V113, P109, DOI 10.1016/j.jaci.2003.10.042; Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V112, P339, DOI 10.1067/mai.2003.1597; Brenner Richard J., 1995, P77; BROSSUT R, 1983, J CHEM ECOL, V9, P143, DOI 10.1007/BF00987778; Eisner T, 2004, J EXP BIOL, V207, P1313, DOI 10.1242/jeb.00849; LIANG D, 1993, EXPERIENTIA, V49, P324, DOI 10.1007/BF01923412; LIANG D, 1993, TISSUE CELL, V25, P763, DOI 10.1016/0040-8166(93)90057-R; LIANG DS, 1994, J INSECT PHYSIOL, V40, P251, DOI 10.1016/0022-1910(94)90048-5; LIANG DS, 1993, J INSECT BEHAV, V6, P603, DOI 10.1007/BF01048126; McConnell R, 2003, ANN ALLERG ASTHMA IM, V91, P546, DOI 10.1016/S1081-1206(10)61532-3; Nishida R., 1983, Memoirs of the College of Agriculture, Kyoto University, P1; Nojima S, 2004, J CHEM ECOL, V30, P2153, DOI 10.1023/B:JOEC.0000048780.26118.c0; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SCHAL C, 1990, ANNU REV ENTOMOL, V35, P521, DOI 10.1146/annurev.en.35.010190.002513; Zurek L, 2004, VET MICROBIOL, V101, P263, DOI 10.1016/j.vetmic.2004.04.011	15	94	104	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2005	307	5712					1104	1106		10.1126/science.1107163	http://dx.doi.org/10.1126/science.1107163			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	900ED	15718472				2022-12-28	WOS:000227197300047
J	Opferman, JT; Iwasaki, H; Ong, CC; Suh, H; Mizuno, S; Akashi, K; Korsmeyer, SJ				Opferman, JT; Iwasaki, H; Ong, CC; Suh, H; Mizuno, S; Akashi, K; Korsmeyer, SJ			Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells	SCIENCE			English	Article							PROGENITORS; LINEAGES; DEATH; MICE; BAX; BCL-2	Apoptosis is important in controlling hematopoietic stem cell (HSC) numbers. However, the specific BCL-2 family member(s) that regulate HSC homeostasis are not precisely defined. We tested myeloid Leukemia-1 (MCL-1) as an attractive candidate that is highly expressed in HSCs and regulated by growth factor signals. Inducible deletion of Mcl-1 in mice resulted in ablation of bone marrow. This resulted in the Loss of early bone marrow progenitor populations, including HSCs. Moreover, growth factors including stem cell factor increased transcription of the Mcl-1 gene and required MCL-1 to augment survival of purified bone marrow progenitors. Deletion of Mcl-1 in other tissues, including liver, did not impair survival. Thus, MCL-1 is a critical and specific regulator essential for ensuring the homeostasis of early hematopoietic progenitors.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS Pathol & Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Akashi, K (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS Pathol & Med, 44 Binney St, Boston, MA 02115 USA.	Koichi_Akashi@dfci.harvard.edu; Stanley_Korsmeyer@dfci.harvard.edu	Opferman, Joseph T/M-5331-2018	Opferman, Joseph T/0000-0002-1147-5621	NCI NIH HHS [R37CA50239, CA072009] Funding Source: Medline; NIDDK NIH HHS [DK061320] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072009, R37CA050239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061320] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Akashi K, 2003, BLOOD, V101, P383, DOI 10.1182/blood-2002-06-1780; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Domen J, 2000, J EXP MED, V191, P253, DOI 10.1084/jem.191.2.253; Domen J, 2001, APOPTOSIS, V6, P239, DOI 10.1023/A:1011347623402; Huang HM, 2000, BLOOD, V96, P1764, DOI 10.1182/blood.V96.5.1764.h8001764_1764_1771; Iwasaki H, 2003, IMMUNITY, V19, P451, DOI 10.1016/S1074-7613(03)00242-5; Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; MA A, 1995, P NATL ACAD SCI USA, V92, P4763, DOI 10.1073/pnas.92.11.4763; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Motoyama N, 1999, J EXP MED, V189, P1691, DOI 10.1084/jem.189.11.1691; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; OPFERMAN JT, UNPUB; Rinkenberger JL, 2000, GENE DEV, V14, P23; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wagers AJ, 2002, GENE THER, V9, P606, DOI 10.1038/sj.gt.3301717; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108	20	440	461	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2005	307	5712					1101	1104		10.1126/science.1106114	http://dx.doi.org/10.1126/science.1106114			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ED	15718471				2022-12-28	WOS:000227197300046
J	Clarke, JT; Gerard, JC; Grodent, D; Wannawichian, S; Gustin, J; Connerney, J; Crary, F; Dougherty, M; Kurth, W; Cowley, SWH; Bunce, EJ; Hill, T; Kim, J				Clarke, JT; Gerard, JC; Grodent, D; Wannawichian, S; Gustin, J; Connerney, J; Crary, F; Dougherty, M; Kurth, W; Cowley, SWH; Bunce, EJ; Hill, T; Kim, J			Morphological differences between Saturn's ultraviolet aurorae and those of Earth and Jupiter	NATURE			English	Article							ALPHA EMISSION; MAGNETOSPHERE; OVAL	It has often been stated that Saturn's magnetosphere and aurorae are intermediate between those of Earth, where the dominant processes are solar wind driven(1), and those of Jupiter, where processes are driven by a large source of internal plasma(2-4). But this view is based on information about Saturn that is far inferior to what is now available. Here we report ultraviolet images of Saturn, which, when combined with simultaneous Cassini measurements of the solar wind(5) and Saturn kilometric radio emission(6), demonstrate that its aurorae differ morphologically from those of both Earth and Jupiter. Saturn's auroral emissions vary slowly; some features appear in partial corotation whereas others are fixed to the solar wind direction; the auroral oval shifts quickly in latitude; and the aurora is often not centred on the magnetic pole nor closed on itself. In response to a large increase in solar wind dynamic pressure(5) Saturn's aurora brightened dramatically, the brightest auroral emissions moved to higher latitudes, and the dawn side polar regions were filled with intense emissions. The brightening is reminiscent of terrestrial aurorae, but the other two variations are not. Rather than being intermediate between the Earth and Jupiter, Saturn's auroral emissions behave fundamentally differently from those at the other planets.	Boston Univ, Boston, MA 02215 USA; Univ Liege, B-4000 Liege, Belgium; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; SW Res Inst, San Antonio, TX 78228 USA; Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England; Univ Iowa, Iowa City, IA 52242 USA; Univ Leicester, Leicester LE1 7RH, Leics, England; Rice Univ, Houston, TX 77005 USA; Yonsei Univ, Sch Civil & Environm Engn, Seoul 120749, South Korea	Boston University; University of Liege; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Southwest Research Institute; Imperial College London; University of Iowa; University of Leicester; Rice University; Yonsei University	Clarke, JT (corresponding author), Boston Univ, 725 Commonwealth Ave, Boston, MA 02215 USA.	jclarke@bu.edu	Bunce, Emma J/I-9067-2016; connerney, john/I-5127-2013; Kurth, William/AAA-7334-2019; Clarke, John/C-8644-2013	Bunce, Emma J/0000-0002-9456-0345; Kurth, William/0000-0002-5471-6202; Cowley, Stanley/0000-0002-4041-0034; GERARD, Jean-Claude/0000-0002-8565-8746				BROADFOOT AL, 1981, SCIENCE, V212, P206, DOI 10.1126/science.212.4491.206; CLARKE JT, 1981, NATURE, V290, P226, DOI 10.1038/290226a0; Cowley SWH, 2003, ANN GEOPHYS-GERMANY, V21, P1691, DOI 10.5194/angeo-21-1691-2003; Cowley SWH, 2001, PLANET SPACE SCI, V49, P1067, DOI 10.1016/S0032-0633(00)00167-7; COWLEY SWH, 2003, ANN GEOPHYS, V21, P1; Gerard JC, 2004, J GEOPHYS RES-SPACE, V109, DOI 10.1029/2004JA010513; Hill TW, 2004, ADV SPACE RES-SERIES, V33, P2021, DOI 10.1016/j.asr.2003.05.037; Hill TW, 2001, J GEOPHYS RES-SPACE, V106, P8101, DOI 10.1029/2000JA000302; JUDGE DL, 1980, SCIENCE, V207, P431, DOI 10.1126/science.207.4429.431; MCGRATH MA, 1992, J GEOPHYS RES-SPACE, V97, P13691, DOI 10.1029/92JA00143; Milan SE, 2003, ANN GEOPHYS-GERMANY, V21, P1121, DOI 10.5194/angeo-21-1121-2003; PRANGE R, IN PRESS NATURE; RICHARDSON JD, 1986, J GEOPHYS RES, V91, P1381, DOI 10.1029/JA091iA02p01381; SANDEL BR, 1981, NATURE, V292, P679, DOI 10.1038/292679a0; Trauger JT, 1998, J GEOPHYS RES-PLANET, V103, P20237, DOI 10.1029/98JE01324	15	138	138	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 17	2005	433	7027					717	719		10.1038/nature03331	http://dx.doi.org/10.1038/nature03331			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897XH	15716945	Green Published			2022-12-28	WOS:000227039200031
J	Talamini, MA; Hanly, EJ				Talamini, MA; Hanly, EJ			Technology in the operating suite	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LAPAROSCOPIC SURGERY; EXPERIENCE; SYSTEM; PROSTATECTOMY; FEASIBILITY; REPAIR; ROBOTS		Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA	Johns Hopkins University	Talamini, MA (corresponding author), Johns Hopkins Univ Hosp, Dept Surg, Blalock 665,500 N Wolfe St, Baltimore, MD 21287 USA.	talamini@jhmi.edu						Anvari Mehran, 2004, Semin Laparosc Surg, V11, P123, DOI 10.1177/107155170401100209; Berci G, 2004, SURG ENDOSC, V18, P1, DOI 10.1007/s00464-003-8270-2; Cadiere GB, 2001, WORLD J SURG, V25, P1467; Cadiere GB, 2001, SURG ENDOSC, V15, P918, DOI 10.1007/s004640000217; Costi R, 2004, SURG ENDOSC, V18, P629, DOI 10.1007/s00464-003-9053-5; Degueldre M, 2000, FERTIL STERIL, V74, P1020, DOI 10.1016/S0015-0282(00)01543-0; Goldberg JM, 2003, HUM REPROD, V18, P145, DOI 10.1093/humrep/deg011; Hanly EJ, 2004, AM J SURG, V188, p19S, DOI 10.1016/j.amjsurg.2004.08.020; Hanly EJ, 2004, AM J SURG, V187, P309, DOI 10.1016/j.amjsurg.2003.11.021; HANLY EJ, IN PRESS SURG ENDOSC; Hashemi M, 2000, J AM COLL SURGEONS, V190, P553, DOI 10.1016/S1072-7515(00)00260-X; Horgan S, 2003, AM SURGEON, V69, P624; Horgan S, 2001, J LAPAROENDOSC ADV A, V11, P415, DOI 10.1089/10926420152761950; Jacobs S, 2003, ANN THORAC SURG, V76, P2029, DOI 10.1016/S0003-4975(03)01058-0; Jacobsen G, 2003, J LAPAROENDOSC ADV A, V13, P279, DOI 10.1089/109264203322333610; Kalloo AN, 2004, GASTROINTEST ENDOSC, V60, P114, DOI 10.1016/S0016-5107(04)01309-4; Kitagawa M, 2004, ST HEAL T, V98, P157; Marescaux J, 2001, NATURE, V413, P379, DOI 10.1038/35096636; Marohn Michael R, 2004, Curr Surg, V61, P466, DOI 10.1016/j.cursur.2004.03.009; Melvin WS, 2002, J GASTROINTEST SURG, V6, P11, DOI 10.1016/S1091-255X(01)00032-4; Menon M, 2004, J ENDOUROL, V18, P611, DOI 10.1089/end.2004.18.611; Menon M, 2002, UROLOGY, V60, P864, DOI 10.1016/S0090-4295(02)01881-2; Nifong LW, 2004, AM J SURG, V188, p16S, DOI 10.1016/j.amjsurg.2004.08.026; Nifong LW, 2003, ANN THORAC SURG, V75, P438, DOI 10.1016/S0003-4975(02)04554-X; Rentschler ME, 2004, ST HEAL T, V98, P316; Satava Richard M, 2004, Semin Laparosc Surg, V11, P129, DOI 10.1177/107155170401100210; Talamini M, 2002, J LAPAROENDOSC ADV A, V12, P225, DOI 10.1089/109264202760267970; Talamini MA, 2003, SURG ENDOSC, V17, P1521, DOI 10.1007/s00464-002-8853-3; TAYLOR RH, 1995, IEEE ENG MED BIOL, V14, P279, DOI 10.1109/51.391776	29	12	12	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	2005	293	7					863	866		10.1001/jama.293.7.863	http://dx.doi.org/10.1001/jama.293.7.863			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DQ	15713777				2022-12-28	WOS:000226984600029
J	Rich, TH; Hopson, JA; Musser, AM; Flannery, TF; Vickers-Rich, P				Rich, TH; Hopson, JA; Musser, AM; Flannery, TF; Vickers-Rich, P			Independent origins of middle ear bones in Monotremes and Therians	SCIENCE			English	Article							OSSIFIED MECKELS CARTILAGE; MAMMALIAN EVOLUTION; MESOZOIC MAMMALS; PLATYPUS	A dentary of the oldest known monotreme, the Early Cretaceous Teinolophos trusleri, has an internal mandibular trough, which in outgroups to mammals houses accessory jaw bones, and probable contact facets for angular, coronoid, and splenial bones. Certain of these accessory bones were detached from the mandible to become middle ear bones in mammals. Evidence that the angular (homologous with the mammalian ectotympanic) and the articular and prearticular (homologous with the mammalian malleus) bones retained attachment to the lower jaw in a basal monotreme indicates that the definitive mammalian middle ear evolved independently in living monotremes and therians (marsupials and placentals).	Museum Victoria, Melbourne, Vic 3001, Australia; Monash Univ, Sch Geosci, Melbourne, Vic 3800, Australia; Univ Chicago, Dept Organismal Biol & Anat, Chicago, IL 60637 USA; Australian Museum, Sydney, NSW 2010, Australia; S Australian Museum, Adelaide, SA 5000, Australia	Museum Victoria; Monash University; University of Chicago; Australian Museum	Rich, TH (corresponding author), Museum Victoria, POB 666E, Melbourne, Vic 3001, Australia.	trich@museum.vic.gov.au						ALLIN EF, 1992, EVOLUTIONARY BIOLOGY OF HEARING, P587; ALLIN EF, 1975, J MORPHOL, V147, P403, DOI 10.1002/jmor.1051470404; CHOW M, 1982, Australian Mammalogy, V5, P127; FLEISCHER G, 1973, Saeugetierkundliche Mitteilungen, V21, P131; Forasiepi A, 2004, J VERTEBR PALEONTOL, V24, p59A; FOURIE S, 1974, Annals of the South African Museum, V65, P337; HOPSON JA, 1966, AM ZOOL, V6, P437; HOPSON JA, 2000, ENCY PALEONTOLOGY, P691; HOPSON JA, 1994, MAJOR FEATURES VERTE, P190; Janke A, 1997, P NATL ACAD SCI USA, V94, P1276, DOI 10.1073/pnas.94.4.1276; JENKINS FA, 1983, SCIENCE, V222, P1233, DOI 10.1126/science.222.4629.1233; Jenkins FA, 1997, NATURE, V385, P715, DOI 10.1038/385715a0; Ji Q, 1999, NATURE, V398, P326; KEMP TS, 1983, ZOOL J LINN SOC-LOND, V77, P353, DOI 10.1111/j.1096-3642.1983.tb00859.x; KERMACK DM, 1968, J LINN SOC ZOOLOGY, V47, P312; KERMACK KA, 1973, ZOOL J LINN SOC-LOND, V53, P87, DOI 10.1111/j.1096-3642.1973.tb00786.x; KIELANJAWOROWSKA Z, 1987, NATURE, V326, P871, DOI 10.1038/326871a0; Krusat G., 1980, MEMORIAS SERVICOS GE, V27, P1; Lillegraven J.A., 1991, Contributions to Geology University of Wyoming, V28, P39; Luo ZX, 2002, ACTA PALAEONTOL POL, V47, P1; Luo ZX, 2001, NATURE, V409, P53, DOI 10.1038/35051023; MENG J, 1995, NATURE, V377, P141, DOI 10.1038/377141a0; Meng J, 2003, ZOOL J LINN SOC-LOND, V138, P431, DOI 10.1046/j.1096-3642.2003.00064.x; Musser AM, 2003, COMP BIOCHEM PHYS A, V136, P927, DOI 10.1016/S1095-6433(03)00275-7; Musser AM, 1998, PHILOS T R SOC B, V353, P1063, DOI 10.1098/rstb.1998.0266; NOVACEK MJ, 1993, SKULL, V2, P438; PARRINGTON FR, 1971, PHILOS T R SOC B, V261, P231, DOI 10.1098/rstb.1971.0055; PATTERSON BRUAN, 1956, FIELDIANA GEOL, V13, P1; PATTERSON C, 1980, VICARIANCE BIOGEOGRA, P446; Penny D, 1997, NATURE, V387, P549, DOI 10.1038/42352; Phillips MJ, 2003, MOL PHYLOGENET EVOL, V28, P171, DOI 10.1016/S1055-7903(03)00057-5; Prothero DR, 1981, B AM MUS NAT HIST, V167, P277; Rauhut OWM, 2002, NATURE, V416, P165, DOI 10.1038/416165a; REICHERT C, 1837, MULLERS ARCH ANAT PH, P120; Rich TH, 2001, ACTA PALAEONTOL POL, V46, P113; Rich Thomas H., 1999, Records of the Queen Victoria Museum, V106, P1; Romer A, 1956, OSTEOLOGY REPTILES; Rougier Guillermo W., 1996, American Museum Novitates, V3183, P1; Rowe T., 1988, Journal of Vertebrate Paleontology, V8, P241; SIMPSON G. G., 1928, CATALOGUE MESOZOIC M; Wang YQ, 2001, SCIENCE, V294, P357, DOI 10.1126/science.1063830; Wible John R., 1995, American Museum Novitates, V3149, P1; WIBLE JR, 1993, MAMMAL PHYLOGENY, V1, P45; Woodburne Michael O., 2003, Journal of Mammalian Evolution, V10, P195, DOI 10.1023/B:JOMM.0000015104.29857.f0; Woodburne MO, 2003, MOL PHYLOGENET EVOL, V28, P360, DOI 10.1016/S1055-7903(03)00113-1; Zeller U., 1993, MAMMAL PHYLOGENY, P95; [No title captured]; [No title captured]	48	84	88	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2005	307	5711					910	914		10.1126/science.1105717	http://dx.doi.org/10.1126/science.1105717			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897DV	15705848				2022-12-28	WOS:000226985100049
J	Dragun, D; Muller, DN; Brasen, JH; Fritsche, L; Nieminen-Kelha, M; Dechend, R; Kintscher, U; Rudolph, B; Hoebeke, J; Eckert, D; Mazak, I; Plehm, R; Schonemann, C; Unger, T; Budde, K; Neumayer, HH; Luft, FC; Wallukat, G				Dragun, D; Muller, DN; Brasen, JH; Fritsche, L; Nieminen-Kelha, M; Dechend, R; Kintscher, U; Rudolph, B; Hoebeke, J; Eckert, D; Mazak, I; Plehm, R; Schonemann, C; Unger, T; Budde, K; Neumayer, HH; Luft, FC; Wallukat, G			Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TISSUE FACTOR; DILATED CARDIOMYOPATHY; AGONISTIC ANTIBODIES; VASCULAR REJECTION; ENDOTHELIAL-CELLS; C4D DEPOSITION; AT(1) RECEPTOR; TRANSPLANTATION; CLASSIFICATION; INJURY	BACKGROUND Antibodies against HLA antigens cause refractory allograft rejection with vasculopathy in some, but not all, patients. METHODS We studied 33 kidney-transplant recipients who had refractory vascular rejection. Thirteen had donor-specific anti-HLA antibodies, whereas 20 did not. Malignant hypertension was present in 16 of the patients without anti- HLA antibodies, 4 of whom had seizures. The remaining 17 patients had no malignant hypertension. We hypothesized that activating antibodies targeting the angiotensin II type 1 (AT(1)) receptor might be involved. RESULTS Activating IgG antibodies targeting the AT(1) receptor were detected in serum from all 16 patients with malignant hypertension and without anti- HLA antibodies, but in no other patients. These receptor-activating antibodies are subclass IgG1 and IgG3 antibodies that bind to two different epitopes on the second extracellular loop of the AT(1) receptor. Tissue factor expression was increased in renal-biopsy specimens from patients with these antibodies. In vitro stimulation of vascular cells with an AT(1)-receptor-activating antibody induced phosphorylation of ERK 1/2 kinase and increased the DNA binding activity of the transcription factors activator protein 1 (AP-1) and nuclear factor-kappaB. The AT(1) antagonist losartan blocked agonistic AT(1) - receptor antibody - mediated effects, and passive antibody transfer induced vasculopathy and hypertension in a rat kidney-transplantation model. CONCLUSIONS A non-HLA, AT(1) - receptor - mediated pathway may contribute to refractory vascular rejection, and affected patients might benefit from removal of AT(1) - receptor antibodies or from pharmacologic blockade of AT(1) receptors.	Charite, Dept Nephrol, D-10117 Berlin, Germany; Charite, Dept Pathol, D-10117 Berlin, Germany; Charite, Cardiovasc Res Ctr, D-10117 Berlin, Germany; Franz Volhard Clin, Berlin, Germany; HELIOS Klin, Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; HLA Lab, Berlin, Germany; CNRS, Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Franz-Volhard Clinical Research Center; Helios Kliniken; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Hamburg; University Medical Center Hamburg-Eppendorf; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Dragun, D (corresponding author), Charite, Dept Nephrol & Transplantat, Campus Mitte,Schumannstr 20-21, D-10117 Berlin, Germany.	duska.dragun@charite.de	Budde, Klemens/AAD-2170-2020	Budde, Klemens/0000-0002-7929-5942; Dragun, Duska/0000-0002-0310-9269; Kintscher, Ulrich/0000-0001-7386-0990; Muller, Dominik N/0000-0003-3650-5644; Luft, Friedrich/0000-0002-8635-1199; Nieminen-Kelha, Melina/0000-0002-7577-8058				AHERN AT, 1982, TRANSPLANTATION, V33, P103, DOI 10.1097/00007890-198201000-00023; Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Bohmig GA, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341091; de Gasparo M, 2000, PHARMACOL REV, V52, P415; Dechend R, 2000, CIRCULATION, V101, P2382, DOI 10.1161/01.CIR.101.20.2382; Dobado-Berrios PM, 2001, ARTHRITIS RHEUM-US, V44, P2467, DOI 10.1002/1529-0131(200111)44:11<2467::AID-ART426>3.0.CO;2-U; Dragun D, 2003, TRANSPLANT P, V35, P2104, DOI 10.1016/S0041-1345(03)00680-8; Dragun D, 2000, KIDNEY INT, V58, P2166, DOI 10.1046/j.1523-1755.2000.00390.x; FU MLX, 1994, LANCET, V344, P1660, DOI 10.1016/S0140-6736(94)90456-1; Heidenreich S, 1998, J AM SOC NEPHROL, V9, P1309; Hisada Y, 1999, J CLIN INVEST, V103, P627, DOI 10.1172/JCI2454; Holschermann H, 1999, AM J PATHOL, V154, P211, DOI 10.1016/S0002-9440(10)65267-4; JEANNET M, 1970, NEW ENGL J MED, V282, P111, DOI 10.1056/NEJM197001152820301; Le Bas-Bernardet S, 2003, AM J TRANSPLANT, V3, P167, DOI 10.1034/j.1600-6143.2003.00021.x; MAGNUSSON Y, 1994, CIRCULATION, V89, P2760, DOI 10.1161/01.CIR.89.6.2760; Masuda MO, 1998, FASEB J, V12, P1551, DOI 10.1096/fasebj.12.14.1551; Mauiyyedi S, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133779; Mellor AL, 2000, ANNU REV IMMUNOL, V18, P367, DOI 10.1146/annurev.immunol.18.1.367; Miller JA, 1999, KIDNEY INT, V56, P2173, DOI 10.1046/j.1523-1755.1999.00770.x; Nahmod KA, 2003, FASEB J, V17, P491, DOI 10.1096/fj.02-0755fje; Nataraj C, 1999, J CLIN INVEST, V104, P1693, DOI 10.1172/JCI7451; PAUL LC, 1985, TRANSPLANTATION, V40, P117, DOI 10.1097/00007890-198508000-00001; Praprotnik S, 2001, ARTHRITIS RHEUM-US, V44, P1484, DOI 10.1002/1529-0131(200107)44:7<1484::AID-ART269>3.0.CO;2-Q; Racusen LC, 2003, AM J TRANSPLANT, V3, P708, DOI 10.1034/j.1600-6143.2003.00072.x; Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x; Rapoport B, 2001, J CLIN INVEST, V108, P1253, DOI 10.1172/JCI14321; Regele H, 2001, NEPHROL DIAL TRANSPL, V16, P2058, DOI 10.1093/ndt/16.10.2058; Remuzzi G, 2002, CURR OPIN NEPHROL HY, V11, P1, DOI 10.1097/00041552-200201000-00001; Ruiz-Ortega M, 2001, CURR OPIN NEPHROL HY, V10, P321, DOI 10.1097/00041552-200105000-00005; SCHWIMMBECK PL, 1989, J CLIN INVEST, V84, P1174, DOI 10.1172/JCI114282; SHIMADA K, 1978, J BIOCHEM-TOKYO, V84, P1013, DOI 10.1093/oxfordjournals.jbchem.a132183; Thway TM, 2004, CIRCULATION, V110, P1612, DOI 10.1161/01.CIR.0000142855.68398.3A; VANDERWOUDE FJ, 1995, KIDNEY INT, V48, pS11; VANSAASE JLCM, 1995, TRANSPLANTATION, V59, P1280, DOI 10.1097/00007890-199505000-00010; Vos IHC, 2000, FASEB J, V14, P815, DOI 10.1096/fasebj.14.5.815; WALLUKAT G, 1995, J MOL CELL CARDIOL, V27, P397, DOI 10.1016/S0022-2828(08)80036-3; Wallukat G, 1999, J CLIN INVEST, V103, P945, DOI 10.1172/JCI4106; WALLUKAT G, 1995, J MOL CELL CARDIOL, V27, P2529; YARD B, 1993, TRANSPLANTATION, V55, P1287, DOI 10.1097/00007890-199306000-00015	39	618	649	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2005	352	6					558	569		10.1056/NEJMoa035717	http://dx.doi.org/10.1056/NEJMoa035717			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895KY	15703421	Green Accepted			2022-12-28	WOS:000226862100006
J	Steinbrook, R				Steinbrook, R			Commercial support and continuing medical education	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		*ACCR COUNC CONT M, 2004, STAND COMM SUPP; *ACCR COUNC CONT M, 2003, ANN REP DAT 2003; *ACCR COUNC CONT M, 2004, 2004 UPD STAND COMM; Angell M., 2004, TRUTH DRUG CO THEY D	4	33	33	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2005	352	6					534	535		10.1056/NEJMp048322	http://dx.doi.org/10.1056/NEJMp048322			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895KY	15703417				2022-12-28	WOS:000226862100002
J	Damiani, M; Propper, C; Dixon, J				Damiani, M; Propper, C; Dixon, J			Mapping choice in the NHS: cross sectional study of routinely collected data	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To identify where in England there are likely to be most constraints on choice of hospital for patients waiting longer than six months for elective care. Design Cross sectional study using routinely collected data. Setting Population of England and NHS trusts and private sector hospitals in England. Participants All residents in England. Main outcome measures Availability of beds (available and unoccupied hospital beds), demand (number of people waiting longer than six months), and access (travel time to facilities) to hospital care in England. Results Most people in England already have an extensive potential choice of hospital. The number of available and unoccupied beds within 60 minutes' travel time was lowest in the Scottish borders, North Yorkshire, and parts of East Anglia, Lincolnshire, Devon, and Cornwall. This pattern was not altered by adding in private facilities. Putting demand with this supply, the number of people in a geographical area waiting longer than six months per bed within 60 minutes' travel time was highest in the south east (except London), parts of the south west (Cornwall, Bristol), East Anglia, and the Welsh border. Conclusion People in the south cast (outside London), East Anglia, and parts of the south west are likely to have to travel further to exercise meaningful choice of hospital for elective care.	Univ Bristol, Dept Econ, Bristol BS8 1TH, Avon, England; Kings Fund, Policy Directorate, London W1G 0AN, England	University of Bristol	Propper, C (corresponding author), Univ Bristol, Dept Econ, Bristol BS8 1TH, Avon, England.	carol.propper@bristol.ac.uk		Propper, Carol/0000-0002-8257-431X	Economic and Social Research Council [RES-343-28-3001] Funding Source: researchfish	Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))		Appleby J., 2003, WHAT IS REAL COST MO; *DEP HLTH, 2005, PERF; Department of Health, 2002, REF NHS FIN FLOWS IN; DIXON J, 2003, CAN MARKET FORCES BE; *ED, 2005, UKBORDERS; *HM GOV, 2001, NHS IMPR PLAN PUTT P; Martin RM, 2003, BMJ-BRIT MED J, V326, P188, DOI 10.1136/bmj.326.7382.188; MARTIN S, 1999, J PUBLIC ECON, V17, P11; *NAT PAT SURV PROG, 2003, 2003 RES PRIM CAR TR; *NHS MOD AG, 2003, TREATM CTR; Propper C, 1996, J PUBLIC ECON, V61, P307, DOI 10.1016/0047-2727(95)01561-2; Propper C, 2004, J PUBLIC ECON, V88, P1247, DOI 10.1016/S0047-2727(02)00216-5; 2002, LAINGS HEALTHCARE MA; 1999, DIRECTORY INDEPENDEN; 2002, FOSTER GOOD HOSP GUI	15	19	20	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 5	2005	330	7486					284	287		10.1136/bmj.330.7486.284	http://dx.doi.org/10.1136/bmj.330.7486.284			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895EM	15695275	Green Published, Bronze			2022-12-28	WOS:000226843700015
J	Randau, L; Munch, R; Hohn, MJ; Jahn, D; Soll, D				Randau, L; Munch, R; Hohn, MJ; Jahn, D; Soll, D			Nanoarchaeum equitans creates functional tRNAs from separate genes for their 5 '- and 3 '-halves	NATURE			English	Article							ESCHERICHIA-COLI; ARCHAEAL; RECOGNITION; ENDONUCLEASE; 3'-TERMINUS; SYNTHETASE; SEQUENCES; INVITRO; ORIGIN	Analysis of the genome sequence of the small hyperthermophilic archaeal parasite Nanoarchaeum equitans(1,2) has not revealed genes encoding the glutamate, histidine, tryptophan and initiator methionine transfer RNA species. Here we develop a computational approach to genome analysis that searches for widely separated genes encoding tRNA halves that, on the basis of structural prediction, could form intact tRNA molecules. A search of the N. equitans genome reveals nine genes that encode tRNA halves; together they account for the missing tRNA genes. The tRNA sequences are split after the anticodon-adjacent position 37, the normal location of tRNA introns. The terminal sequences can be accommodated in an intervening sequence that includes a 12 - 14-nucleotide GC-rich RNA duplex between the end of the 50 tRNA half and the beginning of the 30 tRNA half. Reverse transcriptase polymerase chain reaction and amino-acylation experiments of N. equitans tRNA demonstrated maturation to full-size tRNA and acceptor activity of the tRNA His and tRNA(Glu) species predicted in silico. As the joining mechanism possibly involves tRNA trans-splicing, the presence of an intron might have been required for early tRNA synthesis.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Tech Univ Carolo Wilhelmina Braunschweig, Inst Mikrobiol, D-38023 Braunschweig, Germany; Univ Regensburg, Lehrstuhl Mikrobiol, D-93053 Regensburg, Germany; Univ Regensburg, Archaeenzentrum, D-93053 Regensburg, Germany; Yale Univ, Dept Chem, New Haven, CT 06520 USA	Yale University; Braunschweig University of Technology; University of Regensburg; University of Regensburg; Yale University	Soll, D (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 266 Whitney Ave, New Haven, CT 06520 USA.	soll@trna.chem.yale.edu		Jahn, Dieter/0000-0002-4064-9205; Randau, Lennart/0000-0002-2780-2076				Abelson J, 1998, J BIOL CHEM, V273, P12685, DOI 10.1074/jbc.273.21.12685; Boucher Y, 2002, NATURE, V417, P27, DOI 10.1038/417027a; Connolly SA, 2004, BIOCHEMISTRY-US, V43, P962, DOI 10.1021/bi035708f; Curnow AW, 1998, P NATL ACAD SCI USA, V95, P12838, DOI 10.1073/pnas.95.22.12838; Di Giulio M, 1999, J THEOR BIOL, V197, P403, DOI 10.1006/jtbi.1998.0882; EDDY SR, 1994, NUCLEIC ACIDS RES, V22, P2079, DOI 10.1093/nar/22.11.2079; Fabbri S, 1998, SCIENCE, V280, P284, DOI 10.1126/science.280.5361.284; Gopalan V, 2002, J BIOL CHEM, V277, P6759, DOI 10.1074/jbc.R100067200; HAIN J, 1992, NUCLEIC ACIDS RES, V20, P5423, DOI 10.1093/nar/20.20.5423; Huber H, 2002, NATURE, V417, P63, DOI 10.1038/417063a; KlemanLeyer K, 1997, CELL, V89, P839, DOI 10.1016/S0092-8674(00)80269-X; KONARSKA MM, 1985, CELL, V42, P165, DOI 10.1016/S0092-8674(85)80112-4; Li H, 2000, J MOL BIOL, V302, P639, DOI 10.1006/jmbi.2000.3941; Lohan Amanda J, 2004, Methods Mol Biol, V265, P315; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; MAIZELS N, 1994, P NATL ACAD SCI USA, V91, P6729, DOI 10.1073/pnas.91.15.6729; Marck C, 2003, RNA, V9, P1516, DOI 10.1261/rna.5132503; Marck C, 2002, RNA, V8, P1189, DOI 10.1017/S1355838202022021; Nagaswamy U, 2003, ORIGINS LIFE EVOL B, V33, P199, DOI 10.1023/A:1024658727570; Salgia SR, 2003, RNA, V9, P319, DOI 10.1261/rna.2118203; SCHNEIDER TD, 1986, J MOL BIOL, V188, P415, DOI 10.1016/0022-2836(86)90165-8; Schurer H, 2001, BIOL CHEM, V382, P1147, DOI 10.1515/BC.2001.144; Sekine S, 1996, J MOL BIOL, V256, P685, DOI 10.1006/jmbi.1996.0118; SOLNICK D, 1986, CELL, V44, P211, DOI 10.1016/0092-8674(86)90752-X; Tanaka T., 2001, VIVA ORIGINO, V29, P134; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; Waters E, 2003, P NATL ACAD SCI USA, V100, P12984, DOI 10.1073/pnas.1735403100; Williams MA, 2000, NUCLEIC ACIDS RES, V28, P4444, DOI 10.1093/nar/28.22.4444; WISSINGER B, 1991, CELL, V65, P473, DOI 10.1016/0092-8674(91)90465-B; Xiong Y, 2003, MOL CELL, V12, P1165, DOI 10.1016/S1097-2765(03)00440-4	30	149	160	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 3	2005	433	7025					537	541		10.1038/nature03233	http://dx.doi.org/10.1038/nature03233			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893NT	15690044				2022-12-28	WOS:000226727200052
J	Calonge, N; Allan, JD; Berg, AO; Frame, PS; Gordis, L; Gregory, KD; Harris, R; Johnson, MS; Klein, JD; Loveland-Cherry, C; Moyer, VA; Ockene, JK; Petitti, DB; Siu, AL; Teutsch, SM; Yawn, BP				Calonge, N; Allan, JD; Berg, AO; Frame, PS; Gordis, L; Gregory, KD; Harris, R; Johnson, MS; Klein, JD; Loveland-Cherry, C; Moyer, VA; Ockene, JK; Petitti, DB; Siu, AL; Teutsch, SM; Yawn, BP		U S Preventive Services Task Force	Screening for abdominal aortic aneurysm: Recommendation statement	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; ENDOVASCULAR REPAIR; UNITED-STATES; RISK-FACTORS; SINGLE SCAN; AGE 65; POPULATION; MORTALITY; EPIDEMIOLOGY; SURVEILLANCE	This statement summarizes the U.S. Preventive Services Task Force (USPSTF) recommendations on screening for abdominal aortic aneurysm and the supporting scientific evidence and updates the 1996 recommendations on this topic. The complete information on which this statement is based, including evidence tables and references, is available in the accompanying article in this issue and in the evidence synthesis on this topic, which is available on the USPSTF Web site (www.preventiveservices.ahrq.gov).										Ashton HA, 2002, LANCET, V360, P1531, DOI 10.1016/S0140-6736(02)11522-4; Bengtsson H, 1991, Eur J Vasc Surg, V5, P53; Crow P, 2001, BRIT J SURG, V88, P941, DOI 10.1046/j.0007-1323.2001.01822.x; EMERTON ME, 1994, BRIT J SURG, V81, P1112, DOI 10.1002/bjs.1800810810; Fleming C, 2005, ANN INTERN MED, V142, P203, DOI 10.7326/0003-4819-142-3-200502010-00012; FLEMING C, 2004, PRIMARY CARE SCREENI; GILLUM RF, 1995, J CLIN EPIDEMIOL, V48, P1289, DOI 10.1016/0895-4356(95)00045-3; Glimaker H, 1991, Eur J Vasc Surg, V5, P125, DOI 10.1016/S0950-821X(05)80675-9; Greenhalgh RM, 2004, LANCET, V364, P843, DOI 10.1016/S0140-6736(04)16979-1; Harris PL, 2000, J VASC SURG, V32, P739, DOI 10.1067/mva.2000.109990; Huber TS, 2001, J VASC SURG, V33, P304, DOI 10.1067/mva.2001.112703; JOHNSTON KW, 1991, J VASC SURG, V13, P452, DOI 10.1067/mva.1991.26737; Kent KC, 2004, J VASC SURG, V39, P267, DOI 10.1016/j.jvs.2003.08.019; Lederle FA, 2000, ARCH INTERN MED, V160, P1117, DOI 10.1001/archinte.160.8.1117; Lederle FA, 2002, JAMA-J AM MED ASSOC, V287, P2968, DOI 10.1001/jama.287.22.2968; Lederle FA, 2002, NEW ENGL J MED, V346, P1437, DOI 10.1056/NEJMoa012573; Lederle FA, 1997, ANN INTERN MED, V126, P441, DOI 10.7326/0003-4819-126-6-199703150-00004; Lindholt JS, 1997, BRIT J SURG, V84, P40; Lindholt JS, 2002, EUR J VASC ENDOVASC, V23, P55, DOI 10.1053/ejvs.2001.1534; MEENAN RT, 2004, COST EFFECTIVENESS A; MORRIS GE, 1994, EUR J VASCULAR SURG, V8, P156, DOI 10.1016/S0950-821X(05)80451-7; NEVITT MP, 1989, NEW ENGL J MED, V321, P1009, DOI 10.1056/NEJM198910123211504; Norman PE, 2004, BRIT MED J, V329, P1259, DOI 10.1136/bmj.38272.478438.55; Powell JT, 1998, LANCET, V352, P1649; Prinssen M, 2004, NEW ENGL J MED, V351, P1607, DOI 10.1056/NEJMoa042002; SCOTT RAP, 1995, BRIT J SURG, V82, P1066, DOI 10.1002/bjs.1800820821; Scott RAP, 2001, EUR J VASC ENDOVASC, V21, P535, DOI 10.1053/ejvs.2001.1368; Scott RAP, 2002, BRIT J SURG, V89, P283, DOI 10.1046/j.0007-1323.2001.02014.x; SIMONI G, 1995, EUR J VASC ENDOVASC, V10, P207, DOI 10.1016/S1078-5884(05)80113-3; SMITH FCT, 1993, BRIT J SURG, V80, P1406, DOI 10.1002/bjs.1800801117; Vallabhaneni SR, 2001, EUR J RADIOL, V39, P34, DOI 10.1016/S0720-048X(01)00340-0; van der Vliet J A, 1993, Ned Tijdschr Geneeskd, V137, P1155; Wilmink ABM, 1998, BRIT J SURG, V85, P155	33	227	233	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	2005	142	3					198	202		10.7326/0003-4819-142-3-200502010-00011	http://dx.doi.org/10.7326/0003-4819-142-3-200502010-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900UH	15684208				2022-12-28	WOS:000227239300006
J	Kobayashi, S; Boggon, TJ; Dayaram, T; Janne, PA; Kocher, O; Meyerson, M; Johnson, BE; Eck, MJ; Tenen, DG; Halmos, B				Kobayashi, S; Boggon, TJ; Dayaram, T; Janne, PA; Kocher, O; Meyerson, M; Johnson, BE; Eck, MJ; Tenen, DG; Halmos, B			EGFR mutation and resistance of non-small-cell lung cancer to gefitinib	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE; IMATINIB RESISTANCE; SENSITIVITY; INHIBITOR; TRIAL	Mutations of the epidermal growth factor receptor ( EGFR) gene have been identified in from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors. Despite the dramatic responses to such inhibitors, patients ultimately have a relapse. The mechanism of the drug resistance is unknown. Here we report the case of a patient with EGFR - mutant, gefitinib-responsive, non-small-cell lung cancer who had a relapse after two years of complete remission during treatment with gefitinib. The DNA sequence of the EGFR gene in his biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR. Structural modeling and biochemical studies showed that this second mutation led to gefitinib resistance.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Hematol Oncol, Boston, MA 02215 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Case Western Reserve Univ, Univ Hosp Cleveland, Case Sch Med, Ireland Canc Ctr, Cleveland, OH 44106 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland	Tenen, DG (corresponding author), Harvard Inst Med, HIM-954,77 Louis Pasteur Ave, Boston, MA 02215 USA.	dtenen@bidmc.harvard.edu	Meyerson, Matthew L/E-7123-2012	Tenen, Daniel/0000-0002-6423-3888	NCI NIH HHS [PA20-CA090578-01A1, 1K12CA87723-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K12CA087723, P50CA090578, P20CA090578] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albanell J, 2002, J CLIN ONCOL, V20, P110, DOI 10.1200/JCO.20.1.110; Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Blencke S, 2003, J BIOL CHEM, V278, P15435, DOI 10.1074/jbc.M211158200; Chen LL, 2004, CANCER RES, V64, P5913, DOI 10.1158/0008-5472.CAN-04-0085; Cho D, 2005, J CLIN ONCOL, V23, P235, DOI 10.1200/JCO.2005.07.169; Discafani CM, 1999, BIOCHEM PHARMACOL, V57, P917, DOI 10.1016/S0006-2952(98)00356-6; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Isomura M, 2004, J CLIN ONCOL, V22, p200S; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Miller VA, 2004, J CLIN ONCOL, V22, P1103, DOI 10.1200/JCO.2004.08.158; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Perez-Soler R, 2004, J CLIN ONCOL, V22, P3238, DOI 10.1200/JCO.2004.11.057; Scagliotti GV, 2002, J CLIN ONCOL, V20, P4285, DOI 10.1200/JCO.2002.02.068; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200	24	3152	3327	10	331	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2005	352	8					786	792		10.1056/NEJMoa044238	http://dx.doi.org/10.1056/NEJMoa044238			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899MC	15728811				2022-12-28	WOS:000227147500008
J	Troccoli, M; Belyanin, A; Capasso, F; Cubukcu, E; Sivco, DL; Cho, AY				Troccoli, M; Belyanin, A; Capasso, F; Cubukcu, E; Sivco, DL; Cho, AY			Raman injection laser	NATURE			English	Article							QUANTUM-CASCADE LASERS; GENERATION; OPERATION	Stimulated Raman scattering is a nonlinear optical process that, in a broad variety of materials, enables the generation of optical gain at a frequency that is shifted from that of the incident radiation by an amount corresponding to the frequency of an internal oscillation of the material(1,2). This effect is the basis for a broad class of tunable sources known as Raman lasers(2,3). In general, these sources have only small gain (similar to10(-9) cm W(-1)) and therefore require external pumping with powerful lasers, which limits their applications. Here we report the realization of a semiconductor injection Raman laser designed to circumvent these limitations. The physics underlying our device differs in a fundamental way from existing Raman lasers(3-8): it is based on triply resonant stimulated Raman scattering between quantum-confined states within the active region of a quantum cascade laser that serves as an internal optical pump-the device is driven electrically and no external laser pump is required. This leads to an enhancement of orders of magnitude in the Raman gain, high conversion efficiency and low threshold. Our lasers combine the advantages of nonlinear optical devices and of semiconductor injection lasers, and could lead to a new class of compact and wavelength-agile mid- and far-infrared light sources.	Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA; Texas A&M Univ, Dept Phys, College Stn, TX 77843 USA; Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA	Harvard University; Texas A&M University System; Texas A&M University College Station; Alcatel-Lucent; Lucent Technologies; AT&T	Troccoli, M (corresponding author), Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA.	troccoli@deas.harvard.edu; belyanin@jewel.tamu.edu	Cubukcu, Ertugrul/F-4807-2010; Cubukcu, Ertugrul/D-5007-2012	Troccoli, Mariano/0000-0003-3709-1893				Belyanin A, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.013814; Bengloan JY, 2004, APPL PHYS LETT, V84, P2019, DOI 10.1063/1.1669062; Boyd R. W., 2003, NONLINEAR OPTICS; Capasso F, 2000, IEEE J SEL TOP QUANT, V6, P931, DOI 10.1109/2944.902142; CAPASSO F, 1994, IEEE J QUANTUM ELECT, V30, P1313, DOI 10.1109/3.303697; Faist J, 2002, IEEE J QUANTUM ELECT, V38, P533, DOI 10.1109/JQE.2002.1005404; Gmachl C, 1999, IEEE J SEL TOP QUANT, V5, P808, DOI 10.1109/2944.788454; Gmachl C, 2003, IEEE J QUANTUM ELECT, V39, P1345, DOI 10.1109/JQE.2003.818315; Grabtchikov AS, 1999, APPL PHYS LETT, V75, P3742, DOI 10.1063/1.125440; Helm M, 2000, SEMICONDUCT SEMIMET, V62, P1; Khurgin JB, 1995, J APPL PHYS, V78, P7398, DOI 10.1063/1.360391; Kocharovskaya O, 1998, PHYS REV A, V58, P649, DOI 10.1103/PhysRevA.58.649; Liu HC, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.077402; Liu HC, 2001, APPL PHYS LETT, V78, P3580, DOI 10.1063/1.1377857; NISHIZAWA J, 1980, J APPL PHYS, V51, P2429, DOI 10.1063/1.328012; Owschimikow N, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.043902; Pask HM, 2003, PROG QUANT ELECTRON, V27, P3, DOI 10.1016/S0079-6727(02)00017-4; Rosencher E, 1996, SCIENCE, V271, P168, DOI 10.1126/science.271.5246.168; Shen Y. R., 1984, PRINCIPLES NONLINEAR; Spillane SM, 2002, NATURE, V415, P621, DOI 10.1038/415621a	20	115	116	2	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 24	2005	433	7028					845	848		10.1038/nature03330	http://dx.doi.org/10.1038/nature03330			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	899VT	15729336				2022-12-28	WOS:000227174600036
J	Grant, AM; Altman, DG; Babiker, AG; Campbell, MK; Clemens, F; Darbyshire, JH; Elbourne, DR; McLeer, SK; Parmar, MKB; Pocock, SJ; Spiegelhalter, DJ; Sydes, MR; Walker, AE; Wallace, SA				Grant, AM; Altman, DG; Babiker, AG; Campbell, MK; Clemens, F; Darbyshire, JH; Elbourne, DR; McLeer, SK; Parmar, MKB; Pocock, SJ; Spiegelhalter, DJ; Sydes, MR; Walker, AE; Wallace, SA		DAMOCLES Study Grp	A proposed charter for clinical trial data monitoring committees: helping them to do their job well	LANCET			English	Article							RANDOMIZED CONTROLLED-TRIALS; QUALITY	Formal monitoring of data from randomised controlled trials (RCTs) is becoming more common. Wide variation exists in the structure and organisation of data monitoring committees (DMCs), with little guidance on how they should operate. We used various strategies to consider the behavioural, procedural, and organisational aspects of data monitoring in RCTs: systematic reviews of DMCs and small group processes in decision making; surveys of reports of RCTs, recently completed and ongoing RCTs, and the policies of major organisations connected with RCTs; detailed case studies of four DMCs that faced difficult decisions; and interviews with experienced DMC members. The findings aided the development of a template for a charter for DMCs. We summarise the findings and outline the key considerations at every stage of the data monitoring process. Widespread use of a charter for the structure and organisation of DMCs would promote a systematic and transparent approach, and enable them to operate more effectively and efficiently.	Univ Aberdeen, Hlth Serv Res Unit, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	Grant, AM (corresponding author), Univ Aberdeen, Hlth Serv Res Unit, Polwarth Bldg, Aberdeen AB25 2ZD, Scotland.	m.k.campbell@abdn.ac.uk	Sydes, Matthew/C-3373-2008; Campbell, Marion/ABB-7063-2020; Wallace, Sheila/A-6921-2018	Sydes, Matthew/0000-0002-9323-1371; Wallace, Sheila/0000-0003-2853-3653; Campbell, Marion/0000-0001-5386-4097				Antes G, 2003, LANCET, V361, P978, DOI 10.1016/S0140-6736(03)12838-3; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Clemens F, 2005, CLIN TRIALS, V2, P22, DOI 10.1191/1740774505cn064oa; *DAMOCLES STUD GRO, ISS DAT MON INT AN T; DeMets DL, 1999, LANCET, V354, P1983, DOI 10.1016/S0140-6736(99)03464-9; Devereaux PJ, 2002, CONTROL CLIN TRIALS, V23, P380, DOI 10.1016/S0197-2456(02)00214-3; Egger M, 2001, JAMA-J AM MED ASSOC, V285, P1996, DOI 10.1001/jama.285.15.1996; Ellenberg SS., 2002, DATA MONITORING COMM; Fisher MR, 2001, DRUG INF J, V35, P115, DOI 10.1177/009286150103500113; GRANT A, IN PRESS HLTH TECHNO; ICH Steering Committee, ICH HARM TRIP GUID S; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1992, DOI 10.1001/jama.285.15.1992; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Packer M, 2001, AM HEART J, V141, P542, DOI 10.1067/mhj.2001.113838; Sydes Matthew R, 2004, Clin Trials, V1, P60, DOI 10.1191/1740774504cn004rr; Sydes Matthew R, 2004, Clin Trials, V1, P48, DOI 10.1191/1740774504cn003oa; Walker Anne E, 2004, Clin Trials, V1, P282, DOI 10.1191/1740774504cn023oa; 2001, FED REG, V66, P58151	18	202	207	1	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	2005	365	9460					711	722						12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	898SP	15721478				2022-12-28	WOS:000227096800030
J	Brown, JW; Braver, TS				Brown, JW; Braver, TS			Learned predictions of error likelihood in the anterior cingulate cortex	SCIENCE			English	Article							FRONTAL-CORTEX; COGNITIVE CONTROL; DOPAMINE NEURONS; REWARD; PERFORMANCE; BRAIN; GO	The anterior cingulate cortex (ACC) and the related medial wall play a critical role in recruiting cognitive control. Although ACC exhibits selective error and conflict responses, it has been unclear how these develop and become context-specific. With use of a modified stop-signal task, we show from integrated computational neural modeling and neuroimaging studies that ACC learns to predict error likelihood in a given context, even for trials in which there is no error or response conflict. These results support a more general error-likelihood theory of ACC function based on reinforcement learning, of which conflict and error detection are special cases.	Washington Univ, Dept Psychol, St Louis, MO 63130 USA	Washington University (WUSTL)	Brown, JW (corresponding author), Washington Univ, Dept Psychol, CB 1125, St Louis, MO 63130 USA.	jwbrown@artsci.wustl.edu	Brown, Joshua/G-2867-2011	Braver, Todd/0000-0002-2631-3393				Bao SW, 2001, NATURE, V412, P79, DOI 10.1038/35083586; BERNSTEIN PS, 1995, J EXP PSYCHOL HUMAN, V21, P1312, DOI 10.1037/0096-1523.21.6.1312; Botvinick M, 1999, NATURE, V402, P179, DOI 10.1038/46035; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; BOUSSAOUD D, 1993, EXP BRAIN RES, V95, P28; Brown JW, 2004, NEURAL NETWORKS, V17, P471, DOI 10.1016/j.neunet.2003.08.006; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; Fiorillo CD, 2003, SCIENCE, V299, P1898, DOI 10.1126/science.1077349; GEHRING WJ, 1990, PSYCHOPHYSIOLOGY, V27, P34; HERMSTEIN RJ, 1961, J EXPT ANAL BEHAV, V4, P267; Hohnsbein J., 1989, J PSYCHOPHYSIOL, V3, P32; Holroyd CB, 2004, NAT NEUROSCI, V7, P497, DOI 10.1038/nn1238; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI 10.1037/0033-295X.109.4.679; Ito S, 2003, SCIENCE, V302, P120, DOI 10.1126/science.1087847; Jones AD, 2002, COGN AFFECT BEHAV NE, V2, P300, DOI 10.3758/CABN.2.4.300; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037/0033-295X.91.3.295; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; O'Doherty JP, 2003, NEURON, V38, P329, DOI 10.1016/S0896-6273(03)00169-7; Ridderinkhof KR, 2004, SCIENCE, V306, P443, DOI 10.1126/science.1100301; Rubia K, 2001, NEUROIMAGE, V13, P250, DOI 10.1006/nimg.2000.0685; Schall JD, 2002, NEURON, V36, P309, DOI 10.1016/S0896-6273(02)00964-9; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Stuphorn V, 2000, NATURE, V408, P857, DOI 10.1038/35048576; Sugrue LP, 2004, SCIENCE, V304, P1782, DOI 10.1126/science.1094765	26	649	657	0	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	2005	307	5712					1118	1121		10.1126/science.1105783	http://dx.doi.org/10.1126/science.1105783			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ED	15718473				2022-12-28	WOS:000227197300051
J	Kragelund, C; Gronning, B; Kober, L; Hildebrandt, P; Steffensen, R				Kragelund, C; Gronning, B; Kober, L; Hildebrandt, P; Steffensen, R			N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; VENTRICULAR SYSTOLIC FUNCTION; ARTERY-DISEASE; CARDIOVASCULAR EVENTS; RISK STRATIFICATION; EXPRESSION; PROGNOSIS; ISCHEMIA; ANGINA; ATRIAL	BACKGROUND: The level of the inactive N-terminal fragment of pro-brain (B-type) natriuretic peptide (BNP) is a strong predictor of mortality among patients with acute coronary syndromes and may be a strong prognostic marker in patients with chronic coronary heart disease as well. We assessed the relationship between N-terminal pro-BNP (NT-pro-BNP) levels and long-term mortality from all causes in a large cohort of patients with stable coronary heart disease. METHODS: NT-pro-BNP was measured in baseline serum samples from 1034 patients referred for angiography because of symptoms or signs of coronary heart disease. The rate of death from all causes was determined after a median follow-up of nine years. RESULTS: At follow-up, 288 patients had died. The median NT-pro-BNP level was significantly lower among patients who survived than among those who died (120 pg per milliliter [interquartile range, 50 to 318] vs. 386 pg per milliliter [interquartile range, 146 to 897], P<0.001). Patients with NT-pro-BNP levels in the highest quartile were older, had a lower left ventricular ejection fraction (LVEF) and a lower creatinine clearance rate, and were more likely to have a history of myocardial infarction, clinically significant coronary artery disease, and diabetes than patients with NT-pro-BNP levels in the lowest quartile. In a multivariable Cox regression model, the hazard ratio for death from any cause for the patients with NT-pro-BNP levels in the fourth quartile as compared with those in the first quartile was 2.4 (95 percent confidence interval, 1.5 to 4.0; P<0.001); the NT-pro-BNP level added prognostic information beyond that provided by conventional risk factors, including the patient's age; sex; family history with respect to ischemic heart disease; the presence or absence of a history of myocardial infarction, angina, hypertension, diabetes, or chronic heart failure; creatinine clearance rate; body-mass index; smoking status; plasma lipid levels; LVEF; and the presence or absence of clinically significant coronary artery disease on angiography. CONCLUSIONS: NT-pro-BNP is a marker of long-term mortality in patients with stable coronary disease and provides prognostic information above and beyond that provided by conventional cardiovascular risk factors and the degree of left ventricular systolic dysfunction.	Univ Copenhagen, Frederiksberg Hosp, Dept Cardiol & Endocrinol, DK-2000 Copenhagen, Denmark; Hillerod Univ Hosp, Dept Cardiol, Copenhagen, Denmark; Rigshosp, Dept Cardiol, Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; Rigshospitalet; University of Copenhagen	Kragelund, C (corresponding author), Univ Copenhagen, Frederiksberg Hosp, Dept Cardiol & Endocrinol, Nordre Fasanvej 57, DK-2000 Copenhagen, Denmark.	kragelund@dadlnet.dk		Kober, Lars/0000-0002-6635-1466				Bibbins-Domingo K, 2003, CIRCULATION, V108, P2987, DOI 10.1161/01.CIR.0000103681.04726.9C; Cole JH, 2003, J AM COLL CARDIOL, V41, P521, DOI 10.1016/S0735-1097(02)02862-0; D'Souza SP, 2004, PHARMACOL THERAPEUT, V101, P113, DOI 10.1016/j.pharmthera.2003.11.001; D'Souza SP, 2003, HEART, V89, P707, DOI 10.1136/heart.89.7.707; de Lemos JA, 2001, NEW ENGL J MED, V345, P1014, DOI 10.1056/NEJMoa011053; DODGE HT, 1983, J AM COLL CARDIOL, V1, P73, DOI 10.1016/S0735-1097(83)80012-6; Fox KM, 2003, LANCET, V362, P782; Gardner RS, 2003, EUR HEART J, V24, P1735, DOI 10.1016/j.ehj.2003.07.005; Gill D, 2004, CLIN SCI, V106, P135, DOI 10.1042/CS20030131; Goetze JP, 2003, FASEB J, V17, P1105, DOI 10.1096/fj.02-0796fje; Hall C, 2004, EUR J HEART FAIL, V6, P257, DOI 10.1016/j.ejheart.2003.12.015; James SK, 2003, CIRCULATION, V108, P275, DOI 10.1161/01.CIR.0000079170.10579.DC; Jernberg T, 2002, J AM COLL CARDIOL, V40, P437, DOI 10.1016/S0735-1097(02)01986-1; Levin ER, 1998, NEW ENGL J MED, V339, P321; MARUMOTO K, 1995, CLIN SCI, V88, P551, DOI 10.1042/cs0880551; McGowan JH, 2003, AM HEART J, V146, P388, DOI 10.1016/S0002-8703(03)00248-5; MORITA E, 1993, CIRCULATION, V88, P82, DOI 10.1161/01.CIR.88.1.82; Morrow DA, 2003, J AM COLL CARDIOL, V41, P1264, DOI 10.1016/S0735-1097(03)00168-2; Morrow DA, 2003, J AM COLL CARDIOL, V41, P1853, DOI 10.1016/S0735-1097(03)00571-0; Nilsson JC, 2002, AM HEART J, V143, P696, DOI 10.1067/mhj.2002.120293; Omland T, 2002, CIRCULATION, V106, P2913, DOI 10.1161/01.CIR.0000041661.63285.AE; Omland T, 1996, CIRCULATION, V93, P1963, DOI 10.1161/01.CIR.93.11.1963; Richards AM, 1998, CIRCULATION, V97, P1921, DOI 10.1161/01.CIR.97.19.1921; Sabatine MS, 2002, CIRCULATION, V105, P1760, DOI 10.1161/01.CIR.0000015464.18023.0A; Talwar S, 2000, HEART, V84, P421, DOI 10.1136/heart.84.4.421; Talwar S, 2000, EUR HEART J, V21, P1514, DOI 10.1053/euhj.1999.2045; Tateishi J, 2000, CLIN CARDIOL, V23, P776, DOI 10.1002/clc.4960231016; Tsutamoto T, 1997, CIRCULATION, V96, P509; Wang TJ, 2004, NEW ENGL J MED, V350, P655, DOI 10.1056/NEJMoa031994; Wiviott SD, 2004, CIRCULATION, V109, P580, DOI 10.1161/01.CIR.0000109491.66226.26	30	509	540	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2005	352	7					666	675		10.1056/NEJMoa042330	http://dx.doi.org/10.1056/NEJMoa042330			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897UO	15716560				2022-12-28	WOS:000227031100005
J	Nieschlag, E; Henke, A				Nieschlag, E; Henke, A			Hopes for male contraception	LANCET			English	Editorial Material							HORMONAL MALE CONTRACEPTION; MONKEYS; IMPACT; EPPIN		Univ Munster, Inst Reprod Med, D-48129 Munster, Germany	University of Munster	Nieschlag, E (corresponding author), Univ Munster, Inst Reprod Med, Steinfurter Str 107, D-48129 Munster, Germany.	eberhard.nieschlag@ukmuenster.de						[Anonymous], 1990, Lancet, V336, P955; DARCANGUES C, 2000, DEP REPROD HLTH RES, P109; Diczfalusy E, 2004, MOL CELL ENDOCRINOL, V216, P1, DOI 10.1016/j.mce.2003.10.067; Kamischke A, 2004, TRENDS PHARMACOL SCI, V25, P49, DOI 10.1016/j.tips.2003.11.009; Martin CW, 2000, HUM REPROD, V15, P637, DOI 10.1093/humrep/15.3.637; Moudgal NR, 1997, HUM REPROD UPDATE, V3, P335, DOI 10.1093/humupd/3.4.335; Nieschlag E, 2001, ANDROLOGY, 2ND EDITION, P399; Nieschlag E, 2004, TESTOSTERONE ACTION, P685; Nieschlag E, 1986, MALE CONTRACEPTION A, p[1986, 395]; O'Rand MG, 2004, SCIENCE, V306, P1189, DOI 10.1126/science.1099743; Richardson RT, 2001, GENE, V270, P93, DOI 10.1016/S0378-1119(01)00462-0; THAU RB, 1987, AM J REPROD IMMUNOL, V15, P92; Waites GMH, 2003, FERTIL STERIL, V80, P1, DOI 10.1016/S0015-0282(03)00577-6; 2002, INT J ANDROL, V25, P375	14	28	29	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	2005	365	9459					554	556						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DN	15708085				2022-12-28	WOS:000226984300008
J	Briggman, KL; Abarbanel, HDI; Kristan, WB				Briggman, KL; Abarbanel, HDI; Kristan, WB			Optical imaging of neuronal populations during decision-making	SCIENCE			English	Article							BEHAVIORAL CHOICE; MEDICINAL LEECH; PERCEPTUAL DECISION; PARIETAL CORTEX; NEURAL BASIS; SWIM; PLEUROBRANCHAEA; MECHANISMS; INITIATION; TARGETS	We investigated decision-making in the leech nervous system by stimulating identical sensory inputs that sometimes elicit crawling and other times swimming. Neuronal populations were monitored with voltage-sensitive dyes after each stimulus. By quantifying the discrimination time of each neuron, we found single neurons that discriminate before the two behaviors are evident. We used principal component analysis and linear discriminant analysis to find populations of neurons that discriminated earlier than any single neuron. The analysis highlighted the neuron cell 208. Hyperpolarizing cell 208 during a stimulus biases the leech to swim; depolarizing it biases the leech to crawl or to delay swimming.	Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Phys, La Jolla, CA 92093 USA; Univ Calif San Diego, Scripps Inst Oceanog, Marine Phys Lab, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Institution of Oceanography	Kristan, WB (corresponding author), Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA.	wkristan@ucsd.edu	Abarbanel, Henry Don Isaac/AAX-3192-2021		NIMH NIH HHS [MH43396] Funding Source: Medline; NINDS NIH HHS [NS40110] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH043396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040110] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abarbanel H.D.I., 1996, ANAL OBSERVED CHAOTI; BRODFUEHRER PD, 1995, NEUROBIOL LEARN MEM, V63, P192, DOI 10.1006/nlme.1995.1020; Broomhead D S., 1987, J PHYS A, V20, P563; BROOMHEAD DS, 1986, PHYSICA D, V20, P217, DOI 10.1016/0167-2789(86)90031-X; Cacciatore TW, 2000, J NEUROSCI, V20, P1643; Cacciatore TW, 1999, NEURON, V23, P449, DOI 10.1016/S0896-6273(00)80799-0; Duda R.O., 2000, PATTERN CLASSIFICATI; Eisenhart FJ, 2000, J COMP PHYSIOL A, V186, P631, DOI 10.1007/s003590000117; Esch T, 2002, INTEGR COMP BIOL, V42, P716, DOI 10.1093/icb/42.4.716; Esch T, 2002, J NEUROSCI, V22, P11045; Glimcher PW, 2001, TRENDS NEUROSCI, V24, P654, DOI 10.1016/S0166-2236(00)01932-9; Glimcher PW, 2003, BRADFORD BOOKS, P1; Gold JI, 2000, NATURE, V404, P390, DOI 10.1038/35006062; Gonzalez JE, 1999, DRUG DISCOV TODAY, V4, P431, DOI 10.1016/S1359-6446(99)01383-5; KAPLAN D, 1995, UNDERSTANDING NONLIN; KOVAC MP, 1980, J NEUROPHYSIOL, V43, P469, DOI 10.1152/jn.1980.43.2.469; KOVAC MP, 1977, SCIENCE, V198, P632, DOI 10.1126/science.918659; KRISTAN WB, 1982, J EXP BIOL, V96, P143; Kristan WB, 1997, CURR OPIN NEUROBIOL, V7, P826, DOI 10.1016/S0959-4388(97)80142-0; KRISTAN WB, 1976, J EXP BIOL, V65, P643; KRISTAN WB, 1982, J EXP BIOL, V96, P161; Mardia K.V, 1980, MULTIVARIATE ANAL; MULLER KJ, 1981, NEUROBIOLOGY LEECH; Platt ML, 1999, NATURE, V400, P233, DOI 10.1038/22268; Popescu IR, 2002, J NEUROSCI, V22, P1985, DOI 10.1523/JNEUROSCI.22-05-01985.2002; Romo R, 2001, ANNU REV NEUROSCI, V24, P107, DOI 10.1146/annurev.neuro.24.1.107; Schall JD, 2000, CURR BIOL, V10, pR404, DOI 10.1016/S0960-9822(00)00504-2; Schall JD, 2001, NAT REV NEUROSCI, V2, P33, DOI 10.1038/35049054; Shadlen MN, 2001, J NEUROPHYSIOL, V86, P1916, DOI 10.1152/jn.2001.86.4.1916; Shadlen MN, 1996, P NATL ACAD SCI USA, V93, P628, DOI 10.1073/pnas.93.2.628; Shaw BK, 1997, J NEUROSCI, V17, P786; Taylor AL, 2003, J NEUROSCI, V23, P11402; WEEKS JC, 1978, J EXP BIOL, V77, P71; WEEKS JC, 1982, J COMP PHYSIOL, V148, P265, DOI 10.1007/BF00619133; Zochowski M, 2000, J NEUROSCI, V20, P8485, DOI 10.1523/JNEUROSCI.20-22-08485.2000	35	229	232	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	2005	307	5711					896	901		10.1126/science.1103736	http://dx.doi.org/10.1126/science.1103736			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897DV	15705844				2022-12-28	WOS:000226985100045
J	Hetz, SK; Bradley, TJ				Hetz, SK; Bradley, TJ			Insects breathe discontinuously to avoid oxygen toxicity	NATURE			English	Article							GAS-EXCHANGE CYCLES; SUPEROXIDE-DISMUTASE; OXIDATIVE DAMAGE; LIFE-SPAN; RESPIRATION; OVEREXPRESSION; HYPOTHESES; SCARABAEIDAE; VENTILATION; DIFFUSION	The respiratory organs of terrestrial insects consist of tracheal tubes with external spiracular valves that control gas exchange. Despite their relatively high metabolic rate, many insects have highly discontinuous patterns of gas exchange, including long periods when the spiracles are fully closed. Two explanations have previously been put forward to explain this behaviour: first, that this pattern serves to reduce respiratory water loss(1), and second, that the pattern may have initially evolved in underground insects as a way of dealing with hypoxic or hypercapnic conditions(2). Here we propose a third possible explanation based on the idea that oxygen is necessary for oxidative metabolism but also acts as a toxic chemical that can cause oxidative damage of tissues even at relatively low concentrations. At physiologically normal partial pressures of CO2, the rate of CO2 diffusion out of the insect respiratory system is slower than the rate of O-2 entry; this leads to a build-up of intratracheal CO2. The spiracles must therefore be opened at intervals to rid the insect of accumulated CO2, a process that exposes the tissues to dangerously high levels of O-2. We suggest that the cyclical pattern of open and closed spiracles observed in resting insects is a necessary consequence of the need to rid the respiratory system of accumulated CO2, followed by the need to reduce oxygen toxicity.	Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92697 USA; Humboldt Univ, Dept Anim Physiol, D-10115 Berlin, Germany	University of California System; University of California Irvine; Humboldt University of Berlin	Bradley, TJ (corresponding author), Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92697 USA.	tbradley@uci.edu	Hetz, Stefan/E-9094-2010	Hetz, Stefan/0000-0002-4928-8506				Bradley TJ, 2003, PHYSIOL BIOCHEM ZOOL, V76, P302, DOI 10.1086/367953; Chown SL, 2000, J EXP BIOL, V203, P397; Davis ALV, 1999, PHYSIOL BIOCHEM ZOOL, V72, P555, DOI 10.1086/316698; Fielden LJ, 1996, PHYSIOL ZOOL, V69, P599, DOI 10.1086/physzool.69.3.30164218; FRIDOVICH I, 1977, BIOSCIENCE, V27, P462, DOI 10.2307/1297527; HADLEY NF, 1994, PHYSIOL ZOOL, V67, P175, DOI 10.1086/physzool.67.1.30163841; HETZ SK, 1994, BIOELECTROCH BIOENER, V33, P165, DOI 10.1016/0302-4598(94)85008-9; JAMIESON D, 1989, FREE RADICAL BIO MED, V7, P87, DOI 10.1016/0891-5849(89)90103-2; Krogh A, 1920, PFLUG ARCH GES PHYS, V179, P95, DOI 10.1007/BF01722125; Krogh A, 1920, PFLUG ARCH GES PHYS, V179, P113, DOI 10.1007/BF01722126; LEVY RI, 1966, J INSECT PHYSIOL, V12, P83, DOI 10.1016/0022-1910(66)90068-0; LIGHTON JRB, 1988, J EXP BIOL, V134, P363; LIGHTON JRB, 1995, J EXP BIOL, V198, P1613; Lighton JRB, 1998, AM ZOOL, V38, P483; Lighton JRB, 1996, ANNU REV ENTOMOL, V41, P309, DOI 10.1146/annurev.en.41.010196.001521; Lighton JRB, 1996, J INSECT PHYSIOL, V42, P347, DOI 10.1016/0022-1910(95)00112-3; Lighton JRB, 2002, PHYSIOL BIOCHEM ZOOL, V75, P345, DOI 10.1086/342252; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; RICHARDSON RS, 1995, J CLIN INVEST, V96, P1916, DOI 10.1172/JCI118237; Schwarze SR, 1998, FREE RADICAL BIO MED, V25, P740, DOI 10.1016/S0891-5849(98)00153-1; Slama K, 1999, ANN ENTOMOL SOC AM, V92, P916, DOI 10.1093/aesa/92.6.916; SLAMA K, 1988, BIOL BULL-US, V175, P289, DOI 10.2307/1541570; SOHAL RS, 1995, J BIOL CHEM, V270, P15671, DOI 10.1074/jbc.270.26.15671; Sun JT, 2002, GENETICS, V161, P661; Weibel ER, 1996, J EXP BIOL, V199, P1699; WEIBEL ER, 1998, PRINCIPLES ANIMAL DE; Westneat MW, 2003, SCIENCE, V299, P558, DOI 10.1126/science.1078008; WIGGLESWORTH VB, 1970, PRINCIPLES INSECT PH; Williams AE, 1998, J EXP BIOL, V201, P2953; Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168	30	232	246	3	92	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 3	2005	433	7025					516	519		10.1038/nature03106	http://dx.doi.org/10.1038/nature03106			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893NT	15690040				2022-12-28	WOS:000226727200047
J	Danesh, J				Danesh, J			Antibiotics in the prevention of heart attacks	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; ACUTE MYOCARDIAL-INFARCTION; WAVE CORONARY SYNDROMES; CHLAMYDIA-PNEUMONIAE; SECONDARY PREVENTION; DISEASE; AZITHROMYCIN; EVENTS; TWAR; ROXITHROMYCIN		Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge CB1 8RN, England	University of Cambridge	Danesh, J (corresponding author), Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge CB1 8RN, England.	john.danesh@phpc.cam.ac.uk						CANNON CP, 2004, EUR SOC CARD C AUG 2; Cercek B, 2003, LANCET, V361, P809, DOI 10.1016/S0140-6736(03)12706-7; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; Danesh J, 1998, Expert Opin Investig Drugs, V7, P691, DOI 10.1517/13543784.7.5.691; Danesh J, 2000, BRIT MED J, V321, P208, DOI 10.1136/bmj.321.7255.208; GRAYSTON JT, 1992, CLIN INFECT DIS, V15, P757, DOI 10.1093/clind/15.5.757; GRAYSTON JT, 2004, EUR SOC CARD C AUG 2; Gupta S, 1997, CIRCULATION, V96, P404; Gurfinkel E, 1999, EUR HEART J, V20, P121, DOI 10.1053/euhj.1998.1283; Gurfinkel E, 1997, LANCET, V350, P404, DOI 10.1016/S0140-6736(97)07201-2; Hu H, 1999, J CLIN INVEST, V103, P747, DOI 10.1172/JCI4582; KUO CC, 1995, P NATL ACAD SCI USA, V92, P6911, DOI 10.1073/pnas.92.15.6911; Leowattana Wattana, 2001, Journal of the Medical Association of Thailand, V84, pS669; Muhlestein JB, 2000, CIRCULATION, V102, P1755; O'Connor CM, 2003, JAMA-J AM MED ASSOC, V290, P1459, DOI 10.1001/jama.290.11.1459; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; Sinisalo J, 2002, CIRCULATION, V105, P1555, DOI 10.1161/01.CIR.0000012544.07696.1F; Stone AFM, 2002, CIRCULATION, V106, P1219, DOI 10.1161/01.CIR.0000027820.66786.CF; Zahn R, 2003, CIRCULATION, V107, P1253, DOI 10.1161/01.CIR.0000054613.57105.06	19	28	28	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN-FEB	2005	365	9457					365	367						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891WE	15680439				2022-12-28	WOS:000226610900006
J	Herr, AJ; Jensen, MB; Dalmay, T; Baulcombe, DC				Herr, AJ; Jensen, MB; Dalmay, T; Baulcombe, DC			RNA polymerase IV directs silencing of endogenous DNA	SCIENCE			English	Article							METHYLATION; ARABIDOPSIS; ARGONAUTE4	Plants encode subunits for a fourth RNA polymerase (Pot IV) in addition to the well-known DNA-dependent RNA polymerases I, II, and III. By mutation of the two largest subunits (NRPD1a and NRPD2), we show that Pot IV silences certain transposons and repetitive DNA in a short interfering RNA pathway involving RNA-dependent RNA polymerase-2 and Dicer-like 3. The existence of this distinct silencing polymerase may explain the paradoxical involvement of an RNA silencing pathway in maintenance of transcriptional silencing.	John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England; Univ E Anglia, Norwich NR4 7TJ, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of East Anglia	Baulcombe, DC (corresponding author), John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England.	david.baulcombe@sainsbury-laboratory.ac.uk	Dalmay, Tamas/E-1377-2011	Dalmay, Tamas/0000-0003-1492-5429; Herr, Alan/0000-0002-9498-0972; Baulcombe, David/0000-0003-0780-6878				Baulcombe D, 2004, NATURE, V431, P356, DOI 10.1038/nature02874; Bellaoui M, 2004, PLANTA, V219, P819, DOI 10.1007/s00425-004-1295-5; Chan SWL, 2004, SCIENCE, V303, P1336, DOI 10.1126/science.1095989; Cramer P, 2002, CURR OPIN STRUC BIOL, V12, P89, DOI 10.1016/S0959-440X(02)00294-4; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Dalmay T, 2000, CELL, V101, P543, DOI 10.1016/S0092-8674(00)80864-8; Hamilton A, 2002, EMBO J, V21, P4671, DOI 10.1093/emboj/cdf464; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Myouga F, 2001, GENES GENET SYST, V76, P169, DOI 10.1266/ggs.76.169; Sugiyama T, 2005, P NATL ACAD SCI USA, V102, P152, DOI 10.1073/pnas.0407641102; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Xie ZX, 2004, PLOS BIOL, V2, P642, DOI 10.1371/journal.pbio.0020104; Zilberman D, 2003, SCIENCE, V299, P716, DOI 10.1126/science.1079695; Zilberman D, 2004, CURR BIOL, V14, P1214, DOI 10.1016/j.cub.2004.06.055	14	518	547	2	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 1	2005	308	5718					118	120		10.1126/science.1106910	http://dx.doi.org/10.1126/science.1106910			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	914IQ	15692015				2022-12-28	WOS:000228221500046
J	Elefteriou, F; Ahn, JD; Takeda, S; Starbuck, M; Yang, XL; Liu, XY; Kondo, H; Richards, WG; Bannon, TW; Noda, M; Clement, K; Vaisse, C; Karsenty, G				Elefteriou, F; Ahn, JD; Takeda, S; Starbuck, M; Yang, XL; Liu, XY; Kondo, H; Richards, WG; Bannon, TW; Noda, M; Clement, K; Vaisse, C; Karsenty, G			Leptin regulation of bone resorption by the sympathetic nervous system and CART	NATURE			English	Article							TARGETED DISRUPTION; MICE; ACTIVATION; ELEMENTS; OBESITY; CELLS; GENE	Bone remodelling, the mechanism by which vertebrates regulate bone mass, comprises two phases, namely resorption by osteoclasts and formation by osteoblasts; osteoblasts are multifunctional cells also controlling osteoclast differentiation. Sympathetic signalling via beta 2-adrenergic receptors (Adrb2) present on osteoblasts controls bone formation downstream of leptin(1). Here we show, by analysing Adrb2-deficient mice, that the sympathetic nervous system favours bone resorption by increasing expression in osteoblast progenitor cells of the osteoclast differentiation factor Rankl. This sympathetic function requires phosphorylation ( by protein kinase A) of ATF4, a cell-specific CREB-related transcription factor essential for osteoblast differentiation and function(2). That bone resorption cannot increase in gonadectomized Adrb2-deficient mice highlights the biological importance of this regulation, but also contrasts sharply with the increase in bone resorption characterizing another hypogonadic mouse with low sympathetic tone, the ob/ob mouse(3). This discrepancy is explained, in part, by the fact that CART ('cocaine amphetamine regulated transcript'), a neuropeptide whose expression is controlled by leptin and nearly abolished in ob/ob mice(4), inhibits bone resorption by modulating Rankl expression. Our study establishes that leptin-regulated neural pathways control both aspects of bone remodelling, and demonstrates that integrity of sympathetic signalling is necessary for the increase in bone resorption caused by gonadal failure.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Bone Dis Program Texas, Houston, TX 77030 USA; Baylor Coll Med, Childrens Nutr Res Ctr, Houston, TX 77030 USA; Tokyo Med & Dent Univ, Dept Orthoped, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, Ctr Excellence Program Frontier Res Mol Destruct, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, Dept Mol Pharmacol, Med Res Inst, Tokyo 1010062, Japan; Amgen Inc, Neurosci, Thousand Oaks, CA 91320 USA; CHRU Pitie Salpetriere, Hotel Dieu, Dept Nutr, F-75004 Paris, France; Univ Paris 06, INSERM, Avenir Team, EA3502, F-75004 Paris, France; Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Amgen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Karsenty, G (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.	karsenty@bcm.tmc.edu	Elefteriou, Florent/P-2586-2017; Elefteriou, Florent/GMW-8429-2022; Clément, karine/R-1120-2017; Vaisse, Christian/F-1067-2011; takeda, shu/B-5195-2012	Elefteriou, Florent/0000-0002-2972-5633; Elefteriou, Florent/0000-0002-2972-5633; Elefteriou, Xiangli/0000-0002-2333-8747	NIDDK NIH HHS [R01 DK060540] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060540] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asnicar MA, 2001, ENDOCRINOLOGY, V142, P4394, DOI 10.1210/en.142.10.4394; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; Chruscinski AJ, 1999, J BIOL CHEM, V274, P16694, DOI 10.1074/jbc.274.24.16694; Dominici M, 2004, P NATL ACAD SCI USA, V101, P11761, DOI 10.1073/pnas.0404626101; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Kristensen P, 1998, NATURE, V393, P72, DOI 10.1038/29993; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; ORWOLL B, 2004, ORS AAOS PRESENTATIO; Rohrer DK, 1999, J BIOL CHEM, V274, P16701, DOI 10.1074/jbc.274.24.16701; Satoh N, 1999, DIABETES, V48, P1787, DOI 10.2337/diabetes.48.9.1787; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7	18	890	959	3	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 24	2005	434	7032					514	520		10.1038/nature03398	http://dx.doi.org/10.1038/nature03398			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909CH	15724149				2022-12-28	WOS:000227836000044
J	Lin, DY; Zhang, SZ; Block, E; Katz, LC				Lin, DY; Zhang, SZ; Block, E; Katz, LC			Encoding social signals in the mouse main olfactory bulb	NATURE			English	Article							GAS-CHROMATOGRAPHY; ODORANT RECEPTORS; HOUSE MOUSE; VOLATILE COMPOUNDS; MASS-SPECTROMETRY; FEMALE MICE; BODY ODORS; PHEROMONE; URINE; DISCRIMINATION	Mammalian urine releases complex mixtures of volatile compounds that are used in reproduction, territoriality and conspecific recognition. To understand how such complex mixtures are represented in the main olfactory bulb, we analysed the electrophysiological responses of individual mitral cells to volatile compounds in mouse urine. In both males and females, urine volatile compounds evoke robust responses in a small subset of mitral cells. Fractionation of the volatile compounds using gas chromatography showed that out of the hundreds of compounds present, mitral cells are activated by single compounds. One cohort of mitral cells responded exclusively to male urine; these neurons were activated by ( methylthio) methanethiol, a potent, previously unknown semiochemical present only in male urine. When added to urine, synthetic ( methylthio) methanethiol significantly enhances urine attractiveness to female mice. We conclude that mitral cells represent natural odorant stimuli by acting as selective feature detectors, and that their activation is largely independent of the presence of other components in the olfactory stimulus.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; SUNY Albany, Dept Chem, Albany, NY 12222 USA	Duke University; Howard Hughes Medical Institute; Duke University; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Lin, DY (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3209, Durham, NC 27710 USA.	dayulin@neuro.duke.edu	Block, Eric/D-3989-2014	Block, Eric/0000-0002-4668-1687; Lin, Dayu/0000-0003-2006-0791				ANDREOLINI F, 1987, EXPERIENTIA, V43, P998, DOI 10.1007/BF01952217; Baek HH, 2004, FOOD SCI BIOTECHNOL, V13, P90; BALDWIN BA, 1974, ANIM BEHAV, V22, P220, DOI 10.1016/S0003-3472(74)80072-2; Belluscio L, 2002, NATURE, V419, P296, DOI 10.1038/nature01001; Bocchini P, 1999, RAPID COMMUN MASS SP, V13, P2133, DOI 10.1002/(SICI)1097-0231(19991115)13:21<2133::AID-RCM764>3.0.CO;2-J; Brennan PA, 2004, CURR BIOL, V14, pR81, DOI 10.1016/j.cub.2003.12.052; Brody CD, 2003, NEURON, V37, P843, DOI 10.1016/S0896-6273(03)00120-X; Clyne PJ, 1999, NEURON, V22, P327, DOI 10.1016/S0896-6273(00)81093-4; Contarini G, 2002, J AGR FOOD CHEM, V50, P7350, DOI 10.1021/jf025713a; DOTY RL, 1982, HORM BEHAV, V16, P13, DOI 10.1016/0018-506X(82)90002-2; Dulac C, 2003, NAT REV NEUROSCI, V4, P551, DOI 10.1038/nrn1140; Friedrich RW, 2004, NAT NEUROSCI, V7, P862, DOI 10.1038/nn1292; Friedrich RW, 2001, SCIENCE, V291, P889, DOI 10.1126/science.291.5505.889; Fu SG, 2002, J AGR FOOD CHEM, V50, P549, DOI 10.1021/jf010883t; GALEF BG, 1988, PHYSIOL BEHAV, V42, P119, DOI 10.1016/0031-9384(88)90285-5; HARVEY S, 1989, J CHEM ECOL, V15, P2061, DOI 10.1007/BF01207438; Hildebrand JG, 1997, ANNU REV NEUROSCI, V20, P595, DOI 10.1146/annurev.neuro.20.1.595; JEMIOLO B, 1991, J CHEM ECOL, V17, P353, DOI 10.1007/BF00994338; Kayali-Sayadi MN, 2003, J CHROMATOGR B, V796, P55, DOI 10.1016/j.jchromb.2003.08.001; Laurent G, 2002, NAT REV NEUROSCI, V3, P884, DOI 10.1038/nrn964; Lee SN, 2003, ANAL BIOANAL CHEM, V377, P749, DOI 10.1007/s00216-003-2163-z; Leinders-Zufall T, 2000, NATURE, V405, P792, DOI 10.1038/35015572; Lin WH, 2004, J NEUROSCI, V24, P3703, DOI 10.1523/JNEUROSCI.0188-04.2004; Lodovichi C, 2003, NEURON, V38, P265, DOI 10.1016/S0896-6273(03)00194-6; LOUCH D, 1992, ANAL CHEM, V64, P1187, DOI 10.1021/ac00034a020; MIYASHITA K, 1980, MECH AGEING DEV, V13, P177, DOI 10.1016/0047-6374(80)90060-3; MORI K, 1995, CURR OPIN NEUROBIOL, V5, P467, DOI 10.1016/0959-4388(95)80007-7; Motokizawa F, 1996, EXP BRAIN RES, V112, P24; NGAI J, 1993, CELL, V72, P657, DOI 10.1016/0092-8674(93)90396-8; NOVOTNY M, 1984, EXPERIENTIA, V40, P217, DOI 10.1007/BF01963608; NOVOTNY M, 1990, EXPERIENTIA, V46, P109, DOI 10.1007/BF01955433; Novotny MV, 1999, CHEM BIOL, V6, P377, DOI 10.1016/S1074-5521(99)80049-0; Schaal B, 2003, NATURE, V424, P68, DOI 10.1038/nature01739; Schaefer ML, 2001, J NEUROSCI, V21, P2481, DOI 10.1523/JNEUROSCI.21-07-02481.2001; Schaefer ML, 2002, J NEUROSCI, V22, P9513; SCHUTTE L, 1971, TETRAHEDRON LETT, P2321; SCHWENDE FJ, 1986, J CHEM ECOL, V12, P277, DOI 10.1007/BF01045611; SCOTT JW, 1970, PHYSIOL BEHAV, V5, P407, DOI 10.1016/0031-9384(70)90243-X; SHINODA K, 1989, J COMP NEUROL, V284, P362, DOI 10.1002/cne.902840304; SINGER AG, 1976, SCIENCE, V191, P948, DOI 10.1126/science.1251205; Stensmyr MC, 2003, J EXP BIOL, V206, P715, DOI 10.1242/jeb.00143; TANABE T, 1975, J NEUROPHYSIOL, V38, P1284, DOI 10.1152/jn.1975.38.5.1284; Torrens J, 2004, J CHROMATOGR SCI, V42, P310, DOI 10.1093/chromsci/42.6.310; Vosshall LB, 1999, CELL, V96, P725, DOI 10.1016/S0092-8674(00)80582-6; WADHAMS LJ, 1982, Z NATURFORSCH C, V37, P947; WALLACE P, 1977, PHYSIOL BEHAV, V19, P577, DOI 10.1016/0031-9384(77)90238-4; Wang JW, 2003, CELL, V112, P271, DOI 10.1016/S0092-8674(03)00004-7; Weruaga E, 2001, CHEM SENSES, V26, P7, DOI 10.1093/chemse/26.1.7; Wilson RI, 2004, SCIENCE, V303, P366, DOI 10.1126/science.1090782; YAMAGUCHI M, 1981, P NATL ACAD SCI-BIOL, V78, P5817, DOI 10.1073/pnas.78.9.5817	50	315	327	2	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 24	2005	434	7032					470	477		10.1038/nature03414	http://dx.doi.org/10.1038/nature03414			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909CH	15724148				2022-12-28	WOS:000227836000033
J	Bresalier, RS; Sandler, RS; Quan, H; Bolognese, JA; Oxenius, B; Horgan, K; Lines, C; Riddell, R; Morton, D; Lanas, A; Konstam, MA; Baron, JA				Bresalier, RS; Sandler, RS; Quan, H; Bolognese, JA; Oxenius, B; Horgan, K; Lines, C; Riddell, R; Morton, D; Lanas, A; Konstam, MA; Baron, JA		APPROVe Trial Investigators	Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACUTE MYOCARDIAL-INFARCTION; SELECTIVE CYCLOOXYGENASE-2 INHIBITORS; THROMBOTIC EVENTS; RISK; NAPROXEN; CELECOXIB; IBUPROFEN; OUTCOMES	BACKGROUND: Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an increased risk of thrombotic events, but only limited long-term data have been available for analysis. We report on the cardiovascular outcomes associated with the use of the selective COX-2 inhibitor rofecoxib in a long-term, multicenter, randomized, placebo-controlled, double-blind trial designed to determine the effect of three years of treatment with rofecoxib on the risk of recurrent neoplastic polyps of the large bowel in patients with a history of colorectal adenomas. METHODS: A total of 2586 patients with a history of colorectal adenomas underwent randomization: 1287 were assigned to receive 25 mg of rofecoxib daily, and 1299 to receive placebo. All investigator-reported serious adverse events that represented potential thrombotic cardiovascular events were adjudicated in a blinded fashion by an external committee. RESULTS: A total of 46 patients in the rofecoxib group had a confirmed thrombotic event during 3059 patient-years of follow-up (1.50 events per 100 patient-years), as compared with 26 patients in the placebo group during 3327 patient-years of follow-up (0.78 event per 100 patient-years); the corresponding relative risk was 1.92 (95 percent confidence interval, 1.19 to 3.11; P=0.008). The increased relative risk became apparent after 18 months of treatment; during the first 18 months, the event rates were similar in the two groups. The results primarily reflect a greater number of myocardial infarctions and ischemic cerebrovascular events in the rofecoxib group. There was earlier separation (at approximately five months) between groups in the incidence of nonadjudicated investigator-reported congestive heart failure, pulmonary edema, or cardiac failure (hazard ratio for the comparison of the rofecoxib group with the placebo group, 4.61; 95 percent confidence interval, 1.50 to 18.83). Overall and cardiovascular mortality was similar in the two groups. CONCLUSIONS: Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk.	Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med & Nutr, Houston, TX 77030 USA; Univ N Carolina, Dept Med, Chapel Hill, NC USA; Merck Res Labs, West Point, PA USA; Mt Sinai Hosp, Dept Pathol, Toronto, ON M5G 1X5, Canada; Univ Birmingham, Dept Surg, Birmingham, W Midlands, England; Clin Univ Hosp, Dept Med, Zaragoza, Spain; Tufts Univ New England Med Ctr, Dept Med, Boston, MA USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Med, Hanover, NH 03756 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH 03756 USA	University of Texas System; UTMD Anderson Cancer Center; University of North Carolina; University of North Carolina Chapel Hill; Merck & Company; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Birmingham; Tufts Medical Center; Dartmouth College; Dartmouth College	Bresalier, RS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med & Nutr, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rbresali@mdanderson.org	Riddell, Robert H/J-5557-2016	Horgan, Kevin/0000-0003-0647-9078; Bresalier, Robert/0000-0002-9740-281X				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1994, BMJ-BRIT MED J, V308, P81, DOI DOI 10.1136/BMJ.308.6921.81; Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Crofford LJ, 2000, ARTHRITIS RHEUM-US, V43, P4, DOI 10.1002/1529-0131(200001)43:1<4::AID-ANR2>3.0.CO;2-V; Dannenberg AJ, 2003, CANCER CELL, V4, P431, DOI 10.1016/S1535-6108(03)00310-6; Egan KM, 2005, CIRCULATION, V111, P334, DOI 10.1161/01.CIR.0000153386.95356.78; Farkouh ME, 2004, LANCET, V364, P675, DOI 10.1016/S0140-6736(04)16894-3; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; Graham DJ, 2005, LANCET, V365, P475, DOI 10.1016/S0140-6736(05)17864-7; GUESS HA, 1987, AM J EPIDEMIOL, V125, P340, DOI 10.1093/oxfordjournals.aje.a114535; Howard PA, 2004, J AM COLL CARDIOL, V43, P519, DOI 10.1016/j.jacc.2003.09.043; Juni P, 2004, LANCET, V364, P2021, DOI 10.1016/S0140-6736(04)17514-4; Kimmel SE, 2005, ANN INTERN MED, V142, P157, DOI 10.7326/0003-4819-142-3-200502010-00005; Konstam MA, 2001, CIRCULATION, V104, P2280, DOI 10.1161/hc4401.100078; Mamdani M, 2003, ARCH INTERN MED, V163, P481, DOI 10.1001/archinte.163.4.481; Mamdani M, 2004, LANCET, V363, P1751, DOI 10.1016/S0140-6736(04)16299-5; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; Nussmeier NA, 2005, NEW ENGL J MED, V352, P1081, DOI 10.1056/NEJMoa050330; Rahme, 2002, ARCH INTERN MED, V162, P1858; Rahme E, 2002, ARCH INTERN MED, V162, P1111, DOI 10.1001/archinte.162.10.1111; Ray WA, 2002, LANCET, V360, P1071, DOI 10.1016/S0140-6736(02)11131-7; Reicin AS, 2002, AM J CARDIOL, V89, P204, DOI 10.1016/S0002-9149(01)02201-9; Solomon DH, 2004, CIRCULATION, V109, P2068, DOI 10.1161/01.CIR.0000127578.21885.3E; Solomon DH, 2002, ARCH INTERN MED, V162, P1099, DOI 10.1001/archinte.162.10.1099; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405; Strand V, 2002, ARTHRIT RHEUM-ARTHR, V47, P349, DOI 10.1002/art.10560; Watson, 2002, ARCH INTERN MED, V162, P1779; Watson DJ, 2002, ARCH INTERN MED, V162, P1105, DOI 10.1001/archinte.162.10.1105; Weir MR, 2003, AM HEART J, V146, P591, DOI 10.1016/S0002-8703(03)00398-3; Whelton A, 2002, AM J CARDIOL, V90, P959, DOI 10.1016/S0002-9149(02)02661-9; Whelton A, 2001, Am J Ther, V8, P85, DOI 10.1097/00045391-200103000-00003; WHELTON A, 2001, AM J THER, V8, P220	33	1897	1986	1	84	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 17	2005	352	11					1092	1102		10.1056/NEJMoa050493	http://dx.doi.org/10.1056/NEJMoa050493			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	906PU	15713943				2022-12-28	WOS:000227655000006
J	Hessa, T; White, SH; von Heijne, G				Hessa, T; White, SH; von Heijne, G			Membrane insertion of a potassium-channel voltage sensor	SCIENCE			English	Article							DEPENDENT K+ CHANNEL		Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Program Macromol Struct, Irvine, CA 92697 USA	Stockholm University; University of California System; University of California Irvine; University of California System; University of California Irvine	von Heijne, G (corresponding author), Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden.	gunnar@dbb.su.se	White, Stephen/N-1507-2019; von Heijne, Gunnar/AAH-9389-2019; White, Stephen H/B-1053-2009; von Heijne, Gunnar/F-5576-2011	White, Stephen H/0000-0001-8540-7907; von Heijne, Gunnar/0000-0002-4490-8569	NIGMS NIH HHS [GM46823, GM68002] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046823, R01GM068002] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		FREITES JA, UNPUB; Grabe M, 2004, P NATL ACAD SCI USA, V101, P17640, DOI 10.1073/pnas.0408116101; Hessa T, 2005, NATURE, V433, P377, DOI 10.1038/nature03216; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; MacKinnon R, 2004, SCIENCE, V306, P1304, DOI 10.1126/science.1105528; Tu L, 2000, BIOCHEMISTRY-US, V39, P824, DOI 10.1021/bi991740r	7	160	162	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 4	2005	307	5714					1427	1427		10.1126/science.1109176	http://dx.doi.org/10.1126/science.1109176			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904MT	15681341				2022-12-28	WOS:000227503100035
J	Yamagishi, K; Onuma, K; Suzuki, T; Okada, F; Tagami, J; Otsuki, M; Senawangse, P				Yamagishi, K; Onuma, K; Suzuki, T; Okada, F; Tagami, J; Otsuki, M; Senawangse, P			A synthetic enamel for rapid tooth repair	NATURE			English	Article							GROWTH		FAP Dent Inst, Meguro Ku, Tokyo 1520022, Japan; Natl Inst Adv Ind Sci & Technol, Inst Human Sci & Technol, Tsukuba, Ibaraki 3058566, Japan; Univ Yamanashi, Fac Engn, Dept Appl Chem & Biotechnol, Yamanashi 4008511, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Restorat Sci, Bunkyo Ku, Tokyo 1138549, Japan	National Institute of Advanced Industrial Science & Technology (AIST); University of Yamanashi; Tokyo Medical & Dental University (TMDU)	Yamagishi, K (corresponding author), FAP Dent Inst, Meguro Ku, 3-2-1 Kakinokizaka,502, Tokyo 1520022, Japan.	FZT02705@nifty.com	Onuma, Kazuo/L-8736-2018					Banfield JF, 2000, SCIENCE, V289, P751, DOI 10.1126/science.289.5480.751; Carvalho RM, 1996, OPER DENT, V21, P17; Duschner H, 1997, EUR J ORAL SCI, V105, P466, DOI 10.1111/j.1600-0722.1997.tb00232.x; Elliot J. C., 1994, STRUCTURE CHEM APATI; FRANK RM, 1966, ARCH ORAL BIOL, V11, P883, DOI 10.1016/0003-9969(66)90080-X; GEROULD CH, 1945, J DENT RES, V24, P223, DOI 10.1177/00220345450240050201; Hilton TJ, 2002, AM J DENT, V15, P198; JOHNSON N. W., 1967, CARIES RES, V1, P356; Onuma K, 1998, CHEM MATER, V10, P3346, DOI 10.1021/cm980062c; Raskin A, 1999, J DENT, V27, P13, DOI 10.1016/S0300-5712(98)00026-8; Wilson NHF, 2000, J DENT, V28, P15, DOI 10.1016/S0300-5712(99)00055-X; YAMAGISHI K, 1995, ESTHETIC DENT, V7, P78	12	184	201	5	85	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 24	2005	433	7028					819	819		10.1038/433819a	http://dx.doi.org/10.1038/433819a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	899VT	15729330				2022-12-28	WOS:000227174600030
J	Taylor, R; Forge, A				Taylor, R; Forge, A			Developmental biology - Life after deaf for hair cells?	SCIENCE			English	Editorial Material							SUPPORTING CELLS; INNER-EAR; IN-VIVO; PROLIFERATION; CORTI; ORGAN		UCL, UCL Ear Inst, Ctr Auditory Res, London WC1X 8EE, England	University of London; University College London	Taylor, R (corresponding author), UCL, UCL Ear Inst, Ctr Auditory Res, London WC1X 8EE, England.	a.forge@ucl.ac.uk						Brockes JP, 1997, SCIENCE, V276, P81, DOI 10.1126/science.276.5309.81; Chen P, 2003, NAT CELL BIOL, V5, P422, DOI 10.1038/ncb976; Chen P, 1999, DEVELOPMENT, V126, P1581; Fekete DM, 1998, J NEUROSCI, V18, P7811; Forge A, 1997, SEMIN CELL DEV BIOL, V8, P225, DOI 10.1006/scdb.1997.0147; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Haddon C, 1999, J NEUROCYTOL, V28, P837, DOI 10.1023/A:1007013904913; Kawamoto K, 2003, J NEUROSCI, V23, P4395; Li HW, 2003, NAT MED, V9, P1293, DOI 10.1038/nm925; Lowenheim H, 1999, P NATL ACAD SCI USA, V96, P4084, DOI 10.1073/pnas.96.7.4084; Ruben R.J., 1967, ACTA OTO-LARYNGOL, DOI DOI 10.3109/00016486709127790; Sage C, 2005, SCIENCE, V307, P1114, DOI 10.1126/science.1106642; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461	13	11	11	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	2005	307	5712					1056	1058		10.1126/science.1109680	http://dx.doi.org/10.1126/science.1109680			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ED	15718457				2022-12-28	WOS:000227197300032
J	Li, Y; Di Naro, E; Vitucci, A; Zimmermann, B; Holzgreve, W; Hahn, S				Li, Y; Di Naro, E; Vitucci, A; Zimmermann, B; Holzgreve, W; Hahn, S			Detection of paternally inherited fetal point mutations for beta-thalassemia using size-fractionated cell-free DNA in maternal plasma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TIME QUANTITATIVE PCR; PRENATAL-DIAGNOSIS; CYSTIC-FIBROSIS; BLOOD; ANEMIA	Context Currently, fetal point mutations cannot be reliably analyzed from circulatory fetal DNA in maternal plasma, due to the predominance of maternal DNA sequences. However, analysis of circulatory fetal DNA sequences in maternal plasma have been shown to selectively enrich for fetal DNA molecules on the basis of a smaller molecular size than maternal DNA. Objective To examine the prenatal analysis of 4 common beta-thalassemia point mutations: IVSI-1, IVSI-6, 1VSI-110, and codon 39. Design, Setting, and Patients A total of 32 maternal blood samples were collected at 10 to 12 weeks of gestation (mean, 10.7 weeks) between February 15, 2003, and February 25, 2004, in Bari, Italy, from women with risk for beta-thalassemia in their newborns immediately prior to chorionic villous sampling. Samples in which the father and mother did not carry the same mutation were examined. Circulatory DNA was size-fractionated by gel electrophoresis and polymerase chain reaction (PCR) amplified with a peptide-nucleic-acid clamp, which suppresses amplification of the normal maternal allele. Presence of the paternal mutant allele was detected by allele-specific real-time PCR. Main Outcome Measure Detection of paternally inherited p-globin gene point mutations. Results Presence or absence of the paternal mutant allele was correctly determined in 6 (86%) of 7 cases with the IVSI-1 mutation, 4 (100%) of 4 with the IVSI-6 mutation, 5 (100%) of 5 with the IVSI-110 mutation, and 13 (81%) of 16 with the codon 39 mutation. One false-positive test result was scored for the IVSI-1 mutation. Two cases with the codon 39 mutation were classified as uncertain and 1 case was excluded due to lack of a diagnostic. test result,at the time of analysis. These results yielded an overall sensitivity of 100% and specificity of 93.8%, with classified cases removed. Conclusion Our recently described technique of the size-fractionation of circulatory DNA in maternal plasma may be potentially useful for the noninvasive prenatal determination of fetal point mutations.	Univ Basel Hosp, Univ Womens Hosp, Dept Res, Lab Prenatal Med, CH-4013 Basel, Switzerland; Univ Bari, Dept Obstet & Gynecol, Bari, Italy; Univ Bari, Div Hematol 2, Bari, Italy	University of Basel; Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Hahn, S (corresponding author), Univ Basel Hosp, Univ Womens Hosp, Dept Res, Lab Prenatal Med, Spitalstr 21, CH-4013 Basel, Switzerland.	shahn@uhbs.ch		Zimmermann, Bernhard/0000-0002-5275-4571; di naro, edoardo/0000-0001-7675-7171				Bianchi DW, 2002, PRENATAL DIAG, V22, P609, DOI 10.1002/pd.347; Chan KCA, 2004, CLIN CHEM, V50, P88, DOI 10.1373/clinchem.2003.024893; Cheung MC, 1996, NAT GENET, V14, P264, DOI 10.1038/ng1196-264; Chiu Rossa W K, 2002, Expert Rev Mol Diagn, V2, P32, DOI 10.1586/14737159.2.1.32; Dhallan R, 2004, JAMA-J AM MED ASSOC, V291, P1114, DOI 10.1001/jama.291.9.1114; Di Naro E, 2000, MOL HUM REPROD, V6, P571, DOI 10.1093/molehr/6.6.571; Ding CM, 2004, P NATL ACAD SCI USA, V101, P10762, DOI 10.1073/pnas.0403962101; Hahn S, 2000, ANN NY ACAD SCI, V906, P148; Hahn S, 2002, CLIN OBSTET GYNECOL, V45, P649, DOI 10.1097/00003081-200209000-00008; JACKSON LG, 1992, NEW ENGL J MED, V327, P594, DOI 10.1056/NEJM199208273270903; KAZAZIAN HH, 1988, BLOOD, V72, P1107; Li Y, 2004, CLIN CHEM, V50, P1002, DOI 10.1373/clinchem.2003.029835; Lo YMD, 1998, NEW ENGL J MED, V339, P1734, DOI 10.1056/NEJM199812103392402; Nasis O, 2004, CLIN CHEM, V50, P694, DOI 10.1373/clinchem.2003.025981; Saito H, 2000, LANCET, V356, P1170, DOI 10.1016/S0140-6736(00)02767-7; Simpson JL, 2004, JAMA-J AM MED ASSOC, V291, P1135, DOI 10.1001/jama.291.9.1135; Strom CM, 2004, GENET MED, V6, P136, DOI 10.1097/01.GIM.0000127268.65149.69; Swinkels DW, 2003, CLIN CHEM, V49, P525, DOI 10.1373/49.3.525; TABOR A, 1986, LANCET, V1, P1287; Thiede C, 1996, NUCLEIC ACIDS RES, V24, P983, DOI 10.1093/nar/24.5.983; Weatherall DJ, 2004, NAT REV GENET, V5, P625, DOI 10.1038/nrg1406; WU DY, 1989, P NATL ACAD SCI USA, V86, P2757, DOI 10.1073/pnas.86.8.2757; Zhong XY, 2001, LANCET, V357, P310, DOI 10.1016/S0140-6736(05)71754-2; Zimmermann B, 2002, CLIN CHEM, V48, P362	24	172	242	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	2005	293	7					843	849		10.1001/jama.293.7.843	http://dx.doi.org/10.1001/jama.293.7.843			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DQ	15713774	Bronze			2022-12-28	WOS:000226984600026
J	Asbell, PA; Dualan, L; Mindel, J; Brocks, D; Ahmad, M; Epstein, S				Asbell, PA; Dualan, L; Mindel, J; Brocks, D; Ahmad, M; Epstein, S			Age-related cataract	LANCET			English	Review							MULTIFOCAL INTRAOCULAR-LENS; QUALITY-OF-LIFE; VISUAL FUNCTION; FUNCTIONAL IMPAIRMENT; CONTRAST SENSITIVITY; CLINICAL-EVALUATION; REFRACTIVE SURGERY; CORNEAL POWER; 2ND; PHACOEMULSIFICATION	Cataract, opacification of the lens, is one of the commonest causes of loss of useful vision, with an estimated 16 million people worldwide affected. Several risk factors have been identified in addition to increasing age-genetic composition, exposure to ultraviolet light, and diabetes. However, no method to halt the formation of a cataractous lens has been shown to be effective. Nevertheless, advances in surgical removal of cataracts, including small-incision surgery, use of viscoelastics, and the development of intraocular lenses, have made treatment very effective and visual recovery rapid in most cases, Despite theses advances, cataract continues' to be a leading public-health issue that will grow in importance as the population increases and life expectancy. is extended worldwide.	Mt Sinai Sch Med, Dept Ophthalmol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Asbell, PA (corresponding author), Mt Sinai Sch Med, Dept Ophthalmol, 1 Gustave L Levy Pl,Box 1183, New York, NY 10029 USA.	penny.asbell@mssm.edu		Asbell, Penny/0000-0001-7583-7778				AABERG TM, 1991, OPHTHALMOLOGY, V98, P227; Aasuri M K, 1999, Curr Opin Ophthalmol, V10, P53, DOI 10.1097/00055735-199902000-00010; [Anonymous], 1995, Arch Ophthalmol, V113, P1479; APPLE DJ, 1984, SURV OPHTHALMOL, V29, P1, DOI 10.1016/0039-6257(84)90113-9; Ayala MJ, 2001, J REFRACT SURG, V17, P12; Balazs E A, 1972, Mod Probl Ophthalmol, V10, P3; BERNTHPETERSEN P, 1981, ACTA OPHTHALMOL, V59, P198; Busbee BG, 2003, OPHTHALMOLOGY, V110, P2310, DOI 10.1016/S0161-6420(03)00796-6; Carnahan M C, 2000, Curr Opin Ophthalmol, V11, P478, DOI 10.1097/00055735-200012000-00016; CASSARD SD, 1995, ARCH OPHTHALMOL-CHIC, V113, P1508, DOI 10.1001/archopht.1995.01100120038005; Castells X, 1999, OPHTHALMOLOGY, V106, P676, DOI 10.1016/S0161-6420(99)90150-1; Chan C K, 2001, Ophthalmol Clin North Am, V14, P681, DOI 10.1016/S0896-1549(05)70267-4; Chang DF, 2003, J CATARACT REFR SURG, V29, P935, DOI 10.1016/S0886-3350(02)01843-6; Ciulla TA, 2002, OPHTHALMOLOGY, V109, P13, DOI 10.1016/S0161-6420(01)00899-5; Congdon NG, 2001, BRIT J OPHTHALMOL, V85, P516, DOI 10.1136/bjo.85.5.516; Crandall AS, 2001, CURR OPIN OPHTHALMOL, V12, P9, DOI 10.1097/00055735-200102000-00003; Desai P, 1996, BRIT J OPHTHALMOL, V80, P868, DOI 10.1136/bjo.80.10.868; Donnenfeld ED, 2003, J CATARACT REFR SURG, V29, P1097, DOI 10.1016/S0886-3350(02)01917-X; El-Harazi SM, 2001, CURR OPIN OPHTHALMOL, V12, P4, DOI 10.1097/00055735-200102000-00002; Eller A W, 1993, Semin Ophthalmol, V8, P104, DOI 10.3109/08820539309060217; FLOYD RP, 2000, PRINCIPLES PRACTICE, P1463; Ford JG, 2001, CATARACT SURG INTRAO; Garbe E, 1998, JAMA-J AM MED ASSOC, V280, P539, DOI 10.1001/jama.280.6.539; Glasser A, 1999, OPHTHALMOLOGY, V106, P863, DOI 10.1016/S0161-6420(99)00502-3; Hamilton D Rex, 2003, Curr Opin Ophthalmol, V14, P44, DOI 10.1097/00055735-200302000-00008; Hammond CJ, 2000, NEW ENGL J MED, V342, P1786, DOI 10.1056/NEJM200006153422404; Hammond CJ, 2001, INVEST OPHTH VIS SCI, V42, P601; Han DP, 1996, AM J OPHTHALMOL, V122, P920; Han DP, 1996, AM J OPHTHALMOL, V122, P830; Hankinson SE, 2000, PRINCIPLES PRACTICE, P511; HIGHTOWER KR, 1994, DOC OPHTHALMOL, V88, P205, DOI 10.1007/BF01203675; HOLLOWS F, 1981, LANCET, V2, P1249; JAFFE GJ, 2001, FOCAL POINTS CLIN MO; Jaffe NS, 1997, CATARACT SURG ITS CO; JAMPOL LM, 1988, ARCH OPHTHALMOL-CHIC, V106, P894; Javitt JC, 2000, OPHTHALMOLOGY, V107, P2040, DOI 10.1016/S0161-6420(00)00368-7; JAVITT JC, 1993, ARCH OPHTHALMOL-CHIC, V111, P686, DOI 10.1001/archopht.1993.01090050120041; Jick SS, 2001, EPIDEMIOLOGY, V12, P229, DOI 10.1097/00001648-200103000-00016; JOHNS KJ, 2003, LENS CATARACT SECTIO; KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428; Kanellopoulos AJ, 2001, OPHTHALMOLOGY, V108, P649, DOI 10.1016/S0161-6420(00)00584-4; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439; Kaushik S, 2002, OPHTHALMIC SURG LAS, V33, P298, DOI 10.3928/1542-8877-20020701-08; KELMAN CD, 1967, AM J OPHTHALMOL, V64, P23, DOI 10.1016/0002-9394(67)93340-5; Kim JH, 2002, J CATARACT REFR SURG, V28, P1932, DOI 10.1016/S0886-3350(02)01438-4; KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546; Kuchle M, 2002, J REFRACT SURG, V18, P208; Laidlaw DAH, 1998, LANCET, V352, P925, DOI 10.1016/S0140-6736(97)12536-3; Langenbucher A, 2003, J CATARACT REFR SURG, V29, P677, DOI 10.1016/S0886-3350(02)01893-X; Leyland MD, 2002, EYE, V16, P481, DOI 10.1038/sj.eye.6700077; Liesegang TJ, 2001, CURR OPIN OPHTHALMOL, V12, P68, DOI 10.1097/00055735-200102000-00012; Linebarger EJ, 1999, SURV OPHTHALMOL, V44, P123, DOI 10.1016/S0039-6257(99)00085-5; Mamalis Nick, 2002, Curr Opin Ophthalmol, V13, P14, DOI 10.1097/00055735-200202000-00004; Mamidipudi PR, 2003, J CATARACT REFR SURG, V29, P1143, DOI 10.1016/S0886-3350(03)00043-9; MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004; MANGIONE CM, 1994, ARCH OPHTHALMOL-CHIC, V112, P1419, DOI 10.1001/archopht.1994.01090230033017; MASKET S, 2001, CATARACT ADULT EYE; McCarty CA, 2002, DEV OPHTHALMOL, V35, P21; Miller D, 1980, J Am Intraocul Implant Soc, V6, P13; Montes-Mico R, 2003, J CATARACT REFR SURG, V29, P703, DOI 10.1016/S0886-3350(02)01648-6; Naor J, 2000, Curr Opin Ophthalmol, V11, P7, DOI 10.1097/00055735-200002000-00003; Ng DT, 1998, J CATARACT REFR SURG, V24, P1390, DOI 10.1016/S0886-3350(98)80235-6; NICHAMIN LD, 2003, P ANN AM SOC CAT REF; Nichamin Louis D, 2003, Curr Opin Ophthalmol, V14, P35, DOI 10.1097/00055735-200302000-00006; Novis C, 2000, Curr Opin Ophthalmol, V11, P47, DOI 10.1097/00055735-200002000-00007; Oakley MJ, 2002, J CATARACT REFR SURG, V28, P2244, DOI 10.1016/S0886-3350(02)01903-X; POWE NR, 1994, ARCH OPHTHALMOL-CHIC, V112, P239, DOI 10.1001/archopht.1994.01090140115033; Ridley H, 1951, T OPHTHAL SOC UK, V71, P617; RUBIN GS, 1993, ARCH OPHTHALMOL-CHIC, V111, P56, DOI 10.1001/archopht.1993.01090010060027; Schaumberg DA, 1998, OPHTHALMOLOGY, V105, P1213, DOI 10.1016/S0161-6420(98)97023-3; Schein OD, 2000, NEW ENGL J MED, V342, P168, DOI 10.1056/NEJM200001203420304; SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004; Stakheev AA, 2003, CORNEA, V22, P214, DOI 10.1097/00003226-200304000-00006; STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026; STEINBERG EP, 1993, ARCH OPHTHALMOL-CHIC, V111, P1041, DOI 10.1001/archopht.1993.01090080037016; Steinert R F, 2000, Curr Opin Ophthalmol, V11, P12, DOI 10.1097/00055735-200002000-00004; STREETEN BW, 2000, PRINCIPLES PRACTICE, P3685; Talbot EM, 1998, EYE, V12, P983, DOI 10.1038/eye.1998.254; Taylor M, 2001, POLIT QUART, V72, P5, DOI 10.1111/1467-923X.00339; Till JS, 2002, J CATARACT REFR SURG, V28, P295, DOI 10.1016/S0886-3350(01)01035-5; URBAN RC, 1986, SURV OPHTHALMOL, V31, P102, DOI 10.1016/0039-6257(86)90077-9; VANNEWKIRK M, 2002, INT OPHTHALMOLOGY, P157; Weintraub JM, 2002, OPHTHALMIC EPIDEMIOL, V9, P179, DOI 10.1076/opep.9.3.179.1513; WEST SK, 1995, SURV OPHTHALMOL, V39, P323; *WHO, 2000, 214 WHO; *WHO, 1997, 145 WHO; *WHO, 1997, 143 WHO; *WHO, 2000, 213 WHO; *WHO, 1996, MAN CAT PRIM HLTH CA	89	315	322	4	47	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	2005	365	9459					599	609						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DN	15708105				2022-12-28	WOS:000226984300034
J	Kay, B; Nam, VS				Kay, B; Nam, VS			New strategy against Aedes aegypti in Vietnam	LANCET			English	Article							MESOCYCLOPS COPEPODA; FUNNEL TRAP; DENGUE; ALBOPICTUS; CULICIDAE; DIPTERA; MOSQUITOS; LARVAE	The container-breeding mosquito, Aedes aegypti, is the major global vector of dengue viruses, causing around 50 million infections annually. We have developed-a mosquito control strategy, incorporating four elements: (1) a combined vertical and horizontal approach that depends on community understanding; (2) prioritised control according to the larval productivity of major habitat types; (3) use of predacious copepods of the genus Mesocyclops as a biological control agent; delivered by (4) community activities of health volunteers, schools, and the public.. We have previously reported that, from 1998 to 2003, community-based vector control had resulted in A aegypti elimination in six of nine communes, with only small numbers of larvae detected in the others. Here, we report eradication in two further communes and, as a result of local expansion after the project in three northern provinces, elimination from 32 of 37 communes (309 730 people). As a result, no dengue cases have been detected in any commune since 2002. These findings suggest that this strategy is sustainable in Vietnam and applicable where the major sources of A aegypti are large water storage containers.	Queensland Inst Med Res, Australian Ctr Int & Trop Hlth & Nutr, Brisbane, Qld 4006, Australia; Minist Hlth, Gen Dept Prevent Med & HIV AIDS Control, Hanoi, Vietnam	QIMR Berghofer Medical Research Institute	Kay, B (corresponding author), Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia.	brianK@qimr.edu.au						Almond Jeffrey, 2002, Vaccine, V20, P3043, DOI 10.1016/S0264-410X(02)00246-3; BRETEAU H, 1954, Bull World Health Organ, V11, P453; Dieng H, 2002, MED VET ENTOMOL, V16, P285, DOI 10.1046/j.1365-2915.2002.00377.x; GUBLER DJ, 1989, AM J TROP MED HYG, V40, P571, DOI 10.4269/ajtmh.1989.40.571; Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0; HALSTEAD SB, 1987, ARBOVIRUS RES AUSTR, V4, P30; Halstead Scott B., 1992, World Health Statistics Quarterly, V45, P292; KAY BH, 1992, J AM MOSQUITO CONTR, V8, P372; Kay BH, 2002, AM J TROP MED HYG, V66, P40, DOI 10.4269/ajtmh.2002.66.40; Kay BH, 2002, J MED ENTOMOL, V39, P469, DOI 10.1603/0022-2585-39.3.469; KAY BH, 2001, ARBOVIRUS RES AUST, V8, P187; LARDEUX F, 1992, J MED ENTOMOL, V29, P571, DOI 10.1093/jmedent/29.4.571; Lifson AR, 1996, LANCET, V347, P1201, DOI 10.1016/S0140-6736(96)90730-8; MARTEN GG, 1990, J AM MOSQUITO CONTR, V6, P681; Marten GG, 2000, J VECTOR ECOL, V25, P1; MARTEN GG, 1994, HYDROBIOLOGIA, V293, P491, DOI 10.1007/BF00229976; MARTEN GG, 1990, J AM MOSQUITO CONTR, V6, P689; Meltzer MI, 1998, AM J TROP MED HYG, V59, P265, DOI 10.4269/ajtmh.1998.59.265; Nam VS, 2005, AM J TROP MED HYG, V72, P67, DOI 10.4269/ajtmh.2005.72.67; Nam VS, 2003, J AM MOSQUITO CONTR, V19, P220; Nam VS, 1998, AM J TROP MED HYG, V59, P657, DOI 10.4269/ajtmh.1998.59.657; Nam VS, 2000, AM J TROP MED HYG, V62, P5, DOI 10.4269/ajtmh.2000.62.5; Russell BM, 1999, J MED ENTOMOL, V36, P851, DOI 10.1093/jmedent/36.6.851; *SECR 55 WORLD HLT, 2002, DENGUE B, V26, P218; THAN PV, 2004, J PRACTICE MED, V477, P89; TUNLIN W, 1994, J AM MOSQUITO CONTR, V10, P390; TunLin W, 1995, AM J TROP MED HYG, V53, P595, DOI 10.4269/ajtmh.1995.53.595; United Nations, 2003, WAT PEOPL WAT LIF; *WHO, 1972, WKLY EPIDEMIOL REC, V47, P73; ZHEN TM, 1993, J AM MOSQUITO CONTR, V9, P316	30	160	167	0	28	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	2005	365	9459					613	617		10.1016/S0140-6736(05)17913-6	http://dx.doi.org/10.1016/S0140-6736(05)17913-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DN	15708107				2022-12-28	WOS:000226984300036
J	Martis, L; Patel, M; Giertych, J; Mongoven, J; Taminne, M; Perrier, MA; Mendoza, O; Goud, N; Costigan, A; Denjoy, N; Verger, C; Owen, WF				Martis, L; Patel, M; Giertych, J; Mongoven, J; Taminne, M; Perrier, MA; Mendoza, O; Goud, N; Costigan, A; Denjoy, N; Verger, C; Owen, WF			Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution	LANCET			English	Article							CHEMICAL PERITONITIS; STERILE PERITONITIS; CYTOKINE RELEASE; ICODEXTRIN; ENDOTOXIN; PYROGENS; ASSAY; CAPD	Background Manufacturers of parenteral solutions adhere to European and US Pharmacopoeia standards to define safety and sterility. In response to excess cases of aseptic peritonitis in peritonea,l dialysis patients using icodextrin-containing dialysate that met all Pharmacopoeia standards, a global recall was issued in May, 2002. We aimed to establish the cause of aseptic peritonitis. Methods We analysed 186 reports of aseptic peritonitis between September, 2001, and January, 2003. Extensive physical, chemical, and microbiological investigations of recalled dialysate were done. We calculated dose-response curves for peptidoglycan-induced interleukin 6 elaboration in peripheral blood mononuclear cells (PBMCs) from healthy donors and for sterile peritonitis in rats. Findings Although its chemical constituents and concentrations of endotoxin were within pharmacopoeia specifications, the dialysis solution elicited an interlukin 6 response in vivo and in vitro. We identified peptidoglycan from thermophilic acidophilic bacteria (Aticyclobacillus acidocaidarius) as the contaminating proinflammatory substance. In the PBMC assay, strong dose-response relations were noted between peptidoglycan concentrations and interleukin 6. in rats injected with peptidoglycan, dose-dependent increases of intraperitoneal neutrophils and pyrogenic cytokines were recorded. We measured a positive relation between peptidoglycan concentrations in recalled dialysate and reports of aseptic peritonitis. After implementation of corrective actions, the rate of peritonitis returned to baseline. Interpretation Excess cases of aseptic peritonitis in peritoneal dialysis patients were due to peptidoglycan contamination of dialysate by Alicyclobacillus. This outbreak serves as an example of how contemporary parenteral products with microbial contaminants can be considered safe under current Pharmacopoeia tests, but provoke adverse clinical effects.	Baxter Healthcare Corp, Mcgaw Pk, IL USA; Hosp Pontoise, Serv Nephrol, Pontoise, France; Duke Univ, Med Ctr, Sch Med, Dept Med, Durham, NC 27710 USA	Baxter International Inc; Duke University	Owen, WF (corresponding author), 1620 Waukegan Rd, Mcgaw Pk, IL 60085 USA.	william_owen@baxter.com	Verger, Christian/GQA-4459-2022; Verger, Christian/T-5139-2019	Verger, Christian/0000-0002-8009-5366				BENEVENT D, 1984, PRESSE MED, V13, P1844; Burke RA, 1997, J CHROMATOGR B, V693, P353, DOI 10.1016/S0378-4347(97)00073-X; Fennrich S, 1999, Dev Biol Stand, V101, P131; Garner RE, 1996, INFECT IMMUN, V64, P4561, DOI 10.1128/IAI.64.11.4561-4566.1996; GOKAL R, 1981, CLIN NEPHROL, V15, P328; Gokal R, 2002, PERITON DIALYSIS INT, V22, P445; Henderson B, 1996, MICROBIOL REV, V60, P316, DOI 10.1128/MMBR.60.2.316-341.1996; KARANICOLAS S, 1977, NEW ENGL J MED, V296, P1336, DOI 10.1056/NEJM197706092962309; Mangram AJ, 1998, KIDNEY INT, V54, P1367, DOI 10.1046/j.1523-1755.1998.00110.x; Mascoli C C, 1979, J Parenter Drug Assoc, V33, P81; Matsubara H, 2002, INT J SYST EVOL MICR, V52, P1681, DOI [10.1099/ijs.0.02169-0, 10.1099/00207713-52-5-1681]; MISTRY CD, 1987, LANCET, V2, P178; Nakagawa Y, 2002, CLIN DIAGN LAB IMMUN, V9, P588, DOI 10.1128/CDLI.9.3.588-597.2002; *NAT RES COUNC, 1996, GUID CAR US LAB AN; Pool EJ, 1999, J IMMUNOASSAY, V20, P79, DOI 10.1080/01971529909349315; POOLE S, 1988, LANCET, V1, P130; RAY A, 1991, FEMS MICROBIOL LETT, V79, P211, DOI 10.1016/0378-1097(91)90088-R; Royce CL, 1996, J ENDOTOXIN RES, V3, P437, DOI 10.1177/096805199600300601; SCHWAB JH, 1993, INFECT IMMUN, V61, P4535, DOI 10.1128/IAI.61.11.4535-4539.1993; SMITH TA, 1991, DICP ANN PHARMAC, V25, P602, DOI 10.1177/106002809102500607; SRISKANDAN S, 1999, BACTERIAL SEPSIS SEP, P397; TAKTAK YS, 1991, J PHARM PHARMACOL, V43, P578, DOI 10.1111/j.2042-7158.1991.tb03540.x; Tintillier M, 2002, PERITON DIALYSIS INT, V22, P534; Tsuchiya M, 1996, FEMS IMMUNOL MED MIC, V15, P129, DOI 10.1016/0928-8244(96)00053-3; Tuncer H, 2000, NEPHROL DIAL TRANSPL, V15, P2037, DOI 10.1093/ndt/15.12.2037; Vas SI, 1989, PERITONEAL DIALYSIS, V3rd, P261; WEARY M, 1987, DETECTION BACTERIAL, P307; Williams PF, 2002, PERITON DIALYSIS INT, V22, P89; Wolfson M, 2002, AM J KIDNEY DIS, V40, P1055, DOI 10.1053/ajkd.2002.36344; 2002, EUROPEAN PHARMACOPOE, P131	30	66	71	1	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	2005	365	9459					588	594						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DN	15708102				2022-12-28	WOS:000226984300031
J	Vasavada, AR; Raj, SM				Vasavada, AR; Raj, SM			Cataract treatment where resources are scarce	LANCET			English	Editorial Material							INTRAOCULAR-LENS IMPLANTATION; RURAL EYE CAMP; SURGERY; INDIA; EXTRACTION		Raghudeep Eye Clin, Iladevi Cataract & IOL Res Ctr, Ahmedabad 380052, Gujarat, India		Vasavada, AR (corresponding author), Raghudeep Eye Clin, Iladevi Cataract & IOL Res Ctr, Ahmedabad 380052, Gujarat, India.	Shailadl@sancharnet.in						Balent LC, 2001, OPHTHALMIC SURG LAS, V32, P446; Civerchia L, 1996, OPHTHALMIC SURG LAS, V27, P200; Foster A, 2001, BRIT J OPHTHALMOL, V85, P635, DOI 10.1136/bjo.85.6.635; Gillies M, 1998, ARCH OPHTHALMOL-CHIC, V116, P90, DOI 10.1001/archopht.116.1.90; Khouri AS, 2000, OPHTHALMOLOGY, V107, P1797, DOI 10.1016/S0161-6420(00)00127-5; Ruit S, 2000, CLIN EXP OPHTHALMOL, V28, P274, DOI 10.1046/j.1442-9071.2000.00316.x; Ruit S, 1999, OPHTHALMOLOGY, V106, P1887, DOI 10.1016/S0161-6420(99)90397-4; Singh AJ, 2000, LANCET, V355, P180, DOI 10.1016/S0140-6736(99)07430-9; Yook RH, 2000, OPHTHALMOLOGY, V107, P1797, DOI 10.1016/S0161-6420(00)00134-2	9	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	2005	365	9459					550	551						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DN	15708082				2022-12-28	WOS:000226984300005
J	Koppers, AAP; Staudigel, H				Koppers, AAP; Staudigel, H			Asynchronous bends in Pacific seamount trails: A case for extensional volcanism?	SCIENCE			English	Article							MOTION; MANTLE; PLATE; PLUMES; RIDGES	The Gilbert Ridge and Tokelau Seamounts are the only seamount traits in the Pacific Ocean with a sharp 60degrees bend, similar to the Hawaii-Emperor bend (HEB). These two bends should be coeval with the 47-million-year-old HEB if they were formed by stationary hot spots, and assuming Pacific plate motion only. New 40Ar/39Ar ages indicate that the bends in the Gilbert Ridge and Tokelau seamount trail were formed much earlier than the HEB at 67 and 57 million years ago, respectively. Such asynchronous bends cannot be reconciled with the stationary hot spot paradigm, possibly suggesting hot spot motion or magmatism caused by short-term local lithospheric extension.	Univ Calif San Diego, Scripps Inst Oceanog, Inst Geophys & Planetary Phys, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography	Koppers, AAP (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Inst Geophys & Planetary Phys, La Jolla, CA 92093 USA.	akoppers@ucsd.edu		Koppers, Anthony/0000-0002-8136-5372				Duncan RA, 2004, GEOCHEM GEOPHY GEOSY, V5, DOI 10.1029/2004GC000704; Koppers AAP, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2003GC000574; Koppers AAP, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2003GC000533; Koppers AAP, 2002, COMPUT GEOSCI-UK, V28, P605, DOI 10.1016/S0098-3004(01)00095-4; Koppers AAP, 2001, EARTH PLANET SC LETT, V185, P237, DOI 10.1016/S0012-821X(00)00387-3; Koppers AAP, 2000, CHEM GEOL, V166, P139, DOI 10.1016/S0009-2541(99)00188-6; Kroenke LW, 2004, GEOL SOC SPEC PUBL, V229, P9, DOI 10.1144/GSL.SP.2004.229.01.02; Lithgow-Bertelloni C, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002467; LONSDALE P, 1988, J GEOPHYS RES-SOLID, V93, P3078, DOI 10.1029/JB093iB04p03078; Lowman JP, 2004, GEOCHEM GEOPHY GEOSY, V5, DOI 10.1029/2003GC000583; MOLNAR P, 1987, NATURE, V327, P587, DOI 10.1038/327587a0; NAKANISHI M, 1992, GEOPHYS J INT, V144, P535; NORTON IO, 1995, TECTONICS, V14, P1080, DOI 10.1029/95TC01256; Renne PR, 1998, CHEM GEOL, V145, P117, DOI 10.1016/S0009-2541(97)00159-9; SANDWELL DT, 1995, J GEOPHYS RES-SOL EA, V100, P15087, DOI 10.1029/95JB00156; Smith W. H. F., 1997, Science, V277, P1956, DOI 10.1126/science.277.5334.1956; Steinberger B, 1998, GEOPHYS J INT, V132, P412, DOI 10.1046/j.1365-246x.1998.00447.x; Steinberger B, 2000, J GEOPHYS RES-SOL EA, V105, P11127, DOI 10.1029/1999JB900398; Steinberger B, 2004, NATURE, V430, P167, DOI 10.1038/nature02660; Tarduno JA, 2003, SCIENCE, V301, P1064, DOI 10.1126/science.1086442; WESSEL P, 2003, EOS, V84; WINTERER EL, 1987, NATURE, V329, P534, DOI 10.1038/329534a0	22	56	64	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	2005	307	5711					904	907		10.1126/science.1107260	http://dx.doi.org/10.1126/science.1107260			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897DV	15705846				2022-12-28	WOS:000226985100047
J	McCarthy, M				McCarthy, M			Profile - Alfred Sommer: a life in the field and in the data	LANCET			English	Biographical-Item												m.mcarthy@elsevier.com						SOMMER AA, PUBLICATION LIST	1	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 19	2005	365	9460					649	649						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	898SP	15726696				2022-12-28	WOS:000227096800010
J	Smith, DM; Lopez, LI; Lin, RP; Barrington-Leigh, CP				Smith, DM; Lopez, LI; Lin, RP; Barrington-Leigh, CP			Terrestrial gamma-ray flashes observed up to 20 MeV	SCIENCE			English	Article							RUNAWAY ELECTRONS; ATMOSPHERIC ORIGIN; SPRITES; THUNDERSTORM; BREAKDOWN; ENHANCEMENTS; ASSOCIATION; GENERATION; DISCHARGES; PULSES	Terrestrial gamma-ray flashes (TGFs) from Earth's upper atmosphere have been detected with the Reuven Ramaty High Energy Solar Spectroscopic Imager (RHESSI) satellite. The gamma-ray spectra typically extend up to 10 to 20 megaelectron volts (MeV); a simple bremsstrahlung model suggests that most of the electrons that produce the gamma rays have energies on the order of 20 to 40 MeV. RHESSI detects 10 to 20 TGFs per month, corresponding to similar to50 per day globally, perhaps many more if they are beamed. Both the frequency of occurrence and maximum photon energy are more than an order of magnitude higher than previously known for these events.	Univ Calif Santa Cruz, Dept Phys, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Santa Cruz Inst Particle Phys, Santa Cruz, CA 95064 USA; Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA; Univ Calif Berkeley, Space Sci Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ British Columbia, Vancouver, BC V6T 1Z4, Canada	University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of British Columbia	Smith, DM (corresponding author), Univ Calif Santa Cruz, Dept Phys, 1156 High St, Santa Cruz, CA 95064 USA.	dsmith@scipp.ucsc.edu	Smith, David M/A-1744-2011	Barrington-Leigh, Christopher/0000-0002-3929-5390				Babich LP, 2001, DOKL EARTH SCI, V381, P994; Barrington-Leigh CP, 1999, GEOPHYS RES LETT, V26, P3605, DOI 10.1029/1999GL010692; Christian HJ, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002347; Dwyer JR, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL018770; Eack KB, 1996, GEOPHYS RES LETT, V23, P2915, DOI 10.1029/96GL02570; Feng H, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013992; FISHMAN GJ, 1994, SCIENCE, V264, P1313, DOI 10.1126/science.264.5163.1313; Galper AM, 1999, J GEOPHYS RES-SPACE, V104, P28685, DOI 10.1029/1999JA900201; GUREVICH AV, 1992, PHYS LETT A, V165, P463, DOI 10.1016/0375-9601(92)90348-P; Gurevich AV, 1999, PHYS LETT A, V262, P457, DOI 10.1016/S0375-9601(99)00695-7; Inan US, 1996, GEOPHYS RES LETT, V23, P1017, DOI 10.1029/96GL00746; INAN US, COMMUNICATION; KOCH HW, 1959, REV MOD PHYS, V31, P920, DOI 10.1103/RevModPhys.31.920; Lehtinen NG, 1999, J GEOPHYS RES-SPACE, V104, P24699, DOI 10.1029/1999JA900335; Lehtinen NG, 2000, GEOPHYS RES LETT, V27, P1095, DOI 10.1029/1999GL010765; Lehtinen NG, 2001, J GEOPHYS RES-SPACE, V106, P28841, DOI 10.1029/2000JA000160; Lin RP, 2002, SOL PHYS, V210, P3, DOI 10.1023/A:1022428818870; Milikh G, 1999, GEOPHYS RES LETT, V26, P525, DOI 10.1029/1999GL900001; Moore CB, 2001, GEOPHYS RES LETT, V28, P2141, DOI 10.1029/2001GL013140; Nemiroff RJ, 1997, J GEOPHYS RES-SPACE, V102, P9659, DOI 10.1029/96JA03107; Neubert T, 2003, SCIENCE, V300, P747, DOI 10.1126/science.1083006; PARKS GK, 1981, GEOPHYS RES LETT, V8, P1176, DOI 10.1029/GL008i011p01176; Pasko VP, 1998, GEOPHYS RES LETT, V25, P2123, DOI 10.1029/98GL01242; Roussel-Dupre R, 1998, J ATMOS SOL-TERR PHY, V60, P917, DOI 10.1016/S1364-6826(98)00028-5; ROUSSELDUPRE R, COMMUNICATION; Tonev PT, 2003, ADV SPACE RES, V31, P1443, DOI 10.1016/S0273-1177(03)00009-7; Wilson CTR, 1925, P PHYS SOC LOND, V37, p32D	27	332	342	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2005	307	5712					1085	1088		10.1126/science.1107466	http://dx.doi.org/10.1126/science.1107466			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ED	15718466				2022-12-28	WOS:000227197300041
J	Cattadori, IM; Haydon, DT; Hudson, PJ				Cattadori, IM; Haydon, DT; Hudson, PJ			Parasites and climate synchronize red grouse populations	NATURE			English	Article							TRICHOSTRONGYLUS-TENUIS; DYNAMICS; STABILITY; BEHAVIOR; SYSTEM	There is circumstantial evidence that correlated climatic conditions can drive animal populations into synchronous fluctuations in abundance(1-5). However, it is unclear whether climate directly affects the survival and fecundity of individuals, or indirectly, by influencing food and natural enemies. Here we propose that climate affects trophic interactions and could be an important mechanism for synchronizing spatially distributed populations. We show that in specific years the size of red grouse populations in northern England either increases or decreases in synchrony. In these years, widespread and correlated climatic conditions during May and July affect populations regionally and influence the density-dependent transmission of the gastrointestinal nematode Trichostrongylus tenuis, a parasite that reduces grouse fecundity(6). This in turn forces grouse populations into synchrony. We conclude that specific climatic events may lead to outbreaks of infectious diseases or pests that may cause dramatic, synchronized changes in the abundance of their hosts.	Penn State Univ, Mueller Lab, Ctr Infect Dis Dynam, University Pk, PA 16802 USA; Univ Glasgow, Div Environm & Evolutionary Biol, Glasgow G12 8QQ, Lanark, Scotland	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Glasgow	Cattadori, IM (corresponding author), Penn State Univ, Mueller Lab, Ctr Infect Dis Dynam, University Pk, PA 16802 USA.	imc3@psu.edu	Hudson, Peter/AAB-8080-2020	Hudson, Peter/0000-0003-0468-3403; Haydon, Daniel/0000-0002-1240-1886; Cattadori, Isabella/0000-0001-6618-316X				[Anonymous], 2000, NEMATODE PARASITES V; Bjornstad ON, 2002, SCIENCE, V298, P1020, DOI 10.1126/science.1075182; Buonaccorsi JP, 2001, ECOLOGY, V82, P1668, DOI 10.1890/0012-9658(2001)082[1668:MATFSS]2.0.CO;2; Cattadori IM, 2000, J ANIM ECOL, V69, P620, DOI 10.1046/j.1365-2656.2000.00421.x; Cattadori IM, 2003, OIKOS, V100, P439, DOI 10.1034/j.1600-0706.2003.12072.x; DOBSON AP, 1992, J ANIM ECOL, V61, P487, DOI 10.2307/5339; Greenman JV, 2001, OIKOS, V93, P343, DOI 10.1034/j.1600-0706.2001.930217.x; Grenfell BT, 1998, NATURE, V394, P674, DOI 10.1038/29291; Haydon DT, 2003, P ROY SOC B-BIOL SCI, V270, P435, DOI 10.1098/rspb.2002.2230; Haydon DT, 2002, P ROY SOC B-BIOL SCI, V269, P1609, DOI 10.1098/rspb.2002.2053; Hudson P.J., 1992, GROUSE SPACE TIME; HUDSON PJ, 1992, J ANIM ECOL, V61, P477, DOI 10.2307/5338; HUDSON PJ, 1986, J ANIM ECOL, V55, P85, DOI 10.2307/4694; Hudson PJ, 2002, POPULATION CYCLES: THE CASE FOR TROPHIC INTERACTIONS, P109; Hudson PJ, 2002, PHILOS T R SOC B, V357, P1259, DOI 10.1098/rstb.2002.1126; HUDSON PJ, 1995, INFECT DIS NATURAL P, P144; HUDSON PJ, 1999, SCIENCE, V286, P2425; Lee D. L., 2002, BIOL NEMATODES; Marquardt W.C., 2000, PARASITOLOGY VECTOR; MORAN PAP, 1953, AUST J ZOOL, V1, P291, DOI 10.1071/ZO9530291; Mougeot F, 2003, NATURE, V421, P737, DOI 10.1038/nature01395; Post E, 2002, NATURE, V420, P168, DOI 10.1038/nature01064; Pugesek BH, 2003, STRUCTURAL EQUATION; RANTA E, 1995, P ROY SOC B-BIOL SCI, V262, P113, DOI 10.1098/rspb.1995.0184; Ranta E, 1997, OIKOS, V78, P136, DOI 10.2307/3545809; Shipley B., 2000, CAUSE CORRELATIONS B; SLAGSVOLD T, 1975, Norwegian Journal of Zoology, V23, P269; Stenseth NC, 1999, SCIENCE, V285, P1071, DOI 10.1126/science.285.5430.1071; WATSON A, 1984, J ANIM ECOL, V53, P663, DOI 10.2307/4542	29	129	134	0	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	2005	433	7027					737	741		10.1038/nature03276	http://dx.doi.org/10.1038/nature03276			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897XH	15716952				2022-12-28	WOS:000227039200038
J	Derry, LA; Kurtz, AC; Ziegler, K; Chadwick, OA				Derry, LA; Kurtz, AC; Ziegler, K; Chadwick, OA			Biological control of terrestrial silica cycling and export fluxes to watersheds	NATURE			English	Article							GERMANIUM; FRACTIONATION; GEOCHEMISTRY; ALUMINUM; FOREST; RIVERS; GE/SI	Silicon has a crucial role in many biogeochemical processes - for example, as a nutrient for marine and terrestrial biota, in buffering soil acidification and in the regulation of atmospheric carbon dioxide. Traditionally, silica fluxes to soil solutions and stream waters are thought to be controlled by the weathering and subsequent dissolution of silicate minerals(1,2). Rates of mineral dissolution can be enhanced by biological processes(3). But plants also take up considerable quantities of silica from soil solution, which is recycled into the soil from falling litter in a separate soil - plant silica cycle that can be significant in comparison with weathering input and hydrologic output(4-8). Here we analyse soil water in basaltic soils across the Hawaiian islands to assess the relative contributions of weathering and biogenic silica cycling by using the distinct signatures of the two processes in germanium/silicon ratios. Our data imply that most of the silica released to Hawaiian stream water has passed through the biogenic silica pool, whereas direct mineral - water reactions account for a smaller fraction of the stream silica flux. We expect that other systems exhibiting strong Si depletion of the mineral soils and/or high Si uptake rates by biomass will also have strong biological control on silica cycling and export.	Cornell Univ, Dept Earth & Atmospher Sci, Ithaca, NY 14853 USA; Boston Univ, Dept Earth Sci, Boston, MA 02215 USA; Univ Calif Santa Barbara, Dept Geog, Santa Barbara, CA 93106 USA	Cornell University; Boston University; University of California System; University of California Santa Barbara	Derry, LA (corresponding author), Cornell Univ, Dept Earth & Atmospher Sci, Ithaca, NY 14853 USA.	lad9@cornell.edu	Derry, Louis A/H-5637-2016	Derry, Louis A/0000-0001-7062-7333				Alexandre A, 1997, GEOCHIM COSMOCHIM AC, V61, P677, DOI 10.1016/S0016-7037(97)00001-X; BARTOLI F, 1980, SOIL SCI SOC AM J, V44, P873, DOI 10.2136/sssaj1980.03615995004400040043x; Chadwick OA, 1999, NATURE, V397, P491, DOI 10.1038/17276; Conley DJ, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2002GB001894; DEARGOLLO R, 1978, GEOCHIM COSMOCHIM AC, V42, P623, DOI 10.1016/0016-7037(78)90007-8; Dove P.M., 1995, CHEM WEATHERING RATE, P235; Drees L.R., 1989, MINERALS SOIL ENV, P914; Drever J.I., 1988, GEOCHEMISTRY NATURAL; Exley C, 2002, COORDIN CHEM REV, V228, P127, DOI 10.1016/S0010-8545(02)00077-2; Fraysse F, 2004, GEOCHIM COSMOCHIM AC, V68, pA216; Froelich PN, 1992, PALEOCEANOGRAPHY, V7, P739, DOI 10.1029/92PA02090; FROELICH PN, 1981, SCIENCE, V213, P205, DOI 10.1126/science.213.4504.205; FROELICH PN, 1985, J GEOPHYS RES-OCEANS, V90, P1133, DOI 10.1029/JC090iC01p01133; Garrels R.M., 1967, RES GEOCHEMISTRY, P405; Hedin LO, 2003, ECOLOGY, V84, P2231, DOI 10.1890/02-4066; Kelly EF, 1998, BIOGEOCHEMISTRY, V42, P21, DOI 10.1023/A:1005919306687; Kurtz A., 2004, P 11 INT S WAT ROCK, P833; Kurtz AC, 2001, GEOCHIM COSMOCHIM AC, V65, P1971, DOI 10.1016/S0016-7037(01)00575-0; Kurtz AC, 2002, GEOCHIM COSMOCHIM AC, V66, P1525, DOI 10.1016/S0016-7037(01)00869-9; Lajtha K, 1999, LT EC RES NETWK SER, V2, P166; LUCAS Y, 1993, SCIENCE, V260, P521, DOI 10.1126/science.260.5107.521; Markewitz D, 1998, BIOGEOCHEMISTRY, V42, P235, DOI 10.1023/A:1005901417165; Meunier JD, 2004, GEOCHIM COSMOCHIM AC, V68, pA411; Meunier JD, 1999, GEOLOGY, V27, P835; MORTLOCK RA, 1987, GEOCHIM COSMOCHIM AC, V51, P2075, DOI 10.1016/0016-7037(87)90257-2; Mortlock RA, 1996, ANAL CHIM ACTA, V332, P277, DOI 10.1016/0003-2670(96)00230-9; Moulton KL, 2000, AM J SCI, V300, P539, DOI 10.2475/ajs.300.7.539; MURNANE RJ, 1990, NATURE, V344, P749, DOI 10.1038/344749a0; VITOUSEK PM, 1995, J TROP ECOL, V11, P189, DOI 10.1017/S0266467400008634; VITOUSEK PM, 1997, GSA TODAY, V7, P1	30	343	366	7	193	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	2005	433	7027					728	731		10.1038/nature03299	http://dx.doi.org/10.1038/nature03299			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897XH	15716949				2022-12-28	WOS:000227039200035
J	Ojikutu, BO; Stone, VE				Ojikutu, BO; Stone, VE			Women, inequality, and the burden of HIV	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Div AIDS, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Ojikutu, BO (corresponding author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.			Ojikutu, Bisola/0000-0001-7957-8881				*CDCP, 2004, HIV AIDS SURV REP, V15, P18; Padian NS, 1997, AM J EPIDEMIOL, V146, P350, DOI 10.1093/oxfordjournals.aje.a009276; Shapiro MF, 1999, JAMA-J AM MED ASSOC, V281, P2305, DOI 10.1001/jama.281.24.2305; *UNAIDS, 2004, 2004 REP GLOB AIDS E, P22	4	31	32	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2005	352	7					649	652		10.1056/NEJMp048318	http://dx.doi.org/10.1056/NEJMp048318			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897UO	15716557				2022-12-28	WOS:000227031100002
J	Rong, HS; Jones, R; Liu, AS; Cohen, O; Hak, D; Fang, A; Paniccia, M				Rong, HS; Jones, R; Liu, AS; Cohen, O; Hak, D; Fang, A; Paniccia, M			A continuous-wave Raman silicon laser	NATURE			English	Article							ON-INSULATOR; FABRY-PEROT; GUIDES; AMPLIFICATION; ABSORPTION; GAIN	Achieving optical gain and/or lasing in silicon has been one of the most challenging goals in silicon-based photonics(1-3) because bulk silicon is an indirect bandgap semiconductor and therefore has a very low light emission efficiency. Recently, stimulated Raman scattering has been used to demonstrate light amplification and lasing in silicon(4-9). However, because of the nonlinear optical loss associated with two-photon absorption (TPA)-induced free carrier absorption (FCA)(10-12), until now lasing has been limited to pulsed operation(8,9.) Here we demonstrate a continuous-wave silicon Raman laser. Specifically, we show that TPA-induced FCA in silicon can be significantly reduced by introducing a reverse-biased p-i-n diode embedded in a silicon waveguide. The laser cavity is formed by coating the facets of the silicon waveguide with multilayer dielectric films. We have demonstrated stable single mode laser output with side-mode suppression of over 55 dB and linewidth of less than 80 MHz. The lasing threshold depends on the p-i-n reverse bias voltage and the laser wavelength can be tuned by adjusting the wavelength of the pump laser. The demonstration of a continuous-wave silicon laser represents a significant milestone for silicon-based optoelectronic devices.	Intel Corp, Santa Clara, CA 95054 USA; Intel Corp, SBI Pk Har Hotzvim, IL-91031 Jerusalem, Israel	Intel Corporation; Intel Corporation	Rong, HS (corresponding author), Intel Corp, 2200 Mission Coll Blvd,CHP3-109, Santa Clara, CA 95054 USA.	haisheng.rong@intel.com						AGRAWAL GP, 1995, NONLINEAR FIBER OPTI, P42; Barrios CA, 2004, IEEE PHOTONIC TECH L, V16, P506, DOI 10.1109/LPT.2003.822251; Boyraz O., 2004, IEICE Electronics Express, V1, DOI 10.1587/elex.1.429; Boyraz O, 2004, OPT EXPRESS, V12, P5269, DOI 10.1364/OPEX.12.005269; Brasseur JK, 1998, OPT LETT, V23, P367, DOI 10.1364/OL.23.000367; Claps R, 2004, OPT EXPRESS, V12, P2774, DOI 10.1364/OPEX.12.002774; GARMIRE E, 1989, IEEE J QUANTUM ELECT, V25, P289, DOI 10.1109/3.18542; Headley WR, 2004, APPL PHYS LETT, V85, P5523, DOI 10.1063/1.1827337; Jones R, 2005, OPT EXPRESS, V13, P519, DOI 10.1364/OPEX.13.000519; Kippenberg TJ, 2004, OPT LETT, V29, P1224, DOI 10.1364/OL.29.001224; Koonath P, 2004, APPL PHYS LETT, V85, P1018, DOI 10.1063/1.1781370; Lee MCM, 2003, 2003 IEEE/LEOS INTERNATIONAL CONFERENCE ON OPTICAL MEMS, P28, DOI 10.1109/OMEMS.2003.1233451; Liang TK, 2004, APPL PHYS LETT, V84, P2745, DOI 10.1063/1.1702133; Liang TK, 2004, APPL PHYS LETT, V85, P3343, DOI 10.1063/1.1807960; Liu AS, 2004, OPT EXPRESS, V12, P4261, DOI 10.1364/OPEX.12.004261; Liu MY, 1996, APPL PHYS LETT, V68, P170, DOI 10.1063/1.116449; Pavesi L., 2004, SILICON PHOTONICS; PAVESI L, 2003, NATO SCI SERIES; Reed G. T., 2004, SILICON PHOTONICS IN; Rong HS, 2005, NATURE, V433, P292, DOI 10.1038/nature03273; Rong HS, 2004, APPL PHYS LETT, V85, P2196, DOI 10.1063/1.1794862; Salib M., 2004, Intel Technology Journal; Siegman A.E., 1986, LASERS, P413; SUTO K, 1992, IEE PROC-J, V139, P407, DOI 10.1049/ip-j.1992.0069; Xu QF, 2004, OPT EXPRESS, V12, P4437, DOI 10.1364/OPEX.12.004437	25	994	1055	3	313	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	2005	433	7027					725	728		10.1038/nature03346	http://dx.doi.org/10.1038/nature03346			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897XH	15716948	Bronze			2022-12-28	WOS:000227039200034
J	Larrabee, PB; Johnson, KL; Lai, CQ; Ordovas, J; Cowan, JM; Tantravahi, U; Bianchi, DW				Larrabee, PB; Johnson, KL; Lai, CQ; Ordovas, J; Cowan, JM; Tantravahi, U; Bianchi, DW			Global gene expression analysis of the living human fetus using cell-free messenger RNA in amniotic fluid	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MATERNAL PLASMA; CANCER-PATIENTS; MICROSATELLITE ALTERATIONS; FETAL DNA; SERUM; ARRAYS; OLIGONUCLEOTIDE; AQUAPORIN-1	Context No molecular biological tests are available to monitor the ongoing development of human fetuses in vivo. Objective To determine whether cell-free fetal messenger RNA (mRNA) in amniotic fluid can be detected using oligonucleotide microarrays to study large-scale gene expression in living human fetuses, with analysis of sex, gestational age, and fetal pathology as variables. Design, Setting, and Patients Four samples of cell-free amniotic fluid were analyzed from pregnant women between 20 and 32 weeks' gestation and undergoing amnioreduction for polyhydramnios associated with twin-twin transfusion syndrome or hydrops fetalis (cases). The control consisted of 6 pooled amniotic fluid samples from women at 17 weeks' gestation and undergoing genetic amniocentesis. After extraction from the normally discarded fraction of amniotic fluid, RNA was amplified twice, labeled, and analyzed using gene expression microarrays. Main Outcome Measure Relative mRNA expression in cell-free samples of amniotic fluid from fetuses with polyhydramnios at different gestational ages vs cell-free amniotic fluid from a pooled control. Results Thirty-six percent of 22 283 probe sets represented on the arrays were present in the cell-free amniotic fluid, and a median of 20% of all probe sets differed between cases and the pooled control. Only male samples expressed 1 Y chromosome transcript. The expression of some developmental transcripts, such as surfactant proteins, mucins, and keratins, changed with gestational age by up to 64-fold. A water transporter gene transcript was increased up to 18-fold in both twin-twin transfusion samples. Placental gene transcripts were not present in any samples., Conclusions This pilot study demonstrates that cell-free fetal mRNA can be extracted from amniotic fluid and successfully hybridized to gene expression microarrays. Preliminary analysis suggests that gene expression changes can be detected in fetuses of different sexes, gestational age, and disease status. Cell-free mRNA in amniotic fluid appears to originate from the fetus and not the placenta.	Tufts Univ, New England Med Ctr, Div Genet, Boston, MA 02111 USA; Tufts Univ, New England Med Ctr, Dept Pediat, Div Newborn Med, Boston, MA 02111 USA; Tufts Univ, Jean Mayer US Dept Agr Human Nutr Res Ctr Aging, Nutr & Genom Lab, Boston, MA 02111 USA; Brown Univ, Women & Infants Hosp, Dept Pathol & Lab Med, Providence, RI USA	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; Tufts University; Brown University; Women & Infants Hospital Rhode Island	Bianchi, DW (corresponding author), Tufts Univ, New England Med Ctr, Div Genet, 750 Washington St,NEMC 394, Boston, MA 02111 USA.	dbianchi@tufts-nemc.org	Ordovas, Jose/B-8727-2013	Ordovas, Jose/0000-0002-7581-5680; Lai, Chao-Qiang/0000-0003-1107-8375	NICHD NIH HHS [HD42053] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD042053] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bianchi DW, 2001, CLIN CHEM, V47, P1867; Botezatu I, 2000, CLIN CHEM, V46, P1078; Chen XQ, 1996, NAT MED, V2, P1033; Dekker J, 2002, TRENDS BIOCHEM SCI, V27, P126, DOI 10.1016/S0968-0004(01)02052-7; Hsiao LL, 2001, PHYSIOL GENOMICS, V7, P97, DOI 10.1152/physiolgenomics.00040.2001; Jonker SS, 2003, EXP PHYSIOL, V88, P691, DOI 10.1113/eph8802626; LARSEN WJ, 1993, HUMAN EMBRYOLOGY, P421; LEON SA, 1977, CANCER RES, V37, P646; Li J, 2002, TOXICOL SCI, V69, P383, DOI 10.1093/toxsci/69.2.383; Lo YMD, 1997, LANCET, V350, P485, DOI 10.1016/S0140-6736(97)02174-0; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Mann SE, 2002, AM J OBSTET GYNECOL, V187, P902, DOI 10.1067/mob.2002.127168; Mendelson CR, 2000, ANNU REV PHYSIOL, V62, P875, DOI 10.1146/annurev.physiol.62.1.875; Nawroz H, 1996, NAT MED, V2, P1035, DOI 10.1038/nm0996-1035; Ng EKO, 2003, CLIN CHEM, V49, P727, DOI 10.1373/49.5.727; Ng EKO, 2003, P NATL ACAD SCI USA, V100, P4748, DOI 10.1073/pnas.0637450100; Ng EKO, 2002, CLIN CHEM, V48, P1212; Poon LLM, 2000, CLIN CHEM, V46, P1832; Sekizawa A, 2003, HUM GENET, V113, P307, DOI 10.1007/s00439-003-0987-4; Tsui NBY, 2002, CLIN CHEM, V48, P1647	21	51	53	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	2005	293	7					836	842		10.1001/jama.293.7.836	http://dx.doi.org/10.1001/jama.293.7.836			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DQ	15713773	Bronze			2022-12-28	WOS:000226984600025
J	Nettles, RE; Kieffer, TL; Kwon, P; Monie, D; Han, YF; Parsons, T; Cofrancesco, J; Gallant, JE; Quinn, TC; Jackson, B; Flexner, C; Carson, K; Ray, S; Persaud, D; Siliciano, RF				Nettles, RE; Kieffer, TL; Kwon, P; Monie, D; Han, YF; Parsons, T; Cofrancesco, J; Gallant, JE; Quinn, TC; Jackson, B; Flexner, C; Carson, K; Ray, S; Persaud, D; Siliciano, RF			Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ACTIVE ANTIRETROVIRAL THERAPY; VIRAL LOAD; RNA LEVELS; HIV-1-INFECTED PATIENTS; INFLUENZA VACCINATION; VIROLOGICAL FAILURE; GENOTYPIC ANALYSIS; LATENT RESERVOIR; STEADY-STATE	Context Many patients infected with human immunodeficiency virus type 1 (HIV-1) and receiving highly active antiretroviral therapy experience intermittent episodes of detectable viremia ("blips"), which may raise concerns about drug resistance, lead to costly repeat measurements of viral RNA, and sometimes trigger alterations in therapy. Objective To test the hypothesis that blips represent random biological and statistical variation around mean steady-state HIV-1 RNA levels slightly below 50 copies/mL rather than biologically significant elevations in viremia. Design, Setting, and Patients Between June 19, 2003, and February 9, 2004, patients receiving therapy underwent intensive sampling (every 2-3 days) over 3 to 4 months to define the frequency, magnitude, and duration of blips and their association with drug levels and other clinical variables. Blips were defined as HIV-1 RNA measurements greater than or equal to 50 copies/mL preceded and followed by measurements less than 50 copies/mL without a change in treatment. To-determine whether blips result from or lead to drug resistance, an ultrasensitive genotyping assay was used to detect drug resistance mutations before, during, and after blips. Patients were 10 HIV-1-infected asymptomatic adults recruited by clinicians and followed up in the Moore Clinic at the Johns Hopkins Hospital. Patients had suppression of viremia to below 50 copies/mL while receiving a stable antiretroviral regimen for 6 months or longer. Main Outcome Measures At each time point, plasma HIV-1 RNA levels were measured in 2 independent laboratories and drug resistance mutations were analyzed by clonal sequencing. Results With the intensive sampling, blips were detected in 9 of 10 patients. Statistical analysis was consistent with random assay variation around a mean viral load below 50 copies/mL. Blips were not concordant on independent testing and had a short duration (median, <3 days) and low magnitude (median, 79 copies/mL). Blip frequency was not associated with demographic, clinical, or treatment variables. Blips did not occur in relation to illness, vaccination, or directly measured antiretroviral drug concentrations. Blips were marginally associated (P=.08) with reported episodes of nonadherence. Most importantly, in approximately 1000 independent clones sequenced for both protease and reverse transcriptase, no new resistance mutations were seen before, during, or shortly after blips. Conclusion Most blips in this population appear to represent random biological and statistical variation around mean HIV-1 levels below 50 copies/mL rather than clinically significant elevations in viremia.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; NIAID, NIH, Bethesda, MD 20892 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Howard Hughes Medical Institute; Johns Hopkins University	Siliciano, RF (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, 879 Broadway Res Bldg,733 N Broadway, Baltimore, MD 21205 USA.	rsiliciano@jhmi.edu	Quinn, Thomas/A-2494-2010; Ray, Stuart C./B-7527-2008	Ray, Stuart C./0000-0002-1051-7260; jackson, brooks/0000-0001-9458-135X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043222, F32AI056696, Z01AI000361, R01AI051178, K08AI060367, R37AI051178] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00052] Funding Source: Medline; NIAID NIH HHS [K08 AI060367, F32 AI056696, AI43222, AI51178] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aleman S, 2002, AIDS, V16, P1039, DOI 10.1097/00002030-200205030-00010; Armitage P., 1987, STAT METHODS MED RES; BARTLETT JG, 2004, GUIDELINES USE ANTIR; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Crommentuyn KML, 2004, ANTIVIR THER, V9, P779; Deeks SG, 1997, J INFECT DIS, V176, P514, DOI 10.1086/517278; Di Mascio M, 2004, MATH BIOSCI, V188, P47, DOI 10.1016/j.mbs.2003.08.003; Di Mascio M, 2004, J VIROL, V78, P10566, DOI 10.1128/JVI.78.19.10566-10573.2004; Di Mascio M, 2003, J VIROL, V77, P12165, DOI 10.1128/JVI.77.22.12165-12172.2003; DOMADULA G, 1999, JAMA-J AM MED ASSOC, V282, P1627; Easterbrook PJ, 2002, AIDS, V16, P1521, DOI 10.1097/00002030-200207260-00009; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Frenkel LM, 2003, J VIROL, V77, P5721, DOI 10.1128/JVI.77.10.5721-5730.2003; Garcia PM, 1999, NEW ENGL J MED, V341, P394, DOI 10.1056/NEJM199908053410602; Greub G, 2002, AIDS, V16, P1967, DOI 10.1097/00002030-200209270-00017; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gunthard HF, 2000, J INFECT DIS, V181, P522, DOI 10.1086/315260; Gunthard HF, 1999, J VIROL, V73, P9404; Gunthard HF, 1998, J VIROL, V72, P2422; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HAMMOND J, 2004, LOS ALAMOS HIV SEQUE; Havlir DV, 2001, JAMA-J AM MED ASSOC, V286, P171, DOI 10.1001/jama.286.2.171; Havlir DV, 2003, J VIROL, V77, P11212, DOI 10.1128/JVI.77.20.11212-11219.2003; Hermankova M, 2001, JAMA-J AM MED ASSOC, V286, P196, DOI 10.1001/jama.286.2.196; HOLODNIY M, 1994, J ACQ IMMUN DEF SYND, V7, P363; Huson DH, 1998, BIOINFORMATICS, V14, P68, DOI 10.1093/bioinformatics/14.1.68; Jackson JB, 2004, J CLIN MICROBIOL, V42, P2774, DOI 10.1128/JCM.42.6.2774-2776.2004; Kieffer TL, 2005, J VIROL, V79, P1975, DOI 10.1128/JVI.79.3.1975-1980.2005; Kieffer TL, 2004, J INFECT DIS, V189, P1452, DOI 10.1086/382488; Kolber MA, 2002, AIDS, V16, P537, DOI 10.1097/00002030-200203080-00004; Lamotte C, 1999, J CHROMATOGR B, V735, P159, DOI 10.1016/S0378-4347(99)00419-3; Lassen KG, 2004, J VIROL, V78, P9105, DOI 10.1128/JVI.78.17.9105-9114.2004; Markowitz M, 2003, J VIROL, V77, P5037, DOI 10.1128/JVI.77.8.5037-5038.2003; Miller LG, 2004, J INFECT DIS, V189, P1487, DOI 10.1086/382895; Mira JA, 2002, ANTIVIR THER, V7, P251; Moore AL, 2002, AIDS, V16, P615, DOI 10.1097/00002030-200203080-00013; Parkin NT, 2000, AIDS, V14, P2877, DOI 10.1097/00002030-200012220-00009; Pav JW, 1999, J PHARMACEUT BIOMED, V20, P91, DOI 10.1016/S0731-7085(98)00312-4; Percus JK, 2003, B MATH BIOL, V65, P263, DOI 10.1016/S0092-8240(02)00095-2; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Persaud D, 2004, J VIROL, V78, P968, DOI 10.1128/JVI.78.2.968-979.2004; Powderly WG, 1999, AIDS, V13, P1873, DOI 10.1097/00002030-199910010-00009; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Raboud JM, 2002, AIDS, V16, P1627, DOI 10.1097/00002030-200208160-00008; Ramratnam B, 2000, NAT MED, V6, P82, DOI 10.1038/71577; *ROCH DIAGN CORP, 2002, ROCH AMPL HIV 1 MON; Rozas J, 2003, BIOINFORMATICS, V19, P2496, DOI 10.1093/bioinformatics/btg359; Ruff CT, 2002, J VIROL, V76, P9481, DOI 10.1128/JVI.76.18.9481-9492.2002; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SHAFER RW, 2004, GM STANFORD HIV RT P; Sklar PA, 2002, AIDS, V16, P2035, DOI 10.1097/00002030-200210180-00008; Sterling TR, 2001, NEW ENGL J MED, V344, P720, DOI 10.1056/NEJM200103083441003; Sterling TR, 1999, J INFECT DIS, V180, P666, DOI 10.1086/314967; Stuart JWTC, 2001, J ACQ IMMUN DEF SYND, V28, P105, DOI 10.1097/00042560-200110010-00001; Swofford D. L., 2011, PAUP PHYLOGENETIC AN; Wain-Hobson S, 2003, J GEN VIROL, V84, P885, DOI 10.1099/vir.0.18894-0; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222	59	296	300	1	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	2005	293	7					817	829		10.1001/jama.293.7.817	http://dx.doi.org/10.1001/jama.293.7.817			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DQ	15713771	Bronze			2022-12-28	WOS:000226984600023
J	Kim, K				Kim, K			Historical keywords - Protein	LANCET			English	Editorial Material									Wellcome Trust Ctr Hist Med, London, England	University of London; University College London	Kim, K (corresponding author), Wellcome Trust Ctr Hist Med, London, England.	k.kim@ucl.ac.uk							0	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 12	2005	365	9459					565	565		10.1016/S0140-6736(05)17890-8	http://dx.doi.org/10.1016/S0140-6736(05)17890-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DN	15724277				2022-12-28	WOS:000226984300013
J	Boire, A; Covic, L; Agarwal, A; Jacques, S; Sherifl, S; Kuliopulos, A				Boire, A; Covic, L; Agarwal, A; Jacques, S; Sherifl, S; Kuliopulos, A			PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells	CELL			English	Article							PROTEASE-ACTIVATED RECEPTOR-1; THROMBIN-RECEPTOR; ENDOTHELIAL-CELLS; TISSUE FACTOR; EXPRESSION; INHIBITION; TRANSFORMATION; ANGIOGENESIS; METASTASIS; ANTAGONIST	Protease-activated receptors (PARs) are a unique class of G protein-coupled receptors that play critical roles in thrombosis, inflammation, and vascular biology. PAR1 is proposed to be involved in the invasive and metastatic processes of various cancers. However, the protease responsible for activating the pro-invasive functions of PAR1 remains to be identified. Here, we show that expression of PAR1 is both required and sufficient to promote growth and invasion of breast carcinoma cells in a xenograft model. Further, we show that the matrix metalloprotease, MMP-1, functions as a protease agonist of PAR1 cleaving the receptor at the proper site to generate PAR1-dependent Ca2+ signals and migration. MMP-1 activity is derived from fibroblasts and is absent from the breast cancer cells. These results demonstrate that MMP-1 in the stromal-tumor microenvironment can alter the behavior of cancer cells through PAR1 to promote cell migration and invasion.	Tufts Univ, Sch Med, Mol Oncol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Div Hematol Oncol, Tufts New England Med Ctr, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Mt Auburn Hosp, Dept Pathol, Cambridge, MA 02138 USA	Tufts University; Tufts Medical Center; Tufts University; Tufts University; Harvard University; Mount Auburn Hospital	Kuliopulos, A (corresponding author), Tufts Univ, Sch Med, Mol Oncol Res Inst, Boston, MA 02111 USA.	athan.kuliopulos@tufts.edu	Boire, Adrienne/AAJ-9352-2021; Boire, Adrienne/AAA-3578-2022	Boire, Adrienne/0000-0002-9029-1248; Boire, Adrienne/0000-0002-9029-1248	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064701] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64701] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrade-Gordon P, 1999, P NATL ACAD SCI USA, V96, P12257, DOI 10.1073/pnas.96.22.12257; Bernatowicz MS, 1996, J MED CHEM, V39, P4879, DOI 10.1021/jm960455s; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Caunt M, 2003, J THROMB HAEMOST, V1, P2097, DOI 10.1046/j.1538-7836.2003.00426.x; CHEN J, 1994, J BIOL CHEM, V269, P16041; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Covic L, 2002, P NATL ACAD SCI USA, V99, P643, DOI 10.1073/pnas.022460899; Covic L, 2002, NAT MED, V8, P1161, DOI 10.1038/nm760; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Even-Ram SC, 2003, J PATHOL, V200, P47, DOI 10.1002/path.1338; Even-Ram SC, 2001, J BIOL CHEM, V276, P10952, DOI 10.1074/jbc.M007027200; FISCHER EG, 1995, CANCER RES, V55, P1629; Griffin CT, 2001, SCIENCE, V293, P1666, DOI 10.1126/science.1061259; Heppner KJ, 1996, AM J PATHOL, V149, P273; Jacques SL, 2003, BIOCHEM J, V376, P733, DOI 10.1042/BJ20030954; Kamath L, 2001, CANCER RES, V61, P5933; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Ku DD, 1997, J CARDIOVASC PHARM, V30, P649, DOI 10.1097/00005344-199711000-00016; Kuliopulos A, 1999, BIOCHEMISTRY-US, V38, P4572, DOI 10.1021/bi9824792; Libby P, 2002, NAT MED, V8, P1257, DOI 10.1038/nm1102-1257; Martin CB, 2001, ONCOGENE, V20, P1953, DOI 10.1038/sj.onc.1204281; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murray GI, 1998, J PATHOL, V185, P256; NELKEN NA, 1992, J CLIN INVEST, V90, P1614, DOI 10.1172/JCI116031; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nierodzik ML, 1998, BLOOD, V92, P3694, DOI 10.1182/blood.V92.10.3694.422k40_3694_3700; NIERODZIK MLR, 1992, CANCER RES, V52, P3267; ODAKE S, 1994, BIOCHEM BIOPH RES CO, V199, P1442, DOI 10.1006/bbrc.1994.1392; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Riewald M, 2001, BLOOD, V97, P3109, DOI 10.1182/blood.V97.10.3109; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Seeley S, 2003, CHEM BIOL, V10, P1033, DOI 10.1016/j.chembiol.2003.10.014; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Tsopanoglou NE, 1999, J BIOL CHEM, V274, P23969, DOI 10.1074/jbc.274.34.23969; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Yamamoto A, 2003, INT J CANCER, V103, P822, DOI 10.1002/ijc.10875; Yin YJ, 2003, FASEB J, V17, P163, DOI 10.1096/fj.02-0316com; Youngs SJ, 1997, INT J CANCER, V71, P257, DOI 10.1002/(SICI)1097-0215(19970410)71:2<257::AID-IJC22>3.0.CO;2-D; Zain J, 2000, BLOOD, V95, P3133; Zucker S, 1998, INT J CANCER, V75, P780, DOI 10.1002/(SICI)1097-0215(19980302)75:5<780::AID-IJC19>3.0.CO;2-A	43	649	686	1	45	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 11	2005	120	3					303	313		10.1016/j.cell.2004.12.018	http://dx.doi.org/10.1016/j.cell.2004.12.018			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	897TS	15707890	Bronze			2022-12-28	WOS:000227028900007
J	Sanders, GD; Bayoumi, AM; Sundaram, V; Bilir, SP; Neukermans, CP; Rydzak, CE; Douglass, LR; Lazzeroni, LC; Holodniy, M; Owens, DK				Sanders, GD; Bayoumi, AM; Sundaram, V; Bilir, SP; Neukermans, CP; Rydzak, CE; Douglass, LR; Lazzeroni, LC; Holodniy, M; Owens, DK			Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEASE INHIBITOR THERAPY; CD4 CELL COUNT; VIROLOGICAL TREATMENT FAILURE; PLASMA VIRAL LOAD; SEXUALLY-TRANSMITTED-DISEASES; SAQUINAVIR SOFT GELATIN; RNA LEVELS; HETEROSEXUAL TRANSMISSION; COMBINATION THERAPY	BACKGROUND: The costs, benefits, and cost-effectiveness of screening for human immunodeficiency virus (HIV) in health care settings during the era of highly active antiretroviral therapy (HAART) have not been determined. METHODS: We developed a Markov model of costs, quality of life, and survival associated with an HIV-screening program as compared with current practice. In both strategies, symptomatic patients were identified through symptom-based case finding. Identified patients started treatment when their CD4 count dropped to 350 cells per cubic millimeter. Disease progression was defined on the basis of CD4 levels and viral load. The likelihood of sexual transmission was based on viral load, knowledge of HIV status, and efficacy of counseling. RESULTS: Given a 1 percent prevalence of unidentified HIV infection, screening increased life expectancy by 5.48 days, or 4.70 quality-adjusted days, at an estimated cost of $194 per screened patient, for a cost-effectiveness ratio of $15,078 per quality-adjusted life-year. Screening cost less than $50,000 per quality-adjusted life-year if the prevalence of unidentified HIV infection exceeded 0.05 percent. Excluding HIV transmission, the cost-effectiveness of screening was $41,736 per quality-adjusted life-year. Screening every five years, as compared with a one-time screening program, cost $57,138 per quality-adjusted life-year, but was more attractive in settings with a high incidence of infection. Our results were sensitive to the efficacy of behavior modification, the benefit of early identification and therapy, and the prevalence and incidence of HIV infection. CONCLUSIONS: The cost-effectiveness of routine HIV screening in health care settings, even in relatively low-prevalence populations, is similar to that of commonly accepted interventions, and such programs should be expanded.	Duke Univ, Duke Clin Res Inst, Durham, NC 27715 USA; Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, Dept Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA; St Michaels Hosp, Ctr Res Inner City Hlth, Toronto, ON M5B 1W8, Canada; St Michaels Hosp, Div Gen Med, Toronto, ON M5B 1W8, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Palo Alto Vet Affairs Hlth Care Syst, Palo Alto, CA USA	Duke University; Stanford University; Stanford University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	Sanders, GD (corresponding author), Duke Univ, Duke Clin Res Inst, POB 17969, Durham, NC 27715 USA.	gillian.sanders@duke.edu	Lazzeroni, Laura/F-2903-2010; Abrams, William R/A-5782-2008	Lazzeroni, Laura/0000-0002-1846-6920; Holodniy, Mark/0000-0002-6655-7982	NIDA NIH HHS [R01 DA15612-01] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA015612, R01DA015612] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Ahdieh-Grant L, 2003, AM J EPIDEMIOL, V157, P738, DOI 10.1093/aje/kwg036; Anastos K, 2002, ARCH INTERN MED, V162, P1973, DOI 10.1001/archinte.162.17.1973; Centers of Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; Baxter JD, 2000, AIDS, V14, pF83, DOI 10.1097/00002030-200006160-00001; Bayoumi AM, 1998, AIDS, V12, P1503, DOI 10.1097/00002030-199812000-00013; Bellman PC, 1998, AIDS, V12, P1333, DOI 10.1097/00002030-199811000-00015; Bernasconi E, 2000, AIDS, V14, P95, DOI 10.1097/00002030-200001070-00015; Bindman AB, 1998, JAMA-J AM MED ASSOC, V280, P1416, DOI 10.1001/jama.280.16.1416; Bonfanti P, 2000, J ACQ IMMUN DEF SYND, V23, P236; Bonfanti P, 1998, AIDS, V12, P1111; Bozzette SA, 1998, NEW ENGL J MED, V339, P1897, DOI 10.1056/NEJM199812243392606; Bozzette SA, 2001, NEW ENGL J MED, V344, P817, DOI 10.1056/NEJM200103153441107; BrunVezinet F, 1997, LANCET, V350, P983, DOI 10.1016/S0140-6736(97)03380-1; Buchbinder SP, 1996, J INFECT DIS, V174, P954, DOI 10.1093/infdis/174.5.954; Butcher D, 2000, ARCH INTERN MED, V160, P394, DOI 10.1001/archinte.160.3.394-a; CACERES CF, 1994, AIDS, V8, P1051, DOI 10.1097/00002030-199408000-00004; Cameron DW, 1999, AIDS, V13, P213, DOI 10.1097/00002030-199902040-00009; Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Casado JL, 1998, AIDS, V12, pF131, DOI 10.1097/00002030-199811000-00005; *CDCP, 2001, HIV COUNS TEST PUBL; *CDCP, 2002, HIV AIDS SURV REP, V14; Celentano DD, 1998, SCIENCE, V280, P1889, DOI 10.1126/science.280.5371.1889; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P329; Chene G, 1998, AIDS, V12, P2313, DOI 10.1097/00002030-199817000-00013; Clough LA, 1999, CLIN INFECT DIS, V29, P75, DOI 10.1086/520185; COHEN C, 2000, P 7 C RETR OPP INF S; Cook J, 1999, AIDS RES HUM RETROV, V15, P499, DOI 10.1089/088922299311024; Coombs RW, 1996, J INFECT DIS, V174, P704, DOI 10.1093/infdis/174.4.704; Cooper D, 1999, LANCET, V353, P2061, DOI 10.1016/S0140-6736(98)10391-4; D'Amato RM, 1998, ANTIVIR THER, V3, P147; De Wit S, 1999, AIDS, V13, P864, DOI 10.1097/00002030-199905070-00020; Deeks SG, 1999, AIDS, V13, pF35, DOI 10.1097/00002030-199904160-00001; Deschamps MM, 1996, ANN INTERN MED, V125, P324, DOI 10.7326/0003-4819-125-4-199608150-00011; DEVINCENZI I, 1994, NEW ENGL J MED, V331, P341, DOI 10.1056/NEJM199408113310601; deWolf F, 1997, AIDS, V11, P1799, DOI 10.1097/00002030-199715000-00003; DICLEMENTE RJ, 1995, JAMA-J AM MED ASSOC, V274, P1271, DOI 10.1001/jama.274.16.1271; Drusano GL, 1998, ANTIMICROB AGENTS CH, V42, P358; Durant J, 1999, LANCET, V353, P2195, DOI 10.1016/S0140-6736(98)12291-2; DURANT J, 1999, LANCET, V354, P118; Erb P, 2000, ARCH INTERN MED, V160, P1134, DOI 10.1001/archinte.160.8.1134; ERICKSON B, 1990, SEX TRANSM DIS, V17, P194, DOI 10.1097/00007435-199010000-00009; Fatkenheuer G, 1997, AIDS, V11, pF113, DOI 10.1097/00002030-199714000-00001; FERRER E, 2003, P 10 C RETR OPP INF, P910; Freedberg KA, 2001, NEW ENGL J MED, V344, P824, DOI 10.1056/NEJM200103153441108; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Gable CB, 1996, J ACQ IMMUN DEF SYND, V12, P413, DOI 10.1097/00042560-199608010-00013; GalettoLacour A, 1996, J INFECT DIS, V173, P1388, DOI 10.1093/infdis/173.6.1388; *GEN ACC OFF, 1998, GAOHEHS992; Guardiola JM, 1999, ARCH INTERN MED, V159, P194, DOI 10.1001/archinte.159.2.194; Gulick RM, 2000, ANN INTERN MED, V133, P35, DOI 10.7326/0003-4819-133-1-200007040-00007; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gulick RM, 1998, JAMA-J AM MED ASSOC, V280, P35, DOI 10.1001/jama.280.1.35; Hall CS, 1999, AIDS, V13, P1207, DOI 10.1097/00002030-199907090-00009; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HARRIS RL, 1990, INFECT CONT HOSP EP, V11, P628; Havlir DV, 1998, NEW ENGL J MED, V339, P1261, DOI 10.1056/NEJM199810293391801; HENRARD DR, 1995, JAMA-J AM MED ASSOC, V274, P554, DOI 10.1001/jama.274.7.554; Hightow LB, 2003, AIDS EDUC PREV, V15, P282, DOI 10.1521/aeap.15.4.282.23826; Hogg RS, 1998, AIDS, V12, P279, DOI 10.1097/00002030-199803000-00005; Hogg RS, 2001, JAMA-J AM MED ASSOC, V286, P2568, DOI 10.1001/jama.286.20.2568; HOLMAN S, 1994, PUBLIC HEALTH REP, V109, P521; HONIDEN S, 2002, MED DECIS MAKING, V22, P560; Hughes MD, 1997, ANN INTERN MED, V126, P929, DOI 10.7326/0003-4819-126-12-199706150-00001; Ioannidis JPA, 1996, AIDS, V10, P255, DOI 10.1097/00002030-199603000-00003; Irwin K, 1996, ANN INTERN MED, V125, P471, DOI 10.7326/0003-4819-125-6-199609150-00007; JANSSEN RS, 1992, NEW ENGL J MED, V327, P445, DOI 10.1056/NEJM199208133270701; Kamb ML, 1998, JAMA-J AM MED ASSOC, V280, P1161, DOI 10.1001/jama.280.13.1161; Karon JM, 2001, AM J PUBLIC HEALTH, V91, P1060, DOI 10.2105/AJPH.91.7.1060; Kassler WJ, 1997, AIDS, V11, P1045, DOI 10.1097/00002030-199708000-00014; Katzenstein DA, 1997, NEW ENGL J MED, V337, P1097; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; Kaufmann GR, 1998, AIDS, V12, P1625, DOI 10.1097/00002030-199813000-00009; KEET IPM, 1992, AIDS, V6, P223, DOI 10.1097/00002030-199202000-00014; Keet IPM, 1997, J INFECT DIS, V176, P665, DOI 10.1086/514088; Keiser P, 1999, J ACQ IMMUN DEF SYND, V20, P28, DOI 10.1097/00042560-199901010-00004; Keita-Perse O, 1998, AIDS, V12, pF175, DOI 10.1097/00002030-199815000-00002; Kelen GD, 1999, ANN EMERG MED, V33, P147, DOI 10.1016/S0196-0644(99)70387-2; Kelen GD, 1996, ANN EMERG MED, V27, P687, DOI 10.1016/S0196-0644(96)70184-1; Kempf DJ, 1998, AIDS, V12, pF9, DOI 10.1097/00002030-199805000-00001; Kirk O, 1999, AIDS, V13, pF9, DOI 10.1097/00002030-199901140-00002; KOZAK LJ, 2004, VITAL HLTH STAT, V156, P1; Laumann E. O., 1994, SOCIAL ORG SEXUALITY; Le Moing V, 2002, AIDS, V16, P21, DOI 10.1097/00002030-200201040-00004; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; LEMP GF, 1994, JAMA-J AM MED ASSOC, V272, P449, DOI 10.1001/jama.272.6.449; Lepri AC, 2001, AIDS, V15, P983, DOI 10.1097/00002030-200105250-00006; LOVEDAY C, 1995, LANCET, V345, P790, DOI 10.1016/S0140-6736(95)90668-1; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; LURIE P, 1994, JAMA-J AM MED ASSOC, V272, P1832, DOI 10.1001/jama.272.23.1832; LURIE P, 1995, JAMA-J AM MED ASSOC, V273, P1000; MACDONALD KL, 1989, ANN INTERN MED, V110, P617, DOI 10.7326/0003-4819-110-8-617; Maher K, 1999, J ACQ IMMUN DEF SYND, V22, P358; Mankiw N.G., 2001, PRINCIPLES EC; Marschner IC, 1998, J INFECT DIS, V177, P40, DOI 10.1086/513823; MCCARTHY BD, 1993, ARCH INTERN MED, V153, P1107, DOI 10.1001/archinte.153.9.1107; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Mellors JW, 1997, SCIENCE, V275, P14; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Michael RT, 1998, AM J PUBLIC HEALTH, V88, P749, DOI 10.2105/AJPH.88.5.749; Mocroft A, 1998, AIDS, V12, P2161, DOI 10.1097/00002030-199816000-00011; Mole L, 1999, PHARMACOECONOMICS, V16, P307, DOI 10.2165/00019053-199916030-00007; Monforte AD, 1998, AIDS, V12, P1631, DOI 10.1097/00002030-199813000-00010; Monforte AD, 2000, AIDS, V14, P499, DOI 10.1097/00002030-200003310-00005; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; Montaner JSG, 1998, AIDS, V12, pF23, DOI 10.1097/00002030-199805000-00003; Moyle G, 2000, J ACQ IMMUN DEF SYND, V23, P128; MUSICCO M, 1994, ARCH INTERN MED, V154, P1971, DOI 10.1001/archinte.154.17.1971; Mylonakis E, 2000, AM J MED, V109, P568, DOI 10.1016/S0002-9343(00)00583-0; NEAL JJ, 2002, P 9 C RETR OPP INF S; *NIH, 1998, MMWR-MORBID MORTAL W, V47, P1; Notermans DW, 1998, AIDS, V12, P167, DOI 10.1097/00002030-199802000-00006; O'Brien TR, 1998, J ACQ IMMUN DEF SYND, V18, P155, DOI 10.1097/00042560-199806010-00007; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; OBrien WA, 1997, ANN INTERN MED, V126, P939, DOI 10.7326/0003-4819-126-12-199706150-00002; Operskalski EA, 1997, AM J EPIDEMIOL, V146, P655, DOI 10.1093/oxfordjournals.aje.a009331; Opravil M, 2002, AIDS, V16, P1371, DOI 10.1097/00002030-200207050-00009; Owens DK, 1996, ARCH INTERN MED, V156, P394, DOI 10.1001/archinte.156.4.394; OWENS DK, 2003, MED DECIS MAKING, V23, P569; OWENS DK, 2002, MED DECIS MAKING, V22, P534; Padian NS, 1997, AM J EPIDEMIOL, V146, P350, DOI 10.1093/oxfordjournals.aje.a009276; Palella FJ, 2003, ANN INTERN MED, V138, P620, DOI 10.7326/0003-4819-138-8-200304150-00007; *PAN CLIN PRACT TR, 2004, GUID US ANT AG HIV I; Paredes R, 2000, ARCH INTERN MED, V160, P1123, DOI 10.1001/archinte.160.8.1123; Paredes R, 1999, J ACQ IMMUN DEF SYND, V22, P132; Paris D, 1999, AIDS RES HUM RETROV, V15, P1631, DOI 10.1089/088922299309676; Pedersen C, 1997, J ACQ IMMUN DEF SYND, V16, P93, DOI 10.1097/00042560-199710010-00004; Phillips AN, 1996, AIDS, V10, P859, DOI 10.1097/00002030-199607000-00009; Phillips AN, 2003, AIDS, V17, P1863, DOI 10.1097/00002030-200309050-00004; Phillips AN, 1997, AIDS, V11, P169, DOI 10.1097/00002030-199702000-00006; Phillips KA, 2000, AIDS, V14, P2159, DOI 10.1097/00002030-200009290-00013; Pialoux G, 1998, NEW ENGL J MED, V339, P1269, DOI 10.1056/NEJM199810293391802; Powderly WG, 1999, AIDS, V13, P1873, DOI 10.1097/00002030-199910010-00009; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Raboud JM, 1999, J ACQ IMMUN DEF SYND, V22, P260; Raboud JM, 1998, AIDS, V12, P1619, DOI 10.1097/00002030-199813000-00008; Reijers MHE, 2000, AIDS, V14, P59, DOI 10.1097/00002030-200001070-00007; REVICKI DA, 1995, MED CARE, V33, pAS173; Rhone SA, 1998, AIDS, V12, P619, DOI 10.1097/00002030-199806000-00011; Roca B, 1999, J INFECTION, V39, P141, DOI 10.1016/S0163-4453(99)90006-3; Roca B, 2000, AIDS, V14, P157, DOI 10.1097/00002030-200001280-00011; ROSENBERG PS, 1995, SCIENCE, V270, P1372, DOI 10.1126/science.270.5240.1372; Sabin CA, 2000, J ACQ IMMUN DEF SYND, V23, P172; Sabin CA, 1998, AIDS, V12, P1347, DOI 10.1097/00002030-199811000-00017; Safrin S, 1999, AIDS, V13, P2493, DOI 10.1097/00002030-199912240-00002; Salzberger B, 1999, Eur J Med Res, V4, P449; SAMUEL MC, 1993, J ACQ IMMUN DEF SYND, V6, P303; SCHWARTZ JS, 1990, JAMA-J AM MED ASSOC, V264, P1704, DOI 10.1001/jama.264.13.1704; Shulman NS, 2000, J ACQ IMMUN DEF SYND, V23, P221; Sinclair M, 2004, INT J STD AIDS, V15, P33, DOI 10.1258/095646204322637236; Spijkerman IJB, 1997, AIDS, V11, P1383, DOI 10.1097/00002030-199711000-00013; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; Staszewski S, 1998, AIDS, V12, P2360; Stone PW, 2000, AM J PREV MED, V19, P15, DOI 10.1016/S0749-3797(00)00151-3; Stuart JWTC, 1999, AIDS, V13, pF53, DOI 10.1097/00002030-199905070-00001; Sullivan AK, 1998, INT J STD AIDS, V9, P711, DOI 10.1258/0956462981921251; Sullivan PS, 2004, JAIDS-J ACQ IMM DEF, V35, P511, DOI 10.1097/00126334-200404150-00009; Tebas P, 1999, AIDS, V13, pF23, DOI 10.1097/00002030-199902040-00002; Tengs TO, 2002, MED DECIS MAKING, V22, P475, DOI 10.1177/0272989X02238300; Tsevat J, 1996, MED CARE, V34, P44, DOI 10.1097/00005650-199601000-00004; Tsevat J, 1999, ANN INTERN MED, V131, P194, DOI 10.7326/0003-4819-131-3-199908030-00006; TURNER BJ, 1994, ARCH INTERN MED, V154, P1561, DOI 10.1001/archinte.154.14.1561; *US GOV, 2004, BUDG US GOV; Valdez H, 1999, ARCH INTERN MED, V159, P1771, DOI 10.1001/archinte.159.15.1771; van Roon EN, 1999, J ACQ IMMUN DEF SYND, V20, P290, DOI 10.1097/00042560-199903010-00012; Vlahov D, 1998, JAMA-J AM MED ASSOC, V279, P35, DOI 10.1001/jama.279.1.35; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; Welch K, 2000, CLIN INFECT DIS, V30, P407, DOI 10.1086/313670; Welles SL, 1996, J INFECT DIS, V174, P696, DOI 10.1093/infdis/174.4.696; Yeni PG, 2004, JAMA-J AM MED ASSOC, V292, P251, DOI 10.1001/jama.292.2.251; Yerly S, 1998, ARCH INTERN MED, V158, P247, DOI 10.1001/archinte.158.3.247; Zingmond DS, 2001, AM J PUBLIC HEALTH, V91, P1117, DOI 10.2105/AJPH.91.7.1117; Zolopa AR, 1999, ANN INTERN MED, V131, P813, DOI 10.7326/0003-4819-131-11-199912070-00003; 2001, MMWR MORB MORTAL WKL, V50, P538; 1988, MMWR MORB MORTAL WKL, V36, P833; 2004, MMWR MORB MORTAL WKL, V53, P523; 2004, COMP 2 WAYS MANAGE A; 1998, MMWR MORB MORTAL WKL, V47, P309; 2000, MED LETT DRUGS THER, V42, P1; 2004, ADV HIV PREVENTION N	182	455	464	0	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2005	352	6					570	585		10.1056/NEJMsa042657	http://dx.doi.org/10.1056/NEJMsa042657			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	895KY	15703422				2022-12-28	WOS:000226862100007
J	Bartlett, S				Bartlett, S			A hitch-hiker's guide to Titan	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Bartlett, S (corresponding author), The Lancet, London NW1 7BY, England.							*MUSIC2TITAN, 2005, SIL MUS	1	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 5	2005	365	9458					460	460						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894SS	15705445				2022-12-28	WOS:000226812500009
J	Reiser, SJ				Reiser, SJ			Research compensation and the monetarization of medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Texas, Sch Med, Ctr Hlth Humanities & Human Spirit, Houston, TX 77225 USA	University of Texas System	Reiser, SJ (corresponding author), Univ Texas, Sch Med, Ctr Hlth Humanities & Human Spirit, 6431 Fannin, Houston, TX 77225 USA.	Stanley.J.Reiser@uth.tmc.edu						[Anonymous], 1979, BELMONT REPORT ETHIC; CUNNY KA, 1994, CLIN THER, V16, P273; Dickert N, 2002, ANN INTERN MED, V136, P368, DOI 10.7326/0003-4819-136-5-200203050-00009; Dunn LB, 2005, JAMA-J AM MED ASSOC, V293, P609, DOI 10.1001/jama.293.5.609; HEFFLER S, 2004, HLTH AFF, P79; JONES WHS, 1923, HIPPOCRATES, V1, P319; 1949, NUREMBERG CODE TRIAL, V2, P181	7	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2005	293	5					613	614		10.1001/jama.293.5.613	http://dx.doi.org/10.1001/jama.293.5.613			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	893BL	15687317				2022-12-28	WOS:000226694200025
J	Schulz, O; Diebold, SS; Chen, M; Naslund, TI; Nolte, MA; Alexopoulou, L; Azuma, YT; Flavell, RA; Liljestrom, P; Sousa, CRE				Schulz, O; Diebold, SS; Chen, M; Naslund, TI; Nolte, MA; Alexopoulou, L; Azuma, YT; Flavell, RA; Liljestrom, P; Sousa, CRE			Toll-like receptor 3 promotes cross-priming to virus-infected cells	NATURE			English	Article							CD8-ALPHA(+) DENDRITIC CELLS; DOUBLE-STRANDED-RNA; CD8(+) T-CELLS; IN-VIVO; VIRAL-INFECTION; CUTTING EDGE; DYING CELLS; ANTIGENS; INTERFERON; IMMUNITY	Cross-presentation of cell-associated antigens plays an important role in regulating CD8(+) T cell responses to proteins that are not expressed by antigen-presenting cells (APCs)(1). Dendritic cells are the principal cross-presenting APCs in vivo and much progress has been made in elucidating the pathways that allow dendritic cells to capture and process cellular material(1). However, little is known about the signals that determine whether such presentation ultimately results in a cytotoxic T cell (CTL) response (cross-priming) or in CD8(+) T cell inactivation (cross-tolerance). Here we describe a mechanism that promotes cross-priming during viral infections. We show that murine CD8alpha(+) dendritic cells are activated by double-stranded (ds)RNA present in virally infected cells but absent from uninfected cells. Dendritic cell activation requires phagocytosis of infected material, followed by signalling through the dsRNA receptor, toll-like receptor 3 (TLR3). Immunization with virus-infected cells or cells containing synthetic dsRNA leads to a striking increase in CTL cross-priming against cell-associated antigens, which is largely dependent on TLR3 expression by antigen-presenting cells. Thus, TLR3 may have evolved to permit cross-priming of CTLs against viruses that do not directly infect dendritic cells.	Canc Res UK London Res Inst, Lincolns Inn Fields Labs, Immunobiol Lab, London WC2A 3PX, England; Karolinska Inst, Ctr Microbiol & Tumor Biol, SE-17177 Stockholm, Sweden; Swedish Inst Infect Dis Control, Dept Vaccine Res, S-17177 Stockholm, Sweden; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Howard Hughes Med Inst, New Haven, CT 06520 USA	Cancer Research UK; Karolinska Institutet; Swedish Institute for Infectious Disease Control; Yale University; Howard Hughes Medical Institute	Sousa, CRE (corresponding author), Canc Res UK London Res Inst, Lincolns Inn Fields Labs, Immunobiol Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	caetano@cancer.org.uk	Reis e Sousa, Caetano/O-1657-2014; Nolte, Martijn A./AAC-8092-2022; chen, margaret/B-6757-2014; Azuma, Yasu-Taka/C-7561-2009; Alexopoulou, Lena/A-5041-2017; Reis e Sousa, Caetano/ABD-7322-2021	Reis e Sousa, Caetano/0000-0001-7392-2119; Nolte, Martijn A./0000-0002-5447-0839; Alexopoulou, Lena/0000-0003-4619-697X; Reis e Sousa, Caetano/0000-0001-7392-2119; Azuma, Yasu-Taka/0000-0002-3515-171X; Schulz, Oliver/0000-0002-1493-3341; Sallberg Chen, Margaret/0000-0002-3793-4064; Liljestrom, Peter/0000-0002-2132-0981				Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Allan RS, 2003, SCIENCE, V301, P1925, DOI 10.1126/science.1087576; Belz GT, 2004, J IMMUNOL, V172, P1996, DOI 10.4049/jimmunol.172.4.1996; Belz GT, 2002, J EXP MED, V196, P1099, DOI 10.1084/jem.20020861; Crozat K, 2004, P NATL ACAD SCI USA, V101, P6835, DOI 10.1073/pnas.0401347101; den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685; Diebold SS, 2003, NATURE, V424, P324, DOI 10.1038/nature01783; Edelmann KH, 2004, VIROLOGY, V322, P231, DOI 10.1016/j.virol.2004.01.033; Edwards AD, 2003, EUR J IMMUNOL, V33, P827, DOI 10.1002/eji.200323797; Fonteneau JF, 2003, BLOOD, V101, P3520, DOI 10.1182/blood-2002-10-3063; Freigang S, 2003, P NATL ACAD SCI USA, V100, P13477, DOI 10.1073/pnas.1835685100; Harshyne LA, 2001, J IMMUNOL, V166, P3717, DOI 10.4049/jimmunol.166.6.3717; Heath WR, 2004, IMMUNOL REV, V199, P9, DOI 10.1111/j.0105-2896.2004.00142.x; HELWIG FC, 1945, SCIENCE, V102, P31, DOI 10.1126/science.102.2637.31; Hoebe K, 2004, J ENDOTOXIN RES, V10, P130, DOI 10.1179/096805104225004031; Iyoda T, 2002, J EXP MED, V195, P1289, DOI 10.1084/jem.20020161; Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888; Kaufman RJ, 1999, P NATL ACAD SCI USA, V96, P11693, DOI 10.1073/pnas.96.21.11693; Le Bon A, 2003, NAT IMMUNOL, V4, P1009, DOI 10.1038/ni978; Liu K, 2002, J EXP MED, V196, P1091, DOI 10.1084/jem.20021215; Melief CJM, 2003, EUR J IMMUNOL, V33, P2645, DOI 10.1002/eji.200324341; Muzio M, 2000, J IMMUNOL, V164, P5998, DOI 10.4049/jimmunol.164.11.5998; Salio M, 2004, J EXP MED, V199, P567, DOI 10.1084/jem.20031059; Schulz O, 2002, IMMUNOLOGY, V107, P183, DOI 10.1046/j.1365-2567.2002.01513.x; Smerdou C, 1999, J VIROL, V73, P1092, DOI 10.1128/JVI.73.2.1092-1098.1999; Smith CM, 2003, J IMMUNOL, V170, P4437, DOI 10.4049/jimmunol.170.9.4437; Sousa CRE, 2004, SEMIN IMMUNOL, V16, P27, DOI 10.1016/j.smim.2003.10.004; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; Valdez Y, 2002, J EXP MED, V195, P683, DOI 10.1084/jem.20010898	30	681	718	1	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 24	2005	433	7028					887	892		10.1038/nature03326	http://dx.doi.org/10.1038/nature03326			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	899VT	15711573				2022-12-28	WOS:000227174600048
J	Budson, AE; Price, BH				Budson, AE; Price, BH			Current concepts - Memory dysfunction	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							WORKING-MEMORY; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; PREFRONTAL CORTEX; FRONTAL-CORTEX; BRAIN ACTIVITY; TEMPORAL-LOBE; LEWY BODIES; DEMENTIA; DEFICITS		Edith Nourse Rogers Mem Vet Hosp, GRECC, Bedford, MA 01730 USA; Boston Univ, Dept Neurol, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Neurol, Div Cognit & Behav Neurol, Boston, MA 02115 USA; McLean Hosp, Belmont, MA 02178 USA; Harvard Univ, Sch Med, Boston, MA USA	Geriatric Research Education & Clinical Center; Boston University; Harvard University; Brigham & Women's Hospital; Harvard University; McLean Hospital; Harvard University; Harvard Medical School	Budson, AE (corresponding author), Edith Nourse Rogers Mem Vet Hosp, GRECC, Bldg 62,Rm B30,200 Springs Rd, Bedford, MA 01730 USA.	abudson@partners.org						Baddeley A, 1998, CURR OPIN NEUROBIOL, V8, P234, DOI 10.1016/S0959-4388(98)80145-1; Balota DA, 1999, J INT NEUROPSYCH SOC, V5, P626, DOI 10.1017/S1355617799577060; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; Brewer JB, 1998, SCIENCE, V281, P1185, DOI 10.1126/science.281.5380.1185; Budson A. E., 2002, ENCY LIFE SCI, V11, P529; Budson AE, 2002, BRAIN, V125, P2750, DOI 10.1093/brain/awf277; Calderon J, 2001, J NEUROL NEUROSUR PS, V70, P157, DOI 10.1136/jnnp.70.2.157; CORKIN S, 1984, SEMIN NEUROL, V4, P249, DOI 10.1055/s-2008-1041556; Cummings JL, 2004, NEW ENGL J MED, V351, P56, DOI 10.1056/NEJMra040223; Damasio H, 1996, NATURE, V381, P810, DOI 10.1038/381810b0; Daselaar SM, 2003, NEUROBIOL AGING, V24, P1013, DOI 10.1016/S0197-4580(03)00030-7; Egeland J, 2003, J CLIN EXP NEUROPSYC, V25, P79, DOI 10.1076/jcen.25.1.79.13630; Elia J, 1999, NEW ENGL J MED, V340, P780, DOI 10.1056/NEJM199903113401007; Exner C, 2002, LEARN MEMORY, V9, P376, DOI 10.1101/lm.48402; Fletcher PC, 2001, BRAIN, V124, P849, DOI 10.1093/brain/124.5.849; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GLISKY EL, 1989, NEUROPSYCHOLOGIA, V27, P107, DOI 10.1016/0028-3932(89)90093-6; GOTHAM AM, 1988, BRAIN, V111, P299, DOI 10.1093/brain/111.2.299; Greene JDW, 1996, BRAIN, V119, P111, DOI 10.1093/brain/119.1.111; HEINDEL WC, 1989, J NEUROSCI, V9, P582; HODGES JR, 2001, NEUROLOGY S4, V56, P6; Jaeggi SM, 2003, NEUROIMAGE, V19, P210, DOI 10.1016/S1053-8119(03)00098-3; Johnson MK, 1997, BRAIN COGNITION, V34, P189, DOI 10.1006/brcg.1997.0873; Johnson MK, 1997, NEUROREPORT, V8, P1317, DOI 10.1097/00001756-199703240-00051; Klingberg T, 2002, J CLIN EXP NEUROPSYC, V24, P781, DOI 10.1076/jcen.24.6.781.8395; Kopelman MD, 1998, NEUROPSYCHOLOGIA, V36, P796; Kopelman MD, 1997, NEUROPSYCHOLOGIA, V35, P1533, DOI 10.1016/S0028-3932(97)00076-6; Kubat-Silman AK, 2002, BRAIN COGNITION, V50, P178, DOI 10.1016/S0278-2626(02)00502-X; Lidstrom AM, 1998, EXP NEUROL, V154, P511, DOI 10.1006/exnr.1998.6892; McKeith I, 2000, LANCET, V356, P2031, DOI 10.1016/S0140-6736(00)03399-7; Mehta MA, 2004, J CHILD PSYCHOL PSYC, V45, P293, DOI 10.1111/j.1469-7610.2004.00221.x; Mesulam M., 2000, PRINCIPLES BEHAV COG; Moretti R, 2002, LANCET, V360, P1512, DOI 10.1016/S0140-6736(02)11450-4; Newman MF, 2001, NEW ENGL J MED, V344, P395, DOI 10.1056/NEJM200102083440601; Newman SD, 2003, NEUROPSYCHOLOGIA, V41, P1668, DOI 10.1016/S0028-3932(03)00091-5; Papez JW, 1937, ARCH NEURO PSYCHIATR, V38, P725, DOI 10.1001/archneurpsyc.1937.02260220069003; Perani D, 1999, BRAIN, V122, P2337, DOI 10.1093/brain/122.12.2337; Petrides M, 2002, NEUROBIOL LEARN MEM, V78, P528, DOI 10.1006/nlme.2002.4107; Press DZ, 2004, NEW ENGL J MED, V351, P2547, DOI 10.1056/NEJMe048305; Price JL, 1999, ANN NEUROL, V45, P358, DOI 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X; Purcell R, 1998, BIOL PSYCHIAT, V43, P348, DOI 10.1016/S0006-3223(97)00201-1; RIBOT T, 1982, INT SCI SERIES, V41; Rowe JB, 2000, SCIENCE, V288, P1656, DOI 10.1126/science.288.5471.1656; Sabe L, 1995, J CLIN EXP NEUROPSYC, V17, P841, DOI 10.1080/01688639508402433; SALMON DP, 1998, MEMORY NEURODEGENERA, P210; Schacter D. L., 1994, MEMORY SYSTEMS 1994; Schacter DL, 2000, OXFORD HDB MEMORY, P627; Sfagos C, 2003, J NEUROL NEUROSUR PS, V74, P1231, DOI 10.1136/jnnp.74.9.1231; Simons JS, 2003, NAT REV NEUROSCI, V4, P637, DOI 10.1038/nrn1178; Solomon P. R., 2003, CLIN SCI, V54, P1; Solomon PR, 1998, ARCH NEUROL-CHICAGO, V55, P349, DOI 10.1001/archneur.55.3.349; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Tariot PN, 2004, JAMA-J AM MED ASSOC, V291, P317, DOI 10.1001/jama.291.3.317; Vaidya CJ, 2002, NEUROPSYCHOLOGIA, V40, P2136, DOI 10.1016/S0028-3932(02)00053-2; Wagner AD, 1998, SCIENCE, V281, P1188, DOI 10.1126/science.281.5380.1188; WELSH KA, 1994, NEUROLOGY, V44, P609, DOI 10.1212/WNL.44.4.609; Winblad B, 2001, NEUROLOGY, V57, P489, DOI 10.1212/WNL.57.3.489	57	178	201	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2005	352	7					692	699		10.1056/NEJMra041071	http://dx.doi.org/10.1056/NEJMra041071			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897UO	15716563				2022-12-28	WOS:000227031100008
J	Deregnaucourt, S; Mitra, PP; Feher, O; Pytte, C; Tchernichovski, O				Deregnaucourt, S; Mitra, PP; Feher, O; Pytte, C; Tchernichovski, O			How sleep affects the developmental learning of bird song	NATURE			English	Article							ANTERIOR FOREBRAIN; VOCAL IMITATION; AGE; CONSOLIDATION; MEMORIES; DYNAMICS; NEURONS	Sleep affects learning and development in humans and other animals, but the role of sleep in developmental learning has never been examined. Here we show the effects of night-sleep on song development in the zebra finch by recording and analysing the entire song ontogeny. During periods of rapid learning we observed a pronounced deterioration in song structure after night-sleep. The song regained structure after intense morning singing. Daily improvement in similarity to the tutored song occurred during the late phase of this morning recovery; little further improvement occurred thereafter. Furthermore, birds that showed stronger post-sleep deterioration during development achieved a better final imitation. The effect diminished with age. Our experiments showed that these oscillations were not a result of sleep inertia or lack of practice, indicating the possible involvement of an active process, perhaps neural song-replay during sleep. We suggest that these oscillations correspond to competing demands of plasticity and consolidation during learning, creating repeated opportunities to reshape previously learned motor skills.	CUNY City Coll, Dept Biol, New York, NY 10031 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Wesleyan Univ, Dept Biol, Middletown, CT 06459 USA	City University of New York (CUNY) System; City College of New York (CUNY); Cold Spring Harbor Laboratory; Wesleyan University	Deregnaucourt, S (corresponding author), CUNY City Coll, Dept Biol, 138Th St & Convent Ave, New York, NY 10031 USA.	sderegna@sci.ccny.cuny.edu	Tchernichovski, Ofer/AAC-5678-2019; Galantucci, Bruno/E-5770-2010	Tchernichovski, Ofer/0000-0001-6788-614X; Mitra, Partha/0000-0001-8818-6804	NIDCD NIH HHS [R01 DC004722] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004722] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bottjer SW, 1997, J NEUROBIOL, V33, P602, DOI 10.1002/(SICI)1097-4695(19971105)33:5<602::AID-NEU8>3.0.CO;2-8; Brainard MS, 2002, NATURE, V417, P351, DOI 10.1038/417351a; Brainard MS, 2001, J NEUROSCI, V21, P2501, DOI 10.1523/JNEUROSCI.21-07-02501.2001; Dave AS, 2000, SCIENCE, V290, P812, DOI 10.1126/science.290.5492.812; Doupe AJ, 1997, J NEUROSCI, V17, P1147; Doupe AJ, 1999, ANNU REV NEUROSCI, V22, P567, DOI 10.1146/annurev.neuro.22.1.567; Fenn KM, 2003, NATURE, V425, P614, DOI 10.1038/nature01951; Frank MG, 2001, NEURON, V30, P275, DOI 10.1016/S0896-6273(01)00279-3; GOLANI I, 1992, BEHAV BRAIN SCI, V15, P249, DOI 10.1017/S0140525X00068539; Hahnloser RHR, 2002, NATURE, V419, P65, DOI 10.1038/nature00974; Ho C, 1998, P JOINT S NEUR COMP, V5, P76; Huber R, 2004, NATURE, V430, P78, DOI 10.1038/nature02663; Immelmann K., 1969, P61; Jarvis ED, 1997, P NATL ACAD SCI USA, V94, P4097, DOI 10.1073/pnas.94.8.4097; KARNI A, 1994, SCIENCE, V265, P679, DOI 10.1126/science.8036518; Keasar T, 1996, ANIM BEHAV, V52, P95, DOI 10.1006/anbe.1996.0155; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; Konishi M., 1965, Zeitschrift fuer Tierpsychologie, V22, P770; Leonardo A, 1999, NATURE, V399, P466, DOI 10.1038/20933; Loader C., 1999, LOCAL REGRESSION LIK; Lombardino AJ, 2000, J NEUROSCI, V20, P5054; Maquet P, 2001, SCIENCE, V294, P1048, DOI 10.1126/science.1062856; Margoliash D, 2002, J COMP PHYSIOL A, V188, P851, DOI 10.1007/s00359-002-0351-5; MARINARI E, 1992, EUROPHYS LETT, V19, P451, DOI 10.1209/0295-5075/19/6/002; Nick TA, 2005, J NEUROBIOL, V62, P231, DOI 10.1002/neu.20087; Nick TA, 2001, P NATL ACAD SCI USA, V98, P14012, DOI 10.1073/pnas.251525298; NORDEEN KW, 1988, NATURE, V334, P149, DOI 10.1038/334149a0; NORDEEN KW, 1992, BEHAV NEURAL BIOL, V57, P58, DOI 10.1016/0163-1047(92)90757-U; Peigneux P, 2004, NEURON, V44, P535, DOI 10.1016/j.neuron.2004.10.007; Peigneux P, 2001, NEUROREPORT, V12, pA111, DOI 10.1097/00001756-200112210-00001; Rauske PL, 2003, J NEUROPHYSIOL, V89, P1688, DOI 10.1152/jn.00655.2002; SCHMIDT MF, 2001, NAT NEUROSCI, V1, P513; Stickgold R, 2001, SCIENCE, V294, P1052, DOI 10.1126/science.1063530; Tassi P, 2000, SLEEP MED REV, V4, P341, DOI 10.1053/smrv.2000.0098; Tchernichovski O, 2001, SCIENCE, V291, P2564, DOI 10.1126/science.1058522; Tchernichovski O, 2000, ANIM BEHAV, V59, P1167, DOI 10.1006/anbe.1999.1416; Tchernichovski O, 2004, ANN NY ACAD SCI, V1016, P348, DOI 10.1196/annals.1298.031; Tchernichovski O, 2002, J COMP PHYSIOL A, V188, P867, DOI 10.1007/s00359-002-0352-4; Tchernichovski O, 1998, BIOL CYBERN, V78, P423, DOI 10.1007/s004220050446; Tchernichovski O, 2004, SOUND ANAL PRO USER; Wagner U, 2004, NATURE, V427, P352, DOI 10.1038/nature02223; Walker MP, 2004, NEURON, V44, P121, DOI 10.1016/j.neuron.2004.08.031; Walker MP, 2003, NATURE, V425, P616, DOI 10.1038/nature01930; Wang NG, 2002, J NEUROSCI, V22, P10864; WILSON MA, 1994, SCIENCE, V265, P676, DOI 10.1126/science.8036517; ZUCKERMAN B, 1987, PEDIATRICS, V80, P664	46	224	227	0	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	2005	433	7027					710	716		10.1038/nature03275	http://dx.doi.org/10.1038/nature03275			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897XH	15716944				2022-12-28	WOS:000227039200030
J	Crawford, F; Langhorne, P				Crawford, F; Langhorne, P			Commentary: Time to review all the evidence for hormone replacement therapy	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Tayside Ctr Gen Practice, Dundee DD2 4BF, Scotland; Univ Glasgow, Glasgow Royal Infirm, Acad Dept Geriatr Med, Glasgow G31 2ER, Lanark, Scotland	University of Dundee; University of Glasgow	Crawford, F (corresponding author), Tayside Ctr Gen Practice, MacKenzie Bldg, Dundee DD2 4BF, Scotland.	f.crawford@chs.dundee.ac.uk		Crawford, Fay/0000-0002-0473-9959				Bath PMW, 2005, BRIT MED J, V330, P342, DOI 10.1136/bmj.38331.655347.8F; Grady D, 2003, NEW ENGL J MED, V348, P1835, DOI 10.1056/NEJMp030038; HAYS J, 2004, NEW ENGL J MED, V384, P1839; Hlatky MA, 2002, JAMA-J AM MED ASSOC, V287, P591, DOI 10.1001/jama.287.5.591; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673	5	5	5	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 12	2005	330	7487					345	345		10.1136/bmj.330.7487.345	http://dx.doi.org/10.1136/bmj.330.7487.345			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897OZ	15705691	Green Published			2022-12-28	WOS:000227015800021
J	Guth, AH; Kaiser, DI				Guth, AH; Kaiser, DI			Inflationary cosmology: Exploring the universe from the smallest to the largest scales	SCIENCE			English	Review							DIMENSIONS; FLATNESS; HORIZON; LIGHT	Understanding the behavior of the universe at large depends critically on insights about the Smallest units of matter and their fundamental interactions. inflationary cosmology is a highly successful framework for exploring these interconnections between particle physics and gravitation. Inflation makes several predictions about the present state of the universe such as its overall shape, large-scale smoothness, and smaller scale structure-which are being tested to unprecedented accuracy by a new generation of astronomical measurements. The agreement between these predictions and the latest observations is extremely promising. Meanwhile, physicists are busy trying to understand inflation's ultimate implications for the nature of matter, energy, and spacetime.	MIT, Ctr Theoret Phys, Nucl Sci Lab, Cambridge, MA 02139 USA; MIT, Dept Phys, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Guth, AH (corresponding author), MIT, Ctr Theoret Phys, Nucl Sci Lab, Cambridge, MA 02139 USA.	guth@ctp.mit.edu; dikaiser@mit.edu	Kaiser, David/C-7149-2014	Kaiser, David/0000-0002-5054-6744				ALBRECHT A, 1982, PHYS REV LETT, V48, P1220, DOI 10.1103/PhysRevLett.48.1220; Arkani-Hamed N, 1998, PHYS LETT B, V429, P263, DOI 10.1016/S0370-2693(98)00466-3; Banks T, 2004, J HIGH ENERGY PHYS; Bassett BA, 1999, PHYS LETT B, V455, P84, DOI 10.1016/S0370-2693(99)00478-5; Binetruy P, 2000, NUCL PHYS B, V565, P269, DOI 10.1016/S0550-3213(99)00696-3; Borde A, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.151301; Bousso R, 2004, SCI AM, V291, P78, DOI 10.1038/scientificamerican0904-78; Bousso R, 2000, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2000/06/006; BOYANOVSKY D, 1995, PHYS REV D, V51, P4419, DOI 10.1103/PhysRevD.51.4419; Burgess CP, 2004, PRAMANA-J PHYS, V63, P1269, DOI 10.1007/BF02704894; Dvali G, 1999, PHYS LETT B, V450, P72, DOI 10.1016/S0370-2693(99)00132-X; Fixsen DJ, 1996, ASTROPHYS J, V473, P576, DOI 10.1086/178173; Garriga J, 2000, PHYS REV LETT, V84, P2778, DOI 10.1103/PhysRevLett.84.2778; Garriga J, 2001, PHYS REV D, V64, DOI 10.1103/PhysRevD.64.023507; Giddings SB, 2000, J HIGH ENERGY PHYS; GUTH AH, 1981, PHYS REV D, V23, P347, DOI 10.1103/PhysRevD.23.347; Guth AH, 2000, PHYS REP, V333, P555, DOI 10.1016/S0370-1573(00)00037-5; Guth Alan, 1997, INFLATIONARY UNIVERS; Hoyle CD, 2004, PHYS REV D, V70, DOI 10.1103/PhysRevD.70.042004; Iizuka N, 2004, PHYS REV D, V70, DOI 10.1103/PhysRevD.70.043519; Kachru S, 2003, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2003/10/013; Kachru S, 2003, PHYS REV D, V68, DOI 10.1103/PhysRevD.68.046005; Kaiser DI, 1996, PHYS REV D, V53, P1776, DOI 10.1103/PhysRevD.53.1776; Kirshner RP, 2003, SCIENCE, V300, P1914, DOI 10.1126/science.1086879; Kofman L, 1998, COSMO-97: FIRST INTERNATIONAL WORKSHOP ON PARTICLE PHYSICS AND THE EARLY UNIVERSE, P312; KOFMAN L, 1994, PHYS REV LETT, V73, P3195, DOI 10.1103/PhysRevLett.73.3195; KOLB EW, 1990, EARLY UNIVERSE; Liddle A. R., 2000, COSMOLOGICAL INFLATI; LINDE A, 1994, PHYS REV D, V49, P1783, DOI 10.1103/PhysRevD.49.1783; Linde A.D., 1990, PARTICLE PHYS INFLAT; LINDE AD, 1982, PHYS LETT B, V108, P389, DOI 10.1016/0370-2693(82)91219-9; LINDE AD, 1986, PHYS LETT B, V175, P395, DOI 10.1016/0370-2693(86)90611-8; Lyth DH, 1999, PHYS REP, V314, P1, DOI 10.1016/S0370-1573(98)00128-8; Maartens R, 2000, PHYS REV D, V62, DOI 10.1103/PhysRevD.62.084023; MUKHANOV VF, 1992, PHYS REP, V215, P203, DOI 10.1016/0370-1573(92)90044-Z; Ostriker JP, 2003, SCIENCE, V300, P1909, DOI 10.1126/science.1085976; Pen UL, 1997, PHYS REV LETT, V79, P1611, DOI 10.1103/PhysRevLett.79.1611; Polchinski J., 1998, STRING THEORY, V1; Quevedo F, 2002, CLASSICAL QUANT GRAV, V19, P5721, DOI 10.1088/0264-9381/19/22/304; Randall L, 2002, SCIENCE, V296, P1422, DOI 10.1126/science.1072567; Randall L, 1999, PHYS REV LETT, V83, P3370, DOI 10.1103/PhysRevLett.83.3370; SHTANOV Y, 1995, PHYS REV D, V51, P5438, DOI 10.1103/PhysRevD.51.5438; Spergel DN, 2003, ASTROPHYS J SUPPL S, V148, P175, DOI 10.1086/377226; Steinhardt P. J., 1983, Very Early Universe. Proceedings of the Nuffield Workshop, P251; Tegmark M, 2004, PHYS REV D, V69, DOI 10.1103/PhysRevD.69.103501; Tolman RC, 1932, PHYS REV, V39, P320, DOI 10.1103/PhysRev.39.320; VILENKIN A, 1983, PHYS REV D, V27, P2848, DOI 10.1103/PhysRevD.27.2848; Vilenkin A., 1994, COSMIC STRINGS OTHER; WEINBERG S, 1987, PHYS REV LETT, V59, P2607, DOI 10.1103/PhysRevLett.59.2607; WILL CM, 1993, THEORY EXPT GRAVITAT	50	68	68	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	2005	307	5711					884	890		10.1126/science.1107483	http://dx.doi.org/10.1126/science.1107483			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897DV	15705842				2022-12-28	WOS:000226985100042
J	Huemer, GM; Dunst, KM				Huemer, GM; Dunst, KM			Finger avulsion with pulled-out flexor tendon	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Med Univ Innsbruck, A-6020 Innsbruck, Austria	Medical University of Innsbruck	Huemer, GM (corresponding author), Med Univ Innsbruck, A-6020 Innsbruck, Austria.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2005	352	6					E5	E5		10.1056/NEJMicm030406	http://dx.doi.org/10.1056/NEJMicm030406			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895KY	15703415				2022-12-28	WOS:000226862100011
J	Huisman, M; Kunst, AE; Bopp, M; Borgan, BK; Borrell, C; Costa, G; Deboosere, P; Gadeyne, S; Glickman, M; Marinacci, C; Minder, C; Regidor, E; Valkonen, T; Mackenbach, JP				Huisman, M; Kunst, AE; Bopp, M; Borgan, BK; Borrell, C; Costa, G; Deboosere, P; Gadeyne, S; Glickman, M; Marinacci, C; Minder, C; Regidor, E; Valkonen, T; Mackenbach, JP			Educational inequalities in cause-specific mortality in middle-aged and older men and women in eight western European populations	LANCET			English	Article							ISCHEMIC-HEART-DISEASE; SOCIOECONOMIC INEQUALITIES; RISK-FACTORS; DEATH CERTIFICATION; STROKE MORTALITY; SMOKING; HEALTH; DISPARITIES; PREVALENCE; FINLAND	Background Studies of socioeconomic disparities in patterns of cause of death have been limited to single countries, middle-aged people, men, or broad cause of death groups. We assessed contribution of specific causes of death to disparities in mortality between groups with different levels of education, in men and women, middle-aged and old, in eight western European populations. Methods We analysed data from longitudinal mortality studies by cause of death, between Jan 1, 1990, and Dec 31, 1997. Data were included for more than 1 million deaths in 51 million person years of observation. Findings Absolute educational inequalities in total mortality peaked at 2127 deaths per 100 000 person years in men, and at 1588 deaths per 100 000 person years in women aged 75 years and older. In this age-group, rate ratios were greater than 1 - 00 for total mortality and all specific causes of death, apart form prostate cancer in men and lung cancer in women, showing increased mortality in low versus high eductational groups. In men, cardiovascular diseases accounted for 39% of the difference between low and high eductational groups in total mortality, cancer for 24%, other diseases for 32%, and external causes for 5%. Among women, contributions were 60%, 11%, 30%, and 0%, respectively. The contributions of cerebrovascular disease, other cardiovascular diseases, pneumonia, and COPD strongly increased by age, whereas those of cancer and external causes declined. Although relative inequalities in total mortality were closely similar in all populations, we noted striking differences in the contribution of specific causes to these inequalities. Interpretation Research needs to be broadened to include older populations, other diseases, and populations from different parts of Europe. Effective interventions should be developed and implemented to reduce exposure to cardiovascular risk factors in low-educational groups.	Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands; Univ Zurich, Inst Social & Prevent Med, CH-8006 Zurich, Switzerland; Stat Norway, Div Hlth Stat, Oslo, Norway; Agencia Salut Publ Barcelona, Barcelona, Spain; Univ Turin, Dept Publ Hlth & Microbiol, Turin, Italy; Free Univ Brussels, B-1050 Brussels, Belgium; Off Natl Stat, Div Hlth Care, London, England; Univ Bern, Inst Social & Prevent Med, Bern, Switzerland; Univ Madrid, Dept Prevent Med & Publ Hlth, Madrid, Spain; Univ Helsinki, Dept Sociol, Helsinki, Finland	Erasmus University Rotterdam; Erasmus MC; University of Zurich; Statistics Norway; Public Health Agency of Barcelona; University of Turin; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Bern; University of Helsinki	Mackenbach, JP (corresponding author), Erasmus MC, Univ Med Ctr Rotterdam, Dept Publ Hlth, POB 1738, NL-3000 DR Rotterdam, Netherlands.	j.mackenbach@erasmusmc.nl	Deboosere, Patrick/C-1113-2014; Huisman, Martijn/G-2873-2010; Huisman, Martijn/C-2368-2008; Gadeyne, Sylvie/C-2837-2016	Bopp, Matthias/0000-0003-0766-3723; Deboosere, Patrick/0000-0002-8148-3694; Glickman, Myer/0000-0001-6067-3811; Gadeyne, Sylvie/0000-0002-6890-1855; COSTA, Giuseppe/0000-0003-3187-4889; Regidor, Enrique/0000-0002-2374-9861; Kunst, Anton/0000-0002-3313-5273; Borrell, Carme/0000-0002-1170-2505				Avendano M, 2004, STROKE, V35, P432, DOI 10.1161/01.STR.0000109225.11509.EE; BALKAU B, 1993, INT J EPIDEMIOL, V22, P116, DOI 10.1093/ije/22.1.116; Benach J., 2002, REDUCING INEQUALITIE, P262; Cavelaars A E, 1997, J Health Psychol, V2, P353, DOI 10.1177/135910539700200306; Cavelaars AEJM, 2000, BRIT MED J, V320, P1102, DOI 10.1136/bmj.320.7242.1102; de Gaudemaris R, 2002, HYPERTENSION, V39, P1119, DOI 10.1161/01.HYP.0000018912.05345.55; Fernandez E, 2003, EUR J CANCER PREV, V12, P57, DOI 10.1097/00008469-200302000-00009; Graham H, 1996, SOC SCI MED, V43, P243, DOI 10.1016/0277-9536(95)00369-X; Graham H, 1999, EUR J PUBLIC HEALTH, V9, P137, DOI 10.1093/eurpub/9.2.137; Grundy E, 2001, J EPIDEMIOL COMMUN H, V55, P895, DOI 10.1136/jech.55.12.895; Hart CL, 2000, AM J PUBLIC HEALTH, V90, P1788, DOI 10.2105/AJPH.90.11.1788; Hart CL, 2000, STROKE, V31, P2093, DOI 10.1161/01.STR.31.9.2093; Huisman M, 2004, J EPIDEMIOL COMMUN H, V58, P468, DOI 10.1136/jech.2003.010496; Jakovljevic D, 2001, STROKE, V32, P1492, DOI 10.1161/01.STR.32.7.1492; Kapral MK, 2002, STROKE, V33, P268, DOI 10.1161/hs0102.101169; KELSON M, 1987, INT J EPIDEMIOL, V16, P411, DOI 10.1093/ije/16.3.411; Kilander L, 2001, INT J EPIDEMIOL, V30, P1119, DOI 10.1093/ije/30.5.1119; KOIVULA I, 1994, AM J MED, V96, P313, DOI 10.1016/0002-9343(94)90060-4; Kunst AE, 1998, STROKE, V29, P2285, DOI 10.1161/01.STR.29.11.2285; Kunst AE, 1998, BMJ-BRIT MED J, V316, P1636, DOI 10.1136/bmj.316.7145.1636; Lahti RA, 2003, FORENSIC SCI INT, V131, P113, DOI 10.1016/S0379-0738(02)00418-8; LANGLOIS JA, 1995, INT J EPIDEMIOL, V24, P136, DOI 10.1093/ije/24.1.136; LAVECCHIA C, 1986, PREV MED, V15, P274, DOI 10.1016/0091-7435(86)90046-0; Lozano R, 2001, MISCODING MISCLASSIF; Mackenbach JP, 1999, AM J PUBLIC HEALTH, V89, P1800, DOI 10.2105/AJPH.89.12.1800; Mackenbach JP, 1997, J CLIN EPIDEMIOL, V50, P1069, DOI 10.1016/S0895-4356(97)00165-0; Mackenbach JP, 2003, LANCET, V362, P1409, DOI 10.1016/S0140-6736(03)14639-9; Mackenbach JP, 2003, INT J EPIDEMIOL, V32, P830, DOI 10.1093/ije/dyg209; Mackenbach JP, 2000, EUR HEART J, V21, P1141, DOI 10.1053/euhj.1999.1990; Marik PE, 2003, CHEST, V124, P328, DOI 10.1378/chest.124.1.328; MARTELIN T, 1994, DIFFERNETIAL MORTALI; McKee M, 2000, LANCET, V356, P665, DOI 10.1016/S0140-6736(00)02616-7; PEKKANEN J, 1995, BRIT MED J, V311, P589, DOI 10.1136/bmj.311.7005.589; Prescott E, 1999, THORAX, V54, P737, DOI 10.1136/thx.54.8.737; Roos G, 2001, PUBLIC HEALTH NUTR, V4, P35, DOI 10.1079/PHN200048; Smith GD, 1998, BMJ-BRIT MED J, V316, P1631, DOI 10.1136/bmj.316.7145.1631; Steenland K, 2002, AM J EPIDEMIOL, V156, P11, DOI 10.1093/aje/kwf001; SUADICANI P, 1993, ATHEROSCLEROSIS, V101, P165, DOI 10.1016/0021-9150(93)90113-9; Trichopoulou A, 2002, P NUTR SOC, V61, P553, DOI 10.1079/PNS2002188; Valkonen T, 1999, HLTH MORTALITY ISSUE; van Rossum CTM, 1999, STROKE, V30, P357, DOI 10.1161/01.STR.30.2.357; Vartiainen E, 1998, J EPIDEMIOL COMMUN H, V52, P416, DOI 10.1136/jech.52.7.416; Wamala SP, 1999, AM J PUBLIC HEALTH, V89, P315, DOI 10.2105/AJPH.89.3.315; Wong MD, 2002, NEW ENGL J MED, V347, P1585, DOI 10.1056/NEJMsa012979	44	359	363	0	28	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 5	2005	365	9458					493	500						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894SS	15705459				2022-12-28	WOS:000226812500027
J	Ma, RCW; Chan, WB; So, WY; Tong, PCY; Chan, JCN; Chow, CC				Ma, RCW; Chan, WB; So, WY; Tong, PCY; Chan, JCN; Chow, CC			Lesson of the week - Carbamazepine and false positive dexamethasone suppression tests for Cushing's syndrome	BRITISH MEDICAL JOURNAL			English	Review							CORTISOL; ANTICONVULSANTS; DIAGNOSIS; THERAPY		Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong	Ma, RCW (corresponding author), Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.	rcwma@cuhk.edu.hk	Ma, Ronald/C-2788-2009; Chan, Juliana/B-7918-2016	Ma, Ronald/0000-0002-1227-803X; Chan, Juliana/0000-0003-1325-1194				CRONIN C, 1990, CLIN ENDOCRINOL, V33, P27, DOI 10.1111/j.1365-2265.1990.tb00462.x; EDELSTEIN CK, 1983, AM J PSYCHIAT, V140, P338; Feierman DE, 2003, ALCOHOL CLIN EXP RES, V27, P981, DOI 10.1097/01.ALC.0000071738.53337.F4; Guengrich FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/annurev.pharmtox.39.1.1; KEITNER GI, 1989, CAN J PSYCHIAT, V34, P441, DOI 10.1177/070674378903400514; KYRIAZOPOULOU V, 1992, J CLIN ENDOCR METAB, V75, P315, DOI 10.1210/jcem.75.1.1619024; MEIKLE AW, 1974, ARCH INTERN MED, V134, P1068, DOI 10.1001/archinte.134.6.1068; Ness-Abramof R, 2002, OBES RES, V10, P1217, DOI 10.1038/oby.2002.166; NEWELLPRICE J, 1995, CLIN ENDOCRINOL, V43, P545, DOI 10.1111/j.1365-2265.1995.tb02918.x; NEWSOM G, 1983, AM J PSYCHIAT, V140, P353; Papanicolaou DA, 2002, J CLIN ENDOCR METAB, V87, P4515, DOI 10.1210/jc.2002-020534; Papanicolaou DA, 1998, J CLIN ENDOCR METAB, V83, P1163, DOI 10.1210/jc.83.4.1163; PRIVITERA MR, 1982, BIOL PSYCHIAT, V17, P611; Putignano P, 1998, HORM METAB RES, V30, P389, DOI 10.1055/s-2007-978903; Turpeinen U, 1997, CLIN CHEM, V43, P1386	15	12	13	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 5	2005	330	7486					299	300		10.1136/bmj.330.7486.299	http://dx.doi.org/10.1136/bmj.330.7486.299			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895EM	15695278	Green Published			2022-12-28	WOS:000226843700020
J	Ruchkin, V; Martin, A				Ruchkin, V; Martin, A			SSRIs and the developing brain	LANCET			English	Editorial Material							PSYCHOTROPIC MEDICATION EXPOSURE; BIRTH OUTCOMES; FLUOXETINE; PREGNANCY; PAROXETINE; SYMPTOMS		Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06520 USA	Yale University	Ruchkin, V (corresponding author), Yale Univ, Sch Med, Ctr Child Study, 333 Cedar St, New Haven, CT 06520 USA.	vladislav.ruchkin@yale.edu		Ruchkin, Vladislav/0000-0002-2510-6798				Ansorge MS, 2004, SCIENCE, V306, P879, DOI 10.1126/science.1101678; Casper RC, 2003, J PEDIATR-US, V142, P402, DOI 10.1067/mpd.2003.139; Chambers CD, 1996, NEW ENGL J MED, V335, P1010, DOI 10.1056/NEJM199610033351402; Cohen LS, 2000, BIOL PSYCHIAT, V48, P996, DOI 10.1016/S0006-3223(00)00877-5; Costei AM, 2002, ARCH PEDIAT ADOL MED, V156, P1129, DOI 10.1001/archpedi.156.11.1129; Food and Drug Administration, 2004, ANT US CHILDR AD AD; Isbister GK, 2001, ARCH DIS CHILD-FETAL, V85, pF147; Laine K, 2003, ARCH GEN PSYCHIAT, V60, P720, DOI 10.1001/archpsyc.60.7.720; Martin A, 2004, ARCH PEDIAT ADOL MED, V158, P773, DOI 10.1001/archpedi.158.8.773; Mundo E, 2001, ARCH GEN PSYCHIAT, V58, P539, DOI 10.1001/archpsyc.58.6.539; Oberlander TF, 2004, J CLIN PSYCHIAT, V65, P230; Oberlander TF, 2002, PEDIATR RES, V51, P443, DOI 10.1203/00006450-200204000-00008; SPENCER MJ, 1993, PEDIATRICS, V92, P721; Zeskind PS, 2004, PEDIATRICS, V113, P368, DOI 10.1542/peds.113.2.368	14	14	14	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 5	2005	365	9458					451	453						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894SS	15705440				2022-12-28	WOS:000226812500004
J	Doumbo, OK				Doumbo, OK			It takes a village: Medical research and ethics in Mali	SCIENCE			English	Editorial Material									Univ Bamako, Fac Med Pharm & Odontostomatol, Dept Epidemiol Parasit Dis, Bamako, Mali	University of Bamako	Doumbo, OK (corresponding author), Univ Bamako, Fac Med Pharm & Odontostomatol, Dept Epidemiol Parasit Dis, BP 1805, Bamako, Mali.	okd@mrtcbko.org						DOUMBO O, 1999, MULTILATERAL INITIAT; Kayentao K, 2005, J INFECT DIS, V191, P109, DOI 10.1086/426400; Toure YT, 1998, AM J TROP MED HYG, V59, P481, DOI 10.4269/ajtmh.1998.59.481	3	32	32	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2005	307	5710					679	681		10.1126/science.1109773	http://dx.doi.org/10.1126/science.1109773			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	894TQ	15692036				2022-12-28	WOS:000226814900026
J	Kedar, S; Webb, FH				Kedar, S; Webb, FH			The ocean's seismic hum	SCIENCE			English	Editorial Material									CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Kedar, S (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.	sharon.kedar@jpl.nasa.gov; frank.webb@jpl.nasa.gov						Bromirski PD, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000265; Cooper R. I. B., 1955, P ROY SOC LOND A MAT, V206, P424; HASSELMANN K, 1963, REV GEOPHYS, V1, P177, DOI 10.1029/RG001i002p00177; Haubrich R., 1963, B SEISMOL SOC AM, V53, P27, DOI [10.1785/bssa0530010027, DOI 10.1785/BSSA0530010027]; LONGUETHIGGINS MS, 1950, PHILOS TR R SOC S-A, V243, P1, DOI 10.1098/rsta.1950.0012; Rhie J, 2004, NATURE, V431, P552, DOI 10.1038/nature02942; RODRIGUEZ E, 2004, FALL AGU 2004; Schulte-Pelkum V, 2004, GEOCHEM GEOPHY GEOSY, V5, DOI 10.1029/2003GC000520; STEHLY L, 2004, FALL AGU 2004; TOKSOZ MN, 1964, GEOPHYSICS, V29, P154, DOI 10.1190/1.1439344; TOLMAN H. L, 1999, USER MANUAL SYSTEM D; 2004, AM GEOPH UN FALL 200	12	34	36	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2005	307	5710					682	683		10.1126/science.1108380	http://dx.doi.org/10.1126/science.1108380			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	894TQ	15692037				2022-12-28	WOS:000226814900027
J	Squadrone, V; Coha, M; Cerutti, E; Schellino, MM; Biolino, P; Occella, P; Belloni, G; Vilianis, G; Fiore, G; Cavallo, F; Ranieri, VM				Squadrone, V; Coha, M; Cerutti, E; Schellino, MM; Biolino, P; Occella, P; Belloni, G; Vilianis, G; Fiore, G; Cavallo, F; Ranieri, VM		Piedmont Intensive Care Units Netw	Continuous positive airway pressure for treatment of postoperative hypoxemia - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; FACE MASK; RESPIRATORY-FAILURE; NONINVASIVE VENTILATION; CONSENSUS CONFERENCE; GENERAL-ANESTHESIA; ABDOMINAL-SURGERY; CLINICAL-TRIALS; ATELECTASIS; HELMET	Context Hypoxemia complicates the recovery of 30% to 50% of patients after abdominal surgery; endotracheal intubation and mechanical ventilation may be required in 8% to 10% of cases, increasing morbidity and mortality and prolonging intensive care unit and hospital stay. Objective To determine the effectiveness of continuous positive airway pressure compared with standard treatment in preventing the need for intubation and mechanical ventilation in patients who develop acute hypoxemia after elective major abdominal surgery. Design and Setting Randomized, controlled, unblinded study with concealed allocation conducted between June 2002 and November 2003 at 15 intensive care units of the Piedmont Intensive Care Units Network in Italy. Patients Consecutive patients who developed severe hypoxemia after major elective abdominal surgery. The trial was stopped for efficacy after 209 patients had been enrolled. Interventions Patients were randomly assigned to receive oxygen (n=104) or oxygen plus continuous positive airway pressure (n = 105). Main Outcome Measures The primary end point was incidence of endotracheal intubation; secondary end points were intensive care unit and hospital lengths of stay, incidence of pneumonia, infection and sepsis, and hospital mortality. Results Patients who received oxygen plus continuous positive airway pressure had a lower intubation rate (1% vs 10%; P=.005; relative risk [RR], 0.099; 95% confidence interval [CI], 0.01-0.76) and had a lower occurrence rate of pneumonia (2% vs 10%, RR, 0.19; 95% Cl, 0.04-0.88; P=.02), infection (3% vs 10%, RR, 0.27; 95% Cl, 0.07-0.94; P=.03), and sepsis (2% vs 9%; RR, 0.22; 95% Cl, 0.04-0.99; P=.03) than did patients treated with oxygen alone. Patients who received oxygen plus continuous positive airway pressure also spent fewer mean (SD) days in the intensive care unit (1.4 [1.6] vs 2.6 [4.2], P=.09) than patients treated with oxygen alone. The treatments did riot affect the mean (SD) days that patients spent in the hospital (115 [131 vs 17 [151, respectively; P=.10). None of those treated with oxygen plus continuous positive airway pressure died in the hospital while 3 deaths occurred among those treated with oxygen alone (P=.12). Conclusion Continuous positive airway pressure may decrease the incidence of endotracheal intubation and other severe complications in patients who develop hypoxemia after elective major abdominal surgery.	Univ Turin, Azienda Osped S Giovanni Battista Molinette, Dipartimento Anestesia, I-10126 Turin, Italy; Osped Civile Chivasso, Serv Anestesia & Rianimaz, Chivasso, Italy; Osped Civile Ivrea, Serv Anestesia & Rianimaz, Ivrea, Italy; Osped Civile Pinerolo, Serv Anestesia & Rianimaz, Pinerolo, Italy; Osped S Croce di Monacalieri, Serv Anestesia & Rianimaz, Monacalieri, Italy; Univ Turin, Dipartimento Sanita Pubbl & Microbiol, I-10124 Turin, Italy	A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; University of Turin; University of Turin	Ranieri, VM (corresponding author), Univ Turin, Azienda Osped S Giovanni Battista Molinette, Dipartimento Anestesia, Corso Dogliotti 14, I-10126 Turin, Italy.	marco.ranieri@unito.it	Ranieri, Marco/AFX-8152-2022					Antonelli M, 2001, INTENS CARE MED, V27, P1718, DOI 10.1007/s00134-001-1114-4; Antonelli M, 2004, ANESTHESIOLOGY, V100, P16, DOI 10.1097/00000542-200401000-00007; Arozullah AM, 2000, ANN SURG, V232, P242, DOI 10.1097/00000658-200008000-00015; BENDIXEN HH, 1963, NEW ENGL J MED, V269, P991, DOI 10.1056/NEJM196311072691901; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BERSTEN AD, 1991, NEW ENGL J MED, V325, P1825, DOI 10.1056/NEJM199112263252601; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; CARLSSON C, 1981, INTENS CARE MED, V7, P225, DOI 10.1007/BF01702624; Chiumello D, 2003, INTENS CARE MED, V29, P1671, DOI 10.1007/s00134-003-1825-9; Collins TC, 1999, ANN SURG, V230, P251, DOI 10.1097/00000658-199908000-00016; DEHAVEN CB, 1985, CRIT CARE MED, V13, P46, DOI 10.1097/00003246-198501000-00012; Delclaux C, 2000, JAMA-J AM MED ASSOC, V284, P2352, DOI 10.1001/jama.284.18.2352; Drummond GB, 2002, ANESTHESIOLOGY, V96, P817, DOI 10.1097/00000542-200204000-00007; Duggan M, 2003, AM J RESP CRIT CARE, V167, P1633, DOI 10.1164/rccm.200210-1215OC; Evans T W, 2001, Intensive Care Med, V27, P166, DOI 10.1007/s001340000721; Glanemann M, 2001, ACTA ANAESTH SCAND, V45, P333, DOI 10.1034/j.1399-6576.2001.045003333.x; Hedenstierna G, 1990, Acta Anaesthesiol Scand Suppl, V94, P27; Kaneko Y, 2003, NEW ENGL J MED, V348, P1233, DOI 10.1056/NEJMoa022479; Keenan SP, 2000, JAMA-J AM MED ASSOC, V284, P2376, DOI 10.1001/jama.284.18.2376; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Lang M, 2001, BRIT J SURG, V88, P1006, DOI 10.1046/j.0007-1323.2001.01812.x; LINDBERG P, 1992, ACTA ANAESTH SCAND, V36, P546, DOI 10.1111/j.1399-6576.1992.tb03516.x; LINDNER KH, 1987, CHEST, V92, P66, DOI 10.1378/chest.92.1.66; Mehta S, 2001, AM J RESP CRIT CARE, V163, P540, DOI 10.1164/ajrccm.163.2.9906116; MOLLER JT, 1990, ANESTHESIOLOGY, V73, P890, DOI 10.1097/00000542-199011000-00016; Morse MA, 2001, JAMA-J AM MED ASSOC, V285, P1201, DOI 10.1001/jama.285.9.1201; ODONOHUE WJ, 1985, CHEST, V87, P76, DOI 10.1378/chest.87.1.76; Pang D, 1998, CHEST, V114, P1185, DOI 10.1378/chest.114.4.1185; Patroniti N, 2003, INTENS CARE MED, V29, P1680, DOI 10.1007/s00134-003-1931-8; Plant PK, 2000, LANCET, V355, P1931, DOI 10.1016/S0140-6736(00)02323-0; POCOCK SJ, 1977, BIOMETRIKA, V64, P191, DOI 10.1093/biomet/64.2.191; Rothaar Robert C, 2003, Curr Opin Crit Care, V9, P59, DOI 10.1097/00075198-200302000-00011; Rusca M, 2003, ANESTH ANALG, V97, P1835, DOI 10.1213/01.ANE.0000087042.02266.F6; Slutsky AS, 2004, NEW ENGL J MED, V350, P1143, DOI 10.1056/NEJMsb033476; STOCK MC, 1985, CHEST, V87, P151, DOI 10.1378/chest.87.2.151; Thompson JS, 2003, ARCH SURG-CHICAGO, V138, P596, DOI 10.1001/archsurg.138.6.596; Tonnelier JM, 2003, INTENS CARE MED, V29, P2077, DOI 10.1007/s00134-003-1925-6; van Kaam AH, 2004, AM J RESP CRIT CARE, V169, P1046, DOI 10.1164/rccm.200312-1779OC	38	404	434	2	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2005	293	5					589	595		10.1001/jama.293.5.589	http://dx.doi.org/10.1001/jama.293.5.589			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	893BL	15687314	Bronze			2022-12-28	WOS:000226694200022
J	Jackson, R; Lawes, CMM; Bennett, DA; Milne, RJ; Rodgers, A				Jackson, R; Lawes, CMM; Bennett, DA; Milne, RJ; Rodgers, A			Treating Individuals 5 - Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk	LANCET			English	Article							CORONARY-HEART-DISEASE; PROSPECTIVELY-DESIGNED OVERVIEWS; SERUM-CHOLESTEROL; PRIMARY PREVENTION; NEW-ZEALAND; OPTIMAL AGE; HEALTH; PREDICTION; MANAGEMENT; EVENTS	In this review, we outline the rationale for targeting blood pressure and blood cholesterol lowering drug treatments to patients at high absolute cardiovascular risk, irrespective of their blood pressure or blood cholesterol levels. Because the specific levels of blood pressure and cholesterol are of little clinical relevance when considered in isolation from other risk factors, terms such as hypertension or hypercholesterolaemia have limited value. Separate management guidelines for raised blood pressure and blood cholesterol need to be replaced by integrated cardiovascular risk management guidelines, and absolute cardiovascular risk prediction scores should be used routinely. Since cardiovascular risk factors interact with each other, moderate reductions in several risk factors can be more effective than major reductions in one. An affordable daily pill combining low doses of various drugs could be useful for the many individuals with slightly abnormal cardiovascular risk factors.	Univ Auckland, Fac Med & Hlth Sci, Sch Populat Hlth, Epidemiol & Biostat Sect, Auckland 1, New Zealand; Univ Auckland, Fac Med & Hlth Sci, Dept Med, Clin Trials Res Unit, Auckland 1, New Zealand	University of Auckland; University of Auckland	Jackson, R (corresponding author), Univ Auckland, Fac Med & Hlth Sci, Sch Populat Hlth, Epidemiol & Biostat Sect, POB 92019, Auckland 1, New Zealand.	rt.jackson@auckland.ac.nz	Bennett, Derrick/AAH-1220-2022; Bennett, Derrick/AFL-9254-2022; , Bennett/O-7998-2019	Bennett, Derrick/0000-0002-9170-8447; Bennett, Derrick/0000-0002-9170-8447; Jackson, Rod/0000-0001-5914-6934; Rodgers, Anthony/0000-0003-1282-1896				ALDERMAN MH, 1993, ANN INTERN MED, V119, P329, DOI 10.7326/0003-4819-119-4-199308150-00013; ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; Assmann G, 2002, CIRCULATION, V105, P310, DOI 10.1161/hc0302.102575; Black N, 2003, BRIT MED J, V326, P2, DOI 10.1136/bmj.326.7379.2; Brindle P, 2003, BMJ-BRIT MED J, V327, P1267, DOI 10.1136/bmj.327.7426.1267; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Conroy RM, 2003, EUR HEART J, V24, P987, DOI 10.1016/S0195-668X(03)00114-3; Cruickshank J, 2001, LANCET, V358, P1994, DOI 10.1016/S0140-6736(01)06981-1; D'Agostino RB, 2001, JAMA-J AM MED ASSOC, V286, P180, DOI 10.1001/jama.286.2.180; D'Agostino RB, 2000, AM HEART J, V139, P272, DOI 10.1016/S0002-8703(00)90236-9; Friedmann PD, 1996, ANN INTERN MED, V124, P414, DOI 10.7326/0003-4819-124-4-199602150-00005; Gold MR, 1996, COST EFFECTIVENESS H; Hall LML, 2003, BRIT MED J, V326, P251, DOI 10.1136/bmj.326.7383.251; Hawthorne V, 2002, HEART, V88, P222; IRWIG L, 1991, JAMA-J AM MED ASSOC, V266, P1678, DOI 10.1001/jama.266.12.1678; Isles CG, 2000, BMJ-BRIT MED J, V320, P690, DOI 10.1136/bmj.320.7236.690; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; Jackson R, 2000, BMJ-BRIT MED J, V320, P709, DOI 10.1136/bmj.320.7236.709; Jones DW, 2003, JAMA-J AM MED ASSOC, V289, P1027, DOI 10.1001/jama.289.8.1027; Kannel W B, 2000, J Atheroscler Thromb, V6, P60; KANNEL WB, 1976, AM J CARDIOL, V37, P269, DOI 10.1016/0002-9149(76)90323-4; LaRosa JC, 1999, JAMA-J AM MED ASSOC, V282, P2340, DOI 10.1001/jama.282.24.2340; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; Law MR, 2002, BMJ-BRIT MED J, V324, P1570, DOI 10.1136/bmj.324.7353.1570; Law MR, 2003, BRIT MED J, V326, P1423, DOI 10.1136/bmj.326.7404.1423; Lawes Carlene M M, 2002, Semin Vasc Med, V2, P355, DOI 10.1055/s-2002-36765; Lawes CMM, 2003, J HYPERTENS, V21, P707, DOI 10.1097/01.hjh.0000052492.18130.07; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Lowensteyn I, 1998, PREV MED, V27, P730, DOI 10.1006/pmed.1998.0351; Lundin J, 2003, BRIT MED J, V326, P29, DOI 10.1136/bmj.326.7379.29; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; Marshall T, 2000, BMJ-BRIT MED J, V321, P637; Milne Richard, 2003, N Z Med J, V116, pU662; Montgomery AA, 2000, BRIT MED J, V320, P686, DOI 10.1136/bmj.320.7236.686; MULROW CD, 1994, JAMA-J AM MED ASSOC, V272, P1932, DOI 10.1001/jama.272.24.1932; Neal B, 2000, LANCET, V356, P1955; NEATON JD, 1992, ARCH INTERN MED, V152, P56, DOI 10.1001/archinte.152.1.56; Norris RM, 1998, BMJ-BRIT MED J, V316, P1065; *NZ GUID GROUP, MAN MILDL RAIS BLOOD; Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45; Pocock SJ, 2001, BMJ-BRIT MED J, V323, P75, DOI 10.1136/bmj.323.7304.75; Qizilbash N, 1995, LANCET, V346, P1647; Rodgers A, 1998, LANCET, V352, P1801; RODGERS A, 1997, NEUROL REV INT, V2, P12; Rose G, 2001, INT J EPIDEMIOL, V30, P427, DOI 10.1093/ije/30.3.427; Shepherd J, 1996, LANCET, V348, P1339; Shepherd J, 2002, LANCET, V359, P2271, DOI 10.1016/S0140-6736(02)09299-1; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; Stevens RJ, 2001, CLIN SCI, V101, P671, DOI 10.1042/CS20000335; Trewby PN, 2002, CLIN MED, V2, P527, DOI 10.7861/clinmedicine.2-6-527; Turnbull F, 2003, LANCET, V362, P1527; Ulrich S, 2000, BMJ-BRIT MED J, V320, P1134, DOI 10.1136/bmj.320.7242.1134; Voss R, 2002, INT J EPIDEMIOL, V31, P1253, DOI 10.1093/ije/31.6.1253; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419; Wallis EJ, 2000, BMJ-BRIT MED J, V320, P671, DOI 10.1136/bmj.320.7236.671; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; WHO, 2002, RED RISKS PROM HLTH; Wood D, 2000, BRIT MED J, V320, P705, DOI 10.1136/bmj.320.7236.705; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Zhang X, 2003, INT J EPIDEMIOL, V32, P563, DOI 10.1093/ije/dyg106	63	378	388	1	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN-FEB	2005	365	9457					434	441						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891WE	15680460				2022-12-28	WOS:000226610900032
J	Shawcross, D; Jalan, R				Shawcross, D; Jalan, R			Dispelling myths in the treatment of hepatic encephalopathy	LANCET			English	Review							PORTAL-SYSTEMIC ENCEPHALOPATHY; BLIND CLINICAL-TRIAL; CEREBRAL-BLOOD-FLOW; ACUTE LIVER-FAILURE; INDUCED HYPERAMMONEMIA; INTERORGAN AMMONIA; BRAIN EDEMA; CIRRHOSIS; LACTULOSE; METABOLISM	Context Guidelines for the treatment of hepatic encephalopathy suggest ammonia reduction as the main focus, based on strategies to reduce ammonia's generation and absorption in the colon by using lactulose and a reduced protein diet. Starting point Two studies provide compelling and provocative data questioning the relevance of these interventions. Bodils Als-Nielsen and colleagues, in a systematic review of randomised trials, found insufficient evidence about whether non-absorbable disaccharides; are beneficial (BMJ 2004; 328: 1046-50). In a small randomised study, Juan Cordoba and colleagues showed that diets with normal protein content can be administered safely during episodic hepatic encephalopathy due to cirrhosis and that protein restriction does not have any beneficial effect during such episodes (J Hepatol 2004; 41: 38-43). Where next Two approaches to new therapies for hepatic encephalopathy are needed. First, it is important to focus on the interorgan metabolism of ammonia. The small intestine and kidneys might be important producers of ammonia, and muscle is an important organ that can remove ammonia. Novel therapies targeting these organs reduce ammonia. Second, research is needed to explore factors other than ammonia that might be important in hepatic encephalopathy, including the synergistic role of inflammation. The lack of conclusive data about the efficacy of any treatment supports the view that placebo-controlled trials of newer agents are needed and ethical. The emphasis should shift to aggressive management of the precipitating event.	UCL, Inst Hepatol, London WC1E 6HX, England	University of London; University College London	Jalan, R (corresponding author), UCL, Inst Hepatol, London WC1E 6HX, England.	r.jalan@ucLac.uk	Shawcross, Debbie Lindsay/H-9669-2012	Shawcross, Debbie Lindsay/0000-0001-6133-4619				Ahl B, 2004, HEPATOLOGY, V40, P73, DOI 10.1002/hep.20290; Als-Nielsen B, 2004, BMJ-BRIT MED J, V328, P1046, DOI 10.1136/bmj.38048.506134.EE; ATTERBURY CE, 1978, AM J DIG DIS, V23, P398, DOI 10.1007/BF01072921; Balata S, 2003, HEPATOLOGY, V37, P931, DOI 10.1053/jhep.2003.50156; BIRCHER J, 1966, LANCET, V1, P890; CONN HO, 1977, GASTROENTEROLOGY, V72, P573; Cordoba J, 2004, J HEPATOL, V41, P38, DOI 10.1016/j.jhep.2004.03.023; Cordoba J, 2001, J HEPATOL, V35, P598, DOI 10.1016/S0168-8278(01)00181-7; Damink SWMO, 2003, HEPATOLOGY, V37, P1277, DOI 10.1053/jhep.2003.50221; Damink SWMO, 2002, NEUROCHEM INT, V41, P177, DOI 10.1016/S0197-0186(02)00040-2; Damink SWMO, 2002, HEPATOLOGY, V36, P1163, DOI 10.1053/jhep.2002.36497; DEJONG CHC, 1993, J CLIN INVEST, V92, P2834, DOI 10.1172/JCI116903; Delcker AM, 2000, HEPATOLOGY, V32, p310A; ELKINGTON SG, 1969, NEW ENGL J MED, V281, P408, DOI 10.1056/NEJM196908212810803; Ferenci P, 2002, HEPATOLOGY, V35, P716, DOI 10.1053/jhep.2002.31250; GERMAIN L, 1973, ARCH FR MAL APP DIG, V62, P293; Jalan R, 2004, CLIN SCI, V106, P467, DOI 10.1042/CS20030357; Jalan R, 2003, METAB BRAIN DIS, V18, P37, DOI 10.1023/A:1021978618745; Jalan R, 1999, LANCET, V354, P1164, DOI 10.1016/S0140-6736(98)12440-6; Kircheis G, 1997, HEPATOLOGY, V25, P1351, DOI 10.1002/hep.510250609; Liu Q, 2004, HEPATOLOGY, V39, P1441, DOI 10.1002/hep.20194; Master S, 1999, HEPATOLOGY, V30, P876, DOI 10.1002/hep.510300428; MULLEN KD, 1991, SEMIN LIVER DIS, V11, P292, DOI 10.1055/s-2008-1040447; NANCE FC, 1974, GASTROENTEROLOGY, V66, P108; RODGERS JB, 1973, AM J GASTROENTEROL, V60, P459; Romero-Gomez M, 2004, J HEPATOL, V41, P49, DOI 10.1016/j.jhep.2004.03.021; Rose C, 1999, HEPATOLOGY, V30, P636, DOI 10.1002/hep.510300311; Sen S, 2004, LIVER TRANSPLANT, V10, P1109, DOI 10.1002/lt.20236; Shawcross DL, 2004, J HEPATOL, V40, P247, DOI 10.1016/j.jhep.2003.10.016; SIMMONS F, 1970, GASTROENTEROLOGY, V59, P827; WEBER FL, 1979, GASTROENTEROLOGY, V77, P235; WOLPERT E, 1970, NEW ENGL J MED, V283, P159, DOI 10.1056/NEJM197007232830401	32	75	85	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN-FEB	2005	365	9457					431	433						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891WE	15680459	Green Submitted			2022-12-28	WOS:000226610900031
J	Cammarota, G; Certo, M				Cammarota, G; Certo, M			Corkscrew esophagus	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									A Gemelli Univ Hosp, I-00168 Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Cammarota, G (corresponding author), A Gemelli Univ Hosp, I-00168 Rome, Italy.		Cammarota, Giovanni/AAD-1732-2022	Cammarota, Giovanni/0000-0002-3626-6148					0	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2005	352	8					816	816		10.1056/NEJMicm040492	http://dx.doi.org/10.1056/NEJMicm040492			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899MC	15728814				2022-12-28	WOS:000227147500011
J	Mainprice, D; Tommasi, A; Couvy, H; Cordier, P; Frost, DJ				Mainprice, D; Tommasi, A; Couvy, H; Cordier, P; Frost, DJ			Pressure sensitivity of olivine slip systems and seismic anisotropy of Earth's upper mantle	NATURE			English	Article							LATTICE PREFERRED ORIENTATIONS; PLASTIC-DEFORMATION; SELF-CONSISTENT; GARNET; WAVE	The mineral olivine dominates the composition of the Earth's upper mantle and hence controls its mechanical behaviour and seismic anisotropy. Experiments at high temperature and moderate pressure, and extensive data on naturally deformed mantle rocks, have led to the conclusion that olivine at upper-mantle conditions deforms essentially by dislocation creep with dominant [ 100] slip. The resulting crystal preferred orientation has been used extensively to explain the strong seismic anisotropy observed down to 250 km depth(1-4). The rapid decrease of anisotropy below this depth has been interpreted as marking the transition from dislocation to diffusion creep in the upper mantle(5). But new high-pressure experiments suggest that dislocation creep also dominates in the lower part of the upper mantle, but with a different slip direction. Here we show that this high-pressure dislocation creep produces crystal preferred orientations resulting in extremely low seismic anisotropy, consistent with seismological observations below 250 km depth. These results raise new questions about the mechanical state of the lower part of the upper mantle and its coupling with layers both above and below.	Univ Montpellier 2, CNRS, Lab Tectonophys, F-34095 Montpellier 5, France; Univ Lille 1, CNRS, Lab Struct & Proprietes Etat Solide, F-59650 Villeneuve Dascq, France; Univ Bayreuth, Bayer Geoinst, D-95440 Bayreuth, Germany	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; University of Bayreuth	Mainprice, D (corresponding author), Univ Montpellier 2, CNRS, Lab Tectonophys, F-34095 Montpellier 5, France.	David.Mainprice@dstu.univ-montp2.fr	Frost, Daniel J/B-7526-2016; Tommasi, Andrea/A-7507-2008; Cordier, Patrick/D-2357-2012	Frost, Daniel J/0000-0002-4443-8149; Tommasi, Andrea/0000-0002-6457-1852; Cordier, Patrick/0000-0002-1883-2994				Abramson EH, 1997, J GEOPHYS RES-SOL EA, V102, P12253, DOI 10.1029/97JB00682; Bascou J, 2002, J STRUCT GEOL, V24, P1357, DOI 10.1016/S0191-8141(01)00137-7; Ben Ismail W, 1998, TECTONOPHYSICS, V296, P145; Ben-Ismail W, 2001, GEOPHYS RES LETT, V28, P2497, DOI 10.1029/2000GL012419; CARA M, 1988, GEOPHYS RES LETT, V15, P205, DOI 10.1029/GL015i003p00205; Chai M, 1997, GEOPHYS RES LETT, V24, P523, DOI 10.1029/97GL00371; Collins MD, 1998, PHYS CHEM MINER, V26, P7; Cordier P, 2001, MAT SCI ENG A-STRUCT, V309, P38, DOI 10.1016/S0921-5093(00)01795-0; COUVY H, IN PRESS EUR J MINER; DURHAM WB, 2002, PLASTIC DEFORMATION; Ekstrom G, 1998, NATURE, V394, P168, DOI 10.1038/28148; Gaherty JB, 1996, J GEOPHYS RES-SOL EA, V101, P22291, DOI 10.1029/96JB01882; Gung YC, 2003, NATURE, V422, P707, DOI 10.1038/nature01559; Karato S, 1997, J GEOPHYS RES-SOL EA, V102, P20111, DOI 10.1029/97JB01732; KARATO S, 1992, GEOPHYS RES LETT, V19, P2255, DOI 10.1029/92GL02603; LEBENSOHN RA, 1993, ACTA METALL MATER, V41, P2611, DOI 10.1016/0956-7151(93)90130-K; Leveque JJ, 1998, GEOPHYS J INT, V133, P529, DOI 10.1046/j.1365-246X.1998.00504.x; Li L, 2004, PHYS EARTH PLANET IN, V143, P357, DOI 10.1016/j.pepi.2003.09.022; Li L, 2003, PHYS EARTH PLANET IN, V138, P113, DOI 10.1016/S0031-9201(03)00065-7; Mainprice D, 2004, J STRUCT GEOL, V26, P2089, DOI 10.1016/j.jsg.2004.04.008; Mainprice D., 2000, EARTHS DEEP INTERIOR, P237, DOI [10.1029/GM117p0237, DOI 10.1029/GM117P0237]; Montagner JP, 1996, GEOPHYS J INT, V125, P229, DOI 10.1111/j.1365-246X.1996.tb06548.x; MONTAGNER JP, 1985, PHYS EARTH PLANET IN, V38, P28, DOI 10.1016/0031-9201(85)90120-7; NISHIMURA CE, 1989, GEOPHYS J INT, V96, P203, DOI 10.1111/j.1365-246X.1989.tb04446.x; REVENAUGH J, 1991, J GEOPHYS RES-SOL EA, V96, P19781, DOI 10.1029/91JB01487; Silver PG, 1996, ANNU REV EARTH PL SC, V24, P385, DOI 10.1146/annurev.earth.24.1.385; Tommasi A, 1998, EARTH PLANET SC LETT, V160, P1, DOI 10.1016/S0012-821X(98)00081-8; Tommasi A, 2000, J GEOPHYS RES-SOL EA, V105, P7893, DOI 10.1029/1999JB900411; VAUCHEZ A, IN PRESS EARTH PLANE; WENK HR, 1991, J GEOPHYS RES-SOLID, V96, P8337, DOI 10.1029/91JB00117	30	215	222	2	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	2005	433	7027					731	733		10.1038/nature03266	http://dx.doi.org/10.1038/nature03266			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897XH	15716950				2022-12-28	WOS:000227039200036
J	Krylova, IN; Sablin, EP; Moore, J; Xu, RX; Waitt, GM; MacKay, JA; Juzumiene, D; Bynum, JM; Madauss, K; Montana, V; Lebedeva, L; Suzawa, M; Williams, JD; Williams, SP; Guy, RK; Thornton, JW; Fletterick, RJ; Willson, TM; Ingraham, HA				Krylova, IN; Sablin, EP; Moore, J; Xu, RX; Waitt, GM; MacKay, JA; Juzumiene, D; Bynum, JM; Madauss, K; Montana, V; Lebedeva, L; Suzawa, M; Williams, JD; Williams, SP; Guy, RK; Thornton, JW; Fletterick, RJ; Willson, TM; Ingraham, HA			Structural analyses reveal phosphatidyl inositols as ligands for the NR5 orphan receptors SF-1 and LRH-1	CELL			English	Article							STEROIDOGENIC FACTOR-I; NUCLEAR-RECEPTOR; BINDING DOMAIN; CRYSTAL-STRUCTURE; TRANSFER PROTEIN; ACTIVATION; TRANSCRIPTION; CHOLESTEROL; INFERENCE; FACTOR-1	Vertebrate members of the nuclear receptor NR5A subfamily, which includes steroidogenic factor 1 (SF-1) and liver receptor homolog 1 (LRH-1), regulate crucial aspects of development, endocrine homeostasis, and metabolism. Mouse LRH-1 is believed to be a ligand-independent transcription factor with a large and empty hydrophobic pocket. Here we present structural and biochemical data for three other NR5A members-mouse and human SF-1 and human LRH-1-which reveal that these receptors bind phosphatidyl inositol second messengers and that ligand binding is required for maximal activity. Evolutionary analysis of structure-function relationships across the SF-1/LRH-1 subfamily indicates that ligand binding is the ancestral state of NR5A receptors and was uniquely diminished or altered in the rodent LRH-1 lineage. We propose that phospholipids regulate gene expression by directly binding to NR5A nuclear receptors.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Grad Grp Bioengn, San Francisco, CA 94143 USA; GlaxoSmithKline, Discovery Res, Res Triangle Pk, NC 27709 USA; Univ Oregon, Ctr Ecol & Evolut Biol, Eugene, OR 97403 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; GlaxoSmithKline; University of Oregon	Ingraham, HA (corresponding author), Univ Calif San Francisco, Dept Physiol, 1550 4th St,Miss Bay Campus, San Francisco, CA 94143 USA.	hollyi@itsa.ucsf.edu	Thornton, Joseph/GSN-4190-2022; feinstein, doug/M-9414-2019; Guy, Rodney/J-7107-2013	Guy, Rodney/0000-0002-9638-2060; Williams, Shawn/0000-0001-8311-2638	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058080, R01DK072246] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM070792] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK058080-05, R01 DK072246, R01 DK058080] Funding Source: Medline; NIGMS NIH HHS [1R21-GM70792-1] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bacqueville D, 2001, J BIOL CHEM, V276, P22170, DOI 10.1074/jbc.M011572200; Baker KD, 2003, CELL, V113, P731, DOI 10.1016/S0092-8674(03)00420-3; Billas IML, 2001, J BIOL CHEM, V276, P7465, DOI 10.1074/jbc.M008926200; Bland ML, 2000, P NATL ACAD SCI USA, V97, P14488, DOI 10.1073/pnas.97.26.14488; Botrugno OA, 2004, MOL CELL, V15, P499, DOI 10.1016/j.molcel.2004.07.009; Christenson LK, 1998, J BIOL CHEM, V273, P30729, DOI 10.1074/jbc.273.46.30729; DARIMONT BD, 1998, GENE DEV, V273, P30729; DEFIGUEIREDO BC, 2004, J CLIN ENDOCR METAB, V10, P2004; Deleris P, 2003, J BIOL CHEM, V278, P38884, DOI 10.1074/jbc.M300816200; Delerive P, 2004, MOL ENDOCRINOL, V18, P2378, DOI 10.1210/me.2004-0132; Desclozeaux M, 2002, MOL CELL BIOL, V22, P7193, DOI 10.1128/MCB.22.20.7193-7203.2002; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P37973, DOI 10.1074/jbc.C200420200; Dietschy JM, 2002, J BIOL CHEM, V277, P3801, DOI 10.1074/jbc.R100057200; Escriva H, 2000, BIOESSAYS, V22, P717; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Fayard E, 2004, TRENDS CELL BIOL, V14, P250, DOI 10.1016/j.tcb.2004.03.008; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; Holter E, 2002, MOL ENDOCRINOL, V16, P515, DOI 10.1210/me.16.3.515; Hsuan J, 2001, GENOME BIOL, V2; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; IRVINE RF, 2002, SCI STKE; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; Kallen JA, 2002, STRUCTURE, V10, P1697, DOI 10.1016/S0969-2126(02)00912-7; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; Ledeen RW, 2004, J LIPID RES, V45, P1, DOI 10.1194/jlr.R300015-JLR200; Lee MB, 2005, MOL CELL BIOL, V25, P1879, DOI 10.1128/MCB.25.5.1879-1890.2005; Li Y, 2003, STRUCTURE, V11, P741, DOI 10.1016/S0969-2126(03)00133-3; Lie J, 2002, J LIPID RES, V43, P1875, DOI 10.1194/jlr.M200166-JLR200; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Ludbrook LM, 2004, TRENDS ENDOCRIN MET, V15, P116, DOI 10.1016/j.tem.2004.02.002; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; Madauss K, 2004, ENDOCR RES, V30, P775, DOI 10.1081/ERC-200044038; Martelli AM, 2003, J CELL BIOCHEM, V88, P455, DOI 10.1002/jcb.10379; Mellon SH, 1998, ENDOCRINOLOGY, V139, P3026, DOI 10.1210/en.139.6.3026; Moore JMR, 2004, J BIOL CHEM, V279, P27584, DOI 10.1074/jbc.M403453200; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Pagel M, 1999, NATURE, V401, P877, DOI 10.1038/44766; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Sablin EP, 2003, MOL CELL, V11, P1575, DOI 10.1016/S1097-2765(03)00236-3; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; Steinmetz ACU, 2001, ANNU REV BIOPH BIOM, V30, P329, DOI 10.1146/annurev.biophys.30.1.329; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thornton JW, 2003, SCIENCE, V301, P1714, DOI 10.1126/science.1086185; Thornton JW, 2000, SYST BIOL, V49, P183, DOI 10.1093/sysbio/49.2.183; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Weatherman RV, 1999, ANNU REV BIOCHEM, V68, P559, DOI 10.1146/annurev.biochem.68.1.559; Wellings DA, 1997, METHOD ENZYMOL, V289, P44; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; YANG ZH, 1995, GENETICS, V141, P1641; Yoder MD, 2001, J BIOL CHEM, V276, P9246, DOI 10.1074/jbc.M010131200	50	319	339	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 11	2005	120	3					343	355		10.1016/j.cell.2005.01.024	http://dx.doi.org/10.1016/j.cell.2005.01.024			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	897TS	15707893	Bronze			2022-12-28	WOS:000227028900010
J	Roland, M; Dusheiko, M; Gravelle, H; Parker, S				Roland, M; Dusheiko, M; Gravelle, H; Parker, S			Follow up of people aged 65 and over with a history of emergency admissions: analysis of routine admission data	BRITISH MEDICAL JOURNAL			English	Article							CONGESTIVE-HEART-FAILURE; PRIMARY-CARE; READMISSION; QUALITY; HOSPITALIZATION; INDICATORS; RISK	Objective To determine the subsequent pattern of emergency admissions in older people with a history of frequent emergency admissions. Design Analysis of routine admissions data from NHS hospitals using hospital episode statistics (HES) in England. Subjects Individual patients aged greater than or equal to 65, greater than or equal to 75, and greater than or equal to 85 who had at least two emergency admissions in 1997-8. Main outcome measures Emergency admissions and bed use in this "high risk" cohort of patients were counted for the next five years and compared with the general population of the same age. No account was taken of mortality as the analysis was designed to estimate the future use of beds in this high risk cohort. Results Over four to five years, admission rates and bed use in the high risk cohorts fell to the mean rate for older people. Although patients greater than or equal to 65 with two or more such admissions were responsible for 38% of admissions in the index year, they were responsible for fewer than 10% of admissions' in the following year and just over 3% five years later. Conclusion Patients with multiple emergency admissions are often identified as a high risk group for subsequent admission and substantial claims are made for interventions designed to avoid emergency admission in such patients. Simply monitoring admission rates cannot assess interventions designed to reduce admission among frail older people as rates fall without any intervention. Comparison with a matched control group is necessary. Wider benefits than reduced admissions should be considered when introducing intensive case management of older people.	Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England; Univ York, Ctr Hlth Econ, Natl Primary Care Res & Dev Ctr, York YO1 5DD, N Yorkshire, England; Univ Sheffield, Sheffield Inst Studies Ageing, Sheffield S5 7AU, S Yorkshire, England	University of Manchester; University of York - UK; University of Sheffield	Roland, M (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England.	m.roland@man.ac.uk		Gravelle, Hugh/0000-0002-7753-4233; Parker, Stuart/0000-0002-8675-6276				Ashton CM, 1996, SOC SCI MED, V43, P1533, DOI 10.1016/S0277-9536(96)00049-4; Basu J, 2002, MED CARE, V40, P1260, DOI 10.1097/00005650-200212000-00013; BOADEN R, EVERCARE EVALUATION; Brody KK, 2002, J AM GERIATR SOC, V50, P562, DOI 10.1046/j.1532-5415.2002.50127.x; BROOK GM, 1994, J AM GERIATR SOC, V42, P536; Clarke A, 2004, QUAL SAF HEALTH CARE, V13, P10, DOI 10.1136/qshc.2003.008789; Department of Health, 2005, SUPP PEOPL LONG TERM; Giuffrida A, 1999, BRIT MED J, V319, P94, DOI 10.1136/bmj.319.7202.94; Hutt R, 2004, CASE MANAGING LONG T; *IMPL EV PROGR, 2004, INT REP; Johri M, 2003, INT J GERIATR PSYCH, V18, P222, DOI 10.1002/gps.819; Kane RL, 2003, J AM GERIATR SOC, V51, P1427, DOI 10.1046/j.1532-5415.2003.51461.x; Leng GC, 1999, QUAL HEALTH CARE, V8, P234, DOI 10.1136/qshc.8.4.234; Meldon SW, 2003, ACAD EMERG MED, V10, P224, DOI 10.1111/j.1553-2712.2003.tb01996.x; *OFF NAT STAT, MID 1997 POP EST ENG; PACALA JT, 1995, J AM GERIATR SOC, V43, P374, DOI 10.1111/j.1532-5415.1995.tb05810.x; RICH MW, 1993, J GEN INTERN MED, V8, P585, DOI 10.1007/BF02599709; Ricketts TC, 2001, HEALTH PLACE, V7, P27, DOI 10.1016/S1353-8292(00)00035-6; Sanderson C, 2000, J Health Serv Res Policy, V5, P222; Stewart S, 1998, ARCH INTERN MED, V158, P1067, DOI 10.1001/archinte.158.10.1067	20	103	103	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 5	2005	330	7486					289	292		10.1136/bmj.330.7486.289	http://dx.doi.org/10.1136/bmj.330.7486.289			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895EM	15695276	Green Published, Bronze			2022-12-28	WOS:000226843700017
J	Hill, WG				Hill, WG			A century of corn selection	SCIENCE			English	Editorial Material							ARTIFICIAL SELECTION; BODY-WEIGHT; TRAITS		Univ Edinburgh, Sch Biol Sci, Edinburgh EH9 3JT, Midlothian, Scotland	University of Edinburgh	Hill, WG (corresponding author), Univ Edinburgh, Sch Biol Sci, Edinburgh EH9 3JT, Midlothian, Scotland.	w.g.hill@ed.ac.uk						ANDERSSON L, COMMUNICATION; De Koning DJ, 2004, GENET RES, V83, P211, DOI 10.1017/S0016672304006846; Dudley J. W., 2004, Plant Breeding Reviews, V24, P79; Dunnington EA, 1996, POULTRY SCI, V75, P1168, DOI 10.3382/ps.0751168; Hayes B, 2001, GENET SEL EVOL, V33, P209, DOI 10.1051/gse:2001117; HILL WG, 1982, GENET RES, V40, P255, DOI 10.1017/S0016672300019145; Janick J, 2003, PLANT BREEDING REV 1, V24; Kerje S, 2003, ANIM GENET, V34, P264, DOI 10.1046/j.1365-2052.2003.01000.x; Laurie CC, 2004, GENETICS, V168, P2141, DOI 10.1534/genetics.104.029686; LYNCH M, 1998, INTRO QUANTITATIVE G; ROBERTSON A., 1960, PROC ROY SOC SER B BIOL SCI, V153, P234, DOI 10.1098/rspb.1960.0099; Sewalem A, 2002, POULTRY SCI, V81, P1775, DOI 10.1093/ps/81.12.1775; Walsh B., 2004, Plant Breeding Reviews, V24, P177	13	38	45	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2005	307	5710					683	684		10.1126/science.1105459	http://dx.doi.org/10.1126/science.1105459			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	894TQ	15692038				2022-12-28	WOS:000226814900028
J	Kim, C; Xuong, NH; Taylor, SS				Kim, C; Xuong, NH; Taylor, SS			Crystal structure of a complex between the catalytic and regulatory (RI alpha) subunits of PKA	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; CAMP-BINDING DOMAINS; AMIDE H/H-2 EXCHANGE; PHOSPHORYLASE-KINASE; MOLECULAR-BASIS; SITES; MONOPHOSPHATE; MECHANISM; CLASSIFICATION; RESOLUTION	The 2.0-angstrom structure of the cyclic adenosine monophosphate (cAMP)-dependent protein kinase (PKA) catalytic subunit bound to a deletion mutant of a regulatory subunit (Rlalpha) defines a previously unidentified extended interface. The complex provides a molecular mechanism for inhibition of PKA and suggests how CAMP binding leads to activation. The interface defines the large lobe of the catalytic subunit as a stable scaffold where Tyr(247) in the G helix and Trp(196) in the phosphorylated activation loop serve as anchor points for binding Rlalpha. These residues compete with CAMP for the phosphate binding cassette in Rlalpha. In contrast to the catalytic subunit, Rlalpha undergoes major conformational changes when the complex is compared with CAMP-bound Rlalpha. The inhibitor sequence docks to the active site, whereas the linker, also disordered in free Rlalpha, folds across the extended interface. The beta barrel of CAMP binding domain A, which is the docking site for CAMP, remains largely intact in the complex, whereas the helical subdomain undergoes major reorganization.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Phys & Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Taylor, SS (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.	staylor@ucsd.edu			NIDDK NIH HHS [DK07233] Funding Source: Medline; NIGMS NIH HHS [GM19301, GM34921] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019301, R01GM034921, R01GM019301] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		*ACC, 2003, INS 2; ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; Adams JA, 2001, CHEM REV, V101, P2271, DOI 10.1021/cr000230w; Anand GS, 2003, P NATL ACAD SCI USA, V100, P13264, DOI 10.1073/pnas.2232255100; Anand GS, 2002, J MOL BIOL, V323, P377, DOI 10.1016/S0022-2836(02)00919-1; Banky P, 2003, J MOL BIOL, V330, P1117, DOI 10.1016/S0022-2836(03)00552-7; Berman HM, 2005, P NATL ACAD SCI USA, V102, P45, DOI 10.1073/pnas.0408579102; Brandon EP, 1997, CURR OPIN NEUROBIOL, V7, P397, DOI 10.1016/S0959-4388(97)80069-4; Canaves JM, 2000, BIOCHEMISTRY-US, V39, P15022, DOI 10.1021/bi001563q; Canaves JM, 2002, J MOL EVOL, V54, P17, DOI 10.1007/s00239-001-0013-1; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Diller TC, 2001, STRUCTURE, V9, P73, DOI 10.1016/S0969-2126(00)00556-6; Gibson RM, 1997, J BIOL CHEM, V272, P16343, DOI 10.1074/jbc.272.26.16343; Gibson RM, 1997, J BIOL CHEM, V272, P31998, DOI 10.1074/jbc.272.51.31998; GILL GN, 1971, P NATL ACAD SCI USA, V68, P786, DOI 10.1073/pnas.68.4.786; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hauer JA, 1999, PROTEIN SCI, V8, P545; Heller WT, 2004, J BIOL CHEM, V279, P19084, DOI 10.1074/jbc.M313405200; Herberg FW, 1999, BIOCHEMISTRY-US, V38, P6352, DOI 10.1021/bi982672w; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; IYER G, IN PRESS J BIOL CHEM; Johnson DA, 2001, CHEM REV, V101, P2243, DOI 10.1021/cr000226k; Kim C., UNPUB; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAW D, UNPUB; LEON DA, 1991, BIOCHEMISTRY-US, V30, P3035, DOI 10.1021/bi00226a008; Li F, 2002, J MOL BIOL, V315, P459, DOI 10.1006/jmbi.2001.5256; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nayal M, 1999, PROTEIN SCI, V8, P676; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; Newlon MG, 2001, EMBO J, V20, P1651, DOI 10.1093/emboj/20.7.1651; Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024; OGREID D, 1981, FEBS LETT, V129, P287, DOI 10.1016/0014-5793(81)80185-8; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; Rehmann H, 2003, NAT STRUCT BIOL, V10, P26, DOI 10.1038/nsb878; Song HW, 2001, MOL CELL, V7, P615, DOI 10.1016/S1097-2765(01)00208-8; Stevenson LM, 2002, BIOCHEMISTRY-US, V41, P8528, DOI 10.1021/bi025812h; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; SUTHERLAND EW, 1958, J BIOL CHEM, V232, P1077; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; Valiev M, 2003, J AM CHEM SOC, V125, P9926, DOI 10.1021/ja029618u; Venien-Bryan C, 2002, STRUCTURE, V10, P33, DOI 10.1016/S0969-2126(01)00691-8; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WALSH DA, 1968, J BIOL CHEM, V243, P3763; YANG SMG, 2004, J MOL BIOL; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	50	274	281	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2005	307	5710					690	696		10.1126/science.1104607	http://dx.doi.org/10.1126/science.1104607			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	894TQ	15692043				2022-12-28	WOS:000226814900033
J	Nakagawa, T; Cheng, YF; Ramm, E; Sheng, M; Walz, T				Nakagawa, T; Cheng, YF; Ramm, E; Sheng, M; Walz, T			Structure and different conformational states of native AMPA receptor complexes	NATURE			English	Article							LIGAND-BINDING CORE; GLUTAMATE-RECEPTOR; ION-CHANNEL; KAINATE; DOMAIN; SELECTIVITY; MECHANISMS; TOPOLOGY; SYMMETRY; NEURONS	Ionotropic glutamate receptors mediate fast excitatory synaptic transmission in the central nervous system(1,2). Their modulation is believed to affect learning and memory, and their dysfunction has been implicated in the pathogenesis of neurological and psychiatric diseases(1,2). Despite a wealth of functional data, little is known about the intact, three-dimensional structure of these ligand-gated ion channels. Here, we present the structure of native AMPA receptors (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid; AMPA-Rs) purified from rat brain, as determined by single-particle electron microscopy. Unlike the homotetrameric recombinant GluR2 (ref. 3), the native heterotetrameric AMPA-R adopted various conformations, which reflect primarily a variable separation of the two dimeric extracellular amino-terminal domains. Members of the stargazin/ TARP family of transmembrane proteins co-purified with AMPA-Rs and contributed to the density representing the transmembrane region of the complex. Glutamate and cyclothiazide markedly altered the conformational equilibrium of the channel complex, suggesting that desensitization is related to separation of the N-terminal domains. These data provide a glimpse of the conformational changes of an important ligand-gated ion channel of the brain.	MIT, Howard Hughes Med Inst, RIKEN MIT Neurosci Res Ctr, Picower Ctr Learning & Memory, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); RIKEN; Harvard University; Harvard Medical School	Sheng, M (corresponding author), MIT, Howard Hughes Med Inst, RIKEN MIT Neurosci Res Ctr, Picower Ctr Learning & Memory, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	msheng@mit.edu; twalz@hms.harvard.edu		Walz, Thomas/0000-0003-2606-2835; Cheng, Yifan/0000-0001-9535-0369; Sheng, Morgan/0000-0002-8703-5366				Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Ayalon G, 2001, NEURON, V31, P103, DOI 10.1016/S0896-6273(01)00333-6; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; Chen GQ, 1999, NATURE, V402, P817, DOI 10.1038/45568; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Goodsell DS, 2000, ANNU REV BIOPH BIOM, V29, P105, DOI 10.1146/annurev.biophys.29.1.105; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; Horning MS, 2004, NEURON, V41, P379, DOI 10.1016/S0896-6273(04)00018-2; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Ohi Melanie, 2004, Biol Proced Online, V6, P23, DOI 10.1251/bpo70; Passafaro M, 2003, NATURE, V424, P677, DOI 10.1038/nature01781; Pasternack A, 2002, J BIOL CHEM, V277, P49662, DOI 10.1074/jbc.M208349200; PATNEAU DK, 1993, J NEUROSCI, V13, P3496; RANK J, 1996, 3 DIMENSIONAL ELECT; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; Safferling M, 2001, BIOCHEMISTRY-US, V40, P13948, DOI 10.1021/bi011143g; Sobolevsky AI, 2004, NEURON, V41, P367, DOI 10.1016/S0896-6273(04)00008-X; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; Swanson GT, 1997, J NEUROSCI, V17, P58, DOI 10.1523/JNEUROSCI.17-01-00058.1997; Tichelaar W, 2004, J MOL BIOL, V344, P435, DOI 10.1016/j.jmb.2004.09.048; Tomita S, 2004, SCIENCE, V303, P1508, DOI 10.1126/science.1090262; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; Wollmuth LP, 2004, TRENDS NEUROSCI, V27, P321, DOI 10.1016/j.tins.2004.04.005	30	211	217	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 3	2005	433	7025					545	549		10.1038/nature03328	http://dx.doi.org/10.1038/nature03328			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893NT	15690046				2022-12-28	WOS:000226727200054
J	Nicastro, F; Mathur, S; Elvis, M; Drake, J; Fang, TT; Fruscione, A; Krongold, Y; Marshall, H; Williams, R; Zezas, A				Nicastro, F; Mathur, S; Elvis, M; Drake, J; Fang, TT; Fruscione, A; Krongold, Y; Marshall, H; Williams, R; Zezas, A			The mass of the missing baryons in the X-ray forest of the warm-hot intergalactic medium	NATURE			English	Article							PROBE WMAP OBSERVATIONS; LOW-REDSHIFT; ABSORPTION SYSTEMS; CHANDRA DETECTION; ALPHA ABSORPTION; PKS-2155-304; SPECTRA; CLOUDS; LINE	Recent cosmological measurements indicate that baryons comprise about four per cent of the total mass-energy density of the Universe(1,2), which is in accord with the predictions arising from studies of the production of the lightest elements(3). It is also in agreement with the actual number of baryons detected at early times (redshifts z > 2)(4,5). Close to our own epoch (z < 2), however, the number of baryons detected add up to just over half (, 55 per cent) of the number seen at z > 2 (refs 6 - 11), meaning that about similar to45 per cent are 'missing'. Here we report a determination of the mass-density of a previously undetected population of baryons, in the warm - hot phase of the intergalactic medium. We show that this mass density is consistent, within the uncertainties, with the mass density of the missing baryons.	Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; Ohio State Univ, Dept Astron, Columbus, OH 43210 USA; Univ Calif Berkeley, Berkeley, CA 94720 USA; Univ Nacl Autonoma Mexico, Ist Astron, Mexico City 04510, DF, Mexico; MIT, Cambridge, MA 02139 USA	Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; University System of Ohio; Ohio State University; University of California System; University of California Berkeley; Universidad Nacional Autonoma de Mexico; Massachusetts Institute of Technology (MIT)	Nicastro, F (corresponding author), Harvard Smithsonian Ctr Astrophys, 60 Garden St, Cambridge, MA 02138 USA.	fnicastro@cfa.harvard.edu	Zezas, Andreas/C-7543-2011; Krongold, Yair/AAF-2844-2021; Marshall, Herman/ABD-3260-2021; Williams, Rik/D-4592-2013	Zezas, Andreas/0000-0001-8952-676X; Marshall, Herman/0000-0002-6492-1293; Williams, Rik/0000-0001-9678-9904; Nicastro, Fabrizio/0000-0002-6896-1364				Bennett CL, 2003, ASTROPHYS J SUPPL S, V148, P1, DOI 10.1086/377253; Cagnoni I, 2004, ASTROPHYS J, V603, P449, DOI 10.1086/381698; Cen RY, 1999, ASTROPHYS J, V514, P1, DOI 10.1086/306949; Collins JA, 2004, ASTROPHYS J, V605, P216, DOI 10.1086/382269; Dave R, 2001, ASTROPHYS J, V552, P473, DOI 10.1086/320548; Fang TT, 2003, ASTROPHYS J, V586, pL49, DOI 10.1086/374680; Fang TT, 2002, ASTROPHYS J, V564, P604, DOI 10.1086/324400; Fang TT, 2002, ASTROPHYS J, V572, pL127, DOI 10.1086/341665; FUKUGITA M, IN PRESS P IAU S, V220; GEHRELS N, 1986, ASTROPHYS J, V303, P336, DOI 10.1086/164079; Kirkman D, 2003, ASTROPHYS J SUPPL S, V149, P1, DOI 10.1086/378152; Mathur S, 2003, ASTROPHYS J, V582, P82, DOI 10.1086/344509; Nicastro F, 2002, ASTROPHYS J, V573, P157, DOI 10.1086/340489; Nicastro F, 2003, NATURE, V421, P719, DOI 10.1038/nature01369; NICASTRO F, 2003, INT ASTRONOMICAL UNI, V216, P170; Penton SV, 2004, ASTROPHYS J SUPPL S, V152, P29, DOI 10.1086/382877; Perna R, 1998, ASTROPHYS J, V503, pL135, DOI 10.1086/311544; RASMUSSEN A, 2003, XRAY IGM LOCAL GROUP, P109; Rauch M, 1998, ANNU REV ASTRON ASTR, V36, P267, DOI 10.1146/annurev.astro.36.1.267; Savage BD, 2002, ASTROPHYS J, V564, P631, DOI 10.1086/324288; Sembach KR, 2003, ASTROPHYS J SUPPL S, V146, P165, DOI 10.1086/346231; Shull JM, 2003, ASTROPHYS SPACE SC L, V281, P1; Shull JM, 1996, ASTRON J, V111, P72, DOI 10.1086/117761; Spergel DN, 2003, ASTROPHYS J SUPPL S, V148, P175, DOI 10.1086/377226; STOCKE JT, IN PRESS P 2004 STSC; Tripp TM, 2000, ASTROPHYS J, V534, pL1, DOI 10.1086/312644; Weinberg DH, 1997, ASTROPHYS J, V490, P564, DOI 10.1086/304893	27	160	160	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 3	2005	433	7025					495	498		10.1038/nature03245	http://dx.doi.org/10.1038/nature03245			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893NT	15690033				2022-12-28	WOS:000226727200040
J	Yeo, M; Lee, SK; Lee, B; Ruiz, EC; Pfaff, SL; Gill, GN				Yeo, M; Lee, SK; Lee, B; Ruiz, EC; Pfaff, SL; Gill, GN			Small CTD phosphatases function in silencing neuronal gene expression	SCIENCE			English	Article							TARGET GENES; TRANSCRIPTIONAL REPRESSION; DEACETYLASE COMPLEX; HISTONE H3; LYSINE 9; PROTEIN; DIFFERENTIATION; IDENTIFICATION; DOMAIN	Neuronal gene transcription is repressed in non-neuronal cells by the repressor element 1 (RE-1)-silencing transcription factor/neuron-restrictive silencer factor (REST/NRSF) complex. To understand how this silencing is achieved, we examined a family of class-C RNA polymerase II (RNAPII) carboxyl-terminal domain (CTD) phosphatases [small CTD phosphatases (SCPs) 1 to 3], whose expression is restricted to non-neuronal tissues. We show that REST/NRSF recruits SCPs to neuronal genes that contain RE-1 elements, leading to neuronal gene silencing in non-neuronal cells. Phosphatase-inactive forms of SCP interfere with REST/NRSF function and promote neuronal. differentiation of P19 stem cells. Likewise, small interfering RNA directed to the single Drosophila SCP unmasks neuronal gene expression in S2 cells. Thus, SCP activity is an evolutionarily conserved transcriptional regulator that acts globally to silence neuronal genes.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA	University of California System; University of California San Diego; Salk Institute	Gill, GN (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	ggill@ucsd.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013149, R37DK013149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037116, R37NS037116] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK13149] Funding Source: Medline; NINDS NIH HHS [NS37116] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; Bai G, 2003, J NEUROCHEM, V86, P992, DOI 10.1046/j.1471-4159.2003.01922.x; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Freeman MR, 2003, NEURON, V38, P567, DOI 10.1016/S0896-6273(03)00289-7; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; Kamenski T, 2004, MOL CELL, V15, P399, DOI 10.1016/j.molcel.2004.06.035; Kokura K, 2001, J BIOL CHEM, V276, P34115, DOI 10.1074/jbc.M105747200; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lee SK, 2003, NEURON, V38, P731, DOI 10.1016/S0896-6273(03)00296-4; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; Maile T, 2004, SCIENCE, V304, P1010, DOI 10.1126/science.1095001; Naruse Y, 1999, P NATL ACAD SCI USA, V96, P13691, DOI 10.1073/pnas.96.24.13691; Roopra A, 2000, MOL CELL BIOL, V20, P2147, DOI 10.1128/MCB.20.6.2147-2157.2000; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Tootle TL, 2003, NATURE, V426, P299, DOI 10.1038/nature02097; YAO M, 1995, J NEUROSCI RES, V41, P792, DOI 10.1002/jnr.490410610; Yeo M, 2003, J BIOL CHEM, V278, P26078, DOI 10.1074/jbc.M301791200; Zohn IE, 2001, DEV BIOL, V239, P118, DOI 10.1006/dbio.2001.0420	23	170	184	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2005	307	5709					596	600		10.1126/science.1100801	http://dx.doi.org/10.1126/science.1100801			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893BJ	15681389				2022-12-28	WOS:000226694000052
J	Langevin, Y; Poulet, F; Bibring, JP; Schmitt, B; Doute, S; Gondet, B				Langevin, Y; Poulet, F; Bibring, JP; Schmitt, B; Doute, S; Gondet, B			Summer evolution of the north polar cap of Mars as observed by OMEGA/Mars express	SCIENCE			English	Article							ORBITER CAMERA; WATER ICE; MODEL; SURFACES	The Observatoire pour la Mineralogie, l'Eau, les Gtaces, et l'Activite (OMEGA) visible-infrared imaging spectrometer extensively observed regions of Mars with latitudes above 70degreesN in late 2004 (heliocentric longitude from L-s 93degrees to L-s 127degrees). The extent of water ice at the surface and the size of ice grains were monitored as a function of time. Bright, small-grained frost, which initially covered a large fraction of the polar cap, waned in favor of large-grained ice. In outlying regions, dominated by large-grained ice, the albedo increased over the period. Evaluating the dust content was mode[ dependent. However, contamination of ice by dust was low.	Univ Paris 11, CNRS, Inst Astrophys Spatiale, F-91405 Orsay, France; Univ Grenoble 1, CNRS, Lab Planetol Grenoble, F-38400 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Langevin, Y (corresponding author), Univ Paris 11, CNRS, Inst Astrophys Spatiale, F-91405 Orsay, France.	yves.langevin@ias.u-psud.fr	Schmitt, Bernard/A-1064-2009	Schmitt, Bernard/0000-0002-1230-6627				Bass DS, 2000, ICARUS, V144, P382, DOI 10.1006/icar.1999.6300; Bibring JP, 2005, SCIENCE, V307, P1576, DOI 10.1126/science.1108806; CALVIN WM, 2004, LUNAR PLANET SCI, V35, P1455; Doute S, 1998, J GEOPHYS RES-PLANET, V103, P31367, DOI 10.1029/98JE01894; Grundy WM, 1998, J GEOPHYS RES-PLANET, V103, P25809, DOI 10.1029/98JE00738; HALE AS, 2003, LUNAR PLANET SCI, V34, P1422; James PB, 2001, ICARUS, V154, P131, DOI 10.1006/icar.2001.6653; KIEFFER HH, 1976, SCIENCE, V194, P1341, DOI 10.1126/science.194.4271.1341; KIEFFER HH, 1990, J GEOPHYS RES-SOLID, V95, P1481, DOI 10.1029/JB095iB02p01481; Kieffer HH, 2001, ICARUS, V154, P162, DOI 10.1006/icar.2001.6670; Levrard B, 2004, NATURE, V431, P1072, DOI 10.1038/nature03055; Malin MC, 2001, J GEOPHYS RES-PLANET, V106, P23429, DOI 10.1029/2000JE001455; Mischna MA, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002051; Nolin AW, 1998, J GEOPHYS RES-PLANET, V103, P25851, DOI 10.1029/98JE02082; Poulet F, 2002, ICARUS, V160, P313, DOI 10.1006/icar.2002.6970; Shkuratov Y, 1999, ICARUS, V137, P235, DOI 10.1006/icar.1998.6035	16	117	123	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 11	2005	307	5715					1581	1584		10.1126/science.1109438	http://dx.doi.org/10.1126/science.1109438			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	906ED	15718426				2022-12-28	WOS:000227622400035
J	Mustard, JF; Poulet, F; Gendrin, A; Bibring, JP; Langevin, Y; Gondet, B; Mangold, N; Bellucci, G; Altieri, F				Mustard, JF; Poulet, F; Gendrin, A; Bibring, JP; Langevin, Y; Gondet, B; Mangold, N; Bellucci, G; Altieri, F			Olivine and pyroxene, diversity in the crust of Mars	SCIENCE			English	Article							BASALTIC ROCKS; MGS-TES; SPECTRA; SPECTROSCOPY; REFLECTANCE; METEORITES	Data from the Observatoire pour la Mineralogie, l'Eau, les Glaces, et l'Activite (OMEGA) on the Mars Express spacecraft identify the distinct mafic, rock-forming minerals olivine, low-calcium pyroxene (LCP), and high-calcium pyroxene (HCP) on the surface of Mars. Olivine- and HCP-rich regions are found in deposits that span the age range of geologic units. However, LCP-rich regions are found only in the ancient Noachian-aged units, which suggests that melts for these deposits were derived from a mantle depleted in aluminum and calcium. Extended dark regions in the northern plains exhibit no evidence of strong mafic absorptions or absorptions due to hydrated materials.	Brown Univ, Providence, RI 02912 USA; Inst Astrophys Spatiale, F-91405 Orsay, France; IDES, F-91405 Orsay, France; IFSI INAF, Rome, Italy	Brown University; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Istituto Nazionale Astrofisica (INAF)	Mustard, JF (corresponding author), Brown Univ, Providence, RI 02912 USA.	john_mustard@brown.edu	Bellucci, Giancarlo/ABA-9201-2020	Bellucci, Giancarlo/0000-0003-0867-8679; Altieri, Francesca/0000-0002-6338-8300				ADAMS JB, 1974, J GEOPHYS RES, V79, P4829, DOI 10.1029/JB079i032p04829; Arvidson RE, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE001982; Bandfield JL, 2000, SCIENCE, V287, P1626, DOI 10.1126/science.287.5458.1626; Bibring J.-P., 2004, EUR SPACE AGENCY SPE, V1240, P37; Bibring JP, 2005, SCIENCE, V307, P1576, DOI 10.1126/science.1108806; BIBRING JP, 1989, NATURE, V341, P591, DOI 10.1038/341591a0; Burns R.G., 1970, MINERALOGIC APPL CRY; CLOUTIS EA, 1991, J GEOPHYS RES-PLANET, V96, P22809, DOI 10.1029/91JE02512; Hamilton VE, 2003, METEORIT PLANET SCI, V38, P871, DOI 10.1111/j.1945-5100.2003.tb00284.x; Hamilton VE, 2001, J GEOPHYS RES-PLANET, V106, P14733, DOI 10.1029/2000JE001353; HESS PC, 2002, WORKSH UNM SNCS LUN; Hoefen TM, 2003, SCIENCE, V302, P627, DOI 10.1126/science.1089647; KING TVV, 1987, J GEOPHYS RES-SOLID, V92, P11457, DOI 10.1029/JB092iB11p11457; Kraft MD, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018848; McSween HY, 2002, METEORIT PLANET SCI, V37, P7, DOI 10.1111/j.1945-5100.2002.tb00793.x; McSween HY, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002175; McSween HY, 2004, SCIENCE, V305, P842, DOI 10.1126/science.3050842; MINITTI ME, 2002, J GEOPHYS RES, V107, pE5, DOI DOI 10.1029/2001JE001518; MITTLEFEHLDT D, 1994, METEORITICS, V29, P900, DOI 10.1111/j.1945-5100.1994.tb01106.x; MORRIS RV, 2003, 6 INT C MARS PAS CA; MUSTARD JF, 1995, SCIENCE, V267, P1623, DOI 10.1126/science.7886449; Mustard JF, 1997, J GEOPHYS RES-PLANET, V102, P25605, DOI 10.1029/97JE02354; SUNSHINE JM, 1993, J GEOPHYS RES-PLANET, V98, P9075, DOI 10.1029/93JE00677; SUNSHINE JM, 1990, J GEOPHYS RES-SOLID, V95, P6955, DOI 10.1029/JB095iB05p06955; Wyatt MB, 2002, NATURE, V417, P263, DOI 10.1038/417263a	25	311	313	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 11	2005	307	5715					1594	1597		10.1126/science.1109098	http://dx.doi.org/10.1126/science.1109098			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	906ED	15718427				2022-12-28	WOS:000227622400039
J	Mills, GD; Oehley, MR; Arrol, B				Mills, GD; Oehley, MR; Arrol, B			Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SUSPECTED PNEUMOCOCCAL PNEUMONIA; HIGH-DOSAGE AMOXICILLIN; HIGH-DOSE AMOXICILLIN; ANTIMICROBIAL THERAPY; CO-AMOXICLAV; EFFICACY; AZITHROMYCIN; SPARFLOXACIN; SAFETY; ADULTS	Objective To systematically compare beta lactam antibiotics with antibiotics active against atypical pathogens in the management of community acquired pneumonia. Data sources Medline, Embase, Cochrane register of controlled trials, international conference proceedings, drug registration authorities, and pharmaceutical companies. Review methods Double blind randomised controlled monotherapy trials comparing beta lactam antibiotics with antibiotics active against atypical pathogens in adults with community acquired pneumonia. Primary outcome was failure to achieve clinical cure or improvement. Results 18 trials totalling 6749 participants were identified, with most patients having mild to moderate community acquired pneumonia. The summary relative risk for treatment failure in all cause community acquired pneumonia showed no advantage of antibiotics active against atypical pathogens over P lactam antibiotics (0.97,95% confidence interval 0.87 to 1.07). Subgroup analysis was undertaken in those with a specific diagnosis involving atypical pathogens. We found a significantly lower failure rate in patients with Legionella species who were treated with antibiotics active against atypical pathogens (0.40, 0.19 to 0.85). Equivalence was seen for Mycoplasma pneumoniae (0.60, 0.31 to 1.17) and Chlamydia pneumoniae (2.32, 0.67 to 8.03). Conclusions Evidence is lacking that clinical outcomes are improved by using antibiotics active against atypical pathogens in all cause non-severe community acquired pneumonia. Although such antibiotics were superior in the management of patients later shown to have legionella related pneumonia, this pathogen was rarely responsible for pneumonia within the included trials. beta lactam agents should remain the antibiotics of initial choice in adults with non-severe community acquired pneumonia.	Waikato Hosp, Resp & Infect Dis Dept, Hamilton 2001, New Zealand; Univ Auckland, Sch Med, Auckland 1, New Zealand; Univ Auckland, Dept Gen Practice & Primary Hlth Care, Auckland 1, New Zealand	Waikato Hospital; University of Auckland; University of Auckland	Mills, GD (corresponding author), Waikato Hosp, Resp & Infect Dis Dept, Private Bag 3200, Hamilton 2001, New Zealand.	millsg@waikatodhb.govt.nz						Aubier M, 1998, CLIN INFECT DIS, V26, P1312, DOI 10.1086/516366; Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954; Carbon C., 1999, Clinical Microbiology and Infection, V5, P724, DOI 10.1111/j.1469-0691.1999.tb00705.x; CARBON C, 1992, ANTIMICROB AGENTS CH, V36, P833, DOI 10.1128/AAC.36.4.833; CARBON C, 1999, CLIN MICROBIOL INFEC, V5, P7724; Donowitz GR, 1997, CLIN THER, V19, P936, DOI 10.1016/S0149-2918(97)80047-1; Evans GM, 1938, LANCET, V2, P14; FARR BM, 1989, THORAX, V44, P1031, DOI 10.1136/thx.44.12.1031; FERRARO MJ, 1997, HOSP MED S2, V33, P4; FERRARO MJ, 1997, HOSP MED S2, V33, P14; Ferwerda A, 2001, J ANTIMICROB CHEMOTH, V47, P441, DOI 10.1093/jac/47.4.441; File TM, 1999, CLIN INFECT DIS, V29, P426, DOI 10.1086/520227; File TM, 2004, CHEST, V125, P1888, DOI 10.1378/chest.125.5.1888; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; FOGARTY CM, 1999, J RESP DIS, V20, P60; Friend JAR, 2001, THORAX, V56, P1, DOI 10.1136/thorax.56.1.1; Gleason PP, 1999, ARCH INTERN MED, V159, P2562, DOI 10.1001/archinte.159.21.2562; Hagberg L, 2002, INFECTION, V30, P378, DOI 10.1007/s15010-002-2096-z; Harris JAS, 1998, PEDIATR INFECT DIS J, V17, P865, DOI 10.1097/00006454-199810000-00004; Hedlund J, 2002, SCAND J INFECT DIS, V34, P887, DOI 10.1080/0036554021000026965; Houck PM, 2001, CHEST, V119, P1420, DOI 10.1378/chest.119.5.1420; Huchon G, 1998, EUR RESPIR J, V11, P986, DOI 10.1183/09031936.98.11040986; Johnson RH, 1996, INFECT DIS CLIN PRAC, V5, P265; Kauppinen MT, 1996, THORAX, V51, P185, DOI 10.1136/thx.51.2.185; KINASEWITZ G, 1991, EUR J CLIN MICROBIOL, V10, P872, DOI 10.1007/BF01975846; Leophonte P, 2004, RESP MED, V98, P708, DOI 10.1016/j.rmed.2004.04.007; Lieberman D, 1996, THORAX, V51, P179, DOI 10.1136/thx.51.2.179; Lim WS, 2003, THORAX, V58, P377, DOI 10.1136/thorax.58.5.377; Lode H, 2004, CLIN MICROBIOL INFEC, V10, P512, DOI 10.1111/j.1469-0691.2004.00875.x; Lode H, 1995, EUR RESPIR J, V8, P1999, DOI 10.1183/09031936.95.08121999; MACFARLANE JT, 1983, J INFECTION, V7, P111, DOI 10.1016/S0163-4453(83)90464-4; Mandell LA, 2000, CLIN INFECT DIS, V31, P422, DOI 10.1086/313965; Mundy LM, 1998, CHEST, V113, P1201, DOI 10.1378/chest.113.5.1201; Niederman MS, 2001, AM J RESP CRIT CARE, V163, P1730, DOI 10.1164/ajrccm.163.7.at1010; O'Doherty B, 1997, J ANTIMICROB CHEMOTH, V40, P73, DOI 10.1093/jac/40.suppl_1.73; Oosterheert JJ, 2003, J ANTIMICROB CHEMOTH, V52, P555, DOI 10.1093/jac/dkg413; Petitpretz P, 2001, CHEST, V119, P185, DOI 10.1378/chest.119.1.185; Tillett William S., 1944, BULL NEW YORK ACAD MED, V20, P142; Tremolieres F, 1998, EUR J CLIN MICROBIOL, V17, P447, DOI 10.1007/BF01691581; WATSON DA, 1993, CLIN INFECT DIS, V17, P913, DOI 10.1093/clinids/17.5.913; Yu VL, 2004, CHEST, V125, P2135, DOI 10.1378/chest.125.6.2135	41	123	136	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 26	2005	330	7489					456	460		10.1136/bmj.38334.591586.82	http://dx.doi.org/10.1136/bmj.38334.591586.82			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	901XK	15684024	Bronze, Green Published			2022-12-28	WOS:000227315400021
J	Kennedy, HJ; Crawford, AC; Fettiplace, R				Kennedy, HJ; Crawford, AC; Fettiplace, R			Force generation by mammalian hair bundles supports a role in cochlear amplification	NATURE			English	Article							GUINEA-PIG COCHLEA; MECHANOELECTRICAL TRANSDUCTION; MECHANICAL AMPLIFICATION; CELL MOTILITY; ADAPTATION; AMPLIFIER; STEREOCILIA; STIFFNESS; RESPONSES; CHANNELS	It is generally accepted that the acute sensitivity and frequency discrimination of mammalian hearing requires active mechanical amplification of the sound stimulus within the cochlea(1). The prevailing hypothesis is that this amplification stems from somatic electromotility of the outer hair cells attributable to the motor protein prestin(2,3). Thus outer hair cells contract and elongate in synchrony with the sound-evoked receptor potential(4,5). But problems arise with this mechanism at high frequencies, where the periodic component of the receptor potential will be attenuated by the membrane time constant. On the basis of work in non-mammalian vertebrates, force generation by the hair bundles has been proposed as an alternative means of boosting the mechanical stimulus(6,7). Here we show that hair bundles of mammalian outer hair cells can also produce force on a submillisecond timescale linked to adaptation of the mechano-transducer channels. Because the bundle motor may ultimately be limited by the deactivation rate of the channels, it could theoretically operate at high frequencies. Our results show the existence of another force generator in outer hair cells that may participate in cochlear amplification.	Univ Wisconsin, Sch Med, Dept Physiol, Madison, WI 53706 USA; Univ Bristol, Dept Physiol, Bristol BS8 1TD, Avon, England; Univ Cambridge, Dept Physiol, Cambridge CB2 3EG, England	University of Wisconsin System; University of Wisconsin Madison; University of Bristol; University of Cambridge	Fettiplace, R (corresponding author), Univ Wisconsin, Sch Med, Dept Physiol, Madison, WI 53706 USA.	fettiplace@physiology.wisc.edu						ASHMORE JF, 1987, J PHYSIOL-LONDON, V388, P323, DOI 10.1113/jphysiol.1987.sp016617; ASSAD JA, 1992, J NEUROSCI, V12, P3291; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; CRAWFORD AC, 1985, J PHYSIOL-LONDON, V364, P359, DOI 10.1113/jphysiol.1985.sp015750; DALLOS P, 1992, J NEUROSCI, V12, P4575; DALLOS P, 1995, SCIENCE, V268, P1420, DOI 10.1126/science.7770765; Eatock RA, 2000, ANNU REV NEUROSCI, V23, P285, DOI 10.1146/annurev.neuro.23.1.285; Fettiplace R, 2001, TRENDS NEUROSCI, V24, P169, DOI 10.1016/S0166-2236(00)01740-9; Geleoc GSG, 1997, P ROY SOC B-BIOL SCI, V264, P611, DOI 10.1098/rspb.1997.0087; He DZZ, 2004, NATURE, V429, P766, DOI 10.1038/nature02591; HOWARD J, 1988, NEURON, V1, P189, DOI 10.1016/0896-6273(88)90139-0; Hudspeth AJ, 1997, CURR OPIN NEUROBIOL, V7, P480, DOI 10.1016/S0959-4388(97)80026-8; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; Kennedy HJ, 2003, NAT NEUROSCI, V6, P832, DOI 10.1038/nn1089; KROS CJ, 1992, P ROY SOC B-BIOL SCI, V249, P185, DOI 10.1098/rspb.1992.0102; Kros CJ, 2002, NAT NEUROSCI, V5, P41, DOI 10.1038/nn784; Langer MG, 2001, BIOPHYS J, V80, P2608, DOI 10.1016/S0006-3495(01)76231-5; Liberman MC, 2002, NATURE, V419, P300, DOI 10.1038/nature01059; Martin P, 2000, P NATL ACAD SCI USA, V97, P12026, DOI 10.1073/pnas.210389497; MULLER M, 1991, HEARING RES, V51, P247, DOI 10.1016/0378-5955(91)90041-7; Preyer S, 1996, AUDIT NEUROSCI, V2, P145; Ricci AJ, 2000, J NEUROSCI, V20, P7131; Ricci AJ, 1998, J NEUROSCI, V18, P8261; Ricci AJ, 2002, J NEUROSCI, V22, P44, DOI 10.1523/JNEUROSCI.22-01-00044.2002; RUSSELL IJ, 1992, P ROY SOC B-BIOL SCI, V250, P217, DOI 10.1098/rspb.1992.0152; Rzadzinska AK, 2004, J CELL BIOL, V164, P887, DOI 10.1083/jcb.200310055; SANTOS-SACCHI J, 1992, J NEUROSCI, V12, P1906; STRELIOFF D, 1984, HEARING RES, V15, P19, DOI 10.1016/0378-5955(84)90221-1; van Netten SM, 2000, P ROY SOC B-BIOL SCI, V267, P1915, DOI 10.1098/rspb.2000.1230; Zheng J, 2000, NATURE, V405, P149, DOI 10.1038/35012009	30	229	240	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 24	2005	433	7028					880	883		10.1038/nature03367	http://dx.doi.org/10.1038/nature03367			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	899VT	15696193				2022-12-28	WOS:000227174600046
J	Hales, S; van Panhuis, W				Hales, S; van Panhuis, W			A new strategy for dengue control	LANCET			English	Editorial Material							CLIMATE; FEVER		Wellington Sch Med & Hlth Sci, Wellington 8000, New Zealand; Catholic Univ Louvain, WHO Collaborating Ctr Res Epidemiol Disasters, Brussels, Belgium	University of Otago; Universite Catholique Louvain	Hales, S (corresponding author), Wellington Sch Med & Hlth Sci, Wellington 8000, New Zealand.	simon.hales@otago.ac.nz	hales, simon/E-5768-2010; Van Panhuis, Willem/S-5495-2019	Van Panhuis, Willem/0000-0002-7278-9982; Hales, Simon/0000-0002-4529-7595				Hales S, 2002, LANCET, V360, P830, DOI 10.1016/S0140-6736(02)09964-6; Hopp MJ, 2001, CLIMATIC CHANGE, V48, P441, DOI 10.1023/A:1010717502442; Kay BH, 2002, AM J TROP MED HYG, V66, P40, DOI 10.4269/ajtmh.2002.66.40; LLOYD LS, 2003, BEST PRACTICES DENGU; Renganathan E., 2003, Dengue Bulletin, V27, P6; Saker L., 2004, GLOBALIZATION INFECT; *UN, 2002, WORLD URB PROSP 2001; *WHO, 2003, INS VECT HUM HLTH RE	8	11	12	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	2005	365	9459					551	552						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DN	15708083				2022-12-28	WOS:000226984300006
J	Kempner, J; Perlis, CS; Merz, JF				Kempner, J; Perlis, CS; Merz, JF			Forbidden knowledge	SCIENCE			English	Editorial Material							BIOMEDICAL POLITICS; SCIENCE		Univ Penn, Sch Med, Dept Med Eth, Philadelphia, PA 19104 USA; Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA; Brown Univ, Sch Med, Dept Dermatol, Providence, RI 02903 USA	University of Pennsylvania; University of Michigan System; University of Michigan; Brown University	Merz, JF (corresponding author), Univ Penn, Sch Med, Dept Med Eth, Philadelphia, PA 19104 USA.	merz@med.upenn.edu		Merz, Jon/0000-0002-0612-7104; Kempner, Joanna/0000-0002-9784-6381; Kempner, Joanna/0000-0002-0198-8781				ALLEN B, 1996, MONIST, V79, P294, DOI 10.5840/monist199679221; Charo RA, 2004, J LAW MED ETHICS, V32, P307, DOI 10.1111/j.1748-720X.2004.tb00477.x; COHEN C, 1977, NEW ENGL J MED, V296, P1203, DOI 10.1056/NEJM197705262962105; Couzin J, 2002, SCIENCE, V297, P749, DOI 10.1126/science.297.5582.749; Daley GQ, 2003, NEW ENGL J MED, V349, P211, DOI 10.1056/NEJMp030088; Hernstein R., 1996, BELL CURVE INTELLIGE; Humphreys Laud, 1970, TEAROOM TRADE IMPERS; *J ED AUTH GROUP, 2003, SCIENCE, V299, P1149; Johnson DG, 1999, SCI ENG ETHICS, V5, P445, DOI 10.1007/s11948-999-0045-2; JOHNSON DG, 1996, MONIST, V79, P197, DOI 10.5840/monist19967927; Kaiser J, 2003, SCIENCE, V302, P966; Kaiser J, 2003, SCIENCE, V302, P758, DOI 10.1126/science.302.5646.758; Kaiser J, 2003, SCIENCE, V300, P403, DOI 10.1126/science.300.5618.403; Kinsey A, 1948, SEXUAL BEHAV HUMAN M, DOI 10.1037/t17515-000; Kinsey A.C., 1998, SEXUAL BEHAV HUMAN F; MILGRAM S., 1974, OBEDIENCE AUTHORITY; NELKIN D, 1982, ETHICAL ISSUES SOCIA, P163; Rind B, 1998, PSYCHOL BULL, V124, P22, DOI 10.1037/0033-2909.124.1.22; SHATTUCK R, 1996, FORBIDDEN KNOWLEDGE; SMITH DH, 1978, HASTINGS CENT REP, V8, P30, DOI 10.2307/3561469; [No title captured]	21	34	34	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2005	307	5711					854	854		10.1126/science.1107576	http://dx.doi.org/10.1126/science.1107576			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897DV	15705829				2022-12-28	WOS:000226985100028
J	Yanoviak, SP; Dudley, R; Kaspari, M				Yanoviak, SP; Dudley, R; Kaspari, M			Directed aerial descent in canopy ants	NATURE			English	Article							BEHAVIOR; RAIN	Numerous non- flying arboreal vertebrates use controlled descent ( either parachuting or gliding sensu stricto(1,2)) to avoid predation or to locate resources(3 - 7), and directional control during a jump or fall is thought to be an important stage in the evolution of flight(3,8,9). Here we show that workers of the neotropical ant Cephalotes atratus L. ( Hymenoptera: Formicidae) use directed aerial descent to return to their home tree trunk with > 80% success during a fall. Videotaped falls reveal that C. atratus workers descend abdomen- first through steep glide trajectories at relatively high velocities; a field experiment shows that falling ants use visual cues to locate tree trunks before they hit the forest floor. Smaller workers of C. atratus, and smaller species of Cephalotes more generally, regain contact with their associated tree trunk over shorter vertical distances than do larger workers. Surveys of common arboreal ants suggest that directed descent occurs in most species of the tribe Cephalotini and arboreal Pseudomyrmecinae, but not in arboreal ponerimorphs or Dolichoderinae. This is the first study to document the mechanics and ecological relevance of this form of locomotion in the Earth's most diverse lineage, the insects.	Smithsonian Trop Res Inst, Balboa, Panama; Univ Texas, Med Branch, Galveston, TX 77555 USA; Univ Florida, Florida Med Entomol Lab, Vero Beach, FL 32962 USA; Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; Univ Oklahoma, Dept Zool, Norman, OK 73019 USA	Smithsonian Institution; Smithsonian Tropical Research Institute; University of Texas System; University of Texas Medical Branch Galveston; State University System of Florida; University of Florida; University of California System; University of California Berkeley; University of Oklahoma System; University of Oklahoma - Norman	Kaspari, M (corresponding author), Smithsonian Trop Res Inst, POB 2072, Balboa, Panama.	mkaspari@ou.edu		Kaspari, Michael/0000-0002-9717-5768; Yanoviak, Stephen/0000-0001-6425-1413				COYLE FA, 1966, INSECT SOC, V13, P93, DOI 10.1007/BF02223565; de Andrade Maria L., 1999, Stuttgarter Beitraege zur Naturkunde Serie B (Geologie und Palaeontologie), V271, P1; DUDLEY R, 2000, BIOMECHANICS INSECT, P275; ELLINGTON CP, 1991, ADV INSECT PHYSIOL, V23, P171, DOI 10.1016/S0065-2806(08)60094-6; Federle W, 2002, INTEGR COMP BIOL, V42, P1100, DOI 10.1093/icb/42.6.1100; Haemig PD, 1997, ANIM BEHAV, V54, P89, DOI 10.1006/anbe.1996.0428; HOLLDOBLER B, 1980, SCIENCE, V210, P86, DOI 10.1126/science.210.4465.86; Jackson SM, 2000, MAMMAL REV, V30, P9, DOI 10.1046/j.1365-2907.2000.00056.x; Kempf W. W., 1951, Revista de Entomologia Rio de Janeiro, V22, P1; KINGSOLVER JG, 1994, ANNU REV ENTOMOL, V39, P425, DOI 10.1146/annurev.en.39.010194.002233; Longino JT, 1997, ECOL APPL, V7, P1263, DOI 10.1890/1051-0761(1997)007[1263:BAUSIC]2.0.CO;2; McCay MG, 2001, J EXP BIOL, V204, P2817; Moffett MW, 2000, BIOTROPICA, V32, P569, DOI 10.1646/0006-3606(2000)032[0569:WSUACL]2.0.CO;2; MORI A, 1994, COPEIA, P124; OLIVER JA, 1951, AM NAT, V85, P171, DOI 10.1086/281666; Orivel J, 2001, ANN ENTOMOL SOC AM, V94, P449, DOI 10.1603/0013-8746(2001)094[0449:RBPMAA]2.0.CO;2; Saint-Paul U, 2000, ENVIRON BIOL FISH, V57, P235, DOI 10.1023/A:1007699130333; SMITH JM, 1952, EVOLUTION, V6, P127, DOI 10.2307/2405510; Socha JJ, 2002, NATURE, V418, P603, DOI 10.1038/418603a; Stork N.E., 1997, CANOPY ARTHROPODS; Walker JA, 1998, J EXP BIOL, V201, P981; WEBER NEAL A., 1957, PSYCHE, V64, P60, DOI 10.1155/1957/71981; WILSON EDWARD O., 1962, BULL MUS COMP ZOOL HARVARD UNIV, V127, P401; Wohlgemuth S, 2001, NATURE, V411, P795, DOI 10.1038/35081069; Yanoviak SP, 2000, OIKOS, V89, P259, DOI 10.1034/j.1600-0706.2000.890206.x	25	105	105	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 10	2005	433	7026					624	626		10.1038/nature03254	http://dx.doi.org/10.1038/nature03254			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	895KX	15703745				2022-12-28	WOS:000226862000042
J	Grimes, PE				Grimes, PE			New insights and new therapies in vitiligo	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							308-NM EXCIMER-LASER; UV-B RADIATION; TOPICAL TACROLIMUS; PSORALEN PHOTOCHEMOTHERAPY; 0.1-PERCENT TACROLIMUS; GENERALIZED VITILIGO; T-LYMPHOCYTES; REPIGMENTATION; TRANSPLANTATION; CALCIPOTRIOL		Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Dermatol,Vitiligo & Pigmentat Inst So Calif, Los Angeles, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Grimes, PE (corresponding author), 5670 Wilshire Blvd,Suite 650, Los Angeles, CA 90036 USA.	pegrimesmd@earthlink.net						Alkhateeb A, 2003, PIGM CELL RES, V16, P208, DOI 10.1034/j.1600-0749.2003.00032.x; Baysal V, 2003, J EUR ACAD DERMATOL, V17, P299, DOI 10.1046/j.1468-3083.2003.00795.x; BETTERLE C, 1985, DERMATOLOGICA, V171, P419, DOI 10.1159/000249466; Boissy RE, 1997, PIGM CELL RES, V10, P12, DOI 10.1111/j.1600-0749.1997.tb00461.x; Bystryn JC, 2000, VITILIGO, P129, DOI 10.1002/9780470760116.ch16; Chen YF, 2004, J AM ACAD DERMATOL, V51, P68, DOI 10.1016/j.jaad.2003.12.013; Chiaverini C, 2002, J EUR ACAD DERMATOL, V16, P137, DOI 10.1046/j.1468-3083.2002.00407.x; Dusso AS, 2004, SEMIN NEPHROL, V24, P10, DOI 10.1053/j.semnephrol.2003.08.018; Ermis O, 2001, BRIT J DERMATOL, V145, P472, DOI 10.1046/j.1365-2133.2001.04286.x; Fain PR, 2003, AM J HUM GENET, V72, P1560, DOI 10.1086/375451; Gauthier Y, 2003, PIGM CELL RES, V16, P322, DOI 10.1034/j.1600-0749.2003.00070.x; GHONEUM M, 1987, J AM ACAD DERMATOL, V17, P600, DOI 10.1016/S0190-9622(87)70243-6; GILHAR A, 1989, ARCH DERMATOL, V125, P1363, DOI 10.1001/archderm.125.10.1363; Grimes, 2003, COSM DERMATOL, V16, P18; Grimes PE, 1996, J AM ACAD DERMATOL, V35, P21, DOI 10.1016/S0190-9622(96)90490-9; Grimes PE, 2004, J AM ACAD DERMATOL, V51, P52, DOI 10.1016/j.jaad.2003.12.031; Grimes PE, 2002, J AM ACAD DERMATOL, V47, P789, DOI 10.1067/mjd.2002.126250; Grimes PE, 1997, CLIN DERMATOL, V15, P921, DOI 10.1016/S0738-081X(97)00133-8; GRIMES PE, 2003, ACP MED, P526; Gupta S, 2003, J AM ACAD DERMATOL, V49, P99, DOI 10.1067/mjd.2003.415; Hamzavi I, 2004, ARCH DERMATOL, V140, P677, DOI 10.1001/archderm.140.6.677; Hondo Yoshihide, 1997, Journal of Dermatology (Tokyo), V24, P561; HOOVER R, 1973, LANCET, V2, P55; Imokawa G, 2004, PIGM CELL RES, V17, P96, DOI 10.1111/j.1600-0749.2003.00126.x; Kang S, 2001, J AM ACAD DERMATOL, V44, pS58, DOI 10.1067/mjd.2001.109812; Kawalek AZ, 2004, DERMATOL SURG, V30, P130, DOI 10.1111/j.1524-4725.2004.30058.x; Kovacs SO, 1998, J AM ACAD DERMATOL, V38, P647, DOI 10.1016/S0190-9622(98)70194-X; Kwok YKC, 2002, CLIN EXP DERMATOL, V27, P104, DOI 10.1046/j.1365-2230.2002.00984.x; Le Poole IC, 2004, J INVEST DERM SYMP P, V9, P68, DOI 10.1111/j.1087-0024.2004.00825.x; Leone G, 2003, J EUR ACAD DERMATOL, V17, P531, DOI 10.1046/j.1468-3083.2003.00818.x; Lepe V, 2003, ARCH DERMATOL, V139, P581, DOI 10.1001/archderm.139.5.581; Lotti TM, 1999, J EUR ACAD DERMATOL, V13, P102, DOI 10.1016/S0926-9959(99)00087-2; MAJUMDER PP, 1988, AM J HUM GENET, V43, P119; Mandelcorn-Monson RL, 2003, J INVEST DERMATOL, V121, P550, DOI 10.1046/j.1523-1747.2003.12413.x; Mayoral FA, 2003, DERMATOLOGY, V207, P322, DOI 10.1159/000073099; Moretti S, 2002, PIGM CELL RES, V15, P87, DOI 10.1034/j.1600-0749.2002.1o049.x; NATH SK, 1994, AM J HUM GENET, V55, P981; Natta R, 2003, J AM ACAD DERMATOL, V49, P473, DOI 10.1067/S0190-9622(03)01484-1; NAUGHTON GK, 1983, J INVEST DERMATOL, V81, P540, DOI 10.1111/1523-1747.ep12522891; Njoo M D, 2001, Am J Clin Dermatol, V2, P167; Njoo MD, 1998, ARCH DERMATOL, V134, P1532, DOI 10.1001/archderm.134.12.1532; Njoo MD, 1998, ARCH DERMATOL, V134, P1543, DOI 10.1001/archderm.134.12.1543; Njoo MD, 2000, J AM ACAD DERMATOL, V42, P245, DOI 10.1016/S0190-9622(00)90133-6; NORRIS DA, 1988, J INVEST DERMATOL, V90, P783, DOI 10.1111/1523-1747.ep12461505; Ogg GS, 1998, J EXP MED, V188, P1203, DOI 10.1084/jem.188.6.1203; Ongenae K, 2003, PIGM CELL RES, V16, P90, DOI 10.1034/j.1600-0749.2003.00023.x; PALMERO B, 2001, J INVEST DERMATOL, V117, P326; PARRISH JA, 1981, J INVEST DERMATOL, V76, P359, DOI 10.1111/1523-1747.ep12520022; Parsad D, 1998, DERMATOLOGY, V197, P167, DOI 10.1159/000017991; Parsad D, 1999, PEDIATR DERMATOL, V16, P317, DOI 10.1046/j.1525-1470.1999.00083.x; Passeron T, 2004, ARCH DERMATOL, V140, P1065, DOI 10.1001/archderm.140.9.1065; Porter J, 2000, VITILIGO, P97, DOI 10.1002/9780470760116.ch13; Robins A.H., 1991, BIOL PERSPECTIVES HU; Schallreuter KU, 2003, EXP DERMATOL, V12, P268, DOI 10.1034/j.1600-0625.2003.00084.x; Spencer JM, 2002, J AM ACAD DERMATOL, V46, P727, DOI 10.1067/mjd.2002.121357; Taneja A, 2003, INT J DERMATOL, V42, P658, DOI 10.1046/j.1365-4362.2003.01997.x; Tanghetti EA, 2003, CUTIS, V71, P158; Tharp M, 2002, DERMATOL THER, V15, P325; Tjioe M, 2002, ACTA DERM-VENEREOL, V82, P369, DOI 10.1080/000155502320624113; Travis LB, 2004, PEDIATR DERMATOL, V21, P495, DOI 10.1111/j.0736-8046.2004.21418.x; Travis LB, 2003, ARCH DERMATOL, V139, P571, DOI 10.1001/archderm.139.5.571; Tremblay F, 2002, ANN SURG ONCOL, V9, P785, DOI 10.1245/ASO.2001.06.030; Tu CX, 1999, J DERMATOL SCI, V21, P59, DOI 10.1016/S0923-1811(99)00029-8; van Geel N, 2004, ARCH DERMATOL, V140, P1203, DOI 10.1001/archderm.140.10.1203; Westerhof W, 1997, ARCH DERMATOL, V133, P1525; Woodle ES, 1996, TRANSPLANTATION, V62, P594, DOI 10.1097/00007890-199609150-00009; Yu HS, 1997, J INVEST DERMATOL, V108, P527, DOI 10.1111/1523-1747.ep12289743	69	96	107	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2005	293	6					730	735		10.1001/jama.293.6.730	http://dx.doi.org/10.1001/jama.293.6.730			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895DX	15701915				2022-12-28	WOS:000226842200027
J	O'Brien, CL; Gage, BF				O'Brien, CL; Gage, BF			Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIRECT THROMBIN INHIBITOR; ANTICOAGULANT-THERAPY; RISK-FACTORS; BLEEDING COMPLICATIONS; ANTITHROMBOTIC THERAPY; ORAL ANTICOAGULATION; INTRACEREBRAL HEMORRHAGE; DECISION-ANALYSIS; PREVENT STROKE; WARFARIN	Context Recent trials have found that ximelagatran and warfarin are equally effective in stroke prevention for patients with atrial fibrillation. Because ximelagatran can be taken in a fixed, oral dose without international normalized ratio monitoring and may have a lower risk of hemorrhage, it might improve quality-adjusted survival compared with dose-adjusted warfarin. Objective To compare quality-adjusted survival and cost among 3 alternative therapies for patients with chronic atrial fibrillation: ximelagatran, warfarin, and aspirin. Design Semi-Markov decision model. Patients Hypothetical cohort of 70-year-old patients with chronic atrial fibrillation, varying risk of stroke, and no contraindications to anticoagulation therapy. Main Outcome Measures Quality-adjusted life-years (QALYs) and costs in US dollars. Results For patients with atrial fibrillation but no additional risk factors for stroke, both ximelagatran and warfarin cost more than $50000 per QALY compared with aspirin. For patients with additional stroke risk factors and low hemorrhage risk, ximelagatran modestly increased quality-adjusted survival (0.12 QALY) at a substantial cost ($116000 per QALY) compared with warfarin. For ximelagatran to cost less than $50000 per QALY it would have to cost less than $1100 per year or be prescribed to patients who have an elevated risk of intracranial hemorrhage (>1.0% per year of warfarin) or a low quality of life with warfarin therapy. Conclusion Assuming equal effectiveness in stroke prevention and decreased hemorrhage risk, ximelagatran is not likely to be cost-effective in patients with atrial fibrillation unless they have a high risk of intracranial hemorrhage or a low quality of life with warfarin.	Washington Univ, Sch Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Gage, BF (corresponding author), Washington Univ, Sch Med, Campus Box 8005,660 S Euclid Ave, St Louis, MO 63110 USA.	bgage@im.wustl.edu		Gage, Brian/0000-0002-4727-8742	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010133] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS10133] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Agency for Healthcare Research and Quality, HCUPNET HEALTHC COST; Albers GW, 2005, JAMA-J AM MED ASSOC, V293, P690; Albers GW, 2003, LANCET, V362, P1691; Ariesen MJ, 2003, STROKE, V34, P2060, DOI 10.1161/01.STR.0000080678.09344.8D; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Beyth Rebecca J, 2002, Curr Hematol Rep, V1, P41; Blackshear JL, 1996, LANCET, V348, P633; Buckingham TA, 2002, CLIN CARDIOL, V25, P447, DOI 10.1002/clc.4960251003; Bungard TJ, 2000, ARCH INTERN MED, V160, P41, DOI 10.1001/archinte.160.1.41; Casais P, 2000, AM J HEMATOL, V63, P192, DOI 10.1002/(SICI)1096-8652(200004)63:4<192::AID-AJH5>3.0.CO;2-K; Chesebro JH, 1996, ARCH INTERN MED, V156, P409; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; Copland M, 2001, ARCH INTERN MED, V161, P2125, DOI 10.1001/archinte.161.17.2125; DENNIS MS, 1993, STROKE, V24, P796, DOI 10.1161/01.STR.24.6.796; Dries DL, 1998, J AM COLL CARDIOL, V32, P695, DOI 10.1016/S0735-1097(98)00297-6; Eckman MH, 2003, STROKE, V34, P1710, DOI 10.1161/01.STR.0000078311.18928.16; Elg M, 1999, THROMB RES, V94, P187, DOI 10.1016/S0049-3848(98)00213-8; Eriksson UG, 2003, DRUG METAB DISPOS, V31, P294, DOI 10.1124/dmd.31.3.294; Eriksson UG, 2003, EUR J CLIN PHARMACOL, V59, P35, DOI 10.1007/s00228-003-0565-7; Evans A, 2001, ARCH INTERN MED, V161, P1443, DOI 10.1001/archinte.161.11.1443; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469; Fihn SD, 1996, ANN INTERN MED, V124, P970, DOI 10.7326/0003-4819-124-11-199606010-00004; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Gage BF, 2000, AM J MED, V109, P481, DOI 10.1016/S0002-9343(00)00545-3; Gage BF, 2000, STROKE, V31, P822, DOI 10.1161/01.STR.31.4.822; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; Gage BF, 2004, THROMB HAEMOSTASIS, V91, P87, DOI 10.1160/TH03-06-0379; Gage BF, 2004, CIRCULATION, V110, P2287, DOI 10.1161/01.CIR.0000145172.55640.93; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; GAGE BF, IN PRESS AM HEART J; GAGE BF, IN PRESS AM J MED; GITTER MJ, 1995, MAYO CLIN PROC, V70, P725, DOI 10.4065/70.8.725; Go AS, 2003, JAMA-J AM MED ASSOC, V290, P2685, DOI 10.1001/jama.290.20.2685; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Gorter JW, 1999, NEUROLOGY, V53, P1319, DOI 10.1212/WNL.53.6.1319; Gullov AL, 1998, ARCH INTERN MED, V158, P1513, DOI 10.1001/archinte.158.14.1513; Gullov AL, 1999, ARCH INTERN MED, V159, P1322, DOI 10.1001/archinte.159.12.1322; Gyrd-Hansen D, 2003, HEALTH ECON, V12, P1049, DOI 10.1002/hec.799; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Hellemons BSP, 1999, BMJ-BRIT MED J, V319, P958, DOI 10.1136/bmj.319.7215.958; Holloway RG, 1996, NEUROLOGY, V46, P854; Hylek EM, 2003, NEW ENGL J MED, V349, P1019, DOI 10.1056/NEJMoa022913; Johnston JA, 2003, MED DECIS MAKING, V23, P361, DOI 10.1177/0272989X03256881; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; LAUNBJERG J, 1991, J INTERN MED, V229, P351, DOI 10.1111/j.1365-2796.1991.tb00358.x; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lee SH, 2004, NEUROLOGY, V62, P72, DOI 10.1212/01.WNL.0000101463.50798.0D; Leibson CL, 1996, NEUROLOGY, V46, P861; Man-Son-Hing M, 1999, JAMA-J AM MED ASSOC, V282, P737, DOI 10.1001/jama.282.8.737; Matchar DB, 2000, AHRQ PUBLICATION, V00-N001; MCBRIDE R, 1994, LANCET, V343, P687; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; Minino Arialdi M, 2002, Natl Vital Stat Rep, V50, P1; *NDA, 2004, 21686 NDA; Owens DK, 1998, J GEN INTERN MED, V13, P716, DOI 10.1046/j.1525-1497.1998.00211.x; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; PETERSEN P, 1989, LANCET, V1, P175; Petersen P, 2003, J AM COLL CARDIOL, V41, P1445, DOI 10.1016/S0735-1097(03)00255-9; *PRATT MED GROUP, 1995, SMLTREE COMP PROGR V; *ROCH DIAGN, 2003, COAG SYST 2003 MED R; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; *THOMS PDR, 2003, 2003 DRUG TOP RED BO; Thomson R, 2000, LANCET, V355, P956, DOI 10.1016/S0140-6736(00)90012-6; *US BUR CENS, 1992, STAT ABSTR US; *US DEP LAB BUR LA, CONS PRIC IND TABL C; van Walraven C, 2002, JAMA-J AM MED ASSOC, V288, P2441, DOI 10.1001/jama.288.19.2441; Waterman AD, 2004, AM J HEALTH-SYST PH, V61, P1258, DOI 10.1093/ajhp/61.12.1258; Wehinger C, 2001, STROKE, V32, P2246, DOI 10.1161/hs1001.097090; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; Wyse DG, 2001, J INTERV CARD ELECTR, V5, P267, DOI 10.1023/A:1011460631369; Yuan Z, 1998, AM J PUBLIC HEALTH, V88, P395, DOI 10.2105/AJPH.88.3.395	74	124	124	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2005	293	6					699	706		10.1001/jama.293.6.699	http://dx.doi.org/10.1001/jama.293.6.699			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895DX	15701911	Bronze			2022-12-28	WOS:000226842200023
J	Aradhya, KW; Best, K; Sokal, DC				Aradhya, KW; Best, K; Sokal, DC			Recent developments in vasectomy	BMJ-BRITISH MEDICAL JOURNAL			English	Review							UNITED-STATES		Family Hlth Int, Dept Clin Res, Res Triangle Pk, NC 27709 USA; Family Hlth Int, Field Informat & Training Serv Dept, Res Triangle Pk, NC 27709 USA		Sokal, DC (corresponding author), Family Hlth Int, Dept Clin Res, POB 13950, Res Triangle Pk, NC 27709 USA.	dsokal@fhi.org						Barone MA, 2003, J UROLOGY, V170, P892, DOI 10.1097/01.ju.0000075505.08215.28; Barone Mark A, 2004, BMC Urol, V4, P10; Chen-Mok M, 2003, CONTROL CLIN TRIALS, V24, P78, DOI 10.1016/S0197-2456(02)00267-2; Christiansen CG, 2003, J ANDROL, V24, P293; *ENGENDERHEALTH, 2003, NO SCALP VAS ILL GUI; Haws JM, 1998, UROLOGY, V52, P685, DOI 10.1016/S0090-4295(98)00274-X; LABRECQUE M, 2004, INT WORKSH ORG FAM H; Labrecque M, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-21; LISKIN L, 1983, POPUL REP D, V4, P61; MARQUETTE CM, 1995, AM J PUBLIC HEALTH, V85, P644, DOI 10.2105/AJPH.85.5.644; Nazerali H, 2003, CONTRACEPTION, V67, P397, DOI 10.1016/S0010-7824(03)00028-3; POLLACK A, 2001, P EXP CONS VAS EFF C; SCHMIDT SS, 1992, UROLOGY, V40, P468, DOI 10.1016/0090-4295(92)90468-C; SCHMIDT SS, 1987, UROL CLIN N AM, V14, P149; SEAMANS Y, 2004, INT WORKSH ORG FAM H; Sokal David, 2004, BMC Urol, V4, P12; Sokal D, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-6; TRUSSELL J, 1998, CONTRACEPTIVE TECHNO, P211; Wang DL, 2002, CONTRACEPTION, V66, P173, DOI 10.1016/S0010-7824(02)00334-7	19	21	22	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 5	2005	330	7486					296	299		10.1136/bmj.330.7486.296	http://dx.doi.org/10.1136/bmj.330.7486.296			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895EM	15695277	Green Published			2022-12-28	WOS:000226843700019
J	Couzin, ID; Krause, J; Franks, NR; Levin, SA				Couzin, ID; Krause, J; Franks, NR; Levin, SA			Effective leadership and decision-making in animal groups on the move	NATURE			English	Article							MIGRATORY BEHAVIOR; FISH	For animals that forage or travel in groups, making movement decisions often depends on social interactions among group members(1,2). However, in many cases, few individuals have pertinent information, such as knowledge about the location of a food source(3,4), or of a migration route(5-9). Using a simple model we show how information can be transferred within groups both without signalling and when group members do not know which individuals, if any, have information. We reveal that the larger the group the smaller the proportion of informed individuals needed to guide the group, and that only a very small proportion of informed individuals is required to achieve great accuracy. We also demonstrate how groups can make consensus decisions, even though informed individuals do not know whether they are in a majority or minority, how the quality of their information compares with that of others, or even whether there are any other informed individuals. Our model provides new insights into the mechanisms of effective leadership and decision-making in biological systems.	Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; Univ Oxford, Dept Zool, Oxford OX1 3PS, England; Univ Leeds, Sch Biol, Ctr Biodivers & Conservat, Leeds LS2 9JT, W Yorkshire, England; Univ Bristol, Sch Biol Sci, Ctr Behav Biol, Bristol BS8 1UG, Avon, England	Princeton University; University of Oxford; University of Leeds; University of Bristol	Couzin, ID (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.	iain.couzin@zoo.ox.ac.uk	Levin, Simon A/J-1218-2014; Krause, Jens/C-2750-2011; Couzin, Iain D./Q-6862-2018; Krause, Jens/J-4381-2013; Franks, Nigel/AAG-8207-2019	Levin, Simon A/0000-0002-8216-5639; Couzin, Iain D./0000-0001-8556-4558; Krause, Jens/0000-0002-1289-2857; Franks, Nigel/0000-0001-8139-9604	Engineering and Physical Sciences Research Council [GR/T11241/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		BATSCHELET E, 1981, CIRCULAR STAT BIOL, P34; BERTHOLD P, 1992, NATURE, V360, P668, DOI 10.1038/360668a0; BERTHOLD P, 1981, SCIENCE, V212, P77, DOI 10.1126/science.212.4490.77; Conradt L, 2003, NATURE, V421, P155, DOI 10.1038/nature01294; Couzin ID, 2002, J THEOR BIOL, V218, P1, DOI 10.1006/jtbi.2002.3065; Couzin ID, 2003, ADV STUD BEHAV, V32, P1, DOI 10.1016/S0065-3454(03)01001-5; Franks NR, 2002, PHILOS T R SOC B, V357, P1567, DOI 10.1098/rstb.2002.1066; Gregoire G, 2003, PHYSICA D, V181, P157, DOI 10.1016/S0167-2789(03)00102-7; Grunbaum D, 1998, EVOL ECOL, V12, P503, DOI 10.1023/A:1006574607845; Hoare DJ, 2004, ANIM BEHAV, V67, P155, DOI 10.1016/j.anbehav.2003.04.004; KRAUSE J, 2002, LIVING GROUPS, P84; LINDAUER M, 1957, NATURE, V179, P63, DOI 10.1038/179063a0; NEILL WH, 1979, AM ZOOL, V19, P305; PARTRIDGE BL, 1982, SCI AM, V246, P114, DOI 10.1038/scientificamerican0682-114; Reebs SG, 2000, ANIM BEHAV, V59, P403, DOI 10.1006/anbe.1999.1314; RUBENSTEIN DI, 1992, EVOL ECOL, V6, P254, DOI 10.1007/BF02214165; Seeley T. D., 1995, WISDOM HIVE, p[34, 85]; Seeley TD, 2003, BEHAV ECOL SOCIOBIOL, V53, P417, DOI 10.1007/s00265-003-0598-z; SEELEY TD, 1985, HONEYBEE ECOLOGY STU, P71; Simons AM, 2004, TRENDS ECOL EVOL, V19, P453, DOI 10.1016/j.tree.2004.07.001; Swaney W, 2001, ANIM BEHAV, V62, P591, DOI 10.1006/anbe.2001.1788; VONFRISCH K, 1967, DANCE LANGUAGE ORIEN, P28	22	1689	1753	18	574	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 3	2005	433	7025					513	516		10.1038/nature03236	http://dx.doi.org/10.1038/nature03236			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893NT	15690039	Green Submitted			2022-12-28	WOS:000226727200046
J	Vidailhet, M; Vercueil, L; Houeto, JL; Krystkowiak, P; Benabid, AL; Cornu, P; Lagrange, C; du Montcel, ST; Dormont, D; Grand, S; Blond, S; Detante, O; Pillon, B; Ardouin, C; Agid, Y; Destee, A; Pollak, P				Vidailhet, M; Vercueil, L; Houeto, JL; Krystkowiak, P; Benabid, AL; Cornu, P; Lagrange, C; du Montcel, ST; Dormont, D; Grand, S; Blond, S; Detante, O; Pillon, B; Ardouin, C; Agid, Y; Destee, A; Pollak, P		SPIDY Study Grp	Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERNUS; PALLIDOTOMY; INHIBITION; MECHANISMS; SELECTION; SURGERY	BACKGROUND: Severe forms of dystonia respond poorly to medical treatment. Deep-brain stimulation is a reversible neurosurgical procedure that has been used for the treatment of dystonia, but assessment of its efficacy has been limited to open studies. METHODS: We performed a prospective, controlled, multicenter study assessing the efficacy and safety of bilateral pallidal stimulation in 22 patients with primary generalized dystonia. The severity of dystonia was evaluated before surgery and 3, 6, and 12 months postoperatively during neurostimulation, with the use of the movement and disability subscores of the Burke-Fahn-Marsden Dystonia Scale (range, 0 to 120 and 0 to 30, respectively, with higher scores indicating greater impairment). Movement scores were assessed by a review of videotaped sessions performed by an observer who was unaware of treatment status. At three months, patients underwent a double-blind evaluation in the presence and absence of neurostimulation. We also assessed the patients' quality of life, cognition, and mood at baseline and 12 months. RESULTS: The dystonia movement score improved from a mean (+/-SD) of 46.3+/-21.3 before surgery to 21.0+/-14.1 at 12 months (P<0.001). The disability score improved from 11.6+/-5.5 before surgery to 6.5+/-4.9 at 12 months (P<0.001). General health and physical functioning were significantly improved at month 12; there were no significant changes in measures of mood and cognition. At the three-month evaluation, dystonia movement scores were significantly better with neurostimulation than without neurostimulation (24.6+/-17.7 vs. 34.6+/-12.3, P<0.001). There were five adverse events (in three patients); all resolved without permanent sequelae. CONCLUSIONS: These findings support the efficacy and safety of the use of bilateral stimulation of the internal globus pallidus in selected patients with primary generalized dystonia.	Hop St Antoine, Dept Neurol, F-75571 Paris 12, France; Hop La Pitie Salpetriere, INSERM, U289, Paris, France; Hop La Pitie Salpetriere, Dept Neurosurg, Paris, France; Hop La Pitie Salpetriere, Dept Neuroradiol, Paris, France; Hop La Pitie Salpetriere, Lab Neurosci Cognit & Imagerie Cerebrale, CNRS, UPR 640, Paris, France; Hop La Pitie Salpetriere, INSERM E007, Paris, France; Hop La Pitie Salpetriere, Dept Neurol, Ctr Invest Clin, Paris, France; Grenoble Univ Hosp, Dept Biol & Clin Neurosci, Grenoble, France; Grenoble Univ Hosp, Dept Neuroradiol, Magnet Resonance Imaging Unit, Grenoble, France; Univ Grenoble 1, INSERM, U318, Grenoble, France; Univ Hosp, Dept Neurol, Poitiers, France; Lille Univ Hosp, Neurol & Movement Disorders Unit, Lille, France; Lille Univ Hosp, Dept Neurosurg, Lille, France; Univ Lille, Equipe Associee 2683, Lille, France; Univ Hosp Pitie Salpetriere, Dept Biostat, Villejuif, France; Hop Paul Brousse, INSERM, U535, Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CHU Poitiers; Universite de Poitiers; Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; Universite de Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Vidailhet, M (corresponding author), Hop St Antoine, Dept Neurol, 184 Faubourg St Antoine, F-75571 Paris 12, France.	marie.vidailhet@sat.ap-hop-paris.fr	VERCUEIL, Laurent/AAN-2941-2021; Detante, Olivier/M-1737-2014; Benabid, Alim L/Q-3506-2017; Grand, Sylvie/L-7958-2014; LICEND, CEMND/F-1296-2015; dormont, didier/B-2175-2012; Tezenas du Montcel, Sophie/A-6207-2012; Dormont, Didier/F-5492-2012	VERCUEIL, Laurent/0000-0003-3323-0091; Tezenas du Montcel, Sophie/0000-0002-2866-4330; 				ANDREW J, 1983, BRAIN, V106, P981, DOI 10.1093/brain/106.4.981; Beck A. T., 1997, BECK DEPRESSION INVE; Benabid AL, 1998, MOVEMENT DISORD, V13, P119; Bereznai B, 2002, MOVEMENT DISORD, V17, P138, DOI 10.1002/mds.1250; Bressman SB, 2000, NEUROLOGY, V54, P1746, DOI 10.1212/WNL.54.9.1746; BURKE RE, 1985, NEUROLOGY, V35, P73, DOI 10.1212/WNL.35.1.73; Cif L, 2003, J Neurosurg Sci, V47, P52; Coubes P, 2000, LANCET, V355, P2220, DOI 10.1016/S0140-6736(00)02410-7; Dostrovsky JO, 2002, MOVEMENT DISORD, V17, pS63, DOI 10.1002/mds.10143; Eltahawy HA, 2004, NEUROSURGERY, V54, P613, DOI 10.1227/01.NEU.0000108643.94730.21; Fahn S, 1998, Adv Neurol, V78, P1; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Ford Blair, 2004, Adv Neurol, V94, P287; Hariz MI, 2002, MOVEMENT DISORD, V17, pS162, DOI 10.1002/mds.10159; Jankovic J, 1998, J NEUROL NEUROSUR PS, V65, P434, DOI 10.1136/jnnp.65.4.434; Katayama Y, 2003, ACTA NEUROCHIR SUPPL, V87, P125; Krauss JK, 2002, STEREOT FUNCT NEUROS, V78, P168, DOI 10.1159/000068963; Krauss JK, 2003, J NEUROSURG, V98, P785, DOI 10.3171/jns.2003.98.4.0785; Kumar R, 1999, NEUROLOGY, V53, P871, DOI 10.1212/WNL.53.4.871; Kumar R, 2002, MOVEMENT DISORD, V17, pS198, DOI 10.1002/mds.10164; Kupsch A, 2004, J NEUROL, V251, P1031, DOI 10.1007/s00415-004-0603-0; Lang A E, 1998, Adv Neurol, V78, P185; Lozano AM, 1997, MOVEMENT DISORD, V12, P865, DOI 10.1002/mds.870120606; Lozano Andres M, 2004, Adv Neurol, V94, P301; MCCULLOCH CE, 2001, GEN LINEAR MIXED MOD, P187; Tronnier VM, 2000, J NEUROSURG, V92, P453, DOI 10.3171/jns.2000.92.3.0453; Vercueil L, 2002, MOVEMENT DISORD, V17, pS89, DOI 10.1002/mds.10148; Vercueil L, 2001, J NEUROL, V248, P695, DOI 10.1007/s004150170116; Vesper J, 2002, ACT NEUR S, V79, P83; Vitek J L, 1998, Adv Neurol, V78, P211; Vitek JL, 2002, MOVEMENT DISORD, V17, pS69, DOI 10.1002/mds.10144; Volkmann J, 2002, MOVEMENT DISORD, V17, pS112, DOI 10.1002/mds.10151; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Yianni J, 2003, MOVEMENT DISORD, V18, P436, DOI 10.1002/mds.10380	34	741	794	1	44	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 3	2005	352	5					459	467		10.1056/NEJMoa042187	http://dx.doi.org/10.1056/NEJMoa042187			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	893NE	15689584	Bronze			2022-12-28	WOS:000226725400006
J	Di Fonzo, A; Rohe, CF; Ferreira, RJ; Chien, HF; Vacca, L; Stocchi, F; Guedes, L; Fabrizio, E; Manfredi, M; Vanacore, N; Goldwurm, S; Breedveld, G; Sampaio, C; Meco, G; Barbosa, E; Oostra, BA; Bonifati, V				Di Fonzo, A; Rohe, CF; Ferreira, RJ; Chien, HF; Vacca, L; Stocchi, F; Guedes, L; Fabrizio, E; Manfredi, M; Vanacore, N; Goldwurm, S; Breedveld, G; Sampaio, C; Meco, G; Barbosa, E; Oostra, BA; Bonifati, V		Italian Parkinson Genetics Network	A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease	LANCET			English	Article								Mutations in the LRRK2 gene have been identified in families with autosomal dominant parkinsonism. We amplified and sequenced the coding region of LRRK2 from genomic DNA by PCR, and identified a heterozygous mutation (Gly2019Ser) present in four of 61 (6.6%) unrelated families with Parkinson's disease and autosomal dominant inheritance. The families originated from Italy, Portugal, and Brazil, indicating the presence of the mutation in different populations. The associated phenotype was broad, including early and late disease onset. These findings confirm the association of LRRK2 with neurodegeneration, and identify a common mutation associated with dominantly inherited Parkinson's disease.	Erasmus MC Rotterdam, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; Univ Milan, IRCCS Osped Maggiore Policlin, Ctr Dino Ferrari, Dept Neurol Sci, Milan, Italy; Inst Mol Med, Neurol Clin Res Unit, Lisbon, Portugal; Univ Sao Paulo, Dept Neurol, Sao Paulo, Brazil; Univ Roma La Sapienza, Dept Neurol Sci, Rome, Italy; Natl Inst Hlth, Natl Ctr Epidemiol, Rome, Italy; Ist Clin Perfezionamento, Parkinson Inst, Milan, Italy	Erasmus University Rotterdam; Erasmus MC; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Universidade de Lisboa; Universidade de Sao Paulo; Sapienza University Rome; Istituto Superiore di Sanita (ISS)	Bonifati, V (corresponding author), Erasmus MC Rotterdam, Dept Clin Genet, POB 1738, NL-3000 DR Rotterdam, Netherlands.	v.bonifati@erasmusmc.nl	Barbosa, Egberto R/G-7763-2012; Vanacore, Nicola/ABC-7196-2021; Ferreira, Joaquim/AAA-1837-2020; Di Fonzo, Alessio/A-5702-2013; stocchi, fabrizio/K-5089-2016; Goldwurm, Stefano/Q-8978-2016	Di Fonzo, Alessio/0000-0001-6478-026X; stocchi, fabrizio/0000-0002-5763-0033; Goldwurm, Stefano/0000-0002-1651-567X; Reis Barbosa, Egberto/0000-0002-6996-9130; Ferreira, Joaquim J/0000-0003-3950-5113; Vacca, Laura/0000-0002-6634-4119; Correia Guedes, Leonor/0000-0002-8422-0494				Bonifati V, 2004, CELL MOL LIFE SCI, V61, P1729, DOI 10.1007/s00018-004-4104-1; Funayama M, 2002, ANN NEUROL, V51, P296, DOI 10.1002/ana.10113; HUGHES AJ, 1992, NEUROLOGY, V42, P1142, DOI 10.1212/WNL.42.6.1142; Paisan-Ruiz C, 2004, NEURON, V44, P595, DOI 10.1016/j.neuron.2004.10.023; Zimprich A, 2004, NEURON, V44, P601, DOI 10.1016/j.neuron.2004.11.005	5	412	424	1	31	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN-FEB	2005	365	9457					412	415						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891WE	15680456				2022-12-28	WOS:000226610900028
J	Burgess, C; Cornelius, V; Love, S; Graham, J; Richards, M; Ramirez, A				Burgess, C; Cornelius, V; Love, S; Graham, J; Richards, M; Ramirez, A			Depression and anxiety in women with early breast cancer: five year observational cohort study	BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; PSYCHIATRIC MORBIDITY; PSYCHOLOGICAL MORBIDITY; MASTECTOMY; CONSERVATION; PREVALENCE; PREDICTORS; DISEASE; IMPACT; TRIAL	Objective To examine the prevalence of, and risk factors for, depression and anxiety in women with early breast cancer in the five years after diagnosis. Design Observational cohort study. Setting NHS breast clinic, London. Participants 222 women with early breast cancer: 170 (77%) provided complete interview data up to either five years after diagnosis or recurrence. Main outcome measures Prevalence of clinically important depression and anxiety (structured psychiatric interview with standardised diagnostic criteria) and clinical and patient risk factors, including stressful life experiences (Bedford College life events and difficulties schedule). Results Nearly 50% of the women with early breast cancer had depression, anxiety, or both in the year after diagnosis, 25% in the second, third, and fourth years, and 15% in the fifth year. Point prevalence was 33% at diagnosis, falling to 15% after one year. 45% of those with recurrence experienced depression, anxiety, or both within three months of the diagnosis. Previous psychological treatment predicted depression, anxiety, or both in the period around diagnosis (one month before diagnosis to four months after diagnosis). Longer term depression and anxiety were associated with previous psychological treatment, lack of an intimate confiding relationship, younger age, and severely stressful non-cancer life experiences. Clinical factors were not associated with depression and anxiety at any time. Lack of intimate confiding support also predicted more protracted episodes of depression and anxiety. Conclusion Increased levels of depression and anxiety in the first year after a diagnosis of early breast cancer highlight the need for dedicated service provision during this time. Psychological interventions for women with breast cancer who remain disease free should take account of the broader social context in which the cancer occurs, with a focus on improving social support.	Kings Coll London, St Thomas Hosp, Inst Psychiat, Canc Res UL London Psychosocial Grp, London SE1 7EH, England; Inst Hlth Sci, Canc Res UK Med Stat Grp, Ctr Stat Med, Oxford OX3 7LF, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Cancer Research UK; University of Oxford	Burgess, C (corresponding author), Kings Coll London, St Thomas Hosp, Inst Psychiat, Canc Res UL London Psychosocial Grp, London SE1 7EH, England.	caroline.burgess@kcl.ac.uk		Cornelius, Victoria/0000-0002-0080-1065; Love, Sharon/0000-0002-6695-5390				*AM PSYCH ASS COMM, 1987, DIAGN STAT MAN MENT; [Anonymous], [No title captured]; Brown G., 1978, SOCIAL ORIGINS DEPRE; Burgess CC, 2002, EUR J CANCER, V38, P1622, DOI 10.1016/S0959-8049(02)00132-6; CHIA SKL, 2003, P AN M AM SOC CLIN, V22, P6; CHOCHINOV HM, 1994, AM J PSYCHIAT, V151, P537; DEAN C, 1987, J PSYCHOSOM RES, V31, P385, DOI 10.1016/0022-3999(87)90059-6; FALLOWFIELD LJ, 1994, BRIT MED J, V309, P448, DOI 10.1136/bmj.309.6952.448; FALLOWFIELD LJ, 1986, BMJ-BRIT MED J, V293, P1331, DOI 10.1136/bmj.293.6558.1331; FALLOWFIELD LJ, 1990, BRIT MED J, V301, P575, DOI 10.1136/bmj.301.6752.575; Ganz PA, 2002, JNCI-J NATL CANCER I, V94, P39; Haddad P, 1994, BREAST, V3, P218, DOI DOI 10.1016/0960-9776(94)90049-3; Hall A., 1996, BREAST J, V2, P197; HARRISON J, 1994, BRIT J PSYCHIAT, V165, P593, DOI 10.1192/bjp.165.5.593; HUGHSON AVM, 1986, BMJ-BRIT MED J, V293, P1268, DOI 10.1136/bmj.293.6557.1268; KIEBERT GM, 1991, J CLIN ONCOL, V9, P1059, DOI 10.1200/JCO.1991.9.6.1059; LEE MS, 1992, EUR J CANCER, V28A, P1340, DOI 10.1016/0959-8049(92)90514-3; *NAT I CLIN EXC, 2004, SUPP PALL CAR PEOPL; O'Shaughnessy J, 2002, J CLIN ONCOL, V20, P2812, DOI 10.1200/JCO.2002.09.002; Okamura H, 2000, BREAST CANCER RES TR, V61, P131, DOI 10.1023/A:1006491417791; Peto R, 2000, LANCET, V355, P1822, DOI 10.1016/S0140-6736(00)02277-7; PINDER KL, 1994, PSYCHO-ONCOLOGY, V3, P129; RAMIREZ AJ, 1995, BRIT J CANCER, V72, P1509, DOI 10.1038/bjc.1995.538; Spitzer RL, 1990, STRUCTURED CLIN INTE	24	815	842	4	84	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	MAR 26	2005	330	7493					702	705		10.1136/bmj.38343.670868.D3	http://dx.doi.org/10.1136/bmj.38343.670868.D3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	912IT	15695497	Green Published, Bronze			2022-12-28	WOS:000228071900016
J	Rocks, O; Peyker, A; Kahms, M; Verveer, PJ; Koerner, C; Lumbierres, M; Kuhlmann, J; Waldmann, H; Wittinghofer, A; Bastiaens, PIH				Rocks, O; Peyker, A; Kahms, M; Verveer, PJ; Koerner, C; Lumbierres, M; Kuhlmann, J; Waldmann, H; Wittinghofer, A; Bastiaens, PIH			An acylation cycle regulates localization and activity of palmitoylated Ras isoforms	SCIENCE			English	Article							PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; PROTEIN PALMITOYLATION; CAAX MOTIF; STRUCTURAL DETERMINANTS; GOLGI-APPARATUS; H-RAS; N-RAS; CELLS; TRAFFICKING	We show that the specific subcellular distribution of H- and Nras guanosine triphosphate-binding proteins is generated by a constitutive de/reacylation cycle that operates on palmitoylated proteins, driving their rapid exchange between the plasma membrane (PM) and the Golgi apparatus. Depalmitoylation redistributes farnesylated Ras in all membranes, followed by repalmitoylation and trapping of Ras at the Golgi, from where it is redirected to the PM via the secretory pathway. This continuous cycle prevents Ras from nonspecific residence on endomembranes, thereby maintaining the specific intracellular compartmentalization. The de/reacylation cycle also initiates Ras activation at the Golgi by transport of PM-localized Ras guanosine triphosphate. Different de/repalmitoylation kinetics account for isoform-specific activation responses to growth factors.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Max Planck Inst Mol Physiol, Dept Biol Struct, D-44227 Dortmund, Germany; Max Planck Inst Mol Physiol, Dept Biol Chem, D-44227 Dortmund, Germany	European Molecular Biology Laboratory (EMBL); Max Planck Society; Max Planck Society	Wittinghofer, A (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	alfred.wittinghofer@mpi-dortmund.mpg.de; bastiaen@embl.de	Waldmann, Herbert/B-7406-2017; Rocks, Oliver/AFI-7418-2022; Rocks, Oliver/ABG-3341-2020	Waldmann, Herbert/0000-0002-9606-7247; Rocks, Oliver/0000-0001-6349-9193; Lorentzen, Anna/0000-0002-4405-935X				Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Bader B, 2000, NATURE, V403, P223, DOI 10.1038/35003249; Bastiaens PIH, 1996, EMBO J, V15, P4246, DOI 10.1002/j.1460-2075.1996.tb00799.x; Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Bizzozero OA, 2001, BBA-PROTEIN STRUCT M, V1545, P278, DOI 10.1016/S0167-4838(00)00291-0; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; El-Husseini AED, 2002, NAT REV NEUROSCI, V3, P791, DOI 10.1038/nrn940; Gerlich D, 2003, CELL, V112, P751, DOI 10.1016/S0092-8674(03)00189-2; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; LOWY DR, 1989, NATURE, V341, P384, DOI 10.1038/341384a0; LU JY, 1995, J BIOL CHEM, V270, P7251, DOI 10.1074/jbc.270.13.7251; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; Margarit SM, 2003, CELL, V112, P685, DOI 10.1016/S0092-8674(03)00149-1; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Navarro-Lerida I, 2002, J CELL SCI, V115, P3119; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; Perez de Castro I, 2004, MOL CELL BIOL, V24, P3485, DOI 10.1128/MCB.24.8.3485-3496.2004; ROCKS O, UNPUB; Roth AF, 2002, J CELL BIOL, V159, P23, DOI 10.1083/jcb.200206120; Roy S, 2002, MOL CELL BIOL, V22, P5128, DOI 10.1128/MCB.22.14.5128-5140.2002; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; Schroeder H, 1997, BIOCHEMISTRY-US, V36, P13102, DOI 10.1021/bi9709497; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; Silvius JR, 2002, J MEMBRANE BIOL, V190, P83, DOI 10.1007/s00232-002-1026-4; Smotrys JE, 2004, ANNU REV BIOCHEM, V73, P559, DOI 10.1146/annurev.biochem.73.011303.073954; Ten Brinke A, 2002, BIOCHEM J, V361, P663, DOI 10.1042/0264-6021:3610663; Torii S, 2004, DEV CELL, V7, P33, DOI 10.1016/j.devcel.2004.05.019; Verveer PJ, 2000, SCIENCE, V290, P1567, DOI 10.1126/science.290.5496.1567; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Xue LL, 2004, CELL, V117, P761, DOI 10.1016/j.cell.2004.05.016; Zhao LH, 2002, J BIOL CHEM, V277, P49352, DOI 10.1074/jbc.M209760200	40	605	623	2	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 18	2005	307	5716					1746	1752		10.1126/science.1105654	http://dx.doi.org/10.1126/science.1105654			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909TP	15705808				2022-12-28	WOS:000227883900037
J	Olsen, OE; Myklebust, G; Engebretsen, L; Holme, I; Bahr, R				Olsen, OE; Myklebust, G; Engebretsen, L; Holme, I; Bahr, R			Exercises to prevent lower limb injuries in youth sports: cluster randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							CRUCIATE LIGAMENT INJURIES; TEAM HANDBALL; PROSPECTIVE INTERVENTION; PHYSICAL-ACTIVITY; SOCCER INJURIES; KNEE INJURY; PLAYERS; PATTERNS; SEASONS; HEALTH	Objective To investigate the effect of a structured warm-up programme designed to reduce the incidence of knee and ankle injuries in young people participating in sports. Design Cluster randomised controlled trial with clubs as the unit of randomisation. Setting 120 team handball clubs from central and eastern Norway (61 clubs in the intervention group, 59 in the control group) followed for one league season (eight months). Participants 1837 players aged 15-17 years; 958 players (808 female and 150 male) in the intervention group; 879 players (778 female and 101 male) in the control group. Intervention A structured warm-up programme to improve running, cutting, and landing technique as well as neuromuscular control, balance, and strength. Main outcome measure The rate of acute injuries to the knee or ankle. Results During the season, 129 acute knee or ankle injuries occurred, 81 injuries in the control group (0.9 (SE 0.09) injuries per 1000 player hours; 0.3 (SE 0.17) in training v 5.3 (SE 0.06) during matches) and 48 injuries in the intervention group (0.5 (SE 0.11) injuries per 1000 player hours; 0.2 (SE 0.18) in training v 2.5 (SE 0.06) during matches). Fewer injured players were in the intervention group than in the control group (46 (4.8%) v (76 (8.6%); relative risk intervention group v control group 0.53, 95% confidence interval 0.35 to 0.81). Conclusion A structured programme of warm-up exercises can prevent knee and ankle injuries in young people playing sports. Preventive training should therefore be introduced as an integral part of youth sports programmes.	Norwegian Univ Sport & Phys Educ, Oslo Sports Trauma Res Ctr, N-0806 Oslo, Norway	Norwegian School of Sport Sciences	Olsen, OE (corresponding author), Norwegian Univ Sport & Phys Educ, Oslo Sports Trauma Res Ctr, N-0806 Oslo, Norway.	odd-egil.olsen@nih.no	Bahr, Roald/B-6964-2014	Bahr, Roald/0000-0001-5725-4237				ARENDT E, 1995, AM J SPORT MED, V23, P694, DOI 10.1177/036354659502300611; Bahr R, 1997, SCAND J MED SCI SPOR, V7, P172, DOI 10.1111/j.1600-0838.1997.tb00135.x; Bahr R, 2003, TXB SPORTS MED BASIC, P299, DOI 10.1002/9780470757277.ch1; Caraffa A, 1996, Knee Surg Sports Traumatol Arthrosc, V4, P19, DOI 10.1007/BF01565992; Chappell JD, 2002, AM J SPORT MED, V30, P261, DOI 10.1177/03635465020300021901; Ebstrup JF, 2000, SCAND J MED SCI SPOR, V10, P114, DOI 10.1034/j.1600-0838.2000.010002114.x; Fagenbaum R, 2003, AM J SPORT MED, V31, P233, DOI 10.1177/03635465030310021301; Fletcher GF, 1996, CIRCULATION, V94, P857, DOI 10.1161/01.CIR.94.4.857; Heidt RS, 2000, AM J SPORT MED, V28, P659, DOI 10.1177/03635465000280050601; Hewett TE, 1999, AM J SPORT MED, V27, P699, DOI 10.1177/03635465990270060301; Hewett TE, 1996, AM J SPORT MED, V24, P765, DOI 10.1177/036354659602400611; Holm I, 2004, CLIN J SPORT MED, V14, P88, DOI 10.1097/00042752-200403000-00006; Junge A, 2002, AM J SPORT MED, V30, P652, DOI 10.1177/03635465020300050401; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; Mjolsnes R, 2004, SCAND J MED SCI SPOR, V14, P311, DOI 10.1046/j.1600-0838.2003.367.x; Myklebust G, 2003, CLIN J SPORT MED, V13, P71, DOI 10.1097/00042752-200303000-00002; Myklebust G, 1997, SCAND J MED SCI SPOR, V7, P289, DOI 10.1111/j.1600-0838.1997.tb00155.x; MYKLEBUST G, IN PRESS BR J SPORTS; NIELSEN AB, 1988, INT J SPORTS MED, V9, P341, DOI 10.1055/s-2007-1025037; Olsen OE, 2004, AM J SPORT MED, V32, P1002, DOI 10.1177/0363546503261724; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Powell JW, 2000, AM J SPORT MED, V28, P385, DOI 10.1177/03635465000280031801; Wedderkopp N, 1999, SCAND J MED SCI SPOR, V9, P41	23	426	434	1	108	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 26	2005	330	7489					449	452		10.1136/bmj.38330.632801.8F	http://dx.doi.org/10.1136/bmj.38330.632801.8F			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	901XK	15699058	Green Published, Bronze			2022-12-28	WOS:000227315400017
J	Genda, H; Abe, Y				Genda, H; Abe, Y			Enhanced atmospheric loss on protoplanets at the giant impact phase in the presence of oceans	NATURE			English	Article							EROSION; EVOLUTION; ORIGIN; WATER; DISK	The atmospheric compositions of Venus and Earth differ significantly, with the venusian atmosphere containing about 50 times as much Ar-36 as the atmosphere on Earth(1). The different effects of the solar wind on planet-forming materials for Earth and Venus have been proposed to account for some of this difference in atmospheric composition(2,3), but the cause of the compositional difference has not yet been fully resolved. Here we propose that the absence or presence of an ocean at the surface of a protoplanet during the giant impact phase could have determined its subsequent atmospheric amount and composition. Using numerical simulations, we demonstrate that the presence of an ocean significantly enhances the loss of atmosphere during a giant impact owing to two effects: evaporation of the ocean, and lower shock impedance of the ocean compared to the ground. Protoplanets near Earth's orbit are expected to have had oceans, whereas those near Venus' orbit are not, and we therefore suggest that remnants of the noble-gas rich proto-atmosphere survived on Venus, but not on Earth. Our proposed mechanism explains differences in the atmospheric contents of argon, krypton and xenon on Venus and Earth, but most of the neon must have escaped from both planets' atmospheres later to yield the observed ratio of neon to argon.	Univ Tokyo, Dept Earth & Planetary Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Genda, H (corresponding author), Tokyo Inst Technol, Dept Earth & Planetary Sci, Meguro Ku, 2-12-1 Ookayama, Tokyo 1528551, Japan.	genda@geo.titech.ac.jp	Abe, Yutaka/I-1933-2012; Genda, Hidenori/A-7858-2014					ABE Y, 1993, LITHOS, V30, P223, DOI 10.1016/0024-4937(93)90037-D; ABE Y, 1986, J GEOPHYS RES-SOLID, V91, pE291, DOI 10.1029/JB091iB13p0E291; Abe Y., 2000, ORIGIN EARTH MOON, P413; Ahrens T. J., 1990, ORIGIN EARTH, P211; AHRENS TJ, 1993, ANNU REV EARTH PL SC, V21, P525, DOI 10.1146/annurev.ea.21.050193.002521; ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; CAMERON AGW, 1992, LUNAR PLANET SCI, V23, P199; Chambers JE, 2001, ICARUS, V152, P205, DOI 10.1006/icar.2001.6639; Chen GQ, 1997, PHYS EARTH PLANET IN, V100, P21, DOI 10.1016/S0031-9201(96)03228-1; Dauphas N, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2001JE001617; Donahue T. M., 1983, Venus, P1003; Genda H, 2003, ICARUS, V164, P149, DOI 10.1016/S0019-1035(03)00101-5; HAYASHI C, 1979, EARTH PLANET SC LETT, V43, P22, DOI 10.1016/0012-821X(79)90152-3; HAYASHI C, 1981, SUP PROG THEOR PHYS, P35; KASTING JF, 1983, ICARUS, V53, P479, DOI 10.1016/0019-1035(83)90212-9; Kominami J, 2004, ICARUS, V167, P231, DOI 10.1016/j.icarus.2003.10.005; MELOSH HJ, 1989, NATURE, V338, P487, DOI 10.1038/338487a0; Melosh HJ, 2003, NATURE, V424, P22, DOI 10.1038/424022a; NEWMAN MJ, 1977, SCIENCE, V198, P1035, DOI 10.1126/science.198.4321.1035; Newman WI, 1999, ICARUS, V138, P224, DOI 10.1006/icar.1999.6076; OKEEFE JD, 1982, J GEOPHYS RES, V87, P6668, DOI 10.1029/JB087iB08p06668; PEPIN RO, 1991, ICARUS, V92, P2, DOI 10.1016/0019-1035(91)90036-S; Richtmyer R. D., 1994, DIFFERENCE METHODS I; SASAKI S, 1991, ICARUS, V91, P29, DOI 10.1016/0019-1035(91)90123-B; STORM SE, 1993, PROTOSTARS PLANETS, V3, P837; Tillotson J.H., 1962, GA3216; Wagner W, 2002, J PHYS CHEM REF DATA, V31, P387, DOI 10.1063/1.1461829; WETHERILL GW, 1981, ICARUS, V46, P70, DOI 10.1016/0019-1035(81)90076-2; ZAHNLE K, 1993, PROTOSTARS PLANETS, V3, P1305	30	156	158	3	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 24	2005	433	7028					842	844		10.1038/nature03360	http://dx.doi.org/10.1038/nature03360			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	899VT	15729335				2022-12-28	WOS:000227174600035
J	Strasser, BJ; Dubochet, J				Strasser, BJ; Dubochet, J			Eduard Kellenberger (1920-2004) - Obituary	NATURE			English	Biographical-Item									Univ Lausanne, CH-1015 Lausanne, Switzerland	University of Lausanne	Strasser, BJ (corresponding author), Univ Lausanne, CH-1015 Lausanne, Switzerland.	bruno.strasser@unil.ch	Strasser, Bruno J/E-9337-2012						0	1	1	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 24	2005	433	7028					817	817		10.1038/433817a	http://dx.doi.org/10.1038/433817a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	899VT	15729328	Bronze			2022-12-28	WOS:000227174600029
J	Jensen, LS; Puho, E; Pedersen, L; Mortensen, FV; Sorensen, HT				Jensen, LS; Puho, E; Pedersen, L; Mortensen, FV; Sorensen, HT			Long-term survival after colorectal surgery associated with buffy-coat-poor and leucocyte-depleted blood transfusion: a follow-up study	LANCET			English	Article							CANCER	A Danish clinical trial showed that transfusion with leucocyte-depleted red blood cells reduces postoperative infectious complications compared with cells without buffy-coat. However, the effect on long-term outcome is unknown. We followed up the 142 cancer patients transfused with buffy-coat-poor red cells, the 118 transfused with leucocyte-depleted blood, and the 329 who were not transfused, until 2003. After 7 years' follow-up, survival for those with leucocyte-depleted blood transfusion (46 [41%]) was not significantly different from transfusion of blood without buffy-coat (59 [45%], p=0.51). Although survival is reduced by blood transfusion, it does not differ between the two transfusion regimens.	Aarhus Univ Hosp, Dept Gastrointestinal Surg L, DK-8000 Aarhus C, Denmark; Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University	Jensen, LS (corresponding author), Aarhus Univ Hosp, Dept Gastrointestinal Surg L, Noerrebrogade 44, DK-8000 Aarhus C, Denmark.	lonej@dadlnet.dk	Sorensen, Henrik Toft/Z-6181-2019	Sorensen, Henrik Toft/0000-0003-4299-7040; Mortensen, Frank Viborg/0000-0001-7580-8037				GANTT CL, 1981, LANCET, V2, P363; HOUBIERS JGA, 1994, LANCET, V344, P573, DOI 10.1016/S0140-6736(94)91965-8; Jensen LS, 1996, LANCET, V348, P841, DOI 10.1016/S0140-6736(96)06168-5; van de Watering LMG, 2001, BRIT J SURG, V88, P267, DOI 10.1046/j.1365-2168.2001.01674.x	4	37	37	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	2005	365	9460					681	682						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	898SP	15721474				2022-12-28	WOS:000227096800026
J	Diamond, J				Diamond, J			Ernst Mayr (1904-2005) - Obituary	NATURE			English	Biographical-Item									Univ Calif Los Angeles, Dept Geog, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Diamond, J (corresponding author), Univ Calif Los Angeles, Dept Geog, Los Angeles, CA 90095 USA.	jdiamond@geog.ucla.edu						MAYR E, PUBLICATION LIST	1	2	2	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 17	2005	433	7027					700	701		10.1038/nature03435	http://dx.doi.org/10.1038/nature03435			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897XH	15716939				2022-12-28	WOS:000227039200026
J	Jagasia, R; Grote, P; Westermann, B; Conradt, B				Jagasia, R; Grote, P; Westermann, B; Conradt, B			DRP-1-mediated mitochondrial fragmentation during EGL-1-induced cell death in C-elegans	NATURE			English	Article							PROTEIN; APOPTOSIS; FISSION; CED-9; DYNAMICS; NEMATODE; EGL-1	Genetic analyses in Caenorhabditis elegans have been instrumental in the elucidation of the central cell-death machinery, which is conserved from C. elegans to mammals(1,2). One possible difference that has emerged is the role of mitochondria. By releasing cytochrome c, mitochondria are involved in the activation of caspases in mammals(3,4). However, there has previously been no evidence that mitochondria are involved in caspase activation in C. elegans. Here we show that mitochondria fragment in cells that normally undergo programmed cell death during C. elegans development. Mitochondrial fragmentation is induced by the BH3-only protein EGL-1 and can be blocked by mutations in the bcl-2-like gene ced-9, indicating that members of the Bcl-2 family might function in the regulation of mitochondrial fragmentation in apoptotic cells. Mitochondrial fragmentation is independent of CED-4/Apaf-1 and CED-3/caspase, indicating that it occurs before or simultaneously with their activation. Furthermore, DRP-1/dynamin-related protein, a key component of the mitochondrial fission machinery, is required and sufficient to induce mitochondrial fragmentation and programmed cell death during C. elegans development. These results assign an important role to mitochondria in the cell-death pathway in C. elegans.	Dartmouth Coll, Sch Med, Dept Genet, Hanover, NH 03755 USA; Univ Bayreuth, D-95440 Bayreuth, Germany; Univ Munich, Inst Physiol Chem, D-81377 Munich, Germany; Max Planck Inst Neurobiol, D-82152 Planegg Martinsried, Germany	Dartmouth College; University of Bayreuth; University of Munich; Max Planck Society	Conradt, B (corresponding author), Dartmouth Coll, Sch Med, Dept Genet, 7400 Remsen, Hanover, NH 03755 USA.	barbara.conradt@dartmouth.edu	Westermann, Benedikt/H-7766-2013; Conradt, Barbara/K-2665-2014; Grote, Phillip/AAG-9188-2020	Westermann, Benedikt/0000-0002-2991-1604; Grote, Phillip/0000-0002-9254-1458; Conradt, Barbara/0000-0002-3731-4308				Aspock G, 2003, DEVELOPMENT, V130, P3369, DOI 10.1242/dev.00551; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; Bloss TA, 2003, NATURE, V424, P1066, DOI 10.1038/nature01920; Bossy-Wetzel E, 2003, CURR OPIN CELL BIOL, V15, P706, DOI 10.1016/j.ceb.2003.10.015; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Conradt B, 1999, CELL, V98, P317, DOI 10.1016/S0092-8674(00)81961-3; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; FRANCIS B, 2001, SEX ED, V1, P1; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Horvitz HR, 1999, CANCER RES, V59, p1701S; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; Mello C, 1995, METHOD CELL BIOL, V48, P451; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Parrish J, 2000, P NATL ACAD SCI USA, V97, P11916, DOI 10.1073/pnas.210391597; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Reddien PW, 2001, NATURE, V412, P198, DOI 10.1038/35084096; Riddle DL, 1997, C ELEGANS, P739; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P96, DOI 10.1016/S0962-8924(98)01490-1; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194	30	264	276	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	2005	433	7027					754	760		10.1038/nature03316	http://dx.doi.org/10.1038/nature03316			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897XH	15716954				2022-12-28	WOS:000227039200042
J	McDougall, I; Brown, FH; Fleagle, JG				McDougall, I; Brown, FH; Fleagle, JG			Stratigraphic placement and age of modern humans from Kibish, Ethiopia	NATURE			English	Article							CRANIAL REMAINS; MIDDLE AWASH; OMO; DEPOSITS	In 1967 the Kibish Formation in southern Ethiopia yielded hominid cranial remains identified as early anatomically modern humans, assigned to Homo sapiens(1-4). However, the provenance and age of the fossils have been much debated(5,6). Here we confirm that the Omo I and Omo II hominid fossils are from similar stratigraphic levels in Member I of the Kibish Formation, despite the view that Omo I is more modern in appearance than Omo II1-3. 40Ar/39Ar ages on feldspar crystals from pumice clasts within a tuff in Member I below the hominid levels place an older limit of 198 +/- 14 kyr ( weighted mean age 196 +/- 2 kyr) on the hominids. A younger age limit of 104 +/- 7 kyr is provided by feldspars from pumice clasts in a Member III tuff. Geological evidence indicates rapid deposition of each member of the Kibish Formation. Isotopic ages on the Kibish Formation correspond to ages of Mediterranean sapropels, which reflect increased flow of the Nile River, and necessarily increased flow of the Omo River. Thus the 40Ar/39Ar age measurements, together with the sapropel correlations, indicate that the hominid fossils have an age close to the older limit. Our preferred estimate of the age of the Kibish hominids is 195 +/- 5 kyr, making them the earliest well-dated anatomically modern humans yet described.	Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia; Univ Utah, Dept Geol & Geophys, Salt Lake City, UT 84112 USA; SUNY Stony Brook, Dept Anat Sci, Stony Brook, NY 11794 USA	Australian National University; Utah System of Higher Education; University of Utah; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	McDougall, I (corresponding author), Australian Natl Univ, Res Sch Earth Sci, GPO Box 4, Canberra, ACT 0200, Australia.	ian.mcdougall@anu.edu.au						ARAMBOURG C, 1935, MISSION SCI OMO 1932; Butzer K.W., 1969, QUATERNARIA, V11, P15; BUTZER KW, 1971, NATURWISSENSCHAFTEN, V58, P7, DOI 10.1007/BF00620796; BUTZER KW, 1972, SCIENCE, V175, P1069, DOI 10.1126/science.175.4026.1069; BUTZER KW, 1969, NATURE, V222, P1138, DOI 10.1038/2221138a0; BUTZER KW, 1969, NATURE, V222, P1133, DOI 10.1038/2221133a0; BUTZER KW, 1976, EARLIEST MAN ENV LAK, P12; Clark JD, 2003, NATURE, V423, P747, DOI 10.1038/nature01670; DAVIDSON A, 1983, B ETHIOPIAN I GEOLOG, V2; DAY MH, 1991, ANTHROPOLOGIE, V95, P595; DAY MH, 1991, ANTHROPOLOGIE, V95, P573; DAY MH, 1969, NATURE, V222, P1135, DOI 10.1038/2221135a0; DAY MH, 1982, C INT PAL HUM 1 NIC, V2, P814; Fleagle J, 2003, AM J PHYS ANTHROPOL, P95; Fuchs VE, 1939, PHILOS T ROY SOC B, V229, P219, DOI 10.1098/rstb.1939.0001; Haile-Selassie Y, 2004, AM J PHYS ANTHROPOL, V123, P1, DOI 10.1002/ajpa.10330; Howell F.C., 1978, P154; HOWELL FC, 1994, INTERD CONT, P253; Lourens LJ, 1996, PALEOCEANOGRAPHY, V11, P391, DOI 10.1029/96PA01125; McDougall I, 1999, J GEOL SOC LONDON, V156, P731, DOI 10.1144/gsjgs.156.4.0731; OWEN RB, 1982, NATURE, V298, P523, DOI 10.1038/298523a0; Rightmire G.P., 1984, P295; Rohling EJ, 2002, EARTH PLANET SC LETT, V202, P61, DOI 10.1016/S0012-821X(02)00775-6; Rossi P, 1999, BAKKEN RES, V1, P221; ROSSIGNOLSTRICK M, 1982, NATURE, V295, P105, DOI 10.1038/295105a0; SMITH FH, 1989, YEARB PHYS ANTHROPOL, V32, P35; Spell TL, 2003, CHEM GEOL, V198, P189, DOI 10.1016/S0009-2541(03)00005-6; Spell TL, 1996, GEOL SOC AM BULL, V108, P1549, DOI 10.1130/0016-7606(1996)108<1549:CTRJVF>2.3.CO;2; YORK D, 1969, EARTH PLANET SC LETT, V5, P320	29	612	644	0	97	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 17	2005	433	7027					733	736		10.1038/nature03258	http://dx.doi.org/10.1038/nature03258			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897XH	15716951	Green Published			2022-12-28	WOS:000227039200037
J	Kesselheim, AS; Avorn, J				Kesselheim, AS; Avorn, J			University-based science and biotechnology products - Defining the boundaries of intellectual property	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PATENTS; CYCLOOXYGENASE; COMPENSATION; INNOVATION	The pharmaceutical and biotechnology industries have long relied on patenting as the primary means of allocating ownership and control over new discoveries. Yet, patent protection is a double-edged sword that has major implications for the future of innovation in biomedical science in the United States. Excessive "upstream" patenting of genes and molecular targets could hi rider further research by creating a need for expensive and inefficient cross-licensing. However, limiting such basic science patenting could allow private entities to use the results of years of costly publicly funded research to produce and market lucrative products without compensating university- or public sector-based innovators. Academic and other nonprofit research centers would, therefore, be deprived of revenue for pursuing novel therapeutics or other seminal research work that may not be patentable. Recent court cases illustrate the inherent conflicts in allocating ownership and control of basic biomedical discoveries. Several options exist to avoid the complex problems of overlapping basic science patents while still rewarding pivotal discoveries and encouraging further innovation. These include establishing basic science patent pools and mandating arbitration arrangements that would assign credit and royalties for biotechnology innovations that depend on prior research that was performed, financed, or both in the public sector.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Avorn, J (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.	javorn@partners.org	Kesselheim, Aaron/R-6793-2017	Kesselheim, Aaron/0000-0002-8867-2666				Andrews LB, 2002, NAT REV GENET, V3, P803, DOI 10.1038/nrg909; [Anonymous], 2000, PROTECTING THEIR INT; Avorn J, 2004, POWERFUL MED BENEFIT; Blumenthal D, 1997, JAMA-J AM MED ASSOC, V277, P1224, DOI 10.1001/jama.277.15.1224; BREMER HW, 1 2 DECADES BAYHDOLE; Butler D, 2001, NATURE, V413, P95, DOI 10.1038/35093217; Cho MK, 1997, NATURE, V390, P221, DOI 10.1038/36713; CLARK J, 2001, PATENT POOLS SOLUTIO; Dueker KS, 1997, FOOD DRUG LAW J, V52, P453; FOSSUM D, 2004, VITAL ASSETS FEDERAL; FRIEND T, 2003, NEW YORKER, V79, P160; *FTC, 2003, PROM INN PROP BAL CO; Gelijns AC, 2002, JAMA-J AM MED ASSOC, V287, P72, DOI 10.1001/jama.287.1.72; GLUCK ME, 2002, 3254 KAIS FAM FDN; Heller MA, 1998, SCIENCE, V280, P698, DOI 10.1126/science.280.5364.698; McCluskey MT, 1998, RUTGERS LAW REV, V50, P657; Merz JF, 2002, NATURE, V415, P577, DOI 10.1038/415577a; Mowery DC., 2004, IVORY TOWER IND INNO; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OBANION MK, 1991, J BIOL CHEM, V266, P23261; ONEILL LAJ, 1987, FEBS LETT, V212, P35, DOI 10.1016/0014-5793(87)81551-X; POLLACK A, 2003, NY TIMES        0731; POLLACK A, 2003, NY TIMES        0306, pC3; POLLACK A, 2000, NY TIMES, pC2; Scherer FM, 2002, ACAD MED, V77, P1348, DOI 10.1097/00001888-200212001-00006; SHAPIRO C, 2001, NATL BUREAU EC RES I, V1; Studdert DM, 2001, JAMA-J AM MED ASSOC, V286, P217, DOI 10.1001/jama.286.2.217; TAUTFEST ES, 2003, COMPUTER LAW REV TEC, V7, P117; Young D. A., 2000, US 6048850, Patent No. 6048850; 2001, FED REG         0105, V66, P1092	30	28	28	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	2005	293	7					850	854		10.1001/jama.293.7.850	http://dx.doi.org/10.1001/jama.293.7.850			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DQ	15713775				2022-12-28	WOS:000226984600027
J	Schleinitz, MD; Heidenreich, PA				Schleinitz, MD; Heidenreich, PA			A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: Clopidogrel plus aspirin versus aspirin alone	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY-OF-LIFE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK; ACUTE STROKE CARE; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; ARTERY-DISEASE; RESOURCE USE; BYPASS SURGERY; MEDICAL-CARE	Background: Although clopidogrel plus aspirin is more effective than aspirin alone in preventing subsequent vascular events in patients with unstable angina, the cost-effectiveness of this combination has yet to be examined in this high-risk population. Objective: To determine the cost-effectiveness of clopidogrel plus aspirin compared with aspirin alone. Design: Cost-utility analysis. Data Sources: Published literature. Target Population: Patients with unstable angina and electrocardiographic changes or non-Q-wave myocardial infarction. T ime Horizon: Lifetime. Perspective: Societal. Interventions: Combination therapy with clopidogrel, 75 mg/d, plus aspirin, 325 mg/d, for 1 year, followed by aspirin monotherapy, was compared with lifelong aspirin therapy, 325 mg/d. Outcome Measures: Lifetime costs, life expectancy in quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio. Results of Base-Case Analysis: Patients treated with aspirin alone lived 9.51 QALYs after their initial event and incurred expenses of $127 700; the addition of clopidogrel increased life expectancy to 9.61 QALYs and costs to $129 300. The incremental cost-effectiveness ratio for clopidogrel plus aspirin compared with aspirin alone was $15400 per QALY. Results of Sensitivity Analyses: The analysis of 1 year of therapy was robust to all sensitivity analyses. In the probabilistic sensitivity analysis, fewer than 3% of simulations resulted in cost-effectiveness ratios over $50000 per QALY. The cost-effectiveness of longer combination therapy depends critically on the balance of thrombotic event rates, durable efficacy, and the increased bleeding rate in patients taking clopidogrel. Limitations: This analysis may not apply to patients with severe heart failure, those undergoing long-term anticoagulant therapy, those recently managed with revascularization, or those undergoing short-term treatment with glycoprotein IIb/IIIa inhibitors. Conclusions: in patients with high-risk acute coronary syndromes, I year of therapy with clopidogrel plus aspirin results in greater life expectancy than aspirin alone, at a cost within the traditional limits of cost-effectiveness. The durable efficacy of clopidogrel relative to the risk for hemorrhage should be further explored before more protracted therapy can be recommended.	Brown Univ, Div Gen Internal Med, Providence, RI 02903 USA; Rhode Isl Hosp, Providence, RI 02903 USA; Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA; VA Palo Alto Healthcare Syst, Palo Alto, CA USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Schleinitz, MD (corresponding author), Brown Univ, Div Gen Internal Med, 593 Eddy St,MPB-1, Providence, RI 02903 USA.	Mark-Schleinitz@Brown.edu	Heidenreich, Paul/AAU-6864-2021	Heidenreich, Paul/0000-0001-7730-8490	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K12HD043447] Funding Source: NIH RePORTER; NICHD NIH HHS [HD43447] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alberts MJ, 1996, STROKE, V27, P1825, DOI 10.1161/01.STR.27.10.1825; Ashraf T, 1996, AM J CARDIOL, V78, P409, DOI 10.1016/S0002-9149(96)00328-1; Bennett CL, 2000, NEW ENGL J MED, V343, P1193; Bennett CL, 2000, NEW ENGL J MED, V342, P1773, DOI 10.1056/NEJM200006153422402; BERGER CJ, 1992, JAMA-J AM MED ASSOC, V268, P1545, DOI 10.1001/jama.268.12.1545; BERGMAN L, 1995, STROKE, V26, P1830, DOI 10.1161/01.STR.26.10.1830; Braunwald E, 2002, CIRCULATION, V106, P1893, DOI 10.1161/01.CIR.0000037106.76139.53; Diener HC, 2004, CEREBROVASC DIS, V17, P253, DOI 10.1159/000076962; Diringer MN, 1999, STROKE, V30, P724, DOI 10.1161/01.STR.30.4.724; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Duncan PW, 1997, STROKE, V28, P740, DOI 10.1161/01.STR.28.4.740; Fenwick E, 2001, HEALTH ECON, V10, P779, DOI 10.1002/hec.635; Gage BF, 1998, STROKE, V29, P1083, DOI 10.1161/01.STR.29.6.1083; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; Gaspoz J, 2002, NEW ENGL J MED, V346, P1800, DOI 10.1056/NEJM200206063462309; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Hallan S, 1999, J INTERN MED, V246, P309, DOI 10.1046/j.1365-2796.1999.00531.x; Hlatky MA, 1997, NEW ENGL J MED, V336, P92, DOI 10.1056/NEJM199701093360203; HLATKY MA, 1990, CIRCULATION, V82, P208; *HLTH CAR INV AN I, 1999, DRG HDB; Holloway RG, 1996, NEUROLOGY, V46, P854; Jiranek GC, 1996, SURG CLIN N AM, V76, P83, DOI 10.1016/S0039-6109(05)70424-2; Jorgensen HS, 1997, STROKE, V28, P1138, DOI 10.1161/01.STR.28.6.1138; Kozak LJ, 2002, VITAL HLTH STAT, V13, P1; Leibson CL, 1996, NEUROLOGY, V46, P861; Lipscomb J, 1996, COST EFFECTIVENESS H, P216; Mark DB, 2000, CIRCULATION, V101, P366, DOI 10.1161/01.CIR.101.4.366; Mitchell JB, 1996, STROKE, V27, P1937, DOI 10.1161/01.STR.27.11.1937; Murphy S L, 2000, Natl Vital Stat Rep, V48, P1; MURRAY L, 2002, DRUG TOPICS RED BOOK; Naglie G, 1997, MED DECIS MAKING, V17, P136, DOI 10.1177/0272989X9701700203; *NASA, GROSS DOM PROD DEFL; OSTER G, 1994, STROKE, V25, P1149, DOI 10.1161/01.STR.25.6.1149; Porsdal V, 1998, STROKE, V29, P2321, DOI 10.1161/01.STR.29.11.2321; Roberts JA, 2000, J PUBLIC HEALTH MED, V22, P99, DOI 10.1093/pubmed/22.1.99; Russell MW, 1998, AM J CARDIOL, V81, P1110, DOI 10.1016/S0002-9149(98)00136-2; Samsa GP, 1999, STROKE, V30, P338, DOI 10.1161/01.STR.30.2.338; Samsa GP, 1998, AM HEART J, V136, P703, DOI 10.1016/S0002-8703(98)70019-5; Sanders GD, 2001, ANN INTERN MED, V135, P870, DOI 10.7326/0003-4819-135-10-200111200-00007; Sarasin FP, 2000, ARCH INTERN MED, V160, P2773, DOI 10.1001/archinte.160.18.2773; Schleinitz MD, 2004, AM J MED, V116, P797, DOI 10.1016/j.amjmed.2004.01.014; Shin AY, 1997, STROKE, V28, P2395, DOI 10.1161/01.STR.28.12.2395; SMURAWSKA LT, 1994, STROKE, V25, P1628, DOI 10.1161/01.STR.25.8.1628; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Steinhubl SR, 2002, JAMA-J AM MED ASSOC, V288, P2411, DOI 10.1001/jama.288.19.2411; Torrance GW., 1996, COST EFFECTIVENESS H, P54; TSEVAT J, 1993, MED DECIS MAKING, V13, P161, DOI 10.1177/0272989X9301300210; Tung CY, 1999, CIRCULATION, V99, P370, DOI 10.1161/01.CIR.99.3.370; *US DEP LAB BUR LA, 2003, 966 US DEP LAB BUR L; WEINTRAUB WS, 1995, CIRCULATION, V92, P2831, DOI 10.1161/01.CIR.92.10.2831; Weintraub WS, 1998, CIRCULATION, V98, pII23; Yusuf S, 2001, NEW ENGL J MED, V345, P494	53	68	69	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	2005	142	4					251	259		10.7326/0003-4819-142-4-200502150-00007	http://dx.doi.org/10.7326/0003-4819-142-4-200502150-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900UJ	15710958				2022-12-28	WOS:000227239500003
J	McGraw, JB; Furedi, MA				McGraw, JB; Furedi, MA			Deer browsing and population viability of a forest understory plant	SCIENCE			English	Article							WHITE-TAILED DEER; AMERICAN GINSENG; PANAX-QUINQUEFOLIUS; ARALIACEAE; ECOSYSTEMS; IMPACTS; GROWTH	American ginseng is the premier medicinal plant harvested from the wild in the United States. In this study, seven populations of ginseng plants were censused every 3 weeks during-the growing season over 5 years to monitor deer browse and harvest and to project population growth and viability. The minimum viable population size was similar to800 plants, a value greater than that of all populations currently being monitored. When simulated deer browsing rates were reduced 50% or more, population viability rose sharply. Without more effective deer population control, ginseng and many other valuable understory herbs are Likely to become extinct, in the coming century.	W Virginia Univ, Dept Biol, Morgantown, WV 26506 USA	West Virginia University	McGraw, JB (corresponding author), W Virginia Univ, Dept Biol, POB 6057, Morgantown, WV 26506 USA.	jmcgraw@wvu.edu	Liu, Yi-Chun/H-5463-2012					ANDERSON RC, 1993, AM MIDL NAT, V129, P357, DOI 10.2307/2426517; Augustine DJ, 1998, CONSERV BIOL, V12, P995, DOI 10.1046/j.1523-1739.1998.97248.x; CARLSON AW, 1986, ECON BOT, V40, P233, DOI 10.1007/BF02859148; CARPENTER SG, 1982, CAN J BOT, V60, P2692, DOI 10.1139/b82-328; Caswell, 2000, MATRIX POPULATION MO; CHARRON D, 1991, J ECOL, V79, P431, DOI 10.2307/2260724; Cote SD, 2004, ANNU REV ECOL EVOL S, V35, P113, DOI 10.1146/annurev.ecolsys.35.021103.105725; Knight TM, 2004, ECOL APPL, V14, P915, DOI 10.1890/03-5048; LEFKOVITCH LP, 1965, BIOMETRICS, V21, P1, DOI 10.2307/2528348; McGraw JB, 2003, J TORREY BOT SOC, V130, P62, DOI 10.2307/3557530; McGraw JB, 2001, BIOL CONSERV, V98, P25, DOI 10.1016/S0006-3207(00)00138-5; Morris W. F., 2002, QUANTITATIVE CONSERV; Nantel P, 1996, CONSERV BIOL, V10, P608, DOI 10.1046/j.1523-1739.1996.10020608.x; Robbins CS, 2000, CONSERV BIOL, V14, P1422, DOI 10.1046/j.1523-1739.2000.99100.x; Rooney TP, 2003, FOREST ECOL MANAG, V181, P165, DOI 10.1016/S0378-1127(03)00130-0; Rooney TP, 2001, FORESTRY, V74, P201, DOI 10.1093/forestry/74.3.201; Russell FL, 2001, AM MIDL NAT, V146, P1, DOI 10.1674/0003-0031(2001)146[0001:EOWTDO]2.0.CO;2; SCHEMSKE DW, 1994, ECOLOGY, V75, P584, DOI 10.2307/1941718	18	125	128	5	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2005	307	5711					920	922		10.1126/science.1107036	http://dx.doi.org/10.1126/science.1107036			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897DV	15705851				2022-12-28	WOS:000226985100052
J	Kao, MH; Doupe, AJ; Brainard, MS				Kao, MH; Doupe, AJ; Brainard, MS			Contributions of an avian basal ganglia-forebrain circuit to real-time modulation of song	NATURE			English	Article							PURSUIT EYE-MOVEMENTS; ZEBRA FINCH; NEURAL ACTIVITY; NUCLEUS; MECHANISMS; LESIONS; STIMULATION; BIRDSONG; NEURONS; PATHWAY	Cortical - basal ganglia circuits have a critical role in motor control and motor learning(1). In songbirds, the anterior forebrain pathway ( AFP) is a basal ganglia - forebrain circuit required for song learning and adult vocal plasticity but not for production of learned song(2 - 5). Here, we investigate functional contributions of this circuit to the control of song, a complex, learned motor skill. We test the hypothesis that neural activity in the AFP of adult birds can direct moment- by- moment changes in the primary motor areas responsible for generating song. We show that song- triggered microstimulation in the output nucleus of the AFP induces acute and specific changes in learned parameters of song(6,7). Moreover, under both natural and experimental conditions, variability in the pattern of AFP activity is associated with variability in song structure. Finally, lesions of the output nucleus of the AFP prevent naturally occurring modulation of song variability. These findings demonstrate a previously unappreciated capacity of the AFP to direct real- time changes in song. More generally, they suggest that frontal cortical and basal ganglia areas may contribute to motor learning by biasing motor output towards desired targets or by introducing stochastic variability required for reinforcement learning.	Univ Calif San Francisco, Keck Ctr Integrat Neurosci, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Keck Ctr Integrat Neurosci, Dept Psychiat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kao, MH (corresponding author), Univ Calif San Francisco, Keck Ctr Integrat Neurosci, Dept Physiol, San Francisco, CA 94143 USA.	mimi@phy.ucsf.edu		Kao, Mimi/0000-0001-8884-9022; Brainard, Michael/0000-0002-9425-9907	NIDCD NIH HHS [R01 DC006636] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006636] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BOTTJER SW, 1984, SCIENCE, V224, P901, DOI 10.1126/science.6719123; Brainard MS, 2000, NATURE, V404, P762, DOI 10.1038/35008083; Brumm H, 2004, ANIM BEHAV, V67, P281, DOI 10.1016/j.anbehav.2003.06.006; Canales JJ, 2000, NAT NEUROSCI, V3, P377, DOI 10.1038/73949; Doya Kenji, 2000, P469; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; Hessler NA, 1999, NAT NEUROSCI, V2, P209, DOI 10.1038/6306; Hessler NA, 1999, J NEUROSCI, V19, P10461; Hikosaka O, 2002, CURR OPIN NEUROBIOL, V12, P217, DOI 10.1016/S0959-4388(02)00307-0; Jarvis ED, 1998, NEURON, V21, P775, DOI 10.1016/S0896-6273(00)80594-2; JOHNSON F, 1995, J COMP NEUROL, V358, P260, DOI 10.1002/cne.903580208; Kittelberger JM, 1999, J NEUROSCI, V19, P9385; KOMATSU H, 1989, J NEUROPHYSIOL, V62, P31, DOI 10.1152/jn.1989.62.1.31; Matsumoto N, 1999, J NEUROPHYSIOL, V82, P978, DOI 10.1152/jn.1999.82.2.978; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; MOONEY R, 1991, P NATL ACAD SCI USA, V88, P4075, DOI 10.1073/pnas.88.10.4075; Mooney R, 2000, J NEUROSCI, V20, P5420, DOI 10.1523/JNEUROSCI.20-14-05420.2000; NOTTEBOHM F, 1976, J COMP NEUROL, V165, P457, DOI 10.1002/cne.901650405; Perkel DJ, 2004, ANN NY ACAD SCI, V1016, P736, DOI 10.1196/annals.1298.039; SCHARFF C, 1991, J NEUROSCI, V11, P2896; Stark LL, 1999, J NEUROSCI, V19, P9107, DOI 10.1523/JNEUROSCI.19-20-09107.1999; Tanaka M, 2001, NATURE, V409, P191, DOI 10.1038/35051582; Tchernichovski O, 2001, SCIENCE, V291, P2564, DOI 10.1126/science.1058522; Troyer TW, 2001, CURR OPIN NEUROBIOL, V11, P721, DOI 10.1016/S0959-4388(01)00275-6; Troyer TW, 2000, J NEUROPHYSIOL, V84, P1224, DOI 10.1152/jn.2000.84.3.1224; VICARIO DS, 1995, J NEUROPHYSIOL, V73, P2602, DOI 10.1152/jn.1995.73.6.2602; VU ET, 1994, J NEUROSCI, V14, P6924; Williams H, 1999, J NEUROBIOL, V39, P14, DOI 10.1002/(SICI)1097-4695(199904)39:1<14::AID-NEU2>3.0.CO;2-X; WILLIAMS H, 1989, J COMP PSYCHOL, V103, P366, DOI 10.1037/0735-7036.103.4.366; Yu AC, 1996, SCIENCE, V273, P1871, DOI 10.1126/science.273.5283.1871	30	365	370	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 10	2005	433	7026					638	643		10.1038/nature03127	http://dx.doi.org/10.1038/nature03127			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	895KX	15703748				2022-12-28	WOS:000226862000046
J	Chen, XJ; Wang, XW; Kaufman, BA; Butow, RA				Chen, XJ; Wang, XW; Kaufman, BA; Butow, RA			Aconitase couples metabolic regulation to mitochondrial DNA maintenance	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; TRANSCRIPTION FACTOR; CYTOSOLIC ACONITASE; PROTEIN-COMPONENTS; OXIDATIVE DAMAGE; BINDING-PROTEIN; YEAST; NUCLEOIDS; IDENTIFICATION	Mitochondrial DNA (mtDNA) is essential for cells to maintain respiratory competency and is inherited as a protein-DNA complex called the nucleoid. We have identified 22 mtDNA-associated proteins in yeast, among which is mitochondrial aconitase (Aco1p). We show that this Krebs-cycle enzyme is essential for mtDNA maintenance independent of its catalytic activity. Regulation of ACO1 expression by the HAP and retrograde metabolic signaling pathways directly affects mtDNA maintenance. When constitutively expressed, Aco1p can replace the mtDNA packaging function of the high-mobility-group protein Abf2p. Thus, Aco1p may integrate metabolic signals and mtDNA maintenance.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Butow, RA (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	ronald.butow@utsouthwestern.edu			NIA NIH HHS [R01 AG023731] Funding Source: Medline; NIGMS NIH HHS [GM22525, GM33510] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022525, R37GM022525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG023731] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Blom J, 2000, APPL ENVIRON MICROB, V66, P1970, DOI 10.1128/AEM.66.5.1970-1973.2000; Bogenhagen DF, 2003, MOL CELL PROTEOMICS, V2, P1205, DOI 10.1074/mcp.M300035-MCP200; Bradley JL, 2000, HUM MOL GENET, V9, P275, DOI 10.1093/hmg/9.2.275; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; Dilova I, 2002, CURR BIOL, V12, P389, DOI 10.1016/S0960-9822(02)00677-2; Epstein CB, 2001, MOL BIOL CELL, V12, P297, DOI 10.1091/mbc.12.2.297; Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; Jia YK, 1997, MOL MICROBIOL, V24, P53, DOI 10.1046/j.1365-2958.1997.3011669.x; Kaufman BA, 2000, P NATL ACAD SCI USA, V97, P7772, DOI 10.1073/pnas.140063197; Kaufman BA, 2003, J CELL BIOL, V163, P457, DOI 10.1083/jcb.200306132; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KLAUSNER RD, 1993, MOL BIOL CELL, V4, P1; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; LAUBLE H, 1994, J MOL BIOL, V237, P437, DOI 10.1006/jmbi.1994.1246; LAWRENCE JJ, 1976, BIOCHEMISTRY-US, V15, P3301, DOI 10.1021/bi00660a021; Liu ZC, 1999, MOL CELL BIOL, V19, P6720; McCammon MT, 2003, MOL BIOL CELL, V14, P958, DOI 10.1091/mbc.E02-07-0422; Meeusen S, 1999, J CELL BIOL, V145, P291, DOI 10.1083/jcb.145.2.291; MEGRAW TL, 1993, J BIOL CHEM, V268, P12758; MIYAKAWA I, 1987, J CELL SCI, V88, P431; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; Sato H, 2002, PROTOPLASMA, V219, P51, DOI 10.1007/s007090200005; Sekito T, 2002, MOL BIOL CELL, V13, P795, DOI 10.1091/mbc.01-10-0473; Tate JJ, 2002, J BIOL CHEM, V277, P20477, DOI 10.1074/jbc.M200962200; Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510; Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168	29	248	260	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2005	307	5710					714	717		10.1126/science.1106391	http://dx.doi.org/10.1126/science.1106391			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	894TQ	15692048				2022-12-28	WOS:000226814900040
J	Kobayashi, KS; Chamaillard, M; Ogura, Y; Henegariu, O; Inohara, N; Nunez, G; Flavell, RA				Kobayashi, KS; Chamaillard, M; Ogura, Y; Henegariu, O; Inohara, N; Nunez, G; Flavell, RA			Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract	SCIENCE			English	Article							INFLAMMATORY-BOWEL-DISEASE; AVIUM SUBSPECIES PARATUBERCULOSIS; NF-KAPPA-B; CROHNS-DISEASE; ALPHA-DEFENSIN; PANETH CELLS; NOD2 GENE; ACTIVATION; MUTATIONS; MICE	The gene encoding the Nod2 protein is frequently mutated in Crohn's disease (CD) patients, although the physiological function of Nod2 in the intestine remains elusive. Here we show that protective immunity mediated by Nod2 recognition of bacterial muramyl dipeptide is abolished in Nod2-deficient mice. These animals are susceptible to bacterial infection via the oral route but not through intravenous or peritoneal delivery. Nod2 is required for the expression of a subgroup of intestinal anti-microbial peptides, known as cryptdins. The Nod2 protein is thus a critical regulator of bacterial immunity within the intestine, providing a possible mechanism for Nod2 mutations in CD.	Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	Yale University; Howard Hughes Medical Institute; Yale University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Flavell, RA (corresponding author), Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA.	richard.flavell@yale.edu	Chamaillard, Mathias/L-6542-2013; Nuñez, Gabriel/A-7160-2014	Chamaillard, Mathias/0000-0002-0243-9717; Kobayashi, Koichi/0000-0003-2930-0114				Ahmad T, 2002, GASTROENTEROLOGY, V122, P854, DOI 10.1053/gast.2002.32413; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; Cuthbert AP, 2002, GASTROENTEROLOGY, V122, P867, DOI 10.1053/gast.2002.32415; Darmoul D, 1996, AM J PHYSIOL-GASTR L, V271, pG68, DOI 10.1152/ajpgi.1996.271.1.G68; EISENHAUER PB, 1992, INFECT IMMUN, V60, P3556, DOI 10.1128/IAI.60.9.3556-3565.1992; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Gutierrez O, 2002, J BIOL CHEM, V277, P41701, DOI 10.1074/jbc.M206473200; Hampe J, 2002, LANCET, V359, P1661, DOI 10.1016/S0140-6736(02)08590-2; Hampe J, 2001, LANCET, V357, P1925, DOI 10.1016/S0140-6736(00)05063-7; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hoshino K, 1999, J IMMUNOL, V162, P3749; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Lala S, 2003, GASTROENTEROLOGY, V125, P47, DOI 10.1016/S0016-5085(03)00661-9; Lesage S, 2002, AM J HUM GENET, V70, P845, DOI 10.1086/339432; Li J, 2004, HUM MOL GENET, V13, P1715, DOI 10.1093/hmg/ddh182; Naser SA, 2004, LANCET, V364, P1039, DOI 10.1016/S0140-6736(04)17058-X; Ogura Y, 2003, GUT, V52, P1591, DOI 10.1136/gut.52.11.1591; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Ouellette AJ, 1999, INFECT IMMUN, V67, P6643; OUELLETTE AJ, 1994, INFECT IMMUN, V62, P5040, DOI 10.1128/IAI.62.11.5040-5047.1994; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Schmid M, 2004, Z GASTROENTEROL, V42, P333, DOI 10.1055/s-2004-813072; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Selby WS, 2004, LANCET, V364, P1013, DOI 10.1016/S0140-6736(04)17071-2; Takada H, 2002, J ENDOTOXIN RES, V8, P337, DOI 10.1179/096805102125000669; Tani K, 2000, INT IMMUNOL, V12, P691, DOI 10.1093/intimm/12.5.691; Watanabe T, 2004, NAT IMMUNOL, V5, P800, DOI 10.1038/ni1092; Wehkamp J, 2004, GUT, V53, P1658, DOI 10.1136/gut.2003.032805; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; Yang D, 2002, TRENDS IMMUNOL, V23, P291, DOI 10.1016/S1471-4906(02)02246-9	35	1370	1436	1	112	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2005	307	5710					731	734		10.1126/science.1104911	http://dx.doi.org/10.1126/science.1104911			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	894TQ	15692051				2022-12-28	WOS:000226814900045
J	Goulet, CJ; Moseley, RH; Tonnerre, C; Sandhu, IS; Saint, S				Goulet, CJ; Moseley, RH; Tonnerre, C; Sandhu, IS; Saint, S			The unturned stone	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NECROSIS-FACTOR-ALPHA; GASTROINTESTINAL HISTOPLASMOSIS; CROHNS-DISEASE; INFLIXIMAB		Univ Utah, Dept Internal Med, Div Gastroenterol, Salt Lake City, UT 84132 USA; Ann Arbor Dept Vet Affairs Med Ctr, Med Serv, Ann Arbor, MI USA; Ann Arbor Vet Affairs Hlth Serv Res & Dev Ctr Exc, Ann Arbor, MI USA; Univ Michigan Hlth Syst, Dept Internal Med, Ann Arbor, MI USA	Utah System of Higher Education; University of Utah; University of Michigan System; University of Michigan	Goulet, CJ (corresponding author), Univ Utah, Dept Internal Med, Div Gastroenterol, Rm 4R118,30 N Med, Salt Lake City, UT 84132 USA.	chrisgoulet_98@yahoo.com	Saint, Sanjay/AAF-5126-2019		AHRQ HHS [P20-HS11540] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P20HS011540] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		CAPPELL MS, 1988, DIGEST DIS SCI, V33, P353, DOI 10.1007/BF01535762; Colombel JF, 2004, GASTROENTEROLOGY, V126, P19, DOI 10.1053/j.gastro.2003.10.047; DEEPE GS, 2000, DOUGLAS BENNETTS PRI, P2718; GOODWIN RA, 1981, MEDICINE, V60, P231, DOI 10.1097/00005792-198107000-00001; Hertan H, 2001, AM J GASTROENTEROL, V96, P221, DOI 10.1111/j.1572-0241.2001.03479.x; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; Lamps LW, 2000, AM J CLIN PATHOL, V113, P64, DOI 10.1309/X0Y2-P3GY-TWE8-DM02; LAVY A, 1992, J CLIN GASTROENTEROL, V15, P17, DOI 10.1097/00004836-199207000-00006; Lee JH, 2002, ARTHRITIS RHEUM-US, V46, P2565, DOI 10.1002/art.10583; Mullick SS, 1996, ACTA CYTOL, V40, P989, DOI 10.1159/000334015; SANDS BE, 2002, SLEISENGER FORDTRANS, P2005; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; Wood KL, 2003, AM J RESP CRIT CARE, V167, P1279, DOI 10.1164/rccm.200206-563OC	13	14	14	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 3	2005	352	5					489	494		10.1056/NEJMcps041569	http://dx.doi.org/10.1056/NEJMcps041569			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	893NE	15689588				2022-12-28	WOS:000226725400011
J	Nguyen, HQ; Jumaan, AO; Seward, JF				Nguyen, HQ; Jumaan, AO; Seward, JF			Decline in mortality due to varicella after implementation of varicella vaccination in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEATHS	BACKGROUND: Varicella disease has been preventable in the United States since 1995. Starting in 1999, active and passive surveillance data showed sharp decreases in varicella disease. We reviewed national death records to assess the effect of the vaccination program on mortality associated with varicella. METHODS: Data on deaths for which varicella was listed as an underlying or contributing cause were obtained from National Center for Health Statistics Multiple Cause-of-Death Mortality Data for 1990 through 2001. We calculated the numbers and rates of death due to varicella according to age, sex, race, ethnic background, and birthplace. RESULTS: The rate of death due to varicella fluctuated from 1990 through 1998 and then declined sharply. For the interval from 1990 through 1994, the average number of varicella-related deaths was 145 per year (varicella was listed as the underlying cause in 105 deaths and as a contributing cause in 40); it then declined to 66 per year during 1999 through 2001. For deaths for which varicella was listed as the underlying cause, age-adjusted mortality rates dropped by 66 percent, from an average of 0.41 death per 1 million population during 1990 through 1994 to 0.14 during 1999 through 2001 (P<0.001). This decline was observed in all age groups under 50 years, with the greatest reduction (92 percent) among children 1 to 4 years of age. In addition, by the period from 1999 through 2001, the average rates of mortality due to varicella among all racial and ethnic groups were below 0.15 per 1 million population, as compared with rates ranging from 0.37 per 1 million for whites to 0.66 per 1 million for other races in the period from 1990 through 1994. CONCLUSIONS: The program of universal childhood vaccination against varicella in the United States has resulted in a sharp decline in the rate of death due to varicella.	CDCP, Viral Vaccine Preventable Dis Branch, Natl Immunizat Program, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Seward, JF (corresponding author), CDCP, Viral Vaccine Preventable Dis Branch, Natl Immunizat Program, 1600 Clifton Rd,Mailstop E-61, Atlanta, GA 30333 USA.	jseward@cdc.gov						[Anonymous], 1996, MMWR Recomm Rep, V45, P1; [Anonymous], 1999, MMWR Recomm Rep, V48, P1; Boelle PY, 2002, EPIDEMIOL INFECT, V129, P599, DOI 10.1017/S0950268802007720; Bramley J C, 2000, Commun Dis Public Health, V3, P282; Center for Disease Control and Prevention, NAT IMM SURV NIS; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P884; Chant KG, 1998, AUST NZ J PUBL HEAL, V22, P413, DOI 10.1111/j.1467-842X.1998.tb01405.x; Chant KG, 1998, AUST NZ J PUBL HEAL, V22, P630; Davis MM, 2004, PEDIATRICS, V114, P786, DOI 10.1542/peds.2004-0012; Fairley CK, 1996, J INFECT DIS, V174, pS314, DOI 10.1093/infdis/174.Supplement_3.S314; Galil K, 2002, AM J PUBLIC HEALTH, V92, P1248, DOI 10.2105/AJPH.92.8.1248; KILGORE PE, 2003, J MED VIROL S1, V10, pS111; Lam M. S., 1993, Singapore Medical Journal, V34, P213; Meyer PA, 2000, J INFECT DIS, V182, P383, DOI 10.1086/315714; *NAT CTR HLTH STAT, 2004, ICD 0 ACME DEC TA 2C; *NAT CTR HLTH STAT, 2002, BRIDG RAC VINT 2002; *NAT CTR HLTH STAT, 1999, BRIDG RAC INT POP ES; Rawson H, 2001, BRIT MED J, V323, P1091, DOI 10.1136/bmj.323.7321.1091; Seward JF, 2002, JAMA-J AM MED ASSOC, V287, P606, DOI 10.1001/jama.287.5.606; *US BUR CENS, ANN TIM SER STAT POP; WHO (World Health Organization), 1977, MAN INT STAT CLASS D; World Health Organization, 2004, ICD 10 INT STAT CLAS, V2nd; 2002, MMWR MORB MORTAL WKL, V51, P664	23	271	301	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 3	2005	352	5					450	458		10.1056/NEJMoa042271	http://dx.doi.org/10.1056/NEJMoa042271			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	893NE	15689583				2022-12-28	WOS:000226725400005
J	Vazquez, M; Shapiro, ED				Vazquez, M; Shapiro, ED			Varicella vaccine and infection with varicella-zoster virus	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA	Yale University; Yale University	Vazquez, M (corresponding author), Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA.								0	45	48	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 3	2005	352	5					439	440		10.1056/NEJMp048320	http://dx.doi.org/10.1056/NEJMp048320			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	893NE	15689581				2022-12-28	WOS:000226725400003
J	Marton, ML; Cordts, S; Broadhvest, J; Dresselhaus, T				Marton, ML; Cordts, S; Broadhvest, J; Dresselhaus, T			Micropylar pollen tube guidance by egg apparatus 1 of maize	SCIENCE			English	Article							FERTILIZATION; POLLINATION; PROTEIN; GROWTH; FEMALE; CELL	Pollen tube guidance precedes the double fertilization of flowering plants. Here, we report the identification of a small maize protein of 94 amino acids involved in short-range signaling required for pollen tube attraction by the female gametophyte. ZmEA1 is exclusively expressed in the egg apparatus, consisting of the egg cell and two synergids. Chimeric ZmEA1 fused to green fluorescent protein (ZmEA1:GFP) was first visible within the filiform apparatus and later was localized to nucellar cell watts below the micropylar opening of the ovule. Transgenic down-regulation of the ZmEA1 gene led to ovule sterility caused by loss of close-range pollen tube guidance to the micropyle.	Univ Hamburg, Bioctr Klein Flottbek, D-22609 Hamburg, Germany; Bayer Biosci NV, B-9052 Ghent, Belgium	University of Hamburg; Bayer AG	Dresselhaus, T (corresponding author), Univ Hamburg, Bioctr Klein Flottbek, Ohnhorststr 18, D-22609 Hamburg, Germany.	dresselh@botanik.uni-hamburg.de						Brettschneider R, 1997, THEOR APPL GENET, V94, P737, DOI 10.1007/s001220050473; DIBOLL ALFRED G., 1968, AMER J BOT, V55, P797, DOI 10.2307/2440968; DRESSELHAUS T, 1994, PLANT J, V5, P605, DOI 10.1046/j.1365-313X.1994.5040605.x; Higashiyama T, 2001, SCIENCE, V293, P1480, DOI 10.1126/science.1062429; Higashiyama T, 2003, CURR OPIN PLANT BIOL, V6, P36, DOI 10.1016/S1369-5266(02)00010-9; Ishikawa M, 1918, ANN BOT-LONDON, V32, P279; Kim S, 2003, P NATL ACAD SCI USA, V100, P16125, DOI 10.1073/pnas.2533800100; Marton M., UNPUB; Mol R, 2000, PLANTA, V210, P749, DOI 10.1007/s004250050676; Palanivelu R, 2003, CELL, V114, P47, DOI 10.1016/S0092-8674(03)00479-3; Sanchez AM, 2004, PLANT CELL, V16, pS98, DOI 10.1105/tpc.017806; SHARMA HC, 1995, EUPHYTICA, V82, P43, DOI 10.1007/BF00028709; Shimizu KK, 2000, DEVELOPMENT, V127, P4511; Van der Pluijm JE, 1964, POLLEN PHYSL FERTILI, P8; Weterings K, 2004, PLANT CELL, V16, pS107, DOI 10.1105/tpc.016873; Wu HM, 2000, PLANT J, V22, P165, DOI 10.1046/j.1365-313x.2000.00731.x	16	233	258	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2005	307	5709					573	576		10.1126/science.1104954	http://dx.doi.org/10.1126/science.1104954			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893BJ	15681383				2022-12-28	WOS:000226694000045
J	Lawlor, DA; Ben-Shlomo, Y; Ebrahim, S; Smith, GD; Stansfeld, SA; Yarnell, JWG; Gallacher, JEJ				Lawlor, DA; Ben-Shlomo, Y; Ebrahim, S; Smith, GD; Stansfeld, SA; Yarnell, JWG; Gallacher, JEJ			Insulin resistance and depressive symptoms in middle aged men: findings from the Caerphilly prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							HEART		Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Barts & London Queen Mary Univ London, Ctr Psychiat, London WC1E 7HU, England; Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast BT7 1NN, Antrim, North Ireland; Cardiff Univ, Dept Epidemiol Stat & Publ Hlth, Cardiff CF4 4XN, S Glam, Wales	University of Bristol; University of London; Queen Mary University London; Queens University Belfast; Cardiff University	Lawlor, DA (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	d.a.lawlor@bristol.ac.uk	Ben-Shlomo, Yoav/ABD-2004-2021; Davey Smith, George/A-7407-2013	Ben-Shlomo, Yoav/0000-0001-6648-3007; Davey Smith, George/0000-0002-1407-8314; Venkatasubramanian, Siddharth/0000-0002-5860-0768; s, hema/0000-0002-3440-9475; Lawlor, Debbie A/0000-0002-6793-2262				Golomb BA, 2002, J CLIN EPIDEMIOL, V55, P767, DOI 10.1016/S0895-4356(02)00407-9; Lawlor DA, 2003, BRIT MED J, V327, P1383, DOI 10.1136/bmj.327.7428.1383; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; STANSFELD SA, 1991, PSYCHOL MED, V21, P157, DOI 10.1017/S0033291700014744; Timonen M, 2005, BMJ-BRIT MED J, V330, P17, DOI 10.1136/bmj.38313.513310.F71	5	41	42	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	MAR 26	2005	330	7493					705	706		10.1136/bmj.38377.616921.F7	http://dx.doi.org/10.1136/bmj.38377.616921.F7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912IT	15684022	Green Accepted, Green Published, Bronze, Green Submitted			2022-12-28	WOS:000228071900017
J	Solomon, SD; McMurray, JJV; Pfeffer, MA; Wittes, J; Fowler, R; Finn, P; Anderson, WF; Zauber, A; Hawk, E; Bertagnolli, M				Solomon, SD; McMurray, JJV; Pfeffer, MA; Wittes, J; Fowler, R; Finn, P; Anderson, WF; Zauber, A; Hawk, E; Bertagnolli, M		APC Study Investigators	Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SELECTIVE CYCLOOXYGENASE-2 INHIBITORS; ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CONTROLLED-TRIAL; GASTROINTESTINAL TOXICITY; RHEUMATOID-ARTHRITIS; THROMBOTIC EVENTS; ARACHIDONIC-ACID; COX-2 INHIBITION; ROFECOXIB	BACKGROUND: Selective cyclooxygenase-2 (COX-2) inhibitors have come under scrutiny because of reports suggesting an increased cardiovascular risk associated with their use. Experimental research suggesting that these drugs may contribute to a prothrombotic state provides support for this concern. METHODS: We reviewed all potentially serious cardiovascular events among 2035 patients with a history of colorectal neoplasia who were enrolled in a trial comparing two doses of celecoxib (200 mg or 400 mg twice daily) with placebo for the prevention of colorectal adenomas. All deaths were categorized as cardiovascular or noncardiovascular, and nonfatal cardiovascular events were categorized in a blinded fashion according to a prespecified scheme. RESULTS: For all patients except those who died, 2.8 to 3.1 years of follow-up data were available. A composite cardiovascular end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure was reached in 7 of 679 patients in the placebo group (1.0 percent), as compared with 16 of 685 patients receiving 200 mg of celecoxib twice daily (2.3 percent; hazard ratio, 2.3; 95 percent confidence interval, 0.9 to 5.5) and with 23 of 671 patients receiving 400 mg of celecoxib twice daily (3.4 percent; hazard ratio, 3.4; 95 percent confidence interval, 1.4 to 7.8). Similar trends were observed for other composite end points. On the basis of these observations, the data and safety monitoring board recommended early discontinuation of the study drug. CONCLUSIONS: Celecoxib use was associated with a dose-related increase in the composite end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure. In light of recent reports of cardiovascular harm associated with treatment with other agents in this class, these data provide further evidence that the use of COX-2 inhibitors may increase the risk of serious cardiovascular events.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Cardiovasc Div, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA; Univ Glasgow, Western Infirm, Glasgow G11 6NT, Lanark, Scotland; Stat Collaborat, Washington, DC USA; NCI, Bethesda, MD 20892 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Glasgow; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center	Solomon, SD (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA.	ssolomon@rics.bwh.harvard.edu	Solomon, Scott/I-5789-2013; mcmurray, John/B-2467-2013	mcmurray, John/0000-0002-6317-3975				Baron JA, 2003, PROG EXP TUMOR RES, V37, P1; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Brock TG, 1999, J BIOL CHEM, V274, P11660, DOI 10.1074/jbc.274.17.11660; *CEL, 2005, PHRMA IQ59702001; Chenevard R, 2003, CIRCULATION, V107, P405, DOI 10.1161/01.CIR.0000051361.69808.3A; Crofford LJ, 2000, ARTHRITIS RHEUM-US, V43, P4, DOI 10.1002/1529-0131(200001)43:1<4::AID-ANR2>3.0.CO;2-V; Dieppe PA, 2004, BRIT MED J, V329, P867, DOI 10.1136/bmj.329.7471.867; Farkouh ME, 2004, LANCET, V364, P675, DOI 10.1016/S0140-6736(04)16894-3; FitzGerald G, 2003, NAT REV DRUG DISCOV, V2, P879, DOI 10.1038/nrd1225; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; FitzGerald GA, 2004, NEW ENGL J MED, V351, P1709, DOI 10.1056/NEJMp048288; Furberg CD, 2005, CIRCULATION, V111, P249, DOI 10.1161/01.CIR.0000155081.76164.17; Giardiello FM, 2002, NEW ENGL J MED, V346, P1054, DOI 10.1056/NEJMoa012015; Hawk Ernest T, 2003, Cancer Chemother Biol Response Modif, V21, P759; Josefson D, 2001, BRIT MED J, V323, P767, DOI 10.1136/bmj.323.7316.767a; Juni P, 2004, LANCET, V364, P2021, DOI 10.1016/S0140-6736(04)17514-4; Konstam MA, 2001, CIRCULATION, V104, P2280, DOI 10.1161/hc4401.100078; Mamdani M, 2003, ARCH INTERN MED, V163, P481, DOI 10.1001/archinte.163.4.481; Mamdani M, 2004, LANCET, V363, P1751, DOI 10.1016/S0140-6736(04)16299-5; Marnett LJ, 1999, J BIOL CHEM, V274, P22903, DOI 10.1074/jbc.274.33.22903; Marnett LJ, 1999, TRENDS PHARMACOL SCI, V20, P465, DOI 10.1016/S0165-6147(99)01385-1; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P5890; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; Mukherjee D, 2003, AM HEART J, V146, P563, DOI 10.1016/S0002-8703(03)00399-5; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; Nussmeier NA, 2005, NEW ENGL J MED, V352, P1081, DOI 10.1056/NEJMoa050330; Ott E, 2003, J THORAC CARDIOV SUR, V125, P1481, DOI 10.1016/S0022-5223(03)00125-9; Ray WA, 2002, LANCET, V360, P1071, DOI 10.1016/S0140-6736(02)11131-7; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Solomon DH, 2004, CIRCULATION, V109, P2068, DOI 10.1161/01.CIR.0000127578.21885.3E; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Topol EJ, 2004, LANCET, V364, P639, DOI 10.1016/S0140-6736(04)16906-7; Topol EJ, 2004, NEW ENGL J MED, V351, P1707, DOI 10.1056/NEJMp048286; Topol EJ, 2004, NEW ENGL J MED, V351, P2877; Weir MR, 2003, AM HEART J, V146, P591, DOI 10.1016/S0002-8703(03)00398-3; White WB, 2003, AM J CARDIOL, V92, P411, DOI 10.1016/S0002-9149(03)00659-3; Zhao SZ, 2002, AM J MANAG CARE, V8, pS392	38	1607	1685	1	53	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 17	2005	352	11					1071	1080		10.1056/NEJMoa050405	http://dx.doi.org/10.1056/NEJMoa050405			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	906PU	15713944				2022-12-28	WOS:000227655000004
J	Haug, GH; Ganopolski, A; Sigman, DM; Rosell-Mele, A; Swann, GEA; Tiedemann, R; Jaccard, SL; Bollmann, J; Maslin, MA; Leng, MJ; Eglinton, G				Haug, GH; Ganopolski, A; Sigman, DM; Rosell-Mele, A; Swann, GEA; Tiedemann, R; Jaccard, SL; Bollmann, J; Maslin, MA; Leng, MJ; Eglinton, G			North Pacific seasonality and the glaciation of North America 2.7 million years ago	NATURE			English	Article							ATLANTIC; CLIMATE; CALIBRATION; RECORDS; SILICA; PANAMA; INDEX; MODEL	In the context of gradual Cenozoic cooling, the timing of the onset of significant Northern Hemisphere glaciation 2.7 million years ago is consistent with Milankovitch's orbital theory, which posited that ice sheets grow when polar summertime insolation and temperature are low. However, the role of moisture supply in the initiation of large Northern Hemisphere ice sheets has remained unclear. The subarctic Pacific Ocean represents a significant source of water vapour to boreal North America, but it has been largely overlooked in efforts to explain Northern Hemisphere glaciation. Here we present alkenone unsaturation ratios and diatom oxygen isotope ratios from a sediment core in the western subarctic Pacific Ocean, indicating that 2.7 million years ago late-summer sea surface temperatures in this ocean region rose in response to an increase in stratification. At the same time, winter sea surface temperatures cooled, winter floating ice became more abundant and global climate descended into glacial conditions. We suggest that the observed summer warming extended into the autumn, providing water vapour to northern North America, where it precipitated and accumulated as snow, and thus allowed the initiation of Northern Hemisphere glaciation.	Geoforschungszentrum Potsdam, D-14473 Potsdam, Germany; Potsdam Inst Climate Impact Res, D-14473 Potsdam, Germany; Princeton Univ, Dept Geosci, Princeton, NJ 08544 USA; Autonomous Univ Barcelona, ICREA, Bellaterra 08193, Catalonia, Spain; Autonomous Univ Barcelona, ICTA, Bellaterra 08193, Catalonia, Spain; UCL, Dept Geog, Environm Change Res Ctr, London WC1H 0AP, England; IFM Geomar, D-24148 Kiel, Germany; ETH, Dept Earth Sci, CH-8092 Zurich, Switzerland; British Geol Survey, NERC, Isotope Geosci Lab, Keyworth NG12 5GG, Notts, England; Univ Bristol, Biogeochem Ctr, Bristol BS8 1TS, Avon, England	Helmholtz Association; Helmholtz-Center Potsdam GFZ German Research Center for Geosciences; Potsdam Institut fur Klimafolgenforschung; Princeton University; Autonomous University of Barcelona; ICREA; Autonomous University of Barcelona; University of London; University College London; Helmholtz Association; GEOMAR Helmholtz Center for Ocean Research Kiel; Swiss Federal Institutes of Technology Domain; ETH Zurich; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Geological Survey; University of Bristol	Haug, GH (corresponding author), Geoforschungszentrum Potsdam, D-14473 Potsdam, Germany.	haug@gfz-potsdam.de	Ganopolski, Andrey/F-6811-2013; Jaccard, Samuel/G-3447-2014; Rosell-Melé, Antoni/B-3433-2013; Swann, George/B-2794-2011; Sigman, Daniel M/A-2649-2008	Jaccard, Samuel/0000-0002-5793-0896; Rosell-Melé, Antoni/0000-0002-5513-2647; Swann, George/0000-0002-4750-9504; Sigman, Daniel M/0000-0002-7923-1973; Maslin, Mark/0000-0001-9957-3463; Leng, Melanie/0000-0003-1115-5166; Tiedemann, Ralf/0000-0001-7211-8049	ICREA Funding Source: Custom; NERC [bgs03002] Funding Source: UKRI; Natural Environment Research Council [bgs03002] Funding Source: researchfish	ICREA(ICREA); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		BARD E, 2001, GEOCHEM GEOPHY GEOSY, V2, DOI DOI 10.1029/2000GC000050; BERGER A, 1991, QUATERNARY SCI REV, V10, P297, DOI 10.1016/0277-3791(91)90033-Q; Brandriss ME, 1998, GEOCHIM COSMOCHIM AC, V62, P1119, DOI 10.1016/S0016-7037(98)00054-4; BRASSELL SC, 1986, NATURE, V320, P129, DOI 10.1038/320129a0; Broecker WS, 1997, SCIENCE, V278, P1582, DOI 10.1126/science.278.5343.1582; Cane MA, 2001, NATURE, V411, P157, DOI 10.1038/35075500; Ganopolski A, 1998, NATURE, V391, P351, DOI 10.1038/34839; GARGETT AE, 1991, LIMNOL OCEANOGR, V36, P1527, DOI 10.4319/lo.1991.36.8.1527; GRIMALT JO, 2000, GEOCHEM GEOPHY GEOSY, V1, P1; Haug GH, 1998, NATURE, V393, P673, DOI 10.1038/31447; Haug GH, 1999, NATURE, V401, P779, DOI 10.1038/44550; JUILLETLECLERC A, 1987, EARTH PLANET SCI NEW, V84, P69, DOI DOI 10.1016/0012-821X(87)90177-4; KEIGWIN L, 1982, SCIENCE, V217, P350, DOI 10.1126/science.217.4557.350; KOSTER R, 1986, GEOPHYS RES LETT, V13, P121, DOI 10.1029/GL013i002p00121; Levitus S., 1994, WORLD OCEAN ATLAS 19, V4; Maslin M., 1992, P OCEAN DRILLING PRO, V145, P315, DOI DOI 10.2973/ODP.PROC.SR.145.119.1995; Muller PJ, 1998, GEOCHIM COSMOCHIM AC, V62, P1757, DOI 10.1016/S0016-7037(98)00097-0; Ohkouchi N, 2002, SCIENCE, V298, P1224, DOI 10.1126/science.1075287; Ohkouchi N, 1999, GLOBAL BIOGEOCHEM CY, V13, P695, DOI 10.1029/1998GB900024; Pagani M, 2002, PALEOCEANOGRAPHY, V17, DOI 10.1029/2002PA000756; Petoukhov V, 2000, CLIM DYNAM, V16, P1, DOI 10.1007/PL00007919; Prahl FG, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000853; PRAHL FG, 1987, NATURE, V330, P367, DOI 10.1038/330367a0; Ravelo AC, 2004, NATURE, V429, P263, DOI 10.1038/nature02567; ROSELLMELE A, 1995, ANAL CHEM, V67, P1283, DOI 10.1021/ac00103a021; Sachs G S, 2000, Postgrad Med, VSpec No, P1; Shackleton N.J., 1995, Proceedings of the Ocean Drilling Program Scientific Results, V138, P337, DOI 10.2973/odp.proc.sr.138.117.1995; SHACKLETON NJ, 1984, NATURE, V307, P620, DOI 10.1038/307620a0; SHEMESH A, 1992, SCIENCE, V256, P1434, DOI 10.1126/science.256.5062.1434; Sigman DM, 2004, NATURE, V428, P59, DOI 10.1038/nature02357; TAKAHASHI K, 1986, DEEP-SEA RES, V33, P1225, DOI 10.1016/0198-0149(86)90022-1; TIEDEMANN R, 1994, PALEOCEANOGRAPHY, V9, P619, DOI 10.1029/94PA00208; VOLKMAN JK, 2000, GEOCHEM GEOPHY GEOSY, V1, P1; WONG CS, 1995, GLOBAL FLUXES CARBON, P339	34	275	295	3	114	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 24	2005	433	7028					821	825		10.1038/nature03332	http://dx.doi.org/10.1038/nature03332			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	899VT	15729332	Green Submitted			2022-12-28	WOS:000227174600032
J	McDonald, KR; Bounds, BC; Brachtel, EF; Zhu, AX; Sahani, D; Krakauer, EL; Harris, NL; Billings, JA				McDonald, KR; Bounds, BC; Brachtel, EF; Zhu, AX; Sahani, D; Krakauer, EL; Harris, NL; Billings, JA			A 58-year-old man with esophageal cancer and nausea, vomiting, and intractable hiccups - Adenocarcinoma of the esophagus with gastric linitis plastica and functional duodenal obstruction.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PALLIATIVE CARE; OCTREOTIDE		Massachusetts Gen Hosp, Palliat Care Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Gastroenterol Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University	McDonald, KR (corresponding author), Massachusetts Gen Hosp, Palliat Care Serv, Boston, MA 02114 USA.							Burt RA, 1997, NEW ENGL J MED, V337, P1234, DOI 10.1056/NEJM199710233371712; Cairns W, 1999, PALLIATIVE MED, V13, P429, DOI 10.1191/026921699677473561; Ebell MH, 1998, J GEN INTERN MED, V13, P805, DOI 10.1046/j.1525-1497.1998.00244.x; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Feuer DJ., 2000, COCHRANE DB SYST REV, V2000; Friedman NL, 1996, PHARMACOTHERAPY, V16, P986; HARPER TG, 1982, J CLIN GASTROENTEROL, V4, P29, DOI 10.1097/00004836-198202000-00005; Hasler WL, 1999, DIGEST DIS SCI, V44, p108S; KHOO D, 1994, EUR J CANCER, V30A, P28, DOI 10.1016/S0959-8049(05)80012-7; KOLODZIK PW, 1991, ANN EMERG MED, V20, P565, DOI 10.1016/S0196-0644(05)81620-8; Krakauer E L, 2000, Oncologist, V5, P53, DOI 10.1634/theoncologist.5-1-53; Mannix K. A., 1998, OXFORD TXB PALLIATIV, P489; PARAF F, 1995, AM J SURG PATHOL, V19, P183, DOI 10.1097/00000478-199502000-00007; PAZDUR R, 1988, AM J GASTROENTEROL, V83, P1395; Quigley EMM, 2001, GASTROENTEROLOGY, V120, P263, DOI 10.1053/gast.2001.20516; Smith DE, 2003, J ARTIF INTELL RES, V20, P149, DOI 10.1613/jair.1997; TWYCROSS R, 1998, OXFORD TXB PALLIATIV, P499; Uygur-Bayramicli O, 2003, J CLIN GASTROENTEROL, V37, P86, DOI 10.1097/00004836-200307000-00023; WERNER M, 2000, WHO CLASSIFICATION T, V2, P20	19	23	23	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2005	352	8					817	825		10.1056/NEJMcpc049037	http://dx.doi.org/10.1056/NEJMcpc049037			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899MC	15728815				2022-12-28	WOS:000227147500013
J	Vergani, P; Lockless, SW; Nairn, AC; Gadsby, DC				Vergani, P; Lockless, SW; Nairn, AC; Gadsby, DC			CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains	NATURE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; MULTIDRUG-RESISTANCE PROTEIN; ABC TRANSPORTER; HYDROLYSIS; SUBUNIT; CYCLE; DIMER	ABC (ATP-binding cassette) proteins constitute a large family of membrane proteins that actively transport a broad range of substrates. Cystic fibrosis transmembrane conductance regulator ( CFTR), the protein dysfunctional in cystic fibrosis, is unique among ABC proteins in that its transmembrane domains comprise an ion channel. Opening and closing of the pore have been linked to ATP binding and hydrolysis at CFTR's two nucleotide-binding domains, NBD1 and NBD2 (see, for example, refs 1, 2). Isolated NBDs of prokaryotic ABC proteins dimerize upon binding ATP, and hydrolysis of the ATP causes dimer dissociation(3-5). Here, using single-channel recording methods on intact CFTR molecules, we directly follow opening and closing of the channel gates, and relate these occurrences to ATP-mediated events in the NBDs. We find that energetic coupling(6) between two CFTR residues, expected to lie on opposite sides of its predicted NBD1-NBD2 dimer interface, changes in concert with channel gating status. The two monitored side chains are independent of each other in closed channels but become coupled as the channels open. The results directly link ATP-driven tight dimerization of CFTR's cytoplasmic nucleotide-binding domains to opening of the ion channel in the transmembrane domains. This establishes a molecular mechanism, involving dynamic restructuring of the NBD dimer interface, that is probably common to all members of the ABC protein superfamily.	Rockefeller Univ, Lab Cardiac Membrane Physiol, New York, NY 10021 USA; Rockefeller Univ, Lab Mol Neurobiol & Biophys, New York, NY 10021 USA; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Yale Univ, Dept Psychiat, New Haven, CT 06519 USA	Rockefeller University; Rockefeller University; Rockefeller University; Yale University	Gadsby, DC (corresponding author), Rockefeller Univ, Lab Cardiac Membrane Physiol, 1230 York Ave, New York, NY 10021 USA.	paola.vergani@rockefeller.edu; gadsby@rockefeller.edu	Vergani, Paola/C-2019-2008	Vergani, Paola/0000-0002-5422-4662; Nairn, Angus/0000-0002-7075-0195	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051767] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK051767, R01 DK051767-09] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; Austermuhle MI, 2004, J BIOL CHEM, V279, P28243, DOI 10.1074/jbc.M403508200; Bakos E, 1997, BIOCHEM J, V323, P777, DOI 10.1042/bj3230777; Basso C, 2003, J GEN PHYSIOL, V122, P333, DOI 10.1085/jgp.200308798; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Csanady L, 2000, BIOPHYS J, V78, P785, DOI 10.1016/S0006-3495(00)76636-7; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; Higgins CF, 2004, NAT STRUCT MOL BIOL, V11, P918, DOI 10.1038/nsmb836; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hopfner KP, 2003, CURR OPIN STRUC BIOL, V13, P249, DOI 10.1016/S0959-440X(03)00037-X; Horn C, 2003, J MOL BIOL, V334, P403, DOI 10.1016/j.jmb.2003.09.079; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Janas E, 2003, J BIOL CHEM, V278, P26862, DOI 10.1074/jbc.M301227200; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Lockless SW, 1999, SCIENCE, V286, P295, DOI 10.1126/science.286.5438.295; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Qian YM, 2001, J BIOL CHEM, V276, P38636, DOI 10.1074/jbc.M107025200; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Tombline G, 2004, J BIOL CHEM, V279, P31212, DOI 10.1074/jbc.M404689200; Verdon G, 2003, J MOL BIOL, V330, P343, DOI 10.1016/S0022-2836(03)00575-8; Verdon G, 2003, J MOL BIOL, V334, P255, DOI 10.1016/j.jmb.2003.08.065; Vergani P, 2003, J GEN PHYSIOL, V121, P17, DOI 10.1085/jgp.20028673	28	326	332	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 24	2005	433	7028					876	880		10.1038/nature03313	http://dx.doi.org/10.1038/nature03313			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	899VT	15729345	Green Accepted, Green Published			2022-12-28	WOS:000227174600045
J	Browne, KD; Hamilton-Giachritsis, C				Browne, KD; Hamilton-Giachritsis, C			The influence of violent media on children and adolescents: a public-health approach	LANCET			English	Review							VIDEO GAMES; AGGRESSIVE-BEHAVIOR; TELEVISION VIOLENCE; FILM VIOLENCE; MUSIC VIDEOS; TV VIOLENCE; EXPOSURE; IMPACT; THOUGHTS; PERCEPTIONS	There is continuing debate on the extent of the effects of media violence on children and young people, and how to investigate these effects. The aim of this review is to consider the research evidence from a public-health perspective. A search of published work revealed five meta-analytic reviews and one quasi-systematic review, all of which were from North America. There is consistent evidence that violent imagery in television, film and video, and computer games has substantial short-term effects on arousal, thoughts, and emotions, increasing the likelihood of aggressive or fearful behaviour in younger children, especially in boys. The evidence becomes inconsistent when considering older children and teenagers, and long-term outcomes for all ages. The multifactorial nature of aggression is emphasised, together with the methodological difficulties of showing causation. Nevertheless, a small but significant association is shown in the research, with an effect size that has a substantial effect on public health. By Contrast, only weak evidence from correlation studies links media violence directly to crime.	Univ Birmingham, Sch Psychol, Ctr Forens & Family Psychol, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Browne, KD (corresponding author), Univ Birmingham, Sch Psychol, Ctr Forens & Family Psychol, Birmingham B15 2TT, W Midlands, England.	k.d.browne@bham.ac.uk	Hamilton-Giachritsis, Catherine/B-7844-2013	Hamilton-Giachritsis, Catherine/0000-0001-9796-2107				Anderson CA, 2002, ANNU REV PSYCHOL, V53, P27, DOI 10.1146/annurev.psych.53.100901.135231; Anderson CA, 2000, J PERS SOC PSYCHOL, V78, P772, DOI 10.1037//0022-3514.78.4.772; Anderson CA, 2003, PSYCHOL SCI, P81, DOI 10.1111/j.1529-1006.2003.pspi_1433.x; Anderson CA, 2004, J ADOLESCENCE, V27, P113, DOI 10.1016/j.adolescence.2003.10.009; Anderson CA, 2003, AGGRESSIVE BEHAV, V29, P423, DOI 10.1002/ab.10042; Anderson CA, 2003, J PERS SOC PSYCHOL, V84, P960, DOI 10.1037/0022-3514.84.5.960; Anderson CA, 2001, PSYCHOL SCI, V12, P353, DOI 10.1111/1467-9280.00366; ARCHER J, 1989, HUMAN AGGRESSION NAT, P3; BAILEY SM, 1993, CRIM JUSTICE MATTERS, V6, P6; BANDURA A, 1963, J ABNORM PSYCHOL, V66, P3, DOI 10.1037/h0048687; Bandura A., 1977, SOCIAL LEARNING THEO, DOI [10.1177/105960117700200317, DOI 10.1177/105960117700200317]; Bar-on ME, 2001, PEDIATRICS, V108, P1222; Barker M., 2001, ILL EFFECTS MEDIA VI; Beck A.T., 2015, COGNITIVE THERAPY PE; Bensley L, 2001, J ADOLESCENT HEALTH, V29, P244, DOI 10.1016/S1054-139X(01)00239-7; BERKOWITZ L, 1984, PSYCHOL BULL, V95, P410, DOI 10.1037/0033-2909.95.3.410; Berry M, 1999, J SOC PSYCHOL, V139, P567, DOI 10.1080/00224549909598417; *BRIT BOARD FILM C, 2002, BBFC ANN REP; Brown JD, 2000, J ADOLESCENT HEALTH, V27, P2, DOI 10.1016/S1054-139X(00)00139-7; Browne K.D., 1997, PREVENTING FAMILY VI; Browne K. D., 2000, VIOLENT CHILDREN ADO, P151; Browne KD, 1998, J FAM VIOLENCE, V13, P59, DOI 10.1023/A:1022812816957; BROWNE KD, 1998, RES FINDINGS, V65, P1; BROWNE KD, 2002, EARLY PREDICTION PRE; BROWNE KD, 1998, EFFECTS VIDEO VIOLEN; BROWNE KD, 1999, BEHAV IMPACT VIEWING; Bushman BJ, 2003, AM PSYCHOL, V58, P130, DOI 10.1037/0003-066X.58.2.130; Bushman BJ, 2001, AM PSYCHOL, V56, P477, DOI 10.1037//0003-066X.56.6-7.477; Bushman Brad J, 2001, HDB CHILDREN MEDIA, P223; Cantor J, 2000, J ADOLESCENT HEALTH, V27, P30, DOI 10.1016/S1054-139X(00)00129-4; CHAPIN J, 2002, P ASS ED JOURN MASS; CHOI SC, 1979, KOREAN J PSYCHOL, V2, P259; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; *COMM CHILDR VIOL, 1995, CHILDR VIOL; Comstock G., 1991, TELEVISION AM CHILD; COOK DE, JOINT STATEMENT IMPA; Cooley-Quille M, 2001, J CLIN CHILD PSYCHOL, V30, P199, DOI 10.1207/S15374424JCCP3002_7; Cumberbatch G, 2000, NEW SCI, V166, P44; CUMBERBATCH G, 1995, MEDIA VIOLENCE RES E; Dill KE, 1998, AGGRESS VIOLENT BEH, V3, P407, DOI 10.1016/S1359-1789(97)00001-3; DODGE KA, 1980, CHILD DEV, V51, P162, DOI 10.1111/j.1467-8624.1980.tb02522.x; DONNERSTEIN E, 1985, AGGRESSIVE BEHAV, V11, P161; DONOHUE TR, 1988, CHILD STUDY J, V18, P233; DORR A, 1981, CHILDREN FACES TELEV, P183; FARRINGTON DP, 1995, J CHILD PSYCHOL PSYC, V36, P929, DOI 10.1111/j.1469-7610.1995.tb01342.x; FEDERMAN J, 1998, NATL TELEVISION VIOL; Freedman J.L., 2002, MEDIA VIOLENCE ITS E; Funk JB, 2002, AGGRESSIVE BEHAV, V28, P134, DOI 10.1002/ab.90015; Gauntlett David, 1995, MOVING EXPERIENCES U; GREESON LE, 1986, YOUTH SOC, V18, P177, DOI 10.1177/0044118X86018002005; Griffiths M, 1999, AGGRESS VIOLENT BEH, V4, P203, DOI 10.1016/S1359-1789(97)00055-4; GROEBEL J, 1998, ED MEDIA INT, V35, P216; GUNTER B, 1997, CHILDREN TELEVISION; Gunter B., 1990, CHILDREN TELEVISION; HAGELL A, 1994, YOUNG OFFENDERS MEDI; HEATH L, 1986, VICTIMS VIOLENCE, V13, P177; HOPF C, 2001, Z SOZIOL ERZIEH SOZI, V21, P150; Howell DC, 1987, STAT METHODS PSYCHOL; HUESMANN LR, 1984, DEV PSYCHOL, V20, P746, DOI 10.1037/0012-1649.20.5.746; Huesmann LR, 2003, DEV PSYCHOL, V39, P201, DOI 10.1037/0012-1649.39.2.201; Huesmann LR, 1999, AGGRESSIVE BEHAV, V25, P18; *IND TEL COMM, 1998, TEL PUBL VIEW 1998 I; ITZIN C, 1994, PORNOGRAPHIC VIOLENT; Johnson JG, 2002, SCIENCE, V297, P50; Johnson JG, 2002, SCIENCE, V295, P2468, DOI 10.1126/science.1062929; Jolliffe D, 2004, AGGRESS VIOLENT BEH, V9, P441, DOI 10.1016/j.avb.2003.03.001; Kiewitz C, 2001, PERS INDIV DIFFER, V31, P821, DOI 10.1016/S0191-8869(00)00179-3; Kirsh SJ, 2003, AGGRESS VIOLENT BEH, V8, P377, DOI 10.1016/S1359-1789(02)00056-3; Krug EG, 2002, LANCET, V360, P1083, DOI 10.1016/S0140-6736(02)11133-0; KRUTTSCHNITT C, 1986, CRIMINOLOGY, V24, P235, DOI 10.1111/j.1745-9125.1986.tb01495.x; LAGERSPETZ KM, 1982, PSYKOLOGIA, V17, P320; MCCARRAHER L, 1998, FAMILY VIEWING REPOR; Meloy JR, 2001, J FORENSIC SCI, V46, P1113; Nathanson AI, 2000, J BROADCAST ELECTRON, V44, P125, DOI 10.1207/s15506878jobem4401_9; NEWSON E, 1994, PSYCHOLOGIST, V7, P272; Novaco R.W., 1975, ANGER CONTROL DEV EV; Osofsky JD, 1999, FUTURE CHILD, V9, P33, DOI 10.2307/1602780; PAIK H, 1994, COMMUN RES, V21, P516, DOI 10.1177/009365094021004004; PENNELL A, 1998, PRISON SERVICE J, V120, P23; Pennell AE, 1999, AGGRESS VIOLENT BEH, V4, P13, DOI 10.1016/S1359-1789(97)00048-7; Philo G., 1996, MEDIA MENTAL DISTRES; Potter WJ, 2003, J COMMUN, V53, P315, DOI 10.1093/joc/53.2.315; REHMAN SN, 1985, PA SPEECH COMMUN ANN, V41, P64; REID P, 1995, PSYCHOL WOMEN QUART, V19, P397, DOI 10.1111/j.1471-6402.1995.tb00082.x; REYNOLDS J, 2001, NOT FRONT CHILDREN C; Rosenthal R., 1984, META ANAL PROCEDURES; Sargent JD, 2002, J ADOLESCENT HEALTH, V31, P449, DOI 10.1016/S1054-139X(02)00399-3; Savage J, 2004, AGGRESS VIOLENT BEH, V10, P99, DOI 10.1016/j.avb.2003.10.001; Sherry JL, 2001, HUM COMMUN RES, V27, P409, DOI 10.1093/hcr/27.3.409; Singer D. G., 2001, HDB CHILDREN MEDIA; Slater MD, 2003, COMMUN RES, V30, P713, DOI 10.1177/0093650203258281; Slater MD, 2003, J COMMUN, V53, P105, DOI 10.1111/j.1460-2466.2003.tb03008.x; Smith SL, 2002, J COMMUN, V52, P61, DOI 10.1111/j.1460-2466.2002.tb02533.x; STRASBURGER VC, 1995, PEDIATR ANN, V24, P97, DOI 10.3928/0090-4481-19950201-09; Strasburger VC, 1995, ADOLESCENTS MEDIA ME; Surette R, 2002, CRIME DELINQUENCY, V48, P46, DOI 10.1177/0011128702048001002; Unsworth G, 2001, AUST PSYCHOL, V36, P184, DOI 10.1080/00050060108259654; VANFEILITZEN C, 1999, CHILDREN MEDIA IMAGE; Vidal MA, 2003, AGGRESSIVE BEHAV, V29, P381, DOI 10.1002/ab.10037; VINE I, 1994, ALLEGED CAUSAL LINKS; VONFEILITZEN C, 2001, INFLUENCES MEDIA VIO; VOOIJS MW, 1993, J EDUC TV, V19, P139, DOI 10.1080/0260741930190303; VOOIJS MW, 1993, J RES DEV EDUC, V26, P133; Walker HM, 1999, INTERV SCH CLIN, V35, P67, DOI 10.1177/105345129903500201; WHITNEY C, 2001, VIOLENCE MEDIA INT E; WITHECOMB JL, 1997, J MENTAL HLTH, V6, P433; WOOD W, 1991, PSYCHOL BULL, V109, P371, DOI 10.1037/0033-2909.109.3.371; Yukawa S, 2001, Shinrigaku Kenkyu, V72, P1	108	163	168	14	225	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	2005	365	9460					702	710						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	898SP	15721477	Green Accepted			2022-12-28	WOS:000227096800029
J	Cejka, JC; Gautier, G				Cejka, JC; Gautier, G			Unlucky ... unlucky ...	LANCET			English	Editorial Material									Hop Edouard Herriot, Dept Anesthesiol, Lyon, France; Hop Edouard Herriot, Dept Radiol, Lyon, France	CHU Lyon; CHU Lyon	Cejka, JC (corresponding author), Hop Edouard Herriot, Dept Anesthesiol, Lyon, France.	jc.cejka@free.fr							0	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 19	2005	365	9460					680	680						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	898SP	15721473				2022-12-28	WOS:000227096800025
J	Duster, T				Duster, T			Medicine - Race and reification in science	SCIENCE			English	Article							DNA; BLACKS		NYU, Inst Hist Prod Knowledge, New York, NY 10003 USA	New York University	Duster, T (corresponding author), NYU, Inst Hist Prod Knowledge, 269 Mercer St, New York, NY 10003 USA.	troy.duster@nyu.edu						Cooper RS, 2005, BMC MED, V3, DOI 10.1186/1741-7015-3-2; Cooper RS, 1998, HYPERTENSION, V32, P813, DOI 10.1161/01.HYP.32.5.813; Donohue JJ, 2001, J LAW ECON, V44, P367, DOI 10.1086/322810; Duster T., 2004, DNA CRIMINAL JUSTICE, P315; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; GRIFFITH V, 2001, FINANCIAL TIMES 0309, P13; HACKER A, 1992, 2 NATIONS BLACK WHIT, P197; Hinds DA, 2005, SCIENCE, V307, P1072, DOI 10.1126/science.1105436; Jobling MA, 2004, NAT REV GENET, V5, P739, DOI 10.1038/nrg1455; Kahn J., COMMUNICATION; Kahn Jonathan, 2004, Yale J Health Policy Law Ethics, V4, P1; KLAG MJ, 1991, JAMA-J AM MED ASSOC, V265, P599, DOI 10.1001/jama.265.5.599; Knowles J, 2001, J POLIT ECON, V109, P203, DOI 10.1086/318603; LAZER D, 2004, DNA CRIMINAL JUSTICE, P1; Lowe AL, 2001, FORENSIC SCI INT, V119, P17, DOI 10.1016/S0379-0738(00)00387-X; Mauer M., 1999, RACE INCARCERATE; *NITROMED INC, 2005, PR NEWSWIRE US  0111; Shriver MD, 1997, AM J HUM GENET, V60, P957; Simonov VI, 2003, NATO SCI SER II-MATH, V126, P1; Taylor AL, 2004, NEW ENGL J MED, V351, P2049, DOI 10.1056/NEJMoa042934; Whitehead AN., 1929, PROCESS REALITY, P11	21	234	238	3	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2005	307	5712					1050	1051		10.1126/science.1110303	http://dx.doi.org/10.1126/science.1110303			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ED	15718453				2022-12-28	WOS:000227197300028
J	Biddinger, PD; Isselbacher, EM; Fan, D; Shepard, JO; Egan, D; Fan, D; Harris, NL; Parks, L				Biddinger, PD; Isselbacher, EM; Fan, D; Shepard, JO; Egan, D; Fan, D; Harris, NL; Parks, L			A 53-year-old man with depression and sudden shortness of breath - Invasive endocarditis, possibly due to bartonella	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PSYCHIATRIC-PATIENTS; MEDICAL CLEARANCE; INFECTIVE ENDOCARDITIS; PULMONARY-EDEMA; PERIVALVULAR ABSCESS; MITRAL REGURGITATION; EMERGENCY ROOM		Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Surg, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University	Biddinger, PD (corresponding author), Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.							Abe Y, 2003, J AM COLL CARDIOL, V41, P737, DOI 10.1016/S0735-1097(02)02925-X; Bloom BJ, 2002, NEW ENGL J MED, V347, P921, DOI 10.1056/NEJMcpc020115; Brecker SJD, 1999, HEART, V82, P260, DOI 10.1136/hrt.82.3.260; CARLSON RJ, 1981, CAN J PSYCHIAT, V26, P65, DOI 10.1177/070674378102600114; Chan KL, 2002, CAN MED ASSOC J, V167, P19; DINUBILE MJ, 1986, AM J CARDIOL, V58, P1213, DOI 10.1016/0002-9149(86)90384-X; DRANCOURT M, 1995, NEW ENGL J MED, V332, P419, DOI 10.1056/NEJM199502163320702; GREDEN JF, 1975, AM J PSYCHIAT, V132, P270; HENNEMAN PL, 1994, ANN EMERG MED, V24, P672, DOI 10.1016/S0196-0644(94)70277-2; Korn CS, 2000, J EMERG MED, V18, P173, DOI 10.1016/S0736-4679(99)00191-2; Kramer K, 2000, AM HEART J, V140, P451, DOI 10.1067/mhj.2000.108828; Olshaker JS, 1997, ACAD EMERG MED, V4, P124, DOI 10.1111/j.1553-2712.1997.tb03718.x; Pierard LA, 2004, NEW ENGL J MED, V351, P1627, DOI 10.1056/NEJMoa040532; RAOULT D, 1997, ANN INTERN MED, V127, P249; RIBA M, 1990, PSYCHOSOMATICS, V31, P400, DOI 10.1016/S0033-3182(90)72134-2; Shafran SD, 2002, CAN MED ASSOC J, V167, P38; SUMMERS WK, 1981, J CLIN PSYCHIAT, V42, P99; TINTINALLI JE, 1994, ANN EMERG MED, V23, P859, DOI 10.1016/S0196-0644(94)70326-4; WEISSBERG MP, 1979, AM J PSYCHIAT, V136, P787	19	4	4	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2005	352	7					709	716		10.1056/NEJMcpc049036	http://dx.doi.org/10.1056/NEJMcpc049036			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897UO	15716566				2022-12-28	WOS:000227031100012
J	Dacey, DM; Liao, HW; Peterson, BB; Robinson, FR; Smith, VC; Pokorny, J; Yau, KW; Gamlin, PD				Dacey, DM; Liao, HW; Peterson, BB; Robinson, FR; Smith, VC; Pokorny, J; Yau, KW; Gamlin, PD			Melanopsin-expressing ganglion cells in primate retina signal colour and irradiance and project to the LGN	NATURE			English	Article							ACTION SPECTRUM; S-CONE; BRIGHTNESS; RESPONSES; ADAPTATION; PATHWAY; HUMANS; SYSTEM; MIDGET	Human vision starts with the activation of rod photoreceptors in dim light and short (S)-, medium (M)-, and long (L)-wavelength-sensitive cone photoreceptors in daylight. Recently a parallel, non-rod, non-cone photoreceptive pathway, arising from a population of retinal ganglion cells, was discovered in nocturnal rodents(1). These ganglion cells express the putative photopigment melanopsin and by signalling gross changes in light intensity serve the subconscious, 'non-image-forming' functions of circadian photoentrainment and pupil constriction(1-7). Here we show an anatomically distinct population of 'giant', melanopsin-expressing ganglion cells in the primate retina that, in addition to being intrinsically photosensitive, are strongly activated by rods and cones, and display a rare, S-Off, ( L + M)-On type of colour-opponent receptive field. The intrinsic, rod and (L + M) cone-derived light responses combine in these giant cells to signal irradiance over the full dynamic range of human vision. In accordance with cone-based colour opponency, the giant cells project to the lateral geniculate nucleus, the thalamic relay to primary visual cortex. Thus, in the diurnal trichromatic primate, 'non-image-forming' and conventional 'image-forming' retinal pathways are merged, and the melanopsin-based signal might contribute to conscious visual perception.	Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Washington Natl Primate Res Ctr, Seattle, WA 98195 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; Univ Chicago, Vis Sci Labs, Chicago, IL 60637 USA; Univ Alabama Birmingham, Vis Sci Res Ctr, Birmingham, AL 35294 USA	University of Washington; University of Washington Seattle; Johns Hopkins University; Johns Hopkins University; University of Chicago; University of Alabama System; University of Alabama Birmingham	Dacey, DM (corresponding author), Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA.	dmd@u.washington.edu	Gamlin, Paul/W-2169-2019	Gamlin, Paul/0000-0002-2966-4762; Robinson, Farrel/0000-0002-3903-8327; Dacey, Dennis/0000-0001-8476-5585	NEI NIH HHS [R01 EY006837, R01 EY014596, R01 EY006837-16A1, R37 EY006837, R01 EY006837-17, R37 EY006837-15S1, R01 EY014596-01, R37 EY006837-15, R01 EY006837-18] Funding Source: Medline; NIDCD NIH HHS [R01 DC006904, R01 DC006904-01] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006837, R37EY006837, R01EY014596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006904] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BARLOW HB, 1969, J PHYSIOL-LONDON, V202, P699, DOI 10.1113/jphysiol.1969.sp008836; BARLOW RB, 1976, VISION RES, V16, P1291, DOI 10.1016/0042-6989(76)90056-0; Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262; Brainard GC, 2001, J NEUROSCI, V21, P6405; Cottaris NP, 1998, NATURE, V395, P896, DOI 10.1038/27666; DACEY DM, 1994, NATURE, V367, P731, DOI 10.1038/367731a0; Dacey DM, 2003, NEURON, V37, P15, DOI 10.1016/S0896-6273(02)01143-1; Diller L, 2004, J NEUROSCI, V24, P1079, DOI 10.1523/JNEUROSCI.3828-03.2004; ENROTHCUGELL C, 1983, J PHYSIOL-LONDON, V341, P279, DOI 10.1113/jphysiol.1983.sp014806; Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117; Hankins MW, 2002, CURR BIOL, V12, P191, DOI 10.1016/S0960-9822(02)00659-0; Hannibal J, 2004, INVEST OPHTH VIS SCI, V45, P4202, DOI 10.1167/iovs.04-0313; Hattar S, 2003, NATURE, V424, P76, DOI 10.1038/nature01761; Hattar S, 2002, SCIENCE, V295, P1065, DOI 10.1126/science.1069609; Kaufman L, 1986, HDB PERCEPTION HUMAN, Vfirst, P1; KAYAMA Y, 1979, J NEUROPHYSIOL, V42, P1495, DOI 10.1152/jn.1979.42.6.1495; Kinoshita M, 2001, J NEUROPHYSIOL, V86, P2559, DOI 10.1152/jn.2001.86.5.2559; Klug K, 2003, J NEUROSCI, V23, P9881; KRAUSKOPF J, 1982, VISION RES, V22, P1123, DOI 10.1016/0042-6989(82)90077-3; Lucas RJ, 2003, SCIENCE, V299, P245, DOI 10.1126/science.1077293; MARROCCO RT, 1975, BRAIN RES, V86, P128, DOI 10.1016/0006-8993(75)90644-7; MOLLON JD, 1989, DIE FARBE, V35, P139; Packer O, 2001, VISION RES, V41, P427, DOI 10.1016/S0042-6989(00)00271-6; Panda S, 2003, SCIENCE, V301, P525, DOI 10.1126/science.1086179; Panda S, 2002, SCIENCE, V298, P2213, DOI 10.1126/science.1076848; Provencio I, 2000, J NEUROSCI, V20, P600, DOI 10.1523/JNEUROSCI.20-02-00600.2000; Ruby NF, 2002, SCIENCE, V298, P2211, DOI 10.1126/science.1076701; TAKAHASHI JS, 1984, NATURE, V308, P186, DOI 10.1038/308186a0; Thapan K, 2001, J PHYSIOL-LONDON, V535, P261, DOI 10.1111/j.1469-7793.2001.t01-1-00261.x; VALBERG A, 1986, VISION RES, V26, P1061, DOI 10.1016/0042-6989(86)90040-4	30	905	935	3	110	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	2005	433	7027					749	754		10.1038/nature03387	http://dx.doi.org/10.1038/nature03387			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897XH	15716953				2022-12-28	WOS:000227039200041
J	VandenBussche, HL; Klepser, ME				VandenBussche, HL; Klepser, ME			Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs?	LANCET			English	Editorial Material							ONCE-DAILY TOBRAMYCIN; PEDIATRIC-PATIENTS; ADULT PATIENTS; PHARMACOKINETICS; EXACERBATIONS; METAANALYSIS; AMIKACIN; EFFICACY		Bronson Methodist Hosp, Dept Pharm, Kalamazoo, MI 49007 USA; Ferris State Univ, Coll Pharm, Kalamazoo, MI USA		VandenBussche, HL (corresponding author), Bronson Methodist Hosp, Dept Pharm, Kalamazoo, MI 49007 USA.	vandenbh@bronsonhg.org						Aminimanizani A, 2002, J ANTIMICROB CHEMOTH, V50, P553, DOI 10.1093/jac/dkf168; Barza M, 1996, BRIT MED J, V312, P338; Beringer PM, 2000, ANTIMICROB AGENTS CH, V44, P809, DOI 10.1128/AAC.44.4.809-813.2000; BRAUDE AC, 1983, AM REV RESPIR DIS, V127, P563, DOI 10.1164/arrd.1983.127.5.563; Canis F, 1997, J ANTIMICROB CHEMOTH, V39, P431, DOI 10.1093/jac/39.3.431; Carcas AJ, 1999, CLIN PHARMACOL THER, V65, P245, DOI 10.1016/S0009-9236(99)70103-7; Contopoulos-Ioannidis DG, 2004, PEDIATRICS, V114, pE111, DOI 10.1542/peds.114.1.e111; LEVY J, 1983, J INFECT DIS, V148, P1069, DOI 10.1093/infdis/148.6.1069; MARIK PE, 1991, J ANTIMICROB CHEMOTH, V28, P753, DOI 10.1093/jac/28.5.753; Master V, 2001, PEDIATR PULM, V31, P367, DOI 10.1002/ppul.1060; NAHATA MC, 1987, CHEMOTHERAPY, V33, P302, DOI 10.1159/000238512; Vic P, 1998, ARCH DIS CHILD, V78, P536, DOI 10.1136/adc.78.6.536; Whitehead A, 2002, EUR RESPIR J, V19, P303, DOI 10.1183/09031936.02.00221602	13	8	8	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 12	2005	365	9459					547	548						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DN	15708080				2022-12-28	WOS:000226984300003
J	Graham, DJ; Campen, D; Hui, R; Spence, M; Cheetham, C; Levy, G; Shoor, S; Graham, D				Graham, DJ; Campen, D; Hui, R; Spence, M; Cheetham, C; Levy, G; Shoor, S; Graham, D			Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study	LANCET			English	Article							CARDIOVASCULAR EVENTS; GASTROINTESTINAL TOXICITY; ENDOTHELIAL FUNCTION; COX-2 INHIBITION; HEART-DISEASE; NAPROXEN; ROFECOXIB; ARTHRITIS; HEALTH; USERS	Background Controversy has surrounded the question about whether high-dose rofecoxib increases or naproxen decreases the risk of serious coronary heart disease. We sought to establish if risk was enhanced with rofecoxib at either high or standard doses compared with remote non-steroidal anti-inflammatory drug (NSAID) use or celecoxib use, because celecoxib was the most common alternative to rofecoxib. Methods We used data from Kaiser Permanente in California to assemble a cohort of all patients age 18-84 years treated with a NSAID between Jan 1, 1999, and Dec 31, 2001, within which we did a nested case-control study. Cases of serious coronary heart disease (acute myocardial infarction and sudden cardiac death) were risk-set matched with four controls for age, sex, and health plan region. Current exposure to cyclo-oxygenase 2 selective and non-selective NSAIDs was compared with remote exposure to any NSAID, and rofecoxib was compared with celecoxib. Findings During 2 302 029 person-years of follow-up, 8143 cases of serious coronary heart disease occurred, of which 2210 (27.1%) were fatal. Multivariate adjusted odds ratios versus celecoxib were: for rofecoxib (all doses), 1.59 (95% CI 1.10-2.32, p=0.015); for rofecoxib 25 mg/day or less, 1.47 (0.99-2.17, p=0.054); and for rofecoxib greater than 25 mg/day, 3.58 (1.27-10.11, p=0.016). For naproxen versus remote NSAID use the adjusted odds ratio was 1.14 (1.00-1.30, p=0.05). Interpretation Rofecoxib use increases the risk of serious coronary heart disease compared with celecoxib use. Naproxen use does not protect against serious coronary heart disease.	US FDA, Off Drug Safety, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA; Kaiser Permanente, Permanente Med Grp, Oakland, CA USA; Kaiser Permanente, Pharm Outcomes Res Grp, Oakland, CA USA; Kaiser Permanente, So Calif Permanente Med Grp, Oakland, CA USA; Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Ctr Educ & Res Therapeut, Nashville, TN 37212 USA; Nashville Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Nashville, TN USA	US Food & Drug Administration (FDA); Kaiser Permanente; Permanente Medical Groups; Kaiser Permanente; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups; Vanderbilt University; Vanderbilt University; Geriatric Research Education & Clinical Center	Graham, DJ (corresponding author), US FDA, Off Drug Safety, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA.	GRAHAMD@cder.fda.gov			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS010384] Funding Source: NIH RePORTER; AHRQ HHS [HS1-0384] Funding Source: Medline; FDA HHS [FD-U-001641] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); FDA HHS		*AM COLL RHEUM, VIOXX CARD SAF DAT A; American Heart Association, HEART DIS STROK STAT; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Chenevard R, 2003, CIRCULATION, V107, P405, DOI 10.1161/01.CIR.0000051361.69808.3A; Farkouh ME, 2004, LANCET, V364, P675, DOI 10.1016/S0140-6736(04)16894-3; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; FRIESINGER GC, 1998, HURTS HEART, P1127; GRAHAM DJ, COMMUNICATION; Griffin MR, 2000, AM J EPIDEMIOL, V151, P488; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; Harris Gardiner, 2004, N Y Times Web, pA19; Hermann M, 2003, CIRCULATION, V108, P2308, DOI 10.1161/01.CIR.0000101683.30157.0B; *IMS HLTH, 2004, NAT PRESCR AUD PLUS; Juni P, 2004, LANCET, V364, P2021, DOI 10.1016/S0140-6736(04)17514-4; KAUFMAN M, 2004, WASH POST       1216, pA1; Kimmel SE, 2005, ANN INTERN MED, V142, P157, DOI 10.7326/0003-4819-142-3-200502010-00005; Konstam MA, 2001, CIRCULATION, V104, P2280, DOI 10.1161/hc4401.100078; Mamdani M, 2003, ARCH INTERN MED, V163, P481, DOI 10.1001/archinte.163.4.481; McAlister FA, 2000, JAMA-J AM MED ASSOC, V283, P2829, DOI 10.1001/jama.283.21.2829; Merck, MERCK ANN VOL WORLDW; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; Ott E, 2003, J THORAC CARDIOV SUR, V125, P1481, DOI 10.1016/S0022-5223(03)00125-9; *PFIZ, PFIZ PROV INF HLTH C; Rahme E, 2002, ARCH INTERN MED, V162, P1111, DOI 10.1001/archinte.162.10.1111; Rawson NSB, 1995, STAT MED, V14, P2627, DOI 10.1002/sim.4780142404; Ray WA, 2004, CLIN PHARMACOL THER, V75, P234, DOI 10.1016/j.clpt.2003.09.019; Ray WA, 2002, LANCET, V360, P1071, DOI 10.1016/S0140-6736(02)11131-7; Ray WA, 2004, NEW ENGL J MED, V351, P1089, DOI 10.1056/NEJMoa040582; Ray WA, 2002, LANCET, V359, P118, DOI 10.1016/S0140-6736(02)07370-1; Ray WA, 2001, ARCH GEN PSYCHIAT, V58, P1161, DOI 10.1001/archpsyc.58.12.1161; Rothman KJ, 1998, MODERN EPIDEMIOLOGY, P93; Sidney S, 2004, CONTRACEPTION, V70, P3, DOI 10.1016/j.contraception.2004.02.010; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Smalley W, 1999, ARCH INTERN MED, V159, P161, DOI 10.1001/archinte.159.2.161; Solomon DH, 2004, CIRCULATION, V109, P2068, DOI 10.1161/01.CIR.0000127578.21885.3E; Solomon DH, 2002, ARCH INTERN MED, V162, P1099, DOI 10.1001/archinte.162.10.1099; TARGUM SL, 2001, REV CARDIOVASCULAR S; Topol EJ, 2004, NEW ENGL J MED, V351, P1707, DOI 10.1056/NEJMp048286; Watson DJ, 2002, ARCH INTERN MED, V162, P1105, DOI 10.1001/archinte.162.10.1105; Weir MR, 2003, AM HEART J, V146, P591, DOI 10.1016/S0002-8703(03)00398-3; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	41	683	720	1	51	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 5	2005	365	9458					475	481		10.1016/S0140-6736(05)17864-7	http://dx.doi.org/10.1016/S0140-6736(05)17864-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894SS	15705456				2022-12-28	WOS:000226812500024
J	Langhorne, P; Taylor, G; Murray, G; Dennis, M; Anderson, C; Bautz-Holter, E; Dey, P; Indredavik, B; Mayo, N; Power, M; Rodgers, H; Ronning, OM; Rudd, A; Suwanwela, N; Widen-Holmqvist, L; Wolfe, C				Langhorne, P; Taylor, G; Murray, G; Dennis, M; Anderson, C; Bautz-Holter, E; Dey, P; Indredavik, B; Mayo, N; Power, M; Rodgers, H; Ronning, OM; Rudd, A; Suwanwela, N; Widen-Holmqvist, L; Wolfe, C			Early supported discharge services for stroke patients: a meta-analysis of individual patients' data	LANCET			English	Article							RANDOMIZED CONTROLLED-TRIAL; HOSPITAL DISCHARGE; REHABILITATION; HOME; CONSEQUENCES; CARE	Background Stroke patients conventionally undergo a substantial part of their rehabilitation in hospital. Services have been developed that offer patients early discharge from hospital with rehabilitation at home (early supported discharge [ESD]). We have assessed the effects and costs of such services. Methods We did a meta-analysis of data from individual patients who took part in randomised trials that recruited patients with stroke in hospital to receive either conventional care or any ESD service intervention that provided rehabilitation and support in a community setting with the aim of shortening the duration of hospital care. The primary outcome was death or dependency at the end of scheduled follow-up. Findings Outcome data were available for 11 trials (1597 patients). ESD services were mostly provided by specialist multidisciplinary teams to a selected group (median 41%) of stroke patients admitted to hospital. There was a reduced risk of death or dependency equivalent to six (95% Cl one to ten) fewer adverse outcomes for every 100 patients receiving an ESD service (p=0.02). The hospital stay was 8 days shorter for patients assigned ESD services than for those assigned conventional care (p<0.0001). There were also significant improvements in scores on the extended activities of daily living scale and in the odds of living at home and reporting satisfaction with services. The greatest benefits were seen in the trials evaluating a coordinated multidisciplinary ESD team and in stroke patients with mild to moderate disability. Interpretation Appropriately resourced ESD services provided for a selected group of stroke patients can reduce long-term dependency and admission to institutional care as well as shortening hospital stays.	Royal Infirm, Acad Sect Geriatr Med, Glasgow G4 0SF, Lanark, Scotland; Univ Edinburgh, Sch Med, Edinburgh, Midlothian, Scotland; Western Gen Hosp, Div Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Auckland, Dept Med, Auckland, New Zealand; Ullevaal Univ Hosp, Dept Med Phys & Rehabil, Oslo, Norway; Ctr Canc Epidemiol, Manchester, Lancs, England; Univ Trondheim Hosp, Dept Med, Stroke Unit, N-7006 Trondheim, Norway; McGill Univ, Royal Victoria Hosp, Div Clin Epidemiol, Montreal, PQ H3A 1A1, Canada; Ulster Hosp, Dept Hlth Care Elderly People, Belfast, Antrim, North Ireland; Newcastle Univ, Sch Med, Sch Clin Med Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Newcastle Univ, Sch Med, Sch Populat & Hlth Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Akershus Univ Hosp, Dept Neurol, Nordbyhagen, Norway; St Thomas Hosp, Stroke Unit, London, England; Chulalongkorn Univ, Fac Med, Neurol Unit, Bangkok 10330, Thailand; Karolinska Univ Hosp, Karolinska Inst, Neurotec Dept, Div Neurol, Stockholm, Sweden; Karolinska Univ Hosp, Karolinska Inst, Neurotec Dept, Div Physiotherapy, Stockholm, Sweden; Kings Coll London, London WC2R 2LS, England	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh; University of Auckland; University of Oslo; University of Manchester; Norwegian University of Science & Technology (NTNU); McGill University; Royal Victoria Hospital; Newcastle University - UK; Newcastle University - UK; University of Oslo; Guy's & St Thomas' NHS Foundation Trust; Chulalongkorn University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; University of London; King's College London	Langhorne, P (corresponding author), Royal Infirm, Acad Sect Geriatr Med, Level 3,Ctr Block, Glasgow G4 0SF, Lanark, Scotland.	P.Langhorne@clinmed.gla.ac.uk	Rodgers, Helen/K-4358-2012	dennis, martin/0000-0003-1148-8972; Ronning, Ole Morten/0000-0001-5080-5788; Anderson, Craig/0000-0002-7248-4863; Murray, Gordon/0000-0001-9866-4734; Power, Michael/0000-0001-9481-9225				Anderson C, 2000, STROKE, V31, P1032, DOI 10.1161/01.STR.31.5.1032; Anderson C, 2000, STROKE, V31, P1024, DOI 10.1161/01.STR.31.5.1024; Bautz-Holter E, 2002, DISABIL REHABIL, V24, P348, DOI 10.1080/09638280110093677; Beech R, 1999, STROKE, V30, P729, DOI 10.1161/01.STR.30.4.729; CLARKE M, 2003, COCHRANE LIB; Donnelly M, 2004, STROKE, V35, P127, DOI 10.1161/01.STR.0000106911.96026.8F; *EARL SUPP DISCH T, 2001, COCHRANE LIB; Holmqvist LW, 1998, STROKE, V29, P591, DOI 10.1161/01.STR.29.3.591; Indredavik B, 2000, STROKE, V31, P2989, DOI 10.1161/01.STR.31.12.2989; Kalra L, 2000, LANCET, V356, P894, DOI 10.1016/S0140-6736(00)02679-9; LANGHORNE P, 2001, COCHRANE LIB; Mayo NE, 2000, STROKE, V31, P1016, DOI 10.1161/01.STR.31.5.1016; McNamee P, 1998, AGE AGEING, V27, P345, DOI 10.1093/ageing/27.3.345; Rodgers H, 1997, CLIN REHABIL, V11, P280, DOI 10.1177/026921559701100403; Ronning OM, 1998, STROKE, V29, P779, DOI 10.1161/01.STR.29.4.779; Rudd AG, 1997, BMJ-BRIT MED J, V315, P1039, DOI 10.1136/bmj.315.7115.1039; SANDERCOCK P, 2003, COCHRANE LIB; SCHEINBERG L, 1986, CEREBROVASC DIS, V1, P289; *STROK UN TRIAL CO, 2004, COCHR LIB; Suwanwela NC, 2002, CEREBROVASC DIS, V13, P267, DOI 10.1159/000057854; Teng J, 2003, STROKE, V34, P528, DOI 10.1161/01.STR.0000049767.14156.2C; von Koch L, 2001, CEREBROVASC DIS, V12, P131, DOI 10.1159/000047692; Warlow CP., 2001, STROKE PRACTICAL GUI	23	172	178	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 5	2005	365	9458					501	506						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894SS	15705460				2022-12-28	WOS:000226812500028
J	Smulders, Y; Oostwouder, CJ; Stam, F				Smulders, Y; Oostwouder, CJ; Stam, F			Hair loss and cardiovascular health	LANCET			English	Editorial Material							HYPOTHYROIDISM		VU Univ Med Ctr, Div Internal Med & Vasc Med, NL-1081 HV Amsterdam, Netherlands; Med Ctr Alkmaar, Alkmaar, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Medical Center Of Alkmaar	Smulders, Y (corresponding author), VU Univ Med Ctr, Div Internal Med & Vasc Med, NL-1081 HV Amsterdam, Netherlands.	y.smulders@vumc.nl	Smulders, YM/AAG-7506-2021					Duntas LH, 2002, THYROID, V12, P287, DOI 10.1089/10507250252949405; Fommei E, 2002, J CLIN ENDOCR METAB, V87, P1996, DOI 10.1210/jc.87.5.1996; HAMOLSKY MW, 1961, J CHRON DIS, V14, P558, DOI 10.1016/0021-9681(61)90020-0; Kreisman SH, 1999, ARCH INTERN MED, V159, P79, DOI 10.1001/archinte.159.1.79; LEMAR HJ, 1991, AM J MED, V91, P549, DOI 10.1016/0002-9343(91)90194-3	5	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 5	2005	365	9458					544	544						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894SS	15705465				2022-12-28	WOS:000226812500033
J	Kazakova, SV; Hageman, JC; Matava, M; Srinivasan, A; Phelan, L; Garfinkel, B; Boo, T; McAllister, S; Anderson, J; Jensen, B; Dodson, D; Lonsway, D; McDougal, LK; Arduino, M; Fraser, VJ; Killgore, G; Tenover, FC; Cody, S; Jernigan, DB				Kazakova, SV; Hageman, JC; Matava, M; Srinivasan, A; Phelan, L; Garfinkel, B; Boo, T; McAllister, S; Anderson, J; Jensen, B; Dodson, D; Lonsway, D; McDougal, LK; Arduino, M; Fraser, VJ; Killgore, G; Tenover, FC; Cody, S; Jernigan, DB			A clone of methicillin-resistant Staphylococcus aureus among professional football players	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INDUCIBLE CLINDAMYCIN RESISTANCE; PANTON-VALENTINE LEUKOCIDIN; COMMUNITY; INFECTIONS; DISEASES	BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) is an emerging cause of infections outside of health care settings. We investigated an outbreak of abscesses due to MRSA among members of a professional football team and examined the transmission and microbiologic characteristics of the outbreak strain. METHODS: We conducted a retrospective cohort study and nasal-swab survey of 84 St. Louis Rams football players and staff members. S. aureus recovered from wound, nasal, and environmental cultures was analyzed by means of pulsed-field gel electrophoresis (PFGE) and typing for resistance and toxin genes. MRSA from the team was compared with other community isolates and hospital isolates. RESULTS: During the 2003 football season, eight MRSA infections occurred among 5 of the 58 Rams players (9 percent); all of the infections developed at turf-abrasion sites. MRSA infection was significantly associated with the lineman or linebacker position and a higher body-mass index. No MRSA was found in nasal or environmental samples; however, methicillin-susceptible S. aureus was recovered from whirlpools and taping gel and from 35 of the 84 nasal swabs from players and staff members (42 percent). MRSA from a competing football team and from other community clusters and sporadic cases had PFGE patterns that were indistinguishable from those of the Rams' MRSA; all carried the gene for Panton-Valentine leukocidin and the gene complex for staphylococcal-cassette-chromosome mec type IVa resistance (clone USA300-0114). CONCLUSIONS: We describe a highly conserved, community-associated MRSA clone that caused abscesses among professional football players and that was indistinguishable from isolates from various other regions of the United States.	CDCP, Epidem Intelligence Serv, Div Healthcare Qual Promot, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; CDCP, Epidem Intelligence Serv, Div Appl Publ Hlth Training, Epidemiol Program Off, Atlanta, GA 30333 USA; Washington Univ, Sch Med, Dept Orthoped Surg, St Louis, MO USA; Washington Univ, Sch Med, Dept Internal Med, Div Infect Dis, St Louis, MO 63110 USA; Missouri Dept Hlth & Senior Serv, St Louis, MO USA; BJC Med Grp, St Louis, MO USA; St Louis Rams Profess Football Team, St Louis, MO USA; Santa Clara Cty Hlth Dept, Off Dis Control, San Jose, CA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Washington University (WUSTL); Washington University (WUSTL)	Kazakova, SV (corresponding author), CDCP, Epidem Intelligence Serv, Div Healthcare Qual Promot, Natl Ctr Infect Dis, 1600 Clifton Rd,MS A35, Atlanta, GA 30333 USA.	srk7@cdc.gov	Arduino, Matthew/C-1461-2012	Arduino, Matthew/0000-0001-7072-538X; Fraser, Victoria/0000-0001-6251-0733				Baggett HC, 2004, J INFECT DIS, V189, P1565, DOI 10.1086/383247; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P919; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P88; Chambers HF, 2001, EMERG INFECT DIS, V7, P178, DOI 10.3201/eid0702.010204; Dorman JM, 2000, J AM COLL HEALTH, V49, P105, DOI 10.1080/07448480009596291; Enright MC, 2000, J CLIN MICROBIOL, V38, P1008, DOI 10.1128/JCM.38.3.1008-1015.2000; GOODMAN RA, 1994, JAMA-J AM MED ASSOC, V271, P862, DOI 10.1001/jama.271.11.862; HAGEMAN J, 2004, INT C EM INF DIS ATL; Jorgensen JH, 2004, J CLIN MICROBIOL, V42, P1800, DOI 10.1128/JCM.42.4.1800-1802.2004; Katayama Y, 2000, ANTIMICROB AGENTS CH, V44, P1549, DOI 10.1128/AAC.44.6.1549-1555.2000; Letertre C, 2003, MOL CELL PROBE, V17, P227, DOI 10.1016/S0890-8508(03)00058-6; Lina G, 1999, CLIN INFECT DIS, V29, P1128, DOI 10.1086/313461; Luby S, 2002, AM J TROP MED HYG, V67, P430, DOI 10.4269/ajtmh.2002.67.430; Martinez-Aguilar G, 2004, PEDIATR INFECT DIS J, V23, P701, DOI 10.1097/01.inf.0000133044.79130.2a; Maslow Joel N., 1993, P563; McDougal LK, 2003, J CLIN MICROBIOL, V41, P5113, DOI 10.1128/JCM.41.11.5113-5120.2003; Naimi TS, 2003, JAMA-J AM MED ASSOC, V290, P2976, DOI 10.1001/jama.290.22.2976; *NAT COMM CLIN LAB, 2004, M100S14 NAT COMM S14, V24; *NAT CTR HLTH STAT, 2004, 2002 NAT AMB MED CAR; *NAT CTR HLTH STAT, 2004, 2002 NAT HOSP AMB ME; Schreckenberger PC, 2004, J CLIN MICROBIOL, V42, P2777, DOI 10.1128/JCM.42.6.2777-2779.2004; Shopsin B, 2000, J INFECT DIS, V182, P359, DOI 10.1086/315695; Tenover FC, 1997, INFECT CONT HOSP EP, V18, P426; 2003, MMWR MORB MORTAL WKL, V52, P793; 2003, MMWR MORB MORTAL WKL, V52, P992	25	552	585	1	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 3	2005	352	5					468	475		10.1056/NEJMoa042859	http://dx.doi.org/10.1056/NEJMoa042859			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	893NE	15689585				2022-12-28	WOS:000226725400007
J	Fleming, C; Whitlock, EP; Bell, TL; Lederle, FA				Fleming, C; Whitlock, EP; Bell, TL; Lederle, FA			Screening for abdominal aortic aneurysm: A best-evidence systematic review for the US Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED CONTROLLED-TRIAL; SINGLE SCAN; MORTALITY; METAANALYSIS; REPAIR; ULTRASOUND; SPECIALTY; BENEFITS; OUTCOMES; RISK	Background: While the prognosis for abdominal aortic aneurysm (AAA) rupture is poor, ultrasound imaging is an accurate and reliable test for detecting AAAs before rupture. Purpose: To examine the benefits and harms of population-based AAA screening. Data Sources: MEDLINE (1994 to July 2004) supplemented by the Cochrane Library, a reference list of retrieved articles, and expert suggestions. Study Selection: Randomized trials of AAA population screening, population studies of AAA risk factors, and data on adverse screening and treatment events from randomized trials and cohort studies. Data Extraction: All studies were reviewed, abstracted, and rated for quality by using predefined criteria. Data Synthesis: The authors identified 4 population-based randomized, controlled trials of AAA screening in men 65 years of age and older. On the basis of meta-analysis, an invitation to attend screening was associated with a significant reduction in AAA-related mortality (odds ratio, 0.57 [95% CI, 0.45 to 0.74]). A meta-analysis of 3 trials revealed no significant difference in all-cause mortality (odds ratio, 0.98 [CI, 0.95 to 1.02]). No significant reduction in AAA-related mortality was found in 1 study of AAA screening in women. Screening does not appear to be associated with significant physical or psychological harms. Major treatment harms include an operative mortality rate of 2% to 6% and significant risk for major complications. Limitations: The population screening studies focused on men and provided no information on racial or ethnic groups. No information was available on uninvited control group characteristics, so the importance of risk factors such as tobacco use or family history could not be assessed, Since all trials were conducted in countries other than the United States, generalizability to the U.S. population is uncertain. Conclusion: For men age 65 to 75 years, an invitation to attend AAA screening reduces AAA-related mortality.	Kaiser Permanente, Oregon Evidence Based Practice Ctr, Portland, OR USA; Kaiser Permanente, Ctr Hlth Res, Portland, OR USA; Vet Affairs Med Ctr, Ctr Epidemiol & Clin Res, Minneapolis, MN USA	Kaiser Permanente; Kaiser Permanente; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Fleming, C (corresponding author), Kaiser Permanente, Oregon Evidence Based Practice Ctr, Portland, OR USA.							Adam DJ, 1999, J VASC SURG, V30, P922, DOI 10.1016/S0741-5214(99)70018-2; Ashton HA, 2002, LANCET, V360, P1531, DOI 10.1016/S0140-6736(02)11522-4; Barnett SB, 2000, ULTRASOUND MED BIOL, V26, P355, DOI 10.1016/S0301-5629(00)00204-0; Birkmeyer JD, 2003, NEW ENGL J MED, V349, P2117, DOI 10.1056/NEJMsa035205; Black WC, 2002, JNCI-J NATL CANCER I, V94, P167, DOI 10.1093/jnci/94.3.167; Blankensteijn JD, 1998, BRIT J SURG, V85, P1624; Bown MJ, 2002, BRIT J SURG, V89, P714, DOI 10.1046/j.1365-2168.2002.02122.x; Brady AR, 2002, NEW ENGL J MED, V346, P1445; Crow P, 2001, BRIT J SURG, V88, P941, DOI 10.1046/j.0007-1323.2001.01822.x; DARLING RC, 1977, CIRCULATION, V56, P161; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dimick JB, 2003, J VASC SURG, V38, P739, DOI 10.1016/S0741-5214(03)00470-1; EMERTON ME, 1994, BRIT J SURG, V81, P1112, DOI 10.1002/bjs.1800810810; GILLUM RF, 1995, J CLIN EPIDEMIOL, V48, P1289, DOI 10.1016/0895-4356(95)00045-3; Gueyffier F, 1997, ANN INTERN MED, V126, P761, DOI 10.7326/0003-4819-126-10-199705150-00002; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Huber TS, 2001, J VASC SURG, V33, P304, DOI 10.1067/mva.2001.112703; Jamrozik K, 2000, MED J AUSTRALIA, V173, P345, DOI 10.5694/j.1326-5377.2000.tb125684.x; Juffs HG, 2002, J NATL CANCER I, V94, P156; Kent KC, 2004, J VASC SURG, V39, P267, DOI 10.1016/j.jvs.2003.08.019; Lawrence-Brown MMD, 2001, CARDIOVASC SURG, V9, P234, DOI 10.1016/S0967-2109(00)00143-5; LEDERLE FA, 1995, J VASC SURG, V21, P945, DOI 10.1016/S0741-5214(95)70222-9; Lederle FA, 2000, ARCH INTERN MED, V160, P1117, DOI 10.1001/archinte.160.8.1117; Lederle FA, 2000, ARCH INTERN MED, V160, P1425, DOI 10.1001/archinte.160.10.1425; Lederle FA, 2003, ANN INTERN MED, V139, P516, DOI 10.7326/0003-4819-139-6-200309160-00016; Lederle FA, 2003, J VASC SURG, V38, P329, DOI 10.1016/S0741-5214(03)00136-8; Lederle FA, 2001, J VASC SURG, V34, P122, DOI 10.1067/mva.2001.115275; LEDERLE FA, 1988, ARCH INTERN MED, V148, P1753, DOI 10.1001/archinte.148.8.1753; Lederle FA, 2002, NEW ENGL J MED, V346, P1437, DOI 10.1056/NEJMoa012573; Lederle FA, 1997, ANN INTERN MED, V126, P441, DOI 10.7326/0003-4819-126-6-199703150-00004; Lindholt J S, 1996, J Med Screen, V3, P43; Lindholt JS, 1997, BRIT J SURG, V84, P40; Lindholt JS, 2002, EUR J VASC ENDOVASC, V23, P55, DOI 10.1053/ejvs.2001.1534; Lucarotti ME, 1997, EUR J VASC ENDOVASC, V14, P499, DOI 10.1016/S1078-5884(97)80131-1; *NAT CTR HLTH STAT, 2002, TABL 1 DEATHS PERC T; Norman PE, 2004, BRIT MED J, V329, P1259, DOI 10.1136/bmj.38272.478438.55; Norman PE, 2003, BRIT J SURG, V90, P492; NORMAN PE, 2004, QUESTIONS AAA SCREEN; Normand SLT, 1999, STAT MED, V18, P321, DOI 10.1002/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.0.CO;2-P; NUSBAUM JW, 1971, ARCH SURG-CHICAGO, V102, P385; SCHOENBORN CA, 2004, VITAL HLTH STAT, V10, P219; SCOTT RAP, 1995, BRIT J SURG, V82, P1066, DOI 10.1002/bjs.1800820821; Scott RAP, 2001, EUR J VASC ENDOVASC, V21, P535, DOI 10.1053/ejvs.2001.1368; Scott RAP, 2002, BRIT J SURG, V89, P283, DOI 10.1046/j.0007-1323.2001.02014.x; Spencer CA, 2000, J MED SCREEN, V7, P209, DOI 10.1136/jms.7.4.209; Tu JV, 2001, J VASC SURG, V33, P447, DOI 10.1067/mva.2001.113487; *US CENS, 2001, AG GROUPS SEX 2000 S; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; Vardulaki KA, 2002, BRIT J SURG, V89, P861, DOI 10.1046/j.1365-2168.2002.02133.x; Williamson WK, 2001, J VASC SURG, V33, P913, DOI 10.1067/mva.2001.115164; Wilmink A B, 1997, J Med Screen, V4, P49; Wilmink ABM, 2002, J MED SCREEN, V9, P125, DOI 10.1136/jms.9.3.125	52	369	381	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	2005	142	3					203	211		10.7326/0003-4819-142-3-200502010-00012	http://dx.doi.org/10.7326/0003-4819-142-3-200502010-00012			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900UH	15684209				2022-12-28	WOS:000227239300007
J	Fabra, M; Raldua, D; Power, DM; Deen, PMT; Cerda, J				Fabra, M; Raldua, D; Power, DM; Deen, PMT; Cerda, J			Marine fish egg hydration is aquaporin-mediated	SCIENCE			English	Article							WATER CHANNELS; BUOYANCY; OOCYTES		Ctr Aquaculture, Inst Recerca & Tecnol Agroalimentaries, Tarragona, Spain; Reference Ctr Aquaculture, Barcelona, Spain; Univ Algarve, Ctr Marine Sci, Faro, Portugal; Radboud Univ Nijmegen Med Ctr, Dept Physiol, Nijmegen, Netherlands	IRTA; Universidade do Algarve; Radboud University Nijmegen	Cerda, J (corresponding author), Ctr Aquaculture, Inst Recerca & Tecnol Agroalimentaries, Tarragona, Spain.	jcerda@icm.csic.es	Raldúa, Demetrio/K-6661-2014; Raldua, Demetrio/N-9910-2019; Deen, Peter MT/B-9854-2013; Deen, P.M.T./H-8023-2014; Cerdà, Joan/M-1099-2016; Power, Deborah M/D-3333-2011	Raldúa, Demetrio/0000-0001-5256-1641; Raldua, Demetrio/0000-0001-5256-1641; Deen, Peter MT/0000-0002-7868-4655; Deen, P.M.T./0000-0002-7868-4655; Cerdà, Joan/0000-0003-2568-6398; Power, Deborah M/0000-0003-1366-0246				Adlandsvik B, 2001, FISH RES, V50, P59, DOI 10.1016/S0165-7836(00)00242-3; Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; MELLINGER J, 1994, ANN BIOL-PARIS, V33, P117; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; Selman K, 2001, J EXP ZOOL, V290, P265, DOI 10.1002/jez.1057	5	106	113	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2005	307	5709					545	545		10.1126/science.1106305	http://dx.doi.org/10.1126/science.1106305			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893BJ	15681377	Green Submitted			2022-12-28	WOS:000226694000037
J	Gerber, LR; Hyrenbach, KD; Zacharias, MA				Gerber, LR; Hyrenbach, KD; Zacharias, MA			Ecology - Do the largest protected areas conserve whales or whalers?	SCIENCE			English	Editorial Material							MANAGEMENT; RESERVES; OCEAN		Arizona State Univ, Sch Life Sci, Fac Ecol Evolut & Environm Sci, Tempe, AZ 85287 USA; Duke Univ, Marine Lab, Beaufort, NC 28516 USA; Univ Victoria, Dept Geog, Victoria, BC V8W 3P5, Canada	Arizona State University; Arizona State University-Tempe; Duke University; University of Victoria	Gerber, LR (corresponding author), Arizona State Univ, Sch Life Sci, Fac Ecol Evolut & Environm Sci, Tempe, AZ 85287 USA.	Leah.Gerber@asu.edu; khyrenba@duke.edu; Mark.Zacharias@uvic.ca		Gerber, Leah/0000-0002-6763-6842				Ainley D. G., 2002, Marine Ornithology, V30, P55; Baker CS, 2004, TRENDS ECOL EVOL, V19, P365, DOI 10.1016/j.tree.2004.05.005; Bannister J.D., 2002, ENCY MARINE MAMMALS, P62; Boersma PD, 1999, ECOL ECON, V31, P287, DOI 10.1016/S0921-8009(99)00085-3; Clapham PJ, 2003, BIOSCIENCE, V53, P210, DOI 10.1641/0006-3568(2003)053[0210:WAS]2.0.CO;2; CLAPHAM PJ, 2002, ENCY MARINE MAMMALS, P1328; DAVIS CR, 2004, SC56SOS2 IWC; Gerber LR, 2004, BIOL CONSERV, V120, P121, DOI 10.1016/j.biocon.2004.01.029; Hooker SK, 2004, BIOSCIENCE, V54, P27, DOI 10.1641/0006-3568(2004)054[0027:MRAATF]2.0.CO;2; Hyrenbach KD, 2000, AQUAT CONSERV, V10, P437, DOI 10.1002/1099-0755(200011/12)10:6<437::AID-AQC425>3.3.CO;2-H; *IWC, 1999, ANN REP INT WHAL COM, P42; Mills CE, 1998, CONSERV BIOL, V12, P244, DOI 10.1046/j.1523-1739.1998.96475.x; Murray SN, 1999, FISHERIES, V24, P11, DOI 10.1577/1548-8446(1999)024&lt;0011:NRN&gt;2.0.CO;2; Reilly S.B., 1984, REP INT WHAL COMM SP, V6, P389; Russ GR, 2004, ECOL APPL, V14, P597, DOI 10.1890/03-5076; Stafford KM, 2004, DEEP-SEA RES PT I, V51, P1337, DOI 10.1016/j.dsr.2004.05.007; YOUNG NM, 2002, UNDERSTANDING REVISE; ZACHARIAS MA, 2004, SC56SOS5 IWC	18	12	15	2	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2005	307	5709					525	526		10.1126/science.1106120	http://dx.doi.org/10.1126/science.1106120			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893BJ	15681370				2022-12-28	WOS:000226694000030
J	Simmons, NB				Simmons, NB			Evolution - An eocene big bang for bats	SCIENCE			English	Editorial Material									Amer Museum Nat Hist, Div Vertebrate Zool, New York, NY 10024 USA	American Museum of Natural History (AMNH)	Simmons, NB (corresponding author), Amer Museum Nat Hist, Div Vertebrate Zool, New York, NY 10024 USA.	simmons@amnh.org		Simmons, Nancy B./0000-0001-8807-7499				Arita HT, 1997, TRENDS ECOL EVOL, V12, P53, DOI 10.1016/S0169-5347(96)10058-6; Feduccia A., 1999, ORIGIN EVOLUTION BIR, V2; Simmons NB, 2003, BAT ECOLOGY, P493; Simmons NB, 1998, B AM MUS NAT HIST, P1; SIMMONS NB, IN PRESS MAMMAL SPEC; SIMMONS NB, IN PRESS ORIGINS MAJ; SPEAKMAN JR, 1993, SYM ZOOL S, P39; Teeling EC, 2003, MOL PHYLOGENET EVOL, V28, P308, DOI 10.1016/S1055-7903(03)00117-9; Teeling EC, 2005, SCIENCE, V307, P580, DOI 10.1126/science.1105113; Van den Bussche RA, 2004, J MAMMAL, V85, P321, DOI 10.1644/1545-1542(2004)085<0321:PRARCF>2.0.CO;2	10	76	82	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2005	307	5709					527	528		10.1126/science.1108871	http://dx.doi.org/10.1126/science.1108871			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893BJ	15681371				2022-12-28	WOS:000226694000031
J	Lameire, N; Van Biesen, W; Vanholder, R				Lameire, N; Van Biesen, W; Vanholder, R			Acute renal failure	LANCET			English	Review							INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; GLOMERULAR-FILTRATION-RATE; SERUM CYSTATIN-C; RANDOMIZED CLINICAL-TRIAL; ACUTE TUBULAR-NECROSIS; REPLACEMENT THERAPY; STEM-CELLS; INTERMITTENT HEMODIALYSIS; CARDIAC-SURGERY	This seminar covers the most recent information on definition, epidemiology, and clinical causes of acute renal failure. The mechanisms of acute prerenal failure and the potential interference by commonly used drugs of autoregulation of renal blood flow are discussed. We summarise some basic and recent insights into the haemodynamic and cellular pathophysiological mechanisms, mainly of postischaemic acute renal failure. Recent findings on the repair mechanisms of renal injury and the potential future therapeutic possibilities are discussed. We provide some differential diagnostic approaches for patients with acute renal failure and summarise prevention of the disorder and management of critically ill patients by dialysis and by other means. Finally, some information on the influence of gene polymorphisms on the prognosis of acute renal failure is given.	Ghent Univ Hosp, Dept Med, Div Renal, B-9000 Ghent, Belgium	Ghent University; Ghent University Hospital	Lameire, N (corresponding author), Ghent Univ Hosp, Dept Med, Div Renal, De Pintelaan 185, B-9000 Ghent, Belgium.	norbert.lameire@ugent.be						AGRAHARKAR M, 2001, ACUTE RENAL FAILURE, P365; Al-Awqati Q, 2002, KIDNEY INT, V61, P387, DOI 10.1046/j.1523-1755.2002.00164.x; ALEJANDRO VSJ, 1995, KIDNEY INT, V48, P1308, DOI 10.1038/ki.1995.415; Alon US, 1998, CLIN PEDIATR, V37, P387, DOI 10.1177/000992289803700610; Alonso A, 2004, AM J KIDNEY DIS, V43, P1, DOI 10.1053/j.ajkd.2003.09.009; Anderson Robert J, 2004, Best Pract Res Clin Anaesthesiol, V18, P1, DOI 10.1016/j.bpa.2003.09.009; ATKINSON SJ, 2001, ACUTE RENAL FAILURE, P119; BACH PH, 2001, ACUTE RENAL FAILURE, P414; BADR KF, 1988, NEW ENGL J MED, V319, P623; Barsoum RS, 2004, CONTRIB NEPHROL, V144, P44; BAYLIS C, 1978, CIRC RES, V43, P889, DOI 10.1161/01.RES.43.6.889; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Bellomo R, 2000, LANCET, V356, P2139; Bellomo R, 2004, CONTRIB NEPHROL, V144, P105; Bhandari S, 1995, NEPHROL DIAL TRANSPL, V10, P2337, DOI 10.1093/ndt/10.12.2337; BHANDARI S, 1996, QJM, V489, P415; Birck R, 2003, LANCET, V362, P598, DOI 10.1016/S0140-6736(03)14189-X; Blantz RC, 1998, KIDNEY INT, V53, P512, DOI 10.1046/j.1523-1755.2003_t01-1-00784.x; Boccalandro Fernando, 2003, J Invasive Cardiol, V15, P317; BOHLE A, 1990, AM J NEPHROL, V10, P374, DOI 10.1159/000168153; Bonegio R, 2002, CURR OPIN NEPHROL HY, V11, P301, DOI 10.1097/00041552-200205000-00006; Bonventre JV, 2004, KIDNEY INT, V66, P480, DOI 10.1111/j.1523-1755.2004.761_2.x; Bonventre JV, 2003, J AM SOC NEPHROL, V14, P2199, DOI 10.1097/01.ASN.0000079785.13922.F6; Brater DC, 2002, SEMIN ARTHRITIS RHEU, V32, P33, DOI 10.1053/sarh.2002.37216; Breen D, 1998, KIDNEY INT, V53, pS25; BREZIS M, 1995, NEW ENGL J MED, V332, P647, DOI 10.1056/NEJM199503093321006; Brivet FG, 1996, CRIT CARE MED, V24, P192, DOI 10.1097/00003246-199602000-00003; Brodsky SV, 2002, AM J PHYSIOL-RENAL, V282, pF1140, DOI 10.1152/ajprenal.00329.2001; Carmichael P, 2003, ANZ J SURG, V73, P144, DOI 10.1046/j.1445-2197.2003.02640.x; Carvounis CP, 2002, KIDNEY INT, V62, P2223, DOI 10.1046/j.1523-1755.2002.00683.x; CHAPMAN ME, 1991, BRIT J RADIOL, V64, P318, DOI 10.1259/0007-1285-64-760-318; Choi PTL, 1999, CRIT CARE MED, V27, P200, DOI 10.1097/00003246-199901000-00053; Cole L, 2000, AM J RESP CRIT CARE, V162, P191, DOI 10.1164/ajrccm.162.1.9907016; CONGER JD, 1995, AM J KIDNEY DIS, V26, P565, DOI 10.1016/0272-6386(95)90590-1; CONGER JD, 2001, ACUTE RENAL FAILURE, P13; Coresh J, 2002, AM J KIDNEY DIS, V39, P920, DOI 10.1053/ajkd.2002.32765; d'Avila DO, 2004, RENAL FAILURE, V26, P59, DOI 10.1081/JDI-120028552; D'Intini Vincent, 2004, Best Pract Res Clin Anaesthesiol, V18, P145, DOI 10.1016/j.bpa.2003.09.004; Dagher PC, 2004, KIDNEY INT, V66, P506, DOI 10.1111/j.1523-1755.2004.761_7.x; de Mendonca A, 2000, INTENS CARE MED, V26, P915, DOI 10.1007/s001340051281; De Vriese An S, 2003, Curr Opin Crit Care, V9, P474, DOI 10.1097/00075198-200312000-00003; De Vriese AS, 2003, J AM SOC NEPHROL, V14, P792, DOI 10.1097/01.ASN.0000055652.37763.F7; Delanaye P, 2004, INTENS CARE MED, V30, P980, DOI 10.1007/s00134-004-2189-5; Delanghe J, 2002, ACTA CLIN BELG, V57, P172, DOI 10.1179/acb.2002.038; DEMAN A, 2004, ACTUALITES NEPHROLOG, P227; DENICOLA L, 1992, J CLIN INVEST, V89, P1248, DOI 10.1172/JCI115709; Denton MD, 1996, KIDNEY INT, V50, P4, DOI 10.1038/ki.1996.280; DILLON JJ, 2001, ACUTE RENAL FAILURE, P349; Dishart MK, 2000, DRUGS, V59, P79, DOI 10.2165/00003495-200059010-00005; DZAU VJ, 1984, NEW ENGL J MED, V310, P347, DOI 10.1056/NEJM198402093100603; Evenepoel Pieter, 2004, Best Pract Res Clin Anaesthesiol, V18, P37, DOI 10.1016/j.bpa.2003.09.007; FEEST TG, 1993, BMJ-BRIT MED J, V306, P481, DOI 10.1136/bmj.306.6876.481; Filep JG, 2000, BRIT J PHARMACOL, V129, P975, DOI 10.1038/sj.bjp.0703114; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Finn W. F., 2001, ACUTE RENAL FAILURE, P425; FINN WF, 2003, CLIN NEPHROTOXINS RE, P622; FRANKLIN SS, 1986, NEPHRON, V44, P73, DOI 10.1159/000184052; GAILIT J, 1993, AM J PHYSIOL, V264, pF149, DOI 10.1152/ajprenal.1993.264.1.F149; Gambaro G, 2003, J INTERN MED, V253, P643, DOI 10.1046/j.1365-2796.2003.01146.x; Goligorsky MS, 1999, SEMIN NEPHROL, V19, P263; Gruber SJ, 2003, NEW ENGL J MED, V348, P2257; Guerin C, 2002, INTENS CARE MED, V28, P1411, DOI 10.1007/s00134-002-1433-0; HAMMERMAN MR, 1994, J AM SOC NEPHROL, V5, P1; Hampel DJ, 2001, J AM SOC NEPHROL, V12, P1026, DOI 10.1681/ASN.V1251026; Han WK, 2002, KIDNEY INT, V62, P237, DOI 10.1046/j.1523-1755.2002.00433.x; Herget-Rosenthal S, 2004, KIDNEY INT, V66, P1115, DOI 10.1111/j.1523-1755.2004.00861.x; Hewitt SM, 2004, J AM SOC NEPHROL, V15, P1677, DOI 10.1097/01.ASN.0000129114.92265.32; Heyman Samuel N, 2002, Curr Opin Crit Care, V8, P526, DOI 10.1097/00075198-200212000-00008; Hirschberg R, 1999, KIDNEY INT, V55, P2423, DOI 10.1046/j.1523-1755.1999.00463.x; Hladunewich MA, 2003, KIDNEY INT, V64, P593, DOI 10.1046/j.1523-1755.2003.00100.x; Hoffmann U, 2004, J AM SOC NEPHROL, V15, P407, DOI 10.1097/01.ASN.0000106780.14856.55; HOLLENBE.NK, 1970, NEW ENGL J MED, V282, P1329, DOI 10.1056/NEJM197006112822401; HOLLENBE.NK, 1968, MEDICINE, V47, P455, DOI 10.1097/00005792-196811000-00001; Hoste EAJ, 2003, J AM SOC NEPHROL, V14, P1022, DOI 10.1097/01.ASN.0000059863.48590.E9; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Ikizler TA, 2004, KIDNEY INT, V65, P725, DOI 10.1111/j.1523-1755.2004.00439.x; Isenbarger DW, 2003, AM J CARDIOL, V92, P1454, DOI 10.1016/j.amjcard.2003.08.059; Ito T, 2003, NEPHROL DIAL TRANSPL, V18, P641, DOI 10.1093/ndt/gfg028; Jaber BL, 2004, BLOOD PURIFICAT, V22, P101, DOI 10.1159/000074930; Jaber BL, 2004, CYTOKINE, V25, P212, DOI 10.1016/j.cyto.2003.11.004; Jaber BL, 2002, CLIN NEPHROL, V57, P274; John S, 2001, NEPHROL DIAL TRANSPL, V16, P320, DOI 10.1093/ndt/16.2.320; Juurlink DN, 2004, NEW ENGL J MED, V351, P543, DOI 10.1056/NEJMoa040135; Kale S, 2003, J CLIN INVEST, V112, P42, DOI 10.1172/JCI200317856; Karsou SA, 2000, AM J KIDNEY DIS, V35, P980, DOI 10.1016/S0272-6386(00)70276-9; Kaushal GP, 2004, KIDNEY INT, V66, P500, DOI 10.1111/j.1523-1755.2004.761_6.x; KAUSHAL GP, 2003, CLIN NEPHROTOXINS, P65; Kellum J A, 2004, Minerva Anestesiol, V70, P181; Kellum JA, 2001, CRIT CARE MED, V29, P1526, DOI 10.1097/00003246-200108000-00005; Kellum JA, 1998, KIDNEY INT, V53, pS67; Kellum John A, 2002, Curr Opin Crit Care, V8, P509, DOI 10.1097/00075198-200212000-00005; Khan IH, 1997, QJM-MON J ASSOC PHYS, V90, P781; KIERAN N, 2003, COMPREHENSIVE CLIN N, P183; Klahr S, 2000, KIDNEY PHYSL PATHOPH, P2473; KON V, 1991, KIDNEY INT, V40, P1, DOI 10.1038/ki.1991.172; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Kumar VA, 2004, INT J ARTIF ORGANS, V27, P371, DOI 10.1177/039139880402700505; LADEFOGED SD, 1994, CLIN TRANSPLANT, V8, P128; Lameire N, 1999, NEPHROL DIAL TRANSPL, V14, P2570, DOI 10.1093/ndt/14.11.2570; Lameire N, 2004, CONTRIB NEPHROL, V144, P255; Lameire N, 2003, ADV RENAL REPLACE TH, V10, P93, DOI 10.1053/jarr.2003.50012; Lameire Norbert H, 2003, Curr Opin Crit Care, V9, P481, DOI 10.1097/00075198-200312000-00004; Lameire Norbert H, 2004, Best Pract Res Clin Anaesthesiol, V18, P21, DOI 10.1016/j.bpa.2003.09.008; Landry DW, 2001, NEW ENGL J MED, V345, P588, DOI 10.1056/NEJMra002709; Lassnigg A, 2000, J AM SOC NEPHROL, V11, P97, DOI 10.1681/ASN.V11197; Levy EM, 1996, JAMA-J AM MED ASSOC, V275, P1489, DOI 10.1001/jama.275.19.1489; Liano F, 1998, KIDNEY INT, V53, pS16; Lieberthal W, 2000, AM J PHYSIOL-RENAL, V278, pF1, DOI 10.1152/ajprenal.2000.278.1.F1; Lumlertgul D, 1991, Drugs, V42 Suppl 1, P44; MacDowall P, 1998, LANCET, V352, P13, DOI 10.1016/S0140-6736(97)11060-1; Manns B, 2003, CRIT CARE MED, V31, P449, DOI 10.1097/01.CCM.0000045182.90302.B3; Marshall MR, 2004, NEPHROL DIAL TRANSPL, V19, P877, DOI 10.1093/ndt/gfg625; Marshall MR, 2001, KIDNEY INT, V60, P777, DOI 10.1046/j.1523-1755.2001.060002777.x; McCarthy JT, 1996, MAYO CLIN PROC, V71, P117, DOI 10.4065/71.2.117; Mehta RL, 2002, JAMA-J AM MED ASSOC, V288, P2547, DOI 10.1001/jama.288.20.2547; Mehta RL, 2004, KIDNEY INT, V66, P1613, DOI 10.1111/j.1523-1755.2004.00927.x; Mehta RL, 2003, J AM SOC NEPHROL, V14, P2178, DOI 10.1097/01.ASN.0000079042.13465.1A; Mehta RL, 2001, KIDNEY INT, V60, P1154, DOI 10.1046/j.1523-1755.2001.0600031154.x; Mehta RL, 2003, JAMA-J AM MED ASSOC, V289, P1379; Metcalfe W, 2002, QJM-INT J MED, V95, P579, DOI 10.1093/qjmed/95.9.579; Metnitz PGH, 2002, CRIT CARE MED, V30, P2051, DOI 10.1097/00003246-200209000-00016; MILLER PD, 1980, ARCH INTERN MED, V140, P907, DOI 10.1001/archinte.140.7.907; Molitoris BA, 2004, KIDNEY INT, V66, P496, DOI 10.1111/j.1523-1755.2004.761_5.x; Molitoris BA, 2004, KIDNEY INT, V66, P871, DOI 10.1111/j.1523-1755.2004.00818.x; Molitoris BA, 2003, J AM SOC NEPHROL, V14, P265, DOI 10.1097/01.ASN.0000048852.53881.D9; Morigi M, 2004, J AM SOC NEPHROL, V15, P1794, DOI 10.1097/01.ASN.0000128974.07460.34; Mueller C, 2002, ARCH INTERN MED, V162, P329, DOI 10.1001/archinte.162.3.329; Nash K, 2002, AM J KIDNEY DIS, V39, P930, DOI 10.1053/ajkd.2002.32766; Noiri E, 2001, AM J PHYSIOL-RENAL, V281, pF948, DOI 10.1152/ajprenal.0071.2001; Noiri E, 1996, J CLIN INVEST, V97, P2377, DOI 10.1172/JCI118681; Oberbauer R, 1999, J AM SOC NEPHROL, V10, P2006; Parikh CR, 2004, AM J KIDNEY DIS, V43, P405, DOI 10.1053/j.ajkd.2003.10.040; Piper SN, 2003, CAN J ANAESTH, V50, P285, DOI 10.1007/BF03017799; Polito C, 1998, CLIN PEDIATR, V37, P381, DOI 10.1177/000992289803700609; Poulsom R, 2001, J PATHOL, V195, P229, DOI 10.1002/path.976; Price PM, 2004, KIDNEY INT, V66, P509, DOI 10.1111/j.1523-1755.2004.761_8.x; Rabb H, 2002, KIDNEY INT, V61, P1935, DOI 10.1046/j.1523-1755.2002.00378.x; Racusen LC, 2001, ACUTE RENAL FAILURE, P1; Ragaller MJR, 2001, J AM SOC NEPHROL, V12, pS33; Reinhart K, 2002, CRIT CARE MED, V30, pS302, DOI 10.1097/00003246-200205001-00021; REUBI FC, 1974, KIDNEY INT, V5, P106, DOI 10.1038/ki.1974.14; Ribeiro RC, 2003, CLIN LYMPHOMA, V3, P225, DOI 10.3816/CLM.2003.n.003; Rickli H, 2004, CLIN NEPHROL, V61, P98; Romanov V, 1997, KIDNEY INT, V52, P93, DOI 10.1038/ki.1997.308; Ronco C, 2000, LANCET, V356, P26, DOI 10.1016/S0140-6736(00)02430-2; Rookmaaker MB, 2004, KIDNEY INT, V66, P518, DOI 10.1111/j.1523-1755.2004.761_10.x; Rosen S, 2001, KIDNEY INT, V60, P1220, DOI 10.1046/j.1523-1755.2001.00930.x; Sandy D., 1998, Journal of the American Society of Nephrology, V9, p225A; Schepkens H, 2001, AM J MED, V110, P438, DOI 10.1016/S0002-9343(01)00642-8; Schetz M, 2004, CONTRIB NEPHROL, V144, P119; Schetz Miet, 2004, Best Pract Res Clin Anaesthesiol, V18, P75, DOI 10.1016/j.bpa.2003.09.003; Schiffl H, 2002, NEW ENGL J MED, V346, P305, DOI 10.1056/NEJMoa010877; Schrier RW, 2004, J CLIN INVEST, V114, P5, DOI 10.1172/JC1200422353; Schrier RW, 2004, NEW ENGL J MED, V351, P159, DOI 10.1056/NEJMra032401; Schuck O, 2004, INT J CLIN PHARM TH, V42, P93; Schuck O, 2003, NEPHRON CLIN PRACT, V93, pC146, DOI 10.1159/000070234; Schwartz D, 1997, J CLIN INVEST, V100, P439, DOI 10.1172/JCI119551; Sever MS, 2004, CLIN NEPHROL, V61, P413; Sharples EJ, 2004, J AM SOC NEPHROL, V15, P2115, DOI 10.1097/01.ASN.0000135059.67385.5D; SHAW NJ, 1991, INT J CARDIOL, V31, P161, DOI 10.1016/0167-5273(91)90211-7; Shilliday IR, 1997, NEPHROL DIAL TRANSPL, V12, P2592, DOI 10.1093/ndt/12.12.2592; Singri N, 2003, JAMA-J AM MED ASSOC, V289, P747, DOI 10.1001/jama.289.6.747; Stevens PE, 2001, QJM-INT J MED, V94, P533, DOI 10.1093/qjmed/94.10.533; Subramanian S, 2002, KIDNEY INT, V62, P1819, DOI 10.1046/j.1523-1755.2002.00608.x; Sutton TA, 2002, KIDNEY INT, V62, P1539, DOI 10.1046/j.1523-1755.2002.00631.x; Teehan Geoffrey S, 2003, J Intensive Care Med, V18, P130; Teehan GS, 2003, SEMIN DIALYSIS, V16, P356, DOI 10.1046/j.1525-139X.2003.16071.x; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; Togel F, 2004, J AM SOC NEPHROL, V15, P1261, DOI 10.1097/01.ASN.0000123692.01237.0A; Tonelli M, 2002, AM J KIDNEY DIS, V40, P875, DOI 10.1053/ajkd.2002.36318; TURNEY JH, 2001, ACUTE RENAL FAILURE, P397; Uchino S, 2004, CRIT CARE MED, V32, P1669, DOI 10.1097/01.CCM.0000132892.51063.2F; Uehlinger Dominik E., 2001, Journal of the American Society of Nephrology, V12, p278A; Van Biesen W, 2003, Curr Opin Crit Care, V9, P491, DOI 10.1097/00075198-200312000-00005; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Van KD, 2003, ESIS PUBL, V31, P3, DOI 10.1016/S1566-1369(03)80002-X; Verfaillie Catherine M, 2002, Hematology Am Soc Hematol Educ Program, P369; Waikar SS, 2000, CURR OPIN NEPHROL HY, V9, P501, DOI 10.1097/00041552-200009000-00007; Wangsiripaisan A, 2001, KIDNEY INT, V59, P932, DOI 10.1046/j.1523-1755.2001.059003932.x; Westhuyzen J, 2003, NEPHROL DIAL TRANSPL, V18, P543, DOI 10.1093/ndt/18.3.543; Wuyts B, 2003, CLIN CHEM, V49, P1011, DOI 10.1373/49.6.1011; YARGER WE, 1992, HYPERTENSION RENAL D, P272; Ysebaert DK, 2004, KIDNEY INT, V66, P491, DOI 10.1111/j.1523-1755.2004.761_4.x; Zuk A, 2001, AM J PHYSIOL-RENAL, V280, pF1037, DOI 10.1152/ajprenal.2001.280.6.F1037	184	784	843	2	66	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN-FEB	2005	365	9457					417	430						14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891WE	15680458				2022-12-28	WOS:000226610900030
J	Pincock, S				Pincock, S			Julius Axelrod - Obituary	LANCET			English	Biographical-Item												stephenpincock@blueyonder.co.uk		Pincock, Stephen/0000-0003-1655-2902					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN-FEB	2005	365	9457					380	380						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891WE	15688459				2022-12-28	WOS:000226610900013
J	Das, AK; Olfson, M; Gameroff, MJ; Pilowsky, DJ; Blanco, C; Feder, A; Gross, R; Neria, Y; Lantigua, R; Shea, S; Weissman, MM				Das, AK; Olfson, M; Gameroff, MJ; Pilowsky, DJ; Blanco, C; Feder, A; Gross, R; Neria, Y; Lantigua, R; Shea, S; Weissman, MM			Screening for bipolar disorder in a primary care practice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIAGNOSTIC INTERVIEW SCHEDULE; WEEKLY SYMPTOMATIC STATUS; MENTAL-HEALTH-CARE; PSYCHIATRIC-DISORDERS; FOLLOW-UP; NATURAL-HISTORY; SUICIDE RISK; DEPRESSION; PREVALENCE; SPECTRUM	Context Bipolar disorder consists of episodes of manic and depressive symptoms. Efforts to screen for depressionin a primary care setting without assessment of past manic symptoms can lead to incorrect diagnosis and treatment of bipolar disorder. Objectives To screen for bipolar disorder in adult primary care patients and to examine its clinical presentation and effect on functioning. Design, Setting, and Participants A systematic sample of 1157 patients between 18 and 70 years of age who were seeking primary care at an urban general medicine clinic serving a low-income population. The study was conducted between December 2001 and January 2003. Main Outcome Measures Prevalence of bipolar disorder, its treatment and patient functioning. Study measures included the Mood Disorder Questionnaire, the PRIME-MD Patient Health Questionnaire, the Medical Outcomes Study 12-Item Short Form health survey, the Sheehan Disability Scale, data on past mental health treatments, and a review of medical records and International Classification of Diseases, Ninth Revision codes for each visit dating from 6 months prior to the screening day. Results The prevalence of receiving positive screening results for lifetime bipolar disorder was 9.8% (n=112; 95% confidence interval, 8.0%-11.5%) and did not differ significantly by age, sex, or race/ethnicity. Eighty-one patients (72.3%) who screened positive for bipolar disorder sought professional help for their symptoms, but only 9 (8.4%) reported receiving a diagnosis of bipolar disorder, Seventy-five patients (68.2%) who screened positive for bipolar disorder had a current major depressive episode or an anxiety or substance use disorder. Of 112 patients, only 7 (6.5%) reported taking a mood-stabilizing agent in the past month. Primary care physicians recorded evidence of current depression in 47 patients (49.0%) who screened positive for bipolar disorder, but did not record a bipolar disorder diagnosis either in administrative billing or the medical record of any of these patients. Patients who screened positive for bipolar disorder reported worse health-related quality of life as well as increased social and family life impairment compared with those who screened negative. Conclusions In an urban general medicine clinic, a positive screen for bipolar disorder appears to be common, clinically significant, and underrecognized. Because of the risks associated with treating bipolar disorder with antidepressant monotherapy, efforts are needed to educate primary care physicians educate primary care physicians about the screening, management, and pharmacotherapy of bipolar disorders.	Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Dept Psychiat, Div Clin & Genet Epidemiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, Div Gen Med, New York, NY 10032 USA	Columbia University; New York State Psychiatry Institute; Columbia University; Columbia University	Weissman, MM (corresponding author), Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Dept Psychiat, Div Clin & Genet Epidemiol, 1051 Riverside Dr,Unit 24, New York, NY 10032 USA.	mmw3@columbia.edu	Blanco, Carlos/I-4906-2013; Feder, Adriana/AAX-1225-2021; Olfson, Mark/AAA-8547-2021	Blanco, Carlos/0000-0001-6187-3057; Weissman, Myrna/0000-0003-3490-3075				American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Angst F, 2002, J AFFECT DISORDERS, V68, P167, DOI 10.1016/S0165-0327(01)00377-9; Angst J, 1998, J AFFECT DISORDERS, V50, P143, DOI 10.1016/S0165-0327(98)00142-6; ANGST J, 1995, TROUBLES BIPOLAIRES, P29; BARRETT JE, 1988, ARCH GEN PSYCHIAT, V45, P1100; Berg AO, 2002, ANN INTERN MED, V136, P760, DOI 10.7326/0003-4819-136-10-200205210-00012; BLACKER CVR, 1988, PSYCHOPHARMACOLOGY, V95, pS14; Blanco C, 2002, AM J PSYCHIAT, V159, P1005, DOI 10.1176/appi.ajp.159.6.1005; BLAZER D, 1985, ARCH GEN PSYCHIAT, V42, P651; Boerlin HL, 1998, J CLIN PSYCHIAT, V59, P374, DOI 10.4088/JCP.v59n0706; Bostwick JM, 2000, AM J PSYCHIAT, V157, P1925, DOI 10.1176/appi.ajp.157.12.1925; BRUCE ML, 1991, ARCH GEN PSYCHIAT, V48, P470; Calabrese JR, 2003, J CLIN PSYCHIAT, V64, P425, DOI 10.4088/JCP.v64n0412; Cassano GB, 1999, J AFFECT DISORDERS, V54, P319, DOI 10.1016/S0165-0327(98)00158-X; Cooke RG, 1996, J AFFECT DISORDERS, V39, P93, DOI 10.1016/0165-0327(96)00016-X; CORYELL W, 1993, AM J PSYCHIAT, V150, P720; COYNE JC, 1994, GEN HOSP PSYCHIAT, V16, P267, DOI 10.1016/0163-8343(94)90006-X; Davies HTO, 1998, BRIT MED J, V316, P989, DOI 10.1136/bmj.316.7136.989; DOHRENWEND BP, 1992, SCIENCE, V255, P946, DOI 10.1126/science.1546291; GALLO JJ, 1995, PSYCHOL MED, V25, P1149, DOI 10.1017/S0033291700033122; Ghaemi SN, 2000, J CLIN PSYCHIAT, V61, P804, DOI 10.4088/JCP.v61n1013; Gijsman HJ, 2004, AM J PSYCHIAT, V161, P1537, DOI 10.1176/appi.ajp.161.9.1537; GITLIN MJ, 1995, AM J PSYCHIAT, V152, P1635; GOLDBERG JF, 1995, AM J PSYCHIAT, V152, P379; Goodwin FK, 2003, JAMA-J AM MED ASSOC, V290, P1467, DOI 10.1001/jama.290.11.1467; GUZE SB, 1970, BRIT J PSYCHIAT, V117, P437, DOI 10.1192/bjp.117.539.437; HARROW M, 1990, ARCH GEN PSYCHIAT, V47, P665; HEUN R, 1993, ACTA PSYCHIAT SCAND, V87, P279, DOI 10.1111/j.1600-0447.1993.tb03372.x; Higgins E S, 1994, Arch Fam Med, V3, P908, DOI 10.1001/archfami.3.10.908; Hirschfeld RMA, 2000, AM J PSYCHIAT, V157, P1873, DOI 10.1176/appi.ajp.157.11.1873; Hirschfeld RMA, 2003, AM J PSYCHIAT, V160, P178, DOI 10.1176/appi.ajp.160.1.178; Hirschfeld RMA, 2003, J CLIN PSYCHIAT, V64, P161, DOI 10.4088/JCP.v64n0209; HOEPER EW, 1979, INT J MENT HEALTH, V8, P6, DOI 10.1080/00207411.1979.11448829; HOPPE SK, 1989, SOC PSYCH PSYCH EPID, V24, P63, DOI 10.1007/BF01788628; Howard KI, 1996, ARCH GEN PSYCHIAT, V53, P696; Howland RH, 1996, J CLIN PSYCHOPHARM, V16, P425, DOI 10.1097/00004714-199612000-00003; Judd LL, 2002, ARCH GEN PSYCHIAT, V59, P530, DOI 10.1001/archpsyc.59.6.530; Judd LL, 2003, ARCH GEN PSYCHIAT, V60, P261, DOI 10.1001/archpsyc.60.3.261; Kane JM, 2002, AM J PSYCHIAT, V159, P1, DOI 10.1176/appi.ajp.159.1.1; Katon W, 1997, GEN HOSP PSYCHIAT, V19, P169, DOI 10.1016/S0163-8343(97)00016-9; LEAF PJ, 1988, MED CARE, V26, P9, DOI 10.1097/00005650-198801000-00002; Leon A C, 1995, Arch Fam Med, V4, P857, DOI 10.1001/archfami.4.10.857; LEON AC, 1992, SOC PSYCH PSYCH EPID, V27, P78, DOI 10.1007/BF00788510; LISH JD, 1994, J AFFECT DISORDERS, V31, P281, DOI 10.1016/0165-0327(94)90104-X; MacQueen GM, 2001, ACTA PSYCHIAT SCAND, V103, P163, DOI 10.1034/j.1600-0447.2001.00059.x; Manning JS, 1998, ARCH FAM MED, V7, P63, DOI 10.1001/archfami.7.1.63; Manning JS, 1997, COMPR PSYCHIAT, V38, P102; McQuaid JR, 1999, J AFFECT DISORDERS, V55, P1, DOI 10.1016/S0165-0327(98)00191-8; MUKHERJEE S, 1983, AM J PSYCHIAT, V140, P1571; Olfson M, 2000, ARCH FAM MED, V9, P876, DOI 10.1001/archfami.9.9.876; Olfson M, 1996, AM J PSYCHIAT, V153, P1353; Olfson M, 1997, AM J PSYCHIAT, V154, P1734, DOI 10.1176/ajp.154.12.1734; Olfson M, 2002, JAMA-J AM MED ASSOC, V287, P203, DOI 10.1001/jama.287.2.203; Olfson M, 2002, AM J PSYCHIAT, V159, P1412, DOI 10.1176/appi.ajp.159.8.1412; OLIVER JM, 1985, J CLIN PSYCHOL, V41, P469, DOI 10.1002/1097-4679(198507)41:4<469::AID-JCLP2270410405>3.0.CO;2-R; Parker T, 1997, INT J PSYCHIAT MED, V27, P107, DOI 10.2190/C6FD-7QWB-KNGR-M844; Philbrick JT, 1996, J GEN INTERN MED, V11, P9, DOI 10.1007/BF02603478; REGIER DA, 1993, ACTA PSYCHIAT SCAND, V88, P35, DOI 10.1111/j.1600-0447.1993.tb03411.x; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; SCHULBERG HC, 1985, ARCH GEN PSYCHIAT, V42, P1164; Schurhoff F, 2000, J AFFECT DISORDERS, V58, P215, DOI 10.1016/S0165-0327(99)00111-1; SHARMA R, 1994, J AFFECT DISORDERS, V31, P91, DOI 10.1016/0165-0327(94)90112-0; SIMPSON SG, 1993, AM J PSYCHIAT, V150, P901; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Szadoczky E, 1998, J AFFECT DISORDERS, V50, P153, DOI 10.1016/S0165-0327(98)00056-1; Tiemens BG, 1999, PSYCHOL MED, V29, P833, DOI 10.1017/S0033291799008545; VazquezBarquero JL, 1997, BRIT J PSYCHIAT, V170, P529, DOI 10.1192/bjp.170.6.529; VONKORFF M, 1987, ARCH GEN PSYCHIAT, V44, P152; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Weissman MM, 1996, JAMA-J AM MED ASSOC, V276, P293, DOI 10.1001/jama.276.4.293; Williams JW, 2002, GEN HOSP PSYCHIAT, V24, P225, DOI 10.1016/S0163-8343(02)00195-0; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	73	155	160	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	2005	293	8					956	963		10.1001/jama.293.8.956	http://dx.doi.org/10.1001/jama.293.8.956			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	899LR	15728166				2022-12-28	WOS:000227146400017
J	Bocchia, M; Gentili, S; Abruzzese, E; Fanelli, A; Iuliano, F; Tabilio, A; Amabile, M; Forconi, F; Gozzetti, A; Raspadori, D; Amadori, S; Lauria, F				Bocchia, M; Gentili, S; Abruzzese, E; Fanelli, A; Iuliano, F; Tabilio, A; Amabile, M; Forconi, F; Gozzetti, A; Raspadori, D; Amadori, S; Lauria, F			Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial	LANCET			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; KINASE INHIBITOR STI571; ABL TYROSINE KINASE; FUSION PEPTIDES; PROTEIN; CYTARABINE; INDUCTION; RESPONSES; MESYLATE; ADJUVANT	Background Although imatinib is the standard treatment for chronic myeloid leukaemia, not all patients reach complete cytogenetic remission (CCR) and most maintain detectable disease at the molecular level. We investigated whether a vaccine targeting the BCR-ABL-derived p210 fusion protein was an active and specific immunotherapy. Methods We recruited 16 patients who had chronic myeloid leukaemia (with the b3a2 fusion point of p210), stable residual disease, a minimum treatment of 12 months of imatinib or 24 months of interferon alfa, and no further reduction of residual disease for at least 6 months preceding enrolment. They were given six vaccinations with a peptide vaccine derived from the sequence p210-b3a2 plus molgramostim and QS-21 as adjuvants (CMLVAX100) before assessment of immunological and disease response, which included detecting amounts of b3a2 transcripts by standardised quantitative real-time reverse-transcriptase PIER. Results Of ten patients on imatinib, nine started CMLVAX100 having had a median of 10 months' stable cytogenetic disease (median 10% Philadelphia-chromosome-positive metaphases), whereas one started in stable CCR. All patients' cytogenetic responses improved after six vaccinations, with five reaching CCR. Notably, three of these five patients also had undetectable amounts of b3a2 transcript (BCR-ABL:beta(2)microglobulin ratio <0.00001). Six patients on interferon alfa treatment with a median of 17 months' stable residual disease (median 13% Philadelphia-chromosome-positive cells) were also vaccinated. All but one had improved cytogenetic responses, and two reached CCR. Overall, we recorded peptide-specific delayed-type hypersensitivity (in 11 of 16 patients), CD4 cell proliferation (13 of 14 assessed), and interferon gamma production (five of five assessed). Interpretation Addition of CMLVAX100 to conventional treatment in patients with chronic myeloid leukaemia might favour further reduction of residual disease and increase the number of patients reaching a molecular response.	Univ Siena, Dept Haematol, I-53100 Siena, Italy; Univ Roma Tor Vergata, Dept Haematol, Rome, Italy; Osped Pugliese Ciaccio, Dept Haematol, Catanzaro, Italy; Univ Perugia, Dept Haematol, I-06100 Perugia, Italy; Univ Bologna, Haematol & Clin Oncol Seragnoli Inst, Bologna, Italy	University of Siena; University of Rome Tor Vergata; University of Perugia; University of Bologna	Bocchia, M (corresponding author), Univ Siena, Dept Haematol, Viale Bracci 1, I-53100 Siena, Italy.		gozzetti, alessandro/D-9055-2014; Forconi, Francesco/AAO-2694-2021; Amabile, Marilina/C-8185-2019; Abruzzese, Elisabetta/D-4408-2019; Bocchia, Monica Bocchia/AIB-9508-2022	gozzetti, alessandro/0000-0003-0769-6891; Forconi, Francesco/0000-0002-2211-1831; Amabile, Marilina/0000-0002-2534-9036; Abruzzese, Elisabetta/0000-0001-5228-6491; Amadori, Sergio/0000-0002-2356-8681				Amabile M, 2001, HAEMATOLOGICA, V86, P252; Baccarani M, 2002, BLOOD, V99, P1527, DOI 10.1182/blood.V99.5.1527; Belli F, 2002, J CLIN ONCOL, V20, P4169, DOI 10.1200/JCO.2002.09.134; Bhatia R, 2003, BLOOD, V101, P4701, DOI 10.1182/blood-2002-09-2780; BOCCHIA M, 1995, BLOOD, V85, P2680, DOI 10.1182/blood.V85.10.2680.bloodjournal85102680; Bocchia M, 2002, HAEMATOLOGICA, V87, P675; Bocchia M, 1996, BLOOD, V87, P3587, DOI 10.1182/blood.V87.9.3587.bloodjournal8793587; BOSH GJ, 1996, BLOOD, V88, P3522; Cathcart K, 2004, BLOOD, V103, P1037, DOI 10.1182/blood-2003-03-0954; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Disis ML, 1996, BLOOD, V88, P202; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2003, BLOOD, V102, p182A; Gabert J, 2003, LEUKEMIA, V17, P2318, DOI 10.1038/sj.leu.2403135; Greco G, 1996, LEUKEMIA, V10, P693; Hughes TP, 2003, NEW ENGL J MED, V349, P1423, DOI 10.1056/NEJMoa030513; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; LIVINGSTON PO, 1994, VACCINE, V12, P1275, DOI 10.1016/S0264-410X(94)80052-2; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Norbury LC, 2000, BRIT J HAEMATOL, V109, P616, DOI 10.1046/j.1365-2141.2000.02090.x; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Pinilla-Ibarz J, 2000, BLOOD, V95, P1781, DOI 10.1182/blood.V95.5.1781.005k46_1781_1787; Rosti G, 2004, BLOOD, V103, P2284, DOI 10.1182/blood-2003-07-2575; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Slingluff CL, 2003, J CLIN ONCOL, V21, P4016, DOI 10.1200/JCO.2003.10.005; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505; Yasukawa M, 2001, BLOOD, V98, P1498, DOI 10.1182/blood.V98.5.1498	28	206	214	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	2005	365	9460					657	662						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	898SP	15721470				2022-12-28	WOS:000227096800022
J	Cwiok, S; Heenen, PH; Nazarewicz, W				Cwiok, S; Heenen, PH; Nazarewicz, W			Shape coexistence and triaxiality in the superheavy nuclei	NATURE			English	Review							HEAVY ELEMENT RESEARCH; FISSION-BARRIERS; SELF-CONSISTENT; DEFORMATIONS; STABILITY; ISOTOPES	Superheavy nuclei represent the limit of nuclear mass and charge; they inhabit the remote corner of the nuclear landscape, whose extent is unknown. The discovery of new elements with atomic numbers Z greater than or equal to 110 has brought much excitement to the atomic and nuclear physics communities. The existence of such heavy nuclei hangs on a subtle balance between the attractive nuclear force and the disruptive Coulomb repulsion between protons that favours fission. Here we model the interplay between these forces using self-consistent energy density functional theory; our approach accounts for spontaneous breaking of spherical symmetry through the nuclear Jahn - Teller effect. We predict that the long-lived superheavy elements can exist in a variety of shapes, including spherical, axial and triaxial configurations. In some cases, we anticipate the existence of metastable states and shape isomers that can affect decay properties and hence nuclear half-lives.	Free Univ Brussels, Serv Phys Nucl Theor, B-1050 Brussels, Belgium; Warsaw Univ Technol, Inst Phys, PL-00662 Warsaw, Poland; Univ Tennessee, Dept Phys & Astron, Knoxville, TN 37996 USA; Oak Ridge Natl Lab, Div Phys, Oak Ridge, TN 37831 USA; Univ Warsaw, Inst Theoret Phys, PL-00681 Warsaw, Poland	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Warsaw University of Technology; University of Tennessee System; University of Tennessee Knoxville; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Warsaw	Heenen, PH (corresponding author), Free Univ Brussels, Serv Phys Nucl Theor, CP 229, B-1050 Brussels, Belgium.	phheenen@ulb.ac.be	Nazarewicz, Witold/C-2056-2012	Nazarewicz, Witold/0000-0002-8084-7425				Armbruster P, 2003, ACTA PHYS POL B, V34, P1825; Bender M, 2003, REV MOD PHYS, V75, P121, DOI 10.1103/RevModPhys.75.121; Bender M, 2001, PHYS LETT B, V515, P42, DOI 10.1016/S0370-2693(01)00863-2; Bender M, 1999, PHYS REV C, V60, DOI 10.1103/PhysRevC.60.034304; Burvenich T, 2004, PHYS REV C, V69, DOI 10.1103/PhysRevC.69.014307; Chabanat E, 1998, NUCL PHYS A, V635, P231, DOI 10.1016/S0375-9474(98)00180-8; Cwiok S, 1996, NUCL PHYS A, V611, P211, DOI 10.1016/S0375-9474(96)00337-5; CWIOK S, 1983, NUCL PHYS A, V410, P254, DOI 10.1016/0375-9474(83)90201-4; Ginter TN, 2003, PHYS REV C, V68, DOI 10.1103/PhysRevC.68.029901; Ginter TN, 2003, PHYS REV C, V67, DOI 10.1103/PhysRevC.67.064609; GOTZ U, 1972, PHYS LETT B, VB 39, P436, DOI 10.1016/0370-2693(72)90311-5; Heenen P.-H., 2002, EUROPHYS NEWS, V33, P1; Hoffman D C, 2000, TRANSURANIUM PEOPLE; Hofmann S, 2000, REV MOD PHYS, V72, P733, DOI 10.1103/RevModPhys.72.733; Hofmann S, 2004, NUCL PHYS A, V734, P93, DOI 10.1016/j.nuclphysa.2004.01.018; Julin R, 2001, NUCL PHYS A, V685, p221C, DOI 10.1016/S0375-9474(01)00542-5; KOHN W, 1965, PHYS REV, V140, P1133, DOI 10.1103/PhysRev.140.A1133; Kruppa AT, 2000, PHYS REV C, V61, DOI 10.1103/PhysRevC.61.034313; LARSSON SE, 1972, PHYS LETT B, VB 38, P269, DOI 10.1016/0370-2693(72)90243-2; MOLLER P, 1994, J PHYS G NUCL PARTIC, V20, P1681, DOI 10.1088/0954-3899/20/11/003; Moody K, 2004, NUCL PHYS A, V734, P188, DOI 10.1016/j.nuclphysa.2004.01.031; Morita K, 2004, NUCL PHYS A, V734, P101, DOI 10.1016/j.nuclphysa.2004.01.019; Morita K, 2004, J PHYS SOC JPN, V73, P2593, DOI 10.1143/JPSJ.73.2593; MYERS WD, 1966, NUCL PHYS, V81, P1, DOI 10.1016/0029-5582(66)90639-0; NAZAREWICZ W, 1994, NUCL PHYS A, V574, pC27, DOI 10.1016/0375-9474(94)90037-X; NILSSON SG, 1969, NUCL PHYS A, VA131, P1, DOI 10.1016/0375-9474(69)90809-4; Oganessian YS, 2004, PHYS REV C, V69, DOI 10.1103/PhysRevC.69.054607; Oganessian YT, 2004, NUCL PHYS A, V734, P109, DOI 10.1016/j.nuclphysa.2004.01.020; PASHKEVICH VV, 1969, NUCL PHYS A, VA133, P400, DOI 10.1016/0375-9474(69)90641-1; Perlinska E, 2004, PHYS REV C, V69, DOI 10.1103/PhysRevC.69.014316; Ren ZZ, 2002, PHYS REV C, V65, DOI 10.1103/PhysRevC.65.051304; Schwerdtfeger P, 1998, ENCY COMPUTATIONAL C, V4, P2480; SOBICZEWSKI A, 1966, PHYS LETT, V22, P500, DOI 10.1016/0031-9163(66)91243-1; Stoitsov MV, 2003, PHYS REV C, V68, DOI 10.1103/PhysRevC.68.054312; STRUTINSKY VM, 1967, NUCL PHYS A, V122, P1; WOOD JL, 1992, PHYS REP, V215, P101, DOI 10.1016/0370-1573(92)90095-H	37	202	209	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	2005	433	7027					705	709		10.1038/nature03336	http://dx.doi.org/10.1038/nature03336			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897XH	15716943				2022-12-28	WOS:000227039200029
J	Aceng, JR; Byarugaba, JS; Tumwine, JK				Aceng, JR; Byarugaba, JS; Tumwine, JK			Rectal artemether versus intravenous quinine for the treatment of cerebral malaria in children in Uganda: randomised clinical trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ARTESUNATE; ARTEMISININ; MEFLOQUINE	Objective To compare the efficacy and safety of rectal artemether with intravenous quinine in the treatment of cerebral malaria in children. Design Randomised, single blind, clinical trial. Setting Acute care unit at Mulago Hospital, Uganda's national referral and teaching hospital in Kampala. Participants 103 children aged 6 months to 5 years with cerebral malaria. Intervention Patients were randomised to either intravenous quinine or rectal artemether for seven days. Main outcome measures Time to clearance of parasites and fever; time to regaining consciousness, starting oral intake, and sitting unaided; and adverse effects. Results The difference in parasitological and clinical outcomes between rectal artemether and intravenous quinine did not reach significance (parasite clearance time 54.2 (SD 33.6) hours v 55.0 (SD 24.3) hours, P = 0.90; fever clearance time 33.2 (SD 21.9) hours V 24. I(SD 18.9 hours, P - 0.08; time to regaining consciousness 30.1 (SD 24.1) hours v 22.67 (SD 18.5) hours, P= 0.10; time to starting oral intake 37.9 (SD 27.0) hours v 30.3 (SD 21.1) hours, P= 0.14). Mortality was higher in the quinine group than in the artemether group (10/52 v 6/51; relative risk 1.29, 95% confidence interval 0.84 to 2.01). No serious immediate adverse effects occurred. Conclusion Rectal artemether is effective and well tolerated and could be used as treatment for cerebral malaria.	Makerere Med Sch, Dept Paediat & Child Hlth, Kampala, Uganda	Makerere University	Tumwine, JK (corresponding author), Makerere Med Sch, Dept Paediat & Child Hlth, POB 7072, Kampala, Uganda.	jtumwine@imul.com						Alin MH, 1995, AM J TROP MED HYG, V53, P639, DOI 10.4269/ajtmh.1995.53.639; Barnes KI, 2004, LANCET, V363, P1598, DOI 10.1016/S0140-6736(04)16203-X; Birku Y, 1999, E AFR MED J, V76, P154; BLIKU Y, 1999, E AFR MED J, V76, P154; D'Alessandro U, 2004, BMJ-BRIT MED J, V328, P155, DOI 10.1136/bmj.328.7432.155; Dorsey G, 2002, LANCET, V360, P2031, DOI 10.1016/S0140-6736(02)12021-6; Esamai F, 2000, E AFR MED J, V77, P273; HIEN TT, 1992, T ROY SOC TROP MED H, V86, P582, DOI 10.1016/0035-9203(92)90137-2; HIEN TT, 1993, LANCET, V341, P603; JIANG JB, 1982, LANCET, V2, P285; KWIATKOWSKI D, 1995, T ROY SOC TROP MED H, V89, P215, DOI 10.1016/0035-9203(95)90501-4; Newton CRJC, 1997, T ROY SOC TROP MED H, V91, P161, DOI 10.1016/S0035-9203(97)90207-8; Pe Than Myint, 1986, Southeast Asian J Trop Med Public Health, V17, P19; Peterson S, 2004, LANCET, V363, P1955, DOI 10.1016/S0140-6736(04)16411-8; SHWE T, 1988, T ROY SOC TROP MED H, V82, P665, DOI 10.1016/0035-9203(88)90187-3; SIMOES E, 2003, B WORLD HEALTH ORGAN, V81, P322; TAYLOR TE, 1993, LANCET, V341, P661, DOI 10.1016/0140-6736(93)90423-E; vanHensbroek MB, 1996, NEW ENGL J MED, V335, P69, DOI 10.1056/NEJM199607113350201; WALKER O, 1993, T ROY SOC TROP MED H, V87, P564, DOI 10.1016/0035-9203(93)90092-5; [No title captured]	20	37	38	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 12	2005	330	7487					334	336A		10.1136/bmj.330.7487.334	http://dx.doi.org/10.1136/bmj.330.7487.334			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897OZ	15705690	Green Published, Bronze			2022-12-28	WOS:000227015800016
J	Bennett, CL				Bennett, CL			Astrophysical observations: Lensing and eclipsing Einstein's theories	SCIENCE			English	Review							NEBULAE	Albert Einstein postulated the equivalence of energy' and mass, developed the theory of special relativity, explained the photoelectric effect, and described Brownian motion in five papers, all published in 1905, 100 years ago. With these papers, Einstein provided the framework for understanding modem astrophysical phenomena. Conversely, astrophysical observations provide one of the most effective means for testing Einstein's theories. Here, I review astrophysical advances precipitated by Einstein's insights, including gravitational redshifts, gravitational lensing gravitational waves, the Lense-Thirring effect, and modem cosmology. A complete understanding of cosmology, from the earliest moments to the ultimate fate of the universe, will require developments in physics beyond Einstein, to a unified theory of gravity and quantum physics.	Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA	Johns Hopkins University	Bennett, CL (corresponding author), Johns Hopkins Univ, Dept Phys & Astron, 3400 N Charles St, Baltimore, MD 21218 USA.	cbennett@jhu.edu		Bennett, Charles/0000-0001-8839-7206				ALPHER RA, 1949, PHYS REV, V75, P1089, DOI 10.1103/PhysRev.75.1089; ALPHER RA, 1948, PHYS REV, V73, P803, DOI 10.1103/PhysRev.73.803; Begelman MC, 2003, SCIENCE, V300, P1898, DOI 10.1126/science.1085325; Bennett CL, 2003, ASTROPHYS J SUPPL S, V148, P1, DOI 10.1086/377253; Bertotti B, 2003, NATURE, V425, P374, DOI 10.1038/nature01997; Bethe HA, 1939, PHYS REV, V55, P0103, DOI 10.1103/PhysRev.55.103; BOND JR, 1984, ASTROPHYS J, V285, pL45, DOI 10.1086/184362; Ciufolini I, 2004, NATURE, V431, P958, DOI 10.1038/nature03007; Eddington AS, 1920, NATURE, V105, P37, DOI 10.1038/105037a0; Einstein A, 1905, ANN PHYS-BERLIN, V18, P639; Einstein A, 1905, ANN PHYS-BERLIN, V17, P549, DOI 10.1002/andp.19053220806; Einstein A, 1906, ANN PHYS-BERLIN, V19, P289, DOI 10.1002/andp.19063240204; Einstein A, 1905, ANN PHYS-BERLIN, V17, P132; Einstein A, 1917, PHYS Z, V18, P121; Einstein A, 1916, ANN PHYS-BERLIN, V49, P769; Einstein A, 1905, ANN PHYS-BERLIN, V17, P891; FOMALONT EB, 1976, PHYS REV LETT, V36, P1475, DOI 10.1103/PhysRevLett.36.1475; FOWLER WA, 1955, ASTROPHYS J, V122, P271, DOI 10.1086/146085; Freedman WL, 2001, ASTROPHYS J, V553, P47, DOI 10.1086/320638; Mather JC, 1999, ASTROPHYS J, V512, P511, DOI 10.1086/306805; Newton Isaac, 1675, COMMUNICATION   0205; Peebles PJE, 2003, REV MOD PHYS, V75, P559, DOI 10.1103/RevModPhys.75.559; Percival WJ, 2002, MON NOT R ASTRON SOC, V337, P1068, DOI 10.1046/j.1365-8711.2002.06001.x; Perlmutter S, 1999, ASTROPHYS J, V517, P565, DOI 10.1086/307221; POUND RV, 1960, PHYS REV LETT, V4, P337, DOI 10.1103/PhysRevLett.4.337; Riess AG, 1998, ASTRON J, V116, P1009, DOI 10.1086/300499; RUBIN VC, 1978, ASTROPHYS J, V225, pL107, DOI 10.1086/182804; SHAPIRO II, 1964, PHYS REV LETT, V13, P789, DOI 10.1103/PhysRevLett.13.789; Steinhardt PJ, 2003, PHILOS T R SOC A, V361, P2497, DOI [10.1098/rsta.2003.1288, 10.1098/rsta.2003.1290]; Stella L, 1998, ASTROPHYS J, V492, pL59, DOI 10.1086/311075; TAYLOR JH, 1979, NATURE, V277, P437, DOI 10.1038/277437a0; TAYLOR JH, 1976, ASTROPHYS J, V206, pL53, DOI 10.1086/182131; Tegmark M, 2004, PHYS REV D, V69, DOI 10.1103/PhysRevD.69.103501; VESSOT RFC, 1980, PHYS REV LETT, V45, P2081, DOI 10.1103/PhysRevLett.45.2081; Zwicky F, 1937, PHYS REV, V51, P290, DOI 10.1103/PhysRev.51.290; Zwicky F, 1937, PHYS REV, V51, P0679, DOI 10.1103/PhysRev.51.679; 2003, CONNECTING QUARKS CO	38	9	9	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	2005	307	5711					879	884		10.1126/science.1106444	http://dx.doi.org/10.1126/science.1106444			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897DV	15705841				2022-12-28	WOS:000226985100041
J	Christopherson, KS; Ullian, EM; Stokes, CCA; Mullowney, CE; Hell, JW; Agah, A; Lawler, J; Mosher, DF; Bornstein, P; Barres, BA				Christopherson, KS; Ullian, EM; Stokes, CCA; Mullowney, CE; Hell, JW; Agah, A; Lawler, J; Mosher, DF; Bornstein, P; Barres, BA			Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis	CELL			English	Article							RETINAL GANGLION-CELLS; INDUCE SYNAPSE FORMATION; CENTRAL-NERVOUS-SYSTEM; NEURITE OUTGROWTH; SILENT SYNAPSES; GLIAL-CELLS; NEURONS; SPECIALIZATIONS; EXPRESSION; CULTURE	The establishment of neural circuitry requires vast numbers of synapses to be generated during a specific window of brain development, but it is not known why the developing mammalian brain has a much greater capacity to generate new synapses than the adult brain. Here we report that immature but not mature astrocytes express thrombospondins (TSPs)-1 and -2 and that these TSPs promote CNS synaptogenesis in vitro and in vivo. TSPs induce ultrastructurally normal synapses that are presynaptically active but postsynaptically silent and work in concert with other, as yet unidentified, astrocyte-derived signals to produce functional synapses. These studies identify TSPs as CNS synaptogenic proteins, provide evidence that astrocytes are important contributors to synaptogenesis within the developing CNS, and suggest that TSP-1 and -2 act as a permissive switch that times CNS synaptogenesis by enabling neuronal molecules to assemble into synapses within a specific window of CNS development.	Stanford Univ, Dept Neurobiol, Sch Med, Stanford, CA 94305 USA; Univ Iowa, Dept Pharmacol, Iowa City, IA 52242 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Wisconsin, Med Sci Ctr, Dept Med, Madison, WI 53706 USA	Stanford University; University of Iowa; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Wisconsin System; University of Wisconsin Madison	Christopherson, KS (corresponding author), Stanford Univ, Dept Neurobiol, Sch Med, Stanford, CA 94305 USA.	ksc@stanford.edu	Ritter, Stefanie L/D-9312-2012; Hell, Johannes W./P-5085-2019; Lawler, Jack/AAJ-1379-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045418] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015043] Funding Source: NIH RePORTER; NEI NIH HHS [EY07033] Funding Source: Medline; NHLBI NIH HHS [HL68003] Funding Source: Medline; NIAMS NIH HHS [AR45418] Funding Source: Medline; NIDA NIH HHS [DA15043] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Adams JC, 2000, DEV DYNAM, V218, P280; Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Agah A, 2002, AM J PATHOL, V161, P831, DOI 10.1016/S0002-9440(10)64243-5; ARBER S, 1995, J CELL BIOL, V131, P1083, DOI 10.1083/jcb.131.4.1083; BARRES BA, 1988, NEURON, V1, P791, DOI 10.1016/0896-6273(88)90127-4; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Chen S, 2002, J NEUROSCI, V22, P2165, DOI 10.1523/JNEUROSCI.22-06-02165.2002; CHIH B, 2005, IN PRESS SCIENCE; DEFREITAS MF, 1995, NEURON, V15, P333, DOI 10.1016/0896-6273(95)90038-1; Derouiche A, 2001, GLIA, V36, P330, DOI 10.1002/glia.1120; Graf ER, 2004, CELL, V119, P1013, DOI 10.1016/j.cell.2004.11.035; Hayashi K, 1999, J CELL SCI, V112, P1149; IRUELAARISPE ML, 1993, DEV DYNAM, V197, P40, DOI 10.1002/aja.1001970105; Isaac JTR, 1997, NEURON, V18, P269, DOI 10.1016/S0896-6273(00)80267-6; KRASZEWSKI K, 1995, J NEUROSCI, V15, P4328; Lawler J, 2000, CURR OPIN CELL BIOL, V12, P634, DOI 10.1016/S0955-0674(00)00143-5; Lim IA, 2002, J BIOL CHEM, V277, P21697, DOI 10.1074/jbc.M112339200; Lin TN, 2003, STROKE, V34, P177, DOI 10.1161/01.STR.0000047100.84604.BA; LIUZZI FJ, 1987, SCIENCE, V237, P642, DOI 10.1126/science.3603044; Malenka RC, 1997, NEURON, V19, P473, DOI 10.1016/S0896-6273(00)80362-1; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Moller JC, 1996, GLIA, V17, P121; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; Nagler K, 2001, J PHYSIOL-LONDON, V533, P665, DOI 10.1111/j.1469-7793.2001.00665.x; NEUGEBAUER KM, 1991, NEURON, V6, P345, DOI 10.1016/0896-6273(91)90244-T; Patton BL, 2001, NAT NEUROSCI, V4, P597, DOI 10.1038/88414; Pfrieger FW, 1997, SCIENCE, V277, P1684, DOI 10.1126/science.277.5332.1684; Scheiffele P, 2003, ANNU REV NEUROSCI, V26, P485, DOI 10.1146/annurev.neuro.26.043002.094940; ScottDrew S, 1997, J NEUROSCI RES, V50, P202, DOI 10.1002/(SICI)1097-4547(19971015)50:2<202::AID-JNR9>3.0.CO;2-J; Tooney PA, 1998, MATRIX BIOL, V17, P131, DOI 10.1016/S0945-053X(98)90026-9; Ullian EM, 2004, MOL CELL NEUROSCI, V26, P544, DOI 10.1016/j.mcn.2004.05.002; Ullian EM, 2004, GLIA, V47, P209, DOI 10.1002/glia.20082; Ullian EM, 2004, MOL CELL NEUROSCI, V25, P241, DOI 10.1016/j.mcn.2003.10.011; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; Umemori H, 2004, CELL, V118, P257, DOI 10.1016/j.cell.2004.06.025	37	1125	1173	0	67	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 11	2005	120	3					421	433		10.1016/j.cell.2004.12.020	http://dx.doi.org/10.1016/j.cell.2004.12.020			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	897TS	15707899	Bronze			2022-12-28	WOS:000227028900016
J	Lorimer, DR				Lorimer, DR			A pulsar bonanza	SCIENCE			English	Editorial Material							GLOBULAR-CLUSTERS; NEUTRON-STARS; SYSTEMS		Univ Manchester, Jodrell Bank Observ, Macclesfield SK11 9DL, Cheshire, England	University of Manchester; Jodrell Bank Centre for Astrophysics	Lorimer, DR (corresponding author), Univ Manchester, Jodrell Bank Observ, Macclesfield SK11 9DL, Cheshire, England.	duncan.lorimer@manchester.ac.uk	Lorimer, Duncan/ABH-7909-2020					Camilo F, 2000, ASTROPHYS J, V535, P975, DOI 10.1086/308859; Freire PC, 2001, ASTROPHYS J, V557, pL105, DOI 10.1086/323248; Fruchter AS, 2000, ASTROPHYS J, V536, P865, DOI 10.1086/308948; Lattimer JM, 2004, SCIENCE, V304, P536, DOI 10.1126/science.1090720; LYNE AG, 1990, NATURE, V347, P650, DOI 10.1038/347650a0; Lyne AG, 2000, MON NOT R ASTRON SOC, V316, P491, DOI 10.1046/j.1365-8711.2000.03517.x; PHINNEY ES, 1992, PHILOS T ROY SOC A, V341, P39, DOI 10.1098/rsta.1992.0084; Ransom S.M., 2001, THESIS HARVARD U; Ransom SM, 2005, SCIENCE, V307, P892, DOI 10.1126/science.1108632; SIGURDSSON S, 1995, ASTROPHYS J SUPPL S, V99, P609, DOI 10.1086/192199; Stairs IH, 2004, SCIENCE, V304, P547, DOI 10.1126/science.1096986	11	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2005	307	5711					855	856		10.1126/science.1109555	http://dx.doi.org/10.1126/science.1109555			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897DV	15705830				2022-12-28	WOS:000226985100029
J	MacLean, JA; Chen, MGA; Wayne, CM; Bruce, SR; Rao, M; Meistrich, ML; Macleod, C; Wilkinson, MF				MacLean, JA; Chen, MGA; Wayne, CM; Bruce, SR; Rao, M; Meistrich, ML; Macleod, C; Wilkinson, MF			Rhox: A new homeobox gene cluster	CELL			English	Article							RAPID EVOLUTION; CELL-DEATH; EXPRESSION; SEX; HOX; HOMEODOMAIN; TESTIS; TRANSCRIPTION; TESTOSTERONE; HIERARCHY	Homeobox genes encode transcription factors notable for their ability to regulate embryogenesis. Here, we report the discovery of a cluster of 12 related homeobox genes on the X chromosome expressed in male and female reproductive tissues in adult mice. These reproductive homeobox on the X chromosome (Rhox) genes are expressed in a cell type-specific manner; several are hormonally regulated, and their expression pattern during postnatal testis development corresponds to their chromosomal position. Most of the Rhox genes are expressed in Sertoli cells, the nurse cells in direct contact with developing male germ cells, suggesting that they regulate the expression of somatic-cell gene products critical for germ cell development. In support of this, targeted disruption of Rhox5 increased male germ cell apoptosis and reduced sperm production, sperm motility, and fertility. Identification of this family of homeobox genes provides an opportunity to study colinear gene regulation and the transcriptional control of reproduction.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Calif San Diego, Sch Med, Dept Med, Ctr Canc, La Jolla, CA 92093 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California San Diego	Wilkinson, MF (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	mwilkins@mdanderson.org						Brooke NM, 1998, NATURE, V392, P920, DOI 10.1038/31933; Charlesworth B, 2002, NOVART FDN SYMP, V244, P207; Chun JY, 1999, DEV DYNAM, V216, P257, DOI 10.1002/(SICI)1097-0177(199911)216:3<257::AID-DVDY4>3.0.CO;2-0; Cillo C, 2001, J CELL PHYSIOL, V188, P161, DOI 10.1002/jcp.1115; CLERMONT Y, 1963, AM J ANAT, V112, P35, DOI 10.1002/aja.1001120103; DUBOULE D, 1994, TRENDS GENET, V10, P358, DOI 10.1016/0168-9525(94)90132-5; Duboule D, 1998, CURR OPIN GENET DEV, V8, P514, DOI 10.1016/S0959-437X(98)80004-X; DUBOULE D, 1994, GUIDEBOOK HOMEBOX GE; DYM M, 1971, BIOL REPROD, V4, P195, DOI 10.1093/biolreprod/4.2.195; Gall H, 1999, HAUTARZT, V50, P186, DOI 10.1007/s001050050887; Geserick C, 2002, BIOCHEM J, V366, P367, DOI 10.1042/bj20020399; Gilad Y, 2003, P NATL ACAD SCI USA, V100, P3324, DOI 10.1073/pnas.0535697100; Gould A, 1997, GENE DEV, V11, P900, DOI 10.1101/gad.11.7.900; Hasegawa M, 1997, RADIAT RES, V147, P457, DOI 10.2307/3579503; Hikim APS, 2003, ENDOCRINOLOGY, V144, P3167, DOI 10.1210/en.2003-0175; Hurst LD, 2001, NATURE, V411, P149, DOI 10.1038/35075697; Jackson M, 2002, J BIOL CHEM, V277, P38683, DOI 10.1074/jbc.M203459200; Kang YL, 2004, BIOL REPROD, V70, P828, DOI 10.1095/biolreprod.103.021048; Khil PP, 2004, NAT GENET, V36, P642, DOI 10.1038/ng1368; Kouprina N, 2004, P NATL ACAD SCI USA, V101, P3077, DOI 10.1073/pnas.0308532100; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Kumar TR, 2001, ENDOCRINOLOGY, V142, P3512, DOI 10.1210/en.142.8.3512; Lane RP, 2002, P NATL ACAD SCI USA, V99, P291, DOI 10.1073/pnas.012608399; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LIM K, 1994, J ANDROL, V15, P543; Lue YH, 2000, ENDOCRINOLOGY, V141, P1414, DOI 10.1210/en.141.4.1414; Lysiak JJ, 2001, BIOL REPROD, V65, P718, DOI 10.1095/biolreprod65.3.718; Maiti S, 1996, GENOMICS, V34, P304, DOI 10.1006/geno.1996.0291; Martinez P, 2002, COMP BIOCHEM PHYS B, V133, P571, DOI 10.1016/S1096-4959(02)00121-5; MEISTRICH ML, 1993, EUR UROL, V23, P136; Pedersen AG, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P226; Peterson KJ, 2004, MOL PHYLOGENET EVOL, V31, P1208, DOI 10.1016/j.ympev.2003.10.007; Pitman JL, 1998, DEV BIOL, V202, P196, DOI 10.1006/dbio.1998.8978; Pollard SL, 2000, CURR BIOL, V10, P1059, DOI 10.1016/S0960-9822(00)00676-X; Rao MK, 2003, MOL ENDOCRINOL, V17, P223, DOI 10.1210/me.2002-0232; Rao MK, 2002, J BIOL CHEM, V277, P48771, DOI 10.1074/jbc.M209417200; Rao MK, 2002, J BIOL CHEM, V277, P26036, DOI 10.1074/jbc.M203374200; Reed RR, 2004, CELL, V116, P329, DOI 10.1016/S0092-8674(04)00047-9; RICE WR, 1994, SCIENCE, V263, P230, DOI 10.1126/science.8284674; Rodriguez I, 2002, NAT NEUROSCI, V5, P134, DOI 10.1038/nn795; RUSSELL R, 1993, SERTOLI CELL; Soares MJ, 2001, ENDOCRIN UPDAT, V12, P139; Spitz F, 2003, CELL, V113, P405, DOI 10.1016/S0092-8674(03)00310-6; Sun S, 2004, SCIENCE, V305, P81, DOI 10.1126/science.1093904; Sutton KA, 1997, GENOMICS, V45, P447, DOI 10.1006/geno.1997.4946; Sutton KA, 1997, J MOL EVOL, V45, P579, DOI 10.1007/PL00006262; Swanson WJ, 2002, NAT REV GENET, V3, P137, DOI 10.1038/nrg733; Takasaki N, 2000, DEV BIOL, V223, P181, DOI 10.1006/dbio.2000.9741; TREISMAN J, 1989, CELL, V59, P553; Vallender EJ, 2004, BIOESSAYS, V26, P159, DOI 10.1002/bies.10393; Wang PJ, 2001, NAT GENET, V27, P422, DOI 10.1038/86927; Wayne CM, 2002, GENE, V301, P1, DOI 10.1016/S0378-1119(02)01087-9; Weatherbee SD, 1998, GENE DEV, V12, P1474, DOI 10.1101/gad.12.10.1474; YOMOGIDA K, 1994, DEVELOPMENT, V120, P1759; Zhao M, 2001, MOL CELL BIOL, V21, P7243, DOI 10.1128/MCB.21.21.7243-7255.2001	55	157	164	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 11	2005	120	3					369	382		10.1016/j.cell.2004.12.022	http://dx.doi.org/10.1016/j.cell.2004.12.022			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	897TS	15707895	Bronze			2022-12-28	WOS:000227028900012
J	Sezen, UU; Chazdon, RL; Holsinger, KE				Sezen, UU; Chazdon, RL; Holsinger, KE			Genetic consequences of tropical second-growth forest regeneration	SCIENCE			English	Article									Univ Connecticut, Dept Ecol & Evolutionary Biol, Storrs, CT 06269 USA	University of Connecticut	Sezen, UU (corresponding author), Univ Connecticut, Dept Ecol & Evolutionary Biol, Storrs, CT 06269 USA.	uzay.sezen@huskymail.uconn.edu	Sezen, Uğur Uzay/V-1186-2019; Holsinger, Kent/A-7435-2009	Sezen, Uğur Uzay/0000-0002-2988-8790; Holsinger, Kent/0000-0003-4312-3804				Aldrich PR, 1998, SCIENCE, V281, P103, DOI 10.1126/science.281.5373.103; Cespedes M, 2003, MOL ECOL, V12, P3201, DOI 10.1046/j.1365-294X.2003.01986.x; Chase MR, 1996, NATURE, V383, P398, DOI 10.1038/383398a0; *FAO UN, 2001, 140 FAO UN; HENDESON A, 1990, FLORA NEOTROP MONOGR, V53; Nason JD, 1998, NATURE, V391, P685, DOI 10.1038/35607	6	78	83	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	2005	307	5711					891	891		10.1126/science.1105034	http://dx.doi.org/10.1126/science.1105034			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897DV	15705843	Green Submitted			2022-12-28	WOS:000226985100043
J	Orton, GS; Yanamandra-Fisher, PA				Orton, GS; Yanamandra-Fisher, PA			Saturn's temperature field from high-resolution middle-infrared imaging	SCIENCE			English	Article							JUPITER UPPER TROPOSPHERE; SPATIAL-ORGANIZATION; THERMAL STRUCTURE; TIME-DEPENDENCE; CLOUD LEVEL; ZONAL WINDS; ENCOUNTER; DYNAMICS; PLANETS; SYSTEM	Saturn was imaged between 8 and 24.5 micrometers at similar to3000-kilometer resolution with the Keck I Telescope. Saturn's atmosphere has zonal temperature bands, which are mostly uncorrelated with visible cloud reflectivity, strong 100-millibar zonal temperature oscillations near 32degreesS, a warm south polar cap, and a compact hot point within 3degrees of the south pole.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Orton, GS (corresponding author), CALTECH, Jet Prop Lab, MS 169-237,4800 Oak Grove Dr, Pasadena, CA 91109 USA.		Orton, Glenn/AAD-9862-2020					Achterberg RK, 1996, ICARUS, V119, P350, DOI 10.1006/icar.1996.0024; BEZARD B, 1984, ICARUS, V60, P274, DOI 10.1016/0019-1035(84)90189-1; BEZARD B, 1985, ICARUS, V61, P296, DOI 10.1016/0019-1035(85)90110-1; Flasar FM, 1998, PLANET SPACE SCI, V46, P1125, DOI 10.1016/S0032-0633(97)00223-7; FLASAR FM, 2004, SCIENCE         1223; GILLETT FC, 1975, ASTROPHYS J, V195, pL47, DOI 10.1086/181707; HANEL R, 1981, SCIENCE, V212, P192, DOI 10.1126/science.212.4491.192; HANEL R, 1982, SCIENCE, V215, P544, DOI 10.1126/science.215.4532.544; INGERSOLL AP, 1980, SCIENCE, V207, P434; MAGALHAES JA, 1990, ICARUS, V88, P39, DOI 10.1016/0019-1035(90)90176-A; ORTON GS, 1991, SCIENCE, V252, P537, DOI 10.1126/science.252.5005.537; ORTON GS, 1994, SCIENCE, V265, P625, DOI 10.1126/science.265.5172.625; PIRRAGLIA JA, 1981, NATURE, V292, P677, DOI 10.1038/292677a0; REED RJ, 1963, J ATMOS SCI, V20, P2556; Sanchez-Lavega A, 2000, ICARUS, V147, P405, DOI 10.1006/icar.2000.6449; Sanchez-Lavega A, 2004, ICARUS, V170, P519, DOI 10.1016/j.icarus.2004.05.002; Sanchez-Lavega A, 2003, NATURE, V423, P623, DOI 10.1038/nature01653; Sanchez-Lavega A, 2002, ICARUS, V160, P216, DOI 10.1006/icar.2002.6947; SCHOEBERL MR, 1991, SCIENCE, V251, P46, DOI 10.1126/science.251.4989.46; Yanamandra-Fisher PA, 2001, ICARUS, V150, P189, DOI 10.1006/icar.2000.6580	22	61	61	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2005	307	5710					696	698		10.1126/science.1105730	http://dx.doi.org/10.1126/science.1105730			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	894TQ	15692044				2022-12-28	WOS:000226814900034
J	Ghosal, S; Hemminger, JC; Bluhm, H; Mun, BS; Hebenstreit, ELD; Ketteler, G; Ogletree, DF; Requejo, FG; Salmeron, M				Ghosal, S; Hemminger, JC; Bluhm, H; Mun, BS; Hebenstreit, ELD; Ketteler, G; Ogletree, DF; Requejo, FG; Salmeron, M			Electron spectroscopy of aqueous solution interfaces reveals surface enhancement of halides	SCIENCE			English	Article							SALT-SOLUTIONS; AIR/WATER INTERFACE; MOLECULAR-STRUCTURE; POLAR SUNRISE; CHEMISTRY; OZONE; BROMINE; PHOTOEMISSION; IONS; NACL	It has been suggested that enhanced anion concentrations at the liquid/vapor interface of airborne saline droplets are important to aerosol reactions in the atmosphere. We report ionic concentrations in the surface of such solutions. Using x-ray photoelectron spectroscopy operating at near ambient pressure, we have measured the composition of the liquid/vapor interface for deliquesced samples of potassium bromide and potassium iodide. In both cases, the surface composition of the saturated solution is enhanced in the halide anion compared with the bulk of the solution. The enhancement of anion concentration is more dramatic for the larger, more polarizable iodide anion. By varying photoelectron kinetic energies, we have obtained depth profiles of the liquid/vapor interface. Our results are in good qualitative agreement with classical molecular dynamics simulations. Quantitative comparison between the experiments and the simulations indicates that the experimental results exhibit more interface enhancement than predicted theoretically.	Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Chem Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Adv Light Source, Berkeley, CA 94720 USA; Natl Univ La Plata, Fac Ciencias Exactas, Dept Fis, RA-1900 La Plata, Argentina	University of California System; University of California Irvine; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; National University of La Plata	Hemminger, JC (corresponding author), Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA.	jchemmin@uci.edu	Requejo, Felix G/O-2260-2016; Ogletree, D Frank F/D-9833-2016; Mun, Bongjin/G-1701-2013	Requejo, Felix G/0000-0003-4439-864X; Ogletree, D Frank F/0000-0002-8159-0182; 				Barrie L, 1997, TELLUS B, V49, P450, DOI 10.1034/j.1600-0889.49.issue5.2.x; BARRIE LA, 1988, NATURE, V334, P138, DOI 10.1038/334138a0; Dang LX, 2002, J PHYS CHEM B, V106, P235, DOI 10.1021/jp011853w; Garrett BC, 2004, SCIENCE, V303, P1146, DOI 10.1126/science.1089801; Ghosal S, 2000, GEOPHYS RES LETT, V27, P1879, DOI 10.1029/2000GL011381; HU JH, 1995, J PHYS CHEM-US, V99, P8768, DOI 10.1021/j100021a050; Hunt SW, 2004, J PHYS CHEM A, V108, P11559, DOI 10.1021/jp0467346; Jungwirth P, 2001, J PHYS CHEM B, V105, P10468, DOI 10.1021/jp012750g; Jungwirth P, 2002, J PHYS CHEM B, V106, P6361, DOI 10.1021/jp020242g; Knipping EM, 2000, SCIENCE, V288, P301, DOI 10.1126/science.288.5464.301; LINKE WF, 1958, SOLUBILITIES INORGAN, V2; Liu DF, 2004, J PHYS CHEM B, V108, P2252, DOI 10.1021/jp036169r; Ogletree DF, 2002, REV SCI INSTRUM, V73, P3872, DOI 10.1063/1.1512336; Petersen PB, 2004, CHEM PHYS LETT, V397, P46, DOI 10.1016/j.cplett.2004.08.048; Powell C. J., 2000, NIST ELECT INELASTIC; Raymond EA, 2004, J PHYS CHEM B, V108, P5051, DOI 10.1021/jp037725k; Sander R, 2003, ATMOS CHEM PHYS, V3, P1301, DOI 10.5194/acp-3-1301-2003; Spicer CW, 2002, ATMOS ENVIRON, V36, P2721, DOI 10.1016/S1352-2310(02)00125-5; Spicer CW, 1998, NATURE, V394, P353, DOI 10.1038/28584; Weber R, 2004, J PHYS CHEM B, V108, P4729, DOI 10.1021/jp030776x; YEH JJ, 1985, ATOM DATA NUCL DATA, V32, P1, DOI 10.1016/0092-640X(85)90016-6	21	502	503	7	213	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2005	307	5709					563	566		10.1126/science.1106525	http://dx.doi.org/10.1126/science.1106525			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893BJ	15681380				2022-12-28	WOS:000226694000042
J	Panda, S; Nayak, SK; Campo, B; Walker, JR; Hogenesch, JB; Jegla, T				Panda, S; Nayak, SK; Campo, B; Walker, JR; Hogenesch, JB; Jegla, T			Illumination of the melanopsin signaling pathway	SCIENCE			English	Article							RETINAL GANGLION-CELLS; LIGHT; PHOTOTRANSDUCTION; DROSOPHILA; RESPONSES; MELANOPHORES; EXPRESSION; PROTEIN; SYSTEM; GENE	In mammals, a small population of intrinsically photosensitive retinal ganglion cells (ipRGCs) plays a key role in the regulation of nonvisual photic responses, such as behavioral responses to tight, pineal melatonin synthesis, pupillary light reflex, and steep latency. These ipRGCs also express melanopsin (Opn4), a putative opsin-family photopigment that has been shown to play a rote in mediating these nonvisual photic responses. Melanopsin is required for the function of this inner retinal pathway, but its precise role in generating photic responses has not yet been determined. We found that expression of melanopsin in Xenopus oocytes results in light-dependent activation of membrane currents through the Galpha(q)/Galpha(11) G protein pathway, with an action spectrum closely matching that of melanopsin-expressing ipRGCs and of behavioral responses to light in mice lacking rods and cones. When coexpressed with arrestins, melanopsin could use all-trans-retinaldehyde as a chromophore, which suggests that it may function as a bireactive opsin. We also found that melanopsin could activate the cation channel TRPC3, a mammalian homolog of the Drosophila phototransduction channels TRP and TRPL. Melanopsin therefore signals more like an invertebrate opsin than like a classical vertebrate rod-and-cone opsin.	Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA	Novartis	Panda, S (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	satchin@salk.edu; tjegta@gnf.org	Panda, Satchidananda/J-6891-2012	Jegla, Timothy/0000-0001-8616-2390				Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262; Burns ME, 2001, ANNU REV NEUROSCI, V24, P779, DOI 10.1146/annurev.neuro.24.1.779; Gooley JJ, 2001, NAT NEUROSCI, V4, P1165, DOI 10.1038/nn768; Hannibal J, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-01-j0002.2002; Hardie RC, 2001, NATURE, V413, P186, DOI 10.1038/35093002; Hattar S, 2003, NATURE, V424, P76, DOI 10.1038/nature01761; Hattar S, 2002, SCIENCE, V295, P1065, DOI 10.1126/science.1069609; KHORANA HG, 1988, P NATL ACAD SCI USA, V85, P7917, DOI 10.1073/pnas.85.21.7917; Kiselev A, 1997, BIOCHEMISTRY-US, V36, P2188, DOI 10.1021/bi9621268; Knox BE, 2000, METHOD ENZYMOL, V316, P41; Lucas RJ, 2001, NAT NEUROSCI, V4, P621, DOI 10.1038/88443; Lucas RJ, 2003, SCIENCE, V299, P245, DOI 10.1126/science.1077293; MEYLAN Z, 2005, IN PRESS NATURE 0126, DOI DOI 10.1038/NATURE03344; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Nagel G, 2002, SCIENCE, V296, P2395, DOI 10.1126/science.1072068; Nagel G, 2003, P NATL ACAD SCI USA, V100, P13940, DOI 10.1073/pnas.1936192100; Newman LA, 2003, BIOCHEMISTRY-US, V42, P12734, DOI 10.1021/bi035418z; Panda S, 2003, SCIENCE, V301, P525, DOI 10.1126/science.1086179; Panda S, 2002, SCIENCE, V298, P2213, DOI 10.1126/science.1076848; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; QIU X, 2005, NATURE          0126, DOI DOI 10.1038/NATURE03345; Rollag MD, 2000, METHOD ENZYMOL, V316, P291; Ruby NF, 2002, SCIENCE, V298, P2211, DOI 10.1126/science.1076701; Sekaran S, 2003, CURR BIOL, V13, P1290, DOI 10.1016/S0960-9822(03)00510-4; TAKAHASHI JS, 1984, NATURE, V308, P186, DOI 10.1038/308186a0; Trebak M, 2003, CELL CALCIUM, V33, P451, DOI 10.1016/S0143-4160(03)00056-3; Warren EJ, 2003, EUR J NEUROSCI, V17, P1727, DOI 10.1046/j.1460-9568.2003.02594.x; Zemelman BV, 2002, NEURON, V33, P15, DOI 10.1016/S0896-6273(01)00574-8	29	357	409	2	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2005	307	5709					600	604		10.1126/science.1105121	http://dx.doi.org/10.1126/science.1105121			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893BJ	15681390				2022-12-28	WOS:000226694000053
J	Waters, AP; Mota, MM; van Dijk, MR; Janse, CJ				Waters, AP; Mota, MM; van Dijk, MR; Janse, CJ			Parasitology - Malaria vaccines: Back to the future?	SCIENCE			English	Editorial Material							PLASMODIUM-FALCIPARUM; PROTECTIVE IMMUNITY; IRRADIATED SPOROZOITES; GENOME SEQUENCE		Leiden Univ, Med Ctr, Dept Parasitol, NL-2300 RC Leiden, Netherlands; Inst Gulbenkian Ciencias, P-2780156 Oeiras, Portugal	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Instituto Gulbenkian de Ciencia	Waters, AP (corresponding author), Leiden Univ, Med Ctr, Dept Parasitol, NL-2300 RC Leiden, Netherlands.	a.p.waters@lumc.nl	Waters, Andy P/C-9377-2009; Mota, Maria/AAF-2048-2019	Waters, Andy P/0000-0001-8900-2982; Janse, Chris J/0000-0002-6410-6205; Mota, Maria Manuel/0000-0002-2858-1041				Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1; Carlton JM, 2002, NATURE, V419, P512, DOI 10.1038/nature01099; de Koning-Ward TF, 2000, ANNU REV MICROBIOL, V54, P157, DOI 10.1146/annurev.micro.54.1.157; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Hall N, 2005, SCIENCE, V307, P82, DOI 10.1126/science.1103717; LEIRIAO P, IN PRESS CELL MICROB; Luke TC, 2003, J EXP BIOL, V206, P3803, DOI 10.1242/jeb.00644; Matuschewski K, 2002, J BIOL CHEM, V277, P41948, DOI 10.1074/jbc.M207315200; Morrot A, 2004, IMMUNOL REV, V201, P291, DOI 10.1111/j.0105-2896.2004.00175.x; Mueller AK, 2005, NATURE, V433, P164, DOI 10.1038/nature03188; MUELLER AK, 2004, MOL PAR M WOODS HOL; NUSSENZWEIG RS, 1967, NATURE, V216, P160, DOI 10.1038/216160a0; SCHELLER LF, 1995, P NATL ACAD SCI USA, V92, P4066, DOI 10.1073/pnas.92.9.4066; VANDIJK MR, UNPUB; ZAVALA F, 1991, RES IMMUNOL, V142, P654, DOI 10.1016/0923-2494(91)90144-8	15	24	35	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 28	2005	307	5709					528	530		10.1126/science.1108598	http://dx.doi.org/10.1126/science.1108598			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893BJ	15681372				2022-12-28	WOS:000226694000032
J	Berry, RJ; Kihlberg, R; Devine, O				Berry, RJ; Kihlberg, R; Devine, O			Impact of misclassification of in vitro fertilisation in studies of folic acid and twinning: modelling using population based Swedish vital records	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SUPPLEMENTATION; FORTIFICATION; RATES; BORN; RISK	Objective To determine whether failure to adequately adjust for a reported 40% misclassification of use of in vitro fertilisation (IVF) as reported in a Swedish study could have led to a false finding that folic acid increases dizygotic twinning. Design Modelling with population based data. Setting Swedish vital records for 1995-9. Main outcome measures Rates of twinning calculated according to whether women used AT to become pregnant. Estimated unadjusted and adjusted odds ratios of the association between use of folic acid and twinning by use of IVF. Results In 1995-9, Swedish women who used IVF had almost 20 times the chance of having twins than women who did not use IVF (rate ratio 19.7, 95% confidence interval 18.7 to 20.6). In the absence of true effect of folic acid, the use of a 40% misclassified surrogate variable to adjust for use of IVF would have resulted in a false finding that folic acid was associated with a more than twofold increase in twinning. Conclusion Use of IVF is a strong confounder because it is associated with both use of folic acid and twinning. Even when misclassification of IVF was reduced to 5%, this bias persisted in the adjusted model. Using a 40% misclassified surrogate to adjust for IVF, as reported in the Swedish study, probably led to a false finding that folic acid increased dizygotic twinning.	Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Dept Hlth & Human Serv, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Berry, RJ (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Dept Hlth & Human Serv, 1600 Clifton Rd,MS E-86, Atlanta, GA 30333 USA.	RJBerry@cdc.gov		Berry, Robert/0000-0002-7162-5046				Bergh T, 1999, LANCET, V354, P1579, DOI 10.1016/S0140-6736(99)04345-7; Cornel MC, 1997, TERATOLOGY, V55, P134; Czeizel A. E., 1994, Acta Geneticae Medicae et Gemellologiae, V43, P175; Czeizel AE, 2004, AM J OBSTET GYNECOL, V191, P790, DOI 10.1016/j.ajog.2004.02.018; Ericson A, 2002, HUM REPROD, V17, P929, DOI 10.1093/humrep/17.4.929; Ericson A, 2001, Twin Res, V4, P63, DOI 10.1375/twin.4.2.63; George L, 2002, JAMA-J AM MED ASSOC, V288, P1867, DOI 10.1001/jama.288.15.1867; Kallen B, 2002, OBSTET GYNECOL, V100, P414, DOI 10.1016/S0029-7844(02)02069-0; Kallen B, 2004, EARLY HUM DEV, V80, P143, DOI 10.1016/j.earlhumdev.2004.06.002; KIHLBERG R, 2002, DAGENS MED, V41, P38; Kinzler WL, 2000, J SOC GYNECOL INVEST, V7, P321, DOI 10.1016/S1071-5576(00)00084-8; Kucik J, 2004, J REPROD MED, V49, P707; Li Z, 2003, LANCET, V361, P380, DOI 10.1016/S0140-6736(03)12390-2; Lumley J, 2001, BRIT J OBSTET GYNAEC, V108, P937, DOI 10.1111/j.1471-0528.2001.00228.x; Marshall JR, 2003, J NUTR, V133, p881S, DOI 10.1093/jn/133.3.881S; *NAT BOARD HLTH WE, 2004, ASS BEFR 2001; *NAT BOARD HLTH WE, 2000, BARN FODD SVER PROV; National Board of Health and Welfare Centre for Epidemiology, 2003, SWED MED BIRTH REG S; National Board of Health and Welfare Centre for Epidemiology, 2002, FAKT MAMM FORL NYF B; Shaw GM, 2003, AM J MED GENET A, V119A, P137, DOI 10.1002/ajmg.a.20145; Waller DK, 2003, PAEDIATR PERINAT EP, V17, P378, DOI 10.1046/j.1365-3016.2003.00511.x	21	16	17	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 9	2005	330	7495					815	818		10.1136/bmj.38369.437789.82	http://dx.doi.org/10.1136/bmj.38369.437789.82			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915BZ	15722370	Bronze, Green Published			2022-12-28	WOS:000228273900015
J	Akiyama, T; Maeda, S; Yamane, S; Ogino, K; Kasai, M; Kajiura, F; Matsumoto, M; Inoue, J				Akiyama, T; Maeda, S; Yamane, S; Ogino, K; Kasai, M; Kajiura, F; Matsumoto, M; Inoue, J			Dependence of self-tolerance on TRAF6-directed development of thymic stroma	SCIENCE			English	Article							NF-KAPPA-B; PROMISCUOUS GENE-EXPRESSION; NEGATIVE SELECTION; AIRE EXPRESSION; RECEPTOR; CELLS; RELB; MICE; PROTEIN; KINASE	The microenvironments of the thymus are generated by thymic epithelial cells (TECs) and are essential for inducing immune self-toterance or developing T cells. However, the molecular mechanisms that underlie the differentiation of TECs and thymic compartmentalization are not fully understood. Here we show that deficiency in the tumor necrosis factor receptor-associated factor (TRAF) 6 results in disorganized distribution of medullary TECs (mTECs) and the absence of mature mTECs. Engraftment of thymic stroma of TRAF6(-/-)embryos into athymic nude mice induced autoimmunity. Thus, TRAF6 directs the development of thymic stroma and represents a critical point of regulation for self-tolerance and autoimmunity.	Univ Tokyo, Inst Med Sci, Div Cellular & Mol Biol, Minato Ku, Tokyo 1088639, Japan; Natl Inst Infect Dis, Div Bacterial & Blood Prod, Musashimurayama, Tokyo 2080011, Japan; Univ Tokushima, Inst Enzyme Res, Div Mol Immunol, Tokushima 7708503, Japan	University of Tokyo; National Institute of Infectious Diseases (NIID); Tokushima University	Inoue, J (corresponding author), Univ Tokyo, Inst Med Sci, Div Cellular & Mol Biol, Minato Ku, Tokyo 1088639, Japan.	jun-i@ims.u-tokyo.ac.jp						Anderson G, 2001, NAT REV IMMUNOL, V1, P31, DOI 10.1038/35095500; Anderson G, 1996, ANNU REV IMMUNOL, V14, P73, DOI 10.1146/annurev.immunol.14.1.73; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Boehm T, 2003, J EXP MED, V198, P757, DOI 10.1084/jem.20030794; Bren GD, 2001, ONCOGENE, V20, P7722, DOI 10.1038/sj.onc.1204868; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Chiffoleau E, 2003, J IMMUNOL, V171, P5751, DOI 10.4049/jimmunol.171.11.5751; Chin RK, 2003, NAT IMMUNOL, V4, P1121, DOI 10.1038/ni982; Derbinski J, 2001, NAT IMMUNOL, V2, P1032, DOI 10.1038/ni723; Gill J, 2003, IMMUNOL REV, V195, P28, DOI 10.1034/j.1600-065X.2003.00077.x; Heino M, 2000, EUR J IMMUNOL, V30, P1884, DOI 10.1002/1521-4141(200007)30:7<1884::AID-IMMU1884>3.0.CO;2-P; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Kajiura F, 2004, J IMMUNOL, V172, P2067, DOI 10.4049/jimmunol.172.4.2067; KASAI M, 1991, CELL IMMUNOL, V132, P377, DOI 10.1016/0008-8749(91)90035-A; Kyewski B, 2002, TRENDS IMMUNOL, V23, P364, DOI 10.1016/S1471-4906(02)02248-2; Laufer TM, 1996, NATURE, V383, P81, DOI 10.1038/383081a0; Liston A, 2003, NAT IMMUNOL, V4, P350, DOI 10.1038/ni906; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2; SCHENINKING J, 1993, MOLT SALT FORUM, V1&2, P13; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yoshida H, 2002, IMMUNITY, V17, P823, DOI 10.1016/S1074-7613(02)00479-X; Zuklys S, 2000, J IMMUNOL, V165, P1976, DOI 10.4049/jimmunol.165.4.1976	28	225	233	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 8	2005	308	5719					248	251		10.1126/science.1105677	http://dx.doi.org/10.1126/science.1105677			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915BX	15705807				2022-12-28	WOS:000228273700052
J	Arvidson, RE; Poulet, F; Bibring, JP; Wolff, M; Gendrin, A; Morris, RV; Freeman, JJ; Langevin, Y; Mangold, N; Bellucci, G				Arvidson, RE; Poulet, F; Bibring, JP; Wolff, M; Gendrin, A; Morris, RV; Freeman, JJ; Langevin, Y; Mangold, N; Bellucci, G			Spectral reflectance and morphologic correlations in eastern Terra Meridiani, Mars	SCIENCE			English	Article							OPPORTUNITY ROVER; PLANUM; SPECTROMETER; WATER	The Mars Express Observatoire pour la Mineralogie, l'Eau, les Glaces, et l'Activite (OMEGA) hyperspectral image data covering eastern Terra Meridiani indicate the ubiquitous presence of molecular water in etched terrain materials that disconformabty overlie heavily cratered terrains and underlie the hematite-bearing plains explored by the Opportunity rover. Identification of crystalline water in kieserite (MgSO4.H2O) is linked to materials exposed in a valley and plateau to the north of hematite-bearing plains. The mineralogical similarities between the etched terrain deposits examined with OMEGA data and the layered rocks examined by Opportunity imply that the ancient aqueous environments inferred from analyses of the rover data extend over regional scales.	Washington Univ, Dept Earth & Planetary Sci, St Louis, MO 63130 USA; Inst Astrophys Spatiale, F-91405 Orsay, France; Space Sci Inst, Boulder, CO 80301 USA; NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA; Ist Fis Spazio Interplanetario, Ist Nazl Astrofis, I-00133 Rome, Italy	Washington University (WUSTL); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; Istituto Nazionale Astrofisica (INAF)	Arvidson, RE (corresponding author), Washington Univ, Dept Earth & Planetary Sci, St Louis, MO 63130 USA.	arvidson@wunder.wustl.edu	Bellucci, Giancarlo/ABA-9201-2020	Bellucci, Giancarlo/0000-0003-0867-8679				Arvidson RE, 2004, SCIENCE, V306, P1730, DOI 10.1126/science.1104211; Arvidson RE, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE001982; Baldridge AM, 2004, J GEOPHYS RES-PLANET, V109, DOI 10.1029/2003JE002066; Bell JF, 2004, SCIENCE, V306, P1703, DOI 10.1126/science.1105245; Bibring JP, 2005, SCIENCE, V307, P1576, DOI 10.1126/science.1108806; BISHOP JL, UNPUB; Christensen PR, 2000, J GEOPHYS RES-PLANET, V105, P9623, DOI 10.1029/1999JE001093; Christensen PR, 2004, SCIENCE, V306, P1733, DOI 10.1126/science.1104909; Crowley JK., 2003, GEOCHEM-EXPLOR ENV A, V3, P219, DOI DOI 10.1144/1467-7873/03-001; Gendrin A, 2005, SCIENCE, V307, P1587, DOI 10.1126/science.1109087; GREEN AA, 1988, IEEE T GEOSCI REMOTE, V26, P65, DOI 10.1109/36.3001; Herzberg G, 1945, MOL SPECTRA MOL STRU; Hynek BM, 2004, NATURE, V431, P156, DOI 10.1038/nature02902; Hynek BM, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2002JE001891; Hynek BM, 2001, GEOLOGY, V29, P407, DOI 10.1130/0091-7613(2001)029<0407:EFEDOT>2.0.CO;2; Langevin Y, 2005, SCIENCE, V307, P1584, DOI 10.1126/science.1109091; MORRIS RV, 1985, J GEOPHYS RES-SOLID, V90, P3126, DOI 10.1029/JB090iB04p03126; Murchie S, 2000, ICARUS, V147, P444, DOI 10.1006/icar.2000.6446; Mustard JF, 2005, SCIENCE, V307, P1594, DOI 10.1126/science.1109098; MUSTARD JF, 1994, GEOPHYS RES LETT, V21, P353, DOI 10.1029/94GL00198; Smith DE, 2001, J GEOPHYS RES-PLANET, V106, P23689, DOI 10.1029/2000JE001364; Squyres SW, 2004, SCIENCE, V306, P1698, DOI 10.1126/science.1106171; STAMNES K, 1988, APPL OPTICS, V27, P2502, DOI 10.1364/AO.27.002502; Yen AS, 1998, J GEOPHYS RES-PLANET, V103, P11125, DOI 10.1029/98JE00739	24	150	154	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 11	2005	307	5715					1591	1594		10.1126/science.1109509	http://dx.doi.org/10.1126/science.1109509			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	906ED	15718425				2022-12-28	WOS:000227622400038
J	Jaffer, FA; Weissleder, R				Jaffer, FA; Weissleder, R			Molecular imaging in the clinical arena	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							POSITRON-EMISSION-TOMOGRAPHY; ULTRASMALL SUPERPARAMAGNETIC PARTICLES; SERVICES-TASK-FORCE; IN-VIVO; NONINVASIVE DETECTION; ATHEROSCLEROTIC PLAQUES; COMPUTED-TOMOGRAPHY; PROSTATE-CANCER; ENZYME-ACTIVITY; DRUG DISCOVERY	Molecular imaging is an emerging field that aims to integrate patient-specific and disease-specific molecular information with traditional anatomical imaging readouts. The information provided by this field may ultimately allow for noninvasive or minimally invasive molecular diagnostic capabilities, better clinical risk stratification, more optimal selection of disease therapy, and improved assessment of treatment efficacy. In this update, we first provide an overview of clinically relevant molecular imaging technologies and imaging agents. Next, their applications to disease detection, drug discovery, and biomedical research are discussed. To specifically demonstrate the potential of molecular imaging, we highlight recent advances in clinical and preclinical molecular imaging of cancer and atherosclerosis.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Cardiol Div, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Jaffer, FA (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Mol Imaging Res, 149 13th St,Room 5406, Charlestown, MA 02129 USA.	fjaffer@partners.org; weissleder@helix.mgh.harvard.edu	Jaffer, Farouc/AAK-8803-2020	Jaffer, Farouc/0000-0001-7980-384X; /0000-0003-0828-4143	NCI NIH HHS [P50-CA86355] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA086355] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aboagye EO, 2002, BRIT J CANCER, V86, P1052, DOI 10.1038/sj/bjc/6600212; Blasberg RG, 2003, J CLIN INVEST, V111, P1620, DOI 10.1172/JCI200318855; Boas DA, 2004, NEUROIMAGE, V23, pS275, DOI 10.1016/j.neuroimage.2004.07.011; Bremer C, 2001, NAT MED, V7, P743, DOI 10.1038/89126; Burns HD, 1999, CURR OPIN CHEM BIOL, V3, P388, DOI 10.1016/S1367-5931(99)80059-3; Chen JQ, 2002, CIRCULATION, V105, P2766, DOI 10.1161/01.CIR.0000017860.20619.23; Choudhury RP, 2004, NAT REV DRUG DISCOV, V3, P913, DOI 10.1038/nrd1548; DIVGI CR, 1991, J NATL CANCER I, V83, P97, DOI 10.1093/jnci/83.2.97; Fletcher SW, 2003, NEW ENGL J MED, V348, P1672, DOI 10.1056/NEJMcp021804; Funovics MA, 2004, RADIOLOGY, V231, P659, DOI 10.1148/radiol.2313030831; Gambhir SS, 2002, NAT REV CANCER, V2, P683, DOI 10.1038/nrc882; Guller U, 2003, JNCI-J NATL CANCER I, V95, P1040, DOI 10.1093/jnci/95.14.1040; Hamilton AJ, 2004, J AM COLL CARDIOL, V43, P453, DOI 10.1016/j.jacc.2003.07.048; Harisinghani MG, 2004, PLOS MED, V1, P202, DOI 10.1371/journal.pmed.0010066; Harisinghani MG, 2003, NEW ENGL J MED, V348, P2491, DOI 10.1056/NEJMoa022749; Harris R, 2002, ANN INTERN MED, V137, P917, DOI 10.7326/0003-4819-137-11-200212030-00014; Hofstra L, 2000, LANCET, V356, P209, DOI 10.1016/S0140-6736(00)02482-X; Humphrey LL, 2004, ANN INTERN MED, V140, P740, DOI 10.7326/0003-4819-140-9-200405040-00015; Jaffer FA, 2002, ARTERIOSCL THROM VAS, V22, P1929, DOI 10.1161/01.ATV.0000033089.56970.2D; Jaffer FA, 2004, CIRC RES, V94, P433, DOI 10.1161/01.RES.0000119321.18573.5A; Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4; Kelly K, 2004, CANCER RES, V64, P6247, DOI 10.1158/0008-5472.CAN-04-0817; KELLY KA, DETECTION VASCULAR A; Kietselaer BLJH, 2004, NEW ENGL J MED, V350, P1472, DOI 10.1056/NEJM200404013501425; Koehne G, 2003, NAT BIOTECHNOL, V21, P405, DOI 10.1038/nbt805; Kooi ME, 2003, CIRCULATION, V107, P2453, DOI 10.1161/01.CIR.0000068315.98705.CC; Lanza GM, 2003, CURR PROB CARDIOLOGY, V28, P625, DOI 10.1016/j.cpcardiol.2003.11.001; Lardinois D, 2003, NEW ENGL J MED, V348, P2500, DOI 10.1056/NEJMoa022136; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lindner JR, 2004, NAT REV DRUG DISCOV, V3, P527, DOI 10.1038/nrd1417; Marten K, 2002, GASTROENTEROLOGY, V122, P406, DOI 10.1053/gast.2002.30990; Massoud TF, 2003, GENE DEV, V17, P545, DOI 10.1101/gad.1047403; Matter CM, 2004, CIRC RES, V95, P1225, DOI 10.1161/01.RES.0000150373.15149.ff; Naghavi M, 2003, CIRCULATION, V108, P1664, DOI 10.1161/01.CIR.0000087480.94275.97; Narula J, 2001, NAT MED, V7, P1347, DOI 10.1038/nm1201-1347; National Library of Medicine, PUBCHEM; Ntziachristos V, 2000, P NATL ACAD SCI USA, V97, P2767, DOI 10.1073/pnas.040570597; Ntziachristos V, 2002, OPT LETT, V27, P333, DOI 10.1364/OL.27.000333; Ntziachristos V, 2002, NAT MED, V8, P757, DOI 10.1038/nm729; Rudin M, 2003, NAT REV DRUG DISCOV, V2, P123, DOI 10.1038/nrd1007; Smith-Jones PM, 2004, NAT BIOTECHNOL, V22, P701, DOI 10.1038/nbt968; Taroni P, 2003, PHOTOCH PHOTOBIO SCI, V2, P124, DOI 10.1039/b209651j; Tempany CMC, 2001, JAMA-J AM MED ASSOC, V285, P562, DOI 10.1001/jama.285.5.562; Trivedi RA, 2004, STROKE, V35, P1631, DOI 10.1161/01.STR.0000131268.50418.b7; Tung CH, 2000, CANCER RES, V60, P4953; Van den Abbeele AD, 2002, EUR J CANCER, V38, pS60, DOI 10.1016/S0959-8049(02)80604-9; Walsh JME, 2003, JAMA-J AM MED ASSOC, V289, P1288, DOI 10.1001/jama.289.10.1288; Weissleder R, 1999, NAT BIOTECHNOL, V17, P375, DOI 10.1038/7933; Weissleder R, 2002, NAT REV CANCER, V2, P11, DOI 10.1038/nrc701; Weissleder R, 2001, RADIOLOGY, V219, P316, DOI 10.1148/radiology.219.2.r01ma19316; Weissleder R, 2003, NAT MED, V9, P123, DOI 10.1038/nm0103-123; West CML, 2004, NAT REV CANCER, V4, P457, DOI 10.1038/nrc1368; Winter PM, 2003, CIRCULATION, V108, P2270, DOI 10.1161/01.CIR.0000093185.16083.95; Zerhouni E, 2003, SCIENCE, V302, P63, DOI 10.1126/science.1091867; INFRAREDX TECHNOLOGY	55	279	295	1	42	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	2005	293	7					855	862		10.1001/jama.293.7.855	http://dx.doi.org/10.1001/jama.293.7.855			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DQ	15713776				2022-12-28	WOS:000226984600028
J	Konstantopoulou, M; Belgi, A; Griffiths, KD; Seale, JRC; Macfarlane, AW				Konstantopoulou, M; Belgi, A; Griffiths, KD; Seale, JRC; Macfarlane, AW			Azathioprine-induced pancytopenia in a patient with pompholyx and deficiency of erythrocyte thiopurine methyltransferase	BRITISH MEDICAL JOURNAL			English	Review							GUIDELINES; DERMATOLOGY; MANAGEMENT; UK		Ysbyty Gwynedd, Bangor LL57 2PW, Gwynedd, Wales		Konstantopoulou, M (corresponding author), Ysbyty Gwynedd, Bangor LL57 2PW, Gwynedd, Wales.	konstantopoulou@nww-tr.wales.nhs.uk						ANSTEY A, 1992, J ROY SOC MED, V85, P752; ANSTEY A, 1995, J ROY SOC MED, V88, P155; Anstey AV, 2004, BRIT J DERMATOL, V151, P1123, DOI 10.1111/j.1365-2133.2004.06323.x; el-Azhary RA, 2003, INT J DERMATOL, V42, P335, DOI 10.1046/j.1365-4362.2003.01823.x; Ford LT, 2003, J CHROMATOGR B, V798, P111, DOI 10.1016/j.jchromb.2003.09.017; Harman KE, 2003, BRIT J DERMATOL, V149, P926, DOI 10.1111/j.1365-2133.2003.05665.x; Holme SA, 2002, QJM-INT J MED, V95, P439, DOI 10.1093/qjmed/95.7.439; Jackson AP, 1997, BRIT J DERMATOL, V136, P133, DOI 10.1111/j.1365-2133.1997.tb08765.x; Scerri L, 1999, ADV EXP MED BIOL, V455, P343; SNOW JL, 1995, ARCH DERMATOL, V131, P193, DOI 10.1001/archderm.131.2.193; Tan BB, 1997, BRIT J DERMATOL, V136, P351, DOI 10.1111/j.1365-2133.1997.tb14942.x; WEINSHILBOUM RM, 1980, AM J HUM GENET, V32, P651; WEINSHILBOUM RM, 1978, CLIN CHIM ACTA, V85, P323, DOI 10.1016/0009-8981(78)90311-X; Wojnarowska F, 2002, BRIT J DERMATOL, V147, P214, DOI 10.1046/j.1365-2133.2002.04835.x	14	14	14	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 12	2005	330	7487					350	351		10.1136/bmj.330.7487.350	http://dx.doi.org/10.1136/bmj.330.7487.350			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897OZ	15705694	Green Published			2022-12-28	WOS:000227015800028
J	Smyth, A; Tan, KHV; Hyman-Taylor, P; Mulheran, M; Lewis, S; Stableforth, D; Knox, A				Smyth, A; Tan, KHV; Hyman-Taylor, P; Mulheran, M; Lewis, S; Stableforth, D; Knox, A		TOPIC Study Grp	Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis - the TOPIC study: a randomised controlled trial	LANCET			English	Article							AERUGINOSA LUNG INFECTION; ONCE-DAILY TOBRAMYCIN; PSEUDOMONAS-AERUGINOSA; PHARMACOKINETICS; AMINOGLYCOSIDES; EFFICACY; THERAPY	Background Intravenous tobramycin (three-times daily) is widely used for pulmonary exacerbations in, patients with cystic fibrosis who have chronic Pseudomonas aeruginosa infection. We undertook a double-blind, randomised controlled trial to assess the safety and efficacy of once versus three-times daily tobramycin in these patients. Methods 244 patients from 21 cystic-fibrosis centres in the UK were randomly, assigned to once or three-times daily tobramycin (with ceftazidime) for 14 days. Treatment was given as 30-min infusions of. tobramycin in 0.9% saline. Primary outcome measure was change in forced expiratory volume in 1 s (FEV1), over the 14 days of treatment, expressed as a percentage of the predicted normal value for age, sex, and height. We also measured the change in FEV1 expressed as a percentage of baseline. Secondary outcomes included change in serum creatinine. The study was powered for equivalence, and primary analysis was per protocol. Findings 219 patients (107 once daily, 112 three-times daily) completed the study per protocol. None was lost to follow-up, although 20 discontinued,intervention. Of 122 patients assigned to once daily treatment, three did not receive the study regimen. The mean change in FEV1 (% predicted) over 14 days was similar on the two regimens (10.4% [once daily] vs 10.0% [three-times daily]; adjusted mean difference 0.4% [95% CI -3.3 to 4.1]). Mean % change in FEV1 from baseline was also similar in both treatments (21.9% vs 22.1%; -0.1% [-8.0 to 7.9]). There was no significant difference in % change in creatinine from baseline (-1.5% [once daily] vs 1.7% [three-times daily]). However, in children, once daily treatment was significantly less nephrotoxic than was thrice daily (me an % Change in creatine -4.5% [once daily] vs 3.7% [thrice daily]; adjusted mean difference -8.0%, 95% Cl -15.7 to -0.4). No patients developed hearing loss during the study, although two reported acute dizziness and were withdrawn from the study. Interpretation Intravenous tobramycin has equal efficacy if given once or three-times daily (with ceftazidime) for pulmonary exacerbations of cystic fibrosis. The once daily regimen might be less nephrotoxic in children.	City Hosp Nottingham, Dept Paediat, Nottingham NG5 1PB, England; Univ Nottingham, Dept Child Hlth, Nottingham, England; Univ Nottingham, Div Resp Med, Nottingham, England; Univ Leicester, Med Res Council Ctr Study Mech Human Tox, Leicester, Leics, England; Birmingham Heartlands Hosp, Dept Resp Med, Birmingham, W Midlands, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; University of Nottingham; University of Leicester; Heart of England NHS Foundation Trust; University of Birmingham	Smyth, A (corresponding author), City Hosp Nottingham, Dept Paediat, Nottingham NG5 1PB, England.	alan.smyth@nottingham.ac.uk		Smyth, Alan/0000-0001-5494-5438				Barclay ML, 1996, J ANTIMICROB CHEMOTH, V37, P1155, DOI 10.1093/jac/37.6.1155; CHAN GLC, 1989, DICP ANN PHARMAC, V23, P788, DOI 10.1177/106002808902301010; Cheng K, 1996, LANCET, V348, P639, DOI 10.1016/S0140-6736(96)05169-0; Drew J, 2003, ARCH DIS CHILD, V88, P646, DOI 10.1136/adc.88.7.646; Drew JH, 2002, PAEDIAT PERINATAL DR, V5, P65; FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003; GREEN CG, 1985, J PEDIATR-US, V107, P425, DOI 10.1016/S0022-3476(85)80526-6; JENSEN T, 1987, J ANTIMICROB CHEMOTH, V19, P831, DOI 10.1093/jac/19.6.831; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LUTMAN ME, 1994, AUDIOLOGY, V33, P327; NGUIYEN JH, 1984, J CLIN MICROBIOL, V20, P962, DOI 10.1128/JCM.20.5.962-965.1984; PROOST JH, 1992, COMPUT BIOL MED, V22, P155, DOI 10.1016/0010-4825(92)90011-B; Rappaz I, 2000, EUR J PEDIATR, V159, P919, DOI 10.1007/PL00008370; SMYTH A, 2000, COCHRANE DB SYST REV, V4, P2009; STEINKAMP G, 1986, EUR J PEDIATR, V145, P526, DOI 10.1007/BF02429057; STEPHENS SE, 2001, ARCH DIS CHILD, V84, pG169; Tan KHV, 2002, PEDIATR PULM, V33, P165, DOI 10.1002/ppul.10036; Tan KHV, 2003, AM J RESP CRIT CARE, V167, P819, DOI 10.1164/rccm.200109-012CC; Touw DJ, 1998, PHARM WORLD SCI, V20, P149, DOI 10.1023/A:1008634911114; Vic P, 1998, ARCH DIS CHILD, V78, P536, DOI 10.1136/adc.78.6.536; Whitehead A, 2002, EUR RESPIR J, V19, P303, DOI 10.1183/09031936.02.00221602	22	161	165	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	2005	365	9459					573	578		10.1016/S0140-6736(05)17906-9	http://dx.doi.org/10.1016/S0140-6736(05)17906-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DN	15708100				2022-12-28	WOS:000226984300029
J	Kidwell, SM				Kidwell, SM			Shell composition has no net impact on large-scale evolutionary patterns in mollusks	SCIENCE			English	Article							FOSSIL RECORD; MISSING MOLLUSKS; DISSOLUTION; ARAGONITE; DIVERSITY; CARBONATE; SEAWATER	A major suspected bias in the fossil record of sketetonized groups is variation in preservability owing to differences in shell composition. However, despite extensive changes in shell composition over the 500-million-year history of marine bivalves, genus duration and shell composition show few significant relationships, and of those, virtually all are contrary to bias from preferential loss of highly reactive shell types. Distortion of large-scale temporal patterns in marine bivalves owing to preservability is thus apparently weak or randomly distributed, which increases the likelihood that observed patterns in this and other shelled groups carry a strong biological signal.	Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA	University of Chicago	Kidwell, SM (corresponding author), Univ Chicago, Dept Geophys Sci, 5734 S Ellis Ave, Chicago, IL 60637 USA.	skidwell@uchicago.edu						BAMBACH RK, 1993, PALEOBIOLOGY, V19, P372, DOI 10.1017/S0094837300000336; Bush AM, 2004, J GEOL, V112, P625, DOI 10.1086/424576; Cherns L, 2000, GEOLOGY, V28, P791, DOI 10.1130/0091-7613(2000)28<791:MMAEOL>2.0.CO;2; Foote M, 2000, PALEOBIOLOGY, V26, P578, DOI 10.1666/0094-8373(2000)026<0578:OAECOT>2.0.CO;2; GLOVER CP, 1993, J GEOL, V101, P729, DOI 10.1086/648271; Harper EM, 2000, J ZOOL, V251, P179, DOI 10.1111/j.1469-7998.2000.tb00602.x; Harper EM, 1998, ADEQUACY OF THE FOSSIL RECORD, P243; Jablonski D, 2003, SCIENCE, V300, P1133, DOI 10.1126/science.1083246; Kidwell SM, 2002, ANNU REV ECOL SYST, V33, P561, DOI 10.1146/annurev.ecolsys.33.030602.152151; KOCH CF, 1983, PALEOBIOLOGY, V9, P26, DOI 10.1017/S0094837300007351; Kowalewski M, 1996, GEOLOGY, V24, P977, DOI 10.1130/0091-7613(1996)024<0977:IWATFR>2.3.CO;2; KOWALEWSKI M, 2002, 8 PAL SOC; MALIVA RG, 1988, J GEOL, V96, P387, DOI 10.1086/629235; MILLER AI, 1988, PALEOBIOLOGY, V14, P364, DOI 10.1017/S0094837300012100; MORSE JW, 1980, GEOCHIM COSMOCHIM AC, V44, P85, DOI 10.1016/0016-7037(80)90178-7; PALMER AR, 1992, P NATL ACAD SCI USA, V89, P1379, DOI 10.1073/pnas.89.4.1379; Paul CRC, 1998, ADEQUACY OF THE FOSSIL RECORD, P111; Peters SE, 2001, PALEOBIOLOGY, V27, P583, DOI 10.1666/0094-8373(2001)027<0583:BITPAR>2.0.CO;2; RAUP D M, 1979, Bulletin of Carnegie Museum of Natural History, P85; Sanders D, 2003, J AFR EARTH SCI, V36, P99, DOI 10.1016/S0899-5362(03)00027-7; Schubert JK, 1997, GEOLOGY, V25, P1031, DOI 10.1130/0091-7613(1997)025<1031:SRFTTP>2.3.CO;2; Sepkoski J.J., 2002, B AM PALEONTOL, V363, P1; Smith AB, 2001, PHILOS T R SOC B, V356, P351, DOI 10.1098/rstb.2000.0768; SMITH AB, 2001, PALAEOBIOLOGY, V2, P504; Stanley SM, 1998, PALAEOGEOGR PALAEOCL, V144, P3, DOI 10.1016/S0031-0182(98)00109-6; TAYLOR JD, 1969, B BRIT MUSEUM NATU S, V3, P1; WAINWRIG.SA, 1969, NATURE, V224, P777, DOI 10.1038/224777a0; WALTER LM, 1985, SEPM SPECIAL PUBLICA, V36, P3; Wright P, 2003, GEOLOGY, V31, P211, DOI 10.1130/0091-7613(2003)031<0211:MMFTTL>2.0.CO;2	29	76	77	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	2005	307	5711					914	917		10.1126/science.1106654	http://dx.doi.org/10.1126/science.1106654			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897DV	15705849				2022-12-28	WOS:000226985100050
J	Sumbre, G; Fiorito, G; Flash, T; Hochner, B				Sumbre, G; Fiorito, G; Flash, T; Hochner, B			Motor control of flexible octopus arms	NATURE			English	Editorial Material							REACHING MOVEMENTS; NERVOUS-SYSTEM; MODEL		Hebrew Univ Jerusalem, Inst Life Sci, Interdisciplinary Ctr Neuronal Computat, IL-91904 Jerusalem, Israel; Staz Zool Anton Dohrn, Neurobiol Lab, I-80121 Naples, Italy; Weizmann Inst Sci, Dept Appl Math & Comp Sci, IL-76100 Rehovot, Israel; Hebrew Univ Jerusalem, Inst Life Sci, Dept Neurobiol, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem; Stazione Zoologica Anton Dohrn di Napoli; Weizmann Institute of Science; Hebrew University of Jerusalem	Sumbre, G (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Neurobiol, Berkeley, CA 94720 USA.	bennyh@lobsterls.huji.ac.il	Sumbre, German/K-7538-2017	Sumbre, German/0000-0003-4436-6840				BIZZI E, 1992, BEHAV BRAIN SCI, V15, P603, DOI 10.1017/S0140525X00072538; Bizzi E, 2000, NAT REV NEUROSCI, V1, P101, DOI 10.1038/35039000; FELDMAN AG, 1966, BIOPHYS-USSR, V11, P766; FLASH T, 1985, J NEUROSCI, V5, P1688, DOI 10.1523/jneurosci.05-07-01688.1985; Flash T, 2001, CURR OPIN NEUROBIOL, V11, P655, DOI 10.1016/S0959-4388(01)00265-3; Gutfreund Y, 1998, J NEUROSCI, V18, P5976; Gutfreund Y, 1996, J NEUROSCI, V16, P7297; Harris CM, 1998, NATURE, V394, P780, DOI 10.1038/29528; Sabes PN, 2000, CURR OPIN NEUROBIOL, V10, P740, DOI 10.1016/S0959-4388(00)00149-5; SOECHTING JF, 1995, J NEUROSCI, V15, P6271; Sumbre G, 2001, SCIENCE, V293, P1845, DOI 10.1126/science.1060976; Wolpert DM, 2000, NAT NEUROSCI, V3, P1212, DOI 10.1038/81497	12	115	117	4	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 10	2005	433	7026					595	596		10.1038/433595a	http://dx.doi.org/10.1038/433595a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	895KX	15703737				2022-12-28	WOS:000226862000031
J	Wittstein, IS; Thiemann, DR; Lima, JAC; Baughman, KL; Schulman, SP; Gerstenblith, G; Wu, KC; Rade, JJ; Bivalacqua, TJ; Champion, HC				Wittstein, IS; Thiemann, DR; Lima, JAC; Baughman, KL; Schulman, SP; Gerstenblith, G; Wu, KC; Rade, JJ; Bivalacqua, TJ; Champion, HC			Neurohumoral features of myocardial stunning due to sudden emotional stress	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEFT-VENTRICULAR DYSFUNCTION; GENDER-DIFFERENCES; SUBARACHNOID HEMORRHAGE; NEUROPEPTIDE-Y; CARDIOMYOPATHY; PLASMA; ABNORMALITIES; LESIONS	BACKGROUND: Reversible left ventricular dysfunction precipitated by emotional stress has been reported, but the mechanism remains unknown. METHODS: We evaluated 19 patients who presented with left ventricular dysfunction after sudden emotional stress. All patients underwent coronary angiography and serial echocardiography; five underwent endomyocardial biopsy. Plasma catecholamine levels in 13 patients with stress-related myocardial dysfunction were compared with those in 7 patients with Killip class III myocardial infarction. RESULTS: The median age of patients with stress-induced cardiomyopathy was 63 years, and 95 percent were women. Clinical presentations included chest pain, pulmonary edema, and cardiogenic shock. Diffuse T-wave inversion and a prolonged QT interval occurred in most patients. Seventeen patients had mildly elevated serum troponin I levels, but only 1 of 19 had angiographic evidence of clinically significant coronary disease. Severe left ventricular dysfunction was present on admission (median ejection fraction, 0.20; interquartile range, 0.15 to 0.30) and rapidly resolved in all patients (ejection fraction at two to four weeks, 0.60; interquartile range, 0.55 to 0.65; P<0.001). Endomyocardial biopsy showed mononuclear infiltrates and contraction-band necrosis. Plasma catecholamine levels at presentation were markedly higher among patients with stress-induced cardiomyopathy than among those with Killip class III myocardial infarction (median epinephrine level, 1264 pg per milliliter [interquartile range, 916 to 1374] vs. 376 pg per milliliter [interquartile range, 275 to 476]; norepinephrine level, 2284 pg per milliliter [interquartile range, 1709 to 2910] vs. 1100 pg per milliliter [interquartile range, 914 to 1320]; and dopamine level, 111 pg per milliliter [interquartile range, 106 to 146] vs. 61 pg per milliliter [interquartile range, 46 to 77]; P<0.005 for all comparisons). CONCLUSIONS: Emotional stress can precipitate severe, reversible left ventricular dysfunction in patients without coronary disease. Exaggerated sympathetic stimulation is probably central to the cause of this syndrome.	Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Harvard University; Brigham & Women's Hospital	Wittstein, IS (corresponding author), Johns Hopkins Univ Hosp, Div Cardiol, Carnegie 568,600 N Wolfe St, Baltimore, MD 21287 USA.	iwittste@jhmi.edu	Wu, Katherine C/A-9760-2008					Bolli R, 1999, PHYSIOL REV, V79, P609, DOI 10.1152/physrev.1999.79.2.609; Brandspiegel HZ, 1998, CIRCULATION, V98, P1349, DOI 10.1161/01.CIR.98.13.1349; Bybee KA, 2004, AM J CARDIOL, V94, P343, DOI 10.1016/j.amjcard.2004.04.030; CEBELIN MS, 1980, HUM PATHOL, V11, P123, DOI 10.1016/S0046-8177(80)80129-8; Desmet WJR, 2003, HEART, V89, P1027, DOI 10.1136/heart.89.9.1027; DRISLANE FW, 1987, AM REV RESPIR DIS, V135, P498; FRANKENHAEUSER M, 1976, PSYCHOPHARMACOLOGY, V47, P1, DOI 10.1007/BF00428693; Goldstein DS, 2003, J PHARMACOL EXP THER, V305, P800, DOI 10.1124/jpet.103.049270; Grouzmann E, 2001, CLIN CHEM, V47, P1748; Grouzmann E, 2001, CLIN CHEM, V47, P1075; Hernandez-Pampaloni M, 2001, CIRCULATION, V104, P527, DOI 10.1161/hc3001.093503; Hinojosa-Laborde CM, 1999, CLIN EXP PHARMACOL P, V26, P122, DOI 10.1046/j.1440-1681.1999.02995.x; Jonsson BH, 2000, INTEGR PHYS BEH SCI, V35, P256, DOI 10.1007/BF02688788; Kawai S, 2000, JPN CIRC J, V64, P237; Kawai S, 2000, JPN CIRC J, V64, P156, DOI 10.1253/jcj.64.156; Kawano H, 2003, HEART VESSELS, V18, P32, DOI 10.1007/s003800300005; Kneale BJ, 2000, J AM COLL CARDIOL, V36, P1233, DOI 10.1016/S0735-1097(00)00849-4; KONO T, 1994, J AM COLL CARDIOL, V24, P636, DOI 10.1016/0735-1097(94)90008-6; Kurisu S, 2002, AM HEART J, V143, P448, DOI 10.1067/mhj.2002.120403; LACY CR, 1995, AM J CARDIOL, V75, P503, DOI 10.1016/S0002-9149(99)80590-6; Lambert G, 2002, BRAIN RES BULL, V58, P77, DOI 10.1016/S0361-9230(02)00762-1; MANN DL, 1992, CIRCULATION, V85, P790, DOI 10.1161/01.CIR.85.2.790; Mayer SA, 1999, STROKE, V30, P780, DOI 10.1161/01.STR.30.4.780; MORI H, 1993, CARDIOVASC RES, V27, P192, DOI 10.1093/cvr/27.2.192; NEILDWYER G, 1978, BRIT MED J, V2, P990, DOI 10.1136/bmj.2.6143.990; Onuoha GN, 2000, EUR J CLIN INVEST, V30, P570; Pavin D, 1997, HEART, V78, P509, DOI 10.1136/hrt.78.5.509; PIERPONT GL, 1984, AM J PHYSIOL, V246, pH824, DOI 10.1152/ajpheart.1984.246.6.H824; Redfield MM, 2002, J AM COLL CARDIOL, V40, P976, DOI 10.1016/S0735-1097(02)02059-4; Sadamatsu K, 2000, JPN CIRC J, V64, P789, DOI 10.1253/jcj.64.789; Sader MA, 2002, CARDIOVASC RES, V53, P597, DOI 10.1016/S0008-6363(01)00473-4; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; Sharkey SW, 1998, CHEST, V114, P98, DOI 10.1378/chest.114.1.98; SINGAL PK, 1982, CAN J PHYSIOL PHARM, V60, P1390, DOI 10.1139/y82-207; Spreux-Varoquaux O, 2001, LIFE SCI, V69, P647, DOI 10.1016/S0024-3205(01)01158-4; Tsuchihashi K, 2001, J AM COLL CARDIOL, V38, P11, DOI 10.1016/S0735-1097(01)01316-X; Villareal RP, 2001, MAYO CLIN PROC, V76, P79, DOI 10.4065/76.1.79; Wang TD, 1997, INT J CARDIOL, V58, P308, DOI 10.1016/S0167-5273(96)02879-3; WILKENFELD C, 1992, J HEART LUNG TRANSPL, V11, P363	39	2069	2173	0	68	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2005	352	6					539	548		10.1056/NEJMoa043046	http://dx.doi.org/10.1056/NEJMoa043046			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895KY	15703419				2022-12-28	WOS:000226862100004
J	Banatvala, J; Bell, P; Symonds, M				Banatvala, J; Bell, P; Symonds, M			The Research Assessment Exercise is bad for UK medicine	LANCET			English	Editorial Material									Guys Kings & St Thomas Sch Med & Dent, London SE1 7EH, England; Leicester Royal Infirm, Dept Surg, Leicester, Leics, England; Queens Med Ctr, Sch Human Dev & Midwifery, Nottingham NG7 2UH, England	University of London; King's College London; University of Leicester; University of Nottingham	Banatvala, J (corresponding author), Guys Kings & St Thomas Sch Med & Dent, London SE1 7EH, England.	jangu@btopenworld.com						*AC MED SCI, 2002, CLIN AC MED JEOP REC; *AC MED SCI, 2003, LAB CLIN TRANSL MED; *AC MED SCI, 2003, STRENGTH CLIN RES; [Anonymous], 2004, DEV SUST WORLD CLASS, P9; Banatvala JE, 2001, LANCET, V358, P921, DOI 10.1016/S0140-6736(01)06043-3; *BRIT MED ASS, 2005, MED SPEC FAC CRIS RE; *COUNC HEADS MED S, 2004, CLIN AC STAFF LEV UK; DONALDSON L, 2003, STATE PUBLIC HLTH AN, P36; HALPEN T, 2004, TIMES LOND      1204; Higher Education Funding Council for England, 2004, RES ASS EX; *I PUBL POL RES, 2004, BARR HIGH FURTH ED N; Peters K, 2004, LANCET, V364, P2142, DOI 10.1016/S0140-6736(04)17556-9; *ROYAL COLL PHYS A, 2004, CLIN AC MED WAY FORW	13	14	14	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 5	2005	365	9458					458	460						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894SS	15705444				2022-12-28	WOS:000226812500008
J	Meyerhardt, JA; Mayer, RJ				Meyerhardt, JA; Mayer, RJ			Drug therapy - Systemic therapy for colorectal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FLUOROURACIL PLUS LEUCOVORIN; GROWTH-FACTOR RECEPTOR; SYNTHASE PROTEIN EXPRESSION; HEPATIC ARTERIAL INFUSION; MESSENGER-RNA EXPRESSION; SURGICAL ADJUVANT BREAST; PHASE-II TRIAL; THYMIDYLATE SYNTHASE; RANDOMIZED-TRIAL; STAGE-II		Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Meyerhardt, JA (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [K07 1K07CA097992-01A] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K07CA097992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLENMERSH TG, 1994, LANCET, V344, P1255, DOI 10.1016/S0140-6736(94)90750-1; Ando Y, 1998, ANN ONCOL, V9, P845, DOI 10.1023/A:1008438109725; Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Aschele C, 2000, CLIN CANCER RES, V6, P4797; Barnett KT, 2001, J GASTROINTEST CANC, V30, P147, DOI 10.1385/IJGC:30:3:147; Baselga J, 2002, HEMATOL ONCOL CLIN N, V16, P1041, DOI 10.1016/S0889-8588(02)00055-2; Baselga J, 2002, ONCOLOGIST, V7, P2; Becouarn Y, 1998, J CLIN ONCOL, V16, P2739, DOI 10.1200/JCO.1998.16.8.2739; Benson AB, 2004, J CLIN ONCOL, V22, P3408, DOI 10.1200/JCO.2004.05.063; Berglund A, 2002, ANTICANCER RES, V22, P3653; Berlin JD, 2002, ONCOLOGY-NY, V16, P13; Buyse M, 1996, J NATL CANCER I, V88, P252; BUYSE M, 1988, JAMA-J AM MED ASSOC, V259, P3571; Carmichael J, 2002, J CLIN ONCOL, V20, P3617, DOI 10.1200/JCO.2002.10.129; CASSIDY J, 2004, J CLIN ONCOL, V22, P3509; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Cunningham D, 1998, LANCET, V352, P1413, DOI 10.1016/S0140-6736(98)02309-5; de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938; DEGARAMONT A, 2005, P 2005 GASTR CANC S, P167; deGramont A, 1997, J CLIN ONCOL, V15, P808, DOI 10.1200/JCO.1997.15.2.808; Diaz-Rubio E, 1998, ANN ONCOL, V9, P105, DOI 10.1023/A:1008200825886; Douillard JY, 2000, LANCET, V355, P1372; Douillard JY, 2002, J CLIN ONCOL, V20, P3605, DOI 10.1200/JCO.2002.04.123; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Dukes CE, 1932, J PATHOL BACTERIOL, V35, P323, DOI 10.1002/path.1700350303; Durand-Zaleski I, 1998, CANCER-AM CANCER SOC, V83, P882, DOI 10.1002/(SICI)1097-0142(19980901)83:5<882::AID-CNCR12>3.0.CO;2-R; Erlichman C, 1999, J CLIN ONCOL, V17, P1356, DOI 10.1200/JCO.1999.17.5.1356; Ferlay J, 2004, GLOBOCAN 2002 CANC I; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136; GIANTONIO BJ, 2005, P 2005 GASTR CANC S, P168; Gill S, 2004, J CLIN ONCOL, V22, P1797, DOI 10.1200/JCO.2004.09.059; Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046; Goldberg RM, 2004, J CLIN ONCOL, V22, P3621; Greene FL, 2002, AJCC CANC STAGING HD; Grothey A, 2004, J CLIN ONCOL, V22, P1209, DOI 10.1200/JCO.2004.11.037; Grothey A, 2003, SEMIN ONCOL, V30, P5, DOI 10.1016/S0093-7754(03)00399-3; Grothey A, 2003, P AN M AM SOC CLIN, V22, P255; GROTHEY A, 2002, AM SOC CLIN ONC 38 A; HAHN RG, 1975, CANCER, V35, P1031, DOI 10.1002/1097-0142(197504)35:4<1031::AID-CNCR2820350403>3.0.CO;2-N; HALLER DG, 1993, ADV EXP MED BIOL, V339, P51; HALLER DG, 1998, P AN M AM SOC CLIN, V17, P982; HEMMING AW, 1992, J SURG ONCOL, V51, P147, DOI 10.1002/jso.2930510304; Hoff PM, 2001, J CLIN ONCOL, V19, P2282, DOI 10.1200/JCO.2001.19.8.2282; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Hwang Jimmy J, 2003, Oncology (Williston Park), V17, P37; Innocenti F, 2000, CLIN PHARMACOKINET, V39, P315, DOI 10.2165/00003088-200039050-00001; Innocenti F, 2004, J CLIN ONCOL, V22, P1382, DOI 10.1200/JCO.2004.07.173; Iqbal S, 2001, Curr Oncol Rep, V3, P102, DOI 10.1007/s11912-001-0008-5; Iyer L, 1998, CANCER CHEMOTH PHARM, V42, pS31, DOI 10.1007/s002800051077; Iyer L., 2002, Pharmacogenomics Journal, V2, P43, DOI 10.1038/sj.tpj.6500072; Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Johnston PG, 2003, J CLIN ONCOL, V21, P815, DOI 10.1200/JCO.2003.07.039; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; KABBINAVAR FF, 2004, J CLIN ONCOL, V22, P3516; Kemeny MM, 2002, J CLIN ONCOL, V20, P1499, DOI 10.1200/JCO.20.6.1499; Kemeny N, 1999, NEW ENGL J MED, V341, P2039, DOI 10.1056/NEJM199912303412702; Klein CE, 2002, CLIN PHARMACOL THER, V72, P638, DOI 10.1067/mcp.2002.129502; Kohne CH, 2003, J CLIN ONCOL, V21, P3721, DOI 10.1200/JCO.2003.11.122; Kornmann M, 2003, CLIN CANCER RES, V9, P4116; Kornmann M, 2002, J GASTROINTEST SURG, V6, P331, DOI 10.1016/S1091-255X(02)00018-5; LEVI F, 1993, EUR J CANCER, V29A, P1280, DOI 10.1016/0959-8049(93)90073-O; Lokich JJ, 1996, CANCER, V78, P294, DOI 10.1002/(SICI)1097-0142(19960715)78:2<294::AID-CNCR16>3.0.CO;2-R; LOKICH JJ, 1989, J CLIN ONCOL, V7, P425, DOI 10.1200/JCO.1989.7.4.425; Lokich JJ, 1996, CANCER, V78, P300, DOI 10.1002/(SICI)1097-0142(19960715)78:2<300::AID-CNCR17>3.0.CO;2-#; Lorenz M, 1998, ANN SURG, V228, P756, DOI 10.1097/00000658-199812000-00006; Machover D, 1996, ANN ONCOL, V7, P95; Mamounas E, 1999, J CLIN ONCOL, V17, P1349, DOI 10.1200/JCO.1999.17.5.1349; Marsh S, 2004, BRIT J CANCER, V90, P8, DOI 10.1038/sj.bjc.6601487; Mathijssen RHJ, 2001, CLIN CANCER RES, V7, P2182; MAYER A, 1993, CANCER, V71, P2454, DOI 10.1002/1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2; Mayer RJ, 2001, J CLIN ONCOL, V19, P4093, DOI 10.1200/JCO.2001.19.21.4093; Meropol NJ, 1998, EUR J CANCER, V34, P1509, DOI 10.1016/S0959-8049(98)00226-3; Minsky BD, 2002, CANCER TREAT REV, V28, P181, DOI 10.1016/S0305-7372(02)00037-3; MOERTEL CG, 1995, J CLIN ONCOL, V13, P2936, DOI 10.1200/JCO.1995.13.12.2936; MOERTEL CG, 1994, NEW ENGL J MED, V330, P1136; MOERTEL CG, 1995, ANN INTERN MED, V122, P321, DOI 10.7326/0003-4819-122-5-199503010-00001; Pentheroudakis G, 2002, ANTICANCER RES, V22, P3589; Piedbois P, 2004, J CLIN ONCOL, V22, P3766, DOI 10.1200/JCO.2004.03.104; Raymond E, 2002, MOL CANCER THER, V1, P227; Raymond E, 1997, ANTI-CANCER DRUG, V8, P876, DOI 10.1097/00001813-199710000-00009; Raymond E, 1998, SEMIN ONCOL, V25, P4; Rixe O, 1996, BIOCHEM PHARMACOL, V52, P1855, DOI 10.1016/S0006-2952(97)81490-6; Rothenberg ML, 2003, J CLIN ONCOL, V21, P2059, DOI 10.1200/JCO.2003.11.126; Rothenberg ML, 2001, J CLIN ONCOL, V19, P3801, DOI 10.1200/JCO.2001.19.18.3801; Rougier P, 1998, LANCET, V352, P1407, DOI 10.1016/S0140-6736(98)03085-2; Rougier P, 1998, LANCET, V352, P1634; Sakata Y, 1998, EUR J CANCER, V34, P1715, DOI 10.1016/S0959-8049(98)00211-1; SALTZ L, 2003, P AN M AM SOC CLIN, V22, pA204; SALTZ L, 2001, P AN M AM SOC CLIN, V20, pA3; Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; Saltz LB, 2004, J CLIN ONCOL S, V22, P3500, DOI DOI 10.1200/JC0.2004.22.90140.3500;CITED; Sargent DJ, 2001, NEW ENGL J MED, V345, P1091, DOI 10.1056/NEJMoa010957; SCHEITHAUER W, 1993, BRIT MED J, V306, P752, DOI 10.1136/bmj.306.6880.752; Smyth JE, 1995, ANN ONCOL, V6, P948, DOI 10.1093/oxfordjournals.annonc.a059365; Sobrero A, 2000, SEMIN ONCOL, V27, P72; Sulkes A, 1998, J CLIN ONCOL, V16, P3461, DOI 10.1200/JCO.1998.16.10.3461; Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113; Van Cutsem E, 2001, J CLIN ONCOL, V19, P4097, DOI 10.1200/JCO.2001.19.21.4097; Ward S, 2003, Health Technol Assess, V7, P1; WEH HJ, 1994, ANN ONCOL, V5, P233, DOI 10.1093/oxfordjournals.annonc.a058799; Wolmark N, 1999, J CLIN ONCOL, V17, P3553, DOI 10.1200/JCO.1999.17.11.3553; Wolmark N, 1998, J CLIN ONCOL, V16, P301; WOLMARK N, 2004, J CLIN ONCOL, V22, P3508; ZHANG ZG, 1992, SEMIN ONCOL, V19, P10; 2000, COCHRANE DATABASE SY, V2	109	886	938	2	56	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 3	2005	352	5					476	487		10.1056/NEJMra040958	http://dx.doi.org/10.1056/NEJMra040958			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	893NE	15689586				2022-12-28	WOS:000226725400008
J	Pedersen, TR; Gerken, EA				Pedersen, TR; Gerken, EA			Creation of visible artificial optical emissions in the aurora by high-power radio waves	NATURE			English	Article								Generation of artificial light in the sky by means of high-power radio waves interacting with the ionospheric plasma has been envisaged since the early days of radio exploration of the upper atmosphere, with proposed applications ranging from regional night-time street lighting to atmospheric measurements(1). Weak optical emissions have been produced for decades in such ionospheric 'heating' experiments, where they serve as key indicators of electron acceleration, thermal heating, and other effects of incompletely understood wave - particle interactions in the plasma under conditions difficult to replicate in the laboratory(2). The extremely low intensities produced previously have, however, required sensitive instrumentation for detection, preventing applications beyond scientific research. Here we report observations of radio-induced optical emissions bright enough to be seen by the naked eye, and produced not in the quiet midlatitude ionosphere, but in the midst of a pulsating natural aurora. This may open the door to visual applications of ionospheric heating technology or provide a way to probe the dynamics of the natural aurora and magnetosphere.	USAF, Space Vehicles Directorate, Res Lab, Hanscom AFB, MA 01731 USA; Cornell Univ, Dept Elect & Comp Engn, Ithaca, NY 14853 USA	United States Department of Defense; United States Air Force; Cornell University	Pedersen, TR (corresponding author), USAF, Space Vehicles Directorate, Res Lab, Hanscom AFB, MA 01731 USA.	todd.pedersen@hanscom.af.mil		Pedersen, Todd/0000-0002-6940-0112				Bailey VA, 1938, PHILOS MAG, V26, P425; BAUER SJ, 1973, PHYS CHEM SPACE, V6, P82; BERNHARDT PA, 1988, SCIENCE, V242, P1022, DOI 10.1126/science.242.4881.1022; Blagoveshchenskaya NF, 2001, J GEOPHYS RES-SPACE, V106, P29071, DOI 10.1029/2001JA900002; CARLSON HC, 1995, INTRO SPACE PHYS, P459; CHAMBERLAIN JW, 1961, INT GEOPHYS SERIES, V2; DAVIS N, 1992, AURORA WATCHERS HDB, V58; Djuth FT, 1999, GEOPHYS RES LETT, V26, P1557, DOI 10.1029/1999GL900296; OMHOLT A, 1971, PHYS CHEM SPACE, V4; Rishbeth H., 1969, INTRO IONOSPHERIC PH, VVolume 14; Sergienko T, 1997, J ATMOS SOL-TERR PHY, V59, P2401, DOI 10.1016/S1364-6826(97)88118-7	11	27	28	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 3	2005	433	7025					498	500		10.1038/nature03243	http://dx.doi.org/10.1038/nature03243			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893NT	15690034				2022-12-28	WOS:000226727200041
J	Canup, RM				Canup, RM			A giant impact origin of Pluto-Charon	SCIENCE			English	Article							OUTER SOLAR-SYSTEM; PLANET FORMATION; BINARIES; NEPTUNE; BODIES; ORBIT; MOON	Pluto and its moon, Charon, are the most prominent members of the Kuiper belt, and their existence holds clues to outer solar system formation processes. Here, hydrodynamic simulations are used to demonstrate that the formation of Pluto-Charon by means of a large collision is quite plausible. I show that such an impact probably produced an intact Charon, although it is possible that a disk of material orbited Pluto from which Charon later accumulated. These findings suggest that collisions between 1000-kilometer-class objects occurred in the early inner Kuiper belt.	SW Res Inst, Boulder, CO 80302 USA; CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA	California Institute of Technology	Canup, RM (corresponding author), SW Res Inst, Boulder, CO 80302 USA.	robin@boulder.swri.edu		Canup, Robin/0000-0002-2342-3458				Benz W., 1990, P NATO ADV RES WORKS, P269; BROOKSHAW L, SCMC9813 U SO QUEENS; CAMERON AGW, 1991, ICARUS, V92, P204, DOI 10.1016/0019-1035(91)90046-V; Canup RM, 2001, NATURE, V412, P708, DOI 10.1038/35089010; Canup RM, 2004, ICARUS, V168, P433, DOI 10.1016/j.icarus.2003.09.028; Canup RM, 2004, ANNU REV ASTRON ASTR, V42, P441, DOI 10.1146/annurev.astro.41.082201.113457; Canup RM, 2001, ICARUS, V150, P288, DOI 10.1006/icar.2000.6581; Dobrovolskis A. R, 1997, PLUTO CHARON, P159; Goldreich P, 2004, ANNU REV ASTRON ASTR, V42, P549, DOI 10.1146/annurev.astro.42.053102.134004; HAHN J, 1995, LUNAR PLANET SCI, V26, P541; HOLMAN MJ, 1993, ASTRON J, V105, P1987, DOI 10.1086/116574; Ida S, 1997, NATURE, V389, P353, DOI 10.1038/38669; Kenyon SJ, 2002, PUBL ASTRON SOC PAC, V114, P265, DOI 10.1086/339188; LEVISON HF, 1995, ICARUS, V116, P315, DOI 10.1006/icar.1995.1128; MALHOTRA R, 1993, NATURE, V365, P819, DOI 10.1038/365819a0; MALHOTRA R, 1995, ASTRON J, V110, P420, DOI 10.1086/117532; McKinnon W. B., 1997, PLUTO CHARON, P295; MCKINNON WB, 1984, NATURE, V311, P355, DOI 10.1038/311355a0; MCKINNON WB, 1989, ASTROPHYS J, V344, pL41, DOI 10.1086/185526; MELOSH HJ, 2000, 31 LUN PLAN SCI C HO; Olkin CB, 2003, ICARUS, V164, P254, DOI 10.1016/S0019-1035(03)00136-2; Petit JM, 2004, ICARUS, V168, P409, DOI 10.1016/j.icarus.2003.12.013; Sheppard SS, 2004, ASTRON J, V127, P3023, DOI 10.1086/383558; SRIDHAR S, 1992, ICARUS, V95, P86, DOI 10.1016/0019-1035(92)90193-B; Stern S. A., 1997, PLUTO CHARON, P605; STERN SA, 1991, ICARUS, V90, P271, DOI 10.1016/0019-1035(91)90106-4; TANCREDI G, 1991, ICARUS, V93, P298, DOI 10.1016/0019-1035(91)90214-E; THOMPSON SL, 1972, SCRR710714 SAND NATL; WILLIAMS HA, 1988, ASTROPHYS J, V334, P449, DOI 10.1086/166849	30	196	198	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2005	307	5709					546	550		10.1126/science.1106818	http://dx.doi.org/10.1126/science.1106818			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893BJ	15681378				2022-12-28	WOS:000226694000038
J	Foglia, A				Foglia, A			An unforgivable delay	LANCET			English	Editorial Material									FMH Psichiatria & Psicoterapia, CH-6900 Lugano, Switzerland		Foglia, A (corresponding author), FMH Psichiatria & Psicoterapia, CH-6900 Lugano, Switzerland.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN-FEB	2005	365	9457					445	445						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891WE	15680462				2022-12-28	WOS:000226610900034
J	Gunnell, D; Saperia, J; Ashby, D				Gunnell, D; Saperia, J; Ashby, D			Selective serotonin reuptake inhibitors (SSR1s) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review	BMJ-BRITISH MEDICAL JOURNAL			English	Review							TRICYCLIC ANTIDEPRESSANTS; DEPRESSION; FLUOXETINE	Objective To investigate whether selective serotonin reuptake inhibitor (SSRI) antidepressants are associated with an increased risk of suicide related outcomes in adults. Design Meta-analysis of randomised controlled trials of SSRIs compared with placebo in adults submitted by pharmaceutical companies to the safety review of the Medicines and Healthcare products Regulatory Agency (MHRA). Participants Over 40 000 individuals participating in 477 randomised controlled trials. Main outcome measures Suicide, non-fatal self harm, and suicidal thoughts. Results An estimated 16 suicides, 172 episodes of non-fatal self harm, and 177 episodes of suicidal thoughts were reported. We found no evidence that SSRIs increased the risk of suicide, but important protective or hazardous effects cannot be excluded (odds ratio 0.85, 95% credible interval 0.20 to 3.40). We found weak evidence of an increased risk of self harm (1.57, 0.99 to 2.55). Risk estimates for suicidal thoughts were compatible with a modest protective or adverse effect (0.77, 0.37 to 1.55). The relative frequency of reported self harm and suicidal thoughts in the trials compared with suicide indicates non-fatal end points were under-recorded. Conclusion Increased risks Of Suicide and self harm caused by SSRIs cannot be ruled out, but larger trials with longer follow up are required to assess the balance of risks and benefits fully. Any such risks should be balanced against the effectiveness of SSRIs in treating depression. When prescribing SSRIs, clinicians should warn patients of the possible risk of suicidal behaviour and monitor patients closely in the early stages of treatment.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ London, Queen Mary, Wolfson Inst Prevent Med, London EC1M 6BQ, England	University of Bristol; University of London; Queen Mary University London	Gunnell, D (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	D.J.Gunnell@bristol.ac.uk	Gunnell, David/ABE-6653-2020; anand, amit/A-7222-2009	Gunnell, David/0000-0002-0829-6470; 				Als-Nielsen B, 2003, JAMA-J AM MED ASSOC, V290, P921, DOI 10.1001/jama.290.7.921; Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; [Anonymous], 2004, REPORT CSM EXPERT WO; BEASLEY CM, 1991, BMJ-BRIT MED J, V303, P685, DOI 10.1136/bmj.303.6804.685; Bech P, 2000, BRIT J PSYCHIAT, V176, P421, DOI 10.1192/bjp.176.5.421; FREEMANTLE N, 1993, EFFECTIVE TOLERABILI; Gunnell D, 2004, BRIT J PSYCHIAT, V185, P385, DOI 10.1192/bjp.185.5.385; Gunnell D, 2004, BRIT MED J, V329, P34, DOI 10.1136/bmj.329.7456.34; Hawton K, 1997, BRIT J PSYCHIAT, V171, P556, DOI 10.1192/bjp.171.6.556; Healy D, 2003, PSYCHOTHER PSYCHOSOM, V72, P71, DOI 10.1159/000068691; Healy D, 1999, J PSYCHOPHARMACOL, V13, P94, DOI 10.1177/026988119901300110; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Jick H, 2004, JAMA-J AM MED ASSOC, V292, P338, DOI 10.1001/jama.292.3.338; JICK SS, 1995, BRIT MED J, V310, P215, DOI 10.1136/bmj.310.6974.215; Kelly S, 1998, Popul Trends, P29; Khan A, 2003, AM J PSYCHIAT, V160, P790, DOI 10.1176/appi.ajp.160.4.790; MacGillivray S, 2003, BMJ-BRIT MED J, V326, P1014, DOI 10.1136/bmj.326.7397.1014; *NAT COLL CTR MED, 2004, DEPR MAN DEPR PRIM S; National Collaborating Centre for Mental Health, 2004, DEPR MAN DEPR PRIM S; Nutt DJ, 2003, J PSYCHOPHARMACOL, V17, P355, DOI 10.1177/0269881103174019; Singleton N., 2001, PSYCHIAT MORBIDITY A; Spiegelhalter DJ, 2003, BAYESIAN APPROACHES; Sweeting MJ, 2004, STAT MED, V23, P1351, DOI 10.1002/sim.1761; Whittington CJ, 2004, LANCET, V363, P1341, DOI 10.1016/S0140-6736(04)16043-1	24	286	290	0	35	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 19	2005	330	7488					385	388A		10.1136/bmj.330.7488.385	http://dx.doi.org/10.1136/bmj.330.7488.385			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900NA	15718537	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000227220400016
J	Thompson, JF; Scolyer, RA; Kefford, RF				Thompson, JF; Scolyer, RA; Kefford, RF			Cutaneous melanoma	LANCET			English	Review							AMERICAN JOINT COMMITTEE; SENTINEL NODE BIOPSY; MAGNETIC-RESONANCE SPECTROSCOPY; DISSEMINATED MALIGNANT-MELANOMA; ISOLATED LIMB PERFUSION; CANCER STAGING SYSTEM; RANDOMIZED PHASE-III; TUMOR MITOTIC RATE; HIGH-RISK PRIMARY; LYMPH-NODE	Episodic exposure of fair-skinned individuals to intense sunlight is thought to be responsible for the steadily increasing melanoma incidence worldwide over recent decades. Rarely, melanoma susceptibility is increased more than tenfold by heritable mutations in the cell cycle regulatory genes CDKN2A and CDK4. Effective treatment requires early diagnosis followed by surgical excision with adequately wide margins. Sentinel lymph node biopsy provides accurate staging, but no published results are yet available from clinical trials designed to assess the therapeutic efficacy of early complete regional node dissection in those with metastatic disease in a sentinel node. Magnetic resonance spectroscopy is one technique under investigation for non-invasive, in-situ assessment of sentinel nodes. localised metastatic disease is best treated surgically. No postoperative adjuvant therapy is of proven value for improving overall survival, although numerous clinical trials of vaccines and cytokines are in progress. Medical therapies have contributed little to the control of established metastatic disease, but molecular pathways recently identified as being central to melanoma growth and apoptosis are under intense investigation for their potential as therapeutic targets.	Univ Sydney, Royal Prince Alfred Hosp, Sydney Melanoma Unit, Camperdown, NSW 2050, Australia; Westmead Hosp, Sydney, NSW, Australia	Melanoma Institute Australia; University of Sydney; University of Sydney	Thompson, JF (corresponding author), Univ Sydney, Royal Prince Alfred Hosp, Sydney Melanoma Unit, Missenden Rd, Camperdown, NSW 2050, Australia.	thompson@smu.org.au	Scolyer, Richard/AAE-8511-2019	Scolyer, Richard/0000-0002-8991-0013; Thompson, John/0000-0002-2816-2496; Kefford, Richard/0000-0001-9251-9229				*AIHW AACR, 2003, AIHW CANC SERIES, V23; Aitken J, 2004, TXB MELANOMA, P100; *AJCC, 2002, AM JOINT COMM CANC S; [Anonymous], 1993, AM J DERMATOPATHOL, V15, P34; [Anonymous], 1975, SEER CANC STAT REV; ARMSTRONG B, 2004, TXB MELANOMA, P65; Armstrong BK, 2001, J PHOTOCH PHOTOBIO B, V63, P8, DOI 10.1016/S1011-1344(01)00198-1; Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; ATKINS ME, 2003, PROSPECTIVE RANDOMIZ; AUTIER P, 2004, TXB MELANOMA, P90; Avril MF, 2004, J CLIN ONCOL, V22, P1118, DOI 10.1200/JCO.2004.04.165; Azzola MF, 2003, CANCER-AM CANCER SOC, V97, P1488, DOI 10.1002/cncr.11196; Balch CM, 2000, CANCER-AM CANCER SOC, V88, P1484, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1484::AID-CNCR29>3.0.CO;2-D; Balch CM, 2000, ANN SURG ONCOL, V7, P87, DOI 10.1007/s10434-000-0087-9; BALCH CM, 1993, ANN SURG, V218, P262, DOI 10.1097/00000658-199309000-00005; Balch CM, 2001, J CLIN ONCOL, V19, P3622, DOI 10.1200/JCO.2001.19.16.3622; Balch CM, 2001, J CLIN ONCOL, V19, P3635, DOI 10.1200/JCO.2001.19.16.3635; BALCH CM, 2004, TXB MELANOMA, P181; Bastian BC, 2004, PATHOLOGY, V36, P458, DOI 10.1080/00303020412331282717; Beddingfield FC, 2003, ONCOLOGIST, V8, P459, DOI 10.1634/theoncologist.8-5-459; Berwick Marianne, 1997, Current Opinion in Oncology, V9, P178; BINDER M, 2004, TXB MELANOMA, P234; Bishop DT, 2002, J NATL CANCER I, V94, P894, DOI 10.1093/jnci/94.12.894; Bishop JAN, 2000, J INVEST DERMATOL, V114, P28, DOI 10.1046/j.1523-1747.2000.00823.x; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; BLISS JM, 1995, INT J CANCER, V62, P367, DOI 10.1002/ijc.2910620402; BOURNE RM, IN PRESS EUR J RADIO; Bower CPR, 2000, J AM ACAD DERMATOL, V42, P988, DOI 10.1016/S0190-9622(00)90291-3; Brown TJ, 1999, CUTIS, V63, P275; Busam KJ, 2004, PATHOLOGY, V36, P462, DOI 10.1080/00313020412331283824; BUZAID AC, 1993, J CLIN ONCOL, V11, P638, DOI 10.1200/JCO.1993.11.4.638; BUZAID AC, 2004, TXB MELANOMA, P164; Camacho LH, 2004, J CLIN ONCOL, V22, p164S; *CANC RES UK, STAT CANC STATS REP; Cascinelli N, 1998, LANCET, V351, P793, DOI 10.1016/S0140-6736(97)08260-3; Casula M, 2004, J CLIN ONCOL, V22, P286, DOI 10.1200/JCO.2004.07.112; Chamberlain AJ, 2003, J AM ACAD DERMATOL, V48, P694, DOI 10.1067/mjd.2003.216; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; Clary BM, 2001, ANN SURG ONCOL, V8, P328, DOI 10.1245/aso.2001.8.4.328; Cohn-Cedermark G, 2000, CANCER-AM CANCER SOC, V89, P1495, DOI 10.1002/1097-0142(20001001)89:7<1495::AID-CNCR12>3.0.CO;2-D; Cook MG, 1996, HISTOPATHOLOGY, V28, P497, DOI 10.1046/j.1365-2559.1996.d01-464.x; CROTTY K, 2004, TXB MELANOMA, P115; Crotty KA, 2004, PATHOLOGY, V36, P470, DOI 10.1080/00313020412331283851; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; de Vries E, 2003, EUR J CANCER, V39, P1439, DOI 10.1016/S0959-8049(03)00320-4; Deichmann M, 1999, J CLIN ONCOL, V17, P1891, DOI 10.1200/JCO.1999.17.6.1891; Dennis LK, 2003, ANN INTERN MED, V139, P966, DOI 10.7326/0003-4819-139-12-200312160-00006; Dong JL, 2003, CANCER RES, V63, P3883; Doting MHE, 2002, EUR J SURG ONCOL, V28, P673, DOI 10.1053/ejso.2002.1297; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Eggermont AMM, 2004, EUR J CANCER, V40, P1825, DOI 10.1016/j.ejca.2004.04.030; Eggermont AMM, 2001, EUR J CANCER, V37, P2147, DOI 10.1016/S0959-8049(01)00272-6; Eigentler TK, 2003, LANCET ONCOL, V4, P748, DOI 10.1016/S1470-2045(03)01280-4; Eigtved A, 2000, EUR J NUCL MED, V27, P70, DOI 10.1007/PL00006666; Elwood JM, 1997, INT J CANCER, V73, P198, DOI 10.1002/(SICI)1097-0215(19971009)73:2<198::AID-IJC6>3.0.CO;2-R; Essner R, 1999, ANN SURG ONCOL, V6, P442, DOI 10.1007/s10434-999-0442-4; Estourgie SH, 2003, ANN SURG ONCOL, V10, P681, DOI 10.1245/ASO.2003.01.023; Ferrini RL, 1998, AM J PREV MED, V14, P83, DOI 10.1016/S0749-3797(97)00006-8; Fife K, 2001, LANCET ONCOL, V2, P614, DOI 10.1016/S1470-2045(01)00519-8; Fife KM, 2004, J CLIN ONCOL, V22, P1293, DOI 10.1200/JCO.2004.08.140; Flaherty KT., 2004, AM SOC CLIN ONCOLOGY, P532; FORD D, 1995, INT J CANCER, V62, P377, DOI 10.1002/ijc.2910620403; Francken AB, 2004, ANN SURG ONCOL, V11, P426, DOI 10.1245/ASO.2004.07.014; Franzke A, 1998, BRIT J CANCER, V78, P40, DOI 10.1038/bjc.1998.439; FRIEDMAN RJ, 1985, CA-CANCER J CLIN, V35, P130, DOI 10.3322/canjclin.35.3.130; Gadd MA, 1999, ARCH SURG-CHICAGO, V134, P381, DOI 10.1001/archsurg.134.4.381; Gershenwald JE, 1998, J CLIN ONCOL, V16, P2253, DOI 10.1200/JCO.1998.16.6.2253; GIBSON LE, 1988, MAYO CLIN PROC, V63, P777, DOI 10.1016/S0025-6196(12)62357-X; Gilchrest BA, 1999, NEW ENGL J MED, V340, P1341, DOI 10.1056/NEJM199904293401707; Giles GG, 1996, BMJ-BRIT MED J, V312, P1121; Gillanders E, 2003, AM J HUM GENET, V73, P301, DOI 10.1086/377140; GIULIANO AE, 1982, SEMIN ONCOL, V9, P442; GOLDSTEIN AM, 1995, DERMATOL CLIN, V13, P605, DOI 10.1016/S0733-8635(18)30066-4; Goldstein AM, 2001, ARCH DERMATOL, V137, P1493; Grulich AE, 1996, INT J CANCER, V67, P485, DOI 10.1002/(SICI)1097-0215(19960807)67:4<485::AID-IJC4>3.0.CO;2-O; Grulich AE, 1999, AIDS, V13, P839, DOI 10.1097/00002030-199905070-00014; Hafner J, 2004, BRIT J DERMATOL, V150, P677, DOI 10.1111/j.0007-0963.2004.05870.x; Haigh PI, 2003, CAN J SURG, V46, P419; HALL WH, 1992, JAMA-J AM MED ASSOC, V268, P1314, DOI 10.1001/jama.1992.03490100112037; Harlow SP, 2001, MELANOMA RES, V11, P45, DOI 10.1097/00008390-200102000-00006; HARPOLE DH, 1992, J THORAC CARDIOV SUR, V103, P743; Harris RB, 2004, INT J DERMATOL, V43, P243, DOI 10.1111/j.1365-4632.2004.01966.x; Hayward NK, 2003, ONCOGENE, V22, P3053, DOI 10.1038/sj.onc.1206445; HEALY ME, 1987, RADIOLOGY, V165, P619, DOI 10.1148/radiology.165.3.3317496; Hersey P, 2003, INTERN MED J, V33, P33, DOI 10.1046/j.1445-5994.2002.00289.x; HERSEY P, 2004, TXB MELANOMA, P602; HERSEY P, 2004, TXB MELANOMA, P559; Hodi FS, 2003, P NATL ACAD SCI USA, V100, P4712, DOI 10.1073/pnas.0830997100; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; Jansen L, 2000, BRIT J SURG, V87, P484, DOI 10.1046/j.1365-2168.2000.01362.x; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jensen P, 1999, J AM ACAD DERMATOL, V40, P177, DOI 10.1016/S0190-9622(99)70185-4; Ka VS, 2004, ANN SURG ONCOL, V11, pS60, DOI 10.1007/BF02523999; Kefford R, 2002, LANCET ONCOL, V3, P653, DOI 10.1016/S1470-2045(02)00894-X; Kefford RE, 2003, ANN ONCOL, V14, P358, DOI 10.1093/annonc/mdg120; Kefford RF, 2003, CURR OPIN ONCOL, V15, P157, DOI 10.1097/00001622-200303000-00007; KENET RO, 1993, ARCH DERMATOL, V129, P157, DOI 10.1001/archderm.129.2.157; Khayat D, 2003, CANCER-AM CANCER SOC, V97, P1941, DOI 10.1002/cncr.11272; KHAYAT D, 2004, TXB MELANOMA, P586; Kirkwood JM, 2004, CLIN CANCER RES, V10, P1670, DOI 10.1158/1078-0432.CCR-1103-3; Kirkwood JM, 2002, J CLIN ONCOL, V20, P3703, DOI 10.1200/JCO.2002.03.052; Kittler H, 2002, LANCET ONCOL, V3, P159, DOI 10.1016/S1470-2045(02)00679-4; Kleeberg UR, 2004, EUR J CANCER, V40, P390, DOI 10.1016/j.ejca.2003.07.004; Krige JEJ, 1996, AM SURGEON, V62, P658; Lang J, 2003, HUM MUTAT, V21, P327, DOI 10.1002/humu.10188; Lean CL, 2003, MELANOMA RES, V13, P259, DOI 10.1097/00008390-200306000-00006; Lens MB, 2004, BRIT J DERMATOL, V150, P179, DOI 10.1111/j.1365-2133.2004.05708.x; Lindner P, 2002, ANN SURG ONCOL, V9, P127, DOI 10.1007/BF02557363; MACKIE RM, 1993, AM J DERMATOPATH, V15, P46; MACKIE RM, 1989, LANCET, V2, P487; Marghoob AA, 2004, ATLAS DERMOSCOPY; Marks R, 1999, Australas J Dermatol, V40, P1, DOI 10.1046/j.1440-0960.1999.00307.x; MARRETT LD, 1992, CAN MED ASSOC J, V147, P445; MCCARTHY WH, 1985, SURG GYNECOL OBSTET, V161, P575; MCGOVERN VJ, 1981, PATHOLOGY MALIGNANT, P327; McMasters KM, 2001, ANN SURG ONCOL, V8, P192, DOI 10.1007/s10434-001-0192-4; MCMASTERS KM, 2004, J AM ACAD DERMATOL, V51, P152; Medalie NS, 2003, AM J DERMATOPATH, V25, P399, DOI 10.1097/00000372-200310000-00006; Menzies S W, 1997, Australas J Dermatol, V38 Suppl 1, pS40; Menzies SW, 1996, MELANOMA RES, V6, P55, DOI 10.1097/00008390-199602000-00008; MENZIES SW, 2004, TXB MELANOMA, P225; Meyskens FL, 2004, CLIN CANCER RES, V10, P2581, DOI 10.1158/1078-0432.CCR-03-0638; Middleton MR, 2000, J CLIN ONCOL, V18, P158, DOI 10.1200/JCO.2000.18.1.158; MILLWARD MJ, 2004, RANDOMISED MULTINATI, P708; MILTON GW, 1985, AUST NZ J SURG, V55, P225, DOI 10.1111/j.1445-2197.1985.tb00076.x; Miranda EP, 2004, ARCH SURG-CHICAGO, V139, P831, DOI 10.1001/archsurg.139.8.831; Morton DL, 2004, BRIT J DERMATOL, V151, P308, DOI 10.1111/j.1365-2133.2004.06133.x; Morton DL, 1999, ANN SURG, V230, P453, DOI 10.1097/00000658-199910000-00001; MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392; Muller MGS, 2001, CANCER, V91, P2401; NEWTON JA, 1993, J AM ACAD DERMATOL, V29, P989, DOI 10.1016/0190-9622(93)70279-3; *NH MRC, 1999, CLIN PRACT GUID MAN; Ollila DW, 1996, ARCH SURG-CHICAGO, V131, P975; Pawlik TM, 2004, ANN SURG ONCOL, V11, pS61, DOI 10.1007/BF02524001; PAWLIK TM, IN PRESS EUR J SURG; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Quinn MJ, 1998, CANCER-AM CANCER SOC, V83, P1128, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1128::AID-CNCR11>3.3.CO;2-Y; REINTGEN D, 1994, ANN SURG, V220, P759, DOI 10.1097/00000658-199412000-00009; Reintgen DS, 2004, ANN SURG ONCOL, V11, p186S, DOI 10.1245/ASO.2004.12.935; RICANIADIS N, 1995, SURG ONCOL, V4, P105, DOI 10.1016/S0960-7404(10)80014-3; Rosado B, 2003, ARCH DERMATOL, V139, P361, DOI 10.1001/archderm.139.3.361; Rosenberg SA, 2001, NATURE, V411, P380, DOI 10.1038/35077246; ROSS MI, 1998, CUTANEOUS MELANOMA, P141; Saraiya M, 2004, AM J PREV MED, V27, P422, DOI 10.1016/j.amepre.2004.08.009; Satyamoorthy K, 2002, CANCER BIOL THER, V1, P14, DOI 10.4161/cbt.1.1.32; SCHRAFFORDTKOOP.H, 1998, J CLIN ONCOL, V16, P2906; Scolyer RA, 2004, PATHOLOGY, V36, P385, DOI 10.1080/00313020412331285327; Scolyer RA, 2004, J SURG ONCOL, V86, P200, DOI 10.1002/jso.20083; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Sharpless NE, 2003, ONCOGENE, V22, P3092, DOI 10.1038/sj.onc.1206461; Shinozaki M, 2004, CLIN CANCER RES, V10, P1753, DOI 10.1158/1078-0432.CCR-1169-3; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Starritt EC, 2005, ANN SURG ONCOL, V12, P18, DOI 10.1007/s10434-004-1163-3; STEVENS GN, 2004, TXB MELANOMA, P395; Stretch J, 2004, ANN SURG ONCOL, V11, pS60, DOI 10.1007/BF02523998; TAFRA L, 1995, J THORAC CARDIOV SUR, V110, P119, DOI 10.1016/S0022-5223(05)80017-0; Terhune MH, 1998, ARCH DERMATOL, V134, P569, DOI 10.1001/archderm.134.5.569; Thomas JM, 2000, BRIT MED J, V321, P3, DOI 10.1136/bmj.321.7252.3; Thomas JM, 2004, EJSO-EUR J SURG ONC, V30, P686, DOI 10.1016/j.ejso.2004.04.004; Thomas JM, 2004, BMJ-BRIT MED J, V329, P170, DOI 10.1136/bmj.329.7458.170; Thomas JM, 2004, NEW ENGL J MED, V350, P757, DOI 10.1056/NEJMoa030681; Thompson JF, 1997, ARCH SURG-CHICAGO, V132, P903; Thompson JF, 1997, MELANOMA RES, V7, P500, DOI 10.1097/00008390-199712000-00009; Thompson JF, 2004, PATHOLOGY, V36, P496, DOI 10.1080/00313020412331283897; Thompson JF, 2004, ANN SURG ONCOL, V11, p147S, DOI 10.1245/ASO.2004.11.908; Thompson JF, 2004, J SURG ONCOL, V86, P224, DOI 10.1002/jso.20082; Thompson JF, 1999, J AM COLL SURGEONS, V189, P195, DOI 10.1016/S1072-7515(99)00108-8; Thompson JF, 1998, SEMIN SURG ONCOL, V14, P238; THOMPSON JF, 1995, MELANOMA RES, V5, P255, DOI 10.1097/00008390-199508000-00008; Troxel DB, 2003, AM J SURG PATHOL, V27, P1278, DOI 10.1097/00000478-200309000-00012; Tsao H, 2004, NEW ENGL J MED, V350, P924, DOI 10.1056/NEJMcpc030035; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; Tucker M A, 1985, Natl Cancer Inst Monogr, V68, P161; Tucker MA, 1997, JAMA-J AM MED ASSOC, V277, P1439, DOI 10.1001/jama.277.18.1439; Tucker MA, 2003, ONCOGENE, V22, P3042, DOI 10.1038/sj.onc.1206444; UREN RF, 1994, MELANOMA RES, V4, P395, DOI 10.1097/00008390-199412000-00009; Uren RF, 1999, LYMPHATIC DRAINAGE S; Uribe P, 2003, AM J DERMATOPATH, V25, P365, DOI 10.1097/00000372-200310000-00001; VANPOLL D, IN PRESS ANN SURG ON; Veenhuizen KCW, 1997, J PATHOL, V182, P266, DOI 10.1002/(SICI)1096-9896(199707)182:3<266::AID-PATH812>3.0.CO;2-#; VERONESI U, 1982, CANCER-AM CANCER SOC, V49, P2420, DOI 10.1002/1097-0142(19820601)49:11<2420::AID-CNCR2820491133>3.0.CO;2-2; VERONESI U, 1991, ARCH SURG-CHICAGO, V126, P438; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Vrouenraets BC, 1996, BRIT J SURG, V83, P1319, DOI 10.1002/bjs.1800831004; Westerhoff K, 2000, BRIT J DERMATOL, V143, P1016, DOI 10.1046/j.1365-2133.2000.03836.x; Wheatley K, 2003, CANCER TREAT REV, V29, P241, DOI 10.1016/S0305-7372(03)00074-4; Xu Xiaowei, 2004, Am J Clin Pathol, V121 Suppl, pS3	189	485	504	1	56	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	2005	365	9460					687	701		10.1016/S0140-6736(05)17951-3	http://dx.doi.org/10.1016/S0140-6736(05)17951-3			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	898SP	15721476				2022-12-28	WOS:000227096800028
J	Hering, BJ; Kandaswamy, R; Ansite, JD; Eckman, PM; Nakano, M; Sawada, T; Matsumoto, I; Ihm, SH; Zhang, HJ; Parkey, J; Hunter, DW; Sutherland, DER				Hering, BJ; Kandaswamy, R; Ansite, JD; Eckman, PM; Nakano, M; Sawada, T; Matsumoto, I; Ihm, SH; Zhang, HJ; Parkey, J; Hunter, DW; Sutherland, DER			Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AUTOIMMUNE DESTRUCTION; PANCREAS PRESERVATION; INSULIN INDEPENDENCE; IMMUNOSUPPRESSION; RAT; PERFLUOROCARBON; PREVENTION; INDUCTION; ANTIBODY; MOUSE	Context Islet allografts from 2 to 4 donors can reverse type 1 diabetes. However, for islet transplants to become a widespread clinical reality, diabetes reversal must be achieved with a single donor to reduce risks and costs and increase the availability of transplantation. Objective To assess the safety of a single-donor, marginal-dose islet transplant protocol using potent induction immunotherapy and less diabetogenic maintenance immunosuppression in recipients with type 1 diabetes. A secondary objective was to assess the proportion of islet transplant recipients who achieve insulin independence in the first year after single-donor islet transplantation. Design, Setting, and Participants Prospective, 1-year follow-up trial conducted July 2001 to August 2003 at a single US center and enrolling 8 women with type 1 diabetes accompanied by recurrent hypoglycemia unawareness or advanced secondary complications. Interventions Study participants underwent a primary islet allotransplant with 7271 (SD, 1035) islet equivalents/kg prepared from a single cadaver donor pancreas. Induction immunosuppression was with antithymocyte globulin, daclizumab, and etanercept. Maintenance immunosuppression consisted of mycophenolate mofetil, sirolimus, and no or low-dose tacrolimus. Main Outcome Measures Safety (assessed by monitoring the severity and duration of adverse events) and efficacy (assessed by studying the recipients' insulin requirements, C-peptide levels, oral and intravenous glucose tolerance results, intravenous arginine stimulation responses, glycosylated hemoglobin levels, and hypoglycemic episodes) associated with the study transplant protocol. Results There were no serious, unexpected, or procedure- or immunosuppression-related adverse events. All 8 recipients achieved insulin independence and freedom from hypoglycemia. Five remained insulin-independent for longer than 1 year. Graft failure in 3 recipients was preceded by subtherapeutic sirolimus exposure in the absence of measurable tacrolimus trough levels. Conclusions The tested transplant protocol restored insulin independence and protected against hypoglycemia after single-donor, marginal-dose islet transplantation in 8 of 8 recipients. These results may be related to improved islet engraftment secondary to peritransplant administration of antithymocyte globulin and etanercept. These findings may have implications for the ongoing transition of islet transplantation from clinical investigation to routine clinical care.	Univ Minnesota, Dept Surg, Minneapolis, MN 55455 USA; Univ Minnesota, Diabet Inst Immunol & Transplantat, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Radiol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Hering, BJ (corresponding author), Univ Minnesota, Dept Surg, Mayo Mail Code 195,420 Delaware St SE, Minneapolis, MN 55455 USA.	bhering@umn.edu	MATSUMOTO, IPPEI/AFK-9075-2022		NATIONAL CENTER FOR RESEARCH RESOURCES [U42RR016598, M01RR000400] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00400, U42 RR016598-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Agha IA, 2002, TRANSPLANTATION, V73, P473, DOI 10.1097/00007890-200202150-00025; BARTLETT ST, 1995, SURGERY, V118, P392, DOI 10.1016/S0039-6060(05)80350-2; CLARKE WL, 1995, DIABETES CARE, V18, P517, DOI 10.2337/diacare.18.4.517; FARNEY AC, 1993, TRANSPL P, V25, P865; Fernandez LA, 1999, TRANSPLANTATION, V68, P1532, DOI 10.1097/00007890-199911270-00017; Fraker CA, 2002, TRANSPLANTATION, V74, P1811, DOI 10.1097/01.TP.0000038293.13058.60; Genestier L, 1998, BLOOD, V91, P2360, DOI 10.1182/blood.V91.7.2360.2360_2360_2368; Goss JA, 2002, TRANSPLANTATION, V74, P1761, DOI 10.1097/01.TP.0000038968.06766.D6; HERING BJ, 1994, TRANSPLANT P, V26, P570; Hering BJ, 2002, TRANSPLANTATION, V74, P1813, DOI 10.1097/01.TP.0000038292.24519.C3; Hering BJ, 2004, AM J TRANSPLANT, V4, P390, DOI 10.1046/j.1600-6143.2003.00351.x; Hirshberg B, 2003, DIABETES CARE, V26, P3288, DOI 10.2337/diacare.26.12.3288; Jahr H, 2002, CELL TRANSPLANT, V11, P513; Kaufman DB, 2002, AM J TRANSPLANT, V2, P674, DOI 10.1034/j.1600-6143.2002.20715.x; Lakey JRT, 1999, CELL TRANSPLANT, V8, P285, DOI 10.1177/096368979900800309; Markmann JF, 2003, ANN SURG, V237, P741, DOI 10.1097/00000658-200306000-00001; Markmann JF, 2003, TRANSPLANTATION, V75, P1423, DOI 10.1097/01.TP.0000061119.32575.F4; Matsumoto S, 2002, TRANSPLANTATION, V74, P1804, DOI 10.1097/01.TP.0000038315.74633.DE; RABINOVITCH A, 1990, J CLIN ENDOCR METAB, V71, P152, DOI 10.1210/jcem-71-1-152; RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413; RICORDI C, 1990, ACTA DIABETOL LAT, V27, P185, DOI 10.1007/BF02581331; SCHARP DW, 1973, TRANSPLANTATION, V16, P686, DOI 10.1097/00007890-197312000-00028; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Stegall MD, 1996, TRANSPLANTATION, V61, P1272, DOI 10.1097/00007890-199604270-00027; Stegall MD, 1996, J SURG RES, V64, P156, DOI 10.1006/jsre.1996.0322; Tanioka Y, 1997, SURGERY, V122, P435, DOI 10.1016/S0039-6060(97)90037-4; TERADA M, 1988, TRANSPLANTATION, V45, P622, DOI 10.1097/00007890-198803000-00024; Teuscher AU, 1998, DIABETES, V47, P324, DOI 10.2337/diabetes.47.3.324; Tsujimura T, 2002, TRANSPLANTATION, V74, P1687, DOI 10.1097/01.TP.0000038288.17341.22; Verge CF, 1998, DIABETES, V47, P1857, DOI 10.2337/diabetes.47.12.1857; Vu MD, 1998, TRANSPLANTATION, V66, P1575, DOI 10.1097/00007890-199812270-00002; WANG Y, 1988, TRANSPLANTATION, V46, P101	32	422	445	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	2005	293	7					830	835		10.1001/jama.293.7.830	http://dx.doi.org/10.1001/jama.293.7.830			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DQ	15713772	Bronze			2022-12-28	WOS:000226984600024
J	Freeman, MR				Freeman, MR			Glial control of synaptogenesis	CELL			English	Editorial Material							SILENT SYNAPSES; LTP	Though all communication between neurons occurs through synapses, we know surprisingly little about the mechanisms inducing their formation. In this issue of Cell, Barres and colleagues (Christopherson et al., 2005) demonstrate that glial-derived thrombospondins and additional soluble glial-secreted factors regulate synapse assembly and functional maturation.	Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Freeman, MR (corresponding author), Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA 01605 USA.			Freeman, Marc/0000-0003-3481-3715				Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Christopherson KS, 2005, CELL, V120, P421, DOI 10.1016/j.cell.2004.12.020; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; Nagler K, 2001, J PHYSIOL-LONDON, V533, P665, DOI 10.1111/j.1469-7793.2001.00665.x; Pfrieger FW, 1997, SCIENCE, V277, P1684, DOI 10.1126/science.277.5332.1684; Preuss TM, 2004, NAT REV GENET, V5, P850, DOI 10.1038/nrg1469; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657	8	17	19	0	3	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 11	2005	120	3					292	293		10.1016/j.cell.2005.01.021	http://dx.doi.org/10.1016/j.cell.2005.01.021			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	897TS	15707887	Bronze			2022-12-28	WOS:000227028900004
J	Garwin, L				Garwin, L			Schrodinger's mousetrap - Part 4: A very public humiliation.	NATURE			English	Editorial Material									Harvard Univ, Bauer Ctr Genom Res, Cambridge, MA 02138 USA	Harvard University	Garwin, L (corresponding author), Harvard Univ, Bauer Ctr Genom Res, 7 Divin Ave, Cambridge, MA 02138 USA.								0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 10	2005	433	7026					579	579		10.1038/433579a	http://dx.doi.org/10.1038/433579a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	895KX	15703725	Bronze			2022-12-28	WOS:000226862000021
J	Lee, J; Croen, LA; Backstrand, KH; Yoshida, CK; Henning, LH; Lindan, C; Ferriero, DM; Fullerton, HJ; Barkovich, AJ; Wu, YW				Lee, J; Croen, LA; Backstrand, KH; Yoshida, CK; Henning, LH; Lindan, C; Ferriero, DM; Fullerton, HJ; Barkovich, AJ; Wu, YW			Maternal and infant characteristics associated with perinatal arterial stroke in the infant	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEONATAL CEREBRAL INFARCTION; ISCHEMIC-STROKE; TERM INFANTS; CLINICAL PRESENTATION; RISK-FACTORS; CHILDREN; PALSY; NEWBORN; PREECLAMPSIA; WOMEN	Context Perinatal arterial ischemic stroke (PAS) is a common cause of hemiplegic cerebral palsy. Risk factors for this condition have not been clearly defined. Objective To determine maternal and infant characteristics associated with PAS. Design, Setting, and Patients Case-control study nested within the cohort of all 199176 infants born from 1997 through 2002 in the Kaiser Permanente Medical Care Program, a managed care organization providing care for more than 3 million residents of northern California. Case patients were confirmed by review of brain imaging and medical records (n=40). Three controls per case were randomly selected from the study population. Main Outcome Measure Association of maternal and infant complications with risk of PAS. Results The population prevalence of PAS was 20 per 100000 live births. The majority (85%) of infants with PAS were delivered at term. The following prepartum and intrapartum factors were more common among case than control infants: primiparity (73% vs 44%, P=.002), fetal heart rate abnormality (46% vs 14%, P<.001), emergency cesarean delivery (35% vs 13%, P=.002), chorioamnionitis (27% vs 11%, P=.03), prolonged rupture of membranes (26% vs 7%, P=.002), prolonged second stage of labor (25% vs 4%, P<.001), vacuum extraction (24% vs 11%, P=.04), cord abnormality (22% vs 6%, P=.01), preeclampsia (19% vs 5%, P=.01), and oligohydramnios (14% vs 3%, P=.01). Risk factors independently associated with PAS on multivariate analysis were history of infertility (odds ratio [OR], 7.5; 95% confidence interval [CI], 1.3-45.0), preeclampsia (OR, 5.3; 95% Cl, 1.3-22.0), prolonged rupture of membranes (OR, 3.8; 95% Cl, 1.1-12.8), and chorioamnionitis (OR, 3.4; 95% Cl, 1.1-10.5). The rate of PAS increased dramatically when multiple risk factors were present. Conclusions Perinatal arterial ischemic stroke in infants is associated with several independent maternal risk factors. How these complications, along with their potential effects on the placenta and fetus, may play a role in causing perinatal stroke deserves further study.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA; Kaiser Permanente, Div Res, Oakland, CA USA; Kaiser Permanente, Dept Radiol, Oakland, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Kaiser Permanente; Kaiser Permanente	Wu, YW (corresponding author), UCSF Dept Child Neurol, Box 0137,350 Parnassus Ave,Suite 609, San Francisco, CA 94117 USA.	wuy@neuropeds.ucsf.edu		Fullerton, Heather/0000-0002-4828-1687; Croen, Lisa/0000-0001-7849-9428	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS035902] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35902] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMIT M, 1980, ARCH NEUROL-CHICAGO, V37, P109, DOI 10.1001/archneur.1980.00500510067013; Andrew M E, 2001, Hematology Am Soc Hematol Educ Program, P358; Badawi N, 1998, BMJ-BRIT MED J, V317, P1549, DOI 10.1136/bmj.317.7172.1549; Burke CJ, 1997, DEV MED CHILD NEUROL, V39, P726; deVeber GA, 2000, ANN NEUROL, V48, P514; deVeber GA, 2000, J CHILD NEUROL, V15, P316, DOI 10.1177/088307380001500508; deVries LS, 1997, NEUROPEDIATRICS, V28, P88, DOI 10.1055/s-2007-973679; Ericson A, 2002, HUM REPROD, V17, P929, DOI 10.1093/humrep/17.4.929; Estan J, 1997, ARCH DIS CHILD-FETAL, V76, pF88, DOI 10.1136/fn.76.2.F88; Fullerton HJ, 2003, NEUROLOGY, V61, P189, DOI 10.1212/01.WNL.0000078894.79866.95; Golomb MR, 2001, ANN NEUROL, V50, P163, DOI 10.1002/ana.1078; Govaert P, 2000, ARCH DIS CHILD-FETAL, V82, pF59, DOI 10.1136/fn.82.1.F59; Hagstrom JN, 1998, J PEDIATR-US, V133, P777, DOI 10.1016/S0022-3476(98)70150-7; HEIER LA, 1991, AM J NEURORADIOL, V12, P951; Hnat MD, 2002, AM J OBSTET GYNECOL, V186, P422, DOI 10.1067/mob.2002.120280; Hogeveen M, 2002, J PEDIATR-US, V141, P429, DOI 10.1067/mpd.2002.126598; Humphreys P, 2000, CAN J NEUROL SCI, V27, P210; Hunt RW, 2001, PEDIATR NEUROL, V25, P242, DOI 10.1016/S0887-8994(01)00291-0; Jan MMS, 1998, EUR J PEDIATR, V157, P846, DOI 10.1007/s004310050950; KOELFEN W, 1995, DEV MED CHILD NEUROL, V37, P204; Kraus FT, 1999, HUM PATHOL, V30, P759, DOI 10.1016/S0046-8177(99)90136-3; Kraus FT, 1997, HUM PATHOL, V28, P246, DOI 10.1016/S0046-8177(97)90114-3; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; Kupferminc MJ, 1999, NEW ENGL J MED, V341, P384; Kupferminc MJ, 1999, NEW ENGL J MED, V340, P9, DOI 10.1056/NEJM199901073400102; LIEN JM, 1995, OBSTET GYNECOL, V85, P163, DOI 10.1016/0029-7844(94)00375-N; Lynch JK, 2001, CURR OPIN PEDIATR, V13, P499, DOI 10.1097/00008480-200112000-00002; Lynch JK, 2001, NEUROLOGY, V56, pA10; MANNINO FL, 1983, J PEDIATR-US, V102, P605, DOI 10.1016/S0022-3476(83)80200-5; Ment L R, 1986, Pediatr Neurol, V2, P276, DOI 10.1016/0887-8994(86)90019-6; MENT LR, 1984, ANN NEUROL, V16, P559, DOI 10.1002/ana.410160506; Mercuri E, 1999, PEDIATRICS, V103, P39, DOI 10.1542/peds.103.1.39; Mercuri E, 2001, PEDIATRICS, V107, P1400, DOI 10.1542/peds.107.6.1400; Nelson KB, 2004, LANCET NEUROL, V3, P150, DOI 10.1016/S1474-4422(04)00679-9; Pabinger I, 2001, ARTERIOSCL THROM VAS, V21, P874, DOI 10.1161/01.ATV.21.5.874; PELLICER A, 1992, BRAIN DEV-JPN, V14, P381, DOI 10.1016/S0387-7604(12)80344-5; PERLMAN JM, 1994, PEDIATR NEUROL, V11, P281, DOI 10.1016/0887-8994(94)90002-7; Ramaswamy V, 2004, NEUROLOGY, V62, P2088, DOI 10.1212/01.WNL.0000129909.77753.C4; Redline RW, 2000, ARCH PATHOL LAB MED, V124, P1785; Roberts JM, 2001, LANCET, V357, P53, DOI 10.1016/S0140-6736(00)03577-7; Rogolino A, 2003, BLOOD COAGUL FIBRIN, V14, P277, DOI 10.1097/00001721-200304000-00009; SALAFIA CM, 1995, AM J OBSTET GYNECOL, V173, P1097, DOI 10.1016/0002-9378(95)91333-5; Schneider AT, 2004, STROKE, V35, P1552, DOI 10.1161/01.STR.0000129335.28301.f5; Shah D M, 2001, Semin Pediatr Neurol, V8, P108, DOI 10.1053/spen.2001.25812; Sreenan C, 2000, J PEDIATR-US, V137, P351, DOI 10.1067/mpd.2000.107845; *STAT CAL DEP HLTH, 1976, INTR GROWTH NEON RIS; *STAT CORP, 2000, STATA 7 REF MAN; Stromberg B, 2002, LANCET, V359, P461, DOI 10.1016/S0140-6736(02)07674-2; UVEBRANT P, 1988, ACTA PAEDIATR SCAND, P1; Wu YW, 2004, PEDIATRICS, V114, P612, DOI 10.1542/peds.2004-0385; Wu YW, 2000, JAMA-J AM MED ASSOC, V284, P1417, DOI 10.1001/jama.284.11.1417; Wu YW, 2003, JAMA-J AM MED ASSOC, V290, P2677, DOI 10.1001/jama.290.20.2677; WULFECK BB, 1991, PEDIATR NEUROL, V7, P266, DOI 10.1016/0887-8994(91)90043-K; Yoshii F, 1999, NEUROLOGY, V53, P225, DOI 10.1212/WNL.53.1.225	54	212	220	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2005	293	6					723	729		10.1001/jama.293.6.723	http://dx.doi.org/10.1001/jama.293.6.723			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895DX	15701914	Bronze			2022-12-28	WOS:000226842200026
J	Michiels, S; Koscielny, S; Hill, C				Michiels, S; Koscielny, S; Hill, C			Prediction of cancer outcome with microarrays: a multiple random validation strategy	LANCET			English	Article							GENE-EXPRESSION PROFILES; CLASSIFICATION; SURVIVAL; SIGNATURE	Background General studies of microarray gene-expression profiling have been under-taken to predict cancer outcome. Knowledge of this gene-expression profile or molecular signature should improve treatment of patients by allowing treatment to be tailored to the severity of the disease. We reanalysed data from the seven largest published studies that have attempted to predict prognosis of cancer patients on the basis of DNA microarray analysis. Methods The standard strategy is to identify a molecular signature (ie, the subset of genes most differentially expressed in patients with different outcomes) in a training set of patients and to estimate the proportion of misclassifications with this signature on an independent validation set of patients. We expanded this strategy (based on unique training and validation sets) by using multiple random sets, to study the stability of the molecular signature and the proportion of misclassifications. Findings The list of genes identified as predictors of prognosis was highly unstable; molecular signatures strongly depended on the selection of patients in the training sets. For all but one study, the proportion misclassified decreased as the number of patients in the training set increased. Because of inadequate validation, our chosen studies published overoptimistic results compared with those from our own analyses. Five of the seven studies did not classify patients better than chance. Interpretation The prognostic value of published microarray results in cancer studies should be considered with caution. We advocate the use of validation by repeated random sampling.	Inst Gustave Roussy, Biostat & Epidemiol Unit, F-94805 Villejuif, France; Inst Gustave Roussy, Funct Gen Unit, F-94805 Villejuif, France; Inst Gustave Roussy, INSERM, U605, F-94805 Villejuif, France	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	Koscielny, S (corresponding author), Inst Gustave Roussy, Biostat & Epidemiol Unit, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	koscielny@igr.fr	Michiels, Stefan/L-1516-2013	Michiels, Stefan/0000-0002-6963-2968				Ball CA, 2002, LANCET, V360, P1019, DOI 10.1016/S0140-6736(02)11100-7; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Caldas C, 2002, NATURE, V415, P484, DOI 10.1038/415484a; Dudoit S, 2002, J AM STAT ASSOC, V97, P77, DOI 10.1198/016214502753479248; Iizuka N, 2003, LANCET, V361, P923, DOI 10.1016/S0140-6736(03)12775-4; Kallioniemi O, 2004, NATURE, V428, P379, DOI 10.1038/428379b; Miller LD, 2002, CANCER CELL, V2, P353, DOI 10.1016/S1535-6108(02)00181-2; Ntzani EE, 2003, LANCET, V362, P1439, DOI 10.1016/S0140-6736(03)14686-7; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Simon R, 2003, BRIT J CANCER, V89, P1599, DOI 10.1038/sj.bjc.6601326; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6	17	732	815	0	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 5	2005	365	9458					488	492		10.1016/S0140-6736(05)17866-0	http://dx.doi.org/10.1016/S0140-6736(05)17866-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894SS	15705458				2022-12-28	WOS:000226812500026
J	Gompel, N; Prud'homme, B; Wittkopp, PJ; Kassner, VA; Carroll, SB				Gompel, N; Prud'homme, B; Wittkopp, PJ; Kassner, VA; Carroll, SB			Chance caught on the wing: cis-regulatory evolution and the origin of pigment patterns in Drosophila	NATURE			English	Article							MELANOGASTER SPECIES-GROUP; GROUP DIPTERA; YELLOW LOCUS; PHYLOGENY; EXPRESSION; GENE; DIVERGENCE; MORPHOLOGY; ELEMENTS; LINEAGE	The gain, loss or modification of morphological traits is generally associated with changes in gene regulation during development. However, the molecular bases underlying these evolutionary changes have remained elusive. Here we identify one of the molecular mechanisms that contributes to the evolutionary gain of a male-specific wing pigmentation spot in Drosophila biarmipes, a species closely related to Drosophila melanogaster. We show that the evolution of this spot involved modifications of an ancestral cis-regulatory element of the yellow pigmentation gene. This element has gained multiple binding sites for transcription factors that are deeply conserved components of the regulatory landscape controlling wing development, including the selector protein Engrailed. The evolutionary stability of components of regulatory landscapes, which can be co-opted by chance mutations in cis-regulatory elements, might explain the repeated evolution of similar morphological patterns, such as wing pigmentation patterns in flies.	Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA; Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Carroll, SB (corresponding author), Univ Wisconsin, Howard Hughes Med Inst, 1525 Linden Dr, Madison, WI 53706 USA.	sbcarrol@wisc.edu		Gompel, Nicolas/0000-0003-3358-7963				Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; Averof M, 1997, NATURE, V388, P682, DOI 10.1038/41786; Barolo S, 2000, BIOTECHNIQUES, V29, P726, DOI 10.2144/00294bm10; Belting HG, 1998, P NATL ACAD SCI USA, V95, P2355, DOI 10.1073/pnas.95.5.2355; BLAIR SS, 1992, DEVELOPMENT, V115, P21; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BOCK IR, 1980, SYST ENTOMOL, V5, P341, DOI 10.1111/j.1365-3113.1980.tb00420.x; BOCK IR, 1972, STUDIES GENETICS, P1, DOI DOI 10.1590/S0085-56262014000400004; Carroll S. B., 2004, DNA DIVERSITY MOL GE; CELNIKER SE, 2002, GENOME BIOL, V0003; CHIA W, 1986, EMBO J, V5, P3597, DOI 10.1002/j.1460-2075.1986.tb04688.x; Davidson E. H., 2001, DEV EVOLUTION; de Celis JF, 2003, BIOESSAYS, V25, P443, DOI 10.1002/bies.10258; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GEYER PK, 1987, GENE DEV, V1, P996, DOI 10.1101/gad.1.9.996; Gompel N, 2003, NATURE, V424, P931, DOI 10.1038/nature01787; GONZALEZ P, 1995, MOL BIOL EVOL, V12, P773; HARDY DE, 1965, DIPTERA CYCLORRHAP 1, V2; *HUM GEN SEQ CTR, 2002, DROS GEN PROJ; Kauffman S., 1995, HOME UNIVERSE SEARCH; Kopp A, 2002, EVOL DEV, V4, P278, DOI 10.1046/j.1525-142X.2002.02017.x; Kopp A, 2002, SYST BIOL, V51, P786, DOI 10.1080/10635150290102410; Llopart A, 2002, EVOLUTION, V56, P2262; Majerus M, 1998, MELANISM EVOLUTION A; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; Miller DFB, 2002, BIOTECHNIQUES, V33, P366, DOI 10.2144/02332rr03; Monod J., 1970, HASARD N CESSIT ESSA; Powell J. R., 1997, PROGR PROSPECTS EVOL; Remsen J, 2002, MOL PHYLOGENET EVOL, V24, P249, DOI 10.1016/S1055-7903(02)00226-9; RUSSO CAM, 1995, MOL BIOL EVOL, V12, P391; Schawaroch V, 2002, BIOL J LINN SOC, V76, P21, DOI 10.1111/j.1095-8312.2002.tb01711.x; SCHENDEL PF, 1993, CURRENT PROTOCOLS MO; Shapiro MD, 2004, NATURE, V428, P717, DOI 10.1038/nature02415; SINGH BN, 1987, ETHOLOGY, V75, P81; Solano PJ, 2003, DEVELOPMENT, V130, P1243, DOI 10.1242/dev.00348; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; Stern DL, 2000, EVOLUTION, V54, P1079, DOI 10.1554/0014-3820(2000)054[1079:PEDBAT]2.0.CO;2; Stern DL, 1998, NATURE, V396, P463, DOI 10.1038/24863; Sucena E, 2000, P NATL ACAD SCI USA, V97, P4530, DOI 10.1073/pnas.97.9.4530; True JR, 1999, CURR BIOL, V9, P1382, DOI 10.1016/S0960-9822(00)80083-4; Wang RL, 1999, NATURE, V398, P236, DOI 10.1038/18435; Wang XD, 2002, GENE DEV, V16, P2345, DOI 10.1101/gad.996302; Wheeler M.R., 1965, DROS INFORM SERV, V40, P98; Wittkopp PJ, 2003, P NATL ACAD SCI USA, V100, P1808, DOI 10.1073/pnas.0336368100; Wittkopp PJ, 2002, CURR BIOL, V12, P1547, DOI 10.1016/S0960-9822(02)01113-2; Wittkopp PJ, 2002, DEVELOPMENT, V129, P1849; Yoon HS, 2004, P NATL ACAD SCI USA, V101, P6524, DOI 10.1073/pnas.0401824101	47	465	484	7	102	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 3	2005	433	7025					481	487		10.1038/nature03235	http://dx.doi.org/10.1038/nature03235			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893NT	15690032				2022-12-28	WOS:000226727200038
J	McGaha, TL; Sorrentino, B; Ravetch, JV				McGaha, TL; Sorrentino, B; Ravetch, JV			Restoration of tolerance in lupus by targeted inhibitory receptor expression	SCIENCE			English	Article							HEMATOPOIETIC STEM-CELLS; NEGATIVE SELECTION; CLONAL DELETION; DOWN-REGULATION; B-LYMPHOCYTES; MICE; ERYTHEMATOSUS; AUTOIMMUNITY; SUSCEPTIBILITY; REPERTOIRE	Lupus, a multigenic autoimmune condition in which a breakdown of tolerance results in the development of autoantibodies, leads to a variety of pathologic outcomes. Despite the heterogeneity of factors influencing disease susceptibility, we demonstrate that the partial restoration of inhibitory Fc receptor (FcgammaRIIB) levels on B cells in lupus-prone mouse strains is sufficient to restore tolerance and prevent autoimmunity. FcgammaRIIB regulates a common B cell checkpoint in genetically diverse lupus-prone mouse strains, and modest changes in its expression can result in either tolerance or autoimmunity. Therefore, increasing FcgammaRIIB levels on B cells may be an effective way to treat autoimmune diseases.	Rockefeller Univ, Lab Mol Genet & Immunol, New York, NY 10021 USA; St Jude Childrens Res Hosp, Memphis, TN 38105 USA	Rockefeller University; St Jude Children's Research Hospital	Ravetch, JV (corresponding author), Rockefeller Univ, Lab Mol Genet & Immunol, 1230 York Ave, New York, NY 10021 USA.	ravetch@rockefeller.edu	Ravetch, Jeffrey/Z-1596-2019	Ravetch, Jeffrey/0000-0003-2024-9041; McGaha, Tracy/0000-0003-4721-9301				Bolland S, 2000, IMMUNITY, V13, P277, DOI 10.1016/S1074-7613(00)00027-3; Bouneaud C, 2000, IMMUNITY, V13, P829, DOI 10.1016/S1074-7613(00)00080-7; CHALLITA PM, 1994, P NATL ACAD SCI USA, V91, P2567, DOI 10.1073/pnas.91.7.2567; Cherry SR, 2000, MOL CELL BIOL, V20, P7419, DOI 10.1128/MCB.20.20.7419-7426.2000; Fukuyama H, 2005, NAT IMMUNOL, V6, P99, DOI 10.1038/ni1151; Jiang Y, 2000, IMMUNOGENETICS, V51, P429, DOI 10.1007/s002510050641; Jiang Y, 1999, INT IMMUNOL, V11, P1685, DOI 10.1093/intimm/11.10.1685; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; Klug CA, 2000, BLOOD, V96, P894, DOI 10.1182/blood.V96.3.894.015k35_894_901; Lange C, 1997, GENE THER, V4, P303, DOI 10.1038/sj.gt.3300395; Lund Anders H., 1996, Journal of Biomedical Science, V3, P365, DOI 10.1007/BF02258042; Marion Tony N, 2003, Curr Dir Autoimmun, V6, P123; Morel L, 2000, P NATL ACAD SCI USA, V97, P6670, DOI 10.1073/pnas.97.12.6670; NEMAZEE D, 1989, P NATL ACAD SCI USA, V86, P8039, DOI 10.1073/pnas.86.20.8039; NOSSAL GJV, 1980, P NATL ACAD SCI-BIOL, V77, P1602, DOI 10.1073/pnas.77.3.1602; Pritchard NR, 2000, CURR BIOL, V10, P227, DOI 10.1016/S0960-9822(00)00344-4; Pritchard NR, 2003, IMMUNOLOGY, V108, P263, DOI 10.1046/j.1365-2567.2003.01592.x; RADIC MZ, 1993, J EXP MED, V177, P1165, DOI 10.1084/jem.177.4.1165; SCHWARTZ RH, 1989, COLD SH Q B, V54, P605; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; Vyse TJ, 1998, ANNU REV IMMUNOL, V16, P261, DOI 10.1146/annurev.immunol.16.1.261; Xiu Y, 2002, J IMMUNOL, V169, P4340, DOI 10.4049/jimmunol.169.8.4340; Yan J, 2002, J IMMUNOL, V168, P3188, DOI 10.4049/jimmunol.168.7.3188	24	206	219	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 28	2005	307	5709					590	593		10.1126/science.1105160	http://dx.doi.org/10.1126/science.1105160			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893BJ	15681388				2022-12-28	WOS:000226694000050
J	Teeling, EC; Springer, MS; Madsen, O; Bates, P; O'Brien, SJ; Murphy, WJ				Teeling, EC; Springer, MS; Madsen, O; Bates, P; O'Brien, SJ; Murphy, WJ			A molecular phylogeny for bats illuminates biogeography and the fossil record	SCIENCE			English	Article							EOCENE BAT; CHIROPTERA; SEQUENCES	Bats make up more than 20% of extant mammals, yet their evolutionary history is largely unknown because of a limited fossil record and conflicting or incomplete phylogenies. Here, we present a highly resolved molecular phylogeny for all extant bat families. Our results support the hypothesis that megabats are nested among four major microbat lineages, which originated in the early Eocene [52 to 50 million years ago (Mya)], coincident with a significant global rise in temperature, increase in plant diversity and abundance, and the zenith of Tertiary insect diversity. Our data suggest that bats originated in Laurasia, possibly in North America, and that three of the major microbat lineages are Laurasian in origin, whereas the fourth is Gondwanan. Combining principles of ghost lineage analysis with molecular divergence dates, we estimate that the bat fossil record underestimates (unrepresented basal branch length, UBBL) first occurrences by, on average, 73% and that the sum of missing fossil history is 61%.	NCI, Lab Genom Divers, Basic Res Program, SAIC Frederick Inc, Frederick, MD 21702 USA; Univ Coll Dublin, Dept Zool, Dublin 4, Ireland; Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA; Radboud Univ Nijmegen, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Harrison Inst, Ctr Systemat & Biodivers Res, Sevenoaks TN13 3AQ, Kent, England; NCI, Lab Genom Divers, Frederick, MD 21702 USA; Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Vet Integrat Biosci, College Stn, TX 77843 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University College Dublin; University of California System; University of California Riverside; Radboud University Nijmegen; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Texas A&M University System; Texas A&M University College Station	Teeling, EC (corresponding author), NCI, Lab Genom Divers, Basic Res Program, SAIC Frederick Inc, Frederick, MD 21702 USA.	emma.teeling@ucd.ie; mark.springer@ucr.edu; obrien@mail.ncifcrf.gov	Raleva, Sofiya/A-3114-2011; Yousfi, Mohamed/A-5754-2012; Rossiter, Stephen J/E-2111-2011; OBRIEN, STEPHEN/ABD-1346-2020; Madsen, Ole/E-3730-2012; Ho, Hilary/F-3029-2011	Yousfi, Mohamed/0000-0003-4831-8635; Madsen, Ole/0000-0001-8082-7881; OBRIEN, STEPHEN/0000-0001-7857-0757; Teeling, Emma/0000-0002-3309-1346	NCI NIH HHS [N01-CO-12400] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005367] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baker RJ, 1997, SYST BIOL, V46, P579, DOI 10.2307/2413496; Bates PJJ, 2001, ACTA CHIROPTEROL, V3, P33; Cooper A, 2001, NATURE, V409, P704, DOI 10.1038/35055536; CZAPLEWSKI NJ, EVOLUTION TERTIARY M, V2; Flynn JJ, 1998, TRENDS ECOL EVOL, V13, P449, DOI 10.1016/S0169-5347(98)01457-8; HABERSETZER J, 1992, NATURWISSENSCHAFTEN, V79, P462, DOI 10.1007/BF01139198; HAND S, 1994, J VERTEBR PALEONTOL, V14, P375, DOI 10.1080/02724634.1994.10011565; Hand Suzanne J., 1998, P72; HILL J. E., 1977, B BRIT MUS NAT HIST, V32, P29; Hoofer SR, 2003, J MAMMAL, V84, P809, DOI 10.1644/BWG-034; Hutcheon JM, 1998, PHILOS T R SOC B, V353, P607, DOI 10.1098/rstb.1998.0229; JEPSEN GL, 1966, SCIENCE, V154, P1333, DOI 10.1126/science.154.3754.1333; LABANDEIRA CC, 1993, SCIENCE, V261, P310, DOI 10.1126/science.11536548; MCKENNA MC, 1997, CLASSIFCATION MAMMAL; Murphy WJ, 2001, SCIENCE, V294, P2348, DOI 10.1126/science.1067179; Patterson BD, 2003, BAT ECOLOGY, P536; Simmons Nancy B., 1993, American Museum Novitates, V3077, P1; Simmons NB, 1998, B AM MUS NAT HIST, P1; SIMMONS NB, MAMMALIAN SPECIES WO; Springer MS, 2003, P NATL ACAD SCI USA, V100, P1056, DOI 10.1073/pnas.0334222100; Springer MS, 2001, P NATL ACAD SCI USA, V98, P6241, DOI 10.1073/pnas.111551998; Storch Gerhard, 2002, Palaeontologische Zeitschrift, V76, P189; Teeling EC, 2000, NATURE, V403, P188, DOI 10.1038/35003188; Teeling EC, 2003, MOL PHYLOGENET EVOL, V28, P308, DOI 10.1016/S1055-7903(03)00117-9; Teeling EC, 2002, P NATL ACAD SCI USA, V99, P1431, DOI 10.1073/pnas.022477199; Van den Bussche RA, 2004, J MAMMAL, V85, P321, DOI 10.1644/1545-1542(2004)085<0321:PRARCF>2.0.CO;2; Wilf P, 1999, SCIENCE, V284, P2153, DOI 10.1126/science.284.5423.2153; WING SL, 1992, MESOZOIC EARLY CENOZ, P327; Woodburne Michael O., 1996, Journal of Mammalian Evolution, V3, P121, DOI 10.1007/BF01454359	29	766	816	3	384	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2005	307	5709					580	584		10.1126/science.1105113	http://dx.doi.org/10.1126/science.1105113			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893BJ	15681385				2022-12-28	WOS:000226694000047
J	Botto, LD; Lisi, A; Robert-Gnansia, E; Erickson, JD; Vollset, SE; Mastroiacovo, P; Botting, B; Cocchi, G; de Vigan, C; de Walle, H; Feijoo, M; Irgens, LM; McDonnell, B; Merlob, P; Ritvanen, A; Scarano, G; Siffel, C; Metneki, J; Stoll, C; Smithells, R; Goujard, J				Botto, LD; Lisi, A; Robert-Gnansia, E; Erickson, JD; Vollset, SE; Mastroiacovo, P; Botting, B; Cocchi, G; de Vigan, C; de Walle, H; Feijoo, M; Irgens, LM; McDonnell, B; Merlob, P; Ritvanen, A; Scarano, G; Siffel, C; Metneki, J; Stoll, C; Smithells, R; Goujard, J			International retrospective cohort study of neural tube defects in relation to folic acid recommendations: are the recommendations working?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DIETARY-SUPPLEMENTS; REPRODUCTIVE AGE; FORTIFICATION; ATTITUDES; KNOWLEDGE; FOLATE; WOMEN	Objective To evaluate the effectiveness of policies and recommendations on folic acid aimed at reducing the occurrence of neural tube defects. Design Retrospective cohort study of births monitored by birth defect registries. Setting 13 birth defects registries monitoring rates of neural tube defects from 1988 to 1998 in Norway, Finland, Northern Netherlands, England and Wales, Ireland, France (Paris, Strasbourg, and Central East), Hungary, Italy (Emilia Romagna and Campania), Portugal, and Israel. Cases of neural tube defects were ascertained among liveborn infants, stillbirths, and pregnancy terminations (where legal). Policies and recommendations were ascertained by interview and literature review. Main outcome measures Incidences and trends in rates of neural tube defects before and after 1992 (the year of the first recommendations) and before and after the year of local recommendations (when applicable). Results The issuing of recommendations on folic acid was followed by no detectable improvement in the trends of incidence of neural tube defects. Conclusions Recommendations alone did not seem to influence trends in neural tube defects up to six years after the confirmation of the effectiveness of folic acid in clinical trials. New cases of neural tube defects preventable by folic acid continue to accumulate. A reasonable strategy would be to quickly integrate food fortification with fuller implementation of recommendations on supplements.	Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Botto, LD (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Mailstop E-86,1600 Clifton Rd NE, Atlanta, GA 30333 USA.	icbd@icbd.org		Siffel, Csaba/0000-0002-6491-6953	ODCDC CDC HHS [U50/CCU207141] Funding Source: Medline	ODCDC CDC HHS		Berry RJ, 1999, NEW ENGL J MED, V341, P1485, DOI 10.1056/NEJM199911113412001; Castilla EE, 2003, AM J MED GENET A, V123A, P123, DOI 10.1002/ajmg.a.20230; Daltveit AK, 2004, SCAND J PUBLIC HEALT, V32, P264, DOI 10.1080/14034940310019515; de Walle HEK, 2002, PREV MED, V35, P65, DOI 10.1006/pmed.2002.1040; Hirsch S, 2002, J NUTR, V132, P289, DOI 10.1093/jn/132.2.289; Honein MA, 2001, JAMA-J AM MED ASSOC, V285, P2981, DOI 10.1001/jama.285.23.2981; Landon J, 1998, CHANGING PRECONCEPTI, V1, P61; Ray JG, 2002, LANCET, V360, P2047, DOI 10.1016/S0140-6736(02)11994-5; Rosano A, 2000, J EPIDEMIOL COMMUN H, V54, P660, DOI 10.1136/jech.54.9.660; Vollset SE, 2000, ACTA OBSTET GYN SCAN, V79, P513; 2002, MMWR MORB MORTAL WKL, V51, P808	11	168	176	1	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 12	2005	330	7491					571	573		10.1136/bmj.38336.664352.82	http://dx.doi.org/10.1136/bmj.38336.664352.82			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	906EC	15722368	Green Published, Bronze			2022-12-28	WOS:000227622300017
J	Wilson, D; Aster, R; West, M; Ni, J; Grand, S; Gao, W; Baldridge, WS; Semken, S; Patel, P				Wilson, D; Aster, R; West, M; Ni, J; Grand, S; Gao, W; Baldridge, WS; Semken, S; Patel, P			Lithospheric structure of the Rio Grande rift	NATURE			English	Article							TECTONIC EVOLUTION; UNITED-STATES; TELESEISMIC P; NEW-MEXICO; EXTENSION; BENEATH; REGION; UPLIFT; SCALE; MODEL	A high-resolution, regional passive seismic experiment(1-6) in the Rio Grande rift region of the southwestern United States has produced new images of upper-mantle velocity structure and crust-mantle topography. Synthesizing these results with geochemical(7-9) and other geophysical(10-13) evidence reveals highly symmetric lower-crustal and upper-mantle lithosphere extensional deformation, suggesting a pure-shear rifting mechanism for the Rio Grande rift. Extension in the lower crust is distributed over a region four times the width of the rift's surface expression. Here we propose that the laterally distributed, pure shear extension is a combined effect of low strain rate and a regionally elevated geotherm, possibly abetted by pre-existing lithospheric structures, at the time of rift initiation. Distributed extension in the lower crust and mantle has induced less concentrated vertical mantle upwelling and less vigorous small-scale convection(14) than would have arisen from more localized deformation. This lack of highly focused mantle upwelling may explain a deficit of rift-related volcanics in the Rio Grande rift compared to other major rift systems such as the Kenya rift(15,16).	New Mexico Inst Min & Technol, Dept Earth & Environm Sci, Socorro, NM 87801 USA; New Mexico Inst Min & Technol, Geophys Res Ctr, Socorro, NM 87801 USA; Arizona State Univ, Dept Geol Sci, Tempe, AZ 85287 USA; Los Alamos Natl Lab, Div Earth & Environm Sci, Los Alamos, NM 87545 USA; Univ Texas, Jackson Sch Geosci, Austin, TX 78712 USA; New Mexico State Univ, Dept Phys, Las Cruces, NM 88003 USA	New Mexico Institute of Mining Technology; New Mexico Institute of Mining Technology; Arizona State University; Arizona State University-Tempe; United States Department of Energy (DOE); Los Alamos National Laboratory; University of Texas System; University of Texas Austin; New Mexico State University	Wilson, D (corresponding author), New Mexico Inst Min & Technol, Dept Earth & Environm Sci, Socorro, NM 87801 USA.	davew@ees.nmt.edu	Grand, Stephen/B-4238-2011; Semken, Steven C/B-7572-2009					[Anonymous], [No title captured]; BALDRIDGE WS, 1991, TECTONOPHYSICS, V197, P327, DOI 10.1016/0040-1951(91)90049-X; BUCK WR, 1986, EARTH PLANET SC LETT, V77, P362, DOI 10.1016/0012-821X(86)90146-9; BUCK WR, 1988, TECTONICS, V7, P213, DOI 10.1029/TC007i002p00213; Chapin C.E., 1994, GEOL SOC AM SPEC PAP, V291, P5, DOI DOI 10.1130/SPE291-P5; CORDELL L, 1991, J GEOPHYS RES-SOLID, V96, P6557, DOI 10.1029/91JB00008; DAVIS PM, 1991, TECTONOPHYSICS, V197, P309, DOI 10.1016/0040-1951(91)90048-W; Gao W, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002743; Gok R, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016616; Huismans RS, 2001, J GEOPHYS RES-SOL EA, V106, P11271, DOI 10.1029/2000JB900424; HUMPHREYS ED, 1995, GEOLOGY, V23, P987, DOI 10.1130/0091-7613(1995)023<0987:PLROTF>2.3.CO;2; KARATO S, 1993, GEOPHYS RES LETT, V20, P1623, DOI 10.1029/93GL01767; KELLER GR, 1991, TECTONOPHYSICS, V197, P355, DOI 10.1016/0040-1951(91)90050-3; KELLER GR, 1999, ROCKY MT GEOL, V34, P131; LANGSTON CA, 1977, B SEISMOL SOC AM, V67, P713; Lavier LL, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000513; MCKENZIE D, 1978, EARTH PLANET SC LETT, V40, P25, DOI 10.1016/0012-821X(78)90071-7; McMillan N. J., 1998, NEW MEXICO GEOLOGIC, V49, P107; MORGAN P, 1986, J GEOPHYS RES-SOLID, V91, P6263, DOI 10.1029/JB091iB06p06263; MUTTER JC, 1988, J GEOPHYS RES-SOLID, V93, P1031, DOI 10.1029/JB093iB02p01031; OLSEN KH, 1987, TECTONOPHYSICS, V143, P119, DOI 10.1016/0040-1951(87)90083-7; PARKER EC, 1984, NATURE, V312, P354, DOI 10.1038/312354a0; PERRY FV, 1988, NATURE, V332, P432, DOI 10.1038/332432a0; Slack PD, 1996, J GEOPHYS RES-SOL EA, V101, P16003, DOI 10.1029/96JB00109; WEISSEL JK, 1989, J GEOPHYS RES-SOLID, V94, P13919, DOI 10.1029/JB094iB10p13919; WERNICKE B, 1985, CAN J EARTH SCI, V22, P108, DOI 10.1139/e85-009; West M, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002575; Wilson D, 2002, B SEISMOL SOC AM, V92, P3335, DOI 10.1785/0120010234; WILSON D, UNPUB J GEOPHYS RES; Wilson D, 2003, LEADING EDGE, V22, P232, DOI DOI 10.1190/1.1564528	30	73	75	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 24	2005	433	7028					851	855		10.1038/nature03297	http://dx.doi.org/10.1038/nature03297			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	899VT	15729338				2022-12-28	WOS:000227174600038
J	Gluckman, PD; Wyatt, JS; Azzopardi, D; Ballard, R; Edwards, AD; Ferriero, DM; Polin, RA; Robertson, CM; Thoresen, M; Whitelaw, A; Gunn, AJ				Gluckman, PD; Wyatt, JS; Azzopardi, D; Ballard, R; Edwards, AD; Ferriero, DM; Polin, RA; Robertson, CM; Thoresen, M; Whitelaw, A; Gunn, AJ		CoolCap Study Grp	Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial	LANCET			English	Article							AMPLITUDE-INTEGRATED ELECTROENCEPHALOGRAPHY; CEREBRAL HYPOXIA-ISCHEMIA; WHOLE-BODY HYPOTHERMIA; PERINATAL ASPHYXIA; NEWBORN-INFANTS; TERM INFANTS; BRAIN-INJURY; THERAPEUTIC HYPOTHERMIA; BIRTH ASPHYXIA; CARDIAC-ARREST	Background Cerebral hypothermia can improve outcome of experimental perinatal hypoxia-ischaemia. We did a multicentre randomised controlled trial to find out if delayed head cooling can improve neurodevelopmental outcome in babies with neonatal encephalopathy. Methods 234 term infants with moderate to severe neonatal encephalopathy and abnormal amplitude integrated electroencephalography (aEEG) were randomly assigned to either head cooling for 72 h, within 6 h of birth, with rectal temperature maintained at 34-35degreesC (n=116), or conventional care (n=118). Primary outcome was death or severe disability at 18 months. Analysis was by intention to treat. We examined in two predefined subgroup analyses the effect of hypothermia in babies with the most severe aEEG changes before randomisation-ie, severe loss of background amplitude, and seizures-and those with less severe changes. Findings In 16 babies, follow-up data were not available. Thus in 218 infants (93%), 73/110 (66%) allocated conventional care and 59/108 (55%) assigned head cooling died or had severe disability at 18 months (odds ratio 0.61; 95% CI 0.34-1-09, p=0.1). After adjustment for the severity of aEEG changes with a logistic regression model, the odds ratio for hypothermia treatment was 0.57 (0.32-1.01, p=0.05). No difference was noted in the frequency of clinically important complications. Predefined subgroup analysis suggested that head cooling had no effect in infants with the most severe aEEG changes (n=46, 1.8; 0.49-6.4, p=0.51), but was beneficial in infants with less severe aEEG changes (n=172, 0.42; 0.22-0.80, p=0.009). Interpretation These data suggest that although induced head cooling is not protective in a mixed population of infants with neonatal encephalopathy, it could safely improve survival without severe neurodevelopmental. disability in infants with less severe aEEG changes.	Univ Auckland, Fac Med & Hlth Sci, Dept Physiol, Auckland, New Zealand; Univ Auckland, Liggins Inst, Auckland 1, New Zealand; UCL, London, England; Univ London Imperial Coll Sci Technol & Med, London, England; Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Univ Alberta, Dept Paediat, Edmonton, AB, Canada; Univ Bristol, St Michaels Hosp, Bristol, Avon, England; Univ Bristol, Southmead Hosp, Bristol, Avon, England	University of Auckland; University of Auckland; University of London; University College London; Imperial College London; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of California System; University of California San Francisco; Columbia University; University of Alberta; University of Bristol; Southmead Hospital; University of Bristol	Gunn, AJ (corresponding author), Univ Auckland, Fac Med & Hlth Sci, Dept Physiol, Private Bag 92019, Auckland, New Zealand.	aj.gunn@auckland.ac.nz	Edwards, Anthony/HCI-9626-2022	Edwards, Anthony David/0000-0003-4801-7066; Gunn, Alistair/0000-0003-0656-7035	MRC [MC_U120081323] Funding Source: UKRI; Medical Research Council [MC_U120081323] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		al Naqeeb N, 1999, PEDIATRICS, V103, P1263, DOI 10.1542/peds.103.6.1263; AZZOPARDI D, 1989, PEDIATR RES, V25, P445, DOI 10.1203/00006450-198905000-00004; Azzopardi D, 2000, PEDIATRICS, V106, P684, DOI 10.1542/peds.106.4.684; Battin MR, 2003, PEDIATRICS, V111, P244, DOI 10.1542/peds.111.2.244; Battin MR, 2001, PEDIATRICS, V107, P480, DOI 10.1542/peds.107.3.480; Bayley N, 1993, BAYLEY SCALES INFANT; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bona E, 1998, PEDIATR RES, V43, P738, DOI 10.1203/00006450-199806000-00005; Colbourne F, 1999, J CEREBR BLOOD F MET, V19, P742, DOI 10.1097/00004647-199907000-00003; Compagnoni G, 2002, BIOL NEONATE, V82, P222, DOI 10.1159/000065890; Edwards AD, 1995, BIOCHEM BIOPH RES CO, V217, P1193, DOI 10.1006/bbrc.1995.2895; Gunn AJ, 2000, CURR OPIN PEDIATR, V12, P111, DOI 10.1097/00008480-200004000-00004; Gunn AJ, 1997, J CLIN INVEST, V99, P248, DOI 10.1172/JCI119153; Gunn AJ, 1998, PEDIATRICS, V102, P885, DOI 10.1542/peds.102.4.885; Haaland K, 1997, PEDIATR RES, V41, P505, DOI 10.1203/00006450-199704000-00009; Holzer M, 2002, NEW ENGL J MED, V346, P549; HONZIK MP, 1976, ORIGINS INTELLIGENCE, P46; Nedelcu J, 2000, BRAIN PATHOL, V10, P61; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; ROBERTSON CMT, 1989, J PEDIATR-US, V114, P753, DOI 10.1016/S0022-3476(89)80132-5; ROTH SC, 1992, DEV MED CHILD NEUROL, V34, P285; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; SCHUBERT A, 1995, J NEUROSURG ANESTH, V7, P139, DOI 10.1097/00008506-199504000-00021; Shalak LF, 2003, PEDIATRICS, V111, P351, DOI 10.1542/peds.111.2.351; Shankaran S, 2002, PEDIATRICS, V110, P377, DOI 10.1542/peds.110.2.377; Sirimanne ES, 1996, PEDIATR RES, V39, P591, DOI 10.1203/00006450-199604000-00005; Thoresen M, 2000, PEDIATRICS, V106, P92, DOI 10.1542/peds.106.1.92; THORESEN M, 1995, PEDIATR RES, V37, P667, DOI 10.1203/00006450-199505000-00019; Tooley JR, 2003, ANN NEUROL, V53, P65, DOI 10.1002/ana.10402; Wagner BP, 2002, PEDIATR RES, V51, P354, DOI 10.1203/00006450-200203000-00015	30	1560	1637	2	66	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 19	2005	365	9460					663	670		10.1016/S0140-6736(05)17946-X	http://dx.doi.org/10.1016/S0140-6736(05)17946-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	898SP	15721471				2022-12-28	WOS:000227096800023
J	Smith, E; Delargy, M				Smith, E; Delargy, M			Locked-in syndrome	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PROGNOSIS		Natl Rehabil Hosp, Dun Laoghaire, County Dublin, Ireland		Smith, E (corresponding author), Natl Rehabil Hosp, Dun Laoghaire, County Dublin, Ireland.	eimear.smith@nrh.ic						Allain P, 1998, CORTEX, V34, P629, DOI 10.1016/S0010-9452(08)70520-3; ANDERSON C, 1993, LANCET, V342, P867, DOI 10.1016/0140-6736(93)92728-C; BAUER G, 1979, J NEUROL, V221, P77, DOI 10.1007/BF00313105; Casanova E, 2003, ARCH PHYS MED REHAB, V84, P862, DOI 10.1016/S0003-9993(03)00008-X; Chua KSG, 1996, ARCH PHYS MED REHAB, V77, P194, DOI 10.1016/S0003-9993(96)90167-7; Doble JE, 2003, J HEAD TRAUMA REHAB, V18, P435, DOI 10.1097/00001199-200309000-00005; FISHBURN MJ, 1990, ARCH PHYS MED REHAB, V71, P197; Garrard P, 2002, J NEUROL NEUROSUR PS, V73, P191, DOI 10.1136/jnnp.73.2.191; HAIG AJ, 1987, ARCH PHYS MED REHAB, V68, P24; KATZ RT, 1992, ARCH PHYS MED REHAB, V73, P403; KHURANA RK, 1980, ANN NEUROL, V8, P439, DOI 10.1002/ana.410080418; Leon-Carrion J, 2002, BRAIN INJURY, V16, P571, DOI 10.1080/02699050110119781; PATTERSON JR, 1986, STROKE, V17, P758, DOI 10.1161/01.STR.17.4.758; Plum F, 1966, DIAGNOSIS STUPOR COM, V1st; RICHARD I, 1995, PARAPLEGIA, V33, P640, DOI 10.1038/sc.1995.135; Soderholm S, 2001, J REHABIL MED, V33, P235; WU Y, 1985, ARCH PHYS MED REHAB, V66, P827; Zeman A., 2003, ADV CLIN NEUROSCI RE, V3, P12	18	203	204	0	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 19	2005	330	7488					406	409		10.1136/bmj.330.7488.406	http://dx.doi.org/10.1136/bmj.330.7488.406			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900NA	15718541	Green Published			2022-12-28	WOS:000227220400023
J	Diehl, RA				Diehl, RA			Archaeology - Patterns of cultural primacy	SCIENCE			English	Editorial Material									Univ Alabama, Dept Anthropol, Tuscaloosa, AL 35487 USA	University of Alabama System; University of Alabama Tuscaloosa	Diehl, RA (corresponding author), Univ Alabama, Dept Anthropol, Tuscaloosa, AL 35487 USA.	rdiehl@bama.ua.edu						Blomster JP, 2005, SCIENCE, V307, P1068, DOI 10.1126/science.1107599; Clark John E., 2000, OLMEC ART ARCHAEOLOG, P217; COE MD, 1967, SCIENCE, V155, P1399, DOI 10.1126/science.155.3768.1399; Coe MichaelD, 1989, REGIONAL PERSPECTIVE, P68; Cyphers Ann, 1997, POBLACION SUBSISTENC, P255; Demarest Arthur A., 1989, REGIONAL PERSPECTIVE, P303; DIEHL RA, 2004, OLMECS AM 1 CIVILIZA, P29; Diehl RA., 1995, OLMEC WORLD RITUAL R, P11; DIEHL RA, 2004, OLMECS AM 1 CIVILIZA, P126; Flannery KV, 2000, J ANTHROPOL ARCHAEOL, V19, P1, DOI 10.1006/jaar.1999.0359; Grove David C., 1989, REGIONAL PERSPECTIVE, P8; Wicke C. R., 1971, OLMEC EARLY ART STYL	12	6	6	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	2005	307	5712					1055	1056		10.1126/science.1109441	http://dx.doi.org/10.1126/science.1109441			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	900ED	15718456				2022-12-28	WOS:000227197300031
J	Grossman, HB; Messing, E; Soloway, M; Tomera, K; Katz, G; Berger, Y; Shen, Y				Grossman, HB; Messing, E; Soloway, M; Tomera, K; Katz, G; Berger, Y; Shen, Y			Detection of bladder cancer using a point-of-care proteomic assay	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROSTATE-SPECIFIC ANTIGEN; ASYMPTOMATIC MICROSCOPIC HEMATURIA; AMERICAN-UROLOGICAL-ASSOCIATION; TRANSITIONAL-CELL CARCINOMA; NUCLEAR MATRIX; 5-AMINOLEVULINIC ACID; PRACTICE POLICY; URINE CYTOLOGY; SCREENING-TEST; GOLD STANDARD	Context A combination of methods is used for diagnosis of bladder cancer because no single procedure detects all malignancies. Urine tests are frequently part of an evaluation, but have either been nonspecific for cancer or required specialized analysis at a laboratory. Objective To investigate whether a point-of-care proteomic test that measures the nuclear matrix protein NMP22 in voided urine could enhance detection of malignancy in patients with risk factors or symptoms of bladder cancer. Design, Setting, and Patients Twenty-three academic, private practice, and veterans' facilities in 10 states prospectively enrolled consecutive patients from September 2001 to May 2002. Participants included 1331 patients at elevated risk for bladder cancer due to factors such as history of smoking or symptoms including hematuria and dysuria. Patients at risk for malignancy of the urinary tract provided a voided urine sample for analysis of NMP22 protein and cytology prior to cystoscopy. Main Outcome Measures The diagnosis of bladder cancer, based on cystoscopy with biopsy, was accepted as the reference standard. The performance of the NMP22 test was compared with voided urine cytology as an aid to cancer detection. Testing for the NMP22 tumor marker was conducted in a blinded manner. Results Bladder cancer was diagnosed in 79 patients. The NMP22 assay was positive in 44 of 79 patients with cancer (sensitivity, 55.7%; 95% confidence interval [CI], 44.1%-66.7%), whereas cytology test results were positive in 12 of 76 patients (sensitivity, 15.8%; 95% Cl, 7.6%-24.0%). The specificity of the NMP22 assay was 85.7% (95% Cl, 83.8%-87.6%) compared with 99.2% (95% Cl, 98.7%-99.7%) for cytology. The proteomic marker detected 4 cancers that were not visualized during initial endoscopy, including 3 that were muscle invasive and 1 carcinoma in situ. Conclusion The noninvasive point-of-care assay for elevated urinary NMP22 protein can increase the accuracy of cystoscopy, with test results available during the patient visit.	Univ Texas, MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA; Univ Rochester, Med Ctr, Dept Urol, Rochester, NY 14642 USA; Univ Miami, Sch Med, Dept Urol, Miami, FL USA; Alaska Clin Res Ctr, Anchorage, AK USA; Lake City Vet Adm Hosp, Dept Surg, Urol Serv, Manitowoc, WI USA; LakeShore Urol, Manitowoc, WI USA; Associates Urol, W Orange, NJ USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Rochester; University of Miami	Grossman, HB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Urol, 1515 Holcombe Blvd,Unit 446, Houston, TX 77030 USA.	HBGrossman@mdanderson.org		tomera, kevin/0000-0001-5991-1157; Shen, Yu/0000-0002-3899-7868				*AM JOINT COMM CAN, 1997, CANC STAG MAN; American Cancer Society, OV BLADD CANC; ANDRIOLE GL, 1993, UROL CLIN N AM, V20, P647; Arcangeli CG, 1997, UROL CLIN N AM, V24, P299, DOI 10.1016/S0094-0143(05)70376-1; BADALAMENT RA, 1987, CANCER, V60, P1423, DOI 10.1002/1097-0142(19871001)60:7<1423::AID-CNCR2820600702>3.0.CO;2-6; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BRAWER MK, 1992, J UROLOGY, V147, P841, DOI 10.1016/S0022-5347(17)37401-3; BRITTON JP, 1992, J UROLOGY, V148, P788, DOI 10.1016/S0022-5347(17)36720-4; Brown FM, 2000, UROL CLIN N AM, V27, P25, DOI 10.1016/S0094-0143(05)70231-7; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; Cohen RA, 2003, NEW ENGL J MED, V348, P2330, DOI 10.1056/NEJMcp012694; *CTR MED MED SERV, PHYS FEE SCHED PAYM; Durkalski VL, 2003, STAT MED, V22, P2417, DOI 10.1002/sim.1438; FARROW GM, 1990, J OCCUP ENVIRON MED, V32, P817, DOI 10.1097/00043764-199009000-00012; FEY EG, 1986, J CELL BIOL, V102, P1654, DOI 10.1083/jcb.102.5.1654; Frimberger D, 2000, Semin Urol Oncol, V18, P264; Grossfeld GD, 2001, UROLOGY, V57, P604, DOI 10.1016/S0090-4295(01)00920-7; Grossfeld GD, 2001, UROLOGY, V57, P599, DOI 10.1016/S0090-4295(01)00919-0; HENEY NM, 1983, J UROLOGY, V130, P1083, DOI 10.1016/S0022-5347(17)51695-X; HOLMANG S, 1995, J UROLOGY, V153, P1823, DOI 10.1016/S0022-5347(01)67321-X; HUDSON MA, 1995, J UROLOGY, V153, P564, DOI 10.1016/S0022-5347(01)67650-X; Khadra MH, 2000, J UROLOGY, V163, P524, DOI 10.1016/S0022-5347(05)67916-5; Kriegmair M, 1996, J UROLOGY, V155, P105, DOI 10.1016/S0022-5347(01)66559-5; KUMARASIRI MH, 1986, J BIOL CHEM, V261, P2844; Lerner SP, 2000, COMPREHENSIVE TXB GE, P425; LYDERSEN BK, 1980, CELL, V22, P489, DOI 10.1016/0092-8674(80)90359-1; MARIANI AJ, 1989, J UROLOGY, V141, P350, DOI 10.1016/S0022-5347(17)40763-4; MESSING EM, 1990, J OCCUP ENVIRON MED, V32, P838, DOI 10.1097/00043764-199009000-00016; MESSING EM, 1989, CANCER, V64, P2361, DOI 10.1002/1097-0142(19891201)64:11<2361::AID-CNCR2820641128>3.0.CO;2-4; MILLER TE, 1992, CANCER RES, V52, P422; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; National Cancer Institute, GEN INF BLADD CANC; PARDOLL DM, 1980, CELL, V19, P527, DOI 10.1016/0092-8674(80)90527-9; PARTIN AW, 1993, CANCER RES, V53, P744; Schneeweiss S, 1999, J UROLOGY, V161, P1116, DOI 10.1016/S0022-5347(01)61605-7; Soloway MS, 1996, J UROLOGY, V156, P363, DOI 10.1016/S0022-5347(01)65851-8; Zaak D, 2001, UROLOGY, V57, P690, DOI 10.1016/S0090-4295(00)01053-0; ZEITLIN S, 1987, MOL CELL BIOL, V7, P111, DOI 10.1128/MCB.7.1.111	39	265	277	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	2005	293	7					810	816		10.1001/jama.293.7.810	http://dx.doi.org/10.1001/jama.293.7.810			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DQ	15713770				2022-12-28	WOS:000226984600022
J	Fazio, N; Spaggiari, L; Pelosi, G; Presicci, F; Preda, L				Fazio, N; Spaggiari, L; Pelosi, G; Presicci, F; Preda, L			Langerhans' cell histiocytosis	LANCET			English	Editorial Material									European Inst Oncol, I-20141 Milan, Italy	IRCCS European Institute of Oncology (IEO)	Fazio, N (corresponding author), European Inst Oncol, I-20141 Milan, Italy.	nicola.fazio@ieo.it	Spaggiari, Lorenzo/G-7915-2012; PREDA, LORENZO/AAC-1969-2019; Pelosi, Giuseppe/F-5073-2012	PREDA, LORENZO/0000-0002-5479-2766; Spaggiari, Lorenzo/0000-0002-1068-3541; Pelosi, Giuseppe/0000-0003-4725-4692; fazio, nicola/0000-0001-6869-0704					0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 12	2005	365	9459					598	598						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DN	15708104				2022-12-28	WOS:000226984300033
J	Paltiel, AD; Weinstein, MC; Kimmel, AD; Seage, GR; Losina, E; Zhang, H; Freedberg, KA; Walensky, RP				Paltiel, AD; Weinstein, MC; Kimmel, AD; Seage, GR; Losina, E; Zhang, H; Freedberg, KA; Walensky, RP			Expanded screening for HIV in the United States - An analysis of cost-effectiveness	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PLUS INDINAVIR; CELL COUNTS; INFECTION; VACCINE; TRIALS; CARE; SEX	BACKGROUND: Although the Centers for Disease Control and Prevention (CDC) recommend routine HIV counseling, testing, and referral (HIVCTR) in settings with at least a 1 percent prevalence of HIV, roughly 280,000 Americans are unaware of their human immunodeficiency virus (HIV) infection. The effect of expanded screening for HIV is unknown in the era of effective antiretroviral therapy. METHODS: We developed a computer simulation model of HIV screening and treatment to compare routine, voluntary HIVCTR with current practice in three target populations: ``high-risk'' (3.0 percent prevalence of undiagnosed HIV infection; 1.2 percent annual incidence); ``CDC threshold'' (1.0 percent and 0.12 percent, respectively); and ``U.S. general'' (0.1 percent and 0.01 percent). Input data were derived from clinical trials and observational cohorts. Outcomes included quality-adjusted survival, cost, and cost-effectiveness. RESULTS: In the high-risk population, the addition of one-time screening for HIV antibodies with an enzyme-linked immunosorbent assay (ELISA) to current practice was associated with earlier diagnosis of HIV (mean CD4 cell count at diagnosis, 210 vs. 154 per cubic millimeter). One-time screening also improved average survival time among HIV-infected patients (quality-adjusted survival, 220.7 months vs. 219.8 months). The incremental cost-effectiveness was $36,000 per quality-adjusted life-year gained. Testing every five years cost $50,000 per quality-adjusted life-year gained, and testing every three years cost $63,000 per quality-adjusted life-year gained. In the CDC threshold population, the cost-effectiveness ratio for one-time screening with ELISA was $38,000 per quality-adjusted life-year gained, whereas testing every five years cost $71,000 per quality-adjusted life-year gained, and testing every three years cost $85,000 per quality-adjusted life-year gained. In the U.S. general population, one-time screening cost $113,000 per quality-adjusted life-year gained. CONCLUSIONS: In all but the lowest-risk populations, routine, voluntary screening for HIV once every three to five years is justified on both clinical and cost-effectiveness grounds. One-time screening in the general population may also be cost-effective.	Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Risk Anal, Boston, MA 02115 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gen Med, Boston, MA USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Partners AIDS Res Ctr,Dept Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; Brigham & Womens Hosp, Dept Med, Div Infect Dis, Boston, MA 02115 USA	Yale University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Boston University; Boston University; Harvard University; Brigham & Women's Hospital	Paltiel, AD (corresponding author), Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, 60 Coll St, New Haven, CT 06520 USA.	david.paltiel@yale.edu		Walensky, Rochelle P./0000-0002-8795-379X; Losina, ELENA/0000-0002-3424-0892; Paltiel, A. David/0000-0002-4861-3290	NIAID NIH HHS [K23AI01794, K24 AI062476, K24AI062476, K25AI50436, R01AI42006, P30 AI042851, K25 AI050436, P30AI42851, R01 AI042006, K23 AI001794] Funding Source: Medline; NIDA NIH HHS [R01DA015612, R01 DA015612] Funding Source: Medline; NIMH NIH HHS [R01 MH065869] Funding Source: Medline; PHS HHS [S1396-20/21] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI001794, R01AI042006, K24AI062476, K25AI050436, P30AI042851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH065869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015612, R37DA015612] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Centers of Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; Baxter JD, 2000, AIDS, V14, pF83, DOI 10.1097/00002030-200006160-00001; Bos JM, 2002, AIDS, V16, P1185, DOI 10.1097/00002030-200205240-00015; Bozzette SA, 1998, NEW ENGL J MED, V339, P1897, DOI 10.1056/NEJM199812243392606; CAMPSMITH M, 2001, 2001 NAT HIV PREV C; *CDCP, HIV AIDS UPD GLANC H; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P329; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P1051; *DEP HLTH HUM SERV, GUID US ANT AG HIV I; DIGUISEPPI C, 1996, GUIDE CLIN PREVENTIV; Dybul M, 2002, J INFECT DIS, V185, P1818, DOI 10.1086/340650; Ekwueme DU, 2003, AM J PREV MED, V25, P112, DOI 10.1016/S0749-3797(03)00115-6; Farnham PG, 1996, PUBLIC HEALTH REP, V111, P44; Fleming PL, 2000, AM J PUBLIC HEALTH, V90, P1037, DOI 10.2105/AJPH.90.7.1037; Freedberg KA, 1999, ARCH INTERN MED, V159, P1994, DOI 10.1001/archinte.159.17.1994; Freedberg KA, 2001, NEW ENGL J MED, V344, P824, DOI 10.1056/NEJM200103153441108; Gold MR, 1996, COST EFFECTIVENESS H; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; *HARV CTR RISK AN, COST UT AN PUBL 1976; Kaplan Jonathan E, 2002, MMWR Recomm Rep, V51, P1; *MACS, 1995, MACS PUBL DAT REL PO; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Mylonakis E, 2000, AM J MED, V109, P568, DOI 10.1016/S0002-9343(00)00583-0; *NAT TECHN INF SER, 1992, AIDS COST SERV UT SU; *NIH HLTH RES SERV, 2004, MMWR RECOMM REP, V53, P744; *NIH HLTH RES SERV, 2003, MMWR RECOMM REP, V52, P1; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Schackman BR, 2002, MED DECIS MAKING, V22, P27, DOI 10.1177/02729890222062892; Seage GR, 2001, AM J EPIDEMIOL, V153, P619, DOI 10.1093/aje/153.7.619; Sheon AR, 1998, J ACQ IMMUN DEF SYND, V19, P519, DOI 10.1097/00042560-199812150-00012; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; U.S. Census Bureau, 2002, STAT ABSTR US; Walensky RP, 2005, AM J PUBLIC HEALTH, V95, P71, DOI 10.2105/AJPH.2003.031310; Webster RD, 2003, JAIDS-J ACQ IMM DEF, V33, P223, DOI 10.1097/00126334-200306010-00018; Zaric GS, 2000, J ACQ IMMUN DEF SYND, V25, P403, DOI 10.1097/00126334-200012150-00004; 1998, MMWR MORB MORTAL WKL, V47, P211	36	429	437	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2005	352	6					586	595		10.1056/NEJMsa042088	http://dx.doi.org/10.1056/NEJMsa042088			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	895KY	15703423				2022-12-28	WOS:000226862100008
J	Saitz, R				Saitz, R			Unhealthy alcohol use	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLACEBO-CONTROLLED TRIAL; BEHAVIORAL-COUNSELING INTERVENTIONS; NATIONAL EPIDEMIOLOGIC SURVEY; RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE; UNITED-STATES; USE DISORDERS; DOUBLE-BLIND; PROBLEM DRINKERS; RELAPSE PREVENTION		Boston Med Ctr, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Clin Addict Res & Educ Unit,Sect Gen Internal Med, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Youth Alcohol Prevent Ctr, Boston, MA USA; Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA	Boston Medical Center; Boston University; Boston University; Boston University	Saitz, R (corresponding author), Boston Med Ctr, 91 E Concord St 200, Boston, MA 02118 USA.	rsaitz@bu.edu		/0000-0002-2535-1427	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K30HL004124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P60AA013759, R01AA012617] Funding Source: NIH RePORTER; NHLBI NIH HHS [K30 HL04124] Funding Source: Medline; NIAAA NIH HHS [R-01 AA12617, P60 AA013759] Funding Source: Medline; PHS HHS [R-01 13216, R-25 13822, 04-3314093, R-01 13304] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Allen J, 1997, ADDICTION, V92, P1671; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Angelone SM, 1998, ALCOHOL ALCOHOLISM, V33, P151; *ASAM, 2001, PAT PLAC CRIT TREATM; AZRIN NH, 1982, J BEHAV THER EXP PSY, V13, P105, DOI 10.1016/0005-7916(82)90050-7; Beich A, 2003, BMJ-BRIT MED J, V327, P536, DOI 10.1136/bmj.327.7414.536; Berg AO, 2004, ANN INTERN MED, V140, P554, DOI 10.7326/0003-4819-140-7-200404060-00016; Bradley KA, 2003, ARCH INTERN MED, V163, P821, DOI 10.1001/archinte.163.7.821; Carmen B, 2004, ADDICTION, V99, P811, DOI 10.1111/j.1360-0443.2004.00763.x; CHICK J, 1992, BRIT J PSYCHIAT, V161, P84, DOI 10.1192/bjp.161.1.84; Committee on Treatment of Alcohol Problems, 1990, BROAD BAS TREATM ALC; Cornelius JR, 1997, ARCH GEN PSYCHIAT, V54, P700; D'Onofrio G, 1998, ACAD EMERG MED, V5, P1200, DOI 10.1111/j.1553-2712.1998.tb02696.x; DiClemente C.C., 2002, MOTIVATIONAL INTERVI, V2nd ed., P201; Fiellin DA, 2000, ARCH INTERN MED, V160, P1977, DOI 10.1001/archinte.160.13.1977; Fleming MF, 2002, ALCOHOL CLIN EXP RES, V26, P36, DOI 10.1111/j.1530-0277.2002.tb02429.x; Friedmann PD, 2001, J STUD ALCOHOL, V62, P234, DOI 10.15288/jsa.2001.62.234; Friedmann PD, 1998, JAMA-J AM MED ASSOC, V279, P1227, DOI 10.1001/jama.279.15.1227; Garbutt JC, 1999, JAMA-J AM MED ASSOC, V281, P1318, DOI 10.1001/jama.281.14.1318; Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI 10.1001/archpsyc.61.8.807; Grant BF, 2004, DRUG ALCOHOL DEPEN, V74, P223, DOI 10.1016/j.drugalcdep.2004.02.004; Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P361, DOI 10.1001/archpsyc.61.4.361; Harwood H. J., 2000, UPDATING ESTIMATES E; HEATHER N, 1990, BRIT J ADDICT, V85, P1177; Heinala P, 2001, J CLIN PSYCHOPHARM, V21, P287, DOI 10.1097/00004714-200106000-00006; HORVATH AT, 1997, SUBSTANCE ABUSE COMP, P390; ISBELL H, 1955, Q J STUD ALCOHOL, V16, P1; Johnson BA, 2000, JAMA-J AM MED ASSOC, V284, P963, DOI 10.1001/jama.284.8.963; Johnson BA, 2003, LANCET, V361, P1677, DOI 10.1016/S0140-6736(03)13370-3; Kadden R.M., 1995, COGNITIVE BEHAV COPI, V3; Kiefer F, 2003, ARCH GEN PSYCHIAT, V60, P92, DOI 10.1001/archpsyc.60.1.92; Kranzler HR, 2004, ALCOHOL CLIN EXP RES, V28, P1051, DOI 10.1097/01.ALC.0000130804.08397.29; Kranzler HR, 2003, J CLIN PSYCHOPHARM, V23, P294, DOI 10.1097/00004714-200306000-00010; KRANZLER HR, 1994, ARCH GEN PSYCHIAT, V51, P720; Kristenson H, 2002, ALCOHOL CLIN EXP RES, V26, P478, DOI 10.1097/00000374-200204000-00007; Krystal JH, 2001, NEW ENGL J MED, V345, P1734, DOI 10.1056/NEJMoa011127; Li TK, 2004, BIOL PSYCHIAT, V56, P718, DOI 10.1016/j.biopsych.2004.03.006; Mason BJ, 1996, JAMA-J AM MED ASSOC, V275, P761, DOI 10.1001/jama.275.10.761; MayoSmith MF, 1997, JAMA-J AM MED ASSOC, V278, P144, DOI 10.1001/jama.278.2.144; Miller WR, 2001, J STUD ALCOHOL, V62, P211, DOI 10.15288/jsa.2001.62.211; Miller WR, 1999, J CONSULT CLIN PSYCH, V67, P688, DOI 10.1037/0022-006X.67.5.688; MILLER WR, 1980, ADDICT BEHAV, V5, P13, DOI 10.1016/0306-4603(80)90017-9; Miller WR, 1995, PROJECT MATCH MONOGR, V2; Mokdad AH, 2004, JAMA-J AM MED ASSOC, V291, P1238, DOI 10.1001/jama.291.10.1238; MONTGOMERY HA, 1995, J SUBST ABUSE TREAT, V12, P241, DOI 10.1016/0740-5472(95)00018-Z; Moyer A, 2002, ADDICTION, V97, P279, DOI 10.1046/j.1360-0443.2002.00018.x; National Institute on Alcohol Abuse and Alcoholism, 2003, NIH PUBL; NOWINSKI J, 1995, PROJECT MATCH MONOGR, V1; O'Malley SS, 2003, ARCH INTERN MED, V163, P1695, DOI 10.1001/archinte.163.14.1695; Ouimette PC, 1997, J CONSULT CLIN PSYCH, V65, P230, DOI 10.1037/0022-006X.65.2.230; Rollnick S., 1999, HLTH BEHAV CHANGE GU, V1st; SAITZ R, 2003, PRINCIPLES ADDICTION, P1027; SOBELL MB, 1995, ADDICTION, V90, P1149, DOI 10.1111/j.1360-0443.1995.tb01077.x; Vaillant GE, 2003, ADDICTION, V98, P1043, DOI 10.1046/j.1360-0443.2003.00422.x; WALSH DC, 1991, NEW ENGL J MED, V325, P775, DOI 10.1056/NEJM199109123251105; White IR, 2004, ADDICTION, V99, P749, DOI 10.1111/j.1360-0443.2004.00710.x; Whitlock EP, 2004, ANN INTERN MED, V140, P557, DOI 10.7326/0003-4819-140-7-200404060-00017; Williams R, 2001, J FAM PRACTICE, V50, P307; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; World Health Organization, LEX ALC DRUG TERMS P; Wutzke SE, 2001, SOC SCI MED, V52, P863, DOI 10.1016/S0277-9536(00)00189-1	61	393	402	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2005	352	6					596	607		10.1056/NEJMcp042262	http://dx.doi.org/10.1056/NEJMcp042262			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	895KY	15703424				2022-12-28	WOS:000226862100009
J	Crain, JN; Pierce, DT				Crain, JN; Pierce, DT			End states in one-dimensional atom chains	SCIENCE			English	Article							SURFACE; CONFINEMENT; ELECTRONS; SPIN; WAVE	End states-the zero-dimensional analogs of the two-dimensional states that occur at a crystal surface-were observed at the ends of one-dimensional atom chains that were self-assembled by depositing gold on the vicinal Si(553) surface. Scanning tunneling spectroscopy measurements of the differential conductance along the chains revealed quantized states in isolated segments with differentiated states forming over end atoms. A comparison to a tight-binding model demonstrated how the formation of electronic end states transforms the density of states and the energy levels within the chains.	Natl Inst Stand & Technol, Electron Phys Grp, Gaithersburg, MD 20899 USA	National Institute of Standards & Technology (NIST) - USA	Crain, JN (corresponding author), Natl Inst Stand & Technol, Electron Phys Grp, Gaithersburg, MD 20899 USA.	jason.crain@nist.gov						Ahn JR, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.196403; Altmann KN, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.035406; Bischoff MMJ, 2002, SURF SCI, V501, P155, DOI 10.1016/S0039-6028(01)01946-X; Bollinger MV, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.196803; Burgi L, 1998, PHYS REV LETT, V81, P5370, DOI 10.1103/PhysRevLett.81.5370; Crain JN, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.125401; Crain JN, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.176805; CROMMIE MF, 1993, NATURE, V363, P524, DOI 10.1038/363524a0; CROMMIE MF, 1993, SCIENCE, V262, P218, DOI 10.1126/science.262.5131.218; Davison S.G., 1992, BASIC THEORY SURFACE; Folsch S, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.056803; HASEGAWA Y, 1993, PHYS REV LETT, V71, P1071, DOI 10.1103/PhysRevLett.71.1071; Losio R, 2001, PHYS REV LETT, V86, P4632, DOI 10.1103/PhysRevLett.86.4632; Nilius N, 2002, SCIENCE, V297, P1853, DOI 10.1126/science.1075242; Peierls R.F., 1955, QUANTUM THEORY SOLID; Repp J, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.036803; Wallis TM, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.236802; Yeom HW, 1999, PHYS REV LETT, V82, P4898, DOI 10.1103/PhysRevLett.82.4898; Yoon HS, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.096801; Zangwill A., 1988, PHYS SURFACES	21	154	155	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2005	307	5710					703	706		10.1126/science.1106911	http://dx.doi.org/10.1126/science.1106911			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	894TQ	15692047				2022-12-28	WOS:000226814900037
J	Butland, G; Peregrin-Alvarez, JM; Li, J; Yang, WH; Yang, XC; Canadien, V; Starostine, A; Richards, D; Beattie, B; Krogan, N; Davey, M; Parkinson, J; Greenblatt, J; Emili, A				Butland, G; Peregrin-Alvarez, JM; Li, J; Yang, WH; Yang, XC; Canadien, V; Starostine, A; Richards, D; Beattie, B; Krogan, N; Davey, M; Parkinson, J; Greenblatt, J; Emili, A			Interaction network containing conserved and essential protein complexes in Escherichia coli	NATURE			English	Article							PHYLOGENETIC PROFILES; FUNCTIONAL LINKAGES; SIMPLE DEPENDENCE; EVOLUTION RATE; DATABASE; DNA; IDENTIFICATION; DISCOVERY; SYSTEM; NUMBER	Proteins often function as components of multi-subunit complexes. Despite its long history as a model organism(1), no large-scale analysis of protein complexes in Escherichia coli has yet been reported. To this end, we have targeted DNA cassettes into the E. coli chromosome to create carboxy-terminal, affinity-tagged alleles of 1,000 open reading frames (similar to23% of the genome). A total of 857 proteins, including 198 of the most highly conserved, soluble non-ribosomal proteins essential in at least one bacterial species, were tagged successfully, whereas 648 could be purified to homogeneity and their interacting protein partners identified by mass spectrometry. An interaction network of protein complexes involved in diverse biological processes was uncovered and validated by sequential rounds of tagging and purification. This network includes many new interactions as well as interactions predicted based solely on genomic inference or limited phenotypic data(2). This study provides insight into the function of previously uncharacterized bacterial proteins and the overall topology of a microbial interaction network, the core components of which are broadly conserved across Prokaryota.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Hosp Sick Children, Toronto, ON M4K 1X8, Canada; Affinium Pharmaceut, Toronto, ON M5J 1V6, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Greenblatt, J (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.	jack.greenblatte@utoronto.ca; andrew.emili@utoronto.ca	Parkinson, John/A-4424-2008	Parkinson, John/0000-0001-9815-1189; Davey, Michael/0000-0002-1172-5934; Alvarez, Jose/0000-0002-7184-832X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bader GD, 2003, NUCLEIC ACIDS RES, V31, P248, DOI 10.1093/nar/gkg056; Bowers PM, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-r35; Date SV, 2003, NAT BIOTECHNOL, V21, P1055, DOI 10.1038/nbt861; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Fraser HB, 2003, BMC EVOL BIOL, V3, DOI 10.1186/1471-2148-3-11; Gully D, 2003, FEBS LETT, V548, P90, DOI 10.1016/S0014-5793(03)00746-4; Harmon FG, 2003, J BIOL CHEM, V278, P42668, DOI 10.1074/jbc.M302994200; Haselbeck R, 2002, CURR PHARM DESIGN, V8, P1155, DOI 10.2174/1381612023394818; Jordan IK, 2003, BMC EVOL BIOL, V3, DOI 10.1186/1471-2148-3-1; Kadner R. J., 1996, ESCHERICHIA COLI SAL, V2nd; Krogan NJ, 2004, MOL CELL, V13, P225, DOI 10.1016/S1097-2765(04)00003-6; Nakayama H, 2002, ONCOGENE, V21, P9008, DOI 10.1038/sj.onc.1205959; Overbeek R, 1999, P NATL ACAD SCI USA, V96, P2896, DOI 10.1073/pnas.96.6.2896; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; Peregrin-Alvarez JM, 2003, GENOME RES, V13, P422, DOI 10.1101/gr.246903; Rain JC, 2001, NATURE, V409, P211, DOI 10.1038/35051615; Salwinski L, 2004, NUCLEIC ACIDS RES, V32, pD449, DOI 10.1093/nar/gkh086; SERRES MH, 2001, GENOME BIOL, V2, P7; STUKENBERG PT, 1995, J BIOL CHEM, V270, P13384, DOI 10.1074/jbc.270.22.13384; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034; Witte G, 2003, NUCLEIC ACIDS RES, V31, P4434, DOI 10.1093/nar/gkg498; Wu J, 2003, BIOINFORMATICS, V19, P1524, DOI 10.1093/bioinformatics/btg187; Wuchty S, 2003, NAT GENET, V35, P176, DOI 10.1038/ng1242; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; Yu HY, 2004, GENOME RES, V14, P1107, DOI 10.1101/gr.1774904; Zeghouf M, 2004, J PROTEOME RES, V3, P463, DOI 10.1021/pr034084x; [No title captured]	30	887	922	0	93	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 3	2005	433	7025					531	537		10.1038/nature03239	http://dx.doi.org/10.1038/nature03239			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893NT	15690043				2022-12-28	WOS:000226727200051
J	Greenberg, RN; Kennedy, JS; Clanton, D; Plummer, EA; Hague, L; Cruz, J; Ennis, FA; Blackwelder, WC; Hopkins, RJ				Greenberg, RN; Kennedy, JS; Clanton, D; Plummer, EA; Hague, L; Cruz, J; Ennis, FA; Blackwelder, WC; Hopkins, RJ			Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial	LANCET			English	Article							RESPONSES	Background US government organisations have identified the need for a new smallpox vaccine to replenish limited stocks of the approved, calf-lymph derived vaccine, the manufacture of which is no longer acceptable. We aimed to compare the safety and immunogenicity of the new cell-cultured smallpox vaccine (CCSV) to that of the calf-lymph derived vaccine (as a positive control) in 350 healthy, adult volunteers. Methods We did a randomised controlled study at the University of Kentucky Medical Center. We randomised 150 vaccinia-naive volunteers, aged 18-30 years, and 100 vaccinia-non-naive people, aged 32-65 years, to equivalent doses of either CCSV or test vaccine (2.5x10(5) plaque-forming units) by 15 puncture scarification in double-blind fashion. Immunogenicity was assessed by pock formation (take rate), humoral immune response by plaque-reduction neutralisation titres, and cellular immune response by vaccinia-specific, interferon-gamma T-cell quantification, cytotoxicity, and T-cell proliferation response. A further 100 vaccine-naive individuals, aged 18-30 years, received one of five doses of CCSV (undiluted, diluted 1 in 5, 1 in 10, 1 in 25, and 1 in 50) in single-blind fashion. Routine laboratory assessments, physical examinations, and recording of adverse events were done to assess vaccine safety. The primary endpoints were safety and reactogenicity (take rate) of CCSV. Findings 349 (99.7%) of 350 volunteers developed pock lesions; one vaccinia-naive individual who received a 1 in 25 dilution of CCSV did not. The rate of adverse events related to vaccine and the extent of humoral and cellular immune responses did not differ between the vaccine groups in vaccinia-naive or non-naive people. CCSV was immunogenic in vaccine-naive volunteers at a dose 50 times lower than that approved for Dryvax. Interpretation CCSV seems to be a safe and immunogenic alternative to calf-lymph derived vaccine for both vaccinia-naive and non-naive people.	Univ Kentucky, Med Ctr, Dept Med, Lexington, KY 40536 USA; Dept Vet Affairs Med Ctr, Med Serv, Lexington, KY USA; Univ Massachusetts, Sch Med, Ctr Infect Dis & Vaccine Res, Worcester, MA USA; DynPort Vaccine Co, Frederick, MD USA; Biol Consulting Grp, Alexandria, VA USA	University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center; University of Massachusetts System; University of Massachusetts Worcester	Greenberg, RN (corresponding author), Univ Kentucky, Med Ctr, Dept Med, 800 Rose St, Lexington, KY 40536 USA.	RNgree0l@uky.edu						Centers of Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; COSTER T, 2003, ASM BIOD M; Demkowicz WE, 1996, J VIROL, V70, P2627, DOI 10.1128/JVI.70.4.2627-2631.1996; Ennis FA, 2002, J INFECT DIS, V185, P1657, DOI 10.1086/340517; Frey SE, 2002, NEW ENGL J MED, V346, P1265, DOI 10.1056/NEJMoa020534; Frey SE, 2002, NEW ENGL J MED, V346, P1275, DOI 10.1056/NEJMoa013431; Frey SE, 2003, JAMA-J AM MED ASSOC, V289, P3295, DOI 10.1001/jama.289.24.3295; Fulginiti VA, 2003, CLIN INFECT DIS, V37, P241, DOI 10.1086/375824; Greenberg RN, 2004, CLIN INFECT DIS, V38, P958, DOI 10.1086/382360; Henderson DA, 1999, JAMA-J AM MED ASSOC, V281, P2127, DOI 10.1001/jama.281.22.2127; Jahrling PB, 2000, EMERGING INFECTIONS 4, P187; McClain DJ, 1997, J INFECT DIS, V175, P756, DOI 10.1086/513968; MONATH T, 2003, PHAC VACC FOR NOV 17; PROSS HF, 1981, J CLIN IMMUNOL, V1, P51, DOI 10.1007/BF00915477; RAO AR, 1960, J INDIAN MED ASSOC, V35, P296; Weltzin R, 2003, NAT MED, V9, P1125, DOI 10.1038/nm916; *WORLD MED ASS, 2000, B MED ETHICS, V162, P9	17	44	46	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN-FEB	2005	365	9457					398	409						12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891WE	15680454				2022-12-28	WOS:000226610900026
J	Mendelow, AD; Gregson, BA; Fernandes, HM; Murray, GD; Teasdale, GM; Hope, DT; Karimi, A; Shaw, MDM; Barer, DH				Mendelow, AD; Gregson, BA; Fernandes, HM; Murray, GD; Teasdale, GM; Hope, DT; Karimi, A; Shaw, MDM; Barer, DH		STICH Investigators	Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial	LANCET			English	Article							EDEMA FORMATION; BRAIN EDEMA; BLOOD; CLOT; RAT	Background Spontaneous supratentorial intracerebral haemorrhage accounts for 20% of all stroke-related sudden neurological deficits, has the highest morbidity and mortality of all stroke, and the role of surgery remains controversial. We undertook a prospective randomised trial to compare early surgery with initial conservative treatment for patients with intracerebral haemorrhage. Methods A parallel-group trial design was used. Early surgery combined haematoma evacuation (within 24 h of randomisation) with medical treatment. Initial conservative treatment used medical treatment, although later evacuation was allowed if necessary. We used the eight-point Glasgow outcome scale obtained by postal questionnaires sent directly to patients at 6 months follow-up as the primary outcome measure. We divided the patients into good and poor prognosis groups on the basis of their clinical status at randomisation. For the good prognosis group, a favourable outcome was defined as good recovery or moderate disability on the Glasgow outcome scale. For the poor prognosis group, a favourable outcome also included the upper level of severe disability. Analysis was by intention to treat. Findings 1033 patients from 83 centres in 27 countries were randomised to early surgery (503) or initial conservative treatment (530). At 6 months, 51 patients were lost to follow-up, and 17 were alive with unknown status. Of 468 patients randomised to early surgery, 122 (26%) had a favourable outcome compared with 118 (24%) of 496 randomised to initial conservative treatment (odds ratio 0.89 [95% CI 0.66-1.19], p=0.414); absolute benefit 2.3% (-3.2 to 7.7), relative benefit 10% (-13 to 33). Interpretation Patients with spontaneous supratentorial intracerebral haemorrhage in neurosurgical units show no overall benefit from early surgery when compared with initial conservative treatment.	Newcastle Gen Hosp, Dept Neurosurg, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England	Newcastle General Hospital	Mendelow, AD (corresponding author), Newcastle Gen Hosp, Dept Neurosurg, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.	a_d_mendelow@ncLac.uk	Mendelow, Alexander/AAW-2878-2021; Abdullah, J/C-2828-2011; Piradov, Michael A/B-4407-2012; Hankey, Graeme J/H-4968-2014; Smrcka, Martin/AAM-8872-2021	Abdullah, J/0000-0002-0258-7410; Piradov, Michael A/0000-0002-6338-0392; Hankey, Graeme J/0000-0002-6044-7328; Murray, Gordon/0000-0001-9866-4734; Goodden, John/0000-0003-1115-6310; Woebker, Gabriele/0000-0003-4429-754X; Smrcka, Martin/0000-0002-9191-8700; Gregson, Barbara/0000-0003-4868-9137; Smolanka, Volodymyr/0000-0001-7296-8297; Krivoshapkin, Alexey/0000-0003-0789-8039				Altman DG, 1996, BRIT MED J, V313, P486; [Anonymous], 1988, LANCET, V2, P349; AUER LM, 1989, J NEUROSURG, V70, P530, DOI 10.3171/jns.1989.70.4.0530; BATJER HH, 1990, ARCH NEUROL-CHICAGO, V47, P1103, DOI 10.1001/archneur.1990.00530100071015; Berge E, 2002, CEREBROVASC DIS, V13, P73, DOI 10.1159/000047752; Bhattathiri Parameswaran S, 2003, Neurosurg Focus, V15, pE6; BRODERICK JP, 1994, STROKE, V25, P1081, DOI 10.1161/str.25.5.1081b; CHEN XG, 1992, ACTA ACAD MED SHANGH, V19, P234; Dennis MS, 2003, CEREBROVASC DIS, V16, P9, DOI 10.1159/000069935; Fernandes HM, 2000, STROKE, V31, P2511, DOI 10.1161/01.STR.31.10.2511; Fernandes HM, 1999, BRIT J NEUROSURG, V13, P389; Fernandes HM, 2000, ACT NEUR S, V76, P463; Gregson BA, 2003, STROKE, V34, P2593, DOI 10.1161/01.STR.0000097491.82104.F3; Heiss WD, 2000, J CEREBR BLOOD F MET, V20, P1276, DOI 10.1097/00004647-200009000-00002; HOSSEINI H, 12 EUR STROK C 2003, P57; JUVELA S, 1989, J NEUROSURG, V70, P755, DOI 10.3171/jns.1989.70.5.0755; Kanaya H, 1992, DEV NEUROSURGICAL AP, P197; KINGMAN TA, 1987, J NEUROSURG, V67, P732, DOI 10.3171/jns.1987.67.5.0732; Lee KR, 1997, J NEUROSURG, V86, P272, DOI 10.3171/jns.1997.86.2.0272; Lee KR, 1996, J NEUROSURG, V84, P91, DOI 10.3171/jns.1996.84.1.0091; MCKISSOCK W, 1961, LANCET, V2, P221; Mendelow AD, 2003, ACTA NEUROCHIR, V145, P679, DOI 10.1007/s00701-003-0063-9; Morgenstern LB, 1998, NEUROLOGY, V51, P1359, DOI 10.1212/WNL.51.5.1359; MURRAY GD, IN PRESS J NEUROTRAU; NEHLS DG, 1990, NEUROSURGERY, V27, P674, DOI 10.1227/00006123-199011000-00002; Netten A., 2001, UNIT COSTS HLTH SOCI; Shaw MDM, 2003, LANCET, V362, P1244, DOI 10.1016/S0140-6736(03)14530-8; Siddique MS, 2002, J NEUROSURG, V96, P736, DOI 10.3171/jns.2002.96.4.0736; Teernstra OPM, 2003, STROKE, V34, P968, DOI 10.1161/01.STR.0000063367.52044.40; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Xi GH, 1998, J NEUROSURG, V89, P991, DOI 10.3171/jns.1998.89.6.0991; Xi GH, 1998, STROKE, V29, P2580, DOI 10.1161/01.STR.29.12.2580; YANG GY, 1994, ACTA NEUROCHIR, P555; Zuccarello M, 1999, STROKE, V30, P1833, DOI 10.1161/01.STR.30.9.1833; 2003, LANCET          0714; 1999, LANCET	36	1182	1267	2	70	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN-FEB	2005	365	9457					387	397						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891WE	15680453				2022-12-28	WOS:000226610900025
J	Le Gal, G; Testuz, A; Righini, M; Bounameaux, H; Perrier, A				Le Gal, G; Testuz, A; Righini, M; Bounameaux, H; Perrier, A			Reproduction of chest pain by palpation: diagnostic accuracy in suspected pulmonary embolism	BRITISH MEDICAL JOURNAL			English	Article									Brest Univ Hosp, Equipe Accueil GETBO 3878, F-29609 Brest, France; Univ Hosp Geneva, Geneva Fac Med, Dept Internal Med, Div Gen Internal Med, CH-1211 Geneva, Switzerland	CHU Brest; University of Geneva	Le Gal, G (corresponding author), Brest Univ Hosp, Equipe Accueil GETBO 3878, F-29609 Brest, France.	gregoire.legal@chu-brest.fr	Righini, Marc/AAX-8731-2020; LE GAL, Gregoire/K-1077-2012; Perrier, Arnaud/M-2263-2014	LE GAL, Gregoire/0000-0002-9253-248X				DREYFUSS AI, 1984, ARCH INTERN MED, V144, P2057, DOI 10.1001/archinte.144.10.2057; Perrier A, 2004, AM J MED, V116, P291, DOI 10.1016/j.amjmed.2003.09.041; Pope JH, 2000, NEW ENGL J MED, V342, P1163, DOI 10.1056/NEJM200004203421603; Stein PD, 1997, CHEST, V112, P974, DOI 10.1378/chest.112.4.974; Wicki J, 2001, ARCH INTERN MED, V161, P92, DOI 10.1001/archinte.161.1.92	5	17	17	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 26	2005	330	7489					452	453		10.1136/bmj.38331.602384.8F	http://dx.doi.org/10.1136/bmj.38331.602384.8F			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	901XK	15684025	Green Published, Bronze			2022-12-28	WOS:000227315400018
J	Bradshaw, GA; Schore, AN; Brown, JL; Poole, JH; Moss, CJ				Bradshaw, GA; Schore, AN; Brown, JL; Poole, JH; Moss, CJ			Elephant breakdown	NATURE			English	Article									Oregon State Univ, Environm Sci Grad Programme, Corvallis, OR 97331 USA; Oregon State Univ, Dept Forest Sci, Corvallis, OR 97331 USA; Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA; Smithsonian Natl Zool Pk, Washington, DC USA; Amboseli Elephant Res Project, Nairobi, Kenya	Oregon State University; Oregon State University; University of California System; University of California Los Angeles; Smithsonian Institution; Smithsonian National Zoological Park & Conservation Biology Institute	Bradshaw, GA (corresponding author), Oregon State Univ, Environm Sci Grad Programme, Corvallis, OR 97331 USA.							CLUBB R, 2002, REV WELFARE ELEPHANT; Schore A.N., 2003, AFFECT DYSREGULATION; Slotow R, 2000, NATURE, V408, P425, DOI 10.1038/35044191	3	106	108	3	71	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 24	2005	433	7028					807	807		10.1038/433807a	http://dx.doi.org/10.1038/433807a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	899VT	15729320	Bronze			2022-12-28	WOS:000227174600022
J	Krentz, AJ; Wheeler, DC				Krentz, AJ; Wheeler, DC			New-onset diabetes after transplantation: a threat to graft and patient survival	LANCET			English	Editorial Material							IMMUNOSUPPRESSIVE AGENTS; CALCINEURIN INHIBITORS; KIDNEY-TRANSPLANTATION; MELLITUS; DISEASE; OBESITY		Univ Calif San Diego, Dept Family & Prevent Med, Div Epidemiol, La Jolla, CA 92093 USA; UCL Royal Free & Univ Coll Med Sch, Ctr Nephrol, London, England	University of California System; University of California San Diego; University of London; University College London; UCL Medical School	Krentz, AJ (corresponding author), Univ Calif San Diego, Dept Family & Prevent Med, Div Epidemiol, La Jolla, CA 92093 USA.	akrentz@ucsd.edu	Krentz, Andrew/AAD-2493-2019					Beckebaum S, 2004, TRANSPL P, V36, p574S, DOI 10.1016/j.transproceed.2004.01.044; Boots JMM, 2004, DRUGS, V64, P2047, DOI 10.2165/00003495-200464180-00004; Bostom AD, 2002, AM J TRANSPLANT, V2, P491, DOI 10.1034/j.1600-6143.2002.20602.x; Chen J, 2004, ANN INTERN MED, V140, P167, DOI 10.7326/0003-4819-140-3-200402030-00007; Heisel O, 2004, AM J TRANSPLANT, V4, P583, DOI 10.1046/j.1600-6143.2003.00372.x; Jindal RM, 2000, TRANSPLANTATION, V70, pSS58; John PR, 2002, LIVER TRANSPLANT, V8, P708, DOI 10.1053/jlts.2002.34638; Kambham N, 2001, KIDNEY INT, V59, P1498, DOI 10.1046/j.1523-1755.2001.0590041498.x; Kasiske BL, 2003, AM J TRANSPLANT, V3, P178, DOI 10.1034/j.1600-6143.2003.00010.x; KRENTZ AJ, 1995, CLIN IMMUNOTHER, V4, P103, DOI 10.1007/BF03259076; Markell M, 2004, AM J KIDNEY DIS, V43, P953, DOI 10.1053/j.ajkd.2004.03.020; Montori VM, 2002, DIABETES CARE, V25, P583, DOI 10.2337/diacare.25.3.583; Morris PJ, 2004, NEW ENGL J MED, V351, P2678, DOI 10.1056/NEJMp048256; Pischon T, 2001, NEPHROL DIAL TRANSPL, V16, P14, DOI 10.1093/ndt/16.1.14; Schulak JA, 2004, J SURG RES, V117, P154, DOI 10.1016/j.jss.2003.11.005; Sims RJA, 2003, BRIT MED J, V327, P463, DOI 10.1136/bmj.327.7413.463; Tanabe K, 2003, DRUGS, V63, P1535, DOI 10.2165/00003495-200363150-00002; Valantine H, 2004, J HEART LUNG TRANSPL, V23, pS187, DOI 10.1016/j.healun.2004.03.009; Wilkinson A, 2003, TRANSPLANTATION, V75, pSS1, DOI 10.1097/00007890-200305271-00001; Woodward RS, 2003, AM J TRANSPLANT, V3, P590, DOI 10.1034/j.1600-6143.2003.00082.x	20	32	33	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	2005	365	9460					640	642						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	898SP	15721460				2022-12-28	WOS:000227096800008
J	Fatouros, NE; Huigens, ME; van Loon, JJA; Dicke, M; Hilker, M				Fatouros, NE; Huigens, ME; van Loon, JJA; Dicke, M; Hilker, M			Chemical communication - Butterfly anti-aphrodisiac lures parasitic wasps	NATURE			English	Editorial Material							SCELIONIDAE; HYMENOPTERA		Free Univ Berlin, Inst Biol, D-12163 Berlin, Germany; Univ Wageningen & Res Ctr, Entomol Lab, NL-6700 EH Wageningen, Netherlands	Free University of Berlin; Wageningen University & Research	Fatouros, NE (corresponding author), Free Univ Berlin, Inst Biol, D-12163 Berlin, Germany.	hilker@zedat.fu-berlin.de	Dicke, Marcel/B-2300-2010; van Loon, Joop J.A./B-3744-2009; Fatouros, Nina/AAO-9698-2020	Dicke, Marcel/0000-0001-8565-8896; van Loon, Joop J.A./0000-0002-4260-0501; Fatouros, Nina/0000-0003-0841-3144				Andersson J, 2000, P ROY SOC B-BIOL SCI, V267, P1271, DOI 10.1098/rspb.2000.1138; Andersson J, 2003, J CHEM ECOL, V29, P1489, DOI 10.1023/A:1024277823101; Arakaki N, 1996, J CHEM ECOL, V22, P1079, DOI 10.1007/BF02027946; Bruni R, 2000, J INSECT BEHAV, V13, P165, DOI 10.1023/A:1007728012482; CLAUSEN CP, 1976, ANNU REV ENTOMOL, V21, P343, DOI 10.1146/annurev.en.21.010176.002015; GILBERT LE, 1976, SCIENCE, V193, P419, DOI 10.1126/science.935877; Hilker M., 2002, CHEMOECOLOGY INSECT; ORR DB, 1986, CAN ENTOMOL, V118, P1063, DOI 10.4039/Ent1181063-10; STOWE MK, 1995, P NATL ACAD SCI USA, V92, P23, DOI 10.1073/pnas.92.1.23; Tabata S, 1940, REV APPL ENTOMOL A; Vinson S.B., 1984, Symposia of the Royal Entomological Society of London, V12, P325	11	83	88	0	68	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	2005	433	7027					704	704		10.1038/433704a	http://dx.doi.org/10.1038/433704a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897XH	15716942				2022-12-28	WOS:000227039200028
J	Tomson, T; Forsgren, L				Tomson, T; Forsgren, L			Life expectancy in epilepsy	LANCET			English	Editorial Material							LONG-TERM; MORTALITY; SEIZURE; COHORT; PEOPLE		Karolinska Inst, Sect Neurol, Dept Clin Neurosci, SE-17176 Stockholm, Sweden; Umea Univ, Dept Pharmacol & Clin Neurosci, Neurol Sect, S-90187 Umea, Sweden	Karolinska Institutet; Umea University	Tomson, T (corresponding author), Karolinska Inst, Sect Neurol, Dept Clin Neurosci, SE-17176 Stockholm, Sweden.	torbjorn.tomson@karolinska.se						COCKERELL OC, 1994, LANCET, V344, P918, DOI 10.1016/S0140-6736(94)92270-5; Forsgren L, 1996, EPILEPSIA, V37, P956, DOI 10.1111/j.1528-1157.1996.tb00533.x; Gaitatzis A, 2004, BRAIN, V127, P2427, DOI 10.1093/brain/awh267; HAUSER WA, 1980, EPILEPSIA, V21, P399, DOI 10.1111/j.1528-1157.1980.tb04088.x; HAUSER WA, 1967, EPILEPSIA, V16, P1; Lhatoo SD, 2001, ANN NEUROL, V49, P336; Lindsten H, 2000, EPILEPSIA, V41, P1469, DOI 10.1111/j.1528-1157.2000.tb00124.x; Loiseau J, 1999, EPILEPSIA, V40, P1388, DOI 10.1111/j.1528-1157.1999.tb02010.x; Olafsson E, 1998, EPILEPSIA, V39, P89, DOI 10.1111/j.1528-1157.1998.tb01279.x; ZIELINSKI JJ, 1974, EPILEPSIA, V15, P191, DOI 10.1111/j.1528-1157.1974.tb04941.x	10	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 12	2005	365	9459					557	558						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DN	15708087				2022-12-28	WOS:000226984300010
J	Parmacek, MS; Epstein, JA				Parmacek, MS; Epstein, JA			Pursuing cardiac progenitors: Regeneration redux	CELL			English	Review							STEM-CELLS; ARTERIAL POLE; HEART; DIFFERENTIATION; MYOCARDIUM; EXPRESSION	Recent studies have questioned the accepted dogma that the regenerative capacity of the heart following injury is limited. Several apparently distinct populations of resident cardiac progenitor cells may have the potential to regenerate functional heart muscle. Despite this progress, the physiologic role and therapeutic potential of cardiac resident progenitor cells remain unclear.	Univ Penn, Hlth Syst, Div Cardiovasc, Philadelphia, PA 19104 USA	University of Pennsylvania	Epstein, JA (corresponding author), Univ Penn, Hlth Syst, Div Cardiovasc, Philadelphia, PA 19104 USA.	epsteinj@mail.med.upenn.edu		Epstein, Jonathan/0000-0001-8637-4465; Parmacek, Michael/0000-0003-1449-4665				Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; Cai CL, 2003, DEV CELL, V5, P877, DOI 10.1016/S1534-5807(03)00363-0; Chien KR, 2004, NATURE, V428, P607, DOI 10.1038/nature02500; Couzin J, 2004, SCIENCE, V304, P192, DOI 10.1126/science.304.5668.192; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Jessup M, 2003, NEW ENGL J MED, V348, P2007, DOI 10.1056/NEJMra021498; Kehat I, 2004, NAT BIOTECHNOL, V22, P1282, DOI 10.1038/nbt1014; Kelly RG, 2002, TRENDS GENET, V18, P210, DOI 10.1016/S0168-9525(02)02642-2; Kelly RG, 2001, DEV CELL, V1, P435, DOI 10.1016/S1534-5807(01)00040-5; Lakshmipathy U, 2005, BLOOD REV, V19, P29, DOI 10.1016/j.blre.2004.03.001; Laugwitz KL, 2005, NATURE, V433, P647, DOI 10.1038/nature03215; Martin CM, 2004, DEV BIOL, V265, P262, DOI 10.1016/j.ydbio.2003.09.028; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Poss KD, 2002, SCIENCE, V298, P2188, DOI 10.1126/science.1077857; Waldo KL, 2001, DEVELOPMENT, V128, P3179; WINITSKY SO, 2005, IN PRESS PLOS, V128	19	63	66	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 11	2005	120	3					295	298		10.1016/j.cell.2005.01.025	http://dx.doi.org/10.1016/j.cell.2005.01.025			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	897TS	15707888	Bronze			2022-12-28	WOS:000227028900005
J	Ryu, JS; Kim, JI; Kunkel, T; Kim, BC; Cho, DS; Hong, SH; Kim, SH; Fernandez, AP; Kim, Y; Alonso, JM; Ecker, JR; Nagy, F; Lim, PO; Song, PS; Schafer, E; Nam, HG				Ryu, JS; Kim, JI; Kunkel, T; Kim, BC; Cho, DS; Hong, SH; Kim, SH; Fernandez, AP; Kim, Y; Alonso, JM; Ecker, JR; Nagy, F; Lim, PO; Song, PS; Schafer, E; Nam, HG			Phytochrome-specific type 5 phosphatase controls light signal flux by enhancing phytochrome stability and affinity for a signal transducer	CELL			English	Article							INTERACTING FACTOR-3; HYPOCOTYL ELONGATION; OAT PHYTOCHROME; IN-VITRO; ARABIDOPSIS; PROTEIN; PHOTORECEPTOR; PLANTS; PHOTOMORPHOGENESIS; PHOSPHORYLATION	Environmental light information such as quality, intensity, and duration in red (similar to660 nm) and far-red (similar to730 nm) wavelengths is perceived by phytochrome photoreceptors in plants, critically influencing almost all developmental strategies from germination to flowering. Phytochromes interconvert between red light-absorbing Pr and biologically functional far-red light-absorbing Pfr forms. To ensure optimal photoresponses in plants, the flux of light signal from Pfr-phytochromes should be tightly controlled. Phytochromes are phosphorylated at specific serine residues. We found that a type 5 protein phosphatase (PAPP5) specifically dephosphorylates biologically active Pfr-phytochromes and enhances phytochrome-mediated photoresponses. Depending on the specific serine residues dephosphorylated by PAPP5, phytochrome stability and affinity for a downstream signal transducer, NDPK2, were enhanced. Thus, phytochrome photoreceptors have developed an elaborate biochemical tuning mechanism for modulating the flux of light signal, employing variable phosphorylation states controlled by phosphorylation and PAPP5-mediated dephosphorylation as a mean to control phytochrome stability and affinity for downstream transducers.	Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, Kyungbuk, South Korea; Pohang Univ Sci & Technol, Syst Biodynam Res Ctr, Pohang 790784, Kyungbuk, South Korea; Kumho Life & Environm Sci Lab, Kwangju 500712, South Korea; Gyeongsang Natl Univ, Environm Biotechnol Natl Core Res Ctr, Jinju 660701, South Korea; Univ Freiburg, Inst Bot, D-79104 Freiburg, Germany; Salk Inst Biol Studies, La Jolla, CA 92037 USA	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Gyeongsang National University; University of Freiburg; Salk Institute	Nam, HG (corresponding author), Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, Kyungbuk, South Korea.	nam@postech.ac.kr	Kim, Yumi/AAA-9398-2021; Nagy, Ferenc/D-3532-2015; Ecker, Joseph R/B-9144-2008; Alonso, Jose M/K-6826-2014	Kim, Yumi/0000-0001-6369-5055; Nagy, Ferenc/0000-0002-6157-9269; Ecker, Joseph R/0000-0001-5799-5895; Alonso, Jose M/0000-0001-7087-1571				Ahmad M, 1998, MOL CELL, V1, P939, DOI 10.1016/S1097-2765(00)80094-5; Bauer D, 2004, PLANT CELL, V16, P1433, DOI 10.1105/tpc.021568; BOYLAN MT, 1991, P NATL ACAD SCI USA, V88, P10806, DOI 10.1073/pnas.88.23.10806; Casal JJ, 2002, PLANT PHYSIOL, V129, P1127, DOI 10.1104/pp.010977; Chinkers M, 2001, TRENDS ENDOCRIN MET, V12, P28, DOI 10.1016/S1043-2760(00)00335-0; Choi G, 1999, NATURE, V401, P610, DOI 10.1038/44176; Clough RC, 1997, PLANT CELL ENVIRON, V20, P713, DOI 10.1046/j.1365-3040.1997.d01-107.x; Colon-Carmona A, 2000, PLANT PHYSIOL, V124, P1728, DOI 10.1104/pp.124.4.1728; Fankhauser C, 1999, SCIENCE, V284, P1539, DOI 10.1126/science.284.5419.1539; Gyula N, 2003, CURR OPIN PLANT BIOL, V6, P446, DOI 10.1016/S1369-5266(03)00082-7; Hennig L, 1999, PLANTA, V208, P257, DOI 10.1007/s004250050557; Jacobsen SE, 1996, P NATL ACAD SCI USA, V93, P9292, DOI 10.1073/pnas.93.17.9292; Jordan ET, 1997, PLANT PHYSIOL, V115, P693, DOI 10.1104/pp.115.2.693; Kim J, 2004, PLANT CELL, V16, P2629, DOI 10.1105/tpc.104.023879; Kim JY, 2003, PLANT CELL, V15, P2399, DOI 10.1105/tpc.014498; Lagarias DM, 1997, PLANT CELL, V9, P675, DOI 10.1105/tpc.9.5.675; Lapko VN, 1999, PROTEIN SCI, V8, P1032, DOI 10.1110/ps.8.5.1032; Maeda T, 2003, PROG RETIN EYE RES, V22, P417, DOI 10.1016/S1350-9462(03)00017-X; Moon H, 2003, P NATL ACAD SCI USA, V100, P358, DOI 10.1073/pnas.252641899; Nagy F, 2002, ANNU REV PLANT BIOL, V53, P329, DOI 10.1146/annurev.arplant.53.100301.135302; Neff MM, 2000, GENE DEV, V14, P257; Ni M, 1998, CELL, V95, P657, DOI 10.1016/S0092-8674(00)81636-0; Ni M, 1999, NATURE, V400, P781, DOI 10.1038/23500; Okamoto H, 2001, PLANT CELL, V13, P1639, DOI 10.1105/tpc.13.7.1639; Quail PH, 2002, NAT REV MOL CELL BIO, V3, P85, DOI 10.1038/nrm728; Seo HS, 2004, GENE DEV, V18, P617, DOI 10.1101/gad.1187804; Sullivan JA, 2003, DEV BIOL, V260, P289, DOI 10.1016/S0012-1606(03)00212-4; Yamaguchi R, 1999, J CELL BIOL, V145, P437, DOI 10.1083/jcb.145.3.437; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976	29	121	137	1	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 11	2005	120	3					395	406		10.1016/j.cell.2004.12.019	http://dx.doi.org/10.1016/j.cell.2004.12.019			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	897TS	15707897	Bronze			2022-12-28	WOS:000227028900014
J	Yu, B; Yang, ZY; Li, JJ; Minakhina, S; Yang, MC; Padgett, RW; Steward, R; Chen, XM				Yu, B; Yang, ZY; Li, JJ; Minakhina, S; Yang, MC; Padgett, RW; Steward, R; Chen, XM			Methylation as a crucial step in plant microRNA biogenesis	SCIENCE			English	Article							VIRUS-RESISTANCE; PAZ DOMAIN; RNA; ARABIDOPSIS; GENE; RECOGNITION; METABOLISM; TRANSGENE; GENOMICS; PROTEIN	Methylation on the base or the ribose is prevalent in eukaryotic ribosomal RNAs (rRNAs) and is thought to be crucial for ribosome biogenesis and function. Artificially introduced 2'-O-methyl groups in small interfering RNAs (siRNAs) can stabilize siRNAs in serum without affecting their activities in RNA interference in mammalian cells. Here, we show that plant microRNAs (miRNAs) have a naturally occurring methyl group on the ribose of the last nucleotide. Whereas methylation of rRNAs depends on guide RNAs, the methyltransferase protein HEN1 is sufficient to methylate miRNA/miRNA* duplexes. Our studies uncover a new and crucial step in plant miRNA biogenesis and have profound implications in the function of miRNAs.	Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Chen, XM (corresponding author), Rutgers State Univ, Waksman Inst, POB 759, Piscataway, NJ 08854 USA.	xuemei@waksman.rutgers.edu	Yu, Bin/A-7714-2010	Chen, Xuemei/0000-0002-5209-1157	Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [R01 GM061146, GM61146] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061146] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alefelder S, 1998, NUCLEIC ACIDS RES, V26, P4983, DOI 10.1093/nar/26.21.4983; Anantharaman V, 2002, NUCLEIC ACIDS RES, V30, P1427, DOI 10.1093/nar/30.7.1427; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Boutet S, 2003, CURR BIOL, V13, P843, DOI 10.1016/S0960-9822(03)00293-8; Dalmay T, 2000, CELL, V101, P543, DOI 10.1016/S0092-8674(00)80864-8; Han MH, 2004, P NATL ACAD SCI USA, V101, P1093, DOI 10.1073/pnas.0307969100; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Lingel A, 2004, NAT STRUCT MOL BIOL, V11, P576, DOI 10.1038/nsmb777; Ma JB, 2004, NATURE, V429, P318, DOI 10.1038/nature02519; Mallory AC, 2004, CURR OPIN PLANT BIOL, V7, P120, DOI 10.1016/j.pbi.2004.01.006; Mourrain P, 2000, CELL, V101, P533, DOI 10.1016/S0092-8674(00)80863-6; Parizotto EA, 2004, GENE DEV, V18, P2237, DOI 10.1101/gad.307804; Park W, 2002, CURR BIOL, V12, P1484, DOI 10.1016/S0960-9822(02)01017-5; Tang GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103; Xie ZX, 2004, PLOS BIOL, V2, P642, DOI 10.1371/journal.pbio.0020104; YANG ZB, UNPUB	16	753	822	4	160	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	2005	307	5711					932	935		10.1126/science.1107130	http://dx.doi.org/10.1126/science.1107130			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897DV	15705854	Green Accepted			2022-12-28	WOS:000226985100056
J	Klironomos, JN; Allen, MF; Rillig, MC; Piotrowski, J; Makvandi-Nejad, S; Wolfe, BE; Powell, JR				Klironomos, JN; Allen, MF; Rillig, MC; Piotrowski, J; Makvandi-Nejad, S; Wolfe, BE; Powell, JR			Abrupt rise in atmospheric CO2 overestimates community response in a model plant-soil system	NATURE			English	Article							ARBUSCULAR MYCORRHIZAL FUNGI; ELEVATED CO2; COLONIZATION	Attempts to understand the ecological effect of increasing atmospheric CO2 concentration, [CO2], usually involve exposing today's ecosystems to expected future [CO2] levels(1,2). However, a major assumption of these approaches has not been tested that exposing ecosystems to a single- step increase in [ CO2] will yield similar responses to those of a gradual increase over several decades(3). We tested this assumption on a mycorrhizal fungal community over a period of six years. [ CO2] was either increased abruptly, as is typical of most [ CO2] experiments, or more gradually over 21 generations. The two approaches resulted in different structural and functional community responses to increased [ CO2]. Some fungi were sensitive to the carbon pulse of the abrupt [ CO2] treatment. This resulted in an immediate decline in fungal species richness and a significant change in mycorrhizal functioning. The magnitude of changes in fungal diversity and functioning in response to gradually increasing [ CO2] was smaller, and not significantly different to those with ambient [ CO2]. Our results suggest that studies may overestimate some community responses to increasing [ CO2] because biota may be sensitive to ecosystem changes that occur as a result of abrupt increases.	Univ Guelph, Dept Integrat Biol, Guelph, ON N1G 2W1, Canada; Univ Calif Riverside, Ctr Conservat Biol, Riverside, CA 92521 USA; Univ Montana, Div Biol Sci, Missoula, MT 59812 USA	University of Guelph; University of California System; University of California Riverside; University of Montana System; University of Montana	Klironomos, JN (corresponding author), Univ Guelph, Dept Integrat Biol, Guelph, ON N1G 2W1, Canada.	jklirono@uoguelph.ca	Powell, Jeff R/A-5076-2010; Rillig, Matthias C./AAE-6980-2019; Rillig, Matthias C./B-3675-2009	Powell, Jeff R/0000-0003-1091-2452; Rillig, Matthias C./0000-0003-3541-7853; Rillig, Matthias C./0000-0003-3541-7853				Allen M. F., 1991, ECOLOGY MYCORRHIZAE; BAZZAZ FA, 1990, ANNU REV ECOL SYST, V21, P167, DOI 10.1146/annurev.es.21.110190.001123; BRUNDRETT MC, 1984, CAN J BOT, V62, P2128, DOI 10.1139/b84-290; Gange AC, 2003, ECOL LETT, V6, P1051, DOI 10.1046/j.1461-0248.2003.00540.x; Goverde M, 2000, OECOLOGIA, V125, P362, DOI 10.1007/s004420000465; Hart MM, 2002, NEW PHYTOL, V153, P335, DOI 10.1046/j.0028-646X.2001.00312.x; *IPCC, 2001, CLIM CHANG 2001 SYNT; Kemper W. D., 1986, Methods of soil analysis. Part 1. Physical and mineralogical methods, P425; Klironomos J., 2000, MICROB BIOSYS, V1, P845; Klironomos JN, 2003, ECOLOGY, V84, P2292, DOI 10.1890/02-0413; Klironomos JN, 1998, NEW PHYTOL, V138, P599, DOI 10.1046/j.1469-8137.1998.00141.x; Korner C, 2000, ECOL APPL, V10, P1590, DOI 10.2307/2641226; Luo Y, 1999, CARBON DIOXIDE ENV S; Luo YQ, 1999, ECOLOGY, V80, P1568, DOI 10.1890/0012-9658(1999)080[1568:VOEFCE]2.0.CO;2; MCGONIGLE TP, 1990, NEW PHYTOL, V115, P495, DOI 10.1111/j.1469-8137.1990.tb00476.x; MILLER RM, 1995, OECOLOGIA, V103, P17, DOI 10.1007/BF00328420; Piotrowski JS, 2004, NEW PHYTOL, V164, P365, DOI 10.1111/j.1469-8137.2004.01181.x; Rillig MC, 1999, NATURE, V400, P628, DOI 10.1038/23168; Rillig MC, 2004, ECOL LETT, V7, P740, DOI 10.1111/j.1461-0248.2004.00620.x; Rillig MC, 2002, ECOL STU AN, V157, P135; SINEAD C, NATURE, V431, P566; Smith SE, 1997, MYCORRHIZAL SYMBIOSE; Staddon PL, 1998, TRENDS ECOL EVOL, V13, P455, DOI 10.1016/S0169-5347(98)01493-1; Treseder KK, 2004, NEW PHYTOL, V164, P347, DOI 10.1111/j.1469-8137.2004.01159.x; Treseder KK, 2003, ECOSYSTEMS, V6, P786, DOI 10.1007/s10021-003-0182-4; van der Heijden MGA, 1998, NATURE, V396, P69, DOI 10.1038/23932; Ward JK, 2004, ECOL LETT, V7, P427, DOI 10.1111/j.1461-0248.2004.00589.x; Wolf J, 2003, NEW PHYTOL, V157, P579, DOI 10.1046/j.1469-8137.2003.00696.x	28	132	151	3	110	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 10	2005	433	7026					621	624		10.1038/nature03268	http://dx.doi.org/10.1038/nature03268			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	895KX	15703744				2022-12-28	WOS:000226862000041
J	McCormick, C; Ganem, D				McCormick, C; Ganem, D			The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs	SCIENCE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; AU-RICH ELEMENTS; MAPKAP KINASE-2; NUCLEAR EXPORT; CELL-LINES; C-FOS; DEGRADATION; PHOSPHORYLATION; IDENTIFICATION; COMPLEX	Cytokine production plays a critical role in diseases caused by Kaposi's sarcoma-associated herpesvirus (KSHV). Here we show that a latent KSHV gene product, kaposin B, increases the expression of cytokines by blocking the degradation of their messenger RNAs (mRNAs). Cytokine transcripts are normally unstable because they contain AU-rich elements (AREs) in their 3' noncoding regions that target them for degradation. Kaposin B reverses this instability by binding to and activating the kinase MK2, a target of the p38 mitogen-activated protein kinase signaling pathway and a known inhibitor of ARE-mRNA decay. These findings define an important mechanism linking latent KSHV infection to cytokine production, and also illustrate a distinctive mode by which viruses can selectively modulate mRNA turnover.	Univ Calif San Francisco, Howard Hughes Med Inst, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Ganem, D (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.	ganem@cgl.ucsf.edu	McCormick, Craig/AAH-9069-2019	McCormick, Craig/0000-0003-2794-3722				Asou H, 1998, BLOOD, V91, P2475, DOI 10.1182/blood.V91.7.2475.2475_2475_2481; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Drexler HG, 1999, LEUKEMIA, V13, P634, DOI 10.1038/sj.leu.2401371; Drexler HG, 1998, LEUKEMIA, V12, P1507, DOI 10.1038/sj.leu.2401160; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; Ensoli B, 1998, CYTOKINE GROWTH F R, V9, P63, DOI 10.1016/S1359-6101(97)00037-3; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Komanduri KV, 1996, J ACQ IMMUN DEF SYND, V13, P215, DOI 10.1097/00042560-199611010-00003; Meng WY, 2002, J BIOL CHEM, V277, P37401, DOI 10.1074/jbc.C200418200; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; Nishimoto N, 2000, BLOOD, V95, P56, DOI 10.1182/blood.V95.1.56; Sadler R, 1999, J VIROL, V73, P5722, DOI 10.1128/JVI.73.7.5722-5730.1999; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Underwood KW, 2003, STRUCTURE, V11, P627, DOI 10.1016/S0969-2126(03)00092-3; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969	22	169	186	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2005	307	5710					739	741		10.1126/science.1105779	http://dx.doi.org/10.1126/science.1105779			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	894TQ	15692053				2022-12-28	WOS:000226814900047
J	Endo, M; Muramatsu, H; Hayashi, T; Kim, YA; Terrones, M; Dresselhaus, NS				Endo, M; Muramatsu, H; Hayashi, T; Kim, YA; Terrones, M; Dresselhaus, NS			'Buckypaper' from coaxial nanotubes	NATURE			English	Editorial Material							WALLED CARBON NANOTUBES; RAMAN-SCATTERING; DECOMPOSITION; BENZENE; CCVD		Shinshu Univ, Fac Engn, Nagano 3808553, Japan; IPICYT, Adv Mat Dept, San Luis Potosi 78216, Mexico; MIT, Cambridge, MA 02139 USA	Shinshu University; Instituto Potosino Investigacion Cientifica y Tecnologica; Massachusetts Institute of Technology (MIT)	Endo, M (corresponding author), Shinshu Univ, Fac Engn, 4-17-1 Wakasato, Nagano 3808553, Japan.	endo@endomoribu.shinshu-u.ac.jp	Muramatsu, Hiroyuki/B-8800-2011; Terrones, Mauricio/B-3829-2014	Muramatsu, Hiroyuki/0000-0003-0332-6703; Terrones, Mauricio/0000-0003-0010-2851; kim, yoong ahm/0000-0003-4074-7515; Endo, Morinobu/0000-0002-7034-3143				Bandow S, 2001, CHEM PHYS LETT, V337, P48, DOI 10.1016/S0009-2614(01)00192-0; Endo M, 2004, NANO LETT, V4, P1451, DOI 10.1021/nl0492483; ENDO M, 1988, CHEM TECH, P568; Flahaut E, 2003, CHEM COMMUN, P1442, DOI 10.1039/b301514a; Franklin NR, 2000, ADV MATER, V12, P890, DOI 10.1002/1521-4095(200006)12:12<890::AID-ADMA890>3.0.CO;2-K; Hiraoka T, 2003, CHEM PHYS LETT, V382, P679, DOI 10.1016/j.cplett.2003.10.123; Jorio A, 2001, PHYS REV LETT, V86, P1118, DOI 10.1103/PhysRevLett.86.1118; Kurachi H., 2001, P 21 INT DISPL RES C, P1237; Lyu SC, 2004, J PHYS CHEM B, V108, P2192, DOI 10.1021/jp030955e; Lyu SC, 2003, CHEM MATER, V15, P3951, DOI 10.1021/cm030309s; OBERLIN A, 1976, J CRYST GROWTH, V32, P335, DOI 10.1016/0022-0248(76)90115-9; Sugai T, 2003, NANO LETT, V3, P769, DOI 10.1021/nl034183+; Wei JQ, 2003, J MATER CHEM, V13, P1340, DOI 10.1039/b300484h	13	507	533	9	284	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2005	433	7025					476	476		10.1038/433476a	http://dx.doi.org/10.1038/433476a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893NT	15690030	Bronze, Green Submitted			2022-12-28	WOS:000226727200033
J	Caples, SM; Gami, AS; Somers, VK				Caples, SM; Gami, AS; Somers, VK			Obstructive sleep apnea	ANNALS OF INTERNAL MEDICINE			English	Review							POSITIVE AIRWAY PRESSURE; C-REACTIVE PROTEIN; BLOOD-PRESSURE; GENIOGLOSSAL ELECTROMYOGRAM; CHEMORECEPTOR REFLEX; CLINICAL-FEATURES; HEART-FAILURE; LEPTIN LEVELS; NITRIC-OXIDE; PREVALENCE		Mayo Clin, Rochester, MN 55905 USA	Mayo Clinic	Somers, VK (corresponding author), Mayo Clin, 200 1st St SW, Rochester, MN 55905 USA.	somers.virend@mayo.edu			NCRR NIH HHS [M01-RR00585] Funding Source: Medline; NHLBI NIH HHS [HL65176, HL61560, HL 70302, HL73211] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000585] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073211, R01HL061560, R01HL070302, R01HL065176] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ballester E, 1999, AM J RESP CRIT CARE, V159, P495, DOI 10.1164/ajrccm.159.2.9804061; Barbe F, 2001, ANN INTERN MED, V134, P1015, DOI 10.7326/0003-4819-134-11-200106050-00007; Barbe F, 1998, AM J RESP CRIT CARE, V158, P18, DOI 10.1164/ajrccm.158.1.9709135; Becker HF, 2003, CIRCULATION, V107, P68, DOI 10.1161/01.CIR.0000042706.47107.7A; Bixler EO, 1998, AM J RESP CRIT CARE, V157, P144, DOI 10.1164/ajrccm.157.1.9706079; Bixler EO, 2001, AM J RESP CRIT CARE, V163, P608, DOI 10.1164/ajrccm.163.3.9911064; Bonetti PO, 2003, ARTERIOSCL THROM VAS, V23, P168, DOI 10.1161/01.ATV.0000051384.43104.FC; Bradley TD, 2001, CHEST, V119, P1827, DOI 10.1378/chest.119.6.1827; BROOKS B, 1994, J CLIN ENDOCR METAB, V79, P1681, DOI 10.1210/jc.79.6.1681; Chin KZ, 1999, CIRCULATION, V100, P706, DOI 10.1161/01.CIR.100.7.706; Chiner E, 1999, THORAX, V54, P968, DOI 10.1136/thx.54.11.968; Davidson TM, 2003, SLEEP MED, V4, P185, DOI 10.1016/S1389-9457(02)00237-X; DAVIES RJO, 1992, THORAX, V47, P101, DOI 10.1136/thx.47.2.101; DOUGLAS NJ, 1982, THORAX, V37, P840, DOI 10.1136/thx.37.11.840; Duran J, 2001, AM J RESP CRIT CARE, V163, P685, DOI 10.1164/ajrccm.163.3.2005065; Dyugovskaya L, 2002, AM J RESP CRIT CARE, V165, P934, DOI 10.1164/ajrccm.165.7.2104126; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; Fogel RB, 2001, AM J RESP CRIT CARE, V164, P2025, DOI 10.1164/ajrccm.164.11.2102048; FOUKE JM, 1986, J APPL PHYSIOL, V61, P912, DOI 10.1152/jappl.1986.61.3.912; Gami AS, 2004, CIRCULATION, V110, P364, DOI 10.1161/01.CIR.0000136587.68725.8E; GELFAND R, 1973, J APPL PHYSIOL, V35, P903, DOI 10.1152/jappl.1973.35.6.903; Gotsopoulos H, 2002, AM J RESP CRIT CARE, V166, P743, DOI 10.1164/rccm.200203-208OC; Gottlieb DJ, 2000, AM J RESP CRIT CARE, V162, P1512, DOI 10.1164/ajrccm.162.4.9911073; Harsch IA, 2004, AM J RESP CRIT CARE, V169, P156, DOI 10.1164/rccm.200302-206OC; HEDNER JA, 1992, AM REV RESPIR DIS, V146, P1240, DOI 10.1164/ajrccm/146.5_Pt_1.1240; HEISTAD DD, 1974, J CLIN INVEST, V53, P1226, DOI 10.1172/JCI107669; HORNER RL, 1991, J PHYSIOL-LONDON, V436, P31, DOI 10.1113/jphysiol.1991.sp018537; Hosselet JJ, 2001, AM J RESP CRIT CARE, V163, P398, DOI 10.1164/ajrccm.163.2.9808132; HUDGEL DW, 1988, AM REV RESPIR DIS, V138, P1542, DOI 10.1164/ajrccm/138.6.1542; Ip MSM, 2000, AM J RESP CRIT CARE, V162, P2166, DOI 10.1164/ajrccm.162.6.2002126; Isono S, 1997, J APPL PHYSIOL, V82, P1319, DOI 10.1152/jappl.1997.82.4.1319; Javaheri S, 1998, CIRCULATION, V97, P2154, DOI 10.1161/01.CIR.97.21.2154; Jenkinson C, 1999, LANCET, V353, P2100, DOI 10.1016/S0140-6736(98)10532-9; Kanagala R, 2003, CIRCULATION, V107, P2589, DOI 10.1161/01.CIR.0000068337.25994.21; Kaneko Y, 2003, NEW ENGL J MED, V348, P1233, DOI 10.1056/NEJMoa022479; Kim J, 2004, AM J RESP CRIT CARE, V170, P1108, DOI 10.1164/rccm.200404-519OC; LUGLIANI R, 1971, NEW ENGL J MED, V285, P1105, DOI 10.1056/NEJM197111112852002; Malhotra A, 2002, AM J RESP CRIT CARE, V165, P71, DOI 10.1164/ajrccm.165.1.2011065; Mansfield DR, 2004, AM J RESP CRIT CARE, V169, P361, DOI 10.1164/rccm.200306-752OC; Martin SE, 1997, AM J RESP CRIT CARE, V155, P1596, DOI 10.1164/ajrccm.155.5.9154863; Mehta A, 2001, AM J RESP CRIT CARE, V163, P1457, DOI 10.1164/ajrccm.163.6.2004213; Meier-Ewert HK, 2004, J AM COLL CARDIOL, V43, P678, DOI 10.1016/j.jacc.2003.07.050; MEZZANOTTE WS, 1992, J CLIN INVEST, V89, P1571, DOI 10.1172/JCI115751; Narkiewicz K, 1999, CIRCULATION, V99, P1183, DOI 10.1161/01.CIR.99.9.1183; Narkiewicz K, 1999, CIRCULATION, V100, P2332, DOI 10.1161/01.CIR.100.23.2332; Narkiewicz K, 1998, CIRCULATION, V97, P943; Narkiewicz K, 1998, CIRCULATION, V98, P1071, DOI 10.1161/01.CIR.98.11.1071; Netzer NC, 1999, ANN INTERN MED, V131, P485, DOI 10.7326/0003-4819-131-7-199910050-00002; ONAL E, 1981, AM REV RESPIR DIS, V124, P215; Parker JD, 1999, AM J RESP CRIT CARE, V160, P1888, DOI 10.1164/ajrccm.160.6.9807074; Peppard PE, 2000, JAMA-J AM MED ASSOC, V284, P3015, DOI 10.1001/jama.284.23.3015; Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901; Pepperell JCT, 2002, LANCET, V359, P204, DOI 10.1016/S0140-6736(02)07445-7; Phillips BG, 1999, J HYPERTENS, V17, P61, DOI 10.1097/00004872-199917010-00010; Phillips BG, 2000, AM J PHYSIOL-HEART C, V279, pH234, DOI 10.1152/ajpheart.2000.279.1.H234; Punjabi NM, 2002, AM J RESP CRIT CARE, V165, P677, DOI 10.1164/ajrccm.165.5.2104087; Redline S, 1997, AM J RESP CRIT CARE, V155, P186, DOI 10.1164/ajrccm.155.1.9001310; Redline S, 2000, AM J RESP CRIT CARE, V161, P369, DOI 10.1164/ajrccm.161.2.9904031; Ridker PM, 2003, CIRCULATION, V107, P363, DOI 10.1161/01.CIR.0000053730.47739.3C; Schulz R, 2000, THORAX, V55, P1046, DOI 10.1136/thorax.55.12.1046; Schwab RJ, 2003, AM J RESP CRIT CARE, V168, P522, DOI 10.1164/rccm.200208-866OC; SCHWAB RJ, 1993, AM REV RESPIR DIS, V148, P1385, DOI 10.1164/ajrccm/148.5.1385; SEELAGY MM, 1994, J APPL PHYSIOL, V76, P2692, DOI 10.1152/jappl.1994.76.6.2692; Shahar E, 2003, AM J RESP CRIT CARE, V167, P1186, DOI 10.1164/rccm.200210-1238OC; Shamsuzzaman ASM, 2002, CIRCULATION, V105, P2462, DOI 10.1161/01.CIR.0000018948.95175.03; SHEPARD JW, 1985, CHEST, V88, P335, DOI 10.1378/chest.88.3.335; SHEPARD JW, 1990, AM REV RESPIR DIS, V141, P1350, DOI 10.1164/ajrccm/141.5_Pt_1.1350; Sher AE, 1996, SLEEP, V19, P156, DOI 10.1093/sleep/19.2.156; SMITH PL, 1985, ANN INTERN MED, V103, P850, DOI 10.7326/0003-4819-103-6-850; Somers V K, 1992, Clin Auton Res, V2, P171, DOI 10.1007/BF01818958; SOMERS VK, 1988, HYPERTENSION, V11, P608, DOI 10.1161/01.HYP.11.6.608; SOMERS VK, 1991, J CLIN INVEST, V87, P1953, DOI 10.1172/JCI115221; SOMERS VK, 1993, J AUTONOM NERV SYST, V44, P253, DOI 10.1016/0165-1838(93)90038-V; SOMERS VK, 1995, J CLIN INVEST, V96, P1897, DOI 10.1172/JCI118235; Spiegel K, 1999, LANCET, V354, P1435, DOI 10.1016/S0140-6736(99)01376-8; Svatikova A, 2003, CIRCULATION, V108, P1451, DOI 10.1161/01.CIR.0000089091.09527.B8; Tamura DY, 2002, SHOCK, V17, P269, DOI 10.1097/00024382-200204000-00005; Teran-Santos J, 1999, NEW ENGL J MED, V340, P847, DOI 10.1056/NEJM199903183401104; Trudo FJ, 1998, AM J RESP CRIT CARE, V158, P1259, DOI 10.1164/ajrccm.158.4.9712063; Tsai WH, 2003, AM J RESP CRIT CARE, V167, P1427, DOI 10.1164/rccm.200112-110OC; Tsuji H, 1996, CIRCULATION, V94, P2850, DOI 10.1161/01.CIR.94.11.2850; Udwadia ZF, 2004, AM J RESP CRIT CARE, V169, P168, DOI 10.1164/rccm.200302-265OC; Veasey SC, 1996, AM J RESP CRIT CARE, V153, P776, DOI 10.1164/ajrccm.153.2.8564132; Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Young T, 2002, ARCH INTERN MED, V162, P893, DOI 10.1001/archinte.162.8.893; Young T, 1996, SLEEP, V19, P529, DOI 10.1093/sleep/19.7.529	87	281	295	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	2005	142	3					187	197		10.7326/0003-4819-142-3-200502010-00010	http://dx.doi.org/10.7326/0003-4819-142-3-200502010-00010			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900UH	15684207				2022-12-28	WOS:000227239300005
J	Bignall, T				Bignall, T			Patronising monkeys	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Bignall, T (corresponding author), The Lancet, London NW1 7BY, England.							Bignall J, 2002, LANCET, V360, P504, DOI 10.1016/S0140-6736(02)09761-1; DAWKINS R, 1993, NEW SCI, V138, P36; Emery NJ, 2004, SCIENCE, V306, P1903, DOI 10.1126/science.1098410; Horner V, 2005, ANIM COGN, V8, P164, DOI 10.1007/s10071-004-0239-6; WAKABI W, 2004, E AFRICAN       0209	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN-FEB	2005	365	9457					371	372						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891WE	15680442				2022-12-28	WOS:000226610900009
J	Coras, B; Essbauer, S; Pfeffer, M; Meyer, H; Schroder, J; Stolz, W; Landthaler, M; Vogt, T				Coras, B; Essbauer, S; Pfeffer, M; Meyer, H; Schroder, J; Stolz, W; Landthaler, M; Vogt, T			Cowpox and a cat	LANCET			English	Editorial Material									Univ Regensburg, Dept Dermatol, D-93053 Regensburg, Germany; Bundeswehr, Inst Microbiol, D-80937 Munich, Germany; Univ Regensburg, Dept Pathol, D-93053 Regensburg, Germany; Hosp Munich Schwabing, Clin Dermatol & Allergol, D-80804 Munich, Germany	University of Regensburg; Bundeswehr Institute of Microbiology (IMB); University of Regensburg	Vogt, T (corresponding author), Univ Regensburg, Dept Dermatol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	thomas.vogt@klinik.uni-regensburg.de	Stolz, Wilhelm/M-5074-2019					BAXBY D, 1994, BRIT J DERMATOL, V131, P598, DOI 10.1111/j.1365-2133.1994.tb04969.x; Burton J. L., 1994, Lancet (North American Edition), V343, P67, DOI 10.1016/S0140-6736(94)90808-7; EISHUBINGER AM, 1990, LANCET, V336, P880, DOI 10.1016/0140-6736(90)92387-W; Hazel SM, 2000, EPIDEMIOL INFECT, V124, P551, DOI 10.1017/S0950268899003799; MEYER H, 1994, J GEN VIROL, V75, P1975, DOI 10.1099/0022-1317-75-8-1975	5	23	24	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN-FEB	2005	365	9457					446	446						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891WE	15680463				2022-12-28	WOS:000226610900035
J	Bibring, JP; Langevin, Y; Gendrin, A; Gondet, B; Poulet, F; Berthe, M; Soufflot, A; Arvidson, R; Mangold, N; Mustard, J; Drossart, P				Bibring, JP; Langevin, Y; Gendrin, A; Gondet, B; Poulet, F; Berthe, M; Soufflot, A; Arvidson, R; Mangold, N; Mustard, J; Drossart, P		OMEGA Team	Mars surface diversity as revealed by the OMEGA/Mars Express observations	SCIENCE			English	Article							MGS-TES; CAP; WATER; SOIL	The Observatoire pour [a Mineralogie, l'Eau, les Glaces, et I'Activite (OMEGA) investigation, on board the European Space Agency Mars Express mission, is mapping the surface composition of Mars at a 0.3- to 5-kilometer resolution by means of visible-near-infrared hyperspectral reflectance imagery. The data acquired during, the first 9 months of the mission already reveal a diverse and complex surface mineralogy, offering key insights into the evolution of Mars. OMEGA has identified and mapped mafic iron-bearing silicates of both the northern and southern crust, localized concentrations of hydrated phyllosilicates and sulfates but nocarbonates, and ices and frosts with a water-ice composition of the north polar perennial cap, as for the south cap, covered by a thin carbon dioxide-ice veneer.	Inst Astrophys Spatiale, F-91405 Orsay, France; Washington Univ, St Louis, MO 63130 USA; IDES, F-91405 Orsay, France; Brown Univ, Providence, RI 02912 USA; Observ Paris, LESIA, F-92195 Meudon, France	UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Washington University (WUSTL); Brown University; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris	Bibring, JP (corresponding author), Inst Astrophys Spatiale, Batiment 121,Orsay Campus, F-91405 Orsay, France.	bibring@ias.u-psud.fr	Schmitt, Bernard/A-1064-2009; Bellucci, Giancarlo/ABA-9201-2020; Drossart, Pierre/H-8670-2013; Fouchet, Thierry/C-6374-2017	Schmitt, Bernard/0000-0002-1230-6627; Bellucci, Giancarlo/0000-0003-0867-8679; Altieri, Francesca/0000-0002-6338-8300; Erard, Stephane/0000-0002-9099-8366; Capaccioni, Fabrizio/0000-0003-1631-4314; Cerroni, Priscilla/0000-0003-0239-2741; Ignatiev, Nikolay/0000-0002-6358-7094; Fouchet, Thierry/0000-0001-9040-8285				Arvidson RE, 2005, SCIENCE, V307, P1591, DOI 10.1126/science.1109509; Arvidson RE, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE001982; Bandfield JL, 2000, SCIENCE, V287, P1626, DOI 10.1126/science.287.5458.1626; Bandfield JL, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2000JE001469; Banin A, 1997, J GEOPHYS RES-PLANET, V102, P13341, DOI 10.1029/97JE01160; Bibring J.-P., 2004, EUR SPACE AGENCY SPE, V1240, P37; Bibring JP, 2004, NATURE, V428, P627, DOI 10.1038/nature02461; Bibring JP, 2001, SPACE SCI REV, V96, P293, DOI 10.1023/A:1011909708806; Byrne S, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017597; CHICARRO A, 2004, ESA SPEC PUBL, V1240, P00003; Gendrin A, 2005, SCIENCE, V307, P1587, DOI 10.1126/science.1109087; Hamilton VE, 2003, METEORIT PLANET SCI, V38, P871, DOI 10.1111/j.1945-5100.2003.tb00284.x; Hoefen TM, 2003, SCIENCE, V302, P627, DOI 10.1126/science.1089647; Kieffer HH, 2001, ICARUS, V154, P162, DOI 10.1006/icar.2001.6670; Langevin Y, 2005, SCIENCE, V307, P1584, DOI 10.1126/science.1109091; Langevin Y, 2005, SCIENCE, V307, P1581, DOI 10.1126/science.1109438; Laskar J, 2004, ICARUS, V170, P343, DOI 10.1016/j.icarus.2004.04.005; MILLIKEN MS, 2003, LUNAR PLANET SCI C, V34, P1345; MINITTI ME, 2002, J GEOPHYS RES, V107, pE5, DOI DOI 10.1029/2001JE001518; Mustard JF, 2005, SCIENCE, V307, P1594, DOI 10.1126/science.1109098; Mustard JF, 1997, J GEOPHYS RES-PLANET, V102, P25605, DOI 10.1029/97JE02354; Poulet F, 2004, J GEOPHYS RES-PLANET, V109, DOI 10.1029/2003JE002179; Ruff SW, 2001, J GEOPHYS RES-PLANET, V106, P23921, DOI 10.1029/2000JE001329; Schultz PH, 2004, J GEOPHYS RES-PLANET, V109, DOI 10.1029/2002JE002025; SETTLE M, 1979, J GEOPHYS RES, V84, P8343, DOI 10.1029/JB084iB14p08343; Tosca NJ, 2004, J GEOPHYS RES-PLANET, V109, DOI 10.1029/2003JE002218; Vaniman DT, 2004, NATURE, V431, P663, DOI 10.1038/nature02973; Wyatt MB, 2002, NATURE, V417, P263, DOI 10.1038/417263a; Yen AS, 2000, SCIENCE, V289, P1909, DOI 10.1126/science.289.5486.1909	29	741	752	4	168	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 11	2005	307	5715					1576	1581		10.1126/science.1108806	http://dx.doi.org/10.1126/science.1108806			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	906ED	15718430				2022-12-28	WOS:000227622400034
J	Charon, R				Charon, R			Bearing witness - Sontag and the body	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Columbia Univ Coll Phys & Surg, Program Narrat Med, New York, NY 10032 USA	Columbia University	Charon, R (corresponding author), Columbia Univ Coll Phys & Surg, Program Narrat Med, 630 W 168th St, New York, NY 10032 USA.							Sontag Susan, 1983, ILLNESS METAPHOR AID, P59	1	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2005	352	8					756	756		10.1056/NEJMp058008	http://dx.doi.org/10.1056/NEJMp058008			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899MC	15728807				2022-12-28	WOS:000227147500004
J	Mayer, SA; Brun, NC; Begtrup, K; Broderick, J; Davis, S; Diringer, MN; Skolnick, BE; Steiner, T				Mayer, SA; Brun, NC; Begtrup, K; Broderick, J; Davis, S; Diringer, MN; Skolnick, BE; Steiner, T		Recombinant Activated Factor VII A	Recombinant activated factor VII for acute intracerebral hemorrhage	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	5th World Stroke Conference	JUN 26, 2004	Vancouver, CANADA				TIME-COURSE; SCALE; ENLARGEMENT; GUIDELINES; SAFETY	BACKGROUND: Intracerebral hemorrhage is the least treatable form of stroke and is associated with high mortality. Among patients who undergo computed tomography (CT) within three hours after the onset of intracerebral hemorrhage, one third have an increase in the volume of the hematoma related to subsequent bleeding. We sought to determine whether recombinant activated factor VII (rFVIIa) can reduce hematoma growth after intracerebral hemorrhage. METHODS: We randomly assigned 399 patients with intracerebral hemorrhage diagnosed by CT within three hours after onset to receive placebo (96 patients) or 40 microg of rFVIIa per kilogram of body weight (108 patients), 80 microg per kilogram (92 patients), or 160 microg per kilogram (103 patients) within one hour after the baseline scan. The primary outcome measure was the percent change in the volume of the intracerebral hemorrhage at 24 hours. Clinical outcomes were assessed at 90 days. Results: Hematoma volume increased more in the placebo group than in the rFVIIa groups. The mean increase was 29 percent in the placebo group, as compared with 16 percent, 14 percent, and 11 percent in the groups given 40 microg, 80 microg, and 160 microg of rFVIIa per kilogram, respectively (P=0.01 for the comparison of the three rFVIIa groups with the placebo group). Growth in the volume of intracerebral hemorrhage was reduced by 3.3 ml, 4.5 ml, and 5.8 ml in the three treatment groups, as compared with that in the placebo group (P=0.01). Sixty-nine percent of placebo-treated patients died or were severely disabled (as defined by a modified Rankin Scale score of 4 to 6), as compared with 55 percent, 49 percent, and 54 percent of the patients who were given 40, 80, and 160 microg of rFVIIa, respectively (P=0.004 for the comparison of the three rFVIIa groups with the placebo group). Mortality at 90 days was 29 percent for patients who received placebo, as compared with 18 percent in the three rFVIIa groups combined (P=0.02). Serious thromboembolic adverse events, mainly myocardial or cerebral infarction, occurred in 7 percent of rFVIIa-treated patients, as compared with 2 percent of those given placebo (P=0.12). CONCLUSIONS: Treatment with rFVIIa within four hours after the onset of intracerebral hemorrhage limits the growth of the hematoma, reduces mortality, and improves functional outcomes at 90 days, despite a small increase in the frequency of thromboembolic adverse events.	Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, New York, NY 10032 USA; Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark; Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA; Univ Melbourne, Royal Melbourne Hosp, Melbourne, Vic 3050, Australia; Washington Univ, Sch Med, St Louis, MO USA; Novo Nordisk AS, Princeton, NJ USA; Heidelberg Univ, Heidelberg, Germany	Columbia University; Columbia University; Novo Nordisk; University System of Ohio; University of Cincinnati; Royal Melbourne Hospital; University of Melbourne; Washington University (WUSTL); Novo Nordisk; Ruprecht Karls University Heidelberg	Mayer, SA (corresponding author), Neurol Inst, 710 W 168th St,Box 39, New York, NY 10032 USA.	sam14@columbia.edu	Steiner, Thorsten/A-7391-2014; Demchuk, Andrew M/E-1103-2012; Diringer, Michael N/C-1165-2008; Davis, Stephen M/L-5260-2013; Buchan, Alastair M/B-9095-2009	Demchuk, Andrew M/0000-0002-4930-7789; Diringer, Michael N/0000-0003-2337-5537; Davis, Stephen M/0000-0003-0962-2300; Buchan, Alastair M/0000-0002-2918-5200				Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Brott T, 1997, STROKE, V28, P1, DOI 10.1161/01.STR.28.1.1; COUNSELL C, 1995, CEREBROVASC DIS, V5, P26, DOI 10.1159/000107814; Fewel ME, 2004, NEUROCRIT CARE, V1, P19, DOI 10.1385/NCC:1:1:19; Friederich PW, 2003, LANCET, V361, P201, DOI 10.1016/S0140-6736(03)12268-4; Friederich PW, 2003, LANCET, V361, P1138; FUJII Y, 1994, J NEUROSURG, V80, P51, DOI 10.3171/jns.1994.80.1.0051; FUJITSU K, 1990, J NEUROSURG, V73, P518, DOI 10.3171/jns.1990.73.4.0518; He S, 2003, J THROMB HAEMOST, V1, P1215, DOI 10.1046/j.1538-7836.2003.00242.x; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; Kazui S, 1996, STROKE, V27, P1783, DOI 10.1161/01.STR.27.10.1783; LINDLEY CM, 1994, CLIN PHARMACOL THER, V55, P638, DOI 10.1038/clpt.1994.80; MAHONEY F I, 1965, Md State Med J, V14, P61; Mayer SA, 2005, STROKE, V36, P74, DOI 10.1161/01.STR.0000149628.80251.b8; Mayer SA, 2004, STROKE, V35, P332; Mayer SA, 2003, STROKE, V34, P224, DOI 10.1161/01.STR.0000046458.67968.E4; Monroe DM, 1997, BRIT J HAEMATOL, V99, P542, DOI 10.1046/j.1365-2141.1997.4463256.x; TEASDALE G, 1974, LANCET, V2, P81; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	22	962	1020	1	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2005	352	8					777	785		10.1056/NEJMoa042991	http://dx.doi.org/10.1056/NEJMoa042991			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	899MC	15728810				2022-12-28	WOS:000227147500007
J	Soares, HP; Kumar, A; Daniels, S; Swann, S; Cantor, A; Hozo, Z; Clark, M; Serdarevic, F; Gwede, C; Trotti, A; Djulbegovic, B				Soares, HP; Kumar, A; Daniels, S; Swann, S; Cantor, A; Hozo, Z; Clark, M; Serdarevic, F; Gwede, C; Trotti, A; Djulbegovic, B			Evaluation of new treatments in radiation oncology - Are they better than standard treatments?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RANDOMIZED-TRIALS; CONSORT STATEMENT; UNCERTAINTY PRINCIPLE; STATISTICS; QUALITY; BIAS; PUBLICATION; EQUIPOISE; THERAPY; ABSENCE	Context The superiority of innovative over standard treatments is not known. To describe accurately the outcomes of innovations that are tested in randomized controlled trials (RCTs) 3 factors have to be considered: publication rate, quality of trials, and the choice of the adequate comparator intervention. Objective To determine the success rate of innovative treatments by assessing preferences between experimental and standard treatments according to original investigators' conclusions, determining the proportion of RCTs that achieved primary outcomes' statistical significance, and performing meta-analysis to examine if the summary point estimate favored innovative vs standard treatments. Data Sources Randomized controlled trials conducted by the Radiation Therapy Oncology Group (RTOG). Study Selection All completed phase 3 trials conducted by the RTOG since its creation in 1968 until 2002. For multiple publications of the same study, we used the one with the most complete primary outcomes and with the longest follow-up information. Data Extraction We used the US National Cancer Institute definition of completed studies to determine the publication rate. We extracted data related to publication status, methodological quality, and treatment comparisons. One investigator extracted the data from all studies and 2 independent investigators extracted randomly about 50% of the data. Disagreements were resolved by consensus during a meeting. Data Synthesis Data on 12734 patients from 57 trials were evaluated. The publication rate was 95%. The quality of trials was high. We found no evidence of inappropriateness of the choice of comparator. Although the investigators judged that standard treatments were preferred in 71% of the comparisons, when data were meta-analyzed innovations were as likely as standard treatments to be successful (odds ratio for survival, 1.01; 99% confidence interval, 0.96-1.07; P=.5). In contrast, treatment-related mortality was worse with innovations (odds ratio, 1.76; 99% confidence interval, 1.01-3.07; P=.008). We found no predictable pattern of treatment successes in oncology: sometimes innovative treatments are better than the standard ones and vice versa; in most cases there were no substantive differences between experimental and conventional treatments. Conclusion The finding that the results in individual trials cannot be predicted in advance indicates that the system and rationale for RCTs is well preserved and that successful interventions can only be identified after an RCT is completed.	Univ S Florida, H Lee Moffitt Canc Ctr, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Res Inst, Tampa, FL 33612 USA; Radiat Therapy Oncol Grp, Dept Stat, Philadelphia, PA USA; Univ Indiana NW, Dept Math, Gary, IN USA; UK Cochrane Ctr, Oxford, England	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Radiation Therapy Oncology Group (RTOG); Cochrane Centre	Djulbegovic, B (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr, Dept Interdisciplinary Oncol, 12902 Magnolia Dr,SRB 4,Room 24031, Tampa, FL 33612 USA.	djulbebm@moffitt.usf.edu	Kumar, Ambuj/U-5268-2019; Serdarevic, Fadila/X-4503-2019; Hozo, ihozo@iun.edu/R-3498-2016; Quinn, Gwendolyn/H-7673-2019; Kumar, Ambuj/I-4940-2012; Djulbegovic, Benjamin/I-3661-2012; KUMAR, ASHOK/AAF-4055-2021	Hozo, ihozo@iun.edu/0000-0003-2349-5707; Quinn, Gwendolyn/0000-0002-4208-9889; Djulbegovic, Benjamin/0000-0003-0671-1447; KUMAR, ASHOK/0000-0002-9244-0622	NINDS NIH HHS [1R01NS/NR44417-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044417] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alderson P, 2004, BMJ-BRIT MED J, V328, P476, DOI 10.1136/bmj.328.7438.476; Als-Nielsen B, 2003, JAMA-J AM MED ASSOC, V290, P921, DOI 10.1001/jama.290.7.921; ALTMAN DG, 1995, BRIT MED J, V311, P485, DOI 10.1136/bmj.311.7003.485; ALTMAN DG, 1994, BRIT MED J, V308, P283, DOI 10.1136/bmj.308.6924.283; Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; [Anonymous], 2004, COCHRANE REV HDB 4 2; Chalmers I, 1997, BRIT MED J, V314, P74, DOI 10.1136/bmj.314.7073.74a; Chalmers Iain, 2004, BMJ, V328, P475, DOI 10.1136/bmj.328.7438.475; COCHR COLL, 2003, REV MAN VERS 4 2; Colditz G A, 1988, Int J Technol Assess Health Care, V4, P637; COLDITZ GA, 1989, STAT MED, V8, P441, DOI 10.1002/sim.4780080408; Collins R, 2001, LANCET, V357, P373, DOI 10.1016/S0140-6736(00)03651-5; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; Dickersin K, 1997, AIDS EDUC PREV, V9, P15; Djulbegovic B, 2000, LANCET, V356, P635, DOI 10.1016/S0140-6736(00)02605-2; Djulbegovic B, 2002, BRIT MED J, V325, P1420, DOI 10.1136/bmj.325.7377.1420; Djulbegovic B, 2001, Curr Oncol Rep, V3, P389, DOI 10.1007/s11912-001-0024-5; Djulbegovic B, 2001, JAMA-J AM MED ASSOC, V285, P1206, DOI 10.1001/jama.285.9.1206; Djulbegovic Benjamin, 2003, Account Res, V10, P301; *EARL BREAST CANC, 1990, INTRO METH SECT REPR; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2493, DOI 10.1001/jama.263.18.2493; Edwards SJ., 1998, HEALTH TECHNOL ASSES, V2, P1; Egger M, 2001, SYSTEMATIC REV HLTH; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; GILBERT JP, 1977, SCIENCE, V198, P684, DOI 10.1126/science.333585; Halpern SD, 2001, JAMA-J AM MED ASSOC, V285, P2713, DOI 10.1001/jama.285.21.2713-a; Ioannidis JPA, 2004, ANN INTERN MED, V141, P781, DOI 10.7326/0003-4819-141-10-200411160-00009; JADAD A, 1998, RANDOMIZED CONTROLLE; Juni P, 2001, SYSTEMATIC REV HLTH, P87; Kaptchuk TJ, 2003, BRIT MED J, V326, P1453, DOI 10.1136/bmj.326.7404.1453; KELAHAN AM, 2001, MANAGED CARE CANC, P28; Kuhn T.S., 1970, STRUCTURE SCI REVOLU, P174; Kuhn TS., 1998, PHILOS SCI CENTRAL I, P102; LANDIS JR, 1977, BIOMETRICS, V33, P363, DOI 10.2307/2529786; LAU J, 1995, J CLIN EPIDEMIOL, V48, P45, DOI 10.1016/0895-4356(94)00106-Z; Lilford RJ, 2001, BMJ-BRIT MED J, V322, P795; Machin D, 1997, Clin Oncol (R Coll Radiol), V9, P100; MANN H, COMPARATOR BIAS COMP; Mann Howard, 2003, BMC Med Res Methodol, V3, P7, DOI 10.1186/1471-2288-3-7; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1992, DOI 10.1001/jama.285.15.1992; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; *NCI CTEP, INV HDB; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Peto R, 1998, BMJ-BRIT MED J, V317, P1170, DOI 10.1136/bmj.317.7167.1170; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; *RTOG, 2003, PROC MAN RTOG; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Soares HP, 2004, BRIT MED J, V328, P22, DOI 10.1136/bmj.328.7430.22; *SPSS INC, 2002, SYSTAT VERS 10 2; 2000, N ENGL J MED, V342, P42	50	57	60	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	2005	293	8					970	978		10.1001/jama.293.8.970	http://dx.doi.org/10.1001/jama.293.8.970			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899LR	15728168	Green Accepted			2022-12-28	WOS:000227146400019
J	Carreira, S; Goodall, J; Aksan, I; La Rocca, SA; Galibert, MD; Denat, L; Larue, L; Goding, CR				Carreira, S; Goodall, J; Aksan, I; La Rocca, SA; Galibert, MD; Denat, L; Larue, L; Goding, CR			Mitf cooperates with Rb1 and activates p21(Cip1) expression to regulate cell cycle progression	NATURE			English	Article							MICROPHTHALMIA GENE-PRODUCT; DEPENDENT KINASE INHIBITOR; TRANSCRIPTION FACTOR; MELANOCYTE DEVELOPMENT; FACTOR TBX2; IN-VITRO; S PHASE; PROMOTER; TARGET; DIFFERENTIATION	The controls that enable melanoblasts and melanoma cells to proliferate are likely to be related, but so far no key regulator of cell cycle progression specific to the melanocyte lineage has been identified. The microphthalmia-associated transcription factor Mitf has a crucial but poorly defined role in melanoblast and melanocyte survival and in differentiation(1). Here we show that Mitf can act as a novel anti-proliferative transcription factor able to induce a G1 cell-cycle arrest that is dependent on Mitf-mediated activation of the p21(Cip1) (CDKN1A) cyclin-dependent kinase inhibitor gene. Moreover, cooperation between Mitf and the retinoblastoma protein Rb1 potentiates the ability of Mitf to activate transcription. The results indicate that Mitf-mediated activation of p21(Cip1) expression and consequent hypophosphorylation of Rb1 will contribute to cell cycle exit and activation of the differentiation programme. The mutation of genes associated with melanoma, such as INK4a or BRAF that would affect either Mitf cooperation with Rb1 or Mitf stability respectively, would impair Mitf-mediated cell cycle control.	Inst Curie, CNRS, UMR146, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Goding, CR (corresponding author), Marie Curie Res Inst, Signalling & Dev Lab, The Chart, Oxted RH8 OTL, Surrey, England.	c.goding@mcri.ac.uk	Larue, Lionel/F-7355-2013; Carreira, Suzanne/C-8445-2012; Larue, Lionel/I-6532-2016; la rocca, severina anna/D-8028-2011; KURNAZ, ISIL/GXG-5616-2022	Carreira, Suzanne/0000-0002-5077-5379; Goding, Colin/0000-0002-1614-3909				Aksan I, 1998, MOL CELL BIOL, V18, P6930, DOI 10.1128/MCB.18.12.6930; Allan LA, 2000, MOL CELL BIOL, V20, P1291, DOI 10.1128/MCB.20.4.1291-1298.2000; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Carreira S, 2000, J BIOL CHEM, V275, P21920, DOI 10.1074/jbc.M000035200; Carreira S, 1998, MOL CELL BIOL, V18, P5099, DOI 10.1128/MCB.18.9.5099; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Galibert MD, 2001, EMBO J, V20, P5022, DOI 10.1093/emboj/20.17.5022; Halaban R, 1998, ONCOGENE, V16, P2489, DOI 10.1038/sj.onc.1201773; HIRST K, 1994, EMBO J, V13, P5410, DOI 10.1002/j.1460-2075.1994.tb06876.x; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hornyak TJ, 2001, MECH DEVELOP, V101, P47, DOI 10.1016/S0925-4773(00)00569-4; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; JIANG HP, 1995, ONCOGENE, V10, P1855; KONYUKHOV BV, 1966, FOLIA BIOL-PRAGUE, V12, P116; LERNER AB, 1986, J INVEST DERMATOL, V87, P299, DOI 10.1111/1523-1747.ep12524353; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; OKURA M, 1995, J INVEST DERMATOL, V105, P322, DOI 10.1111/1523-1747.ep12319939; Prince S, 2004, CANCER RES, V64, P1669, DOI 10.1158/0008-5472.CAN-03-3286; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; Takahashi Y, 2000, GENE DEV, V14, P804; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Vance KW, 2004, PIGM CELL RES, V17, P318, DOI 10.1111/j.1600-0749.2004.00164.x; Vigo E, 1999, MOL CELL BIOL, V19, P6379; YAVUZER U, 1995, ONCOGENE, V10, P123; Yu BD, 2003, P NATL ACAD SCI USA, V100, P14881, DOI 10.1073/pnas.2431391100	30	299	308	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	2005	433	7027					764	769		10.1038/nature03269	http://dx.doi.org/10.1038/nature03269			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897XH	15716956				2022-12-28	WOS:000227039200044
J	Swanson, DL; Vetter, RS				Swanson, DL; Vetter, RS			Medical progress - Bites of brown recluse spiders and suspected necrotic arachnidism	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HYPERBARIC-OXYGEN; LOXOSCELES-LAETA; DAPSONE; ENVENOMATION; VENOM; DIAGNOSIS; THERAPY; VERIFICATIONS; IMMUNIZATION; SICARIIDAE		Mayo Clin, Dept Dermatol, Scottsdale, AZ 85259 USA; Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA	Mayo Clinic; Mayo Clinic Phoenix; University of California System; University of California Riverside	Swanson, DL (corresponding author), Mayo Clin, Dept Dermatol, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.							Anderson P C, 1998, Mo Med, V95, P318; ANDERSON PC, 1991, AM J OBSTET GYNECOL, V165, P1454; Araujo SC, 2003, TOXICON, V41, P261, DOI 10.1016/S0041-0101(02)00282-9; ATKINS JA, 1957, SCIENCE, V126, P73, DOI 10.1126/science.126.3263.73; AUER AI, 1974, ARCH SURG-CHICAGO, V108, P612; BARRETT SM, 1994, ANN EMERG MED, V24, P21, DOI 10.1016/S0196-0644(94)70156-3; Bennett RG, 2004, CAN FAM PHYSICIAN, V50, P1098; BERGER RS, 1973, JAMA-J AM MED ASSOC, V225, P1109, DOI 10.1001/jama.225.9.1109; Binford GJ, 2001, TOXICON, V39, P955, DOI 10.1016/S0041-0101(00)00234-8; Brescovit Antonio D., 2000, Bulletin of the British Arachnological Society, V11, P320; Bryant SM, 2003, AM J EMERG MED, V21, P89, DOI 10.1053/ajem.2003.50021; de Roodt AR, 2002, J NAT TOXINS, V11, P193; Dillaha C. J., 1963, Journal of the Arkansas Medical Society, V60, P91; FARDON DW, 1967, PLAST RECONSTR SURG, V40, P482, DOI 10.1097/00006534-196711000-00011; FUTRELL JM, 1992, AM J MED SCI, V304, P261, DOI 10.1097/00000441-199210000-00008; Glied M, 1999, DERMATOL CLIN, V17, P431, DOI 10.1016/S0733-8635(05)70097-8; Gomez HF, 1999, ACAD EMERG MED, V6, P1195, DOI 10.1111/j.1553-2712.1999.tb00133.x; GUDERIAN RH, 1986, LANCET, V2, P229; Hobbs GD, 1996, ACAD EMERG MED, V3, P758, DOI 10.1111/j.1553-2712.1996.tb03511.x; Isbister GK, 2004, INTERN MED J, V34, P287, DOI 10.1111/j.1444-0903.2004.00562.x; Isbister GK, 2004, INTERN MED J, V34, P38, DOI 10.1111/j.1444-0903.2004.00506.x; Isbister GK, 2003, MED J AUSTRALIA, V179, P199, DOI 10.5694/j.1326-5377.2003.tb05499.x; JANSEN GT, 1971, SOUTHERN MED J, V64, P1194, DOI 10.1097/00007611-197110000-00008; JETER WS, 1983, TOXICON, V21, P729, DOI 10.1016/0041-0101(83)90278-7; KING LE, 1983, JAMA-J AM MED ASSOC, V250, P648, DOI 10.1001/jama.250.5.648; Krywko DM, 2002, ANN EMERG MED, V39, P475, DOI 10.1067/mem.2002.123551; Macchiavello Atilio, 1947, PUERTO RICO JOUR PUBL HEALTH AND TROP MED, V22, P425; MÁLAQUE Ceila Maria Sant'Ana, 2002, Rev. Inst. Med. trop. S. Paulo, V44, P139, DOI 10.1590/S0036-46652002000300005; MARA JE, 1977, ROCKY MT MED J, V74, P257; MAYNOR ML, 1992, J HYPERBARIC MED, V7, P89; Moaven LD, 1999, MED J AUSTRALIA, V171, P685, DOI 10.5694/j.1326-5377.1999.tb123858.x; NISHIOKA SA, 2001, W J MED, V174, P240; Osborn C D, 1991, J Okla State Med Assoc, V84, P257; Osterhoudt KC, 2004, CLIN PEDIATR, V43, P407, DOI 10.1177/000992280404300417; Osterhoudt KC, 2002, ANN EMERG MED, V39, P558, DOI 10.1067/mem.2002.119509; Paniker U, 2001, DERMATOL CLIN, V19, P79, DOI 10.1016/S0733-8635(05)70231-X; PHILLIPS S, 1995, ANN EMERG MED, V25, P363, DOI 10.1016/S0196-0644(95)70296-2; Pincus SJ, 1999, MED J AUSTRALIA, V171, P99, DOI 10.5694/j.1326-5377.1999.tb123537.x; Platnick NI., 1993, ADV SPIDER TAXONOMY; REDMAN JF, 1974, ARCH DERMATOL, V110, P111, DOI 10.1001/archderm.110.1.111; REES R, 1987, ANN EMERG MED, V16, P945, DOI 10.1016/S0196-0644(87)80738-2; REES RS, 1985, ANN SURG, V202, P659, DOI 10.1097/00000658-198511000-00020; RIBEIRO LA, 1990, TOXICON, V28, P715, DOI 10.1016/0041-0101(90)90260-E; Roche KJ, 2001, NEW ENGL J MED, V345, P1611, DOI 10.1056/NEJMicm010777; SCHENONE H, 1970, AM J TROP MED HYG, V19, P564, DOI 10.4269/ajtmh.1970.19.564; SCHMAUS L. F., 1929, Journal of the American Medical Association, V92, P1265; Sezerino UM, 1998, T ROY SOC TROP MED H, V92, P546, DOI 10.1016/S0035-9203(98)90909-9; SPIELMAN A, 1970, AM J TROP MED HYG, V19, P729, DOI 10.4269/ajtmh.1970.19.729; SUTHERLAND SK, 1983, MED J AUSTRALIA, V2, P597, DOI 10.5694/j.1326-5377.1983.tb122690.x; Svendsen F J, 1986, J Ark Med Soc, V83, P199; van den Berg CW, 2002, IMMUNOLOGY, V107, P102, DOI 10.1046/j.1365-2567.2002.01468.x; VanAswegen G, 1997, TOXICON, V35, P1149, DOI 10.1016/S0041-0101(96)00203-6; VEST DK, 1987, TOXICON, V25, P175, DOI 10.1016/0041-0101(87)90239-X; Vetter R, 1999, Dermatol Online J, V5, P7; VETTER R, 2001, HOBO SPIDER; Vetter RS, 2000, WESTERN J MED, V173, P357, DOI 10.1136/ewjm.173.5.357; Vetter RS, 2004, ANN EMERG MED, V44, P605, DOI 10.1016/j.annemergmed.2004.03.016; Vetter RS, 2004, AM J EMERG MED, V22, P494, DOI 10.1016/j.ajem.2004.07.001; Vetter RS, 2004, J MED ENTOMOL, V41, P593, DOI 10.1603/0022-2585-41.4.593; Vetter RS, 2002, J MED ENTOMOL, V39, P948, DOI 10.1603/0022-2585-39.6.948; Vetter RS, 2002, CLIN INFECT DIS, V35, P442, DOI 10.1086/341244; Vettera RS, 2003, TOXICON, V42, P413, DOI 10.1016/S0041-0101(03)00173-9; White Julian, 1995, P259; WOLVERTON SE, 2001, COMPREHENSIVE DETERM, P238; Wright SW, 1997, ANN EMERG MED, V30, P28, DOI 10.1016/S0196-0644(97)70106-9; 1996, MMWR MORB MORTAL WKL, V45, P433	66	111	119	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2005	352	7					700	707		10.1056/NEJMra041184	http://dx.doi.org/10.1056/NEJMra041184			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897UO	15716564				2022-12-28	WOS:000227031100009
J	Boyce, M; Bryant, KF; Jousse, C; Long, K; Harding, HP; Scheuner, D; Kaufman, RJ; Ma, DW; Coen, DM; Ron, D; Yuan, JY				Boyce, M; Bryant, KF; Jousse, C; Long, K; Harding, HP; Scheuner, D; Kaufman, RJ; Ma, DW; Coen, DM; Ron, D; Yuan, JY			A selective inhibitor-of eIF2 alpha dephosphorylation protects cells from ER stress	SCIENCE			English	Article							ENDOPLASMIC-RETICULUM STRESS; TRANSLATIONAL CONTROL; PHOSPHORYLATION; IRE1; INTEGRATION; INFECTION; SURVIVAL; MUTANTS; SHUTOFF; GROWTH	Most protein phosphatases have little intrinsic substrate specificity, making selective pharmacological inhibition of specific dephosphorylation reactions a challenging problem. In a screen for small molecules that protect cells from endoplasmic reticulum (ER) stress, we,identified salubrinal, a selective inhibitor of cellular complexes that dephosphorylate eukaryotic translation initiation factor 2 subunit alpha (eIF2alpha). Salubrinal also blocks eIF2alpha dephosphorylation mediated by a herpes simplex virus protein and inhibits viral replication. These results suggest that selective chemical inhibitors of eIF2a dephosphorylation may be useful in diseases involving ER stress or viral infection. More broadly, salubrinal demonstrates the feasibility of selective pharmacological targeting of cellular dephosphorylation events.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Comm Virol, Boston, MA 02115 USA; NYU, Sch Med, Skirball Inst, New York, NY 10016 USA; Shanghai Inst Organ Chem, Shanghai, Peoples R China; Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; New York University; Chinese Academy of Sciences; Shanghai Institute of Organic Chemistry, CAS; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Yuan, JY (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	jyuan@hms.harvard.edu		Ron, David/0000-0002-3014-5636; Harding, Heather P/0000-0002-7359-7974; Boyce, Michael/0000-0002-2729-4876	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026077, R01AI019838, U01AI026077, R56AI026077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042394, R01DK047119, R37DK047119, R37DK042394, R29DK047119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS035138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG012859] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19838, AI26077] Funding Source: Medline; NIA NIH HHS [R37-AG012859] Funding Source: Medline; NIDDK NIH HHS [DDK42394, DK47119] Funding Source: Medline; NIEHS NIH HHS [ES08681] Funding Source: Medline; NIGMS NIH HHS [GM64703] Funding Source: Medline; NINDS NIH HHS [NS35138] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; BOYCE MC, UNPUB; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chen JJ, 2000, COLD SPRING HARBOR M, V39, P529; CHOU J, 1990, SCIENCE, V250, P1262, DOI 10.1126/science.2173860; CHOU J, 1995, P NATL ACAD SCI USA, V92, P10516, DOI 10.1073/pnas.92.23.10516; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Jousse C, 2003, J CELL BIOL, V163, P767, DOI 10.1083/jcb.200308075; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; LEIB DA, 1989, J VIROL, V63, P759, DOI 10.1128/JVI.63.2.759-768.1989; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; McCluskey A, 2002, J MED CHEM, V45, P1151, DOI 10.1021/jm010066k; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Sood R, 2000, GENETICS, V154, P787; Unlu M, 1997, ELECTROPHORESIS, V18, P2071, DOI 10.1002/elps.1150181133; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0	30	1144	1210	3	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	2005	307	5711					935	939		10.1126/science.1101902	http://dx.doi.org/10.1126/science.1101902			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897DV	15705855				2022-12-28	WOS:000226985100057
J	Dunningham, J; Rau, A; Burnett, K				Dunningham, J; Rau, A; Burnett, K			From pedigree cats to fluffy-bunnies	SCIENCE			English	Editorial Material							QUANTUM LIMIT; DECOHERENCE; PHASE; ATOMS; INTERFEROMETRY; LOCALIZATION; STANDARD	We consider two distinct classes of quantum mechanical entanglement. The first "pedigree" class consists of delicate highly entangled states, which hold great potential for use in future quantum technologies. By focusing on Schrodinger cat states, we demonstrate not only the possibilities these states hold but also the difficulties they present. The second "fluffy-bunny" class is made up of robust states that arise naturally as a result of measurements and interactions between particles. This class of entanglement may be responsible for the classical-like world we see around us.	Univ Oxford, Dept Phys, Clarendon Lab, Oxford OX1 3PU, England	University of Oxford	Burnett, K (corresponding author), Univ Oxford, Dept Phys, Clarendon Lab, Oxford OX1 3PU, England.	k.burnett1@physics.ox.ac.uk			Engineering and Physical Sciences Research Council [GR/S99297/01, GR/S99297/02] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Arndt M, 1999, NATURE, V401, P680, DOI 10.1038/44348; Bach R, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.200401; Bollinger JJ, 1996, PHYS REV A, V54, pR4649, DOI 10.1103/PhysRevA.54.R4649; Brune M, 1996, PHYS REV LETT, V77, P4887, DOI 10.1103/PhysRevLett.77.4887; Dunningham JA, 1999, PHYS REV LETT, V82, P3729, DOI 10.1103/PhysRevLett.82.3729; Dunningham JA, 2004, J MOD OPTIC, V51, P2323, DOI 10.1080/09500340410001731002; GHIRARDI GC, 1986, PHYS REV D, V34, P470, DOI 10.1103/PhysRevD.34.470; Giovannetti V, 2004, SCIENCE, V306, P1330, DOI 10.1126/science.1104149; Hackermuller L, 2004, NATURE, V427, P711, DOI 10.1038/nature02276; Javanainen J, 1996, PHYS REV LETT, V76, P161, DOI 10.1103/PhysRevLett.76.161; JOOS E, 1985, Z PHYS B CON MAT, V59, P223, DOI 10.1007/BF01725541; KASEVICH M, 1991, PHYS REV LETT, V67, P181, DOI 10.1103/PhysRevLett.67.181; Marshall W, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.130401; Ou ZY, 1997, PHYS REV A, V55, P2598, DOI 10.1103/PhysRevA.55.2598; Rau AV, 2003, SCIENCE, V301, P1081, DOI 10.1126/science.1084867; Schrodinger E, 1935, NATURWISSENSCHAFTEN, V23, P807, DOI 10.1007/BF01491891; TAN SM, 1993, PHYS REV A, V47, P4663, DOI 10.1103/PhysRevA.47.4663; Zurek WH, 2003, REV MOD PHYS, V75, P715, DOI 10.1103/RevModPhys.75.715	21	23	23	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2005	307	5711					872	875		10.1126/science.1109545	http://dx.doi.org/10.1126/science.1109545			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897DV	15705839				2022-12-28	WOS:000226985100039
J	Griffitts, JS; Haslam, SM; Yang, TL; Garczynski, SF; Mulloy, B; Morris, H; Cremer, PS; Dell, A; Adang, MJ; Aroian, RV				Griffitts, JS; Haslam, SM; Yang, TL; Garczynski, SF; Mulloy, B; Morris, H; Cremer, PS; Dell, A; Adang, MJ; Aroian, RV			Glycolipids as receptors for Bacillus thuringiensis crystal toxin	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; HELIOTHIS-VIRESCENS; PINK-BOLLWORM; RESISTANCE; BINDING; IDENTIFICATION; GLYCOSYLATION; ENDOTOXIN; PROTEINS	The development of pest resistance threatens the effectiveness of Bacillus thuringiensis (Bt) toxins used in transgenic and organic farming. Here, we demonstrate that (i) the major mechanism for Bt toxin resistance in Caenorhabditis elegans entails a loss of glycolipid carbohydrates; (ii) Bt toxin directly and specifically binds glycotipids; and (iii) this binding is carbohydrate-dependent and relevant for toxin action in vivo. These carbohydrates contain the arthroseries core conserved in insects and nematodes but lacking in vertebrates. We present evidence that insect glycolipids are also receptors for Bt toxin.	Univ Calif San Diego, Sect Cell & Dev Biol, La Jolla, CA 92093 USA; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Univ Georgia, Dept Entomol, Athens, GA 30602 USA; Natl Inst Biol Stand & Controls, Mol Struct Lab, Potters Bar EN6 3QG, Herts, England; MSCAN Mass Spectrometry Res & Training Ctr, Ascot SL5 7PZ, Berks, England	University of California System; University of California San Diego; Imperial College London; Texas A&M University System; Texas A&M University College Station; University System of Georgia; University of Georgia; National Institute for Biological Standards & Control	Aroian, RV (corresponding author), Univ Calif San Diego, Sect Cell & Dev Biol, La Jolla, CA 92093 USA.	raroian@ucsd.edu	Yang, Tinglu/N-3569-2013	Yang, Tinglu/0000-0003-0872-8218				Betz FS, 2000, REGUL TOXICOL PHARM, V32, P156, DOI 10.1006/rtph.2000.1426; Collins BE, 2004, CURR OPIN CHEM BIOL, V8, P617, DOI 10.1016/j.cbpa.2004.10.004; de Maagd RA, 2003, ANNU REV GENET, V37, P409, DOI 10.1146/annurev.genet.37.110801.143042; de Maagd RA, 2001, TRENDS GENET, V17, P193, DOI 10.1016/S0168-9525(01)02237-5; Dennis R D, 1986, Biomed Chromatogr, V1, P31, DOI 10.1002/bmc.1130010108; Gahan LJ, 2001, SCIENCE, V293, P857, DOI 10.1126/science.1060949; GARCZYNSKI SF, 2000, ENTOMOPATHOGENIC BAC, P181; Gerdt S, 1999, EUR J BIOCHEM, V266, P952, DOI 10.1046/j.1432-1327.1999.00937.x; Gonzalez-Cabrera J, 2003, INSECT BIOCHEM MOLEC, V33, P929, DOI 10.1016/S0965-1748(03)00099-7; Gould F, 1998, ANNU REV ENTOMOL, V43, P701, DOI 10.1146/annurev.ento.43.1.701; Griffitts JS, 2001, SCIENCE, V293, P860, DOI 10.1126/science.1062441; Griffitts JS, 2003, J BIOL CHEM, V278, P45594, DOI 10.1074/jbc.M308142200; Heckel DG, 1997, J ECON ENTOMOL, V90, P75, DOI 10.1093/jee/90.1.75; James C, 2002, ISAAA BRIEFS, V27, P1; Jurat-Fuentes JL, 2002, APPL ENVIRON MICROB, V68, P5711, DOI 10.1128/AEM.68.11.5711-5717.2002; Kawar ZS, 2002, J BIOL CHEM, V277, P34924, DOI 10.1074/jbc.M206112200; Kumaraswami NS, 2001, COMP BIOCHEM PHYS B, V129, P173, DOI 10.1016/S1096-4959(01)00327-X; LEE MK, 1995, APPL ENVIRON MICROB, V61, P3836, DOI 10.1128/AEM.61.11.3836-3842.1995; Marroquin LD, 2000, GENETICS, V155, P1693; Morin S, 2003, P NATL ACAD SCI USA, V100, P5004, DOI 10.1073/pnas.0831036100; Mucha J, 2004, BIOCHEM J, V382, P67, DOI 10.1042/BJ20040535; Oppert B, 1997, J BIOL CHEM, V272, P23473, DOI 10.1074/jbc.272.38.23473; Qaim M, 2003, SCIENCE, V299, P900, DOI 10.1126/science.1080609; Rajagopal R, 2002, J BIOL CHEM, V277, P46849, DOI 10.1074/jbc.C200523200; Wei JZ, 2003, P NATL ACAD SCI USA, V100, P2760, DOI 10.1073/pnas.0538072100; Yang TL, 2003, J AM CHEM SOC, V125, P4779, DOI 10.1021/ja029469f	26	261	309	4	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2005	307	5711					922	925		10.1126/science.1104444	http://dx.doi.org/10.1126/science.1104444			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897DV	15705852				2022-12-28	WOS:000226985100053
J	Nakata, K; Abrams, B; Grill, B; Goncharov, A; Huang, X; Chisholm, AD; Jin, YS				Nakata, K; Abrams, B; Grill, B; Goncharov, A; Huang, X; Chisholm, AD; Jin, YS			Regulation of a DLK-1 and p38 MAP kinase pathway by the ubiquitin ligase RPM-1 is required for presynaptic development	CELL			English	Article							ZIPPER-BEARING KINASE; AMPA RECEPTOR TRAFFICKING; CAENORHABDITIS-ELEGANS; C-ELEGANS; SYNAPTIC GROWTH; PROTEIN-KINASE; ACTIVE ZONES; IN-VIVO; SYNAPSES; LINEAGE	Synapses display a stereotyped ultrastructural organization, commonly containing a single electron-dense presynaptic density surrounded by a cluster of synaptic vesicles. The mechanism controlling subsynaptic proportion is not understood. Loss of function in the C. elegans rpm-1 gene, a putative RING finger/E3 ubiquitin ligase, causes disorganized presynaptic cytoarchitecture. RPM-1 is localized to the presynaptic periactive zone. We report that RPM-1 negatively regulates a p38 MAP kinase pathway composed of the dual leucine zipper-bearing MAPKKK DLK-1, the MAPKK MKK-4, and the p38 MAP kinase PMK-3. Inactivation of this pathway suppresses rpm-1 loss of function phenotypes, whereas overexpression or constitutive activation of this pathway causes synaptic defects resembling rpm-1(lf) mutants. DLK-1, like RPM-1, is localized to the periactive zone. DLK-1 protein levels are elevated in rpm-1 mutants. The RPM-1 RING finger can stimulate ubiquitination of DLK-1. Our data reveal a presynaptic role of a previously unknown p38 MAP kinase cascade.	Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Howard Hughes Med Inst, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz; Howard Hughes Medical Institute; University of California System; University of California Santa Cruz	Jin, YS (corresponding author), Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA.	jin@biology.ucsc.edu		Grill, Brock/0000-0002-0379-3267; Huang, Xun/0000-0002-2653-8293; Chisholm, Andrew/0000-0001-5091-0537; Jin, Yishi/0000-0002-9371-9860				Acsady L, 1998, J NEUROSCI, V18, P3386; Ahmari SE, 2000, NAT NEUROSCI, V3, P445, DOI 10.1038/74814; Berman Kevin, 2001, Molecular Cell Biology Research Communications, V4, P337, DOI 10.1006/mcbr.2001.0300; Bolshakov VY, 2000, NAT NEUROSCI, V3, P1107, DOI 10.1038/80624; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; BRENNER S, 1974, GENETICS, V77, P71; Burgess RW, 2004, MOL CELL BIOL, V24, P1096, DOI 10.1128/MCB.24.3.1096-1105.2004; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Coyle IP, 2004, NEURON, V41, P521, DOI 10.1016/S0896-6273(04)00016-9; DiAntonio A, 2001, NATURE, V412, P449, DOI 10.1038/35086595; Dikic I, 2003, CELL MOL LIFE SCI, V60, P1805, DOI 10.1007/s00018-003-3029-4; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Grill B, 2004, J IMMUNOL, V172, P2389, DOI 10.4049/jimmunol.172.4.2389; Guan ZH, 2003, J NEUROSCI, V23, P7317; Guo QB, 1998, P NATL ACAD SCI USA, V95, P9172, DOI 10.1073/pnas.95.16.9172; Hallam SJ, 1998, NATURE, V395, P78, DOI 10.1038/25757; Hallam SJ, 2002, NAT NEUROSCI, V5, P1137, DOI 10.1038/nn959; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; Huang CC, 2004, J BIOL CHEM, V279, P12286, DOI 10.1074/jbc.M312868200; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Koushika SP, 2001, NAT NEUROSCI, V4, P997, DOI 10.1038/nn732; Krapivinsky G, 2004, NEURON, V43, P563, DOI 10.1016/j.neuron.2004.08.003; Liao EH, 2004, NATURE, V430, P345, DOI 10.1038/nature02647; Mata M, 1996, J BIOL CHEM, V271, P16888, DOI 10.1074/jbc.271.28.16888; McCabe BD, 2004, NEURON, V41, P891, DOI 10.1016/S0896-6273(04)00073-X; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Morozov A, 2003, NEURON, V39, P309, DOI 10.1016/S0896-6273(03)00404-5; Murthy V, 2004, J BIOL CHEM, V279, P1351, DOI 10.1074/jbc.M310208200; Murthy VN, 2001, NEURON, V32, P673, DOI 10.1016/S0896-6273(01)00500-1; Murthy VN, 2003, ANNU REV NEUROSCI, V26, P701, DOI 10.1146/annurev.neuro.26.041002.131445; Niell CM, 2004, NAT NEUROSCI, V7, P254, DOI 10.1038/nn1191; Nihalani D, 2001, EMBO J, V20, P3447, DOI 10.1093/emboj/20.13.3447; Nihalani D, 2003, J BIOL CHEM, V278, P28694, DOI 10.1074/jbc.M304212200; Nonet ML, 1997, J NEUROSCI, V17, P8061; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Schaefer AM, 2000, NEURON, V26, P345, DOI 10.1016/S0896-6273(00)81168-X; Schikorski T, 1999, P NATL ACAD SCI USA, V96, P4107, DOI 10.1073/pnas.96.7.4107; Schikorski T, 1997, J NEUROSCI, V17, P5858; Scholich K, 2001, J BIOL CHEM, V276, P47583, DOI 10.1074/jbc.M107816200; Shapira M, 2003, NEURON, V38, P237, DOI 10.1016/S0896-6273(03)00207-1; Shen K, 2004, CELL, V116, P869, DOI 10.1016/S0092-8674(04)00251-X; Shepherd GMG, 1998, J NEUROSCI, V18, P8300; Sone M, 2000, DEVELOPMENT, V127, P4157; Thomas GM, 2004, NAT REV NEUROSCI, V5, P173, DOI 10.1038/nrn1346; Wan HI, 2000, NEURON, V26, P313, DOI 10.1016/S0896-6273(00)81166-6; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Wicks SR, 2001, NAT GENET, V28, P160, DOI 10.1038/88878; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Zhen M, 2000, NEURON, V26, P331, DOI 10.1016/S0896-6273(00)81167-8; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8	55	249	263	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 11	2005	120	3					407	420		10.1016/j.cell.2004.12.017	http://dx.doi.org/10.1016/j.cell.2004.12.017			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	897TS	15707898	Bronze			2022-12-28	WOS:000227028900015
J	Yang, HJ; Li, QB; Fan, J; Holloman, WK; Pavletich, NP				Yang, HJ; Li, QB; Fan, J; Holloman, WK; Pavletich, NP			The BRCA2 homologue Brh2 nucleates RAD51 filament formation at a dsDNA-ssDNA junction	NATURE			English	Article							REPLICATION PROTEIN-A; DNA STRAND EXCHANGE; PRESYNAPTIC COMPLEX-FORMATION; BREAST-CANCER SUSCEPTIBILITY; RAD51-MEDIATED RECOMBINATION; SACCHAROMYCES-CEREVISIAE; GENOME STABILITY; DIRECTED REPAIR; USTILAGO-MAYDIS; BINDING PROTEIN	The BRCA2 tumour suppressor(1) is essential for the error- free repair of double- strand breaks ( DSBs) in DNA by homologous recombination(2,3). This is mediated by RAD51, which forms a nucleoprotein filament with the 30 overhanging single- stranded DNA ( ssDNA) of the resected DSB, searches for a homologous donor sequence, and catalyses strand exchange with the donor DNA(4). The 3,418- amino- acid BRCA2 contains eight similar to 30- amino-acid BRC repeats that bind RAD51 ( refs 5, 6) and a similar to 700- amino-acid DBD domain that binds ssDNA(7). The isolated BRC and DBD domains have the opposing effects of inhibiting(8,9) and stimulating recombination(7), respectively, and the role of BRCA2 in repair has been unclear. Here we show that a full- length BRCA2 homologue ( Brh2) stimulates Rad51- mediated recombination at substoichiometric concentrations relative to Rad51. Brh2 recruits Rad51 to DNA and facilitates the nucleation of the filament, which is then elongated by the pool of free Rad51. Brh2 acts preferentially at a junction between double- stranded DNA ( dsDNA) and ssDNA, with strict specificity for the 30 overhang polarity of a resected DSB. These results establish a BRCA2 function in RAD51- mediated DSB repair and explain the loss of this repair capacity in BRCA2- associated cancers.	Mem Sloan Kettering Canc Ctr, Struct Biol Program, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Hearst Microbiol Res Ctr, Dept Microbiol & Immunol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Pavletich, NP (corresponding author), Mem Sloan Kettering Canc Ctr, Struct Biol Program, 1275 York Ave, New York, NY 10021 USA.	nikola@xray2.mskcc.org	fan, jie/A-3922-2012					Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Gupta RC, 1999, MOL CELL, V4, P705, DOI 10.1016/S1097-2765(00)80381-0; Kojic M, 2002, MOL CELL, V10, P683, DOI 10.1016/S1097-2765(02)00632-9; Kojic M, 2003, MOL CELL, V12, P1043, DOI 10.1016/S1097-2765(03)00367-8; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; Lo T, 2003, DNA REPAIR, V2, P1015, DOI 10.1016/S1568-7864(03)00097-1; McIlwraith MJ, 2000, J MOL BIOL, V304, P151, DOI 10.1006/jmbi.2000.4180; Morimatsu K, 2003, MOL CELL, V11, P1337, DOI 10.1016/S1097-2765(03)00188-6; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Sugawara N, 2003, MOL CELL, V12, P209, DOI 10.1016/S1097-2765(03)00269-7; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sugiyama T, 2002, J BIOL CHEM, V277, P31663, DOI 10.1074/jbc.M203494200; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; Wang X, 2004, PLOS BIOL, V2, P104, DOI 10.1371/journal.pbio.0020021; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; Wolner B, 2003, MOL CELL, V12, P221, DOI 10.1016/S1097-2765(03)00242-9; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837	30	244	249	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 10	2005	433	7026					653	657		10.1038/nature03234	http://dx.doi.org/10.1038/nature03234			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	895KX	15703751				2022-12-28	WOS:000226862000049
J	Esser-Kochling, BG; Hirsch, FW				Esser-Kochling, BG; Hirsch, FW			Ascaris lumbricoides blocking the common bile duct	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Klinikum Offenburg, D-77654 Offenburg, Germany		Esser-Kochling, BG (corresponding author), Klinikum Offenburg, D-77654 Offenburg, Germany.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 3	2005	352	5					E4	E4		10.1056/NEJMicm030773	http://dx.doi.org/10.1056/NEJMicm030773			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	893NE	15689578				2022-12-28	WOS:000226725400010
J	Frist, WH				Frist, WH			Recovering from the tsunami	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									US Senate, Washington, DC 20510 USA		Frist, WH (corresponding author), US Senate, Washington, DC 20510 USA.								0	10	10	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 3	2005	352	5					438	438		10.1056/NEJMp058017	http://dx.doi.org/10.1056/NEJMp058017			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	893NE	15689580				2022-12-28	WOS:000226725400002
J	Hoebe, K; Georgel, P; Rutschmann, S; Du, X; Mudd, S; Crozat, K; Sovath, S; Shamel, L; Hartung, T; Zahringer, U; Beutler, B				Hoebe, K; Georgel, P; Rutschmann, S; Du, X; Mudd, S; Crozat, K; Sovath, S; Shamel, L; Hartung, T; Zahringer, U; Beutler, B			CD36 is a sensor of diacylglycerides	NATURE			English	Article							TOLL-LIKE RECEPTOR-2; PATTERN-RECOGNITION; LIPOTEICHOIC ACID; IMMUNE-RESPONSE; FATTY-ACID; LIPOPOLYSACCHARIDE; IDENTIFICATION; GENE; LIPOPROTEINS; METABOLISM	Toll-like receptor 2 (TLR2) is required for the recognition of numerous molecular components of bacteria(1-8), fungi(9,10) and protozoa(11). The breadth of the ligand repertoire seems unusual, even if one considers that TLR2 may form heteromers with TLRs 1 and 6 (ref. 12), and it is likely that additional proteins serve as adapters for TLR2 activation. Here we show that an N-ethyl-N-nitrosourea-induced nonsense mutation of Cd36 ( oblivious) causes a recessive immunodeficiency phenotype in which macrophages are insensitive to the R-enantiomer of MALP-2 ( a diacylated bacterial lipopeptide) and to lipoteichoic acid. Homozygous mice are hypersusceptible to Staphylococcus aureus infection. Cd36(obl) macrophages readily detect S-MALP-2, PAM(2)CSK(4), PAM(3)CSK(4) and zymosan, revealing that some - but not all TLR2 ligands are dependent on CD36. Already known as a receptor for endogenous molecules, CD36 is also a selective and nonredundant sensor of microbial diacylglycerides that signal via the TLR2/6 heterodimer.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; EU Joint Res Ctr, ECVAM, I-21020 Ispra, Italy; Leibniz Ctr Med & Biosci, Res Ctr Borstel, D-23845 Borstel, Germany	Scripps Research Institute; Forschungszentrum Borstel	Beutler, B (corresponding author), Scripps Res Inst, Dept Immunol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	bruce@scripps.edu	Crozat, Karine/L-7297-2019; georgel, philippe/P-5676-2016; Eckhardt, Erik/G-1567-2010	Crozat, Karine/0000-0003-4761-3675; georgel, philippe/0000-0001-6853-7080; Rutschmann, Sophie/0000-0003-3932-1162; Hoebe, Kasper/0000-0002-3626-8098				Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; CALVO D, 1995, GENOMICS, V25, P100, DOI 10.1016/0888-7543(95)80114-2; Campos MA, 2001, J IMMUNOL, V167, P416, DOI 10.4049/jimmunol.167.1.416; Deininger S, 2003, J IMMUNOL, V170, P4134, DOI 10.4049/jimmunol.170.8.4134; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Glazier AN, 2002, MAMM GENOME, V13, P108, DOI 10.1007/s00335-001-2132-9; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Hoebe K, 2003, J ENDOTOXIN RES, V9, P250, DOI 10.1179/096805103225001459; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Kim SO, 2001, AM J PHYSIOL-LUNG C, V281, pL1095, DOI 10.1152/ajplung.2001.281.5.L1095; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; Means TK, 1999, J IMMUNOL, V163, P3920; Morath S, 2002, J EXP MED, V195, P1635, DOI 10.1084/jem.20020322; Morr M, 2002, EUR J IMMUNOL, V32, P3337, DOI 10.1002/1521-4141(2002012)32:12<3337::AID-IMMU3337>3.0.CO;2-I; Opitz B, 2001, J BIOL CHEM, V276, P22041, DOI 10.1074/jbc.M010481200; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Poltorak A, 1998, BLOOD CELL MOL DIS, V24, P340, DOI 10.1006/bcmd.1998.0201; ROSENTHAL RS, 1994, METHOD ENZYMOL, V235, P253; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Werts C, 2001, NAT IMMUNOL, V2, P346, DOI 10.1038/86354; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	24	643	666	2	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 3	2005	433	7025					523	527		10.1038/nature03253	http://dx.doi.org/10.1038/nature03253			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893NT	15690042				2022-12-28	WOS:000226727200049
J	Anson, BD; Weaver, JGR; Ackerman, MJ; Akinsete, O; Henry, K; January, CT; Badley, AD				Anson, BD; Weaver, JGR; Ackerman, MJ; Akinsete, O; Henry, K; January, CT; Badley, AD			Blockade of HERG channels by HIV protease inhibitors	LANCET			English	Article							PROLONGATION	The HIV protease inhibitor class of antiretroviral drug causes unpredicted adverse effects by changing elements of normal cellular metabolism. A case of QT prolongation in a patient receiving protease inhibitors made us question whether these drugs might be responsible. We identified 24 patients with QT prolongation or torsade de pointes, or both, associated with protease inhibitors, using the Food and Drug Administration's voluntary adverse event reporting system. Attending physicians thought that protease inhibitors were the most probable cause of these symptoms in 14 of the patients. Drug-induced QT prolongation is usually caused by block of human ether-a-go-go-related gene (HERG) potassium channels, and we showed that lopinavir, nelfinavir, ritonavir, and saquinavir caused dose-dependent block of HERG channels heterologously expressed in HEK293 cells in vitro. We also recorded block by lopinavir of repolarising potassium current (I-Kr) channels in neonatal mouse cardiac myocytes. Our data show that four protease inhibitors block HERG channels, suggesting that protease inhibitors could predispose individuals to QT prolongation and torsade de pointes.	Mayo Clin & Mayo Fdn, Coll Med, Div Infect Dis, Dept Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Div Infect Dis, Dept Pediat, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Div Infect Dis, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Univ Wisconsin, Dept Med, Madison, WI USA; Mayo Clin & Mayo Fdn, Coll Med, Program Translat Immunovirol & Biodefense, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Div Pediat Cardiol, Rochester, MN 55905 USA; Univ Ottawa, Dept Surg, Ottawa, ON, Canada; Univ Minnesota, Div Infect Dis, Minneapolis, MN 55415 USA; Hennepin Cty Med Ctr, HIV Program Hennepin, Minneapolis, MN 55415 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Wisconsin System; University of Wisconsin Madison; Mayo Clinic; Mayo Clinic; University of Ottawa; University of Minnesota System; University of Minnesota Twin Cities; Hennepin County Medical Center	Badley, AD (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Div Infect Dis, Dept Med, 200 1st St SW, Rochester, MN 55905 USA.	badley.andrew@mayo.edu	badley, andrew d/O-9022-2014	Badley, Andrew/0000-0001-7796-7680				Anson BD, 2004, AM J PHYSIOL-HEART C, V286, pH2434, DOI 10.1152/ajpheart.00891.2003; Castillo R, 2002, ANN PHARMACOTHER, V36, P1006; Devic E, 2001, MOL PHARMACOL, V60, P577; Moyle G, 2004, LANCET, V364, P8, DOI 10.1016/S0140-6736(04)16608-7; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Roden DM, 2004, NEW ENGL J MED, V350, P1013, DOI 10.1056/NEJMra032426; Roden DM, 1999, J CARDIOVASC ELECTR, V10, P1664, DOI 10.1111/j.1540-8167.1999.tb00231.x	7	127	131	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	2005	365	9460					682	686						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	898SP	15721475				2022-12-28	WOS:000227096800027
J	Viner, R; Booy, R				Viner, R; Booy, R			ABC of adolescence - Epidemiology of health and illness	BRITISH MEDICAL JOURNAL			English	Review									UCL Hosp NHS Fdn Trust, London, England; Great Ormond St Hosp Sick Children, London WC1N 3JH, England; Barts & London Sch Med & Dent Med Sch, London, England	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; Queen Mary University London	Viner, R (corresponding author), UCL Hosp NHS Fdn Trust, London, England.	rviner@ich.ucl.ac.uk	Booy, Robert/D-4188-2011; Viner, Russell M/A-1441-2009	Viner, Russell M/0000-0003-3047-2247				Coleman J., 2003, KEY DATA ADOLESCENCE; Neinstein LS, 2002, ADOLESCENT HLTH CARE; VINER RM, 2003, OXFORD TXB MED	3	31	32	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 19	2005	330	7488					411	414		10.1136/bmj.330.7488.411	http://dx.doi.org/10.1136/bmj.330.7488.411			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900NA	15718543	Green Published			2022-12-28	WOS:000227220400025
J	Hinds, DA; Stuve, LL; Nilsen, GB; Halperin, E; Eskin, E; Ballinger, DG; Frazer, KA; Cox, DR				Hinds, DA; Stuve, LL; Nilsen, GB; Halperin, E; Eskin, E; Ballinger, DG; Frazer, KA; Cox, DR			Whole-genome patterns of common DNA variation in three human populations	SCIENCE			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISMS; LINKAGE-DISEQUILIBRIUM; HAPLOTYPE; ASSOCIATION; DISEASE; ADMIXTURE; SELECTION; MAP; SUSCEPTIBILITY; DIVERSITY	Individual differences in DNA sequence are the genetic basis of human variability. We have characterized whole-genome patterns of common human DNA variation by genotyping 1,586,383 single-nucleotide polymorphisms (SNPs) in 71 Americans of European, African, and Asian ancestry. Our results indicate that these SNPs capture most common genetic variation as a result of linkage disequilibrium, the correlation among common SNP alleles. We observe a strong correlation between extended regions of linkage disequilibrium and functional genomic elements. Our data provide a toot for exploring many questions that remain regarding the causal role of common human DNA variation in complex human traits and for investigating the nature of genetic variation within and between human populations.	Perlegen Sci Inc, Mountain View, CA 94043 USA; Int Comp Sci Inst, Berkeley, CA 94704 USA; Univ Calif San Diego, Dept Comp Sci & Engn, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Cox, DR (corresponding author), Perlegen Sci Inc, 2021 Stierlin Court, Mountain View, CA 94043 USA.	david_cox@perlegen.com	Eskin, Eleazar/J-9187-2012	Eskin, Eleazar/0000-0003-1149-4758; Hinds, David/0000-0002-4911-803X; Frazer, Kelly/0000-0002-6060-8902				Akey JM, 2002, GENOME RES, V12, P1805, DOI 10.1101/gr.631202; Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216; Bader JS, 2001, PHARMACOGENOMICS, V2, P11, DOI 10.1517/14622416.2.1.11; BOWCOCK AM, 1991, P NATL ACAD SCI USA, V88, P839, DOI 10.1073/pnas.88.3.839; Carlson CS, 2003, NAT GENET, V33, P518, DOI 10.1038/ng1128; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; Dawson E, 2002, NATURE, V418, P544, DOI 10.1038/nature00864; De Kloet ER, 2004, ANN NY ACAD SCI, V1018, P1, DOI 10.1196/annals.1296.001; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; Duggal P, 2003, GENES IMMUN, V4, P245, DOI 10.1038/sj.gene.6363950; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Halperin E, 2004, BIOINFORMATICS, V20, P1842, DOI 10.1093/bioinformatics/bth149; Hinds DA, 2004, AM J HUM GENET, V74, P317, DOI 10.1086/381716; Hinds David A., 2004, Human Genomics, V1, P421; Hosking L, 2004, EUR J HUM GENET, V12, P395, DOI 10.1038/sj.ejhg.5201164; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Huttley GA, 1999, GENETICS, V152, P1711; Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776; Nakayama K, 2002, J HUM GENET, V47, P92, DOI 10.1007/s100380200007; Parra EJ, 1998, AM J HUM GENET, V63, P1839, DOI 10.1086/302148; Patil N, 2001, SCIENCE, V294, P1719, DOI 10.1126/science.1065573; Patterson N, 2004, AM J HUM GENET, V74, P979, DOI 10.1086/420871; Pennacchio LA, 2001, SCIENCE, V294, P169, DOI 10.1126/science.1064852; Pittman AM, 2004, HUM MOL GENET, V13, P1267, DOI 10.1093/hmg/ddh138; Pritchard JK, 2001, AM J HUM GENET, V69, P1, DOI 10.1086/321275; Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718; Romualdi C, 2002, GENOME RES, V12, P602, DOI 10.1101/gr.214902; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; Roses AD, 1997, NEUROGENETICS, V1, P3, DOI 10.1007/s100480050001; Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Serre D, 2004, GENOME RES, V14, P1679, DOI 10.1101/gr.2529604; Stein LD, 2002, GENOME RES, V12, P1599, DOI 10.1101/gr.403602; *U WASH FRED HUTCH, SEATTLESNPS; Van Gassen G, 2003, NEUROSCIENTIST, V9, P117, DOI 10.1177/1073858403252227; WEIR BS, 1984, EVOLUTION, V38, P1358, DOI [10.2307/2408641, 10.1111/j.1558-5646.1984.tb05657.x]; Xiao Q, 1996, J CLIN INVEST, V98, P2027, DOI 10.1172/JCI119007	38	890	958	0	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2005	307	5712					1072	1079		10.1126/science.1105436	http://dx.doi.org/10.1126/science.1105436			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ED	15718463				2022-12-28	WOS:000227197300038
J	Sarbassov, DD; Guertin, DA; Ali, SM; Sabatini, DM				Sarbassov, DD; Guertin, DA; Ali, SM; Sabatini, DM			Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex	SCIENCE			English	Article							PROTEIN-KINASE-B; INTEGRIN-LINKED KINASE; INSULIN-RESISTANCE; BINDING PARTNER; S6 KINASE; DNA-PK; RAPAMYCIN; ACTIVATION; MECHANISM; GROWTH	Deregulation of Akt/protein kinase B (PKB) is implicated in the pathogenesis of cancer and diabetes. Akt/PKB activation requires the phosphorylation of Thr(308) in the activation loop by the phosphoinositide-dependent kinase 1 (PDK1) and Ser(473) within the carboxyl-terminal hydrophobic motif by an unknown kinase. We show that in Drosophila and human cells the target of rapamycin (TOR) kinase and its associated protein rictor are necessary for Ser(473) phosphorylation and that a reduction in rictor or mammalian TOR (mTOR) expression inhibited an Akt/PKB effector. The rictor-mTOR complex directly phosphorylated Akt/PKB on Ser(473) in vitro and facilitated Thr(308) phosphorylation by PDK1. Rictor-mTOR may serve as a drug target in tumors that have lost the expression of PTEN, a tumor suppressor that opposes Akt/PKB activation.	MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Broad Inst, Cambridge, MA 02141 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Sabatini, DM (corresponding author), MIT, Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	sabatini@wi.mit.edu	Ali, Siraj/AAE-2958-2019; Sarbassov, Dos/AAS-4950-2020	Sarbassov, Dos/0000-0002-6848-1133; /0000-0002-1446-7256	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047389] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI47389] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Dore AS, 2004, DNA REPAIR, V3, P33, DOI 10.1016/j.dnarep.2003.09.003; Edinger AL, 2003, CANCER RES, V63, P8451; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Tremblay F, 2001, J BIOL CHEM, V276, P38052; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6	29	5005	5224	17	610	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2005	307	5712					1098	1101		10.1126/science.1106148	http://dx.doi.org/10.1126/science.1106148			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ED	15718470				2022-12-28	WOS:000227197300045
J	Begovac, J; Lukas, D				Begovac, J; Lukas, D			Condylomata lata of secondary syphilis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Zagreb, Univ Hosp Infect Dis, Zagreb 10000, Croatia	University of Zagreb	Begovac, J (corresponding author), Univ Zagreb, Univ Hosp Infect Dis, Zagreb 10000, Croatia.		Begovac, Josip/AAI-5672-2021	Begovac, Josip/0000-0003-2641-4327					0	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2005	352	7					708	708		10.1056/NEJMicm040514	http://dx.doi.org/10.1056/NEJMicm040514			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897UO	15716565				2022-12-28	WOS:000227031100010
J	Casey, G; Lindor, NM; Papadopoulos, N; Thibodeau, SN; Moskow, J; Steelman, S; Buzin, CH; Sommer, SS; Collins, CE; Butz, M; Aronson, M; Gallinger, S; Barker, MA; Young, JP; Jass, JR; Hopper, JL; Diep, A; Bapat, B; Salem, M; Seminara, D; Haile, R				Casey, G; Lindor, NM; Papadopoulos, N; Thibodeau, SN; Moskow, J; Steelman, S; Buzin, CH; Sommer, SS; Collins, CE; Butz, M; Aronson, M; Gallinger, S; Barker, MA; Young, JP; Jass, JR; Hopper, JL; Diep, A; Bapat, B; Salem, M; Seminara, D; Haile, R		Colon Canc Family Registry	Conversion analysis for mutation detection in MLH1 and MSH2 in patients with colorectal cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MICROSATELLITE INSTABILITY; GENOMIC DELETIONS; UNITED-STATES; FAMILIES; GENE	Context The accurate identification and interpretation of germline mutations in mismatch repair genes in colorectal cancer cases is critical for clinical management. Current data suggest that mismatch repair mutations are highly heterogeneous and that many mutations are not detected when conventional DNA sequencing alone is used. Objective To evaluate the potential of conversion analysis compared with DNA sequencing alone to detect heterogeneous germline mutations in MLH1, MSH2, and MSH6 in colorectal cancer patients. Design, Setting, and Participants Multicenter study with patients who participate in the Colon Cancer Family Registry. Mutation analyses were performed in participant samples determined to have a high probability of carrying mismatch repair germline mutations. Samples from a total of 64 hereditary nonpolyposis colorectal cancer cases, 8 hereditary nonpolyposis colorectal cancer-like cases, and 17 cases diagnosed prior to age 50 years were analyzed from June 2002 to June 2003. Main Outcome Measures Classification of family members as carriers or noncarriers of germline mutations in MLH1, MSH2, or MSH6; mutation data from conversion analysis compared with genomic DNA sequencing. Results Genomic DNA sequencing identified 28 likely deleterious exon mutations, 4 in-frame deletion mutations, 16 missense changes, and 22 putative splice site mutations. Conversion analysis identified all mutations detected by genomic DNA sequencing-plus an additional exon mutation, 12 large genomic deletions, and 1 exon duplication mutation-yielding an increase of 33% (14/42) in diagnostic yield of deleterious mutations. Conversion analysis also showed that 4 of 16 missense changes resulted in exon skipping in transcripts and that 17 of 22 putative splice site mutations affected splicing or mRNA transcript stability. Conversion analysis provided an increase of 56% (35/63) in the diagnostic yield of genetic testing compared with genomic DNA sequencing alone. Conclusions The data confirm the heterogeneity of mismatch repair mutations and reveal that many mutations in colorectal cancer cases would be missed using conventional genomic DNA sequencing alone. Conversion analysis substantially increases the diagnostic yield of genetic testing for mismatch repair mutations in patients diagnosed as having colorectal cancer.	Cleveland Clin, Lerner Coll Med, Dept Canc Biol, Cleveland, OH 44195 USA; Mayo Clin & Mayo Fdn, Dept Med Genet, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; GMP Genet, Waltham, MA USA; City Hope Natl Med Ctr, Clin Mol Diagnost Lab, Duarte, CA 91010 USA; Mt Sinai Hosp, Dept Surg, Toronto, ON M5G 1X5, Canada; Mt Sinai Hosp, Dept Pathol, Toronto, ON M5G 1X5, Canada; Bancroft Ctr, Cojoint Gastroenterol Lab, Herston, Qld, Australia; McGill Univ, Dept Pathol, Montreal, PQ, Canada; Univ Melbourne, Ctr Genet Epidemiol, Melbourne, Vic, Australia; Univ So Calif, Norris Canc Ctr, Dept Prevent Med, Los Angeles, CA USA; NCI, NIH, Bethesda, MD 20892 USA	Case Western Reserve University; Cleveland Clinic Foundation; Mayo Clinic; Mayo Clinic; City of Hope; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; McGill University; University of Melbourne; University of Southern California; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Casey, G (corresponding author), Cleveland Clin, Lerner Coll Med, Dept Canc Biol, ND50,9500 Euclid Ave, Cleveland, OH 44195 USA.	caseyg@ccf.org	Papadopoulos, Nickolas/K-7272-2012; Young, Joanne P/B-9981-2011; Young, Joanne P/H-7774-2014; Bapat, Bharati/B-5839-2014; Gallinger, Steven/E-4575-2013	Young, Joanne/0000-0002-1514-1522	NCI NIH HHS [U01 CA74800, U01 CA074799, U01 CA074800-06, UO1 CA074800, UO1 CA074799, U01 CA074794, UO1 CA074806, UO1 CA078296, U01 CA097735, UO1 CA074794, CA-95-011, U01 CA074783, U01 CA074806, U01 CA078296, U01 CA074800, UO1 CA074783, UO1 CA097735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA074800, U01CA074794, U01CA078296, U01CA097735, K22CA095011, U01CA074799, U01CA074783, U01CA074806] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUDHUIN LM, IN PRESS J MOL DIAGN; Boland CR, 1998, CANCER RES, V58, P5248; de la Chapelle A, 2003, AM J HUM GENET, V72, P236, DOI 10.1086/346215; Gille JJP, 2002, BRIT J CANCER, V87, P892, DOI 10.1038/sj.bjc.6600565; Jass JR, 2003, DIS COLON RECTUM, V46, P1305, DOI 10.1007/s10350-004-6738-3; Lindor NM, 2002, J CLIN ONCOL, V20, P1043, DOI 10.1200/JCO.20.4.1043; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; Liu T, 2001, CANCER RES, V61, P7798; Lynch HT, 2004, JAMA-J AM MED ASSOC, V291, P718, DOI 10.1001/jama.291.6.718; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; Marra G, 2001, CANCER RES, V61, P7719; Nakagawa H, 2002, CANCER RES, V62, P4579; Nakagawa Hidewaki, 2003, Hum Mutat, V22, P258, DOI 10.1002/humu.9171; PAPADOPOULOS N, 1995, NAT GENET, V11, P99, DOI 10.1038/ng0995-99; Taylor CE, 2003, HUM MUTAT, V22, P428, DOI 10.1002/humu.10291; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Wagner A, 2003, AM J HUM GENET, V72, P1088, DOI 10.1086/373963; Yan H, 2000, NATURE, V403, P723, DOI 10.1038/35001659	20	73	80	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	2005	293	7					799	809		10.1001/jama.293.7.799	http://dx.doi.org/10.1001/jama.293.7.799			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DQ	15713769	Green Accepted, Bronze			2022-12-28	WOS:000226984600021
J	Sharma, P; Bentley, P				Sharma, P; Bentley, P			Of rats and men: superwarfarin toxicity	LANCET			English	Editorial Material							WARFARIN; GENE		Univ London, Dept Cellular & Mol Neurosci, London W6 8RF, England; Univ London, Imperial Coll, Hammersmith Hosp Acute Stroke Unit, London W6 8RF, England	University of London; Imperial College London; University of London	Sharma, P (corresponding author), Univ London, Dept Cellular & Mol Neurosci, London W6 8RF, England.	psharma@imperial.ac.uk		Bentley, Paul/0000-0001-8036-7010				Budnitz DS, 2005, ANN EMERG MED, V45, P197, DOI 10.1016/j.annemergmed.2004.09.020; Chua JD, 1998, ARCH INTERN MED, V158, P1929, DOI 10.1001/archinte.158.17.1929; D'Andrea G, 2005, BLOOD, V105, P645, DOI 10.1182/blood-2004-06-2111; Freeman WD, 2004, MAYO CLIN PROC, V79, P1495, DOI 10.4065/79.12.1495; Hankey GJ, 1999, LANCET, V354, P1457, DOI 10.1016/S0140-6736(99)04407-4; Hart RG, 2000, NEUROLOGY, V55, P907, DOI 10.1212/WNL.55.7.907; Hirsh J, 2001, CHEST, V119, p8S, DOI 10.1378/chest.119.1_suppl.8S; MARTINBOUYER G, 1983, LANCET, V1, P230; Montefiore SS., 2004, STALIN COURT RED TSA; PELFRENE AF, 1991, HDB PESTICIDE TOXICO; Rost S, 2004, NATURE, V427, P537, DOI 10.1038/nature02214; Rusconi CP, 2002, NATURE, V419, P90, DOI 10.1038/nature00963; Sam C, 2004, AM J CARDIOL, V94, P947, DOI 10.1016/j.amjcard.2004.06.038; Shikata E, 2004, BLOOD, V103, P2630, DOI 10.1182/blood-2003-09-3043; 2004, NAT REV DRUG DISC, V3, P819	15	20	20	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	2005	365	9459					552	554						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DN	15708084				2022-12-28	WOS:000226984300007
J	Fountain, AG; Jacobel, RW; Schlichting, R; Jansson, P				Fountain, AG; Jacobel, RW; Schlichting, R; Jansson, P			Fractures as the main pathways of water flow in temperate glaciers	NATURE			English	Article							BASAL ICE; STORGLACIAREN; HYDROLOGY; SURFACE; RADAR; VELOCITY; DRAINAGE	Understanding the flow of water through the body of a glacier is important, because the spatial distribution of water and the rate of infiltration to the glacier bottom is one control on water storage and pressure, glacier sliding and surging, and the release of glacial outburst floods(1 - 3). According to the prevailing hypothesis, this water flow takes place in a network of tubular conduits(4,5). Here we analyse video images from 48 boreholes drilled into the small Swedish glacier Storglaciaren, showing that the glacier's hydrological system is instead dominated by fractures that convey water at slow speeds. We detected hydraulically connected fractures at all depths, including near the glacier bottom. Our observations indicate that fractures provide the main pathways for surface water to reach deep within the glacier, whereas tubular conduits probably form only in special circumstances. A network of hydraulically linked fractures offers a simple explanation for the origin and evolution of the englacial water flow system and its seasonal regeneration. Such a fracture network also explains radar observations that reveal a complex pattern of echoes rather than a system of conduits. Our findings may be important in understanding the catastrophic collapse of ice shelves and rapid hydraulic connection between the surface and bed of an ice sheet.	Portland State Univ, Dept Geol, Portland, OR 97207 USA; Portland State Univ, Dept Geog, Portland, OR 97207 USA; Cleveland High Sch, Portland, OR 97202 USA; St Olaf Coll, Dept Phys, Northfield, MN 55057 USA; Stockholm Univ, Dept Phys Geog & Quaternary Geol, SE-10691 Stockholm, Sweden	Portland State University; Portland State University; Saint Olaf College; Stockholm University	Fountain, AG (corresponding author), Portland State Univ, Dept Geol, Portland, OR 97207 USA.	andrew@pdx.edu	Jansson, Peter/B-5761-2012	Jansson, Peter/0000-0002-8832-8806				Anderson SP, 2003, J GEOPHYS RES-EARTH, V108, DOI 10.1029/2002JF000004; ARCONE SA, 1995, J GLACIOL, V41, P68, DOI 10.3189/S0022143000017779; Copland L, 1997, ANN GLACIOL, V24, P277, DOI 10.3189/S0260305500012301; DEROBIN GQ, 1974, J GLACIOL, V13, P543; Fountain AG, 1997, ANN GLACIOL, V24, P303, DOI 10.3189/S0260305500012350; Fountain AG, 1998, REV GEOPHYS, V36, P299, DOI 10.1029/97RG03579; Gordon S, 1998, HYDROL PROCESS, V12, P105, DOI 10.1002/(SICI)1099-1085(199801)12:1<105::AID-HYP566>3.3.CO;2-R; Gordon S, 2001, HYDROL PROCESS, V15, P797, DOI 10.1002/hyp.184; HARPER JT, 1995, GEOLOGY, V23, P901, DOI 10.1130/0091-7613(1995)023<0901:BVAOAT>2.3.CO;2; Hock R, 1999, ANN GLACIOL, V28, P253, DOI 10.3189/172756499781821742; HOLMLUND P, 1988, J GLACIOL, V34, P242, DOI 10.3189/S0022143000032305; HOOKE RL, 1994, J GLACIOL, V40, P140; HUMPHREY N, 1993, J GEOPHYS RES-SOL EA, V98, P837, DOI 10.1029/92JB01869; Iken A, 1997, J GLACIOL, V43, P328, DOI 10.3189/S0022143000003282; Jansson P, 1996, GEOGR ANN A, V78A, P171, DOI 10.2307/520979; Murray T, 2000, J GLACIOL, V46, P389, DOI 10.3189/172756500781833188; PATERSON WSB, 1996, PHYS GLACIERS, P103; PETTERSSON R, 2003, J GEOPHYS RES, V108, DOI DOI 10.1029/20034F000024; POHJOLA VA, 1994, J GLACIOL, V40, P231; POHJOLA VA, 1993, ICE DYNAMICAL STUDIE; Ru┬thlisberger H., 1972, J GLACIOL, V11, P177, DOI [10.3189/S0022143000022188, DOI 10.1017/S0022143000022188]; Scambos TA, 2000, J GLACIOL, V46, P516, DOI 10.3189/172756500781833043; Shreve R.L., 1972, J GLACIOL, V11, P205, DOI [DOI 10.3189/S002214300002219X, 10.3189/S002214300002219X]; Stenborg T., 1973, IASH PUBL, V95, P117; Stuart G, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2003JB002435; van der Veen CJ, 1998, COLD REG SCI TECHNOL, V27, P31, DOI 10.1016/S0165-232X(97)00022-0; WALDER JS, 1982, J GLACIOL, V28, P273, DOI 10.3189/S0022143000011631; Zwally HJ, 2002, SCIENCE, V297, P218, DOI 10.1126/science.1072708	28	149	153	1	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 10	2005	433	7026					618	621		10.1038/nature03296	http://dx.doi.org/10.1038/nature03296			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	895KX	15703743				2022-12-28	WOS:000226862000040
J	Spar, D				Spar, D			Reproductive tourism and the regulatory map	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Sch Business, Boston, MA 02163 USA	Harvard University	Spar, D (corresponding author), Harvard Univ, Sch Business, Boston, MA 02163 USA.								0	56	57	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2005	352	6					531	533		10.1056/NEJMp048295	http://dx.doi.org/10.1056/NEJMp048295			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895KY	15703416				2022-12-28	WOS:000226862100001
J	Miller, WC				Miller, WC			Screening for chlamydial infection: are we doing enough?	LANCET			English	Editorial Material							BARRIERS; WOMEN		Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Miller, WC (corresponding author), Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27599 USA.	bill_miller@unc.edu	Miller, William C/H-4800-2014	Miller, William C/0000-0002-1934-7827				Andersen B, 2002, J INFECT DIS, V185, P252, DOI 10.1086/338268; CATES W, 1991, AM J OBSTET GYNECOL, V164, P1771, DOI 10.1016/0002-9378(91)90559-A; *CDCP, 2002, SEX TRANSM DIS SURV; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P983; Cook RL, 2001, J ADOLESCENT HEALTH, V28, P204, DOI 10.1016/S1054-139X(00)00152-X; Idahl A, 2004, HUM REPROD, V19, P1121, DOI 10.1093/humrep/deh155; La Montagne DS, 2004, SEX TRANSM DIS, V31, P283, DOI 10.1097/01.OLQ.0000124613.85111.6B; LaMontagne DS, 2004, SEX TRANSM INFECT, V80, P335, DOI 10.1136/sti.2004.012856; Low N, 2002, INT J EPIDEMIOL, V31, P891, DOI 10.1093/ije/31.5.891; Low N, 2004, SEX TRANSM INFECT, V80, P342, DOI 10.1136/sti.2003.006197; McNulty CAM, 2004, BRIT J GEN PRACT, V54, P508; Miller WC, 2004, JAMA-J AM MED ASSOC, V291, P2229, DOI 10.1001/jama.291.18.2229; QUINN K, 2000, THEIR OWN YOUNG ADUL; Rani S, 2022, SPAT INF RES, V30, P417, DOI 10.1007/s41324-022-00442-9; Sandman D, 2000, OUT TOUCH AM MEN HLT; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103	16	20	20	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 5	2005	365	9458					456	458						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894SS	15705443				2022-12-28	WOS:000226812500007
J	Berndt, T; Boge, O; Stratmann, F; Heintzenberg, J; Kulmala, M				Berndt, T; Boge, O; Stratmann, F; Heintzenberg, J; Kulmala, M			Rapid formation of sulfuric acid particles at near-atmospheric conditions	SCIENCE			English	Article							GAS-PHASE REACTION; AEROSOL FORMATION; NUCLEATION; H2SO4; WATER; H2O; OH; TROPOSPHERE; KINETICS; AMMONIA	We investigated the formation of new particles in a laboratory study, starting from H2SO4 produced in situ through the reaction of OH radicals with SO.. Newly formed particles were observed for H2SO4 concentrations above 7 x 106 per cubic centimeter. At 293 kelvin, a rough estimate yielded a nucleation rate of 0.3 to 0.4 particles per cubic centimeter per second for similar to10(7) particles per cubic centimeter of H2SO4 (particle size greater than or equal to 3 nanometers). These findings are in agreement with observations from the atmosphere. The results demonstrate that under laboratory conditions similar to the atmosphere, particle formation occurs at atmospheric H2SO4 concentration levels.	Leibniz Inst Tropospharenforsch eV, D-04318 Leipzig, Germany; Univ Helsinki, FIN-00014 Helsinki, Finland	Leibniz Institut fur Tropospharenforschung (TROPOS); University of Helsinki	Berndt, T (corresponding author), Leibniz Inst Tropospharenforsch eV, Permoserstr 15, D-04318 Leipzig, Germany.	berndt@tropos.de	Kulmala, Markku T/I-7671-2016	Kulmala, Markku T/0000-0003-3464-7825				ATKINSON R, 1986, CHEM REV, V86, P69, DOI 10.1021/cr00071a004; Ball SM, 1999, J GEOPHYS RES-ATMOS, V104, P23709, DOI 10.1029/1999JD900411; Berndt T, 2004, ATMOS ENVIRON, V38, P2145, DOI 10.1016/j.atmosenv.2004.01.018; Birmili W, 2000, GEOPHYS RES LETT, V27, P2205, DOI 10.1029/1999GL011334; Birmili W, 2003, ATMOS CHEM PHYS, V3, P361, DOI 10.5194/acp-3-361-2003; COFFMAN DJ, 1995, J GEOPHYS RES-ATMOS, V100, P7147, DOI 10.1029/94JD03253; DOYLE GJ, 1961, J CHEM PHYS, V35, P795, DOI 10.1063/1.1701218; Erisman JW, 2001, ATMOS ENVIRON, V35, P1913, DOI 10.1016/S1352-2310(00)00544-6; Hanson DR, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001100; Hanson DR, 2000, J PHYS CHEM A, V104, P1715, DOI 10.1021/jp993622j; Jayne JT, 1997, J PHYS CHEM A, V101, P10000, DOI 10.1021/jp972549z; Kalberer M, 2004, SCIENCE, V303, P1659, DOI 10.1126/science.1092185; KASHCHIEV D, 1982, J CHEM PHYS, V76, P5098, DOI 10.1063/1.442808; Kolb CE, 2002, NATURE, V417, P597, DOI 10.1038/417597a; Korhonen P, 1999, J GEOPHYS RES-ATMOS, V104, P26349, DOI 10.1029/1999JD900784; Kramp F, 1998, J PHYS CHEM A, V102, P2685, DOI 10.1021/jp973289o; Kulmala M, 2004, J AEROSOL SCI, V35, P143, DOI 10.1016/j.jaerosci.2003.10.003; LECHNER MD, 1992, TASCHENBUCH CHEM PHY; Lee SH, 2003, SCIENCE, V301, P1886, DOI 10.1126/science.1087236; Lovejoy ER, 1996, J PHYS CHEM-US, V100, P19911, DOI 10.1021/jp962414d; Lushnikov AA, 1998, PHYS REV E, V58, P3157, DOI 10.1103/PhysRevE.58.3157; Napari I, 2002, J CHEM PHYS, V116, P4221, DOI 10.1063/1.1450557; O'Dowd CD, 2002, NATURE, V417, P632, DOI 10.1038/nature00775; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376, DOI 10.1164/ajrccm.155.4.9105082; Pitts Jr J. N., 2000, CHEM UPPER LOWER ATM; Pruppacher H.R., 2011, MICROPHYSICS CLOUDS; ROWLEY DM, 1991, J CHEM SOC FARADAY T, V87, P3221, DOI 10.1039/ft9918703221; Seinfeld J. H., 1998, ATMOSPHERIC CHEM PHY; Swartz E, 1999, J PHYS CHEM A, V103, P8824, DOI 10.1021/jp991697h; Vehkamaki H, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2002JD002184; Viisanen Y, 1997, J CHEM PHYS, V107, P920, DOI 10.1063/1.474445; Watson AJ, 2000, NATURE, V407, P730, DOI 10.1038/35037561; Weber RJ, 1999, GEOPHYS RES LETT, V26, P307, DOI 10.1029/1998GL900308; Wilson C., 1971, INADVERTENT CLIMATE; WYSLOUZIL BE, 1991, J CHEM PHYS, V94, P6842, DOI 10.1063/1.460262; ZELLNER R, 1978, BER BUNSEN PHYS CHEM, V82, P1172, DOI 10.1002/bbpc.19780821120; Zhang RY, 2004, SCIENCE, V304, P1487, DOI 10.1126/science.1095139	37	136	139	1	127	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2005	307	5710					698	700		10.1126/science.1104054	http://dx.doi.org/10.1126/science.1104054			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	894TQ	15692045				2022-12-28	WOS:000226814900035
J	Cohen, O; Bartal, G; Buljan, H; Carmon, T; Fleischer, JW; Segev, M; Christodoulides, DN				Cohen, O; Bartal, G; Buljan, H; Carmon, T; Fleischer, JW; Segev, M; Christodoulides, DN			Observation of random-phase lattice solitons	NATURE			English	Article							OPTICAL BLOCH OSCILLATIONS; WAVE-GUIDE ARRAYS; DISCRETE SOLITONS; MODES; LIGHT	The coherence of waves in periodic systems ( lattices) is crucial to their dynamics, as interference effects, such as Bragg reflections, largely determine their propagation. Whereas linear systems allow superposition, nonlinearity introduces a non-trivial interplay between localization effects, coupling between lattice sites, and incoherence. Until recently, all research on solitary waves (solitons) in nonlinear lattices has involved only coherent waves. In such cases, linear dispersion or diffraction of wave packets can be balanced by nonlinear effects, resulting in coherent lattice ( or 'discrete') solitons(1,2); these have been studied in many branches of science(3-11). However, in most natural systems, waves with only partial coherence are more common, because fluctuations ( thermal, quantum or some other) can reduce the correlation length to a distance comparable to the lattice spacing. Such systems should support random-phase lattice solitons displaying distinct features(12). Here we report the experimental observation of randomphase lattice solitons, demonstrating their self-trapping and local periodicity in real space, in addition to their multi-peaked power spectrum in momentum space. We discuss the relevance of such solitons to other nonlinear periodic systems in which fluctuating waves propagate, such as atomic systems, plasmas and molecular chains.	Technion Israel Inst Technol, Dept Phys, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Inst Solid State, IL-32000 Haifa, Israel; Univ Zagreb, Dept Phys, Zagreb 10000, Croatia; Princeton Univ, Dept Elect Engn, Princeton, NJ 08544 USA; Univ Cent Florida, CREOL, Sch Opt, Orlando, FL 32816 USA	Technion Israel Institute of Technology; Technion Israel Institute of Technology; University of Zagreb; Princeton University; State University System of Florida; University of Central Florida	Segev, M (corresponding author), Technion Israel Inst Technol, Dept Phys, IL-32000 Haifa, Israel.	msegev@tx.technion.ac.il	Buljan, Hrvoje/L-9155-2013	Buljan, Hrvoje/0000-0002-9808-6628; Cohen, Oren/0000-0002-1592-6530				[Anonymous], 1995, TURBULENCE; Ashcroft N.W., 1976, SOLID STATE PHYS; Buljan H, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.223901; Campbell DK, 2004, PHYS TODAY, V57, P43, DOI 10.1063/1.1650069; CHRISTODOULIDES DN, 1995, J OPT SOC AM B, V12, P1628, DOI 10.1364/JOSAB.12.001628; Christodoulides DN, 2003, NATURE, V424, P817, DOI 10.1038/nature01936; CHRISTODOULIDES DN, 1988, OPT LETT, V13, P794, DOI 10.1364/OL.13.000794; DAVYDOV AS, 1973, PHYS STATUS SOLIDI B, V59, P465, DOI 10.1002/pssb.2220590212; Efremidis NK, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.046602; Eiermann B, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.230401; Eisenberg HS, 1998, PHYS REV LETT, V81, P3383, DOI 10.1103/PhysRevLett.81.3383; FERMI E, 1955, LA1940 LANL; Fleischer JW, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.023902; Fleischer JW, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.123904; Fleischer JW, 2003, NATURE, V422, P147, DOI 10.1038/nature01452; Goodman J. W., 2000, STAT OPTICS, V1; Martin H, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.123902; Meier J, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.163902; Mitchell M, 1997, NATURE, V387, P880, DOI 10.1038/43079; Mitchell M, 1996, PHYS REV LETT, V77, P490, DOI 10.1103/PhysRevLett.77.490; Morandotti R, 1999, PHYS REV LETT, V83, P4756, DOI 10.1103/PhysRevLett.83.4756; Neshev D, 2003, OPT LETT, V28, P710, DOI 10.1364/OL.28.000710; Neshev DN, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.123903; Pertsch T, 1999, PHYS REV LETT, V83, P4752, DOI 10.1103/PhysRevLett.83.4752; Schwarz UT, 1999, PHYS REV LETT, V83, P223, DOI 10.1103/PhysRevLett.83.223; SEGEV M, 1994, PHYS REV LETT, V73, P3211, DOI 10.1103/PhysRevLett.73.3211; SIEVERS AJ, 1988, PHYS REV LETT, V61, P970, DOI 10.1103/PhysRevLett.61.970; SU WP, 1979, PHYS REV LETT, V42, P1698, DOI 10.1103/PhysRevLett.42.1698; Trombettoni A, 2001, PHYS REV LETT, V86, P2353, DOI 10.1103/PhysRevLett.86.2353; Xie AH, 2000, PHYS REV LETT, V84, P5435, DOI 10.1103/PhysRevLett.84.5435	30	81	83	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2005	433	7025					500	503		10.1038/nature03267	http://dx.doi.org/10.1038/nature03267			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893NT	15690035				2022-12-28	WOS:000226727200042
J	Smith, PC; Araya-Guerra, R; Bublitz, C; Parnes, B; Dickinson, LM; Van Vorst, R; Westfall, JM; Pace, WD				Smith, PC; Araya-Guerra, R; Bublitz, C; Parnes, B; Dickinson, LM; Van Vorst, R; Westfall, JM; Pace, WD			Missing clinical information during primary care visits	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE DRUG EVENTS; OUTPATIENT VISITS; REFERRAL PROCESS; MEDICAL ERRORS; PATIENT SAFETY; COMMUNICATION; CONTINUITY; PHYSICIANS; GAPS	Context The coordinating function of primary care is information-intensive and may be impeded by missing clinical information. However, missing clinical in formation has not been explicitly investigated in the primary care setting. Objective To describe primary care clinicians' reports of missing clinical information. Design, Setting, and Participants Cross-sectional survey conducted in 32 primary care clinics within State Networks of Colorado Ambulatory Practices and Partners (SNOCAP), a consortium of practice-based research networks participating in the Applied Strategies for Improving Patient Safety medical error reporting study. Two hundred fifty-three clinicians were surveyed about 1614 patient visits between May and December 2003. For every visit during 1 half-day session, each clinician completed a questionnaire about patient and visit characteristics and stated whether important clinical information had been missing. Clinician characteristics were also recorded. Main Outcome Measures Reports of missing clinical information frequency, type, and presumed location; perceived likelihood of adverse effects, delays in care, and additional services; and time spent looking for missing information. Multivariate analysis was conducted to assess the relationship of missing information to patient, visit, or clinician characteristics, adjusting for potential confounders and effects of clustering. Results Clinicians reported missing clinical information in 13.6% of visits; missing information included laboratory results (6.1% of all visits), letters/clictation (5.4%), radiology results (3.8%), history and physical examination (3.7%), and Medications (3.2%). Missing clinical information was frequently reported to be located outside their clinical system but within the United States (52.3%), to be at least somewhat likely to adversely affect patients (44%), and to potentially result in delayed care or additional services (59.5%). Significant time was reportedly spent unsuccessfully searching for missing clinical information (5-10 minutes, 25.6%; >10 minutes, 10.4%). After adjustment, reported missing clinical information was more likely when patients were recent immigrants (odds ratio [OR], 1.78; 95% confidence interval [CI], 1.06-2.99), new patients (OR, 2.39; 95% Cl, 1.70-3.35), or had multiple medical problems compared with no problems (1 problem: OR, 1.09; 95% Cl, 0.69-1.73; 2-5 problems: OR, 1, 87; 95% Cl, 1.21-2.89; >5 problems: OR, 2.78; 95% Cl, 1.61-4.80). Missing clinical information was less likely in rural practices (OR, 0.52; 95% Cl, 0.29-0.92) and when individual clinicians reported having full electronic records (OR, 0.40; 95% Cl, 0.17-0.94). Conclusions Primary care clinicians report that missing clinical information is common, multifaceted, likely to consume time and other resources, and may adversely affect patients. Additional research on missing information is needed to focus on validating clinicians' perceptions and on conducting prospective studies of its causes and sequelae.	Univ Colorado, Hlth Sci Ctr, Fitzsimons Army Med Ctr, Dept Family Med, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus	Smith, PC (corresponding author), Univ Colorado, Hlth Sci Ctr, Fitzsimons Army Med Ctr, Dept Family Med, POB 6508,Mail Stop F496,12474 E 19th Ave,Bldg 402, Aurora, CO 80045 USA.	peter.smith@uchsc.edu	Westfall, John/AAD-3570-2021		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS011878] Funding Source: NIH RePORTER; AHRQ HHS [U18 HS11878] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 2001, AM FAM PHYSICIAN, V63, P847; [Anonymous], 2001, CROSSING QUALITY CHA, DOI DOI 10.17226/10027; Bhasale AL, 1998, MED J AUSTRALIA, V169, P73, DOI 10.5694/j.1326-5377.1998.tb140186.x; Bourguet C, 1998, J FAM PRACTICE, V46, P47; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Burton LC, 2004, MILBANK Q, V82, P457, DOI 10.1111/j.0887-378X.2004.00318.x; CHERRY DK, 2003, NATL AMBULATORY MED; Cook RI, 2000, BRIT MED J, V320, P791, DOI 10.1136/bmj.320.7237.791; Donaldson M, 1996, PRIMARY CARE AM HLTH; Dovey S M, 2003, Am Fam Physician, V67, P915; Ebell MH, 2001, FAM MED, V33, P311; Elder NC, 2004, ANN FAM MED, V2, P125, DOI 10.1370/afm.16; Fernald DH, 2004, ANN FAM MED, V2, P327, DOI 10.1370/afm.221; Fink A., 1995, MEASURE SURVEY RELIA, V7; Forster AJ, 2003, ANN INTERN MED, V138, P161, DOI 10.7326/0003-4819-138-3-200302040-00007; Gandhi TK, 2000, J GEN INTERN MED, V15, P626, DOI 10.1046/j.1525-1497.2000.91119.x; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; Gilchrist VJ, 2004, MED CARE, V42, P276, DOI 10.1097/01.mlr.0000114916.95639.af; Gorey TM, 2004, ANN FAM MED, V2, pS3, DOI 10.1370/afm.130; GORMAN PN, 1995, J AM SOC INFORM SCI, V46, P729, DOI 10.1002/(SICI)1097-4571(199512)46:10<729::AID-ASI3>3.0.CO;2-2; Hasson F, 2000, J ADV NURS, V32, P1008, DOI 10.1046/j.1365-2648.2000.01567.x; Holden J, 1998, BRIT J GEN PRACT, V48, P1409; Institute of Medicine, 2004, PATIENT SAFETY ACHIE; Kibbe DC, 2004, AM FAM PHYSICIAN, V70, P1220; Kohn L.T., 2000, TO ERR IS HUMAN BUIL; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; Lesar TS, 1997, JAMA-J AM MED ASSOC, V277, P312, DOI 10.1001/jama.277.4.312; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; Parkerton PH, 2004, FAM MED, V36, P15; Parnes B, 2002, J FAM PRACTICE, V51, P65; Poon EG, 2004, ARCH INTERN MED, V164, P2223, DOI 10.1001/archinte.164.20.2223; Poon EG, 2004, J GEN INTERN MED, V19, P316, DOI 10.1111/j.1525-1497.2004.30357.x; ROULIDIS ZC, 1994, J FAM PRACTICE, V39, P446; Smith R, 1996, BRIT MED J, V313, P1062; Stiell A, 2003, CAN MED ASSOC J, V169, P1023; VANVORST R, 2001, HIGH PLAINS RES NETW; Wilson RM, 1999, MED J AUSTRALIA, V170, P411, DOI 10.5694/j.1326-5377.1999.tb127814.x; Woolf SH, 2004, ANN FAM MED, V2, P317, DOI 10.1370/afm.126	38	212	213	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2005	293	5					565	571		10.1001/jama.293.5.565	http://dx.doi.org/10.1001/jama.293.5.565			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	893BL	15687311	Bronze			2022-12-28	WOS:000226694200019
J	Pease, PJ; Levy, O; Cost, GJ; Gore, J; Ptacin, JL; Sherratt, D; Bustamante, C; Cozzarelli, NR				Pease, PJ; Levy, O; Cost, GJ; Gore, J; Ptacin, JL; Sherratt, D; Bustamante, C; Cozzarelli, NR			Sequence-directed DNA translocation by purified FtsK	SCIENCE			English	Article							ESCHERICHIA-COLI CHROMOSOME; CELL-DIVISION; SINGLE-MOLECULE; RNA-POLYMERASE; RECOMBINATION; REPLICATION; HELICASE; PROTEIN; FORCE; XERC	DNA translocases are molecular motors that move rapidly along DNA using adenosine triphosphate as the source of energy. We directly observed the movement of purified FtsK, an Escherichia coli translocase, on single DNA molecules. The protein moves at 5 kilobases per second and against forces up to 60 piconewtons, and locally reverses direction without dissociation. On three natural substrates, independent of its initial binding position, FtsK efficiently translocates over long distances to the terminal region of the E. coli chromosome, as it does in vivo. Our results imply that FtsK is a bidirectional motor that changes direction in response to short, asymmetric directing DNA sequences.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Biophys Grad Grp, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Oxford, Dept Biochem, Div Mol Genet, Oxford OX1 3QU, England	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of Oxford	Bustamante, C (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.	carios@alice.berkeley.edu; ncozzare@socrates.berkeley.edu		Cost, Gregory/0000-0002-8509-4653; Bustamante, Carlos/0000-0002-2970-0073	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031657, R01GM032543, R01GM031657, R37GM032543] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM08295-15, GM07232-27, GM32543, GM31657] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aussel L, 2002, CELL, V108, P195, DOI 10.1016/S0092-8674(02)00624-4; Barre FX, 2001, P NATL ACAD SCI USA, V98, P8189, DOI 10.1073/pnas.111008998; Bath J, 2000, SCIENCE, V290, P995, DOI 10.1126/science.290.5493.995; Bianco PR, 2001, NATURE, V409, P374, DOI 10.1038/35053131; BLAKELY G, 1991, NEW BIOL, V3, P789; Corre J, 2002, J BACTERIOL, V184, P3801, DOI 10.1128/JB.184.14.3801-3807.2002; Errington J, 2001, NAT REV MOL CELL BIO, V2, P538, DOI 10.1038/35080005; Espeli O, 2003, J BIOL CHEM, V278, P44639, DOI 10.1074/jbc.M308926200; Forde NR, 2002, P NATL ACAD SCI USA, V99, P11682, DOI 10.1073/pnas.142417799; Hendricks EC, 2000, MOL MICROBIOL, V36, P973, DOI 10.1046/j.1365-2958.2000.01920.x; Kaplan DL, 2004, MOL CELL, V15, P453, DOI 10.1016/j.molcel.2004.06.039; Lau IF, 2003, MOL MICROBIOL, V49, P731, DOI 10.1046/j.1365-2958.2003.03640.x; Liu GW, 1998, MOL MICROBIOL, V29, P893, DOI 10.1046/j.1365-2958.1998.00986.x; LOUARN J, 1994, J BACTERIOL, V176, P7524, DOI 10.1128/JB.176.24.7524-7531.1994; Postow L, 2004, GENE DEV, V18, P1766, DOI 10.1101/gad.1207504; Recchia GD, 1999, EMBO J, V18, P5724, DOI 10.1093/emboj/18.20.5724; Ristic D, 2001, P NATL ACAD SCI USA, V98, P8454, DOI 10.1073/pnas.151056798; Saleh OA, 2004, EMBO J, V23, P2430, DOI 10.1038/sj.emboj.7600242; Salzberg SL, 1998, GENE, V217, P57, DOI 10.1016/S0378-1119(98)00374-6; Singleton MR, 2003, EMBO J, V22, P4579, DOI 10.1093/emboj/cdg441; Smith DE, 2001, NATURE, V413, P748, DOI 10.1038/35099581; Smith SB, 1996, SCIENCE, V271, P795, DOI 10.1126/science.271.5250.795; Spies M, 2003, CELL, V114, P647, DOI 10.1016/S0092-8674(03)00681-0; Tan TLR, 2003, DNA REPAIR, V2, P787, DOI 10.1016/S1568-7864(03)00070-3; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; Wuite GJL, 2000, NATURE, V404, P103, DOI 10.1038/35003614	27	152	155	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2005	307	5709					586	590		10.1126/science.1104885	http://dx.doi.org/10.1126/science.1104885			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893BJ	15681387				2022-12-28	WOS:000226694000049
J	Nichols, WC; Pankratz, N; Hernandez, D; Paisan-Ruiz, C; Jain, S; Halter, CA; Michaels, VE; Reed, T; Rudolph, A; Shults, CW; Singleton, A; Foroud, T				Nichols, WC; Pankratz, N; Hernandez, D; Paisan-Ruiz, C; Jain, S; Halter, CA; Michaels, VE; Reed, T; Rudolph, A; Shults, CW; Singleton, A; Foroud, T		Parkinson Study Grp PROGENI Invest	Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease	LANCET			English	Article							SAMPLE	Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene cause some forms of autosomal dominant Parkinson's disease. We measured the frequency of a novel mutation (Gly2019Ser) in familial Parkinson's disease by screening genomic DNA of patients and controls. Of 767 affected individuals from 358 multiplex families, 35 (5%) individuals were either heterozygous (34) or homozygous (one) for the mutation, and had typical clinical findings of idiopathic Parkinson's disease. Thus, our results suggest that a single LRRK2 mutation causes Parkinson's disease in 5% of individuals with familial disease. Screening for this mutation should be a component of genetic testing for Parkinson's disease.	Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA; Indiana Univ, Med Ctr, Dept Med & Mol Genet, Indianapolis, IN USA; NIA, Mol Genet Unit, NIH, Bethesda, MD 20892 USA; CSIC, Dept Genom & Proteom, Inst Biomed Valencia, Unitat Genet Mol, Valencia, Spain; Inst Neurol, Dept Mol Neurosci, London WC1N 3BG, England; Univ Rochester, Dept Neurol, Rochester, NY USA; Univ Calif, Dept Neurosci, La Jolla, CA USA; Vet Affairs San Diego Healthcare Syst, San Diego, CA USA	Cincinnati Children's Hospital Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); University of London; University College London; University of Rochester; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Nichols, WC (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Human Genet, 3333 Burnet Ave,1469 TCHRF, Cincinnati, OH 45229 USA.	Bill.nichols@cchmc.org	Sander-Effron, Samuel/AAX-2231-2020; Singleton, Andrew B/C-3010-2009; Ruiz, Coro Paisán/C-2912-2009; Resource Center, NINDS Human Genetics/AGF-2474-2022	Pankratz, Nathan/0000-0001-5958-693X; Walker, Francis/0000-0002-7817-9421	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS037167, R01NS037167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000957, Z01AG000958, R01AG018736] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR-00750] Funding Source: Medline; NIA NIH HHS [AG18736] Funding Source: Medline; NINDS NIH HHS [NS37167] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		deRijk MC, 1997, J NEUROL NEUROSUR PS, V62, P10, DOI 10.1136/jnnp.62.1.10; HERNANDEZ DG, IN PRESS ANN NEUROL; Nichols WC, 2004, MOVEMENT DISORD, V19, P649, DOI 10.1002/mds.20097; Paisan-Ruiz C, 2004, NEURON, V44, P595, DOI 10.1016/j.neuron.2004.10.023; Pankratz N, 2002, AM J HUM GENET, V71, P124, DOI 10.1086/341282; Vila M, 2004, NAT MED, V10, pS58, DOI 10.1038/nm1068; Zimprich A, 2004, NEURON, V44, P601, DOI 10.1016/j.neuron.2004.11.005	7	366	379	1	20	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN-FEB	2005	365	9457					410	412		10.1016/S0140-6736(05)17828-3	http://dx.doi.org/10.1016/S0140-6736(05)17828-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891WE	15680455				2022-12-28	WOS:000226610900027
J	Martinez, C; Rietbrock, S; Wise, L; Ashby, D; Chick, J; Moseley, J; Evans, S; Gunnell, D				Martinez, C; Rietbrock, S; Wise, L; Ashby, D; Chick, J; Moseley, J; Evans, S; Gunnell, D			Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study	BRITISH MEDICAL JOURNAL			English	Article							SEROTONIN REUPTAKE INHIBITORS; SUICIDE; PREVENTION; OXFORD	Objective To compare the risk of non-fatal self harm and suicide in patients taking selective serotonin reuptake inhibitors (SSRIs) with that of patients taking tricyclic antidepressants, as well as between different SSRIs and different tricyclic antidepressants. Design Nested case-control study. Setting Primary care in the United Kingdom. Participants 146 095 individuals with a first prescription of an antidepressant for depression. Main outcome measures Suicide and non-fatal self harm. Results 1968 cases of non-fatal self harm and 69 suicides occurred. The overall adjusted odds ratio of non-fatal self harm was 0.99 (95% confidence interval 0.86 to 1.14) and that of suicide 0.57 (0.26 to 1.25) in people prescribed SSRIs compared with those prescribed tricyclic antidepressants. We found little evidence that associations differed over time since starting or stopping treatment. We found some evidence that risks of non-fatal self harm in people prescribed SSRIs compared with those prescribed tricyclic antidepressants differed by age group (interaction P = 0.02). The adjusted odds ratio of non-fatal self harm for people prescribed SSRIs compared with users of tricylic antidepressants for those aged 18 or younger was 1.59 (1.01 to 2.50), but no association was apparent in other age groups. No suicides occur-red in those aged 18 or younger currently or recently prescribed tricyclic antidepressants or SSRIs. Conclusion We found no evidence that the risk of suicide or non-fatal self harm in adults prescribed SSRIs was greater than in those prescribed tricyclic antidepressants. We found some weak evidence of air increased risk of non-fatal self harm for current SSRI use among those aged 18 or younger. However, preferential prescribing of SSRIs to patients at higher risk of suicidal behaviour cannot be ruled out.	Med & Healthcare Prod Regulatory Agcy, Gen Practice Res Database Div, London SW8 5NQ, England; Med & Healthcare Prod Regulatory Agcy, Post Licensing Div, London SW8 5NQ, England; Univ London, Queen Mary, Wolfson Inst Prevent Med, London WC1E 7HU, England; Univ Edinburgh, Dept Psychiat, Edinburgh EH8 9YL, Midlothian, Scotland; London Sch Hyg & Trop Med, Med Stat Unit, London, England; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	The Medicines & Healthcare Products Regulatory Agency; The Medicines & Healthcare Products Regulatory Agency; University of London; Queen Mary University London; University of Edinburgh; University of London; London School of Hygiene & Tropical Medicine; University of Bristol	Martinez, C (corresponding author), Med & Healthcare Prod Regulatory Agcy, Gen Practice Res Database Div, London SW8 5NQ, England.	carlos.martinez@gprd.de	anand, amit/A-7222-2009; Gunnell, David/ABE-6653-2020	Gunnell, David/0000-0002-0829-6470; Martinez, Carlos/0000-0001-6498-6428; Evans, Stephen/0000-0002-1474-2596				Breslow NE., 1987, STAT METHODS CANC RE, P81; Brock A, 2003, HLTH STAT Q, V20, P7; Buckley NA, 2002, BRIT MED J, V325, P1332, DOI 10.1136/bmj.325.7376.1332; Gunnell D, 2004, BRIT MED J, V329, P34, DOI 10.1136/bmj.329.7456.34; GUNNELL D, 1994, BMJ-BRIT MED J, V308, P1227, DOI 10.1136/bmj.308.6938.1227; Hawton K, 2003, PSYCHOL MED, V33, P987, DOI 10.1017/S0033291703007943; Hawton K, 1997, BRIT J PSYCHIAT, V171, P556, DOI 10.1192/bjp.171.6.556; Healy D, 2003, PSYCHOTHER PSYCHOSOM, V72, P71, DOI 10.1159/000068691; International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2005, ICH HARM TRIP GUID C; Jick H, 2004, JAMA-J AM MED ASSOC, V292, P338, DOI 10.1001/jama.292.3.338; JICK SS, 1995, BRIT MED J, V310, P215, DOI 10.1136/bmj.310.6974.215; Medawar C, 1997, Int J Risk Saf Med, V10, P75, DOI 10.3233/JRS-1997-10203; Medawar C, 2002, INT J RISK SAFETY ME, V15, P161; *NAT STAT ONL, CENS 2001; *NAT STAT ONL, TRENDS SUIC METH ENG, P7; *NAT STAT ONL, TRENDS SUIC METH ENG; Vandenbroucke JP, 2004, LANCET, V363, P1728, DOI 10.1016/S0140-6736(04)16261-2; Whittington CJ, 2004, LANCET, V363, P1341, DOI 10.1016/S0140-6736(04)16043-1; Wood L, 2004, DRUG SAFETY, V27, P871, DOI 10.2165/00002018-200427120-00004; Zahl DL, 2004, BRIT J PSYCHIAT, V185, P70, DOI 10.1192/bjp.185.1.70; 2003, CURR PROBL PHARMACOV, V29, P4	21	179	183	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 19	2005	330	7488					389	393		10.1136/bmj.330.7488.389	http://dx.doi.org/10.1136/bmj.330.7488.389			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900NA	15718538	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000227220400017
J	Asher, RJ; Meng, J; Wible, JR; McKenna, MC; Rougier, GW; Dashzeveg, D; Novacek, MJ				Asher, RJ; Meng, J; Wible, JR; McKenna, MC; Rougier, GW; Dashzeveg, D; Novacek, MJ			Stem lagomorpha and the antiquity of Glires	SCIENCE			English	Article							RODENTS; SYSTEMATICS; TIMESCALE; RADIATION; RELATIVES; MAMMALIA; RABBITS	We describe several fossils referable to Gomphos elkema from deposits close to the Paleocene-Eocene boundary at Tsagan Khushu, Mongolia. Gomphos shares a suite of cranioskeletal characters with extant rabbits, hares, and pikas but retains a primitive dentition and jaw compared to its modern relatives. Phylogenetic analysis supports the position of Gomphos as a stem lagomorph and excludes Cretaceous taxa from the crown radiation of placental mammals. Our results support the hypothesis that rodents and lagomorphs radiated during the Cenozoic and diverged from other placental mammals close to the Cretaceous-Tertiary boundary.	Humboldt Univ, Museum Nat, D-10115 Berlin, Germany; Amer Museum Nat Hist, Div Paleontol, New York, NY 10024 USA; Carnegie Museum Nat Hist, Sect Mammals, Pittsburgh, PA 15206 USA; Univ Wyoming, Dept Geol & Geophys, Laramie, WY 82071 USA; Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA; Mongolian Acad Sci, Geol Ctr, Ulaanbaatar, Mongolia	Humboldt University of Berlin; American Museum of Natural History (AMNH); University of Wyoming; University of Louisville; Mongolian Academy of Sciences	Asher, RJ (corresponding author), Humboldt Univ, Museum Nat, Invalidenstr 43, D-10115 Berlin, Germany.	robert.asher@museum.hu-berlin.de						Adkins RM, 2003, MOL PHYLOGENET EVOL, V26, P409, DOI 10.1016/S1055-7903(02)00304-4; Archibald JD, 2001, NATURE, V414, P62, DOI 10.1038/35102048; Bowen GJ, 2002, SCIENCE, V295, P2062, DOI 10.1126/science.1068700; DASHZEVEG D, 1987, P K NED AKAD B PHYS, V90, P133; Douzery EJP, 2003, J MOL EVOL, V57, pS201, DOI 10.1007/s00239-003-0028-x; GOLOBOFF P, NONA VERS 1 9; Hartenberger JL, 1998, CR ACAD SCI II A, V326, P439, DOI 10.1016/S1251-8050(98)80068-2; HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540; Huchon D, 2002, MOL BIOL EVOL, V19, P1053, DOI 10.1093/oxfordjournals.molbev.a004164; KIELANJAWOROWSK.Z, 1978, PALAEONTOL POL, V37, P32; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Lee MSY, 2000, SYST BIOL, V49, P829, DOI 10.1080/106351500750049879; Li C., 1985, EVOLUTIONARY RELATIO, P35; Luckett W.P., 1985, EVOLUTIONARY RELATIO; Matthee CA, 2004, SYST BIOL, V53, P433, DOI 10.1080/10635150490445715; MCKENNA MC, 1994, NAT HIST, V103, P56; McKenna MC, 2001, J VERTEBR PALEONTOL, V21, P565, DOI 10.1671/0272-4634(2001)021[0565:APRORF]2.0.CO;2; McKenna MC, 1997, CLASSIFICATION MAMMA; Meng J, 2004, AM MUS NOVIT, P1, DOI 10.1206/0003-0082(2004)425<0001:GEGMFT>2.0.CO;2; Meng J, 2003, B AM MUS NAT HIST, P1; Montgelard C, 2002, MOL PHYLOGENET EVOL, V22, P220, DOI 10.1006/mpev.2001.1056; Nilsson MA, 2003, J MOL EVOL, V57, pS3, DOI 10.1007/s00239-003-0001-8; NIXON KC, WINCLADA BETA VER 0; Rohlf F.J., 1995, STAT TABLES; SHEVYREVA NS, 1975, B GEORGIAN ACAD SCI, V77, P225; Springer MS, 2003, P NATL ACAD SCI USA, V100, P1056, DOI 10.1073/pnas.0334222100; Swofford D.L., 2002, PHYLOGENETIC ANAL US; VANVALEN L, 1964, EVOLUTION, V18, P484, DOI 10.1111/j.1558-5646.1964.tb01624.x; Wible JR, 2004, B AM MUS NAT HIST, P1, DOI 10.1206/0003-0090(2004)281<0001:NDOTSA>2.0.CO;2; Wyss AR, 1996, SYST BIOL, V45, P559, DOI 10.2307/2413531; ZHEGALLO VI, 1976, JT SOV MONG PALEONTO, V3, P269	31	142	157	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2005	307	5712					1091	1094		10.1126/science.1107808	http://dx.doi.org/10.1126/science.1107808			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ED	15718468				2022-12-28	WOS:000227197300043
J	Blomster, JP; Neff, H; Glascock, MD				Blomster, JP; Neff, H; Glascock, MD			Olmec pottery production and export in ancient Mexico determined through elemental analysis	SCIENCE			English	Article								The first Mesoamerican civilization, the Gulf Coast Olmec, is associated with hierarchical society, monumental art, and an internally consistent ideology, expressed in a distinct style and salient iconography. Whether the Otmec style arose in just one area or emerged from interactions among scattered contemporaneous societies remains controversial. Using elemental analysis, we determined the regional day sources of 725 archaeological ceramic samples from across Mesoamerica. Exported Olmec-style ceramics originated from the San Lorenzo region of the Gulf Coast, supporting Olmec priority in the creation and spread of the first unified style and iconographic system in Mesoamerica.	George Washington Univ, Dept Anthropol, Washington, DC 20052 USA; Calif State Univ Long Beach, Dept Anthropol, Long Beach, CA 90840 USA; Univ Missouri, Res Reactor Ctr, Columbia, MO 65211 USA	George Washington University; California State University System; California State University Long Beach; University of Missouri System; University of Missouri Columbia	Blomster, JP (corresponding author), George Washington Univ, Dept Anthropol, Washington, DC 20052 USA.	blomster@gwu.edu	Glascock, Michael/O-8951-2014	Glascock, Michael/0000-0003-0686-7556				Benson Elizabeth P., 1996, OLMEC ART ANCIENT ME; BISHOP RL, 1989, ARCHAEOL CHEM, V4, P576; BLOMSTER J, 1998, ANCIENT MESOAMERICA, V9, P171; Blomster Jeffrey P., 2004, ETLATONGO SOCIAL COM; Clark John E., 2000, OLMEC ART ARCHAEOLOG, P217; COE MD, 1965, HDB MIDDLE AM INDIAN, V3, P739; Coe Michael, 1980, LAND OLMEC, V1; Cyphers A., 1997, OLMEC AZTEC SETTLEME, P96; Flannery K., 1968, DUMBARTON OAKS C OLM, P79; Flannery K. V., 1994, MEMOIRS MUSEUM ANTHR, V27; Flannery KV, 2000, J ANTHROPOL ARCHAEOL, V19, P1, DOI 10.1006/jaar.1999.0359; Glascock M., 1992, CHEM CHARACTERIZATIO, P11; Grove DC, 1997, J WORLD PREHIST, V11, P51, DOI 10.1007/BF02221201; Herrera RS, 1999, J ARCHAEOL SCI, V26, P967, DOI 10.1006/jasc.1999.0433; Joralemon Peter David, 1971, STUDIES PRECOLUMBIAN, V7; Kirkby M. J., 1972, VANDERBILT U PUBLICA, V2; LORENZO JL, 1960, REV MEXICANA ESTUDIO, V16, P49; NEFF H, 2002, REPORT INSTRUMENTAL; Neff H., 2000, MODERN ANAL METHODS, P81; Sharer Robert J., 1989, REGIONAL PERSPECTIVE; THIEME M, 2001, PROCESOS CAMBIO CONC, P341	21	103	104	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	2005	307	5712					1068	1072		10.1126/science.1107599	http://dx.doi.org/10.1126/science.1107599			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ED	15718462				2022-12-28	WOS:000227197300037
J	Malsam, J; Satoh, A; Pelletier, L; Warren, G				Malsam, J; Satoh, A; Pelletier, L; Warren, G			Goigin tethers define subpopulations of COPI vesicles	SCIENCE			English	Article							GOLGI; TRANSPORT; PROTEIN; ARCHITECTURE; RECRUITMENT; CONTAINS; REVEALS; COMPLEX; P115	Coiled-coil proteins of the golgin family have been implicated in intra-Golgi transport through tethering coat protein complex I (COPI) vesicles. The p115-golgin tether is the best studied, and here we characterize the golgin-84-CASP tether. The vesicles bound by this tether were strikingly different from those bound by the p115-golgin tether in that they lacked members of the p24 family of putative cargo receptors and contained enzymes instead of anterograde cargo. Microinjected golgin-84 or CASP also inhibited Golgi-enzyme transport to the endoplasmic reticulum, further implicating this tether in retrograde transport. These and other golgins may modulate the flow patterns within the Golgi stack.	Yale Univ, Sch Med, Dept Cell Biol, Ludwig Inst Canc Res, New Haven, CT 06520 USA	Ludwig Institute for Cancer Research; Yale University	Warren, G (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, Ludwig Inst Canc Res, 333 Cedar St, New Haven, CT 06520 USA.	graham.warren@yale.edu	Pelletier, Laurence/F-8858-2013; Satoh, Ayano/B-2423-2011	Satoh, Ayano/0000-0003-3736-1283				Allan BB, 2000, SCIENCE, V289, P444, DOI 10.1126/science.289.5478.444; Axelsson MAB, 2004, MOL BIOL CELL, V15, P1843, DOI 10.1091/mbc.E03-07-0459; Diao A, 2003, J CELL BIOL, V160, P201, DOI 10.1083/jcb.200207045; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; Gillingham AK, 2003, BBA-MOL CELL RES, V1641, P71, DOI 10.1016/S0167-4889(03)00088-0; Gillingham AK, 2002, MOL BIOL CELL, V13, P3761, DOI 10.1091/mbc.E02-06-0349; Girod A, 1999, NAT CELL BIOL, V1, P423, DOI 10.1038/15658; Glick BS, 1998, CELL, V95, P883, DOI 10.1016/S0092-8674(00)81713-4; ITIN C, 1995, J CELL BIOL, V131, P57, DOI 10.1083/jcb.131.1.57; Lanoix J, 2001, J CELL BIOL, V155, P1199, DOI 10.1083/jcb.200108017; Malsam J, 1999, FEBS LETT, V462, P267, DOI 10.1016/S0014-5793(99)01543-4; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Nelson DS, 1998, J CELL BIOL, V143, P319, DOI 10.1083/jcb.143.2.319; Nickel W, 2002, J CELL SCI, V115, P3235; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; Pelham HRB, 2000, CELL, V102, P713, DOI 10.1016/S0092-8674(00)00060-X; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Puthenveedu MA, 2004, P NATL ACAD SCI USA, V101, P1253, DOI 10.1073/pnas.0306373101; Rojo M, 1997, J CELL BIOL, V139, P1119, DOI 10.1083/jcb.139.5.1119; Satoh A, 2003, TRAFFIC, V4, P153, DOI 10.1034/j.1600-0854.2003.00103.x; Seemann J, 2000, NATURE, V407, P1022, DOI 10.1038/35039538; Seemann J, 2000, MOL BIOL CELL, V11, P635, DOI 10.1091/mbc.11.2.635; Shorter J, 2002, ANNU REV CELL DEV BI, V18, P379, DOI 10.1146/annurev.cellbio.18.030602.133733; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Storrie B, 1998, J CELL BIOL, V143, P1505, DOI 10.1083/jcb.143.6.1505; Trucco A, 2004, NAT CELL BIOL, V6, P1071, DOI 10.1038/ncb1180; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; Whyte JRC, 2002, J CELL SCI, V115, P2627	28	150	161	0	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2005	307	5712					1095	1098		10.1126/science.1108061	http://dx.doi.org/10.1126/science.1108061			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ED	15718469				2022-12-28	WOS:000227197300044
J	Shrimpton, R; Gross, R; Darnton-Hill, I; Young, M				Shrimpton, R; Gross, R; Darnton-Hill, I; Young, M			Zinc deficiency: what are the most appropriate interventions?	BMJ-BRITISH MEDICAL JOURNAL			English	Review							IRON FORTIFICATION; INDONESIAN INFANTS; SUPPLEMENTAL ZINC; YOUNG-WOMEN; ABSORPTION; MORBIDITY; CHILDREN; GROWTH; TRIAL; MORTALITY		Inst Child Hlth, Ctr Int Child Hlth, London WC1N 1EH, England; Unicef, Programme Div, Nutr Sect, New York, NY USA; Unicef, Programme Div, Hlth Sect, New York, NY USA	University of London; University College London; UNICEF; UNICEF	Shrimpton, R (corresponding author), Inst Child Hlth, Ctr Int Child Hlth, 30 Guilford St, London WC1N 1EH, England.	Roger.Shrimpton@ich.ucl.ac.uk						*ADB MI ILSI, 2000, P FOR FOOD FORT POL; *AINC INV COLL GRO, 2000, AM J CLIN NUTR, V72, P1516; ALLEN LH, 1993, NUTR REV, V51, P255, DOI 10.1111/j.1753-4887.1993.tb03117.x; Annan Kofi, 2001, WE CHILDREN M PROMIS; [Anonymous], 1972, World Health Organ Tech Rep Ser, V503, P1; Bahl R, 2002, J PEDIATR-US, V141, P677, DOI 10.1067/mpd.2002.128543; BATES CJ, 1993, BRIT J NUTR, V69, P243, DOI 10.1079/BJN19930026; Begin F, 2002, FOOD FORTIFICATION W; Bhutta ZA, 1999, J PEDIATR-US, V135, P689, DOI 10.1016/S0022-3476(99)70086-7; Black R, 2003, B WORLD HEALTH ORGAN, V81, P79; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Brown KH, 2002, AM J CLIN NUTR, V75, P1062, DOI 10.1093/ajcn/75.6.1062; Bryce J, 2003, LANCET, V362, P159, DOI 10.1016/S0140-6736(03)13870-6; Dary O, 2002, NUTR REV, V60, pS30, DOI 10.1301/002966402320285074; Dewey Kathryn G., 2003, Food and Nutrition Bulletin, V24, P5; Dijkhuizen MA, 2001, AM J CLIN NUTR, V73, P786; Dijkhuizen MA, 2001, J NUTR, V131, P2860, DOI 10.1093/jn/131.11.2860; Donangelo CM, 2002, J NUTR, V132, P1860, DOI 10.1093/jn/132.7.1860; Gibson RS, 1998, AM J CLIN NUTR, V68, p484S, DOI 10.1093/ajcn/68.2.484S; Herman S, 2002, AM J CLIN NUTR, V76, P813, DOI 10.1093/ajcn/76.4.813; Hertrampf E, 2002, NUTR REV, V60, pS22, DOI 10.1301/002966402320285056; HUFFMAN SL, 1998, CASE PROMOTING MULTI; *INT ZINC NUTR CON, 2004, FOOD NUTR BULL, V25, pS91; *IRIS 1 STUD GROUP, 2002, FOOD NUTR B, V24, pS27; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Lind T, 2003, AM J CLIN NUTR, V77, P883, DOI 10.1093/ajcn/77.4.883; Lira PIC, 1998, AM J CLIN NUTR, V68, p418S, DOI 10.1093/ajcn/68.2.418S; Mason J., 2001, MICRONUTRIENT REPORT; Nestel P, 2003, J PEDIATR GASTR NUTR, V36, P316, DOI 10.1097/00005176-200303000-00005; Nestel P, 1996, IRON MULTIMICRONUTRI; O'Brien KO, 2000, J NUTR, V130, P2251, DOI 10.1093/jn/130.9.2251; Osendarp SJM, 2003, J NUTR, V133, p817S; Osendarp SJM, 2002, AM J CLIN NUTR, V76, P1401, DOI 10.1093/ajcn/76.6.1401; Prasad AS, 2003, BMJ-BRIT MED J, V326, P409, DOI 10.1136/bmj.326.7386.409; Rivera JA, 2001, AM J CLIN NUTR, V74, P657; Robberstad B, 2004, B WORLD HEALTH ORGAN, V82, P523; Salgueiro MJ, 2002, NUTR REV, V60, P52, DOI 10.1301/00296640260085958; Sazawal S, 2001, PEDIATRICS, V108, P1280, DOI 10.1542/peds.108.6.1280; Shankar AH, 2000, AM J TROP MED HYG, V62, P663, DOI 10.4269/ajtmh.2000.62.663; TURNLUND JR, 1991, AM J CLIN NUTR, V54, P1059, DOI 10.1093/ajcn/54.6.1059; *UNICEF, 1998, UNICEF UNU WHO MI TE; *UNICEF UNU WHO ST, 2002, MULT MICR SUPPL PREG; *UNICEF WHO UNU, 1999, WORKSH UNICEF HEADQ; Whittaker P, 1998, AM J CLIN NUTR, V68, p442S, DOI 10.1093/ajcn/68.2.442S; *WHO, 2004, JOINT STAT MAN AC DI; Wieringa FT, 2003, AM J CLIN NUTR, V77, P651, DOI 10.1093/ajcn/77.3.651; World Health Organization, 1998, COMPL FEED YOUNG CHI; World Health Organization, 1992, WHOMCHMSM922, V2nd; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20; Yip R, 2002, J NUTR, V132, p859S, DOI 10.1093/jn/132.4.859S; Zlotkin S, 2003, J NUTR, V133, P1075, DOI 10.1093/jn/133.4.1075	52	59	59	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 12	2005	330	7487					347	349		10.1136/bmj.330.7487.347	http://dx.doi.org/10.1136/bmj.330.7487.347			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897OZ	15705693	Green Published			2022-12-28	WOS:000227015800027
J	Broothaerts, W; Mitchell, HJ; Weir, B; Kaines, S; Smith, LMA; Yang, W; Mayer, JE; Roa-Rodriguez, C; Jefferson, RA				Broothaerts, W; Mitchell, HJ; Weir, B; Kaines, S; Smith, LMA; Yang, W; Mayer, JE; Roa-Rodriguez, C; Jefferson, RA			Gene transfer to plants by diverse species of bacteria	NATURE			English	Article							AGROBACTERIUM-TUMEFACIENS C58/; TI-PLASMID; RHIZOBIUM; GENOME; TRANSFORMATION; IDENTIFICATION; ARABIDOPSIS; VIRULENCE; MELILOTI; SEQUENCE	Agrobacterium is widely considered to be the only bacterial genus capable of transferring genes to plants. When suitably modified, Agrobacterium has become the most effective vector for gene transfer in plant biotechnology(1). However, the complexity of the patent landscape(2) has created both real and perceived obstacles to the effective use of this technology for agricultural improvements by many public and private organizations worldwide. Here we show that several species of bacteria outside the Agrobacterium genus can be modified to mediate gene transfer to a number of diverse plants. These plant-associated symbiotic bacteria were made competent for gene transfer by acquisition of both a disarmed Ti plasmid and a suitable binary vector. This alternative to Agrobacterium-mediated technology for crop improvement, in addition to affording a versatile 'open source' platform for plant biotechnology, may lead to new uses of natural bacteria-plant interactions to achieve plant transformation.	Charles Sturt Univ, Affiliated Res Ctr, CAMBIA, Canberra, ACT 2601, Australia	Charles Sturt University	Jefferson, RA (corresponding author), Charles Sturt Univ, Affiliated Res Ctr, CAMBIA, GPO Box 3200, Canberra, ACT 2601, Australia.	r.jefferson@cambia.org	broothaerts, wim/AAF-1287-2020	broothaerts, wim/0000-0003-3420-6368; Jefferson, Richard/0000-0001-5352-4498				Brown JR, 2003, NAT REV GENET, V4, P121, DOI 10.1038/nrg1000; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Cottage A, 2001, PLANT MOL BIOL REP, V19, P321, DOI 10.1007/BF02772830; Dennis C, 2004, NATURE, V431, P494, DOI 10.1038/431494a; Galibert F, 2001, SCIENCE, V293, P668, DOI 10.1126/science.1060966; Gelvin SB, 2003, MICROBIOL MOL BIOL R, V67, P16, DOI 10.1128/MMBR.67.1.16-37.2003; Goethals K, 2001, ANNU REV PHYTOPATHOL, V39, P27, DOI 10.1146/annurev.phyto.39.1.27; Goodner B, 2001, SCIENCE, V294, P2323, DOI 10.1126/science.1066803; HIEI Y, 1994, PLANT J, V6, P271, DOI 10.1046/j.1365-313X.1994.6020271.x; HOOD EE, 1993, TRANSGENIC RES, V2, P208, DOI 10.1007/BF01977351; HOOYKAAS PJJ, 1977, J GEN MICROBIOL, V98, P477, DOI 10.1099/00221287-98-2-477; Jefferson R. A., 2003, US Patent, Patent No. [6, 391-547, 6391547]; KLEIN DT, 1953, J BACTERIOL, V66, P220, DOI 10.1128/JB.66.2.220-228.1953; Kondo N, 2002, P NATL ACAD SCI USA, V99, P14280, DOI 10.1073/pnas.222228199; LAMBERT B, 1990, APPL ENVIRON MICROB, V56, P1093, DOI 10.1128/AEM.56.4.1093-1102.1990; Martin W, 2002, P NATL ACAD SCI USA, V99, P12246, DOI 10.1073/pnas.182432999; Nair GR, 2003, PLANT PHYSIOL, V133, P989, DOI 10.1104/pp.103.030262; Pueppke SG, 1999, MOL PLANT MICROBE IN, V12, P293, DOI 10.1094/MPMI.1999.12.4.293; REIMMANN C, 1993, BACTERIAL CONJUGATIO, P137; ROARODRIGUEZ C, 2003, AGROBACTERIUM MEDIAT; Stabb EV, 2002, METHOD ENZYMOL, V358, P413; Suzuki K, 2002, PLANT J, V32, P775, DOI 10.1046/j.1365-313X.2002.01468.x; Svab Zora, 1995, P55; Van Montagu M, 2003, TRENDS PLANT SCI, V8, P353, DOI 10.1016/S1360-1385(03)00160-2; VANVEEN RJM, 1989, ARCH MICROBIOL, V153, P85, DOI 10.1007/BF00277546; Veen R. J. M. van, 1988, Molecular Plant-Microbe Interactions, V1, P231, DOI 10.1094/MPMI-1-231; Watts RA, 2001, P NATL ACAD SCI USA, V98, P10119, DOI 10.1073/pnas.191349198; Wood DW, 2001, SCIENCE, V294, P2317, DOI 10.1126/science.1066804; Young JM, 2003, INT J SYST EVOL MICR, V53, P1689, DOI 10.1099/ijs.0.02762-0	29	201	291	2	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 10	2005	433	7026					629	633		10.1038/nature03309	http://dx.doi.org/10.1038/nature03309			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	895KX	15703747				2022-12-28	WOS:000226862000044
J	Meijer, R; van Limbeek, J				Meijer, R; van Limbeek, J			Early supported discharge: a valuable alternative for some stroke patients	LANCET			English	Editorial Material							OF-THE-LITERATURE; PROGNOSTIC-FACTORS; SUBACUTE PHASE		Rehabil Ctr, Dept Neurol Rehabil, NL-6800 GG Arnhem, Netherlands; Sint Maartensklin Nijmegen, Dept Rehabil Med, Nijmegen, Netherlands; Sint Maartensklin Nijmegen, SMK Res, Nijmegen, Netherlands	Sint Maartens Clinic; Sint Maartens Clinic	Meijer, R (corresponding author), Rehabil Ctr, Dept Neurol Rehabil, Groot Klimmendaal, NL-6800 GG Arnhem, Netherlands.	r.meijer@grootklimmendaal.nl						Asplund K, 1997, STROKE, V28, P2139, DOI 10.1161/01.STR.28.11.2139; *EARL SUPP DISCH T, 2000, COCHRANE DATABASE SY, V2, DOI UNSP CD0004433; *EARL SUPP DISCH T, IN PRESS COCHRANE DA; Meijer R, 2004, DISABIL REHABIL, V26, P191, DOI 10.1080/09638280310001636437; Meijer R, 2003, INT J REHABIL RES, V26, P265, DOI 10.1097/00004356-200312000-00003; Meijer R, 2003, CLIN REHABIL, V17, P512, DOI 10.1191/0269215503cr644oa; Meijer R, 2003, CLIN REHABIL, V17, P119, DOI 10.1191/0269215503cr585oa; MULDER T, 1991, PHYS THER, V71, P157, DOI 10.1093/ptj/71.2.157; Mulder Theo, 2001, Neural Plasticity, V8, P131, DOI 10.1155/NP.2001.131; *STROK UN TRIAL CO, 2002, COCHRANE DB SYST REV, V1	10	5	5	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 5	2005	365	9458					455	456						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894SS	15705442				2022-12-28	WOS:000226812500006
J	Felton, LM; Anthony, C				Felton, LM; Anthony, C			Role of PQQ as a mammalian enzyme cofactor?	NATURE			English	Editorial Material									Univ Southampton, Sch Biol Sci, Southampton SO16 7PX, Hants, England	University of Southampton	Felton, LM (corresponding author), Univ Southampton, Sch Biol Sci, Southampton SO16 7PX, Hants, England.	c.anthony@soton.ac.uk						Anthony C, 1998, PROG BIOPHYS MOL BIO, V69, P1, DOI 10.1016/S0079-6107(97)00020-5; Ehmann DE, 1999, BIOCHEMISTRY-US, V38, P6171, DOI 10.1021/bi9829940; Goodwin PM, 1998, ADV MICROB PHYSIOL, V40, P1, DOI 10.1016/S0065-2911(08)60129-0; Kasahara T, 2003, NATURE, V422, P832, DOI 10.1038/422832a; McIntire WS, 1998, ANNU REV NUTR, V18, P145, DOI 10.1146/annurev.nutr.18.1.145; Paoli M, 2001, PROG BIOPHYS MOL BIO, V76, P103, DOI 10.1016/S0079-6107(01)00007-4; Steinberg F, 2003, EXP BIOL MED, V228, P160, DOI 10.1177/153537020322800205	7	62	68	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 3	2005	433	7025					E10	E10		10.1038/nature03322	http://dx.doi.org/10.1038/nature03322			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893NT	15689995				2022-12-28	WOS:000226727200034
J	Sink, KM; Holden, KF; Yaffe, K				Sink, KM; Holden, KF; Yaffe, K			Pharmacological treatment of neuropsychiatric symptoms of dementia - A review of the evidence	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PLACEBO-CONTROLLED TRIAL; NURSING-HOME PLACEMENT; ALZHEIMERS-DISEASE; DOUBLE-BLIND; BEHAVIORAL DISTURBANCES; LEWY BODIES; NEUROLEPTIC SENSITIVITY; PSYCHOLOGICAL SYMPTOMS; DIVALPROEX SODIUM; RANDOMIZED-TRIAL	Context Neuropsychiatric symptoms of dementia are common and associated with poor outcomes for patients and caregivers. Although non pharmacological interventions should be the first line of treatment, a wide variety of pharmacological agents are used in the management of neuropsychiatric symptoms; therefore, concise, current, evidence-based recommendations are needed. Objective To evaluate the efficacy of pharmacological agents used in the treatment of neuropsychiatric symptoms of dementia. Evidence Acquisition A systematic review of English-language articles published from 1966 to July 2004 using MEDLINE, the Cochrane Database of Systematic Reviews, and a manual search of bibliographies was conducted. Inclusion criteria were double-blind, placebo-controlled, randomized controlled trials (RCTs) or meta-analyses of any drug therapy for patients with dementia that included neuropsychiatric outcomes. Trials reporting only depression outcomes were excluded. Data on the inclusion criteria, patients, methods, results, and quality of each study were independently abstracted. Twenty-nine articles met inclusion criteria. Evidence Synthesis For typical antipsychotics, 2 meta-analyses and 2 RCTs were included. Generally, no difference among specific agents was found, efficacy was small and adverse effects were common. Six RCTs with atypical antipsychotics were at best, included; results showed modest, statistically significant efficacy of olanzapine and risperidone, with minimal adverse effects at lower doses. Atypical antipsychotics are associated with an increased risk of stroke. There have been no RCTs designed to directly compare the efficacy of typical and atypical antipsychotics. Five trials of antidepressants were included; results showed no efficacy for treating neuropsychiatric symptoms other than depression, with the exception of 1 study of citalopram. For mood stabilizers, 3 RCTs investigating valproate showed no efficacy. Two small RCTs of carbamazepine had conflicting results. Two meta-analyses and 6 RCTs of cholinesterase inhibitors generally showed small, although statistically significant, efficacy. Two RCTs of memantine also had conflicting results for treatment of neuro psychiatric symptoms. Conclusions Pharmacological therapies are not particularly effective for management of neuropsychiatric symptoms of dementia. Of the agents reviewed, the atypical antipsychotics risperidone and olanzapine currently have the best evidence for efficacy. However, the effects are modest and further complicated by an increased risk of stroke. Additional trials of cholinesterase inhibitors enrolling patients with high levels of neuropsychiatric symptoms may be warranted.	Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Sticht Ctr Aging, Winston Salem, NC 27157 USA; Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA	Wake Forest University; Wake Forest Baptist Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Sink, KM (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Sticht Ctr Aging, 1 Med Ctr Blvd, Winston Salem, NC 27157 USA.	kmsink@wfubmc.edu	Sink, Kaycee/AAY-5920-2020		NIA NIH HHS [R01 AG021918-01] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R25MH060482] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021918] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Auchus AP, 1997, J NEUROPSYCH CLIN N, V9, P591; Bains J, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003944; Ballard C, 1998, LANCET, V351, P1032, DOI 10.1016/S0140-6736(05)78999-6; Ballard CG, 2002, J CLIN PSYCHIAT, V63, P553, DOI 10.4088/JCP.v63n0703; Baskys A, 2004, J CLIN PSYCHIAT, V65, P16; Beeri MS, 2002, INT J GERIATR PSYCH, V17, P403, DOI 10.1002/gps.490; Bentham P, 2004, LANCET, V363, P2105; Borson S, 1997, NEUROLOGY, V48, pS17, DOI 10.1212/WNL.48.5_Suppl_6.17S; Brodaty H, 2003, J CLIN PSYCHIAT, V64, P134, DOI 10.4088/JCP.v64n0205; CAVAZZONI P, 2003, LANCET, V362, P1689; Clark M E, 1998, J Gerontol Nurs, V24, P10; Clyburn LD, 2000, J GERONTOL B-PSYCHOL, V55, pS2, DOI 10.1093/geronb/55.1.s2; Coen RF, 1997, INT J GERIATR PSYCH, V12, P331, DOI 10.1002/(SICI)1099-1166(199703)12:3<331::AID-GPS495>3.3.CO;2-A; Cohen-Mansfield J, 2001, AM J GERIAT PSYCHIAT, V9, P361, DOI 10.1176/appi.ajgp.9.4.361; Covinsky KE, 2001, J GERONTOL A-BIOL, V56, pM707, DOI 10.1093/gerona/56.11.M707; De Deyn PP, 1999, NEUROLOGY, V53, P946, DOI 10.1212/WNL.53.5.946; De Deyn PP, 2004, INT J GERIATR PSYCH, V19, P115, DOI 10.1002/gps.1032; Donaldson C, 1998, INT J GERIATR PSYCH, V13, P248; Doody RS, 2001, NEUROLOGY, V56, P1154, DOI 10.1212/WNL.56.9.1154; Erkinjuntti T, 2002, LANCET, V359, P1283, DOI 10.1016/S0140-6736(02)08267-3; *EXP CONC PAN AG D, 1998, POSTGRAD MED; Feldman H, 2001, NEUROLOGY, V57, P613, DOI 10.1212/WNL.57.4.613; Finkel SI, 2001, J CLIN PSYCHIAT, V62, P3; Finkel SI, 2004, INT J GERIATR PSYCH, V19, P9, DOI 10.1002/gps.998; Gerdner LA, 2000, INT PSYCHOGERIATR, V12, P49, DOI 10.1017/S1041610200006190; GREENSPAN A, 2004, 24 C C INT NEUR CINP; Hogan David B, 2003, Can J Clin Pharmacol, V10, P72; Holmes C, 2004, NEUROLOGY, V63, P214, DOI 10.1212/01.WNL.0000129990.32253.7B; Holmes C, 2002, INT J GERIATR PSYCH, V17, P305, DOI 10.1002/gps.593; Katz IR, 1999, J CLIN PSYCHIAT, V60, P107, DOI 10.4088/JCP.v60n0207; Lonergan E., 2002, COCHRANE DB SYST REV, V(2), pCD002852; Lyketsos CG, 2000, AM J PSYCHIAT, V157, P708, DOI 10.1176/appi.ajp.157.5.708; Lyketsos CG, 2002, JAMA-J AM MED ASSOC, V288, P1475, DOI 10.1001/jama.288.12.1475; Lyketsos CG, 2003, ARCH GEN PSYCHIAT, V60, P737, DOI 10.1001/archpsyc.60.7.737; Lyketsos CG, 2004, DEMENT GERIATR COGN, V17, P55, DOI 10.1159/000074277; McKeith I, 2000, LANCET, V356, P2031, DOI 10.1016/S0140-6736(00)03399-7; MCKEITH IG, 1995, LANCET, V346, P699, DOI 10.1016/S0140-6736(95)92307-1; Meehan KM, 2002, NEUROPSYCHOPHARMACOL, V26, P494, DOI 10.1016/S0893-133X(01)00365-7; Mega MS, 1996, NEUROLOGY, V46, P130, DOI 10.1212/WNL.46.1.130; MILES SH, 1992, GERONTOLOGIST, V32, P762, DOI 10.1093/geront/32.6.762; Nagaratnam N, 1998, ALZ DIS ASSOC DIS, V12, P330, DOI 10.1097/00002093-199812000-00013; Olin J.T., 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001747; Olin JT, 2001, AM J GERIAT PSYCHIAT, V9, P400, DOI 10.1176/appi.ajgp.9.4.400; Pollock BG, 2002, AM J PSYCHIAT, V159, P460, DOI 10.1176/appi.ajp.159.3.460; Porsteinsson AP, 2001, AM J GERIAT PSYCHIAT, V9, P58, DOI 10.1176/appi.ajgp.9.1.58; Rahkonen T, 2003, J NEUROL NEUROSUR PS, V74, P720, DOI 10.1136/jnnp.74.6.720; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; Rockwood K, 2001, NEUROEPIDEMIOLOGY, V20, P51, DOI 10.1159/000054761; Rockwood K, 2001, J NEUROL NEUROSUR PS, V71, P589, DOI 10.1136/jnnp.71.5.589; Ruths S, 2004, J AM GERIATR SOC, V52, P1737, DOI 10.1111/j.1532-5415.2004.52470.x; Schneider LS, 2001, AM J GERIAT PSYCHIAT, V9, P346, DOI 10.1176/appi.ajgp.9.4.346; SCHNEIDER LS, 1990, J AM GERIATR SOC, V38, P553, DOI 10.1111/j.1532-5415.1990.tb02407.x; Sechi G, 2000, PROG NEURO-PSYCHOPH, V24, P1043, DOI 10.1016/S0278-5846(00)00123-8; Sink KM, 2004, J AM GERIATR SOC, V52, P1277, DOI 10.1111/j.1532-5415.2004.52356.x; Sival RC, 2002, INT J GERIATR PSYCH, V17, P579, DOI 10.1002/gps.653; Small GW, 1997, JAMA-J AM MED ASSOC, V278, P1363, DOI 10.1001/jama.278.16.1363; STEELE C, 1990, AM J PSYCHIAT, V147, P1049; Stern Y, 1997, JAMA-J AM MED ASSOC, V277, P806, DOI 10.1001/jama.277.10.806; STOTSKY B, 1984, CLIN THER, V6, P546; Stoudemire A, 1996, GEN HOSP PSYCHIAT, V18, P77, DOI 10.1016/0163-8343(95)00130-1; Street JS, 2000, ARCH GEN PSYCHIAT, V57, P968, DOI 10.1001/archpsyc.57.10.968; Sultzer DL, 2001, J AM GERIATR SOC, V49, P1294, DOI 10.1046/j.1532-5415.2001.49256.x; Tariot PN, 1998, AM J PSYCHIAT, V155, P54, DOI 10.1176/ajp.155.1.54; Tariot PN, 2000, NEUROLOGY, V54, P2269, DOI 10.1212/WNL.54.12.2269; Tariot PN, 2004, JAMA-J AM MED ASSOC, V291, P317, DOI 10.1001/jama.291.3.317; Tariot PN, 2001, J AM GERIATR SOC, V49, P1590, DOI 10.1046/j.1532-5415.2001.t01-1-49266.x; Tariot PN, 2001, CURR THER RES CLIN E, V62, P51, DOI 10.1016/S0011-393X(01)80042-4; Taylor DH, 2004, J GERONTOL A-BIOL, V59, P762; Teri L, 2000, NEUROLOGY, V55, P1271, DOI 10.1212/WNL.55.9.1271; Trinh NH, 2003, JAMA-J AM MED ASSOC, V289, P210, DOI 10.1001/jama.289.2.210; Wagner AK, 2004, ARCH INTERN MED, V164, P1567, DOI 10.1001/archinte.164.14.1567; Walker Z, 1999, INT J GERIATR PSYCH, V14, P459; Wancata J, 2003, INT J PSYCHIAT MED, V33, P257, DOI 10.2190/ABXK-FMWG-98YP-D1CU; Yaffe K, 2002, JAMA-J AM MED ASSOC, V287, P2090, DOI 10.1001/jama.287.16.2090	74	595	615	0	70	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2005	293	5					596	608		10.1001/jama.293.5.596	http://dx.doi.org/10.1001/jama.293.5.596			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	893BL	15687315				2022-12-28	WOS:000226694200023
J	Schanda, H				Schanda, H			Psychiatry reforms and illegal behaviour of the severely mentally ill	LANCET			English	Editorial Material							DISORDERS; DEINSTITUTIONALIZATION; SCHIZOPHRENIA; HOMICIDES; ILLNESS; 25-YEAR; CARE		Justizanstalt Gollersdorf, A-2013 Gollersdorf 17, Austria; Psychiat Univ Clin, Vienna, Austria		Schanda, H (corresponding author), Justizanstalt Gollersdorf, A-2013 Gollersdorf 17, Austria.	hans.schanda@meduniwien.ac.at						Erb Martin, 2001, Crim Behav Ment Health, V11, P6, DOI 10.1002/cbm.366; Eronen M, 1996, ARCH GEN PSYCHIAT, V53, P497; Fazel S, 2002, LANCET, V359, P545, DOI 10.1016/S0140-6736(02)07740-1; GOTTLIEB P, 1987, ACTA PSYCHIAT SCAND, V76, P285, DOI 10.1111/j.1600-0447.1987.tb02897.x; HODGINS S, 1996, ARCH GEN PSYCHIAT, V53, P486; Mullen PE, 2000, LANCET, V355, P614, DOI 10.1016/S0140-6736(99)05082-5; Munk-Jorgensen P, 1999, EUR ARCH PSY CLIN N, V249, P136, DOI 10.1007/s004060050078; Schanda H, 2000, INT J LAW PSYCHIAT, V23, P481, DOI 10.1016/S0160-2527(00)00045-5; Schanda H, 2004, EUR PSYCHIAT, V19, p30S; Schanda H, 2004, ACTA PSYCHIAT SCAND, V110, P98, DOI 10.1111/j.1600-0047.2004.00305.x; Simpson AIF, 2004, BRIT J PSYCHIAT, V185, P394, DOI 10.1192/bjp.185.5.394; Taylor PJ, 1999, BRIT J PSYCHIAT, V174, P9, DOI 10.1192/bjp.174.1.9; TAYLOR PJ, 1997, CRIMINAL BEHAV MENT, V7, P19; Wallace C, 2004, AM J PSYCHIAT, V161, P716, DOI 10.1176/appi.ajp.161.4.716	14	14	14	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN-FEB	2005	365	9457					367	369						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	891WE	15680440				2022-12-28	WOS:000226610900007
J	Ballard, C; Margallo-Lana, M; Juszczak, E; Douglas, S; Swann, A; Thomas, A; O'Brien, J; Everratt, A; Sadler, S; Maddison, C; Lee, L; Bannister, C; Elvish, R; Jacoby, R				Ballard, C; Margallo-Lana, M; Juszczak, E; Douglas, S; Swann, A; Thomas, A; O'Brien, J; Everratt, A; Sadler, S; Maddison, C; Lee, L; Bannister, C; Elvish, R; Jacoby, R			Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEMENTIA; AGITATION; MODERATE; DRUGS	Objectives To determine the respective efficacy of quetiapine and rivastigmine for agitation in people with dementia in institutional care and to evaluate these treatments with respect to change in cognitive performance. Design Randomised double blind (clinician, patient, outcomes assessor) placebo controlled trial. Setting Care facilities in the north cast of England. Participants 93 patients with Alzheimer's disease, dementia, and clinically significant agitation. Intervention Atypical antipsychotic (quetiapine), cholinesterase inhibitor (rivastigmine), or placebo (double dummy). Main outcome measures Agitation (Cohen-Mansfield agitation inventory) and cognition (severe impairment battery) at baseline and at six weeks and 26 weeks. ne primary outcome was agitation inventory at six weeks. Results 31 patients were randomised to each group, and 80 (86%) started treatment (25 rivastigmine, 26 quetiapine, 29 placebo), of whom 71 (89%) tolerated the maximum protocol dose (22 rivastigmine, 23 quetiapine, 26 placebo). Compared with placebo, neither group showed significant differences in improvement on the agitation inventory either at six weeks or 26 weeks. Fifty six patients scored > 10 on the severe impairment battery at baseline, 46 (82%) of whom were included in the analysis at six week follow up (14 rivastigmine, 14 quetiapine, 18 placebo). For quetiapine the change in severe impairment battery score from baseline was estimated as an average of -14.6 points (95% confidence interval -25.3 to -4.0) lower (that is, worse) than m the placebo group at six weeks (P = 0.009) and -15.4 points (-27.0 to -3.8) lower at 26 weeks (P = 0.01). The corresponding changes with rivastigmine were -3.5 points (-13.1 to 6.2) lower at six weeks (P = 0.5) and -7.5 points (-21.0 to 6.0) lower at 26 weeks (P = 0.3). Conclusions Neither quetiapine nor rivastigmine is effective in the treatment of agitation in people with dementia in institutional care. Compared with placebo, quetiapine is associated with significantly greater cognitive decline.	Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England; Kings Coll London, Inst Psychiat, London SE5 8AF, England; Univ Oxford, Ctr Stat Med, Oxford OX3 7LF, England; Newcastle Univ, Newcastle Gen Hosp, Inst Ageing, Newcastle Upon Tyne NE4 4BE, Tyne & Wear, England; Horton Hosp, Oxfordshire Mental Healthcare NHS Trust, Fiennes Unit, Banbury OX16 9BF, England; Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England	University of Oxford; University of London; King's College London; University of Oxford; Newcastle General Hospital; Newcastle University - UK; University of Oxford	Jacoby, R (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.	Robin.Jacoby@psych.ox.ac.uk	Elvish, Ruth/O-7105-2014; Thomas, Alan J/G-4807-2011	Elvish, Ruth/0000-0002-3044-2358; O'Brien, John/0000-0002-0837-5080; Ballard, Clive/0000-0003-0022-5632				Ballard C, 1999, BRIT MED J, V319, P138, DOI 10.1136/bmj.319.7203.138; Ballard C, 2001, BRIT MED J, V323, P426, DOI 10.1136/bmj.323.7310.426; Ballard C, 1999, AM J PSYCHIAT, V156, P1039; Coffey ET, 1997, NEUROSCI LETT, V227, P177, DOI 10.1016/S0304-3940(97)00335-2; COHENMANSFIELD J, 1995, J GERIATR PSYCH NEUR, V8, P52; *COMM SAF MED, AT ANT DRUGS STROK; Cummings JL, 2003, AM J GERIAT PSYCHIAT, V11, P131, DOI 10.1176/appi.ajgp.11.2.131; Feldman H, 2001, NEUROLOGY, V57, P613, DOI 10.1212/WNL.57.4.613; Fleming K, 2001, J CLIN PSYCHOPHARM, V21, P527, DOI 10.1097/00004714-200110000-00011; McGrath AM, 1996, BRIT MED J, V312, P611; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; McShane R, 1997, BMJ-BRIT MED J, V314, P266, DOI 10.1136/bmj.314.7076.266; Perry EK, 2003, ANN NEUROL, V54, P235, DOI 10.1002/ana.10639; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; REISBERG B, 1988, PSYCHOPHARMACOL BULL, V24, P653; Richelson E, 1999, J CLIN PSYCHIAT, V60, P5; Saxton J, 1990, PSYCHOL ASSESS, V2, P298, DOI DOI 10.1037/1040-3590.2.3.298; Scharre DW, 2002, ALZ DIS ASSOC DIS, V16, P128, DOI 10.1097/00002093-200204000-00011; Schmitt FA, 1997, ALZ DIS ASSOC DIS, V11, pS51; TARIOT P, IN PRESS INT PSYCHOG; Tariot PN, 1998, AM J PSYCHIAT, V155, P54, DOI 10.1176/ajp.155.1.54	21	204	218	0	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 16	2005	330	7496					874	877		10.1136/bmj.38369.459988.8F	http://dx.doi.org/10.1136/bmj.38369.459988.8F			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	917UA	15722369	Green Published, Bronze			2022-12-28	WOS:000228493500016
J	Connell, TG; Rele, M; Daley, AJ; Curtis, N				Connell, TG; Rele, M; Daley, AJ; Curtis, N			Skin ulcers in a returned traveller	LANCET			English	Article							DIPHTHERIAE		Univ Melbourne, Royal Childrens Hosp Melbourne, Dept Gen Med, Paediat Infect Dis Unit, Parkville, Vic 3052, Australia; Univ Melbourne, Royal Childrens Hosp Melbourne, Dept Microbiol, Parkville, Vic 3052, Australia; Univ Melbourne, Royal Childrens Hosp Melbourne, Dept Paediat, Parkville, Vic 3052, Australia	Royal Children's Hospital Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne	Curtis, N (corresponding author), Univ Melbourne, Royal Childrens Hosp Melbourne, Dept Gen Med, Paediat Infect Dis Unit, Parkville, Vic 3052, Australia.	nigel.curtis@rch.org.au	Curtis, Nigel/B-3491-2012	Curtis, Nigel/0000-0003-3446-4594; Daley, Andrew/0000-0001-8470-6438				BAKER M, 1998, NZ PUBLIC HLTH REP, V5, P73; BELSEY MA, 1975, AM J EPIDEMIOL, V102, P179, DOI 10.1093/oxfordjournals.aje.a112145; LIEBOW AA, 1946, ARCH INTERN MED, V78, P255, DOI 10.1001/archinte.1946.00220030002001; TILEY SM, 1993, CLIN INFECT DIS, V16, P271, DOI 10.1093/clind/16.2.271; WOLFRAM H, 1991, INT J DERMATOL, V30, P845	5	7	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	2005	365	9460					726	726						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	898SP	15721480				2022-12-28	WOS:000227096800032
J	de Jong, MD; Van Cam, B; Qui, PT; Hien, VM; Thanh, TT; Hue, NB; Beld, M; Phuong, LT; Khanh, TH; Chau, NVV; Hien, TT; Ha, DQ; Farrar, J				de Jong, MD; Van Cam, B; Qui, PT; Hien, VM; Thanh, TT; Hue, NB; Beld, M; Phuong, LT; Khanh, TH; Chau, NVV; Hien, TT; Ha, DQ; Farrar, J			Brief report: Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HONG-KONG; ACUTE ENCEPHALOPATHY; VIRUS-INFECTION; PROVED VIREMIA; MICE; ENCEPHALITIS; PATHOGENESIS; HUMANS; ASSAY; PCR	In southern Vietnam, a four-year-old boy presented with severe diarrhea, followed by seizures, coma, and death. The cerebrospinal fluid contained 1 white cell per cubic millimeter, normal glucose levels, and increased levels of protein (0.81 g per liter). The diagnosis of avian influenza A (H5N1) was established by isolation of the virus from cerebrospinal fluid, fecal, throat, and serum specimens. The patient's nine-year-old sister had died from a similar syndrome two weeks earlier. In both siblings, the clinical diagnosis was acute encephalitis. Neither patient had respiratory symptoms at presentation. These cases suggest that the spectrum of influenza H5N1 is wider than previously thought.	Univ Oxford, Clin Res Unit, Hosp Trop Dis, Ho Chi Minh City, Vietnam; Paediat Hosp One, Ho Chi Minh City, Vietnam; Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; Dong Thap Hosp, Cao Lanh, Vietnam	University of Oxford; University of Amsterdam; Academic Medical Center Amsterdam	de Jong, MD (corresponding author), Univ Oxford, Clin Res Unit, Hosp Trop Dis, Ho Chi Minh City, Vietnam.		Farrar, Jeremy J./HGA-7610-2022	Farrar, Jeremy/0000-0002-2700-623X; Tran Tan, Thanh/0000-0002-8096-7750				Apisarnthanarak A, 2004, EMERG INFECT DIS, V10, P1321; Beld M, 2004, J CLIN MICROBIOL, V42, P3059, DOI 10.1128/JCM.42.7.3059-3064.2004; Chen H, 2004, P NATL ACAD SCI USA, V101, P10452, DOI 10.1073/pnas.0403212101; Dybing JK, 2000, J VIROL, V74, P1443, DOI 10.1128/JVI.74.3.1443-1450.2000; Fujimoto S, 1998, LANCET, V352, P873, DOI 10.1016/S0140-6736(98)12449-2; Gao P, 1999, J VIROL, V73, P3184, DOI 10.1128/JVI.73.4.3184-3189.1999; Guan Y, 2004, P NATL ACAD SCI USA, V101, P8156, DOI 10.1073/pnas.0402443101; Hien TT, 2004, NEW ENGL J MED, V350, P1179, DOI 10.1056/NEJMoa040419; Keawcharoen J, 2004, EMERG INFECT DIS, V10, P2189, DOI 10.3201/eid1012.040759; KHAKPOUR M, 1969, BRIT MED J, V4, P208, DOI 10.1136/bmj.4.5677.208; LEHMANN NI, 1971, MED J AUSTRALIA, V2, P1166, DOI 10.5694/j.1326-5377.1971.tb92768.x; Lu XH, 1999, J VIROL, V73, P5903, DOI 10.1128/JVI.73.7.5903-5911.1999; Maricich SM, 2004, PEDIATRICS, V114, pE626, DOI 10.1542/peds.2004-0143; Morishima T, 2002, CLIN INFECT DIS, V35, P512, DOI 10.1086/341407; NAFICY K, 1963, NEW ENGL J MED, V269, P964, DOI 10.1056/NEJM196310312691807; Nishimura H, 2000, J GEN VIROL, V81, P2503, DOI 10.1099/0022-1317-81-10-2503; Nishimura H, 2001, J GEN VIROL, V82, P971, DOI 10.1099/0022-1317-82-4-971; Park CH, 2002, ARCH VIROL, V147, P1425, DOI 10.1007/s00705-001-0750-x; Ryncarz AJ, 1999, J CLIN MICROBIOL, V37, P1941, DOI 10.1128/JCM.37.6.1941-1947.1999; Shortridge KF, 1998, VIROLOGY, V252, P331, DOI 10.1006/viro.1998.9488; Stanley E D, 1966, Trans Assoc Am Physicians, V79, P376; Steininger C, 2003, CLIN INFECT DIS, V36, P567, DOI 10.1086/367623; Tanaka H, 2003, VET MICROBIOL, V95, P1, DOI 10.1016/S0378-1135(03)00132-9; WHO, 2002, GLOB SOL UV IND PRAC	24	381	401	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2005	352	7					686	691		10.1056/NEJMoa044307	http://dx.doi.org/10.1056/NEJMoa044307			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897UO	15716562				2022-12-28	WOS:000227031100007
J	Kelly, JW				Kelly, JW			Attacking amyloid	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DISEASE; INHIBITORS		Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA USA	Scripps Research Institute; Scripps Research Institute	Kelly, JW (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.							Findeis MA, 2000, BBA-MOL BASIS DIS, V1502, P76, DOI 10.1016/S0925-4439(00)00034-X; Gestwicki JE, 2004, SCIENCE, V306, P865, DOI 10.1126/science.1101262; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; Hammarstrom P, 2003, SCIENCE, V299, P713, DOI 10.1126/science.1079589; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a	5	21	21	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2005	352	7					722	723		10.1056/NEJMcibr044231	http://dx.doi.org/10.1056/NEJMcibr044231			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897UO	15716569				2022-12-28	WOS:000227031100015
J	Inouye, SK; Fiellin, DA				Inouye, SK; Fiellin, DA			An evidence-based guide to writing grant proposals for clinical research	ANNALS OF INTERNAL MEDICINE			English	Article							STEPS	The competition for funds to conduct clinical research is intense, and only a minority of grant proposals receive funding. In particular, funding for patient-oriented research lags behind that allocated for basic science research. Grant writing is a skill of fundamental importance to the clinical researcher, and conducting high-quality clinical research requires funds received through successful grant proposals. This article provides recommendations for the grant-writing process for clinical researchers. on the basis of observations from a National Institutes of Health study section, we describe types and sources of grant funds, provide key recommendations regarding the process of grant writing, and highlight the sections of grants that are frequently scrutinized and critiqued. We also provide specific recommendations to help grant writers improve the quality of areas commonly cited as deficient Application of this systematic approach will make the task more manageable for anyone who writes grants.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA	Yale University	Inouye, SK (corresponding author), Yale Univ, Sch Med, Dept Internal Med, 333 Cedar St,DC013K,POB 208025, New Haven, CT 06520 USA.		Inouye, Sharon/R-7216-2019	Fiellin, David/0000-0002-4006-010X	NATIONAL INSTITUTE ON AGING [R01AG012551, P30AG021342, K24AG000949] Funding Source: NIH RePORTER; NIA NIH HHS [K24AG00949, P30AG21342, R01AG12551] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barbieri RL, 1996, FERTIL STERIL, V66, P690, DOI 10.1016/S0015-0282(16)58619-1; Barnard J, 2002, J PEDIATR GASTR NUTR, V35, P107, DOI 10.1097/00005176-200208000-00001; Bordage G, 2003, MED EDUC, V37, P376, DOI 10.1046/j.1365-2923.2003.01468.x; BROWNER WS, 1999, PUBL PRES CLIN RES; Feinstein AR, 1985, CLIN EPIDEMIOLOGY AR; Fletcher R, 1996, CLIN EPIDEMIOLOGY; Gill TM, 2004, J GEN INTERN MED, V19, P472, DOI 10.1111/j.1525-1497.2004.30293.x; Goldblatt D, 1998, BRIT MED J, V317, P1647, DOI 10.1136/bmj.317.7173.1647; Hulley SB, 2013, DESIGNING CLIN RES; Kotchen TA, 2004, JAMA-J AM MED ASSOC, V291, P836, DOI 10.1001/jama.291.7.836; Lusk SL, 2004, WESTERN J NURS RES, V26, P367, DOI 10.1177/0193945903261843; MCCABE LL, 1999, SUCCEED ACAD, P41; *NIH, NOTOD05002; *OFF REP AN, NIH COMP RES GRAN AP; *OFF REP AN, NIH COMP RES PROJ AP; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; Sandler RS, 2002, INFLAMM BOWEL DIS, V8, P196, DOI 10.1097/00054725-200205000-00007; Schwinn DA, 1998, ANESTHESIOLOGY, V88, P1660, DOI 10.1097/00000542-199806000-00031; *SCI DIR PREF, 2004, NA I CHILD HTLH HUM; Throckmorton Terry, 2002, J Perianesth Nurs, V17, P196, DOI 10.1053/jpan.2002.33214; 1997, NIH GUIDE, V26	21	57	58	1	33	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	2005	142	4					274	282		10.7326/0003-4819-142-4-200502150-00009	http://dx.doi.org/10.7326/0003-4819-142-4-200502150-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900UJ	15710960				2022-12-28	WOS:000227239500005
J	Burch, D; Sheerin, F				Burch, D; Sheerin, F			Parkinson's disease	LANCET			English	Editorial Material							SUBTHALAMIC NUCLEUS		John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England; UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England	University of Oxford; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Burch, D (corresponding author), John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England.	druinburch@yahoo.com						ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; BERGMAN H, 1994, J NEUROPHYSIOL, V72, P507, DOI 10.1152/jn.1994.72.2.507; Hartemann-Heurtier A, 2002, LANCET, V360, P1776, DOI 10.1016/S0140-6736(02)11671-0; Hattori N, 2003, J NEUROL, V250, P2, DOI 10.1007/s00415-003-1302-y; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4; PARKINSON J, 1807, OBSERVATION EXCESSIV; PARKINSON J, 1833, ORGANIC REMAINS FORM	9	27	34	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	2005	365	9459					622	627						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DN	15708109				2022-12-28	WOS:000226984300038
J	de Heer, WA; Poncharal, P; Berger, C; Gezo, J; Song, ZM; Bettini, J; Ugarte, D				de Heer, WA; Poncharal, P; Berger, C; Gezo, J; Song, ZM; Bettini, J; Ugarte, D			Liquid carbon, carbon-glass beads, and the crystallization of carbon nanotubes	SCIENCE			English	Article							ELECTRON-MICROSCOPY	The formation of carbon nanotubes in a pure carbon arc in a helium atmosphere is found to involve liquid carbon. Electron microscopy shows a viscous liquid-like amorphous carbon layer covering the surfaces of nanotube-containing millimeter-sized columnar structures from which the cathode deposit is composed. Regularly spaced, submicrometer-sized spherical beads of amorphous carbon are often found on the nanotubes at the surfaces of these columns. Apparently, at the anode, liquid-carbon drops form, which acquire a carbon-glass surface due to rapid evaporative cooling. Nanotubes crystallize inside the supercooled, glass-coated liquid-carbon drops. The carbon-glass layer ultimately coats and beads on the nanotubes near the surface.	Georgia Inst Technol, Sch Phys, Atlanta, GA 30332 USA; Univ Montpellier 2, GDPC, F-34095 Montpellier 5, France; CNRS, LEPES, F-38042 Grenoble 9, France; Univ Illinois, Dept Phys, Urbana, IL 61801 USA; Lab Nacl Luz Sincrotron, BR-13084971 Campinas, SP, Brazil; Univ Estadual Campinas, Inst Fis Gleb Wataghin, BR-13083970 Campinas, SP, Brazil	University System of Georgia; Georgia Institute of Technology; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Illinois System; University of Illinois Urbana-Champaign; Laboratorio Nacional de Luz Sincrotron (LNLS); Universidade Estadual de Campinas	de Heer, WA (corresponding author), Georgia Inst Technol, Sch Phys, Atlanta, GA 30332 USA.	walt.deheer@physics.gatech.edu	Bettini, Jefferson/G-4554-2013; Ugarte, Daniel/C-2326-2012	Bettini, Jefferson/0000-0001-7316-0804; Ugarte, Daniel Mario/0000-0003-3332-9139				Ajayan PM, 1997, REP PROG PHYS, V60, P1025, DOI 10.1088/0034-4885/60/10/001; ANGELL CA, 1988, J PHYS CHEM SOLIDS, V49, P863, DOI 10.1016/0022-3697(88)90002-9; Brice JC., 1986, CRYSTAL GROWTH PROCE; COLBERT DT, 1994, SCIENCE, V266, P1218, DOI 10.1126/science.266.5188.1218; DEHEER WA, 1993, CHEM PHYS LETT, V207, P480, DOI 10.1016/0009-2614(93)89033-E; DEHEER WA, 1993, REV MOD PHYS, V65, P611, DOI 10.1103/RevModPhys.65.611; EBBESEN TW, 1992, NATURE, V358, P220, DOI 10.1038/358220a0; GAMALY EG, 1995, PHYS REV B, V52, P2083, DOI 10.1103/PhysRevB.52.2083; GOREN SL, 1962, J FLUID MECH, V137, P363; HARRIS PJF, 1994, J CHEM SOC FARADAY T, V90, P2799, DOI 10.1039/ft9949002799; Kliakhandler IL, 2001, J FLUID MECH, V429, P381, DOI 10.1017/S0022112000003268; KLOTS CE, 1987, Z PHYS D ATOM MOL CL, V5, P83, DOI 10.1007/BF01436578; KRATSCHMER W, 1990, NATURE, V347, P354, DOI 10.1038/347354a0; Musella M, 1998, J APPL PHYS, V84, P2530, DOI 10.1063/1.368414; O'Malley B, 1998, PHYS REV B, V57, P14148, DOI 10.1103/PhysRevB.57.14148; Poncharal P, 1999, SCIENCE, V283, P1513, DOI 10.1126/science.283.5407.1513; RAYLEIGH L, 1879, P R SOC A, V8, P425; UGARTE D, 1992, NATURE, V359, P707, DOI 10.1038/359707a0	18	70	70	7	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2005	307	5711					907	910		10.1126/science.1107035	http://dx.doi.org/10.1126/science.1107035			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897DV	15705847				2022-12-28	WOS:000226985100048
J	Weinstein, BM				Weinstein, BM			Vessels and nerves: Marching to the same tune	CELL			English	Review							ANGIOGENIC FACTOR; AXON GUIDANCE; SEMAPHORIN; RECEPTOR; NEUROPILIN-1; MORPHOGENESIS; NETRIN-1; PATTERN; GROWTH; VEINS	The patterning of the nervous system is achieved through coordinated action of a variety of repulsive or attractive neuronal guidance factors that direct the growth of growing axons to specific pathways. Recent studies suggest that the same or similar sets of factors also guide migration of endothelial cells, helping to direct the stereotypical embryonic patterning of the developing vertebrate vascular system.	NICHHD, Genet Mol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Weinstein, BM (corresponding author), NICHHD, Genet Mol Lab, NIH, 6 Ctr Dr, Bethesda, MD 20892 USA.	flyingfish@nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001011] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001011] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alva JA, 2004, CURR OPIN HEMATOL, V11, P278, DOI 10.1097/01.moh.0000130309.44976.ad; Bates D, 2003, DEV BIOL, V255, P77, DOI 10.1016/S0012-1606(02)00045-3; Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165; Gitler AD, 2004, DEV CELL, V7, P107, DOI 10.1016/j.devcel.2004.06.002; Gu CH, 2003, DEV CELL, V5, P45, DOI 10.1016/S1534-5807(03)00169-2; Gu CH, 2005, SCIENCE, V307, P265, DOI 10.1126/science.1105416; Helbling PM, 2000, DEVELOPMENT, V127, P269; Honma Y, 2002, NEURON, V35, P267, DOI 10.1016/S0896-6273(02)00774-2; Hopker VH, 1999, NATURE, V401, P69, DOI 10.1038/43441; Kirchmair R, 2004, CIRCULATION, V109, P777, DOI 10.1161/01.CIR.0000112574.07422.C1; Long H, 2004, NEURON, V42, P213, DOI 10.1016/S0896-6273(04)00179-5; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; Lu XW, 2004, NATURE, V432, P179, DOI 10.1038/nature03080; Mukouyama Y, 2002, CELL, V109, P693, DOI 10.1016/S0092-8674(02)00757-2; Park KW, 2004, P NATL ACAD SCI USA, V101, P16210, DOI 10.1073/pnas.0405984101; Park KW, 2003, DEV BIOL, V261, P251, DOI 10.1016/S0012-1606(03)00258-6; Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092; Takashima S, 2002, P NATL ACAD SCI USA, V99, P3657, DOI 10.1073/pnas.022017899; Torres-Vazquez J, 2004, DEV CELL, V7, P117, DOI 10.1016/j.devcel.2004.06.008; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1	20	114	122	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 11	2005	120	3					299	302		10.1016/j.cell.2005.01.010	http://dx.doi.org/10.1016/j.cell.2005.01.010			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	897TS	15707889	Bronze			2022-12-28	WOS:000227028900006
J	Milward, GC; Calderon, MJ; Littlewood, PB				Milward, GC; Calderon, MJ; Littlewood, PB			Electronically soft phases in manganites	NATURE			English	Article							NEUTRON-DIFFRACTION; CHARGE; MAGNETORESISTANCE; COEXISTENCE; TRANSITION	The phenomenon of colossal magnetoresistance in manganites(1) is generally agreed to be a result of competition between crystal phases with different electronic, magnetic and structural order; a competition which can be strong enough to cause phase separation between metallic ferromagnetic and insulating charge-modulated states(2 - 5). Nevertheless, closer inspection of phase diagrams in many manganites reveals complex phases where the two order parameters of magnetism and charge modulation unexpectedly coexist(6,7). Here we show that such experiments can be naturally explained within a phenomenological Ginzburg-Landau theory. In contrast to models where phase separation originates from disorder(8) or as a strain- induced kinetic phenomenon(9), we argue that magnetic and charge modulation coexist in new thermodynamic phases. This leads to a rich diagram of equilibrium phases, qualitatively similar to those seen experimentally. The success of this model argues for a fundamental reinterpretation of the nature of charge modulation in these materials, from a localized to a more extended ' charge- density wave' picture. The same symmetry considerations that favour textured coexistence of charge and magnetic order may apply to many electronic systems with competing phases. The resulting electronically soft' phases of matter with incommensurate, inhomogeneous and mixed order may be general phenomena in correlated systems.	Univ Cambridge, Cavendish Lab, Cambridge CB3 0HE, England	University of Cambridge	Milward, GC (corresponding author), Univ Cambridge, Cavendish Lab, Madingley Rd, Cambridge CB3 0HE, England.	gcm24@cam.ac.uk	Calderon, Maria Jose/A-4888-2009; Littlewood, Peter/M-4960-2019; Littlewood, Peter B/B-7746-2008	Calderon, Maria Jose/0000-0001-5827-4731; 				Ahn KH, 2004, NATURE, V428, P401, DOI 10.1038/nature02364; Brey L, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.127202; Burgy J, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.097202; Chen CH, 1999, PHYS REV LETT, V83, P4792, DOI 10.1103/PhysRevLett.83.4792; Chen CH, 1997, J APPL PHYS, V81, P4326, DOI 10.1063/1.364758; Chen CH, 1996, PHYS REV LETT, V76, P4042, DOI 10.1103/PhysRevLett.76.4042; Coey M, 2004, NATURE, V430, P155, DOI 10.1038/430155a; DAGOTTO E, 2002, SPRINGER SERIES SOLI, V136; GOODENOUGH JB, 1955, PHYS REV, V100, P564, DOI 10.1103/PhysRev.100.564; Herrero-Martin J, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.024408; JIRAK Z, 1985, J MAGN MAGN MATER, V53, P153, DOI 10.1016/0304-8853(85)90144-1; Kajimoto R, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.212407; Kajimoto R, 1998, PHYS REV B, V58, pR11837, DOI 10.1103/PhysRevB.58.R11837; Kivelson SA, 1998, NATURE, V393, P550, DOI 10.1038/31177; Larochelle S, 2001, PHYS REV LETT, V87, part. no., DOI 10.1103/PhysRevLett.87.095502; Loudon JC, 2002, NATURE, V420, P797, DOI 10.1038/nature01299; LOUDON JC, 2003, WEAK CHARGE LATTICE; Mathur N, 2003, PHYS TODAY, V56, P25, DOI 10.1063/1.1554133; Mathur ND, 2001, SOLID STATE COMMUN, V119, P271, DOI 10.1016/S0038-1098(01)00112-0; Mathur ND, 1999, J APPL PHYS, V86, P6287, DOI 10.1063/1.371687; MCELROY K, 2004, HOMOGENOUS NODAL SUP; Murakami S, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.197201; Rzchowski MS, 2004, EUROPHYS LETT, V67, P287, DOI 10.1209/epl/i2004-10050-8; SCHIFFER P, 1995, PHYS REV LETT, V75, P3336, DOI 10.1103/PhysRevLett.75.3336; Tokura Y., 2000, COLOSSAL MAGNETORESI; TOLEDANO JC, 1987, LANDAU THEORY PHASE, pCH5; Uehara M, 1999, NATURE, V399, P560, DOI 10.1038/21142; von Zimmermann M, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.195133; Yamada Y, 2002, J PHYS SOC JPN, V71, P2480, DOI 10.1143/JPSJ.71.2480; YOSHIZAWA H, 1995, PHYS REV B, V52, P13145, DOI 10.1103/PhysRevB.52.R13145	30	237	240	2	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 10	2005	433	7026					607	610		10.1038/nature03300	http://dx.doi.org/10.1038/nature03300			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	895KX	15703740	Green Submitted			2022-12-28	WOS:000226862000037
J	Christie, D; Viner, R				Christie, D; Viner, R			ABC of adolescence - Adolescent development	BRITISH MEDICAL JOURNAL			English	Review									UCL Hosp NHS Fdn Trust, Middlesex Adolescent Unit, London, England; Great Ormond St Hosp NHS Trust, London, England	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Christie, D (corresponding author), UCL Hosp NHS Fdn Trust, Middlesex Adolescent Unit, London, England.		Viner, Russell M/A-1441-2009	Viner, Russell M/0000-0003-3047-2247				Neinstein LS, 2002, ADOLESCENT HLTH CARE; *ROYAL COLL PAED C, 2003, BRIDG GAPS HEALTHC A; STRASBURGER VC, 1998, ADOLESCENT MED PRACT	3	329	332	5	22	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 5	2005	330	7486					301	304		10.1136/bmj.330.7486.301	http://dx.doi.org/10.1136/bmj.330.7486.301			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895EM	15695279	Green Published			2022-12-28	WOS:000226843700021
J	Reimann, S; Manning, AJ; Simmonds, PG; Cunnold, DM; Wang, RHJ; Li, JL; McCulloch, A; Prinn, RG; Huang, J; Weiss, RF; Fraser, PJ; O'Doherty, S; Greally, BR; Stemmler, K; Hill, M; Folini, D				Reimann, S; Manning, AJ; Simmonds, PG; Cunnold, DM; Wang, RHJ; Li, JL; McCulloch, A; Prinn, RG; Huang, J; Weiss, RF; Fraser, PJ; O'Doherty, S; Greally, BR; Stemmler, K; Hill, M; Folini, D			Low European methyl chloroform emissions inferred from long-term atmospheric measurements	NATURE			English	Article							TROPOSPHERIC OH; TRACE GASES; VARIABILITY; HYDROXYL; HISTORY; TRENDS	Methyl chloroform (CH3CCl3, 1,1,1,-trichloroethane) was used widely as a solvent before it was recognized to be an ozone-depleting substance and its phase-out was introduced under the Montreal Protocol(1). Subsequently, its atmospheric concentration has declined steadily(2-4) and recent European methyl chloroform consumption and emissions were estimated to be less than 0.1 gigagrams per year(1,5). However, data from a short-term tropospheric measurement campaign ( EXPORT) indicated that European methyl chloroform emissions could have been over 20 gigagrams in 2000 (ref. 6), almost doubling previously estimated global emissions(1,4). Such enhanced emissions would significantly affect results from the CH3CCl3 method of deriving global abundances of hydroxyl radicals ( OH) (refs 7 - 12) - the dominant reactive atmospheric chemical for removing trace gases related to air pollution, ozone depletion and the greenhouse effect. Here we use long-term, high-frequency data from MaceHead, Ireland and Jungfraujoch, Switzerland, to infer European methyl chloroform emissions. We find that European emission estimates declined from about 60 gigagrams per year in the mid-1990s to 0.3 - 1.4 and 1.9 - 3.4 gigagrams per year in 2000 - 03, based on Mace Head and Jungfraujoch data, respectively. Our European methyl chloroform emission estimates are therefore higher than calculated from consumption data(1,5), but are considerably lower than those derived from the EXPORT campaign in 2000 ( ref. 6).	Empa, Inst Mat Sci & Technol, CH-8600 Dubendorf, Switzerland; Met Off, Exeter EX1 3PB, Devon, England; Univ Bristol, Sch Chem, Bristol BS8 1TS, Avon, England; Georgia Inst Technol, Sch Earth & Atmospher Sci, Atlanta, GA 30332 USA; MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; CSIRO, PMBI, Aspendale, Vic 3195, Australia	Swiss Federal Institutes of Technology Domain; Swiss Federal Laboratories for Materials Science & Technology (EMPA); Met Office - UK; University of Bristol; University System of Georgia; Georgia Institute of Technology; Massachusetts Institute of Technology (MIT); University of California System; University of California San Diego; Scripps Institution of Oceanography; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Reimann, S (corresponding author), Empa, Inst Mat Sci & Technol, Ueberlandstr 129, CH-8600 Dubendorf, Switzerland.	stefan.reimann@empa.ch	Fraser, Paul J. B./D-1755-2012; Reimann, Stefan/A-2327-2009	Reimann, Stefan/0000-0002-9885-7138				Cunnold DM, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001226; Forrer J, 2000, J GEOPHYS RES-ATMOS, V105, P12241, DOI 10.1029/1999JD901178; Gros V, 2003, ATMOS CHEM PHYS, V3, P1223, DOI 10.5194/acp-3-1223-2003; Krol M, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002423; Krol M, 1998, J GEOPHYS RES-ATMOS, V103, P10697, DOI 10.1029/98JD00459; Krol MC, 2003, NATURE, V421, P131, DOI 10.1038/nature01311; Manning AJ, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002312; McCulloch A, 2001, ATMOS ENVIRON, V35, P5311, DOI 10.1016/S1352-2310(01)00306-5; MIDGLEY PM, 1995, ATMOS ENVIRON, V29, P1601, DOI 10.1016/1352-2310(95)00078-D; Montzka SA, 1999, NATURE, V398, P690, DOI 10.1038/19499; Montzka SA, 2000, SCIENCE, V288, P500, DOI 10.1126/science.288.5465.500; MONTZKA SA, 2003, 47 WMO GLOB OZ RES M; O'Doherty S, 2001, J GEOPHYS RES-ATMOS, V106, P20429, DOI 10.1029/2000JD900792; Prinn RG, 2001, SCIENCE, V292, P1882, DOI 10.1126/science.1058673; PRINN RG, 1995, SCIENCE, V269, P187, DOI 10.1126/science.269.5221.187; Prinn RG, 2000, J GEOPHYS RES-ATMOS, V105, P17751, DOI 10.1029/2000JD900141; Reimann S, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD003923; Ryall DB, 2001, ATMOS ENVIRON, V35, P2507, DOI 10.1016/S1352-2310(00)00433-7; Spivakovsky CM, 2000, J GEOPHYS RES-ATMOS, V105, P8931, DOI 10.1029/1999JD901006; UNEP, 2003, 15 M PART MONTR PROT; UNEP ( United Nations Environment Programme), 2002, PROD CONS OZ DEPL SU; VESTRENG V, 2004, 12004 EMEPEEA EMEPMS	22	47	51	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 3	2005	433	7025					506	508		10.1038/nature03220	http://dx.doi.org/10.1038/nature03220			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893NT	15690037				2022-12-28	WOS:000226727200044
J	Kern, LM; Powe, NR; Levine, MA; Fitzpatrick, AL; Harris, TB; Robbins, J; Fried, LP				Kern, LM; Powe, NR; Levine, MA; Fitzpatrick, AL; Harris, TB; Robbins, J; Fried, LP			Association between screening for osteoporosis and the incidence of hip fracture	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	25th Annual Meeting of the Society-of-General-Internal-Medicine	MAY 01-05, 2002	ATLANTA, GA	Soc Gen Internal Med			POSTMENOPAUSAL OSTEOPOROSIS; BONE-DENSITY; VITAMIN-D; NONVERTEBRAL FRACTURES; RISK; WOMEN; ALENDRONATE; RISEDRONATE; PREVENTION; OUTCOMES	Background: Because direct evidence for the effectiveness of screening is lacking, guidelines disagree on whether people should be screened for osteoporosis. Objective: To determine whether population-based screening for osteoporosis in older adults is associated with fewer incident hip fractures than usual medical care. Design: Nonconcurrent cohort study. Setting: Population-based cohort enrolled in the Cardiovascular Health Study (CHS) from 4 states (California, Pennsylvania, Maryland, and North Carolina). Patients: 3107 adults 65 years of age and older who attended their CHS study visits in 1994-1995. Measurements: 31 participant characteristics (including demographic characteristics, medical histories, medications, and physical examination findings) and incident hip fractures over 6 years of follow-up. Intervention: Bone density scans (dual-energy x-ray absorptiometry [DEXA] at the hip) for participants in California and Pennsylvania (n = 1422) and usual care for participants in Maryland and North Carolina (n = 1685). Results: The incidence of hip fractures per 1000 person-years was 4.8 in the screened group and 8.2 in the usual care group. Screening was associated with a statistically significant lower hazard of hip fracture than usual care after adjustment for sex and propensity to be screened (Cox proportional hazard ratio, 0.64 [95% CI, 0.41 to 0.99]). Limitations: The mechanism of the association was unclear. A small unmeasured confounder that decreased the hazard of hip fracture could diminish or erase the observed association. Conclusions: Use of hip DEXA scans to screen for osteoporosis in older adults was associated with 36% fewer incident hip fractures over 6 years compared with usual medical care. Further research is needed to explore the mechanism of this association.	Johns Hopkins Bloomberg Sch Publ Hlth, Sch Med, Robert Wood Johnson Clin Scholars Program, Baltimore, MD USA; Univ Washington, Seattle, WA 98195 USA; Univ Calif Davis, Sacramento, CA 95817 USA; NIA, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Washington; University of Washington Seattle; University of California System; University of California Davis; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Kern, LM (corresponding author), Cornell Univ, Weill Med Coll, Dept Publ Hlth, 411 E 69th St,Room KB-311, New York, NY 10021 USA.	lmk2003@med.cornell.edu	Kern, Lisa/AAI-9781-2021	Kern, Lisa/0000-0003-1191-8100; Levine, Michael/0000-0003-0036-7809	NHLBI NIH HHS [N01-HC-85079, N01-HC-85080, N01-HC-35129, N01-HC-85083, N01-HC-85085, N01-HC-85082, N01-HC-85084, N01-HC-85086, 1-Y02-HC-40205, N01-HC-15103, N01-HC-85081] Funding Source: Medline; NIA NIH HHS [Y02-AG-4-0251] Funding Source: Medline; NIDDK NIH HHS [K24DK02643] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085082, N01HC015103, N01HC085086, N01HC085083, N01HC085079, N01HC085081, N01HC085084, N01HC085085, N01HC035129, N01HC085080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK002643] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1994, World Health Organ Tech Rep Ser, V843, P1; Berg AO, 2002, ANN INTERN MED, V137, P526, DOI 10.7326/0003-4819-137-6-200209170-00014; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Braitman LE, 2002, ANN INTERN MED, V137, P693, DOI 10.7326/0003-4819-137-8-200210150-00015; Carlin JB, 2003, STATA J, V3, P226, DOI 10.1177/1536867X0300300302; *CTR DRUG EV RES F, 2004, EL OR BOOK APPR DRUG; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140-6736(02)08657-9; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; FELSON DT, 1988, AM J EPIDEMIOL, V128, P1102; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; Gillespie LD, 2002, COCHRANE LIB; Guo ZC, 1998, AM J EPIDEMIOL, V148, P887; Guyatt GH, 2002, ENDOCRIN METAB CLIN, V31, P659, DOI 10.1016/S0889-8529(02)00024-5; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; HONAKER J, 2001, AMELIA PROGR MISSING; HORWITZ RI, 1990, AM J MED, V89, P630, DOI 10.1016/0002-9343(90)90182-D; Karpf DB, 1997, JAMA-J AM MED ASSOC, V277, P1159; King G, 2001, AM POLIT SCI REV, V95, P49, DOI 10.1017/S0003055401000235; Klibanski A, 2001, JAMA-J AM MED ASSOC, V285, P785; Lin DY, 1998, BIOMETRICS, V54, P948, DOI 10.2307/2533848; Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477; McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503; MCPHILLIPS JB, 1989, AM J PREV MED, V5, P65, DOI 10.1016/S0749-3797(18)31107-3; *MED PREV SERV, 2004, OST DIAB PROST CANC; *NAT OS FDN, 2003, PHYS GUID PREV TREAT; Nelson HD, 2002, ANN INTERN MED, V137, P529, DOI 10.7326/0003-4819-137-6-200209170-00015; Rodriguez-Martinez MA, 2002, PHARMACOL THERAPEUT, V93, P37, DOI 10.1016/S0163-7258(02)00164-X; Rosenbaum PR, 1998, ENCY BIOSTATISTICS, V5, P3551; Schwartz AV, 2001, J CLIN ENDOCR METAB, V86, P32, DOI 10.1210/jc.86.1.32; Stevens JA, 2000, MMWR-MORBID MORTAL W, V49, P1; TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9; Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; *U CAL CHS BON DEN, 1994, CARD HLTH STUD DXA Q; van Staa TP, 2001, JAMA-J AM MED ASSOC, V285, P1850, DOI 10.1001/jama.285.14.1850; Wang PS, 2000, JAMA-J AM MED ASSOC, V283, P3211, DOI 10.1001/jama.283.24.3211	42	71	72	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	2005	142	3					173	181		10.7326/0003-4819-142-3-200502010-00007	http://dx.doi.org/10.7326/0003-4819-142-3-200502010-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	900UH	15684205				2022-12-28	WOS:000227239300003
J	Fabbiano, G				Fabbiano, G			Astronomy - The hunt for intermediate-mass black holes	SCIENCE			English	Editorial Material							X-RAY SOURCES		Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA	Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution	Fabbiano, G (corresponding author), Harvard Smithsonian Ctr Astrophys, 60 Garden St, Cambridge, MA 02138 USA.	pepi@head.cfa.harvard.edu						Begelman MC, 2002, ASTROPHYS J, V568, pL97, DOI 10.1086/340457; COLBERT EJ, 2001, ASTROPHYS J, V519, P89; Fabbiano G, 2003, ASTROPHYS J, V584, pL5, DOI 10.1086/368174; FABBIANO G, IN PRESS COMPACT STE; Kaaret P, 2004, MON NOT R ASTRON SOC, V348, pL28, DOI 10.1111/j.1365-2966.2004.07516.x; KING A, IN PRESS MON NOT R A; King AR, 2001, ASTROPHYS J, V552, pL109, DOI 10.1086/320343; Kording E, 2002, ASTRON ASTROPHYS, V382, pL13, DOI 10.1051/0004-6361:20011776; Madau P, 2001, ASTROPHYS J, V551, pL27, DOI 10.1086/319848; Makishima K, 2000, ASTROPHYS J, V535, P632, DOI 10.1086/308868; Miller JM, 2004, ASTROPHYS J, V614, pL117, DOI 10.1086/425316; Miller JM, 2003, ASTROPHYS J, V585, pL37, DOI 10.1086/368373; PODSIADLOWSKI P, 2004, REVMEXAA, V20, P97; Strohmayer TE, 2003, ASTROPHYS J, V586, pL61, DOI 10.1086/374732; ZEZAS A, UNPUB; Zwart SFP, 2004, NATURE, V428, P724, DOI 10.1038/nature02448	16	17	21	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2005	307	5709					533	534		10.1126/science.1107110	http://dx.doi.org/10.1126/science.1107110			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893BJ	15681375				2022-12-28	WOS:000226694000035
J	Ravussin, E				Ravussin, E			Physiology - A NEAT way to control weight?	SCIENCE			English	Editorial Material							PHYSICAL-ACTIVITY; OBESITY		Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Ravussin, E (corresponding author), Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	ravusse@pbrc.edu	Ravussin, Eric/N-1985-2017	Ravussin, Eric/0000-0003-2129-547X				Hayes M, 2005, INT J OBESITY, V29, P151, DOI 10.1038/sj.ijo.0802842; Hill JO, 2003, SCIENCE, V299, P853, DOI 10.1126/science.1079857; Hill JO, 1998, SCIENCE, V280, P1371, DOI 10.1126/science.280.5368.1371; Levine JA, 2005, SCIENCE, V307, P584, DOI 10.1126/science.1106561; Levine James A., 1999, Science (Washington D C), V283, P212, DOI 10.1126/science.283.5399.212; PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437; RAVUSSIN E, 1986, J CLIN INVEST, V78, P1568, DOI 10.1172/JCI112749; WIDDOWSON EM, 1954, BRIT J NUTR, V8, P147, DOI 10.1079/BJN19540023; ZURLO F, 1992, AM J PHYSIOL, V263, pE296, DOI 10.1152/ajpendo.1992.263.2.E296	9	34	37	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2005	307	5709					530	531		10.1126/science.1108597	http://dx.doi.org/10.1126/science.1108597			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893BJ	15681373				2022-12-28	WOS:000226694000033
J	Stafford, N; Stohr, K				Stafford, N; Stohr, K			Klaus Stohr: preparing for the next influenza pandemic	LANCET			English	Editorial Material												ns@europefn.de							0	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN-FEB	2005	365	9457					379	379						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891WE	15688458				2022-12-28	WOS:000226610900012
J	Langevin, Y; Poulet, F; Bibring, JP; Gondet, B				Langevin, Y; Poulet, F; Bibring, JP; Gondet, B			Sulfates in the north polar region of Mars detected by OMEGA/Mars express	SCIENCE			English	Article							EVOLUTION; DEPOSITS	The Observatoire pour la Mineralogie, l'Eau, les Glaces, et l'Activite (OMEGA) imaging spectrometer observed the northern circumpolar regions of Mars at a resolution of a few kilometers. An extended region at 240degreesE, 85degreesN, with an area of 60 kilometers by 200 kilometers, exhibits absorptions at wavelengths of 1.45, 1.75, 1.94, 2.22, 2.26, and 2.48 micrometers. These signatures can be unambiguously attributed to calcium-rich sulfates, most likely gypsum. This region corresponds to the dark longitudinal dunes of Olympia Planitia. These observations reveal that Water alteration played a major role in the formation of the constituting minerals of northern circumpolar terrains.	Inst Astrophys Spatiale, F-91405 Orsay, France	UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay	Langevin, Y (corresponding author), Inst Astrophys Spatiale, Batiment 121, F-91405 Orsay, France.	yves.langevin@ias.u-psud.fr						Baker V.R., 1992, CHANNELS VALLEY NETW, P493; Bibring J.-P., 2004, EUR SPACE AGENCY SPE, V1240, P37; Bibring JP, 2005, SCIENCE, V307, P1576, DOI 10.1126/science.1108806; BISHOP JL, IN PRESS INT J ASTRO; BURNS RG, 1990, J GEOPHYS RES-SOLID, V95, P14415, DOI 10.1029/JB095iB09p14415; Byrne S, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2001JE001615; Clifford SM, 2000, ICARUS, V144, P210, DOI 10.1006/icar.1999.6290; CLIFFORD SM, 1999, LUNAR PLANET SCI, V30, P1619; Fishbaugh KE, 2000, J GEOPHYS RES-PLANET, V105, P22455, DOI 10.1029/1999JE001230; FISHBAUGH KE, 2004, LUN PLAN SCI C, V25, P1156; Gendrin A, 2005, SCIENCE, V307, P1587, DOI 10.1126/science.1109087; Herkenhoff KE, 1999, J GEOPHYS RES-PLANET, V104, P16487, DOI 10.1029/1998JE000589; IVANOV S, 2003, 6 INT C MARS PAS CA; Langevin Y, 2005, SCIENCE, V307, P1581, DOI 10.1126/science.1109438; Mischna MA, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002051; PAIGE DA, 1994, J GEOPHYS RES-PLANET, V99, P25959, DOI 10.1029/93JE03428; PARKER TJ, 1989, ICARUS, V82, P111, DOI 10.1016/0019-1035(89)90027-4; PATHARE AV, 1998, 1 INT C MARS POL SCI; Wyatt M. B., 2003, 3 INT C MARS POL SCI	19	387	398	0	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 11	2005	307	5715					1584	1586		10.1126/science.1109091	http://dx.doi.org/10.1126/science.1109091			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	906ED	15718428				2022-12-28	WOS:000227622400036
J	Krogsgaard, M; Li, QJ; Sumen, C; Huppa, JB; Huse, M; Davis, MM				Krogsgaard, M; Li, QJ; Sumen, C; Huppa, JB; Huse, M; Davis, MM			Agonist/endogenous peptide-MHC heterodimers drive T cell activation and sensitivity	NATURE			English	Article							IMMUNOLOGICAL SYNAPSE FORMATION; HLA-DR MOLECULES; CLASS-II; LIGAND RECOGNITION; FOREIGN ANTIGEN; BINDING-SITE; CD8; PROLIFERATION; EXPRESSION; CONTRIBUTE	alphabeta T lymphocytes are able to detect even a single peptide - major histocompatibility complex (MHC) on the surface of an antigen-presenting cell(1,2). This is despite clear evidence, at least with CD4(+) T cells, that monomeric ligands are not stimulatory(3,4). In an effort to understand how this remarkable sensitivity is achieved, we constructed soluble peptide - MHC heterodimers in which one peptide is an agonist and the other is one of the large number of endogenous peptide - MHCs displayed by presenting cells. We found that some specific combinations of these heterodimers can stimulate specific T cells in a CD4-dependent manner. This activation is severely impaired if the CD4-binding site on the agonist ligand is ablated, but the same mutation on an endogenous ligand has no effect. These data correlate well with analyses of lipid bilayers and cells presenting these ligands, and indicate that the basic unit of helper T cell activation is a heterodimer of agonist peptide - and endogenous peptide MHC complexes, stabilized by CD4.	Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA	Stanford University; Howard Hughes Medical Institute; Stanford University	Davis, MM (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA.	mdavis@cmgm.stanford.edu		Davis, Mark/0000-0001-6868-657X; Huppa, Johannes/0000-0003-2634-8198				Aivazian D, 2000, NAT STRUCT BIOL, V7, P1023; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; Cochran JR, 2000, IMMUNITY, V12, P241, DOI 10.1016/S1074-7613(00)80177-6; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Deane JA, 2004, ANNU REV IMMUNOL, V22, P563, DOI 10.1146/annurev.immunol.22.012703.104721; Delon J, 1998, IMMUNITY, V9, P467, DOI 10.1016/S1074-7613(00)80630-5; Ernst B, 1999, IMMUNITY, V11, P173, DOI 10.1016/S1074-7613(00)80092-8; Fremont DH, 1996, SCIENCE, V272, P1001, DOI 10.1126/science.272.5264.1001; Ge Q, 2002, P NATL ACAD SCI USA, V99, P13729, DOI 10.1073/pnas.212515299; Huppa JB, 2003, NAT IMMUNOL, V4, P749, DOI 10.1038/ni951; Irvine DJ, 2002, NATURE, V419, P845, DOI 10.1038/nature01076; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; Krogsgaard M, 2003, MOL CELL, V12, P1367, DOI 10.1016/S1097-2765(03)00474-X; Lee SJE, 2002, TRENDS IMMUNOL, V23, P492, DOI 10.1016/S1471-4906(02)02285-8; Li QJ, 2004, NAT IMMUNOL, V5, P791, DOI 10.1038/ni1095; MARRACK P, 1993, J EXP MED, V178, P2173, DOI 10.1084/jem.178.6.2173; MICELI MC, 1993, ADV IMMUNOL, V53, P59, DOI 10.1016/S0065-2776(08)60498-8; Purbhoo MA, 2004, NAT IMMUNOL, V5, P524, DOI 10.1038/ni1058; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; Schild H, 1995, INT IMMUNOL, V7, P1957, DOI 10.1093/intimm/7.12.1957; Sporri R, 2002, EUR J IMMUNOL, V32, P3161, DOI 10.1002/1521-4141(200211)32:11<3161::AID-IMMU3161>3.0.CO;2-6; Stefanova I, 2002, NATURE, V420, P429, DOI 10.1038/nature01146; Sumen C, 2004, J CELL BIOL, V166, P579, DOI 10.1083/jcb.200404059; Sun ZYJ, 2001, CELL, V105, P913, DOI 10.1016/S0092-8674(01)00395-6; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.neuro.12.1.227; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219; Wu LC, 2002, NATURE, V418, P552, DOI 10.1038/nature00920; Wulfing C, 2002, NAT IMMUNOL, V3, P42, DOI 10.1038/ni741	30	266	271	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 10	2005	434	7030					238	243		10.1038/nature03391	http://dx.doi.org/10.1038/nature03391			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904JU	15724150				2022-12-28	WOS:000227494500051
J	Yoshimura, Y; Dantzker, JLM; Callaway, EM				Yoshimura, Y; Dantzker, JLM; Callaway, EM			Excitatory cortical neurons form fine-scale functional networks	NATURE			English	Article							PRIMARY VISUAL-CORTEX; ORIENTATION SELECTIVITY; INHIBITORY NEURONS; RECEPTIVE-FIELDS; PYRAMIDAL CELLS; RAT; CONNECTIONS; CIRCUITS; LAYERS; INTERNEURONS	The specificity of cortical neuron connections creates columns of functionally similar neurons spanning from the pia to the white matter(1-6). Here we investigate whether there is an additional, finer level of specificity that creates subnetworks of excitatory neurons within functional columns. We tested for fine-scale specificity of connections to cortical layer 2/3 pyramidal neurons in rat visual cortex by using cross-correlation analyses of synaptic currents evoked by photostimulation. Recording simultaneously from adjacent layer 2/3 pyramidal cells, we find that when they are connected to each other (20% of all recorded pairs) they share common input from layer 4 and within layer 2/3. When adjacent layer 2/3 neurons are not connected to each other, they share very little ( if any) common excitatory input from layers 4 and 2/3. In contrast, all layer 2/3 neurons share common excitatory input from layer 5 and inhibitory input from layers 2/3 and 4, regardless of whether they are connected to each other. Thus, excitatory connections from layer 4 to layer 2/3 and within layer 2/3 form fine-scale assemblies of selectively interconnected neurons; inhibitory connections and excitatory connections from layer 5 link neurons across these fine-scale subnetworks. Relatively independent subnetworks of excitatory neurons are therefore embedded within the larger-scale functional architecture; this allows neighbouring neurons to convey information more independently than suggested by previous descriptions of cortical circuitry.	Salk Inst Biol Studies, Syst Neurobiol Labs, La Jolla, CA 92037 USA	Salk Institute	Callaway, EM (corresponding author), Salk Inst Biol Studies, Syst Neurobiol Labs, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	callaway@salk.edu	Callaway, Edward/D-4336-2011	Callaway, Edward/0000-0002-6366-5267; Yoshimura, Yumiko/0000-0002-7526-4153	NIMH NIH HHS [R01 MH063912] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063912] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900, DOI 10.1152/jn.1989.61.5.900; AGMON A, 1992, J NEUROSCI, V12, P319; Alonso JM, 2001, J NEUROSCI, V21, P4002, DOI 10.1523/JNEUROSCI.21-11-04002.2001; Binzegger T, 2004, J NEUROSCI, V24, P8441, DOI 10.1523/JNEUROSCI.1400-04.2004; Braitenberg V, 1991, ANATOMY CORTEX; Callaway EM, 1998, ANNU REV NEUROSCI, V21, P47, DOI 10.1146/annurev.neuro.21.1.47; CHAPMAN B, 1991, J NEUROSCI, V11, P1347; Dantzker JL, 2000, NAT NEUROSCI, V3, P701, DOI 10.1038/76656; DeAngelis GC, 1999, J NEUROSCI, V19, P4046; Ferster D, 1996, NATURE, V380, P249, DOI 10.1038/380249a0; Gibson JR, 1999, NATURE, V402, P75, DOI 10.1038/47035; Girman SV, 1999, J NEUROPHYSIOL, V82, P301, DOI 10.1152/jn.1999.82.1.301; Gonchar Y, 2003, J NEUROSCI, V23, P10904; Gonchar Y, 1999, CEREB CORTEX, V9, P683, DOI 10.1093/cercor/9.7.683; Hebb Donald O., 1949, ORG BEHAV; HELLWIG B, 1994, BIOL CYBERN, V71, P1, DOI 10.1007/BF00198906; Hellwig B, 2000, BIOL CYBERN, V82, P111, DOI 10.1007/PL00007964; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kawaguchi Y, 2002, J NEUROCYTOL, V31, P277, DOI 10.1023/A:1024126110356; Meskenaite V, 1997, J COMP NEUROL, V379, P113; Mooser F, 2004, NAT NEUROSCI, V7, P872, DOI 10.1038/nn1287; Mountcastle VB, 2003, CEREB CORTEX, V13, P2, DOI 10.1093/cercor/13.1.2; Sawatari A, 2000, NEURON, V25, P459, DOI 10.1016/S0896-6273(00)80908-3; Schubert D, 2003, J NEUROSCI, V23, P2961; Staiger JF, 2002, EUR J NEUROSCI, V16, P11, DOI 10.1046/j.1460-9568.2002.02048.x; Sur M, 2002, CURR BIOL, V12, pR168, DOI 10.1016/S0960-9822(02)00733-9; Thomson AM, 2002, CEREB CORTEX, V12, P936, DOI 10.1093/cercor/12.9.936; Thomson AM, 2002, J NEUROCYTOL, V31, P239, DOI 10.1023/A:1024117908539; Yoshimura Y, 2003, J NEUROSCI, V23, P6557	30	425	465	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 24	2005	433	7028					868	873		10.1038/nature03252	http://dx.doi.org/10.1038/nature03252			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	899VT	15729343				2022-12-28	WOS:000227174600043
J	Fergusson, D; Doucette, S; Cranley, K; Glass, KC; Shapiro, S; Healy, D; Hebert, P; Hutton, B				Fergusson, D; Doucette, S; Cranley, K; Glass, KC; Shapiro, S; Healy, D; Hebert, P; Hutton, B			Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ANTIDEPRESSANTS; FLUOXETINE; DEPRESSION; RISK	Objective To establish whether an association exists between use of selective serotonin reuptake inhibitors (SSRIs) and suicide attempts. Design Systematic review of randomised controlled trials. Data sources Medline and the Cochrane Collaboration's register of controlled trials (November 2004) for trials produced by the Cochrane depression, anxiety, and neurosis group. Selection of studies Studies had to be randomised controlled trials comparing an SSRI with either placebo or an active non-SSRl control. We included clinical trials that evaluated SSRIs for any clinical condition. We excluded abstracts, crossover trials, and all trials whose follow up was less than one week. Results Seven hundred and two trials met our inclusion criteria. A significant increase in the odds of suicide attempts (odds ratio 2.28, 95% confidence 1. 14 to 4.55, number needed to treat to harm 684) was observed for patients receiving SSRIs compared with placebo. An increase in the odds ratio of suicide attempts was also observed in comparing SSRIs with therapeutic interventions other than tricyclic antidepressants (1.94, 1.06 to 3.57, 239). In the pooled analysis of SSRIs versus tricyclic antidepressants, we did not detect a difference in the odds ratio of suicide attempts (0.88, 0.54 to 1.42). Discussion Our systematic review, which included a total of 87 650 patients, documented an association between suicide attempts and the use of SSRIs. We also observed several major methodological limitations in the published trials. A more accurate estimation of risks of suicide could be garnered from investigators fully disclosing all events.	Ottawa Hlth Res Inst, Clin Epidemiol Program, Ottawa, ON K1H 8L6, Canada; McGill Univ, Dept Human Genet, Montreal, PQ, Canada; McGill Univ, Dept Pediat, Montreal, PQ H3A 2T5, Canada; McGill Univ, Biomed Eth Unit, Montreal, PQ, Canada; McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada; Cardiff Univ, Dept Psychol Med, Bangor, Gwynedd, Wales	University of Ottawa; Ottawa Hospital Research Institute; McGill University; McGill University; McGill University; McGill University; Cardiff University	Fergusson, D (corresponding author), Ottawa Hlth Res Inst, Clin Epidemiol Program, 501 Smyth Rd,Box 201, Ottawa, ON K1H 8L6, Canada.	dafergusson@ohri.ca	anand, amit/A-7222-2009	Hutton, Brian/0000-0001-5662-8647; Fergusson, Dean/0000-0002-3389-2485				[Anonymous], 2004, COCHRANE REV HDB 4 2; BALDWIN D, 1991, INT CLIN PSYCHOPHARM, V6, P49, DOI 10.1097/00004850-199112003-00005; BALDWIN D, 1991, INT CLIN PSYCHOPH S3, V6, P19; BARBUI C, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002791; *COMM SAF MED HEAL, US SEL SER REUPT INH; *COMM SAF MED MED, US SEL SER REUPT INH; *CTR DRUG EV RES U, WORS DEPR SUIC PAT B; DEEKS J, 1998, P 6 COCHR COLL BALT, P50; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; GEDDES JR, 2000, COCHRANE DB SYST REV; GUZE BH, 1994, J FAM PRACTICE, V38, P49; HAYNES RB, 1987, CONTROL CLIN TRIALS, V8, P12, DOI 10.1016/0197-2456(87)90021-3; Healy D, 2003, J PSYCHIATR NEUROSCI, V28, P331; Jick H, 2004, JAMA-J AM MED ASSOC, V292, P338, DOI 10.1001/jama.292.3.338; Khan A, 2003, AM J PSYCHIAT, V160, P790, DOI 10.1176/appi.ajp.160.4.790; MASAND P, 1991, NEW ENGL J MED, V324, P420; *N ENGL EV BAS GUI, 1993, 91 N ENGL EV BAS GUI; ROTHSCHILD AJ, 1991, J CLIN PSYCHIAT, V52, P491; Stafford Randall S., 2001, Prim Care Companion J Clin Psychiatry, V3, P232; STEINER M, 1995, NEW ENGL J MED, V332, P1529, DOI 10.1056/NEJM199506083322301; STEINER M, 1995, NEW ENGL J MED, V8, P332; SWEETING MJ, 2002, 4 S SYST REV PUSH BO; TEICHER MH, 1990, AM J PSYCHIAT, V147, P207; Vanderhoff BT, 1997, AM FAM PHYSICIAN, V55, P249; Whittington CJ, 2004, LANCET, V363, P1341, DOI 10.1016/S0140-6736(04)16043-1	25	349	358	1	34	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 19	2005	330	7488					396	399		10.1136/bmj.330.7488.396	http://dx.doi.org/10.1136/bmj.330.7488.396			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900NA	15718539	Bronze, Green Published			2022-12-28	WOS:000227220400020
J	Ridderinkhof, KR; van den Wildenberg, WPM				Ridderinkhof, KR; van den Wildenberg, WPM			Neuroscience - Adaptive coding	SCIENCE			English	Editorial Material							ERROR-RELATED NEGATIVITY; MEDIAL FRONTAL-CORTEX; COGNITIVE CONTROL; DOPAMINE		Univ Amsterdam, Dept Psychol, NL-1012 WX Amsterdam, Netherlands; Leiden Univ, NL-2300 RA Leiden, Netherlands; CNRS, Lab Neurobiol & Cognit, F-75700 Paris, France; Univ Aix Marseille 1, Marseille, France	University of Amsterdam; Leiden University; Leiden University - Excl LUMC; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Ridderinkhof, KR (corresponding author), Univ Amsterdam, Dept Psychol, NL-1012 WX Amsterdam, Netherlands.	k.r.ridderinkhof@uva.nl; wery@dds.nl						Ach N., 1910, WILLENSAKT TEMPERAME; Brown JW, 2005, SCIENCE, V307, P1118, DOI 10.1126/science.1105783; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI 10.1037/0033-295X.109.4.679; Hommel B, 2002, PSYCHOL RES-PSYCH FO, V66, P215, DOI 10.1007/s00426-002-0096-3; James W., 1890, PRINCIPLES PSYCHOL, P449, DOI [https://doi.org/10.1037/11059-009, DOI 10.1037/11059-009]; LOGAN GD, 1986, J EXP PSYCHOL HUMAN, V12, P549, DOI 10.1037/0096-1523.12.4.549; Machens CK, 2005, SCIENCE, V307, P1121, DOI 10.1126/science.1104171; Ridderinkhof KR, 2004, SCIENCE, V306, P443, DOI 10.1126/science.1100301; Ridderinkhof KR, 2003, NEUROSCI LETT, V348, P1, DOI 10.1016/S0304-3940(03)00566-4; Rushworth MFS, 2004, TRENDS COGN SCI, V8, P410, DOI 10.1016/j.tics.2004.07.009; Schultz W, 2002, NEURON, V36, P241, DOI 10.1016/S0896-6273(02)00967-4; Yeung N, 2004, PSYCHOL REV, V111, P931, DOI [10.1037/0033-295X.111.4.931, 10.1037/0033-295x.111.4.931]	12	10	10	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2005	307	5712					1059	1060		10.1126/science.1109837	http://dx.doi.org/10.1126/science.1109837			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ED	15718459				2022-12-28	WOS:000227197300034
J	Golden, MR; Whittington, WLH; Handsfield, HH; Hughes, JP; Stamm, WE; Hogben, M; Clark, A; Malinski, C; Helmers, JRL; Thomas, KK; Holmes, KK				Golden, MR; Whittington, WLH; Handsfield, HH; Hughes, JP; Stamm, WE; Hogben, M; Clark, A; Malinski, C; Helmers, JRL; Thomas, KK; Holmes, KK			Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRACHOMATIS INFECTION; PRIVATE-SECTOR; UNITED-STATES; NOTIFICATION; STD; WOMEN	BACKGROUND: Many sex partners of persons with gonorrhea or chlamydial infections are not treated, which leads to frequent reinfections and further transmission. METHODS: We randomly assigned women and heterosexual men with gonorrhea or chlamydial infection to have their partners receive expedited treatment or standard referral. Patients in the expedited-treatment group were offered medication to give to their sex partners, or if they preferred, study staff members contacted partners and provided them with medication without a clinical examination. Patients assigned to standard partner referral were advised to refer their partners for treatment and were offered assistance notifying partners. The primary outcome was persistent or recurrent gonorrhea or chlamydial infection in patients 3 to 19 weeks after treatment. RESULTS: Persistent or recurrent gonorrhea or chlamydial infection occurred in 121 of 931 patients (13 percent) assigned to standard partner referral and 92 of 929 (10 percent) assigned to expedited treatment of sexual partners (relative risk, 0.76; 95 percent confidence interval, 0.59 to 0.98). Expedited treatment was more effective than standard referral of partners in reducing persistent or recurrent infection among patients with gonorrhea (3 percent vs. 11 percent, P=0.01) than in those with chlamydial infection (11 percent vs. 13 percent, P=0.17) (P=0.05 for the comparison of treatment effects) and remained independently associated with a reduced risk of persistent or recurrent infection after adjustment for other predictors of infection at follow-up (relative risk, 0.75; 95 percent confidence interval, 0.57 to 0.97). Patients assigned to expedited treatment of sexual partners were significantly more likely than those assigned to standard referral of partners to report that all of their partners were treated and significantly less likely to report having sex with an untreated partner. CONCLUSIONS: Expedited treatment of sex partners reduces the rates of persistent or recurrent gonorrhea or chlamydial infection.	Univ Washington, Div Infect Dis, Seattle, WA 98195 USA; Univ Washington, Ctr AIDS & Sexually Transmitted Dis, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Publ Hlth Seattle & King Cty, Seattle, WA USA; Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Ctr Human Immunodeficiency Virus Sexually Transmi, Atlanta, GA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centers for Disease Control & Prevention - USA	Golden, MR (corresponding author), Univ Washington, Div Infect Dis, Seattle, WA 98195 USA.		Golden, Matthew/AAE-4314-2020; , Holmes/K-6215-2019	Thomas, Katherine K/0000-0002-7024-468X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031448, U19AI031448, K23AI001846] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		*CDCP, 2004, OR ALT CEF TREATM UN; David LM, 1997, INT J STD AIDS, V8, P311, DOI 10.1258/0956462971920154; Fortenberry JD, 1999, SEX TRANSM DIS, V26, P26, DOI 10.1097/00007435-199901000-00005; Fortenberry JD, 2002, ARCH PEDIAT ADOL MED, V156, P1133, DOI 10.1001/archpedi.156.11.1133; Golden MR, 2003, SEX TRANSM DIS, V30, P490, DOI 10.1097/00007435-200306000-00004; Golden MR, 1999, SEX TRANSM DIS, V26, P543, DOI 10.1097/00007435-199910000-00011; Golden MR, 2001, SEX TRANSM DIS, V28, P658, DOI 10.1097/00007435-200111000-00009; Hethcote H., 1984, LECT NOTES BIOMATHEM; Kissinger P, 1998, SEX TRANSM INFECT, V74, P331, DOI 10.1136/sti.74.5.331; Kjaer HO, 2000, SEX TRANSM INFECT, V76, P169, DOI 10.1136/sti.76.3.169; Klausner JD, 2003, SEX TRANSM DIS, V30, P509, DOI 10.1097/00007435-200306000-00007; Kretzschmar M, 1996, AM J EPIDEMIOL, V144, P306; Macke BA, 1999, AM J PREV MED, V17, P230, DOI 10.1016/S0749-3797(99)00076-8; MARTIN DH, 1992, NEW ENGL J MED, V327, P921, DOI 10.1056/NEJM199209243271304; McCormack WM, 1999, SEX TRANSM DIS, V26, P531, DOI 10.1097/00007435-199910000-00009; Oh MK, 1996, J ADOLESCENT HEALTH, V18, P4, DOI 10.1016/1054-139X(95)00109-6; Orr DP, 1996, J PEDIATR-US, V128, P288, DOI 10.1016/S0022-3476(96)70413-4; Parran T, 1937, SHADOW LAND SYPHILIS; POTTERAT JJ, 1977, AM J PUBLIC HEALTH, V67, P174, DOI 10.2105/AJPH.67.2.174; RAMSTEDT K, 1991, INT J STD AIDS, V2, P428, DOI 10.1177/095646249100200607; RUDEN AK, 1993, INT J STD AIDS, V4, P284, DOI 10.1177/095646249300400507; Schiller JH, 2003, SEMIN ONCOL, V30, P49, DOI [10.1053/sonc.2003.50032, 10.1097/00007435-200301000-00011]; St Lawrence JS, 2002, AM J PUBLIC HEALTH, V92, P1784, DOI 10.2105/AJPH.92.11.1784; WACHOLDER S, 1986, AM J EPIDEMIOL, V123, P174, DOI 10.1093/oxfordjournals.aje.a114212; Whittington WLH, 2001, SEX TRANSM DIS, V28, P117, DOI 10.1097/00007435-200102000-00011; WOODHOUSE DE, 1985, PUBLIC HEALTH REP, V100, P61	26	330	344	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2005	352	7					676	685		10.1056/NEJMoa041681	http://dx.doi.org/10.1056/NEJMoa041681			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897UO	15716561				2022-12-28	WOS:000227031100006
J	Lim, LP; Lau, NC; Garrett-Engele, P; Grimson, A; Schelter, JM; Castle, J; Bartel, DP; Linsley, PS; Johnson, JM				Lim, LP; Lau, NC; Garrett-Engele, P; Grimson, A; Schelter, JM; Castle, J; Bartel, DP; Linsley, PS; Johnson, JM			Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs	NATURE			English	Article							EXPRESSION; PREDICTION; SIRNAS; PLANT	MicroRNAs ( miRNAs) are a class of noncoding RNAs that post-transcriptionally regulate gene expression in plants and animals(1,2). To investigate the influence of miRNAs on transcript levels, we transfected miRNAs into human cells and used microarrays to examine changes in the messenger RNA profile. Here we show that delivering miR-124 causes the expression profile to shift towards that of brain, the organ in which miR-124 is preferentially expressed, whereas delivering miR-1 shifts the profile towards that of muscle, where miR-1 is preferentially expressed. In each case, about 100 messages were downregulated after 12 h. The 30 untranslated regions of these messages had a significant propensity to pair to the 50 region of the miRNA, as expected if many of these messages are the direct targets of the miRNAs(3). Our results suggest that metazoan miRNAs can reduce the levels of many of their target transcripts, not just the amount of protein deriving from these transcripts. Moreover, miR-1 and miR-124, and presumably other tissue-specific miRNAs, seem to downregulate a far greater number of targets than previously appreciated, thereby helping to define tissue-specific gene expression in humans.	Rosetta Inpharmat, Seattle, WA 98109 USA; MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Merck & Company; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lim, LP (corresponding author), Rosetta Inpharmat, 401 Terry Ave N, Seattle, WA 98109 USA.	lee_lim@merck.com	Huang, H/E-9490-2010	Lau, Nelson/0000-0001-9907-1404				Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; BAILEY TL, 1994, P 2 INT C INT SYST M, P28; Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Haley B, 2004, NAT STRUCT MOL BIOL, V11, P599, DOI 10.1038/nsmb780; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Janz R, 1998, J BIOL CHEM, V273, P2851, DOI 10.1074/jbc.273.5.2851; John B, 2005, PLOS BIOL, V3, P1328, DOI 10.1371/journal.pbio.0030264; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403; Martinez J, 2004, GENE DEV, V18, P975, DOI 10.1101/gad.1187904; Palatnik JF, 2003, NATURE, V425, P257, DOI 10.1038/nature01958; Pruitt KD, 2001, NUCLEIC ACIDS RES, V29, P137, DOI 10.1093/nar/29.1.137; Rhoades MW, 2002, CELL, V110, P513, DOI 10.1016/S0092-8674(02)00863-2; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vartiainen MK, 2003, J BIOL CHEM, V278, P34347, DOI 10.1074/jbc.M303642200; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100	30	3835	4138	5	348	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 17	2005	433	7027					769	773		10.1038/nature03315	http://dx.doi.org/10.1038/nature03315			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897XH	15685193				2022-12-28	WOS:000227039200045
J	Sword, GA; Lorch, PD; Gwynne, DT				Sword, GA; Lorch, PD; Gwynne, DT			Migratory bands give crickets protection	NATURE			English	Editorial Material									ARS, USDA, No Plains Agr Res Lab, Sidney, MT 59270 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ Toronto, Mississauga, ON L5L 1C6, Canada	United States Department of Agriculture (USDA); University of North Carolina; University of North Carolina Chapel Hill; University of Toronto; University Toronto Mississauga	Sword, GA (corresponding author), ARS, USDA, No Plains Agr Res Lab, Sidney, MT 59270 USA.	gsword@sidney.ars.usda.gov		Sword, Gregory/0000-0003-2094-2436				[Anonymous], 2020, ECONOMIST 0326; GWYNNE DT, 1993, ECOLOGY, V74, P1406, DOI 10.2307/1940070; Gwynne DT, 2001, CORNELL S ARTHR BIOL; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; KARBAN R, 1982, ECOLOGY, V63, P321, DOI 10.2307/1938949; Krause J, 2002, LIVING GROUPS; Lorch PD, 2000, NATURWISSENSCHAFTEN, V87, P370, DOI 10.1007/s001140050743; MacVean C.M., 1987, P116; Sword GA, 2005, ANIM BEHAV, V69, P437, DOI 10.1016/j.anbehav.2004.04.016; Uvarov B. P., 1977, GRASSHOPPERS LOCUSTS, V2; WILLIAMS KS, 1993, ECOLOGY, V74, P1143, DOI 10.2307/1940484	11	65	69	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	2005	433	7027					703	703		10.1038/433703a	http://dx.doi.org/10.1038/433703a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897XH	15716941	Bronze			2022-12-28	WOS:000227039200027
J	Zegers, R				Zegers, R			Schrodinger's mousetrap - Part 5: Refracted glory	NATURE			English	Editorial Material									Michigan State Univ, Natl Superconducting Cyclotron Lab, Joint Inst Nucl Astrophys, E Lansing, MI 48824 USA; Michigan State Univ, Dept Phys & Astron, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Zegers, R (corresponding author), Michigan State Univ, Natl Superconducting Cyclotron Lab, Joint Inst Nucl Astrophys, E Lansing, MI 48824 USA.		Zegers, Remco G. T./A-6847-2008	Zegers, Remco G. T./0000-0001-6076-5898					0	0	0	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 17	2005	433	7027					689	689		10.1038/433689a	http://dx.doi.org/10.1038/433689a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897XH	15716930				2022-12-28	WOS:000227039200018
J	Chan, HLY; Leung, NWY; Hui, AY; Wong, VWS; Liew, CT; Chim, AML; Chan, FKL; Hung, LCT; Lee, YT; Tam, JSL; Lam, CWK; Sung, JJY				Chan, HLY; Leung, NWY; Hui, AY; Wong, VWS; Liew, CT; Chim, AML; Chan, FKL; Hung, LCT; Lee, YT; Tam, JSL; Lam, CWK; Sung, JJY			A randomized, controlled trial of combination therapy for chronic hepatitis B: Comparing pegylated interferon-alpha 2b and lamivudine with lamivudine alone	ANNALS OF INTERNAL MEDICINE			English	Article							E-ANTIGEN; ALPHA-INTERFERON; VIRUS DNA; LONG-TERM; ADEFOVIR DIPIVOXIL; ANTIVIRAL THERAPY; INITIAL TREATMENT; DURABILITY; SEROCONVERSION; MONOTHERAPY	Background: conventional interferon and lamivudine monotherapy are unsatisfactory in treating hepatitis B virus (HBV) infection. Objective: To evaluate the efficacy and safety of pegylated interferon-alpha2b and lamivudine combination therapy for chronic hepatitis B. Design: Randomized, controlled, open-label trial. Setting: Outpatient clinic in a referral center. Participants: 100 treatment-naive patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B and moderately elevated alanine aminotransferase levels. Measurement: The primary end point was sustained virologic response (HBeAg seroconversion and HBV DNA level < 500 000 copies/mL) at 24 weeks after cessation of treatment. Intervention: A staggered regimen of combination therapy with pegylated interferon-alpha2b (1.5 mug/kg of body weight per week; maximum, 100 mug) given for 32 weeks plus lamivudine (100 mg daily) given for 52 weeks versus lamivudine (100 mg daily) monotherapy given for 52 weeks. Of the 100 participants, 96% completed treatment and 80% completed post-treatment follow-up. Results: The rate of sustained virologic response was 36% for the combination treatment group and 14% for the lamivudine monotherapy group (absolute difference, 22 percentage points [95% CI, 6 to 38 percentage points]). End-of-treatment outcomes showed that, compared with monotherapy, patients receiving combination therapy more often had virologic response (60% vs. 28% [absolute difference, 32 percentage points (CI, 14 to 50 percentage points)]); had more substantial reductions of HBV DNA (3.91 log(10) copies/mL vs. 2.83 log(10) copies/mL); and less often had lamivudine-resistant mutants (21% vs. 40%). The percentages of patients with normalization of alanine aminotransferase levels and histologic improvement did not differ. Adverse effects, such as transient influenza-like symptoms, alopecia, and local erythernatous reactions, were more common with combination therapy. Limitations: This study lacked a double-blind design and was conducted at 1 institution. Because of the staggered pegylated interferon-lamivudine regimen, patients assigned to combination therapy received treatment for 8 weeks longer than those assigned to monotherapy. Conclusions: In patients with HBeAg-positive chronic hepatitis B, staggered combination treatment with pegylated interferon-a2b and lamivudine may lead to a higher rate of virologic response than lamivudine monotherapy.	Chinese Univ Hong Kong, Sha Tin 100083, Peoples R China; Nethersole Hosp, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong	Sung, JJY (corresponding author), 9 F Prince Wales Hosp, Dept Med & Therapeut, 30-32 Ngan Shing St, Shatin, Hong Kong, Peoples R China.	joesung@cuhk.edu.hk	Chan, Henry Lik-Yuen/B-9636-2008; Chan, Francis K. L./F-4851-2010; Wong, Vincent WS/K-3864-2014; Sung, Joseph J. Y./R-3203-2018	Chan, Henry Lik-Yuen/0000-0002-7790-1611; Chan, Francis K. L./0000-0001-7388-2436; Wong, Vincent WS/0000-0003-2215-9410; Sung, Joseph J. Y./0000-0003-3125-5199				Barbaro G, 2001, J HEPATOL, V35, P406, DOI 10.1016/S0168-8278(01)00145-3; Chan HLY, 2000, J CLIN MICROBIOL, V38, P3205, DOI 10.1128/JCM.38.9.3205-3208.2000; Chan HLY, 2003, J CLIN MICROBIOL, V41, P1277, DOI 10.1128/JCM.41.3.1277-1279.2003; Chan HLY, 2002, J MED VIROL, V68, P182, DOI 10.1002/jmv.10185; Cooksley WGE, 2003, J VIRAL HEPATITIS, V10, P298, DOI 10.1046/j.1365-2893.2003.00450.x; Dienstag JL, 2003, HEPATOLOGY, V37, P748, DOI 10.1053/jhep.2003.50117; Dienstag JL, 1999, NEW ENGL J MED, V341, P1256, DOI 10.1056/NEJM199910213411702; Feld J, 2003, HEPATOLOGY, V38, P545, DOI 10.1053/jhep.2003.50389; Hasan F, 2003, HEPATO-GASTROENTEROL, V50, P2040; Janssen HLA, 1999, HEPATOLOGY, V30, P238, DOI 10.1002/hep.510300113; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; Lai CL, 2003, HEPATOLOGY, V38, p262A; Lai CL, 2003, CLIN INFECT DIS, V36, P687, DOI 10.1086/368083; LIAW YF, 1994, J HEPATOL, V20, P175, DOI 10.1016/S0168-8278(05)80055-8; Lindh M, 1997, J INFECT DIS, V175, P1285, DOI 10.1086/516458; Lindsay KL, 2001, HEPATOLOGY, V34, P395, DOI 10.1053/jhep.2001.26371; Loeb KR, 2000, HEPATOLOGY, V32, P626, DOI 10.1053/jhep.2000.9878; Lok ASF, 2002, J CLIN MICROBIOL, V40, P3729, DOI 10.1128/JCM.40.10.3729-3734.2002; LOK ASF, 1992, GASTROENTEROLOGY, V102, P2091, DOI 10.1016/0016-5085(92)90337-X; Marcellin P, 2003, NEW ENGL J MED, V348, P808, DOI 10.1056/NEJMoa020681; MAYNARD JE, 1990, VACCINE, V8, pS18, DOI 10.1016/0264-410X(90)90209-5; Ryu SH, 2003, J HEPATOL, V39, P614, DOI 10.1016/S0168-8278(03)00394-5; Santantonio T, 2002, J HEPATOL, V36, P799, DOI 10.1016/S0168-8278(02)00056-9; *SCH PLOUGH CORP, 2001, PROD MON; Schalm SW, 2000, GUT, V46, P562, DOI 10.1136/gut.46.4.562; Schiff ER, 2003, J HEPATOL, V38, P818, DOI 10.1016/S0168-8278(03)00076-X; Song BC, 2000, HEPATOLOGY, V32, P803, DOI 10.1053/jhep.2000.16665; Sung JJY, 2003, J HEPATOL, V38, P25, DOI 10.1016/S0168-8278(03)80485-3; Tatulli I, 2001, J HEPATOL, V35, P805, DOI 10.1016/S0168-8278(01)00201-X; van Nunen AB, 2003, GUT, V52, P420, DOI 10.1136/gut.52.3.420; VANZONNEVELD M, 2004, J HEPATOL S1, V40, P132; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011; Yalcin K, 2003, CLIN INFECT DIS, V36, P1516, DOI 10.1086/375085; Yang HI, 2002, NEW ENGL J MED, V347, P168, DOI 10.1056/NEJMoa013215; Zaman A, 2003, ALIMENT PHARM THER, V18, P661, DOI 10.1046/j.1365-2036.2003.01747.x	35	215	238	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	2005	142	4					240	250		10.7326/0003-4819-142-4-200502150-00006	http://dx.doi.org/10.7326/0003-4819-142-4-200502150-00006			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900UJ	15710957				2022-12-28	WOS:000227239500002
J	Turnidge, J; Christiansen, K				Turnidge, J; Christiansen, K			Antibiotic use,and resistance - proving the obvious	LANCET			English	Editorial Material							ANTIMICROBIAL USE; CONSUMPTION; ERYTHROMYCIN; COMMUNITY		Womens & Childrens Hosp, Adelaide, SA 5062, Australia; Royal Perth Hosp, Perth, WA, Australia	Womens & Childrens Hospital Australia; Royal Perth Hospital; University of Western Australia	Turnidge, J (corresponding author), Womens & Childrens Hosp, Adelaide, SA 5062, Australia.	turnidgej@wch.sa.gov.au						Austin DJ, 1999, P NATL ACAD SCI USA, V96, P1152, DOI 10.1073/pnas.96.3.1152; Berger VW, 2004, DRUG INF J, V38, P1; Bruinsma N, 2003, J ANTIMICROB CHEMOTH, V51, P385, DOI 10.1093/jac/dkg072; Garcia-Rey C, 2002, J CLIN MICROBIOL, V40, P159, DOI 10.1128/JCM.40.1.159-164.2002; Garcia-Rey C, 2002, J CLIN MICROBIOL, V40, P2959, DOI 10.1128/JCM.40.8.2959-2963.2002; Hjaltested EKR, 2003, SCAND J INFECT DIS, V35, P21, DOI 10.1080/0036554021000026996; Holmes SJ, 1996, EPIDEMIOL REV, V18, P10, DOI 10.1093/oxfordjournals.epirev.a017913; Kahlmeter G, 2003, J ANTIMICROB CHEMOTH, V52, P1005, DOI 10.1093/jac/dkg488; Monnet DL, 1998, INFECT CONT HOSP EP, V19, P388; MUNCHPETERSEN E, 1962, B WORLD HEALTH ORGAN, V26, P241; Sommet A, 2004, J ANTIMICROB CHEMOTH, V54, P524, DOI 10.1093/jac/dkh342; Whitney Cynthia G, 2004, Semin Pediatr Infect Dis, V15, P86, DOI 10.1053/j.spid.2004.01.011	12	81	84	0	18	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 12	2005	365	9459					548	549						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DN	15708081				2022-12-28	WOS:000226984300004
J	Hogeveen, KN				Hogeveen, KN			Homeobox galore: When reproduction goes RHOX and roll	CELL			English	Editorial Material							GENES	Homeobox transcription factors exert essential roles in embryogenesis and are thought to govern regenerative cell differentiation. In this issue of Cell, MacLean and colleagues (MacLean et al., 2005) describe a new homeobox gene cluster composed of genes selectively expressed in reproductive tissues. Remarkably, the cluster is on the X chromosome, and the genes display a colinear pattern of expression.	Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Hogeveen, KN (corresponding author), Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France.							Cheng CY, 2002, PHYSIOL REV, V82, P825, DOI 10.1152/physrev.00009.2002; Cillo C, 2001, J CELL PHYSIOL, V188, P161, DOI 10.1002/jcp.1115; Kmita M, 2003, SCIENCE, V301, P331, DOI 10.1126/science.1085753; MacLean JA, 2005, CELL, V120, P369, DOI 10.1016/j.cell.2004.12.022; Saifi GM, 1999, P ROY SOC B-BIOL SCI, V266, P203, DOI 10.1098/rspb.1999.0623; Sassone-Corsi P, 2002, SCIENCE, V296, P2176, DOI 10.1126/science.1070963; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; Trainor PA, 2000, NAT REV NEUROSCI, V1, P116, DOI 10.1038/35039056; Wang PJ, 2001, NAT GENET, V27, P422, DOI 10.1038/86927	9	8	11	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 11	2005	120	3					287	288		10.1016/j.cell.2004.12.028	http://dx.doi.org/10.1016/j.cell.2004.12.028			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	897TS	15707884	Bronze			2022-12-28	WOS:000227028900001
J	Johnston, LA				Johnston, LA			Regeneration and transdetermination: New tricks from old cells	CELL			English	Editorial Material								In this issue of Cell, Sustar and Schubiger (2005) address a longstanding question in regeneration biology: How is pluripotency achieved during regeneration? The authors have examined the cell cycle and growth characteristics of multipotent regenerating and transdetermining Drosophila cells and come up with some surprising findings.	Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA	Columbia University	Johnston, LA (corresponding author), Columbia Univ Coll Phys & Surg, Dept Genet & Dev, 701 W 168th St, New York, NY 10032 USA.		Johnston, Laura A/ABC-1945-2021	JOHNSTON, LAURA A/0000-0001-9477-7897	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD042770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017373, R01GM078464] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD042770-02, R01 HD042770, R01 HD042770-01A1, R01 HD042770-05, R01 HD042770-03, R01 HD042770-04] Funding Source: Medline; NIGMS NIH HHS [F32 GM017373-01, F32 GM017373-04, F32 GM017373-02, R01 GM078464, F32 GM017373-03, F32 GM017373] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		HADORN E, 1978, GENET BIOL DROSOPHIL, P555; Maves L, 2003, CURR OPIN GENET DEV, V13, P472, DOI 10.1016/j.gde.2003.08.006; Okubo Tadashi, 2004, J Biol, V3, P11, DOI 10.1186/jbiol3; SCHUBIGER G, 1971, DEV BIOL, V26, P277, DOI 10.1016/0012-1606(71)90127-8; Sustar A, 2005, CELL, V120, P383, DOI 10.1016/j.cell.2004.12.008	5	7	7	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 11	2005	120	3					288	290		10.1016/j.cell.2005.01.022	http://dx.doi.org/10.1016/j.cell.2005.01.022			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	897TS	15707885	Bronze			2022-12-28	WOS:000227028900002
J	Maiorano, D; Cuvier, O; Danis, E; Mechali, M				Maiorano, D; Cuvier, O; Danis, E; Mechali, M			MCM8 is an MCM2-7-related protein that functions as a DNA helicase during replication elongation and not initiation	CELL			English	Article							XENOPUS EGG EXTRACTS; CELL-CYCLE REGULATION; S-PHASE; POLYMERASE-ALPHA; SCHIZOSACCHAROMYCES-POMBE; ATP HYDROLYSIS; IN-VITRO; CHROMATIN; COMPLEX; FAMILY	MCM2-7 proteins are replication factors required to initiate DNA synthesis and are currently the best candidates for replicative helicases. We show that the MCM2-7-related protein MCM8 is required to efficiently replicate chromosomal DNA in Xenopus egg extracts. MCM8 does not associate with the soluble MCM2-7 complex and binds chromatin upon initiation of DNA synthesis. MCM8 depletion does not affect replication licensing or MCM3 loading but slows down DNA synthesis and reduces chromatin recruitment of RPA34 and DNA polymerase-alpha. Recombinant MCM8 displays both DNA helicase and ATPase activities in vitro. Reconstitution experiments show that ATP binding in MCM8 is required to rescue DNA synthesis in MCM8-depleted extracts. MCM8 colocalizes with replication foci and RPA34 on chromatin. We suggest that MCM8 functions in the elongation step of DNA replication as a helicase that facilitates the recruitment of RPA34 and stimulates the processivity of DNA polymerases at replication foci.	CNRS, Inst Human Genet, F-34396 Montpellier 05, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Mechali, M (corresponding author), CNRS, Inst Human Genet, 141 Rue Cardonille, F-34396 Montpellier 05, France.	mechali@igh.cnrs.fr	Cuvier, Olivier/ADO-0657-2022; CUVIER, Olivier/AAC-4693-2019; Maiorano, Domenico/N-5755-2017	CUVIER, Olivier/0000-0003-0644-2734; Maiorano, Domenico/0000-0003-4229-5903				ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; ALMOUZNI G, 1988, EMBO J, V7, P665, DOI 10.1002/j.1460-2075.1988.tb02861.x; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Coue M, 1998, EXP CELL RES, V245, P282, DOI 10.1006/excr.1998.4271; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; Davey MJ, 2003, J BIOL CHEM, V278, P4491, DOI 10.1074/jbc.M210511200; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Dimitrova DS, 1999, J CELL BIOL, V146, P709, DOI 10.1083/jcb.146.4.709; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; Francon P, 2004, J CELL SCI, V117, P4909, DOI 10.1242/jcs.01361; Gozuacik D, 2003, NUCLEIC ACIDS RES, V31, P570, DOI 10.1093/nar/gkg136; Gozuacik D, 2001, ONCOGENE, V20, P6233, DOI 10.1038/sj.onc.1204835; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; Ishimi Y, 1998, J BIOL CHEM, V273, P8369, DOI 10.1074/jbc.273.14.8369; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Johnson EM, 2003, NUCLEIC ACIDS RES, V31, P2915, DOI 10.1093/nar/gkg395; Kearsey SE, 1998, BBA-GENE STRUCT EXPR, V1398, P113, DOI 10.1016/S0167-4781(98)00033-5; Krude T, 1996, J CELL SCI, V109, P309; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Kubota Y, 1997, EMBO J, V16, P3320, DOI 10.1093/emboj/16.11.3320; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Labib K, 1999, NAT CELL BIOL, V1, P415, DOI 10.1038/15649; Labib K, 2001, CURR OPIN GENET DEV, V11, P64, DOI 10.1016/S0959-437X(00)00158-1; Laskey RA, 2003, EMBO REP, V4, P26, DOI 10.1038/sj.embor.embor706; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; LEIBOVICI M, 1992, J CELL SCI, V102, P63; Liang DT, 1999, J CELL SCI, V112, P559; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MADINE MA, 1995, CURR BIOL, V5, P1270, DOI 10.1016/S0960-9822(95)00253-3; Maiorano D, 2000, J BIOL CHEM, V275, P8426, DOI 10.1074/jbc.275.12.8426; Maiorano D, 2004, EXP CELL RES, V295, P138, DOI 10.1016/j.yexcr.2003.11.018; Maiorano D, 1996, EMBO J, V15, P861, DOI 10.1002/j.1460-2075.1996.tb00421.x; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; MECHALI M, 1982, CELL, V30, P93, DOI 10.1016/0092-8674(82)90015-0; MELENDY T, 1993, J BIOL CHEM, V268, P3389; Mendez J, 2003, BIOESSAYS, V25, P1158, DOI 10.1002/bies.10370; MENUT S, 1988, ADV MOL BIOL COMP ME, P196; Michael WM, 2000, SCIENCE, V289, P2133, DOI 10.1126/science.289.5487.2133; Mimura S, 2000, GENES CELLS, V5, P439, DOI 10.1046/j.1365-2443.2000.00340.x; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Pacek M, 2004, EMBO J, V23, P3667, DOI 10.1038/sj.emboj.7600369; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; Rowles A, 1999, J CELL SCI, V112, P2011; Schwacha A, 2001, MOL CELL, V8, P1093, DOI 10.1016/S1097-2765(01)00389-6; Shechter D, 2004, J BIOL CHEM, V279, P45586, DOI 10.1074/jbc.M407772200; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Vuillard L, 1998, EUR J BIOCHEM, V256, P128, DOI 10.1046/j.1432-1327.1998.2560128.x; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; You ZY, 1999, MOL CELL BIOL, V19, P8003	63	96	103	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 11	2005	120	3					315	328		10.1016/j.cell.2004.12.010	http://dx.doi.org/10.1016/j.cell.2004.12.010			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	897TS	15707891	Bronze			2022-12-28	WOS:000227028900008
J	Borchert, R; Renner, SS; Calle, Z; Navarrete, D; Tye, A; Gautier, L; Spichiger, R; von Hildebrand, P				Borchert, R; Renner, SS; Calle, Z; Navarrete, D; Tye, A; Gautier, L; Spichiger, R; von Hildebrand, P			Photoperiodic induction of synchronous flowering near the Equator	NATURE			English	Article							LENGTH; TREES	In tropical rainforests, 30 - 65% of tree species grow at densities of less than one individual per hectare(1). At these low population densities, successful cross- pollination relies on synchronous flowering. In rainforests with low climatic seasonality, photoperiodic control is the only reliable mechanism for inducing synchronous flowering(2,3). This poses a problem because there is no variation in day length at the Equator. Here we propose a new mechanism of photoperiodic timekeeping based on the perception of variation in sunrise or sunset time, which explains and predicts the annually repeated, staggered, synchronous and bimodal flowering of many tree species in Amazonian rainforests near the Equator.	Univ Kansas, Div Biol, Lawrence, KS 66045 USA; Univ Munich, Dept Biol, D-80638 Munich, Germany; CIPAV, Ctr Res Sustainable Agr, Cali AA 20591, Colombia; Fdn Puerto Rastrojo, Bogota AA 241438, Colombia; Charles Darwin Res Stn, Dept Bot, Quito, Ecuador; Conservatoire & Jardin Bot Ville Geneve, CH-1292 Chambesy, GE, Switzerland	University of Kansas; University of Munich	Borchert, R (corresponding author), Univ Kansas, Div Biol, Lawrence, KS 66045 USA.	borchert@ku.edu						Borchert R, 2004, GLOBAL ECOL BIOGEOGR, V13, P409, DOI 10.1111/j.1466-822X.2004.00111.x; Borchert R, 2001, TREE PHYSIOL, V21, P213, DOI 10.1093/treephys/21.4.213; BORCHERT R, 2004, ENV CONTROL TROPICAL; CALLE Z, 2002, BIOTROPICA, V34, P621; CONDIT R, IN PRESS BIOL SKR DA; DORE J, 1959, NATURE, V183, P413, DOI 10.1038/183413a0; GAUTIER L, 1986, Candollea, V41, P193; GAUTIER L, 1985, THESIS U GENEVE; Holttum R. E., 1940, Gardens' Bulletin, V11, P119; Imaizumi T, 2003, NATURE, V426, P302, DOI 10.1038/nature02090; Justiniano MJ, 2000, BIOTROPICA, V32, P276, DOI 10.1111/j.1744-7429.2000.tb00470.x; *NAT MAR MUS, TIM EQ TIM; Rivera G, 2002, TREES-STRUCT FUNCT, V16, P445, DOI 10.1007/s00468-002-0185-3; Rivera G, 2001, TREE PHYSIOL, V21, P201, DOI 10.1093/treephys/21.4.201; SNOW DW, 1966, OIKOS, V15, P274, DOI 10.2307/3565124; Thomas B., 1997, PHOTOPERIODISM PLANT; Valverde F, 2004, SCIENCE, V303, P1003, DOI 10.1126/science.1091761	17	151	168	2	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 10	2005	433	7026					627	629		10.1038/nature03259	http://dx.doi.org/10.1038/nature03259			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	895KX	15703746				2022-12-28	WOS:000226862000043
J	Di Matteo, T; Springel, V; Hernquist, L				Di Matteo, T; Springel, V; Hernquist, L			Energy input from quasars regulates the growth and activity of black holes and their host galaxies	NATURE			English	Article							MODEL; STARBURSTS; OUTFLOW; MASS	In the early Universe, while galaxies were still forming, black holes as massive as a billion solar masses powered quasars. Supermassive black holes are found at the centres of most galaxies today(1 - 3), where their masses are related to the velocity dispersions of stars in their host galaxies and hence to the mass of the central bulge of the galaxy(4,5). This suggests a link between the growth of the black holes and their host galaxies(6 - 9), which has indeed been assumed for a number of years. But the origin of the observed relation between black hole mass and stellar velocity dispersion, and its connection with the evolution of galaxies, have remained unclear. Here we report simulations that simultaneously follow star formation and the growth of black holes during galaxy - galaxy collisions. We find that, in addition to generating a burst of star formation(10), a merger leads to strong inflows that feed gas to the supermassive black hole and thereby power the quasar. The energy released by the quasar expels enough gas to quench both star formation and further black hole growth. This determines the lifetime of the quasar phase ( approaching 100 million years) and explains the relationship between the black hole mass and the stellar velocity dispersion.	Max Planck Inst Astrophys, D-85740 Garching, Germany; Harvard Univ, Dept Astron, Cambridge, MA 02138 USA	Max Planck Society; Harvard University	Di Matteo, T (corresponding author), Carnegie Mellon Univ, Dept Phys, 5000 Forbes Ave, Pittsburgh, PA 15213 USA.	tiziana@phys.cmu.edu	Di Matteo, Tiziana/O-4762-2014	Di Matteo, Tiziana/0000-0002-6462-5734; Springel, Volker/0000-0001-5976-4599				BARGER AJ, IN PRESS ASTROPHYS J; BARNES JE, 1992, ANNU REV ASTRON ASTR, V30, P705, DOI 10.1146/annurev.aa.30.090192.003421; BONDI H, 1952, MON NOT R ASTRON SOC, V112, P195, DOI 10.1093/mnras/112.2.195; Chartas G, 2003, ASTROPHYS J, V595, P85, DOI 10.1086/377299; Crenshaw DM, 2003, ANNU REV ASTRON ASTR, V41, P117, DOI 10.1146/annurev.astro.41.082801.100328; Fabian AC, 1999, MON NOT R ASTRON SOC, V308, pL39, DOI 10.1046/j.1365-8711.1999.03017.x; Ferrarese L, 2000, ASTROPHYS J, V539, pL9, DOI 10.1086/312838; FERRARESE L, IN PRESS SPACE SCI R; Gebhardt K, 2000, ASTROPHYS J, V539, pL13, DOI 10.1086/312840; Granato GL, 2004, ASTROPHYS J, V600, P580, DOI 10.1086/379875; GREENE JE, IN PRESS ASTROPHYS J; HASINGER G, UNPUB ASTRON ASTROPH; HERNQUIST L, 1989, NATURE, V340, P687, DOI 10.1038/340687a0; Kauffmann G, 2000, MON NOT R ASTRON SOC, V311, P576, DOI 10.1046/j.1365-8711.2000.03077.x; King A, 2003, ASTROPHYS J, V596, pL27, DOI 10.1086/379143; KORMENDY J, 1995, ANNU REV ASTRON ASTR, V33, P581, DOI 10.1146/annurev.aa.33.090195.003053; Magorrian J, 1998, ASTRON J, V115, P2285, DOI 10.1086/300353; Mihos JC, 1996, ASTROPHYS J, V464, P641, DOI 10.1086/177353; Pounds KA, 2003, MON NOT R ASTRON SOC, V345, P705, DOI 10.1046/j.1365-8711.2003.07006.x; SHAKURA NI, 1973, ASTRON ASTROPHYS, V24, P337; Silk J, 1998, ASTRON ASTROPHYS, V331, pL1; SOLTAN A, 1982, MON NOT R ASTRON SOC, V200, P115, DOI 10.1093/mnras/200.1.115; Springel V, 2003, MON NOT R ASTRON SOC, V339, P289, DOI 10.1046/j.1365-8711.2003.06206.x; SPRINGEL V, 2004, ASTROPH04111108; SPRINGEL V, UNPUB ASTROPHYS J; SPRINGEL V, UNPUB MON NOT R ASTR; Tremaine S, 2002, ASTROPHYS J, V574, P740, DOI 10.1086/341002; Volonteri M, 2003, ASTROPHYS J, V582, P559, DOI 10.1086/344675; Wyithe JSB, 2003, ASTROPHYS J, V595, P614, DOI 10.1086/377475; Yu QJ, 2002, MON NOT R ASTRON SOC, V335, P965, DOI 10.1046/j.1365-8711.2002.05532.x	30	2339	2339	1	83	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 10	2005	433	7026					604	607		10.1038/nature03335	http://dx.doi.org/10.1038/nature03335			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	895KX	15703739				2022-12-28	WOS:000226862000036
J	Funabashi, N; Komuro, I				Funabashi, N; Komuro, I			Heart-shaped tumor in pulmonary trunk	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Chiba Univ, Grad Sch Med, Chiba 2608670, Japan	Chiba University	Funabashi, N (corresponding author), Chiba Univ, Grad Sch Med, Chiba 2608670, Japan.								0	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2005	352	6					608	608		10.1056/NEJMicm040835	http://dx.doi.org/10.1056/NEJMicm040835			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895KY	15703425				2022-12-28	WOS:000226862100010
J	Grossman, DC; Mueller, BA; Riedy, C; Dowd, MD; Villaveces, A; Prodzinski, J; Nakagawara, J; Howard, J; Thiersch, N; Harruff, R				Grossman, DC; Mueller, BA; Riedy, C; Dowd, MD; Villaveces, A; Prodzinski, J; Nakagawara, J; Howard, J; Thiersch, N; Harruff, R			Gun storage practices and risk of youth suicide and unintentional firearm injuries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADOLESCENT SUICIDE; US HOMES; CHILDREN; PATTERNS; DEATHS; LAWS	Context Household firearms are associated with an elevated risk of firearm death to occupants in the home. Many organizations and health authorities advocate locking firearms and ammunition to prevent access to guns by children and adolescents. The association of these firearm storage practices with the reduction of firearm injury risk is unclear. Objective To measure the association of specific household firearm storage practices (locking guns, locking ammunition, keeping guns unloaded) and the risk of unintentional and self-inflicted firearm injuries. Design and Setting Case-control study of firearms in events identified by medical examiner and coroner offices from 37 counties in Washington, Oregon, and Missouri, and 5 trauma centers in Seattle, Spokane, and Tacoma, Wash, and Kansas City, Mo. Cases and Controls Case firearms were identified by involvement in an incident in which a child or adolescent younger than 20 years gained access to a firearm and shot himself/herself intentionally or unintentionally or shot another individual unintentionally. Firearm assaults and homicides were excluded. We used records from hospitals and medical examiners to ascertain these incidents. Using random-digit dial telephone sampling, control firearms were identified by identification of eligible households with at least 1 firearm and children living or visiting in the home. Controls were frequency matched by age group and county. Main Exposure Measures The key exposures of interest in this study were: (1) whether the subject firearm was stored in a locked location or with an extrinsic lock; (2) whether the firearm was stored unloaded; (3) whether the firearm was stored both unloaded in a locked location; (4) whether the ammunition for the firearm was stored separately; and (5) whether the ammunition was stored in a locked location. Data regarding the storage status of case and control guns were collected by interview with respondents from the households of case and control firearms. Results We interviewed 106 respondents with case firearms and 480 with control firearms. Of the shootings associated with the case firearms, 82 were suicide attempts (95% fatal) and 24 were unintentional injuries (52% fatal). After adjustment for potentially confounding variables, guns from case households were less likely to be stored unloaded than control guns (odds ratio [OR], 0.30; 95% confidence interval [Cl], 0.16-0.56). Similarly, case guns were less likely to be stored locked (OR, 0.27; 95 % Cl, 0.17-0.45), stored separately from ammunition (OR, 0.45; 95% Cl, 0.34-0.93), or to have ammunition that was locked (OR, 0.39; 95% Cl, 0.23-0.66) than were control guns. These findings were consistent for both handguns and long guns and were also similar for both suicide attempts and unintentional injuries. Conclusions The 4 practices of keeping a gun locked, unloaded, storing ammunition locked, and in a separate location are each associated with a protective effect and suggest a feasible strategy to reduce these types of injuries in homes with children and teenagers where guns are stored.	Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; Med Examiner Off King Cty, Washington, DC USA; Med Examiner Off Pierce Cty, Washington, DC USA; Med Examiner Off Snohomish Cty, Washington, DC USA; Childrens Mercy Hosp, Dept Pediat, Kansas City, MO 64108 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Children's Mercy Hospital	Grossman, DC (corresponding author), Grp Hlth Cooperat Puget Sound, Dept Prevent Care, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.	grossman.d@ghc.org		Villaveces, Andres/0000-0002-3725-2741	ODCDC CDC HHS [R49/CCR015592] Funding Source: Medline	ODCDC CDC HHS		Azrael D, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.3.e31; Biener L, 2004, AM J PREV MED, V27, P254, DOI 10.1016/j.amepre.2004.05.006; BRENT DA, 1988, ARCH GEN PSYCHIAT, V45, P581, DOI 10.1001/archpsyc.1988.01800300079011; BRENT DA, 1991, JAMA-J AM MED ASSOC, V266, P2989, DOI 10.1001/jama.266.21.2989; BRENT DA, 1993, AM J DIS CHILD, V147, P1066, DOI 10.1001/archpedi.1993.02160340052013; BUKSTEIN OG, 1993, ACTA PSYCHIAT SCAND, V88, P403, DOI 10.1111/j.1600-0447.1993.tb03481.x; Centers for Disease Control and Prevention, 2002, BEH RISK FACT SURV S; Coyne-Beasley T, 2001, ARCH PEDIAT ADOL MED, V155, P659, DOI 10.1001/archpedi.155.6.659; Cummings P, 1997, JAMA-J AM MED ASSOC, V278, P1084, DOI 10.1001/jama.278.13.1084; CUMMINGS P, 1987, AM J PUBLIC HEALTH, V87, P899; Grossman DC, 1999, ARCH PEDIAT ADOL MED, V153, P875, DOI 10.1001/archpedi.153.8.875; Grossman DC, 2000, PEDIATRICS, V106, P22, DOI 10.1542/peds.106.1.22; HEMENWAY D, 1995, JAMA-J AM MED ASSOC, V273, P46, DOI 10.1001/jama.273.1.46; Horn A, 2003, INJURY PREV, V9, P231, DOI 10.1136/ip.9.3.231; Johnson RM, 2004, AM J PREV MED, V27, P173, DOI 10.1016/j.amepre.2004.04.015; KELLERMANN AL, 1992, NEW ENGL J MED, V327, P467, DOI 10.1056/NEJM199208133270705; Schuster MA, 2000, AM J PUBLIC HEALTH, V90, P588, DOI 10.2105/AJPH.90.4.588; Senturia YD, 1996, ARCH PEDIAT ADOL MED, V150, P265, DOI 10.1001/archpedi.1996.02170280035006; Stennies G, 1999, ARCH PEDIAT ADOL MED, V153, P586; Vernick JS, 2003, INJURY PREV, V9, P307, DOI 10.1136/ip.9.4.307; Webster DW, 2004, JAMA-J AM MED ASSOC, V292, P594, DOI 10.1001/jama.292.5.594; WEIL DS, 1992, JAMA-J AM MED ASSOC, V267, P3033, DOI 10.1001/jama.267.22.3033; WINTEMUTE GJ, 1987, JAMA-J AM MED ASSOC, V257, P3107, DOI 10.1001/jama.257.22.3107	23	345	348	1	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2005	293	6					707	714		10.1001/jama.293.6.707	http://dx.doi.org/10.1001/jama.293.6.707			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895DX	15701912	Bronze			2022-12-28	WOS:000226842200024
J	de Lichtenberg, U; Jensen, LJ; Brunak, S; Bork, P				de Lichtenberg, U; Jensen, LJ; Brunak, S; Bork, P			Dynamic complex formation during the yeast cell cycle	SCIENCE			English	Article							PROTEIN-PROTEIN INTERACTIONS; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-ORGANIZATION; BUDDING YEAST; IDENTIFICATION; DATABASE; BIOLOGY	To analyze the dynamics of protein complexes during the yeast cell cycle, we integrated data on protein interactions and gene expression. The resulting time-dependent interaction network places both periodically and constitutively expressed proteins in a temporal cell cycle context, thereby revealing previously unknown components and modules. We discovered that most complexes consist of both periodically and constitutively expressed subunits, which suggests that the former control complex activity by a mechanism of just-in-time assembly. Consistent with this, we show that additional regulation through targeted degradation and phosphorylation by Cdc28p (Cdk1) specifically affects the periodically expressed proteins.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Tech Univ Denmark, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	European Molecular Biology Laboratory (EMBL); Technical University of Denmark; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Bork, P (corresponding author), European Mol Biol Lab, D-69117 Heidelberg, Germany.	bork@embl.de	Bork, Peer/F-1813-2013; Jensen, Lars Juhl/C-6492-2008; de Lichtenberg, Ulrik/AAY-7279-2020; Brunak, Soren/O-6621-2016	Bork, Peer/0000-0002-2627-833X; Jensen, Lars Juhl/0000-0001-7885-715X; Brunak, Soren/0000-0003-0316-5866; de Lichtenberg, Ulrik/0000-0002-0985-9343				Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Christie KR, 2004, NUCLEIC ACIDS RES, V32, pD311, DOI 10.1093/nar/gkh033; DELICHTENBERG U, 2004, BIOINFORMATICS; DePamphilis ML, 2003, GENE, V310, P1, DOI 10.1016/S0378-1119(03)00546-8; Edwards AM, 2002, TRENDS GENET, V18, P529, DOI 10.1016/S0168-9525(02)02763-4; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Ito T, 2000, P NATL ACAD SCI USA, V97, P1143, DOI 10.1073/pnas.97.3.1143; JENSEN LJ, 2004, DRUG DISCOV TODAY, V3, P51; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; McAdams HH, 2003, SCIENCE, V301, P1874, DOI 10.1126/science.1087694; Measday V, 2000, MOL MICROBIOL, V35, P825, DOI 10.1046/j.1365-2958.2000.01754.x; Ruepp A, 2004, NUCLEIC ACIDS RES, V32, P5539, DOI 10.1093/nar/gkh894; Rustici G, 2004, NAT GENET, V36, P809, DOI 10.1038/ng1377; Simon I, 2001, CELL, V106, P697, DOI 10.1016/S0092-8674(01)00494-9; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034	21	316	321	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2005	307	5710					724	727		10.1126/science.1105103	http://dx.doi.org/10.1126/science.1105103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	894TQ	15692050				2022-12-28	WOS:000226814900043
J	Tatar, M				Tatar, M			Comment on "Long-lived Drosophila with overexpressed dFOXO in adult fat body"	SCIENCE			English	Editorial Material							LIFE-SPAN; SYSTEM		Brown Univ, Div Biol & Med, Providence, RI 02912 USA	Brown University	Tatar, M (corresponding author), Brown Univ, Div Biol & Med, Box G-W, Providence, RI 02912 USA.	marc_tatar@brown.edu		Tatar, Marc/0000-0003-3232-6884				GIANNAKOU M, COMMUNICATION; Giannakou ME, 2004, SCIENCE, V305, P361, DOI 10.1126/science.1098219; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Junger Martin A, 2003, J Biol, V2, P20, DOI 10.1186/1475-4924-2-20; Kramer Jamie M, 2003, BMC Dev Biol, V3, P5, DOI 10.1186/1471-213X-3-5; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; Puig O, 2003, GENE DEV, V17, P2006, DOI 10.1101/gad.1098703; Roman G, 2001, P NATL ACAD SCI USA, V98, P12602, DOI 10.1073/pnas.221303998; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; Wolkow CA, 2002, TRENDS NEUROSCI, V25, P212, DOI 10.1016/S0166-2236(02)02133-1	10	9	9	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2005	307	5710								10.1126/science.1104721	http://dx.doi.org/10.1126/science.1104721			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	894TQ	15692034				2022-12-28	WOS:000226814900021
J	Debayle, E; Kennett, B; Priestley, K				Debayle, E; Kennett, B; Priestley, K			Global azimuthal seismic anisotropy and the unique plate-motion deformation of Australia	NATURE			English	Article							UPPER-MANTLE; SURFACE-WAVES; RAYLEIGH; LOVE	Differences in the thickness of the high-velocity lid underlying continents as imaged by seismic tomography, have fuelled a long debate on the origin of the 'roots' of continents(1-5). Some of these differences may be reconciled by observations of radial anisotropy between 250 and 300 km depth, with horizontally polarized shear waves travelling faster than vertically polarized ones(2). This azimuthally averaged anisotropy could arise from present-day deformation at the base of the plate, as has been found for shallower depths beneath ocean basins(6). Such deformation would also produce significant azimuthal variation, owing to the preferred alignment of highly anisotropic minerals(7). Here we report global observations of surface-wave azimuthal anisotropy, which indicate that only the continental portion of the Australian plate displays significant azimuthal anisotropy and strong correlation with present-day plate motion in the depth range 175 - 300 km. Beneath other continents, azimuthal anisotropy is only weakly correlated with plate motion and its depth location is similar to that found beneath oceans. We infer that the fast-moving Australian plate contains the only continental region with a sufficiently large deformation at its base to be transformed into azimuthal anisotropy. Simple shear leading to anisotropy with a plunging axis of symmetry may explain the smaller azimuthal anisotropy beneath other continents.	Ctr Natl Rech Sci, Ecole & Observ Sci Terre, Inst Phys Globe Strasbourg, F-61084 Strasbourg, France; Univ Strasbourg, F-61084 Strasbourg, France; Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia; Univ Cambridge, Bullard Labs, Cambridge CB3 0EZ, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Australian National University; University of Cambridge	Debayle, E (corresponding author), Ctr Natl Rech Sci, Ecole & Observ Sci Terre, Inst Phys Globe Strasbourg, F-61084 Strasbourg, France.	Eric.Debayle@eost.u-strasbg.fr	Debayle, Eric/D-3738-2012	Debayle, Eric/0000-0002-9438-7060; Kennett, Brian/0000-0003-2206-5350				BABUSKA V, 1991, SEISMIC ANISOTROPY E; Becker TW, 2003, GEOPHYS J INT, V155, P696, DOI 10.1046/j.1365-246X.2003.02085.x; Beghein C, 2004, EARTH PLANET SC LETT, V217, P151, DOI 10.1016/S0012-821X(03)00575-2; CARA M, 1987, GEOPHYS RES LETT, V14, P1046, DOI 10.1029/GL014i010p01046; CLITHEROE G, 1998, GEODYNAMICS, V26, P73; Debayle E, 1999, GEOPHYS J INT, V137, P747, DOI 10.1046/j.1365-246x.1999.00832.x; Debayle E, 2000, J GEOPHYS RES-SOL EA, V105, P25423, DOI 10.1029/2000JB900212; Debayle E, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002652; Debayle E, 2000, EARTH PLANET SC LETT, V184, P339, DOI 10.1016/S0012-821X(00)00314-9; DEMETS C, 1990, GEOPHYS J INT, V101, P425, DOI 10.1111/j.1365-246X.1990.tb06579.x; Ekstrom G, 1998, NATURE, V394, P168, DOI 10.1038/28148; FORSYTH DW, 1975, GEOPHYS J ROY ASTR S, V43, P103, DOI 10.1111/j.1365-246X.1975.tb00630.x; GAHERTY JB, 1995, SCIENCE, V268, P1468, DOI 10.1126/science.268.5216.1468; Gung YC, 2003, NATURE, V422, P707, DOI 10.1038/nature01559; JORDAN TH, 1975, REV GEOPHYS, V13, P1, DOI 10.1029/RG013i003p00001; Jung H, 2001, SCIENCE, V293, P1460, DOI 10.1126/science.1062235; Kaminski E, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL014710; Leveque JJ, 1998, GEOPHYS J INT, V133, P529, DOI 10.1046/j.1365-246X.1998.00504.x; MAUPIN V, 1992, PURE APPL GEOPHYS, V138, P429, DOI 10.1007/BF00876881; MONTAGNER JP, 1991, J GEOPHYS RES-SOL EA, V96, P20337, DOI 10.1029/91JB01890; MONTAGNER JP, 1986, J GEOPHYS RES-SOLID, V91, P511, DOI 10.1029/JB091iB01p00511; Montagner JP, 2000, J GEOPHYS RES-SOL EA, V105, P19015, DOI 10.1029/2000JB900015; Nicolas A., 1987, FORMATION ANISOTROPY, DOI DOI 10.1029/GD016P0111; Ozalaybey S, 1999, PHYS EARTH PLANET IN, V114, P197, DOI 10.1016/S0031-9201(99)00058-8; Park J, 2002, SCIENCE, V296, P485, DOI 10.1126/science.1067319; Ritsema J, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002610; Savage MK, 1999, REV GEOPHYS, V37, P65, DOI 10.1029/98RG02075; Simons FJ, 2003, EARTH PLANET SC LETT, V211, P271, DOI 10.1016/S0012-821X(03)00198-5; SMITH ML, 1973, J GEOPHYS RES, V78, P3321, DOI 10.1029/JB078i017p03321; Trampert J, 2003, GEOPHYS J INT, V154, P154, DOI 10.1046/j.1365-246X.2003.01952.x; ZHANG SQ, 1995, NATURE, V375, P774, DOI 10.1038/375774a0	31	237	248	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 3	2005	433	7025					509	512		10.1038/nature03247	http://dx.doi.org/10.1038/nature03247			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893NT	15690038				2022-12-28	WOS:000226727200045
J	Chang, SM; Parney, IF; Huang, W; Anderson, FA; Asher, AL; Bernstein, M; Lillehei, KO; Brem, H; Berger, MS; Laws, ER				Chang, SM; Parney, IF; Huang, W; Anderson, FA; Asher, AL; Bernstein, M; Lillehei, KO; Brem, H; Berger, MS; Laws, ER		Glioma Outcomes Project Investigat	Patterns of care for adults with newly diagnosed malignant glioma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH-GRADE GLIOMA; BRAIN-TUMORS; VENOUS THROMBOEMBOLISM; OUTCOMES PROJECT; GLIOBLASTOMA-MULTIFORME; COMPRESSION STOCKINGS; RESECTION; CHEMOTHERAPY; SURVIVAL; TRIAL	Context Patients with malignant glioma (grade III or IV) face a poor prognosis, and few evidence-based treatment guidelines are available. There is a dearth of prospective data on patterns of care for these patients. Objective To provide benchmark data to enable comparison of individual practice patterns and outcomes. Design, Setting, and Patients The Glioma Outcomes (GO) Project enrolled 788 patients at 52 clinical sites, both academic and community practices, between December 1997 and July 2000. The enrollment criteria included adult patients with primary grade III or IV glioma undergoing a first or second operation for diagnosis or treatment. The data collection instruments included questionnaire forms given at enrollment, during the perioperative period, and at follow-up intervals of 3 months until death or a maximum of 24 months. Of the patients recorded in the GO database, 565 patients with newly diagnosed tumors were used for this analysis. Main Outcome Measures Patterns of care (surgical management, perioperative care, postoperative management). Results Most patients underwent magnetic resonance imaging (n=518; 92%) and an attempt at tumor resection (n=425; 75%). Cortical mapping (n=107; 19%) and intraoperative image guidance (n=161; 29%) were uncommon. Most received perioperative corticosteroids (n=535; 99%) and antiepileptic medications (n=497; 88%), but few received antidepressants (n=38; 8%) or prophylactic heparin (n=42; 7%). Most received adjuvant radiation therapy (n=479; 87%), but fewer received chemotherapy, (n=300; 54%). Practice patterns varied significantly between academic and community settings. Conclusions Reliance on magnetic resonance imaging, surgery, and radiation is generally accepted; however, relatively infrequent chemotherapy use may conflict with published literature, and frequent use of prophylactic antiepileptic medications contradicts established practice guidelines. Other practice patterns involving surgical adjuncts, prophylactic heparin, and antidepressants require further investigation to clarify appropriateness. Establishing further clinical guidelines may help reduce variability in practice patterns.	Univ Calif San Francisco, Dept Neurol Surg, Neurooncol Serv, San Francisco, CA 94143 USA; Univ Massachusetts, Sch Med, Ctr Outcome Res, Dept Surg, Worcester, MA USA; Carolina Neurosurg & Spine Associates, Charlotte, NC USA; Univ Toronto, Div Neurosurg, Toronto, ON, Canada; Univ Colorado, Dept Neurol Surg, Denver, CO 80202 USA; Johns Hopkins Univ, Dept Neurol Surg & Oncol, Baltimore, MD USA; Univ Virginia, Dept Neurol Surg, Charlottesville, VA USA	University of California System; University of California San Francisco; University of Massachusetts System; University of Massachusetts Worcester; University of Toronto; University of Colorado System; University of Colorado Denver; Johns Hopkins University; University of Virginia	Chang, SM (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, Neurooncol Serv, 400 Parnassus Ave,A808, San Francisco, CA 94143 USA.	changs@neurosurg.ucsf.edu		Parney, Ian/0000-0002-9702-8047	NCI NIH HHS [P01 CA13525] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013525] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afra D, 2002, LANCET, V359, P1011; Agnelli G, 1998, NEW ENGL J MED, V339, P80, DOI 10.1056/NEJM199807093390204; ANDERSON FA, 1998, NEUROSURG FOCUS, V4, P8; Bernstein M, 2000, NEUROSURGERY, V46, P900, DOI 10.1097/00006123-200004000-00023; CASCINO GD, 1990, EPILEPSIA, V31, pS37, DOI 10.1111/j.1528-1157.1990.tb05858.x; Chang SM, 2003, J NEUROSURG, V98, P1175, DOI 10.3171/jns.2003.98.6.1175; Chang SM, 2002, CANCER-AM CANCER SOC, V94, P2681, DOI 10.1002/cncr.10536; Chen PC, 2001, CANCER RES, V61, P3949; Cowan JA, 2003, NEUROSURGERY, V52, P48, DOI 10.1097/00006123-200301000-00005; DEVAUX BC, 1993, J NEUROSURG, V78, P767, DOI 10.3171/jns.1993.78.5.0767; Dickinson LD, 1998, NEUROSURGERY, V43, P1074, DOI 10.1097/00006123-199811000-00039; FINE HA, 1993, CANCER, V71, P2585, DOI 10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO;2-S; FORSYTH PA, 1993, NEUROLOGY, V43, P1678, DOI 10.1212/WNL.43.9.1678; Frappaz D, 2003, BRIT J CANCER, V89, pS73, DOI 10.1038/sj.bjc.6601087; GALICICH JH, 1961, J LANCET, V81, P46; Glantz MJ, 2000, NEUROLOGY, V54, P1886, DOI 10.1212/WNL.54.10.1886; Kaibara T, 2000, NEUROSURGERY, V47, P131; KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L; Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190; Laperriere N, 2002, RADIOTHER ONCOL, V64, P259, DOI 10.1016/S0167-8140(02)00078-6; Laws ER, 2003, J NEUROSURG, V99, P467, DOI 10.3171/jns.2003.99.3.0467; Litofsky NS, 2004, NEUROSURGERY, V54, P358, DOI 10.1227/01.NEU.0000103450.94724.A2; Long DM, 2003, NEUROSURGERY, V52, P1056, DOI 10.1227/01.NEU.0000057745.48813.93; Marras LC, 2000, CANCER, V89, P640, DOI 10.1002/1097-0142(20000801)89:3<640::AID-CNCR20>3.0.CO;2-E; Matz PG, 1999, J NEURO-ONCOL, V42, P233, DOI 10.1023/A:1006122122404; MCDERMOTT MW, 1992, CAN J NEUROL SCI, V19, P34, DOI 10.1017/S0317167100042505; MCKERAN RO, 1990, BRAIN TUMORS SCI BAS, P194; Nurmohamed MT, 1996, THROMB HAEMOSTASIS, V75, P233; Parney IF, 2003, CANCER J, V9, P149, DOI 10.1097/00130404-200305000-00003; Sawaya R, 1999, J NEURO-ONCOL, V42, P303, DOI 10.1023/A:1006167412835; Stupp R, 2002, J CLIN ONCOL, V20, P1375, DOI 10.1200/JCO.20.5.1375; STUPP R, 2004, AM SOC CLIN ONC 40 A; Taylor MD, 1999, J NEUROSURG, V90, P35, DOI 10.3171/jns.1999.90.1.0035; VECHT CJ, 1994, NEUROLOGY, V44, P675, DOI 10.1212/WNL.44.4.675; Wen PY, 2002, CURR OPIN ONCOL, V14, P299, DOI 10.1097/00001622-200205000-00008; Westphal M, 2003, NEURO-ONCOLOGY, V5, P79, DOI 10.1215/15228517-5-2-79; Wrensch M, 2002, NEURO-ONCOLOGY, V4, P278, DOI 10.1093/neuonc/4.4.278	37	243	248	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2005	293	5					557	564		10.1001/jama.293.5.557	http://dx.doi.org/10.1001/jama.293.5.557			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	893BL	15687310	Bronze			2022-12-28	WOS:000226694200018
J	Nussmeier, NA; Whelton, AA; Brown, MT; Langford, RM; Hoeft, A; Parlow, JL; Boyce, SW; Verburg, KM				Nussmeier, NA; Whelton, AA; Brown, MT; Langford, RM; Hoeft, A; Parlow, JL; Boyce, SW; Verburg, KM			Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ARTERY-BYPASS SURGERY; CARDIOPULMONARY BYPASS; MYOCARDIAL-INFARCTION; ASPIRIN RESISTANCE; CLINICAL-TRIALS; RISK; STROKE; PAIN; PROSTACYCLIN; THROMBOXANE	BACKGROUND: Valdecoxib and its intravenous prodrug parecoxib are used to treat postoperative pain but may involve risk after coronary-artery bypass grafting (CABG). We conducted a randomized trial to assess the safety of these drugs after CABG. METHODS: In this randomized, double-blind study involving 10 days of treatment and 30 days of follow-up, 1671 patients were randomly assigned to receive intravenous parecoxib for at least 3 days, followed by oral valdecoxib through day 10; intravenous placebo followed by oral valdecoxib; or placebo for 10 days. All patients had access to standard opioid medications. The primary end point was the frequency of predefined adverse events, including cardiovascular events, renal failure or dysfunction, gastroduodenal ulceration, and wound-healing complications. RESULTS: As compared with the group given placebo alone, both the group given parecoxib and valdecoxib and the group given placebo and valdecoxib had a higher proportion of patients with at least one confirmed adverse event (7.4 percent in each of these two groups vs. 4.0 percent in the placebo group; risk ratio for each comparison, 1.9; 95 percent confidence interval, 1.1 to 3.2; P=0.02 for each comparison with the placebo group). In particular, cardiovascular events (including myocardial infarction, cardiac arrest, stroke, and pulmonary embolism) were more frequent among the patients given parecoxib and valdecoxib than among those given placebo (2.0 percent vs. 0.5 percent; risk ratio, 3.7; 95 percent confidence interval, 1.0 to 13.5; P=0.03). CONCLUSIONS: The use of parecoxib and valdecoxib after CABG was associated with an increased incidence of cardiovascular events, arousing serious concern about the use of these drugs in such circumstances.	St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX 77225 USA; Universal Clin Res Ctr, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Pfizer, Global Res & Dev, Ann Arbor, MI USA; St Bartholomews Hosp, London, England; Univ Bonn, Dept Anesthesiol & Intens Care Med, D-5300 Bonn, Germany; Queens Univ, Kingston, ON, Canada; Kingston Gen Hosp, Kingston, ON K7L 2V7, Canada; Washington Hosp Ctr, Washington, DC 20010 USA	Saint Lukes Episcopal Hospital; Texas Heart Institute; Johns Hopkins University; Pfizer; University of London; Queen Mary University London; University of Bonn; Queens University - Canada; Queens University - Canada; MedStar Washington Hospital Center	Nussmeier, NA (corresponding author), St Lukes Episcopal Hosp, Texas Heart Inst, POB 20345,MC 1-226, Houston, TX 77225 USA.	nnussmeier@heart.thi.tmc.edu						ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Antithrombotic Trialists' Collaboration, 2002, BMJ-BRIT MED J, V324, P141, DOI DOI 10.1136/BMJ.324.7330.141; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Braunwald E, 2000, J AM COLL CARDIOL, V36, P970, DOI 10.1016/S0735-1097(00)00889-5; Braunwald E, 2001, J AM COLL CARDIOL, V38, P294; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Couzin J, 2004, SCIENCE, V306, P2170; Daniels SE, 2001, CLIN THER, V23, P1018, DOI 10.1016/S0149-2918(01)80088-6; DAVIES GC, 1980, CIRCULATION, V61, P808, DOI 10.1161/01.CIR.61.4.808; FAYMONVILLE ME, 1986, J THORAC CARDIOV SUR, V91, P858; FitzGerald GA, 2004, NEW ENGL J MED, V351, P1709, DOI 10.1056/NEJMp048288; Gilron I, 2003, ANESTHESIOLOGY, V99, P1198, DOI 10.1097/00000542-200311000-00029; Joshi GP, 2004, ANESTH ANALG, V98, P336, DOI 10.1213/01.ANE.0000093390.94921.4A; Konstam MA, 2001, CIRCULATION, V104, P2280, DOI 10.1161/hc4401.100078; KONSTANTOPOULOS K, 1995, THROMB HAEMOSTASIS, V74, P1329; Malan TP, 2003, ANESTHESIOLOGY, V98, P950, DOI 10.1097/00000542-200304000-00023; Mangano CM, 1998, ANN INTERN MED, V128, P194, DOI 10.7326/0003-4819-128-3-199802010-00005; Mangano DT, 2002, NEW ENGL J MED, V347, P1309, DOI 10.1056/NEJMoa020798; Mohnle P, 2005, J CARDIOTHOR VASC AN, V19, P19, DOI 10.1053/j.jvca.2004.11.004; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; Ng A, 2003, BRIT J ANAESTH, V90, P746, DOI 10.1093/bja/aeg139; Ott E, 2003, J THORAC CARDIOV SUR, V125, P1481, DOI 10.1016/S0022-5223(03)00125-9; Park JL, 1999, ANN THORAC SURG, V68, P1905, DOI 10.1016/S0003-4975(99)01073-5; Ray WA, 2002, LANCET, V360, P1071, DOI 10.1016/S0140-6736(02)11131-7; Rocca B, 2002, P NATL ACAD SCI USA, V99, P7634, DOI 10.1073/pnas.112202999; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405; Wan S, 1997, CHEST, V112, P676, DOI 10.1378/chest.112.3.676; WATKINS WD, 1982, J THORAC CARDIOV SUR, V84, P250; Zimmermann N, 2003, CIRCULATION, V108, P542, DOI 10.1161/01.CIR.0000081770.51929.5A; Zimmermann N, 2001, J THORAC CARDIOV SUR, V121, P982, DOI 10.1067/mtc.2001.111416	30	757	783	0	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 17	2005	352	11					1081	1091		10.1056/NEJMoa050330	http://dx.doi.org/10.1056/NEJMoa050330			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	906PU	15713945				2022-12-28	WOS:000227655000005
J	Okajima, T; Xu, AG; Lei, L; Irvine, KD				Okajima, T; Xu, AG; Lei, L; Irvine, KD			Chaperone activity of protein O-fucosyltransferase 1 promotes Notch receptor folding	SCIENCE			English	Article							FUCOSYL-TRANSFERASE; ENDOPLASMIC-RETICULUM; DELTA INTERACTIONS; SIGNALING PATHWAY; C-MANNOSYLATION; QUALITY-CONTROL; IDENTIFICATION; GLYCOSYLATION; DROSOPHILA; ENCODES	Notch proteins are receptors for a conserved signaling pathway that affects numerous cell fate decisions. We found that in, Drosophila, Protein O-fucosyltransferase 1 (OFUT1), an enzyme that glycosylates epidermal growth factor-like domains of Notch, also has a distinct Notch chaperone activity. OFUT1 is an endoplasmic reticulum protein, and its localization was essential for function in vivo. OFUT1 could bind to Notch, was required for the trafficking of wild-type Notch out of the endoplasmic reticulum, and could partially rescue defects in secretion and ligand binding associated with Notch. point mutations. This ability of OFUT1 to facilitate folding of Notch did not require its fucosyltransferase activity. Thus, a glycosyltransferase can bind its substrate in the endoplasmic reticulum to facilitate normal folding.	Rutgers State Univ, Howard Hughes Med Inst, Waksman Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Irvine, KD (corresponding author), Rutgers State Univ, Howard Hughes Med Inst, Waksman Inst, Piscataway, NJ 08854 USA.	irvine@waksman.rutgers.edu	Okajima, Tetsuya/I-7332-2014	Okajima, Tetsuya/0000-0002-3677-648X	NIGMS NIH HHS [R01-GM54594] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054594] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Becker DJ, 2003, GLYCOBIOLOGY, V13, p41R, DOI 10.1093/glycob/cwg054; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Chazalet V, 2001, J BACTERIOL, V183, P7067, DOI 10.1128/JB.183.24.7067-7075.2001; Chen DP, 2004, ANN CLIN LAB SCI, V34, P314; Culi J, 2004, EMBO J, V23, P1372, DOI 10.1038/sj.emboj.7600132; Culi J, 2003, CELL, V112, P343, DOI 10.1016/S0092-8674(02)01279-5; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; HALTIWANGER R, COMMUNICATION; Haltiwanger RS, 2002, CURR OPIN STRUC BIOL, V12, P593, DOI 10.1016/S0959-440X(02)00371-8; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; Hsieh JC, 2003, CELL, V112, P355, DOI 10.1016/S0092-8674(03)00045-X; Joutel A, 2004, AM J HUM GENET, V74, P338, DOI 10.1086/381506; Joutel A, 1998, SEMIN CELL DEV BIOL, V9, P619, DOI 10.1006/scdb.1998.0261; Karlstrom H, 2002, P NATL ACAD SCI USA, V99, P17119, DOI 10.1073/pnas.252624099; Kleizen B, 2004, CURR OPIN CELL BIOL, V16, P343, DOI 10.1016/j.ceb.2004.06.012; Manya H, 2004, P NATL ACAD SCI USA, V101, P500, DOI 10.1073/pnas.0307228101; Martinez-Duncker I, 2003, GLYCOBIOLOGY, V13, p1C, DOI 10.1093/glycob/cwg113; Okajima T, 2003, J BIOL CHEM, V278, P42340, DOI 10.1074/jbc.M308687200; Okajima T, 2002, CELL, V111, P893, DOI 10.1016/S0092-8674(02)01114-5; Panin VM, 2002, J BIOL CHEM, V277, P29945, DOI 10.1074/jbc.M204445200; Perez-Vilar J, 2004, GLYCOBIOLOGY, V14, P325, DOI 10.1093/glycob/cwh041; Puglielli L, 1999, J BIOL CHEM, V274, P35596, DOI 10.1074/jbc.274.50.35596; Sasamura T, 2003, DEVELOPMENT, V130, P4785, DOI 10.1242/dev.00679; Schweisguth F, 2004, CURR BIOL, V14, pR129, DOI 10.1016/j.cub.2004.01.023; Shao L, 2002, GLYCOBIOLOGY, V12, P763, DOI 10.1093/glycob/cwf085; Shi SL, 2003, P NATL ACAD SCI USA, V100, P5234, DOI 10.1073/pnas.0831126100; Takahashi T, 2000, GLYCOBIOLOGY, V10, P503, DOI 10.1093/glycob/10.5.503; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Wang Y, 1998, J BIOL CHEM, V273, P8112, DOI 10.1074/jbc.273.14.8112	32	188	193	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 11	2005	307	5715					1599	1603		10.1126/science.1108995	http://dx.doi.org/10.1126/science.1108995			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	906ED	15692013				2022-12-28	WOS:000227622400041
J	Kinast, J; Turlapov, A; Thomas, JE; Chen, QJ; Stajic, J; Levin, K				Kinast, J; Turlapov, A; Thomas, JE; Chen, QJ; Stajic, J; Levin, K			Heat capacity of a strongly interacting Fermi gas	SCIENCE			English	Article							PAIRING GAP; ATOMS; LI-6	We have measured the heat capacity of an optically trapped, strongly interacting Fermi gas of atoms. A precise addition of energy to the gas is followed by single-parameter thermometry, which determines the empirical temperature parameter of the gas cloud. Our measurements reveal a clear transition in the heat capacity. The energy and the spatial profile of the gas are computed using a theory of the crossover from Fermi to Bose superfluids at finite temperatures. The theory calibrates the empirical temperature parameter, yields excellent agreement with the data, and predicts the onset of superfluiclity at the observed transition point.	Duke Univ, Dept Phys, Durham, NC 27708 USA; Univ Chicago, James Franck Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Phys, Chicago, IL 60637 USA	Duke University; University of Chicago; University of Chicago	Thomas, JE (corresponding author), Duke Univ, Dept Phys, Durham, NC 27708 USA.	jet@phy.duke.edu	Turlapov, Andrey/S-1786-2016; Chen, Qijin/A-7798-2009; Thomas, John/Q-9759-2018	Chen, Qijin/0000-0002-7168-162X; Thomas, John/0000-0002-0018-2831				BAKER JGA, 1999, PHYS REV C, V60; Bartenstein M, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.203201; Bartenstein M, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.120401; Bourdel T, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.050401; Carlson J, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.050401; Carr LD, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.150404; Chen JC, 2001, J ENVIRON ENG-ASCE, V127, P63, DOI 10.1061/(ASCE)0733-9372(2001)127:1(63); Chin C, 2004, SCIENCE, V305, P1128, DOI 10.1126/science.1100818; Combescot R, 1999, PHYS REV LETT, V83, P3766, DOI 10.1103/PhysRevLett.83.3766; Gehm ME, 2003, PHYS REV A, V68, DOI 10.1103/PhysRevA.68.011401; Heiselberg H, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.040402; Heiselberg H, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.043606; Ho TL, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.090402; Holland M, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.120406; Houbiers M, 1997, PHYS REV A, V56, P4864, DOI 10.1103/PhysRevA.56.4864; Hu H, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.190403; Jackson B, 2004, EUROPHYS LETT, V67, P524, DOI 10.1209/epl/i2004-10086-8; Kinast J, 2004, PHYS REV A, V70, DOI 10.1103/PhysRevA.70.051401; Kinast J, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.150402; Kinnunen J, 2004, SCIENCE, V305, P1131, DOI 10.1126/science.1100782; Leggett A. J., 1980, Modern Trends in the Theory of Condensed Matter. Proceedings of the XVIth Karpacz Winter School of Theoretical Physics, P13; London F, 1938, PHYS REV, V54, P947, DOI 10.1103/PhysRev.54.947; Menotti C, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.250402; O'Hara KM, 2002, SCIENCE, V298, P2179, DOI 10.1126/science.1079107; Ohashi Y, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.130402; Perali A, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.100404; Regal CA, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.040403; Stajic J, 2004, PHYS REV A, V69, DOI 10.1103/PhysRevA.69.063610; Stringari S, 2004, EUROPHYS LETT, V65, P749, DOI 10.1209/epl/i2004-10001-5; Thomas JE, 2004, AM SCI, V92, P238; Timmermans E, 2001, PHYS LETT A, V285, P228, DOI 10.1016/S0375-9601(01)00346-2; Williams JE, 2004, NEW J PHYS, V6, DOI 10.1088/1367-2630/6/1/123; Zwierlein MW, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.120403	33	335	337	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 25	2005	307	5713					1296	1299		10.1126/science.1109220	http://dx.doi.org/10.1126/science.1109220			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	901WP	15681340	Green Submitted			2022-12-28	WOS:000227313200054
J	Kishi, M; Pan, YA; Crump, JG; Sanes, JR				Kishi, M; Pan, YA; Crump, JG; Sanes, JR			Mammalian SAD kinases are required for neuronal polarization	SCIENCE			English	Article							HIPPOCAMPAL-NEURONS; PROTEIN-KINASE; TAU-PROTEIN; PHOSPHORYLATION; POLARITY; ESTABLISHMENT; PAR-1	Electrical activity in neurons is generally initiated in dendritic processes then propagated along axons to synapses, where it is passed to other neurons. Major structural features of neurons-their dendrites and axons-are thus related to their fundamental functions: the receipt and transmission of information. The acquisition of these distinct properties by dendrites and axons, called polarization, is a critical step in neuronat differentiation. We show here that SAD-A and SAD-B, mammalian orthologs of a kinase needed for presynaptic differentiation in Caenorhabditis elegans, are required for neuronal polarization. These kinases will provide entry points for unraveling signaling mechanisms that polarize neurons.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	Washington University (WUSTL); Harvard University; University of California System; University of California San Francisco	Sanes, JR (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA.	sanesj@mcb.harvard.edu	Kishi, Masashi/GLU-0437-2022					Arimura N, 2004, J NEUROBIOL, V58, P34, DOI 10.1002/neu.10269; Biernat J, 2002, MOL BIOL CELL, V13, P4013, DOI 10.1091/mbc.02-03-0046; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; Bradke F, 1999, SCIENCE, V283, P1931, DOI 10.1126/science.283.5409.1931; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; Crump JG, 2001, NEURON, V29, P115, DOI 10.1016/S0896-6273(01)00184-2; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Gan WB, 2000, NEURON, V27, P219, DOI 10.1016/S0896-6273(00)00031-3; Goslin K., 1998, CULTURING NERVE CELL, P339; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Hevner RF, 2003, DEV NEUROSCI-BASEL, V25, P139, DOI 10.1159/000072263; Mandell JW, 1996, J NEUROSCI, V16, P5727; Marin O, 2003, ANNU REV NEUROSCI, V26, P441, DOI 10.1146/annurev.neuro.26.041002.131058; Molnar Z, 1998, J NEUROSCI, V18, P5723; Nishimura I, 2004, CELL, V116, P671, DOI 10.1016/S0092-8674(04)00170-9; Pan Y., UNPUB; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Sasakura Y, 1998, MECH DEVELOP, V76, P161, DOI 10.1016/S0925-4773(98)00100-2; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Silverman MA, 2001, P NATL ACAD SCI USA, V98, P7051, DOI 10.1073/pnas.111146198; Spicer J, 2004, CURR BIOL, V14, pR383, DOI 10.1016/j.cub.2004.05.012; Timm T, 2003, EMBO J, V22, P5090, DOI 10.1093/emboj/cdg447; Wodarz A, 2002, NAT CELL BIOL, V4, pE39, DOI 10.1038/ncb0202-e39	25	256	270	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	2005	307	5711					929	932		10.1126/science.1107403	http://dx.doi.org/10.1126/science.1107403			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897DV	15705853				2022-12-28	WOS:000226985100055
J	Albers, GW; Diener, HC; Frison, L; Grind, M; Nevinson, M; Partridge, S; Halperin, JL; Horrow, J; Olsson, SB; Petersen, P; Vahanian, A				Albers, GW; Diener, HC; Frison, L; Grind, M; Nevinson, M; Partridge, S; Halperin, JL; Horrow, J; Olsson, SB; Petersen, P; Vahanian, A		SPORTIF Executive Steering Comm; SPORTIF V Investigators	Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation - A Randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIRECT THROMBIN INHIBITOR; VENOUS THROMBOEMBOLISM; ORAL XIMELAGATRAN; KNEE REPLACEMENT; CLINICAL-TRIALS; TOTAL HIP; MELAGATRAN; MANAGEMENT; RISK; PHARMACOKINETICS	Context Inpatients with nonvalvular atrial fibrillation, warfarin prevents ischemic stroke, but dose adjustment, coagulation monitoring, and bleeding limit its use. Objective To compare the efficacy of the oral direct thrombin inhibitor ximelagatran with warfarin for prevention of stroke and systemic embolism. Design, Setting, and Participants Double-blind, randomized, multicenter trial (20002001) conducted at 409 North American sites, involving 3922 patients with nonvalvular atrial fibrillation and additional stroke risk factors. Interventions Adjusted-dose warfarin (aiming for an international normalized ratio [INR] 2.0 to 3.0) or fixed-dose oral ximelagatran, 36 mg twice daily. Main Outcome Measures The primary end point was all strokes (ischemic or hemorrhagic) and systemic embolic events. The primary analysis was based on demonstrating noninferiority within an absolute margin of 2.0% per year according to the intention-to-treat model. Results During 6405 patient-years (mean 20 months) of follow-up, 88 patients experienced primary events. The mean (SD) INR with warfarin (2.4 [0.8]) was within target during 68% of the treatment period. The primary event rate with ximelagatran was 1.6% per year and with warfarin was 1.2% per year (absolute difference, 0.45% per year; 95% confidence interval, -0.13% to 1.03% per year; P<.001 for the pre-defined noninferiority hypothesis). When all-cause mortality was included in addition to stroke and systemic embolic events, the rate difference was 0.10% per year (95% confidence interval, -0.97% to 1.2% per year; P=.86). There was no difference between treatment groups in rates of major bleeding, but total bleeding (major and minor) was lower with ximelagatran (37% vs 47% per year; 95% confidence interval for the difference, -14% to -6.0% per year; P<.001). Serum alanine aminotransferase levels rose to greater than 3 times the upper limit of normal in 6.0% of patients treated with ximelagatran, usually within 6 months and typically declined whether or not treatment continued; however, one case of documented fatal liver disease and one other suggestive case occurred. Conclusions The results establish the efficacy of fixed-dose oral ximelagatran without coagulation monitoring compared with well-controlled warfarin for prevention of thromboembolism in patients with atrial fibrillation requiring chronic anticoagulant therapy, but the potential for hepatotoxicity requires further investigation.	Mt Sinai Med Ctr, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10024 USA; Mt Sinai Med Ctr, Marie Josee & Henry R Kravis Ctr Cardiovasc Hlth, New York, NY 10024 USA; Stanford Stroke Ctr, Palo Alto, CA USA; Univ Essen Gesamthsch, Dept Neurol, Essen, Germany; AstraZeneca R&D, Dept Biostat, Molndal, Sweden; AstraZeneca Res & Dev Charnwood, Dept Clin Sci, Charnwood, England; AstraZeneca Res & Dev Charnwood, Dept Clin Project Management, Charnwood, England; AstraZeneca Res & Dev Charnwood, Dept Clin Dev, Charnwood, England; Mt Sinai Med Ctr, Cardiovasc Inst, New York, NY 10029 USA; AstraZeneca LP, Dept Clin Dev, Wilmington, DE USA; Univ Lund Hosp, Dept Cardiol, S-22185 Lund, Sweden; Univ Copenhagen Hosp, Dept Neurol, DK-2100 Copenhagen, Denmark; Hosp Tenon, Dept Cardiol, Paris, France	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Stanford University; University of Duisburg Essen; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Icahn School of Medicine at Mount Sinai; AstraZeneca; Lund University; Skane University Hospital; University of Copenhagen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite	Albers, GW (corresponding author), Mt Sinai Med Ctr, Zena & Michael A Wiener Cardiovasc Inst, 1 Gustave L Levy Pl, New York, NY 10024 USA.		Diener, Hans-Christoph/AAF-7275-2019; Halperin, Jonathan/AAJ-4721-2020	Halperin, Jonathan/0000-0002-8318-5471; Albers, Gregory/0000-0003-0263-4632				ALBERS GW, 1994, ARCH INTERN MED, V154, P1443, DOI 10.1001/archinte.154.13.1443; Albers GW, 2003, LANCET, V362, P1691; Albers GW, 2001, CHEST, V119, p194S, DOI 10.1378/chest.119.1_suppl.194S; Andersson TB, 2004, DRUG METAB REV, V36, P101; Andersson TB, 2004, DRUG METAB REV, V36, P198; ASINGER RW, 1989, ARCH NEUROL-CHICAGO, V46, P727; Blackshear JL, 1996, LANCET, V348, P633; Bredberg E, 2003, CLIN PHARMACOKINET, V42, P765, DOI 10.2165/00003088-200342080-00005; Bungard TJ, 2000, ARCH INTERN MED, V160, P41, DOI 10.1001/archinte.160.1.41; Chapman N, 2004, STROKE, V35, P116, DOI 10.1161/01.STR.0000106480.76217.6F; Collin C, 1988, Int Disabil Stud, V10, P61; Ebbutt AF, 1998, STAT MED, V17, P1691, DOI 10.1002/(SICI)1097-0258(19980815/30)17:15/16<1691::AID-SIM971>3.3.CO;2-A; Eriksson B, 2002, LANCET, V360, P1441, DOI 10.1016/S0140-6736(02)11469-3; Eriksson BI, 2003, THROMB HAEMOSTASIS, V89, P288; Eriksson UG, 2003, EUR J CLIN PHARMACOL, V59, P35, DOI 10.1007/s00228-003-0565-7; Francis CW, 2003, NEW ENGL J MED, V349, P1703, DOI 10.1056/NEJMoa035162; Frykman V, 2001, EUR HEART J, V22, P1954, DOI 10.1053/euhj.2000.2300; Fuster V, 2001, J AM COLL CARDIOL, V38, P1231, DOI 10.1016/S0735-1097(01)01587-X; Gadisseur APA, 2003, ARCH INTERN MED, V163, P2639, DOI 10.1001/archinte.163.21.2639; Go AS, 1999, ANN INTERN MED, V131, P927, DOI 10.7326/0003-4819-131-12-199912210-00004; Gomberg-Maitland M, 2003, AM HEART J, V146, P398, DOI 10.1016/S0002-8703(03)00324-7; Halperin JL, 2003, AM HEART J, V146, P431, DOI 10.1016/S0002-8703(03)00325-9; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Johansson LC, 2003, CLIN PHARMACOKINET, V42, P381, DOI 10.2165/00003088-200342040-00006; Klement P, 2003, J THROMB HAEMOST, V1, P587, DOI 10.1046/j.1538-7836.2003.00060.x; LAN KKG, 1971, BRIT J RADIOL, V44, P793; Lebrazi J, 2003, THROMB RES, V110, P249, DOI 10.1016/S0049-3848(03)00345-1; Petersen P, 2003, J AM COLL CARDIOL, V41, P1445, DOI 10.1016/S0735-1097(03)00255-9; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236; Samsa GP, 2000, ARCH INTERN MED, V160, P967, DOI 10.1001/archinte.160.7.967; Sarich TC, 2003, CLIN PHARMACOKINET, V42, P485, DOI 10.2165/00003088-200342050-00006; Schulman S, 2003, NEW ENGL J MED, V349, P1713, DOI 10.1056/NEJMoa030104; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Wallentin L, 2003, LANCET, V362, P789, DOI 10.1016/S0140-6736(03)14287-0; WELLS PS, 1994, ANN INTERN MED, V121, P676, DOI 10.7326/0003-4819-121-9-199411010-00009	37	538	561	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2005	293	6					690	698						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895DX	15701910				2022-12-28	WOS:000226842200022
J	Vineis, P				Vineis, P		EPIC Prospective Study Grp	Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study	BRITISH MEDICAL JOURNAL			English	Article							LUNG-CANCER; EPIDEMIOLOGIC EVIDENCE; EXPOSURE; WOMEN; GSTM1	Objectives To investigate the association between environmental tobacco smoke, Plasma cotinine concentration, and respiratory cancer or death. Design Nested case-control study within the European prospective investigation into cancer and nutrition (EPIC). Participants 303 020 people from the EPIC cohort (total 7 00 000) who had never smoked or who had stopped smoking for at least 10 years, 123 479 of whom Provided information on exposure to environmental tobacco smoke. Cases were people who developed respiratory cancers or died from respiratory conditions. Controls were matched for sex, age (plus or minus 5 years), smoking status, country of recruitment, and time elapsed since treatment. Main Outcome measures Newly diagnosed cancer of lung, pharynx, and larynx: deaths from chronic obstructive pulmonary disease or emphysema. Plasma cotinine concentration was measured in 1574 people. Results Over seven years of follow up, 97 people had newly diagnosed lung cancer, 20 had upper respiratory cancers (pharynx, larynx), and 14 died from chronic obstructive pulmonary disease or emphysema. In the whole cohort exposure to environmental tobacco smoke was associated with increased risks (hazard ratio 1.30, 95% confidence interval 0.87 to 1.95), for all respiratory diseases; 1.34, 0.85 to 2.13. for lung cancer alone). Higher results were found in the nested case-control study (odds ratio 1.70, 1.02 to 2.82. for respiratory diseases; 1.76, 0.96 to 3.23. for lung cancer alone). Odds ratios were consistently higher in former smokers than in those who had never smoked; the association was limited to exposure related to work. Continue concentration was clearly associated with self reported exposure (3.30, 2.07 to 5.23, for detectable/non-detectable continine), but it was not associated with the risk of respiratory diseases or lung cancer. Frequent exposure to environmental tobacco smoke during childhood was associated with lung cancer in adulthood (hazard ratio 3.63, 1.19 to 11.11, for daily exposure tor many hours). Conclusions This large prospective study, in which the smoking status was supported by cotinine measurements, confirms that environmental tobacco smoke is a risk factor for lung cancer and other respiratory diseases, particularly in ex-smokers.	Univ London Imperial Coll Sci Technol & Med, London W2 1PG, England	Imperial College London	Vineis, P (corresponding author), Univ London Imperial Coll Sci Technol & Med, London W2 1PG, England.	p.vineis@imperial.ac.uk	Veglia, Fabrizio/K-1958-2016; Matullo, Giuseppe/K-6383-2016; Krogh, Vittorio/K-2628-2016; Clavel-Chapelon, Francoise/G-6733-2014; Hainaut, Pierre/B-6018-2012; Peluso, Marco/I-5187-2018	Veglia, Fabrizio/0000-0002-9378-8874; Matullo, Giuseppe/0000-0003-0674-7757; Krogh, Vittorio/0000-0003-0122-8624; Hainaut, Pierre/0000-0002-1303-1610; Peluso, Marco/0000-0001-7646-7967; Overvad, Kim/0000-0001-6429-7921; Riboli, Elio/0000-0001-6795-6080				Bennett WP, 1999, JNCI-J NATL CANCER I, V91, P2009, DOI 10.1093/jnci/91.23.2009; Benowitz NL, 1999, ENVIRON HEALTH PERSP, V107, P349, DOI 10.2307/3434427; BRESLOW NE, 1980, 32 IARC; Hackshaw AK, 1997, BMJ-BRIT MED J, V315, P980, DOI 10.1136/bmj.315.7114.980; Hecht SS, 2001, CANCER EPIDEM BIOMAR, V10, P1109; *INT AG RES CANC, IN PRESS IARC MON EV, V83; Kiyohara C, 2003, INT J CANCER, V107, P139, DOI 10.1002/ijc.11355; Korn EL, 1997, AM J EPIDEMIOL, V145, P72; Lee CH, 2000, INT J EPIDEMIOL, V29, P224, DOI 10.1093/ije/29.2.224; Malats N, 2000, CANCER EPIDEM BIOMAR, V9, P827; Riboli E, 2002, PUBLIC HEALTH NUTR, V5, P1113, DOI 10.1079/PHN2002394; Smith GD, 2004, INT J EPIDEMIOL, V33, P30, DOI 10.1093/ije/dyh132; TREDANIEL J, 1994, PAEDIATR PERINAT EP, V8, P233, DOI 10.1111/j.1365-3016.1994.tb00455.x; VINCIS P, 1999, IARC SCI PUBL, V148; Vineis P, 2004, JNCI-J NATL CANCER I, V96, P99, DOI 10.1093/jnci/djh014	15	185	193	0	11	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 5	2005	330	7486					277	280A		10.1136/bmj.38327.648472.82	http://dx.doi.org/10.1136/bmj.38327.648472.82			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895EM	15681570	Green Published, Bronze			2022-12-28	WOS:000226843700013
J	Szegedi, A; Kohnen, R; Dienel, A; Kieser, M				Szegedi, A; Kohnen, R; Dienel, A; Kieser, M			Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PERFORATUM; IMIPRAMINE; DISORDER; PLACEBO	Objective To investigate the efficacy of hypericum extract (St John's wort) compared with paroxetine in patients with moderate to severe major depression. Design Randomised double blind, double dummy, reference controlled, multicentre non-inferiority trial. Setting 21 psychiatric primary care practices in Germany. Participants 251 adult outpatients with acute major depression with total store 22 on the 17 item Hamilton depression scale. Interventions 900 mg/day hypericum extract WS 5570 three times a day or 20 mg paroxetine once a day for six weeks. In initial non-responders doses were increased to 1800 mg/day hypcricum or 40 mg/day paroxetine after two weeks. Main outcome measures Change in score on Hamilton depression scale from baseline to day 42 (primary outcome). Secondary measures were change in scores on Montgomery-Asberg depression rating scale, clinical global impressions, and Beck depression inventory. Results The Hamilton depression total score decreased by mean 14.4 (SD 8.8) points, corresponding to 56.6% (SD 34.3%) of the baseline value, in the hypericum group and by 11.4 (SD 8.6) points (44.8% (SD 33.5%) of baseline value) in the paroxetine group (intention to treat analysis; similar results were observed in the per protocol analysis). The intention to treat analysis (lower one sided 97.5% confidence limit 1.5 points for the difference hypericum minus paroxetine) and the per protocol analysis (lower confidence limit 0.7 points) showed non-inferiority of hypericum and statistical superiority over paroxetine. The lower limits in both cases exceeded the pre-specified non-inferiority margin of - 2.5 points and the superiority margin of 0. The incidence of adverse events was 0.035 and 0.060 events per day of exposure for hypericum and paroxetine, respectively. Conclusions In the treatment of moderate to severe major depression, hypcricum extract WS 5570 is at least as effective as paroxetine and is better tolerated.	Dr Willmar Schwabe Pharmaceut, Dept Biometry, D-76209 Karlsruhe, Germany; Charite Univ Med Berlin, Dept Psychiat & Psychotherapy, D-14050 Berlin, Germany; Inst Med Res Management & Biometr GmbH, Sci Affairs, D-90478 Nurnberg, Germany; Dr Willmar Schwabe Pharmaceut, Dept Clin Trials, D-76209 Karlsruhe, Germany	Dr. Willmar Schwabe GmbH & Co. KG; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Dr. Willmar Schwabe GmbH & Co. KG	Kieser, M (corresponding author), Dr Willmar Schwabe Pharmaceut, Dept Biometry, POB 410925, D-76209 Karlsruhe, Germany.	meinhard.kieser@schwabe.de	Szegedi, Armin/M-9184-2016	Szegedi, Armin/0000-0001-6487-4071				[Anonymous], 2000, POINTS CONS SWITCH S; BAUER P, 1994, BIOMETRICS, V50, P1029, DOI 10.2307/2533441; Bourin M, 2001, CNS DRUG REV, V7, P25; Brannath W, 2002, J AM STAT ASSOC, V97, P236, DOI 10.1198/016214502753479374; *COMM PROP MED PRO, 2000, POINTS CONSIDER SWIT; Davidson JRT, 2002, JAMA-J AM MED ASSOC, V287, P1807, DOI 10.1001/jama.287.14.1807; DUNNER DL, 1992, J CLIN PSYCHIAT, V53, P21; EDERER F, 1974, AM J EPIDEMIOL, V100, P165, DOI 10.1093/oxfordjournals.aje.a112024; Golsch S, 1997, HAUTARZT, V48, P249, DOI 10.1007/s001050050578; Harrer G, 1994, J Geriatr Psychiatry Neurol, V7 Suppl 1, pS24, DOI 10.1177/089198879400700108; HARRER G, 1998, ARZNEIMITTEL-FORSCH, V49, P3; HARRER G, 1994, J GERIATR PSYCHIA S1, V7, P24; Izzo AA, 2004, INT J CLIN PHARM TH, V42, P139; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; KUPFER DJ, 1991, J CLIN PSYCHIAT, V52, P12; Lecrubier Y, 2002, AM J PSYCHIAT, V159, P1361, DOI 10.1176/appi.ajp.159.8.1361; Lindahl M, 2004, PROTEOMICS, V4, P448, DOI 10.1002/pmic.200300604; LINDE K, 2004, COCHRANE DB SYST REV; Montgomery SA., 1994, EUROPEAN NEUROPSYCHO, V4, P283, DOI [DOI 10.1016/0924-977X(94)90093-0, 10.1016/0924-977X(94)90093-0]; PAYKEL ES, 1983, BRIT J CLIN PHARMACO, V15, pS155, DOI 10.1111/j.1365-2125.1983.tb05860.x; Philipp M, 1999, BRIT MED J, V319, P1534, DOI 10.1136/bmj.319.7224.1534; PHILIPP M, 1999, BMJ-BRIT MED J, V3119, P1534; PRESKORN SH, 1995, J CLIN PSYCHIAT, V56, P12; Schulz V, 2001, PHYTOMEDICINE, V8, P152; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Vorbach E U, 1994, J Geriatr Psychiatry Neurol, V7 Suppl 1, pS19, DOI 10.1177/089198879400700107; Wheatley D, 1997, PHARMACOPSYCHIATRY, V30, P77, DOI 10.1055/s-2007-979523; Winkler D, 2002, CURR OPIN PSYCHIATR, V15, P63, DOI 10.1097/00001504-200201000-00011	28	136	145	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 5	2005	330	7490					503	506		10.1136/bmj.38356.655266.82	http://dx.doi.org/10.1136/bmj.38356.655266.82			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	905PM	15708844	Green Published, Bronze			2022-12-28	WOS:000227581400015
J	Parkes, J; Chase, DL; Grace, A; Cunningham, D; Roderick, PJ				Parkes, J; Chase, DL; Grace, A; Cunningham, D; Roderick, PJ			Inequity of use of implantable cardioverter defibrillators in England: retrospective analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SERVICES		Univ Southampton, Hlth Care Res Unit, Southampton SO16 6YD, Hants, England; Papworth Hosp, Cambridge, England; NHS Informat Author, Cent Cardiac Audit Database, London, England	University of Southampton; Papworth Hospital	Parkes, J (corresponding author), Univ Southampton, Hlth Care Res Unit, Southampton SO16 6YD, Hants, England.	jules@soton.ac.uk		Parkes, Julie/0000-0002-6490-395X				Ezekowitz JA, 2003, ANN INTERN MED, V138, P445, DOI 10.7326/0003-4819-138-6-200303180-00007; Langham S, 2003, J PUBLIC HEALTH MED, V25, P202, DOI 10.1093/pubmed/fdg054; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; *NAT I CLIN EXC, 2000, 11 NICE; Payne N, 1997, BRIT MED J, V314, P257, DOI 10.1136/bmj.314.7076.257	5	13	13	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 26	2005	330	7489					454	455		10.1136/bmj.38337.635648.82	http://dx.doi.org/10.1136/bmj.38337.635648.82			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	901XK	15695498	Green Published, Bronze			2022-12-28	WOS:000227315400019
J	Klein, EM; Smith, DK; Williams, CM; Schouten, H				Klein, EM; Smith, DK; Williams, CM; Schouten, H			Counter-rotating microplates at the Galapagos triple junction	NATURE			English	Article							TECTONIC EVOLUTION; INTENSITY; INVERSION; BOUNDARY	An 'incipient' spreading centre east of (and orthogonal to) the East Pacific Rise at 2degrees 40' N has been identified as forming a portion of the northern boundary of the Galapagos microplate(1,2). This spreading centre was described as a slowly diverging, westward propagating rift, tapering towards the East Pacific Rise. Here we present evidence that the 'incipient rift' has also rifted towards the east and opens anticlockwise about a pivot at its eastern end. The 'incipient rift' then bounds a second microplate, north of the clockwise-rotating Galapagos microplate. The Galapagos triple junction region, in the eastern equatorial Pacific Ocean, thus consists of two counter-rotating microplates partly separated by the Hess Deep rift. Our kinematic solution for microplate motion relative to the major plates indicates that the two counter-rotating microplates may be treated as rigid blocks driven by drag on the microplates' edges(3).	Duke Univ, Nicholas Sch Environm & Earth Sci, Durham, NC 27708 USA; Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA	Duke University; Woods Hole Oceanographic Institution	Klein, EM (corresponding author), Duke Univ, Nicholas Sch Environm & Earth Sci, Durham, NC 27708 USA.	ek4@duke.edu		Klein, Emily/0000-0003-1023-7186				Baker E.T., 1997, RIDGE EVENTS, V8, P23; Carey S.W., 1958, CONTINENTAL DRIFT S, P177; DEMETS C, 1994, GEOPHYS RES LETT, V21, P2191, DOI 10.1029/94GL02118; Gee J, 1997, J GEOPHYS RES-SOL EA, V102, P24873, DOI 10.1029/97JB02544; Gee JS, 2000, NATURE, V408, P827, DOI 10.1038/35048513; Guyodo Y, 1999, NATURE, V399, P249, DOI 10.1038/20420; HANNA HD, 2003, EOS, V84, P1495; HEY R, 1977, GEOL SOC AM BULL, V88, P1404, DOI 10.1130/0016-7606(1977)88<1404:TEOTCS>2.0.CO;2; Karson JA, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000155; LARSON RL, 1992, NATURE, V356, P571, DOI 10.1038/356571a0; LONSDALE P, 1988, J GEOPHYS RES-SOLID, V93, P13551, DOI 10.1029/JB093iB11p13551; Lonsdale P., 1977, Marine Geophysical Researches, V3, P295, DOI 10.1007/BF00285657; LONSDALE P, 1985, TECTONOPHYSICS, V116, P255, DOI 10.1016/0040-1951(85)90211-2; LONSDALE P, 1992, EARTH PLANET SC LETT, V109, P73, DOI 10.1016/0012-821X(92)90075-7; MACDONALD KC, 1980, J GEOPHYS RES, V85, P3670, DOI 10.1029/JB085iB07p03670; MITCHELL NC, 1991, J GEOPHYS RES-SOLID, V96, P8019, DOI 10.1029/91JB00177; NAAR DF, 1991, J GEOPHYS RES-SOLID, V96, P7961, DOI 10.1029/90JB02398; PARKER RL, 1974, J GEOPHYS RES, V79, P1587, DOI 10.1029/JB079i011p01587; RAFF AD, 1968, J GEOPHYS RES, V73, P3699, DOI 10.1029/JB073i012p03699; SCHOUTEN H, 1993, J GEOPHYS RES-SOL EA, V98, P6689, DOI 10.1029/92JB02749; SEARLE RC, 1986, MAR GEOPHYS RES, V8, P95; Sims KWW, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2002GC000443	22	22	25	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 24	2005	433	7028					855	858		10.1038/nature03262	http://dx.doi.org/10.1038/nature03262			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	899VT	15729339				2022-12-28	WOS:000227174600039
J	Kuhl, M; Chen, M; Ralph, PJ; Schreiber, U; Larkum, AWD				Kuhl, M; Chen, M; Ralph, PJ; Schreiber, U; Larkum, AWD			A niche for cyanobacteria containing chlorophyll d	NATURE			English	Article							OXYGENIC PHOTOSYNTHETIC PROKARYOTE; ACARYOCHLORIS-MARINA; MAJOR PIGMENT		Univ Copenhagen, Marine Biol Lab, Inst Biol, DK-3000 Helsingor, Denmark; Univ Sydney, Sch Biol Sci, Sydney, NSW 2006, Australia; Univ Technol Sydney, Inst Water & Environm Resource Management, Gore Hill, NSW 2065, Australia; Univ Wurzburg, Julius von Sachs Inst Biowissensch, D-97082 Wurzburg, Germany	University of Copenhagen; University of Sydney; University of Technology Sydney; University of Wurzburg	Kuhl, M (corresponding author), Univ Copenhagen, Marine Biol Lab, Inst Biol, Strandpromenaden 5, DK-3000 Helsingor, Denmark.	mkuhl@bi.ku.dk	Ralph, Peter J/C-5029-2009; Ralph, Peter/L-1527-2019; Kühl, Michael/A-1977-2009	Ralph, Peter J/0000-0002-3103-7346; Ralph, Peter/0000-0002-3103-7346; Kühl, Michael/0000-0002-1792-4790; Chen, Min/0000-0001-8070-3248				Boichenko VA, 2000, PHOTOSYNTH RES, V65, P269, DOI 10.1023/A:1010637631417; Chen M, 2005, MOL BIOL EVOL, V22, P21, DOI 10.1093/molbev/msh250; Kuhl M, 2000, MICROBIAL ECOL, V40, P94; KUHL M, 2002, SYMBIOSIS MECH MODEL, P273; Miller SR, 2005, P NATL ACAD SCI USA, V102, P850, DOI 10.1073/pnas.0405667102; Miyashita H, 2003, J PHYCOL, V39, P1247, DOI 10.1111/j.0022-3646.2003.03-158.x; Miyashita H, 1997, PLANT CELL PHYSIOL, V38, P274, DOI 10.1093/oxfordjournals.pcp.a029163; Miyashita H, 1996, NATURE, V383, P402, DOI 10.1038/383402a0; Murakami A, 2004, SCIENCE, V303, P1633, DOI 10.1126/science.1095459; Schiller H, 1997, FEBS LETT, V410, P433, DOI 10.1016/S0014-5793(97)00620-0	10	150	172	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 24	2005	433	7028					820	820		10.1038/433820a	http://dx.doi.org/10.1038/433820a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	899VT	15729331	Bronze			2022-12-28	WOS:000227174600031
J	Zerr, DM; Meier, AS; Selke, SS; Frenkel, LM; Huang, M; Wald, A; Rhoads, MP; Nguy, L; Bornemann, R; Morrow, RA; Corey, L				Zerr, DM; Meier, AS; Selke, SS; Frenkel, LM; Huang, M; Wald, A; Rhoads, MP; Nguy, L; Bornemann, R; Morrow, RA; Corey, L			A population-based study of primary human herpesvirus 6 infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN HERPESVIRUS-6 INFECTION; CHILDREN; REACTIVATION; DNA	BACKGROUND: Serologic studies indicate that human herpesvirus 6 (HHV-6) infects 90 percent of children by two years of age. Little is known about the acquisition, virologic course, and clinical manifestations of HHV-6 infection. METHODS: We prospectively studied a cohort of 277 children from birth through the first two years of life to define the pattern of acquisition of HHV-6. The children's saliva was tested weekly for HHV-6 DNA with the use of the polymerase chain reaction. Parents maintained a daily log of signs and symptoms of illness in their children. RESULTS: Primary HHV-6 infection occurred in 130 children, with cumulative percentages of 40 percent by the age of 12 months and 77 percent by the age of 24 months. The peak age of acquisition was between 9 and 21 months. The acquisition of HHV-6 was associated with female sex (adjusted hazard ratio, 1.7; 95 percent confidence interval, 1.2 to 2.4) and having older siblings (adjusted hazard ratio, 2.1; 95 percent confidence interval, 1.4 to 2.9). Among 81 children with a well-defined time of acquisition of HHV-6, 93 percent had symptoms, and 38 percent were seen by a physician. None had seizures. As compared with children who had other illnesses, those with primary HHV-6 infection were more likely to have fever (P=0.003), fussiness (P=0.02), diarrhea (P=0.03), rash (P=0.003), and roseola (P=0.002) and were more likely to visit a physician (P=0.003). CONCLUSIONS: The acquisition of HHV-6 in infancy is usually symptomatic and often results in medical evaluation. Roseola occurs in a minority of patients, and febrile seizures are infrequently associated with primary HHV-6 infection. Older siblings appear to serve as a source of HHV-6 transmission.	Childrens Hosp, Seattle, WA 98105 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Program Biostat, Seattle, WA 98104 USA; Fred Hutchinson Canc Res Ctr, Program Infect Dis, Seattle, WA 98104 USA	Seattle Children's Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Zerr, DM (corresponding author), Childrens Hosp, 8G-1,4800 Sand Point Way NE, Seattle, WA 98105 USA.	zerr@u.washington.edu	Wald, Anna/B-6272-2012	Wald, Anna/0000-0003-3486-6438	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI001679, P01AI030731] Funding Source: NIH RePORTER; NIAID NIH HHS [AI001679, AI-30731] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Black JB, 1996, CLIN DIAGN LAB IMMUN, V3, P79, DOI 10.1128/CDLI.3.1.79-83.1996; CHERRY JD, 1998, TXB PEDIAT INFECT DI, V1, P738; DALESSIO J, 1992, J CLIN MICROBIOL, V30, P1005, DOI 10.1128/JCM.30.4.1005-1007.1992; HALL CB, 1994, NEW ENGL J MED, V331, P432, DOI 10.1056/NEJM199408183310703; Ljungman P, 2000, BRIT J HAEMATOL, V111, P774, DOI 10.1046/j.1365-2141.2000.02422.x; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; OKUNO T, 1989, J CLIN MICROBIOL, V27, P651, DOI 10.1128/JCM.27.4.651-653.1989; PRUKSANANONDA P, 1992, NEW ENGL J MED, V326, P1445, DOI 10.1056/NEJM199205283262201; Ryncarz AJ, 1999, J CLIN MICROBIOL, V37, P1941, DOI 10.1128/JCM.37.6.1941-1947.1999; YAMAMOTO M, 1990, J CLIN MICROBIOL, V28, P1957, DOI 10.1128/JCM.28.9.1957-1962.1990; Zerr DM, 2000, J CLIN MICROBIOL, V38, P1981, DOI 10.1128/JCM.38.5.1981-1983.2000; Zerr DM, 2002, CLIN INFECT DIS, V34, P309, DOI 10.1086/338044; Zerr DM, 2001, CLIN INFECT DIS, V33, P763, DOI 10.1086/322642	13	282	298	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2005	352	8					768	776		10.1056/NEJMoa042207	http://dx.doi.org/10.1056/NEJMoa042207			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899MC	15728809				2022-12-28	WOS:000227147500006
J	Deahl, M				Deahl, M			Smoke, mirrors, and Gulf War illness	LANCET			English	Editorial Material							MORTALITY; VETERANS		256 City London Field Hosp V, London SE17 3RF, England		Deahl, M (corresponding author), 256 City London Field Hosp V, 71 Braganza St, London SE17 3RF, England.	martindeahl@fsmail.net						Barrett DH, 2002, EPIDEMIOL REV, V24, P218, DOI 10.1093/epirev/mxf003; DANDEKER C, IN PRESS ARMED FORCE; Davis LE, 2004, NEUROLOGY, V63, P1070, DOI 10.1212/01.WNL.0000138426.88460.CB; Haley RW, 2003, LANCET NEUROL, V2, P272, DOI 10.1016/S1474-4422(03)00376-4; INST. OF MED, 2000, GULF WAR HLTH; IVERSEN A, IN PRESS BR J PSYCHI; Kang HK, 2002, OCCUP ENVIRON MED, V59, P794, DOI 10.1136/oem.59.12.794; Macfarlane GJ, 2000, LANCET, V356, P17, DOI 10.1016/S0140-6736(00)02428-4; *RES ADV COMM GULF, 2004, 2004 REP REC; SHANE S, 2004, NY TIMES        1116, P6; TURNER MA, IN PRESS BR J PSYCHI; 2004, TIMES LOND      1207, P18	12	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	2005	365	9460					635	638						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	898SP	15721458				2022-12-28	WOS:000227096800006
J	Ravitsky, V				Ravitsky, V			Timers on ventilators	BRITISH MEDICAL JOURNAL			English	Article									NIH, Warren G Magnuson Clin Ctr, Dept Clin Bioeth, Bethesda, MD 20892 USA; NHGRI, Social & Behav Res Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Ravitsky, V (corresponding author), NIH, Warren G Magnuson Clin Ctr, Dept Clin Bioeth, 9000 Rockville Pike, Bethesda, MD 20892 USA.	vravitsky@mail.mih.gov						Barilan YM, 2004, J MED ETHICS, V30, P353, DOI 10.1136/jme.2002.000885; Barilan YM, 2003, KENNEDY INST ETHIC J, V13, P141, DOI 10.1353/ken.2003.0008; *BRIT MED ASS, 2001, WITHH WITHDR LIF PRO, P12; Glick SM, 1997, NEW ENGL J MED, V336, P954, DOI 10.1056/NEJM199703273361312; Grosch W, 1999, J CEREAL SCI, V29, P1, DOI 10.1006/jcrs.1998.0218; HALPERIN M, 2002, CLIN EXP SEC SYST TR; *ISR MED ASS, 1997, POS PAP DYING PAT; President ' Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DEC FOR LIF SUST TRE, P73; *PUBL COMM DYING P, 2002, PROP LAW DYING PAT; Steinberg A, 2003, ENCY JEWISH MED ETHI, V3, P1046; ZOHAR NJ, 1997, ALTERNATIVES JEWISH, P43	11	45	45	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 19	2005	330	7488					415	417		10.1136/bmj.330.7488.415	http://dx.doi.org/10.1136/bmj.330.7488.415			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900NA	15718544	Green Published			2022-12-28	WOS:000227220400026
J	Leman, P; Greene, S				Leman, P; Greene, S			Commentary: Testing patients to allow tailored drug treatment	BRITISH MEDICAL JOURNAL			English	Editorial Material							PHARMACOGENETICS		Univ Western Australia, Royal Perth Hosp, Emergency Dept, Perth, WA 6009, Australia; Guys & St Thomas Hosp, Natl Poisons Informat Serv, London, England	Royal Perth Hospital; University of Western Australia; Guy's & St Thomas' NHS Foundation Trust	Leman, P (corresponding author), Univ Western Australia, Royal Perth Hosp, Emergency Dept, Perth, WA 6009, Australia.	peter.leman@health.wa.gov.au						Kirchheiner J, 2005, CLIN PHARMACOL THER, V77, P1, DOI 10.1016/j.clpt.2004.08.009; Konstantopoulou M, 2005, BRIT MED J, V330, P350, DOI 10.1136/bmj.330.7487.350; Lindpaintner K, 2002, BRIT J CLIN PHARMACO, V54, P221, DOI 10.1046/j.1365-2125.2002.01630.x; Pirmohamed M, 2001, BRIT J CLIN PHARMACO, V52, P345, DOI 10.1046/j.0306-5251.2001.01498.x; Shah J, 2004, BMJ-BRIT MED J, V328, P1482, DOI 10.1136/bmj.328.7454.1482	5	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 12	2005	330	7487					352	352		10.1136/bmj.330.7487.352	http://dx.doi.org/10.1136/bmj.330.7487.352			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897OZ	15705695	Green Published			2022-12-28	WOS:000227015800029
J	Leggett, AJ				Leggett, AJ			The quantum measurement problem	SCIENCE			English	Editorial Material								Despite the spectacular success of quantum mechanics. (QM) over the last 80- years in explaining phenomena observed at the atomic and subatomic level, the conceptual status of the theory is still a topic of lively controversy. Most of the discussion centers around two famous paradoxes (or, as some would have it, pseudoparadoxes) associated, respectively, with the names of Einstein, Podolsky, and Rosen (EPR) and with Schrodinger's cat. In this Viewpoint, I will concentrate on the paradox of Schrodinger's cat or, as it is often known (to my mind somewhat misleadingly), the quantum measurement paradox.	Univ Illinois, Dept Phys, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Leggett, AJ (corresponding author), Univ Illinois, Dept Phys, 1110 W Green St, Urbana, IL 61801 USA.							Leggett AJ, 2002, J PHYS-CONDENS MAT, V14, pR415, DOI 10.1088/0953-8984/14/15/201	1	51	53	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2005	307	5711					871	872		10.1126/science.1109541	http://dx.doi.org/10.1126/science.1109541			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897DV	15705838				2022-12-28	WOS:000226985100038
J	Room, R; Babor, T; Rehm, J				Room, R; Babor, T; Rehm, J			Alcohol and public health	LANCET			English	Review							CORONARY-HEART-DISEASE; BREAST-CANCER; BRIEF INTERVENTIONS; RELAPSE PREVENTION; DRINKING PATTERN; CARDIOVASCULAR-DISEASE; DISULFIRAM TREATMENT; COST-EFFECTIVENESS; AVERAGE VOLUME; UNITED-STATES	Alcoholic beverages, and the problems they engender, have been familiar fixtures in human societies since the beginning of recorded history. We review advances in alcohol science in terms of three topics: the epidemiology of alcohol's role in health and illness; the treatment of alcohol use disorders in a public health perspective; and policy research and options. Research has contributed substantially to our understanding of the relation of drinking to specific disorders, and has shown that the relation between alcohol consumption and health outcomes is complex and multidimensional. Alcohol is causally related to more than 60 different medical conditions. Overall, 4% of the global burden of disease is attributable to alcohol, which accounts for about as much death and disability globally as tobacco and hypertension. Treatment research shows that early intervention in primary care is feasible and effective, and a variety of behavioural and pharmacological interventions are available to treat alcohol dependence. This evidence suggests that treatment of alcohol-related problems should be incorporated into a public health response to alcohol problems. Additionally, evidence-based preventive measures are available at both the individual and population levels, with alcohol taxes, restrictions on alcohol availability, and drinking-driving countermeasures among the most effective policy options. Despite the scientific advances, alcohol problems continue to present a major challenge to medicine and public health, in part because population-based public health approaches have been neglected in favour of approaches oriented to the individual that tend to be more palliative than preventative.	Stockholm Univ, Ctr Social Res Alcohol & Drugs, S-10691 Stockholm, Sweden; Univ Connecticut, Sch Med, Dept Community Med & Hlth Care, Farmington, CT USA; Res Inst Addict, Zurich, Switzerland; Ctr Addict & Mental Hlth, Toronto, ON, Canada	Stockholm University; University of Connecticut; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada	Room, R (corresponding author), Stockholm Univ, Ctr Social Res Alcohol & Drugs, S-10691 Stockholm, Sweden.	Robin.Room@sorad.su.se	Stockwell, Tim/B-6662-2012; Room, Robin/ABF-7460-2021	Room, Robin/0000-0002-5618-385X; Babor, Thomas/0000-0002-2580-0835				Allen JP, 1997, J STUD ALCOHOL, V58, P7; ALLEN JP, 1992, ALCOHOL CLIN EXP RES, V16, P1035, DOI 10.1111/j.1530-0277.1992.tb00695.x; [Anonymous], J PRIMARY PREVENTION, DOI DOI 10.1023/A:1021302302085; Anton RF, 1999, AM J PSYCHIAT, V156, P1758; Babor T.F., 2003, TREATMENT MATCHING A; Babor TF, 2003, ALCOHOL NO ORDINARY; BABOR TF, 2001, AUDIT ALCOHOL DISORD; BABOR TF, 2003, PSYCHIATRY, P936; Bagnardi V, 2001, BRIT J CANCER, V85, P1700, DOI 10.1054/bjoc.2001.2140; BEICH A, 2003, BMJ-BRIT MED J, V327, P1; BERGLUND M, 2003, TREATMENT ALCOHOL DR; BIEN TH, 1993, ADDICTION, V88, P315, DOI 10.1111/j.1360-0443.1993.tb00820.x; BORSCHOS B, 2000, 15 INT C ALC DRUGS T; BRIDGEMAN J, 2000, 317 OFT; Britton A, 2001, J EPIDEMIOL COMMUN H, V55, P383, DOI 10.1136/jech.55.6.383; Bushman B J, 1997, Recent Dev Alcohol, V13, P227; CASSWELL S, 1989, J STUD ALCOHOL, V50, P339, DOI 10.15288/jsa.1989.50.339; Chaloupka FJ, 2002, ALCOHOL RES HEALTH, V26, P22; CHICK J, 1992, BRIT J PSYCHIAT, V161, P84, DOI 10.1192/bjp.161.1.84; Chick J, 2000, ALCOHOL ALCOHOLISM, V35, P176, DOI 10.1093/alcalc/35.2.176; Chikritzhs T, 2002, J STUD ALCOHOL, V63, P591, DOI 10.15288/jsa.2002.63.591; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; Cook P. J., 1993, ALCOHOL HEALTH RES W, V17, P151; COOK PJ, 1981, ALCOHOL PUBLIC POLIC, P255; Corrao G, 2000, ADDICTION, V95, P1505, DOI 10.1046/j.1360-0443.2000.951015056.x; Ellison RC, 2001, AM J EPIDEMIOL, V154, P740, DOI 10.1093/aje/154.8.740; Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6; Finney JW, 1996, J STUD ALCOHOL, V57, P229, DOI 10.15288/jsa.1996.57.229; Finney JW, 1996, ADDICTION, V91, P1773, DOI 10.1046/j.1360-0443.1996.911217733.x; Foxcroft DR, 2003, ADDICTION, V98, P397, DOI 10.1046/j.1360-0443.2003.00355.x; Freudenheim JL, 1999, CANCER CAUSE CONTROL, V10, P369, DOI 10.1023/A:1008950717205; FULLER RK, 1986, JAMA-J AM MED ASSOC, V256, P1449, DOI 10.1001/jama.256.11.1449; Garbutt JC, 1999, JAMA-J AM MED ASSOC, V281, P1318, DOI 10.1001/jama.281.14.1318; Geerlings PJ, 1997, EUR ADDICT RES, V3, P129, DOI 10.1159/000259166; GERRA G, 1992, CURR THER RES CLIN E, V52, P291, DOI 10.1016/S0011-393X(05)80480-1; Ginsburg ES, 1999, J STEROID BIOCHEM, V69, P299, DOI 10.1016/S0960-0760(99)00047-3; Gmel G., 2003, SUCHT, V49, P105, DOI [https://doi.org/10.1024/suc.2003.49.2.105, DOI 10.1024/SUC.2003.49.2.105]; GOODLIFFE J, 2003, ALCOHOL ALERT, V3, P20; Graham K, 2004, DRUG ALCOHOL REV, V23, P31, DOI 10.1080/09595230410001645538; Graham K., 2001, INT HDB ALCOHOL DEPE, P439; GRUENEWALD PJ, 1993, ALCOHOL CLIN EXP RES, V17, P38, DOI 10.1111/j.1530-0277.1993.tb00723.x; Heinala P, 2001, J CLIN PSYCHOPHARM, V21, P287, DOI 10.1097/00004714-200106000-00006; Hemstrom O, 2001, ADDICTION, V96, pS93, DOI 10.1080/09652140020021206; Henstridge J., 1997, LONG TERM EFFECTS RA; HOFFMANN NG, 1983, INT J ADDICT, V18, P311, DOI 10.3109/10826088309039350; HOLDER HD, 1994, ACCIDENT ANAL PREV, V26, P89, DOI 10.1016/0001-4575(94)90071-X; HUANG CD, 2003, ECONOMETRIC MODELS A; HUMPHREYS K, 2004, CIRCLE RECOVERY SELF; *I MED, 1990, PREV TREATM ALC PROB, P169; Kabel DI, 1996, ALCOHOL CLIN EXP RES, V20, P780, DOI 10.1111/j.1530-0277.1996.tb01686.x; KAHAN M, 1995, CAN MED ASSOC J, V152, P851; Kauhanen J, 1997, BMJ-BRIT MED J, V315, P846, DOI 10.1136/bmj.315.7112.846; Kranzler HR, 2001, ALCOHOL CLIN EXP RES, V25, P1335, DOI 10.1097/00000374-200109000-00014; KRANZLER HR, 1995, AM J PSYCHIAT, V152, P391; Kranzler HR, 2000, ALCOHOL ALCOHOLISM, V35, P537, DOI 10.1093/alcalc/35.6.537; Kuo MC, 2003, ALCOHOL CLIN EXP RES, V27, P720, DOI [10.1097/01.ALC.0000065064.61199.79, 10.1111/j.1530-0277.2003.tb04410.x]; LIDNSTROM L, 1992, MANAGING ALCOHOLISM; Logan P, 1999, AM J PREV MED, V16, P278, DOI 10.1016/S0749-3797(99)00022-7; LONGABAUGH R, 1983, J STUD ALCOHOL, V44, P1049, DOI 10.15288/jsa.1983.44.1049; MAKELA K, 1981, ALCOHOL SOC STATE, V1; MAKELA K, 1993, ALCOHOL HEALTH RES W, V17, P228; Mann K, 2004, ALCOHOL CLIN EXP RES, V28, P51, DOI 10.1097/01.ALC.0000108656.81563.05; Mann RE, 2000, ADDICTION, V95, P60; MATTICK RP, 1995, DRUG ALCOHOL REV, V14, P134, DOI 10.1080/09595239400185211; Mccarthy P, 2001, APPL ECON, V33, P701, DOI 10.1080/00036840151135175; McCrady B.S., 1993, RES ALCOHOLICS ANONY; McElduff P, 1997, BRIT MED J, V314, P1159, DOI 10.1136/bmj.314.7088.1159; McKee M, 1998, J ROY SOC MED, V91, P402, DOI 10.1177/014107689809100802; MCKNIGHT AJ, 1991, J STUD ALCOHOL, V52, P389, DOI 10.15288/jsa.1991.52.389; MICZEK KA, 1993, J STUD ALCOHOL, P170, DOI 10.15288/jsas.1993.s11.170; MILLER WR, 1986, AM PSYCHOL, V41, P794, DOI 10.1037/0003-066X.41.7.794; MILLER WR, 1993, RES ALCOHOLICS ANONY, P3; Monterosso JR, 2001, AM J ADDICTION, V10, P258; Morris PLP, 2001, ADDICTION, V96, P1565, DOI 10.1046/j.1360-0443.2001.961115654.x; MURDOCH D, 1990, INT J ADDICT, V25, P1065, DOI 10.3109/10826089009058873; Murray RP, 2002, AM J EPIDEMIOL, V155, P242, DOI 10.1093/aje/155.3.242; Naranjo C A, 1986, Recent Dev Alcohol, V4, P265; NARANJO CA, 1983, CLIN PHARMACOL THER, V41, P266; Norstrom T, 2003, J STUD ALCOHOL, V64, P393, DOI 10.15288/jsa.2003.64.393; Norstrom T., 2002, ALCOHOL POSTWAR EURO, P157; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; Oslin D, 1997, AM J GERIAT PSYCHIAT, V5, P324, DOI 10.1097/00019442-199700540-00007; Ouimette PC, 1999, ALCOHOL CLIN EXP RES, V23, P545, DOI 10.1111/j.1530-0277.1999.tb04151.x; Pearl R., 1926, ALCOHOL LONGEVITY; PETERSON JB, 1990, J STUD ALCOHOL, V51, P114, DOI 10.15288/jsa.1990.51.114; PIHL RO, 1993, J STUD ALCOHOL, P128, DOI 10.15288/jsas.1993.s11.128; PIHL RO, 2001, VIOLENCE ADDICTION E, P25; PLINER P, 1974, J ABNORM PSYCHOL, V83, P418, DOI 10.1037/h0036884; Poikolainen K, 1999, PREV MED, V28, P503, DOI 10.1006/pmed.1999.0467; Poldrugo F, 1997, ADDICTION, V92, P1537; POLICH JM, 1980, J STUD ALCOHOL, V41, P397, DOI 10.15288/jsa.1980.41.397; Project Match Research Group, 1998, J MENTAL HLTH, P589, DOI DOI 10.1080/09638239817743; Puddey IB, 1999, ADDICTION, V94, P649, DOI 10.1046/j.1360-0443.1999.9456493.x; *R HOW ASS, 2003, LIQ LIC PUBL DIS REV; RAGNARSDOTTIR T, 2002, EFFECTS NORDIC ALCOH, P145; Rehm J, 2003, ADDICTION, V98, P1209, DOI 10.1046/j.1360-0443.2003.00467.x; Rehm J, 2003, ALCOHOL RES HEALTH, V27, P39; Rehm J, 2003, J CARDIOVASC RISK, V10, P15, DOI 10.1097/00043798-200302000-00004; Rehm J, 1996, ADDICTION, V91, P1615; REHM J, 2004, GLOBAL REGIONAL BURD, V1, P959; Rehm JT, 1997, AM J EPIDEMIOL, V146, P495, DOI 10.1093/oxfordjournals.aje.a009303; Ridolfo B, 2001, QUANTIFICATION DRUG; Rimm EB, 1999, BMJ-BRIT MED J, V319, P1523, DOI 10.1136/bmj.319.7224.1523; Room, 2002, EFFECTS NORDIC ALCOH, P17; Room R, 2001, SOC SCI MED, V53, P189, DOI 10.1016/S0277-9536(00)00330-0; ROOM R, 2001, NICOTINE PUBLIC HLTH, P37; Room R., 2002, EFFECTS NORDIC ALCOH; ROOM R, 2004, ADDICTION, V99, P1038; Room R, 2001, J SUBST USE, V4, P218, DOI DOI 10.1080/146598901753325048; Room R, 2002, ALCOHOL DEV SOC PUBL; Ross L, 2001, J VIROL METHODS, V96, P1, DOI 10.1016/S0166-0934(00)00275-5; Sass H, 1996, ARCH GEN PSYCHIAT, V53, P673; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SAYETTE MA, 1993, J STUD ALCOHOL, V54, P399, DOI 10.15288/jsa.1993.54.399; Shkolnikov V. M., 1997, PREMATURE DEATH NEW, P239; Shults RA, 2001, AM J PREV MED, V21, P66, DOI 10.1016/S0749-3797(01)00381-6; Skog OJ, 1996, ADDICTION, V91, P325, DOI 10.1111/j.1360-0443.1996.tb02283.x; Sloan Frank A., 2000, DRINKERS DRIVERS BAR; Smith-Warner SA, 1998, JAMA-J AM MED ASSOC, V279, P535, DOI 10.1001/jama.279.7.535; Swift RM, 1999, NEW ENGL J MED, V340, P1482, DOI 10.1056/NEJM199905133401907; Tempesta E, 2000, ALCOHOL ALCOHOLISM, V35, P202, DOI 10.1093/alcalc/35.2.202; The 1999 ESPAD Report, 2000, 1999 ESPAD REPORT AL; Timko C, 2000, J STUD ALCOHOL, V61, P529, DOI 10.15288/jsa.2000.61.529; Trevisan M, 2001, ANN EPIDEMIOL, V11, P312, DOI 10.1016/S1047-2797(00)00183-6; Trevisan M, 2001, AM J EPIDEMIOL, V153, pS97; *UK HOM OFF, 2003, TACKL ALC REL CRIM D; Vaillant G.E., 1995, WISDOM EGO; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; Vuchinich RE, 1999, NBER CONF R, P103; Wagenaar AC, 2002, J STUD ALCOHOL, P206, DOI 10.15288/jsas.2002.s14.206; Wallin E, 2003, J STUD ALCOHOL, V64, P270, DOI 10.15288/jsa.2003.64.270; Wallin E., 2003, NORDISK ALKOHOL NARK, V20, P97, DOI [10.1177/145507250302001S09, DOI 10.1177/145507250302001S09]; WALSH DC, 1991, NEW ENGL J MED, V325, P775, DOI 10.1056/NEJM199109123251105; WANNAMETHEE G, 1992, BRIT HEART J, V68, P443; Wechsler H, 2003, J STUD ALCOHOL, V64, P484, DOI 10.15288/jsa.2003.64.484; Whetten-Goldstein K, 2000, ACCIDENT ANAL PREV, V32, P723, DOI 10.1016/S0001-4575(99)00122-0; WHITFIELD CL, 1978, JAMA-J AM MED ASSOC, V239, P1409, DOI 10.1001/jama.239.14.1409; Whitworth AB, 1996, LANCET, V347, P1438, DOI 10.1016/S0140-6736(96)91682-7; *WHO, 1994, POCK GUID ICD 10 CLA; WHO, 2002, RED RISKS PROM HLTH; Wilk AI, 1997, J GEN INTERN MED, V12, P274; World Health Organization, 2000, WORLD HLTH REP 2000; World Health Organization, 2004, NEUR PSYCH SUBST US; Zakhari S, 1997, ALCOHOL HEALTH RES W, V21, P21; Zheng T, 2003, BRIT J CANCER, V88, P58, DOI 10.1038/sj.bjc.6600708	145	1046	1083	0	256	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 5	2005	365	9458					519	530		10.1016/S0140-6736(05)17870-2	http://dx.doi.org/10.1016/S0140-6736(05)17870-2			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	894SS	15705462	Green Published			2022-12-28	WOS:000226812500030
J	Richter, JD; Sonenberg, N				Richter, JD; Sonenberg, N			Regulation of cap-dependent translation by eIF4E inhibitory proteins	NATURE			English	Article							MESSENGER-RNA TRANSLATION; TERM SYNAPTIC PLASTICITY; BINDING-PROTEIN; CYTOPLASMIC POLYADENYLATION; DROSOPHILA CUP; INITIATION; PHOSPHORYLATION; COMPLEX; RECRUITMENT; REPRESSION	Eukaryotic messenger RNAs contain a modified guanosine, termed a cap, at their 50 ends. Translation of mRNAs requires the binding of an initiation factor, eIF4E, to the cap structure. Here, we describe a family of proteins that through a shared sequence regulate cap-dependent translation. The biological importance of this translational regulation is immense, and affects such processes as cell growth, development, oncogenic transformation and perhaps even axon pathfinding and memory consolidation.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	University of Massachusetts System; University of Massachusetts Worcester; McGill University; McGill University	Richter, JD (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA.	joel.richter@umassmed.edu						Alarcon JM, 2004, LEARN MEMORY, V11, P318, DOI 10.1101/lm.72704; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Campbell DS, 2001, NEURON, V32, P1013, DOI 10.1016/S0896-6273(01)00551-7; Cao QP, 2002, EMBO J, V21, P3852, DOI 10.1093/emboj/cdf353; Casadio A, 1999, CELL, V99, P221, DOI 10.1016/S0092-8674(00)81653-0; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; DUNCAN R, 1987, J BIOL CHEM, V262, P380; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Heesom KJ, 2001, CURR BIOL, V11, P1374, DOI 10.1016/S0960-9822(01)00422-5; Huang YS, 2002, EMBO J, V21, P2139, DOI 10.1093/emboj/21.9.2139; Kelleher RJ, 2004, CELL, V116, P467, DOI 10.1016/S0092-8674(04)00115-1; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; MADER S, 1995, MOL CELL BIOL, V15, P4990; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; Martin KC, 2002, NAT REV NEUROSCI, V3, P813, DOI 10.1038/nrn942; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; Nakamura A, 2004, DEV CELL, V6, P69, DOI 10.1016/S1534-5807(03)00400-3; Nedelec S, 2004, P NATL ACAD SCI USA, V101, P10815, DOI 10.1073/pnas.0403824101; Nelson MR, 2004, EMBO J, V23, P150, DOI 10.1038/sj.emboj.7600026; Niessing D, 2002, GENE DEV, V16, P2576, DOI 10.1101/gad.240002; Pyronnet S, 2001, GENE DEV, V15, P2083, DOI 10.1101/gad.889201; Rau M, 1996, J BIOL CHEM, V271, P8983, DOI 10.1074/jbc.271.15.8983; Richter JD, 2002, CURR OPIN NEUROBIOL, V12, P300, DOI 10.1016/S0959-4388(02)00318-5; Rousseau D, 1996, ONCOGENE, V13, P2415; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7; Sonenberg N, 1993, CURR OPIN CELL BIOL, V5, P955, DOI 10.1016/0955-0674(93)90076-3; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; Steward O, 2001, ANNU REV NEUROSCI, V24, P299, DOI 10.1146/annurev.neuro.24.1.299; Tang SJ, 2002, P NATL ACAD SCI USA, V99, P467, DOI 10.1073/pnas.012605299; Topisirovic I, 2003, EMBO J, V22, P689, DOI 10.1093/emboj/cdg069; Tsukiyama-Kohara K, 2001, NAT MED, V7, P1128, DOI 10.1038/nm1001-1128; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Wilhelm JE, 2003, J CELL BIOL, V163, P1197, DOI 10.1083/jcb.200309088; Wu L, 1998, NEURON, V21, P1129, DOI 10.1016/S0896-6273(00)80630-3	39	725	741	0	68	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 3	2005	433	7025					477	480		10.1038/nature03205	http://dx.doi.org/10.1038/nature03205			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893NT	15690031	Green Published			2022-12-28	WOS:000226727200037
J	Dunn, LB; Gordon, NE				Dunn, LB; Gordon, NE			Improving informed consent and enhancing recruitment for research by understanding economic behavior	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CLINICAL-TRIALS; THERAPEUTIC MISCONCEPTION; RESEARCH PARTICIPANTS; DECISION-MAKING; OLDER-ADULTS; PHASE-I; SUBJECT; SCHIZOPHRENIA; CAPACITY; PAYMENT		Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Econ, La Jolla, CA 92093 USA; Natl Bur Econ Res, Cambridge, MA 02138 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; National Bureau of Economic Research	Dunn, LB (corresponding author), Univ Calif San Diego, Dept Psychiat, 0603-V,9500 Gilman Dr, La Jolla, CA 92093 USA.	dunn@ucsd.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [K23MH066062] Funding Source: NIH RePORTER; NIMH NIH HHS [MH66062] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ackerman Terrence F, 1989, IRB, V11, P1, DOI 10.2307/3564170; [Anonymous], 1986, HIST THEORY INFORM C; Appelbaum Paul S, 2004, IRB, V26, P1, DOI 10.2307/3564231; APPELBAUM PS, 1982, INT J LAW PSYCHIAT, V5, P319, DOI 10.1016/0160-2527(82)90026-7; APPELBAUM PS, 1987, HASTINGS CENT REP, V17, P20, DOI 10.2307/3562038; Appelbaum PS, 1996, KENNEDY INST ETHIC J, V6, P283, DOI 10.1353/ken.1996.0019; Beauchamp TL, 2002, KENNEDY INST ETHIC J, V12, P389, DOI 10.1353/ken.2002.0021; Bentley JP, 2004, J MED ETHICS, V30, P293, DOI 10.1136/jme.2002.001594; Borzekowski DLG, 2003, J ADOLESCENT HEALTH, V33, P378, DOI 10.1016/S1054-139X(03)00228-3; CHRISTENSEN K, 1995, B AM ACAD PSYCH LAW, V23, P353; Corbie-Smith G, 2002, ARCH INTERN MED, V162, P2458, DOI 10.1001/archinte.162.21.2458; Criscione LG, 2003, ARTHRIT RHEUM-ARTHR, V49, P361, DOI 10.1002/art.11057; Cummings JL, 2003, AM J GERIAT PSYCHIAT, V11, P131, DOI 10.1176/appi.ajgp.11.2.131; CUNNY KA, 1994, CLIN THER, V16, P273; DAUGHERTY C, 1995, J CLIN ONCOL, V13, P1062, DOI 10.1200/JCO.1995.13.5.1062; DeRenzo E G, 2000, IRB, V22, P1, DOI 10.2307/3563568; Dickert N, 2002, ANN INTERN MED, V136, P368, DOI 10.7326/0003-4819-136-5-200203050-00009; Dickert N, 1999, NEW ENGL J MED, V341, P198, DOI 10.1056/NEJM199907153410312; Dunn LB, 2001, NEUROPSYCHOPHARMACOL, V24, P595, DOI 10.1016/S0893-133X(00)00218-9; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; Emanuel EJ, 2004, J LAW MED ETHICS, V32, P100, DOI 10.1111/j.1748-720X.2004.tb00453.x; Fouad MN, 2004, CONTROL CLIN TRIALS, V25, P335, DOI 10.1016/j.cct.2004.03.005; Frank E, 2003, PSYCHOPHARMACOLOGY, V171, P19, DOI 10.1007/s00213-003-1477-z; GOTAY CC, 1991, SOC SCI MED, V33, P569, DOI 10.1016/0277-9536(91)90214-W; Grady Christine, 2001, American Journal of Bioethics, V1, P40, DOI 10.1162/152651601300169031; Grisso T, 1998, ASSESSING COMPETENCE; Gross CP, 2002, ANN INTERN MED, V137, P10, DOI 10.7326/0003-4819-137-1-200207020-00007; Halpern SD, 2004, ARCH INTERN MED, V164, P801, DOI 10.1001/archinte.164.7.801; Halpern SD, 2002, CONTROL CLIN TRIALS, V23, P274, DOI 10.1016/S0197-2456(02)00191-5; HAMMERSCHMIDT DE, 1992, AM J MED SCI, V304, P348, DOI 10.1097/00000441-199212000-00003; Helft PR, 2004, JNCI-J NATL CANCER I, V96, P656, DOI 10.1093/jnci/djh121; Kaminsky A, 2003, ETHICS BEHAV, V13, P279, DOI 10.1207/S15327019EB1303_06; Karlawish JHT, 2002, J AM GERIATR SOC, V50, P2019, DOI 10.1046/j.1532-5415.2002.50615.x; Katz, 2000, Ann Epidemiol, V10, P456, DOI 10.1016/S1047-2797(00)00153-8; Kent G, 1996, SOC SCI MED, V43, P1517, DOI 10.1016/0277-9536(96)00173-6; Kuczewski Mark, 2001, American Journal of Bioethics, V1, P49, DOI 10.1162/152651601300169086; Latterman Jessica, 2001, American Journal of Bioethics, V1, P45, DOI 10.1162/152651601300169040; Lidz CW, 2004, SOC SCI MED, V58, P1689, DOI 10.1016/S0277-9536(03)00338-1; Lidz CW, 2002, MED CARE, V40, P55, DOI 10.1097/01.MLR.0000023956.25813.18; LIDZ CW, 1988, ARCH INTERN MED, V148, P1385, DOI 10.1001/archinte.148.6.1385; Macklin Ruth, 1981, IRB, V3, P1, DOI 10.2307/3564136; Macklin Ruth, 1989, IRB, V11, P1, DOI 10.2307/3564182; Madsen SM, 2002, J INTERN MED, V251, P156, DOI 10.1046/j.1365-2796.2002.00949.x; MATTSON ME, 1985, CONTROL CLIN TRIALS, V6, P156, DOI 10.1016/0197-2456(85)90121-7; McGee G, 1997, JAMA-J AM MED ASSOC, V278, P199, DOI 10.1001/jama.278.3.199; McNeill P, 1997, BIOETHICS, V11, P390, DOI 10.1111/1467-8519.00079; MORROW GR, 1980, JAMA-J AM MED ASSOC, V244, P56, DOI 10.1001/jama.244.1.56; Natl. Comm. Prot. Hum. Subj. Biomed. Behav. Res, 1978, BELM REP ETH PRINC G; Nelson RM, 2002, MED CARE, V40, P69, DOI 10.1097/01.MLR.0000023958.28108.9C; Olin JT, 2002, ALZ DIS ASSOC DIS, V16, pS82, DOI 10.1097/00002093-200200002-00009; Paasche-Orlow MK, 2003, NEW ENGL J MED, V348, P721, DOI 10.1056/NEJMsa021212; Pace C, 2003, CRIT CARE MED, V31, pS121, DOI 10.1097/01.CCM.0000054907.33928.48; Raich PC, 2001, CANCER INVEST, V19, P437, DOI 10.1081/CNV-100103137; Roberts LW, 2004, SCHIZOPHR RES, V67, P283, DOI 10.1016/S0920-9964(03)00101-4; Roberts LW, 2002, AM J PSYCHIAT, V159, P705, DOI 10.1176/appi.ajp.159.5.705; RODENHUIS S, 1984, EUR J CANCER CLIN ON, V20, P457, DOI 10.1016/0277-5379(84)90229-3; Sanfey AG, 2003, SCIENCE, V300, P1755, DOI 10.1126/science.1082976; Sengupta S, 2000, J ACQ IMMUN DEF SYND, V24, P275; Shavers VL, 2000, J NATL MED ASSOC, V92, P563; Sugarman J, 1998, J AM GERIATR SOC, V46, P517, DOI 10.1111/j.1532-5415.1998.tb02477.x; Sugarman J, 2001, J AM GERIATR SOC, V49, P1110, DOI 10.1046/j.1532-5415.2001.49218.x; THOMPSON MG, 1994, PSYCHOL AGING, V9, P121, DOI 10.1037/0882-7974.9.1.121; *US OFF INSP GEN, 2000, PUBL US OFF INSP GEN; Verheggen FWSM, 1996, HEALTH POLICY, V36, P131, DOI 10.1016/0168-8510(95)00805-5; Verheggen FWSM, 1998, PATIENT EDUC COUNS, V35, P111, DOI 10.1016/S0738-3991(98)00060-3; Warner TD, 2003, COMPR PSYCHIAT, V44, P227, DOI 10.1016/S0010-440X(03)00042-7; Weijer C, 1999, NEW ENGL J MED, V341, P1551; Wilkinson M, 1997, BIOETHICS, V11, P373, DOI 10.1111/1467-8519.00078; Wilkinson M, 1999, BIOETHICS, V13, P114, DOI 10.1111/1467-8519.00136	69	64	65	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2005	293	5					609	612		10.1001/jama.293.5.609	http://dx.doi.org/10.1001/jama.293.5.609			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	893BL	15687316				2022-12-28	WOS:000226694200024
J	Fonarow, GC; Adams, KF; Abraham, WT; Yancy, CW; Boscardin, WJ				Fonarow, GC; Adams, KF; Abraham, WT; Yancy, CW; Boscardin, WJ		ADHERE Sci Advisory Comm Study Grp	Risk stratification for in-hospital mortality in acutely decompensated heart failure - Classification and regression tree analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; WORSENING RENAL-FUNCTION; NATRIURETIC PEPTIDE; EJECTION FRACTION; OLDER PATIENTS; TRIAL; SCORE; PROGNOSIS; SURVIVAL; PREDICTORS	Context Estimation of mortality risk in patients hospitalized with acute decompensated heart failure (ADHF) may help clinicians guide care. Objective To develop a practical user-friendly bedside tool for risk stratification for patients hospitalized with ADHF. Design, Setting, and Patients The Acute Decompensated Heart Failure National Registry (ADHERE) of patients hospitalized with a primary diagnosis of ADHF in 263 hospitals in the United States was queried with analysis of patient data to develop a risk stratification model. The first 33 046 hospitalizations (derivation cohort; October 2001-February 2003) were analyzed to develop the model and then the validity of the model was prospectively tested using data from 32 229 subsequent hospitalizations (validation cohort; March-July 2003). Patients had a mean age of 72.5 years and 52% were female. Main Outcome Measure Variables predicting mortality in ADHF. Results When the derivation and validation cohorts are combined, 37 772 (58%) of 65 275 patient-records had coronary artery disease. Of a combined cohort consisting of 52 164 patient-records, 23 910 (46%) had preserved left ventricular systolic function. In-hospital mortality was similar in the derivation (4.2%) and validation (4.0%) cohorts. Recursive partitioning of the derivation cohort for 39 variables indicated that the best single predictor for mortality was high admission levels of blood urea nitrogen (greater than or equal to43 mg/dL [15.35 mmol/L]) followed by low admission systolic blood pressure (<115 mm Hg) and then by high levels of serum creatinine (&GE;2.75 mg/dL [243.1 &mu;mol/L]). A simple risk tree identified patient groups with mortality ranging from 2.1% to 21.9%. The odds ratio for mortality between patients identified as high and low risk was 12.9 (95% confidence interval, 10.4-15.9) and similar results were seen when this risk stratification was applied prospectively to the validation cohort. Conclusions These results suggest that ADHF patients at low, intermediate, and high risk for in-hospital mortality can be easily identified using vital sign and laboratory data obtained on hospital admission. The ADHERE risk tree provides clinicians with a validated, practical bedside tool for mortality risk stratification.	Univ Calif Los Angeles, Div Cardiol, Ahmanson UCLA Cardiomyopathy Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA USA; Univ N Carolina, Div Cardiol, Chapel Hill, NC USA; Ohio State Univ, Med Ctr, Dept Cardiol, Columbus, OH 43210 USA; Univ Texas, SW Med Ctr, Div Cardiol, Dallas, TX USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of North Carolina; University of North Carolina Chapel Hill; University System of Ohio; Ohio State University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Fonarow, GC (corresponding author), Univ Calif Los Angeles, Div Cardiol, Ahmanson UCLA Cardiomyopathy Ctr, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	gfonarow@mednet.ucla.edu	Fonarow, Gregg C/D-5988-2014	Fonarow, Gregg C/0000-0002-3192-8093				Aaronson KD, 1997, CIRCULATION, V95, P2660, DOI 10.1161/01.CIR.95.12.2660; *ACC AHA WRIT COMM, ACC AHA KEY DAT EL D; ADAMS KF, IN PRESS AM HEART J; *AM HEART ASS, 2004, HEART DIS STROK STAT; Ansari M, 2003, AM HEART J, V146, P1, DOI 10.1016/S0002-8703(02)94801-5; Antman EM, 2000, JAMA-J AM MED ASSOC, V284, P835, DOI 10.1001/jama.284.7.835; Blackledge HM, 2003, HEART, V89, P615, DOI 10.1136/heart.89.6.615; Boersma E, 2000, CIRCULATION, V101, P2557, DOI 10.1161/01.CIR.101.22.2557; Bongartz LG, 2004, HYPERTENSION, V43, pE14, DOI 10.1161/01.HYP.0000118521.06245.b8; Breiman L., 1984, CLASSIFICATION REGRE; Califf RM, 2000, CIRCULATION, V101, P2231, DOI 10.1161/01.CIR.101.19.2231; Cheng V, 2001, J AM COLL CARDIOL, V37, P386, DOI 10.1016/S0735-1097(00)01157-8; COHN JN, 1993, CIRCULATION, V87, P5; Cowie MR, 2003, EUR HEART J, V24, P1710, DOI 10.1016/S0195-668X(03)00476-7; Cuffe MS, 2002, JAMA-J AM MED ASSOC, V287, P1541, DOI 10.1001/jama.287.12.1541; Ezekowitz JA, 2003, CIRCULATION, V107, P223, DOI 10.1161/01.CIR.0000052622.51963.FC; Felker GM, 2003, AM HEART J, V145, pS18, DOI 10.1067/mhj.2003.150; Felker GM, 2003, AM J CARDIOL, V92, P625, DOI 10.1016/S0002-9149(03)00740-9; Felker GM, 2003, J AM COLL CARDIOL, V41, P997, DOI 10.1016/S0735-1097(02)02968-6; Fonarow Gregg C, 2003, Rev Cardiovasc Med, V4 Suppl 7, pS21; Forman DE, 2004, J AM COLL CARDIOL, V43, P61, DOI 10.1016/j.jacc.2003.07.031; GARBE C, 1995, CANCER-AM CANCER SOC, V75, P2484, DOI 10.1002/1097-0142(19950515)75:10<2484::AID-CNCR2820751014>3.0.CO;2-U; Gerald LB, 2002, AM J RESP CRIT CARE, V166, P1122, DOI 10.1164/rccm.200202-124OC; Havranek EP, 2002, AM HEART J, V143, P412, DOI 10.1067/mhj.2002.120773; HUNT SA, GUIDELINES EVALUATIO; Ishii J, 2003, CLIN CHEM, V49, P2020, DOI 10.1373/clinchem.2003.021311; Jacobs DR, 1999, CIRCULATION, V100, P599, DOI 10.1161/01.CIR.100.6.599; Kearney MT, 2002, J AM COLL CARDIOL, V40, P1801, DOI 10.1016/S0735-1097(02)02490-7; Kerzner R, 2003, AM HEART J, V146, P286, DOI 10.1016/S0002-8703(03)00151-0; Kosiborod M, 2003, AM J MED, V114, P112, DOI 10.1016/S0002-9343(02)01498-5; Krum H, 2003, LANCET, V362, P147, DOI 10.1016/S0140-6736(03)13869-X; Krumholz HM, 2001, J AM COLL CARDIOL, V38, P453, DOI 10.1016/S0735-1097(01)01395-X; Kvasnicka HM, 2001, J CLIN ONCOL, V19, P2994, DOI 10.1200/JCO.2001.19.12.2994; Lee DS, 2003, JAMA-J AM MED ASSOC, V290, P2581, DOI 10.1001/jama.290.19.2581; Lehmann G, 2003, INT J CARDIOL, V89, P79, DOI 10.1016/S0167-5273(02)00408-4; Lewis RJ., INTRO CLASSIFICATION; Luthi J C, 2000, Eff Clin Pract, V3, P69; Morrow DA, 2001, LANCET, V358, P1571, DOI 10.1016/S0140-6736(01)06649-1; Morrow DA, 2000, CIRCULATION, V102, P2031, DOI 10.1161/01.CIR.102.17.2031; Nohria A, 2003, J AM COLL CARDIOL, V41, P1797, DOI 10.1016/S0735-1097(03)00309-7; Philbin EF, 1999, J AM COLL CARDIOL, V33, P1560, DOI 10.1016/S0735-1097(99)00059-5; Smith GL, 2003, J CARD FAIL, V9, P13, DOI 10.1054/jcaf.2003.3; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; Teo K, 1996, ARCH INTERN MED, V156, P1669, DOI 10.1001/archinte.156.15.1669; Yohannes Y, CLASSIFICATION REGRE; Zugck C, 2001, EUR J HEART FAIL, V3, P577, DOI 10.1016/S1388-9842(01)00167-2	46	1123	1198	1	39	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2005	293	5					572	580		10.1001/jama.293.5.572	http://dx.doi.org/10.1001/jama.293.5.572			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	893BL	15687312	Bronze			2022-12-28	WOS:000226694200020
J	Levine, JA; Lanningham-Foster, LM; McCrady, SK; Krizan, AC; Olson, LR; Kane, PH; Jensen, MD; Clark, MM				Levine, JA; Lanningham-Foster, LM; McCrady, SK; Krizan, AC; Olson, LR; Kane, PH; Jensen, MD; Clark, MM			Interindividual variation in posture allocation: Possible rote in human obesity	SCIENCE			English	Article							SPONTANEOUS PHYSICAL-ACTIVITY; SYSTEM	Obesity occurs when energy intake exceeds energy expenditure. Humans expend energy through purposeful exercise and through changes in posture and movement that are associated with the routines of daily life [called non-exercise activity thermogenesis (NEAT)]. To examine NEAT's role in obesity, we recruited 10 lean and 10 mildly obese sedentary volunteers and measured their body postures and movements every half-second for 10 days. Obese individuals were seated, on average, 2 hours longer per day than lean individuals. Posture allocation did not change when the obese individuals lost weight or when lean individuals gained weight, suggesting that it is biologically determined. If obese individuals adopted the NEAT-enhanced behaviors of their lean counterparts, they might expend an additional 350 calories (kcal) per day.	Mayo Clin & Mayo Fdn, Endocrine Res Unit, Rochester, MN 55905 USA	Mayo Clinic	Levine, JA (corresponding author), Mayo Clin & Mayo Fdn, Endocrine Res Unit, Rochester, MN 55905 USA.	Jim@Mayo.edu	Lanningham-Foster, Lorraine/A-5426-2012		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000585] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK066270, R01DK063226, R01DK056650] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00585] Funding Source: Medline; NIDDK NIH HHS [DK56650, DK63226, DK66270] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Finkelstein EA, 2004, OBES RES, V12, P18, DOI 10.1038/oby.2004.4; Hill JO, 2003, SCIENCE, V299, P853, DOI 10.1126/science.1079857; Kiwaki K, 2004, AM J PHYSIOL-ENDOC M, V286, pE551, DOI 10.1152/ajpendo.00126.2003; KOTZ CM, COMMUNICATION; Lanningham-Foster L, 2003, OBES RES, V11, P1178, DOI 10.1038/oby.2003.162; Levine J, 2003, EUR J CLIN NUTR, V57, P1176, DOI 10.1038/sj.ejcn.1601673; Levine J, 2001, AM J PHYSIOL-ENDOC M, V281, pE670, DOI 10.1152/ajpendo.2001.281.4.E670; Levine JA, 2003, J APPL PHYSIOL, V94, P165, DOI 10.1152/japplphysiol.00499.2002; Levine JA, 2001, MED SCI SPORT EXER, V33, P1593, DOI 10.1097/00005768-200109000-00024; Levine James A., 1999, Science (Washington D C), V283, P212, DOI 10.1126/science.283.5399.212; Mokdad AH, 2004, JAMA-J AM MED ASSOC, V291, P1238, DOI 10.1001/jama.291.10.1238; SCHOELLER DA, 1986, AM J PHYSIOL, V251, pR1137, DOI 10.1152/ajpregu.1986.251.6.R1137; Sutcliffe JG, 2004, NAT MED, V10, P673, DOI 10.1038/nm0704-673; World Health Organization, 1997, OB PREV MAN GLOB EP	14	473	490	5	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2005	307	5709					584	586		10.1126/science.1106561	http://dx.doi.org/10.1126/science.1106561			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893BJ	15681386				2022-12-28	WOS:000226694000048
J	Michalet, X; Pinaud, FF; Bentolila, LA; Tsay, JM; Doose, S; Li, JJ; Sundaresan, G; Wu, AM; Gambhir, SS; Weiss, S				Michalet, X; Pinaud, FF; Bentolila, LA; Tsay, JM; Doose, S; Li, JJ; Sundaresan, G; Wu, AM; Gambhir, SS; Weiss, S			Quantum dots for live cells, in vivo imaging, and diagnostics	SCIENCE			English	Review							SEMICONDUCTOR NANOCRYSTALS; CDTE NANOCRYSTALS; LUMINESCENT; PROTEINS; LIGANDS; PROBES; SPECTROSCOPY; CONJUGATION; RECEPTORS; DYNAMICS	Research on fluorescent semiconductor nanocrystais (also known as quantum dots or qdots) has evolved over the past two decades from electronic materials science to biological applications. We review current approaches to the synthesis, solubilization, and functionalization of qdots and their applications to cell and animal biology. Recent examples of their experimental use include the observation of diffusion of individual glycine receptors in living neurons and the identification of lymph nodes in live animals by near-infrared emission during surgery. The new generations of qdots have far-reaching potential for the study of intracellular processes at the single-molecule level, high-resolution cellular imaging, long-term in vivo observation of cell trafficking, tumor targeting, and diagnostics.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Crump Inst Mol Imaging, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Stanford Univ, Sch Med, Dept Radiol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Stanford MIPS, Mol Imaging Program,Bio X Program, Stanford, CA 94305 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Stanford University; Stanford University	Michalet, X (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 607 Charles E Young Dr E, Los Angeles, CA 90095 USA.	michalet@chem.ucla.edu; fpinaud@chem.ucla.edu; sweiss@chem.ucla.edu	Michalet, Xavier/A-9704-2009; Pinaud, Fabien/F-2306-2010; weiss, shimon/B-4164-2009; Bentolila, Laurent/L-5535-2019	Michalet, Xavier/0000-0001-6602-7693; weiss, shimon/0000-0002-0720-5426; Doose, Soren/0000-0002-6983-1182; Wu, Anna/0000-0001-8487-823X; Pinaud, Fabien/0000-0002-4272-3616; Gobalakrishnan, Sundaresan/0000-0002-9620-5611	NIBIB NIH HHS [R01 EB000312, 5-R01-EB000312] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000312] Funding Source: NIH RePORTER	NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Adams SR, 2002, J AM CHEM SOC, V124, P6063, DOI 10.1021/ja017687n; Akerman ME, 2002, P NATL ACAD SCI USA, V99, P12617, DOI 10.1073/pnas.152463399; Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; Alivisatos P, 2004, NAT BIOTECHNOL, V22, P47, DOI 10.1038/nbt927; Bailey RE, 2003, J AM CHEM SOC, V125, P7100, DOI 10.1021/ja035000o; Ballou B, 2004, BIOCONJUGATE CHEM, V15, P79, DOI 10.1021/bc034153y; BENTOLILA LA, UNPUB; Boder ET, 2000, P NATL ACAD SCI USA, V97, P10701, DOI 10.1073/pnas.170297297; Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013; Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016; Dahan M, 2001, OPT LETT, V26, P825, DOI 10.1364/OL.26.000825; Dahan M, 2003, SCIENCE, V302, P442, DOI 10.1126/science.1088525; DAMERON CT, 1989, NATURE, V338, P596, DOI 10.1038/338596a0; Derfus AM, 2004, ADV MATER, V16, P961, DOI 10.1002/adma.200306111; Derfus AM, 2004, NANO LETT, V4, P11, DOI 10.1021/nl0347334; DOOSE S, UNPUB; Dubertret B, 2002, SCIENCE, V298, P1759, DOI 10.1126/science.1077194; Efros AL, 2000, ANNU REV MATER SCI, V30, P475, DOI 10.1146/annurev.matsci.30.1.475; Empedocles SA, 1996, PHYS REV LETT, V77, P3873, DOI 10.1103/PhysRevLett.77.3873; Gao XH, 2002, J BIOMED OPT, V7, P532, DOI 10.1117/1.1506706; Gao XH, 2004, NAT BIOTECHNOL, V22, P969, DOI 10.1038/nbt994; Gaponik N, 2002, J PHYS CHEM B, V106, P7177, DOI 10.1021/jp025541k; Gerion D, 2001, J PHYS CHEM B, V105, P8861, DOI 10.1021/jp0105488; Goldman ER, 2002, ANAL CHEM, V74, P841, DOI 10.1021/ac010662m; Guo WZ, 2003, CHEM MATER, V15, P3125, DOI 10.1021/cm034341y; Guzelian AA, 1996, APPL PHYS LETT, V69, P1432, DOI 10.1063/1.117605; Guzelian AA, 1996, J PHYS CHEM-US, V100, P7212, DOI 10.1021/jp953719f; Hanaki K, 2003, BIOCHEM BIOPH RES CO, V302, P496, DOI 10.1016/S0006-291X(03)00211-0; Hohng S, 2004, J AM CHEM SOC, V126, P1324, DOI 10.1021/ja039686w; Hurtley SM, 2003, SCIENCE, V300, P75, DOI 10.1126/science.300.5616.75; Ishii D, 2003, NATURE, V423, P628, DOI 10.1038/nature01663; Jaiswal JK, 2003, NAT BIOTECHNOL, V21, P47, DOI 10.1038/nbt767; Kapanidis AN, 2001, J AM CHEM SOC, V123, P12123, DOI 10.1021/ja017074a; Kapitonov AM, 1999, J PHYS CHEM B, V103, P10109, DOI 10.1021/jp9921809; Keppler A, 2004, P NATL ACAD SCI USA, V101, P9955, DOI 10.1073/pnas.0401923101; Kim S, 2003, J AM CHEM SOC, V125, P14652, DOI 10.1021/ja0368094; Kim S, 2004, NAT BIOTECHNOL, V22, P93, DOI 10.1038/nbt920; Kloepfer JA, 2003, APPL ENVIRON MICROB, V69, P4205, DOI 10.1128/AEM.69.7.4205-4213.2003; Lacoste TD, 2000, P NATL ACAD SCI USA, V97, P9461, DOI 10.1073/pnas.170286097; Larson DR, 2003, SCIENCE, V300, P1434, DOI 10.1126/science.1083780; Lidke DS, 2004, NAT BIOTECHNOL, V22, P198, DOI 10.1038/nbt929; Lim Yong Taik, 2003, Mol Imaging, V2, P50, DOI 10.1162/153535003765276282; Mansson A, 2004, BIOCHEM BIOPH RES CO, V314, P529, DOI 10.1016/j.bbrc.2003.12.133; Marks KM, 2004, CHEM BIOL, V11, P347, DOI 10.1016/j.chembiol.2004.03.004; Mattheakis LC, 2004, ANAL BIOCHEM, V327, P200, DOI 10.1016/j.ab.2004.01.031; Mattoussi H, 2000, J AM CHEM SOC, V122, P12142, DOI 10.1021/ja002535y; Medintz IL, 2003, NAT MATER, V2, P630, DOI 10.1038/nmat961; Michalet X, 2003, ANNU REV BIOPH BIOM, V32, P161, DOI 10.1146/annurev.biophys.32.110601.142525; Michalet X, 2001, SINGLE MOL, V2, P261, DOI 10.1002/1438-5171(200112)2:4<261::AID-SIMO261>3.0.CO;2-P; Mikulec FV, 2000, J AM CHEM SOC, V122, P2532, DOI 10.1021/ja991249n; Mitchell GP, 1999, J AM CHEM SOC, V121, P8122, DOI 10.1021/ja991662v; Mokari T, 2004, SCIENCE, V304, P1787, DOI 10.1126/science.1097830; Nirmal M, 1996, NATURE, V383, P802, DOI 10.1038/383802a0; O'Neal DP, 2004, CANCER LETT, V209, P171, DOI 10.1016/j.canlet.2004.02.004; Osaki F, 2004, J AM CHEM SOC, V126, P6520, DOI 10.1021/ja048792a; Parak WJ, 2002, ADV MATER, V14, P882, DOI 10.1002/1521-4095(20020618)14:12<882::AID-ADMA882>3.0.CO;2-Y; Pathak S, 2001, J AM CHEM SOC, V123, P4103, DOI 10.1021/ja0058334; Patolsky F, 2003, J AM CHEM SOC, V125, P13918, DOI 10.1021/ja035848c; Pellegrino T, 2003, DIFFERENTIATION, V71, P542, DOI 10.1111/j.1432-0436.2003.07109006.x; Pellegrino T, 2004, NANO LETT, V4, P703, DOI 10.1021/nl035172j; Pinaud F, 2004, J AM CHEM SOC, V126, P6115, DOI 10.1021/ja031691c; PINAUD F, UNPUB; Poznyak SK, 2004, NANO LETT, V4, P693, DOI 10.1021/nl049713w; Reiss P, 2002, NANO LETT, V2, P781, DOI 10.1021/nl025596y; Rogach AL, 2001, PHYS STATUS SOLIDI B, V224, P153, DOI 10.1002/1521-3951(200103)224:1<153::AID-PSSB153>3.0.CO;2-3; Rosenthal SJ, 2002, J AM CHEM SOC, V124, P4586, DOI 10.1021/ja003486s; Shim M, 2000, NATURE, V407, P981, DOI 10.1038/35039577; Sukhanova A, 2004, ANAL BIOCHEM, V324, P60, DOI 10.1016/j.ab.2003.09.031; Tkachenko AG, 2004, BIOCONJUGATE CHEM, V15, P482, DOI 10.1021/bc034189q; Tokumasu F, 2003, J MICROSC-OXFORD, V211, P256, DOI 10.1046/j.1365-2818.2003.01219.x; Tsay JM, 2004, J AM CHEM SOC, V126, P1926, DOI 10.1021/ja039227v; TSAY JM, IN PRESS J PHYS CH B; Weiss S, 1999, SCIENCE, V283, P1676, DOI 10.1126/science.283.5408.1676; Whaley SR, 2000, NATURE, V405, P665, DOI 10.1038/35015043; Winter JO, 2001, ADV MATER, V13, P1673, DOI 10.1002/1521-4095(200111)13:22<1673::AID-ADMA1673>3.0.CO;2-6; Wu XY, 2003, NAT BIOTECHNOL, V21, P41, DOI 10.1038/nbt764; Xiao Y, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh024; Yin J, 2004, J AM CHEM SOC, V126, P7754, DOI 10.1021/ja047749k; Yu WW, 2004, CHEM MATER, V16, P3318, DOI 10.1021/cm049476y; Yu WW, 2003, CHEM MATER, V15, P4300, DOI 10.1021/cm034729t; Yu WW, 2004, CHEM MATER, V16, P560, DOI 10.1021/cm033007z; Yu WW, 2002, ANGEW CHEM INT EDIT, V41, P2368, DOI 10.1002/1521-3773(20020703)41:13<2368::AID-ANIE2368>3.0.CO;2-G	82	6609	6920	84	5034	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2005	307	5709					538	544		10.1126/science.1104274	http://dx.doi.org/10.1126/science.1104274			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893BJ	15681376	Green Accepted			2022-12-28	WOS:000226694000036
J	Moles, AT; Ackerly, DD; Webb, CO; Tweddle, JC; Dickie, JB; Westoby, M				Moles, AT; Ackerly, DD; Webb, CO; Tweddle, JC; Dickie, JB; Westoby, M			A brief history of seed size	SCIENCE			English	Article							DISPERSAL; PLANTS; ANGIOSPERMS; MASS; DIVERSIFICATION; EVOLUTION; PATTERNS; TESTS	Improved phylogenies and the accumulation of broad comparative data sets have opened the way for phylogenetic analyses to trace trait evolution in major groups of organisms. We arrayed seed mass data for 12,987 species on the seed plant phylogeny and show the history of seed size from the emergence of the angiosperms through to the present day. The largest single contributor to the present-day spread of seed mass was the divergence between angiosperms and gymnosperms, whereas the widest divergence was between Celastraceae and Parnassiaceae. Wide divergences in seed size were more often associated with divergences in growth form than with divergences in dispersal syndrome or latitude. Cross-species studies and evolutionary theory are consistent with this evidence that growth form and seed size evolve in a coordinated manner.	Natl Ctr Ecol Anal & Synth, Santa Barbara, CA 93101 USA; Macquarie Univ, Dept Biol Sci, Sydney, NSW 2109, Australia; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06520 USA; Museum Nat Hist, London SW7 5BD, England; Royal Bot Gardens, Ardingly RH17 6TN, W Sussex, England	National Center for Ecological Analysis & Synthesis; Macquarie University; Stanford University; Yale University; Natural History Museum London; Royal Botanic Gardens, Kew	Moles, AT (corresponding author), Natl Ctr Ecol Anal & Synth, 735 State St, Santa Barbara, CA 93101 USA.	amotes@bio.mq.edu.au	Moles, Angela T/C-3083-2008; Ackerly, David/A-1247-2009; Webb, Campbell/B-1488-2009	Moles, Angela T/0000-0003-2041-7762; Ackerly, David/0000-0002-1847-7398; Webb, Campbell/0000-0003-1031-3249; Westoby, Mark/0000-0001-7690-4530				Aarssen LW, 2001, ECOSCIENCE, V8, P471, DOI 10.1080/11956860.2001.11682677; Ackerly DD, 2004, EVOL ECOL, V18, P249, DOI 10.1023/B:EVEC.0000035031.50566.60; AXELROD DI, 1959, SCIENCE, V130, P203, DOI 10.1126/science.130.3369.203; Burleigh JG, 2004, AM J BOT, V91, P1599, DOI 10.3732/ajb.91.10.1599; Charnov Eric L., 1993, P1; CRANE PR, 1989, SCIENCE, V246, P675, DOI 10.1126/science.246.4930.675; Donoghue MJ, 2000, CURR BIOL, V10, pR106, DOI 10.1016/S0960-9822(00)00304-3; Eriksson O, 2000, AM NAT, V156, P47, DOI 10.1086/303367; FOSTER SA, 1985, ECOLOGY, V66, P773, DOI 10.2307/1940538; HAIG D, 1991, EVOL ECOL, V5, P231, DOI 10.1007/BF02214230; HAMMOND DS, 1995, ECOLOGY, V76, P2544, DOI 10.2307/2265827; Henery ML, 2001, OIKOS, V92, P479, DOI 10.1034/j.1600-0706.2001.920309.x; Judd W.S., 2002, PLANT SYSTEMATICS PH, V2nd ed., P55; Leishman M. R., 2000, Seeds: the ecology of regeneration in plant communities, P31, DOI 10.1079/9780851994321.0031; LEISHMAN MR, 1995, J ECOL, V83, P517, DOI 10.2307/2261604; LEISHMAN MR, 1994, AM NAT, V143, P890, DOI 10.1086/285638; LEVIN DA, 1974, AM NAT, V108, P193, DOI 10.1086/282899; Lord J, 1997, J BIOGEOGR, V24, P205, DOI 10.1046/j.1365-2699.1997.00126.x; METCALFE DJ, 1995, CAN J BOT, V73, P817, DOI 10.1139/b95-090; Moles AT, 2004, J ECOL, V92, P384, DOI 10.1111/j.0022-0477.2004.00880.x; MOLES AT, UNPUB; Raven JA, 1999, FUNCT ECOL, V13, P5, DOI 10.1046/j.1365-2435.1999.00293.x; SALISBURY E, 1974, PROC R SOC SER B-BIO, V186, P83, DOI 10.1098/rspb.1974.0039; Schmidt M, 2002, J MOL EVOL, V54, P715, DOI 10.1007/s00239-001-0042-9; Soltis DE, 2002, AM J BOT, V89, P1670, DOI 10.3732/ajb.89.10.1670; THOMPSON K, 1993, FUNCT ECOL, V7, P236, DOI 10.2307/2389893; TIFFNEY BH, 1984, ANN MO BOT GARD, V71, P551, DOI 10.2307/2399037; Tiffney BH, 2004, ANNU REV ECOL EVOL S, V35, P1, DOI 10.1146/annurev.ecolsys.34.011802.132535; WARDLE P, 1991, VEGETATION NZ; WEBB CO, IN PRESS MOL ECOL NO; WEBB CO, 2004, PHYLOCOM; Wikstrom N, 2001, P ROY SOC B-BIOL SCI, V268, P2211, DOI 10.1098/rspb.2001.1782; Wing SL, 1998, ANNU REV EARTH PL SC, V26, P379, DOI 10.1146/annurev.earth.26.1.379	33	401	460	4	253	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2005	307	5709					576	580		10.1126/science.1104863	http://dx.doi.org/10.1126/science.1104863			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893BJ	15681384				2022-12-28	WOS:000226694000046
J	Maeda, H; Norum, DVL; Gallagher, TF				Maeda, H; Norum, DVL; Gallagher, TF			Microwave manipulation of an atomic electron in a classical orbit	SCIENCE			English	Article							LAGRANGE EQUILIBRIUM POINTS; NONSPREADING WAVE-PACKETS; CELESTIAL MECHANICS; RYDBERG	Although an atom is a manifestly quantum mechanical system, the electron in an atom can be made to move in a classical orbit almost indefinitely if it is exposed to a weak microwave field oscillating at its orbital frequency. The field effectively tethers the electron, phase-locking its motion to the oscillating microwave field. By exploiting this phase-locking, we have sped up or slowed down the orbital motion of the electron in excited lithium atoms by increasing or decreasing the microwave frequency between 13 and 19 gigahertz; the binding energy and orbital size change concurrently.	Univ Virginia, Dept Phys, Charlottesville, VA 22904 USA	University of Virginia	Maeda, H (corresponding author), Univ Virginia, Dept Phys, 382 McCormick Rd, Charlottesville, VA 22904 USA.	hm3c@virginia.edu						Ahn J, 2000, SCIENCE, V287, P463, DOI 10.1126/science.287.5452.463; Bensky TJ, 1998, PHYS REV LETT, V81, P3112, DOI 10.1103/PhysRevLett.81.3112; BIALYNICKIBIRULA I, 1994, PHYS REV LETT, V73, P1777, DOI 10.1103/PhysRevLett.73.1777; BUCHLEITNER A, 1995, PHYS REV LETT, V75, P1487, DOI 10.1103/PhysRevLett.75.1487; BUCHLEITNER A, 1993, THESIS U P M CURIE; FARRELLY D, 1995, PHYS LETT A, V204, P359, DOI 10.1016/0375-9601(95)00505-W; FARRELLY D, 1995, PHYS REV LETT, V75, P972, DOI 10.1103/PhysRevLett.75.972; Gabrielse G, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.213401; GALLAGHER TF, 1994, RYDBERG ATOMS, P103; Jones RR, 1996, PHYS REV LETT, V76, P3927, DOI 10.1103/PhysRevLett.76.3927; Kalinski M, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.032503; Kalinski M, 1997, OPT EXPRESS, V1, P216, DOI 10.1364/OE.1.000216; Maeda H, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.133004; MEHRA J, 1987, HIST DEV QUANTUM THE, V5, P633; MESSIAH A, 1962, QUANTUM MECH, P216; MULLERDETHLEFS K, 1991, ANNU REV PHYS CHEM, V42, P109, DOI 10.1146/annurev.pc.42.100191.000545; SCHRODINGER E, 1928, COLLECTED PAPERS WAV, P41; SLICHTER CP, 1964, PHYS REV, V135, P1099, DOI 10.1103/PhysRev.135.A1099; SLICHTER CP, 1980, PRINCIPLES MAGNETIC, P25; TENWOLDE A, 1988, PHYS REV LETT, V61, P2099, DOI 10.1103/PhysRevLett.61.2099; Villeneuve DM, 2000, PHYS REV LETT, V85, P542, DOI 10.1103/PhysRevLett.85.542; Wesdorp C, 2000, PHYS REV LETT, V84, P3799, DOI 10.1103/PhysRevLett.84.3799; YEAZELL JA, 1988, PHYS REV LETT, V60, P1494, DOI 10.1103/PhysRevLett.60.1494; YOU D, 1993, OPT LETT, V18, P290, DOI 10.1364/OL.18.000290	24	62	69	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 18	2005	307	5716					1757	1760		10.1126/science.1108470	http://dx.doi.org/10.1126/science.1108470			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909TP	15705805				2022-12-28	WOS:000227883900039
J	Novas, FE; Pol, D				Novas, FE; Pol, D			New evidence on deinonychosaurian dinosaurs from the Late Cretaceous of Patagonia	NATURE			English	Article							CHINA; THEROPOD; ARGENTINA	Most of what is known about the evolution of deinonychosaurs ( that is, the group of theropods most closely related to birds) is based on discoveries from North America and Asia(1). Except for Unenlagia comahuensis(2,3) and some fragmentary remains from northern Africa(4), no other evidence was available on deinonychosaurian diversity in Gondwana. Here we report a new, Late Cretaceous member of the clade, Neuquenraptor argentinus gen. et sp. nov., representing uncontroversial evidence of a deinonychosaurian theropod in the Southern Hemisphere. The new discovery demonstrates that Cretaceous theropod faunas from the southern continents shared greater similarity with those of the northern landmasses than previously thought. Available evidence suggests that deinonychosaurians were probably distributed worldwide at least by the beginning of the Cretaceous period. The phylogenetic position of the new deinonychosaur, as well as other Patagonian coelurosaurian theropods, is compatible with a vicariance model of diversification for some groups of Gondwanan and Laurasian dinosaurs.	Consejo Nacl Invest Cient & Tecn, Museo Argentino Ciencias Nat Bernardino Rivadavia, RA-1405 Buenos Aires, DF, Argentina; Ohio State Univ, Math Biosci Inst, Columbus, OH 43210 USA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Museo Argentino de Ciencias Naturales Bernardino Rivadavia (MACN); University System of Ohio; Ohio State University	Novas, FE (corresponding author), Consejo Nacl Invest Cient & Tecn, Museo Argentino Ciencias Nat Bernardino Rivadavia, Av Angel Gallardo 470, RA-1405 Buenos Aires, DF, Argentina.	fernovas@yahoo.com.ar	Pol, Diego/A-8007-2008	Pol, Diego/0000-0002-9690-7517				Baumel JJ, 1993, HDB AVIAN ANATOMY NO, V23, P45; BONAPARTE JF, 1987, 4 S MES TERR EC SHOR, P24; Bonaparte Jose F., 1996, Muenchner Geowissenschaftliche Abhandlungen Reihe A Geologie und Palaeontologie, V30, P73; Chiappe Luis M., 2002, P87; Clark James M., 2002, P31; Frankfurt NG, 1999, J VERTEBR PALEONTOL, V19, P101, DOI 10.1080/02724634.1999.10011126; Gauthier J.A., 1986, ORIGIN BIRDS EVOLUTI, V8, P1; HOLTZ TR, 1994, J PALEONTOL, V68, P1100, DOI 10.1017/S0022336000026706; Hwang SH, 2002, AM MUS NOVIT, P1, DOI 10.1206/0003-0082(2002)381<0001:NSOMZT>2.0.CO;2; Hwang Sunny H., 2004, Journal of Systematic Palaeontology, V2, P13, DOI 10.1017/S1477201903001081; Leanza HA, 2004, CRETACEOUS RES, V25, P61, DOI 10.1016/j.cretres.2003.10.005; Nelson G., 1981, SYSTEMATICS BIOGEORA; Norell Mark A., 1999, American Museum Novitates, V3282, P1; Novas FE, 1998, J VERTEBR PALEONTOL, V18, P4, DOI 10.1080/02724634.1998.10011030; Novas FE, 2004, LIFE O PAST, P150; Novas FE, 1997, J VERTEBR PALEONTOL, V17, P137, DOI 10.1080/02724634.1997.10010959; Novas FE, 1997, NATURE, V387, P390, DOI 10.1038/387390a0; NOVAS FE, 1996, QUEENSLAND MUS MEM, V39, P675; Novas F, 2004, J VERTEBR PALEONTOL, V24, p98A; Novas Fernando E., 2004, Revista del Museo Argentino de Ciencias Naturales Nueva Serie, V6, P61; Novas Fernando E., 2002, P121; Rauhut Oliver W. M., 1995, Palaeontologische Zeitschrift, V69, P475; Senter Phil, 2004, Bulletin of Gunma Museum of Natural History, V8, P1; Sereno PC, 1999, SCIENCE, V284, P2137, DOI 10.1126/science.284.5423.2137; Upchurch P, 2002, P ROY SOC B-BIOL SCI, V269, P613, DOI 10.1098/rspb.2001.1921; Xu X, 1999, NATURE, V401, P262, DOI 10.1038/45769; Xu X, 2000, NATURE, V408, P705, DOI 10.1038/35047056; Xu X, 2004, NATURE, V431, P838, DOI 10.1038/nature02898; Xu X, 2002, NATURE, V415, P780, DOI 10.1038/415780a; Xu X., 2002, THESIS CHINESE ACAD	30	74	80	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 24	2005	433	7028					858	861		10.1038/nature03285	http://dx.doi.org/10.1038/nature03285			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	899VT	15729340	Green Published			2022-12-28	WOS:000227174600040
J	Gersh, BJ; Stone, GW; White, HD; Holmes, DR				Gersh, BJ; Stone, GW; White, HD; Holmes, DR			Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction - Is the slope of the curve the shape of the future?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ST-SEGMENT-ELEVATION; GLYCOPROTEIN IIB/IIIA INHIBITION; MECHANICAL REPERFUSION THERAPY; OPEN-ARTERY HYPOTHESIS; TO-BALLOON TIME; PRIMARY ANGIOPLASTY; THROMBOLYTIC THERAPY; RANDOMIZED-TRIAL; IMMEDIATE THROMBOLYSIS; PLASMINOGEN-ACTIVATOR	Current options for reperfusion therapy in patients admitted to a community hospital without cardiac catheterization facilities include administration of fibrinolytic drugs followed by observation, with referral to angiography driven by symptoms and signs of ischemia; transfer to a tertiary care center for primary percutaneous coronary intervention (PCI); ora strategy of facilitated PCI in which administration of fibrinolytics and platelet glycoprotein IIb/IIIa inhibitors (alone or in combination) is followed by transfer for immediate angiography and PCI if appropriate. We systematically analyzed multiple randomized and nonrandomized trials to review the pathophysiology of reperfusion therapy in acute myocardial infarction to derive insights about the likelihood of success of a strategy of facilitated PCI compared with transfer only or fibrinolysis only. The basis for the recommendations made herein is a hypothetical curve relating the duration of symptoms before reperfusion to reduction in mortality and extent of myocardial salvage. During the first 2 to 3 hours after symptom onset, a striking benefit of reperfusion is present; within this period, time to treatment is critical. Subsequently, a mortality benefit is still present but of decreasing magnitude over time. In this situation, the priority is to open the artery, and time to treatment is less critical. Results of facilitated PCI may depend largely on timing of presentation. If presentation is late after symptom onset (ie, on the "flat" part of the curve), there will be little mortality benefit from earlier patency and patients will be subject to the bleeding risks of fibrinolytic drugs. In contrast, among patients presenting very early (60-90 minutes after symptom onset), outcomes with fibrinolytic therapy alone are excellent, and it will be difficult for any other strategy to result in a significant improvement. But in patients presenting 2 to 3 hours after onset of symptoms, a strategy of facilitated PCI may move patients from the plateau to the descending limb of the curve, with a substantial improvement in myocardial salvage and mortality. Two large ongoing trials may provide definitive answers to these issues.	Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Rochester, MN 55905 USA; Columbia Univ, Dept Cardiol, New York, NY USA; Cardiovasc Res Fdn, New York, NY USA; Auckland City Hosp, Auckland, New Zealand	Mayo Clinic; Columbia University; Cardiovascular Research Foundation (CRF); Auckland City Hospital	Gersh, BJ (corresponding author), Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA.							Angeja BG, 2002, AM J CARDIOL, V89, P1156, DOI 10.1016/S0002-9149(02)02296-8; [Anonymous], 1986, LANCET, V1, P397; Antoniucci D, 2002, AM J CARDIOL, V89, P1248, DOI 10.1016/S0002-9149(02)02320-2; BARBASH GI, 1990, AM J CARDIOL, V66, P538, DOI 10.1016/0002-9149(90)90478-J; Bax M, 2004, J AM COLL CARDIOL, V43, P534, DOI 10.1016/j.jacc.2003.08.055; BECKER RC, 1995, J AM COLL CARDIOL, V25, P1063, DOI 10.1016/0735-1097(94)00524-T; Berger PB, 1999, CIRCULATION, V100, P14, DOI 10.1161/01.CIR.100.1.14; BERGER PB, 1990, CIRCULATION, V81, P401, DOI 10.1161/01.CIR.81.2.401; Boersma E, 1996, LANCET, V348, P771, DOI 10.1016/S0140-6736(96)02514-7; BRAUNWALD E, 1989, CIRCULATION, V79, P441, DOI 10.1161/01.CIR.79.2.441; Brodie BR, 2000, AM J CARDIOL, V85, P13, DOI 10.1016/S0002-9149(99)00598-6; Brodie BR, 2003, J AM COLL CARDIOL, V41, p368A; Brodie BR, 2001, AM J CARDIOL, V88, P1085, DOI 10.1016/S0002-9149(01)02039-2; CALIFF RM, 1989, J AM COLL CARDIOL, V14, P1382, DOI 10.1016/0735-1097(89)90445-2; Cannon CP, 2000, JAMA-J AM MED ASSOC, V283, P2941, DOI 10.1001/jama.283.22.2941; Canto JG, 2002, CIRCULATION, V106, P3018, DOI 10.1161/01.CIR.0000041246.20352.03; Canto JG, 1999, CLIN CARDIOL, V22, P519, DOI 10.1002/clc.4960220806; Dalby M, 2003, CIRCULATION, V108, P1809, DOI 10.1161/01.CIR.0000091088.63921.8C; De Luca G, 2004, J AM COLL CARDIOL, V43, P1363, DOI 10.1016/j.jacc.2003.11.042; De Luca G, 2004, CIRCULATION, V109, P1223, DOI 10.1161/01.CIR.0000121424.76486.20; De Luca G, 2003, J AM COLL CARDIOL, V42, P991, DOI 10.1016/S0735-1097(03)00919-7; DEBONO DP, 1991, BMJ-BRIT MED J, V302, P555; Eagle KA, 2002, LANCET, V359, P373, DOI 10.1016/S0140-6736(02)07595-5; Eisenberg MJ, 2003, J AM COLL CARDIOL, V42, P1, DOI 10.1016/S0735-1097(03)00566-7; Ellis SG, 2004, AM HEART J, V147, DOI 10.1016/j.ahj.2003.07.025; Fernandez-Aviles F, 2004, LANCET, V364, P1045, DOI 10.1016/S0140-6736(04)17059-1; Fernandez-Aviles F, 2003, CIRCULATION, V108, P468; French JK, 2003, AM HEART J, V146, P804, DOI 10.1016/S0002-8703(03)00392-2; GERSH BJ, 1993, CIRCULATION, V88, P296, DOI 10.1161/01.CIR.88.1.296; Gibson CM, 2000, CIRCULATION, V101, P125, DOI 10.1161/01.CIR.101.2.125; Giugliano RP, 2003, CIRCULATION, V108, P2828, DOI 10.1161/01.CIR.0000106684.71725.98; Grech ED, 2000, AM J CARDIOL, V86, P400, DOI 10.1016/S0002-9149(00)00954-1; Halkin A, 2004, J AM COLL CARDIOL, V43, P1780, DOI 10.1016/j.jacc.2003.10.068; Herrmann HC, 2000, J AM COLL CARDIOL, V36, P1489, DOI 10.1016/S0735-1097(00)00923-2; HONAN MB, 1990, J AM COLL CARDIOL, V16, P359, DOI 10.1016/0735-1097(90)90586-E; Kastrati A, 2004, JAMA-J AM MED ASSOC, V291, P947, DOI 10.1001/jama.291.8.947; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; LEMAY M, 2004, ANN SCI SESS AM COLL; LEW AS, 1985, CIRCULATION, V72, P1053, DOI 10.1161/01.CIR.72.5.1053; Magid DJ, 2000, JAMA-J AM MED ASSOC, V284, P3131, DOI 10.1001/jama.284.24.3131; Mathew V, 2004, EUR HEART J, V25, P2177, DOI 10.1016/j.ehj.2004.10.002; Moliterno DJ, 2003, J AM COLL CARDIOL, V41, p49S, DOI 10.1016/S0735-1097(02)02835-8; Nallamothu BK, 2003, AM J CARDIOL, V92, P824, DOI 10.1016/S0002-9149(03)00891-9; O'Neill WW, 2003, J AM COLL CARDIOL, V42, P17, DOI 10.1016/S0735-1097(03)00507-2; ONEILL WW, 1992, CIRCULATION, V86, P1710, DOI 10.1161/01.CIR.86.6.1710; Prasad A, 2004, AM HEART J, V147, P669, DOI 10.1016/j.ahj.2003.11.010; REIMER KA, 1979, LAB INVEST, V40, P633; Roe MT, 2001, J AM COLL CARDIOL, V37, P9, DOI 10.1016/S0735-1097(00)01101-3; Rogers WJ, 2000, J AM COLL CARDIOL, V36, P2056, DOI 10.1016/S0735-1097(00)00996-7; ROGERS WJ, 1990, CIRCULATION, V81, P1457, DOI 10.1161/01.CIR.81.5.1457; Ross AM, 1999, J AM COLL CARDIOL, V34, P1954, DOI 10.1016/S0735-1097(99)00444-1; Sadanandan S, 2001, AM HEART J, V142, P411, DOI 10.1067/mhj.2001.117774; Scheller B, 2003, J AM COLL CARDIOL, V42, P634, DOI 10.1016/S0735-1097(03)00763-0; Schomig A, 2004, J AM COLL CARDIOL, V44, P2073, DOI 10.1016/j.jacc.2004.09.043; Schomig A, 2003, CIRCULATION, V108, P1084, DOI 10.1161/01.CIR.0000086346.32856.9C; Schweiger MJ, 2001, AM J CARDIOL, V88, P831, DOI 10.1016/S0002-9149(01)01887-2; SIMOONS ML, 1988, LANCET, V1, P199; Singh M, 2004, MAYO CLIN PROC, V79, P738; Singh M, 2002, J AM COLL CARDIOL, V39, P1881, DOI 10.1016/S0735-1097(02)01901-0; Steg PG, 2004, EUR HEART J, V25, P2187, DOI 10.1016/j.ehj.2004.10.019; Steg PG, 2003, CIRCULATION, V108, P2851, DOI 10.1161/01.CIR.0000103122.10021.F2; Stone GW, 2002, NEW ENGL J MED, V346, P957, DOI 10.1056/NEJMoa013404; Stone GW, 2001, CIRCULATION, V104, P636, DOI 10.1161/hc3101.093701; Sutton AGC, 2004, J AM COLL CARDIOL, V44, P287, DOI 10.1016/j.jacc.2003.12.059; Taher T, 2004, J AM COLL CARDIOL, V44, P38, DOI 10.1016/j.jacc.2004.03.041; Tcheng JE, 2003, CIRCULATION, V108, P1316, DOI 10.1161/01.CIR.0000087601.45803.86; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; Topol EJ, 2003, J AM COLL CARDIOL, V42, P1886, DOI 10.1016/j.jacc.2003.09.010; Van de Werf F, 2001, EUR HEART J, V22, P2253, DOI 10.1053/euhj.2001.2686; VANTHOF A, 2003, ANN SCI SESS AM COLL; Verheugt FWA, 2004, LANCET, V364, P1014, DOI 10.1016/S0140-6736(04)17072-4; Vermeer F, 1999, HEART, V82, P426, DOI 10.1136/hrt.82.4.426; Waters RE, 2004, J AM COLL CARDIOL, V43, P2153, DOI 10.1016/j.jacc.2003.12.057; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; Welsh RC, 2003, AM HEART J, V145, P1, DOI 10.1067/mhj.2003.47; Wennberg DE, 2004, JAMA-J AM MED ASSOC, V292, P1961, DOI 10.1001/jama.292.16.1961; White HD, 2000, LANCET, V356, P2028, DOI 10.1016/S0140-6736(00)03397-3; Widimsky P, 2000, EUR HEART J, V21, P823, DOI 10.1053/euhj.1999.1993; Widimsky P, 2003, EUR HEART J, V24, P94, DOI 10.1016/S0195-668X(02)00468-2; Zeymer U, 1999, AM HEART J, V137, P34, DOI 10.1016/S0002-8703(99)70457-6	80	310	324	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	2005	293	8					979	986		10.1001/jama.293.8.979	http://dx.doi.org/10.1001/jama.293.8.979			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899LR	15728169				2022-12-28	WOS:000227146400020
J	Jenssen, TK; Hovig, E				Jenssen, TK; Hovig, E			Gene-expression profiling in breast cancer	LANCET			English	Editorial Material							SIGNATURE; PATTERNS		PubGene AS, NO-0319 Vinderen, Norway; Norwegian Radium Hosp, Inst Canc Res, Dept Tumor Biol, Montebello, Norway	University of Oslo	Jenssen, TK (corresponding author), PubGene AS, NO-0319 Vinderen, Norway.	tkj@pubgene.com	Hovig, Eivind/H-2474-2011	Hovig, Eivind/0000-0002-9103-1077				Cleator S, 2004, BRIT J CANCER, V90, P1120, DOI 10.1038/sj.bjc.6601667; Ein-Dor L, 2005, BIOINFORMATICS, V21, P171, DOI 10.1093/bioinformatics/bth469; Gruvberger S, 2001, CANCER RES, V61, P5979; Gruvberger SK, 2003, BREAST CANCER RES, V5, P23, DOI 10.1186/bcr548; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Shi LM, 2004, EXPERT REV MOL DIAGN, V4, P761, DOI 10.1586/14737159.4.6.761; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998	11	28	29	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 19	2005	365	9460					634	635						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	898SP	15721457				2022-12-28	WOS:000227096800005
J	Rondelez, Y; Tresset, G; Nakashima, T; Kato-Yamada, Y; Fujita, H; Takeuchi, S; Noji, H				Rondelez, Y; Tresset, G; Nakashima, T; Kato-Yamada, Y; Fujita, H; Takeuchi, S; Noji, H			Highly coupled ATP synthesis by F-1-ATPase single molecules	NATURE			English	Article							EPSILON-SUBUNIT; ESCHERICHIA-COLI; THERMOPHILIC F1-ATPASE; F0F1-ATP SYNTHASE; ROTATION; RESOLUTION; CATALYSIS; ENZYME; MOTOR	F-1-ATPase is the smallest known rotary motor, and it rotates in an anticlockwise direction as it hydrolyses ATP(1-5). Single-molecule experiments(6-9) point towards three catalytic events per turn, in agreement with the molecular structure of the complex(10). The physiological function of F-1 is ATP synthesis. In the ubiquitous F0F1 complex, this energetically uphill reaction is driven by F-0, the partner motor of F-1, which forces the backward ( clockwise) rotation of F-1, leading to ATP synthesis(11-13). Here, we have devised an experiment combining single- molecule manipulation and microfabrication techniques to measure the yield of this mechanochemical transformation. Single F-1 molecules were enclosed in femtolitre-sized hermetic chambers and rotated in a clockwise direction using magnetic tweezers. When the magnetic field was switched off, the F-1 molecule underwent anticlockwise rotation at a speed proportional to the amount of synthesized ATP. At 10 Hz, the mechanochemical coupling efficiency was low for the alpha(3)beta(3)gamma subcomplex (F-1(-epsilon)), but reached up to 77% after reconstitution with the epsilon-subunit (F-1(+epsilon)). We provide here direct evidence that F-1 is designed to tightly couple its catalytic reactions with the mechanical rotation. Our results suggest that the epsilon-subunit has an essential function during ATP synthesis.	Univ Tokyo, Inst Ind Sci, Tokyo 1538505, Japan; Univ Tokyo, CNRS IIS, LIMMS, Tokyo 1538505, Japan; Rikkyo St Pauls Univ, Coll Sci, Dept Life Sci, Tokyo 1718501, Japan; Univ Tokyo, Inst Ind Sci, CIRMM, Tokyo 1538505, Japan	University of Tokyo; University of Tokyo; Rikkyo University; University of Tokyo	Noji, H (corresponding author), Univ Tokyo, Inst Ind Sci, Tokyo 1538505, Japan.	hnoji@iis.u-tokyo.ac.jp	Takeuchi, Shoji/J-5349-2019; Rondelez, Yannick/F-3315-2014; Tresset, Guillaume/B-9009-2008	Rondelez, Yannick/0000-0002-2565-476X; Takeuchi, Shoji/0000-0001-6946-0409				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Adachi K, 2003, METHOD ENZYMOL, V361, P211; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Bulygin VV, 2004, J BIOL CHEM, V279, P35616, DOI 10.1074/jbc.M405012200; Diez M, 2004, NAT STRUCT MOL BIOL, V11, P135, DOI 10.1038/nsmb718; DUNN SD, 1987, BIOCHEMISTRY-US, V26, P4488, DOI 10.1021/bi00388a047; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Hirono-Hara Y, 2001, P NATL ACAD SCI USA, V98, P13649, DOI 10.1073/pnas.241365698; HIRONOHARA Y, IN PRESS P NATL ACAD; Itoh H, 2004, NATURE, V427, P465, DOI 10.1038/nature02212; Kato Y, 1997, J BIOL CHEM, V272, P24906, DOI 10.1074/jbc.272.40.24906; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; Kinosita K Jr, 2000, Essays Biochem, V35, P3; LAGET PP, 1979, ARCH BIOCHEM BIOPHYS, V197, P83, DOI 10.1016/0003-9861(79)90222-4; Leslie AGW, 2000, PHILOS T ROY SOC B, V355, P465, DOI 10.1098/rstb.2000.0588; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; McDonald JC, 2002, ACCOUNTS CHEM RES, V35, P491, DOI 10.1021/ar010110q; Nishizaka T, 2004, NAT STRUCT MOL BIOL, V11, P142, DOI 10.1038/nsmb721; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 2001, J BIOL CHEM, V276, P25480, DOI 10.1074/jbc.M102200200; Nowak KF, 2002, BIOCHEMISTRY-US, V41, P15130, DOI 10.1021/bi026594v; RONDELEZ Y, IN PRESS NATURE BIOT; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; Suzuki T, 2003, J BIOL CHEM, V278, P46840, DOI 10.1074/jbc.M307165200; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P6560, DOI 10.1073/pnas.111128098; Unger MA, 2000, SCIENCE, V288, P113, DOI 10.1126/science.288.5463.113; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P10583, DOI 10.1073/pnas.94.20.10583	30	264	281	3	70	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	2005	433	7027					773	777		10.1038/nature03277	http://dx.doi.org/10.1038/nature03277			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897XH	15716957	Bronze			2022-12-28	WOS:000227039200046
J	Rosenfield, A; Schwartz, K				Rosenfield, A; Schwartz, K			Population and development - Shifting paradigms, setting goals	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Columbia Univ, Mailman Sch Publ Hlth, New York, NY 10027 USA	Columbia University	Rosenfield, A (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, New York, NY 10027 USA.							Population Reference Bureau, 2004, 2004 WORLD POP DAT S; ROSENFIELD A., 1982, International Family Planning Perspectives, V8, P43, DOI 10.2307/2948087; Sinding S. W., 1994, International Family Planning Perspectives, V20, P23, DOI 10.2307/2133334; Sinding Steven, 1994, INT FAMILY PLANNING, V20, P32; *UN POP FUND, 2004, STAT WORLD POP REP 2; United Nations, 1999, WORLD 6 BILL	6	9	9	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2005	352	7					647	649		10.1056/NEJMp048281	http://dx.doi.org/10.1056/NEJMp048281			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	897UO	15716556				2022-12-28	WOS:000227031100001
J	Wong, CA; Scavone, BM; Peaceman, AM; McCarthy, RJ; Sullivan, JT; Diaz, NT; Yaghmour, E; Marcus, RJL; Sherwani, SS; Sproviero, MT; Yilmaz, M; Patel, R; Robles, C; Grouper, S				Wong, CA; Scavone, BM; Peaceman, AM; McCarthy, RJ; Sullivan, JT; Diaz, NT; Yaghmour, E; Marcus, RJL; Sherwani, SS; Sproviero, MT; Yilmaz, M; Patel, R; Robles, C; Grouper, S			The risk of cesarean delivery with neuraxial analgesia given early versus late in labor	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SPINAL-EPIDURAL ANALGESIA; INTRAVENOUS MEPERIDINE; NULLIPAROUS WOMEN; PAIN; MORPHINE; OPIOIDS	BACKGROUND: Epidural analgesia initiated early in labor (when the cervix is less than 4.0 cm dilated) has been associated with an increased risk of cesarean delivery. It is unclear, however, whether this increase in risk is due to the analgesia or is attributable to other factors. METHODS: We conducted a randomized trial of 750 nulliparous women at term who were in spontaneous labor or had spontaneous rupture of the membranes and who had a cervical dilatation of less than 4.0 cm. Women were randomly assigned to receive intrathecal fentanyl or systemic hydromorphone at the first request for analgesia. Epidural analgesia was initiated in the intrathecal group at the second request for analgesia and in the systemic group at a cervical dilatation of 4.0 cm or greater or at the third request for analgesia. The primary outcome was the rate of cesarean delivery. RESULTS: The rate of cesarean delivery was not significantly different between the groups (17.8 percent after intrathecal analgesia vs. 20.7 percent after systemic analgesia; 95 percent confidence interval for the difference, -9.0 to 3.0 percentage points; P=0.31). The median time from the initiation of analgesia to complete dilatation was significantly shorter after intrathecal analgesia than after systemic analgesia (295 minutes vs. 385 minutes, P<0.001), as was the time to vaginal delivery (398 minutes vs. 479 minutes, P<0.001). Pain scores after the first intervention were significantly lower after intrathecal analgesia than after systemic analgesia (2 vs. 6 on a 0-to-10 scale, P<0.001). The incidence of one-minute Apgar scores below 7 was significantly higher after systemic analgesia (24.0 percent vs. 16.7 percent, P=0.01). CONCLUSIONS: Neuraxial analgesia in early labor did not increase the rate of cesarean delivery, and it provided better analgesia and resulted in a shorter duration of labor than systemic analgesia.	Northwestern Univ, Feinberg Sch Med, Dept Anesthesiol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Obstet & Gynecol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Wong, CA (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Anesthesiol, 251 E Huron,F 5-704, Chicago, IL 60611 USA.	c-wong2@northwestern.edu	McCarthy, Robert J/J-9113-2018	McCarthy, Robert J/0000-0002-0966-5311; Wong, Cynthia/0000-0002-7144-7008; Sullivan, John/0000-0001-5445-708X; Peaceman, Alan/0000-0002-4515-4850				Alexander JM, 2001, ANESTH ANALG, V92, P1524; CAMANN WR, 1991, BRIT J ANAESTH, V67, P565, DOI 10.1093/bja/67.5.565; Cascio M, 1997, CAN J ANAESTH, V44, P605, DOI 10.1007/BF03015443; CHESTNUT DH, 1994, ANESTHESIOLOGY, V80, P1201, DOI 10.1097/00000542-199406000-00006; CHESTNUT DH, 1994, ANESTHESIOLOGY, V80, P1193, DOI 10.1097/00000542-199406000-00005; Gambling DR, 1998, ANESTHESIOLOGY, V89, P1336, DOI 10.1097/00000542-199812000-00010; Goetzl Laura M, 2002, Obstet Gynecol, V100, P177; Halpern SH, 1998, JAMA-J AM MED ASSOC, V280, P2105, DOI 10.1001/jama.280.24.2105; Hess PE, 2001, ANESTH ANALG, V93, P414; Hess PE, 2000, ANESTH ANALG, V90, P881, DOI 10.1213/00000539-200004000-00020; Hughes SC, 1997, INT J OBSTET ANESTH, V6, P145, DOI 10.1016/S0959-289X(97)80077-5; Kowalski WB, 1998, BIOL REPROD, V58, P971, DOI 10.1095/biolreprod58.4.971; Leighton BL, 1999, ANESTHESIOLOGY, V90, P1039, DOI 10.1097/00000542-199904000-00017; Leighton BL, 1999, ANESTHESIOLOGY, V91, pU472; Lieberman E, 1997, PEDIATRICS, V99, P415, DOI 10.1542/peds.99.3.415; Luxman D, 1998, INT J OBSTET ANESTH, V7, P161, DOI 10.1016/S0959-289X(98)80004-6; MacArthur C, 2001, LANCET, V358, P19; Mardirosoff C, 2002, BJOG-INT J OBSTET GY, V109, P274, DOI 10.1111/j.1471-0528.2002.01380.x; Nageotte MP, 1997, NEW ENGL J MED, V337, P1715, DOI 10.1056/NEJM199712113372402; NEUMARK J, 1985, ACTA ANAESTH SCAND, V29, P555, DOI 10.1111/j.1399-6576.1985.tb02253.x; Panni MK, 2003, ANESTHESIOLOGY, V98, P957, DOI 10.1097/00000542-200304000-00024; PETRIE RH, 1993, J MATERNAL FETAL MED, V2, P159; Seyb ST, 1999, OBSTET GYNECOL, V94, P600, DOI 10.1016/S0029-7844(99)00377-4; Sharma SK, 2002, ANESTHESIOLOGY, V96, P546, DOI 10.1097/00000542-200203000-00007; SIVALINGAM T, 1985, BRIT J ANAESTH, V57, P430, DOI 10.1093/bja/57.4.430; THORP JA, 1993, AM J OBSTET GYNECOL, V169, P851, DOI 10.1016/0002-9378(93)90015-B; Tsen LC, 1999, ANESTHESIOLOGY, V91, P920, DOI 10.1097/00000542-199910000-00010; WONG CA, 2002, ANESTHESIOLOGY S1, V96; Yoo KY, 2001, ANESTH ANALG, V92, P1006	29	221	251	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2005	352	7					655	665		10.1056/NEJMoa042573	http://dx.doi.org/10.1056/NEJMoa042573			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897UO	15716559				2022-12-28	WOS:000227031100004
J	Choudhry, NK; Fletcher, RH; Soumerai, SB				Choudhry, NK; Fletcher, RH; Soumerai, SB			Systematic review: The relationship between clinical experience and quality of health care	ANNALS OF INTERNAL MEDICINE			English	Review							PHYSICIAN CHARACTERISTICS; PRACTICE BEHAVIORS; DIABETES-MELLITUS; PRACTICE PATTERNS; KNOWLEDGE-BASE; MEDICALLY ILL; OF-CARE; PATIENT; MANAGEMENT; MORTALITY	Background: Physicians with more experience are generally believed to have accumulated knowledge and skills during years in practice and therefore to deliver high-quality care. However, evidence suggests that there is an inverse relationship between the number of years that a physician has been in practice and the quality of care that the physician provides. Purpose: To systematically review studies relating medical knowledge and health care quality to years in practice and physician age. Data Sources: English-language articles in MEDLINE from 1966 to June 2004 and reference lists of retrieved articles. Study Selection: Studies that provided empirical results about knowledge or a quality-of-care outcome and included years since graduation or physician age as explanatory variables. Data Extraction: We categorized studies on the basis of the nature of the association between years in practice or age and performance. Data Synthesis: Overall, 32 of the 62 (52%) evaluations reported decreasing performance with increasing years in practice for all outcomes assessed; 13 (21%) reported decreasing performance with increasing experience for some outcomes but no association for others; 2 (3%) reported that performance initially increased with increasing experience, peaked, and then decreased (concave relationship); 13 (21%) reported no association, 1 (2%) reported increasing performance with increasing years in practice for some outcomes but no association for others; and 1 (2%) reported increasing performance with increasing years in practice for all outcomes. Results did not change substantially when the analysis was restricted to studies that used the most objective outcome measures. Limitations: Because of the lack of reliable search terms for physician experience, reports that provided relevant data may have been missed. Conclusions: Physicians who have been in practice longer may be at risk for providing lower-quality care. Therefore, this subgroup of physicians may need quality improvement interventions.	Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Brigham & Womens Hosp, Harvard Pilgrim Hlth Care, Boston, MA 02115 USA; Harvard Univ, PhD Program Hlth Policy, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Harvard University; Brigham & Women's Hospital; Harvard University	Choudhry, NK (corresponding author), Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, 133 Brookline Ave,6th Floor, Boston, MA 02215 USA.	choudhry@fas.harvard.edu	Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285				Adams AS, 1999, INT J QUAL HEALTH C, V11, P187, DOI 10.1093/intqhc/11.3.187; Anderson G M, 1997, J Eval Clin Pract, V3, P283, DOI 10.1046/j.1365-2753.1997.t01-1-00005.x; Anis NA, 2004, PREV MED, V38, P198, DOI 10.1016/j.ypmed.2003.09.046; AUBIN M, 1994, CAN MED ASSOC J, V150, P509; AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; Beaulieu MD, 2001, QJM-INT J MED, V94, P301, DOI 10.1093/qjmed/94.6.301; BECKER MH, 1971, HEALTH SERV REP, V86, P993, DOI 10.2307/4594369; BEERS MH, 1993, J AM GERIATR SOC, V41, P802, DOI 10.1111/j.1532-5415.1993.tb06173.x; Birkmeyer JD, 2003, NEW ENGL J MED, V349, P2117, DOI 10.1056/NEJMsa035205; Blanc PD, 2003, AM J MED, V114, P581, DOI 10.1016/S0002-9343(03)00053-6; BLANCHARD CG, 1990, CANCER, V65, P186, DOI 10.1002/1097-0142(19900101)65:1<186::AID-CNCR2820650136>3.0.CO;2-4; BURNS LR, 1991, MED CARE, V29, P251, DOI 10.1097/00005650-199103000-00007; Carthy P, 2000, FAM PRACT, V17, P36, DOI 10.1093/fampra/17.1.36; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Cook RL, 2001, J ADOLESCENT HEALTH, V28, P204, DOI 10.1016/S1054-139X(00)00152-X; CRUFT GE, 1981, ARCH SURG-CHICAGO, V116, P1093; CZAJA R, 1994, ANN INTERN MED, V120, P602, DOI 10.7326/0003-4819-120-7-199404010-00012; DAVIDSON W, 1995, CAN MED ASSOC J, V152, P1227; Dhalla IA, 2002, J AM GERIATR SOC, V50, P995, DOI 10.1046/j.1532-5415.2002.50252.x; Ely J W, 1998, Fam Med, V30, P34; Epstein SA, 2001, PSYCHOSOMATICS, V42, P482, DOI 10.1176/appi.psy.42.6.482; Epstein SA, 1996, PSYCHOSOMATICS, V37, P356, DOI 10.1016/S0033-3182(96)71549-9; EVANS CE, 1984, CAN MED ASSOC J, V130, P719; Fehrenbach SN, 2001, AM J MANAG CARE, V7, P717; FORD LG, 1987, J CLIN ONCOL, V5, P504, DOI 10.1200/JCO.1987.5.3.504; FREIMAN MP, 1985, MED CARE, V23, P939, DOI 10.1097/00005650-198508000-00001; Geller SE, 1996, HEALTH SERV RES, V30, P729; GEMSON DH, 1991, ARCH INTERN MED, V151, P1102, DOI 10.1001/archinte.151.6.1102; Golden NH, 2001, PEDIATRICS, V107, P287, DOI 10.1542/peds.107.2.287; Greer A L, 1988, Int J Technol Assess Health Care, V4, P5; GRIMSHAW JM, 2001, MED CARE S, V39, P112; HALL JA, 1994, MED CARE, V32, P1216, DOI 10.1097/00005650-199412000-00005; Halm EA, 2002, ANN INTERN MED, V137, P511, DOI 10.7326/0003-4819-137-6-200209170-00012; Hartz AJ, 1999, MED CARE, V37, P93, DOI 10.1097/00005650-199901000-00013; Heath K, 1997, INT J STD AIDS, V8, P609, DOI 10.1258/0956462971918869; HLATKY MA, 1988, AM J CARDIOL, V61, P510, DOI 10.1016/0002-9149(88)90755-2; HULKA BS, 1976, AM J PUBLIC HEALTH, V66, P1173, DOI 10.2105/AJPH.66.12.1173; HYNES DM, 1994, MED CARE, V32, P328, DOI 10.1097/00005650-199404000-00002; Jackson JL, 2001, SOC SCI MED, V52, P609, DOI 10.1016/S0277-9536(00)00164-7; JACQUES CHM, 1991, DIABETES CARE, V14, P712, DOI 10.2337/diacare.14.8.712; Jencks SF, 2000, JAMA-J AM MED ASSOC, V284, P1670, DOI 10.1001/jama.284.13.1670; Jha AK, 2003, NEW ENGL J MED, V348, P2218, DOI 10.1056/NEJMsa021899; Katon W, 2000, MED CARE, V38, P552, DOI 10.1097/00005650-200006000-00002; KENNY SJ, 1993, DIABETES CARE, V16, P1507, DOI 10.2337/diacare.16.11.1507; LEWIS CE, 1987, AM J PUBLIC HEALTH, V77, P795, DOI 10.2105/AJPH.77.7.795; Marrero D G, 1991, J Community Health, V16, P259, DOI 10.1007/BF01320334; MCFALL SL, 1994, MED CARE, V32, P106, DOI 10.1097/00005650-199402000-00002; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; MESKAUSKAS JA, 1975, ANN INTERN MED, V82, P577, DOI 10.7326/0003-4819-82-4-577; Montaner J S, 1996, Antivir Ther, V1, P157; Moride Y, 2002, J AM GERIATR SOC, V50, P1365, DOI 10.1046/j.1532-5415.2002.50357.x; Norcini JJ, 2000, ACAD MED, V75, P1193, DOI 10.1097/00001888-200012000-00016; NORCINI JJ, 1985, ANN INTERN MED, V102, P385, DOI 10.7326/0003-4819-102-3-385; O'Neill L, 2000, NEUROLOGY, V55, P773, DOI 10.1212/WNL.55.6.773; PAYNE BC, 1984, HEALTH SERV RES, V19, P307; RAMSEY PG, 1991, JAMA-J AM MED ASSOC, V266, P1103, DOI 10.1001/jama.266.8.1103; Rattay KT, 2004, OBES RES, V12, P161, DOI 10.1038/oby.2004.21; RAY WA, 1976, ANN INTERN MED, V84, P266, DOI 10.7326/0003-4819-84-3-266; RHEE SO, 1976, MED CARE, V14, P733, DOI 10.1097/00005650-197609000-00002; Richards C, 1998, AM J PREV MED, V15, P246, DOI 10.1016/S0749-3797(98)00075-0; Roetzheim R G, 1991, J Fla Med Assoc, V78, P426; Roy-Byrne Peter, 2002, J Am Board Fam Pract, V15, P443; SALEMSCHATZ SR, 1990, JAMA-J AM MED ASSOC, V264, P476, DOI 10.1001/jama.264.4.476; SANAZARO PJ, 1985, MED CARE, V23, P1097, DOI 10.1097/00005650-198509000-00007; Saraiya M, 2002, AM J PUBLIC HEALTH, V92, P826, DOI 10.2105/AJPH.92.5.826; Schmittdiel J, 1997, JAMA-J AM MED ASSOC, V278, P1596, DOI 10.1001/jama.278.19.1596; Schroen AT, 2000, CHEST, V118, P129, DOI 10.1378/chest.118.1.129; Schuster MA, 1998, MILBANK Q, V76, P517, DOI 10.1111/1468-0009.00105; SCHWARTZ JS, 1991, ANN INTERN MED, V114, P46, DOI 10.7326/0003-4819-114-1-46; SHAPIRO JA, 1989, BRIT MED J, V298, P1563, DOI 10.1136/bmj.298.6687.1563; SHERMAN SE, 1993, J GEN INTERN MED, V8, P243, DOI 10.1007/BF02600089; Skotniski EM, 1996, CAN J PUBLIC HEALTH, V87, P172; Stolley P D, 1972, Med Care, V10, P17, DOI 10.1097/00005650-197201000-00003; Streja DA, 1999, ARCH INTERN MED, V159, P294, DOI 10.1001/archinte.159.3.294; Thompson JW, 2003, JAMA-J AM MED ASSOC, V290, P1486, DOI 10.1001/jama.290.11.1486; Tu JV, 2001, JAMA-J AM MED ASSOC, V285, P3116, DOI 10.1001/jama.285.24.3116; Willison DJ, 2000, MED CARE, V38, P1092, DOI 10.1097/00005650-200011000-00004; YOUNG MJ, 1987, HEALTH SERV RES, V22, P623; Zerr DM, 1999, PEDIATR INFECT DIS J, V18, P232, DOI 10.1097/00006454-199903000-00005	79	892	914	0	44	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	2005	142	4					260	273		10.7326/0003-4819-142-4-200502150-00008	http://dx.doi.org/10.7326/0003-4819-142-4-200502150-00008			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	900UJ	15710959				2022-12-28	WOS:000227239500004
J	Valadkhan, S				Valadkhan, S			Construction of a minimal, protein-free spliceosome	SCIENCE			English	Editorial Material							TERTIARY INTERACTION; SNRNAS; U6		Case Western Reserve Univ, Cleveland, OH 44106 USA	Case Western Reserve University	Valadkhan, S (corresponding author), Case Western Reserve Univ, 2109 Adelbert Rd,Wood RT 100-8, Cleveland, OH 44106 USA.	saba.valadkhan@case.edu	Valadkhan, Saba/G-5561-2010; Valadkhan, Saba/G-7271-2012					Collins CA, 2000, NAT STRUCT BIOL, V7, P850; MADHANI HD, 1994, GENE DEV, V8, P1071, DOI 10.1101/gad.8.9.1071; Nilsen TW, 2003, BIOESSAYS, V25, P1147, DOI 10.1002/bies.10394; Valadkhan S, 2000, RNA, V6, P206, DOI 10.1017/S1355838200992197; Valadkhan S, 2003, RNA, V9, P892, DOI 10.1261/rna.5440303; Valadkhan S, 2002, NAT STRUCT BIOL, V9, P498, DOI 10.1038/nsb0702-498; Valadkhan S, 2001, NATURE, V413, P701, DOI 10.1038/35099500; YU YT, 1993, CELL, V75, P1049, DOI 10.1016/0092-8674(93)90315-H	8	2	2	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2005	307	5711					863	864		10.1126/science.1110022	http://dx.doi.org/10.1126/science.1110022			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897DV	15705832				2022-12-28	WOS:000226985100034
J	Weller, PF; Durand, ML; Pilch, BZ; Harris, NL; Kazda, G; Ryan, ET; Hooper, D				Weller, PF; Durand, ML; Pilch, BZ; Harris, NL; Kazda, G; Ryan, ET; Hooper, D			Case 4-2005: A 35-year-old man with nasal congestion, swelling, and pain - Mucocutaneous leishmaniasis due to infection by Leishmania viannia braziliensis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MUCOSAL LEISHMANIASIS; ESPUNDIA		Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Allerg & Inflammat, Boston, MA 02215 USA; Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA; Massachusetts Eye & Ear Infirm, Infect Dis Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Eye & Ear Infirmary; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Weller, PF (corresponding author), Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA.							Almeida OP, 2003, CRIT REV ORAL BIOL M, V14, P377, DOI 10.1177/154411130301400508; Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002; Berman JD, 1997, CLIN INFECT DIS, V24, P684, DOI 10.1093/clind/24.4.684; CONNOR DH, 1976, PATHOLOGY TROPICAL E, V1, P258; de Castro CC, 1999, BRIT J RADIOL, V72, P717, DOI 10.1259/bjr.72.859.10624334; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Jha TK, 1999, NEW ENGL J MED, V341, P1795, DOI 10.1056/NEJM199912093412403; MARSDEN PD, 1986, T ROY SOC TROP MED H, V80, P859, DOI 10.1016/0035-9203(86)90243-9; Mota Sasaki Md, 1997, Braz J Infect Dis, V1, P142; Pearson RD, 1996, CLIN INFECT DIS, V22, P1, DOI 10.1093/clinids/22.1.1; PEARSON RD, 1999, TROPICAL INFECT DIS, P797; PETZLERLER ML, 1991, HUM IMMUNOL, V32, P254, DOI 10.1016/0198-8859(91)90088-Q; Pirmez C, 1999, J CLIN MICROBIOL, V37, P1819, DOI 10.1128/JCM.37.6.1819-1823.1999; SAENZ RE, 1991, AM J TROP MED HYG, V44, P394, DOI 10.4269/ajtmh.1991.44.394; Scope A, 2003, CLIN INFECT DIS, V37, pE83, DOI 10.1086/377045; Soto J, 2001, Clin Infect Dis, V33, pE57, DOI 10.1086/322689; WALTON BC, 1973, AM J TROP MED HYG, V22, P696, DOI 10.4269/ajtmh.1973.22.696; WEEDON D, 2002, SKIN PATHOLOGY, P721; ZAJTCHUK JT, 1989, LARYNGOSCOPE, V99, P925, DOI 10.1288/00005537-198909000-00006; 2003, MMWR MORB MORTAL WKL, V52, P1009	20	15	15	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2005	352	6					609	615		10.1056/NEJMcpc049035	http://dx.doi.org/10.1056/NEJMcpc049035			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895KY	15703426				2022-12-28	WOS:000226862100012
J	Maxwell, SRJ; Webb, DJ				Maxwell, SRJ; Webb, DJ			COX-2 selective inhibitors - important lessons learned	LANCET			English	Editorial Material							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GASTROINTESTINAL TOXICITY; CARDIOVASCULAR EVENTS; RISK; ROFECOXIB; ARTHRITIS; NAPROXEN		Univ Edinburgh, Western Gen Hosp, Clin Pharmacol Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Webb, DJ (corresponding author), Univ Edinburgh, Western Gen Hosp, Clin Pharmacol Unit, Edinburgh EH4 2XU, Midlothian, Scotland.	d.j.webb@ed.ac.uk						Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Emery P, 2001, LANCET, V357, P809, DOI 10.1016/S0140-6736(05)71242-3; Hawkey CJ, 1999, LANCET, V353, P307, DOI 10.1016/S0140-6736(98)12154-2; Horton R, 1999, LANCET, V354, P1138, DOI 10.1016/S0140-6736(99)00328-1; Juni P, 2004, LANCET, V364, P2021, DOI 10.1016/S0140-6736(04)17514-4; Kimmel SE, 2005, ANN INTERN MED, V142, P157, DOI 10.7326/0003-4819-142-3-200502010-00005; Mamdani M, 2004, LANCET, V363, P1751, DOI 10.1016/S0140-6736(04)16299-5; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; *MERCK, 2004, MERCK ANN VOL WITHDR; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; Ott E, 2003, J THORAC CARDIOV SUR, V125, P1481, DOI 10.1016/S0022-5223(03)00125-9; *PFIZ, 2005, PFIZ STAT NEW INF RE; Ray WA, 2002, LANCET, V360, P1071, DOI 10.1016/S0140-6736(02)11131-7; Schnitzer TJ, 2004, LANCET, V364, P665, DOI 10.1016/S0140-6736(04)16893-1; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Warner TD, 2004, FASEB J, V18, P790, DOI 10.1096/fj.03-0645rev; Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407	17	45	48	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 5	2005	365	9458					449	451						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894SS	15705439				2022-12-28	WOS:000226812500003
J	Chisholm, MF; Kumar, S; Hazzledine, P				Chisholm, MF; Kumar, S; Hazzledine, P			Dislocations in complex materials	SCIENCE			English	Article							BASAL SLIP; SAPPHIRE ALPHA-AL2O3; LAVES PHASES; ALLOY; DEFORMATION; LATTICE; DEFECT	Deformation of metals and alloys by dislocations gliding between well-separated slip planes is a well-understood process, but most crystal structures do not possess such simple geometric arrangements. Examples are the Laves phases, the most common class of intermetallic compounds and exist with ordered cubic, hexagonal, and rhombohedral structures. These compounds are usually brittle at low temperatures, and transformation from one structure to another is slow. On the basis of geometric and energetic considerations, a dislocation-based mechanism consisting of two shears in different directions on adjacent atomic planes has been used to explain both deformation and phase transformations in this class of materials. We report direct observations made by Z-contrast atomic resolution microscopy of stacking faults and dislocation cores in the Laves phase Cr2Hf. These results show that this complex dislocation scheme does indeed operate in this material. Knowledge gained of the dislocation core structure will enable improved understanding of deformation mechanisms and,phase transformation kinetics in this and other complex structures.	Brown Univ, Div Engn, Providence, RI 02912 USA; Oak Ridge Natl Lab, Condensed Matter Sci Div, Oak Ridge, TN 37831 USA	Brown University; United States Department of Energy (DOE); Oak Ridge National Laboratory	Kumar, S (corresponding author), Brown Univ, Div Engn, Providence, RI 02912 USA.	Sharvan_Kumar@brown.edu	Chisholm, Matthew F./F-7198-2017	Chisholm, Matthew F./0000-0003-0546-5109				ALLEN CW, 1972, PHYS STATUS SOLIDI A, V9, P237, DOI 10.1002/pssa.2210090127; BARRETT C, 1987, INT SERIES MAT SCI T, V35; BildeSorensen JB, 1996, ACTA MATER, V44, P2145, DOI 10.1016/1359-6454(95)00264-2; Geipel T, 1996, ACTA MATER, V44, P2165, DOI 10.1016/1359-6454(95)00288-X; HAZZLEDINE PM, 1993, SCRIPTA METALL MATER, V28, P1277, DOI 10.1016/0956-716X(93)90468-8; HIRTH J, 1968, MCGRAWHILL SERIES MA; HUSIMI K, 1950, PROG THEOR PHYS, V5, P177, DOI 10.1143/ptp/5.2.177; KITANO Y, 1980, ACTA CRYSTALLOGR A, V36, P16, DOI 10.1107/S0567739480000034; KRONBERG ML, 1957, ACTA METALL MATER, V5, P507, DOI 10.1016/0001-6160(57)90090-1; KUMAR KS, 1994, INTERMETALLICS, V2, P257, DOI 10.1016/0966-9795(94)90012-4; LIU YP, 1995, METALL MATER TRANS A, V26, P1441, DOI 10.1007/BF02647594; LIU YP, 1992, METALL TRANS A, V23, P3303, DOI 10.1007/BF02663439; LIVINGSTON JD, 1992, PHYS STATUS SOLIDI A, V131, P415, DOI 10.1002/pssa.2211310215; Nellist PD, 2004, SCIENCE, V305, P1741, DOI 10.1126/science.1100965; Nellist PD, 1998, PHYS REV LETT, V81, P4156, DOI 10.1103/PhysRevLett.81.4156; Pirouz P, 1996, ACTA MATER, V44, P2153, DOI 10.1016/1359-6454(95)00265-0; Witte H, 1936, METALLWIRTSCHAFT, V15, P840	17	130	134	3	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2005	307	5710					701	703		10.1126/science.1105962	http://dx.doi.org/10.1126/science.1105962			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	894TQ	15692046				2022-12-28	WOS:000226814900036
J	Todo, Y; Kitazato, H; Hashimoto, J; Gooday, AJ				Todo, Y; Kitazato, H; Hashimoto, J; Gooday, AJ			Simple foraminifera flourish at the ocean's deepest point	SCIENCE			English	Article							CHALLENGER DEEP; MARIANA TRENCH		Japan Agcy Marine Earth Sci & Technol, Inst Res Earth Evolut, Yokosuka, Kanagawa 2370061, Japan; Shizuoka Univ, Sch Sci, Dept Life & Earth Sci, Shizuoka, Japan; U Dom Corp, Tokyo, Japan; Nagasaki Univ, Fac Fisheries, Nagasaki 852, Japan; Southampton Oceanog Ctr, DEEPSEAS Benth Biol Grp, Southampton SO143 ZH, Hants, England	Japan Agency for Marine-Earth Science & Technology (JAMSTEC); Shizuoka University; Nagasaki University; NERC National Oceanography Centre	Kitazato, H (corresponding author), Japan Agcy Marine Earth Sci & Technol, Inst Res Earth Evolut, Natsushimacho 2-15, Yokosuka, Kanagawa 2370061, Japan.	kitazatoh@jamstec.go.jp; ang@soton.soc.ac.jp	Gooday, Andrew/ABB-4267-2020; Gooday, Andrew/AAH-8991-2021	Gooday, Andrew/0000-0002-5661-7371; 				Akimoto K, 2001, MAR MICROPALEONTOL, V42, P95, DOI 10.1016/S0377-8398(01)00012-3; Fujioka K, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013595; Gooday AJ, 2002, J FORAMIN RES, V32, P384, DOI 10.2113/0320384; HASHIMOTO J, 2002, KR0213 JAMSTEC; Meisterfeld R, 2001, PROTIST, V152, P185, DOI 10.1078/1434-4610-00058; Pawlowski J, 2003, P NATL ACAD SCI USA, V100, P11494, DOI 10.1073/pnas.2035132100; Sabbatini A, 2002, J MICROPALAEONTOL, V21, P131, DOI 10.1144/jm.21.2.131	7	61	66	2	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2005	307	5710					689	689		10.1126/science.1105407	http://dx.doi.org/10.1126/science.1105407			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	894TQ	15692042				2022-12-28	WOS:000226814900032
J	Chan, AW; Altman, DG				Chan, AW; Altman, DG			Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LIFE	Objective To examine the extent and nature of outcome reporting bias in a broad cohort of published randomised trials. Design Retrospective review of publications and follow up survey of authors. Cohort All journal articles of randomised trials indexed in PubMed whose primary publication appeared in December 2000. Main outcome measures Prevalence of incompletely reported outcomes per trial; reasons for not reporting outcomes; association between completeness of reporting and statistical significance. Results 519 trials with 553 publications and 10 557 outcomes were identified. Survey responders (response rate 69%) provided information on unreported outcomes but were often unreliable-for 32% of those who denied the existence of such outcomes there was evidence to the contrary in their publications. On average, over 20% of the outcomes measured in a parallel group trial were incompletely reported. Within a trial, such outcomes had a higher odds of being statistically non-significant compared with fully reported outcomes (odds ratio 2.0 (95% confidence interval 1.6 to 2.7) for efficacy outcomes; 1.9 (1.1 to 3.5) for harm outcomes). The most commonly reported reasons for omitting efficacy outcomes included space constraints, lack of clinical importance, and lack of statistical significance. Conclusions Incomplete reporting of outcomes Within published articles of randomised trials is common and is associated with statistical non-significance. The medical literature therefore represents a selective and biased subset of study outcomes, and trial protocols should be made publicly available.	Univ Hlth Network, Dept Med, Toronto, ON M5G 2C4, Canada; Canc Res UK, NHS Ctr Stat Med, Oxford, England	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Cancer Research UK	Chan, AW (corresponding author), Univ Hlth Network, Dept Med, Suite RFE 3-805,190 Elizabeth St, Toronto, ON M5G 2C4, Canada.	anwen.chan@utoronto.ca						Blumenthal D, 1997, JAMA-J AM MED ASSOC, V277, P1224, DOI 10.1001/jama.277.15.1224; Chalmers I, 1999, LANCET, V353, P490, DOI 10.1016/S0140-6736(98)07618-1; Chan AW, 2004, CAN MED ASSOC J, V171, P735, DOI 10.1503/cmaj.1041086; Chan AW, 2004, JAMA-J AM MED ASSOC, V291, P2457, DOI 10.1001/jama.291.20.2457; CHAN AW, IN PRESS LANCET; CODLEE F, 2001, BMC NEWS VIEWS, V2, P4; Elbourne DR, 2002, INT J EPIDEMIOL, V31, P140, DOI 10.1093/ije/31.1.140; FELSON DT, 1992, J CLIN EPIDEMIOL, V45, P885, DOI 10.1016/0895-4356(92)90072-U; Goldbeck-Wood S, 2001, BRIT MED J, V322, P1460; Hahn S, 2002, J EVAL CLIN PRACT, V8, P353, DOI 10.1046/j.1365-2753.2002.00314.x; HAMPTON JR, 1987, LANCET, V2, P1258; Ioannidis JPA, 2004, ANN INTERN MED, V141, P781, DOI 10.7326/0003-4819-141-10-200411160-00009; Johansen HK, 1999, JAMA-J AM MED ASSOC, V282, P1752, DOI 10.1001/jama.282.18.1752; McCormack K, 2001, 9 INT COCHR C OCT 9, P34; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Murray GD, 2001, BRIT MED J, V322, P1461; Roberts I, 1997, BRIT MED J, V315, P686, DOI 10.1136/bmj.315.7109.686a; Robinson KA, 2002, INT J EPIDEMIOL, V31, P150, DOI 10.1093/ije/31.1.150; Song, 2000, HEALTH TECHNOL ASSES, V4, P1, DOI DOI 10.3310/HTA4100; SONG F, 2000, HEALTH TECHNOL ASSES, V4, P10; Staessen JA, 2003, LANCET, V362, P1009, DOI 10.1016/S0140-6736(03)14448-0; Streiner DL, 1998, CAN J PSYCHIAT, V43, P1026, DOI 10.1177/070674379804301008; Tannock IF, 1996, J NATL CANCER I, V88, P206, DOI 10.1093/jnci/88.3-4.206; Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V; WEST RR, 1997, P 2 INT C SCI BAS HL, P82	25	382	383	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 2	2005	330	7494					753	756		10.1136/bmj.38356.424606.8F	http://dx.doi.org/10.1136/bmj.38356.424606.8F			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914JE	15681569	Green Published, Bronze			2022-12-28	WOS:000228222900015
J	Raftery, JP; Yao, GQL; Murchie, P; Campbell, NC; Ritchie, LD				Raftery, JP; Yao, GQL; Murchie, P; Campbell, NC; Ritchie, LD			Cost effectiveness of nurse led secondary prevention clinics for coronary heart disease in primary care: follow up of a randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							BRITISH FAMILY HEART; HEALTH; OXCHECK	Objective To establish the cost effectiveness of nurse led secondary prevention clinics for coronary heart disease based on four years' follow up of a randomised controlled trial. Design Cost effectiveness analysis. Setting 19 general practices in north east Scotland. Participants 1343 patients (673 in intervention group and 670 in control group, as originally randomised) aged under 80 years with a diagnosis of coronary heart disease but without terminal illness or dementia and not housebound. Intervention Nurse led clinics to promote medical and lifestyle components of secondary prevention. Main outcome measures Costs of clinics; overall costs to health service; and cost per life year and per quality adjusted life year QALY) gained, expressed as incremental gain in intervention group compared with control group. Results The cost of the intervention (clinics and drugs) was 136 pound ($254; E195) per patient higher (1998-9 prices) in the intervention group, but the difference in other NHS costs, although lower for the intervention group, was not statistically significant. Overall, 28 fewer deaths occurred in the intervention group leading to a gain in mean life years per patient of 0.110 and of 0.124 QALYs. The incremental cost per life year saved was 11236 and that per QALY was 1097. pound Conclusion Nurse led clinics for the secondary prevention of coronary heart disease in primary care seem to be cost effective compared with most interventions in health care, with the main gains in life years saved.	Univ Birmingham, Hlth Econ Facil, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England; Univ Aberdeen, Dept Gen Practice & Primary Care, Aberdeen AB25 2AY, Scotland	University of Birmingham; University of Aberdeen	Raftery, JP (corresponding author), Univ Birmingham, Hlth Econ Facil, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England.	j.p.raftery@bham.ac.uk		Murchie, Peter/0000-0001-9968-5991				*BMA NHS CONF, NEW GMS CONTR; Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8; Campbell NC, 1998, HEART, V80, P447, DOI 10.1136/hrt.80.5.447; Campbell NC, 1998, BMJ-BRIT MED J, V316, P1434, DOI 10.1136/bmj.316.7142.1434; Lancaster T, 2003, EVID BASED MED, V8, P158; Langham S, 1996, BRIT MED J, V312, P1265, DOI 10.1136/bmj.312.7041.1265; McAlister FA, 2001, BRIT MED J, V323, P957, DOI 10.1136/bmj.323.7319.957; Moher M, 2001, BMJ-BRIT MED J, V322, P1338, DOI 10.1136/bmj.322.7298.1338; Murchie P, 2003, BRIT MED J, V326, P84, DOI 10.1136/bmj.326.7380.84; *NAT I CLIN EXC, 2002, 39 NICE; National Institute for Clinical Excellence, 2004, GUID METH TECHN APPR; Netten A.P., 2000, UNIT COSTS HLTH SOCI; *NHS SCOTL INF STA, 1999, SCOTT HLTH SERV COST; *NHS SCOTL SCOTT E, 1998, SCOTT DRUG TAR; ONeill C, 1996, J EPIDEMIOL COMMUN H, V50, P538, DOI 10.1136/jech.50.5.538; Polsky D, 1997, HEALTH ECON, V6, P243, DOI 10.1002/(SICI)1099-1050(199705)6:3<243::AID-HEC269>3.0.CO;2-Z; Raftery J, 2001, BRIT MED J, V323, P1300, DOI 10.1136/bmj.323.7324.1300; *SCOTT INT GUID NE, 2000, GUID 41 SEC PREV COR; Ware JE, 1993, SF36 HLTH SURVEY MAN; Wonderling D, 1996, BRIT MED J, V312, P1274, DOI 10.1136/bmj.312.7041.1274; Wonderling D, 1996, BRIT MED J, V312, P1269, DOI 10.1136/bmj.312.7041.1269	21	78	83	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 26	2005	330	7493					707	710A		10.1136/bmj.38342.665417.8F	http://dx.doi.org/10.1136/bmj.38342.665417.8F			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912IT	15716289	Green Published, Bronze			2022-12-28	WOS:000228071900018
J	Clarkson, JR; Baquero, E; Shubert, VA; Myshakin, EM; Jordan, KD; Zwier, TS				Clarkson, JR; Baquero, E; Shubert, VA; Myshakin, EM; Jordan, KD; Zwier, TS			Laser-initiated shuttling of a water molecule between H-bonding sites	SCIENCE			English	Article							N-PHENYL FORMAMIDE; CONFORMATIONAL ISOMERIZATION; DOUBLE-RESONANCE; FREE-ENERGY; TRANS-FORMANILIDE; GAS-PHASE; SPECTROSCOPY; CLUSTERS; DYNAMICS; SOLVENT	The two-step laser excitation scheme of stimulated emission pumping (SEP) induces shifts of a single water molecule between two remote hydrogen bonding sites on trans-formanilide. This reaction can be initiated by selective excitation of. either isomer (C=O-bound or NH-bound) with different SEP excitation wavelengths. Energy (E) thresholds for isomerization in both directions have been measured [796 wave numbers less than or equal to E(C=O-->NH) less than or equal to 988 wave numbers and 750 wave numbers less than or equal to E(NH-->C=O) :S 988 wave numbers], and the energy difference DeltaE between the C=O-bound and NH-bound isomers was extracted (-238 wave numbers less than or equal to DeltaE less than or equal to +192 wave numbers).	Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA; Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zwier, TS (corresponding author), Purdue Univ, Dept Chem, 560 Oval Dr, W Lafayette, IN 47907 USA.	zwier@purdue.edu	Shubert, V. Alvin/C-6736-2011					Alfonso DR, 2002, J CHEM PHYS, V116, P3612, DOI 10.1063/1.1447903; Bach A, 2000, J CHEM PHYS, V113, P9032, DOI 10.1063/1.1319352; Bertran J, 1998, THEOR CHEM ACC, V99, P143, DOI 10.1007/s002140050316; CROOKS J, 1988, J PHYS CHEM-US, V92, P3554, DOI 10.1021/j100323a046; Deng YQ, 2002, J CHEM PHYS, V117, P1735, DOI 10.1063/1.1489417; Dian BC, 2004, J CHEM PHYS, V120, P9033, DOI 10.1063/1.1697389; Dian BC, 2004, SCIENCE, V303, P1169, DOI 10.1126/science.1093731; Dian BC, 2004, J CHEM PHYS, V120, P133, DOI 10.1063/1.1626540; Dian BC, 2002, SCIENCE, V296, P2369, DOI 10.1126/science.1071563; Dickinson JA, 1999, J PHYS CHEM A, V103, P6938, DOI 10.1021/jp991254d; Fedorov AV, 2000, J PHYS CHEM A, V104, P4943, DOI 10.1021/jp994449u; Frisch M.J., 2009, GAUSSIAN 09 LINUX VE; FRISCH MJ, 1984, J CHEM PHYS, V80, P3265, DOI 10.1063/1.447079; Gao JL, 2003, ADV PHYS ORG CHEM, V38, P161, DOI 10.1016/S0065-3160(03)38005-0; Henkelman G, 2000, J CHEM PHYS, V113, P9901, DOI 10.1063/1.1329672; JOHNSON DD, 1988, PHYS REV B, V38, P12807, DOI 10.1103/PhysRevB.38.12807; Keutsch FN, 2001, P NATL ACAD SCI USA, V98, P10533, DOI 10.1073/pnas.191266498; Kiefer PM, 2002, J PHYS CHEM A, V106, P1834, DOI 10.1021/jp0134244; Korter TM, 1998, J PHYS CHEM A, V102, P7211, DOI 10.1021/jp982456x; LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785; Leitner DM, 2003, J PHYS CHEM A, V107, P10706, DOI 10.1021/jp0305180; Levy RM, 2003, J AM CHEM SOC, V125, P9523, DOI 10.1021/ja029833a; MacKerell AD, 2001, BIOPOLYMERS, V56, P257; Mahoney MW, 2000, J CHEM PHYS, V112, P8910, DOI 10.1063/1.481505; Matsumoto Y, 1998, J CHEM PHYS, V109, P6303, DOI 10.1063/1.477272; MILLS G, 1994, PHYS REV LETT, V72, P1124, DOI 10.1103/PhysRevLett.72.1124; Mons M, 2001, J PHYS CHEM A, V105, P969, DOI 10.1021/jp003152p; Ponder JW, 2003, ADV PROTEIN CHEM, V66, P27; Rey R, 2004, CHEM REV, V104, P1915, DOI 10.1021/cr020675f; Robertson EG, 2000, CHEM PHYS LETT, V325, P299, DOI 10.1016/S0009-2614(00)00661-8; Roth W, 1998, CHEM PHYS, V239, P1, DOI 10.1016/S0301-0104(98)00252-3; Townsend D, 2004, SCIENCE, V306, P1158, DOI 10.1126/science.1104386; Truhlar DG, 1996, J PHYS CHEM-US, V100, P12771, DOI 10.1021/jp953748q; Tubergen MJ, 2003, J CHEM PHYS, V119, P8397, DOI 10.1063/1.1612919; Ullrich S, 2002, PHYS CHEM CHEM PHYS, V4, P2897, DOI 10.1039/b200125j; Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035; Watanabe T, 1996, J CHEM PHYS, V105, P408, DOI 10.1063/1.471917; Zwier TS, 1996, ANNU REV PHYS CHEM, V47, P205, DOI 10.1146/annurev.physchem.47.1.205	38	87	87	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 4	2005	307	5714					1443	1446		10.1126/science.1106977	http://dx.doi.org/10.1126/science.1106977			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904MT	15692014				2022-12-28	WOS:000227503100039
J	Libow, LS				Libow, LS			Geriatrics in the United States - Baby boomer's boon?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Jewish Home & Hosp Lifecare Syst New York, New York, NY USA; CUNY Mt Sinai Sch Med, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Libow, LS (corresponding author), Jewish Home & Hosp Lifecare Syst New York, New York, NY USA.							Campion EW, 2002, NEW ENGL J MED, V346, P874, DOI 10.1056/NEJM200203213461202; Cohen HJ, 2002, NEW ENGL J MED, V346, P905, DOI 10.1056/NEJMsa010285; Leigh JP, 2002, ARCH INTERN MED, V162, P1577, DOI 10.1001/archinte.162.14.1577; LIBOW LS, 1978, COMMITTEE PUBLICATIO; Warshaw GA, 2003, J AM GERIATR SOC, V51, pS338, DOI 10.1046/j.1365-2389.2003.51345.x	5	19	19	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2005	352	8					750	752		10.1056/NEJMp048140	http://dx.doi.org/10.1056/NEJMp048140			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899MC	15728805				2022-12-28	WOS:000227147500002
J	Cooke, R				Cooke, R			Head cooling in neonatal hypoxic-ischaemic encephalopathy	LANCET			English	Editorial Material							MAGNETIC-RESONANCE-SPECTROSCOPY; ASPHYXIA; HYPOTHERMIA		Liverpool Womens Hosp, Neonatal Unit, Liverpool L8 7SS, Merseyside, England	University of Liverpool	Cooke, R (corresponding author), Liverpool Womens Hosp, Neonatal Unit, Liverpool L8 7SS, Merseyside, England.	mc19@liv.ac.uk						Bona E, 1998, PEDIATR RES, V43, P738, DOI 10.1203/00006450-199806000-00005; BOO NY, 1991, J TROP PEDIATRICS, V38, P284; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; Hanrahan JD, 1999, DEV MED CHILD NEUROL, V41, P76, DOI 10.1017/S0012162299000171; JACOBS S, 2004, COCHRANE LIB; KINOTI SN, 1993, E AFR MED J, V70, P422; Robertson NJ, 1999, PEDIATR RES, V46, P287, DOI 10.1203/00006450-199909000-00007; Roth SC, 1997, DEV MED CHILD NEUROL, V39, P718; SHANKARAN S, 1991, EARLY HUM DEV, V25, P135, DOI 10.1016/0378-3782(91)90191-5	9	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	2005	365	9460					632	634						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	898SP	15721456				2022-12-28	WOS:000227096800004
J	Jenkins, V; Fallowfield, L; Solis-Trapala, I; Langridge, C; Farewell, V				Jenkins, V; Fallowfield, L; Solis-Trapala, I; Langridge, C; Farewell, V			Discussing randomised clinical trials of cancer therapy: evaluation of a Cancer Research LTK training programme	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COMMUNICATION-SKILLS; KEY	Objective To evaluate a training intervention aimed at improving healthcare professionals' communication with cancer patients about randomised clinical trials. Design Before and after evaluation of training programme. Setting Members of the National Cancer Research Network, Scottish Trials Network, and the Welsh Cancer Trials Network Participants 101 healthcare professionals (33 clinicians and 68 research nurses). Intervention Four modules delivered by a trained facilitator using videotapes and interactive exercises to cover general issues about discussing randomised clinical trials with patients, problems specific to adjuvant trials, trials with palliation as the goal, and trials where patients had a strong preference for one treatment arm. Main outcome measures Before and after the intervention, participants were videotaped discussing a trial with an actor portraying a patient. These consultations were assessed for presence of information required by good clinical practice guidelines. The actor patients gave an assessment after each interview Participants reported their self confidence about key aspects of trial discussion. Results Analysis of the videotaped consultations showed that, after intervention, significantly more participants displayed key communication behaviours such as explaining randomisation (69 v 8 1, odds ratio 2.33, P = 0.033), checking patients' understanding (I I v 3 1, odds ratio 3.22, P = 0.002), and discussing standard treatment (73 v 88, odds ratio 4.75, P = 0.005) and side effects (69 v 85, odds ratio 3.29, P = 0.006). Participants' self confidence increased significantly (P < 0.001) across all areas. Actor patients' ratings of participants' communication showed significant improvements for 12/15 key items. Conclusion This intensive 8 hour intervention significantly improved participants' confidence and competence when communicating about randomised clinical trials.	Univ Sussex, Brighton & Sussex Med Sch, Sussex Psychosocial Oncol Grp, Brighton BN1 9QG, E Sussex, England; Ctr Invest Matemat, Guanajuato, Mexico; Inst Publ Hlth, MRC, Biostat Unit, Cambridge, England	University of Brighton; University of Sussex; CIMAT - Centro de Investigacion en Matematicas; MRC Biostatistics Unit; University of Cambridge	Jenkins, V (corresponding author), Univ Sussex, Brighton & Sussex Med Sch, Sussex Psychosocial Oncol Grp, Brighton BN1 9QG, E Sussex, England.	val@sussex.ac.uk	Solis-Trapala, Ivonne/AAZ-2105-2021; Solis-Trapala, Ivonne/D-8144-2011	Solis-Trapala, Ivonne/0000-0002-1264-1396; Solis-Trapala, Ivonne/0000-0002-1264-1396; Fallowfield, Lesley/0000-0003-0577-4518; Farewell, Vernon/0000-0001-6704-5295				Albrecht TL, 1999, J CLIN ONCOL, V17, P3324, DOI 10.1200/JCO.1999.17.10.3324; *DEP HLTH, 2000, 6 DEP HLTH; Donovan J, 2002, BMJ-BRIT MED J, V325, P766, DOI 10.1136/bmj.325.7367.766; Fallowfield L, 1999, EUR J CANCER, V35, P1592, DOI 10.1016/S0959-8049(99)00212-9; Fallowfield L, 2003, BRIT J CANCER, V89, P1445, DOI 10.1038/sj.bjc.6601309; Fallowfield L, 2002, LANCET, V359, P650, DOI 10.1016/S0140-6736(02)07810-8; Fallowfield L, 2004, LANCET, V363, P312, DOI 10.1016/S0140-6736(03)15392-5; Fallowfield L, 2001, CANCER NURS, V24, P185, DOI 10.1097/00002820-200106000-00005; Jenkins V, 2002, BRIT J CANCER, V87, P854, DOI 10.1038/sj.bjc.6600527; Jenkins VA, 1999, EUR J CANCER, V35, P1187, DOI 10.1016/S0959-8049(99)00116-1; Maguire P, 2002, BRIT MED J, V325, P697, DOI 10.1136/bmj.325.7366.697; *MED RES COUNC, 1998, MRC GUID GOOD CLIN P; Pope JE, 2003, J RHEUMATOL, V30, P815; Razavi D, 2003, J CLIN ONCOL, V21, P3141, DOI 10.1200/JCO.2003.08.031	14	67	68	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 19	2005	330	7488					400	403		10.1136/bmj.38366.562685.8F	http://dx.doi.org/10.1136/bmj.38366.562685.8F			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900NA	15705666	Green Published, Bronze, Green Accepted			2022-12-28	WOS:000227220400021
J	Raimondo, G; Pollicino, T; Squadrito, G				Raimondo, G; Pollicino, T; Squadrito, G			What is the clinical impact of occult hepatitis B virus infection?	LANCET			English	Editorial Material							ANTIGEN		Univ Messina, Dept Internal Med, Unit Clin & Mol Hepatol, I-98124 Messina, Italy	University of Messina	Raimondo, G (corresponding author), Univ Messina, Dept Internal Med, Unit Clin & Mol Hepatol, I-98124 Messina, Italy.	raimondo@unime.it	Pollicino, Teresa/HDN-3708-2022; Pollicino, Teresa/K-5790-2016	Pollicino, Teresa/0000-0001-6602-3035				Allain JP, 2004, VOX SANG, V86, P83, DOI 10.1111/j.0042-9007.2004.00406.x; Brechot C, 2001, HEPATOLOGY, V34, P194, DOI 10.1053/jhep.2001.25172; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Cacciola I, 1999, NEW ENGL J MED, V341, P22, DOI 10.1056/NEJM199907013410104; CARMAN W, 1993, LANCET, V341, P349, DOI 10.1016/0140-6736(93)90146-8; CHAZOUILLERES O, 1994, LANCET, V343, P142, DOI 10.1016/S0140-6736(94)90934-2; Chemin I, 2001, J HEPATOL, V34, P447, DOI 10.1016/S0168-8278(00)00100-8; GRUMAYER ER, 1989, J HEPATOL, V8, P232, DOI 10.1016/0168-8278(89)90012-3; Marusawa H, 2000, HEPATOLOGY, V31, P488, DOI 10.1002/hep.510310232; Minuk GY, 2004, HEPATOLOGY, V40, P1072, DOI 10.1002/hep.20435; Pollicino T, 2004, GASTROENTEROLOGY, V126, P102, DOI 10.1053/j.gastro.2003.10.048; Raimondo C, 2001, J HEPATOL, V34, P471, DOI 10.1016/S0168-8278(01)00016-2; Torbenson M, 2002, LANCET INFECT DIS, V2, P479, DOI 10.1016/S1473-3099(02)00345-6; WAITE J, 1988, AIDS, V2, P443, DOI 10.1097/00002030-198812000-00006; Werle-Lapostolle B, 2004, GASTROENTEROLOGY, V126, P1750, DOI 10.1053/j.gastro.2004.03.018; Wieland SF, 2004, P NATL ACAD SCI USA, V101, P2129, DOI 10.1073/pnas.0308478100	16	46	53	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	2005	365	9460					638	640						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	898SP	15721459				2022-12-28	WOS:000227096800007
J	Snir, Y; Kamien, RD				Snir, Y; Kamien, RD			Entropically driven helix formation	SCIENCE			English	Article							SHAPES		Univ Penn, Dept Phys & Astron, Philadelphia, PA 19104 USA	University of Pennsylvania	Kamien, RD (corresponding author), Univ Penn, Dept Phys & Astron, Philadelphia, PA 19104 USA.	kamien@physics.upenn.edu						ASAKURA S, 1954, J CHEM PHYS, V22, P1255, DOI 10.1063/1.1740347; Banavar JR, 2003, REV MOD PHYS, V75, P23, DOI 10.1103/RevModPhys.75.23; BELLO J, 1993, BIOPOLYMERS, V33, P491, DOI 10.1002/bip.360330315; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; Gellman SH, 1998, ACCOUNTS CHEM RES, V31, P173, DOI 10.1021/ar960298r; Gonzalez O, 1999, P NATL ACAD SCI USA, V96, P4769, DOI 10.1073/pnas.96.9.4769; LAU KF, 1989, MACROMOLECULES, V22, P3986, DOI 10.1021/ma00200a030; Maritan A, 2000, NATURE, V406, P287, DOI 10.1038/35018538; Pickett GT, 2000, PHYS REV LETT, V85, P3652, DOI 10.1103/PhysRevLett.85.3652	9	217	223	4	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2005	307	5712					1067	1067		10.1126/science.1106243	http://dx.doi.org/10.1126/science.1106243			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ED	15718461	Green Submitted			2022-12-28	WOS:000227197300036
J	Zhang, ZX; Roman, GC; Hong, Z; Wu, CB; Qu, QM; Huang, JB; Zhou, B; Geng, ZP; Wu, JX; Wen, HB; Zhao, H; Zahner, GEP				Zhang, ZX; Roman, GC; Hong, Z; Wu, CB; Qu, QM; Huang, JB; Zhou, B; Geng, ZP; Wu, JX; Wen, HB; Zhao, H; Zahner, GEP			Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai	LANCET			English	Article								A cross-sectional prevalence study of Parkinson's disease in China was undertaken in 1997-98. We assessed 29 454 residents aged greater than or equal to55 years from 79 rural and 58 urban communities in Beijing, Xian, and Shanghai, who were selected through stratified, multistage, cluster sampling. With a standardised diagnostic protocol, we identified 277 people with the disease. Prevalence of Parkinson's disease for those aged greater than or equal to65 years was 1.7% (95% CI 1.5-1.9). We estimate that 1.7 million people in China have the disease (aged greater than or equal to55 years). Our findings suggest that prevalence of Parkinson's disease in China is similar to that in developed countries.	Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Neurol, Beijing 100730, Peoples R China; Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Clin Epidemiol, Beijing 100037, Peoples R China; Univ Texas, Hlth Sci Ctr, Dept Med & Neurol, San Antonio, TX USA; Fudan Univ, Huashan Hosp, Dept Neurol, Shanghai 200433, Peoples R China; Xian Transportat Univ, First Hosp, Dept Neurol, Xian, Peoples R China; Tongren Hosp, Dept Neurol, Beijing, Peoples R China; Beijing Sixth Hosp, Dept Neurol, Beijing, Peoples R China; Natl Res Inst Family Planning, Dept Stat, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; University of Texas System; University of Texas Health San Antonio; Fudan University; National Research Institute for Family Planning - China	Zhang, ZX (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Neurol, Beijing 100730, Peoples R China.	zhangzx@pumch.ac.cn						CALNE DB, 1992, ANN NEUROL S, V32, P125; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; SAS Institute, 2000, SAS STAT VERS 8; Tanner C. M., 2004, MOVEMENT DISORDERS N, P177; ZHANG ZX, 1993, NEUROEPIDEMIOLOGY, V12, P195, DOI 10.1159/000110318; Zhang ZX, 2003, MOVEMENT DISORD, V18, P764, DOI 10.1002/mds.10445	6	279	441	4	114	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 12	2005	365	9459					595	597						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DN	15708103				2022-12-28	WOS:000226984300032
J	Aharonov, Y; Zubairy, MS				Aharonov, Y; Zubairy, MS			Time and the quantum: Erasing the past and impacting the future	SCIENCE			English	Review							DELAYED CHOICE; DISENTANGLEMENT ERASER; COMPLEMENTARITY; MECHANICS; ENGLERT; WALTHER		Texas A&M Univ, Inst Quantum Studies, College Stn, TX 77843 USA; Texas A&M Univ, Dept Phys, College Stn, TX 77843 USA; Tel Aviv Univ, Sch Phys & Astron, IL-69978 Tel Aviv, Israel; Univ S Carolina, Dept Phys, Columbia, SC 29208 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Tel Aviv University; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Zubairy, MS (corresponding author), Texas A&M Univ, Inst Quantum Studies, College Stn, TX 77843 USA.	zubairy@physics.tamu.edu						BEGLEY S, 1995, NEWSWEEK        0213, P67; Bramon A, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.020405; Durr S, 1998, NATURE, V395, P33, DOI 10.1038/25653; ENGLERT BG, 1988, FOUND PHYS, V18, P1045, DOI 10.1007/BF01909939; Garisto R, 1999, PHYS REV A, V60, P827, DOI 10.1103/PhysRevA.60.827; Greene Brian, 2004, FABRIC COSMOS; Kim YH, 2000, PHYS REV LETT, V84, P1, DOI 10.1103/PhysRevLett.84.1; Mohrhoff U, 1999, AM J PHYS, V67, P330, DOI 10.1119/1.19258; Mohrhoff U, 1996, AM J PHYS, V64, P1468, DOI 10.1119/1.18411; Scully M.O., 1997, QUANTUM OPT; SCULLY MO, 1982, PHYS REV A, V25, P2208, DOI 10.1103/PhysRevA.25.2208; SCULLY MO, 1991, NATURE, V351, P111, DOI 10.1038/351111a0; SCULLY MO, UNPUB; STOREY P, 1994, NATURE, V367, P626, DOI 10.1038/367626a0; Teklemariam G, 2001, PHYS REV LETT, V86, P5845, DOI 10.1103/PhysRevLett.86.5845; Walborn SP, 2003, AM SCI, V91, P336; Weaire D. L., 1987, FEYNMAN LECT PHYS; Zubairy MS, 2004, PHYS REV A, V70, DOI 10.1103/PhysRevA.70.012316	18	63	65	4	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2005	307	5711					875	879		10.1126/science.1107787	http://dx.doi.org/10.1126/science.1107787			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897DV	15705840	Green Submitted			2022-12-28	WOS:000226985100040
J	Gital, Z; Dye, NA; Reisenauer, A; Wachi, M; Shapiro, L				Gital, Z; Dye, NA; Reisenauer, A; Wachi, M; Shapiro, L			MreB actin-mediated segregation of a specific region of a bacterial chromosome	CELL			English	Article							CELL-CYCLE PROGRESSION; ESCHERICHIA-COLI; CAULOBACTER-CRESCENTUS; BACILLUS-SUBTILIS; DNA-REPLICATION; POLAR LOCALIZATION; CONTROLLED PROTEOLYSIS; PROTEINS; DIVISION; ORIGIN	Faithful chromosome segregation is an essential component of cell division in all organisms. The eukaryotic mitotic machinery uses the cytoskeleton to move specific chromosomal regions. To investigate the potential role of the actin-like MreB protein in bacterial chromosome segregation, we first demonstrate that MreB is the direct target of the small molecule A22. We then demonstrate that A22 completely blocks the movement of newly replicated loci near the origin of replication but has no qualitative or quantitative effect on the segregation of other loci if added after origin segregation. MreB selectively interacts, directly or indirectly, with origin-proximal regions of the chromosome, arguing that the origin-proximal region segregates via an MreB-dependent mechanism not used by the rest of the chromosome.	Stanford Univ, Beckman Ctr, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Beckman Ctr, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Tokyo Inst Technol, Dept Bioengn, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Stanford University; Stanford University; Princeton University; Tokyo Institute of Technology	Gital, Z (corresponding author), Stanford Univ, Beckman Ctr, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA.	zgitai@stanford.edu; shapiro@cmgm.stanford.edu	Dye, Natalie/X-4910-2019; Wachi, Masaaki/D-1220-2015	Dye, Natalie/0000-0002-4859-6670; Wachi, Masaaki/0000-0002-3655-4035	NIGMS NIH HHS [R01GM51426] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051426] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alley MRK, 2001, MOL MICROBIOL, V40, P1335, DOI 10.1046/j.1365-2958.2001.02476.x; BlondeletRouault MH, 1997, GENE, V190, P315, DOI 10.1016/S0378-1119(97)00014-0; Britton RA, 1998, GENE DEV, V12, P1254, DOI 10.1101/gad.12.9.1254; Dworkin J, 2002, P NATL ACAD SCI USA, V99, P14089, DOI 10.1073/pnas.182539899; Easter J, 2002, MOL CELL, V10, P427, DOI 10.1016/S1097-2765(02)00594-4; ELY B, 1991, METHOD ENZYMOL, V204, P372; Fenteany G, 2003, CURR TOP MED CHEM, V3, P593, DOI 10.2174/1568026033452348; Figge RM, 2004, MOL MICROBIOL, V51, P1321, DOI 10.1111/j.1365-2958.2003.03936.x; Gerdes K, 2000, MOL MICROBIOL, V37, P455, DOI 10.1046/j.1365-2958.2000.01975.x; Gitai Z, 2004, P NATL ACAD SCI USA, V101, P8643, DOI 10.1073/pnas.0402638101; Gordon GS, 2002, MOL MICROBIOL, V44, P501, DOI 10.1046/j.1365-2958.2002.02901.x; Holtzendorff J, 2004, SCIENCE, V304, P983, DOI 10.1126/science.1095191; Iwai N, 2002, BIOSCI BIOTECH BIOCH, V66, P2658, DOI 10.1271/bbb.66.2658; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; Jaffe A, 1997, J BACTERIOL, V179, P3494, DOI 10.1128/jb.179.11.3494-3499.1997; Jenal U, 1996, EMBO J, V15, P2393, DOI 10.1002/j.1460-2075.1996.tb00597.x; Jensen RB, 2002, NAT REV MOL CELL BIO, V3, P167, DOI 10.1038/nrm758; Jensen RB, 1999, P NATL ACAD SCI USA, V96, P10661, DOI 10.1073/pnas.96.19.10661; Jensen RB, 2001, EMBO J, V20, P4952, DOI 10.1093/emboj/20.17.4952; Jones LJF, 2001, CELL, V104, P913, DOI 10.1016/S0092-8674(01)00287-2; Kline-Smith SL, 2004, MOL CELL, V15, P317, DOI 10.1016/j.molcel.2004.07.012; Kruse T, 2003, EMBO J, V22, P5283, DOI 10.1093/emboj/cdg504; Lau IF, 2003, MOL MICROBIOL, V49, P731, DOI 10.1046/j.1365-2958.2003.03640.x; Laub MT, 2002, P NATL ACAD SCI USA, V99, P4632, DOI 10.1073/pnas.062065699; Lemon KP, 2001, GENE DEV, V15, P2031, DOI 10.1101/gad.913301; Li YF, 2002, MOL MICROBIOL, V46, P985, DOI 10.1046/j.1365-2958.2002.03234.x; Lin DCH, 1998, CELL, V92, P675, DOI 10.1016/S0092-8674(00)81135-6; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Lutkenhaus J, 1997, ANNU REV BIOCHEM, V66, P93, DOI 10.1146/annurev.biochem.66.1.93; MARCZYNSKI GT, 1990, J MOL BIOL, V212, P709, DOI 10.1016/0022-2836(90)90232-B; MARCZYNSKI GT, 1992, J MOL BIOL, V226, P959, DOI 10.1016/0022-2836(92)91045-Q; Marczynski GT, 2002, ANNU REV MICROBIOL, V56, P625, DOI 10.1146/annurev.micro.56.012302.161103; Mohl DA, 2001, MOL MICROBIOL, V42, P741, DOI 10.1046/j.1365-2958.2001.02643.x; Mohl DA, 1997, CELL, V88, P675, DOI 10.1016/S0092-8674(00)81910-8; Moller-Jensen J, 2003, MOL CELL, V12, P1477, DOI 10.1016/S1097-2765(03)00451-9; Moller-Jensen J, 2002, EMBO J, V21, P3119, DOI 10.1093/emboj/cdf320; Morton WM, 2000, NAT CELL BIOL, V2, P376, DOI 10.1038/35014075; Niki H, 2000, GENE DEV, V14, P212; Quardokus E, 1996, P NATL ACAD SCI USA, V93, P6314, DOI 10.1073/pnas.93.13.6314; Ryan KR, 2002, J MOL BIOL, V324, P443, DOI 10.1016/S0022-2836(02)01042-2; Shih YL, 2003, P NATL ACAD SCI USA, V100, P7865, DOI 10.1073/pnas.1232225100; Soufo HJD, 2003, CURR BIOL, V13, P1916, DOI 10.1016/j.cub.2003.10.024; Soufo HJD, 2004, EMBO REP, V5, P789, DOI 10.1038/sj.embor.7400209; Teleman AA, 1998, CURR BIOL, V8, P1102, DOI 10.1016/S0960-9822(98)70464-6; van den Ent F, 2001, NATURE, V413, P39, DOI 10.1038/35092500; Viollier PH, 2004, P NATL ACAD SCI USA, V101, P9257, DOI 10.1073/pnas.0402606101; Viollier PH, 2002, EMBO J, V21, P4420, DOI 10.1093/emboj/cdf454; Webb CD, 1997, CELL, V88, P667, DOI 10.1016/S0092-8674(00)81909-1; Webb CD, 1998, MOL MICROBIOL, V28, P883, DOI 10.1046/j.1365-2958.1998.00808.x; WINZELER E, 1995, J MOL BIOL, V251, P346, DOI 10.1006/jmbi.1995.0439; Yamaichi Y, 2004, EMBO J, V23, P221, DOI 10.1038/sj.emboj.7600028	51	323	328	1	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 11	2005	120	3					329	341		10.1016/j.cell.2005.01.007	http://dx.doi.org/10.1016/j.cell.2005.01.007			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	897TS	15707892	Bronze			2022-12-28	WOS:000227028900009
J	Shen, KM; Ronning, F; Lu, DH; Baumberger, F; Ingle, NJC; Lee, WS; Meevasana, W; Kohsaka, Y; Azuma, M; Takano, M; Takagi, H; Shen, ZX				Shen, KM; Ronning, F; Lu, DH; Baumberger, F; Ingle, NJC; Lee, WS; Meevasana, W; Kohsaka, Y; Azuma, M; Takano, M; Takagi, H; Shen, ZX			Nodal quasiparticles and antinodal charge ordering in Ca2-xNaxCuO2Cl2	SCIENCE			English	Article							SUPERCONDUCTORS; BI2SR2CACU2O8+DELTA; CA2CUO2CL2; PSEUDOGAP; OXIDES; STATES; MODEL	Understanding the role of competing states in the cuprates is essential for developing a theory for high-temperature superconductivity. We report angle-resolved photoemission spectroscopy experiments which probe the 4a(o) x 4a(o) charge-ordered state discovered by scanning tunneling microscopy in the lightly doped cuprate superconductor Ca2-x NaxCuO2Cl2. Our measurements reveal a marked dichotomy between the real- and momentum-space probes, for which charge. ordering is emphasized in the tunneling measurements and photoemission is most sensitive to excitations near the node of the d-wave superconducting gap. These results emphasize the importance of momentum anisotropy in determining the complex electronic properties of the cuprates and places strong constraints on theoretical models of the charge-ordered state.	Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; Stanford Univ, Stanford Synchrotron Lab, Stanford, CA 94305 USA; Univ Tokyo, Dept Adv Mat Sci, Chiba 2778561, Japan; Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan	Stanford University; Stanford University; University of Tokyo; Kyoto University; RIKEN	Shen, ZX (corresponding author), Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA.	zxshen@stanford.edu	TAKAGI, HIDENORI/Q-1041-2019; Azuma, Masaki/C-2945-2009; Takagi, Hidenori/B-2935-2010; Kohsaka, Yuhki/A-4428-2009; Baumberger, Felix/A-5170-2008; Shen, Kyle/B-3693-2008	TAKAGI, HIDENORI/0000-0001-5700-3761; Azuma, Masaki/0000-0002-8378-321X; Kohsaka, Yuhki/0000-0002-6459-2661; Baumberger, Felix/0000-0001-7104-7541; 				Ando Y, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.017001; Brouet V, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.126405; Chen HD, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.187002; Chuang YD, 2001, SCIENCE, V292, P1509, DOI 10.1126/science.1059255; Damascelli A, 2003, REV MOD PHYS, V75, P473, DOI 10.1103/RevModPhys.75.473; DESSAU DS, 1991, PHYS REV LETT, V66, P2160, DOI 10.1103/PhysRevLett.66.2160; EMERY VJ, 1990, PHYS REV LETT, V64, P475, DOI 10.1103/PhysRevLett.64.475; FU H, UNPUB; Gabovich AM, 2001, SUPERCOND SCI TECH, V14, pR1, DOI 10.1088/0953-2048/14/4/201; Hanaguri T, 2004, NATURE, V430, P1001, DOI 10.1038/nature02861; Hoffman JE, 2002, SCIENCE, V295, P466, DOI 10.1126/science.1066974; Kohsaka Y, 2002, J AM CHEM SOC, V124, P12275, DOI 10.1021/ja026680i; Lu DH, 2001, PHYS REV LETT, V86, P4370, DOI 10.1103/PhysRevLett.86.4370; MATTHEISS LF, 1990, PHYS REV B, V42, P354, DOI 10.1103/PhysRevB.42.354; MCELROY K, UNPUB; Mishchenko AS, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.036402; Nakagawa T, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.241401; Perebeinos V, 2000, PHYS REV LETT, V85, P5178, DOI 10.1103/PhysRevLett.85.5178; Sachdev S, 2000, SCIENCE, V288, P475, DOI 10.1126/science.288.5465.475; Salamon MB, 2001, REV MOD PHYS, V73, P583, DOI 10.1103/RevModPhys.73.583; Salkola MI, 1996, PHYS REV LETT, V77, P155, DOI 10.1103/PhysRevLett.77.155; Shen KM, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.267002; Timusk T, 1999, REP PROG PHYS, V62, P61, DOI 10.1088/0034-4885/62/1/002; TRANQUADA JM, 1995, NATURE, V375, P561, DOI 10.1038/375561a0; Vershinin M, 2004, SCIENCE, V303, P1995, DOI 10.1126/science.1093384; Waku K, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.134501; Yoshida T, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.027001; ZAANEN J, 1989, PHYS REV B, V40, P7391, DOI 10.1103/PhysRevB.40.7391; Zhou XJ, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.187001	30	309	312	1	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2005	307	5711					901	904		10.1126/science.1103627	http://dx.doi.org/10.1126/science.1103627			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897DV	15705845				2022-12-28	WOS:000226985100046
J	Laugwitz, KL; Moretti, A; Lam, J; Gruber, P; Chen, YH; Woodard, S; Lin, LZ; Cai, CL; Lu, MM; Reth, M; Platoshyn, O; Yuan, JXJ; Evans, S; Chien, KR				Laugwitz, KL; Moretti, A; Lam, J; Gruber, P; Chen, YH; Woodard, S; Lin, LZ; Cai, CL; Lu, MM; Reth, M; Platoshyn, O; Yuan, JXJ; Evans, S; Chien, KR			Postnatal isl1+cardioblasts enter fully differentiated cardiomyocyte lineages	NATURE			English	Article							HEMATOPOIETIC STEM-CELLS; TAMOXIFEN-INDUCIBLE FORM; CARDIAC MYOCYTES; CRE; EXPRESSION; PATHWAYS; DISEASE; FUSION	The purification, renewal and differentiation of native cardiac progenitors would form a mechanistic underpinning for unravelling steps for cardiac cell lineage formation, and their links to forms of congenital and adult cardiac diseases(1 - 3). Until now there has been little evidence for native cardiac precursor cells in the postnatal heart(4). Herein, we report the identification of isl1(+) cardiac progenitors in postnatal rat, mouse and human myocardium. A cardiac mesenchymal feeder layer allows renewal of the isolated progenitor cells with maintenance of their capability to adopt a fully differentiated cardiomyocyte phenotype. Tamoxifen- inducible Cre/ lox technology enables selective marking of this progenitor cell population including its progeny, at a defined time, and purification to relative homogeneity. Coculture studies with neonatal myocytes indicate that isl1(+) cells represent authentic, endogenous cardiac progenitors ( cardioblasts) that display highly efficient conversion to a mature cardiac phenotype with stable expression of myocytic markers ( 25%) in the absence of cell fusion, intact Ca2+- cycling, and the generation of action potentials. The discovery of native cardioblasts represents a genetically based system to identify steps in cardiac cell lineage formation and maturation in development and disease.	Univ Calif San Diego, Sch Med, Inst Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; Childrens Hosp Philadelphia, Cardiac Ctr, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Div Cardiovasc, Philadelphia, PA 19104 USA; Univ Freiburg, Max Planck Inst Immunbiol, D-79108 Freiburg, Germany	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Max Planck Society; University of Freiburg	Chien, KR (corresponding author), Univ Calif San Diego, Sch Med, Inst Mol Med, La Jolla, CA 92093 USA.	syevans@ucsd.edu; kchien@partners.org	Evans, Sylvia/G-1980-2015; Moretti, Alessandra/O-9271-2015	Moretti, Alessandra/0000-0001-5782-7832	NHLBI NIH HHS [DP1 HL117649, R01 HL070867] Funding Source: Medline; NIH HHS [DP1 OD006428] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070867, DP1HL117649] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD006428] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Bischoff R., 1994, MYOLOGY, VVolume 1, P97; Cai CL, 2003, DEV CELL, V5, P877, DOI 10.1016/S1534-5807(03)00363-0; Chien KR, 2002, CELL, V110, P153, DOI 10.1016/S0092-8674(02)00834-6; Chien KR, 2004, NATURE, V428, P607, DOI 10.1038/nature02500; D'Amour KA, 2002, NAT MED, V8, P213, DOI 10.1038/nm0302-213; Danielian PS, 1998, CURR BIOL, V8, P1323, DOI 10.1016/S0960-9822(07)00562-3; Epstein J. A., 2001, TRENDS GENET, V17, pS13; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; He JQ, 2003, CIRC RES, V93, P32, DOI 10.1161/01.RES.0000080317.92718.99; Maltsev VA, 1999, CIRC RES, V84, P136, DOI 10.1161/01.RES.84.2.136; Martin CM, 2004, DEV BIOL, V265, P262, DOI 10.1016/j.ydbio.2003.09.028; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Nygren JM, 2004, NAT MED, V10, P494, DOI 10.1038/nm1040; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Pashmforoush M, 2004, CELL, V117, P373, DOI 10.1016/S0092-8674(04)00405-2; Rosenthal N, 2003, NEW ENGL J MED, V349, P267, DOI 10.1056/NEJMra020849; Schwenk F, 1998, NUCLEIC ACIDS RES, V26, P1427, DOI 10.1093/nar/26.6.1427; Seale P, 2000, DEV BIOL, V218, P115, DOI 10.1006/dbio.1999.9565; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Verrou C, 1999, BIOL CHEM, V380, P1435, DOI 10.1515/BC.1999.184; Voura EB, 2004, NAT MED, V10, P993, DOI 10.1038/nm1096; Wurmser AE, 2004, NATURE, V430, P350, DOI 10.1038/nature02604	25	980	1071	0	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 10	2005	433	7026					647	653		10.1038/nature03215	http://dx.doi.org/10.1038/nature03215			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	895KX	15703750	Green Accepted			2022-12-28	WOS:000226862000048
J	McFiggans, G				McFiggans, G			Marine aerosols and iodine emissions	NATURE			English	Editorial Material							CHEMISTRY		Univ Manchester, Sch Earth Atmospher & Environm Sci, Atmospher Sci Grp, Manchester M60 1QD, Lancs, England	University of Manchester	McFiggans, G (corresponding author), Univ Manchester, Sch Earth Atmospher & Environm Sci, Atmospher Sci Grp, POB 88, Manchester M60 1QD, Lancs, England.	g.mcfiggans@manchester.ac.uk	McFiggans, Gordon B/B-8689-2011	McFiggans, Gordon B/0000-0002-3423-7896	Natural Environment Research Council [NE/B501104/1] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Allan BJ, 2000, J GEOPHYS RES-ATMOS, V105, P14363, DOI 10.1029/1999JD901188; Carpenter LJ, 1999, J GEOPHYS RES-ATMOS, V104, P1679, DOI 10.1029/98JD02746; GARLAND JA, 1981, J GEOPHYS RES-OCEANS, V86, P3183, DOI 10.1029/JC086iC04p03183; McFiggans G, 2000, J GEOPHYS RES-ATMOS, V105, P14371, DOI 10.1029/1999JD901187; McFiggans G, 2004, ATMOS CHEM PHYS, V4, P701, DOI 10.5194/acp-4-701-2004; O'Dowd C, 1999, GEOPHYS RES LETT, V26, P1707, DOI 10.1029/1999GL900335; O'Dowd CD, 2001, ATMOS RES, V58, P167, DOI 10.1016/S0169-8095(01)00098-9; O'Dowd CD, 2002, NATURE, V417, P632, DOI 10.1038/nature00775; Saiz-Lopez A, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL019215	9	28	27	4	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 10	2005	433	7026					E13	E13		10.1038/nature03372	http://dx.doi.org/10.1038/nature03372			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	895KX	15703706				2022-12-28	WOS:000226862000033
J	Torgerson, DJ; Adamson, J; Cockayne, S; Dumville, J; Petherick, E				Torgerson, DJ; Adamson, J; Cockayne, S; Dumville, J; Petherick, E			Submission to multiple journals: a method of reducing time to publication?	BRITISH MEDICAL JOURNAL			English	Article							INGELFINGER RULE; EMBARGOES; TRIALS		Univ York, Dept Hlth Sci, York Trials Unit, York YO10 5DD, N Yorkshire, England	University of York - UK	Torgerson, DJ (corresponding author), Univ York, Dept Hlth Sci, York Trials Unit, York YO10 5DD, N Yorkshire, England.	djt5@york.ac.uk	Torgerson, David/L-4566-2019; Petherick, Emily s/J-9755-2012; Dumville, Jo C/O-7867-2014	Torgerson, David/0000-0002-1667-4275; Petherick, Emily s/0000-0001-6778-8128; Dumville, Jo C/0000-0002-6546-3685; Adamson, Joy/0000-0002-9860-0850				Altman LK, 1996, LANCET, V347, P1382, DOI 10.1016/S0140-6736(96)91016-8; Altman LK, 1996, LANCET, V347, P1459, DOI 10.1016/S0140-6736(96)91689-X; Greenberg D, 2004, BMJ-BRIT MED J, V328, P1536, DOI 10.1136/bmj.38079.502326.AE; Ioannidis JPA, 1998, JAMA-J AM MED ASSOC, V279, P281, DOI 10.1001/jama.279.4.281; PIRON R, 2001, CHALLENGE        SEP	5	30	30	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 5	2005	330	7486					305	307		10.1136/bmj.330.7486.305	http://dx.doi.org/10.1136/bmj.330.7486.305			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895EM	15695280	Green Published			2022-12-28	WOS:000226843700022
J	Maeda, S; Hsu, LC; Liu, HJ; Bankston, LA; Iimura, M; Kagnoff, MF; Eckmann, L; Karin, M				Maeda, S; Hsu, LC; Liu, HJ; Bankston, LA; Iimura, M; Kagnoff, MF; Eckmann, L; Karin, M			Nod2 mutation in Crohn's disease potentiates NF-kappa B activity and IL-10 processing	SCIENCE			English	Article							INFLAMMATORY-BOWEL-DISEASE; TOLL-LIKE RECEPTORS; RECOGNITION; SUSCEPTIBILITY; MACROPHAGES; COLITIS; IKK	Variants of NOD2, an intracellular sensor of bacteria-derived muramyl dipeptide (MDP), increase susceptibility to Crohn's disease (CD). These variants are thought to be defective in activation of nuclear factor kappaB (NF-kappaB) and antibacterial defenses, but CD clinical specimens display elevated NF-kappaB activity. To illuminate the pathophysiological function of NOD2, we introduced such a variant to the mouse Nod2 locus. Mutant mice exhibited elevated NF-kappaB activation in response to MDP and more efficient processing and secretion of the cytokine interleukin-1beta (IL-1beta). These effects are linked to increased susceptibility to bacterial-induced intestinal inflammation and identify NOD2 as a positive regulator of NF-kappaB activation and IL-1beta secretion.	Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, Lab Mucosal Immunol, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Pediat, Lab Mucosal Immunol, La Jolla, CA 92093 USA; Burnham Inst, Program Cell Adhes, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Sanford Burnham Prebys Medical Discovery Institute	Karin, M (corresponding author), Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA.	karinoffice@ucsd.edu		Hsu, Li-Chung/0000-0001-7206-5231	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043477, R01AI056075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK035108, T32DK007202] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43477, AI56075] Funding Source: Medline; NIDDK NIH HHS [DK07202, DK35108] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; Fiocchi C, 1998, GASTROENTEROLOGY, V115, P182, DOI 10.1016/S0016-5085(98)70381-6; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2003, TRENDS IMMUNOL, V24, P652, DOI 10.1016/j.it.2003.10.007; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Kopp E, 2003, CURR OPIN IMMUNOL, V15, P396, DOI 10.1016/S0952-7915(03)00080-3; Le Feuvre RA, 2002, J BIOL CHEM, V277, P3210, DOI 10.1074/jbc.M104388200; MAEDA S, UNPUB; Martinon F, 2004, CELL, V117, P561, DOI 10.1016/j.cell.2004.05.004; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Pauleau AL, 2003, MOL CELL BIOL, V23, P7531, DOI 10.1128/MCB.23.21.7531-7539.2003; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rath HC, 2001, INFECT IMMUN, V69, P2277, DOI 10.1128/IAI.69.4.2277-2285.2001; Sands BE, 2004, NEW ENGL J MED, V350, P876, DOI 10.1056/NEJMoa030815; Strober W, 2002, ANNU REV IMMUNOL, V20, P495, DOI 10.1146/annurev.immunol.20.100301.064816; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Watanabe T, 2004, NAT IMMUNOL, V5, P800, DOI 10.1038/ni1092; Weinrauch Y, 1999, ANNU REV MICROBIOL, V53, P155, DOI 10.1146/annurev.micro.53.1.155	24	626	655	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2005	307	5710					734	738		10.1126/science.1103685	http://dx.doi.org/10.1126/science.1103685			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	894TQ	15692052				2022-12-28	WOS:000226814900046
J	Catania, KC; Remple, FE				Catania, KC; Remple, FE			Asymptotic prey profitability drives star-nosed moles to the foraging speed limit	NATURE			English	Article							FOOD	Foraging theory provides models for predicting predator diet choices assuming natural selection has favoured predators that maximize their rate of energy intake during foraging(1-6). Prey profitability ( energy gained divided by prey handling time) is an essential variable for estimating the optimal diet. Time constraints of capturing and consuming prey generally result in handling times ranging from minutes to seconds, yet profitability increases dramatically as handling time approaches zero, providing the potential for strong directional selection for increasing predator speed at high encounter rates ( tiny increments in speed increase profitability markedly, allowing expanded diets of smaller prey). We provide evidence that the unusual anatomical and behavioural specializations characterizing star-nosed moles resulted from progressively stronger selection for speed, allowing the progressive addition of small prey to their diet. Here we report handling times as short as 120 ms (mean 227 ms) for moles identifying and eating prey. 'Double takes' during prey identification suggest that star-nosed moles have reached the speed limit for processing tactile information. The exceptional speed of star-nosed moles, coupled with unusual specializations for finding and eating tiny prey, provide new support for optimal foraging theory.	Vanderbilt Univ, Dept Biol Sci, VU Stn B, Nashville, TN 37235 USA	Vanderbilt University	Catania, KC (corresponding author), Vanderbilt Univ, Dept Biol Sci, VU Stn B, Box 351634, Nashville, TN 37235 USA.	ken.catania@Vanderbilt.edu						Anderson JT, 2000, ECOL APPL, V10, P550, DOI 10.1890/1051-0761(2000)010[0550:IRTMSM]2.0.CO;2; Carpenter R.H.S., 1977, MOVEMENTS EYES; Catania KC, 2004, BRAIN BEHAV EVOLUT, V63, P1, DOI 10.1159/000073755; Catania KC, 1997, J COMP NEUROL, V387, P215; CHARNOV EL, 1976, AM NAT, V110, P141, DOI 10.1086/283054; CUMMINS KW, 1971, INT ASS THEOR APPL L, V18, P2; EMLEN JM, 1966, AM NAT, V100, P611, DOI 10.1086/282455; Finke MD, 2002, ZOO BIOL, V21, P269, DOI 10.1002/zoo.10031; GOULD SJ, 1982, PALEOBIOLOGY, V8, P4, DOI 10.1017/S0094837300004310; HAMILTON WILLIAM JOHN, 1931, JOUR MAMMAL, V12, P345, DOI 10.2307/1373758; Kamil A. C., 1981, FORAGING BEHAV ECOLO; MAIOROV V I, 1980, Neuroscience and Behavioral Physiology, V10, P374, DOI 10.1007/BF01184053; PYKE GH, 1977, Q REV BIOL, V52, P137, DOI 10.1086/409852; PYKE GH, 1984, ANNU REV ECOL SYST, V15, P523, DOI 10.1146/annurev.es.15.110184.002515; Sachdev RNS, 2002, J NEUROPHYSIOL, V87, P2602, DOI 10.1152/jn.2002.87.5.2602; Schoener T. W., 1971, A Rev Ecol Syst, V2, P369, DOI 10.1146/annurev.es.02.110171.002101; Stephens D.W., 1986, pi; SUGA N, 1976, SCIENCE, V194, P542, DOI 10.1126/science.973140; WITZ BW, 1993, COMP BIOCHEM PHYS A, V105, P151, DOI 10.1016/0300-9629(93)90188-A; WONGRILEY MTT, 1984, J COMP NEUROL, V222, P18, DOI 10.1002/cne.902220103	20	55	57	2	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 3	2005	433	7025					519	522		10.1038/nature03250	http://dx.doi.org/10.1038/nature03250			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893NT	15690041				2022-12-28	WOS:000226727200048
J	VanRooyen, M; Leaning, J				VanRooyen, M; Leaning, J			After the tsunami - Facing the public health challenges	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Brigham & Womens Hosp, Div Int Hlth & Humanitarian Programs, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Francois Xavier Bagnoud Ctr Hlth & Human Rights, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	VanRooyen, M (corresponding author), Brigham & Womens Hosp, Div Int Hlth & Humanitarian Programs, 75 Francis St, Boston, MA 02115 USA.							[Anonymous], FLOOD COMM DIS FACT; BURKHOLDER BT, 1995, LANCET, V346, P1012, DOI 10.1016/S0140-6736(95)91694-6; Connolly MA, 2004, LANCET, V364, P1974, DOI 10.1016/S0140-6736(04)17481-3; The Sphere Project, 2004, HUM CHART MIN STAND	4	50	51	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 3	2005	352	5					435	438		10.1056/NEJMp058013	http://dx.doi.org/10.1056/NEJMp058013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	893NE	15689579	Green Published			2022-12-28	WOS:000226725400001
J	Loftus, B; Anderson, I; Davies, R; Alsmark, UCM; Samuelson, J; Amedeo, P; Roncaglia, P; Berriman, M; Hirt, RP; Mann, BJ; Nozaki, T; Suh, B; Pop, M; Duchene, M; Ackers, J; Tannich, E; Leippe, M; Hofer, M; Bruchhaus, I; Willhoeft, U; Bhattacharya, A; Chillingworth, T; Churcher, C; Hance, Z; Harris, B; Harris, D; Jagels, K; Moule, S; Mungall, K; Ormond, D; Squares, R; Whitehead, S; Quail, MA; Rabbinowitsch, E; Norbertczak, H; Price, C; Wang, Z; Guillen, N; Gilchrist, C; Stroup, SE; Bhattacharya, S; Lohia, A; Foster, PG; Sicheritz-Ponten, T; Weber, C; Singh, U; Mukherjee, C; El-Sayed, NM; Petri, WA; Clark, CG; Embley, TM; Barrell, B; Fraser, CM; Hall, N				Loftus, B; Anderson, I; Davies, R; Alsmark, UCM; Samuelson, J; Amedeo, P; Roncaglia, P; Berriman, M; Hirt, RP; Mann, BJ; Nozaki, T; Suh, B; Pop, M; Duchene, M; Ackers, J; Tannich, E; Leippe, M; Hofer, M; Bruchhaus, I; Willhoeft, U; Bhattacharya, A; Chillingworth, T; Churcher, C; Hance, Z; Harris, B; Harris, D; Jagels, K; Moule, S; Mungall, K; Ormond, D; Squares, R; Whitehead, S; Quail, MA; Rabbinowitsch, E; Norbertczak, H; Price, C; Wang, Z; Guillen, N; Gilchrist, C; Stroup, SE; Bhattacharya, S; Lohia, A; Foster, PG; Sicheritz-Ponten, T; Weber, C; Singh, U; Mukherjee, C; El-Sayed, NM; Petri, WA; Clark, CG; Embley, TM; Barrell, B; Fraser, CM; Hall, N			The genome of the protist parasite Entamoeba histolytica	NATURE			English	Article							GENE; EVOLUTION; INFERENCE; PROGRAM	Entamoeba histolytica is an intestinal parasite and the causative agent of amoebiasis, which is a significant source of morbidity and mortality in developing countries(1). Here we present the genome of E. histolytica, which reveals a variety of metabolic adaptations shared with two other amitochondrial protist pathogens: Giardia lamblia and Trichomonas vaginalis. These adaptations include reduction or elimination of most mitochondrial metabolic pathways and the use of oxidative stress enzymes generally associated with anaerobic prokaryotes. Phylogenomic analysis identifies evidence for lateral gene transfer of bacterial genes into the E. histolytica genome, the effects of which centre on expanding aspects of E. histolytica's metabolic repertoire. The presence of these genes and the potential for novel metabolic pathways in E. histolytica may allow for the development of new chemotherapeutic agents. The genome encodes a large number of novel receptor kinases and contains expansions of a variety of gene families, including those associated with virulence. Additional genome features include an abundance of tandemly repeated transfer-RNA-containing arrays, which may have a structural function in the genome. Analysis of the genome provides new insights into the workings and genome evolution of a major human pathogen.	TIGR, Rockville, MD 20850 USA; Sanger Inst, Cambridge CB10 1SA, England; Newcastle Univ, Sch Biol, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA; Univ Virginia, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Natl Inst Infect Dis, Dept Parasitol, Shinjuku Ku, Tokyo 1628640, Japan; Med Univ Vienna, Ctr Physiol & Pathophysiol, Div Specif Prophylaxis & Trop Med, A-1095 Vienna, Austria; Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England; Bernhard Nocht Inst Trop Med, Dept Mol Parasitol, D-20359 Hamburg, Germany; Univ Kiel, Inst Zool, D-24098 Kiel, Germany; Jawaharlal Nehru Univ, Sch Environm Sci, New Delhi 110067, India; Inst Pasteur, INSERM, U389, Unite Biol Cellulaire Parasitisme, F-75724 Paris 15, France; Bose Inst, Dept Biochem, Kolkata 700054, India; Nat Hist Museum, Dept Zool, London SW7 5BD, England; Tech Univ Denmark, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark; Stanford Univ, Sch Med, Dept Internal Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Microbiol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Immunol, Stanford, CA 94305 USA	J. Craig Venter Institute; Wellcome Trust Sanger Institute; Newcastle University - UK; Boston University; University of Virginia; University of Virginia; National Institute of Infectious Diseases (NIID); Medical University of Vienna; University of London; London School of Hygiene & Tropical Medicine; Bernhard Nocht Institut fur Tropenmedizin; University of Kiel; Jawaharlal Nehru University, New Delhi; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Department of Science & Technology (India); Bose Institute; Natural History Museum London; Technical University of Denmark; Stanford University; Stanford University; Stanford University	Loftus, B (corresponding author), TIGR, 9712 Med Ctr Dr, Rockville, MD 20850 USA.	bjloftus@tigr.org	MIRELMAN, DAVID/K-1596-2012; El-Sayed, Najib M.A./K-7266-2015; Duchêne, Michael/G-6659-2019; Hall, Neil/A-8717-2013; Hirt, Robert/R-5429-2017; Clark, C Graham/H-3683-2011; Petri, William/AAL-3642-2020; Petri, William A./D-3639-2019; Alsmark, Cecilia/AAO-1330-2021; Pop, Mihai/A-7987-2013; Puigbò, Pere/A-2214-2008; Quail, michael/ABE-6131-2020; Leippe, Matthias/AAP-1677-2020; Willhoeft, Ute H/K-5970-2015; Sicheritz-Ponten, Thomas/A-4325-2017	El-Sayed, Najib M.A./0000-0001-7970-3312; Duchêne, Michael/0000-0003-1232-3600; Hall, Neil/0000-0002-7995-3810; Hirt, Robert/0000-0002-3760-9958; Clark, C Graham/0000-0002-0521-0977; Petri, William/0000-0002-7268-1218; Pop, Mihai/0000-0001-9617-5304; Willhoeft, Ute H/0000-0003-3313-2125; Lohia, Anuradha/0000-0003-3686-5738; Embley, Thomas Martin/0000-0002-1484-340X; loftus, brendan/0000-0001-8871-8356; Sicheritz-Ponten, Thomas/0000-0001-6615-1141; Singh, Upinder/0000-0003-0630-0306; Hall, Neil/0000-0003-2808-0009; Fraser, Claire/0000-0003-1462-2428; Foster, Peter/0000-0003-0194-9237; Samuelson, John/0000-0001-9533-3040; Roncaglia, Paola/0000-0002-2825-0621				Abrahamsen MS, 2004, SCIENCE, V304, P441, DOI 10.1126/science.1094786; Allen JE, 2004, GENOME RES, V14, P142, DOI 10.1101/gr.1562804; Azachi M, 2002, PLANT PHYSIOL, V129, P1320, DOI 10.1104/pp.001909; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; BAUM KF, 1989, J BIOL CHEM, V264, P21087; Cawley SE, 2001, MOL BIOCHEM PARASIT, V118, P167, DOI 10.1016/S0166-6851(01)00363-2; Coppi A, 2002, J BIOL CHEM, V277, P8083, DOI 10.1074/jbc.M111895200; Cummings MP, 2003, SYST BIOL, V52, P477, DOI 10.1080/10635150390218213; Desper R, 2004, MOL BIOL EVOL, V21, P587, DOI 10.1093/molbev.msh049; Duhon D, 2002, J MUSCLE RES CELL M, V23, P803, DOI 10.1023/A:1024435913949; FAHEY RC, 1984, SCIENCE, V224, P70, DOI 10.1126/science.6322306; Gomes CM, 2002, J BIOL CHEM, V277, P25273, DOI 10.1074/jbc.M203886200; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; Huston CD, 2004, TRENDS PARASITOL, V20, P23, DOI 10.1016/j.pt.2003.10.013; JAMES DW, 1995, PLANT CELL, V7, P309, DOI 10.2307/3869853; Jordan IK, 2003, J MOL MICROB BIOTECH, V5, P172, DOI 10.1159/000070268; Lawrence JG, 2003, MOL MICROBIOL, V50, P739, DOI 10.1046/j.1365-2958.2003.03778.x; Leon-Avila G, 2004, MICROBIOL-SGM, V150, P1245, DOI 10.1099/mic.0.26923-0; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Majoros WH, 2004, BIOINFORMATICS, V20, P2878, DOI 10.1093/bioinformatics/bth315; Mazzuco A, 1997, MICRON, V28, P241, DOI 10.1016/S0968-4328(97)00024-3; Melville SE, 1999, CHROMOSOME RES, V7, P191, DOI 10.1023/A:1009247315947; Mullikin JC, 2003, GENOME RES, V13, P81, DOI 10.1101/gr.731003; PATARAPOTIKUL J, 1988, NUCLEIC ACIDS RES, V16, P4331, DOI 10.1093/nar/16.10.4331; Sicheritz-Ponten T, 2001, NUCLEIC ACIDS RES, V29, P545, DOI 10.1093/nar/29.2.545; Stanley SL, 2003, LANCET, V361, P1025, DOI 10.1016/S0140-6736(03)12830-9; Sztukowska M, 2002, MOL MICROBIOL, V44, P479, DOI 10.1046/j.1365-2958.2002.02892.x; Voigt H, 1999, CELL MICROBIOL, V1, P195, DOI 10.1046/j.1462-5822.1999.00021.x; Welter BH, 2004, MOL BIOCHEM PARASIT, V135, P183, DOI 10.1016/j.molbiopara.2004.02.002	30	630	683	5	76	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 24	2005	433	7028					865	868		10.1038/nature03291	http://dx.doi.org/10.1038/nature03291			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	899VT	15729342	hybrid, Green Accepted			2022-12-28	WOS:000227174600042
J	Alaedini, A; Green, PHR				Alaedini, A; Green, PHR			Narrative review: Celiac disease: Understanding a complex autoimmune disorder	ANNALS OF INTERNAL MEDICINE			English	Review							GLUTEN-FREE DIET; ANTITISSUE TRANSGLUTAMINASE ANTIBODIES; GROWTH-FACTOR-BETA; MAJOR HISTOCOMPATIBILITY COMPLEX; GANGLIOSIDE-LIKE STRUCTURE; GUILLAIN-BARRE-SYNDROME; DENTAL ENAMEL DEFECTS; T-CELL RESPONSES; TISSUE TRANSGLUTAMINASE; DERMATITIS-HERPETIFORMIS	Celiac disease is a common autoimmune disorder that has genetic, environmental, and immunologic components. It is characterized by an immune response to ingested wheat gluten and related proteins of rye and barley that leads to inflammation, villous atrophy, and crypt hyperplasia in the intestine. The disease is closely associated with genes that code for human leukocyte antigens DQ2 and DQ8. Transglutaminase 2 appears to be an important component of the disease, both as a deamidating enzyme that can enhance the immunostimulatory effect of gluten and as a target autoantigen in the immune response. Sensitive and specific serologic tests, including those for anti-transglutaminase antibody, are facilitating fast and noninvasive screening for celiac disease. Thus, they are contributing to a more accurate estimate of the prevalence of the disease and its association with other disorders. Celiac disease is associated with increased rates of anemia, osteoporosis, cancer, neurologic deficits, and additional autoimmune disorders. A gluten-free diet is the mainstay of safe and effective treatment of celiac disease, although its effect on some of the extraintestinal manifestations of the disease remains to be determined.	Cornell Univ, Dept Neurol & Neurosci, New York, NY 10021 USA; Columbia Univ, New York, NY USA	Cornell University; Columbia University	Alaedini, A (corresponding author), Cornell Univ, Dept Neurol & Neurosci, LC-807,1300 York Ave, New York, NY 10021 USA.	ara2004@med.cornell.edu						Abdulkarim AS, 2002, AM J GASTROENTEROL, V97, P2016; Agardh D, 2002, ACTA PAEDIATR, V91, P34, DOI 10.1080/080352502753457914; AINE L, 1990, J ORAL PATHOL MED, V19, P241, DOI 10.1111/j.1600-0714.1990.tb00834.x; Alaedini A, 2002, J NEUROIMMUNOL, V127, P145, DOI 10.1016/S0165-5728(02)00102-9; Arentz-Hansen H, 2004, PLOS MED, V1, P84, DOI 10.1371/journal.pmed.0010001; Askling J, 2002, GASTROENTEROLOGY, V123, P1428, DOI 10.1053/gast.2002.36585; Atkinson MA, 2001, LANCET, V358, P221, DOI 10.1016/S0140-6736(01)05415-0; Bao F, 1999, J AUTOIMMUN, V13, P143, DOI 10.1006/jaut.1999.0303; Basu D, 2000, J IMMUNOL, V164, P5788, DOI 10.4049/jimmunol.164.11.5788; Bingley PJ, 2004, BRIT MED J, V328, P322, DOI 10.1136/bmj.328.7435.322; Bonamico M, 2004, J PEDIATR GASTR NUTR, V38, P204, DOI 10.1097/00005176-200402000-00019; Bonamico M, 2002, J CLIN ENDOCR METAB, V87, P5495, DOI 10.1210/jc.2002-020855; Bonamico M, 2001, AM J GASTROENTEROL, V96, P1536; BRUCE SE, 1985, CLIN SCI, V68, P573, DOI 10.1042/cs0680573; Bushara KO, 2001, ANN NEUROL, V49, P540, DOI 10.1002/ana.108; Buzzetti R, 1998, DIABETES METAB REV, V14, P111, DOI 10.1002/(SICI)1099-0895(199806)14:2<111::AID-DMR211>3.3.CO;2-U; Carroccio A, 2001, GUT, V49, P506, DOI 10.1136/gut.49.4.506; Cataldo F, 1998, GUT, V42, P362, DOI 10.1136/gut.42.3.362; Cellier C, 2000, LANCET, V356, P203, DOI 10.1016/S0140-6736(00)02481-8; Chin RL, 2003, NEUROLOGY, V60, P1581, DOI 10.1212/01.WNL.0000063307.84039.C7; Chin Russell L, 2004, J Clin Neuromuscul Dis, V5, P129, DOI 10.1097/00131402-200403000-00004; Cicarelli G, 2003, NEUROL SCI, V24, P311, DOI 10.1007/s10072-003-0181-4; Clemente MG, 2002, J PEDIATR GASTR NUTR, V34, P31, DOI 10.1097/00005176-200201000-00008; Collin P, 2002, ENDOCR REV, V23, P464, DOI 10.1210/er.2001-0035; CORAZZA GR, 1995, GASTROENTEROLOGY, V109, P1333, DOI 10.1016/0016-5085(95)90597-9; Culliford Andrea N, 2003, Curr Gastroenterol Rep, V5, P373, DOI 10.1007/s11894-003-0049-z; Curione M, 1999, LANCET, V354, P222, DOI 10.1016/S0140-6736(99)01501-9; DALTON TA, 1992, AM J MED, V92, P183, DOI 10.1016/0002-9343(92)90110-W; DANDALIDES SM, 1989, GASTROINTEST ENDOSC, V35, P197, DOI 10.1016/S0016-5107(89)72757-7; Daum S, 1999, GUT, V44, P17, DOI 10.1136/gut.44.1.17; Davison S, 2002, ARCH DIS CHILD, V87, P293, DOI 10.1136/adc.87.4.293; Dewar D, 2004, INT J BIOCHEM CELL B, V36, P17, DOI 10.1016/S1357-2725(03)00239-5; Dieterich W, 1997, NAT MED, V3, P797, DOI 10.1038/nm0797-797; DIGNASS AU, 1993, GASTROENTEROLOGY, V105, P1323, DOI 10.1016/0016-5085(93)90136-Z; Driscoll HK, 1997, PANCREAS, V15, P69, DOI 10.1097/00006676-199707000-00010; Esposito C, 2003, AM J GASTROENTEROL, V98, P1813, DOI [10.1016/S0002-9270(03)00431-3, 10.1111/j.1572-0241.2003.07582.x]; Esposito C, 2002, GUT, V51, P177, DOI 10.1136/gut.51.2.177; Fasano A, 2000, LANCET, V355, P1518, DOI 10.1016/S0140-6736(00)02169-3; Fasano A, 2003, ARCH INTERN MED, V163, P286, DOI 10.1001/archinte.163.3.286; Fasano A, 2001, GASTROENTEROLOGY, V120, P636, DOI 10.1053/gast.2001.22123; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; Fine KD, 1997, GASTROENTEROLOGY, V112, P1830, DOI 10.1053/gast.1997.v112.pm9178673; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; Frustaci A, 2002, CIRCULATION, V105, P2611, DOI 10.1161/01.CIR.0000017880.86166.87; Fry L, 2002, EUR J DERMATOL, V12, P523; Gabrielli M, 2003, AM J GASTROENTEROL, V98, P625, DOI [10.1111/j.1572-0241.2003.07300.x, 10.1016/S0002-9270(02)06022-7]; Gianfrani C, 2003, J IMMUNOL, V170, P2719, DOI 10.4049/jimmunol.170.5.2719; Gillett HR, 2000, CAN J GASTROENTEROL, V14, P672, DOI 10.1155/2000/934709; Gomez JC, 1998, GASTROENTEROLOGY, V114, P621, DOI 10.1016/S0016-5085(98)70562-1; GOMIS R, 1983, BIOCHIM BIOPHYS ACTA, V760, P384, DOI 10.1016/0304-4165(83)90378-1; Greco L, 2002, GUT, V50, P624, DOI 10.1136/gut.50.5.624; Green PHR, 2003, AM J MED, V115, P191, DOI 10.1016/S0002-9343(03)00302-4; Green PHR, 2003, LANCET, V362, P383, DOI 10.1016/S0140-6736(03)14027-5; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; Hadjivassiliou M, 1999, J NEUROL NEUROSUR PS, V67, P257, DOI 10.1136/jnnp.67.2.257; Hadjivassiliou M, 2003, J NEUROL NEUROSUR PS, V74, P1221, DOI 10.1136/jnnp.74.9.1221; Halttunen T, 1996, GASTROENTEROLOGY, V111, P1252, DOI 10.1053/gast.1996.v111.pm8898639; HOWELL MD, 1986, J EXP MED, V164, P333, DOI 10.1084/jem.164.1.333; Hue S, 2004, IMMUNITY, V21, P367, DOI 10.1016/j.immuni.2004.06.018; Hurlstone DP, 2003, GASTROINTEST ENDOSC, V58, P815, DOI 10.1016/S0016-5107(03)01999-0; Iltanen S, 1999, AM J GASTROENTEROL, V94, P1042; KAPLAN JG, 1988, NEUROLOGY, V38, P642, DOI 10.1212/WNL.38.4.642; Kaukinen K, 1999, DIABETES CARE, V22, P1747, DOI 10.2337/diacare.22.10.1747a; Kemppainen T, 1999, BONE, V24, P249, DOI 10.1016/S8756-3282(98)00178-1; Korponay-Szabo IR, 2003, GUT, V52, P199, DOI 10.1136/gut.52.2.199; Korponay-Szabo IR, 2000, J PEDIATR GASTR NUTR, V31, P520, DOI 10.1097/00005176-200011000-00013; Lai TS, 1998, J BIOL CHEM, V273, P1776, DOI 10.1074/jbc.273.3.1776; Lampasona V, 1999, DIABETOLOGIA, V42, P1195, DOI 10.1007/s001250051291; Lang HLE, 2002, NAT IMMUNOL, V3, P940, DOI 10.1038/ni835; Lepore L, 1996, J PEDIATR-US, V129, P311, DOI 10.1016/S0022-3476(96)70262-7; Lo WS, 2003, DIGEST DIS SCI, V48, P395, DOI 10.1023/A:1021956200382; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; Lundqvist C, 1996, J IMMUNOL, V157, P1926; Luostarinen L, 2003, J NEUROL NEUROSUR PS, V74, P490, DOI 10.1136/jnnp.74.4.490; Luostarinen L, 2001, EUR NEUROL, V46, P187, DOI 10.1159/000050802; Mainardi E, 2002, J CLIN GASTROENTEROL, V35, P245, DOI 10.1097/00004836-200209000-00009; Maiuri L, 2003, LANCET, V362, P30, DOI 10.1016/S0140-6736(03)13803-2; Maki M, 2003, NEW ENGL J MED, V348, P2517, DOI 10.1056/NEJMoa021687; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P; Meloni GF, 1999, HUM REPROD, V14, P2759, DOI 10.1093/humrep/14.11.2759; Meresse B, 2004, IMMUNITY, V21, P357, DOI 10.1016/j.immuni.2004.06.020; Molberg O, 2003, GASTROENTEROLOGY, V125, P337, DOI 10.1016/S0016-5085(03)00890-4; Molberg O, 2000, J PEDIATR GASTR NUTR, V30, P232, DOI 10.1097/00005176-200003000-00005; Mori M, 1999, NEUROLOGY, V52, P1282, DOI 10.1212/WNL.52.6.1282; Muller AF, 1996, AM J GASTROENTEROL, V91, P1430; Murray JA, 2003, CLIN GASTROENTEROL H, V1, P19, DOI 10.1053/jcgh.2003.50004; Nemes Z, 1999, EXP MOL MED, V31, P5, DOI 10.1038/emm.1999.2; Nunes I, 1997, J CELL BIOL, V136, P1151, DOI 10.1083/jcb.136.5.1151; O'Leary C, 2002, QJM-INT J MED, V95, P79, DOI 10.1093/qjmed/95.2.79; Oberhuber G, 1996, AM J PATHOL, V148, P1351; Pender SLF, 1997, J IMMUNOL, V158, P1582; Polizzi A, 2000, J NEUROL NEUROSUR PS, V68, P104, DOI 10.1136/jnnp.68.1.104; Porter WM, 1999, GASTROENTEROLOGY, V117, P749, DOI 10.1016/S0016-5085(99)70482-8; Ransford RAJ, 2002, J CLIN GASTROENTEROL, V35, P228, DOI 10.1097/00004836-200209000-00006; Reunala TL, 2001, CLIN DERMATOL, V19, P728, DOI 10.1016/S0738-081X(00)00184-X; Rostami K, 2001, EUR J OBSTET GYN R B, V96, P146, DOI 10.1016/S0301-2115(00)00457-7; Rostami K, 1999, AM J GASTROENTEROL, V94, P888; ROSTOM A, 2004, AHRQ PUBLCATION; Sardy M, 1999, CLIN CHEM, V45, P2142; Sardy M, 2002, J EXP MED, V195, P747, DOI 10.1084/jem.20011299; SategnaGuidetti C, 1996, J CLIN GASTROENTEROL, V23, P101, DOI 10.1097/00004836-199609000-00006; Sbarbati A, 2003, DIGEST LIVER DIS, V35, P768, DOI 10.1016/S1590-8658(03)00457-2; SCOTT BB, 1976, GUT, V17, P984, DOI 10.1136/gut.17.12.984; Shan L, 2002, SCIENCE, V297, P2275, DOI 10.1126/science.1074129; Shill HA, 2003, NEUROLOGY, V60, P1672, DOI 10.1212/01.WNL.0000060185.30001.46; Siegel LM, 1997, GASTROINTEST ENDOSC, V46, P226, DOI 10.1016/S0016-5107(97)70091-9; Sjoberg K, 1997, SCAND J GASTROENTERO, V32, P1162, DOI 10.3109/00365529709002997; Sollid LM, 2000, ANNU REV IMMUNOL, V18, P53, DOI 10.1146/annurev.immunol.18.1.53; SOLLID LM, 1989, J EXP MED, V169, P345, DOI 10.1084/jem.169.1.345; Sulkanen S, 1998, GASTROENTEROLOGY, V115, P1322, DOI 10.1016/S0016-5085(98)70008-3; Thompson T, 2004, NEW ENGL J MED, V351, P2021, DOI 10.1056/NEJM200411043511924; Thompson T, 2003, J AM DIET ASSOC, V103, P376, DOI 10.1053/jada.2003.50044; Tommasini A, 2004, ARCH DIS CHILD, V89, P512, DOI 10.1136/adc.2003.029603; Tursi A, 2003, J CLIN GASTROENTEROL, V37, P387, DOI 10.1097/00004836-200311000-00007; Tursi A, 2003, J CLIN GASTROENTEROL, V36, P219, DOI 10.1097/00004836-200303000-00007; Ventura A, 1997, ARCH DIS CHILD, V77, P91, DOI 10.1136/adc.77.1.91; Volta U, 1998, DIGEST DIS SCI, V43, P2190, DOI 10.1023/A:1026650118759; WALKERSMITH JA, 1990, ARCH DIS CHILD, V65, P909, DOI 10.1136/adc.65.8.909; Wong RCW, 2002, J CLIN PATHOL, V55, P488, DOI 10.1136/jcp.55.7.488; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; YUKI N, 1993, J EXP MED, V178, P1771, DOI 10.1084/jem.178.5.1771; 2004, NIH CONS DEV C STAT	122	212	232	0	29	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	2005	142	4					289	298		10.7326/0003-4819-142-4-200502150-00011	http://dx.doi.org/10.7326/0003-4819-142-4-200502150-00011			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900UJ	15710962				2022-12-28	WOS:000227239500006
J	Hall, J; Maynard, A				Hall, J; Maynard, A			Healthcare lessons from Australia: what can Michael Howard learn from John Howard?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INSURANCE		Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England; Univ Technol Sydney, Ctr Hlth Econ Res & Evaluat, Sydney, NSW 2007, Australia	University of York - UK; University of Technology Sydney	Maynard, A (corresponding author), Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England.	akm3@york.ac.uk	Hall, Jane P/I-3469-2014	Hall, Jane/0000-0002-2191-0543				*AUSTR I HLTH WELF, 2004, AUSTR HLTH 2004; Butler J. R. G., 2001, POLICY CHANGE PRIVAT; *DEP HLTH AG, INF MEDICAREPLUS; Duckett SJ, 2000, MED J AUSTRALIA, V172, P439, DOI 10.5694/j.1326-5377.2000.tb124043.x; Hall J, 1999, HEALTH ECON, V8, P653, DOI 10.1002/(SICI)1099-1050(199912)8:8<653::AID-HEC491>3.0.CO;2-I; Hall J, 1999, HEALTH AFFAIR, V18, P95, DOI 10.1377/hlthaff.18.3.95; *PRIV HLTH INS ADV, 2003, 200203 AGPS PRIV HLT; *PRIV HLTH INS ADV, INS STAT; Senate Community Affairs References Committee, 2000, HEAL OUR HOSP REP PU	9	7	7	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 12	2005	330	7487					357	359		10.1136/bmj.330.7487.357	http://dx.doi.org/10.1136/bmj.330.7487.357			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897OZ	15705697	Green Published			2022-12-28	WOS:000227015800031
J	Jarman, B; Bottle, A; Aylin, P; Browne, M				Jarman, B; Bottle, A; Aylin, P; Browne, M			Dr Foster's case notes	BRITISH MEDICAL JOURNAL			English	Article									Univ London Imperial Coll Sci Technol & Med, Dr Foster Unit, London SW7 2AZ, England; Walsall Hosp NHS Trust, Walsall, W Midlands, England	Imperial College London	Jarman, B (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dr Foster Unit, London SW7 2AZ, England.		Aylin, Paul/A-1073-2014	Aylin, Paul/0000-0003-4589-1743; Bottle, Alex/0000-0001-9978-2011				*I MED, 1999, TO ERR IS HUM BUILD; Jarman B, 1999, BMJ-BRIT MED J, V318, P1515, DOI 10.1136/bmj.318.7197.1515; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; Steiner S H, 2000, Biostatistics, V1, P441, DOI 10.1093/biostatistics/1.4.441; 2001, CMND5207	5	40	41	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 12	2005	330	7487					329	+		10.1136/bmj.330.7487.329	http://dx.doi.org/10.1136/bmj.330.7487.329			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897OZ	15705689	Green Published			2022-12-28	WOS:000227015800014
J	Pavlu, F; Harrington, DJ; Voong, K; Savidge, GF; JAn-Mohamed, R; Kaczmarski, R				Pavlu, F; Harrington, DJ; Voong, K; Savidge, GF; JAn-Mohamed, R; Kaczmarski, R			Superwarfarin poisoning	LANCET			English	Editorial Material									Hillingdon Hosp, Dept Haematol, Uxbridge UB8 3NN, Middx, England; St Thomas Hosp, Ctr Haemostasis & Thrombosis, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust	Pavlu, F (corresponding author), Hillingdon Hosp, Dept Haematol, Uxbridge UB8 3NN, Middx, England.	pavluj@yahoo.com						BABOCK J, 1993, AM J PEDIAT HEMATOL, V15, P1826; BARLOW AM, 1982, BRIT MED J, V285, P541, DOI 10.1136/bmj.285.6341.541; British Medical Association, 2004, MED ETH TOD BMAS HDB, P165; Chua JD, 1998, ARCH INTERN MED, V158, P1929, DOI 10.1001/archinte.158.17.1929; Suttie J W, 1987, Adv Exp Med Biol, V214, P3	5	33	38	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	2005	365	9459					628	628						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DN	15708110				2022-12-28	WOS:000226984300039
J	Mattick, JS; Gagen, MJ				Mattick, JS; Gagen, MJ			Accelerating networks	SCIENCE			English	Editorial Material							EVOLUTION		Univ Queensland, Inst Mol Biosci, ARC Special Res Ctr Funct & Appl Gen, Brisbane, Qld 4072, Australia	University of Queensland	Mattick, JS (corresponding author), Univ Queensland, Inst Mol Biosci, ARC Special Res Ctr Funct & Appl Gen, Brisbane, Qld 4072, Australia.	j.mattick@imb.uq.edu.au; m.gagen@imb.uq.edu.au	Mattick, John/ABH-6130-2020; Mattick, John S/I-7789-2012	Mattick, John/0000-0002-7680-7527; Mattick, John S/0000-0002-7680-7527; Gagen, Michael/0000-0001-7702-9635				Albert R, 2002, REV MOD PHYS, V74, P47, DOI 10.1103/RevModPhys.74.47; Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Dorogovtsev SN, 2002, ADV PHYS, V51, P1079, DOI 10.1080/00018730110112519; Foster I, 2003, SCI AM, V288, P78, DOI 10.1038/scientificamerican0403-78; GAGEN MJ, IN PRESS THEORY BIOS; Habata S, 2003, NEC RES DEV, V44, P21; Hargrove WW, 2001, SCI AM, V285, P72, DOI 10.1038/scientificamerican0801-72; Jones D. T., 1990, MACHINE CHANGED WORL; KERBYSON DJ, 2003, P INT PAR DISTR PROC; Mattick JS, 2004, NAT REV GENET, V5, P316, DOI 10.1038/nrg1321; Mattick JS, 2001, MOL BIOL EVOL, V18, P1611, DOI 10.1093/oxfordjournals.molbev.a003951; Newman MEJ, 2002, P NATL ACAD SCI USA, V99, P2566, DOI 10.1073/pnas.012582999; Sommerhalder R., 1988, THEORY COMPUTABILITY	14	65	67	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	2005	307	5711					856	858		10.1126/science.1103737	http://dx.doi.org/10.1126/science.1103737			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897DV	15705831				2022-12-28	WOS:000226985100030
J	Rubio, V; Deng, XW				Rubio, V; Deng, XW			Phy tunes: Phosphorylation status and phytochrome-mediated signaling	CELL			English	Editorial Material							TRANSCRIPTION-FACTOR; LIGHT SIGNALS; ARABIDOPSIS; PATHWAYS	Phytochromes are photoreceptors that regulate various aspects of plant growth and development. In this issue of Cell, Ryu et al. (2005) show that PAPP5, a type 5 protein phosphatase, acts on a biologically active phytochrome, increasing its stability and affinity for a downstream signal transducer and thus enhancing plant photoresponses.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University	Rubio, V (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA.		Rubio, Vicente/M-2962-2014; Deng, Xing Wang/ABF-4107-2020	Rubio, Vicente/0000-0002-8800-2400; 				FRANKHAUSER C, 2000, SEMIN CELL DEV BIOL, V11, P467; Kim DH, 2002, PLANT CELL, V14, P3043, DOI 10.1105/tpc.005306; Kim J, 2004, PLANT CELL, V16, P2629, DOI 10.1105/tpc.104.023879; Ma LG, 2001, PLANT CELL, V13, P2589, DOI 10.1105/tpc.13.12.2589; Martinez-Garcia JF, 2000, SCIENCE, V288, P859, DOI 10.1126/science.288.5467.859; Matsushita T, 2003, NATURE, V424, P571, DOI 10.1038/nature01837; Nagy F, 2002, ANNU REV PLANT BIOL, V53, P329, DOI 10.1146/annurev.arplant.53.100301.135302; Ryu JS, 2005, CELL, V120, P395, DOI 10.1016/j.cell.2004.12.019; Seo HS, 2004, GENE DEV, V18, P617, DOI 10.1101/gad.1187804; Tepperman JM, 2001, P NATL ACAD SCI USA, V98, P9437, DOI 10.1073/pnas.161300998	10	4	6	1	12	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 11	2005	120	3					290	292		10.1016/j.cell.2005.01.023	http://dx.doi.org/10.1016/j.cell.2005.01.023			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	897TS	15707886	Bronze			2022-12-28	WOS:000227028900003
J	Tard, C; Liu, XM; Ibrahim, SK; Bruschi, M; De Gioia, L; Davies, SC; Yang, X; Wang, LS; Sawers, G; Pickett, CJ				Tard, C; Liu, XM; Ibrahim, SK; Bruschi, M; De Gioia, L; Davies, SC; Yang, X; Wang, LS; Sawers, G; Pickett, CJ			Synthesis of the H-cluster framework of iron-only hydrogenase	NATURE			English	Article							DENSITY-FUNCTIONAL THEORY; ELECTRONIC-STRUCTURE; DIIRON SUBSITE; ACTIVE-SITE; STRUCTURAL ELEMENTS; MODEL COMPLEXES; APPROXIMATION; MECHANISM; EVOLUTION; LIGANDS	The metal- sulphur active sites of hydrogenases catalyse hydrogen evolution or uptake at rapid rates. Understanding the structure and function of these active sites - through mechanistic studies of hydrogenases(1 - 4), synthetic assemblies(5 - 12) and in silico models(13 - 15) - will help guide the design of new materials for hydrogen production or uptake(16). Here we report the assembly of the iron- sulphur framework of the active site of iron- only hydrogenase ( the H- cluster), and show that it functions as an electrocatalyst for proton reduction. Through linking of a di- iron subsite to a {4Fe4S} cluster, we achieve the first synthesis of a metallosulphur cluster core involved in small- molecule catalysis. In addition to advancing our understanding of the natural biological system, the availability of an active, free- standing analogue of the H- cluster may enable us to develop useful electrocatalytic materials for application in, for example, reversible hydrogen fuel cells. ( Platinum is currently the preferred electrocatalyst for such applications, but is expensive, limited in availability and, in the long term, unsustainable(17).)	John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England; John Innes Ctr Plant Sci Res, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England; Univ Milano Bicocca, Dept Biosci & Biotechnol, I-20126 Milan, Italy; Washington State Univ, Dept Phys, Richland, WA USA; Pacific NW Natl Lab, WR Wiley Environm Sci Lab, Richland, WA 99352 USA; Pacific NW Natl Lab, Div Chem Sci, Richland, WA 99352 USA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Milano-Bicocca; Washington State University; United States Department of Energy (DOE); Pacific Northwest National Laboratory; United States Department of Energy (DOE); Pacific Northwest National Laboratory	Pickett, CJ (corresponding author), John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England.	chris.pickett@bbsrc.ac.uk	PICKETT, CHRISTOPHER J/F-3896-2010; Liu, Xiaoming/C-4030-2008; De Gioia, Luca/K-6439-2016; Tard, Cédric/A-9318-2008	PICKETT, CHRISTOPHER J/0000-0003-3142-0780; Liu, Xiaoming/0000-0003-0038-6292; Tard, Cédric/0000-0002-1515-1915; BRUSCHI, MAURIZIO/0000-0002-5709-818X; Yang, Xin/0000-0002-9173-1188				Armstrong FA, 2004, CURR OPIN CHEM BIOL, V8, P133, DOI 10.1016/j.cbpa.2004.02.004; BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098; Bruschi M, 2004, INORG CHEM, V43, P3733, DOI 10.1021/ic035326y; Cao ZX, 2001, J AM CHEM SOC, V123, P3734, DOI 10.1021/ja000116v; Evans DJ, 2003, CHEM SOC REV, V32, P268, DOI 10.1039/b201317g; George SJ, 2002, CHEM-EUR J, V8, P4037, DOI 10.1002/1521-3765(20020902)8:17<4037::AID-CHEM4037>3.0.CO;2-O; Gloaguen F, 2002, INORG CHEM, V41, P6573, DOI 10.1021/ic025838x; Le Cloirec A, 1999, CHEM COMMUN, P2285; Liu ZP, 2002, J AM CHEM SOC, V124, P5175, DOI 10.1021/ja0118690; Lyon EJ, 1999, ANGEW CHEM INT EDIT, V38, P3178, DOI 10.1002/(SICI)1521-3773(19991102)38:21<3178::AID-ANIE3178>3.3.CO;2-W; Nicolet Y, 2000, TRENDS BIOCHEM SCI, V25, P138, DOI 10.1016/S0968-0004(99)01536-4; Nicolet Y, 1999, STRUCTURE, V7, P13, DOI 10.1016/S0969-2126(99)80005-7; Ott S, 2004, ANGEW CHEM INT EDIT, V43, P1006, DOI 10.1002/anie.200353190; PERDEW JP, 1986, PHYS REV B, V33, P8822, DOI 10.1103/PhysRevB.33.8822; Peters JW, 1998, SCIENCE, V282, P1853, DOI 10.1126/science.282.5395.1853; PICKETT CJ, 1994, J CHEM SOC DALTON, P2181, DOI 10.1039/dt9940002181; Popescu CV, 1999, J AM CHEM SOC, V121, P7877, DOI 10.1021/ja991243y; Razavet M, 2003, DALTON T, P586, DOI 10.1039/b209690k; Razavet M, 2002, CHEM COMMUN, P700, DOI 10.1039/b111613b; Reihlen H, 1929, LIEBIGS ANN CHEM, V472, P268; SCHAFER A, 1994, J CHEM PHYS, V100, P5829, DOI 10.1063/1.467146; Schmidt M, 1999, J AM CHEM SOC, V121, P9736, DOI 10.1021/ja9924187; STACK TDP, 1987, J AM CHEM SOC, V109, P2546, DOI 10.1021/ja00242a067; Tard C, 2005, CHEM COMMUN, P133, DOI 10.1039/b411559g; *UK DEP TRANSP, 2003, PLAT HYDR FUEL CELL; *US DEP EN OFF SCI, 2003, BAS EN SCI WORKSH HY; Wang LS, 1999, REV SCI INSTRUM, V70, P1957, DOI 10.1063/1.1149694; Wang XB, 2003, J AM CHEM SOC, V125, P14072, DOI 10.1021/ja036831x; Yang X, 2003, J PHYS CHEM A, V107, P4612, DOI 10.1021/jp034432i; Zhao X, 2002, INORG CHEM, V41, P3917, DOI 10.1021/ic020237r	30	446	449	1	155	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 10	2005	433	7026					610	613		10.1038/nature03298	http://dx.doi.org/10.1038/nature03298			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	895KX	15703741				2022-12-28	WOS:000226862000038
J	Anderson, BE; Billingsley, E				Anderson, BE; Billingsley, E			Growing plaque on the foot	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Penn State Univ, Coll Med, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Anderson, BE (corresponding author), Penn State Univ, Coll Med, Hershey, PA 17033 USA.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 3	2005	352	5					488	488		10.1056/NEJMicm040261	http://dx.doi.org/10.1056/NEJMicm040261			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	893NE	15689587				2022-12-28	WOS:000226725400009
J	Li, ZH; Kosorok, MR; Farrell, PM; Laxova, A; West, SEH; Green, CG; Collins, J; Rock, MJ; Splaingard, ML				Li, ZH; Kosorok, MR; Farrell, PM; Laxova, A; West, SEH; Green, CG; Collins, J; Rock, MJ; Splaingard, ML			Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BRONCHOPULMONARY DISEASE; ANTIBIOTIC-TREATMENT; CROSS-INFECTION; YOUNG-CHILDREN; COLONIZATION; TOBRAMYCIN; INHIBITION; RESISTANCE; CONVERSION	Context Although Pseudomonas aeruginosa is the most common virulent respiratory pathogen in cystic fibrosis (CF), the longitudinal development of P aeruginosa infection and its effect on antibody responses and lung disease progression in children with CF remain unclear. Objective To prospectively examine the epidemiology of Paeruginosa infection and its impact on CF pulmonary morbidity. Design, Setting, and Patients We prospectively evaluated 56 CF patients at 2 CF centers in Madison and Milwaukee, Wis, from birth up to age 16 years between April 15, 1985, and April 15, 2004, with diagnoses made through the Wisconsin CF Neonatal Screening Project. Main Outcome Measures Timing of nonmucoid P aeruginosa and mucoid P aeruginosa acquisition was assessed by first positive result. Longitudinal development from no P aeruginosa to nonmucoid P aeruginosa and from nonmucoid Paerugginosa to mucoid Paeruginosa was examined. Outcome measurements included antibody titers, respiratory symptoms, quantitative chest radiography, and pulmonary function tests. Results Sixteen patients (29%) acquired nonmucoid Paeruginosa in the first 6 months of life. The age-specific prevalence of mucoid Paeruginosa increased markedly from age 4 to 16 years. Nonmucoid and mucoid P aeruginosa were acquired at median ages of 1.0 and 13.0 years, respectively. In contrast with the short transition time from no Paeruginosa to nonmucoid P aeruginosa, the transition time from nonmucoid to mucoid P aeruginosa was relatively long (median, 10.9 years) and could be slightly extended by brief/low anti-Paeruginosa antibiotic treatment. Antibody titers increased with both transitions, but the deterioration in cough scores, chest radiograph scores, and pulmonary function correlated best with transition from nonmucoid to mucoid P aeruginosa. Conclusions Early prevention and detection of nonmucoid and mucoid P aeruginosa are critical because of early acquisition and prevalence. There is a Window of opportunity for suppression and possible eradication (by aggressive anti-P aeruginosa treatment) of initial nonmucoid Paeruginosa. Mucoid Paeruginosa plays a much greater role in CF lung disease progression than nonmucoid Paeruginosa. Antibody titers, cough scores, and chest radiographs are early signs of nonmucoid P aeruginosa and especially mucoid P aeruginosa stages.	Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI 53705 USA; Univ Wisconsin, Dept Biostat Med Informat, Madison, WI 53705 USA; Univ Wisconsin, Dept Pathobiol Sci, Madison, WI 53705 USA; Univ Wisconsin, Dept Radiol, Madison, WI 53705 USA; Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Medical College of Wisconsin	Farrell, PM (corresponding author), Univ Wisconsin, Sch Med, Dept Pediat, Room 4129 HSLC,750 Highland Ave, Madison, WI 53705 USA.	pmfarrel@facstaff.wics.edu	Kosorok, Michael/ABB-7427-2021; Splaingard, Mark/AAL-7356-2021; Splaingard, Mark/D-9206-2012	Splaingard, Mark/0000-0002-1361-4947	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR003186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK034108, R01DK034108] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR03186] Funding Source: Medline; NIDDK NIH HHS [DK 34108] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANWAR H, 1989, J ANTIMICROB CHEMOTH, V24, P647, DOI 10.1093/jac/24.5.647; Armstrong DS, 2002, AM J RESP CRIT CARE, V166, P983, DOI 10.1164/rccm.200204-269OC; Ballmann M, 1998, THORAX, V53, P732, DOI 10.1136/thx.53.9.732; Burns JL, 2001, J INFECT DIS, V183, P444, DOI 10.1086/318075; CABRAL DA, 1987, PEDIATR RES, V22, P429, DOI 10.1203/00006450-198710000-00013; DORING G, 1988, CHEST, V94, pS109, DOI 10.1378/chest.94.2.109S; Emerson J, 2002, PEDIATR PULM, V34, P91, DOI 10.1002/ppul.10127; Farrell P M, 2000, Adv Pediatr, V47, P79; Farrell PM, 2003, AM J RESP CRIT CARE, V168, P1100, DOI 10.1164/rccm.200303-434OC; Farrell PM, 2003, PEDIATR PULM, V36, P230, DOI 10.1002/ppul.10336; Farrell PM, 1997, NEW ENGL J MED, V337, P963, DOI 10.1056/NEJM199710023371403; Farrell PM, 2001, PEDIATRICS, V107, P1, DOI 10.1542/peds.107.1.1; FEGAN M, 1990, J CLIN MICROBIOL, V28, P1143, DOI 10.1128/JCM.28.6.1143-1146.1990; FITZSIMMONS SC, 1993, J PEDIATR-US, V122, P1, DOI 10.1016/S0022-3476(05)83478-X; Frederiksen B, 1997, PEDIATR PULM, V23, P330, DOI 10.1002/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO;2-O; Gibson RL, 2003, AM J RESP CRIT CARE, V168, P918, DOI 10.1164/rccm.200304-505SO; Griese M, 2002, EUR J MED RES, V7, P79; Hassett DJ, 2002, ADV DRUG DELIVER REV, V54, P1425, DOI 10.1016/S0169-409X(02)00152-7; Heinzl B, 2002, PEDIATR PULM, V33, P32, DOI 10.1002/ppul.10019; HENRY RL, 1992, PEDIATR PULM, V12, P158, DOI 10.1002/ppul.1950120306; HODGES NA, 1991, ANTIMICROB AGENTS CH, V35, P2450, DOI 10.1128/AAC.35.11.2450; Hoiby N, 2000, Paediatr Drugs, V2, P451; Koch C, 2002, PEDIATR PULM, V34, P232, DOI 10.1002/ppul.10135; Kosorok MR, 2001, PEDIATR PULM, V32, P277, DOI 10.1002/ppul.2009.abs; Li ZH, 2004, PEDIATR PULM, V38, P277, DOI 10.1002/ppul.20092; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MARTIN DW, 1993, MOL MICROBIOL, V9, P497, DOI 10.1111/j.1365-2958.1993.tb01711.x; NICHOLS WW, 1988, ANTIMICROB AGENTS CH, V32, P518, DOI 10.1128/AAC.32.4.518; Nixon GM, 2001, J PEDIATR-US, V138, P699, DOI 10.1067/mpd.2001.112897; Ojeniyi B, 2000, PEDIATR PULM, V29, P177, DOI 10.1002/(SICI)1099-0496(200003)29:3<177::AID-PPUL4>3.0.CO;2-U; Parad RB, 1999, INFECT IMMUN, V67, P4744, DOI 10.1128/IAI.67.9.4744-4750.1999; Pier GB, 2001, INFECT IMMUN, V69, P1895, DOI 10.1128/IAI.69.3.1895-1901.2001; Ratjen F, 2001, LANCET, V358, P983, DOI 10.1016/S0140-6736(01)06124-4; Sawa T, 1999, NAT MED, V5, P392, DOI 10.1038/7391; SOKOL PA, 1994, J BACTERIOL, V176, P553, DOI 10.1128/jb.176.3.553-562.1994; STIVER HG, 1988, CLIN INVEST MED, V11, P247; Tubbs D, 2001, RESP MED, V95, P147, DOI 10.1053/rmed.2000.1009; VALERIUS NH, 1991, LANCET, V338, P725, DOI 10.1016/0140-6736(91)91446-2; West SEH, 2002, JAMA-J AM MED ASSOC, V287, P2958, DOI 10.1001/jama.287.22.2958; Yu HW, 2002, FRONT BIOSCI-LANDMRK, V7, pD442	40	396	401	1	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2005	293	5					581	588		10.1001/jama.293.5.581	http://dx.doi.org/10.1001/jama.293.5.581			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	893BL	15687313	Bronze			2022-12-28	WOS:000226694200021
J	Carratala, J; Fernandez-Sabe, N; Ortega, L; Castellsague, X; Roson, B; Dorca, J; Fernandez-Aguera, A; Verdaguer, R; Martinez, J; Manresa, F; Gudiol, F				Carratala, J; Fernandez-Sabe, N; Ortega, L; Castellsague, X; Roson, B; Dorca, J; Fernandez-Aguera, A; Verdaguer, R; Martinez, J; Manresa, F; Gudiol, F			Outpatient care compared with hospitalization for community-acquired pneumonia - A randomized trial in low-risk patients	ANNALS OF INTERNAL MEDICINE			English	Article							PRACTICE GUIDELINES; PREDICTION RULE; MANAGEMENT; LEVOFLOXACIN; SEVERITY; OUTCOMES; THERAPY; FAILURE; ADULTS	Background: The Pneumonia Severity Index (PSI) has been advocated as an objective measure of risk stratification to help determine the initial site of treatment for patients with community-acquired pneumonia. Objective: To determine whether outpatient care of PSI-defined low-risk patients with community-acquired pneumonia is as safe and effective as hospitalization. Design: Unblinded, randomized, controlled trial. Setting: 2 tertiary care hospitals. Patients: 224 immunocompetent adults in risk class II or III (PSI scores less than or equal to 90 points) who received a diagnosis of community-acquired pneumonia in the emergency department and had no extenuating circumstances. Intervention: outpatient care with oral levofloxacin therapy or hospitalization with sequential intravenous and oral levofloxacin therapy. Measurements: The primary end point was the percentage of patients with an overall successful outcome at the end of treatment, according to 7 predefined criteria. Secondary end points included patients' quality of life and satisfaction. Results: Overall successful outcome was achieved in 83.6% of outpatients and 80.7% of hospitalized patients (absolute difference, 2.9 percentage points [95% CI, -7.1 to 12.9 percentage points]). More outpatients were satisfied with their overall care (91.2% vs. 79.1%; absolute difference, 12.1 percentage points [CI, 1.8 to 22.5 percentage points]). Quality of life and the percentages of patients with adverse drug reactions (9.1% vs. 9.6%), medical complications (0.9% vs. 2.6%), subsequent hospital admissions (6.3% vs. 7.0%), and overall mortality (0.9% vs. 0%) were similar in the outpatient and hospitalization groups. Limitations: The power to detect a serious complication, such as death, was limited given the relatively small sample size. Conclusions: in selected patients who had community-acquired pneumonia, PSI risk class II and III, and were treated with levofloxacin, outpatient care in the absence of respiratory failure, unstable comorbid conditions, complicated pleural effusions, and social problems was as safe and effective as hospitalization and provided greater patient satisfaction.	Univ Barcelona, Hosp Univ Bellvitge, IDIBELL, Barcelona, Spain; Hosp Barcelona, SCIAS, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona	Carratala, J (corresponding author), Hosp Univ Bellvitge, Infect Dis Serv, Hosp Llobregat, Feixa Llarga S-N, Barcelona 08907, Spain.	jcarratala@wanadoo.es	Pique, Xavier Castellsagué/N-5795-2014; Carratalà, Jordi/B-8410-2011; Carratala, Jordi/AAC-2639-2020; Dorca, Jordi/Q-3617-2016	Pique, Xavier Castellsagué/0000-0002-0802-3595; Carratalà, Jordi/0000-0003-3209-2563; Carratala, Jordi/0000-0003-3209-2563; Sabe, Nuria/0000-0003-1697-4347; Dorca, Jordi/0000-0002-8137-878X				Alonso J, 1998, MED CLIN-BARCELONA, V111, P410; Arnold FW, 2003, CHEST, V124, P121, DOI 10.1378/chest.124.1.121; Atlas SJ, 1998, ARCH INTERN MED, V158, P1350, DOI 10.1001/archinte.158.12.1350; BARTLETT JG, 1995, NEW ENGL J MED, V333, P1618, DOI 10.1056/NEJM199512143332408; Blackwelder WC, 1998, ENCY BIOSTATISTICS; Coley CM, 1996, ARCH INTERN MED, V156, P1565, DOI 10.1001/archinte.156.14.1565; Davidson R, 2002, NEW ENGL J MED, V346, P747, DOI 10.1056/NEJMoa012122; Dean NC, 1999, CLIN CHEST MED, V20, P521, DOI 10.1016/S0272-5231(05)70233-1; Fine MJ, 1996, JAMA-J AM MED ASSOC, V275, P134, DOI 10.1001/jama.275.2.134; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Furlanut M, 2003, J ANTIMICROB CHEMOTH, V51, P101, DOI 10.1093/jac/dkg035; Halm EA, 2002, NEW ENGL J MED, V347, P2039, DOI 10.1056/NEJMcp020499; Halm EA, 1998, JAMA-J AM MED ASSOC, V279, P1452, DOI 10.1001/jama.279.18.1452; Mandell LA, 2003, CLIN INFECT DIS, V37, P1405, DOI 10.1086/380488; Marras TK, 2000, CHEST, V118, P1339, DOI 10.1378/chest.118.5.1339; Marrie TJ, 2000, JAMA-J AM MED ASSOC, V283, P749, DOI 10.1001/jama.283.6.749; Metlay JP, 2003, ANN INTERN MED, V138, P109, DOI 10.7326/0003-4819-138-2-200301210-00012; Metlay JP, 1997, J GEN INTERN MED, V12, P423, DOI 10.1046/j.1525-1497.1997.00074.x; *NCCLS, 2001, M100S11; Niederman MS, 1998, CLIN THER, V20, P820, DOI 10.1016/S0149-2918(98)80144-6; Niederman MS, 2001, AM J RESP CRIT CARE, V163, P1730, DOI 10.1164/ajrccm.163.7.at1010; Roson B, 2004, ARCH INTERN MED, V164, P502, DOI 10.1001/archinte.164.5.502; Roson B, 2001, CLIN INFECT DIS, V33, P158, DOI 10.1086/321808; Vergis EN, 1999, EUR J CLIN MICROBIOL, V18, P847, DOI 10.1007/s100960050418; Ware JE, 1994, SF 36 PHYSL MENTAL H	25	189	191	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	2005	142	3					165	172		10.7326/0003-4819-142-3-200502010-00006	http://dx.doi.org/10.7326/0003-4819-142-3-200502010-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900UH	15684204				2022-12-28	WOS:000227239300002
J	Jain, A; Atreja, A; Harris, M; Lehmann, M; Burns, J; Young, J				Jain, A; Atreja, A; Harris, M; Lehmann, M; Burns, J; Young, J			Responding to the rofecoxib withdrawal crisis: A new model for notifying patients at risk and their health care providers	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICIAN ORDER ENTRY; SAFETY; MEDICATION; RECALL; INFORMATION; MEDICINES; ARTHRITIS; MERCK; FDA	Background: We decided to inform our patients of the withdrawal of rofecoxib, one of the largest drug withdrawals in United States history, and instruct them to contact their providers for guidance. Objective: To identify and inform patients and providers affected by the rofecoxib withdrawal. Design: Descriptive observational study. Setting: Tertiary care center with an electronic medical record (EMR) system. Patients: Patients with an active rofecoxib prescription within the EMR. Intervention: Existing information technology and traditional communication resources were used to automate the identifying and notifying of patients and providers and to deactivate rofecoxib prescriptions in the EMR. Measurements: characteristics of patients receiving rofecoxib at our institution, details of their prescription and provider, number of EMR alerts, and medication discontinuations. Results: The 11699 patients with a rofecoxib prescription in our practice were sent notifications within 24 hours of the withdrawal. Limitations: we did not directly measure the effect of our notification on patients or providers. Conclusions: information technology enabled our institution to rapidly identify and notify individual patients and their providers about an important drug withdrawal. The methods modeled a feasible way for health care organizations with EMRs to participate in notification processes that may be applicable in a variety of situations.	Cleveland Clin Fdn, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Jain, A (corresponding author), Cleveland Clin Fdn, 9500 Euclid Ave,A91, Cleveland, OH 44195 USA.			Atreja, Ashish/0000-0002-0628-4417				Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; *CAMH, 2004, OFF HDB CAMH; Delorio NM, 2004, J EMERG MED, V26, P305, DOI 10.1016/j.jemermed.2003.09.009; DICK S, 1997, COMPUTER BASED PATIE; Folz-Murphy N, 1998, J AM MED INFORM ASSN, P260; Foster Erica, 2003, J AHIMA, V74, P34; Friedman MA, 1999, JAMA-J AM MED ASSOC, V281, P1728, DOI 10.1001/jama.281.18.1728; Greene H L, 2000, Health News, V6, P4; Harris C Martin, 2003, J Healthc Inf Manag, V17, P37; Houston TK, 2002, J MED INTERNET RES, V4, DOI 10.2196/jmir.4.2.e7; JOHNSON LJ, 2001, MED ECON, V78, P118; Kaushal R, 2003, ARCH INTERN MED, V163, P1409, DOI 10.1001/archinte.163.12.1409; Kleinke JD, 1998, BRIT MED J, V317, P899; LIMA HA, 1995, AM J HEALTH-SYST PH, V52, P1010, DOI 10.1093/ajhp/52.9.1010; *MERCK CO INC, 2004, NEWS REL, P1; Murphy GF, 1999, ELECT HLTH RECORDS C; Poland GA, 1997, JAMA-J AM MED ASSOC, V278, P1022, DOI 10.1001/jama.278.12.1022; Rich D S, 1995, Hosp Pharm, V30, P165; Schiff GD, 2002, PHARMACOEPIDEM DR S, V11, P643, DOI 10.1002/pds.778; Singh D, 2004, BRIT MED J, V329, P816, DOI 10.1136/bmj.329.7470.816-a; SMITHELLS RW, 1963, LANCET, V1, P1095; SPOONER T, 2003, INTERNET USE REGION, P2; Topol EJ, 2004, NEW ENGL J MED, V351, P1707, DOI 10.1056/NEJMp048286; *US DEP HLTH HUM S, 2001, STAND PRIV IND ID HL; US Food and Drug Administration, 2004, FDA ISS PUBL HLTH AD; Wolfe SM, 2002, PHARMACOEPIDEM DR S, V11, P641, DOI 10.1002/pds.776; Wood AJJ, 1999, JAMA-J AM MED ASSOC, V281, P1753, DOI 10.1001/jama.281.18.1753; Zaidi STR, 2002, AM J HEALTH-SYST PH, V59, P1569, DOI 10.1093/ajhp/59.16.1569a; *ZIX CORP E PRESCR, 2004, FORB BUS WIRE; 2004, FAMILYMEDS USES NEW, P1	31	17	17	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	2005	142	3					182	186		10.7326/0003-4819-142-3-200502010-00008	http://dx.doi.org/10.7326/0003-4819-142-3-200502010-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900UH	15684206				2022-12-28	WOS:000227239300004
J	Kamakoti, P; Morreale, BD; Ciocco, MV; Howard, BH; Killmeyer, RP; Cugini, AV; Sholl, DS				Kamakoti, P; Morreale, BD; Ciocco, MV; Howard, BH; Killmeyer, RP; Cugini, AV; Sholl, DS			Prediction of hydrogen flux through sulfur-tolerant binary alloy membranes	SCIENCE			English	Article							DILUTE-SOLUTIONS; PALLADIUM; DIFFUSION; THERMODYNAMICS; PD; TEMPERATURES; PERMEANCE	Metal membranes play a vital rote in hydrogen purification. Defect-free membranes can exhibit effectively infinite selectivity but must also provide high fluxes, resistance to poisoning, long operational lifetimes, and low cost. Alloying offers one route to improve on membranes based on pure metals such as palladium. We show how ab initio calculations and coarse-grained modeling can accurately predict hydrogen fluxes through binary alloy membranes as functions of alloy composition, temperature, and pressure. Our approach, which requires no experimental input apart from knowledge of bulk crystal structures, is demonstrated for palladium-copper alloys, which show nontrivial behavior due to the existence of face-centered cubic and body-centered cubic crystal structures and have the potential to resist sulfur poisoning. The accuracy of our approach is examined by a comparison with extensive experiments using thick foils at elevated temperatures. Our experiments also demonstrate the ability of these membranes to resist poisoning by hydrogen sulfide.	Carnegie Mellon Univ, Dept Chem Engn, Pittsburgh, PA 15213 USA; US DOE, Natl Energy Technol Lab, Pittsburgh, PA 15236 USA	Carnegie Mellon University; United States Department of Energy (DOE); National Energy Technology Laboratory - USA	Sholl, DS (corresponding author), Carnegie Mellon Univ, Dept Chem Engn, Pittsburgh, PA 15213 USA.	shotl@andrew.cmu.edu						EDLUND D, 1996, ADV COALF POW SYST 9; Fowler R.H., 1937, P ROY SOC LOND A MAT, V145, P699; FUKAI Y, 1985, ADV PHYS, V34, P263, DOI 10.1080/00018738500101751; Greeley J, 2004, ANGEW CHEM INT EDIT, V43, P4296, DOI 10.1002/anie.200454062; GRYAZNOV VM, 1986, Z PHYS CHEM NEUE FOL, V147, P123, DOI 10.1524/zpch.1986.147.1_2.123; Hansen M., 1958, CONSTITUTION BINARY, V2nd ed., P1175; Howard BH, 2004, J MEMBRANE SCI, V241, P207, DOI 10.1016/j.memsci.2004.04.031; Jiang DE, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.064102; Kamakoti P, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.014301; Kamakoti P, 2003, J MEMBRANE SCI, V225, P145, DOI 10.1016/j.memsci.2003.07.008; Keil FJ, 2000, REV CHEM ENG, V16, P71; KLEPPA OJ, 1979, J CHEM PHYS, V71, P1656, DOI 10.1063/1.438503; Kulprathipanja A, 2004, IND ENG CHEM RES, V43, P4188, DOI 10.1021/ie030853a; Lin YS, 2001, SEP PURIF TECHNOL, V25, P39, DOI 10.1016/S1383-5866(01)00089-2; Lovvik OM, 2002, J ALLOY COMPD, V330, P332, DOI 10.1016/S0925-8388(01)01491-8; Ma YH, 2004, IND ENG CHEM RES, V43, P2936, DOI 10.1021/ie034002e; McCool BA, 2001, J MATER SCI, V36, P3221, DOI 10.1023/A:1017938403725; MCKINLEY DL, 1967, Patent No. 3350845; MCLELLAN RB, 1987, ACTA METALL MATER, V35, P197, DOI 10.1016/0001-6160(87)90229-X; Morreale BD, 2004, J MEMBRANE SCI, V241, P219, DOI 10.1016/j.memsci.2004.04.033; Morreale BD, 2003, J MEMBRANE SCI, V212, P87, DOI 10.1016/S0376-7388(02)00456-8; Paglieri SN, 2002, SEPAR PURIF METHOD, V31, P1, DOI 10.1081/SPM-120006115; PIPER J, 1966, J APPL PHYS, V37, P715, DOI 10.1063/1.1708243; Roa F, 2003, IND ENG CHEM RES, V42, P5827, DOI 10.1021/ie030426x; Roa F, 2003, CHEM ENG J, V93, P11, DOI 10.1016/S1385-8947(02)00106-7; Schlapbach L, 2001, NATURE, V414, P353, DOI 10.1038/35104634; She Y, 2001, CATAL TODAY, V67, P43, DOI 10.1016/S0920-5861(01)00280-2; Volkl J., 1978, Hydrogen in metals I, P321; WAGNER C, 1973, ACTA METALL MATER, V21, P1297, DOI 10.1016/0001-6160(73)90171-5; Ward TL, 1999, J MEMBRANE SCI, V153, P211, DOI 10.1016/S0376-7388(98)00256-7; Weiss A, 1997, Z PHYS CHEM, V199, P165, DOI 10.1524/zpch.1997.199.Part_2.165; Wicke E, 1978, HYDROGEN METALS, P73; YOSHIHARA M, 1983, ACTA METALL MATER, V31, P61, DOI 10.1016/0001-6160(83)90064-0	33	222	226	1	84	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2005	307	5709					569	573		10.1126/science.1107041	http://dx.doi.org/10.1126/science.1107041			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893BJ	15681382				2022-12-28	WOS:000226694000044
J	PELLI, DG; CHAMBERLAIN, SC				PELLI, DG; CHAMBERLAIN, SC			THE VISIBILITY OF 350-DEGREES-C BLACK-BODY RADIATION BY THE SHRIMP RIMICARIS-EXOCULATA AND MAN	NATURE			English	Article									SYRACUSE UNIV,DEPT BIOENGN,SYRACUSE,NY 13244	Syracuse University	PELLI, DG (corresponding author), SYRACUSE UNIV,INST SENSORY RES,SYRACUSE,NY 13244, USA.							BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; BROWNE MW, 1988, NY TIMES        0809, pB5; DRTNALL HJA, 1972, HDB SENSORY PHYSL 2, V7; Pirenne M. H., 1962, EYE, V2; STILES WS, 1974, VISION RES, V14, P195, DOI 10.1016/0042-6989(74)90101-1; THOMPSON G, 1988, CAN MINERAL, V26, P697; VANDOVER CL, 1988, MAR BIOL, V98, P209, DOI 10.1007/BF00391196; VANDOVER CL, 1989, NATURE, V337; Wyszecki G., 1982, COLOR SCI, V8	9	45	45	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 2	1989	337	6206					460	461		10.1038/337460a0	http://dx.doi.org/10.1038/337460a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	T0720	15726721				2022-12-28	WOS:A1989T072000066
J	Nakagawa, T; Sakurai, T; Nishioka, T; Touhara, K				Nakagawa, T; Sakurai, T; Nishioka, T; Touhara, K			Insect sex-pheromone signals mediated by specific combinations of olfactory receptors	SCIENCE			English	Article							MOTH HELIOTHIS-VIRESCENS; BOMBYX-MORI; FLY BRAIN; DROSOPHILA; ACTIVATION; MECHANISMS; RESPONSES; ANTHERAEA; SILKMOTH; NEURONS	We describe two mate-specific olfactory receptors (ORs) in the silk moth, Bombyx mori, that are mutually exclusively expressed in a pair of adjacent pheromone-sensitive neurons of mate antennae: One is specifically tuned to bombykol, the sex pheromone, and the other to bombykal, its oxidized form. Both pheromone ORs are coexpressed with an OR from the highly conserved insect OR subfamily. This coexpression promotes the functional expression of pheromone receptors and confers ligand-stimulated nonselective cation channel activity. The same effects were also observed for general ORs. Both odorant and pheromone signaling pathways are mediated by means of a common mechanism in insects.	Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Chiba 2778562, Japan; Kyoto Univ, Grad Sch Agr, Div Appl Biosci, Kyoto 6068502, Japan; Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Kyoto 6068502, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Kawaguchi 3320012, Japan	University of Tokyo; Kyoto University; Kyoto University; Japan Science & Technology Agency (JST)	Nishioka, T (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Kyoto 6068502, Japan.	nishioka@scl.kyoto-u.ac.jp; touhara@k.u-tokyo.ac.jp						Hallem EA, 2004, TRENDS GENET, V20, P453, DOI 10.1016/j.tig.2004.06.015; Hallem EA, 2004, CELL, V117, P965, DOI 10.1016/j.cell.2004.05.012; HANSSON BS, 1992, SCIENCE, V256, P1313, DOI 10.1126/science.1598574; Hildebrand JG, 1997, ANNU REV NEUROSCI, V20, P595, DOI 10.1146/annurev.neuro.20.1.595; Kaissling KE, 1996, CHEM SENSES, V21, P257, DOI 10.1093/chemse/21.2.257; Kanzaki R, 2003, CHEM SENSES, V28, P113, DOI 10.1093/chemse/28.2.113; Krieger J, 2004, P NATL ACAD SCI USA, V101, P11845, DOI 10.1073/pnas.0403052101; Krieger J, 2003, J COMP PHYSIOL A, V189, P519, DOI 10.1007/s00359-003-0427-x; Krieger J, 2002, EUR J NEUROSCI, V16, P619, DOI 10.1046/j.1460-9568.2002.02109.x; Larsson MC, 2004, NEURON, V43, P703, DOI 10.1016/j.neuron.2004.08.019; Mori K, 1998, CHIRALITY, V10, P578, DOI 10.1002/(SICI)1520-636X(1998)10:7<578::AID-CHIR5>3.0.CO;2-Z; NAKAGAWA T, UNPUB; Neuhaus EM, 2005, NAT NEUROSCI, V8, P15, DOI 10.1038/nn1371; Pitts RJ, 2004, P NATL ACAD SCI USA, V101, P5058, DOI 10.1073/pnas.0308146101; Pophof B, 2004, CHEM SENSES, V29, P117, DOI 10.1093/chemse/bjh012; Sakurai T, 2004, P NATL ACAD SCI USA, V101, P16653, DOI 10.1073/pnas.0407596101; STEINBRECHT RA, 1995, CELL TISSUE RES, V282, P203, DOI 10.1007/BF00319112; TOPAZZINI A, 1990, J INSECT PHYSIOL, V36, P619, DOI 10.1016/0022-1910(90)90065-N; Tozzi A, 2003, EUR J NEUROSCI, V18, P2133, DOI 10.1046/j.1460-9568.2003.02936.x; Vosshall LB, 2000, CELL, V102, P147, DOI 10.1016/S0092-8674(00)00021-0; Vosshall LB, 2001, CHEM SENSES, V26, P207, DOI 10.1093/chemse/26.2.207; Wang JW, 2003, CELL, V112, P271, DOI 10.1016/S0092-8674(03)00004-7	24	392	436	9	136	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 11	2005	307	5715					1638	1642		10.1126/science.1106267	http://dx.doi.org/10.1126/science.1106267			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	906ED	15692016				2022-12-28	WOS:000227622400051
J	Woodhead, M; Verheij, TJM				Woodhead, M; Verheij, TJM			Commentary: A step forward in the everyday management of adults with community acquired pneumonia	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Manchester Royal Infirm, Dept Resp Med, Manchester M13 9WL, Lancs, England; Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3584 CG Utrecht, Netherlands	University of Manchester; Utrecht University; Utrecht University Medical Center	Woodhead, M (corresponding author), Manchester Royal Infirm, Dept Resp Med, Oxford Rd, Manchester M13 9WL, Lancs, England.							*BRIT THOR SOC PNE, BTS GUID MAN COMM AC; Friend JAR, 2001, THORAX, V56, P1, DOI 10.1136/thorax.56.1.1; Hedlund J, 2002, SCAND J INFECT DIS, V34, P887, DOI 10.1080/0036554021000026965; Mills GD, 2005, BMJ-BRIT MED J, V330, P456, DOI 10.1136/bmj.38334.591586.82; Woodhead M, 1996, EUR RESPIR J, V9, P1596, DOI 10.1183/09031936.96.09081596	5	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 26	2005	330	7489					460	460		10.1136/bmj.38378.607130.55	http://dx.doi.org/10.1136/bmj.38378.607130.55			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	901XK	15684021	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000227315400022
J	Chiorazzi, N; Rai, KR; Ferrarini, M				Chiorazzi, N; Rai, KR; Ferrarini, M			Mechanisms of disease: Chronic lymphocytic leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							B-CELL RECEPTOR; GENE MUTATIONAL STATUS; V-H GENES; VARIABLE-REGION MUTATIONS; CD38 EXPRESSION; SOMATIC HYPERMUTATION; ZAP-70 EXPRESSION; SURFACE IGM; IMMUNOGLOBULIN HEAVY; GENOMIC ABERRATIONS		N Shore LIJ Hlth Syst, Inst Med Res, Manhasset, NY 11030 USA; N Shore Univ Hosp, Manhasset, NY USA; NYU, Sch Med, New York, NY USA; Long Isl Jewish Med Ctr, Dept Med, New Hyde Pk, NY 11042 USA; Albert Einstein Coll Med, Bronx, NY USA; Ist Nazl Ric Canc, Div Med Oncol C, I-16132 Genoa, Italy; Univ Genoa, Dipartimento Oncol Clin & Sperimentale, Genoa, Italy	Northwell Health; Northwell Health; North Shore University Hospital; New York University; Northwell Health; Yeshiva University; Albert Einstein College of Medicine; University of Genoa; IRCCS AOU San Martino IST; University of Genoa	Chiorazzi, N (corresponding author), N Shore LIJ Hlth Syst, Inst Med Res, 350 Community Dr, Manhasset, NY 11030 USA.	nchizzi@nshs.edu		Ferrarini, Manlio/0000-0002-6154-2570	NCI NIH HHS [CA 87956, R01 CA 81554, P01 CA 081534] Funding Source: Medline; NCRR NIH HHS [M01 RR018535] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081554, R01CA087956, P01CA081534] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR018535] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Alfarano A, 1999, BLOOD, V93, P2327, DOI 10.1182/blood.V93.7.2327.407a08_2327_2335; Bernal A, 2001, BLOOD, V98, P3050, DOI 10.1182/blood.V98.10.3050; Bichi R, 2002, P NATL ACAD SCI USA, V99, P6955, DOI 10.1073/pnas.102181599; BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V; Boes M, 2000, MOL IMMUNOL, V37, P1141, DOI 10.1016/S0161-5890(01)00025-6; BORCHE L, 1990, BLOOD, V76, P562; BROKER BM, 1988, J AUTOIMMUN, V1, P469, DOI 10.1016/0896-8411(88)90068-6; Burger JA, 2002, LEUKEMIA LYMPHOMA, V43, P461, DOI 10.1080/10428190290011921; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Casola S, 2004, NAT IMMUNOL, V5, P317, DOI 10.1038/ni1036; Cavalli F, 2001, Hematology Am Soc Hematol Educ Program, P241; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Chen HJ, 2000, BLOOD, V96, P3181; Chen LG, 2002, BLOOD, V100, P4609, DOI 10.1182/blood-2002-06-1683; Chiorazzi N, 2003, ANNU REV IMMUNOL, V21, P841, DOI 10.1146/annurev.immunol.21.120601.141018; Chu P, 2002, P NATL ACAD SCI USA, V99, P3854, DOI 10.1073/pnas.022604399; Chung JB, 2003, TRENDS IMMUNOL, V24, P343, DOI 10.1016/S1471-4906(03)00119-4; Crespo M, 2003, NEW ENGL J MED, V348, P1764, DOI 10.1056/NEJMoa023143; DALLAFAVERA R, 2001, MOL BIOL LYMPHOMAS; DAMESHEK W, 1959, BLOOD, V14, P1151, DOI 10.1182/blood.V14.10.1151.1151; DAMESHEK W, 1967, BLOOD-J HEMATOL, V29, P566, DOI 10.1182/blood.V29.4.566.566; Damle RN, 2004, BLOOD, V103, P375, DOI 10.1182/blood-2003-04-1345; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; Damle RN, 2002, BLOOD, V99, P4087, DOI 10.1182/blood.V99.11.4087; de Vinuesa CG, 2000, J EXP MED, V191, P485, DOI 10.1084/jem.191.3.485; Deaglio S, 2003, BLOOD, V102, P2146, DOI 10.1182/blood-2003-03-0989; Deaglio S, 1998, J IMMUNOL, V160, P395; Diaw L, 1997, J IMMUNOL, V158, P968; Diaw L, 1999, J EXP MED, V190, P1405, DOI 10.1084/jem.190.10.1405; Dighiero G, 1999, IMMUNOL TODAY, V20, P423, DOI 10.1016/S0167-5699(99)01509-1; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Fais F, 1998, J CLIN INVEST, V102, P1515, DOI 10.1172/JCI3009; Ghia P, 2004, BLOOD, V103, P2337, DOI 10.1182/blood-2003-09-3277; Ghia P, 2003, BLOOD, V101, P1262, DOI 10.1182/blood-2002-06-1801; Ghia P, 2000, ADV CANCER RES, V79, P157, DOI 10.1016/S0065-230X(00)79005-1; Ghiotto F, 2004, J CLIN INVEST, V113, P1008, DOI 10.1172/JCI200419399; Gordon MS, 2000, P NATL ACAD SCI USA, V97, P5504, DOI 10.1073/pnas.090087097; Granziero L, 2001, BLOOD, V97, P2777, DOI 10.1182/blood.V97.9.2777; Hamblin TJ, 2002, BLOOD, V99, P1023, DOI 10.1182/blood.V99.3.1023; Hamblin TJ, 1999, BLOOD, V94, P1848, DOI 10.1182/blood.V94.6.1848; HARINDRANATH N, 1991, INT IMMUNOL, V3, P865, DOI 10.1093/intimm/3.9.865; HASHIMOTO S, 1995, J EXP MED, V181, P1507, DOI 10.1084/jem.181.4.1507; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; HIVROZ C, 1986, EUR J IMMUNOL, V16, P1001, DOI 10.1002/eji.1830160821; Hultdin M, 2003, BRIT J CANCER, V88, P593, DOI 10.1038/sj.bjc.6600763; Ibrahim S, 2001, BLOOD, V98, P181, DOI 10.1182/blood.V98.1.181; Jelinek DF, 2001, BRIT J HAEMATOL, V115, P854, DOI 10.1046/j.1365-2141.2001.03149.x; Johnson TA, 1997, J IMMUNOL, V158, P235; KARRAY S, 1987, BLOOD, V70, P1105; Keating Michael J, 2003, Hematology Am Soc Hematol Educ Program, P153, DOI 10.1182/asheducation-2003.1.153; KELSOE G, 1994, J EXP MED, V180, P5, DOI 10.1084/jem.180.1.5; Klein U, 2001, J EXP MED, V194, P1625, DOI 10.1084/jem.194.11.1625; KONG GH, 1995, IMMUNITY, V2, P485, DOI 10.1016/1074-7613(95)90029-2; Krober A, 2002, BLOOD, V100, P1410, DOI 10.1182/blood.V100.4.1410.h81602001410_1410_1416; Lanham S, 2003, BLOOD, V101, P1087, DOI 10.1182/blood-2002-06-1822; LANKESTER AC, 1995, BLOOD, V86, P1090; Lee YK, 2004, BLOOD, V104, P788, DOI 10.1182/blood-2003-08-2763; Lin K, 2002, BLOOD, V100, P1404, DOI 10.1182/blood-2001-11-0066; Lin K, 2002, BLOOD, V100, P2291; Lund FE, 1996, J IMMUNOL, V157, P1455; Maloum K, 2000, BLOOD, V96, P377, DOI 10.1182/blood.V96.1.377.013k56f_377_379; MANGIOLA M, 2003, LEUKEMIA LYMPHOMA, V44, pS4; Martin F, 2001, CURR OPIN IMMUNOL, V13, P195, DOI 10.1016/S0952-7915(00)00204-1; MATUTES E, 1994, LEUKEMIA, V8, P1640; Meffre E, 2004, J EXP MED, V199, P145, DOI 10.1084/jem.20031550; MESSMER B, IN PRESS J CLIN INVE; Messmer BT, 2004, J EXP MED, V200, P519, DOI 10.1084/jem.20040544; Messmer BT, 2004, BLOOD, V103, P3490, DOI 10.1182/blood-2003-10-3407; MICHEL F, 1993, J IMMUNOL, V150, P3624; Migliazza A, 2001, BLOOD, V97, P2098, DOI 10.1182/blood.V97.7.2098; Monroe JG, 2004, CURR OPIN IMMUNOL, V16, P288, DOI 10.1016/j.coi.2004.03.010; Monson NL, 2001, CLIN IMMUNOL, V100, P71, DOI 10.1006/clim.2001.5049; Moreau EJ, 1997, AM J CLIN PATHOL, V108, P378; Narducci MG, 2000, CANCER RES, V60, P2095; Niiro H, 2002, NAT REV IMMUNOL, V2, P945, DOI 10.1038/nri955; Ochsenbein AF, 1999, SCIENCE, V286, P2156, DOI 10.1126/science.286.5447.2156; Orchard JA, 2004, LANCET, V363, P105, DOI 10.1016/S0140-6736(03)15260-9; ORSINI E, 2001, CHRONIC LYMPHOID LEU, P127; Oscier DG, 2002, BLOOD, V100, P1177, DOI 10.1182/blood.V100.4.1177.h81602001177_1177_1184; Oscier DG, 1997, BLOOD, V89, P4153, DOI 10.1182/blood.V89.11.4153; Panayiotidis P, 1996, BRIT J HAEMATOL, V92, P97, DOI 10.1046/j.1365-2141.1996.00305.x; Patel D.V., 2005, HEMATOLOGY PRINCIPLE, P1437; Payelle-Brogard B, 2003, LEUKEMIA, V17, P1196, DOI 10.1038/sj.leu.2402944; Payelle-Brogard B, 2002, BRIT J HAEMATOL, V118, P976, DOI 10.1046/j.1365-2141.2002.03759.x; Pedersen IM, 2002, BLOOD, V100, P1795, DOI 10.1182/blood.V100.5.1795.h81702001795_1795_1801; Potter KN, 2003, BLOOD, V101, P3082, DOI 10.1182/blood-2002-08-2432; Pugh-Bernard AE, 2001, J CLIN INVEST, V108, P1061, DOI 10.1172/JCI12462; RAI KR, 1975, BLOOD, V46, P219, DOI 10.1182/blood.V46.2.219.219; RAI KR, 1987, CHRONIC LYMPHOCYTIC, P253; Rassenti LZ, 2004, NEW ENGL J MED, V351, P893, DOI 10.1056/NEJMoa040857; Rawstron AC, 2002, BLOOD, V100, P635, DOI 10.1182/blood.V100.2.635; Rawstron AC, 2002, BLOOD, V100, P2289, DOI 10.1182/blood-2002-03-0892; REED JC, 2001, CHRONIC LYMPHOID LEU, P111; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; ROZMAN C, 1995, NEW ENGL J MED, V333, P1052, DOI 10.1056/NEJM199510193331606; ROZMAN C, 1995, NEW ENGL J MED, V333, P1515; SCHIFFER LM, 1969, BRIT J HAEMATOL, V17, P408; SCHROEDER HW, 1994, IMMUNOL TODAY, V15, P288, DOI 10.1016/0167-5699(94)90009-4; SCHWARTZ RS, 1994, IMMUNOL TODAY, V15, P27, DOI 10.1016/0167-5699(94)90022-1; SILVERMAN GJ, 1988, J CLIN INVEST, V82, P469, DOI 10.1172/JCI113620; STEVENSON FK, 1993, J AUTOIMMUN, V6, P809, DOI 10.1006/jaut.1993.1066; Stevenson FK, 2004, BLOOD, V103, P4389, DOI 10.1182/blood-2003-12-4312; STHOEGER ZM, 1989, J EXP MED, V169, P255, DOI 10.1084/jem.169.1.255; STILGENBAUER S, 2001, CHRONIC LYMPHOID LEU, P353; TERNYNCK T, 1974, BLOOD, V43, P789, DOI 10.1182/blood.V43.6.789.789; THEML H, 1973, BLOOD, V42, P623, DOI 10.1182/blood.V42.4.623.623; Thunberg U, 2001, BLOOD, V97, P1892, DOI 10.1182/blood.V97.6.1892; Tobin G, 2002, BLOOD, V99, P2262, DOI 10.1182/blood.V99.6.2262; Tobin G, 2004, BLOOD, V104, P2879, DOI 10.1182/blood-2004-01-0132; Tobin G, 2003, BLOOD, V101, P4952, DOI 10.1182/blood-2002-11-3485; Toellner KM, 2002, J EXP MED, V195, P383, DOI 10.1084/jem.20011112; Tsukada N, 2002, BLOOD, V99, P1030, DOI 10.1182/blood.V99.3.1030; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; Weller S, 2001, P NATL ACAD SCI USA, V98, P1166, DOI 10.1073/pnas.98.3.1166; Widhopf GF, 2004, BLOOD, V104, P2499, DOI 10.1182/blood-2004-03-0818; Widhopf GF, 2001, J IMMUNOL, V166, P95, DOI 10.4049/jimmunol.166.1.95; Wiestner A, 2003, BLOOD, V101, P4944, DOI 10.1182/blood-2002-10-3306; William J, 2002, SCIENCE, V297, P2066, DOI 10.1126/science.1073924; Zupo S, 2002, BLOOD, V99, P2277, DOI 10.1182/blood-2001-11-0126; Zupo S, 1996, BLOOD, V88, P1365, DOI 10.1182/blood.V88.4.1365.bloodjournal8841365; Zupo S, 2000, BLOOD, V95, P1199, DOI 10.1182/blood.V95.4.1199.004k21_1199_1206	122	1102	1147	1	104	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2005	352	8					804	815		10.1056/NEJMra041720	http://dx.doi.org/10.1056/NEJMra041720			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899MC	15728813				2022-12-28	WOS:000227147500010
J	Goldhaber-Gordon, I; Goldhaber-Gordon, D				Goldhaber-Gordon, I; Goldhaber-Gordon, D			Schrodinger's mousetrap - Part 6: A cryptic response.	NATURE			English	Article									Stanford Univ, Dept Phys, Stanford, CA 94305 USA; Stanford Univ, NSF Stanford IBM Ctr Probing Nanoscale, Stanford, CA 94305 USA	Stanford University; Stanford University				Goldhaber-Gordon, David/0000-0001-8549-0560					0	0	0	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 24	2005	433	7028					805	805		10.1038/433805a	http://dx.doi.org/10.1038/433805a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	899VT	15729319	Bronze			2022-12-28	WOS:000227174600021
J	Prober, C				Prober, C			Sixth disease and the ubiquity of human herpesviruses	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Stanford Univ, Sch Med, Stanford, CA 94305 USA; Glaser Pediat res Network, Stanford, CA USA	Stanford University	Prober, C (corresponding author), Stanford Univ, Sch Med, Stanford, CA 94305 USA.								0	15	16	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2005	352	8					753	755		10.1056/NEJMp048302	http://dx.doi.org/10.1056/NEJMp048302			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899MC	15728806				2022-12-28	WOS:000227147500003
J	Inan, U				Inan, U			Atmospheric science - Gamma rays made on Earth	SCIENCE			English	Editorial Material							ELECTROSTATIC THUNDERCLOUD FIELDS; RUNAWAY ELECTRONS; RED SPRITES; FLASHES; BREAKDOWN; DISCHARGES; DRIVEN; MODEL		Stanford Univ, Dept Elect Engn, Stanford, CA 94305 USA	Stanford University	Inan, U (corresponding author), Stanford Univ, Dept Elect Engn, Stanford, CA 94305 USA.	inan@stanford.edu	Inan, Umran/V-3634-2019	Inan, Umran/0000-0001-5837-5807				Christian HJ, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002347; FISHMAN GJ, 1994, SCIENCE, V264, P1313, DOI 10.1126/science.264.5163.1313; FISHMAN GJ, COMMUNICATION; Gurevich AV, 1996, RADIO SCI, V31, P1541, DOI 10.1029/96RS02441; Inan US, 1996, GEOPHYS RES LETT, V23, P1017, DOI 10.1029/96GL00746; Lehtinen NG, 1999, J GEOPHYS RES-SPACE, V104, P24699, DOI 10.1029/1999JA900335; Lehtinen NG, 1996, GEOPHYS RES LETT, V23, P2645, DOI 10.1029/96GL02573; Lehtinen NG, 2000, GEOPHYS RES LETT, V27, P1095, DOI 10.1029/1999GL010765; Lehtinen NG, 1997, GEOPHYS RES LETT, V24, P2639, DOI 10.1029/97GL52738; Milikh G, 1999, GEOPHYS RES LETT, V26, P525, DOI 10.1029/1999GL900001; Pasko VP, 1997, J GEOPHYS RES-SPACE, V102, P4529, DOI 10.1029/96JA03528; Reising SC, 1996, GEOPHYS RES LETT, V23, P3639, DOI 10.1029/96GL03480; RousselDupre R, 1996, J GEOPHYS RES-SPACE, V101, P2297, DOI 10.1029/95JA03278; SENTMAN DD, 1995, GEOPHYS RES LETT, V22, P1205, DOI 10.1029/95GL00583; Smith DM, 2005, SCIENCE, V307, P1085, DOI 10.1126/science.1107466; Taranenko Y, 1996, GEOPHYS RES LETT, V23, P571, DOI 10.1029/95GL03502; WILSON RP, 1992, INT OPHTHALMOL CLIN, V32, P1	17	10	11	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	2005	307	5712					1054	1055		10.1126/science.1109392	http://dx.doi.org/10.1126/science.1109392			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ED	15718455				2022-12-28	WOS:000227197300030
J	Machens, CK; Romo, R; Brody, CD				Machens, CK; Romo, R; Brody, CD			Flexible control of mutual inhibition: A neural model of two-interval discrimination	SCIENCE			English	Article							PARAMETRIC WORKING-MEMORY; PREFRONTAL CORTEX; DECISION-MAKING; PERSISTENT ACTIVITY; RECURRENT NETWORK; PREMOTOR CORTEX; REVERBERATION; MECHANISMS; DYNAMICS; STIMULI	Networks adapt to environmental demands by switching between distinct dynamical behaviors. The activity of frontal-lobe neurons during two-interval discrimination tasks is an example of these adaptable dynamics. Subjects first perceive a stimulus, then hold it in working memory, and finally make a decision by comparing it with a second stimulus. We present a simple mutual-inhibition network model that captures all three task phases within a single framework. The model integrates both working memory and decision making because its dynamical properties are easily controlled without changing its connectivity. Mutual inhibition between nonlinear units is a useful design motif for networks that must display multiple behaviors.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Mexico City 04510, DF, Mexico	Cold Spring Harbor Laboratory; Universidad Nacional Autonoma de Mexico	Brody, CD (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	brody@cshl.edu		Machens, Christian/0000-0003-1717-1562; romo, ranulfo/0000-0003-3529-3635	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH067991] Funding Source: NIH RePORTER; NIMH NIH HHS [1R01MH067991-01] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abarbanel HD, 2001, CURR OPIN NEUROBIOL, V11, P423, DOI 10.1016/S0959-4388(00)00229-4; BRODY C, UNPUB; Brody CD, 2003, CEREB CORTEX, V13, P1196, DOI 10.1093/cercor/bhg100; Brody CD, 2003, CURR OPIN NEUROBIOL, V13, P204, DOI 10.1016/S0959-4388(03)00050-3; BROWN E, IN PRESS INT J BIFUR; Carmichael ST, 1995, J COMP NEUROL, V363, P642, DOI 10.1002/cne.903630409; Cowan N, 1999, MODELS WORKING MEMOR, P62, DOI [10.1017/CBO9781139174909.006, DOI 10.1017/CBO9781139174909.006]; Dayan P, 2001, COMPUTATIONAL NEUROS; Green DM, 1966, SIGNAL DETECTION THE; Hernandez A, 1997, J NEUROSCI, V17, P6391; Hernandez A, 2002, NEURON, V33, P959, DOI 10.1016/S0896-6273(02)00613-X; HOPPENSTEADT FC, 1997, INTRO MATH NEURONS, P155; Koulakov AA, 2002, NAT NEUROSCI, V5, P775, DOI 10.1038/nn893; Link SW, 1992, WAVE THEORY DIFFEREN; Loewenstein Y, 2003, NAT NEUROSCI, V6, P961, DOI 10.1038/nn1109; Luce R.D., 1991, RESPONSE TIMES THEIR; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miller P, 2003, CEREB CORTEX, V13, P1208, DOI 10.1093/cercor/bhg101; Moody SL, 1998, J NEUROSCI, V18, P399; MORISHITA I, 1972, KYBERNETIK, V11, P154, DOI 10.1007/BF00270672; RATCLIFF R, 1981, PSYCHOL REV, V88, P552, DOI 10.1037/0033-295X.88.6.552; Romo R, 2003, NAT REV NEUROSCI, V4, P203, DOI 10.1038/nrn1058; Romo R, 2001, ANNU REV NEUROSCI, V24, P107, DOI 10.1146/annurev.neuro.24.1.107; Romo R, 1999, NATURE, V399, P470, DOI 10.1038/20939; Romo R, 2004, NEURON, V41, P165, DOI 10.1016/S0896-6273(03)00817-1; Romo R, 2002, NAT NEUROSCI, V5, P1217, DOI 10.1038/nn950; Rudolph U, 2004, ANNU REV PHARMACOL, V44, P475, DOI 10.1146/annurev.pharmtox.44.101802.121429; Salinas E, 2004, J NEUROSCI, V24, P1113, DOI 10.1523/JNEUROSCI.4569-03.2004; Salinas E, 2003, NEURAL COMPUT, V15, P1439, DOI 10.1162/089976603321891756; Salinas E, 2000, J NEUROSCI, V20, P5503, DOI 10.1523/JNEUROSCI.20-14-05503.2000; Seung HS, 2000, J COMPUT NEUROSCI, V9, P171, DOI 10.1023/A:1008971908649; Seung HS, 1996, P NATL ACAD SCI USA, V93, P13339, DOI 10.1073/pnas.93.23.13339; Seung HS, 2000, NEURON, V26, P259, DOI 10.1016/S0896-6273(00)81155-1; Seung HS., 2003, HDB BRAIN THEORY NEU, V2, P94; Usher M, 2001, PSYCHOL REV, V108, P550, DOI 10.1037//0033-295X.108.3.550; Wang XJ, 2002, NEURON, V36, P955, DOI 10.1016/S0896-6273(02)01092-9; Wang XJ, 2001, TRENDS NEUROSCI, V24, P455, DOI 10.1016/S0166-2236(00)01868-3; Wilson H.R., 1999, SPIKES DECISIONS ACT; ZOHARY E, 1994, NATURE, V370, P140, DOI 10.1038/370140a0	39	338	340	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2005	307	5712					1121	1124		10.1126/science.1104171	http://dx.doi.org/10.1126/science.1104171			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ED	15718474				2022-12-28	WOS:000227197300052
J	Turelli, P; Trono, D				Turelli, P; Trono, D			Editing at the crossroad of innate and adaptive immunity	SCIENCE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-B-VIRUS; VIRAL VIF PROTEIN; CYTIDINE DEAMINASE; SOMATIC HYPERMUTATION; ANTIRETROVIRAL FACTOR; ENZYME APOBEC3G; HIV-1 VIRIONS; CLASS SWITCH; RNA	Genetic information can be altered through the enzymatic modification of nucleotide sequences. This process, known as editing, was originally identified in the mitochondrial RNA of trypanosomes and later found to condition events as diverse as neurotransmission and lipid metabolism in mammals. Recent evidence reveals that editing enzymes may fulfill one of their most essential roles in the defense against infectious agents: first, as the mediators of antibody diversification, a step crucial for building adaptive immunity, and second, as potent intracellular poisons for the replication of viruses. Exciting questions are raised, which take us to the depth of the intimate relations between vertebrates and the microbial underworld.	Ecole Polytech Fed Lausanne, Sch Life Sci, CH-1015 Lausanne, Switzerland; Frontiers Genet Natl Ctr Competence Res, CH-1211 Geneva 4, Switzerland; Univ Geneva, Dept Microbiol & Mol Med, Sch Med, CH-1211 Geneva 4, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Geneva; University of Geneva	Trono, D (corresponding author), Ecole Polytech Fed Lausanne, Sch Life Sci, CH-1015 Lausanne, Switzerland.	Didier.Trono@medecine.epfl.ch						Alce TM, 2004, J BIOL CHEM, V279, P34083, DOI 10.1074/jbc.C400235200; An P, 2004, J VIROL, V78, P11070, DOI 10.1128/JVI.78.20.11070-11076.2004; Azumi K, 2003, IMMUNOGENETICS, V55, P570, DOI 10.1007/s00251-003-0606-5; Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; Begum NA, 2004, SCIENCE, V305, P1160, DOI 10.1126/science.1098444; Berkhout B, 2004, AIDS, V18, P1861, DOI 10.1097/00002030-200409030-00022; Bishop KN, 2004, SCIENCE, V305, P645, DOI 10.1126/science.1100658; Bishop KN, 2004, CURR BIOL, V14, P1392, DOI 10.1016/j.cub.2004.06.057; Blanc V, 2003, J BIOL CHEM, V278, P1395, DOI 10.1074/jbc.R200024200; Bogerd HP, 2004, P NATL ACAD SCI USA, V101, P3770, DOI 10.1073/pnas.0307713101; Cen S, 2004, J BIOL CHEM, V279, P33177, DOI 10.1074/jbc.M402062200; Chaudhuri J, 2004, NATURE, V430, P992, DOI 10.1038/nature02821; Dewannieux M, 2004, NAT GENET, V36, P534, DOI 10.1038/ng1353; Esnault C, 2005, NATURE, V433, P430, DOI 10.1038/nature03238; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; Gerber AP, 2001, TRENDS BIOCHEM SCI, V26, P376, DOI 10.1016/S0968-0004(01)01827-8; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Harris RS, 2002, MOL CELL, V10, P1247, DOI 10.1016/S1097-2765(02)00742-6; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Kobayashi M, 2004, J VIROL, V78, P8238, DOI 10.1128/JVI.78.15.8238-8244.2004; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; Li ZQ, 2004, GENE DEV, V18, P1, DOI 10.1101/gad.1161904; Liddament MT, 2004, CURR BIOL, V14, P1385, DOI 10.1016/j.cub.2004.06.050; Madani N, 1998, J VIROL, V72, P10251, DOI 10.1128/JVI.72.12.10251-10255.1998; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mangeat B, 2004, J BIOL CHEM, V279, P14481, DOI 10.1074/jbc.C400060200; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Neuberger MS, 2003, TRENDS BIOCHEM SCI, V28, P305, DOI 10.1016/S0968-0004(03)00111-7; Ngui SL, 1999, REV MED VIROL, V9, P183, DOI 10.1002/(SICI)1099-1654(199907/09)9:3&lt;183::AID-RMV248&gt;3.0.CO;2-P; Prak ETL, 2000, NAT REV GENET, V1, P134; Rose KM, 2004, J BIOL CHEM, V279, P41744, DOI 10.1074/jbc.M406760200; Rosler C, 2004, SCIENCE, V305, p1403A, DOI 10.1126/science.1100464; Sawyer SL, 2004, PLOS BIOL, V2, P1278, DOI 10.1371/journal.pbio.0020275; Schrofelbauer R, 2004, P NATL ACAD SCI USA, V101, P3927, DOI 10.1073/pnas.0307132101; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Simon JHM, 1998, NAT MED, V4, P1397, DOI 10.1038/3987; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; Svarovskaia ES, 2004, J BIOL CHEM, V279, P35822, DOI 10.1074/jbc.M405761200; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; Turelli P, 2004, J BIOL CHEM, V279, P43371, DOI 10.1074/jbc.C400334200; Turelli P, 2004, SCIENCE, V305, p1403B; Turelli P, 2004, SCIENCE, V303, P1829, DOI 10.1126/science.1092066; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Wedekind JE, 2003, TRENDS GENET, V19, P207, DOI 10.1016/S0168-9525(03)00054-4; Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246; Wieland SF, 2000, J VIROL, V74, P4165, DOI 10.1128/JVI.74.9.4165-4173.2000; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Zhang JZ, 2004, HUM MOL GENET, V13, P1785, DOI 10.1093/hmg/ddh183; Zheng YH, 2004, J VIROL, V78, P6073, DOI 10.1128/JVI.78.11.6073-6076.2004	52	76	78	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2005	307	5712					1061	1065		10.1126/science.1105964	http://dx.doi.org/10.1126/science.1105964			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ED	15718460				2022-12-28	WOS:000227197300035
J	Dong, ZG; Hoven, CW; Rosenfield, A				Dong, ZG; Hoven, CW; Rosenfield, A			Lessons from the past	NATURE			English	Editorial Material							HEALTH; CHINA		Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Columbia Univ, Mailman Sch Publ Hlth, New York, NY 10032 USA	University of Minnesota System; Columbia University	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.			Hoven, Christina/0000-0003-1274-2936				[Anonymous], WORLD HLTH REP 2004; Bloom G, 1997, SOC SCI MED, V45, P351, DOI 10.1016/S0277-9536(96)00350-4; Lee LM, 2004, ANNU REV PUBL HEALTH, V25, P327, DOI 10.1146/annurev.publhealth.25.101802.123116; Rosenfield A G, 1977, Man Med, V2, P279; Sidel Victor W., 1982, HLTH CHINA; SIDEL VW, 1977, SOC SCI MED, V11, P415, DOI 10.1016/0037-7856(77)90105-6; World Health Organization, WORLD HLTH REP 2000; GLOBAL CORRUPTION RE	8	5	5	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 10	2005	433	7026					573	574		10.1038/433573a	http://dx.doi.org/10.1038/433573a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	895KX	15703721	Bronze			2022-12-28	WOS:000226862000017
J	Bitton, A; Neuman, MD; Barnoya, J; Glantz, SA				Bitton, A; Neuman, MD; Barnoya, J; Glantz, SA			The p53 tumour suppressor gene and the tobacco industry: research, debate, and conflict of interest	LANCET			English	Article							TP53 MUTATION SPECTRUM; LUNG-CANCER; MUTAGENIC SIGNATURE; SMOKE; SCIENCE; COMPONENTS; HOTSPOTS; POLICIES; LESSONS	Mutations in the p53 tumour suppressor gene lead to uncontrolled cell division and are found in over 50% of all human tumours, including 60% of lung cancers. Research published in 1996 by Denissenko and colleagues demonstrated patterned in-vitro mutagenic effects on p53 of benzo[a]pyrene, a carcinogen present in tobacco smoke. We investigated the tobacco industry's response to p53 research linking smoking to cancer. We searched online tobacco document archives, including the Legacy Tobacco Documents Library and Tobacco Documents Online, and archives maintained by tobacco companies such as Philip Morris and R J Reynolds. Documents were also obtained from the British American Tobacco Company depository in Guildford, UK. Informal correspondence was carried out with scientists, lawyers, and tobacco control experts in the USA and Europe. We found that executives and scientists at the highest levels of the tobacco industry anticipated and carefully monitored p53 research. The tobacco industry's own scientists conducted research which appeared to cast doubt on the link between smoking and p53 mutations. Researchers and a journal editor with tobacco industry ties participated in the publication of this research in a peer-reviewed journal without clear disclosure of their tobacco industry links. Tobacco industry responses to research linking smoking to carcinogenic p53 mutations mirror prior industry efforts to challenge the science linking smoking and lung cancer. The extent of tobacco industry involvement in p53 research and the potential conflict of interest discussed here demonstrate the need for consistent standards for the disclosure and evaluation of such potential conflicts in biomedical research.	Univ Calif San Francisco, Ctr Tobacco Control Res & Educ, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Glantz, SA (corresponding author), Univ Calif San Francisco, Ctr Tobacco Control Res & Educ, San Francisco, CA 94143 USA.	glantz@medicine.ucsf.edu		Barnoya, Joaquin/0000-0002-1731-479X	NATIONAL CANCER INSTITUTE [R01CA087472] Funding Source: NIH RePORTER; NCI NIH HHS [CA-87472] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM ASS CANC RES, 2000, AM ASS CANC RES 91 A; Barnes DE, 1998, JAMA-J AM MED ASSOC, V279, P1566, DOI 10.1001/jama.279.19.1566; Barnoya J, 2002, TOB CONTROL, V11, P305, DOI 10.1136/tc.11.4.305; BARNOYA J, IN PRESS EUR J PUB H; BINNS RM, 1988, COMMUNICATION   0506; BORELLI T, 1993, WALL STREET J   0728; BOULLIN J, 2004, COMMUNICATION; BOULLIN JM, 2003, COMMUNICATION; BOULLIN JM, 2001, COMMUNICATION   0404; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; Clever LH, 1997, ANN INTERN MED, V126, P36, DOI 10.7326/0003-4819-126-1-199701010-00006; COGGINS C, 2000, VERBANDT PAPER KEIN; DEMPSEY R, 1996, COMMUNICATION   1219; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; DIETHELM PA, WHOLE TRUTH NOTHING; Drope J, 2001, J EPIDEMIOL COMMUN H, V55, P588, DOI 10.1136/jech.55.8.588; *ED BOARD, 2003, MUTAGENESIS; Francey N, 2000, BRIT MED J, V321, P371, DOI 10.1136/bmj.321.7257.371; Friedman LS, 2004, J GEN INTERN MED, V19, P51, DOI 10.1111/j.1525-1497.2004.30617.x; GERNTENBACH R, 1988, 135R1 COUNC TOB RES; GERTENBACH R, 1988, 135R2 COUNC TOB RES; Glantz S.A., 1996, CIGARETTE PAPERS; GORI G, 1993, INVOICE CONSULTING; GORI G, 1992, INVOICE CONSULTATION; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Hainaut P, 2001, MUTAGENESIS, V16, P551, DOI 10.1093/mutage/16.6.551; HAINAUT P, 2001, COMMUNICATION   0112; HELLER WD, 1999, AD HOC ARBEITSGRUPPE; Hernandez-Boussard TM, 1998, ENVIRON HEALTH PERSP, V106, P385, DOI 10.2307/3434065; Hirschhorn N, 2000, TOB CONTROL, V9, P242, DOI 10.1136/tc.9.2.242; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Hong MK, 2002, BRIT MED J, V325, P1413, DOI 10.1136/bmj.325.7377.1413; Horton R, 2003, BRIT MED J, V327, P503, DOI 10.1136/bmj.327.7413.503-a; *INBIFO, 1997, P53 ADD; *INT COMM MED J ED, 2001, UN REQ MAN SUBM BIOM; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; Krawczak M, 1998, MUTAGENESIS, V13, P319, DOI 10.1093/mutage/13.4.319; Krimsky S, 2001, SCI ENG ETHICS, V7, P205, DOI 10.1007/s11948-001-0041-7; LAEK R, 2000, ANAL MISSENSE POINT; MASSEY ED, 1998, COMMUNICATION   0427; MASSEY ED, 1988, COMMUNICATION   0603; ME R, 1998, P53 MUTATIONS LUNG C; MUELLER T, 1996, TECHNICAL REV SCI PA; Muggli ME, 2003, NICOTINE TOB RES, V5, P303, DOI 10.1080/1462220031000094169; Muggli ME, 2001, AM J PUBLIC HEALTH, V91, P1419, DOI 10.2105/AJPH.91.9.1419; *NAT PUBL GROUP, ONC; Ong E, 2000, B WORLD HEALTH ORGAN, V78, P938; Ong EK, 2000, LANCET, V355, P1253, DOI 10.1016/S0140-6736(00)02098-5; Ong EK, 2001, AM J PUBLIC HEALTH, V91, P1749, DOI 10.2105/AJPH.91.11.1749; PARRY JM, 2001, COMMUNICATION   0212; Paschke T, 2001, MUTAGENESIS, V16, P555, DOI 10.1093/mutage/16.6.555; Paschke T, 2000, MUTAGENESIS, V15, P457, DOI 10.1093/mutage/15.6.457; *PHIL MORR US, 2003, HLTH ISS; Rampton S, 2002, PUBLIC HEALTH REP, V117, P331, DOI 10.1093/phr/117.4.331; RENNIE D, 1993, JAMA-J AM MED ASSOC, V270, P1742, DOI 10.1001/jama.270.14.1742; ROE F, 1993, FUTURE DIRECTIONS HL; Samet JM, 2001, AM J PUBLIC HEALTH, V91, P1742, DOI 10.2105/AJPH.91.11.1742; Scollo M, 2003, TOB CONTROL, V12, P13, DOI 10.1136/tc.12.1.13; SOLANA R, 1996, PM US SAYS NEW STUDY; THORNTON R, 1993, SMOKE CLUE CANC MUTA; THORNTON R, 1991, VISIT M CURIE RES I; THORNTON RE, 1991, VISIT US CANADA; THORNTON RE, 1993, SRG CONSULTANTS; THORNTON RE, 1993, NOTE TOBACCO STRATEG; TRICKER A, 1998, LIST ACCOUNTABILITIE; TRICKER A, 1998, TRIP REPORT; WYNDER EL, 1994, CANCER RES, V54, P5284; Yach D, 2001, AM J PUBLIC HEALTH, V91, P1745, DOI 10.2105/AJPH.91.11.1745; 1995, SCI RES REV COMMITTE; 2000, SCI RES REV COMMITTE; 1993, SMOKING HLTH REGULAT; 1999, POTENTIAL AREAS CONS; 1996, REV PREFERENTIAL FOR; 1996, BENZO ALPHA PYRENE P	77	19	19	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 5	2005	365	9458					531	540						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894SS	15705463				2022-12-28	WOS:000226812500031
J	Frankino, WA; Zwaan, BJ; Stern, DL; Brakefield, PM				Frankino, WA; Zwaan, BJ; Stern, DL; Brakefield, PM			Natural selection and developmental constraints in the evolution of allometries	SCIENCE			English	Article							QUANTITATIVE VARIATION; SEXUAL SELECTION; BODY-SIZE; FLIGHT; BUTTERFLIES; SURVIVAL; CANALIZATION; DIOPSIDAE; INSECTS; DIPTERA	In animals, scaling relationships between appendages and body size exhibit high interspecific variation but low intraspecific variation. This pattern could result from natural selection for specific allometries or from developmental constraints on patterns of differential growth. We performed artificial selection on the allometry between forewing area and body size in a butterfly to test for developmental constraints, and then used the resultant increased range of phenotypic variation to quantify natural selection on the scaling relationship. Our results show that the short-term evolution of allometries is not limited by developmental constraints. Instead, scaling relationships are shaped by strong natural selection.	Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; Leiden Univ, Inst Biol, Sect Evolutionary Biol, NL-2300 RA Leiden, Netherlands	Princeton University; Leiden University; Leiden University - Excl LUMC	Frankino, WA (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.	frankino@alumni.indiana.edu	Zwaan, Bas J/D-8721-2015	Zwaan, Bas J/0000-0002-8221-4998; Stern, David/0000-0002-1847-6483	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063622] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM063622, R01 GM063622-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURKHARDT D, 1987, ENTOMOL GEN, V12, P221; Dudley R., 2000, BIOMECHANICS INSECT; EBERHARD WG, 1991, EVOLUTION, V45, P18, DOI 10.1111/j.1558-5646.1991.tb05262.x; Emlen DJ, 2000, ANNU REV ENTOMOL, V45, P661, DOI 10.1146/annurev.ento.45.1.661; Emlen DJ, 1996, EVOLUTION, V50, P1219, DOI [10.1111/j.1558-5646.1996.tb02362.x, 10.2307/2410662]; Emlen DJ, 2001, SCIENCE, V291, P1534, DOI 10.1126/science.1056607; Falconer D.S., 1997, INTRO QUANTITATIVE G, VFourth; GOULD SJ, 1966, BIOL REV, V41, P587, DOI 10.1111/j.1469-185X.1966.tb01624.x; Huxley J., 1932, PROBLEMS RELATIVE GR; Joron M, 2003, NATURE, V424, P191, DOI 10.1038/nature01713; Kingsolver JG, 1999, EVOLUTION, V53, P1479, DOI 10.1111/j.1558-5646.1999.tb05412.x; Kingsolver JG, 2000, EVOL ECOL RES, V2, P593; Kooi RE, 1996, ENTOMOL EXP APPL, V80, P149, DOI 10.1007/BF00194745; Rice SH, 1998, EVOLUTION, V52, P647, DOI 10.1111/j.1558-5646.1998.tb03690.x; Schluter D, 1996, EVOLUTION, V50, P1766, DOI 10.1111/j.1558-5646.1996.tb03563.x; SMITH JM, 1985, Q REV BIOL, V60, P265, DOI 10.1086/414425; Srygley RB, 2000, BIOL J LINN SOC, V70, P707, DOI 10.1111/j.1095-8312.2000.tb00225.x; Stern DL, 1999, DEVELOPMENT, V126, P1091; STRAUSS RE, 1990, EVOLUTION, V44, P86, DOI [10.2307/2409526, 10.1111/j.1558-5646.1990.tb04281.x]; Strauss Richard E., 1992, P157; Thompson D.W, 1917, GROWTH FORM; Van Dyck H, 1999, TRENDS ECOL EVOL, V14, P172, DOI 10.1016/S0169-5347(99)01610-9; VOGEL S, 2003, COMP BIOMECHANICS; Wagner GP, 1997, EVOLUTION, V51, P329, DOI [10.2307/2411105, 10.1111/j.1558-5646.1997.tb02420.x]; Wagner GP, 1996, AM ZOOL, V36, P36; WEBER KE, 1990, GENETICS, V126, P975; WICKMAN PO, 1992, EVOLUTION, V46, P1525, DOI 10.1111/j.1558-5646.1992.tb01142.x; WILKINSON GS, 1993, GENET RES, V62, P213, DOI 10.1017/S001667230003192X; Wolf JB, 2001, EVOLUTION, V55, P232	29	173	177	0	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2005	307	5710					718	720		10.1126/science.1105409	http://dx.doi.org/10.1126/science.1105409			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	894TQ	15692049	Green Accepted			2022-12-28	WOS:000226814900041
J	Gilks, WP; Abou-Sleiman, PM; Gandhi, S; Jain, S; Singleton, A; Lees, AJ; Shaw, K; Bhatia, KP; Bonifati, V; Quinn, NP; Lynch, J; Healy, DG; Holton, JL; Revesz, T; Wood, NW				Gilks, WP; Abou-Sleiman, PM; Gandhi, S; Jain, S; Singleton, A; Lees, AJ; Shaw, K; Bhatia, KP; Bonifati, V; Quinn, NP; Lynch, J; Healy, DG; Holton, JL; Revesz, T; Wood, NW			Common LRRK2 mutation in idiopathic Parkinson's disease	LANCET			English	Article								Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene have been shown to cause autosomal dominant Parkinson's disease. Few mutations in this gene have been identified. We investigated the frequency of a common heterozygous mutation, 2877510G-->A, which produces a glycine to serine aminoacid substitution at codon 2019 (Gly2019Ser), in idiopathic Parkinson's disease. We assessed 482 patients with the disorder, of whom 263 had pathologically confirmed disease, by direct sequencing for mutations in exon 41 of LRRK2. The mutation was present in eight (1.6%) patients. We have shown that a common single Mendelian mutation is implicated in sporadic Parkinson's disease. We suggest that testing for this mutation will be important in the management and genetic counselling of patients with Parkinson's disease.	Inst Neurol, Dept Mol Neurosci, London WC1N 3BG, England; Inst Neurol, Dept Motor Neurosci, London WC1N 3BG, England; UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England; NIA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA; Erasmus Univ, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; Reta Lila Weston Inst Neurol Studies, London, England	University of London; University College London; University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Erasmus University Rotterdam; University of London; University College London	Wood, NW (corresponding author), Inst Neurol, Dept Mol Neurosci, Queen Sq, London WC1N 3BG, England.	n.wood@ion.ucLac.uk	Singleton, Andrew B/C-3010-2009; Revesz, Tamas/A-8732-2010; Lees, Andrew J/A-6605-2009; Holton, Janice L/F-6831-2011; Wood, Nicholas W/C-2505-2009; Gilks, William/P-9137-2015	Revesz, Tamas/0000-0003-2501-0259; Lees, Andrew J/0000-0002-2476-4385; Holton, Janice L/0000-0002-3882-5249; Wood, Nicholas W/0000-0002-9500-3348; Gilks, William/0000-0001-7814-3173	NATIONAL INSTITUTE ON AGING [ZIAAG000957, Z01AG000958, ZIAAG000958, Z01AG000957] Funding Source: NIH RePORTER; Parkinson&apos;s UK [G-4062, G-4029] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Parkinson&apos;s UK(Parkinson&apos;s UK)		Healy DG, 2004, LANCET NEUROL, V3, P652, DOI 10.1016/S1474-4422(04)00905-6; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; Paisan-Ruiz C, 2004, NEURON, V44, P595, DOI 10.1016/j.neuron.2004.10.023; Vila M, 2004, NAT MED, V10, pS58, DOI 10.1038/nm1068; Zimprich A, 2004, NEURON, V44, P601, DOI 10.1016/j.neuron.2004.11.005	5	581	610	2	49	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN-FEB	2005	365	9457					415	416		10.1016/S0140-6736(05)17830-1	http://dx.doi.org/10.1016/S0140-6736(05)17830-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891WE	15680457				2022-12-28	WOS:000226610900029
J	McKee, M; Raine, R				McKee, M; Raine, R			Choosing health? First choose your philosophy	LANCET			English	Editorial Material									Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	McKee, M (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England.	martin.mckee@lshtm.ac.uk	Mckee, Martin/E-6673-2018; McKee, Marc D/E-2187-2011	Mckee, Martin/0000-0002-0121-9683; McKee, Marc D/0000-0001-8349-965X				*BIG, BIG CONV SURV RES; COOTE A, 2004, FINDING WHAT WORKS U; *DEP HLTH ENGL, 2004, CHOOS HLTH MAK HLTH; Giddens A., 2013, 3 WAY RENEWAL SOCIAL; Jackson MC, 2000, ADDICTION, V95, pS597, DOI 10.1046/j.1360-0443.95.12s4.11.x; JOHNSON S, 2003, COUNTERING OBESITY E; Kobus K, 2003, ADDICTION, V98, P37, DOI 10.1046/j.1360-0443.98.s1.4.x; Kotchick BA, 2001, CLIN PSYCHOL REV, V21, P493, DOI 10.1016/S0272-7358(99)00070-7; Leventhal H., 2003, SELF REGULATION HLTH, P42, DOI DOI 10.4324/9780203553220; MARX K, 1974, SURVEYS EXILE POLITI, V2, P143; McKee M, 1999, BMJ-BRIT MED J, V318, P1300, DOI 10.1136/bmj.318.7194.1300; McKee M, 1996, BRIT MED J, V312, P691; Mill John S, 1982, LIBERTY; Wanless D., 2004, SECURING GOOD HLTH W	14	24	24	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN-FEB	2005	365	9457					369	371						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891WE	15680441				2022-12-28	WOS:000226610900008
J	Revankar, CM; Cimino, DF; Sklar, LA; Arterburn, JB; Prossnitz, ER				Revankar, CM; Cimino, DF; Sklar, LA; Arterburn, JB; Prossnitz, ER			A transmembrane intracellular estrogen receptor mediates rapid cell signaling	SCIENCE			English	Article							PROTEIN-COUPLED RECEPTORS; GROWTH-FACTOR RECEPTOR; BREAST-CANCER CELLS; PLASMA-MEMBRANE; ACTIVATION; TRANSACTIVATION; MECHANISMS; GPR30	The steroid hormone estrogen regulates many functionally unrelated processes in numerous tissues. Although it is traditionally thought to control transcriptional activation through the classical nuclear estrogen receptors, it also initiates many rapid nongenomic signaling events. W. found that of all G protein-coupled receptors characterized to date, GPR30 is uniquely localized to the endoplasmic reticulum, where it specifically bind.,. estrogen and fluorescent estrogen derivatives. Activating GPR30 by estrogen resulted in intracellular calcium mobilization and synthesis of phosphatidylinositol 3,4,5-trisphosphate in the nucleus. Thus, GPR30 represents an intracellular transmembrane estrogen receptor that may contribute to normal estrogen physiology as well as pathophysiology.	Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Canc Res & Treatment Ctr, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA; New Mexico State Univ, Dept Chem & Biochem, Las Cruces, NM 88003 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; New Mexico State University	Prossnitz, ER (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA.	eprossnitz@salud.unm.edu	Prossnitz, Eric/I-4599-2019; Prossnitz, Eric R./B-4543-2008	Prossnitz, Eric/0000-0001-9190-8302; 	NATIONAL CANCER INSTITUTE [R24CA088339] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011830, S10RR014668] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI036357, R01AI036357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R24EB000264] Funding Source: NIH RePORTER; NCI NIH HHS [R24 CA88339] Funding Source: Medline; NCRR NIH HHS [P20 RR11830, 1 S10 RR14668] Funding Source: Medline; NIAID NIH HHS [AI36357] Funding Source: Medline; NIBIB NIH HHS [EB00264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Arterburn JB, 2000, TETRAHEDRON LETT, V41, P839, DOI 10.1016/S0040-4039(99)02205-4; Balla Tamas, 2002, Sci STKE, V2002, ppl3, DOI 10.1126/stke.2002.125.pl3; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; Filardo EJ, 2002, J STEROID BIOCHEM, V80, P231, DOI 10.1016/S0960-0760(01)00190-X; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Govind AP, 2003, MOL CELL BIOCHEM, V253, P233, DOI 10.1023/A:1026068017309; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Ho KJ, 2002, ARTERIOSCL THROM VAS, V22, P1952, DOI 10.1161/01.ATV.0000041200.85946.4A; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; Levin ER, 2002, STEROIDS, V67, P471, DOI 10.1016/S0039-128X(01)00179-9; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; Nicholson KM, 2003, BREAST CANCER RES TR, V81, P117, DOI 10.1023/A:1025765215765; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Prossnitz ER, 2004, LIFE SCI, V75, P893, DOI 10.1016/j.lfs.2004.04.003; Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200; Shao WL, 2004, BREAST CANCER RES, V6, P39, DOI 10.1186/bcr742; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; Tsai EM, 2001, CANCER RES, V61, P8390; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040	22	1733	1848	5	183	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 11	2005	307	5715					1625	1630		10.1126/science.1106943	http://dx.doi.org/10.1126/science.1106943			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	906ED	15705806				2022-12-28	WOS:000227622400048
J	Chien, JY; Yu, CJ				Chien, JY; Yu, CJ			Malposition of a Sengstaken-Blakemore tube	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Natl Taiwan Univ Hosp, Yun Lin Branch, Douliu 640, Taiwan; Natl Taiwan Univ Hosp, Taipei 100, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Chien, JY (corresponding author), Natl Taiwan Univ Hosp, Yun Lin Branch, Douliu 640, Taiwan.			Yu, Chong-Jen/0000-0001-5664-9392; CHIEN, JUNG-YIEN/0000-0002-7718-0594					0	3	3	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2005	352	8					E7	E7		10.1056/NEJMicm040003	http://dx.doi.org/10.1056/NEJMicm040003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899MC	15728803				2022-12-28	WOS:000227147500012
J	Powell, FC				Powell, FC			Rosacea	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PAPULOPUSTULAR ROSACEA; OCULAR ROSACEA; CLASSIFICATION; METRONIDAZOLE; RHINOPHYMA; THERAPIES; EFFICACY; SPECTRUM; SAFETY; TRIAL		Mater Misericordiae Univ Hosp, Reg Ctr Dermatol, Dublin 7, Ireland	Mater Misericordiae University Hospital; University College Dublin	Powell, FC (corresponding author), Mater Misericordiae Univ Hosp, Reg Ctr Dermatol, Eccles St, Dublin 7, Ireland.	fpowell@eircom.net						Aloi F, 2000, J AM ACAD DERMATOL, V42, P468, DOI 10.1016/S0190-9622(00)90220-2; Antille C, 2004, ARCH DERMATOL, V140, P457, DOI 10.1001/archderm.140.4.457; Bamford J, 2004, J AM ACAD DERMATOL, V50, P907, DOI 10.1016/j.jaad.2004.01.048; BARTHOLOMEW RS, 1982, BRIT J OPHTHALMOL, V66, P386, DOI 10.1136/bjo.66.6.386; BERG M, 1989, ACTA DERM-VENEREOL, V69, P419; Crawford GH, 2004, J AM ACAD DERMATOL, V51, P327, DOI 10.1016/j.jaad.2004.03.030; Dahl MV, 1998, ARCH DERMATOL, V134, P679, DOI 10.1001/archderm.134.6.679; Del Rosso JQ, 2004, EXPERT OPIN PHARMACO, V5, P5, DOI 10.1517/eoph.5.1.5.25509; Diaz C, 2003, ACTA DERM-VENEREOL, V83, P282, DOI 10.1080/00015550310016544; Drott C, 1998, BRIT J DERMATOL, V138, P639; ELAZHARY RA, 1991, MAYO CLIN PROC, V66, P899, DOI 10.1016/S0025-6196(12)61576-6; Elewski BE, 2003, ARCH DERMATOL, V139, P1444, DOI 10.1001/archderm.139.11.1444; ERLT GA, 1994, ARCH DERMATOL, V130, P319; Ernst E, 2000, BRIT J DERMATOL, V142, P857, DOI 10.1046/j.1365-2133.2000.03463.x; Fernandez-Obregon A, 2004, ARCH DERMATOL, V140, P489, DOI 10.1001/archderm.140.4.489; Greaves MW, 1997, J EUR ACAD DERMATOL, V8, P91, DOI 10.1016/S0926-9959(97)00615-6; GUDMUNDSEN KJ, 1992, J AM ACAD DERMATOL, V26, P211, DOI 10.1016/0190-9622(92)70029-F; HELM KF, 1991, J AM ACAD DERMATOL, V25, P1038, DOI 10.1016/0190-9622(91)70304-K; Jansen T, 1997, J ROY SOC MED, V90, P144, DOI 10.1177/014107689709000308; Kligman AM, 1997, ARCH DERMATOL, V133, P89, DOI 10.1001/archderm.133.1.89; Kligman AM, 2004, DERMATOLOGY, V208, P191, DOI 10.1159/000077298; KNIGHT AG, 1975, BRIT J DERMATOL, V93, P577, DOI 10.1111/j.1365-2133.1975.tb02252.x; Lebwohl M., 1995, J GERIATR DERMATOL, V3, P183; LITT JZ, 1993, AM FAM PHYSICIAN, V48, P67; LOMHOLT GUNNAR, 1964, DANISH MED BULL, V11, P1; Lonne-Rahm SB, 1999, ACTA DERM-VENEREOL, V79, P460; MILLS OH, 1976, ARCH DERMATOL, V112, P553, DOI 10.1001/archderm.1976.01630280071021; Murphy A, 1998, J AM ACAD DERMATOL, V38, P310, DOI 10.1016/S0190-9622(98)70571-7; Pelle MT, 2004, J AM ACAD DERMATOL, V51, P499, DOI 10.1016/j.jaad.2004.03.033; Plewig G., 1993, ACNE ROSACEA; Powell FC, 2004, DERMATOLOGY, V209, P173, DOI 10.1159/000079884; Powell FC, 2000, J EUR ACAD DERMATOL, V14, P351, DOI 10.1046/j.1468-3083.2000.00144.x; POWELL FC, 2003, EUROPEAN HDB DERMATO; PYE RJ, 1976, LANCET, V1, P1211; Quaterman MJ, 1997, ARCH DERMATOL, V133, P49; RAMELET AA, 1994, ARCH DERMATOL, V130, P1448, DOI 10.1001/archderm.1994.01690110118022; REBORA A, 1993, CLIN DERMATOL, V11, P225, DOI 10.1016/0738-081X(93)90058-K; ROBERTS JO, 1985, J ROY SOC MED, V78, P678, DOI 10.1177/014107688507800819; SAIHAN EM, 1980, BRIT J DERMATOL, V102, P565, DOI 10.1111/j.1365-2133.1980.tb07656.x; Sauder DN, 1997, J DERMATOL TREAT, V8, P79, DOI 10.3109/09546639709160276; SOBYE P, 1950, Acta Derm Venereol, V30, P137; SOBYE P, 1951, Acta Derm Venereol, V31, P174; STARR PAJ, 1969, P ROY SOC MED, V62, P9, DOI 10.1177/003591576906200107; Sugarman JH, 2002, J AM ACAD DERMATOL, V47, P217, DOI 10.1067/mjd.2002.120469; Tan SR, 2004, J AM ACAD DERMATOL, V51, P592, DOI 10.1016/j.jaad.2004.04.010; Thiboutot D, 2003, J AM ACAD DERMATOL, V48, P836, DOI 10.1067/mjd.2003.308; VANZUUREN EJ, 2004, COCHRANE DB SYST REV, V1; Wilkin J, 2002, J AM ACAD DERMATOL, V46, P584, DOI 10.1067/mjd.2002.120625; Wilkin JK, 1999, ARCH DERMATOL, V135, P79, DOI 10.1001/archderm.135.1.79; WILKIN JK, 1989, J AM ACAD DERMATOL, V20, P202, DOI 10.1016/S0190-9622(89)70022-0; WILKIN JK, 1994, ARCH DERMATOL, V130, P359, DOI 10.1001/archderm.130.3.359; WILKIN JK, 1983, INT J DERMATOL, V22, P393, DOI 10.1111/j.1365-4362.1983.tb02157.x	52	170	182	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2005	352	8					793	803		10.1056/NEJMcp042829	http://dx.doi.org/10.1056/NEJMcp042829			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899MC	15728812				2022-12-28	WOS:000227147500009
J	Schippers, A; Neretin, LN; Kallmeyer, J; Ferdelman, TG; Cragg, BA; Parkes, RJ; Jorgensen, BB				Schippers, A; Neretin, LN; Kallmeyer, J; Ferdelman, TG; Cragg, BA; Parkes, RJ; Jorgensen, BB			Prokaryotic cells of the deep sub-seafloor biosphere identified as living bacteria	NATURE			English	Article							IN-SITU HYBRIDIZATION; CATALYZED REPORTER DEPOSITION; SUBSEAFLOOR SEDIMENTS; MARINE-BACTERIA; METHANE HYDRATE; COPY NUMBER; COMMUNITY; OCEAN; QUANTIFICATION; DISSOCIATION	Chemical analyses of the pore waters from hundreds of deep ocean sediment cores have over decades provided evidence for ongoing processes that require biological catalysis by prokaryotes(1-3). This sub-seafloor activity of microorganisms may influence the surface Earth by changing the chemistry of the ocean and by triggering the emission of methane, with consequences for the marine carbon cycle and even the global climate(4-6). Despite the fact that only about 1% of the total marine primary production of organic carbon is available for deep-sea microorganisms(7,8), subseafloor sediments harbour over half of all prokaryotic cells on Earth(7). This estimation has been calculated from numerous microscopic cell counts in sediment cores of the Ocean Drilling Program(1,9). Because these counts cannot differentiate between dead and alive cells, the population size of living microorganisms is unknown(10,11). Here, using ribosomal RNA as a target for the technique known as catalysed reporter deposition-fluorescence in situ hybridization (CARD-FISH), we provide direct quantification of live cells as defined by the presence of ribosomes. We show that a large fraction of the sub-seafloor prokaryotes is alive, even in very old (16 million yr) and deep (>400 m) sediments. All detectable living cells belong to the Bacteria and have turnover times of 0.25-22 yr, comparable to surface sediments.	Fed Inst Geosci & Nat Resources, Sect Geomicrobiol, D-30655 Hannover, Germany; Max Planck Inst Marine Microbiol, Dept Biogeochem, D-28359 Bremen, Germany; Geoforschungszentrum Potsdam, D-14473 Potsdam, Germany; Univ Wales Coll Cardiff, Sch Earth Ocean & Planetary Sci, Cardiff CF10 3YE, S Glam, Wales	Max Planck Society; Helmholtz Association; Helmholtz-Center Potsdam GFZ German Research Center for Geosciences; Cardiff University	Schippers, A (corresponding author), Fed Inst Geosci & Nat Resources, Sect Geomicrobiol, Stilleweg 2, D-30655 Hannover, Germany.	a.schippers@bgr.de	Kallmeyer, Jens/I-3554-2012; Ferdelman, Timothy G/A-3758-2013; Jorgensen, Bo B/C-2214-2013; Kallmeyer, Jens/AAF-6906-2020; Parkes, Ronald/B-1731-2010; Cragg, Barry/D-2690-2009; Schippers, Axel/AAB-3919-2021	Kallmeyer, Jens/0000-0002-6440-1140; Ferdelman, Timothy G/0000-0002-9701-3793; Jorgensen, Bo B/0000-0001-9398-8027; Kallmeyer, Jens/0000-0002-6440-1140; Parkes, Ronald/0000-0001-9402-5943; Schippers, Axel/0000-0002-4469-9883				Bach W, 2003, GEOCHIM COSMOCHIM AC, V67, P3871, DOI 10.1016/S0016-7037(03)00304-1; Berg P, 1998, LIMNOL OCEANOGR, V43, P1500, DOI 10.4319/lo.1998.43.7.1500; D'Hondt S, 2004, SCIENCE, V306, P2216, DOI 10.1126/science.1101155; D'Hondt S. L., 2003, CONTROLS MICROBIAL C; DAVIS BD, 1986, J BACTERIOL, V166, P439, DOI 10.1128/jb.166.2.439-445.1986; DICKENS GR, 1995, PALEOCEANOGRAPHY, V10, P965, DOI 10.1029/95PA02087; Fogel GB, 1999, MICROB ECOL, V38, P93, DOI 10.1007/s002489900162; HEDGES J, 1993, MAR CHEM, V39, P67; HEIJNEN JJ, 1992, BIOTECHNOL BIOENG, V39, P833, DOI 10.1002/bit.260390806; Hesselbo SP, 2000, NATURE, V406, P392, DOI 10.1038/35019044; Holland HD., 1984, CHEM EVOLUTION ATMOS; JORGENSEN BB, 1982, NATURE, V296, P643, DOI 10.1038/296643a0; Kallmeyer J, 2004, LIMNOL OCEANOGR-METH, V2, P171, DOI 10.4319/lom.2004.2.171; Kennett JP, 2000, SCIENCE, V288, P128, DOI 10.1126/science.288.5463.128; KEPNER RL, 1994, MICROBIOL REV, V58, P603, DOI 10.1128/MMBR.58.4.603-615.1994; Klappenbach JA, 2001, NUCLEIC ACIDS RES, V29, P181, DOI 10.1093/nar/29.1.181; Loferer-Krossbacher M, 1999, ARCH HYDROBIOL SPEC, V54, P185; Morita RY, 1997, BACTERIA OLIGOTROPHI; Nadkarni MA, 2002, MICROBIOL-SGM, V148, P257, DOI 10.1099/00221287-148-1-257; Parkes RJ, 2000, HYDROGEOL J, V8, P11, DOI 10.1007/PL00010971; PARKES RJ, 1994, NATURE, V371, P410, DOI 10.1038/371410a0; Pernthaler A, 2002, APPL ENVIRON MICROB, V68, P3094, DOI 10.1128/AEM.68.6.3094-3101.2002; Ravenschlag K, 2001, APPL ENVIRON MICROB, V67, P387, DOI 10.1128/AEM.67.1.387-395.2001; Sekar R, 2003, APPL ENVIRON MICROB, V69, P2928, DOI 10.1128/AEm.69.5.2928-2935.2003; SIMON M, 1989, MAR ECOL PROG SER, V51, P201, DOI 10.3354/meps051201; Takai K, 2000, APPL ENVIRON MICROB, V66, P5066, DOI 10.1128/AEM.66.11.5066-5072.2000; Teira E, 2004, APPL ENVIRON MICROB, V70, P4411, DOI 10.1128/AEM.70.7.4411-4414.2004; Webster G, 2003, J MICROBIOL METH, V55, P155, DOI 10.1016/S0167-7012(03)00140-4; Whitman WB, 1998, P NATL ACAD SCI USA, V95, P6578, DOI 10.1073/pnas.95.12.6578; Zubkov MV, 2001, APPL ENVIRON MICROB, V67, P5210, DOI 10.1128/AEM.67.11.5210-5218.2001	30	326	350	2	104	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 24	2005	433	7028					861	864		10.1038/nature03302	http://dx.doi.org/10.1038/nature03302			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	899VT	15729341				2022-12-28	WOS:000227174600041
J	Claus, EB; Petruzella, S; Matloff, E; Carter, D				Claus, EB; Petruzella, S; Matloff, E; Carter, D			Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ONSET BREAST-CANCER; POPULATION-BASED SERIES; OVARIAN-CANCER; GERMLINE MUTATIONS; FAMILY-HISTORY; JEWISH WOMEN; CARRIER FREQUENCY; 185DELAG MUTATION; SEQUENCE-ANALYSIS; SINGLE-FAMILY	Context The distribution of BRCA1 and BRCA2 mutations in women diagnosed with noninvasive breast carcinoma is unknown. Objective To estimate the BRCA1 and BRCA2 mutation prevalence in women with ductal carcinoma in situ (DCIS), unselected for age, family history, or ethnicity. Design, Setting, and Participants The data were 369 DCIS cases diagnosed among female residents aged 20 to 79 years from the state of Connecticut between September 15,1994, and March 14, 1998. These women were participants in a large population-based case-control study of breast carcinoma in situ. Telephone interviews were used to collect risk factor information and blood or buccal specimens were collected for BRCA1 and BRCA2 mutation testing. Main Outcome Measures Prevalence of disease-associated mutations of BRCA1 and BRCA2 in women diagnosed with DCIS. Results Three (0.8%) and 9 (2.4%) of 369 DCIS cases had disease-associated mutations in BRCA1 or BRCA2, respectively. One woman had a mutation in both genes (BRCA1 W321X and BRCA2 3398del5). Carriers were significantly more likely than noncarriers to report a first-degree (mother, sister, or daughter) family history of breast cancer (odds ratio [OR], 3.7; 95% confidence interval [CI], 1.1 -12.4), as well as a personal history of ovarian cancer. In addition, carriers were more likely than noncarriers to be diagnosed at an early age (<50 years) (OR, 3.4; 95% Cl, 1.0-11.7), as well as to report at least 1 first-degree relative diagnosed with breast cancer before 50 years (OR, 10.6; 95% Cl, 3.0-37.0). Conclusions Ductal carcinoma in situ is a part of the breast/ovarian cancer syndromes defined by BRCA1 and BRCA2, with mutation rates similar to those found for invasive breast cancer. These findings suggest that patients with breast cancer with an appropriate personal or family history of breast and/or ovarian cancer should be screened and followed according to high-risk protocols, regardless of whether they are diagnosed with in situ or invasive breast cancer.	Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Yale Comprehens Canc Ctr, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Brigham & Womens Hosp, Dept Neurosurg, Boston, MA USA	Yale University; Yale University; Harvard University; Brigham & Women's Hospital	Claus, EB (corresponding author), Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Yale Comprehens Canc Ctr, 60 Coll St,POB 208034, New Haven, CT 06520 USA.	elizabeth.claus@yale.edu			NCI NIH HHS [R01-CA81393] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081393] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adem C, 2003, CANCER, V97, P1, DOI 10.1002/cncr.11048; Anton-Culver H, 2000, EUR J CANCER, V36, P1200, DOI 10.1016/S0959-8049(00)00110-6; Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Armes JE, 1998, CANCER-AM CANCER SOC, V83, P2335, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.3.CO;2-E; Armes JE, 2002, PATHOLOGY, V34, P309, DOI 10.1080/00313020220147113; Caldes T, 2002, J MED GENET, V39, DOI 10.1136/jmg.39.8.e44; Claus EB, 2003, BREAST, V12, P451, DOI 10.1016/S0960-9776(03)00152-8; Claus EB, 2003, BREAST CANCER RES TR, V81, P129, DOI 10.1023/A:1025728524310; Claus EB, 2003, BREAST CANCER RES TR, V78, P7, DOI 10.1023/A:1022147920262; CLAUS EB, 1993, CANCER, V71, P147, DOI 10.1002/1097-0142(19930101)71:1<147::AID-CNCR2820710124>3.0.CO;2-V; Claus EB, 2001, J NATL CANCER I, V93, P1811, DOI 10.1093/jnci/93.23.1811; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; de Sanjose S, 2003, INT J CANCER, V106, P588, DOI 10.1002/ijc.11271; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FORD D, 1995, AM J HUM GENET, V57, P1457; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Frank TS, 1998, J CLIN ONCOL, V16, P2417, DOI 10.1200/JCO.1998.16.7.2417; Frank TS, 2002, J CLIN ONCOL, V20, P1480, DOI 10.1200/JCO.20.6.1480; Friedman E, 1998, AM J HUM GENET, V63, P1224, DOI 10.1086/302040; Ganguly A, 2001, AM J MED GENET, V101, P146, DOI 10.1002/1096-8628(20010615)101:2<146::AID-AJMG1342>3.0.CO;2-E; Gershoni-Baruch R, 1997, EUR J CANCER, V33, P2283, DOI 10.1016/S0959-8049(97)00223-2; Hoogerbrugge N, 2003, J CLIN ONCOL, V21, P41, DOI 10.1200/JCO.2003.02.137; Jacquemier J, 1996, LANCET, V348, P1098, DOI 10.1016/S0140-6736(05)64441-8; Johannesdottir G, 1996, CANCER RES, V56, P3663; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Krainer M, 1997, NEW ENGL J MED, V336, P1416, DOI 10.1056/NEJM199705153362003; Lakhani SR, 1997, LANCET, V349, P1505; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; Liede A, 1998, AM J HUM GENET, V62, P1543, DOI 10.1086/301889; Loader S, 1998, GENET TEST, V2, P75, DOI 10.1089/gte.1998.2.75; Loman N, 2001, JNCI-J NATL CANCER I, V93, P1215, DOI 10.1093/jnci/93.16.1215; Malone KE, 1998, JAMA-J AM MED ASSOC, V279, P922, DOI 10.1001/jama.279.12.922; Martin AM, 2001, J CLIN ONCOL, V19, P2247, DOI 10.1200/JCO.2001.19.8.2247; Neuhausen S, 1996, NAT GENET, V13, P126, DOI 10.1038/ng0596-126; Newman B, 1998, JAMA-J AM MED ASSOC, V279, P915, DOI 10.1001/jama.279.12.915; Offit K, 1996, LANCET, V347, P1643, DOI 10.1016/S0140-6736(96)91484-1; Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943; Ramus SJ, 1997, NAT GENET, V15, P14, DOI 10.1038/ng0197-14; Randall TC, 1998, GYNECOL ONCOL, V70, P432, DOI 10.1006/gyno.1998.5081; ShattuckEidens D, 1997, JAMA-J AM MED ASSOC, V278, P1242, DOI 10.1001/jama.278.15.1242; Smith RA, 2003, CA-CANCER J CLIN, V53, P141, DOI 10.3322/canjclin.53.3.141; StoppaLyonnet D, 1996, AM J HUM GENET, V59, P479; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; Sun CC, 1996, LANCET, V348, P408, DOI 10.1016/S0140-6736(05)65027-1; Syrjakoski K, 2000, J NATL CANCER I, V92, P1529, DOI 10.1093/jnci/92.18.1529; Tesoriero A, 1999, AM J HUM GENET, V65, P567, DOI 10.1086/302503; Thorlacius S, 1997, AM J HUM GENET, V60, P1079; Tsongalis GJ, 1998, ARCH PATHOL LAB MED, V122, P548; Unger MA, 2000, AM J HUM GENET, V67, P841, DOI 10.1086/303076; Verhoog LC, 1998, LANCET, V351, P316, DOI 10.1016/S0140-6736(97)07065-7	51	65	66	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	2005	293	8					964	969		10.1001/jama.293.8.964	http://dx.doi.org/10.1001/jama.293.8.964			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899LR	15728167	Bronze			2022-12-28	WOS:000227146400018
J	Phillips, B; Tyerman, K; Whiteley, SM				Phillips, B; Tyerman, K; Whiteley, SM			Evidence based case report - Use of antibiotics in suspected haemolytic-uraemic syndrome	BMJ-BRITISH MEDICAL JOURNAL			English	Review							METAANALYSIS		St James Hosp, Paediat Intens Care Unit, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital	Phillips, B (corresponding author), St James Hosp, Paediat Intens Care Unit, Leeds LS9 7TF, W Yorkshire, England.	bob.phillips@doctors.org.uk		Tyerman, Kay/0000-0003-2152-2708				FLOREY H. W., 1951, JOUR HIST MED AND ALLIED SCI, V6, P302; MEYERS K, 1999, PAEDIAT NEPHROLOGY; Safdar N, 2002, JAMA-J AM MED ASSOC, V288, P996, DOI 10.1001/jama.288.8.996; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008	4	9	10	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 19	2005	330	7488					409	410		10.1136/bmj.330.7488.409	http://dx.doi.org/10.1136/bmj.330.7488.409			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900NA	15718542	Green Published			2022-12-28	WOS:000227220400024
J	Wang, YX; Klijn, JGM; Zhang, Y; Sieuwerts, A; Look, MP; Yang, F; Talantov, D; Timmermans, M; Meijer-van Gelder, ME; Yu, J; Jatkoe, T; Berns, EMJJ; Atkins, D; Foekens, JA				Wang, YX; Klijn, JGM; Zhang, Y; Sieuwerts, A; Look, MP; Yang, F; Talantov, D; Timmermans, M; Meijer-van Gelder, ME; Yu, J; Jatkoe, T; Berns, EMJJ; Atkins, D; Foekens, JA			Gene-expression pro-files to predict distant metastasis of lymph-node-negative primary breast cancer	LANCET			English	Article							PROGNOSTIC VALUE; PROFILES; RECEPTORS; SIGNATURE; CONSENSUS; SURVIVAL; ESTROGEN; THERAPY	Background Genome-wide measures of gene expression can identify patterns of gene activity that subclassify tumours and might provide a better means than is currently available for individual risk assessment in patients with lymph-node-negative breast cancer. Methods We analysed, with Affymetrix Human U133a GeneChips, the expression of 22 000 transcripts from total RNA of frozen tumour samples from 286 lymph-node-negative patients who had not received adjuvant systemic treatment. Findings In a training set of 115 tumours, we identified a 76-gene signature consisting of 60 genes for patients positive for oestrogen receptors (ER) and 16 genes for ER-negative patients. This signature showed 93% sensitivity and 48% specificity in a subsequent independent testing set of 171 lymph-node-negative patients. The gene profile was highly informative in identifying patients who developed distant metastases within 5 years (hazard ratio 5.67 [95% CI 2.59-12.4]), even when corrected for traditional prognostic factors in multivariate analysis (5.55 [2.46-12.5]). The 76-gene profile also represented a strong prognostic factor for the development of metastasis in the subgroups of 84 premenopausal patients (9.60 [2.28-40.5]), 87 postmenopausal patients (4.04 [1.57-10.4]), and 79 patients with tumours of 10-20 mm (14.1 [3.34-59.2]), a group of patients for whom prediction of prognosis is especially difficult. Interpretation The identified signature provides a powerful tool for identification of patients at high risk of distant recurrence. The ability to identify patients who have a favourable prognosis could, after independent confirmation, allow clinicians to avoid adjuvant systemic therapy or to choose less aggressive therapeutic options.	Veridex LLC, San Diego, CA USA; Veridex LLC, Warren, NY USA; Erasmus MC Daniel den Hoed, Dept Med Oncol, Rotterdam, Netherlands	Johnson & Johnson; Johnson & Johnson USA; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	Foekens, JA (corresponding author), Erasmus MC, Josephine Nefkens Inst, Rm BE-426,Dr Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands.	j.foekens@erasmusmc.nl	li, jie/A-3133-2011					ABE O, 1995, NEW ENGL J MED, V333, P1444; Abe O, 1998, LANCET, V352, P930; Ahr A, 2002, LANCET, V359, P131, DOI 10.1016/S0140-6736(02)07337-3; Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8; Clarke M, 1998, LANCET, V351, P1451; EFRON B, 1981, J AM STAT ASSOC, V76, P312, DOI 10.2307/2287832; Eifel P, 2001, JNCI-J NATL CANCER I, V93, P979; FOEKENS JA, 1989, CANCER RES, V49, P5823; FOEKENS JA, 1989, CANCER RES, V49, P7002; Goldhirsch A, 2003, J CLIN ONCOL, V21, P3357, DOI 10.1200/JCO.2003.04.576; Gruvberger S, 2001, CANCER RES, V61, P5979; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Herrera-Gayol A, 1999, EXP MOL PATHOL, V66, P149, DOI 10.1006/exmp.1999.2251; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Ntzani EE, 2003, LANCET, V362, P1439, DOI 10.1016/S0140-6736(03)14686-7; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Ransohoff DF, 2004, NAT REV CANCER, V4, P309, DOI 10.1038/nrc1322; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Sotiriou C, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr433; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang YX, 2004, J CLIN ONCOL, V22, P1564, DOI 10.1200/JCO.2004.08.186; Woelfle U, 2003, CANCER RES, V63, P5679	30	2128	2267	3	133	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	2005	365	9460					671	679		10.1016/S0140-6736(05)17947-1	http://dx.doi.org/10.1016/S0140-6736(05)17947-1			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	898SP	15721472				2022-12-28	WOS:000227096800024
J	Collins, S; Ruina, A; Tedrake, R; Wisse, M				Collins, S; Ruina, A; Tedrake, R; Wisse, M			Efficient bipedal robots based on passive-dynamic walkers	SCIENCE			English	Article							WALKING; REINFORCEMENT; LOCOMOTION	Passive-dynamic walkers are simple mechanical devices, composed of solid parts connected by joints, that walk stably down a slope. They have no motors or controllers, yet can have remarkably humanlike motions. This suggests that these machines are useful models of human locomotion; however, they cannot walk on level. ground. Here we present three robots based on passive-dynamics, with small active power sources substituted for gravity, which can walk on level ground. These robots use less control and less energy than other powered robots, yet walk more naturally, further suggesting the importance of passive-dynamics in human locomotion.	Cornell Univ, Ithaca, NY 14853 USA; Univ Michigan, Ann Arbor, MI 48104 USA; MIT, Ctr Bits & Atoms, Cambridge, MA 02139 USA; Delft Univ Technol, NL-2628 CD Delft, Netherlands	Cornell University; University of Michigan System; University of Michigan; Massachusetts Institute of Technology (MIT); Delft University of Technology	Ruina, A (corresponding author), Cornell Univ, Ithaca, NY 14853 USA.	ruina@cornell.edu	Ruina, Andy L/A-8725-2018	Ruina, Andy L/0000-0001-5493-6048; Collins, Steve/0000-0002-3997-3374				Atzler E, 1927, PFLUG ARCH GES PHYS, V215, P291, DOI 10.1007/BF01731318; Benbrahim H, 1997, ROBOT AUTON SYST, V22, P283, DOI 10.1016/S0921-8890(97)00043-2; Chevallereau C, 2003, IEEE CONTR SYST MAG, V23, P57, DOI 10.1109/MCS.2003.1234651; Collins SH, 2001, INT J ROBOT RES, V20, P607, DOI 10.1177/02783640122067561; Donelan JM, 2002, J EXP BIOL, V205, P3717; Garcia M, 2000, DYNAM STABIL SYST, V15, P75, DOI 10.1080/713603737; Kato I., 1973, P CISM IFTOMM S THEO, p[12, 12]; KUN A, 1996, P IEEE INT C ROB AUT; Kuo AD, 2002, J BIOMECH ENG-T ASME, V124, P113, DOI 10.1115/1.1427703; MCGEER T, 1990, INT J ROBOT RES, V9, P62, DOI 10.1177/027836499000900206; MCGEER T, 1993, J THEOR BIOL, V163, P277, DOI 10.1006/jtbi.1993.1121; MOLEN NH, 1972, P K NED AKAD C BIOL, V75, P305; Pfeiffer F, 2002, 2002 IEEE INTERNATIONAL CONFERENCE ON ROBOTICS AND AUTOMATION, VOLS I-IV, PROCEEDINGS, P3129, DOI 10.1109/ROBOT.2002.1013708; RUINA A, IN PRESS J THEOR BIO; Sakagami Y, 2002, 2002 IEEE/RSJ INTERNATIONAL CONFERENCE ON INTELLIGENT ROBOTS AND SYSTEMS, VOLS 1-3, PROCEEDINGS, P2478, DOI 10.1109/IRDS.2002.1041641; Seung HS, 2003, NEURON, V40, P1063, DOI 10.1016/S0896-6273(03)00761-X; TEDRAKE R, 2004, P IEEE INT C ROB AUT; Tedrake R., 2004, P IEEE RSJ INT C INT; Todorov E, 2002, NAT NEUROSCI, V5, P1226, DOI 10.1038/nn963; WILSON JE, Patent No. 2140275; Winter David A., 2009, BIOMECHANICS MOTOR C, V4th, P75; WISSE M, IN PRESS IEEE T ROBO; ZAJAC FE, 1989, CRIT REV BIOMED ENG, V17, P359; [No title captured]; [No title captured]	25	1248	1325	12	386	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2005	307	5712					1082	1085		10.1126/science.1107799	http://dx.doi.org/10.1126/science.1107799			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ED	15718465				2022-12-28	WOS:000227197300040
J	Rouxel, OJ; Bekker, A; Edwards, KJ				Rouxel, OJ; Bekker, A; Edwards, KJ			Iron isotope constraints on the Archean and Paleoproterozoic ocean redox state	SCIENCE			English	Article							FE ISOTOPE; ATMOSPHERIC OXYGEN; REACTIVE IRON; BLACK-SEA; FRACTIONATION; SEDIMENTS; EARTH; CHEMISTRY; SULFUR; ADSORPTION	The response of the ocean redox state to the rise of atmospheric oxygen about 2.3 billion years ago (Ga) is a matter of controversy. Here we provide iron isotope evidence that the change in the ocean iron cycle occurred at the same time as the change in the atmospheric redox state. Variable and negative iron isotope values in pyrites older than about 2.3 Ga suggest that an iron-rich global ocean was strongly affected by the deposition of iron oxides. Between 2.3 and 1.8 Ga, positive iron isotope values of pyrite likely reflect an increase in the precipitation of iron sulfides relative to iron oxides in a redox stratified ocean.	Woods Hole Oceanog Inst, Marine Chem & Geochem Dept, Geomicrobiol Grp, Woods Hole, MA 02543 USA; Carnegie Inst Washington, Geophys Lab, Washington, DC 20015 USA	Woods Hole Oceanographic Institution; Carnegie Institution for Science	Rouxel, OJ (corresponding author), Woods Hole Oceanog Inst, Marine Chem & Geochem Dept, Geomicrobiol Grp, Mail Stop 8, Woods Hole, MA 02543 USA.	orouxel@whoi.edu	Rouxel, Olivier J/F-3954-2014	Rouxel, Olivier J/0000-0002-1431-222X; Bekker, Andrey/0000-0002-1154-0585				Anbar AD, 2002, SCIENCE, V297, P1137, DOI 10.1126/science.1069651; Anderson TF, 2004, AM J SCI, V304, P203, DOI 10.2475/ajs.304.3.203; Arnold GL, 2004, SCIENCE, V304, P87, DOI 10.1126/science.1091785; Beard BL, 2004, REV MINERAL GEOCHEM, V55, P319, DOI 10.2138/gsrmg.55.1.319; Beard BL, 2003, GEOLOGY, V31, P629, DOI 10.1130/0091-7613(2003)031<0629:IICOFC>2.0.CO;2; Bekker A, 2004, NATURE, V427, P117, DOI 10.1038/nature02260; BEKKER A, IN PRESS PRECAMBRIAN; BEUKES NJ, 1990, ECON GEOL BULL SOC, V85, P663, DOI 10.2113/gsecongeo.85.4.663; Bjerrum CJ, 2002, NATURE, V417, P159, DOI 10.1038/417159a; BRATERMAN PS, 1983, NATURE, V303, P163, DOI 10.1038/303163a0; Bullen TD, 2001, GEOLOGY, V29, P699, DOI 10.1130/0091-7613(2001)029<0699:DOSAII>2.0.CO;2; Butler IB, 2003, GEOCHIM COSMOCHIM AC, V67, pA51; CANFIELD DE, 1989, GEOCHIM COSMOCHIM AC, V53, P619, DOI 10.1016/0016-7037(89)90005-7; Canfield DE, 1998, NATURE, V396, P450, DOI 10.1038/24839; Croal LR, 2004, GEOCHIM COSMOCHIM AC, V68, P1227, DOI 10.1016/j.gca.2003.09.011; Farquhar J, 2000, SCIENCE, V289, P756, DOI 10.1126/science.289.5480.756; Holland HD., 1984, CHEM EVOLUTION ATMOS; Icopini GA, 2004, GEOLOGY, V32, P205, DOI 10.1130/G20184.1; Isley AE, 1999, J GEOPHYS RES-SOL EA, V104, P15461, DOI 10.1029/1999JB900066; Johnson CM, 2003, CONTRIB MINERAL PETR, V144, P523, DOI 10.1007/s00410-002-0418-x; Johnson CM, 2004, REV MINERAL GEOCHEM, V55, P359, DOI 10.2138/gsrmg.55.1.359; Karhu JA, 1996, GEOLOGY, V24, P867, DOI 10.1130/0091-7613(1996)024<0867:CIATRO>2.3.CO;2; Levasseur S, 2004, EARTH PLANET SC LETT, V224, P91, DOI 10.1016/j.epsl.2004.05.010; Matthews A, 2004, GEOCHIM COSMOCHIM AC, V68, P3107, DOI 10.1016/j.gca.2004.01.019; Polyakov VB, 2000, GEOCHIM COSMOCHIM AC, V64, P849, DOI 10.1016/S0016-7037(99)00329-4; Rouxel O, 2004, GEOCHIM COSMOCHIM AC, V68, P2295, DOI 10.1016/j.gca.2003.11.029; Rouxel O, 2003, CHEM GEOL, V202, P155, DOI 10.1016/j.chemgeo.2003.08.011; SEVERMANN S, 2003, EOS S, V84; Shen Y, 2003, NATURE, V423, P632, DOI 10.1038/nature01651; Summons RE, 1999, NATURE, V400, P554, DOI 10.1038/23005; Vargas M, 1998, NATURE, V395, P65, DOI 10.1038/25720; Welch SA, 2003, GEOCHIM COSMOCHIM AC, V67, P4231, DOI 10.1016/S0016-7037(03)00266-7; WIDDEL F, 1993, NATURE, V362, P834, DOI 10.1038/362834a0; Wijsman JWM, 2001, MAR CHEM, V74, P261, DOI 10.1016/S0304-4203(01)00019-6	34	379	417	1	136	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	2005	307	5712					1088	1091		10.1126/science.1105692	http://dx.doi.org/10.1126/science.1105692			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ED	15718467	Green Published			2022-12-28	WOS:000227197300042
J	Conboy, IM; Conboy, MJ; Wagers, AJ; Girma, ER; Weissman, IL; Rando, TA				Conboy, IM; Conboy, MJ; Wagers, AJ; Girma, ER; Weissman, IL; Rando, TA			Rejuvenation of aged progenitor cells by exposure to a young systemic environment	NATURE			English	Article							HEMATOPOIETIC STEM-CELLS; SKELETAL-MUSCLE; SATELLITE CELLS; C/EBP-ALPHA; OLD RATS; HETEROGENEITY; REGENERATION; PLASTICITY; PARABIOSIS; EXPRESSION	The decline of tissue regenerative potential is a hallmark of ageing and may be due to age-related changes in tissue-specific stem cells(1-5). A decline in skeletal muscle stem cell ( satellite cell) activity due to a loss of Notch signalling results in impaired regeneration of aged muscle(1,6). The decline in hepatic progenitor cell proliferation owing to the formation of a complex involving cEBP-alpha and the chromatin remodelling factor brahma (Brm) inhibits the regenerative capacity of aged liver(7). To examine the influence of systemic factors on aged progenitor cells from these tissues, we established parabiotic pairings ( that is, a shared circulatory system) between young and old mice (heterochronic parabioses), exposing old mice to factors present in young serum. Notably, heterochronic parabiosis restored the activation of Notch signalling as well as the proliferation and regenerative capacity of aged satellite cells. The exposure of satellite cells from old mice to young serum enhanced the expression of the Notch ligand ( Delta), increased Notch activation, and enhanced proliferation in vitro. Furthermore, heterochronic parabiosis increased aged hepatocyte proliferation and restored the cEBP-alpha complex to levels seen in young animals. These results suggest that the age-related decline of progenitor cell activity can be modulated by systemic factors that change with age.	Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; VA Palo Alto Hlth Care Syst, GRECC, Palo Alto, CA 94304 USA; VA Palo Alto Hlth Care Syst, Neurol Serv, Palo Alto, CA 94304 USA	Stanford University; Stanford University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Rando, TA (corresponding author), Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.	rando@stanford.edu	Ladoux, Benoit/A-9879-2013	Rando, Thomas/0000-0001-5843-8564				Beauchamp JR, 2000, J CELL BIOL, V151, P1221, DOI 10.1083/jcb.151.6.1221; CARLSON BM, 1989, AM J PHYSIOL, V256, pC1262; Carlson BM, 2001, J GERONTOL A-BIOL, V56, pB224, DOI 10.1093/gerona/56.5.B224; Conboy IM, 2002, DEV CELL, V3, P397, DOI 10.1016/S1534-5807(02)00254-X; Conboy IM, 2003, SCIENCE, V302, P1575, DOI 10.1126/science.1087573; FINERTY JC, 1952, PHYSIOL REV, V32, P277, DOI 10.1152/physrev.1952.32.3.277; FULLER J, 2002, SCI AGING KNOWLEDGE, pE11; Golden TR, 2002, AGING CELL, V1, P117, DOI 10.1046/j.1474-9728.2002.00015.x; Hasty P, 2003, SCIENCE, V299, P1355, DOI 10.1126/science.1079161; Hekimi S, 2003, SCIENCE, V299, P1351, DOI 10.1126/science.1082358; Iakova P, 2003, CELL, V113, P495, DOI 10.1016/S0092-8674(03)00318-0; Kuhn HG, 1996, J NEUROSCI, V16, P2027; MCCAY CM, 1957, GERONTOLOGY, V1, P7, DOI 10.1159/000210677; Morrison SJ, 1996, NAT MED, V2, P1011, DOI 10.1038/nm0996-1011; Partridge TA, 2002, GENE THER, V9, P752, DOI 10.1038/sj.gt.3301764; ROSENBLATT JD, 1995, IN VITRO CELL DEV-AN, V31, P773; Sell S, 2001, HEPATOLOGY, V33, P738, DOI 10.1053/jhep.2001.21900; Sherwood RI, 2004, STEM CELLS, V22, P1292, DOI 10.1634/stemcells.2004-0090; Sherwood RI, 2004, CELL, V119, P543, DOI 10.1016/j.cell.2004.10.021; SIDORENKO AV, 1986, MECH AGEING DEV, V36, P41, DOI 10.1016/0047-6374(86)90137-5; SIGAL SH, 1992, AM J PHYSIOL, V263, P139; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; TAUCHI H, 1977, MECH AGEING DEV, V6, P333, DOI 10.1016/0047-6374(77)90034-3; Timchenko NA, 1998, NUCLEIC ACIDS RES, V26, P3293, DOI 10.1093/nar/26.13.3293; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wright DE, 2001, BLOOD, V97, P2278, DOI 10.1182/blood.V97.8.2278	26	1532	1624	13	198	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	2005	433	7027					760	764		10.1038/nature03260	http://dx.doi.org/10.1038/nature03260			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897XH	15716955				2022-12-28	WOS:000227039200043
J	Kurth, WS; Gurnett, DA; Clarke, JT; Zarka, P; Desch, MD; Kaiser, ML; Cecconi, B; Lecacheux, A; Farrell, WM; Galopeau, P; Gerard, JC; Grodent, D; Prange, R; Dougherty, MK; Crary, FJ				Kurth, WS; Gurnett, DA; Clarke, JT; Zarka, P; Desch, MD; Kaiser, ML; Cecconi, B; Lecacheux, A; Farrell, WM; Galopeau, P; Gerard, JC; Grodent, D; Prange, R; Dougherty, MK; Crary, FJ			An Earth-like correspondence between Saturn's auroral features and radio emission	NATURE			English	Article							KILOMETRIC RADIATION; MAGNETIC-FIELD; VOYAGER-1; MODEL	Saturn is a source of intense kilometre-wavelength radio emissions that are believed to be associated with its polar aurorae(1,2), and which provide an important remote diagnostic of its magnetospheric activity. Previous observations implied that the radio emission originated in the polar regions, and indicated a strong correlation with solar wind dynamic pressure(1,3-7). The radio source also appeared to be fixed near local noon and at the latitude of the ultraviolet aurora(1,2). There have, however, been no observations relating the radio emissions to detailed auroral structures. Here we report measurements of the radio emissions, which, along with high-resolution images of Saturn's ultraviolet auroral emissions(8), suggest that although there are differences in the global morphology of the aurorae, Saturn's radio emissions exhibit an Earth-like correspondence between bright auroral features and the radio emissions. This demonstrates the universality of the mechanism that results in emissions near the electron cyclotron frequency narrowly beamed at large angles to the magnetic field(9,10).	Univ Iowa, Dept Phys & Astron, Iowa City, IA 52242 USA; Boston Univ, Boston, MA 02215 USA; Observ Paris, Space Res Dept, F-92195 Meudon, France; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; UVSQ, CETP, F-78140 Velizy Villacoublay, France; Univ Liege, LPAP, B-4000 Liege, Belgium; Univ London Imperial Coll Sci Technol & Med, Blackett Lab, London SW7 2BZ, England; SW Res Inst, San Antonio, TX 78288 USA	University of Iowa; Boston University; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; UDICE-French Research Universities; Universite Paris Saclay; University of Liege; Imperial College London; Southwest Research Institute	Kurth, WS (corresponding author), Univ Iowa, Dept Phys & Astron, Iowa City, IA 52242 USA.	william-kurth@uiowa.edu	Clarke, John/C-8644-2013; Cecconi, Baptiste/ABF-3912-2020; Kurth, William/AAA-7334-2019; Farrell, William/I-4865-2013	Cecconi, Baptiste/0000-0001-7915-5571; Kurth, William/0000-0002-5471-6202; GERARD, Jean-Claude/0000-0002-8565-8746				CONNERNEY JEP, 1982, NATURE, V298, P44, DOI 10.1038/298044a0; Cowley SWH, 2001, PLANET SPACE SCI, V49, P1067, DOI 10.1016/S0032-0633(00)00167-7; DEFERAUDY H, 1988, PLANETARY RADIO EMIS, V2, P41; DESCH MD, 1982, J GEOPHYS RES-SPACE, V87, P4549, DOI 10.1029/JA087iA06p04549; GALOPEAU P, 1991, J GEOPHYS RES-SPACE, V96, P14129, DOI 10.1029/91JA00696; GALOPEAU P, 1992, J GEOPHYS RES-SPACE, V97, P12291, DOI 10.1029/92JA00323; GALOPEAU P, 1989, J GEOPHYS RES, V94, P8739, DOI 10.1029/JA094iA07p08739; Galopeau PHM, 1995, J GEOPHYS RES-PLANET, V100, P26397, DOI 10.1029/95JE02132; Galopeau PHM, 2000, J GEOPHYS RES-SPACE, V105, P13089, DOI 10.1029/1999JA005089; GURNETT DA, 1974, J GEOPHYS RES, V79, P4227, DOI 10.1029/JA079i028p04227; GURNETT DA, IN PRESS SPACE SCI R; HUFF RL, 1988, J GEOPHYS RES, V93, P11445, DOI 10.1029/JA093iA10p11445; Imhof WL, 2003, J GEOPHYS RES-SPACE, V108, DOI 10.1029/2002JA009274; Kaiser M. L., 1984, SATURN, P378; KNIGHT S, 1973, PLANET SPACE SCI, V21, P741, DOI 10.1016/0032-0633(73)90093-7; STONE RG, 1992, ASTRON ASTROPHYS SUP, V92, P291; WARWICK JW, 1981, SCIENCE, V212, P239, DOI 10.1126/science.212.4491.239; WENZEL KP, 1992, ASTRON ASTROPHYS SUP, V92, P207; WU CS, 1979, ASTROPHYS J, V230, P621, DOI 10.1086/157120; Zarka P, 1998, J GEOPHYS RES-PLANET, V103, P20159, DOI 10.1029/98JE01323; ZARKA P, 1988, PLANETARY RADIO EMIS, V2, P327	21	93	93	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	2005	433	7027					722	725		10.1038/nature03334	http://dx.doi.org/10.1038/nature03334			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897XH	15716947				2022-12-28	WOS:000227039200033
J	Schumacher, B; Hanazawa, M; Lee, MH; Nayak, S; Volkmann, K; Hofmann, R; Hengartner, M; Schedl, T; Gartner, A				Schumacher, B; Hanazawa, M; Lee, MH; Nayak, S; Volkmann, K; Hofmann, R; Hengartner, M; Schedl, T; Gartner, A			Translational repression of C-elegans p53 by GLD-1 regulates DNA damage-induced apoptosis	CELL			English	Article							MESSENGER-RNA TARGETS; PROGRAMMED CELL-DEATH; TUMOR-SUPPRESSOR GENE; CAENORHABDITIS-ELEGANS; MEIOTIC RECOMBINATION; BINDING PROTEIN; T-REGION; CHECKPOINT; GERMLINE; ENCODES	p53 is a tumor suppressor gene whose regulation is crucial to maintaining genome stability and for the apoptotic elimination of abnormal, potentially cancer-predisposing cells. C. elegans contains a primordial p53 gene, cep-1, that acts as a transcription factor necessary for DNA damage-induced apoptosis. In a genetic screen for negative regulators of CEP-1, we identified a mutation in GLD-1, a translational repressor implicated in multiple C. elegans germ cell fate decisions and related to mammalian Quaking proteins. CEP-1-dependent transcription of proapoptotic genes is upregulated in the gld-1(op236) mutant and an elevation of p53-mediated germ cell apoptosis in response to DNA damage is observed. Further, we demonstrate that GLD-1 mediates its repressive effect by directly binding to the 3'UTR of cep-1/p53 mRNA and repressing its translation. This study reveals that the regulation of cep-1/p53 translation influences DNA damage-induced apoptosis and demonstrates the physiological importance of this mechanism.	Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland	Max Planck Society; Washington University (WUSTL); University of Zurich	Gartner, A (corresponding author), Univ Dundee, Sch Life Sci, Dow St, Dundee DD1 5EH, Scotland.	a.gartner@dundee.ac.uk	Hengartner, Michael O/E-6235-2011; Hengartner, Michael O/A-7058-2008; Schumacher, Björn/I-4829-2013	Schumacher, Björn/0000-0001-6097-5238; Gartner, Anton/0000-0003-4639-9902; Hengartner, Michael/0000-0002-7584-596X	NIGMS NIH HHS [R01 GM63310, R01 GM063310] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063310] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed S, 2001, CURR BIOL, V11, P1934, DOI 10.1016/S0960-9822(01)00604-2; Alpi A, 2003, CHROMOSOMA, V112, P6, DOI 10.1007/s00412-003-0237-5; Baehrecke EH, 1997, DEVELOPMENT, V124, P1323; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; BODE VC, 1984, GENETICS, V108, P457; Boulton SJ, 2002, SCIENCE, V295, P127, DOI 10.1126/science.1065986; Chene P, 2003, NAT REV CANCER, V3, P102, DOI 10.1038/nrc991; Cohen PE, 2001, BIOESSAYS, V23, P996, DOI 10.1002/bies.1145; Colaiacovo MP, 2003, DEV CELL, V5, P463, DOI 10.1016/S1534-5807(03)00232-6; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Cooke HJ, 2002, NAT REV GENET, V3, P790, DOI 10.1038/nrg911; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; FRANCIS R, 1995, GENETICS, V139, P579; FRANCIS R, 1995, GENETICS, V139, P607; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Fu LN, 1999, ONCOGENE, V18, P6419, DOI 10.1038/sj.onc.1203064; Gartner A, 2000, MOL CELL, V5, P435, DOI 10.1016/S1097-2765(00)80438-4; Gartner Anton, 2004, Methods Mol Biol, V280, P257; Gumienny TL, 1999, DEVELOPMENT, V126, P1011; Hasegawa M, 1998, RADIAT RES, V149, P263, DOI 10.2307/3579959; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Hillers KJ, 2003, CURR BIOL, V13, P1641, DOI 10.1016/j.cub.2003.08.026; Hofmann ER, 2002, CURR BIOL, V12, P1908, DOI 10.1016/S0960-9822(02)01262-9; Hofmann ER, 2000, COLD SPRING HARB SYM, V65, P467, DOI 10.1101/sqb.2000.65.467; Hubbard EJA, 2000, DEV DYNAM, V218, P2, DOI 10.1002/(SICI)1097-0177(200005)218:1<2::AID-DVDY2>3.0.CO;2-W; Jan E, 1999, EMBO J, V18, P258, DOI 10.1093/emboj/18.1.258; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; JUSTICE MJ, 1988, GENET RES, V51, P95, DOI 10.1017/S0016672300024101; Kelly WG, 1997, GENETICS, V146, P227; Lain S, 2003, EUR J CANCER, V39, P1053, DOI 10.1016/S0959-8049(03)00063-7; Lee MH, 2004, GENE DEV, V18, P1047, DOI 10.1101/gad.1188404; Lee MH, 2001, GENE DEV, V15, P2408, DOI 10.1101/gad.915901; Lydall D, 1996, NATURE, V383, P840, DOI 10.1038/383840a0; Marin VA, 2003, DEVELOPMENT, V130, P2623, DOI 10.1242/dev.00486; Matzuk MM, 2002, NAT CELL BIOL, V4, pS41; Mootz D, 2004, DEVELOPMENT, V131, P3263, DOI 10.1242/dev.01196; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Odorisio T, 1998, NAT GENET, V18, P257, DOI 10.1038/ng0398-257; PIEROTTI M A, 1992, Current Opinion in Oncology, V4, P127, DOI 10.1097/00001622-199202000-00017; Roeder GS, 2000, TRENDS GENET, V16, P395, DOI 10.1016/S0168-9525(00)02080-1; Roemer K, 1999, BIOL CHEM, V380, P879, DOI 10.1515/BC.1999.108; Ryder SP, 2004, NAT STRUCT MOL BIOL, V11, P20, DOI 10.1038/nsmb706; SAMORAJS.T, 1970, J NEUROPATH EXP NEUR, V29, P507, DOI 10.1097/00005072-197010000-00001; Schumacher B, 2005, CELL DEATH DIFFER, V12, P153, DOI 10.1038/sj.cdd.4401539; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; Schwartz D, 1999, CELL GROWTH DIFFER, V10, P665; Seydoux G, 2001, INT REV CYTOL, V203, P139; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; SHEDLOVSKY A, 1988, P NATL ACAD SCI USA, V85, P180, DOI 10.1073/pnas.85.1.180; SIDMAN RL, 1964, SCIENCE, V144, P309, DOI 10.1126/science.144.3616.309; Sjoblom T, 1996, ONCOGENE, V12, P2499; Tunquist BJ, 2003, GENE DEV, V17, P683, DOI 10.1101/gad.1071303; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WOOD WB, 1996, NEMATODE CAENORHABDI; Xu L, 2001, GENETICS, V159, P1007; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zaffran S, 1997, DEVELOPMENT, V124, P2087; Zhou Z, 2001, CELL, V104, P43, DOI 10.1016/S0092-8674(01)00190-8	63	168	177	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 11	2005	120	3					357	368		10.1016/j.cell.2004.12.009	http://dx.doi.org/10.1016/j.cell.2004.12.009			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	897TS	15707894	Bronze			2022-12-28	WOS:000227028900011
J	de Duve, C				de Duve, C			The onset of selection	NATURE			English	Editorial Material							UNIVERSAL ANCESTOR		ICP, B-1200 Brussels, Belgium; Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	de Duve, C (corresponding author), ICP, B-1200 Brussels, Belgium.							DEDUVE C, 2002, SINGULARITIES; DEDUVE C, 2002, LIFE EVOLVING; Doolittle WF, 2000, CURR OPIN STRUC BIOL, V10, P355, DOI 10.1016/S0959-440X(00)00096-8; EIGEN M, 1977, NATURWISSENSCHAFTEN, V64, P541, DOI 10.1007/BF00450633; EIGEN M, 1981, NATURWISSENSCHAFTEN, V68, P282, DOI 10.1007/BF01047470; Freeland SJ, 2003, ORIGINS LIFE EVOL B, V33, P457, DOI 10.1023/A:1025771327614; Morris Simon Conway, 2003, LIFES SOLUTION; Woese C, 1998, P NATL ACAD SCI USA, V95, P6854, DOI 10.1073/pnas.95.12.6854	8	40	41	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 10	2005	433	7026					581	582		10.1038/433581a	http://dx.doi.org/10.1038/433581a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	895KX	15703726				2022-12-28	WOS:000226862000022
J	Blom, JW; Doggen, CJM; Osanto, S; Rosendaal, FR				Blom, JW; Doggen, CJM; Osanto, S; Rosendaal, FR			Malignancies, prothrombotic mutations, and the risk of venous thrombosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEEP-VEIN THROMBOSIS; ACTIVATED PROTEIN-C; THROMBOEMBOLIC DISEASE; CANCER; GENE; THROMBOPHILIA; LEIDEN; BLOOD	Context Venous thrombosis is a common complication inpatients with cancer, leading to additional morbidity and compromising quality of life. Objective To identify individuals with cancer with an increased thrombotic risk, evaluating different tumor sites, the presence of distant metastases, and carrier status of prothrombotic mutations. Design, Setting, and Patients A large population-based, case-control (Multiple Environmental and Genetic Assessment [MEGA] of risk factors for venous thrombosis) study of 3220 consecutive patients aged 18 to 70 years, with a first deep venous thrombosis of the leg or pulmonary embolism, between March 1, 1999, and May 31, 2002, at 6 anticoagulation clinics in the Netherlands, and separate 2131 control participants (partners of the patients) reported via a questionnaire on acquired risk factors forvenous thrombosis. Three months after discontinuation of the anticoagulant therapy, all patients and controls were interviewed, a blood sample was taken, and DNA was isolated to ascertain the factor V Leiden and prothrombin 20210A mutations. Main Outcome Measure Risk of venous thrombosis. Results The overall risk of venous thrombosis was increased 7-fold in patients with a malignancy (odds ratio [OR], 6.7; 95% confidence interval [Cl], 5.2-8.6) vs persons without malignancy. Patients with hematological malignancies had the highest risk of venous thrombosis, adjusted for age and sex (adjusted OR, 28.0; 95% Cl, 4.0-199.7), followed by lung cancer and gastrointestinal cancer. The risk of venous thrombosis was highest in the first few months after the diagnosis of malignancy (adjusted OR, 53.5; 95% Cl, 8.6-334.3). Patients with cancer with distant metastases had a higher risk vs patients without distant metastases (adjusted OR, 19.8; 95% Cl, 2.6-149.1). Carriers of the factor V Leiden mutation who also had cancer had a 12-fold increased risk vs individuals without cancer and factor V Leiden (adjusted OR, 12.1; 95% Cl, 1.6-88.1). Similar results were indirectly calculated for the prothrombin 20210A mutation in patients with cancer. Conclusions Patients with cancer have a highly increased risk of venous thrombosis especially in the first few months after diagnosis and in the presence of distant metastases. Carriers of the factor V Leiden and prothrombin 20210A mutations appear to have an even higher risk.	Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Oncol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Ctr Hemostasis & Thrombosis Res, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Rosendaal, FR (corresponding author), Leiden Univ, Med Ctr, Dept Clin Epidemiol, C9-P,POB 9600, NL-2300 RC Leiden, Netherlands.	f.r.rosendaal@lumc.nl	Rosendaal, Frits/Q-3842-2017	Rosendaal, Frits/0000-0003-2558-7496				Baron JA, 1998, LANCET, V351, P1077, DOI 10.1016/S0140-6736(97)10018-6; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Buller H R, 2000, Ned Tijdschr Geneeskd, V144, P1531; COGO A, 1994, ARCH INTERN MED, V154, P164, DOI 10.1001/archinte.154.2.164; Falanga A, 1999, SEMIN THROMB HEMOST, V25, P173, DOI 10.1055/s-2007-994919; Falanga A, 1998, HAEMOSTASIS, V28, P50; Francis JL, 1998, SEMIN THROMB HEMOST, V24, P93, DOI 10.1055/s-2007-995829; Gale AJ, 2001, ACTA HAEMATOL-BASEL, V106, P25, DOI 10.1159/000046586; Gomez E, 1998, BLOOD, V91, P2208, DOI 10.1182/blood.V91.6.2208.2208_2208_2209; Heit JA, 2000, ARCH INTERN MED, V160, P809, DOI 10.1001/archinte.160.6.809; Khoury MJ, 1996, AM J EPIDEMIOL, V144, P207; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; Lane DA, 1996, THROMB HAEMOSTASIS, V76, P651; Levitan N, 1999, MEDICINE, V78, P285, DOI 10.1097/00005792-199909000-00001; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Monreal M, 1997, THROMB HAEMOSTASIS, V78, P1316; NORDSTROM M, 1994, BRIT MED J, V308, P891, DOI 10.1136/bmj.308.6933.891; Otterson GA, 1996, AM J MED, V101, P406, DOI 10.1016/S0002-9343(96)00235-5; Palareti G, 2000, THROMB HAEMOSTASIS, V84, P805; Pihusch R, 2002, CANCER, V94, P3120, DOI 10.1002/cncr.10590; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; Rosendaal FR, 1999, LANCET, V353, P1167, DOI 10.1016/S0140-6736(98)10266-0; Sallah S, 2002, THROMB HAEMOSTASIS, V87, P575; Sorensen HT, 2000, NEW ENGL J MED, V343, P1846, DOI 10.1056/NEJM200012213432504; Thodiyil PA, 2001, ACTA HAEMATOL-BASEL, V106, P73, DOI 10.1159/000046592; TROUSSEAU A, 1868, PHLEGMASIA ALBA DOLE, V5, P281; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x	27	1316	1438	1	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2005	293	6					715	722		10.1001/jama.293.6.715	http://dx.doi.org/10.1001/jama.293.6.715			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895DX	15701913	Bronze, Green Published			2022-12-28	WOS:000226842200025
J	Sanz, EJ; De-las-Cuevas, C; Kiuru, A; Bate, A; Edwards, R				Sanz, EJ; De-las-Cuevas, C; Kiuru, A; Bate, A; Edwards, R			Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis	LANCET			English	Article							ANTIDEPRESSANT WITHDRAWAL; DISCONTINUATION; SIGNALS	Background Selective serotonin reuptake inhibitors (SSRIs) have been associated with withdrawal symptoms. We investigated whether use of these drugs in pregnant women might cause neonatal withdrawal syndrome. Methods An association between paroxetine and neonatal convulsions was identified in December, 2001, by the data mining method routinely used to screen the WHO database of adverse drug reactions. An information component (IC) measure was used to screen for unexpected adverse reactions relative to the information in the database. We then assessed cases of neonatal convulsions and neonatal withdrawal syndrome associated with drugs included in the anatomical therapeutic chemical groups N06AB and N06AX. Findings By November, 2003, a total of 93 suspected cases of SSRI-induced neonatal withdrawal syndrome had been reported, and were regarded as enough information to confirm a possible causal relation. 64 of the cases were associated with paroxetine, 14 with fluoxetine, nine with sertraline, and seven with citalopram. The IC-2 SD for the group became greater than 0 in the first quarter of 1991, and the IC increased to 2.68 (IC-2 SD 0-32) by the second quarter of 2003. For each individual compound, the IC-2 SD was greater than 0. Interpretation SSRIs, especially paroxetine, should be cautiously managed in the treatment of pregnant women with a psychiatric disorder.	Univ La Laguna, Sch Med, Tenerife 38071, Spain; WHO, Collaborating Ctr Int Drug Monitoring, Uppsala Monitoring Ctr, Uppsala, Sweden	Universidad de la Laguna; World Health Organization	Sanz, EJ (corresponding author), Univ La Laguna, Sch Med, Tenerife 38071, Spain.	esanz@ull.es	De las Cuevas, Carlos/F-6423-2011; Sanz Alvarez, Emilio J/M-3535-2019; Sanz, Emilio J/C-9793-2009; Bate, Andrew/J-3799-2019	De las Cuevas, Carlos/0000-0001-5742-905X; Sanz Alvarez, Emilio J/0000-0001-6788-4435; Sanz, Emilio J/0000-0001-6788-4435; 				Bate A, 2002, EUR J CLIN PHARMACOL, V58, P483, DOI 10.1007/s00228-002-0484-x; Bate A, 1998, EUR J CLIN PHARMACOL, V54, P315, DOI 10.1007/s002280050466; BAUMAN HE, 1995, ADV MEAT RES, V10, P1; Benazzi F, 1996, CAN J PSYCHIAT, V41, P487, DOI 10.1177/070674379604100722; *BRIT MED ASS ROYA, 1990, BRIT NAT FORM; BROSEN K, 1993, CLIN INVESTIGATOR, V71, P1002; BRYOIS C, 1998, SCHWEIZERISCHE RUNDS, V87, P345; CECCHERININELLI A, 1993, AM J PSYCHIAT, V150, P165; *COMM SAF MED, 2003, SER MUST NOT BE US T; Dahl ML, 1997, BRIT J PSYCHIAT, V171, P391, DOI 10.1192/bjp.171.4.391c; DILSAVER SC, 1984, BIOL PSYCHIAT, V19, P237; Edwards I, 2002, PHARMACOVIGILANCE, P169; EDWARDS IR, 1994, DRUG SAFETY, V10, P93, DOI 10.2165/00002018-199410020-00001; Haddad P, 1998, BMJ-BRIT MED J, V316, P1105, DOI 10.1136/bmj.316.7138.1105; Hiemke C, 2000, PHARMACOL THERAPEUT, V85, P11, DOI 10.1016/S0163-7258(99)00048-0; Lejoyeux M, 1997, J CLIN PSYCHIAT, V58, P11; Lindquist M, 2000, DRUG SAFETY, V23, P533, DOI 10.2165/00002018-200023060-00004; Mareth TR, 1996, J CLIN PSYCHIAT, V57, P310; Mavissakalian MR, 1999, ARCH GEN PSYCHIAT, V56, P821, DOI 10.1001/archpsyc.56.9.821; Nijhuis IJM, 2001, ARCH DIS CHILD-FETAL, V84, pF77; Orre R, 2000, COMPUT STAT DATA AN, V34, P473, DOI 10.1016/S0167-9473(99)00114-0; Rosenbaum JF, 1998, BIOL PSYCHIAT, V44, P77, DOI 10.1016/S0006-3223(98)00126-7; SPENCER MJ, 1993, PEDIATRICS, V92, P721; Stahl MMS, 1997, EUR J CLIN PHARMACOL, V53, P163, DOI 10.1007/s002280050357; Stiskal JA, 2001, ARCH DIS CHILD-FETAL, V84, pF134, DOI 10.1136/fn.84.2.F134; VALDESSARINI RJ, 2001, PHARMACOL BASIS THER, P431; Young AH, 1997, BRIT J PSYCHIAT, V170, P288, DOI 10.1192/bjp.170.3.288a	27	257	260	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 5	2005	365	9458					482	487		10.1016/S0140-6736(05)17865-9	http://dx.doi.org/10.1016/S0140-6736(05)17865-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894SS	15705457				2022-12-28	WOS:000226812500025
J	Annas, GJ				Annas, GJ			Family privacy and death Antigone, war, and medical research.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DATABASE; ICELAND; ETHICS		Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA	Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA.			Annas, George/0000-0001-5836-7831				Abbott A, 2004, NATURE, V429, P118, DOI 10.1038/429118b; Annas GJ, 2000, NEW ENGL J MED, V342, P1830, DOI 10.1056/NEJM200006153422412; CLINTON B, 2004, MY LIFE, P531; Davies Frank, 2004, MIAMI HERALD    0424, p1A; Gulcher JR, 2000, NEW ENGL J MED, V342, P1827, DOI 10.1056/NEJM200006153422411; KORNBLUT AE, 2004, BOSTON GLOBE    0424, pA1; Merz JF, 2004, SOC SCI MED, V58, P1201, DOI 10.1016/S0277-9536(03)00256-9; Offit K, 2004, JAMA-J AM MED ASSOC, V292, P1469, DOI 10.1001/jama.292.12.1469; Parker M, 2004, BRIT MED J, V329, P165, DOI 10.1136/bmj.329.7458.165; Stanley Alessandra, 1991, N Y Times Web, pC13; STOLBERG SG, 2004, NY TIMES        0622, pA17; WARISH LA, 2004, COMMUNICATION   0414	12	4	4	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 3	2005	352	5					501	505		10.1056/NEJMlim042648	http://dx.doi.org/10.1056/NEJMlim042648			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	893NE	15689591	Green Published			2022-12-28	WOS:000226725400014
J	Jeong, PY; Jung, M; Yim, YH; Kim, H; Park, M; Hong, EM; Lee, W; Kim, YH; Kim, K; Paik, YK				Jeong, PY; Jung, M; Yim, YH; Kim, H; Park, M; Hong, EM; Lee, W; Kim, YH; Kim, K; Paik, YK			Chemical structure and biological activity of the Caenorhabditis elegans dauer-inducing pheromone	NATURE			English	Article							MULTIPLE-QUANTUM NMR; CHEMOSENSORY NEURONS; LARVAL DEVELOPMENT; SPECTROSCOPY; PARALLEL; FOOD	Pheromones are cell type-specific signals used for communication between individuals of the same species. When faced with overcrowding or starvation, Caenorhabditis elegans secrete the pheromone daumone, which facilitates communication between individuals for adaptation to adverse environmental stimuli(1-4). Daumone signals C. elegans to enter the dauer stage, an enduring and non-ageing stage of the nematode life cycle with distinctive adaptive features and extended life. Because daumone is a key regulator of chemosensory processes in development and ageing(5,6), the chemical identification of daumone is important for elucidating features of the daumone-mediated signalling pathway. Here we report the isolation of natural daumone from C. elegans by large-scale purification, as well as the total chemical synthesis of daumone. We present the stereospecific chemical structure of purified daumone, a fatty acid derivative. We demonstrate that both natural and chemically synthesized daumones equally induce dauer larva formation in C. elegans (N2 strain) and certain dauer mutants, and also result in competition between food and daumone. These results should help to elucidate the daumone-mediated signalling pathway, which might in turn influence ageing and obesity research and the development of antinematodal drugs.	Yonsei Univ, Dept Biochem, Seoul 120749, South Korea; Yonsei Univ, Yonsei Proteome Res Ctr, Seoul 120749, South Korea; Yonsei Univ, Dept Chem, Seoul 120749, South Korea; Yonsei Univ, Bioprod Res Ctr, Seoul 120749, South Korea; Korea Res Inst Stand & Sci, Taejon 305600, South Korea; Korea Basic Sci Inst, Taejon 305333, South Korea	Yonsei University; Yonsei University; Yonsei University; Yonsei University; Korea Research Institute of Standards & Science (KRISS); Korea Basic Science Institute (KBSI)	Paik, YK (corresponding author), Yonsei Univ, Dept Biochem, Seoul 120749, South Korea.	paikyk@yonsei.ac.kr	LEE, WEON TAE/AAQ-9088-2021; Kim, Young Hwan/AAA-5484-2022	Kim, Young Hwan/0000-0003-3478-8839; Lee, Weontae/0000-0003-2347-1262				Antebi A, 1998, DEVELOPMENT, V125, P1191; Apfeld J, 1999, NATURE, V402, P804, DOI 10.1038/45544; BARGMANN CI, 1991, SCIENCE, V251, P1243, DOI 10.1126/science.2006412; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; Bird DM, 1998, J NEMATOL, V30, P299; BRENNER S, 1974, GENETICS, V77, P71; CASSADA RC, 1975, DEV BIOL, V46, P326, DOI 10.1016/0012-1606(75)90109-8; Choi BK, 2003, MOL CELL PROTEOMICS, V2, P1086, DOI 10.1074/mcp.M300036-MCP200; GOLDEN JW, 1984, J CHEM ECOL, V10, P1265, DOI 10.1007/BF00988553; GOLDEN JW, 1982, SCIENCE, V218, P578, DOI 10.1126/science.6896933; GOLDEN JW, 1984, DEV BIOL, V102, P368, DOI 10.1016/0012-1606(84)90201-X; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Koga M, 1999, DEVELOPMENT, V126, P5387; Patterson GI, 1997, GENE DEV, V11, P2679, DOI 10.1101/gad.11.20.2679; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REGNIER FE, 1968, J LIPID RES, V9, P541; Schackwitz WS, 1996, NEURON, V17, P719, DOI 10.1016/S0896-6273(00)80203-2; SCHLEUCHER J, 1994, J BIOMOL NMR, V4, P301; THOMAS JH, 1993, GENETICS, V134, P1105; Viney ME, 2004, NATURWISSENSCHAFTEN, V91, P123, DOI 10.1007/s00114-004-0503-2; VOWELS JJ, 1994, GENETICS, V138, P303	25	271	287	4	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 3	2005	433	7025					541	545		10.1038/nature03201	http://dx.doi.org/10.1038/nature03201			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	893NT	15690045				2022-12-28	WOS:000226727200053
J	Rucker, R; Storms, D; Sheets, A; Tchaparian, E; Fascetti, A				Rucker, R; Storms, D; Sheets, A; Tchaparian, E; Fascetti, A			Is pyrroloquinoline quinone a vitamin?	NATURE			English	Editorial Material							COFACTOR; MAMMALS; LIVER		Univ Calif Davis, Sch Vet Med, Coll Agr & Environm Sci, Dept Nutr, Davis, CA 95616 USA; Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Rucker, R (corresponding author), Univ Calif Davis, Sch Vet Med, Coll Agr & Environm Sci, Dept Nutr, Davis, CA 95616 USA.	rbrucker@ucdavis.edu						BLEMINGS KP, 1994, J NUTR, V124, P1215, DOI 10.1093/jn/124.8.1215; CHANG YF, 1990, BIOCHIM BIOPHYS ACTA, V1038, P300, DOI 10.1016/0167-4838(90)90241-7; Kasahara T, 2003, NATURE, V422, P832, DOI 10.1038/422832a; KILLGORE J, 1989, SCIENCE, V245, P850, DOI 10.1126/science.2549636; Papes F, 1999, BIOCHEM J, V344, P555, DOI 10.1042/0264-6021:3440555; STEINBERG FM, 1994, J NUTR, V124, P744, DOI 10.1093/jn/124.5.744; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078	7	46	56	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2005	433	7025					E10	E11		10.1038/nature03323	http://dx.doi.org/10.1038/nature03323			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893NT	15689994				2022-12-28	WOS:000226727200035
J	White, JD; Chen, J; Matsiev, D; Auerbach, DJ; Wodtke, AM				White, JD; Chen, J; Matsiev, D; Auerbach, DJ; Wodtke, AM			Conversion of large-amplitude vibration to electron excitation at a metal surface	NATURE			English	Article							DISSOCIATIVE CHEMISORPTION; EXOELECTRON EMISSION; CHEMICAL-REACTIONS; QUANTUM-THEORY; CS FILMS; MOLECULES; STATE; N2O; OXIDATION; DYNAMICS	Gaining insight into the nature and dynamics of the transition state is the essence of mechanistic investigations of chemical reactions(1), yet the fleeting configuration when existing chemical bonds dissociate while new ones form is extremely difficult to examine directly(2). Adiabatic potential-energy surfaces - usually derived using quantum chemical methods(3) that assume mutually independent nuclear and electronic motion(4) - quantify the fundamental forces between atoms involved in reaction and thus provide accurate descriptions of a reacting system as it moves through its transition state(5,6). This approach, widely tested for gas-phase reactions(7), is now also commonly applied to chemical reactions at metal surfaces(8). There is, however, some evidence calling into question the correctness of this theoretical approach for surface reactions: electronic excitation upon highly exothermic chemisorption has been observed(9), and indirect evidence suggests that large-amplitude vibrations of reactant molecules can excite electrons at metal surfaces(10,11). Here we report the detection of 'hot' electrons leaving a metal surface as vibrationally highly excited NO molecules collide with it. Electron emission only occurs once the vibrational energy exceeds the surface work function, and is at least 10,000 times more efficient than the emissions seen in similar systems where large-amplitude vibrations were not involved(12-18). These observations unambiguously demonstrate the direct conversion of vibrational to electronic excitation, thus questioning one of the basic assumptions currently used in theoretical approaches to describing bond-dissociation at metal surfaces.	Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA; Hitachi Global Storage Technol, San Jose, CA 95120 USA	University of California System; University of California Santa Barbara	Wodtke, AM (corresponding author), Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA.	wodtke@chem.ucsb.edu	Auerbach, Daniel J/J-7109-2014; Wodtke, Alec M/I-4848-2012	Auerbach, Daniel J/0000-0001-9494-3066; Wodtke, Alec/0000-0002-6509-2183				Born M, 1927, ANN PHYS-BERLIN, V84, P0457; BOTTCHER A, 1991, J CHEM PHYS, V95, P3756, DOI 10.1063/1.460826; Bottcher A, 1998, SURF SCI, V408, P212, DOI 10.1016/S0039-6028(98)00229-5; BOTTCHER A, 1993, CHEM PHYS LETT, V208, P404, DOI 10.1016/0009-2614(93)87163-W; Brandt M, 1998, PHYS REV LETT, V81, P2376, DOI 10.1103/PhysRevLett.81.2376; Brandt M, 1999, SURF SCI, V439, P49, DOI 10.1016/S0039-6028(99)00692-5; Chao SD, 2002, J CHEM PHYS, V117, P8341, DOI 10.1063/1.1504083; Chen J, 2004, CHEM PHYS, V301, P161, DOI 10.1016/j.chemphys.2004.01.025; Diekhoner L, 2002, J CHEM PHYS, V117, P5018, DOI 10.1063/1.1498476; Eyring H, 1935, J CHEM PHYS, V3, P786, DOI 10.1063/1.1749593; Eyring H, 1931, Z PHYS CHEM B-CHEM E, V12, P279; Eyring H, 1935, J CHEM PHYS, V3, P107, DOI 10.1063/1.1749604; GREBER T, 1994, CHEM PHYS LETT, V222, P292, DOI 10.1016/0009-2614(94)00344-0; GROBECKER R, 1994, PHYS STATUS SOLIDI A, V146, P259, DOI 10.1002/pssa.2211460122; HETTEMA H, 2000, WORLD SCI SERIES 20, V8; Huang YH, 2000, SCIENCE, V290, P111, DOI 10.1126/science.290.5489.111; KOHN W, 1965, PHYS REV, V140, P1133, DOI 10.1103/PhysRev.140.A1133; Kroes GJ, 2002, ACCOUNTS CHEM RES, V35, P193, DOI 10.1021/ar010104u; MANOLOPOULOS DE, 1993, SCIENCE, V262, P1852, DOI 10.1126/science.262.5141.1852; Nienhaus H, 2002, SURF SCI REP, V45, P3, DOI 10.1016/S0167-5729(01)00019-X; Silva M, 2001, ANNU REV PHYS CHEM, V52, P811, DOI 10.1146/annurev.physchem.52.1.811; SKOTTKEKLEIN M, 1991, THIN SOLID FILMS, V203, P131, DOI 10.1016/0040-6090(91)90524-2; WANG CS, 1977, J APPL PHYS, V48, P1477, DOI 10.1063/1.323864; WORATSCHEK B, 1987, J CHEM PHYS, V86, P2411, DOI 10.1063/1.452089	24	160	160	3	81	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 3	2005	433	7025					503	505		10.1038/nature03213	http://dx.doi.org/10.1038/nature03213			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893NT	15690036				2022-12-28	WOS:000226727200043
J	Kimmel, SE; Berlin, JA; Reilly, M; Jaskowiak, J; Kishel, L; Chittams, J; Strom, BL				Kimmel, SE; Berlin, JA; Reilly, M; Jaskowiak, J; Kishel, L; Chittams, J; Strom, BL			Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SELECTIVE CYCLOOXYGENASE-2 INHIBITORS; RANDOMIZED CONTROLLED-TRIAL; CARDIOVASCULAR THROMBOTIC EVENTS; THERAPEUTIC ARTHRITIS RESEARCH; GASTROINTESTINAL TOXICITY; RHEUMATOID-ARTHRITIS; ENDOTHELIAL FUNCTION; NAPROXEN; COX-2	Background: Studies have postulated that cyclooxygenase-2 (COX-2) selective inhibitors affect cardiovascular risk through various mechanisms. Some of these mechanisms could increase risk (for example, inhibition of prostacyclin production), and some could decrease risk (for example, inhibition of inflammation). Objective: To determine the effect of COX-2 inhibitors on risk for nonfatal myocardial infarction (MI). Design: Case-control study. Setting: 36 hospitals in a 5-county area. Participants: 1718 case-patients with a first, nonfatal MI admitted to these hospitals and 6800 controls randomly selected from the same counties. Measurements: Self-reported medication use assessed through telephone interviews. Results: The adjusted odds ratio for MI among celecoxib users, relative to persons who did not use nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs), was 0.43 (95% CI, 0.23 to 0.79) compared with 1.16 (Cl, 0.70 to 1.93) among rofecoxib users. The use of rofecoxib was associated with a statistically significant higher odds of MI compared with the use of celecoxib (adjusted odds ratio for rofecoxib vs. celecoxib, 2.72 [CI, 1.24 to 5.95]; P = 0.01). Nonselective NSAIDs were associated with a reduced odds of nonfatal MI relative to nonusers. Comparisons of COX-2 inhibitors with nonselective NSAIDs were the following: rofecoxib versus naproxen (odds ratio, 3.39 [CI, 1.37 to 8.40]) and celecoxib versus ibuprofen or diclofenac (odds ratio, 0.77 [CI, 0.40 to 1.48]). Limitations: The possibility of recall bias and uncontrolled confounding in this observational study limit the ability to make definitive conclusions. The association of celecoxib with a lower odds of MI could have occurred by chance. Only about 50% of eligible participants completed telephone interviews. Conclusion: Celecoxib and rofecoxib were associated with different odds of MI. Cardiovascular effects among the COX-2 inhibitors seem different, but further studies, preferably randomized trials, are needed to fully understand the spectrum of effects of COX-2 inhibitors and potential differences among them.	Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Kimmel, SE (corresponding author), Univ Penn, Sch Med, 717 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.			Reilly, Muredach/0000-0002-3035-9386	NHLBI NIH HHS [R01HL57312] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057312] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altman R, 2002, CIRCULATION, V106, P191, DOI 10.1161/01.CIR.0000021599.56755.A1; BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; BROCHIER ML, 1993, EUR HEART J, V14, P951, DOI 10.1093/eurheartj/14.7.951; Burleigh ME, 2002, CIRCULATION, V105, P1816, DOI 10.1161/01.CIR.0000014927.74465.7F; Chenevard R, 2003, CIRCULATION, V107, P405, DOI 10.1161/01.CIR.0000051361.69808.3A; Farkouh ME, 2004, LANCET, V364, P675, DOI 10.1016/S0140-6736(04)16894-3; FitzGerald G, 2003, NAT REV DRUG DISCOV, V2, P879, DOI 10.1038/nrd1225; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; GRAHAM DJ, 2004, PHARMACOEPIDEM DR S, V13, pS287; Harley C, 2003, CLIN THER, V25, P139, DOI 10.1016/S0149-2918(03)90017-8; Hayden M, 2002, ANN INTERN MED, V136, P161, DOI 10.7326/0003-4819-136-2-200201150-00016; Hermann M, 2003, CIRCULATION, V108, P2308, DOI 10.1161/01.CIR.0000101683.30157.0B; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; Kimmel SE, 2004, J AM COLL CARDIOL, V43, P985, DOI 10.1016/j.jacc.2003.08.064; Kimmel SE, 2003, PHARMACOEPIDEM DR S, V12, P1, DOI 10.1002/pds.764; Konstam MA, 2001, CIRCULATION, V104, P2280, DOI 10.1161/hc4401.100078; Mamdani M, 2003, ARCH INTERN MED, V163, P481, DOI 10.1001/archinte.163.4.481; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Pitt B, 2002, CIRCULATION, V106, P167, DOI 10.1161/01.CIR.0000025261.58465.62; Ray WA, 2002, LANCET, V360, P1071, DOI 10.1016/S0140-6736(02)11131-7; Riendeau D, 2001, J PHARMACOL EXP THER, V296, P558; SCHAFER AI, 1995, J CLIN PHARMACOL, V35, P209, DOI 10.1002/j.1552-4604.1995.tb04050.x; Schnitzer TJ, 2004, LANCET, V364, P665, DOI 10.1016/S0140-6736(04)16893-1; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Solomon DH, 2004, CIRCULATION, V109, P2068, DOI 10.1161/01.CIR.0000127578.21885.3E; *US FOOD DRUG ADM, 2001, CARD SAF REV ROF; VANDERWAL AC, 1994, CIRCULATION, V89, P36, DOI 10.1161/01.CIR.89.1.36; Whelton A, 2001, Am J Ther, V8, P85, DOI 10.1097/00045391-200103000-00003; White WB, 2003, AM J CARDIOL, V92, P411, DOI 10.1016/S0002-9149(03)00659-3	31	148	157	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	2005	142	3					157	164		10.7326/0003-4819-142-3-200502010-00005	http://dx.doi.org/10.7326/0003-4819-142-3-200502010-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900UH	15684203				2022-12-28	WOS:000227239300001
J	Reid, PC; Mukri, F				Reid, PC; Mukri, F			Trends in number of hysterectomies performed in England for menorrhagia: examination of health episode statistics, 1989 to 2002-3	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED-TRIAL; OUTCOMES; AUDIT		Luton & Dunstable Hosp NHS Trust, Directorate Obstet & Gynaecol, Luton LU4 0DZ, Beds, England		Reid, PC (corresponding author), Luton & Dunstable Hosp NHS Trust, Directorate Obstet & Gynaecol, Luton LU4 0DZ, Beds, England.	Peter.Reid@ldh-tr.anglox.nhs.uk						COULTER A, 1991, BRIT J OBSTET GYNAEC, V98, P789, DOI 10.1111/j.1471-0528.1991.tb13484.x; Fender GRK, 2001, BRIT MED J, V322, P523, DOI 10.1136/bmj.322.7285.523; Grant A, 1999, BRIT J OBSTET GYNAEC, V106, P360; Hurskainen R, 2004, JAMA-J AM MED ASSOC, V291, P1456, DOI 10.1001/jama.291.12.1456; Kennedy A D M, 2003, Health Technol Assess, V7, P1	5	67	68	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 23	2005	330	7497					938	939		10.1136/bmj.38376.505382.AE	http://dx.doi.org/10.1136/bmj.38376.505382.AE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	920UP	15695496	Green Published, Bronze			2022-12-28	WOS:000228715900020
J	Leontiadis, GI; Sharma, VK; Howden, CW				Leontiadis, GI; Sharma, VK; Howden, CW			Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding	BMJ-BRITISH MEDICAL JOURNAL			English	Article							UPPER GASTROINTESTINAL HEMORRHAGE; INTRAVENOUS OMEPRAZOLE; ENDOSCOPIC THERAPY; INTRAGASTRIC PH; DOUBLE-BLIND; RANITIDINE; PLACEBO; PANTOPRAZOLE; ANTAGONISTS; HEMOSTASIS	Objectives To review randomised controlled trials of treatment with a proton pump inhibitor in patients with ulcer bleeding and to determine the impact on mortality, rebleeding, and surgical intervention. Design Systematic review and meta-analysis. Data sources Cochrane Collaboration's trials register, Medline, and Embase, handsearched abstracts, and pharmaceutical companies. Review methods Included randomised controlled trials that compared proton pump inhibitor with placebo or H, receptor antagonist in endoscopically proved bleeding ulcer and reported at least one of mortality, rebleeding, or surgical intervention. Trials were graded for methodological quality. Two assessors independently reviewed each trial, and disagreements were resolved by consensus. Results We included 21 randomised controlled trials comprising 2915 patients. Proton pump inhibitor treatment had no significant effect on mortality (odds ratio 1.11, 95% confidence interval 0.79 to 1.57; number needed to treat (NNT) incalculable) but reduced rebleeding (0.46,0.33 to 0.64; NNT 12) and surgery (0.59,0.46 to 0.76; NNT 20). Results were similar when the meta-analysis was restricted to the 10 trials with the highest methodological quality: 0.96, 0.46 to 2.01, for mortality; 0.41, 0.25 to 0.68, NNT 10, for rebleeding; 0.62,0.46 to 0.83, NNT 25, for surgery. Conclusions Treatment with a proton pump inhibitor reduces the risk of rebleeding and the requirement for surgery after ulcer bleeding but has no benefit on overall mortality.	Northwestern Univ, Feinberg Sch Med, Div Gastroenterol, Chicago, IL 60611 USA; Univ Hosp N Durham, Dept Gastroenterol, Durham DH1 5TW, England; Mayo Clin, Div Gastroenterol, Scottsdale, AZ 85259 USA	Northwestern University; Feinberg School of Medicine; Mayo Clinic; Mayo Clinic Phoenix	Howden, CW (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Gastroenterol, Chicago, IL 60611 USA.	c-howden@northwestern.edu						*AG HEALTHC RES QU, 1997, HCUP NAT INP SAMPL; *AG HEALTHC RES QU, 1997, HCGP NAT INP SAMPL; Andrews C, 2002, GASTROINTEST ENDOSC, V55, pAB190; Brunner G, 1996, YALE J BIOL MED, V69, P225; BRUNNER G, 1990, DIGESTION, V45, P217, DOI 10.1159/000200249; Cardi M, 1997, ANN CHIR, V51, P136; Chan EP, 2003, GASTROENTEROLOGY, V124, pA626, DOI 10.1016/S0016-5085(03)83173-6; COLLINS R, 1985, NEW ENGL J MED, V313, P660, DOI 10.1056/NEJM198509123131104; COOK DJ, 1992, GASTROENTEROLOGY, V102, P139, DOI 10.1016/0016-5085(92)91793-4; Coraggio F, 1998, EUR J GASTROEN HEPAT, V10, P673; DANESHMEND TK, 1992, BRIT MED J, V304, P143, DOI 10.1136/bmj.304.6820.143; DeMuckadell OBS, 1997, SCAND J GASTROENTERO, V32, P320, DOI 10.3109/00365529709007679; DESPREZ D, 1995, GASTROENTEROLOGY, V108, pA82, DOI 10.1016/0016-5085(95)22991-4; DUVNJAK M, 2001, GUT, V49, P2379; Ebrahim S, 2001, SYSTEMATIC REV HLTH, P386; FLORES RP, 1994, REV ESP ENFERM DIG, V86, P637; FRIED R, 1999, GUT, V45, pA100; Hasselgren G, 1997, SCAND J GASTROENTERO, V32, P328, DOI 10.3109/00365529709007680; Javid G, 2001, AM J MED, V111, P280, DOI 10.1016/S0002-9343(01)00812-9; Jensen DM, 2002, GASTROENTEROLOGY, V123, P407, DOI 10.1053/gast.2002.34782; Kaplan GG, 2002, AM J GASTROENTEROL, V97, pS236, DOI 10.1016/S0002-9270(02)05203-6; Kaviani MJ, 2003, ALIMENT PHARM THER, V17, P211, DOI 10.1046/j.1365-2036.2003.01416.x; Khuroo MS, 1997, NEW ENGL J MED, V336, P1054, DOI 10.1056/NEJM199704103361503; Labenz J, 1997, GUT, V40, P36, DOI 10.1136/gut.40.1.36; Laine L, 2002, GASTROENTEROLOGY, V123, P632, DOI 10.1053/gast.2002.35133; LAINE L, 1994, NEW ENGL J MED, V331, P717, DOI 10.1056/NEJM199409153311107; LANAS A, 1995, J CLIN GASTROENTEROL, V21, P103, DOI 10.1097/00004836-199509000-00008; Lau JYW, 2000, NEW ENGL J MED, V343, P310, DOI 10.1056/NEJM200008033430501; Levine JE, 2002, ALIMENT PHARM THERAP, V16, P1137, DOI 10.1046/j.1365-2036.2002.01274.x; Lin HJ, 1998, ARCH INTERN MED, V158, P54, DOI 10.1001/archinte.158.1.54; Lin HJ, 1997, HEPATO-GASTROENTEROL, V44, P1495; Mainie I, 2003, GASTROINTEST ENDOSC, V57, pAB155; MERKI HS, 1994, GASTROENTEROLOGY, V106, P60, DOI 10.1016/S0016-5085(94)94341-9; MICHEL P, 1994, GASTROEN CLIN BIOL, V18, P1102; Rockall TA, 1996, GUT, V38, P316, DOI 10.1136/gut.38.3.316; Sheu BS, 2002, ALIMENT PHARM THER, V16, P137, DOI 10.1046/j.1365-2036.2002.01137.x; Sung JJY, 2003, ANN INTERN MED, V139, P237, DOI 10.7326/0003-4819-139-4-200308190-00005; van Leerdam ME, 2003, AM J GASTROENTEROL, V98, P1494, DOI 10.1016/S0002-9270(03)00299-5; vanRensburg CJ, 1997, GUT, V41, pA98; VILLANUEVA C, 1995, ENDOSCOPY, V27, P308, DOI 10.1055/s-2007-1005698	40	95	98	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 12	2005	330	7491					568	570C		10.1136/bmj.38356.641134.8F	http://dx.doi.org/10.1136/bmj.38356.641134.8F			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	906EC	15684023	Green Published, Bronze			2022-12-28	WOS:000227622300016
J	Gendrin, A; Mangold, N; Bibring, JP; Langevin, Y; Gondet, B; Poulet, F; Bonello, G; Quantin, C; Mustard, J; Arvidson, R; LeMouelic, S				Gendrin, A; Mangold, N; Bibring, JP; Langevin, Y; Gondet, B; Poulet, F; Bonello, G; Quantin, C; Mustard, J; Arvidson, R; LeMouelic, S			Suffates in martian layered terrains: the OMEGA/Mars Express view	SCIENCE			English	Article							EARLY MARS; VALLES-MARINERIS; MERIDIANI; EVOLUTION; SULFATE; HISTORY; SOIL	The OMEGA/Mars Express hyperspectral imager identified hydrated sulfates on light-toned layered terrains on Mars. Outcrops in Valles Marineris, Margaritifer Sinus, and Terra Meridiani show evidence for kieserite, gypsum, and polyhydrated sulfates. This identification has its basis in vibrational absorptions between 1.3 and 2.5 micrometers. These minerals constitute direct records of the past aqueous activity on Mars.	Inst Astrophys Spatiale, F-91405 Orsay, France; Interact & Dynam Environm Surface, F-91405 Orsay, France; Lab Sci Terre, F-69100 Villeurbanne, France; Brown Univ, Providence, RI 02912 USA; Washington Univ, St Louis, MO 63130 USA; Univ Nantes, F-44322 Nantes, France	UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Brown University; Washington University (WUSTL); Nantes Universite	Gendrin, A (corresponding author), Inst Astrophys Spatiale, Batiment 121, F-91405 Orsay, France.	Aline_Gendrin@brown.edu	Quantin, Cathy/H-1516-2014	Le Mouelic, Stephane/0000-0001-5260-1367				Arvidson RE, 2005, SCIENCE, V307, P1591, DOI 10.1126/science.1109509; ARVIDSON RE, 2003, J GEOPHYS RES, V108; Banin A, 1997, J GEOPHYS RES-PLANET, V102, P13341, DOI 10.1029/97JE01160; Bibring J.-P., 2004, EUR SPACE AGENCY SPE, V1240, P37; Bibring JP, 2005, SCIENCE, V307, P1576, DOI 10.1126/science.1108806; BISHOP J, IN PRESS AM MINER; Bullock MA, 2004, ICARUS, V170, P404, DOI 10.1016/j.icarus.2004.03.016; Catling DC, 1999, J GEOPHYS RES-PLANET, V104, P16453, DOI 10.1029/1998JE001020; Chapman MG, 2002, ICARUS, V155, P324, DOI 10.1006/icar.2001.6735; CLARK RN, 1990, J GEOPHYS RES-SOLID, V95, P12653, DOI 10.1029/JB095iB08p12653; Crowley JK., 2003, GEOCHEM-EXPLOR ENV A, V3, P219, DOI DOI 10.1144/1467-7873/03-001; Fairen AG, 2004, NATURE, V431, P423, DOI 10.1038/nature02911; GREEN, 1993, IEEE T GEOSC REM SEN, V26, P65; Hunten D. M., 1971, Comments on Astrophysics and Space Physics, V3, P1; Huston DL, 2004, EARTH PLANET SC LETT, V220, P41, DOI 10.1016/S0012-821X(04)00034-2; Hynek BM, 2004, NATURE, V431, P156, DOI 10.1038/nature02902; Lane MD, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL021231; Langevin Y, 2005, SCIENCE, V307, P1584, DOI 10.1126/science.1109091; LUCCHITTA BK, 1994, J GEOPHYS RES-PLANET, V99, P3783, DOI 10.1029/93JE03095; LUCCHITTA BK, 1982, 85127 NASA, P233; Malin MC, 2000, SCIENCE, V290, P1927, DOI 10.1126/science.290.5498.1927; MCCAULEY JF, 1972, ICARUS, V17, P289, DOI 10.1016/0019-1035(72)90003-6; Mustard JF, 2005, SCIENCE, V307, P1594, DOI 10.1126/science.1109098; NEDELL SS, 1987, ICARUS, V70, P409, DOI 10.1016/0019-1035(87)90086-8; Squyres SW, 2004, SCIENCE, V306, P1698, DOI 10.1126/science.1106171; Vaniman DT, 2004, NATURE, V431, P663, DOI 10.1038/nature02973; WARREN J, 1999, EVAPORITES THEIR EVO	27	765	778	2	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 11	2005	307	5715					1587	1591		10.1126/science.1109087	http://dx.doi.org/10.1126/science.1109087			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	906ED	15718429				2022-12-28	WOS:000227622400037
J	Chen, B; Vogan, EM; Gong, HY; Skehel, JJ; Wiley, DC; Harrison, SC				Chen, B; Vogan, EM; Gong, HY; Skehel, JJ; Wiley, DC; Harrison, SC			Structure of an unliganded simian immunodeficiency virus gp120 core	NATURE			English	Article							ENVELOPE GLYCOPROTEIN; TYPE-1 GP120; NEUTRALIZATION SENSITIVITY; CD4 INDEPENDENCE; HIV-1 ENVELOPE; SOLUBLE CD4; RECEPTOR; PROTEIN; ANTIBODY; GP41	Envelope glycoproteins of human and simian immunodeficiency virus (HIV and SIV) undergo a series of conformational changes when they interact with receptor (CD4) and co-receptor on the surface of a potential host cell, leading ultimately to fusion of viral and cellular membranes. Structures of fragments of gp120 and gp41 from the envelope protein are known, in conformations corresponding to their post-attachment and postfusion states, respectively. We report the crystal structure, at 4 A resolution, of a fully glycosylated SIV gp120 core, in a conformation representing its prefusion state, before interaction with CD4. Parts of the protein have a markedly different organization than they do in the CD4-bound state. Comparison of the unliganded and CD4-bound structures leads to a model for events that accompany receptor engagement of an envelope glycoprotein trimer. The two conformations of gp120 also present distinct antigenic surfaces. We identify the binding site for a compound that inhibits viral entry.	Harvard Univ, Childrens Hosp, Sch Med, Mol Med Lab, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA; Natl Inst Med Res, Ridgeway, London NW7 1AA, England	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	Harrison, SC (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Mol Med Lab, 320 Longwood Ave, Boston, MA 02115 USA.	harrison@crystal.harvard.edu		Vogan, Erik/0000-0002-2939-8070	Medical Research Council [MC_U117512711] Funding Source: Medline; MRC [MC_U117512711] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALLAN JS, 1985, SCIENCE, V228, P1091, DOI 10.1126/science.2986290; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; Center RJ, 2002, J VIROL, V76, P7863, DOI 10.1128/JVI.76.15.7863-7867.2002; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chen B, 2004, J VIROL, V78, P4508, DOI 10.1128/JVI.78.9.4508-4516.2004; CHEN B, IN PRESS STRUCTURE C; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Etemad-Moghadam B, 1998, J VIROL, V72, P8437, DOI 10.1128/JVI.72.10.8437-8445.1998; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Ferrer M, 1999, J VIROL, V73, P5795, DOI 10.1128/JVI.73.7.5795-5802.1999; Guo Q, 2003, J VIROL, V77, P10528, DOI 10.1128/JVI.77.19.10528-10536.2003; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kolchinsky P, 2001, J VIROL, V75, P2041, DOI 10.1128/JVI.75.5.2041-2050.2001; Kwong PD, 2000, J VIROL, V74, P1961, DOI 10.1128/JVI.74.4.1961-1972.2000; Kwong PD, 1999, J BIOL CHEM, V274, P4115, DOI 10.1074/jbc.274.7.4115; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188; Lin PF, 2003, P NATL ACAD SCI USA, V100, P11013, DOI 10.1073/pnas.1832214100; Madani N, 2004, J VIROL, V78, P3742, DOI 10.1128/JVI.78.7.3742-3752.2004; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Moore JP, 1996, J VIROL, V70, P1863, DOI 10.1128/JVI.70.3.1863-1872.1996; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pantophlet R, 2003, J VIROL, V77, P642, DOI 10.1128/JVI.77.1.642-658.2003; POLLARD SR, 1991, P NATL ACAD SCI USA, V88, P11320, DOI 10.1073/pnas.88.24.11320; Puffer BA, 2004, VIROLOGY, V327, P16, DOI 10.1016/j.virol.2004.03.016; Puffer BA, 2002, J VIROL, V76, P2595, DOI 10.1128/JVI.76.6.2595-2605.2002; Pugach P, 2004, VIROLOGY, V321, P8, DOI 10.1016/j.virol.2003.12.012; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; RUD EW, 1992, VACCINE, V92, P229; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; TURNER S, 1992, P NATL ACAD SCI USA, V89, P1335, DOI 10.1073/pnas.89.4.1335; VERONESE FD, 1985, SCIENCE, V229, P1402, DOI 10.1126/science.2994223; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; WYATT R, 1993, J VIROL, V67, P4557, DOI 10.1128/JVI.67.8.4557-4565.1993; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Zwick MB, 2003, J VIROL, V77, P6965, DOI 10.1128/JVI.77.12.6965-6978.2003	50	439	462	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 24	2005	433	7028					834	841		10.1038/nature03327	http://dx.doi.org/10.1038/nature03327			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	899VT	15729334				2022-12-28	WOS:000227174600034
J	Basso, O; Olsen, J				Basso, O; Olsen, J			Subfecundity and neonatal mortality: longitudinal study within the Danish national birth cohort	BRITISH MEDICAL JOURNAL			English	Article							PRETERM DELIVERY		Aarhus Univ, Danish Epidemiol Sci Ctr, Dept Epidemiol & Social Med, DK-8000 Aarhus, Denmark	Aarhus University	Basso, O (corresponding author), Aarhus Univ, Danish Epidemiol Sci Ctr, Dept Epidemiol & Social Med, DK-8000 Aarhus, Denmark.	bassoo2@niehs.nih.gov	Basso, Olga/E-5384-2010	Basso, Olga/0000-0001-9298-4921				Basso O, 2003, HUM REPROD, V18, P2478, DOI 10.1093/humrep/deg444; Helmerhorst FM, 2004, BRIT MED J, V328, P261, DOI 10.1136/bmj.37957.560278.EE; Henriksen TB, 1997, OBSTET GYNECOL, V89, P594; OLIVENNES F, 1993, HUM REPROD, V8, P1297, DOI 10.1093/oxfordjournals.humrep.a138245; Olsen J, 2001, SCAND J PUBLIC HEALT, V29, P300, DOI 10.1177/14034948010290040201	5	40	42	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 19	2005	330	7488					393	394		10.1136/bmj.38336.616806.8F	http://dx.doi.org/10.1136/bmj.38336.616806.8F			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900NA	15695499	Green Published, Bronze			2022-12-28	WOS:000227220400018
J	Wong, KK; Chatterjee, S				Wong, KK; Chatterjee, S			Vaccine development for chronic myelogenous leukaemia	LANCET			English	Editorial Material							CHRONIC MYELOID-LEUKEMIA; DENDRITIC CELLS; IN-VITRO; PROTEIN		City Hope Natl Med Ctr, Beckman Res Inst, Div Virol, Duarte, CA 91024 USA; City Hope Natl Med Ctr, CML Dis Study Grp, Div Hematol & Hematopoiet Cell Transplantat, Duarte, CA 91024 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope	Chatterjee, S (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Virol, Duarte, CA 91024 USA.	schatterjee@coh.org						Appel S, 2004, BLOOD, V103, P538, DOI 10.1182/blood-2003-03-0975; Bhatia R, 2003, BLOOD, V101, P4701, DOI 10.1182/blood-2002-09-2780; Butt NM, 2004, BLOOD, V103, P3245, DOI 10.1182/blood-2003-11-4086; Cathcart K, 2004, BLOOD, V103, P1037, DOI 10.1182/blood-2003-03-0954; CHEN W, 1992, P NATL ACAD SCI USA, V89, P1468, DOI 10.1073/pnas.89.4.1468; Clark RE, 2001, BLOOD, V98, P2887, DOI 10.1182/blood.V98.10.2887; Cortes J, 1998, LEUKEMIA, V12, P860, DOI 10.1038/sj.leu.2401033; Dietz AB, 2004, BLOOD, V104, P1094, DOI 10.1182/blood-2003-12-4266; Dong R, 2003, BLOOD, V101, P3560, DOI 10.1182/blood-2002-06-1841; Druker BJ, 2003, SEMIN HEMATOL, V40, P1, DOI 10.1053/shem.2003.50033; Garcia-Manero G, 2003, CANCER-AM CANCER SOC, V98, P437, DOI 10.1002/cncr.11520; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Pinilla-Ibarz J, 2000, BLOOD, V95, P1781, DOI 10.1182/blood.V95.5.1781.005k46_1781_1787; Wong S, 2004, ANNU REV IMMUNOL, V22, P247, DOI 10.1146/annurev.immunol.22.012703.104753	14	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	2005	365	9460					631	632						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	898SP	15721455				2022-12-28	WOS:000227096800003
J	Rovansek, KA; Papadopolous, A				Rovansek, KA; Papadopolous, A			Tinea circinata	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Texas, Med Sch Houston, Houston, TX 77030 USA; Georgetown Univ, Washington, DC 20007 USA	University of Texas System; University of Texas Health Science Center Houston; Georgetown University	Rovansek, KA (corresponding author), Univ Texas, Med Sch Houston, Houston, TX 77030 USA.								0	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2005	352	7					E6	E6		10.1056/NEJMicm030862	http://dx.doi.org/10.1056/NEJMicm030862			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897UO	15716555				2022-12-28	WOS:000227031100011
J	Ruxin, J; Paluzzi, JE; Wilson, PA; Tozan, Y; Kruk, M; Teklehaimanot, A				Ruxin, J; Paluzzi, JE; Wilson, PA; Tozan, Y; Kruk, M; Teklehaimanot, A			Emerging consensus in HIV/AIDS, malaria, tuberculosis, and access to essential medicines	LANCET			English	Article									Columbia Univ, Mailman Sch Publ Hlth, Ctr Global Hlth & Econ Dev, New York, NY 10027 USA; Columbia Univ, Earth Inst, New York, NY 10027 USA; Partners Hlth, Boston, MA USA; UN Millennium Project Secretariat, New York, NY USA	Columbia University; Columbia University; Partners Healthcare System	Ruxin, J (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Ctr Global Hlth & Econ Dev, 215 W 125th St, New York, NY 10027 USA.	jnr4@columbia.edu	Kruk, Margaret E/E-3058-2010	Kruk, Margaret E/0000-0002-9549-8432				[Anonymous], 2004, HUM RES HLTH OV CRIS; Breman JG, 2004, AM J TROP MED HYG, V71, P1; Chen XY, 2004, LANCET, V364, P417; *GFATM, GFATM PROGR REP; *GLOB HIV PREV WOR, HIV PREV ER EXP TREA; Lonnroth K, 2004, B WORLD HEALTH ORGAN, V82, P580; Salomon JA, 2005, PLOS MED, V2, P50, DOI 10.1371/journal.pmed.0020016; STOP TB, 2004, PARTNERSHIP PROGR RE; *UN MILL PROJ, 2005, COMB AIDS DEV WORLD; *UN MILL PROJ, 2005, COM GRIPS MAL NEW MI; UN Millennium Project, 2005, PRESCR HLTH DEV INCR; UN Millennium Project 2005, 2005, INV STRAT REV GLOB I; *UNAIDS, 2004, 2004 REP GLOB HIV AI; WHO, WORLD MED SIT; *WHO, 2000, TECHN REP SER WHO, V892; *WHO, 2004, 3 WHO; World Health Organization, 2004, Wkly Epidemiol Rec, V79, P6	17	28	29	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	2005	365	9459					618	621						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DN	15708108				2022-12-28	WOS:000226984300037
J	Moberg, A; Sonechkin, DM; Holmgren, K; Datsenko, NM; Karlen, W				Moberg, A; Sonechkin, DM; Holmgren, K; Datsenko, NM; Karlen, W			Highly variable Northern Hemisphere temperatures reconstructed from low- and high-resolution proxy data	NATURE			English	Article							SURFACE AIR-TEMPERATURE; CLIMATE-CHANGE; PAST MILLENNIUM; LAST MILLENNIUM; MODEL; SIMULATION	A number of reconstructions of millennial- scale climate variability have been carried out in order to understand patterns of natural climate variability, on decade to century timescales, and the role of anthropogenic forcing(1 - 8). These reconstructions have mainly used tree- ring data and other data sets of annual to decadal resolution. Lake and ocean sediments have a lower time resolution, but provide climate information at multicentennial timescales that may not be captured by tree- ring data(9,10). Here we reconstruct Northern Hemisphere temperatures for the past 2,000 years by combining low- resolution proxies with tree- ring data, using a wavelet transform technique(11) to achieve timescale- dependent processing of the data. Our reconstruction shows larger multicentennial variability than most previous multi- proxy reconstructions(1 - 4,7), but agrees well with temperatures reconstructed from borehole measurements(12) and with temperatures obtained with a general circulation model(13,14). According to our reconstruction, high temperatures - similar to those observed in the twentieth century before 1990 occurred around AD 1000 to 1100, and minimum temperatures that are about 0.7K below the average of 1961 - 90 occurred around AD 1600. This large natural variability in the past suggests an important role of natural multicentennial variability that is likely to continue.	Stockholm Univ, Dept Meteorol, SE-10691 Stockholm, Sweden; Hydrometeorol Res Ctr Russia, Dynam Stochast Lab, Moscow 123242, Russia; Stockholm Univ, Dept Phys Geog & Quaternary Geol, SE-10691 Stockholm, Sweden	Stockholm University; Stockholm University	Moberg, A (corresponding author), Stockholm Univ, Dept Meteorol, SE-10691 Stockholm, Sweden.	anders.moberg@misu.su.se		Moberg, Anders/0000-0002-5177-9347; Sonechkin, Dmitry/0000-0003-3771-3824				Bauer E, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016639; Bertrand C, 2002, TELLUS A, V54, P221, DOI 10.1034/j.1600-0870.2002.00287.x; Bradley R. S., 1999, PALEOCLIMATOLOGY REC; Briffa KR, 2001, J GEOPHYS RES-ATMOS, V106, P2929, DOI 10.1029/2000JD900617; Briffa KR, 2000, QUATERNARY SCI REV, V19, P87, DOI 10.1016/S0277-3791(99)00056-6; COOK ER, 1995, HOLOCENE, V5, P229, DOI 10.1177/095968369500500211; Crowley TJ, 2000, SCIENCE, V289, P270, DOI 10.1126/science.289.5477.270; Crowley TJ, 2000, AMBIO, V29, P51, DOI 10.1579/0044-7447-29.1.51; Esper J, 2002, SCIENCE, V295, P2250, DOI 10.1126/science.1066208; Esper J., 2004, EOS, V85, P113, DOI DOI 10.1029/2004EO120002; Gonzalez-Rouco F, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018264; Intergovernmental Panel on Climate Change, 2001, CLIM CHANG 2001 SCI; Jones PD, 1998, HOLOCENE, V8, P455, DOI 10.1191/095968398667194956; Jones PD, 1997, J CLIMATE, V10, P2548, DOI 10.1175/1520-0442(1997)010<2548:ESEILS>2.0.CO;2; Jones PD, 2004, REV GEOPHYS, V42, DOI 10.1029/2003RG000143; Jones PD, 2003, J CLIMATE, V16, P206, DOI 10.1175/1520-0442(2003)016<0206:HALSSA>2.0.CO;2; Legutke S, 1999, 18 DTSCH KLIM; Mallat S., 1999, WAVELET TOUR SIGNAL, DOI 10.1016/B978-012466606-1/50008-8; Mann ME, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017814; Mann ME, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014554; Mann ME, 1998, NATURE, V392, P779, DOI 10.1038/33859; Mann ME, 1999, GEOPHYS RES LETT, V26, P759, DOI 10.1029/1999GL900070; Pollack HN, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD004163; Shindell DT, 2003, J CLIMATE, V16, P4094, DOI 10.1175/1520-0442(2003)016<4094:VASFOC>2.0.CO;2; Shindell DT, 2001, SCIENCE, V294, P2149, DOI 10.1126/science.1064363; Stott PA, 2000, SCIENCE, V290, P2133, DOI 10.1126/science.290.5499.2133; von Storch H, 2004, SCIENCE, V306, P679, DOI 10.1126/science.1096109; WIDMANN M, 2003, PAGES NEWSLETTER, V11, P21; Zorita E, 2004, METEOROL Z, V13, P271, DOI 10.1127/0941-2948/2004/0013-0271; Zorita E, 2003, J CLIMATE, V16, P1378, DOI 10.1175/1520-0442(2003)16&lt;1378:TTMEAA&gt;2.0.CO;2	30	1113	1191	19	316	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 10	2005	433	7026					613	617		10.1038/nature03265	http://dx.doi.org/10.1038/nature03265			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	895KX	15703742				2022-12-28	WOS:000226862000039
J	Ioannidis, JPA				Ioannidis, JPA			Microarrays and molecular research: noise discovery?	LANCET			English	Editorial Material							GENETIC ASSOCIATION		Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece; Fdn Res & Technol Hellas, Biomed Res Inst, Ioannina, Greece; Tufts Univ, Sch Med, Tufts New England Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA	University of Ioannina; Foundation for Research & Technology - Hellas (FORTH); Tufts Medical Center; Tufts University	Ioannidis, JPA (corresponding author), Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece.	jioannid@cc.uoi.gr						Altman DG, 2000, STAT MED, V19, P453, DOI 10.1002/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.0.CO;2-5; Boguski MS, 2003, NATURE, V422, P233, DOI 10.1038/nature01515; COUNSELL CE, 1994, BMJ-BRIT MED J, V309, P1677, DOI 10.1136/bmj.309.6970.1677; Huizinga TWJ, 2004, ARTHRITIS RHEUM, V50, P2066, DOI 10.1002/art.20360; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Ioannidis JPA, 2003, TRENDS MOL MED, V9, P135, DOI 10.1016/S1471-4914(03)00030-3; Lander ES, 1999, NAT GENET, V21, P3, DOI 10.1038/4427; Liu ET, 2004, NEW ENGL J MED, V350, P1595, DOI 10.1056/NEJMp048050; Ntzani EE, 2003, LANCET, V362, P1439, DOI 10.1016/S0140-6736(03)14686-7; Ransohoff DF, 2004, NAT REV CANCER, V4, P309, DOI 10.1038/nrc1322; SCHENA M, 2003, MICROARRAY ANAL, P21	12	188	199	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 5	2005	365	9458					454	455		10.1016/S0140-6736(05)17878-7	http://dx.doi.org/10.1016/S0140-6736(05)17878-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894SS	15705441				2022-12-28	WOS:000226812500005
J	Dorgan, KM; Jumars, PA; Johnson, B; Boudreau, BP; Landis, E				Dorgan, KM; Jumars, PA; Johnson, B; Boudreau, BP; Landis, E			Burrow extension by crack propagation	NATURE			English	Editorial Material							GROWTH		Univ Maine, Darling Marine Ctr, Walpole, ME 04573 USA; Dalhousie Univ, Dept Oceanog, Halifax, NS B3H 4J1, Canada; Univ Maine, Dept Civil & Environm Engn, Orono, ME 04469 USA	University of Maine System; University of Maine Orono; Dalhousie University; University of Maine System; University of Maine Orono	Dorgan, KM (corresponding author), Univ Maine, Darling Marine Ctr, Walpole, ME 04573 USA.	kelly.dorgan@umit.maine.edu		Boudreau, Bernard/0000-0002-7748-1151				ABDALLA AM, 1969, J AGR ENG RES, V14, P236, DOI 10.1016/0021-8634(69)90126-7; BOUDREAU BP, IN PRESS GEOLOGY; Broek D., 1978, ELEMENTARY ENG FRACT; ELDER HY, 1980, ASPECTS ANIMAL MOVEM, P71; FULL RJ, 1995, J EXP BIOL, V198, P2441; HAMILTON EL, 1980, J ACOUST SOC AM, V68, P1313, DOI 10.1121/1.385100; HUNTER RD, 1989, J ZOOL, V218, P209, DOI 10.1111/j.1469-7998.1989.tb02533.x; Johnson BD, 2002, MAR GEOL, V187, P347, DOI 10.1016/S0025-3227(02)00383-3; KANAZAWA K, 1992, PALAEONTOLOGY, V35, P733; Menand T, 2001, NATURE, V411, P678, DOI 10.1038/35079552; Meysman FJR, 2003, J MAR RES, V61, P391, DOI 10.1357/002224003322201241	11	121	122	4	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2005	433	7025					475	475		10.1038/433475a	http://dx.doi.org/10.1038/433475a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893NT	15690029				2022-12-28	WOS:000226727200032
J	Bertaux, JL; Leblanc, F; Perrier, SV; Quemerais, E; Korablev, O; Dimarellis, E; Reberac, A; Forget, F; Simon, PC; Stern, SA; Sandel, B				Bertaux, JL; Leblanc, F; Perrier, SV; Quemerais, E; Korablev, O; Dimarellis, E; Reberac, A; Forget, F; Simon, PC; Stern, SA; Sandel, B		SPICAM Team	Nightglow in the upper atmosphere of Mars and implications for atmospheric transport	SCIENCE			English	Article							MARTIAN ATMOSPHERE; ODD NITROGEN; VENUS; AIRGLOW; MODEL	We detected light emissions in the nightside martian atmosphere with the SPICAM (spectroscopy for the investigation of the characteristics of the atmosphere of Mars) ultraviolet (UV) spectrometer on board the Mars Express. The UV spectrum of this nightglow is composed of hydrogen Lyman a emission (121.6 nanometers) and the gamma and delta bands of nitric oxide (NO) (190 to 270 nanometers) produced when N and O atoms combine to produce the NO molecule. N and O atoms are produced by extreme UV photodissociation of O-2, CO2, and N-2 in the dayside upper atmosphere and transported to the night side. The NO emission is brightest in the winter south polar night because of continuous downward transport of air in this region at night during winter and because of freezing at ground level.	CNRS, Serv Aeron, Inst Pierre Simon Laplace, F-91371 Verrieres Le Buisson, France; Moscow Space Res Inst, Moscow 117810, Russia; Univ Paris 06, Meteorol Dynam Lab, IPSL, F-75252 Paris, France; Inst Aeron Spatiale Belgique, B-1180 Brussels, Belgium; SW Res Inst, Boulder, CO 80302 USA; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Russian Academy of Sciences; Space Research Institute of the Russian Academy of Sciences; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; University of Arizona	Bertaux, JL (corresponding author), CNRS, Serv Aeron, Inst Pierre Simon Laplace, BP 3, F-91371 Verrieres Le Buisson, France.	bertaux@aerov.jussieu.fr	Korablev, Oleg I/K-6770-2017; Korablev, Oleg/L-5083-2013	Korablev, Oleg I/0000-0003-1115-0656; Korablev, Oleg/0000-0003-1115-0656				BARTH CA, 1971, J GEOPHYS RES, V76, P2213, DOI 10.1029/JA076i010p02213; BARTH CA, 1967, SCIENCE, V158, P1675, DOI 10.1126/science.158.3809.1675; BARTH CA, 1992, MARS, P1054; Bertaux JL, 2000, PLANET SPACE SCI, V48, P1303, DOI 10.1016/S0032-0633(00)00111-2; BERTAUX JL, 2004, EUROPEAN SPACE AGENC, P95; BERTAUX JL, IN PRESS ADV SPACE R; BOUGHER SW, 1990, J GEOPHYS RES-SPACE, V95, P6271, DOI 10.1029/JA095iA05p06271; Bougher SW, 1997, SPACE SCI S, P259; FELDMAN PD, 1979, NATURE, V279, P221, DOI 10.1038/279221a0; Forget F, 1999, J GEOPHYS RES-PLANET, V104, P24155, DOI 10.1029/1999JE001025; Fox J. L., 1992, VENUS MARS ATMOSPHER, V66, P191, DOI [10.1029/GM066p0191, DOI 10.1029/GM066P0191]; GERARD JC, 1981, GEOPHYS RES LETT, V8, P633, DOI 10.1029/GL008i006p00633; GERARD JC, 1988, ICARUS, V75, P171, DOI 10.1016/0019-1035(88)90135-2; HEDIN AE, 1983, J GEOPHYS RES-SPACE, V88, P73, DOI 10.1029/JA088iA01p00073; KEATING GM, 2003, P MARS ATM MOD OBS W; MCCOY RP, 1983, J GEOPHYS RES-SPACE, V88, P3197, DOI 10.1029/JA088iA04p03197; QUEMERAIS X, UNPUB; STEWART A. M., 1961, AUSTRALIAN JOUR EXPTL AGRIC AND ANIMAL HUSBANDRY, V1, P85; STEWART AI, 1979, SCIENCE, V203, P777, DOI 10.1126/science.203.4382.777; STEWART AI, 1979, SCIENCE, V205, P59, DOI 10.1126/science.205.4401.59	20	79	80	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2005	307	5709					566	569		10.1126/science.1106957	http://dx.doi.org/10.1126/science.1106957			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893BJ	15681381				2022-12-28	WOS:000226694000043
J	Sharma, P				Sharma, P			Physics - How to create a spin current	SCIENCE			English	Editorial Material							SPINTRONICS		Argonne Natl Lab, Argonne, IL 60439 USA	United States Department of Energy (DOE); Argonne National Laboratory	Sharma, P (corresponding author), Argonne Natl Lab, 9700 S Cass Ave, Argonne, IL 60439 USA.	psharma@anl.gov		Sharma, Prashant/0000-0003-0584-9612				Aleiner IL, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.256801; Altshuler BL, 1999, SCIENCE, V283, P1864, DOI 10.1126/science.283.5409.1864; Brouwer PW, 1998, PHYS REV B, V58, P10135, DOI 10.1103/PhysRevB.58.R10135; GIAMARCHI T., 2004, INT SERIES MONOGRAPH; Kato YK, 2004, SCIENCE, V306, P1910, DOI 10.1126/science.1105514; Mucciolo ER, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.146802; Sharma P, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.096401; Sharma P, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.166801; Switkes M, 1999, SCIENCE, V283, P1905, DOI 10.1126/science.283.5409.1905; THOULESS DJ, 1983, PHYS REV B, V27, P6083, DOI 10.1103/PhysRevB.27.6083; Watson SK, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.258301; Wolf SA, 2001, SCIENCE, V294, P1488, DOI 10.1126/science.1065389; Zutic I, 2004, REV MOD PHYS, V76, P323, DOI 10.1103/RevModPhys.76.323	13	59	61	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2005	307	5709					531	533		10.1126/science.1099388	http://dx.doi.org/10.1126/science.1099388			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893BJ	15681374	Green Published			2022-12-28	WOS:000226694000034
J	He, JX; Gendron, JM; Sun, Y; Gampala, SSL; Gendron, N; Sun, CQ; Wang, ZY				He, JX; Gendron, JM; Sun, Y; Gampala, SSL; Gendron, N; Sun, CQ; Wang, ZY			BZR1 is a transcriptional repressor with dual roles in brassinosteroid homeostasis and growth responses	SCIENCE			English	Article							REGULATED GENES; ARABIDOPSIS; CYTOCHROME-P450; RECEPTOR; KINASE; BIOSYNTHESIS; ELONGATION; EXPRESSION; STEROIDS; RESCUE	Brassinosteroid (BR) homeostasis and signaling are crucial for normal growth and development of plants. BR signaling through cell-surface receptor kinases and intracellular components leads to dephosphorylation and accumulation of the nuclear protein BZR1. How BR signaling regulates gene expression, however, remains unknown. Here we show that BZR1 is a transcriptional repressor that has a previously unknown DNA binding domain and binds directly to the promoters of feed back-regulated BR biosynthetic genes. Microarray analyses identified additional potential targets of BZR1 and illustrated, together with physiological studies, that BZR1 coordinates BR homeostasis and signaling by playing dual roles in regulating BR biosynthesis and downstream growth responses.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Wang, ZY (corresponding author), Carnegie Inst, Dept Plant Biol, Stanford, CA 94305 USA.	zywang24@stanford.edu	Wang, Zhi-Yong/E-3810-2012	Wang, Zhi-Yong/0000-0003-4602-3390	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066258, T32GM007276] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GM007276, R01 GM066258, R01 GM066258-04, T32 GM007276, R01 GM66258-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altmann T, 1998, TRENDS GENET, V14, P490, DOI 10.1016/S0168-9525(98)01598-4; Bancos S, 2002, PLANT PHYSIOL, V130, P504, DOI 10.1104/pp.005439; Bishop GJ, 1996, PLANT CELL, V8, P959, DOI 10.1105/tpc.8.6.959; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; Clouse SD, 1996, PLANT PHYSIOL, V111, P671, DOI 10.1104/pp.111.3.671; Dharmasiri N, 2004, TRENDS PLANT SCI, V9, P302, DOI 10.1016/j.tplants.2004.04.003; Goda H, 2002, PLANT PHYSIOL, V130, P1319, DOI 10.1104/pp.011254; Goda H, 2004, PLANT PHYSIOL, V134, P1555, DOI 10.1104/pp.103.034736; GODA H, ARABIDOPSIS INFORMAT; He JX, 2002, P NATL ACAD SCI USA, V99, P10185, DOI 10.1073/pnas.152342599; Li J, 2002, CELL, V110, P213, DOI 10.1016/S0092-8674(02)00812-7; Li JM, 2003, CURR OPIN PLANT BIOL, V6, P494, DOI 10.1016/S1369-5266(03)00088-8; Li JM, 2002, SCIENCE, V295, P1299; Li JM, 2001, PLANT PHYSIOL, V127, P14, DOI 10.1104/pp.127.1.14; Mathur J, 1998, PLANT J, V14, P593, DOI 10.1046/j.1365-313X.1998.00158.x; Mora-Garcia S, 2004, GENE DEV, V18, P448, DOI 10.1101/gad.1174204; Shimada Y, 2003, PLANT PHYSIOL, V131, P287, DOI 10.1104/pp.013029; Symons GM, 2004, PLANT PHYSIOL, V135, P2196, DOI 10.1104/pp.104.043034; Szekeres M, 1996, CELL, V85, P171, DOI 10.1016/S0092-8674(00)81094-6; Thummel CS, 2002, GENE DEV, V16, P3113, DOI 10.1101/gad.1042102; Tiwari SB, 2004, PLANT CELL, V16, P533, DOI 10.1105/tpc.017384; Wang ZY, 2004, TRENDS PLANT SCI, V9, P91, DOI 10.1016/j.tplants.2003.12.009; Wang ZY, 2002, DEV CELL, V2, P505, DOI 10.1016/S1534-5807(02)00153-3; Wang ZY, 2001, NATURE, V410, P380, DOI 10.1038/35066597; Yin YH, 2002, CELL, V109, P181, DOI 10.1016/S0092-8674(02)00721-3	25	542	604	4	176	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 11	2005	307	5715					1634	1638		10.1126/science.1107580	http://dx.doi.org/10.1126/science.1107580			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	906ED	15681342	Green Accepted			2022-12-28	WOS:000227622400050
J	Chih, B; Engelman, H; Scheiffele, P				Chih, B; Engelman, H; Scheiffele, P			Control of excitatory and inhibitory synapse formation by neuroligins	SCIENCE			English	Article							HIPPOCAMPAL-NEURONS; MENTAL-RETARDATION; ADHESION MOLECULE; AUTISM; CELLS; DISORDERS; MUTATIONS; RECEPTORS; BALANCE; PSD-95	The normal function of neural networks depends on a delicate balance between excitatory and inhibitory synaptic inputs. Synapse formation is thought to be regulated by bidirectional signaling between pre- and postsynaptic cells. We demonstrate that members of the Neuroligin family promote postsynaptic differentiation in cultured rat hippocampal neurons. Down-regulation of neuroligin isoform expression by RNA interference results in a loss of excitatory and inhibitory synapses. Etectrophysiological analysis revealed a predominant reduction of inhibitory synaptic function. Thus, neuroligins control the formation and functional balance of excitatory and inhibitory synapses in hippocampal neurons.	Columbia Univ, Ctr Neurobiol & Behav, Dept Physiol & Cellular Biophys, New York, NY 10032 USA	Columbia University	Scheiffele, P (corresponding author), Columbia Univ, Ctr Neurobiol & Behav, Dept Physiol & Cellular Biophys, New York, NY 10032 USA.	ps20l8@columbia.edu						Anderson TR, 2004, NEUROPHARMACOLOGY, V47, P694, DOI 10.1016/j.neuropharm.2004.07.023; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; Chih B, 2004, HUM MOL GENET, V13, P1471, DOI 10.1093/hmg/ddh158; CHIH B, UNPUB; Comoletti D, 2004, J NEUROSCI, V24, P4889, DOI 10.1523/JNEUROSCI.0468-04.2004; Dean C, 2003, NAT NEUROSCI, V6, P708, DOI 10.1038/nn1074; Dorsett Y, 2004, NAT REV DRUG DISCOV, V3, P318, DOI 10.1038/nrd1345; Fu ZY, 2003, J NEUROPHYSIOL, V90, P3950, DOI 10.1152/jn.00647.2003; Goda Y, 2003, NEURON, V40, P243, DOI 10.1016/S0896-6273(03)00608-1; Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870; Hausser M, 2000, SCIENCE, V290, P739, DOI 10.1126/science.290.5492.739; Hussman JP, 2001, J AUTISM DEV DISORD, V31, P247, DOI 10.1023/A:1010715619091; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Jamain S, 2003, NAT GENET, V34, P27, DOI 10.1038/ng1136; Kaufmann WE, 2000, CEREB CORTEX, V10, P981, DOI 10.1093/cercor/10.10.981; Laumonnier F, 2004, AM J HUM GENET, V74, P552, DOI 10.1086/382137; Liu GS, 2004, NAT NEUROSCI, V7, P373, DOI 10.1038/nn1206; Nusser Z, 1998, J NEUROSCI, V18, P1693; Prange O, 2004, P NATL ACAD SCI USA, V101, P13915, DOI 10.1073/pnas.0405939101; Rao A, 2000, J NEUROSCI, V20, P8344, DOI 10.1523/JNEUROSCI.20-22-08344.2000; Scheiffele P, 2003, ANNU REV NEUROSCI, V26, P485, DOI 10.1146/annurev.neuro.26.043002.094940; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; Song JY, 1999, P NATL ACAD SCI USA, V96, P1100, DOI 10.1073/pnas.96.3.1100; Turrigiano GG, 2004, NAT REV NEUROSCI, V5, P97, DOI 10.1038/nrn1327; Varoqueaux F, 2004, EUR J CELL BIOL, V83, P449, DOI 10.1078/0171-9335-00410; Yamagata M, 2003, CURR OPIN CELL BIOL, V15, P621, DOI 10.1016/S0955-0674(03)00107-8; Zoghbi HY, 2003, SCIENCE, V302, P826, DOI 10.1126/science.1089071	27	528	544	0	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 25	2005	307	5713					1324	1328		10.1126/science.1107470	http://dx.doi.org/10.1126/science.1107470			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	901WP	15681343				2022-12-28	WOS:000227313200063
J	Gagliardi, L; Roos, BO				Gagliardi, L; Roos, BO			Quantum chemical calculations show that the uranium molecule U-2 has a quintuple bond	NATURE			English	Article							CHEMISTRY	Covalent bonding is commonly described by Lewis's theory(1), with an electron pair shared between two atoms constituting one full bond. Beginning with the valence bond description(2) for the hydrogen molecule, quantum chemists have further explored the fundamental nature of the chemical bond for atoms throughout the periodic table, confirming that most molecules are indeed held together by one electron pair for each bond. But more complex binding may occur when large numbers of atomic orbitals can participate in bond formation. Such behaviour is common with transition metals. When involving heavy actinide elements, metal-metal bonds might prove particularly complicated. To date, evidence for actinide-actinide bonds is restricted to the matrix-isolation(3) of uranium hydrides, including H2U-UH2, and the gas-phase detection(4) and preliminary theoretical study(5) of the uranium molecule, U-2. Here we report quantum chemical calculations on U-2, showing that, although the strength of the U-2 bond is comparable to that of other multiple bonds between transition metals, the bonding pattern is unique. We find that the molecule contains three electron-pair bonds and four one-electron bonds (that is, 10 bonding electrons, corresponding to a quintuple bond), and two ferromagnetically coupled electrons localized on one U atom each-so all known covalent bonding types are contributing.	Univ Palermo, Dipartimento Chim Fis F Accascina, I-90128 Palermo, Italy; Chem Ctr Lund, Dept Theoret Chem, S-22100 Lund, Sweden	University of Palermo; Lund University	Gagliardi, L (corresponding author), Univ Palermo, Dipartimento Chim Fis F Accascina, Viale Sci,Parco Orleans 2, I-90128 Palermo, Italy.	laura.gagliardi@unipa.it	Gagliardi, Laura/S-3023-2017	Gagliardi, Laura/0000-0001-5227-1396				ANDERSSON K, 1990, J PHYS CHEM-US, V94, P5483, DOI 10.1021/j100377a012; Cotton F.A, 1982, MULTIPLE BONDS METAL; COTTON FA, 1965, INORG CHEM, V4, P330, DOI 10.1021/ic50025a015; GAGLIARDI L, IN PRESS J AM CHEM S; GOROKHOV LN, 1974, HIGH TEMP+, V12, P1156; Heitler W., 1927, Z PHYS, V44, P455, DOI [DOI 10.1007/BF01397394, 10.1007/BF01397394]; Karlstrom G, 2003, COMP MATER SCI, V28, P222, DOI 10.1016/S0927-0256(03)00109-5; Lewis GN, 1916, J AM CHEM SOC, V38, P762, DOI 10.1021/ja02261a002; PEPPER M, 1990, J AM CHEM SOC, V112, P7803, DOI 10.1021/ja00177a055; PYYKKO P, 1988, CHEM REV, V88, P563, DOI 10.1021/cr00085a006; Roos B.O., 1987, ADV CHEM PHYS, V69, P399, DOI DOI 10.1002/9780470142943.CH7; Roos BO, 2004, PHYS CHEM CHEM PHYS, V6, P2919, DOI 10.1039/b401472n; Roos BO, 2003, COLLECT CZECH CHEM C, V68, P265, DOI 10.1135/cccc20030265; Souter PF, 1997, J AM CHEM SOC, V119, P1682, DOI 10.1021/ja9630809	14	256	257	3	110	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 24	2005	433	7028					848	851		10.1038/nature03249	http://dx.doi.org/10.1038/nature03249			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	899VT	15729337	Green Published			2022-12-28	WOS:000227174600037
J	Lang, D; Lu, MM; Huang, L; Engleka, KA; Zhang, MZ; Chu, EY; Lipner, S; Skoultchi, A; Millar, SE; Epstein, JA				Lang, D; Lu, MM; Huang, L; Engleka, KA; Zhang, MZ; Chu, EY; Lipner, S; Skoultchi, A; Millar, SE; Epstein, JA			Pax3 functions at a nodal point in melanocyte stem cell differentiation	NATURE			English	Article							HAIR FOLLICLE DEVELOPMENT; TRANSCRIPTION FACTOR; NEURAL CREST; BETA-CATENIN; WAARDENBURG-SYNDROME; SOX10; MITF; MORPHOGENESIS; INITIATION; INTERACTS	Most stem cells are not totipotent. Instead, they are partially committed but remain undifferentiated. Upon appropriate stimulation they are capable of regenerating mature cell types(1). Little is known about the genetic programmes that maintain the undifferentiated phenotype of lineage-restricted stem cells. Here we describe the molecular details of a nodal point in adult melanocyte stem cell differentiation in which Pax3 simultaneously functions to initiate a melanogenic cascade while acting downstream to prevent terminal differentiation. Pax3 activates expression of Mitf, a transcription factor critical for melanogenesis(2,3), while at the same time it competes with Mitf for occupancy of an enhancer required for expression of dopachrome tautomerase, an enzyme that functions in melanin synthesis(4). Pax3-expressing melanoblasts are thus committed but undifferentiated until Pax3-mediated repression is relieved by activated beta-catenin. Thus, a stem cell transcription factor can both determine cell fate and simultaneously maintain an undifferentiated state, leaving a cell poised to differentiate in response to external stimuli.	Univ Penn, Dept Med, Div Cardiovasc, Philadelphia, PA 19104 USA; Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	University of Pennsylvania; University of Pennsylvania; Yeshiva University; Albert Einstein College of Medicine	Epstein, JA (corresponding author), Univ Penn, Dept Med, Div Cardiovasc, Philadelphia, PA 19104 USA.	epsteinj@mail.med.upenn.edu		Epstein, Jonathan/0000-0001-8637-4465; Lang, Deborah/0000-0003-1057-0923; Millar, Sarah/0000-0001-8792-6890				Aksan I, 1998, MOL CELL BIOL, V18, P6930, DOI 10.1128/MCB.18.12.6930; Andl T, 2002, DEV CELL, V2, P643, DOI 10.1016/S1534-5807(02)00167-3; Ashery-Padan R, 2001, CURR OPIN CELL BIOL, V13, P706, DOI 10.1016/S0955-0674(00)00274-X; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Bondurand N, 2000, HUM MOL GENET, V9, P1907, DOI 10.1093/hmg/9.13.1907; Brault V, 2001, DEVELOPMENT, V128, P1253; Cai Y, 2003, EMBO J, V22, P5522, DOI 10.1093/emboj/cdg536; Chu EY, 2004, DEVELOPMENT, V131, P4819, DOI 10.1242/dev.01347; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Garcia-Castro MI, 2002, SCIENCE, V297, P848, DOI 10.1126/science.1070824; Hari L, 2002, J CELL BIOL, V159, P867, DOI 10.1083/jcb.200209039; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Ikeya M, 1997, NATURE, V389, P966, DOI 10.1038/40146; Jin ZX, 2002, J IMMUNOL, V169, P3783, DOI 10.4049/jimmunol.169.7.3783; Kim J, 2003, NEURON, V38, P17, DOI 10.1016/S0896-6273(03)00163-6; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Lee HY, 2004, SCIENCE, V303, P1020, DOI 10.1126/science.1091611; Marquardt T, 2001, CELL, V105, P43, DOI 10.1016/S0092-8674(01)00295-1; Nishimura EK, 2002, NATURE, V416, P854, DOI 10.1038/416854a; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; Potterf SB, 2000, HUM GENET, V107, P1, DOI 10.1007/s004390050001; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; STEEL KP, 1992, DEVELOPMENT, V115, P1111; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Widlund HR, 2003, ONCOGENE, V22, P3035, DOI 10.1038/sj.onc.1206443; Yasumoto K, 2002, EMBO J, V21, P2703, DOI 10.1093/emboj/21.11.2703	30	283	300	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 24	2005	433	7028					884	887		10.1038/nature03292	http://dx.doi.org/10.1038/nature03292			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	899VT	15729346				2022-12-28	WOS:000227174600047
J	Hooton, TM; Scholes, D; Gupta, K; Stapleton, AE; Roberts, PL; Stamm, WE				Hooton, TM; Scholes, D; Gupta, K; Stapleton, AE; Roberts, PL; Stamm, WE			Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URINARY-TRACT INFECTIONS; UROPATHOGENIC ESCHERICHIA-COLI; ACUTE BACTERIAL; HOST DEFENSES; ACID; AUGMENTIN; AMOXICLAV; CEFACLOR	Context The high prevalence of resistance to trimethoprim-sulfamethoxazole and other antimicrobials among Escherichia coli causing acute cystitis in women has led to increased use of alternative antibiotics. One such antibiotic, amoxicillin-clavulanate, has not been well studied. Objective To compare the efficacy of a 3-day regimen of amoxicillin-clavulanate to that of a 3-day regimen of ciprofloxacin in the treatment of acute cystitis in women. The primary study hypothesis was that the amoxicillin-clavulanate and ciprofloxacin treatment groups would differ in clinical cure. Design, Setting, and Patients Randomized, single-blind treatment trial of 370 women, aged 18 to 45 years, with symptoms of acute uncomplicated cystitis and a urine culture with at least 102 colony-forming units of uropathogens per milliliter from a university student health center or a health maintenance organization. Interventions Women were randomly assigned to receive amoxicillin-clavulanate (500 mg/125 mg twice daily) or ciprofloxacin (250 mg twice daily) for 3 days and were followed up for 4 months. Main Outcome Measures The main outcome measure was clinical cure. Secondary study outcomes of interest were microbiological cure and vaginal E coli colonization at the 2-week follow-up visit. Results Clinical cure was observed in 93 (58%) of 160 women treated with amoxicillin-clavulanate compared with 124 (77%) of 162 women treated with ciprofloxacin (P<.001). Amoxicillin-clavulanate was not as effective as ciprofloxacin even among women infected with strains susceptible to amoxicillin-clavulanate (65 [60%] of 109 women in the amoxicillin-clavulanate group vs 114 [77%] of 149 women in the ciprofloxacin group; P=.004). The difference in clinical cure rates occurred almost entirely within the first 2 weeks after therapy. Microbiological cure at 2 weeks was observed in 118 (76%) of 156 women treated with amoxicillin-clavulanate compared with 153 (95%) of 161 women treated with ciprofloxacin (P<.001). At this visit, 45% of women in the amoxicillin-clavulanate group compared with 10% in the ciprofloxacin group had vaginal colonization with E coli (P<.001). Conclusions A 3-day regimen of amoxicillin-clavulanate is not as effective as ciprofloxacin for the treatment of acute uncomplicated cystitis, even in women infected with susceptible strains. This difference may be due to the inferior ability of amoxicillin-clavulanate to eradicate vaginal E coli, facilitating early reinfection.	Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative	Hooton, TM (corresponding author), Harbor Med Ctr, 325 9th Ave,Box 359930, Seattle, WA 98104 USA.	hooton@u.washington.edu	Stapleton, Ann E/N-2428-2015	Stapleton, Ann E/0000-0003-0130-8659	NIDDK NIH HHS [1 PO DK53369, P01 DK053369] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK053369] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY RR, 1983, NEW ZEAL MED J, V96, P970; BAILEY RR, 1995, NEW ZEAL MED J, V108, P465; BRUMFITT W, 1984, ANTIMICROB AGENTS CH, V25, P276, DOI 10.1128/AAC.25.2.276; COOPER J, 1990, INFECTION, V18, P65, DOI 10.1007/BF01641417; COUNTS GW, 1982, REV INFECT DIS, V4, P484; CROKAERT F, 1982, ANTIMICROB AGENTS CH, V22, P346, DOI 10.1128/AAC.22.2.346; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GALLACHER G, 1986, J INFECTION, V12, P229, DOI 10.1016/S0163-4453(86)94164-2; GURWITH MJ, 1983, ANTIMICROB AGENTS CH, V24, P716, DOI 10.1128/AAC.24.5.716; Hooton Thomas M., 1996, P67; Hooton TM, 2004, CLIN INFECT DIS, V39, P75, DOI 10.1086/422145; Hooton TM, 2003, INFECT DIS CLIN N AM, V17, P303, DOI 10.1016/S0891-5520(03)00004-7; Huang ES, 2002, ARCH INTERN MED, V162, P41, DOI 10.1001/archinte.162.1.41; JOHNSON CE, 1993, AM J DIS CHILD, V147, P1090, DOI 10.1001/archpedi.1993.02160340076018; Kahlmeter G, 2003, J ANTIMICROB CHEMOTH, V51, P69, DOI 10.1093/jac/dkg028; Leflon-Guibout W, 2002, J ANTIMICROB CHEMOTH, V49, P367, DOI 10.1093/jac/49.2.367; MASTERTON RG, 1995, J ANTIMICROB CHEMOTH, V35, P129, DOI 10.1093/jac/35.1.129; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; Mulvey MA, 2000, P NATL ACAD SCI USA, V97, P8829, DOI 10.1073/pnas.97.16.8829; Pabich WL, 2003, J INFECT DIS, V188, P1054, DOI 10.1086/378203; RAZ R, 1991, ANTIMICROB AGENTS CH, V35, P1688, DOI 10.1128/AAC.35.8.1688; RODRIGUEZ JC, 1990, ATEN PRIMARIA, V7, P127; SAMADPOUR M, 1993, J CLIN MICROBIOL, V31, P3179, DOI 10.1128/JCM.31.12.3179-3183.1993; Scheid MW, 2003, EMERG INFECT DIS, V9, P1; Schutz W, 1990, Fortschr Med, V108, P365; Steinman MA, 2003, ANN INTERN MED, V138, P525, DOI 10.7326/0003-4819-138-7-200304010-00008; Warren JW, 1999, CLIN INFECT DIS, V29, P745, DOI 10.1086/520427; WILLIAMS KJ, 1987, DRUG EXP CLIN RES, V13, P95	28	114	127	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	2005	293	8					949	955		10.1001/jama.293.8.949	http://dx.doi.org/10.1001/jama.293.8.949			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899LR	15728165	Bronze			2022-12-28	WOS:000227146400016
J	Sjoholm, A; Nystrom, T				Sjoholm, A; Nystrom, T			Endothelial inflammation in insulin resistance	LANCET			English	Review							C-REACTIVE PROTEIN; SCOTLAND CORONARY PREVENTION; CHRONIC HEART-FAILURE; CARDIOVASCULAR-DISEASE; DIABETES-MELLITUS; RANDOMIZED-TRIAL; RISK; ATHEROSCLEROSIS; THERAPY; HYPERTENSION	Context Type 2 diabetes and attendant cardiovascular morbidity are becoming major health concerns globally. Obesity-related type 2 diabetes is rapidly rising in prevalence, probably largely because of increased longevity and sedentary lifestyles. Insulin resistance and type 2 diabetes are associated with increased coronary heart disease, but the severity of glycaemia during the diabetic phase can only to a minor extent explain the increased risk. Increased levels of the acute-phase inflammatory marker, C-reactive protein (CRP), are related to insulin resistance and the metabolic syndrome, suggesting a role for chronic low-grade inflammation. CRP levels might predict the development of type 2 diabetes. Starting point Subodh Verma and associates (Circulation 2004; 109: 2058-67) recently showed that CRP attenuates the survival, differentiation, and function of endothelial progenitor cells, partly by CRP reducing expression of endothelial nitric-oxide synthase. Rosiglitazone, a peroxisome-proliferator-activator receptor gamma agonist, inhibits the negative effects of CRP on endothelial progenitor cells. The results are consistent with the suggestion that CRP directly promotes atherosclerotic processes and endothelial cell inflammation. CRP might thus directly trigger the development of a proinflammatory and proatherosclerotic state, leading to atherothrombosis. Where next Cell-surface CRP receptors and signalling pathways need to be characterised. From such study might come novel drugs that will defer proinflammatory reactions leading to insulin resistance and atherothrombosis.	Karolinska Inst, Stockholm S Hosp, Dept Internal Med, SE-11883 Stockholm, Sweden	Karolinska Institutet	Sjoholm, A (corresponding author), Karolinska Inst, Stockholm S Hosp, Dept Internal Med, SE-11883 Stockholm, Sweden.	ake.sjoholm@sodersjukhuset.se						Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Cooper ME, 2004, AM J HYPERTENS, V17, p16S, DOI 10.1016/j.amjhyper.2004.08.004; Dandona P, 2003, J CLIN ENDOCR METAB, V88, P2422, DOI 10.1210/jc.2003-030178; Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013; Duncan BB, 2003, DIABETES, V52, P1799, DOI 10.2337/diabetes.52.7.1799; Fernandez-Real JM, 2003, ENDOCR REV, V24, P278, DOI 10.1210/er.2002-0010; Festa A, 2000, CIRCULATION, V102, P42, DOI 10.1161/01.CIR.102.1.42; Fiordaliso F, 2001, DIABETES, V50, P2363, DOI 10.2337/diabetes.50.10.2363; Fonseca V, 2004, ENDOCR REV, V25, P153, DOI 10.1210/er.2002-0034; Freeman DJ, 2001, CIRCULATION, V103, P357; Freeman DJ, 2002, DIABETES, V51, P1596, DOI 10.2337/diabetes.51.5.1596; Han TS, 2002, DIABETES CARE, V25, P2016, DOI 10.2337/diacare.25.11.2016; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lindholm LH, 2002, J HYPERTENS, V20, P1879, DOI 10.1097/00004872-200209000-00035; Lindholm LH, 2003, J HYPERTENS, V21, P1563, DOI 10.1097/00004872-200308000-00022; Lyon CJ, 2003, ENDOCRINOLOGY, V144, P2195, DOI 10.1210/en.2003-0285; McLaughlin T, 2002, CIRCULATION, V106, P2908, DOI 10.1161/01.CIR.0000041046.32962.86; Osei SY, 2000, HYPERTENSION, V36, P122, DOI 10.1161/01.HYP.36.1.122; Ouchi N, 2000, CIRCULATION, V102, P1296, DOI 10.1161/01.CIR.102.11.1296; Padwal R, 2004, DIABETES CARE, V27, P247, DOI 10.2337/diacare.27.1.247; Pfeffer MA, 2003, LANCET, V362, P759, DOI 10.1016/S0140-6736(03)14282-1; Pickup JC, 2004, DIABETES CARE, V27, P813, DOI 10.2337/diacare.27.3.813; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Reaven GM, 2003, J CLIN ENDOCR METAB, V88, P2399, DOI 10.1210/jc.2003-030087; Sharma AM, 2002, HYPERTENSION, V40, P609, DOI 10.1161/01.HYP.0000036448.44066.53; Steinberg HO, 1996, J CLIN INVEST, V97, P2601, DOI 10.1172/JCI118709; STOUT RW, 1990, DIABETES CARE, V13, P631, DOI 10.2337/diacare.13.6.631; Verma S, 2003, CIRCULATION, V108, P2054, DOI 10.1161/01.CIR.0000089191.72957.ED; Verma S, 2003, AM J PHYSIOL-REG I, V285, pR1253, DOI 10.1152/ajpregu.00170.2003; Verma S, 2004, CIRCULATION, V109, P2058, DOI 10.1161/01.CIR.0000127577.63323.24; Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001; Yusuf S, 2003, LANCET, V362, P777, DOI 10.1016/S0140-6736(03)14285-7; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	36	208	222	2	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 12	2005	365	9459					610	612		10.1016/S0140-6736(05)70804-7	http://dx.doi.org/10.1016/S0140-6736(05)70804-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897DN	15708106				2022-12-28	WOS:000226984300035
J	Tomoyasu, Y; Wheeler, SR; Denell, RE				Tomoyasu, Y; Wheeler, SR; Denell, RE			Ultrabithorax is required for membranous wing identity in the beetle Tribolium castaneum	NATURE			English	Article							GENE-COMPLEX; DROSOPHILA-MELANOGASTER; HOMEOTIC COMPLEX; EVOLUTION; EXPRESSION; SPECIFICATION; MORPHOGENESIS; ORTHOLOG; SEQUENCE; DPP	The two pairs of wings that are characteristic of ancestral pterygotes ( winged insects) have often undergone evolutionary modification. In the fruitfly, Drosophila melanogaster, differences between the membranous forewings and the modified hindwings ( halteres) depend on the Hox gene Ultrabithorax ( Ubx). The Drosophila forewings develop without Hox input, while Ubx represses genes that are important for wing development, promoting haltere identity(1,2). However, the idea that Hox input is important to the morphologically specialized wing derivatives such as halteres, and not the more ancestral wings, requires examination in other insect orders. In beetles, such as Tribolium castaneum, it is the forewings that are modified ( to form elytra), while the hindwings retain a morphologically more ancestral identity. Here we show that in this beetle Ubx ' despecializes' the hindwings, which are transformed to elytra when the gene is knocked down. We also show evidence that elytra result from a Hox- free state, despite their diverged morphology. Ubx function in the hindwing seems necessary for a change in the expression of spalt, iroquois and achaete- scute homologues from elytron- like to more typical wing- like patterns. This counteracting effect of Ubx in beetle hindwings represents a previously unknown mode of wing diversification in insects.	Kansas State Univ, Div Biol, Manhattan, KS 66506 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Kansas State University; Washington University (WUSTL)	Tomoyasu, Y (corresponding author), Kansas State Univ, Div Biol, Chalmers Hall, Manhattan, KS 66506 USA.	tomoyasu@ksu.edu	Tomoyasu, Yoshinori/D-3061-2017	Tomoyasu, Yoshinori/0000-0001-9824-3454				Abouheif E, 2002, SCIENCE, V297, P249, DOI 10.1126/science.1071468; Beeman R.W., 1990, P21; BEEMAN RW, 1987, NATURE, V327, P247, DOI 10.1038/327247a0; BEEMAN RW, 1989, DEV BIOL, V133, P196, DOI 10.1016/0012-1606(89)90311-4; Beeman RW, 1997, INSECT MOL BIOL, V6, P83, DOI 10.1046/j.1365-2583.1997.00159.x; Bennett RL, 1999, DEV GENES EVOL, V209, P608, DOI 10.1007/s004270050295; Brown SJ, 2002, GENETICS, V160, P1067; CAMPUZANO S, 1985, CELL, V40, P327, DOI 10.1016/0092-8674(85)90147-3; CARROLL SB, 1995, NATURE, V375, P58, DOI 10.1038/375058a0; Curtis CD, 2001, GENESIS, V30, P12, DOI 10.1002/gene.1027; de Celis JF, 2000, MECH DEVELOP, V91, P31, DOI 10.1016/S0925-4773(99)00261-0; deCelis JF, 1996, NATURE, V381, P421, DOI 10.1038/381421a0; El-Kifl A. H., 1953, Bulletin de la Societe Fouad ler d'Entomologie, V37, P173; GomezSkarmeta JL, 1996, CELL, V85, P95, DOI 10.1016/S0092-8674(00)81085-5; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; KELSH R, 1994, DEV GENET, V15, P19, DOI 10.1002/dvg.1020150104; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Lorenzen MD, 2003, INSECT MOL BIOL, V12, P433, DOI 10.1046/j.1365-2583.2003.00427.x; QUENNEDEY A, 1990, TISSUE CELL, V22, P721, DOI 10.1016/0040-8166(90)90067-J; SanchezSalazar J, 1996, DEV GENES EVOL, V206, P237, DOI 10.1007/s004270050049; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; STUART JJ, 1991, NATURE, V350, P72, DOI 10.1038/350072a0; Sturtevant MA, 1997, DEVELOPMENT, V124, P21; Tomoyasu Y, 2004, DEV GENES EVOL, V214, P575, DOI 10.1007/s00427-004-0434-0; WARREN RW, 1994, NATURE, V372, P458, DOI 10.1038/372458a0; Weatherbee SD, 1998, GENE DEV, V12, P1474, DOI 10.1101/gad.12.10.1474; Weatherbee SD, 1999, CURR BIOL, V9, P109, DOI 10.1016/S0960-9822(99)80064-5; Wheeler SR, 2003, DEVELOPMENT, V130, P4373, DOI 10.1242/dev.00646	28	145	149	5	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 10	2005	433	7026					643	647		10.1038/nature03272	http://dx.doi.org/10.1038/nature03272			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	895KX	15703749				2022-12-28	WOS:000226862000047
J	Fiessinger, JN; Huisman, MV; Davidson, BL; Bounameaux, H; Francis, CW; Eriksson, H; Lundstrom, T; Berkowitz, SD; Nystrom, P; Thorsen, M; Ginsberg, JS				Fiessinger, JN; Huisman, MV; Davidson, BL; Bounameaux, H; Francis, CW; Eriksson, H; Lundstrom, T; Berkowitz, SD; Nystrom, P; Thorsen, M; Ginsberg, JS		THRIVE Treatment Study Investigato	Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTRAVENOUS UNFRACTIONATED HEPARIN; VENOUS THROMBOEMBOLISM; INHIBITOR XIMELAGATRAN; SECONDARY PREVENTION; ORAL XIMELAGATRAN; KNEE REPLACEMENT; ENOXAPARIN; MELAGATRAN; ABSORPTION; THERAPY	Context Ximelagatran, an oral direct thrombin inhibitor with a rapid onset of action and predictable antithrombotic effect, has the potential to be a simple therapeutic alternative to current standard treatment of acute venous thromboembolism. Objective To compare the efficacy and safety of ximelagatran with standard enoxaparin/warfarin treatment for the prevention of recurrent venous thromboembolism. Design, Setting, and Patients Randomized, double-blind, noninferiority trial (Thrombin Inhibitor in Venous Thromboembolism [THRIVE] Treatment Study) of 2489 patients with acute deep vein thrombosis, of whom approximately one third had concomitant pulmonary embolism. The study was conducted at 279 centers in 28 countries from September 2000 through December 2002. Interventions Patients were randomized to receive 6 months of treatment with either oral ximelagatran, 36 mg twice daily, or subcutaneous enoxaparin, 1 mg/kg twice daily, for 5 to 20 days followed by warfarin adjusted to maintain an international normalized ratio of 2.0 to 3.0. Main Outcome Measures Recurrent venous thromboembolism, bleeding, and mortality. Results Venous thromboembolism recurred in 26 of the 1240 patients assigned to receive ximelagatran (estimated cumulative risk, 2.1%) and in 24 of the 1249 patients assigned to receive enoxaparin/warfarin (2.0%). The absolute difference between ximelagatran and enoxaparin/warfarin was 0.2% (95% confidence interval [Cl], -1.0% to 1.3%). This met the prespecified criterion for noninferiority. Corresponding values for major bleeding were 1.3% and 2.2% (difference, -1.0%; 95% Cl, -2.1% to 0.1%), and for mortality were 2.3% and 3.4% (difference, -1.1%; 95% Cl, -2.4% to 0.2%). Alanine aminotransferase levels increased to more than 3 times the upper limit of normal in 119 patients (9.6%) and 25 patients (2.0%) receiving ximelagatran and enoxaparin/warfarin, respectively. increased enzyme levels were mainly asymptomatic. Retrospective analysis of locally reported adverse events showed a higher rate of serious coronary events with ximelagatran (10/1240 patients) compared with enoxaparin/warfarin (1/1249 patients). Conclusions Oral ximelagatran administered in a fixed dose without coagulation monitoring, was as effective as enoxaparin/warfarin for treatment of deep vein thrombosis with or without pulmonary embolism and showed similar, low rates of bleeding. increased levels of liver enzymes in 9.6% of xi melagatran-treated patients require regular monitoring; the mechanism requires further evaluation. Prospective assessment of coronary events in future studies is warranted.	Leiden Univ, Med Ctr, Dept Gen Internal Med, NL-2300 RC Leiden, Netherlands; Hop Europeen Georges Pompidou, Dept Vasc Med, Paris, France; Swedish Med Ctr, Seattle, WA USA; Univ Washington, Sch Med, Seattle, WA USA; Univ Hosp Geneva, Dept Internal Med, Geneva, Switzerland; Univ Rochester, Dept Med, Rochester, NY USA; Sahlgrenska Univ Hosp Ostra, Gothenburg, Sweden; AstraZeneca Res & Dev Molndal, Molndal, Sweden; AstraZeneca PL, Dept Clin Dev, Wilmington, DE USA; McMaster Univ, Dept Med, Hamilton, ON, Canada	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Swedish Medical Center; University of Washington; University of Washington Seattle; University of Geneva; University of Rochester; Sahlgrenska University Hospital; AstraZeneca; AstraZeneca; McMaster University	Huisman, MV (corresponding author), Leiden Univ, Med Ctr, Dept Gen Internal Med, Room C1 R43,POB 9600, NL-2300 RC Leiden, Netherlands.	m.v.huisman@lumc.nl	Berkowitz, Scott Darrell/AAS-9397-2021; ginsberg, jeffrey s/ABC-1065-2020; Kovacs, Michael/G-3315-2011	Berkowitz, Scott Darrell/0000-0002-9428-4408; 				Albers GW, 2003, LANCET, V362, P1691; Ansell J, 2001, CHEST, V119, p22S, DOI 10.1378/chest.119.1_suppl.22S; Bredberg E, 2003, CLIN PHARMACOKINET, V42, P765, DOI 10.2165/00003088-200342080-00005; Buller HR, 2004, ANN INTERN MED, V140, P867, DOI 10.7326/0003-4819-140-11-200406010-00007; Charbonnier BA, 1998, THROMB HAEMOSTASIS, V79, P897; Eriksson BI, 2003, THROMB HAEMOSTASIS, V89, P288; Eriksson H, 2003, J THROMB HAEMOST, V1, P41, DOI 10.1046/j.1538-7836.2003.00034.x; Eriksson UG, 2003, DRUG METAB DISPOS, V31, P294, DOI 10.1124/dmd.31.3.294; Eriksson UG, 2003, EUR J CLIN PHARMACOL, V59, P35, DOI 10.1007/s00228-003-0565-7; Francis CW, 2003, NEW ENGL J MED, V349, P1703, DOI 10.1056/NEJMoa035162; Gustafsson D, 2001, THROMB RES, V101, P171, DOI 10.1016/S0049-3848(00)00399-6; Hirsh J, 2001, CHEST, V119, p8S, DOI 10.1378/chest.119.1_suppl.8S; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; *ICH GUID, INT C HARM TECHN REQ; Klement P, 2003, J THROMB HAEMOST, V1, P587, DOI 10.1046/j.1538-7836.2003.00060.x; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; Merli G, 2001, ANN INTERN MED, V134, P191, DOI 10.7326/0003-4819-134-3-200102060-00009; Meyer G, 2002, ARCH INTERN MED, V162, P1729, DOI 10.1001/archinte.162.15.1729; Prandoni P, 2002, BLOOD, V100, P3484, DOI 10.1182/blood-2002-01-0108; Schulman S, 2003, NEW ENGL J MED, V349, P1713, DOI 10.1056/NEJMoa030104; Siegel JP, 2000, AM HEART J, V139, pS166, DOI 10.1016/S0002-8703(00)90066-8; tenCate JW, 1997, NEW ENGL J MED, V337, P657; Wallentin L, 2003, LANCET, V362, P789, DOI 10.1016/S0140-6736(03)14287-0	24	250	263	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	2005	293	6					681	689		10.1001/jama.293.6.681	http://dx.doi.org/10.1001/jama.293.6.681			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895DX	15701909	Bronze			2022-12-28	WOS:000226842200021
J	Grown, C; Gupta, GR; Pande, R				Grown, C; Gupta, GR; Pande, R			Taking action to improve women's health through gender equality and women's empowerment	LANCET			English	Article							CARE UTILIZATION; RISK BEHAVIORS; POPULATION; VIOLENCE; HIV; SURVEILLANCE; PREVALENCE; EDUCATION		Int Ctr Res Women, Washington, DC 20036 USA		Grown, C (corresponding author), Int Ctr Res Women, 1717 Massachusetts Ave NW,Suite 302, Washington, DC 20036 USA.	cgrown@icrw.org						Basu A.M., 1992, CULTURE STATUS WOMEN; Beegle K, 2001, STUD FAMILY PLANN, V32, P130, DOI 10.1111/j.1728-4465.2001.00130.x; Bhatia JC., 1995, HLTH TRANSITION REV, V5, P127; Bloom SS, 2001, DEMOGRAPHY, V38, P67, DOI 10.1353/dem.2001.0001; BOURNE KL, 1991, POP STUD-J DEMOG, V45, P203, DOI 10.1080/0032472031000145396; ELGIBALY O, 1999, DECLINE FEMALE CIRCU; Ellsberg MC, 2001, J EPIDEMIOL COMMUN H, V55, P547, DOI 10.1136/jech.55.8.547; Elo I T, 1992, Health Transit Rev, V2, P49; Fylkesnes K, 2001, AIDS, V15, P907, DOI 10.1097/00002030-200105040-00011; *GLOB CAMP ED, 2004, LEARN SURV ED ALL WO; GOVINDASAMY P, 2000, WOMEN POVERTY DEMOGR, P263; GOVINDASAMY P, 1996, 61 ANN M POP ASS AM; Gregson S, 2002, AIDS, V16, P643, DOI 10.1097/00002030-200203080-00017; Hallman K.K., 2000, FCND DISCUSSION PAPE; HEISE L, 1994, 225 WORLD BANK; Herz Barbara, 2004, WHAT WORKS GIRLS ED; *J HOPK SCH PUBL H, 1999, ED VIOL WOM POP REP; Jewkes RK, 2003, SOC SCI MED, V56, P125, DOI 10.1016/S0277-9536(02)00012-6; KISHOR S, 2004, PROFILING DOMENSTIC; LEVINE RA, 1991, POPUL DEV REV, V17, P459, DOI 10.2307/1971950; Malhotra A, 2003, IMPACT INVESTMENTS F; Maman S, 2000, SOC SCI MED, V50, P459, DOI 10.1016/S0277-9536(99)00270-1; Mathur S, 2003, TOO YOUNG WED LIVES; Mwaniki P K, 2002, East Afr Med J, V79, P184; OBERMEYER CM, 1991, STUD FAMILY PLANN, V22, P177, DOI 10.2307/1966644; PANDA P, 2002, 344 INT CTR RES WOM; PANDE R, 2001, 66 ANN M POP ASS AM; *POP REF BUR, 2000, WORLDS YOUTH 2000; QUIMSUMBING A, 2000, 86 INT FOOD POL RES; SCHULTZ TP, 1993, WOMENS ED DEV COUNTR; Sen Purna, 1999, EUR J DEV RES, V11, P65, DOI [10.1080/09578819908426739, DOI 10.1080/09578819908426739]; Silveira MF, 2002, SEX TRANSM DIS, V29, P536, DOI 10.1097/00007435-200209000-00008; SUBBARAO K, 1995, ECON DEV CULT CHANGE, V44, P105, DOI 10.1086/452202; *UN, 2003, WORLD FERT REP 2003; UN Millennium Project, 2005, TAK ACT ACH GEND EQ; Visaria L, 1999, DOMESTIC VIOLENCE IN, P9; Wolff B., 2000, CULTURE HLTH SEXUALI, V2, P303, DOI [10.1080/136910500422278, DOI 10.1080/136910500422278]; *WORLD BANK, 1993, WORLD DEV REP 1993 I	38	94	94	1	21	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 5	2005	365	9458					541	543						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	894SS	15705464				2022-12-28	WOS:000226812500032
J	Oransky, I				Oransky, I			Susan Sontag - Obituary	LANCET			English	Biographical-Item												ivan-oransky@erols.com						SONTAG S, PUBLICATION LIST	1	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 5	2005	365	9458					468	468						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894SS	15724276				2022-12-28	WOS:000226812500013
J	Elion, EA; Qi, MS; Chen, WD				Elion, EA; Qi, MS; Chen, WD			Signaling specificity in yeast	SCIENCE			English	Editorial Material							TRANSCRIPTION FACTOR; INVASIVE GROWTH; TEC1; DIFFERENTIATION		Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Elion, EA (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	elaine_elion@hms.harvard.edu						Andersson J, 2004, EMBO J, V23, P2564, DOI 10.1038/sj.emboj.7600250; Bao MZ, 2004, CELL, V119, P991, DOI 10.1016/j.cell.2004.11.052; Bruckner S, 2004, CURR GENET, V46, P331, DOI 10.1007/s00294-004-0545-1; Chou S, 2004, CELL, V119, P981, DOI 10.1016/j.cell.2004.11.053; Cullen PJ, 2004, GENE DEV, V18, P1695, DOI 10.1101/gad.1178604; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; Maleri S, 2004, MOL CELL BIOL, V24, P9221, DOI 10.1128/MCB.24.20.9221-9238.2004; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Palecek SP, 2000, GENETICS, V156, P1005; Sabbagh W, 2001, MOL CELL, V8, P683, DOI 10.1016/S1097-2765(01)00322-7; Zeitlinger J, 2003, CELL, V113, P395, DOI 10.1016/S0092-8674(03)00301-5	12	44	44	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2005	307	5710					687	688		10.1126/science.1109500	http://dx.doi.org/10.1126/science.1109500			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	894TQ	15692041				2022-12-28	WOS:000226814900031
J	Lazio, TJW; LaRosa, TN				Lazio, TJW; LaRosa, TN			At the heart of the Milky Way	SCIENCE			English	Editorial Material							GALACTIC-CENTER; MAGNETIC-FIELDS; NONTHERMAL FILAMENTS; WIND		USN, Remote Sensing Div, Res Lab, Washington, DC 20375 USA; Kennesaw State Univ, Dept Biol & Phys Sci, Kennesaw, GA 30144 USA	United States Department of Defense; United States Navy; Naval Research Laboratory; University System of Georgia; Kennesaw State University	Lazio, TJW (corresponding author), USN, Remote Sensing Div, Res Lab, Washington, DC 20375 USA.	lazio@nrl.navy.mil						Beck R, 2001, SPACE SCI REV, V99, P243, DOI 10.1023/A:1013805401252; Bland-Hawthorn J, 2003, ASTROPHYS J, V582, P246, DOI 10.1086/344573; Bower GC, 2004, SCIENCE, V304, P704, DOI 10.1126/science.1094023; CHAKRABARTI SK, 1994, NATURE, V368, P434, DOI 10.1038/368434a0; Chandran BDG, 2000, ASTROPHYS J, V528, P723, DOI 10.1086/308184; CHEVALIER RA, 1992, ASTROPHYS J, V397, pL39, DOI 10.1086/186539; Chuss DT, 2003, ASTROPHYS J, V599, P1116, DOI 10.1086/379538; Lang CC, 1999, ASTROPHYS J, V521, pL41, DOI 10.1086/312180; LaRosa TN, 2004, ASTROPHYS J, V607, P302, DOI 10.1086/383233; Morris M, 1996, ANNU REV ASTRON ASTR, V34, P645, DOI 10.1146/annurev.astro.34.1.645; Nord ME, 2004, ASTRON J, V128, P1646, DOI 10.1086/424001; Novak G, 2003, ASTROPHYS J, V583, pL83, DOI 10.1086/368156; Shore SN, 1999, ASTROPHYS J, V521, P587, DOI 10.1086/307601; Wang QD, 2002, ASTROPHYS J, V581, P1148, DOI 10.1086/344401; YUSEFZADEH F, 1984, NATURE, V310, P557, DOI 10.1038/310557a0	15	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2005	307	5710					686	687		10.1126/science.1100793	http://dx.doi.org/10.1126/science.1100793			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	894TQ	15692040				2022-12-28	WOS:000226814900030
J	Storch, D; Marquet, PA; Gaston, KJ				Storch, D; Marquet, PA; Gaston, KJ			Untangling an entangled bank	SCIENCE			English	Editorial Material							BIODIVERSITY; PATTERNS		Charles Univ Prague, Ctr Theoret Study, CZ-11000 Prague 1, Czech Republic; Pontificia Univ Catolica Chile, Dept Ecol, Ctr Adv Studies Ecol & Biodivers, Santiago, Chile; Univ Sheffield, Dept Anim & Plant Sci, Biodivers & Macroecol Grp, Sheffield S10 2TN, S Yorkshire, England	Charles University Prague; Pontificia Universidad Catolica de Chile; University of Sheffield	Storch, D (corresponding author), Charles Univ Prague, Ctr Theoret Study, CZ-11000 Prague 1, Czech Republic.		Marquet, Pablo A/B-7732-2009; Storch, David/C-3339-2017	Marquet, Pablo A/0000-0001-6369-9339; Storch, David/0000-0001-5967-1544				Allen AP, 2002, SCIENCE, V297, P1545, DOI 10.1126/science.1072380; Brown JH, 2004, ECOLOGY, V85, P1771, DOI 10.1890/03-9000; CURRIE DJ, 1991, AM NAT, V137, P27, DOI 10.1086/285144; *CZECH REP, 2004, SCAL BIOD; Darwin C., 1959, ORIGIN SPECIES MEANS; Gaston KJ, 2000, NATURE, V405, P220, DOI 10.1038/35012228; Harte J, 1999, SCIENCE, V284, P334, DOI 10.1126/science.284.5412.334; Hubbell Stephen P., 2001, V32, pi; Sizling AL, 2004, ECOL LETT, V7, P60, DOI 10.1046/j.1461-0248.2003.00549.x; Storch D, 2003, SCIENCE, V299	10	11	11	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2005	307	5710					684	686		10.1126/science.1106935	http://dx.doi.org/10.1126/science.1106935			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	894TQ	15692039				2022-12-28	WOS:000226814900029
J	Thomas, WG				Thomas, WG			Double trouble for type 1 angiotensin receptors in atherosclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Baker Heart Res Inst, Melbourne, Vic, Australia	Baker Heart and Diabetes Institute	Thomas, WG (corresponding author), Baker Heart Res Inst, Melbourne, Vic, Australia.		Thomas, Walter/I-2208-2015	Thomas, Walter/0000-0003-0685-2952				AbdAlla S, 2004, CELL, V119, P343, DOI 10.1016/j.cell.2004.10.006; AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; Barki-Harrington L, 2003, CIRCULATION, V108, P1611, DOI 10.1161/01.CIR.0000092166.30360.78; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Milligan G, 2004, MOL PHARMACOL, V66, P1, DOI 10.1124/mol.104.000497.	5	5	6	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 3	2005	352	5					506	508		10.1056/NEJMcibr043928	http://dx.doi.org/10.1056/NEJMcibr043928			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	893NE	15689592				2022-12-28	WOS:000226725400015
J	Venema, L				Venema, L			Schrodinger's mousetrap - Part 3: Negative thoughts.	NATURE			English	Editorial Material														Venema, Liesbeth/0000-0002-5896-1766					0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2005	433	7025					463	463		10.1038/433463a	http://dx.doi.org/10.1038/433463a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893NT	15690017	Bronze			2022-12-28	WOS:000226727200022
